<SEC-DOCUMENT>0001193125-20-249556.txt : 20200921
<SEC-HEADER>0001193125-20-249556.hdr.sgml : 20200921
<ACCEPTANCE-DATETIME>20200921061034
ACCESSION NUMBER:		0001193125-20-249556
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		38
FILED AS OF DATE:		20200921
DATE AS OF CHANGE:		20200921

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GRAYBUG VISION, INC.
		CENTRAL INDEX KEY:			0001534133
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				452120079
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-248611
		FILM NUMBER:		201185130

	BUSINESS ADDRESS:	
		STREET 1:		275 SHORELINE DRIVE, SUITE 450
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94065
		BUSINESS PHONE:		650-487-2800

	MAIL ADDRESS:	
		STREET 1:		275 SHORELINE DRIVE, SUITE 450
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94065

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GRAYBUG, Inc.
		DATE OF NAME CHANGE:	20150303

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GRAYBUG LLC
		DATE OF NAME CHANGE:	20111102
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>d796801ds1a.htm
<DESCRIPTION>AMENDMENT NO. 1 TO FORM S-1
<TEXT>
<HTML><HEAD>
<TITLE>Amendment No. 1 to Form S-1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission September 21, 2020. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-248611</FONT> </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>  <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT
NO. 1 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">S-1</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:15pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>452120079</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>275 Shoreline Drive, Suite 450 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Redwood City, CA 94065 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(650) <FONT STYLE="white-space:nowrap">487-2800</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of registrant&#146;s principal executive offices) </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Frederic Guerard </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Chief
Executive Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Graybug Vision, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>275 Shoreline Drive, Suite 450 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Redwood City, CA 94065 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(650) <FONT STYLE="white-space:nowrap">487-2800</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service) </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Effie Toshav, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Robert A. Freedman, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Julia Forbess, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Fenwick&nbsp;&amp; West LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>555 California Street</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>San
Francisco, CA 94104</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">(415)&nbsp;875-2300</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Lisa Firenze, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Christopher D. Barnstable-Brown, Esq.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Craig Hilts, Esq.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Wilmer
Cutler Pickering Hale and Dorr LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>7 World Trade Center</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>250 Greenwich Street</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>New
York, NY 10007</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(212) <FONT STYLE="white-space:nowrap">230-8800</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale to the public:</B> As soon as practicable after the effective date of this registration
statement. </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415
under the Securities Act of 1933 check the following box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If this form is filed to register additional securities for an
offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If
this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT
STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company, or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company,&#148;
and &#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">Large&nbsp;accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">Accelerated filer</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"><FONT STYLE="font-size:8pt"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:8pt"><B>&nbsp;&nbsp;</B>&#9746;<B></B><B></B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">Smaller reporting company</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:8pt">Emerging&nbsp;growth&nbsp;company</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#9746;</TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&#9744; </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of Each Class&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Securities to be Registered</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>Amount<BR>to Be<BR>Registered<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>Proposed<BR>Maximum<BR>Offering Price<BR>Per Share</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Maximum</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Offering Price<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><B>Amount of<BR>Registration Fee<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Common Stock, par value $0.0001 per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">5,390,625</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$17.00</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$91,640,625</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$11,895</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(a) under
the Securities Act of 1933, as amended. Includes an additional 703,125 shares that the underwriters have the option to purchase. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Estimated solely for the purpose of calculating the amount of the registration fee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">The Registrant previously paid $11,196 of this amount in connection with the initial filing of this Registration
Statement. </P></TD></TR></TABLE>  <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman"><B>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the
Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the Registration
Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#cc062a"><B>The information in this prospectus is not complete and may be changed. We may not sell
these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities, and we are not soliciting offers to buy these securities in any jurisdiction
where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#cc062a"><B>SUBJECT TO COMPLETION, DATED SEPTEMBER 21, 2020 </B></FONT></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PRELIMINARY PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>4,687,500 Shares </B></P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g796801g01e22.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are offering 4,687,500 shares of our common stock. This is our initial public offering and no public market currently exists for our common
stock. We expect the initial public offering price to be between $15.00 and $17.00 per share. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have applied to list our common
stock on the Nasdaq Global Market under the symbol &#147;GRAY.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; and a &#147;smaller
reporting company&#148; as defined under the federal securities laws and, as such, we have elected to comply with certain reduced reporting requirements for this prospectus and may elect to do so in future filings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>Investing in our common stock involves a high degree of risk. See &#147;<A HREF="#toc796801_3">Risk Factors</A>&#148; beginning on page 13
of this prospectus. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of
these securities or passed on the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial Public Offering Price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting Discounts and
Commissions<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds to Graybug Vision, Inc. (before expenses)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We refer you to &#147;Underwriting&#148; beginning on page 169 for additional information regarding underwriter
compensation. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Delivery of the shares of common stock is expected to be made on or about
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020. We have granted the underwriters an option for a period of 30 days to purchase up to 703,125 additional shares of our common stock. If the
underwriters exercise the option in full, the total underwriting discounts and commissions payable by us will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and the total proceeds to us, before expenses, will be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:16pt">
<TD VALIGN="top"><B>SVB Leerink</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Piper Sandler</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" NOWRAP><B>Needham&nbsp;&amp;&nbsp;Company</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right"><B>Wedbush&nbsp;PacGrow</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The date of this prospectus
is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc796801_1">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc796801_2">The Offering</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc796801_3">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc796801_4">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc796801_6">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc796801_7">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc796801_8">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc796801_9">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc796801_10">Selected Financial Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc796801_11">Management&#146;s Discussion and Analysis of Financial Condition and Results
 of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc796801_12">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc796801_13">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc796801_14">Executive Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc796801_15">Certain Relationships and Related Party Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc796801_16">Principal Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc796801_17">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc796801_18">Shares Eligible for Future Sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc796801_19">Material U.S. Federal Income Tax Consequences to <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc796801_20">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc796801_21">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc796801_22">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc796801_23">Additional Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc796801_24">Index to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the underwriters have authorized anyone to provide you with information different from, or in addition to, that contained in
this prospectus, any amendment or supplement to this prospectus and any related free writing prospectus prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance
as to the reliability of, any information that others may give you. This prospectus is not an offer to sell, nor is it seeking an offer to buy, these securities in any jurisdiction where the offer or sale is not permitted. The information contained
in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or the time of any sale of shares of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Persons who come into possession of this prospectus in jurisdictions outside the United States are required to inform themselves about and to
observe any restrictions as to this offering and the distribution of this prospectus and any applicable free writing prospectus applicable to that jurisdiction. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc796801_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information contained elsewhere in this prospectus and does not contain all of the information that you
should consider in making your investment decision. Before investing in our common stock, you should carefully read this entire prospectus, including our financial statements and the related notes thereto and the information set forth under the
sections entitled &#147;Risk Factors,&#148; &#147;Selected Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; in each case included in this prospectus. Some of the
statements in this prospectus constitute forward-looking statements that involve risks and uncertainties. See the section entitled &#147;Special Note Regarding Forward-Looking Statements.&#148; Unless the context otherwise requires, we use the terms
&#147;Graybug Vision,&#148; &#147;company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; in this prospectus to refer to Graybug Vision, Inc</I>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage
biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve. Our novel proprietary technologies are designed to release drugs in ocular tissue at a controlled rate for up to 12
months in order to improve patient compliance, reduce healthcare burdens and, ultimately, deliver better clinical outcomes. Our lead product candidate, <FONT STYLE="white-space:nowrap">GB-102,</FONT> is an intravitreal injection of a microparticle
depot formulation of sunitinib, a potent inhibitor of neovascular growth and permeability, which are leading causes of retinal disease. We are developing <FONT STYLE="white-space:nowrap">GB-102</FONT> as a
<FONT STYLE="white-space:nowrap">once-every-six</FONT> months intravitreal injection for the treatment of wet <FONT STYLE="white-space:nowrap">age-related</FONT> macular degeneration, or wet AMD, and diabetic macular edema, or DME. In our Phase 1/2a
clinical trial, <FONT STYLE="white-space:nowrap">GB-102</FONT> administered as a single 1 mg dose was well-tolerated in wet AMD patients and demonstrated durable clinical evidence of disease control of at least six months in approximately 88% of
patients in this cohort. <FONT STYLE="white-space:nowrap">GB-102</FONT> is currently in a dose-ranging, controlled and masked safety and efficacy Phase 2b clinical trial in patients with wet AMD. We expect to report topline data from this trial in
the first half of 2021. We are also using our proprietary technologies to develop <FONT STYLE="white-space:nowrap">GB-103,</FONT> a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">once-a-year</FONT></FONT> formulation of <FONT
STYLE="white-space:nowrap">GB-102,</FONT> for the treatment of diabetic retinopathy, or DR, as well as <FONT STYLE="white-space:nowrap">GB-401,</FONT> an intravitreally injectable depot formulation of a beta-adrenergic blocking agent prodrug with a
dosing regimen of once every six months or longer for the treatment of primary open-angle glaucoma, or POAG. We believe that our product candidates could significantly improve clinical outcomes versus the respective standards of care for several
ocular diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Age-related macular degeneration, or AMD, is a chronic, progressive disease, a leading cause of vision loss in the
elderly and estimated to affect approximately 15&nbsp;million people in North America. The disease prevalence is approximately 85 to 90% nonexudative, or dry, AMD and 10 to 15% wet AMD. The therapeutic market for wet AMD in 2019 was estimated to be
$7.9&nbsp;billion worldwide and has historically grown by approximately 8% as a consequence of an aging population and the lack of preventative measures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no cure for wet AMD. To maintain vision, patients must receive frequent intravitreal injections, up to 12 times per year, with
short-acting anti-vascular endothelial growth factor, or VEGF, agents. Although the use of anti-VEGF treatments has revolutionized visual outcomes for patients, the need for frequent injection visits combined with the increasing prevalence of this
disease puts an enormous pressure on healthcare systems and represents a severe burden for patients, caregivers and physicians. These dynamics often lead to a reduced frequency of treatment and result in suboptimal visual outcomes in real-world
practice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Damage to the retina as a result of DR includes a number of vision-threatening complications such as DME, and has been an
important cause of acquired vision loss in the young and <FONT STYLE="white-space:nowrap">middle-age</FONT> adult population. It is estimated that the number of patients with DR will increase globally to over 190&nbsp;million by 2030. <FONT
STYLE="white-space:nowrap">One-third</FONT> of DR patients over 40 years of age in the United States are at risk of developing vision-threatening complications, including DME. DME is the second largest market for anti-VEGF therapies, accounting for
approximately </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
$3.7&nbsp;billion of sales worldwide and approximately $1.8&nbsp;billion in the United States in 2019. Multiple clinical trials have shown that anti-VEGFs are also beneficial for the treatment of
patients with DR but without DME; however, the need for frequent injections and <FONT STYLE="white-space:nowrap">follow-up</FONT> for this often asymptomatic population leads to inadequate compliance and suboptimal clinical benefit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">GB-102</FONT> is designed to provide <FONT STYLE="white-space:nowrap">pan-VEGF</FONT> inhibition for six
months or longer while minimizing fluctuations in retinal thickness in between treatments, which is emerging as predictive of visual outcomes. We believe durable and sustained drug delivery of a single dose offered by
<FONT STYLE="white-space:nowrap">GB-102</FONT> could provide improved visual outcomes for patients with wet AMD and DME, better patient <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">quality-of-life</FONT></FONT> and reduced
disease-monitoring requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">GB-103,</FONT> a longer-acting formulation of sunitinib, is designed to
maintain therapeutic drug levels in the retinal tissue for up to 12 months following a single intravitreal injection. This potentially longer duration of clinical benefit and consequently less frequent need for intravitreal injections may be more
conducive to maintaining a typically asymptomatic patient with DR on an effective anti-VEGF therapy regimen. If approved, <FONT STYLE="white-space:nowrap">GB-103</FONT> could provide a paradigm shift in the treatment of patients with DR who are
currently managed either by observation alone, <FONT STYLE="white-space:nowrap">pan-retinal</FONT> laser photocoagulation or, in rare instances, with short-acting anti-VEGF injections. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Glaucoma is an optic neuropathy that is characterized by the progressive degeneration of the optic nerve that leads to visual impairment. It
is a leading cause of irreversible vision loss that is projected to affect approximately 76&nbsp;million people worldwide in 2020, including approximately 2.7&nbsp;million people in the United States. The most common type of glaucoma is POAG, which
is characterized by an increase in intraocular pressure, or IOP, because fluid, which is continuously generated by cells inside the front of the eye, cannot drain properly<I>. </I>The global POAG therapeutics market is estimated to reach
approximately $3.8&nbsp;billion in 2026, of which the United States represents approximately $2.9&nbsp;billion. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The most common
treatment options for glaucoma are topical eye drops, which must be administered daily, or invasive medical procedures. Topical eye drops can lower IOP and have been shown to both delay and prevent the progressive degeneration associated with POAG.
However, these medications must be administered up to four times per day, and approximately 30% of patients often require more than one class of drug to control IOP. It is estimated that approximately&nbsp;50%&nbsp;of patients stop using their
glaucoma medications in the first six months post-diagnosis due to various reasons, including forgetfulness, lack of disease awareness and/or cost, thus leading to uncontrolled IOP and progressive loss of peripheral vision. Laser-based or surgical
treatments to permanently reduce IOP are invasive and achievement of IOP targets may require multiple surgeries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our third product
candidate, <FONT STYLE="white-space:nowrap">GB-401,</FONT> is an intravitreally administered, proprietary formulation of a beta-adrenergic beta-blocker prodrug designed to provide a controlled release of the active drug to maintain a reduced IOP for
six months or longer after a single injection, thus addressing the patient compliance problem and improving outcomes. If approved, <FONT STYLE="white-space:nowrap">GB-401</FONT> could represent a significant paradigm shift in the way physicians
treat POAG. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following chart summarizes the status and development plan for the product candidates in our pipeline. We own worldwide rights to each of
our programs. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g796801g93b67.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our proprietary technologies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our proprietary technologies are designed to allow sustained delivery of pharmacologic agents to the eye in a well-tolerated and controlled
manner to achieve extended duration of effectiveness. Our proprietary technologies utilize depot formulations of microparticles containing biodegradable polymers such as
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">poly(lactic-co-glycolic</FONT></FONT> acid), or PLGA. The microparticles are engineered to carry a hydrophilic coating such as polyethylene glycol, or PEG, that helps eliminate or
minimize inflammation typically associated with intraocular administration of conventional PLGA microparticles. Our preclinical studies and Phase 1/2a clinical trial provided preliminary evidence that our microparticles are well-tolerated in the
eye. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, our microparticles are designed to aggregate after intravitreal injection upon exposure to the vitreous fluid at body
temperature to form a depot near the bottom of the eye, outside of the visual axis. Our biodegradable microparticles then gradually release the active ingredient at a rate dependent on the composition of the polymers and biodegrade into lactic acid,
glycolic acid and PEG that are naturally cleared from the body. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g796801g56d66.jpg" ALT="LOGO">
 </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some molecules, due to their physicochemical properties, are difficult to encapsulate and
deliver in a controlled manner. For that purpose, we have developed a proprietary prodrug technology to enable sustained delivery of these therapeutics. Our research and development team has developed our product candidates with different
pharmacologic agents using these prodrug technologies. For example, <FONT STYLE="white-space:nowrap">GB-401</FONT> has been developed using this approach. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our lead program <FONT STYLE="white-space:nowrap">GB-102</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing our lead product candidate, <FONT STYLE="white-space:nowrap">GB-102,</FONT> as a
<FONT STYLE="white-space:nowrap">once-every-six</FONT> months intravitreally delivered microparticle depot formulation of sunitinib for the treatment of wet AMD and DME. Sunitinib is a <FONT STYLE="white-space:nowrap">pan-VEGF</FONT> inhibitor <FONT
STYLE="white-space:nowrap">(VEGF-A,</FONT> B, C and D). We believe that <FONT STYLE="white-space:nowrap">GB-102</FONT> is differentiated from the current standard of care, which requires more frequent dosing, up to 12 times per year, and primarily
targets one neovascular pathway <FONT STYLE="white-space:nowrap">(VEGF-A).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Phase 1/2a and 2b clinical trials of <FONT
STYLE="white-space:nowrap">GB-102</FONT> in wet AMD. </I><FONT STYLE="white-space:nowrap">GB-102</FONT> has been evaluated in multiple Phase 1/2 trials to assess its safety, tolerability, durability and pharmacodynamic effects, as well as to
identify the optimal dose. In January 2019, we completed our Phase 1/2a ADAGIO clinical trial of <FONT STYLE="white-space:nowrap">GB-102</FONT> in 32 patients with wet AMD that previously received at least three anti-VEGF injections, which we refer
to as our ADAGIO trial. This trial met its primary endpoint of safety and tolerability. No ocular serious adverse event, or SAE, or dose-limiting toxicity was reported, and the majority of patients had no drug-related adverse events, or AEs. The
most common AE was the presence of medication in the anterior chamber. These AEs were reversible and with no long-term consequences. In this trial, 88% of patients who were previously treated with an average of eight injections annually were able to
maintain stable central retinal thickness and visual acuity for six months or more with a single injection of 1 mg of <FONT STYLE="white-space:nowrap">GB-102.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the data from the ADAGIO trial, we initiated the Phase 2b ALTISSIMO clinical trial in September 2019 to evaluate an improved product
that would minimize the presence of medication within the anterior chamber. This trial compares two doses of <FONT STYLE="white-space:nowrap">GB-102</FONT> (1 or 2 mg) administered every six months to aflibercept administered every two months in up
to 56 patients with anti-VEGF-responsive wet AMD. On the basis of a safety analysis of the Phase 2a clinical trial of GB-102 in ME, described below, and the interim safety data in the ALTISSIMO trial, we terminated the development of the GB-102 2 mg
dose in all of our clinical trial programs. The primary endpoint of the ALTISSIMO trial is to determine <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-additional</FONT></FONT> anti-VEGF supportive therapy. ALTISSIMO
topline results are expected in the first half of 2021. If successful, we plan to advance two pivotal clinical trials in wet AMD in the second half of 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Phase 2a clinical trial of <FONT STYLE="white-space:nowrap">GB-102</FONT> in ME secondary to various diseases, including DME and central or
branch Retinal Vein Occlusion, or RVO</I>. In September 2019, we initiated a Phase 2a clinical trial of <FONT STYLE="white-space:nowrap">GB-102</FONT> in 21 patients with ME secondary to DME and branch or central RVO. This trial was designed to be a
<FONT STYLE="white-space:nowrap">six-month,</FONT> single injection, multicenter, open-label, parallel arm trial with a primary <FONT STYLE="white-space:nowrap">end-point</FONT> of safety and tolerability of two dose levels of <FONT
STYLE="white-space:nowrap">GB-102</FONT> (1 and 2 mg) in patients with ME secondary to DME or RVO who had been previously treated with anti-VEGFs. All patients have completed the study and the final safety analysis has been performed. An interim
data analysis from the ALTISSIMO and ME trials identified 1 mg of <FONT STYLE="white-space:nowrap">GB-102</FONT> as the optimal dose for future clinical trials. We intend to conduct a Phase 2b trial in patients with DME in the second half of 2021.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional pipeline programs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">GB-103</FONT> is designed to be a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">once-a-year</FONT></FONT> intravitreally delivered formulation of sunitinib, and has the potential to become an important
therapy for patients with DR. Our Phase 1/2a clinical trial with <FONT STYLE="white-space:nowrap">GB-103</FONT> in patients with DR is planned to initiate in the first half of 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also applying our proprietary technologies to develop <FONT STYLE="white-space:nowrap">GB-401,</FONT> a depot formulation of a
beta-adrenergic receptor inhibitor, designed to be injected once every six months to reduce IOP in POAG patients. We </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expect to submit an investigational new drug application, or IND, for <FONT STYLE="white-space:nowrap">GB-401</FONT> and initiate a dose-escalating Phase 1/2a clinical trial of <FONT
STYLE="white-space:nowrap">GB-401</FONT> in patients with POAG in the second half of 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our proprietary technologies will
allow us to develop other novel therapeutics, either alone or in combination, that can achieve extended durations of effectiveness and, thus improve the care and quality of life for patients with chronic diseases and disorders of the eye. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Differentiation of our product candidates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our proprietary technologies will allow us to develop therapeutics that may provide superior results to patients compared to
existing ocular treatments, which present several critical limitations. We believe our product candidates present a number of competitive advantages over existing therapeutics: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Extended durability and sustained drug delivery to improve visual outcomes in clinical practice</B>: If
approved, we believe that <FONT STYLE="white-space:nowrap">GB-102</FONT> would be an important intravitreal injection offering a <FONT STYLE="white-space:nowrap">six-month</FONT> duration of action. We believe
<FONT STYLE="white-space:nowrap">GB-102,</FONT> with only two injections a year, could provide a better balance between patient quality of life and disease-monitoring requirements, and deliver, in a real-world setting, increased compliance and
ultimately improved visual outcomes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Differentiated mechanism of action</B>: Our retina programs, <FONT STYLE="white-space:nowrap">GB-102</FONT>
and <FONT STYLE="white-space:nowrap">GB-103,</FONT> use sunitinib, a <FONT STYLE="white-space:nowrap">pan-VEGF</FONT> inhibitor, which blocks all VEGF receptor types associated with angiogenesis, vascular permeability, cellular proliferation and
fibrosis. Moreover, sunitinib is a dual leucine zipper kinase, or DLK, inhibitor, which may result in a neuroprotective effect. Sunitinib&#146;s broader mechanism of action has the potential to provide visual outcome benefits superior to the
traditional <FONT STYLE="white-space:nowrap">anti-VEGF-A</FONT> treatments. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Versatile proprietary technologies</B>: Our polymers can be tuned to provide varying drug elution profiles for
a significant number of small molecules. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Designed for Safety</B>: Our polymers are biodegradable and bioabsorbable. They are designed to hydrolyze over
a determined period of time and leave no residue in the eye. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our executive leadership team </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are led by a team of experienced pharmaceutical industry executives with significant experience in ophthalmology: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Frederic Guerard, Pharm.D., our Chief Executive Officer, has 20 years of leadership, strategic and commercial
pharmaceutical experience, including as Worldwide Business Franchise Head of Ophthalmology at Novartis AG and Global Franchise Head of Pharmaceuticals at Alcon Laboratories, Inc. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Parisa Zamiri, M.D., Ph.D., our Chief Medical Officer, is an ophthalmologist and was previously Vice President,
Global Head of Clinical Development and Therapeutic Area Head for Ophthalmology at Novartis AG. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Daniel Salain, our Chief Technical Operations Officer, has 30 years of global pharmaceutical experience in
manufacturing, operations and business development, and previously served as Senior Vice President of Technical Operations at Ophthotech Corporation (now IVERIC bio, Inc.). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Robert S. Breuil, our Chief Financial Officer, has over 20 years of experience in the biopharmaceutical and drug
delivery industries, and previously served as Chief Financial Officer of Corium, Inc. and Codexis, Inc. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have raised
approximately $134&nbsp;million of capital in gross proceeds from a group of leading life sciences investors, including Deerfield Management, OrbiMed Advisors, a fund managed by Blackstone Life Sciences, Hatteras Venture Partners, CBC Group
(formerly known as <FONT STYLE="white-space:nowrap">C-Bridge</FONT> Capital) and Crown Venture Fund. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our goal is to become a leading biopharmaceutical company focused on developing and commercializing transformative medicines for the treatment
of chronic vision-threatening diseases of the retina and optic nerve. To achieve this goal, the key elements of our strategy are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Advance <FONT STYLE="white-space:nowrap">GB-102</FONT> through clinical development in patients with wet AMD and
DME. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Advance development of <FONT STYLE="white-space:nowrap">GB-103</FONT> to offer patients a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">once-a-year</FONT></FONT> treatment for DR. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Develop <FONT STYLE="white-space:nowrap">GB-401</FONT> for the treatment of elevated IOP in patients with POAG.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Leverage our ocular delivery technologies to expand our pipeline into other vision-threatening conditions.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Commercialize our approved product candidates with our own specialty sales force and through partnerships.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Associated with our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is subject to a number of risks and uncertainties, including those highlighted in the section entitled &#147;Risk Factors&#148;
immediately following this prospectus summary. These risks include, among others, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are a clinical-stage biopharmaceutical company with a limited operating history and no products approved. We
have incurred significant losses since inception, and we expect to incur continued and increasing losses over the next several years and may never achieve or maintain profitability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we will need substantial additional funding to support our operations and pursue our growth strategy. If we are
unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our limited operating history may make it difficult for you to evaluate the success of our business to date and
to assess our future viability; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our recurring losses and negative cash flows have raised substantial doubt regarding our ability to continue as a
going concern, and the report of our independent registered public accounting firm for the year ended December&nbsp;31, 2019 includes an explanatory paragraph indicating the conditions that raise substantial doubt about our ability to continue as a
going concern; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ongoing COVID-19 pandemic may, directly or indirectly, adversely affect our business, results of operations
and financial condition; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our approach to the treatment of retinal diseases is unproven, and we do not know whether we will be able to
successfully develop any products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have not yet successfully initiated or completed any Phase 3 clinical trials nor commercialized any
pharmaceutical products, which may make it difficult to evaluate our future prospects; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we depend heavily on the success of our wet AMD product candidates, in particular
<FONT STYLE="white-space:nowrap">GB-102.</FONT> Clinical trials of our product candidates may not be successful. If we are unable to successfully complete clinical development of and obtain marketing approvals for our product candidates, or
experience significant delays in doing so, or if after obtaining marketing approvals, we fail to commercialize these product candidates, our business will be materially harmed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if clinical trials of <FONT STYLE="white-space:nowrap">GB-102</FONT> or any other product candidate that we
develop fail to demonstrate safety and efficacy to the satisfaction of the U.S. Food and Drug Administration, the European Medicines Agency or other regulatory authorities or do not otherwise produce favorable results, we may incur
</P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
additional costs or experience delays in completing, or ultimately be delayed or unable to complete, the development and commercialization of such product candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the outcome of preclinical testing and early clinical trials may not be predictive of the success of later-stage
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if serious adverse or unacceptable side effects are identified during the development of <FONT
STYLE="white-space:nowrap">GB-102</FONT> or any other product candidates that we may develop, we may need to abandon or limit our development of such product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we face substantial competition, which may result in others discovering, developing or commercializing products
before or more successfully than we do; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manufacture of our product development candidates requires outsourced, custom manufacturing and we may
encounter difficulties in production, particularly with respect to formulation, process development or scaling up of our manufacturing capabilities. If we, or our CMOs, encounter such difficulties, our ability to provide supply of our product
candidates for preclinical studies, clinical trials or our products for patients, if approved, could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were
incorporated under the laws of the State of Delaware in February 2015 under the name Graybug, Inc. upon the conversion of Graybug LLC, a Maryland Limited Liability Company organized in May 2011. We subsequently changed our name to Graybug Vision,
Inc. in 2016. Our principal executive offices are located at 275 Shoreline Drive, Suite 450, Redwood City, CA, 94065, and our telephone number is (650) <FONT STYLE="white-space:nowrap">487-2800.</FONT> Our website address is www.graybug.com. The
information contained on, or that can be accessed through, our website is not part of, and is not incorporated by reference into, this prospectus. Investors should not rely on any such information in deciding whether to purchase our common stock.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All service marks, trademarks and trade names appearing in this prospectus are the property of their respective owners. Solely for
convenience, the trademarks and tradenames referred to in this prospectus appear without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and <SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> symbols, but those references are
not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the right of the applicable licensor to these trademarks and tradenames. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company and a Smaller Reporting Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a company with less than $1.07&nbsp;billion in revenue during our prior fiscal year, we qualify as an &#147;emerging growth company&#148; as
defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. An emerging growth company may take advantage of reduced reporting requirements that are otherwise applicable to public companies. These provisions include, but are not
limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">being permitted to present only two years of audited financial statements and only two years of related
Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with the independent registered public accounting firm attestation requirements on
the effectiveness of our internal controls over financial reporting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure obligations regarding executive compensation arrangements; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder
approval of any golden parachute payments not previously approved. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may use these provisions until the last day of
our fiscal year following the fifth anniversary of the completion of this offering. However, if certain events occur prior to the end of such five-year period, including </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
if we become a &#147;large accelerated filer,&#148; our annual gross revenues exceed $1.07&nbsp;billion or we issue more than $1.0&nbsp;billion of
<FONT STYLE="white-space:nowrap">non-convertible</FONT> debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have elected to take advantage of certain of the reduced disclosure obligations for emerging growth companies and smaller reporting
companies in the registration statement of which this prospectus is a part and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information that we provide to our stockholders may be different
than you might receive from other public reporting companies in which you hold equity interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The JOBS Act provides that an emerging
growth company can take advantage of an extended transition period for complying with new or revised accounting standards, until those standards apply to private companies. We have elected to use this extended transition period to enable us to
comply with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i)&nbsp;are no longer an emerging growth company or (ii)&nbsp;affirmatively and irrevocably opt
out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effect dates. Until the date that
we are no longer an emerging growth company or affirmatively and irrevocably opt out of the exemption provided by Section&nbsp;7(a)(2)(B) of the Securities Act of 1933, as amended, upon issuance of a new or revised accounting standard that applies
to our financial statements and that has a different effective date for public and private companies, we will disclose the date on which adoption is required for <FONT STYLE="white-space:nowrap">non-emerging</FONT> growth companies and the date on
which we will adopt the recently issued accounting standard. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also a &#147;smaller reporting company,&#148; meaning that the market
value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> plus the proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700.0&nbsp;million and our annual revenue is less than
$100.0&nbsp;million during the most recently completed fiscal year. We may continue to be a smaller reporting company after this offering if either (i)&nbsp;the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT>
is less than $250.0&nbsp;million or (ii)&nbsp;our annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal year and the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less
than $700.0&nbsp;million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies.
Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> and, similar to emerging
growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc796801_2"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock offered </P></TD>
<TD>4,687,500 shares </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding immediately <BR>after this offering </P></TD>
<TD>19,155,613 shares (or 19,858,738 shares, if the underwriters exercise their option to purchase additional shares in full) </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Option to purchase additional shares </P></TD>
<TD>We have granted the underwriters an option, exercisable for 30 days after the date of this prospectus, to purchase up to an additional 703,125 shares from us. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We estimate that the net proceeds from this offering will be approximately $65.8 million (or approximately $76.2 million if the underwriters exercise their option to purchase additional shares in full), based upon the assumed initial public
offering price of $16.00 per share, which is the midpoint of the estimated price range set forth on the cover of this prospectus, after deducting the estimated underwriting discounts and commissions and estimated offering expenses.
</TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We intend to use the net proceeds that we receive in this offering, together with our existing cash and cash equivalents: (i)&nbsp;to fund the development of <FONT STYLE="white-space:nowrap">GB-102,</FONT> including the
completion of our ongoing Phase 2b clinical trial in wet AMD, the initiation of our Phase 2b clinical trial in DME, the initiation of our Phase 3 clinical trials in wet AMD, and&nbsp;the initiation of our
<FONT STYLE="white-space:nowrap">GB-401</FONT> Phase 1 clinical trial in glaucoma; (ii)&nbsp;to fund Chemistry, Manufacturing and Controls capital expenditures; (iii)&nbsp;to fund arrangements with contract manufacturing organizations to manufacture
clinical material for our wet AMD and glaucoma clinical trials; and (iv)&nbsp;for working capital and general corporate purposes. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See the section entitled &#147;Use of Proceeds&#148; for additional information. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>You should read the section entitled &#147;Risk Factors&#148; in this prospectus for a discussion of factors to consider carefully before deciding to invest in shares of our common stock. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Proposed Nasdaq Global Market symbol </P></TD>
<TD>&#147;GRAY&#148; </TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering is based on (i)
1,382,200 shares of our common stock outstanding as of June 30, 2020 and (ii)&nbsp;the automatic conversion of all 117,809,883 shares of our outstanding convertible preferred stock as of June 30, 2020 into an aggregate of 13,085,913 shares of common
stock immediately prior to the completion of this offering, and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,066,076 shares of common stock issuable upon the exercise of options outstanding as of June&nbsp;30, 2020, with
a weighted-average exercise price of $2.52 per share under our 2015 Stock Incentive Plan, or 2015 Plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">428,621 shares of our common stock issuable upon the exercise of stock options granted after June 30, 2020, with
a weighted-average exercise price of $9.25 per share under our 2015 Plan; </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">27,759 shares of common stock issuable upon the exercise of a common stock warrant outstanding as of June 30,
2020, with an exercise price of $3.88 per share; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,708,587 shares of common stock reserved for future issuance under our stock-based compensation plans,
consisting of (i) 648,587 shares of common stock reserved for future issuance under our 2015 Stock Incentive Plan as of June 30, 2020, (ii) 1,850,000&nbsp;shares of common stock reserved for future issuance under our 2020 Equity Incentive Plan,
which will become effective on the date immediately prior to the date of this prospectus, which number will be reduced as a result of the grant of 166,624&nbsp;shares of common stock issuable upon the exercise of stock options (with an exercise
price equal to the initial public offering price) and restricted stock units covering 80,000&nbsp;shares of common stock, each to be granted on the date of this prospectus, and (iii) 210,000 shares of common stock reserved for future issuance under
our 2020 Employee Stock Purchase Plan, which will become effective on the date of this prospectus. Upon completion of this offering, any remaining shares available for issuance under our 2015 Stock Incentive Plan will be added to the shares reserved
under our 2020 Equity Incentive Plan and we will cease granting awards under our 2015 Stock Incentive Plan. Our 2020 Equity Incentive Plan and 2020 Employee Stock Purchase Plan also provide for automatic annual increases in the number of shares
reserved under the plans each year, as more fully described in &#147;Executive Compensation&#151;Equity Compensation Plans.&#148; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise indicated, all information in this prospectus assumes or gives effect to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the automatic conversion of all outstanding shares of our convertible preferred stock as of June&nbsp;30, 2020
into an aggregate of 13,085,913 shares of common stock immediately prior to the completion of this offering; </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effectiveness of our restated certificate of incorporation and restated bylaws in connection with the
completion of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">9.0058-for-1</FONT></FONT> reverse stock
split, which became effective on September&nbsp;18, 2020; </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise of outstanding options, warrants or stock purchase rights described above after June&nbsp;30, 2020;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise of the underwriters&#146; option to purchase additional shares of our common stock.
</P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUMMARY FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following tables present the summary financial data for our business. We derived the statements of operations data for the years ended
December&nbsp;31, 2019 and 2018 from our audited financial statements appearing elsewhere in this prospectus. The summary statements of operations data presented below for the six months ended June 30, 2020 and 2019 and the balance sheet data as of
June 30, 2020 are derived from our unaudited financial statements included elsewhere in this prospectus. Our unaudited interim condensed financial statements have been prepared on the same basis as our audited annual financial statements and
reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair statement of the information for the interim periods presented. The following summary financial data should be read with
&#147;Selected Financial Data,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our financial statements and related notes included elsewhere in this prospectus. Our historical results
are not necessarily indicative of the results that may be expected in any future period. The summary financial data in this section are not intended to replace the financial statements and are qualified in their entirety by the financial statements
and related notes included elsewhere in this prospectus. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended June 30, </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statements of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,836</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,609</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,502</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,570</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest and other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,663</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,558</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,037</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,378</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cumulative dividends on convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,793</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,585</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,055</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,317</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,456</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19,143</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(44,092</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,695</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per common share&#151;basic and
diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13.40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14.78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(33.41</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25.77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used in computing net loss per common share&#151;basic and
diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,377,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,295,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,319,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,268,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per common share&#151;basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.94</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.09</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used in computing pro forma net loss per common share&#151;basic
and diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,463,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,001,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See Notes 2, 13 and 14 of our audited financial statements for the years ended December&nbsp;31, 2019 and 2018
and Notes 9 and 10 of our unaudited financial statements for the six month periods ended June&nbsp;30, 2020 and 2019 included elsewhere in this prospectus for a description of the calculations of our basic and diluted net loss per common share, pro
forma basic and diluted net loss per common share, and the weighted-average number of shares used in the computation of the per share amounts. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June 30, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma&nbsp;As<BR>Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(2)(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="9" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">83,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(119,499</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(119,499</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(119,499</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(116,157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The pro forma balance sheet data give effect to the automatic conversion of all outstanding shares of our
convertible preferred stock as of June 30, 2020 into an aggregate of 13,085,913&nbsp;shares of common stock immediately prior to the completion of this offering. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The pro forma as adjusted balance sheet data give effect to (i)&nbsp;the pro forma adjustments above described
in footnote (1)&nbsp;and (ii) the receipt of $65.8 million in net proceeds from the sale of 4,687,500 shares of common stock in this offering, based upon an assumed initial public offering price of $16.00&nbsp;per share, which is the midpoint of the
estimated price range set forth on the cover of this prospectus, after deducting the estimated underwriting discounts and commissions and estimated offering expenses. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each $1.00 increase (decrease) in the assumed initial public offering price of $16.00&nbsp;per share, which is
the midpoint of the estimated price range set forth on the cover of this prospectus, would increase (decrease) each of our pro forma as adjusted cash and cash equivalents, working capital, total assets and total stockholders&#146; equity (deficit)
by approximately $4.4&nbsp;million, assuming that the number of shares offered, as set forth on the cover of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions. Similarly, each increase (decrease)
of 1.0&nbsp;million shares in the number of shares of common stock offered would increase (decrease) each of our pro forma as adjusted cash and cash equivalents, working capital, total assets and total stockholders&#146; equity (deficit) by
approximately $14.9&nbsp;million, assuming the assumed initial public offering price per share as set forth on the cover of this prospectus remains the same and after deducting estimated underwriting discounts and commissions. The pro forma as
adjusted information is illustrative only, and we will adjust this information based on the actual initial public offering price and other terms of this offering determined at pricing. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We define working capital as current assets less current liabilities. See our unaudited financial statements
and related notes included elsewhere in this prospectus for further details regarding our current assets and current liabilities. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In connection with our Series&nbsp;C convertible preferred stock financing, up to 17,014,902&nbsp;shares of
convertible preferred stock could have been issuable upon achievement of certain milestones. Subsequent to June&nbsp;30, 2020, the Series&nbsp;C stock purchase agreement was amended such that this option is no longer exercisable, and this option
will terminate upon the effectiveness of the registration statement of which this prospectus forms a part. The expiration of this purchase right would have the effect of reducing both liabilities and accumulated deficit by $2.1&nbsp;million. This
has not been reflected in the above balance sheet data. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc796801_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below
together with all of the other information contained in this prospectus, including our financial statements and the related notes appearing at the end of this prospectus, before deciding to invest in our common stock. If any of the following risks
actually occur, our business, prospects, operating results and financial condition could suffer materially. Additionally, to the extent the <FONT STYLE="white-space:nowrap">ongoing&nbsp;COVID-19&nbsp;public</FONT> health emergency adversely affects
our business and financial results, it may also have the effect of heightening many of the other risks incorporated by reference or set forth below. In such event, the trading price of our common stock could decline and you might lose all or part of
your investment. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Financial Position and Need For Additional Capital </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are a clinical-stage biopharmaceutical company with a limited operating history and no products approved. We have incurred significant losses since
inception, and we expect to incur continued and increasing losses over the next several years and may never achieve or maintain profitability. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception, we have incurred significant operating losses. Our net loss was $37.0&nbsp;million for the year ended December&nbsp;31, 2019
and $13.7 million for the six months ended June 30, 2020. As of December&nbsp;31, 2019 and June 30, 2020, we had an accumulated deficit of $105.8&nbsp;million and $119.5 million, respectively. To date, we have financed our operations primarily
through private placements of convertible preferred stock and convertible promissory notes. We have devoted substantially all of our financial resources and efforts to research and development, including preclinical studies and clinical trials and
general and administrative costs to support such efforts. We expect to continue to incur significant expenses and operating losses for the foreseeable future. Our net losses may fluctuate significantly from quarter to quarter and year to year, such
that a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> comparison of our results of operations may not be a good indication of our future performance. Our independent registered public accounting firm
included an explanatory paragraph in their audit report on our financial statements as of and for the years ended December&nbsp;31, 2018 and 2019 stating that our recurring losses from operations and negative cash flows since inception and our need
to raise additional funding to finance our operations raise substantial doubt about our ability to continue as a going concern. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
expect to continue to incur significant and increasingly higher expenses and operating losses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pursue the clinical development and potential commercialization of our most advanced product candidate, <FONT
STYLE="white-space:nowrap">GB-102,</FONT> which includes two Phase 3 clinical trials in wet <FONT STYLE="white-space:nowrap">age-related</FONT> macular degeneration, or wet AMD, and a Phase 2b clinical trial in diabetic macular edema, or DME,
starting in 2021; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">commence clinical trials of our product candidates <FONT STYLE="white-space:nowrap">GB-401</FONT> and <FONT
STYLE="white-space:nowrap">GB-103;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue the research and development of other product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek to identify and develop additional product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek marketing approvals for any of our product candidates that successfully complete clinical development;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">develop and expand our sales, marketing and distribution capabilities for any of our product candidates for which
we obtain marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">scale up our manufacturing processes and capabilities or, in the future, establish and operate a manufacturing
facility, to support sales of our product candidates, our ongoing clinical trials of our product candidates and commercialization of any of our product candidates for which we obtain marketing approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain, expand and protect our intellectual property portfolio; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expand our operational, financial and management systems and personnel, including personnel to support our
clinical development, manufacturing and commercialization efforts and our operations as a public company; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increase our product liability and clinical trial insurance coverage as we expand our clinical trials and
commercialization efforts. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and uncertainties associated with pharmaceutical product
development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Our expenses will increase if: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are required by the U.S. Food and Drug Administration, or the FDA, the European Medicines Agency, or the EMA,
or any additional international regulatory agency to perform trials or studies in addition to those currently expected; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there are any delays in receipt of regulatory clearances or approvals to begin our planned clinical programs; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there are any delays in enrollment of patients in or completing our clinical trials or the development of our
product candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have no product sales. We do not expect sales of any product candidate in the near future. For
us to become profitable, we will need to succeed in developing and commercializing products. This will require us to be successful in a range of challenging activities, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successfully completing clinical development of our product candidates, which will require establishing a
strategic partnership; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining marketing approval for these product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing at commercial scale and selling and distributing those products for which we obtain marketing
approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">achieving an adequate level of market acceptance of and obtaining and maintaining coverage and adequate
reimbursement from third-party payors for our products, which will require establishing a strategic partnership; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">protecting our rights to our intellectual property portfolio. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may never succeed in these activities and may never generate revenue that is sufficient or great enough to achieve profitability. Even if
we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would reduce the value of our company and could impair our ability to raise capital,
expand our business, maintain our research and development efforts, diversify our product offerings or even continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will need substantial additional funding to support our operations and pursue our growth strategy. If we are unable to raise capital when needed, we
could be forced to delay, reduce or eliminate our product development programs or commercialization efforts. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to devote
substantial financial resources to our ongoing and planned activities, particularly as we conduct clinical trials for our wet AMD product candidates, in particular, late-stage clinical trials for <FONT STYLE="white-space:nowrap">GB-102,</FONT>
preclinical studies and clinical trials for our other product candidates, and seek marketing approval for any such product candidate for which we obtain favorable clinical results. We also expect to devote significant financial resources to
conducting research and development and potentially seeking regulatory approval for our other product candidates. In addition, we plan to devote substantial financial resources to our commercialization
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
efforts, including product manufacturing, sales, marketing and distribution for any of our product candidates for which we obtain marketing approval. Accordingly, we will need to obtain
substantial additional funding in connection with our continuing and planned operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or
any future commercialization efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our independent registered public accounting firm included an explanatory paragraph in their audit
report on the financial statements and related notes as of and for the years ended December&nbsp;31, 2019 and 2018 stating that our recurring losses from operations and negative cash flows since inception and our need to raise additional funding to
finance our operations raise substantial doubt about our ability to continue as a going concern. See &#147;<I>Our recurring losses and negative cash flows have raised substantial doubt regarding our ability to continue as a going concern, and the
report of our independent registered public accounting firm for the year ended December 31, 2019 includes an explanatory paragraph</I> <I>indicating the conditions that raise substantial doubt about our ability to continue as a going
concern</I>&#148; below for additional information. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June 30, 2020, we had cash and cash equivalents of $17.5&nbsp;million. We
believe that the net proceeds from this offering, together with our existing cash and cash equivalents, will enable us to fund our operating expenses and capital expenditure requirements into the fourth quarter of 2021. We have based this estimate
on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our future funding requirements will depend on many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, costs and outcome of the clinical trials of our product candidates, in particular <FONT
STYLE="white-space:nowrap">GB-102;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, costs and outcome of preclinical development and clinical trials of our other product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs, timing and outcome of regulatory review of our product candidates by the FDA, the EMA or other
regulatory authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of manufacturing, sales, marketing, distribution and other commercialization efforts with respect to
any products for which we obtain marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to receipt of marketing approval, revenue received from product sales; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our headcount growth and associated costs as we expand our research and development and establish a commercial
infrastructure; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we choose to establish collaboration, distribution or other marketing arrangements for our
products and product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of competing technological and market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our
intellectual property rights and defending any intellectual property-related claims; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we acquire or invest in other businesses, products and technologies; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete. We may
never generate the necessary data or results required to obtain regulatory approval of products with the market potential sufficient to enable us to achieve profitability. We do not expect to generate sales of any commercial product for several
years, if at all. Accordingly, we may need to obtain substantial additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. In addition, we may seek additional
capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our limited operating history may make it difficult for you to evaluate the success of our business to
date and to assess our future viability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an early-stage company. Our operations to date have been limited to organizing and
staffing our company, acquiring rights to intellectual property, business planning, raising capital, developing our technology, identifying potential product candidates, undertaking preclinical studies and clinical trials and manufacturing initial
quantities of our products and product candidates. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, as a new business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors.
We will need to transition from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our financial condition and operating results to continue to fluctuate significantly from <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">quarter-to-quarter</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-year</FONT></FONT> due to a variety of factors, many of which are beyond our control. Accordingly, you should
not rely upon the results of any quarterly or annual period as an indication of future operating performance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our recurring losses and negative
cash flows have raised substantial doubt regarding our ability to continue as a going concern, and the report of our independent registered public accounting firm for the year ended December&nbsp;31, 2019 includes an explanatory paragraph indicating
the conditions that raise substantial doubt about our ability to continue as a going concern. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our cash balances,
recurring losses and our projected spending, there is a substantial doubt about our ability to continue as a going concern. If we are unable to obtain sufficient capital in this offering, even if the offering is consummated, our business, financial
condition and results of operations will be materially and adversely affected, and we will need to obtain alternative financing or significantly modify our operational plans to continue as a going concern. If we are unable to continue as a going
concern, we might have to liquidate our assets and, the values we receive for our assets in liquidation or dissolution could be significantly lower than the values reflected in our financial statements. Further, even if we successfully complete and
receive net proceeds from this offering, given our planned expenditures for the next several years, including, expenditures in connection with our clinical trials of <FONT STYLE="white-space:nowrap">GB-102,</FONT>
<FONT STYLE="white-space:nowrap">GB-103</FONT> and <FONT STYLE="white-space:nowrap">GB-401</FONT> and other new compounds, we may conclude, in connection with the issuance of our financial statements for any subsequent period, that there is
substantial doubt regarding our ability to continue as a going concern. In addition, our lack of cash resources and our potential inability to continue as a going concern may materially adversely affect the price of our common stock and our ability
to raise new capital or to enter into critical contractual relations with third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, our independent registered public
accounting firm included an explanatory paragraph in their audit report on the financial statements as of and for the years ended December&nbsp;31, 2018 and 2019 stating that our recurring losses from operations and negative cash flows since
inception and our need to raise additional funding to finance our operations raise substantial doubt about our ability to continue as a going concern. The inclusion of a&nbsp;going&nbsp;concern&nbsp;explanatory paragraph by our auditors, our lack of
cash resources and our potential inability to continue as a&nbsp;going&nbsp;concern&nbsp;may materially adversely affect our share price and our ability to raise new capital or to enter into critical contractual relations with third parties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Product Development, Regulatory Approval and Commercialization </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B><I>The ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may, directly or indirectly, adversely affect our business, results of
operations and financial condition</I></B><B>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business could be materially adversely affected, directly or indirectly, by the
widespread outbreak of contagious disease, including the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, which has spread to many of the countries in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which we and our suppliers do business. National, state and local governments in affected regions have implemented and may continue to implement safety precautions, including quarantines, border
closures, increased border controls, travel restrictions, shelter in place orders and shutdowns, business closures, cancellations of public gatherings and other measures. Organizations, businesses and individuals are taking additional steps to avoid
or reduce infection, including business and facility closures or suspensions, limitations on travel and remote working measures. These measures are disrupting normal business operations both in and outside of affected areas and have had significant
negative impacts on businesses and financial markets worldwide. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has caused
us to modify our business practices (including but not limited to curtailing or modifying employee travel, moving to full remote work for many employees, and cancelling physical participation in meetings, events and conferences) and we may take
further actions as may be required by government authorities or that we determine are in the best interests of our employees, patients and business partners. Our office-based employees have been working from home since March 2020, while we ensure
essential staffing levels in our physical operations remain in place, including maintaining key personnel in our laboratories. Further, given that a greater number of our employees are working remotely than usual in response to the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic and related government actions, we could be exposed to greater risks related to cybersecurity and our information technologies systems. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding these measures, the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic could affect the health and availability of our
workforce as well as those of the third parties we rely on taking similar measures. If members of our management and other key personnel in critical functions across our organization are unable to perform their duties or have limited availability
due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, we may not be able to execute on our business strategy and/or our operations may be negatively impacted. We may also experience limitations in employee resources, including
because of sickness of employees or their families or the desire of employees to avoid contact with individuals or large groups of people. In addition, we have experienced and will continue to experience disruptions to our business operations
resulting from quarantines, self-isolations and other restrictions on the ability of our employees to perform their jobs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Separately, in
response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, in March 2020, the FDA announced its intention to postpone most foreign inspections of manufacturing facilities and temporarily postpone routine surveillance inspections of
domestic manufacturing facilities. In July 2020, the FDA announced that it intended to restart <FONT STYLE="white-space:nowrap">on-site</FONT> inspections based on its determination of when and where it is safest to conduct prioritized domestic
inspections. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. If a prolonged government shutdown occurs, or if
global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory
authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic has disrupted business operations. The extent and severity of the impact on our business and clinical trials will be determined largely by the extent of disruptions in the supply chains for <FONT
STYLE="white-space:nowrap">GB-102</FONT> and our future product candidates and delays in the conduct of current and future clinical trials. Further, our ability to continue our clinical trials may be adversely affected, directly or indirectly, by
the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. Currently we are experiencing disruptions in our ability to monitor patients in person due to clinics and hospitals closing sites or diverting the resources that are necessary to conduct
our clinical trials to care for <FONT STYLE="white-space:nowrap">COVID-19</FONT> patients. Further, our suppliers, vendors and manufacturing and clinical trial partners have been adversely affected by the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, including by adversely impacting the ability of their employees to get to their places of work and maintain the continuity of their <FONT STYLE="white-space:nowrap">on-site</FONT>
operations. <FONT STYLE="white-space:nowrap">COVID-19</FONT> could potentially lead to the closure of our research lab and potentially delay <FONT STYLE="white-space:nowrap">IND-enabling</FONT> activities, which could delay the start of clinical
trials. In addition, the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on the operations of the FDA and other health authorities may delay potential approvals of <FONT STYLE="white-space:nowrap">GB-102</FONT> and our future
product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has also impacted and may
further impact the global economic and capital markets, including by negatively impacting capital markets, which may adversely affect our business, liquidity and access to capital. It is further possible that the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic will cause an economic slowdown of potentially extended duration, and it is possible it could cause a global recession. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While it is not possible at this time to estimate the entirety of the impact that the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic will have on our business, operations, employees, customers or suppliers, continued spread of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> measures taken by governments, actions taken to protect employees and the broad impact of the
pandemic on all business activities may materially and adversely affect our business, results of operations and financial condition, and the nature and extent of such impact is highly uncertain and unpredictable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our approach to the treatment of retinal diseases is unproven, and we do not know whether we will be able to successfully develop any products.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">GB-102</FONT> is designed to deliver therapeutic drug levels to the retinal tissue for up to six
months from a single intravitreal injection. There are currently no <FONT STYLE="white-space:nowrap">FDA-approved</FONT> therapies that treat retinal diseases with a <FONT STYLE="white-space:nowrap">six-month</FONT> dosing regimen. Our future
success depends on the successful development of product candidates, including <FONT STYLE="white-space:nowrap">GB-102,</FONT> based on this novel therapeutic approach. We have not yet demonstrated efficacy and safety for <FONT
STYLE="white-space:nowrap">GB-102</FONT> or any other product candidates in a pivotal trial or obtained marketing approval of any product candidate. <FONT STYLE="white-space:nowrap">GB-102</FONT> may not demonstrate in patients any or all of the
pharmacological benefits we believe it may possess. If we are unsuccessful in our development efforts, we may not be able to advance the development of <FONT STYLE="white-space:nowrap">GB-102</FONT> or any other product candidate, commercialize
products, raise capital, expand our business or continue our operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have not yet successfully initiated or completed any Phase 3 clinical
trials nor commercialized any pharmaceutical products, which may make it difficult to evaluate our future prospects. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
operations to date have been limited to financing and staffing our company, developing our technology and conducting preclinical research and Phase 1 and Phase 2 clinical trials for our product candidates. We have not yet demonstrated an ability to
successfully initiate or complete Phase 3 clinical trials, obtain marketing approvals, manufacture a commercial-scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful
product commercialization. Accordingly, you should consider our prospects in light of the costs, uncertainties, delays and difficulties frequently encountered by clinical-stage biopharmaceutical companies such as ours. Any predictions made about our
future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing pharmaceutical products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving our business
objectives. We will eventually need to transition from a company with a development focus to a company capable of supporting commercial activities. We may not be successful in such a transition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We depend heavily on the success of our wet AMD product candidates, in particular <FONT STYLE="white-space:nowrap">GB-102.</FONT> Clinical trials of our
product candidates may not be successful. If we are unable to successfully complete clinical development of, and obtain marketing approvals for, our product candidates, or experience significant delays in doing so, or if after obtaining marketing
approvals, we fail to commercialize these product candidates, our business will be materially harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have devoted a
significant portion of our financial resources and business efforts to the development of our product candidates for diseases and conditions of the eye. In particular, we are investing substantial resources to complete the development of <FONT
STYLE="white-space:nowrap">GB-102</FONT> for wet AMD. We cannot accurately predict when or if any of our retinal disease product candidates will prove effective or safe in humans or whether these product candidates will receive marketing approval.
Our ability to generate product revenues sufficient to achieve profitability will depend heavily on our obtaining marketing approval for and commercializing <FONT STYLE="white-space:nowrap">GB-102.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The success of <FONT STYLE="white-space:nowrap">GB-102</FONT> and other product candidates
will depend on many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful completion of preclinical studies and clinical trials that demonstrate to the satisfaction of the FDA,
the EMA or comparable foreign regulatory authorities that our product candidates are safe and effective for any of their proposed indications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acceptance of our products, if and when approved, by patients, the medical community and third-party payors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effectively competing with other therapies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining a continued acceptable safety profile of our products following approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and maintaining coverage and adequate reimbursement from third-party payors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">applying for and receiving marketing approvals from applicable regulatory authorities for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">scaling up our manufacturing processes and capabilities to support additional or larger clinical trials of our
product candidates and commercialization of any of our product candidates for which we obtain marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing, validating and maintaining a commercially viable manufacturing process that is compliant with current
good manufacturing practices; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing and expanding our sales, marketing and distribution capabilities and launching commercial sales of our
product candidates, if and when approved, whether alone or in collaboration with others; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">minimizing and managing any delay or disruption to our ongoing or planned clinical trials, and any adverse
impacts to the U.S. and global market for pharmaceutical products, as a result of the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">protecting our rights in our intellectual property portfolio. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to
successfully commercialize our product candidates, which would materially harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If clinical trials of
<FONT STYLE="white-space:nowrap">GB-102</FONT> or any other product candidate that we develop fail to demonstrate safety and efficacy to the satisfaction of the FDA, the EMA or other regulatory authorities or do not otherwise produce favorable
results, we may incur additional costs or experience delays in completing, or ultimately be delayed or unable to complete, the development and commercialization of such product candidate. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, including
<FONT STYLE="white-space:nowrap">GB-102,</FONT> we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans<I>.</I><I></I>&nbsp;Clinical testing is
expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome<I>.</I><I></I>&nbsp;A failure of one or more clinical trials can occur at any stage of testing<I>.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We designed our Phase 1/2a, Phase 2a and Phase 2b clinical trials of <FONT STYLE="white-space:nowrap">GB-102</FONT> to assess safety and
preliminary efficacy and did not power the trials to measure any efficacy endpoints with statistical significance. We expect that our Phase 3 clinical trials for <FONT STYLE="white-space:nowrap">GB-102</FONT> for the treatment of wet AMD will be the
first clinical trial for <FONT STYLE="white-space:nowrap">GB-102</FONT> to be powered with an appropriate number of patients to allow us to measure with statistical significance the <FONT STYLE="white-space:nowrap">non-inferiority</FONT> of <FONT
STYLE="white-space:nowrap">GB-102</FONT> compared to the standard of care. As a result, favorable results from our Phase 1/2a, Phase 2a and Phase 2b clinical trials may not necessarily predict a likelihood of achieving statistical significance of
our primary efficacy endpoint in the Phase 3 clinical trials, which will be required for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
us to obtain marketing approval of <FONT STYLE="white-space:nowrap">GB-102.</FONT> Additionally, our clinical trials are only evaluating <FONT STYLE="white-space:nowrap">GB-102</FONT> against
treatment with Eylea, and there may be current or future products that deliver better results in terms of safety and/or efficacy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
success of our product candidates is dependent upon the drug-elution profile during the course of intended therapy. Our Phase 1/2a and our Phase 2a trials have been open label and have not been compared to any active treatments. The ongoing Phase 2b
trial with <FONT STYLE="white-space:nowrap">GB-102</FONT> in wet AMD contains a control arm with Eylea, which is the current standard of care. It is possible that, compared to Eylea, <FONT STYLE="white-space:nowrap">GB-102</FONT> will not
demonstrate sufficient efficacy, durability and safety. For example, in our Phase 2a clinical trial of <FONT STYLE="white-space:nowrap">GB-102,</FONT> three of ten patients in the 1 mg dose and five out of 11 in the 2 mg dose experienced adverse
events, or AEs, with the most common being presence of medication in the anterior chamber. We have since terminated the development of the 2 mg dose of <FONT STYLE="white-space:nowrap">GB-102</FONT> in all of our clinical trial programs. If we
determine to make any future changes to the formulation, such changes could affect the outcome of any subsequent clinical trials. As a result of any of these therapeutic or formulation changes, the outcome of our Phase 2b clinical trial or Phase 3
clinical trials may differ from the outcome of our Phase 1/2a clinical trial. If the results of clinical trials with any potential new therapeutic or product formulation, including therapies that do not involve intravitreal delivery, differs from
the Phase 1/2a results, we may not be able to obtain regulatory approvals or, even if approved, achieve market acceptance of our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The outcome of preclinical testing and early clinical trials may not be predictive of the success of later-stage clinical trials. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interim results of a clinical trial do not necessarily predict final results<I>.</I><I></I>&nbsp;In addition, successful results in preclinical
or early clinical trials do not ensure that later-stage clinical trials will be successful. In January 2019, we completed our Phase 1/2a trial of <FONT STYLE="white-space:nowrap">GB-102</FONT> evaluating various doses of <FONT
STYLE="white-space:nowrap">GB-102</FONT> in patients with wet AMD. Although the data indicated that <FONT STYLE="white-space:nowrap">GB-102</FONT> was well-tolerated and reduced the need for supportive anti-vascular endothelial growth factor, or
anti-VEGF, treatments, these results may not be indicative of future clinical trials with different designs. Moreover, as is common for early trials, in our Phase 1/2a trial, we looked at a number of efficacy measures without accounting for
multiplicity. Accordingly, it is possible that positive results, including nominally statistically significant results, observed in our Phase 1/2a trial will not be replicated in our ongoing Phase 2b trial with a different design or in other future
trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We tested two doses of an optimized formulation of <FONT STYLE="white-space:nowrap">GB-102</FONT> in the Phase 2a macular edema,
or ME, clinical trial and in the Phase 2b in wet AMD. However, we observed that there were more incidences of medication present in the anterior chamber with the 2 mg dose of <FONT STYLE="white-space:nowrap">GB-102,</FONT> which, in a single
patient, resulted in two serious adverse events, or SAEs (severe vision loss due to presence of medication in anterior chamber and corneal edema as a result of <FONT STYLE="white-space:nowrap">wash-out</FONT> of the anterior chamber). On the basis
of a safety analysis of the Phase 2a trial and an interim safety analysis of the data in the Phase 2b trial, we terminated the development of the 2 mg dose of <FONT STYLE="white-space:nowrap">GB-102</FONT> in all of our clinical trial programs,
resulting in a pause of our Phase 2a trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of our clinical trials, including our Phase 1/2a clinical trial and our ongoing Phase 2b
clinical trial of <FONT STYLE="white-space:nowrap">GB-102</FONT> for the treatment of wet AMD, had or have small patient populations, making it difficult to predict whether the favorable results from such trials will be repeatable in larger, more
advanced clinical trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and
clinical trials have nonetheless failed to obtain marketing approval of their products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if the results of future Phase 3 clinical
trials are positive, we may have to commit substantial time and additional resources to conducting further preclinical studies and clinical trials before obtaining FDA approval for any of our drug candidates.<B> </B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If serious adverse or unacceptable side effects are identified during the development of <FONT
STYLE="white-space:nowrap">GB-102</FONT> or any other product candidates that we may develop, we may need to abandon or limit our development of such product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If <FONT STYLE="white-space:nowrap">GB-102</FONT> or any of our other product candidates are associated with SAEs or other undesirable side
effects in clinical trials or have characteristics that are unexpected, we may need to abandon their development or limit development to more narrow uses or subpopulations in which the SAEs, undesirable side effects or other characteristics are less
prevalent, less severe or more acceptable from a risk-benefit perspective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Out of 32 patients enrolled in our Phase 1/2a trial, no <FONT
STYLE="white-space:nowrap">GB-102</FONT> related <FONT STYLE="white-space:nowrap">non-ocular</FONT> adverse events, or AEs, and no SAEs or dose limiting toxicities were reported. All drug-related AEs were mild or moderate and transient and resolved
by the end of the trial. The most common AE observed in more than one patient was vitreous floaters (n=5). Most vitreous floaters are caused by age-related changes that occur as the vitreous becomes more liquid. Microscopic fibers in the vitreous
tend to clump and can cast tiny shadows on the retina, commonly referred to as floaters. Intravitreal injections can increase the number of floaters, and any other particle that similarly casts a shadow may also be referred to as a floater. For nine
patients enrolled in the higher dose cohorts, medication presence was observed in the anterior chamber. All nine of those patients completed the trial. Overall, the medication presence in the anterior chamber appeared to be self-limited and
reversible, with no long-term consequences. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our Phase 2a clinical trial, there were no drug related
<FONT STYLE="white-space:nowrap">non-ocular</FONT> AEs. The patients in the 1 mg dose experienced nine drug related AEs, and seven out of ten patients demonstrated no AEs. One patient had only vitreous floaters and one patient had vitreous floaters,
medication present in the vitreous, and reduction in vision. The other AEs occurred in a single patient with medication present in the anterior chamber. The 2 mg dose was associated with medication present in the anterior chamber in five out of 11
patients. The majority of AEs occurred in this patient. Two SAEs were reported in a single patient (severe vision loss due to presence of medication in the anterior chamber and corneal edema as a result of
<FONT STYLE="white-space:nowrap">wash-out</FONT> of the anterior chamber). We also conducted an interim safety analysis in the Phase 2b study. No drug related SAEs were reported in the Phase 2b study, but presence of medication in the anterior
chamber was reported in four patients in the <FONT STYLE="white-space:nowrap">GB-102</FONT> 2 mg dose group and one patient in the 1 mg dose group. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the basis of this data, we terminated the development of the 2 mg dose of <FONT STYLE="white-space:nowrap">GB-102</FONT> in all of our
clinical trial programs. We believe that the number of microparticles injected in the 2&nbsp;mg dose (approximately 2&nbsp;million) were too numerous to allow adequate aggregation. All patients in the Phase&nbsp;2b trial having received <FONT
STYLE="white-space:nowrap">GB-102</FONT> at either the 1&nbsp;mg or 2&nbsp;mg doses for the first <FONT STYLE="white-space:nowrap">six-month</FONT> period of the study have now received the 1&nbsp;mg dose as repeat therapy at month six.
Notwithstanding the results from our clinical trials to date, the 1 mg dose of <FONT STYLE="white-space:nowrap">GB-102,</FONT> as well as <FONT STYLE="white-space:nowrap">GB-102</FONT> for other indications and our other product candidates, may fail
to demonstrate favorable efficacy, safety and tolerability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are potential side effects that are related to intravitreal injection
procedures. These side effects are shared by any treatment that uses intravitreal injection as a means of delivering medication. These can include conjunctival hemorrhage, punctate keratitis, eye pain, conjunctival hyperemia, intraocular pressure
rise, intraocular inflammation, retinal detachment and endophthalmitis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finally, clinical trials by their nature utilize a sample of the
potential patient population. However, with a limited number of patients and limited duration of exposure, rare and severe side effects of our product candidates may only be uncovered when a significantly larger number of patients are exposed to the
product. If safety problems occur or are identified after one of our products reaches the market, the FDA, the EMA or other regulatory authorities may require that we amend the labeling of our product, recall our product or even withdraw approval
for our product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we experience any of a number of possible unforeseen events in connection with our clinical trials,
potential marketing approval or commercialization of our product candidates could be delayed or prevented. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may experience
numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our retinal disease product candidates or any other product candidates that we may develop,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trials of our product candidates may not produce statistically significant, positive results, and we may
decide, or regulators may require us, to conduct additional clinical trials or amend product development programs, or abandon product development programs entirely; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of patients required for clinical trials of our product candidates may be larger than we anticipate,
enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our contractors may fail to comply with regulatory requirements or meet their obligations to us in a timely
manner, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulators or institutional review boards may not authorize us or our investigators to commence a clinical trial
or conduct a clinical trial at a prospective trial site; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or
clinical trial protocols with prospective trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may decide, or regulators or institutional review boards may require us, to suspend or terminate clinical
research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of clinical trials of our product candidates may be greater than we anticipate; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the supply or quality of our clinical trial material or other materials necessary to conduct clinical trials of
our product candidates may be insufficient or inadequate. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are required to conduct additional clinical trials or
other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not favorable or
are only modestly favorable or if there are safety concerns, we may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be delayed in obtaining or unable to obtain marketing approval for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain approval for indications or patient populations that are not as broad as intended or desired;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be subject to additional post-marketing testing requirements; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">have the product removed from the market after obtaining marketing approval. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product development costs will also increase if we experience delays in testing or marketing approvals. We do not know whether any of our
preclinical studies or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant preclinical or clinical trial delays also could shorten any periods during which we may have the
exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed
or prevented. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to initiate or continue clinical trials for our wet AMD, DME, diabetic retinopathy, or DR, or
glaucoma product candidates or our other product candidates that we may develop if we are unable to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA, the EMA or similar regulatory authorities outside the United States. Although
there is a significant prevalence of disease in the areas of ophthalmology in which we are focused, we may nonetheless experience unanticipated difficulty with patient enrollment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A variety of factors affect patient enrollment, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prevalence and severity of the ophthalmic disease or condition under investigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the eligibility criteria for the study in question; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the perceived risks and benefits of the product candidate under study; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the perceived risks and benefits of switching patients from treatment with eye drops to intravitreal therapy, in
the case of certain glaucoma patients; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efforts to facilitate timely enrollment in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any delay or disruption to enrollment or attendance for injections as a result of the ongoing <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patient referral practices of physicians; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to monitor patients adequately during and after treatment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proximity and availability of experienced clinical trial sites for prospective patients;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the conduct of clinical trials by competitors for product candidates that treat the same indications as our
product candidates; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of adequate compensation for prospective patients. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays, could require us to
abandon one or more clinical trials altogether and could delay or prevent our receipt of necessary regulatory approvals. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which would cause
the value of our company to decline and limit our ability to obtain additional financing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in our efforts to develop
product candidates based on our proprietary technology other than <FONT STYLE="white-space:nowrap">GB-102</FONT> or expand the use of our proprietary technology for treating additional eye diseases and conditions. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently directing all of our development efforts towards applying our proprietary technology to product candidates that are designed
to provide sustained delivery of therapeutic agents to the eye using active pharmaceutical ingredients that are currently used in <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drugs. We have a number of product candidates at various stages of
development and are exploring the potential use of our proprietary technologies in other eye diseases and conditions. Our existing product candidates and any other potential product candidates that we identify may not be suitable for continued
preclinical or clinical development, including as a result of being shown to have harmful side effects or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance.
If we do not successfully develop and commercialize our product candidates that we develop based upon our technological approach, we will not be able to obtain substantial product revenues in future periods. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sunitinib, the active ingredient of <FONT STYLE="white-space:nowrap">GB-102</FONT> and <FONT STYLE="white-space:nowrap">GB-103,</FONT> has a boxed
warning regarding hepatotoxicity for its use in oncology indications. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sunitinib, which was originally developed for the treatment
of renal cell carcinoma and gastrointestinal stromal tumors, has been shown to cause liver damage, or hepatotoxicity, in some patients. As a result, in 2010, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the prescribing information for orally administered sunitinib for its use in treating renal cell carcinoma and gastrointestinal stromal tumors was revised to include a boxed warning regarding
hepatotoxicity. A boxed warning is a warning put in the labeling of a drug product that is designed to call attention to serious or life-threatening risks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no approved therapy for retinal diseases using sunitinib. We have not seen any evidence of hepatotoxicity in our preclinical studies
or clinical trials. Moreover, preclinical toxicity studies and the results of our Phase 1/2a clinical trials with <FONT STYLE="white-space:nowrap">GB-102</FONT> have not detected the presence of sunitinib in the systemic blood circulation at any
time point. However, the boxed warning for orally administered sunitinib may make it more difficult for us to achieve widespread market acceptance or regulatory approval for our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, there can be no assurance that comparable AEs and other side effects will appear over the course of our trials, which could have a
material adverse effect on our business and operating results. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may expend our limited resources to pursue a particular product candidate or
indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific
indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to
capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we
do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it
would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We intend to conduct,
and may in the future conduct, clinical trials for product candidates at sites outside of the United States, and the FDA may not accept data from trials conducted in such locations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to conditions
imposed by the FDA. For example, the clinical trial must be well-designed and conducted and performed by qualified investigators in accordance with ethical principles. The trial population must also adequately represent the U.S. population, and the
data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. In addition, while these clinical trials are subject to applicable local laws, FDA acceptance of the data will depend on its
determination that the trials also complied with all applicable U.S. laws and regulations. If the FDA does not accept the data from any trial that we conduct outside the United States, it would likely result in the need for additional trials, which
would be costly and time-consuming and delay or permanently halt our development of the applicable product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other risks
inherent in conducting international clinical trials include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign regulatory requirements that could restrict or limit our ability to conduct our clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">administrative burdens of conducting clinical trials under multiple sets of foreign regulations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure of enrolled patients to adhere to clinical protocols as a result of differences in healthcare services or
cultural customs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign exchange fluctuations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diminished protection of intellectual property in some countries; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">political and economic risks relevant to foreign countries. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business and operations would suffer in the event of computer system failures or security
breaches. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of our business, we collect, store and transmit confidential information, including intellectual
property, proprietary business information and personal information. Despite the implementation of security measures, our internal computer systems, and those of our contract research organizations, or CROs, and other third parties on which we rely,
are vulnerable to damage from computer viruses, unauthorized access, cyberattacks, natural disasters, fire, terrorism, war and telecommunication and electrical failures. Cyberattacks are increasing in their frequency, sophistication and intensity.
Cyberattacks could include the deployment of harmful malware, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">denial-of-service</FONT></FONT> attacks, social engineering and other means to affect service reliability and threaten
the confidentiality, integrity and availability of information. Significant disruptions of our information technology systems or security breaches could adversely affect our business operations and/or result in the loss, misappropriation, and/or
unauthorized access, use or disclosure of, or the prevention of access to, confidential information (including trade secrets or other intellectual property, proprietary business information and personal information), and could result in financial,
legal, business and reputational harm to us.&nbsp;If such disruptions were to occur and cause interruptions in our operations, it could result in a material disruption of our product development programs. For example, the loss of clinical trial data
from completed, ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Further, the COVID-19 pandemic has resulted in a significant number
of our employees and partners working remotely, which increases the risk of a data breach or issues with data and cybersecurity. To the extent that any disruption or security breach results in a loss of, or damage to, our data or applications, or
inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development of our future product candidates could be delayed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Manufacturing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We could
potentially contract with third parties for the production of our product candidates. This could increase the risk that we will not have sufficient quantities of our product candidates or such quantities at an acceptable cost, which could delay,
prevent or impair our development or commercialization efforts. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently rely on third parties for the production of <FONT
STYLE="white-space:nowrap">GB-102</FONT> and our product candidates for preclinical testing and clinical trials, including supply of active pharmaceutical ingredient drug substance, sunitinib, as well as polymers used in the formulations, such as <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">poly(lactic-co-glycolic</FONT></FONT> acid), or PLGA, and other raw materials and for sterilization of the finished product. We intend to build our own manufacturing capabilities, but could
also decide to keep contracting with third parties if it is more advantageous. While we believe that our existing manufacturing partners have facilities that will be sufficient to meet our requirements for manufacturing <FONT
STYLE="white-space:nowrap">GB-102</FONT> and any of our product candidates for which we obtain marketing approval, we may in the future need to rely on additional contract manufacturing organizations, or CMOs, for some aspects of the manufacture of
our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reliance on third parties for aspects of the supply of our product candidates entails additional risks,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lack of direct control over regulatory compliance and quality assurance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possible misappropriation of our proprietary information, including our trade secrets and <FONT
STYLE="white-space:nowrap">know-how;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possible breach of an agreement by the third party; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possible termination or nonrenewal of an agreement by the third party at a time that is costly or
inconvenient for us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, or our third-party suppliers or CMOs, may not be able to comply with quality assurance
standards, current good manufacturing practices regulations or similar regulatory requirements outside the United States. If we or our CMOs cannot successfully manufacture material that conforms to our specifications and the strict regulatory
requirements of the FDA and comparable regulatory authorities in other jurisdictions, if the quality and accuracy of the manufacturing and quality control data is compromised due to failure to adhere to protocols
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or to regulatory requirements or if we or our CMOs fail to maintain a compliance status acceptable to the FDA or comparable regulatory authorities in other jurisdictions, we may not be able to
secure and/or maintain regulatory approval for our product candidates. In addition, we or our CMOs must maintain adequate quality control, quality assurance and qualified personnel. If we or our CMOs cannot maintain a compliance status acceptable to
the FDA or a comparable regulatory authority in another jurisdiction, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates,
if approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any failure to achieve and maintain compliance with these laws, regulations and standards could subject us to the risk that
we may have to suspend the manufacturing of our product candidates and that obtained approvals could be revoked, which would adversely affect our business and reputation. Our failure, or the failure of our suppliers or CMOs, to comply with
applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or
products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products and product candidates. The same risks, however, would also apply to any internal manufacturing facilities,
should we in the future decide to build internal manufacturing capacity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our potential future dependence upon others for the manufacture
of our product candidates may adversely affect our future profit margins and our ability to commercialize any products that receive regulatory approval on a timely and competitive basis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The manufacture of our product development candidates requires outsourced, custom manufacturing and we may encounter difficulties in production,
particularly with respect to formulation, process development or scaling up of our manufacturing capabilities. If we, or our CMOs, encounter such difficulties, our ability to provide supply of our product candidates for preclinical studies, clinical
trials or our products for patients, if approved, could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As product candidates are developed, it is common that various aspects of the development program, such as manufacturing methods, are altered
along the way in an effort to optimize processes and results. For example, due to adverse events related to presence of medication in the anterior chamber observed in some patients in the Phase 1/2a trial for
<FONT STYLE="white-space:nowrap">GB-102,</FONT> changes were made to the manufacturing process for <FONT STYLE="white-space:nowrap">GB-102.</FONT> Such changes carry the risk that they will not achieve these intended objectives, and any of these
changes could cause our product candidates to perform differently and affect the results of planned preclinical studies or future clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently, <FONT STYLE="white-space:nowrap">GB-102</FONT> is manufactured by Lubrizol Life Science Health. Although we have secured sufficient
quantities of drug substance and drug product to supply our trials, we will need to obtain additional supplies from our own manufacturing or from third-party manufacturers that we have engaged, or expect to engage. Although we are working to develop
commercially viable manufacturing processes, doing so is a difficult and uncertain task, and there are risks associated with scaling to the level required for advanced clinical trials or commercialization, including, among others, cost overruns,
potential problems with process scale up, formulation or formulation changes, process reproducibility, stability issues, lot consistency and timely availability of reagents or raw materials. Any of these challenges could delay completion of
preclinical studies or clinical trials, require bridging studies or trials, or the repetition of one or more studies or trials, increase development costs, delay approval of our product candidates, impair commercialization efforts, increase our cost
of goods and have an adverse effect on our business, financial condition, results of operations and growth prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have no experience manufacturing any of our product candidates at a commercial scale. We, or our
CMOs, may be unable to successfully scale up manufacturing of our product candidates in sufficient quality and quantity, which would delay or prevent us from developing our product candidates and commercializing approved products, if any.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to conduct clinical trials of, and commercialize, our product candidates, we will need to manufacture them in large
quantities. We may, in the future, establish and operate our own manufacturing facility, which will require significant amounts of additional capital and adequate personnel infrastructure. We, or any manufacturing partners, may be unable to
successfully increase the manufacturing capacity for any of our product candidates in a timely or cost-effective manner, or at all. In addition, quality issues may arise during <FONT STYLE="white-space:nowrap">scale-up</FONT> activities. If we, or
any manufacturing partners, are unable to successfully scale up the manufacture of our product candidates in sufficient quality and quantity, the development, testing and clinical trials of that product candidate may be delayed or infeasible, and
regulatory approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in methods of product candidate manufacturing, including changes introduced by building our own manufacturing capabilities, may result in
additional costs or delay. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently rely on third parties for the production of <FONT STYLE="white-space:nowrap">GB-102</FONT>
and our product candidates for preclinical testing and clinical trials, including supply of active pharmaceutical ingredient drug substance, sunitinib, as well as polymers used in the formulations, such as PLGA and other raw materials and for
sterilization of the finished product. We intend to build our own manufacturing capabilities, and it is common that various aspects of the development program, such as manufacturing methods, may be altered in an effort to optimize yield,
manufacturing batch size, minimize costs and achieve consistent quality and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and
affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more
clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commercialize our product candidates and generate revenue. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our current operations are in two locations, and we or the third parties upon whom we depend may be adversely affected by earthquakes or other natural
disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
current operations are located in Baltimore, Maryland and Redwood City, California, and our clinical trials are currently conducted at a limited number of other sites. Any unplanned event, such as earthquake, flood, fire, explosion, extreme weather
condition, medical epidemic or pandemic, power shortage, telecommunication failure or other natural or manmade accidents or incidents that result in us being unable to fully utilize our facilities, or the manufacturing facilities of our CMOs, may
have a material and adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in
increased costs, delays in the development of our product candidates or interruption of our business operations. Earthquakes or other natural disasters could further disrupt our operations and have a material and adverse effect on our business,
financial condition, operating results and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our
research or manufacturing facilities or the manufacturing facilities of our CMOs, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The
disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business
continuity plans, which could have a material adverse effect on our business. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or
incident at these facilities, we cannot </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assure you that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities, or the manufacturing facilities of our CMOs, are unable to operate because of an
accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed. Any business interruption could have a material and adverse effect on our business, financial
condition, operating results and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Commercialization </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our products may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community
necessary for commercial success, and the market opportunity for these products may be smaller than we estimate. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">GB-102</FONT> or any of our product candidates that receives marketing approval may fail to gain market acceptance by physicians, patients, third-party payors and others in the medical community. We have not received
marketing approval and have not commercially launched <FONT STYLE="white-space:nowrap">GB-102</FONT> and cannot yet accurately predict whether it will gain market acceptance and become commercially successful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of market acceptance of <FONT STYLE="white-space:nowrap">GB-102</FONT> or any product candidate for which we obtain marketing
approval will depend on a number of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efficacy and potential advantages compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to offer our products for sale at competitive prices, particularly in light of the lower cost of
alternative treatments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the clinical indications for which the product is approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the convenience and ease of administration compared to alternative treatments, including the retention of <FONT
STYLE="white-space:nowrap">GB-102</FONT> as preferred treatment by patients and doctors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these
therapies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the strength of our marketing and distribution support; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of market introduction of competitive products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of third-party coverage and adequate reimbursement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prevalence and severity of any side effects; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any restrictions on the use of our products together with other medications. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, even though we believe that <FONT STYLE="white-space:nowrap">GB-102</FONT> will have a longer duration of effect compared to
approved treatments for wet AMD, it is possible that the market acceptance of <FONT STYLE="white-space:nowrap">GB-102,</FONT> if it is approved for marketing, could be less than anticipated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our assessment of the potential market opportunity for <FONT STYLE="white-space:nowrap">GB-102</FONT> and our other product candidates is
based on industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties. Industry publications and third-party research, surveys and studies generally indicate that their information
has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe these industry publications and third-party research, surveys and studies are reliable, we have
not independently verified such data. If the actual market for <FONT STYLE="white-space:nowrap">GB-102</FONT> or any of our product candidates is smaller than we expect, our product revenue may be limited, and it may be more difficult for us to
achieve or maintain profitability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to establish and maintain adequate sales, marketing and distribution capabilities, we
may not be successful in commercializing <FONT STYLE="white-space:nowrap">GB-102</FONT> or any product candidates if and when they are approved. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have no experience in the sales, marketing and distribution of drug and device products, or in building a commercial team to do so. To
achieve commercial success for <FONT STYLE="white-space:nowrap">GB-102</FONT> and any product candidate for which we obtain marketing approval, we will need to establish and maintain adequate sales, marketing and distribution capabilities, either
ourselves or through collaborations or other arrangements with third parties. If <FONT STYLE="white-space:nowrap">GB-102</FONT> is approved for marketing, we plan on commercializing <FONT STYLE="white-space:nowrap">GB-102</FONT> through our own
specialty sales force. Alternatively, we may rely on a network of independent distributors across the United States to sell <FONT STYLE="white-space:nowrap">GB-102.</FONT> We expect that a direct sales force will be required to effectively market
and sell <FONT STYLE="white-space:nowrap">GB-102.</FONT> We cannot be certain when, if ever, we will recognize revenue from commercialization of our product candidates in any international market. If we decide to commercialize our potential products
outside of the United States, we expect to utilize a variety of collaboration, distribution and other marketing arrangements with one or more third parties. These may include independent distributors, pharmaceutical companies or our own direct sales
organization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are risks involved with both establishing our own sales, marketing and distribution capabilities and with entering
into arrangements with third parties to perform these services. We may not be successful in entering into arrangements with third parties to sell, market and distribute our products or may be unable to do so on terms that are most beneficial to us.
We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to market, sell and distribute our products effectively. Our product revenues and our profitability, if any, under
third-party collaboration, distribution or other marketing arrangements may also be lower than if we were to sell, market and distribute a product ourselves. On the other hand, recruiting and training a sales force is expensive and time-consuming
and could delay any product launch. If the commercial launch of any product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily
incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other factors that may inhibit our efforts to commercialize products on our own include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to use
or prescribe our products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of complementary products to be offered by sales personnel, which may put us at a competitive
disadvantage relative to companies with more extensive product lines; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unforeseen costs and expenses associated with creating an independent sales and marketing organization.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we do not establish sales, marketing and distribution capabilities successfully, either on our own or in
collaboration with third parties, we will not be successful in commercializing <FONT STYLE="white-space:nowrap">GB-102</FONT> or any of our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The development and commercialization of new drug and device products is highly competitive. We face competition with respect to
our product candidates that we may seek to develop or commercialize, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. Potential competitors also include academic institutions, government
agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current standard of care for wet AMD is monotherapy administration of anti-VEGF drugs,
principally Eylea, Avastin and Lucentis, which are well-established therapies and are widely accepted by physicians, patients and third-party payors, as well as Beovu, the most recently approved anti-VEGF drug. There are also several product
candidates in late-stage clinical development, including those being developed by F. <FONT STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche AG, Kodiak Sciences Inc., Chengdu Kanghong Pharmaceutical Group Co., Ltd and Opthea Limited. Physicians,
patients and third-party payors may not accept the addition of <FONT STYLE="white-space:nowrap">GB-102</FONT> to their current treatment regimens for a variety of potential reasons, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if they do not wish to incur the additional cost, if any, of <FONT STYLE="white-space:nowrap">GB-102;</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if they perceive the addition of <FONT STYLE="white-space:nowrap">GB-102</FONT> to be of limited benefit to
patients compared to existing treatment options; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if sufficient coverage and reimbursement are not available; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if they do not perceive <FONT STYLE="white-space:nowrap">GB-102</FONT> to have a favorable risk-benefit profile.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <FONT STYLE="white-space:nowrap">GB-102</FONT> as an alternative to existing anti-VEGF drugs,
including Eylea, Avastin, Lucentis, and Beovu. Accordingly, if approved, <FONT STYLE="white-space:nowrap">GB-102</FONT> would directly compete with these therapies. While we believe <FONT STYLE="white-space:nowrap">GB-102</FONT> will compete
favorably with existing anti-VEGF drugs, future approved standalone or combination therapies for wet AMD with demonstrated improved efficacy over <FONT STYLE="white-space:nowrap">GB-102</FONT> or currently marketed therapies with a favorable safety
profile and any of the following characteristics might pose a significant competitive threat to us: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a mechanism of action that does not involve VEGF; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a duration of action that obviates the need for twice-yearly intravitreal injection; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a method of administration that effectively avoids intravitreal injection; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant cost savings or reimbursement advantages compared to <FONT STYLE="white-space:nowrap">GB-102</FONT>
and other anti-VEGF therapies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also expect that product candidates currently in clinical development, or that could
enter clinical development in the near future, could represent additional competition, if approved. These product candidates may provide efficacy, safety, convenience and other benefits that are not provided by currently marketed therapies. Because
there are a variety of means to treat wet AMD, our patents and other proprietary protections for <FONT STYLE="white-space:nowrap">GB-102</FONT> will not prevent development or commercialization of product candidates that are different from <FONT
STYLE="white-space:nowrap">GB-102.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial opportunity could be reduced or eliminated if our competitors develop and
commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than our products. Our competitors also may obtain FDA or other regulatory approval for their products more
rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, certain of these products may be available on a biosimilar basis, and our
product candidates may not demonstrate sufficient additional clinical benefits to physicians, patients or payors to justify a higher price compared to generic products. In many cases, insurers or other third-party payors, particularly Medicare, seek
to encourage the use of biosimilar products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of the companies against which we are competing or against which we may compete in the
future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and
acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early stage companies may also prove to be significant competitors,
particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our
programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any product candidate for which we obtain marketing approval may become subject to unfavorable pricing regulations, third-party coverage
or reimbursement practices or healthcare reform initiatives, which could harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to commercialize our
product candidates that we may develop successfully will depend, in part, on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government healthcare programs, private health
insurers, managed care plans and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels.
A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications.
Increasingly, third-party payors are requiring that drug and device companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Coverage and reimbursement may not be available for
<FONT STYLE="white-space:nowrap">GB-102</FONT> or any other product that we commercialize and, even if they are available, the level of reimbursement may not be satisfactory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inadequate reimbursement may adversely affect the demand for, or the price of, <FONT STYLE="white-space:nowrap">GB-102</FONT> or any product
candidate for which we obtain marketing approval. Obtaining and maintaining adequate reimbursement for our products may be difficult. We may be required to conduct expensive pharmacoeconomic studies to justify coverage and reimbursement or the level
of reimbursement relative to other therapies. If coverage and adequate reimbursement are not available or reimbursement is available only to limited levels, we may not be able to successfully commercialize
<FONT STYLE="white-space:nowrap">GB-102</FONT> or any other product candidates for which we obtain marketing approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There may be
significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the indications for which the drug is approved by the FDA or similar regulatory authorities outside the United States.
Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution expenses. Interim reimbursement
levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on
reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private
payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations
in setting their own reimbursement policies. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any <FONT STYLE="white-space:nowrap">FDA-approved</FONT> products that we
develop would compromise our ability to generate revenues and become profitable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulations that govern marketing approvals, pricing,
coverage and reimbursement for new drug and device products vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in
obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets,
prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price
regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the product in that country. To obtain reimbursement or pricing approval in
some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. Adverse pricing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any product candidate for which we obtain marketing approval in the United States or in other countries may not be considered medically
reasonable and necessary for a specific indication, may not be considered cost-effective by third-party payors, coverage and an adequate level of reimbursement may not be available and reimbursement policies of third-party payors may adversely
affect our ability to sell our product candidates profitably. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Product liability lawsuits against us could cause us to incur substantial liabilities
and to limit commercialization of any products that we develop. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face an inherent risk of product liability exposure related to
the use of our product candidates that we develop in clinical trials. We face an even greater risk for any products we develop and sell commercially. If we cannot successfully defend ourselves against claims that our product candidates or products
caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased demand for any product candidates that we develop; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injury to our reputation and significant negative media attention; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of clinical trial participants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant costs to defend the related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial monetary awards to trial participants or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of revenue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced time and attention of our management to pursue our business strategy; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to commercialize any products that we develop. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently hold $10&nbsp;million in product liability insurance coverage, with a per incident limit of $250,000, which may not be adequate
to cover all liabilities that we may incur. We will need to increase our insurance coverage as we expand our clinical trials and should we eventually realize sales of any product candidate for which we obtain marketing approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate
to satisfy any liability that may arise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Dependence on Third Parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may enter into collaborations with third parties for the development and commercialization of <FONT STYLE="white-space:nowrap">GB-102</FONT> or other
product candidates. If our collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may utilize a variety of types of collaboration arrangements with third parties to develop or commercialize any of our product candidates.
We also may enter into arrangements with third parties to perform these services in the United States if we do not establish our own sales, marketing and distribution capabilities in the United States for our product candidates or if we determine
that such arrangements are otherwise beneficial. We also may seek collaborators for development and commercialization of other product candidates. Our likely collaborators for any sales, marketing, distribution, development, licensing or broader
collaboration arrangements include large and <FONT STYLE="white-space:nowrap">mid-size</FONT> pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. We are not currently party to any such arrangement.
Our ability to generate revenues from these arrangements will depend on our collaborators&#146; abilities and efforts to successfully perform the functions assigned to them in these arrangements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Collaborations that we enter into may pose a number of risks, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators have significant discretion in determining the amount and timing of efforts and resources that they
will apply to these collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not perform their obligations as expected; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not pursue development and commercialization of our product candidates that receive marketing
approval or may elect not to continue or renew development or commercialization programs based on results of clinical trials or other studies, changes in the collaborators&#146; strategic focus or available funding or external factors, such as an
acquisition, that divert resources or create competing priorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a
clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators could independently develop, or develop with third parties, products that compete directly or
indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with
their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve
regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the
preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in
litigation or arbitration, any of which would divert management attention and resources and be time-consuming and expensive; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary
information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation
and potential liability; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required
to raise additional capital to pursue further development or commercialization of the applicable product candidates. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner, or at all. If
any collaborations that we enter into do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or
royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our development of our product candidates could be delayed and we may need additional resources to develop our product candidates. All of
the risks relating to product development, regulatory approval and commercialization described in this prospectus also apply to the activities of our collaborators. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, subject to its contractual obligations to us, if a collaborator of ours were to be involved in a business combination, it might
deemphasize or terminate the development or commercialization of any product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
candidate licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and our perception in the business and
financial communities could be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are not able to establish additional collaborations, we may have to alter our development and
commercialization plans and our business could be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For some of our product candidates, we may decide to
collaborate with pharmaceutical, biotechnology and medical device companies for the development and potential commercialization of those product candidates. We face significant competition in seeking appropriate collaborators. Whether we reach a
definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#146;s evaluation
of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the product candidate, the costs
and complexities of manufacturing and delivering a product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such
ownership without regard to the merits of the challenge, and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on
and whether such a collaboration could be more attractive than the one with us for our product candidate. We may also be restricted under future license agreements from entering into agreements on certain terms with potential collaborators.
Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential
future collaborators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms or at all,
we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities,
or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and
additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may
not be able to further develop our product candidates or bring them to market or continue to develop our product platform. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have relied, and may
continue to rely, on third parties for certain aspects of our clinical development, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have relied and may continue to rely on third parties, such as CROs to conduct clinical trials of
<FONT STYLE="white-space:nowrap">GB-102</FONT> and other product candidates. If we deem necessary, we may engage CROs, clinical data management organizations, medical institutions and clinical investigators to conduct or assist in our clinical
trials or other clinical development work. If we are unable to enter into an agreement with a service provider when required, our product development activities would be delayed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our reliance on third parties for development activities reduces our control over these activities but does not relieve us of our
responsibilities. For example, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with standards,
commonly referred to as good clinical practices, or GCPs, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of
trial participants are protected. We are also required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
database, ClinicalTrials.gov, within specified timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. If we engage third parties and they do not
successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing
approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our
patent position does not adequately protect our product candidates, others could compete against us more directly, which would harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own and exclusively license a number of U.S. issued patents, pending U.S. provisional and
<FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications, as well as pending Patent Cooperating Treaty applications and associated foreign patents and patent applications. Our success depends in large part on our ability to obtain
and maintain patent protection both in the United States and in other countries for our product candidates. Our ability to protect our product candidates from unauthorized or infringing use by third parties depends in substantial part on our ability
to obtain and maintain valid and enforceable patents. Due to evolving legal standards relating to the patentability, validity and enforceability of patents covering pharmaceutical inventions and the scope of claims made under these patents, our
ability to maintain, obtain and enforce patents is uncertain and involves complex legal and factual questions. Accordingly, rights under any issued patents may not provide us with sufficient protection for our product candidates or provide
sufficient protection to afford us a commercial advantage against competitive products or processes. We cannot guarantee that any patents will issue from any pending or future patent applications owned by or licensed to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent prosecution process is expensive and time-consuming. We may not be able to file and prosecute all necessary or desirable patent
applications at a reasonable cost or in a timely manner. We may choose not to seek patent protection for certain innovations and may choose not to pursue patent protection in certain jurisdictions. Under the laws of certain jurisdictions, patents or
other intellectual property rights may be unavailable or limited in scope. It is also possible that we will fail to identify patentable aspects of our research and development before it is too late to obtain patent protection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently solely own or exclusively license patents and patent applications that encompass our proposed clinical assets. We do not control
the prosecution of the exclusively licensed patents and patent applications from Johns Hopkins University, or JHU, although we have input into the prosecution. In the future, we may choose to license additional patents or patent applications from
third parties that we conclude are useful or necessary for our business goals. We may not have the right to control the preparation, filing, prosecution or maintenance of such additional licensed patent applications. Therefore, if we do license
additional patents or patent applications in the future, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patent applications in the United States are maintained in confidence for up to 18 months after their filing. In some cases, however, patent
applications remain confidential in the U.S. Patent and Trademark Office, or PTO, for the entire time prior to issuance as a U.S. patent. Similarly, publication of discoveries in the scientific or patent literature often lags behind actual
discoveries. Consequently, we cannot be certain that we or our licensors were the first to invent, or the first to file patent applications on, our product candidates or their intended uses. Furthermore, we may not have identified all U.S. and
foreign patents or published applications that affect our business either by blocking our ability to commercialize our products or by covering similar technologies that affect our product market or patentability, or all prior art that could be
considered relevant to our patent claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The claims of any patents which have already issued or may issue in the future and are owned by
or licensed to us, may not confer on us significant commercial protection against competing products. Additionally, our patents may be challenged by third parties, resulting in the patent being deemed invalid, cancelled, unenforceable or narrowed in
scope, or the third party may circumvent any such issued patents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our patents may be challenged, for example, in a U.S. federal court or alternatively
challenged in an adversarial proceeding at the Patent Trial and Appeals Board, or PTAB, at the PTO, using an <I>Inter Partes</I> Review or Post Grant Review process. The cost of these procedures is often substantial, and it is possible that our
efforts would be unsuccessful resulting in a loss of our U.S. patent position. Further, even if a U.S. federal court or PTAB rules that a patent owned by us is valid and enforceable, if the other venue takes a contrary position, the patent can be
considered invalid and not enforceable. Therefore, a party seeking to invalidate a patent owned by or licensed to us in the United States has the procedural advantage of two alternative venues. To date, the PTAB has cancelled over 60% of the patent
claims it has reviewed and is considered to be a forum of choice for infringers for patent cancellation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also, our pending patent
applications may not issue, and we may not receive any additional patents. Our patents might not contain claims that are sufficiently broad to prevent others from utilizing our technologies. For instance,
<FONT STYLE="white-space:nowrap">GB-102</FONT> and <FONT STYLE="white-space:nowrap">GB-103</FONT> use our proprietary aggregating microparticle technologies to deliver sunitinib for ocular treatment. If a competitor develops a product that uses a
different particle or <FONT STYLE="white-space:nowrap">non-particle</FONT> technology to deliver sunitinib to the eye, it may be able to compete with us without infringing our owned or licensed patents after the patents on sunitinib expire in August
2021. <FONT STYLE="white-space:nowrap">GB-401</FONT> includes our proprietary beta-adrenergic blocking agent prodrug molecule in our proprietary aggregating microparticle technology. If a competitor develops a product that uses a different prodrug
of the same beta-blocker, or the beta-blocker itself, or uses a delivery system that is different from our proprietary aggregating microparticle technologies, then it may be able to compete with our <FONT STYLE="white-space:nowrap">GB-401</FONT>
product without infringing our owned or licensed patent claims. Consequently, our competitors may independently develop competing products that do not infringe our patents or other intellectual property. To the extent a competitor can develop
similar products using a different delivery system, microparticle or molecule, our patents may not prevent them from directly competing with us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Leahy-Smith America Invents Act, or America Invents Act, was signed into law in September 2011, and many of the substantive changes became
effective in March 2013. The America Invents Act revised U.S. patent law in part by changing the standard for patent approval from a &#147;first to invent&#148; standard to a &#147;first to file&#148; standard and developing a post-grant review
system. This legislation changes U.S. patent law in a way that may weaken our ability to obtain patent protection in the United States for those applications filed after March 2013. For example, if we were the first to invent a new product or its
use, but another party is the first to file a patent application on this invention, under the new law the other party may be entitled to the patent rights on the invention. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The America Invents Act created for the first time new procedures to challenge issued patents in the United States, including post-grant
review and <I>inter partes</I> review proceedings, which some third parties have been using to cause the cancellation of selected or all claims of issued patents of competitors. For a patent with a priority date of March&nbsp;16, 2013 or later, a
petition for post-grant review can be filed by a third party in a nine-month window from issuance of the patent. A petition for <I>inter partes</I> review can be filed immediately following the issuance of a patent if the patent was filed prior to
March&nbsp;16, 2013. A petition for <I>inter partes</I> review can be filed after the nine-month period for filing a post-grant review petition has expired for a patent with a priority date of March&nbsp;16, 2013 or later. Post-grant review
proceedings can be brought on any ground of challenge, whereas <I>inter partes</I> review proceedings can only be brought to raise a challenge based on published prior art. These adversarial actions at the PTO review patent claims without the
presumption of validity afforded to U.S. patents in lawsuits in U.S. federal courts and use a lower burden of proof than used in litigation in U.S. federal courts. The PTO issued a Final Rule on November&nbsp;11, 2018, announcing that it will now
use the same claim construction currently used in the U.S. federal courts to interpret patent claims, which is the plain and ordinary meaning of words used. If any of our patents are challenged by a third party in such a PTO proceeding, there is no
guarantee that we or our licensors will be successful in defending the patent, which would result in a loss of the challenged patent right to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The U.S. Supreme Court has issued opinions in patent cases in the last few years that many consider may weaken patent protection in the United
States, either by narrowing the scope of patent protection available in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
certain circumstances, holding that certain kinds of innovations are not patentable or generally otherwise making it easier to invalidate patents in court. Additionally, there have been recent
proposals for additional changes to the patent laws of the United States and other countries that, if adopted, could impact our ability to obtain patent protection for our proprietary technology or our ability to enforce our proprietary technology.
Depending on future actions by the U.S. Congress, the U.S. courts, the PTO and the relevant <FONT STYLE="white-space:nowrap">law-making</FONT> bodies in other countries, the laws and regulations governing patents could change in unpredictable ways
that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The laws of some foreign jurisdictions do not protect intellectual property rights to the same extent as in the United States and many
companies have encountered significant difficulties in protecting and defending such rights in foreign jurisdictions. If we encounter such difficulties in protecting or are otherwise precluded from effectively protecting our intellectual property
rights in foreign jurisdictions, our business prospects could be substantially harmed. For example, we could become a party to foreign opposition proceedings, such as at the European Patent Office, or patent litigation and other proceedings in a
foreign court. If so, uncertainties resulting from the initiation and continuation of such proceedings could have a material adverse effect on our ability to compete in the market-place. The cost of foreign adversarial proceedings can also be
substantial, and in many foreign jurisdictions, the losing party must pay the attorney fees of the winning party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the
extensive time required for development, testing and regulatory review of a potential product, it is possible that, before any of our product candidates can be commercialized, any related patent may expire or remain in force for only a short period
following commercialization of our product candidates, thereby reducing any advantages of the patent. To the extent our product candidates based on that technology are not commercialized significantly ahead of the date of any applicable patent, or
to the extent we have no other patent protection on such product candidates, those product candidates would not be protected by patents, and we would then rely solely on other forms of exclusivity, such as regulatory exclusivity provided by the
Federal Food, Drug and Cosmetic Act, or FDCA, or trade secret protection. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patents filed by our licensor, Johns Hopkins University, may have been
discovered through government funded programs and thus may be subject to federal regulations such as <FONT STYLE="white-space:nowrap">&#147;march-in&#148;</FONT> rights, certain reporting requirements and a preference for U.S.-based companies.
Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with <FONT STYLE="white-space:nowrap">non-U.S.</FONT> manufacturers. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any patents licensed from JHU that cover inventions generated in whole or part through the use of U.S. government funding are subject to
certain federal regulations. As a result, the U.S. government may have certain rights to licensed patents embodied in our current or future product candidates pursuant to the Bayh-Dole Act of 1980, or Bayh-Dole Act. These U.S. government rights in
certain inventions developed under a government-funded program include a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> <FONT STYLE="white-space:nowrap">non-transferable,</FONT> irrevocable worldwide license to use inventions for any
governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require JHU, and thus us, to grant exclusive, partially exclusive or <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses to any
of these inventions to a third party if it determines that: (i)&nbsp;adequate steps have not been taken to commercialize the invention; (ii)&nbsp;government action is necessary to meet public health or safety needs; or (iii)&nbsp;government action
is necessary to meet requirements for public use under federal regulations (also referred to as <FONT STYLE="white-space:nowrap">&#147;march-in</FONT> rights&#148;). The U.S. government also has the right to take title to these inventions if JHU
fails to disclose the invention to the government or fails to file an application to register the patents within specified time limits. Patents generated under a government-funded program are also subject to certain reporting requirements,
compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying the subject invention or produced through the use of the subject invention be manufactured substantially in
the United States. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would
be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. manufacturers may limit our ability to contract with <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> product manufacturers for products covered by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such intellectual property. To the extent any of our current or future intellectual property is generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may
similarly apply. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sunitinib, the active ingredient in certain of our product candidates, is currently expected to lose patent protection in 2021, as
a result, new competitors with similar products or treatments may challenge our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sunitinib, the active ingredient in both
<FONT STYLE="white-space:nowrap">GB-102</FONT> and <FONT STYLE="white-space:nowrap">GB-103,</FONT> is currently under patent protection by Pfizer in the United States until August 2021 and in the European Union until July 2021, subject to any
extensions that Pfizer may obtain. Although we separately own or license patents or patent applications relating to <FONT STYLE="white-space:nowrap">GB-102</FONT> and <FONT STYLE="white-space:nowrap">GB-103</FONT> that will not expire until dates
ranging from 2031 to 2039, it is possible that new competing products utilizing sunitinib will be introduced for ocular diseases that could compete with our product candidates. We do not currently expect to commercialize any of our product
candidates until after the expiration of Pfizer&#146;s patent protection. As a result, it is possible that other products may impair our ability to successfully commercialize our product candidates or gain market acceptance, which could adversely
affect our business and operating results. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we infringe or are alleged to infringe intellectual property rights of third parties, our business
could be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research, development or commercialization activities, including any product candidates or products resulting
from these activities, may infringe or be claimed to infringe patents or other proprietary rights owned by third parties and to which we do not hold licenses or other rights. We may not be aware of third-party patents that a third party might assert
against us. For example, there may be third-party applications that have been filed but not published that, if issued, could be asserted against us. If a patent infringement suit were brought against us, we could be forced to stop or delay research,
development, manufacturing or sales of the product or product candidate that is the subject of the suit. Further, if we are found to have infringed a third-party patent, we could be obligated to pay royalties and/or other payments to the third party
for the sale of our product, which may be substantial, or we could be enjoined from selling our product. We could also incur substantial litigation costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Litigation regarding patents, intellectual property and other proprietary rights may be expensive and time-consuming. If we are involved in such
litigation, it could cause delays in bringing product candidates to market and harm our ability to operate. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success will
depend in part on our ability to operate without infringing the proprietary rights of third parties. Although we are not currently aware of any litigation or other proceedings or third-party claims of patent infringement against us related to our
product candidates, the pharmaceutical industry is characterized by extensive litigation regarding patents and other intellectual property rights. Other parties may obtain patents in the future and allege that the use of our technologies infringes
these patent claims or that we are employing their proprietary technology without authorization. Likewise, third parties may challenge or infringe upon our existing or future patents. Proceedings involving our patents or patent applications or those
of others could result in adverse decisions regarding: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patentability of our inventions relating to our product candidates; and/or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the enforceability, validity or scope of protection offered by our patents relating to our product candidates.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we are successful in these proceedings, we may incur substantial costs and divert management time and attention
in pursuing these proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, defend an infringement action or challenge the validity of the
patents in court. Patent litigation is costly and time consuming. We may not have sufficient resources to bring these actions to a successful conclusion. In addition, if we do not obtain a license, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
develop or obtain <FONT STYLE="white-space:nowrap">non-infringing</FONT> technology, fail to defend an infringement action successfully or have infringed patents declared invalid, we may: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incur substantial monetary damages; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">encounter significant delays in bringing our product candidates to market; and/or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be precluded from participating in the manufacture, use or sale of our product candidates or methods of treatment
requiring licenses. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, because of the substantial amount of discovery required in connection with
intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, during the course of this kind of litigation, there could be public
announcements of the results of hearings, motions or other interim proceedings or developments. If investors perceive these results to be negative, the market price for our common stock could be significantly harmed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because our clinical candidates incorporate small molecules, after commercialization they will be subject in the United States to the patent
litigation process of the Hatch-Waxman Amendments, which allows a generic company to submit an Abbreviated New Drug Application, or ANDA, to the FDA to obtain approval to sell our drug using bioequivalence data only. Under the Hatch-Waxman
Amendments, we will have the opportunity to list all of our patents that cover our drug product or its method of use in the FDA&#146;s compendium of &#147;Approved Drug Products with Therapeutic Equivalence Evaluation,&#148; sometimes referred to as
the FDA&#146;s Orange Book. Currently, in the United States, the FDA may grant three years of exclusivity to a new formulation, for which our <FONT STYLE="white-space:nowrap">GB-102</FONT> and <FONT STYLE="white-space:nowrap">GB-103</FONT> products
would qualify, and other changes to a drug, such as the addition of a new indication to the package insert, if the application contains reports of new clinical investigations (other than bioavailability studies) conducted or sponsored by the sponsor
that were essential to the approval of the application. The FDA also may grant five years of exclusivity for new chemical entities, or NCEs, for which <FONT STYLE="white-space:nowrap">GB-401</FONT> would qualify. An NCE is a drug that contains no
active moiety that has been approved by the FDA in any other NDA. A generic company can submit an ANDA to the FDA immediately after FDA approval of our <FONT STYLE="white-space:nowrap">GB-102</FONT> and <FONT STYLE="white-space:nowrap">GB-103</FONT>
products and four years after approval of <FONT STYLE="white-space:nowrap">GB-401.</FONT> The submission of the ANDA by a generic company is considered a technical act of patent infringement. The generic company can certify that it will wait until
the natural expiration date of our listed patents to sell a generic version of our product or can certify that one or more of our listed patents are invalid, unenforceable or not infringed. If the latter, we will have 45 days to bring a patent
infringement lawsuit against the generic company. This will initiate a challenge to one or more of our Orange Book listed patents based on arguments from the generic company that either our patent is invalid, unenforceable or not infringed. Under
the Hatch-Waxman Amendments, if a lawsuit is brought, the FDA is prevented from issuing a final approval on the generic drug until 30 months after the end of the data exclusivity period, or a final decision of a court holding that our asserted
patent claims are invalid, unenforceable or not infringed. If we do not properly list our relevant patents in the Orange Book, or timely file a lawsuit in response to a certification from a generic company under an ANDA, or if we do not prevail in
the resulting patent litigation, we can lose our proprietary market, which can rapidly become generic. Further, even if we do correctly list our relevant patents in the Orange Book, bring a lawsuit in a timely manner and prevail in that lawsuit, it
may be at a very significant cost to us of attorneys&#146; fees and employee time and distraction over a long period. Further, it is common for more than one generic company to try to sell an innovator drug at the same time, and so we may be faced
with the cost and distraction of multiple lawsuits. We may also determine it is necessary to settle the lawsuit in a manner that allows the generic company to enter our market prior to the expiration of our patent or otherwise in a manner that
adversely affects the strength, validity or enforceability of our patent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A number of pharmaceutical companies have been the subject of intense review by the U.S. Federal Trade
Commission or a corresponding agency in another country based on how they have conducted or settled drug patent litigation, and certain reviews have led to an allegation of an anti-trust violation, sometimes resulting in a fine or loss of rights. We
cannot be sure that we would not also be subject to such a review or that the result of the review would be favorable to us, which could result in a fine or penalty. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The U.S. Federal Trade Commission, or FTC, has brought a number of lawsuits in federal court in the past few years to challenge Hatch-Waxman
ANDA litigation settlements between innovator companies and generic companies as anti-competitive. The FTC has taken an aggressive position that anything of value is a payment, whether money is paid or not. Under their approach, if an innovator as
part of a patent settlement agrees not to launch or delay launch of an authorized generic during the <FONT STYLE="white-space:nowrap">180-day</FONT> period granted to the first generic company to challenge an Orange Book listed patent covering an
innovator drug, or negotiates a delay in entry without payment, the FTC may consider it an unacceptable reverse payment. The biopharmaceutical industry has argued that such agreements are rational business decisions to dismiss risk and are immune
from antitrust attack if the terms of the settlement are within the scope of the exclusionary potential of the patent. In 2013, the U.S. Supreme Court, in a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">five-to-three</FONT></FONT> decision in FTC v. Actavis, Inc. rejected both the biopharmaceutical industry&#146;s and the FTC&#146;s arguments with regard to <FONT
STYLE="white-space:nowrap">so-called</FONT> reverse payments, and held that whether a &#147;reverse payment&#148; settlement involving the exchange of consideration for a delay in entry is subject to an anticompetitive analysis depends on five
considerations: (a)&nbsp;the potential for genuine adverse effects on competition; (b)&nbsp;the justification of payment; (c)&nbsp;the patentee&#146;s ability to bring about anticompetitive harm; (d)&nbsp;whether the size of the payment is a
workable surrogate for the patent&#146;s weakness; and (e)&nbsp;that antitrust liability for large unjustified payments does not prevent litigating parties from settling their lawsuits, for example, by allowing the generic to enter the market before
the patent expires without the patentee&#146;s paying the generic. Furthermore, whether a reverse payment is justified depends upon its size, its scale in relation to the patentee&#146;s anticipated future litigation costs, its independence from
other services for which it might represent payment, as was the case in Actavis, and the lack of any other convincing justification. The Court held that reverse payment settlements can potentially violate antitrust laws and are subject to the
standard antitrust <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">rule-of-reason</FONT></FONT> analysis, with the burden of proving that an agreement is unlawful on the FTC and leaving to lower courts the structuring of such rule
of reason analysis. If we are faced with drug patent litigation, including Hatch-Waxman litigation with a generic company, we could be faced with such an FTC challenge based on that activity, including how or whether we settle the case, and even if
we strongly disagree with the FTC&#146;s position, we could face a significant expense or penalty. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to enforce our intellectual
property rights throughout the world. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Filing, prosecuting and defending patents on our product candidates in all countries
throughout the world would be prohibitively expensive. The requirements for patentability may differ in certain countries, particularly in developing countries. Competitors may use our technologies in jurisdictions where we have not obtained patent
protection to develop their own products and, further, may export otherwise infringing products to territories where we may obtain patent protection, but where patent enforcement is not as strong as that in the United States. These products may
compete with our products in jurisdictions where we do not have any issued or licensed patents and any future patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, our ability to protect and enforce our intellectual property rights may be adversely affected by changes in foreign intellectual
property laws. Additionally, laws of some countries outside of the United States and Europe do not afford intellectual property protection to the same extent as the laws of the United States and Europe. Many companies have encountered significant
problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, including India, China and other developing countries, may not favor the enforcement of our patents and other
intellectual property rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This could make it difficult for us to stop the infringement of our patents or the misappropriation of our
other intellectual property rights in certain foreign countries. A number of foreign countries have stated that they </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
are willing to issue compulsory licenses to patents held by innovator companies on approved drugs to allow the government or one or more third-party companies to sell the approved drug without
the permission of the innovator patentee where the foreign government concludes it is in the public interest. India, for example, has used such a procedure to allow domestic companies to make and sell patented drugs without innovator approval. There
is no guarantee that patents covering any of our drugs will not be subject to a compulsory license in a foreign country, or that we will have any influence over if or how such a compulsory license is granted. Further, Brazil allows its regulatory
agency ANVISA to participate in deciding whether to grant a drug patent in Brazil, and patent grant decisions are made based on several factors, including whether the patent meets the requirements for a patent and whether such a patent is deemed in
the country&#146;s interest. In addition, several other countries have created laws that make it more difficult to enforce drug patents than patents on other kinds of technologies. Further, under the treaty on the Trade-Related Aspects of
Intellectual Property (TRIPS), as interpreted by the Doha Declaration, countries in which drugs are manufactured are required to allow exportation of the drug to a developing country that lacks adequate manufacturing capability. Therefore, our drug
markets in the United States or foreign countries may be affected by the influence of current public policy on patent issuance, enforcement or involuntary licensing in the healthcare area. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in November 2015, members of the World Trade Organization, or WTO, which administers TRIPS, voted to extend the exemption against
enforcing pharmaceutical drug patents in least developed countries until 2033. We currently have no patent applications filed in least developed countries, and our current intent is not to file in these countries in the future, at least in part due
to this WTO pharmaceutical patent exemption. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural,
document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be
due to be paid to the PTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we employ an outside
firm and rely on our outside counsel to pay these fees due to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> patent agencies. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be
cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which <FONT STYLE="white-space:nowrap">non-compliance</FONT> can result in abandonment or lapse of the patent or patent
application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market and this circumstance would have a material adverse effect on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on our ability to stop others from competing by enforcing our patents; however, some jurisdictions may require us to grant licenses to third
parties. Such compulsory licenses could be extended to include some of our product candidates, which may limit our potential revenue opportunities. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties, in certain
circumstances. For example, compulsory licensing, or the threat of compulsory licensing, of life-saving products and expensive products is becoming increasingly popular in developing countries, either through direct legislation or international
initiatives. Compulsory licenses could be extended to include some of our product candidates, if they receive marketing approval, which may limit our potential revenue opportunities. Consequently, we may not be able to prevent third parties from
practicing our inventions in certain countries outside the United States and Europe. Competitors may also use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export
otherwise infringing products to territories where we have patent protection, if our ability to enforce our patents to stop infringing activities is inadequate. These products may compete with our products, and our patents or other intellectual
property rights may not be effective or sufficient to prevent them from competing. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
efforts and resources from other aspects of our business. Furthermore, while we intend to protect our intellectual property rights in major markets for our products where such patent rights
exist, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our products. Accordingly, our efforts to protect our intellectual property rights in such countries may be
inadequate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, some countries limit the enforceability of patents against government agencies or government contractors. In
these countries, the patent owner may be limited to monetary relief and may be unable to enjoin infringement if a government is the infringer, which could materially diminish the value of the patent. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with our obligations under the license agreement with JHU, we could lose license rights that are necessary for developing and
commercializing our clinical assets. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our exclusive license with JHU for technology relating to our clinical assets imposes various
development, commercialization, royalty payment, diligence and other obligations on us. Specifically, we are required to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay JHU a minimum royalty fee and potential milestone payments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay JHU low single-digit royalties on all net sales of products and a share of any sublicensing revenues;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">use commercially reasonable efforts to bring products to market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide royalty reports to JHU; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">indemnify JHU against certain claims and maintain insurance coverage. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we breach any of these obligations, JHU may have the right to terminate the license, which would result in our being unable to develop,
manufacture and sell products that are covered by the licensed technology, or in a competitor&#146;s gaining access to the licensed technology. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The
rights we rely upon to protect our unpatented trade secrets may be inadequate. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on unpatented trade secrets, <FONT
STYLE="white-space:nowrap">know-how</FONT> and technology, which are difficult to protect, especially in the pharmaceutical industry, where much of the information about a product must be made public during the regulatory approval process. We seek
to protect trade secrets, in part, by entering into confidentiality agreements with employees, consultants and others. These parties may breach or terminate these agreements or may refuse to enter into such agreements with us, and we may not have
adequate remedies for such breaches. Furthermore, these agreements may not provide meaningful protection for our trade secrets or other proprietary information or result in the effective assignment to us of intellectual property and may not provide
an adequate remedy in the event of unauthorized use or disclosure of confidential information or other breaches of the agreements. Despite our efforts to protect our trade secrets, we or our collaboration partners, board members, employees,
consultants, contractors or scientific and other advisors may unintentionally or willfully disclose our proprietary information to competitors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to maintain trade secret protection, our competitive position may be adversely affected. Competitors may also independently
discover our trade secrets. Enforcement of claims that a third party has illegally obtained and is using trade secrets is expensive, time consuming and uncertain. If our competitors independently develop equivalent knowledge, methods and <FONT
STYLE="white-space:nowrap">know-how,</FONT> we would not be able to assert our trade secrets against them and our business could be harmed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Confidentiality agreements with employees and others may not adequately prevent disclosure of trade secrets and other proprietary information and may
not adequately protect our intellectual property. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on trade secrets to protect our technology, especially where we do not
believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. To protect our proprietary technology </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and processes, we also rely in part on confidentiality and intellectual property assignment agreements with our corporate partners, employees, consultants, outside scientific collaborators and
sponsored researchers and other advisors. These agreements may not effectively prevent disclosure of confidential information nor result in the effective assignment to us of intellectual property and may not provide an adequate remedy in the event
of unauthorized disclosure of confidential information or other breaches of the agreements. In addition, others may independently discover our trade secrets and proprietary information, and in such case, we could not assert any trade secret rights
against such party. Enforcing a claim that a party illegally obtained and is using our trade secrets is difficult, expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States may be less willing to
protect trade secrets. Costly and time-consuming litigation could be necessary to seek to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive
business position. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be required, or choose, to suspend, repeat or terminate our clinical trials if they are not conducted in accordance with regulatory requirements,
the results are negative or inconclusive, the trials are not well-designed, or research participants experience adverse safety outcomes. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulatory agencies, institutional review boards, or IRBs, or data safety monitoring boards may at any time recommend the temporary or
permanent discontinuation of our clinical trials or request that we cease using investigators in the clinical trials if they believe that the clinical trials are not being conducted in accordance with applicable regulatory requirements, or that they
present an unacceptable safety risk to participants. Clinical trials must be conducted in accordance with GCPs and other applicable foreign regulatory authority guidelines. Clinical trials are subject to oversight by the FDA, foreign regulatory
authorities and IRBs at the study sites where the clinical trials are conducted. In addition, clinical trials must be conducted with product candidates produced in accordance with applicable current good manufacturing practices. Clinical trials may
be placed on a full or partial clinical hold by the FDA, foreign regulatory authorities, or us for various reasons, including, but not limited to: deficiencies in the conduct of the clinical trials, including failure to conduct the clinical trial in
accordance with regulatory requirements or clinical protocols; deficiencies in the clinical trial operations or trial sites; deficiencies in the trial designs necessary to demonstrate efficacy; fatalities or other AEs arising during a clinical trial
due to medical problems that may or may not be related to clinical trial treatments; the product candidates may not appear to be more effective than current therapies; or the quality or stability of the product candidates may fall below acceptable
standards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we have never been asked by a regulatory agency, IRB or data safety monitoring board to temporarily or permanently
discontinue a clinical trial, if we elect or are forced to suspend or terminate a clinical trial of any of our current or future product candidates, the commercial prospects for that product may be harmed and our ability to generate product revenue
from that product may be delayed or eliminated. Furthermore, any of these events could prevent us or our partners from achieving or maintaining market acceptance of the affected product and could substantially increase the costs of commercializing
our product candidates and impair our ability to generate revenue from the commercialization of these products either by us or by our collaboration partners. In our Phase 2a trial of <FONT STYLE="white-space:nowrap">GB-102</FONT> for the treatment
of DME and retinal vein occlusion, or RVO, 16 of the 21 patients had at least one drug-related AE, with the majority of them in the 2 mg dosing arm. In addition, one patient in the 2 mg dosing arm experienced two ocular SAEs. As a result, we decided
to pause enrollment of new patients in our Phase 2b trial until we could collect more data on the Phase 2a trial. We subsequently conducted an interim safety analysis which led to the selection of the 1 mg dose for
<FONT STYLE="white-space:nowrap">GB-102.</FONT> All patients having received <FONT STYLE="white-space:nowrap">GB-102</FONT> at either the 1 mg or 2 mg doses previously will now receive the 1 mg dose as repeat therapy at six months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any additional SAEs could result in the FDA delaying our clinical trials or denying or delaying clearance or approval of a product. Even
though an AE may not be the result of the failure of our drug candidate, the FDA or an IRB could delay or halt a clinical trial for an indefinite period of time while an AE is reviewed, and likely </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
would do so in the event of multiple such events. Any delay or termination of our current or future clinical trials as a result of the risks summarized above, including delays in obtaining or
maintaining required approvals from IRBs, delays in patient enrollment, the failure of patients to continue to participate in a clinical trial, and delays or termination of clinical trials as a result of protocol modifications or AEs during the
trials, may cause an increase in costs and delays in the submission of any New Drug Applications, or NDAs, to the FDA, delay the approval and commercialization of our products or result in the failure of the clinical trial, which could adversely
affect our business, operating results and prospects. Lengthy delays in the completion of clinical trials of our products would adversely affect our business and prospects and could cause us to cease operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If preliminary data demonstrate that any of our product candidates has an unfavorable safety profile and is unlikely to receive regulatory
approval or be successfully commercialized, we may voluntarily suspend or terminate future development of such product candidate. Any one or a combination of these events could prevent us from obtaining approval and achieving or maintaining market
acceptance of the affected product or could substantially increase the costs and expenses of commercializing the product candidate, which in turn could delay or prevent us from generating significant revenues from the sale of the product. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are not able to obtain required regulatory approvals, we will not be able to commercialize our product candidates and our ability to generate
significant revenue will be materially impaired. The regulatory approval process is expensive, time-consuming and uncertain. As a result, we cannot predict when or if we, or any collaborators we may have in the future, will obtain regulatory
approval to commercialize our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The activities associated with the development of our product candidates,
including design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA and other regulatory agencies in the United
States and by the EMA and similar regulatory authorities outside the United States. Failure to obtain regulatory approval for a product candidate will prevent us from commercializing a product candidate. We have not submitted for approval to market <FONT
STYLE="white-space:nowrap">GB-102</FONT> or any other product candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process of obtaining regulatory approvals, both in the
United States and abroad, is expensive and may take many years, especially if additional clinical trials are required, if approval is obtained at all. Securing regulatory approval requires the submission of extensive preclinical and clinical data
and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#146;s safety and purity. The FDA&#146;s and other regulatory agencies&#146; decision to grant us regulatory approval will depend
on our ability to demonstrate with substantial clinical evidence through adequate well-controlled clinical trials, that the product candidates are effective, as measured statistically by comparing the overall improvement in actively-treated patients
against improvement in the control group. However, there is a possibility that our data may fail to show a statistically significant difference from the placebo control or the active control. Alternatively, there is a possibility that our data may
be statistically significant, but that the actual clinical benefit of the product candidates may not be considered to be clinically significant, clinically relevant or clinically meaningful. We cannot predict whether the regulatory agencies will
find that our clinical trial results provide compelling data. Even if we believe that the data from our trials will support regulatory approval in the United States or in Europe, we cannot predict whether the agencies will agree with our analysis
and approve our applications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securing regulatory approval also requires the submission of information about the product manufacturing
process to, and inspection of manufacturing facilities by, the regulatory authorities. The FDA, the EMA or other regulatory authorities may determine that our product candidates are not safe or effective, are only moderately effective or have
undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining regulatory approval or prevent or limit commercial use. In addition, while we have had general discussions with the FDA concerning the design of
some of our clinical trials, we have not discussed with the FDA the specifics of the regulatory pathways for our product candidates. Any regulatory approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments
that render the approved product not commercially viable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval of our product candidates may be delayed or refused for many reasons, including the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that
our product candidates are safe and effective for any of their proposed indications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of clinical trials may not meet the level of statistical significance required by the FDA or
comparable foreign regulatory authorities for approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate that our product candidates&#146; clinical and other benefits outweigh their
safety risks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from
preclinical programs or clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the data collected from clinical trials of our product candidates may not be sufficient to support the submission
of an NDA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential delays in enrollment, site visits, evaluations, dosing of patients participating in the clinical trial
as hospitals prioritize the treatment of <FONT STYLE="white-space:nowrap">COVID-19</FONT> patients or patients decide to not enroll in the study as a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">government regulations that may be imposed in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic may restrict the movement of our global supply chain, divert hospital resources that are necessary to administer our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the facilities of the third-party manufacturers with which we contract may not be adequate to support approval of
our product candidates; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly
change in a manner rendering our clinical data insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if our product candidates meet their
safety and efficacy endpoints in clinical trials, the regulatory authorities may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA Advisory Committee
or other regulatory authority recommends <FONT STYLE="white-space:nowrap">non-approval</FONT> or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or
administrative action, or changes in regulatory authority policy during the period of product development, clinical trials and the review process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The regulatory process can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product
candidates involved. If we experience delays in obtaining approval, the commercial prospects for our product candidates may be harmed and our ability to generate revenues will be materially impaired. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Failure to obtain regulatory approval in international jurisdictions would prevent our product candidates from being marketed abroad. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to market and sell our product candidates in the European Union and many other jurisdictions, we or our third-party collaborators must
obtain separate regulatory approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from
that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that
the product be approved for reimbursement before the product can be sold in that country. We or our collaborators may not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or
jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. However, a failure or delay in obtaining regulatory approval in
one country may have a negative effect on the regulatory process in other countries. We may not be able to file for regulatory approvals and may not receive necessary approvals to commercialize our products in any market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, on June&nbsp;23, 2016, the electorate in the United Kingdom voted in favor of leaving the European Union, commonly referred to
as Brexit. Following protracted negotiations, the United Kingdom left the European Union on January&nbsp;31, 2020. Under the withdrawal agreement, there is a transitional period until December&nbsp;31, 2020 (extendable up to two years). Discussions
between the United Kingdom and the European Union have so far mainly focused on finalizing withdrawal issues and transition agreements but have been extremely difficult to date. To date, only an outline of a trade agreement has been reached. Much
remains open but the Prime Minister has indicated that the United Kingdom will not seek to extend the transitional period beyond the end of 2020. If no trade agreement has been reached before the end of the transitional period, there may be
significant market and economic disruption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since the regulatory framework for pharmaceutical products in the United Kingdom covering
quality, safety, and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales and distribution of pharmaceutical products is derived from European Union directives and regulations, Brexit could materially
impact the future regulatory regime that applies to products and the approval of product candidates in the United Kingdom. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, may force us
to restrict or delay efforts to seek regulatory approval in the United Kingdom for our product candidates, which could significantly and materially harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The terms of approvals, ongoing regulations and post-marketing restrictions for our products may limit how we manufacture and market our products, which
could materially impair our ability to generate revenue. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once regulatory approval has been granted, an approved product and its
manufacturer and marketer are subject to ongoing review and extensive regulation. We, and any collaborators we may have in the future, must therefore comply with requirements concerning advertising and promotion for any of our products for which we
or our collaborators obtain regulatory approval. Promotional communications with respect to drug products and medical devices are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the
product&#146;s approved labeling. Thus, if any of our product candidates receives regulatory approval, the accompanying approved labeling may limit the promotion of our product, which could limit sales of the product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, manufacturers of approved products and those manufacturers&#146; facilities are required to comply with extensive FDA
requirements, including ensuring that quality control and manufacturing procedures conform to current good manufacturing practices applicable to drug manufacturers or quality assurance standards applicable to medical device manufacturers, which
include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation and reporting requirements. We, any CMOs we may engage in the future, our future collaborators and their
CMOs will also be subject to other regulatory requirements, including submissions of safety and other post-marketing information and reports, registration and listing requirements, requirements regarding the distribution of samples to physicians,
recordkeeping and costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the product such as the requirement to implement a risk evaluation and mitigation strategy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If any of our product candidates receives regulatory approval and we or others later identify
undesirable side effects caused by the product, our ability to market and derive revenue from the products could be compromised. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event any of our product candidates receive regulatory approval and we or others identify undesirable side effects, AEs or other
problems caused by one of our products, any of the following adverse events could occur, which could result in the loss of significant revenue to us and materially and adversely affect our operating results and business: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may withdraw or modify their approval of the product and require us to take the product
off the market or seize the product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may need to recall the product or change the way the product is administered to patients;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may need to conduct additional preclinical studies or clinical trials or change the labeling of the product;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additional restrictions may be imposed on the marketing and promotion of the particular product or the
manufacturing processes for the product or any component thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be able to secure or maintain adequate coverage and reimbursement for our products from government
(including U.S. federal health care programs) and private payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require the addition of labeling statements, such as a boxed warning, or equivalent,
or contraindications or limitations on the indications for use; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require us to implement a Risk Evaluation and Mitigation Strategy, or REMS, plan, or
to conduct post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to create a Medication Guide outlining the risks of such side effects for distribution to
patients; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be exposed to potential lawsuits and associated legal expenses, including costs of resolving claims;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the product may become less competitive and sales may decrease; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reputation may suffer both among clinicians and patients. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these events could have a material and adverse effect on our operations and business. The commercial prospects for our product
candidates may be harmed and our ability to generate revenues will be materially impaired. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our product candidates receive regulatory approval,
we will also be subject to ongoing FDA obligations and continued regulatory review, such as continued safety reporting requirements, and we may also be subject to additional FDA post-marketing obligations or new regulations, all of which may result
in significant expense and limit our ability to commercialize our drugs. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any regulatory approvals that we receive for our product
candidates will require surveillance to monitor the safety and efficacy of the product candidate and may require us to conduct post-approval clinical studies. The FDA has significant post-market authority, including the authority to require labeling
changes based on new safety information and to require post-market studies or clinical trials to evaluate safety risks related to the use of a product or to require withdrawal of the product from the market. The manufacturing facilities used to
manufacture our product candidates will also be subject to periodic review and inspection by the FDA and other regulatory agencies, including for continued compliance with current good manufacturing practices requirements. The discovery of any new
or previously unknown problems with our third-party manufacturers, manufacturing processes or facilities may result in restrictions on the product, manufacturer or facility, including </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
withdrawal of the product from the market. Any product promotion and advertising will also be subject to regulatory requirements and continuing regulatory review. The FDA imposes stringent
restrictions on manufacturers&#146; communications regarding use of their products. If we promote our product candidates in a manner inconsistent with <FONT STYLE="white-space:nowrap">FDA-approved</FONT> labeling or otherwise not in compliance with
FDA regulations, we may be subject to enforcement action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if the FDA or a foreign regulatory authority approves our product
candidates, the manufacturing processes, labeling, packaging, distribution, AE reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements.
These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with current good manufacturing practices and GCPs, for any clinical trials that we conduct
post-approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, if we obtain regulatory approval for our product candidates, we will only be permitted to market our products
for the indication approved by the FDA or foreign regulatory authority, and such approval may involve limitations on the indicated uses or promotional claims we may make for our products, or otherwise not permit labeling that sufficiently
differentiates our product candidates from competitive products with comparable therapeutic profiles. For example, we will not be able to claim that our products have fewer side effects, or improve compliance or efficacy as compared to other drugs
unless we can demonstrate those attributes to the FDA or foreign regulatory authority in comparative clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or our CMOs
or service providers fail to comply with applicable continuing regulatory requirements in the United States or foreign jurisdictions in which we seek to market our products, we or they may be subject to, among other things, fines, warning or
untitled letters, holds on clinical trials, delay of approval or refusal by the FDA or similar foreign regulatory bodies to approve pending applications or supplements to approved applications, suspension or withdrawal of regulatory approval,
product recalls and seizures, administrative detention of products, refusal to permit the import or export of products, operating restrictions, injunction, civil penalties and criminal prosecution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA&#146;s and foreign regulatory authorities&#146; policies may change, and additional government regulations may be enacted that could
prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or
abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any regulatory approval that we may have obtained,
and we may not achieve or sustain profitability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to substantial penalties if we fail to comply with regulatory requirements or if
we experience unanticipated problems with our products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Violations of the FDCA relating to the promotion or manufacturing of drug
products may lead to investigations by the FDA, the Department of Justice and state Attorneys General alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws. In addition, later discovery
of previously unknown AEs or other problems with our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on such products, manufacturers or manufacturing processes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the labeling or marketing of a product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on product distribution or use; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requirements to conduct post-marketing studies or clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">warning or untitled letters; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of the products from the market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal to approve pending applications or supplements to approved applications that we submit;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recall of products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, restitution or disgorgement of profits or revenues; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspension or withdrawal of regulatory approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal to permit the import or export of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-compliance</FONT> with European Union requirements regarding safety monitoring or pharmacovigilance, and
with requirements related to the development of products for the pediatric population, can also result in significant financial penalties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the
FDA does not conclude that our product candidates satisfy the requirements for the Section&nbsp;505(b)(2) regulatory approval pathway, or if the requirements for such product candidates under Section&nbsp;505(b)(2) are not as we expect, the approval
pathway for those product candidates will likely take significantly longer, cost significantly more and entail significantly greater complications and risks than anticipated, and in either case may not be successful. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to seek FDA approval through the Section&nbsp;505(b)(2) regulatory pathway for each of our current product candidates. The Hatch-Waxman
Amendments added Section&nbsp;505(b)(2) to the FDCA. Section&nbsp;505(b)(2) permits the submission of an NDA where at least some of the information required for approval comes from studies that were not conducted by or for the applicant and for
which the applicant has not obtained a right of reference. Section&nbsp;505(b)(2), if applicable to us under the FDCA, would allow an NDA to rely in part on data in the public domain or the FDA&#146;s prior conclusions regarding the safety and
effectiveness of approved drug products, which could expedite the development program for our product candidates by potentially decreasing the amount of preclinical or clinical data that we would need to generate in order to obtain FDA approval. For
GB-102 and GB-103, we are seeking to rely on the FDA&#146;s prior conclusions regarding the safety and effectiveness of sunitinib, which has previously been approved for the treatment of gastrointestinal stromal tumors, advanced renal cell
carcinoma, and a certain type of pancreatic cancer. For GB-401, we intend to rely in part on the FDA&#146;s prior findings for the previously approved active pharmaceutical ingredient, or API, as well as relevant publications, and to conduct
additional good laboratory practice, or GLP, toxicology studies with <FONT STYLE="white-space:nowrap">GB-401,</FONT> to support the GB-401 IND and any future 505(b)(2) NDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we cannot pursue the Section&nbsp;505(b)(2) regulatory pathway, we may need to conduct additional clinical trials, provide additional data
and information, and meet additional standards for regulatory approval. If this were to occur, the time and financial resources required to obtain FDA approval for these product candidates, and complications and risks associated with these product
candidates, would likely substantially increase. Moreover, our inability to pursue the Section&nbsp;505(b)(2) regulatory pathway would likely result in new competitive products reaching the market more quickly than GB-102, GB-103 or <FONT
STYLE="white-space:nowrap">GB-401,</FONT> which would likely adversely impact our competitive position and prospects. Even if we can pursue the Section&nbsp;505(b)(2) regulatory pathway, we cannot assure you that GB-102, GB-103 or <FONT
STYLE="white-space:nowrap">GB-401</FONT> will receive the requisite approvals for commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, notwithstanding the
approval of products by the FDA under Section&nbsp;505(b)(2), certain pharmaceutical companies and others have objected to the FDA&#146;s interpretation of Section&nbsp;505(b)(2). If the FDA&#146;s interpretation of Section&nbsp;505(b)(2) is
successfully challenged, the FDA may change its 505(b)(2) policies and practices, which could delay or even prevent the FDA from approving any NDA that we submit under Section&nbsp;505(b)(2). In addition, the pharmaceutical industry is highly
competitive, and Section&nbsp;505(b)(2) NDAs </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
are subject to special requirements designed to protect the patent rights of sponsors of previously approved drugs that are referenced in a Section&nbsp;505(b)(2) NDA. These requirements may give
rise to patent litigation and mandatory delays in approval of our NDAs for up to 30 months or longer depending on the outcome of any litigation. It is not uncommon for the owner of the NDA of an approved product to file a citizen petition with the
FDA seeking to delay approval of, or impose additional approval requirements for, pending competing products. If successful, such petitions could significantly delay, or even prevent, the approval of a new product. However, even if the FDA
ultimately denies such a petition, the FDA may substantially delay approval while it considers and responds to the petition. In addition, even if we are able to utilize the Section&nbsp;505(b)(2) regulatory pathway, there is no guarantee this would
ultimately lead to earlier approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, even if our product candidates are approved under Section&nbsp;505(b)(2), the approval may
be subject to limitations on the indicated uses for which the products may be marketed or to other conditions of approval, or may contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the
products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our relationships with customers and third-party payors may be subject, directly or indirectly, to applicable anti-kickback, fraud and
abuse, false claims, transparency, health information privacy and security, and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and
diminished profits and future earnings. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Healthcare providers, physicians and third-party payors will play a primary role in the
recommendation and prescription and use of any product candidates for which we obtain regulatory approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws
and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any products for which we obtain regulatory approval. In addition, we may be subject to transparency laws and
patient privacy regulation by U.S. federal and state governments and by governments in foreign jurisdictions in which we conduct our business. The applicable federal, state and foreign healthcare laws and regulations that may affect our ability to
operate include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully
soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service,
for which payment may be made under a federal healthcare program such as Medicare and Medicaid; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal civil and criminal false claims laws and civil monetary penalty laws, including the federal False Claims
Act, which impose criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid
programs, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and
civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and their
respective implementing regulations, which imposes obligations, including mandatory contractual terms, on covered healthcare providers, health plans and healthcare clearinghouses, as well as their business associates, with respect to safeguarding
the privacy, security and transmission of individually identifiable health information; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may
apply to sales or marketing arrangements and claims involving healthcare items or services </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers; state and foreign laws that require pharmaceutical companies to comply with
the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; state and foreign laws that
require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state and foreign laws governing the privacy and security of health
information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations may involve
substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and
regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, including, without
limitation, damages, fines, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other healthcare
providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, it may be subject to criminal, civil or administrative sanctions, including exclusions from participation in government funded healthcare
programs. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause
us to incur significant legal expenses and could divert our management&#146;s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may
be costly to us in terms of money, time and resources. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently enacted and future legislation, including healthcare legislative reform measures,
may affect our ability to commercialize and the prices we obtain for any products that are approved in the United States or foreign jurisdictions, and negatively impact our business and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes
regarding the healthcare system that could affect our ability to profitably sell or commercialize any product candidate for which we obtain regulatory approval. The pharmaceutical industry and medical device industry have been a particular focus of
these efforts and have been significantly affected by legislative initiatives. Current laws, as well as other healthcare reform measures that may be adopted, may result in more rigorous coverage criteria and in additional downward pressure on the
price that we receive for any FDA approved product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the Medicare Prescription Drug, Improvement, and Modernization
Act of 2003, or MMA, changed the way Medicare covers and pays for pharmaceutical products. Cost reduction initiatives and other provisions of this legislation could limit coverage of and reduce the price that we receive for any FDA approved
products. While the MMA applies only to product benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement
that results from the MMA or other healthcare reform measures may result in a similar reduction in payments from private payors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March
2010, President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively, PPACA. Among the provisions of PPACA of importance to our business,
including, without limitation, our ability to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercialize and the prices we may obtain for any of our product candidates and that are approved for sale, are the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and
biologic agents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a Medicare Part D coverage gap discount program, in which participating manufacturers must agree to offer 70% <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated drug prices during the coverage gap period as a condition for the manufacturer&#146;s outpatient drugs to be covered under Medicare Part
D; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expansion of healthcare fraud and abuse laws, including the federal False Claims Act and the federal
Anti-Kickback Statute, and the addition of new government investigative powers, and enhanced penalties for noncompliance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">extension of manufacturers&#146; Medicaid rebate liability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expansion of eligibility criteria for Medicaid programs; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As implementation of the PPACA is ongoing, the law appears likely to continue the downward pressure on pharmaceutical
pricing, especially under the Medicare program, and may also increase our regulatory burdens and operating costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, other
legislative changes have been proposed and adopted since PPACA was enacted. These changes include aggregate reductions to Medicare payments to providers of up to 2%&nbsp;per fiscal year, which went into effect in April 2013. In January 2013,
President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several types of providers, and increased the statute of limitations period for the government to recover overpayments
to providers from three to five years. The CARES Act, which was signed into law on March&nbsp;27, 2020 and designed to provide financial support and resources to individuals and businesses affected by the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, suspended the 2% Medicare sequester from May&nbsp;1, 2020 to December&nbsp;31, 2020 and extended the sequester by one year, through 2030, in order to offset the added expense of the 2020
cancellation. These new laws may result in additional reductions in Medicare and other healthcare funding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pricing of prescription
pharmaceuticals is also subject to governmental control outside the United States. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of regulatory approval for a product. To obtain
reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidates to other available therapies. If reimbursement of our products is unavailable or
limited in scope or amount, or if pricing is set at unsatisfactory levels, our ability to generate revenues and become profitable could be impaired. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing and selling certain
products outside of the United States and require us to develop and implement costly compliance programs. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we expand our
operations outside of the United States, we must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate. The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual
or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order
to assist the individual or business in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain
books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the
FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in
connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with
certain <FONT STYLE="white-space:nowrap">non-U.S.</FONT> nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we expand our presence outside of the United
States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit
our growth potential and increase our development costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The failure to comply with laws governing international business practices may
result in substantial civil and criminal penalties and suspension or debarment from government contracting. The Securities and Exchange Commission, or SEC, also may suspend or bar issuers from trading securities on U.S. exchanges for violations of
the FCPA&#146;s accounting provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we or any CMOs we engage fail to comply with environmental, health and safety laws and regulations, we
could become subject to fines or penalties or incur significant costs. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and any CMOs we may engage in the future are subject to
numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our
operations may involve the use of hazardous materials, including chemicals and biological materials, and produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate
the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also
could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we maintain general liability insurance as well as workers&#146; compensation insurance to cover us for costs and expenses we may
incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that
may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we
may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Our failure to
comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, with respect to the
operations of any CMOs, it is possible that if they fail to operate in compliance with applicable environmental, health and safety laws and regulations or properly dispose of wastes associated with our products, we could be held liable for any
resulting damages, suffer reputational harm or experience a disruption in the manufacture and supply of our product candidates or products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Employee Matters and Managing Growth </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are highly dependent on the research and development, clinical and business development expertise of Frederic Guerard, our chief executive
officer, as well as other principal members of our management, scientific and clinical team. Although we have entered into employment agreements with our executive officers, each of them may terminate their employment with us at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success.
The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. For
example, our former Chief Medical Officer departed in March 2020 and Parisa Zamiri joined us in June 2020 as Chief Medical Officer. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time
because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize products. Competition to hire from this limited pool is intense,
and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of
scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and
commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to
continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect to expand our
development, regulatory and manufacturing capabilities and potentially implement sales, marketing and distribution capabilities and, as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of product
development, clinical, regulatory affairs, manufacturing, sales, marketing, finance and distribution, which growth we expect to begin before we receive regulatory approval from the FDA or other regulatory authorities, and we may never receive such
regulatory approval for any of our product approvals. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train
additional qualified personnel. Due to our limited financial resources and our limited experience in managing such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified
personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Common Stock and This Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may
cause our stock price to fluctuate or decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our operating results to be subject to quarterly fluctuations. Our net
loss and other operating results will be affected by numerous factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">variations in the level of expense related to the ongoing development of our product candidates or future
development programs; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">results of clinical trials, or the addition or termination of clinical trials or funding support by us, or
existing or future collaborators or licensing partners; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our execution of any additional collaboration, licensing or similar arrangements, and the timing of payments we
may make or receive under existing or future arrangements or the termination or modification of any such existing or future arrangements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any intellectual property infringement lawsuit or opposition, interference or cancellation proceeding in which we
may become involved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions and departures of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures,
strategic investments or changes in business strategy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if any of our product candidates receives regulatory approval, the terms of such approval and market acceptance
and demand for such product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory developments affecting our product candidates or those of our competitors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in general market and economic conditions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could
decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our common stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily
meaningful and should not be relied upon as an indication of our future performance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The market price of our stock may be volatile, and you could
lose all or part of your investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading price of our common stock following this offering is likely to be highly volatile
and subject to wide fluctuations in response to various factors, some of which we cannot control. As a result of this volatility, investors may not be able to sell their common stock at or above the initial public offering price. The market price
for our common stock may be influenced by many factors, including the other risks described in this section of the prospectus entitled &#147;Risk Factors&#148; and the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">results of preclinical studies and clinical trials of our product candidates, or those of our competitors or our
existing or future collaborators; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our employees, trials,
collaboration partners, suppliers, our results of operations, liquidity and financial condition; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory or legal developments in the United States and other countries, especially changes in laws or
regulations applicable to our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of competitive products or technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">introductions and announcements of new products by us, our future commercialization partners, or our competitors,
and the timing of these introductions or announcements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actions taken by regulatory agencies with respect to our products, clinical trials, manufacturing process or
sales and marketing terms; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated variations in our financial results or those of companies that are perceived to be similar
to us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of our efforts to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> additional
technologies, products or product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments concerning any future collaborations, including but not limited to those with our sources of
manufacturing supply and our commercialization partners; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market conditions in the pharmaceutical and biotechnology sectors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures or
capital commitments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments or disputes concerning patents or other proprietary rights, including patents, litigation matters
and our ability to obtain patent protection for our product candidates and products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability or inability to raise additional capital and the terms on which we raise it; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the structure of healthcare payment systems; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated changes in earnings estimates or changes in stock market analyst recommendations regarding
our common stock, other comparable companies or our industry generally; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our failure or the failure of our competitors to meet analysts&#146; projections or guidance that we or our
competitors may give to the market; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fluctuations in the valuation of companies perceived by investors to be comparable to us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcement and expectation of additional financing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">speculation in the press or investment community; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">trading volume of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of our common stock by us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the concentrated ownership of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in accounting principles; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">terrorist acts, acts of war or periods of widespread civil unrest; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">natural disasters, pandemics and other calamities; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic, industry and market conditions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the stock market in general, and the markets for pharmaceutical, biopharmaceutical and biotechnology stocks in particular, have
experienced extreme price and volume fluctuations that have been often unrelated or disproportionate to the operating performance of the issuer. These broad market and industry factors may seriously harm the market price of our common stock,
regardless of our actual operating performance. The realization of any of the above risks or any of a broad range of other risks, including those described in this &#147;Risk Factors&#148; section, could have a dramatic and adverse impact on the
market price of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You will experience immediate and substantial dilution as a result of this offering and may experience additional
dilution in the future. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you purchase common stock in this offering, assuming an initial public offering price of $16.00 per
share, the midpoint of the estimated price range set forth on the cover of this prospectus, you will incur immediate and substantial dilution of $11.85 per share, representing the difference between the assumed initial public offering price of
$16.00 per share and our pro forma net tangible book value per share as of June&nbsp;30,&nbsp;2020 after giving effect to this offering and the conversion of all outstanding shares of our redeemable convertible preferred stock upon the completion of
this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, we issued options in the past to acquire common stock at prices significantly below the assumed initial public
offering price. As of June 30, 2020, there were 2,066,076 shares of common stock subject to outstanding options at a weighted average exercise price per share of $2.52. After June 30, 2020, we granted stock options to purchase 428,621 shares of our
common stock for a weighted average exercise price per share of $9.25. To the extent that these outstanding options are ultimately exercised, you will incur further dilution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that we raise additional capital through the sale of equity or convertible
debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if
available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The future sale and issuance of equity or of debt securities that are convertible into equity will dilute our share capital. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may choose to raise additional capital in the future, depending on market conditions, strategic considerations and operational requirements.
To the extent that additional capital is raised through the sale and issuance of shares or other securities convertible into shares, our stockholders will be diluted. Future issuances of our common stock or other equity securities, or the perception
that such sales may occur, could adversely affect the trading price of our common stock and impair our ability to raise capital through future offerings of shares or equity securities. No prediction can be made as to the effect, if any, that future
sales of common stock or the availability of common stock for future sales will have on the trading price of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>An active and liquid
trading market for our common stock may not develop and you may not be able to resell your shares of common stock at or above the public offering price. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, no market for shares of our common stock existed and an active trading market for our shares may never develop or be
sustained following this offering. The initial public offering, or IPO, price for our common stock will be determined through negotiations with the underwriters and the negotiated price may not be indicative of the market price of our common stock
after this offering. The market value of our common stock may decrease from the IPO price. As a result of these and other factors, you may be unable to resell your shares of our common stock at or above the IPO price. The lack of an active market
may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. The lack of an active market may also reduce the fair market value of your shares. Furthermore, an inactive market may also
impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic collaborations or acquire companies or products by using our shares of common stock as consideration. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A sale of a substantial number of shares of our common stock may cause the price of our common stock to decline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on shares outstanding as of June 30, 2020, upon completion of this offering, we will have outstanding a total of 19,155,613 shares of
common stock. Of these shares, only 4,687,500 shares of common stock sold in this offering, or 5,390,625 shares if the underwriters exercise their option to purchase additional shares in full, will be freely tradable, without restriction, in the
public market immediately after this offering. Each of our officers and directors and substantially all our stockholders have entered or will enter into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters that restrict
their ability to sell or transfer their shares. The <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements pertaining to this offering will expire 180 days from the date of this prospectus. However, our underwriters may, in their sole
discretion, permit our officers, directors and other current stockholders who are subject to the contractual <FONT STYLE="white-space:nowrap">lock-up</FONT> to sell shares prior to the expiration of the
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. After the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements expire, based on shares outstanding as of June 30, 2020, up to an additional 14,468,113 shares of common stock will be
eligible for sale in the public market, approximately 11,521,724 of which are held by our officers, directors and their affiliated entities, and will be subject to volume limitations under Rule 144 under the Securities Act of 1933, as amended, or
Securities Act. In addition, 2,066,076 shares of our common stock that are subject to outstanding options as of June 30, 2020 and 428,621 shares of our common stock that are subject to options granted after June&nbsp;30,&nbsp;2020 will become
eligible for sale in the public market to the extent permitted by the provisions of various vesting agreements, the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements and Rules 144 and 701 under the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After this offering, the holders of an aggregate of 13,145,104 shares of our outstanding
common stock as of June 30, 2020 will have rights, subject to some conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or our
stockholders. We also intend to register shares of common stock that we may issue under our equity incentive plans. Once we register these shares, they will be able to be sold freely in the public market upon issuance, subject to the <FONT
STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> period under the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above and in the section entitled &#147;Underwriting.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot predict what effect, if any, sales of our shares in the public market or the availability of shares for sale will have on the market
price of our common stock. However, future sales of substantial amounts of our common stock in the public market, including shares issued upon exercise of outstanding options or warrants, or the perception that such sales may occur, could adversely
affect the market price of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also expect that significant additional capital may be needed in the future to continue
our planned operations. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. These sales, or the perception in the market
that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B><I>We will have broad
discretion in the use of the net proceeds from this offering and may not use them effectively</I></B><B>. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management will have
broad discretion in the application of the net proceeds from this offering, and you will be relying on the judgment of our management regarding the application of these proceeds. You will not have the opportunity, as part of your investment
decision, to assess whether we are using the proceeds appropriately. Our management might not apply our net proceeds in ways that ultimately increase the value of your investment. If we do not invest or apply the net proceeds from this offering in
ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause our stock price to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities
or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or
our business. We do not currently have and may never obtain research coverage by securities and industry analysts. If no or few securities or industry analysts commence coverage of us, the trading price for our common stock could be impacted
negatively. In the event we obtain securities or industry analyst coverage, if any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our
target studies and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of such analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the
financial markets, which in turn could cause a decline in our stock price or trading volume. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our principal stockholders and management own a
significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the beneficial ownership of our common stock as of June 30, 2020, prior to this offering, our executive officers, directors, holders
of 5% or more of our capital stock and their respective affiliates beneficially owned approximately 88% of our voting stock and, upon the completion of this offering, that same group will hold approximately 68% of our outstanding voting stock
(assuming no exercise of the underwriters&#146; option to purchase additional shares, no exercise of outstanding options or warrants and no purchases of shares in this offering by any of this group), in each case assuming the conversion of all
outstanding shares of our redeemable convertible preferred stock into shares of our common stock and the net exercise of warrants outstanding that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
would otherwise expire upon the completion of this offering. As a result, these stockholders, if acting together, will continue to have significant influence over the outcome of corporate actions
requiring stockholder approval, including the election of directors, amendment of our organizational documents, any merger, consolidation or sale of all or substantially all of our assets and any other significant corporate transaction. The
interests of these stockholders may not be the same as or may even conflict with your interests. For example, these stockholders could delay or prevent a change of control of our company, even if such a change of control would benefit our other
stockholders, which could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of our company or our assets and might affect the prevailing market price of our common stock. The significant
concentration of stock ownership may adversely affect the trading price of our common stock due to investors&#146; perception that conflicts of interest may exist or arise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an &#147;emerging growth company&#148; and a &#147;smaller reporting company&#148; and we cannot be certain if the reduced reporting requirements
applicable to emerging growth companies and smaller reporting companies will make our common stock less attractive to investors. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act. For as long as we
continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including (1)&nbsp;not being required to comply
with the independent auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, as amended, or Sarbanes-Oxley Act, (2)&nbsp;reduced disclosure obligations regarding executive compensation in this prospectus and our
periodic reports and proxy statements and (3)&nbsp;exemptions from the requirements of holding nonbinding advisory stockholder votes on executive compensation and stockholder approval of any golden parachute payments not approved previously. In
addition, as an emerging growth company, we are only required to provide two years of audited financial statements and two years of selected financial data in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We could be an emerging growth company for up to five years following the completion of this offering, although circumstances could cause us
to lose that status earlier, including if we are deemed to be a &#147;large accelerated filer,&#148; which occurs when the market value of our common stock that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds
$700&nbsp;million as of the prior June&nbsp;30, or if we have total annual gross revenue of $1.07&nbsp;billion or more during any fiscal year before that time, in which cases we would no longer be an emerging growth company as of the following
December&nbsp;31, or if we issue more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt during any three-year period before that time, in which case we would no longer be an emerging growth company immediately.
Even after we no longer qualify as an emerging growth company, we may still qualify as a &#147;smaller reporting company,&#148; which would allow us to take advantage of many of the same exemptions from disclosure requirements, including not being
required to comply with the independent auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in this prospectus and in our periodic reports and proxy
statements. Even after we no longer qualify as an emerging growth company, we may still qualify as a smaller reporting company, which would allow us to take advantage of many of the same exemptions from disclosure requirements, including not being
required to comply with the independent auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in this prospectus and in our periodic reports and proxy
statements.&nbsp;We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for
our common stock and our share price may be more volatile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the JOBS Act, emerging growth companies can also delay adopting new or
revised accounting standards until such time as those standards apply to private companies. We have elected to take advantage of the benefits of this extended transition period. Our financial statements may therefore not be comparable to those of
companies that comply with such new or revised accounting standards. Until the date that we are no longer an &#147;emerging growth company&#148; or affirmatively and irrevocably opt out of the exemption provided by Section&nbsp;7(a)(2)(B) of the
Securities Act, upon issuance of a new or revised accounting standard that applies to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our financial statements and that has a different effective date for public and private companies, we will disclose the date on which adoption is required for
<FONT STYLE="white-space:nowrap">non-emerging</FONT> growth companies and the date on which we will adopt the recently issued accounting standard. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also a &#147;smaller reporting company,&#148; meaning that the market value of our stock held by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> plus the proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700.0&nbsp;million and our annual revenue is less than $100.0&nbsp;million during the most
recently completed fiscal year. We may continue to be a smaller reporting company after this offering if either (i)&nbsp;the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million or
(ii)&nbsp;our annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal year and the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million. If we are
a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting
company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> and, similar to emerging growth companies, smaller reporting
companies have reduced disclosure obligations regarding executive compensation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-takeover provisions in our charter documents and under
Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our restated certificate of incorporation and our restated bylaws that will be in effect upon completion of this offering contain provisions
that could delay or prevent a change in control of our company. These provisions could also make it difficult for stockholders to elect directors who are not nominated by current members of our board of directors or take other corporate actions,
including effecting changes in our management. These provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish a classified board of directors so that not all members of our board are elected at one time;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">permit only the board of directors to establish the number of directors and fill vacancies on the board;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that directors may only be removed &#147;for cause&#148; and only with the approval of <FONT
STYLE="white-space:nowrap">two-thirds</FONT> of our stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require super-majority voting to amend some provisions in our restated certificate of incorporation and restated
bylaws; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize the issuance of &#147;blank check&#148; preferred stock that our board could use to implement a
stockholder rights plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">eliminate the ability of our stockholders to call special meetings of stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting
of our stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prohibit cumulative voting; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish advance notice requirements for nominations for election to our board or for proposing matters that can
be acted upon by stockholders at annual stockholder meetings. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our restated certificate of incorporation
will provide that the Court of Chancery of the State of Delaware will be the exclusive forum for: any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us
arising pursuant to the Delaware General Corporation Law, or DGCL, our restated certificate of incorporation, or our restated bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all claims brought to enforce any duty
or liability created by the Securities Act or the rules and regulations thereunder. Our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
restated bylaws will provide that the federal district courts of the United States of America will, to the fullest extent permitted by law, be the exclusive forum for resolving any complaint
asserting a cause of action arising under the Securities Act, referred to as a Federal Forum Provision. Our decision to adopt a Federal Forum Provision followed a decision by the Supreme Court of the State of Delaware holding that such provisions
are facially valid under Delaware law. While there can be no assurance that federal courts or state courts will follow the holding of the Delaware Supreme Court or determine that the Federal Forum Provision should be enforced in a particular case,
application of the Federal Forum Provision means that suits brought by our stockholders to enforce any duty or liability created by the Securities Act must be brought in federal court and cannot be brought in state court. While neither the exclusive
forum provision nor the Federal Forum Provision applies to suits brought to enforce any duty or liability created by the Exchange Act of 1934, as amended, or Exchange Act, Section&nbsp;27 of the Exchange Act creates exclusive federal jurisdiction
over all claims brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. Accordingly, actions by our stockholders to enforce any duty or liability created by the Exchange Act or the rules and
regulations thereunder also must be brought in federal court. Our stockholders will not be deemed to have waived our compliance with the federal securities laws and the regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any person or entity purchasing or otherwise acquiring or holding any interest in any of our securities shall be deemed to have notice of and
consented to our exclusive forum provisions, including the Federal Forum Provision. These provisions may limit a stockholder&#146;s ability to bring a claim in a judicial forum of their choosing for disputes with us or our directors, officers or
other employees, which may discourage lawsuits against us and our directors, officers, and other employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Section&nbsp;203
of the DGCL may discourage, delay or prevent a change in control of our company. Section&nbsp;203 imposes certain restrictions on mergers, business combinations and other transactions between us and holders of 15% or more of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new
compliance initiatives and corporate governance practices. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, and particularly after we are no longer an
emerging growth company or smaller reporting company, we will incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act,
the listing requirements of the Nasdaq Global Market and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and
corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, we expect these rules and regulations to substantially increase our legal and financial
compliance costs and to make some activities more time consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance and we may
be required to incur substantial costs to maintain sufficient coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more
difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers. Moreover, these rules and regulations are often subject to varying interpretations, in many cases due to
their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs
necessitated by ongoing revisions to disclosure and governance practices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not currently required to comply with the SEC&#146;s
rules that implement Section&nbsp;404 of the Sarbanes-Oxley Act and are therefore not required to make a formal assessment of the effectiveness of our internal control over financial reporting for that purpose. Pursuant to Section&nbsp;404, we will
be required to furnish a report by our management on our internal control over financial reporting. However, while we remain an emerging growth company or a smaller reporting company, we will not be required to include an attestation report on
internal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section&nbsp;404 within the prescribed period, we will be engaged in a
process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a
detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a
continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over
financial reporting is effective as required by Section&nbsp;404. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial
statements. In addition, if we are not able to continue to meet these requirements, we may not be able to remain listed on the Nasdaq Global Market. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole
source of gain. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our
future earnings, if any, to finance the growth and development of our business. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to securities litigation, which is expensive and could divert management attention. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market price of our common stock may be volatile and, in the past, companies that have experienced volatility in the market price of their
stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#146;s attention from other
business concerns, which could seriously harm our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc796801_4"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus, including the sections entitled &#147;Prospectus Summary,&#148; &#147;Risk Factors,&#148; &#147;Use of Proceeds,&#148;
&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; and &#147;Business&#148; contains forward-looking statements. The words &#147;believe,&#148; &#147;may,&#148; &#147;will,&#148;
&#147;potentially,&#148; &#147;estimate,&#148; &#147;continue,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;could,&#148; &#147;would,&#148; &#147;project,&#148; &#147;plan&#148; &#147;expect,&#148; and similar expressions that convey
uncertainty of future events or outcomes are intended to identify forward-looking statements. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in &#147;Risk Factors&#148; and
elsewhere in this prospectus. Moreover, we operate in a competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on
our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the
forward-looking events and circumstances discussed in this prospectus may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. The forward-looking statements include,
but are not limited to, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ongoing and planned clinical trials of <FONT STYLE="white-space:nowrap">GB-102</FONT> and our planned
clinical trials of GB-103 and <FONT STYLE="white-space:nowrap">GB-401;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success, cost and timing of our development activities, preclinical studies and clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the translation of our preclinical results and data and early clinical trial results into future clinical trials
in humans; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effects of the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, and the corresponding
responses of businesses and governments, on our business and financial results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing or likelihood of regulatory filings and approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to receive the required regulatory approvals to market and sell our products in the United States and
other countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to develop sales and marketing capabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate and degree of market acceptance of any products we are able to commercialize; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effects of increased competition as well as innovations by new and existing competitors in our market;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain funding for our operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish and maintain collaborations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to effectively manage our anticipated growth; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain, protect and enhance our intellectual property rights and proprietary technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to operate our business without infringing the intellectual property rights and proprietary
technology of third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs associated with defending intellectual property infringement, product liability and other claims;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory developments in the United States and other foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain qualified employees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the period during which we qualify as an emerging growth company under the JOBS Act;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">statements regarding future revenue, hiring plans, expenses, capital expenditures, capital requirements and stock
performance; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expected use of proceeds of this offering. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The forward-looking statements in this prospectus represent our views as of the date of this prospectus. You should not rely upon
forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events
and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this prospectus to conform these statements to
actual results or to changes in our expectations, except as required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus and the documents that we
reference in this prospectus and have filed with the Securities and Exchange Commission as exhibits to the registration statement of which this prospectus is a part with the understanding that our actual future results, levels of activity,
performance, and events and circumstances may be materially different from what we expect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains estimates and other
statistical data made by independent parties and by us relating to our industry and the markets in which we operate, including our general expectations and market position, market opportunity, the incidence of certain medical conditions and other
industry data. These data, to the extent they contain estimates or projections, involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates or projections. Industry publications and other reports
we have obtained from independent parties generally state that the data contained in these publications or other reports have been obtained in good faith or from sources considered to be reliable, but they do not guarantee the accuracy or
completeness of such data. The industry in which we operate is subject to risks and uncertainties due to a variety of factors, including those described in the section entitled &#147;Risk Factors.&#148; These and other factors could cause results to
differ materially from those expressed in these publications and reports. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc796801_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds from our sale of shares of common stock in this offering at an assumed initial public offering price of
$16.00 per share, which is the midpoint of the estimated price range set forth on the cover of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses, will be approximately $65.8 million, or
$76.2 million if the underwriters exercise their option to purchase additional shares in full. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each $1.00 increase (decrease) in the
assumed initial public offering price of $16.00 per share, which is the midpoint of the estimated price range set forth on the cover of this prospectus, would increase (decrease) the net proceeds to us from this offering by $4.4 million, assuming
the number of shares offered, as set forth on the cover of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions. Similarly, each increase (decrease) of 1.0&nbsp;million shares in the number of
shares of common stock offered would increase (decrease) the net proceeds that we receive from this offering by $14.9 million, assuming that the assumed initial public offering price remains the same and after deducting estimated underwriting
discounts and commissions. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June 30, 2020, we had cash and cash equivalents of approximately $17.5&nbsp;million. We currently
intend to use the net proceeds we receive from this offering, together with our existing cash and cash equivalents, as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $17.0 million to fund the development of GB-102, including $6.1&nbsp;million for the completion of
our ongoing Phase&nbsp;2b clinical trial in wet AMD, $1.8 million for the initiation of our Phase&nbsp;2b clinical trial in DME, $8.5 million for the initiation of our Phase&nbsp;3 clinical trials in wet AMD, subject to the success of the
Phase&nbsp;2b trial, and $0.6 million for the initiation of our GB-401 Phase&nbsp;1 clinical trial in glaucoma; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $20.8 million to fund Chemistry, Manufacturing and Controls, or CMC, capital expenditures;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $8.4 million to fund arrangements with contract manufacturing organizations to manufacture clinical
material for our wet AMD and glaucoma clinical trials; and </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any remaining amounts for working capital and general corporate purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our current plans, we estimate that the net proceeds of this offering, together with our existing cash and cash equivalents, will be
sufficient for us to fund our operating expenses and capital expenditure requirements into the fourth quarter of 2021. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The expected
use of the net proceeds from the offering represents our intentions based upon our current plans and business conditions. The amounts we actually expend in these areas, and the timing thereof, may vary significantly from our current intentions and
will depend on a number of factors, including the success of research and product development efforts, cash generated from future operations and actual expenses to operate our business. We may use a portion of the net proceeds for the acquisition
of, or investment in, businesses that complement our business, although we have no present commitments or agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not expect
the net proceeds of this offering to be sufficient for us to fund any of our product candidates through regulatory approval, and we will need to raise substantial additional capital to complete the development and commercialization of our product
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amounts and timing of our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and CMC, manufacturing and controls
expenditures and the extent of clinical development may vary significantly depending on numerous factors, including the status, results and timing of our current preclinical studies and clinical trials and those which we may commence in the future,
product approval process with the FDA and other regulatory agencies, our current collaborations and any new collaborations we may enter into with third parties and any unforeseen cash needs. As a result, we cannot
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
predict with any certainty all of the particular uses for the net proceeds or the amounts that we will actually spend on the uses set forth above. Accordingly, our management will have broad
discretion in the application of the net proceeds, and investors will be relying on the judgment of our management regarding the application of the net proceeds of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pending the uses described above, we intend to invest the net proceeds from this offering in short term, investment-grade interest-bearing
securities such as money market accounts, certificates of deposit, commercial paper and guaranteed obligations of the U.S. government. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc796801_7"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our common stock. We currently intend to retain all available funds and any future earnings
for use in the operation of our business and do not anticipate paying any cash dividends on our common stock in the foreseeable future. Any future determination to declare dividends will be made at the discretion of our board of directors and will
depend on our financial condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc796801_8"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash and cash equivalents and capitalization as of June&nbsp;30, 2020 on: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a pro forma basis, giving effect to (i)&nbsp;the automatic conversion of all outstanding shares of our
convertible preferred stock as of June 30, 2020 into an aggregate of 13,085,913 shares of common stock immediately prior to the completion of this offering and (ii)&nbsp;the filing and effectiveness of our restated certificate of incorporation in
connection with the completion of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a pro forma as adjusted basis, giving effect to (i)&nbsp;the pro forma adjustments described above and
(ii)&nbsp;the sale of 4,687,500 shares of common stock in this offering, based upon an assumed initial public offering price of $16.00&nbsp;per share, which is the midpoint of the estimated price range set forth on the cover of this prospectus,
after deducting estimated underwriting discounts and commissions and estimated offering expenses. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pro forma as
adjusted information set forth in the table below is illustrative only and will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this table together with &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations&#148; and our audited financial statements and related notes, each included elsewhere in this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June 30, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma&nbsp;As<BR>Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(1) </SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(In thousands, except share amounts and<BR>par value share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 17,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">83,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock (Series A, <FONT STYLE="white-space:nowrap">A-2,</FONT> B and C),
$0.0001 par value&#151;142,150,096 shares authorized; 117,809,883 shares issued and outstanding, actual; no shares authorized, issued or outstanding, pro forma or pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.0001 par value: no shares authorized, issued and outstanding, actual;
10,000,000&nbsp;shares authorized, no shares issued and outstanding pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value: 188,000,000 shares authorized; 1,382,200 shares issued and
outstanding, actual; 500,000,000 shares authorized, 14,468,113 shares issued and outstanding, pro forma; 500,000,000&nbsp;shares authorized, 19,155,613 shares issued and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(119,499</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(119,499</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(119,499</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(116,157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">80,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman; " ALIGN="left">Each $1.00 increase (decrease) in the assumed initial public offering price of $16.00&nbsp;per share, which is
the midpoint of the estimated price range set forth on the cover of this prospectus, would increase (decrease) each of our pro forma as adjusted cash and cash equivalents, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total
stockholders&#146; equity (deficit) and total capitalization by approximately $4.4&nbsp;million, assuming that the number of shares offered remains the same and after deducting estimated underwriting discounts and commissions. Similarly, each
increase (decrease) of 1.0&nbsp;million shares in the number of shares of common stock offered would increase (decrease) each of our pro forma as adjusted cash and cash equivalents,
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; equity (deficit) and total capitalization by approximately $14.9 million, assuming the assumed initial
public offering price remains the same and after deducting estimated underwriting discounts and commissions. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman; " ALIGN="left">In connection with our Series C convertible preferred stock financing, up to 17,014,902 shares of convertible
preferred stock could have been issuable upon achievement of certain milestones. Subsequent to June 30, 2020, the Series C stock purchase agreement was amended such that this option is no longer exercisable, and this option will terminate upon the
effectiveness of the registration statement of which this prospectus forms a part. The expiration of this purchase right would have the effect of reducing both liabilities and accumulated deficit by $2.1 million. This has not been reflected in the
above balance sheet data. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table above excludes the following shares: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,066,076 shares of common stock issuable upon the exercise of options outstanding as of June&nbsp;30, 2020, with
a weighted-average exercise price of $2.52 per share under our 2015 Plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">428,621 shares of our common stock issuable upon the exercise of stock options granted after June&nbsp;30, 2020,
with a weighted-average exercise price of $9.25 per share under our 2015 Plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">27,759 shares of common stock issuable upon the exercise of a common stock warrant outstanding as of
June&nbsp;30, 2020, with an exercise price of $3.88 per share; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,708,587 shares of common stock reserved for future issuance under our stock-based compensation plans,
consisting of (i)&nbsp;648,587 shares of common stock reserved for future issuance under our 2015 Stock Incentive Plan as of June&nbsp;30, 2020, (ii) 1,850,000 shares of common stock reserved for future issuance under our 2020 Equity Incentive Plan,
which will become effective on the date immediately prior to the date of this prospectus, which number will be reduced as a result of the grant of 166,624 shares of common stock issuable upon the exercise of stock options (with an exercise price
equal to the initial public offering price) and restricted stock units covering 80,000 shares of common stock, each to be granted on the date of this prospectus, and (iii) 210,000 shares of common stock reserved for future issuance under our 2020
Employee Stock Purchase Plan, which will become effective on the date of this prospectus. Upon completion of this offering, any remaining shares available for issuance under our 2015 Stock Incentive Plan will be added to the shares reserved under
our 2020 Equity Incentive Plan and we will cease granting awards under our 2015 Stock Incentive Plan. Our 2020 Equity Incentive Plan and 2020 Employee Stock Purchase Plan also provide for automatic annual increases in the number of shares reserved
under the plans each year, as more fully described in &#147;Executive Compensation&#151;Equity Compensation Plans.&#148; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc796801_9"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference
between the amount per share paid by purchasers of shares of common stock in this offering and the pro forma as adjusted net tangible book value per share of common stock immediately after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net tangible book value (deficit) per share is determined by dividing our total tangible assets (which excludes deferred offering costs) less
our total liabilities and convertible preferred stock by the number of shares of common stock outstanding. Our historical net tangible book value (deficit) as of June 30, 2020 was $(117.6) million, or $(85.06) per share. Our pro forma net tangible
book value as of June 30, 2020 was approximately $13.8 million, or $0.95 per share of common stock. Our pro forma net tangible book value per share represents the amount of our total tangible assets (which excludes deferred offering costs) reduced
by the amount of our total liabilities and divided by the total number of shares of our common stock outstanding as of June 30, 2020, after giving effect to the automatic conversion of all outstanding shares of our convertible preferred stock into
an aggregate of 13,085,913&nbsp;shares of common stock immediately prior to the completion of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net tangible book value
dilution per share to new investors represents the difference between the amount per share paid by purchasers of shares of common stock in this offering and the pro forma as adjusted net tangible book value per share of common stock immediately
after completion of this offering. After giving effect to (i)&nbsp;the pro forma adjustments set forth above and (ii)&nbsp;our sale in this offering of shares of our common stock at an assumed initial public offering price of $16.00 per share, which
is the midpoint of the estimated price range set forth on the cover of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses, our pro forma as adjusted net tangible book value as of
June 30, 2020 would have been approximately $79.5&nbsp;million, or $4.15 per share of our common stock. This represents an immediate increase in pro forma net tangible book value of $3.20 per share to our existing stockholders and an immediate
dilution of $11.85 per share to investors in this offering, as illustrated in the following table: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value per share as of June 30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(85.06</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in net tangible book value per share attributable to the conversion of outstanding
preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net tangible book value per share as of June 30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in pro forma net tangible book value per share attributable to new investors in this
offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each $1.00 increase (decrease) in the assumed initial public offering price of $16.00 per share,
which is the midpoint of the estimated price range set forth on the cover of this prospectus, would increase (decrease) our pro forma as adjusted net tangible book value by $4.4 million, or $0.23 per share and the dilution in pro forma as adjusted
net tangible book value per share to new investors in this offering by $0.77 per share, assuming the number of shares offered, as set forth on the cover of this prospectus, remains the same, and after deducting estimated underwriting discounts and
commissions. Similarly, each increase of 1.0&nbsp;million shares in the number of shares of common stock offered in this offering would increase our pro forma as adjusted net tangible book value by approximately $14.9 million, or approximately $0.53
per share, and would decrease dilution per share to new investors in this offering by approximately $0.53 per share and each decrease of 1.0&nbsp;million shares in the number of shares of common stock offered in this offering would decrease our pro
forma as adjusted net tangible book value by approximately $14.9 million, or approximately $0.59 per share, and would increase dilution per share to new investors in this offering by approximately $0.59 per share, assuming the assumed initial public
offering price per share remains the same and after deducting the estimated underwriting discounts and commissions. The pro forma as adjusted information is illustrative only, and we will adjust this information based on the actual initial public
offering price and other terms of this offering determined at pricing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the underwriters exercise their option in full to purchase additional shares, the pro
forma as adjusted net tangible book value per share after this offering would be $4.53 per share, the increase in pro forma as adjusted net tangible book value per share to existing stockholders would be $0.38 per share and the dilution to new
investors in this offering would be $11.47 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows, as of June 30, 2020, on a pro forma as adjusted basis
described above, the differences between the existing stockholders and the purchasers of shares in this offering with respect to the number of shares purchased from us, the total consideration paid, which includes net proceeds received from the
issuance of common and convertible preferred stock, cash received from the exercise of stock options, and the value of any stock issued for services and the average price paid per share (in thousands, except share and per share amounts, and
percentages): </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average<BR>Price<BR>Per<BR>Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">14,468,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">133,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New public investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,687,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">19,155,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">208,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each $1.00 increase (decrease) in the assumed initial public offering price of $16.00 per share,
which is the midpoint of the estimated price range set forth on the cover of this prospectus, would increase (decrease) total consideration paid by new investors and total consideration paid by all stockholders by approximately $4.7&nbsp;million,
assuming that the number of shares offered, as set forth on the cover of this prospectus, remains the same. Similarly, each increase (decrease) of 1.0&nbsp;million shares in the number of shares of common stock offered in this offering would
increase (decrease) total consideration paid by new investors and total consideration paid by all stockholders by approximately $16.0&nbsp;million, assuming the assumed initial public offering price remains the same. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, to the extent that any outstanding options or warrants are exercised, investors in this offering will experience further
dilution. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise indicated, the above discussion and tables assume no exercise of the underwriters&#146; option to
purchase additional shares. If the underwriters exercise their option to purchase additional shares in full, our existing stockholders would own 72.9% and our new investors would own 27.1% of the total number of shares of our common stock
outstanding upon the completion of this offering. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of common stock outstanding as of June&nbsp;30, 2020
excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,066,076 shares of common stock issuable upon the exercise of options outstanding as of June&nbsp;30, 2020, with
a weighted-average exercise price of $2.52 per share under our 2015 Plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">428,621 shares of our common stock issuable upon the exercise of stock options granted after June&nbsp;30, 2020,
with a weighted-average exercise price of $9.25 per share under our 2015 Plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">27,759 shares of common stock issuable upon the exercise of a common stock warrant outstanding as of
June&nbsp;30, 2020, with an exercise price of $3.88 per share; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,708,587 shares of common stock reserved for future issuance under our stock-based compensation plans,
consisting of (i) 648,587 shares of common stock reserved for future issuance under our 2015 Stock Incentive Plan as of June&nbsp;30, 2020, (ii) 1,850,000 shares of common stock reserved for future issuance under our 2020 Equity Incentive Plan,
which will become effective on the date immediately prior to the date of this prospectus, which number will be reduced as a result of the grant of 166,624 shares of common stock issuable upon the exercise of stock options (with an exercise price
equal to the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
initial public offering price) and restricted stock units covering 80,000 shares of common stock, each to be granted on the date of this prospectus, and (iii) 210,000 shares of common stock
reserved for future issuance under our 2020 Employee Stock Purchase Plan, which will become effective on the date of this prospectus. Upon completion of this offering, any remaining shares available for issuance under our 2015 Stock Incentive Plan
will be added to the shares reserved under our 2020 Equity Incentive Plan and we will cease granting awards under our 2015 Stock Incentive Plan. Our 2020 Equity Incentive Plan and 2020 Employee Stock Purchase Plan also provide for automatic annual
increases in the number of shares reserved under the plans each year, as more fully described in &#147;Executive Compensation&#151;Equity Compensation Plans.&#148; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc796801_10"></A>SELECTED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The statements of operations data for the years ended December&nbsp;31, 2019 and 2018 and the balance sheet data as of December 31, 2019
have been derived from our audited financial statements and related notes included elsewhere in this prospectus. The summary statements of operations data presented below for the six months ended June&nbsp;30, 2020 and 2019 and the balance sheet
data as of June 30, 2020 are derived from our unaudited financial statements included elsewhere in this prospectus. Our unaudited interim condensed financial statements have been prepared on the same basis as our audited annual financial statements
and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair statement of the information for the interim periods presented. You should read this data together with our financial
statements and related notes included elsewhere in this prospectus and in the section of this prospectus titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; Our historical results are not
necessarily indicative of the results to be expected in the future. The selected financial data included in this section are not intended to replace the financial statements and related notes included elsewhere in this prospectus. </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statements of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,836</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,609</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,502</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,570</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest and other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,663</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,558</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,037</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,378</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cumulative dividends on convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,793</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,585</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,055</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,317</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,456</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19,143</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(44,092</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,695</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per common share&#151;basic and
diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13.40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14.78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(33.41</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25.77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used in</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">computing net loss per common share&#151;basic and
diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,377,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,295,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,319,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,268,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per common share&#151;basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.94</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.09</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used in computing pro forma net loss per common share&#151;basic
and diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,463,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,001,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See Notes 2, 13 and 14 of our audited financial statements for the years ended December&nbsp;31, 2019 and 2018
and Notes 9 and 10 of our unaudited financial statements for the six month periods ended June 30, 2020 and 2019 included elsewhere in this prospectus for a description of the calculations of our basic and diluted net loss per common share, pro forma
basic and diluted net loss per common share, and the weighted-average number of shares used in the computation of the per share amounts. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of<BR>June&nbsp;30,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of<BR>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(119,499</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(105,836</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(116,157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102,954</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We define working capital as current assets less current liabilities. See our audited and unaudited financial
statements and related notes included elsewhere in this prospectus for further details regarding our current assets and current liabilities. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In connection with our Series&nbsp;C convertible preferred stock financing, up to 17,014,902&nbsp;shares of
convertible preferred stock could have been issuable upon achievement of certain milestones. Subsequent to June&nbsp;30, 2020, the Series&nbsp;C stock purchase agreement was amended such that this option is no longer exercisable, and this option
will terminate upon the effectiveness of the registration statement of which this prospectus for. The expiration of this purchase right would have the effect of reducing both liabilities and accumulated deficit by $2.1&nbsp;million. This has not
been reflected in the above balance sheet data. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc796801_11"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion and analysis of our financial condition and results of operations together with the section
entitled &#147;Selected Financial Information&#148; and our financial statements and related notes appearing elsewhere in this prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this prospectus,
including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the
section entitled &#147;Risk Factors,&#148; our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. You should carefully read the
section entitled &#147;Risk Factors&#148; to gain an understanding of the important factors that could cause actual results to differ materially from our forward- looking statements. Please also see the section entitled &#147;Special Note Regarding
Forward-Looking Statements.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina
and optic nerve. Our novel proprietary technologies are designed to release drugs in ocular tissue at a controlled rate for up to 12 months in order to improve patient compliance, reduce healthcare burdens and, ultimately, deliver better clinical
outcomes. Our lead product candidate, GB-102, is an intravitreal injection of a microparticle depot formulation of sunitinib, a potent inhibitor of neovascular growth and permeability, which are leading causes of retinal disease. We are developing
GB-102 as a once-every-six months intravitreal injection for the treatment of wet age-related macular degeneration, or wet AMD, and diabetic macular edema, or DME. In our Phase 1/2a clinical trial, GB-102 administered as a single 1 mg dose was
well-tolerated in wet AMD patients and demonstrated durable clinical evidence of disease control of at least six months in approximately 88% of patients in this cohort. GB-102 is currently in a dose-ranging, controlled and masked safety and efficacy
Phase 2b clinical trial in patients with wet AMD. We expect to report topline data from this trial in the first half of 2021. We are also using our proprietary technologies to develop GB-103, a once-a-year formulation of GB-102, for the treatment of
diabetic retinopathy, or DR, as well as GB-401, an intravitreally injectable depot formulation of a beta-adrenergic blocking agent prodrug with a dosing regimen of once every six months or longer for the treatment of primary open-angle glaucoma, or
POAG. We believe that our product candidates could significantly improve clinical outcomes versus the respective standards of care for several ocular diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated in May 2011 and our operations to date have been financed primarily by gross proceeds of approximately $134&nbsp;million
from the issuance of convertible promissory notes and convertible preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception, we have had significant operating
losses. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures and, to a lesser extent, general and administrative expenditures. Our net loss was $37.0&nbsp;million and
$28.4&nbsp;million for the years ended December&nbsp;31, 2019 and 2018, respectively, and $13.7 million for the six months ended June 30, 2020. As of December&nbsp;31, 2019 and June 30, 2020, we had an accumulated deficit of $105.8&nbsp;million and
$119.5 million, respectively. As of June 30, 2020, we had $17.5&nbsp;million in cash and cash equivalents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue to incur
net losses for the foreseeable future, and we expect our research and development expenses, general and administrative expenses, and capital expenditures will continue to increase. In particular, we expect our expenses to increase as we continue our
development of, and seek regulatory approvals for, our product candidates, and begin to commercialize any approved products, as well as hire additional personnel, develop commercial infrastructure, pay fees to outside consultants, lawyers and
accountants, and incur increased costs associated with being a public company, such as expenses related to services associated with maintaining compliance with Nasdaq listing rules and Securities and Exchange Commission, or SEC, reporting
requirements, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
insurance and investor relations costs. Our net losses may fluctuate significantly from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">quarter-to-quarter</FONT></FONT> and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-year,</FONT></FONT> depending upon the timing of our clinical trials and our expenditures on other research and development activities. Cash used to fund operating expenses is
impacted by the timing of when we pay these expenses, as reflected in the change in our accounts payable and accrued expenses. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based
upon our operating plan, we believe that the net proceeds from this initial public offering, or IPO, together with our existing cash and cash equivalents as of June 30, 2020, will enable us to fund our operating expenses and capital expenditure
requirements into the fourth quarter of 2021. To date, we have not had any products approved for sale and, therefore, have not generated any product revenue. We do not expect to generate any revenues from product sales unless and until we
successfully complete development and obtain regulatory approval for one or more of our product candidates, which we expect will take a number of years. If we obtain regulatory approval for any of our product candidates, we expect to incur
significant commercialization expenses related to product sales, marketing, manufacturing and distribution. As a result, until such time, if ever, that we can generate substantial product revenue, if ever, we expect to finance our cash needs through
equity offerings, debt financings or other capital sources, including collaborations, licenses or similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed or on favorable terms, if
at all. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies, including our research and development activities. If we are unable to
raise capital, we will need to delay, reduce or terminate planned activities to reduce costs. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our independent registered public
accounting firm included an explanatory paragraph in their audit report on the financial statements as of and for the years ended December&nbsp;31, 2018 and 2019 stating that our recurring losses from operations and negative cash flows since
inception and our need to raise additional funding to finance our operations raise substantial doubt about our ability to continue as a going concern. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Business Effects of <FONT STYLE="white-space:nowrap">COVID-19</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has presented a substantial public health and economic challenge around
the world and is affecting our employees, patients, communities and business operations, as well as the U.S. economy and financial markets. To date, our financial conditions and operations have not been significantly impacted by the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> outbreak; however, the full extent to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic will directly or indirectly impact our business, results of operations, liquidity and financial
condition will depend on future developments, which are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning <FONT STYLE="white-space:nowrap">COVID-19,</FONT> the actions taken to contain it or
treat its impact and the economic impact on local, regional, national and international markets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, our contract research
organizations, or CROs, contract manufacturing organizations, or CMOs, and other vendors have been able to continue to provide services and supply reagents, materials, and products and currently do not anticipate any disruption in services or
interruptions in supply. Our third-party contract manufacturing partners continue to operate their manufacturing facilities at or near normal levels. While we currently do not anticipate any interruptions in our manufacturing process, it is possible
that the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and response efforts may have an impact in the future on our third-party suppliers and contract manufacturing partners&#146; ability to manufacture reagents, materials or products
that we need to use in our research and clinical trial. However, we are continuing to assess the potential impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our business and operations, including our expenses, our clinical
trial, and our ability to hire and retain employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we are currently continuing to dose patients in our clinical trial at sites
across the United States, we expect that <FONT STYLE="white-space:nowrap">COVID-19</FONT> precautions may directly or indirectly impact the timeline for some of our clinical trial activities due to hospitals closing sites and/or diverting the
resources that are necessary to conduct our observational study to care for <FONT STYLE="white-space:nowrap">COVID-19</FONT> patients. Currently we have experienced minor delays in the dosing of patients due to
<FONT STYLE="white-space:nowrap">COVID-19.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has caused us to modify our
business practices (including but not limited to curtailing or modifying employee travel, moving to partial remote work, and cancelling physical participation in meetings, events and conferences), and we may take further actions as may be required
by government authorities or that we determine are in the best interests of our employees, patients and business partners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
office-based employees have been working from home since March 2020, while ensuring essential staffing levels in our operations remain in place, including maintaining key personnel in our laboratories. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For additional information on the various risks posed by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, please read Item 1A.
Risk Factors included in this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of Operating Results </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development expenses include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">personnel costs, which include salaries, benefits and stock-based compensation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses incurred under agreements with consultants, third-party contract organizations that conduct research and
development activities on our behalf; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to sponsored research service agreements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to production of preclinical and clinical materials, including fees paid to contract manufacturers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">laboratory and vendor expenses related to the execution of preclinical studies and planned clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">milestones and royalty expense from our Johns Hopkins University Exclusive License Agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">laboratory supplies and materials used for internal research and development activities; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">facilities and equipment costs. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Most of our research and development expenses have been related to the preclinical and clinical development of
<FONT STYLE="white-space:nowrap">GB-102.</FONT> We have not reported program costs since inception because we have not tracked or recorded our research and development expenses on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis historically. We use our personnel and infrastructure resources across the breadth of our research and development activities, which are
directed toward identifying and developing product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expense all research and development costs in the periods in which they
are incurred. Costs for certain research and development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and third-party service providers.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our research and development expenses to increase substantially for the foreseeable future as we continue to invest in research
and development activities related to developing our product candidates, including investments in manufacturing, as we advance our programs and conduct clinical trials. The process of conducting the necessary clinical research to obtain regulatory
approval is costly and time-consuming, and the successful development of our product candidates is highly uncertain. As a result, we are unable to determine the duration and completion costs of our research and development projects or when and to
what extent we will generate revenue from the commercialization and sale of any of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the numerous risks
and uncertainties associated with product development, we cannot determine with certainty the duration and completion costs of the current or future preclinical studies and clinical trials or if, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
when, or to what extent we will generate revenues from the commercialization and sale of our product candidates. We may never succeed in achieving regulatory approval for our product candidates.
The duration, costs and timing of preclinical studies and clinical trials and development of our product candidates will depend on a variety of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful completion of preclinical studies and clinical trials to the satisfaction of the FDA, EMA or other
regulatory authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that our product candidates are safe and effective for any of their proposed indications; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acceptance of our products, if and when approved, by patients, the medical community and third-party payors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effectively competing with other therapies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining a continued acceptable safety and profile of our products following approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and maintaining coverage and adequate reimbursement from third-party payors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">applying for and receiving marketing approvals from applicable regulatory authorities for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">scaling up our manufacturing processes and capabilities to support additional or larger clinical trials of our
product candidates and commercialization of any of our product candidates for which we obtain marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing, validating and maintaining a commercially viable manufacturing process that is compliant with current
good manufacturing practices; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing and expanding our sales, marketing and distribution capabilities and launching commercial sales of our
product candidates, if and when approved, whether alone or in collaboration with others; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">minimizing and managing any delay or disruption to our ongoing or planned clinical trials, and any adverse
impacts to the U.S. and global market for pharmaceutical products, as a result of the current <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">protecting our rights in our intellectual property portfolio; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and the corresponding responses of
businesses and governments. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may never succeed in achieving regulatory approval for any of our product candidates. We
may obtain unexpected results from our preclinical studies and clinical trials. We may elect to discontinue, delay or modify clinical trials of some product candidates or focus on others. A change in the outcome of any of these factors could mean a
significant change in the costs and timing associated with the development of our current and future preclinical and clinical product candidates. For example, if the U.S. Food and Drug Administration, or FDA, or another regulatory authority, were to
require us to conduct clinical trials beyond those that we currently anticipate will be required for the completion of clinical development, or if we experience significant delays in execution of or enrollment in any of our preclinical studies or
clinical trials, we could be required to expend significant additional financial resources and time on the completion of preclinical and clinical development. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our general and administrative expenses consist primarily of personnel costs, costs related to maintenance and filing of intellectual property
and other expenses for outside professional services, including legal, human resources, audit and accounting services. Personnel costs consist of salaries, benefits and stock-based compensation expense. We expect our general and administrative
expenses to increase over the next several </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
years to support our continued research and development activities, manufacturing activities, increased costs of operating as a public company and the potential commercialization of our product
candidates. We also anticipate our general and administrative costs will increase and with respect to the hiring of additional personnel, developing commercial infrastructure, fees to outside consultants, lawyers and accountants, and increased costs
associated with being a public company such as expenses related to services associated with maintaining compliance with Nasdaq listing rules and SEC reporting requirements, insurance and investor relations costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Interest and Other Income </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our interest and other income principally reflects interest earned on our investments, including U.S. government-backed money-market funds,
corporate debt securities, commercial paper and government agency bonds. Interest and other income also includes changes in the fair value of our preferred stock tranche obligation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of operations for the Six Months Ended June 30, 2020 and 2019 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following sets forth our results of operations: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,450</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,773</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,836</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,609</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest and other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">239</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,663</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,558</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses were comprised of: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CRO, CMC, nonclinical and other services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,925</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consulting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(188</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Materials and supplies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,225</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(76</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facility costs, travel and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(127</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,450</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June 30, 2020 and 2019, we had 20 and 22 employees, respectively, engaged in research and development
activities in our Baltimore, Maryland and Redwood City, California facilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development activities consist primarily
of costs associated with the development of <FONT STYLE="white-space:nowrap">GB-102</FONT> for which we are conducting two U.S. Phase&nbsp;2 clinical trials in patients with wet age-related macular degeneration, or wet AMD, and diabetic macular
edema, or DME. The decrease for the six months ended June&nbsp;30, 2020 as compared to 2019 was primarily due to the completion of preparations ahead of the commencement of our development program for GB-102. In addition, we were not engaged in any
primary CMC manufacturing activities in the six month period ended June&nbsp;30, 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses to support our business activities were comprised of: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(75</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">157</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent filing and portfolio costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facility costs, travel and other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(188</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2020 and 2019, we had four and five employees, respectively, engaged in general and
administrative activities principally in our Redwood City, California facility. Professional service costs increased in the six months ended June 30, 2020 as compared to 2019 due to additional audit, tax, legal and other consulting services related
in part to our expected initial public offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Interest and Other Income </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest and other income include interest income of $117,000 and $51,000 for the six months ended June&nbsp;30, 2020 and 2019, respectfully.
Following our Series&nbsp;C convertible preferred stock, or Series C preferred, financing in July 2019, we expanded our investments to include U.S. government backed money market funds, corporate debt securities, commercial paper and government
agency bonds. Cash in excess of immediate requirements is placed in a custodial account and invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest and other income for the six months ended June&nbsp;30, 2020 also includes fair value adjustments of $56,000 with respect to our
preferred stock tranche obligation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations for years ended December&nbsp;31, 2019 and 2018 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following sets forth our results of operations: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,502</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,570</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,932</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest and other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">142</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(37,037</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,378</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,659</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses were comprised of: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CRO, CMC, nonclinical and other services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consulting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(476</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Materials and supplies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facility costs, travel and other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019 and 2018, we had 25 and 24 employees, respectively, engaged in research and
development activities in our Baltimore, Maryland and Redwood City, California facilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development activities
consist primarily of costs associated with the development of <FONT STYLE="white-space:nowrap">GB-102</FONT> for which we are conducting two U.S. trials in patients with wet AMD.&nbsp;The increase for the year ended December&nbsp;31, 2019 as
compared to 2018 was primarily due to the commencement of our development program for <FONT STYLE="white-space:nowrap">GB-102</FONT> including the enrollment and site activation of our Phase 2b trial of <FONT STYLE="white-space:nowrap">GB-102</FONT>
in patients with wet AMD and the initiation of Phase 2a trial of <FONT STYLE="white-space:nowrap">GB-102</FONT> in patients with macular edema. CMC activities in support of the studies and clinical trials included internal formulation development,
preclinical and clinical programs, comparator drug, GMP drug product batches, including sunitinib active pharmaceutical ingredient and polymers, and clinical packaging costs.&nbsp;Nonclinical activities included in good laboratory practice, or GLP,
toxicity studies and several ocular <FONT STYLE="white-space:nowrap">non-GLP</FONT> pharmacokinetic/pharmacodynamic studies in experimental animal models. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses to support the business activities of the company and were comprised of: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent filing and portfolio costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(317</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facility costs, travel and other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019 and 2018, we had four employees engaged in general and administrative activities
principally in our Redwood City, California facility. Personnel and professional service costs increased in the year ended December&nbsp;31, 2019 as compared to 2018 as a result of changes in our chief executive and chief financial officers,
including severance costs paid to our former interim chief executive and chief financial officers, the hiring of Frederic Guerard as chief executive officer and the contracting of Daniel Geffken as interim chief financial officer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Interest and Other Income </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following our Series B convertible preferred stock, or Series B preferred, financings in 2018, we began investing a portion of our capital in
U.S. government backed money market funds held in a custodial account. Following our Series C preferred financing in July 2019, we expanded our investments to include corporate debt </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
securities, commercial paper and government agency bonds. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to liquidity and
capital preservation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Overview </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were
incorporated in May 2011 and our operations to date have been financed primarily by gross proceeds of approximately $134&nbsp;million from the sale of convertible promissory notes and our convertible preferred stock, including our most recent
financing in July 2019. As of June 30, 2020, we had $17.5&nbsp;million in cash and cash equivalents. We have incurred losses since our inception and, as of June&nbsp;30, 2020, we had an accumulated deficit of $119.5&nbsp;million. Our primary use of
cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay
these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our independent registered public
accounting firm included an explanatory paragraph in their audit report on the financial statements as of and for the years ended December&nbsp;31, 2018 and 2019 stating that our recurring losses from operations and negative cash flows since
inception and our need to raise additional funding to finance our operations raise substantial doubt about our ability to continue as a going concern. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Funding Requirements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any
product candidates we may develop may never achieve commercialization and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses, and
capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital
sources, including potentially collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research, manufacturing and
development services, costs relating to the <FONT STYLE="white-space:nowrap">build-out</FONT> of our headquarters, laboratories and manufacturing facility, license payments or milestone obligations that may arise, laboratory and related supplies,
clinical costs, manufacturing costs, legal and other regulatory expenses and general overhead costs. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon our current operating
plan, we believe that the net proceeds from this offering, together with our existing cash and cash equivalents, will enable us to fund our operating expenses and capital expenditure requirements into the fourth quarter of 2021. We base this
estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. As noted in our audited financial statements, there were conditions that raised substantial doubt about our
ability to continue as a going concern for a period of one year from the date of the issuance of our financial statements. Our ability to continue as a going concern is dependent upon our ability to successfully secure sources of financing and
ultimately achieve profitable operations. Our independent registered public accounting firm included an explanatory paragraph in their audit report on the financial statements as of and for the years ended December&nbsp;31, 2018 and 2019 stating
that our recurring losses from operations and negative cash flows since inception and our need to raise additional funding to finance our operations raise substantial doubt about our ability to continue as a going concern. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire
or <FONT STYLE="white-space:nowrap">in-license</FONT> other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including
potentially collaborations, licenses and other similar arrangements. However, we may be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If we do raise additional capital through public or private equity offerings, the
ownership interest of our existing stockholders, including investors in this offering, will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#146; rights. If we raise
additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Any failure to raise
capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. If we are unable to raise capital, we will need to delay, reduce or terminate planned activities to
reduce costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and uncertainties associated with research, development and commercialization of
pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, results and costs of researching, developing and manufacturing our lead product candidates
or any future product candidates, and conducting preclinical studies and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of, and the costs involved in, obtaining regulatory approvals or clearances for our lead product
candidates or any future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and characteristics of any additional product candidates we develop or acquire; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of manufacturing our lead product candidate or any future product candidates and any products we
successfully commercialize, including costs associated with <FONT STYLE="white-space:nowrap">building-out</FONT> our manufacturing capabilities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial
terms of any such agreements that we may enter into; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expenses needed to attract and retain skilled personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs associated with being a public company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, receipt and amount of sales of any future approved or cleared products, if any; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and the corresponding responses of
businesses and governments. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, our operating plans may change, and we may need additional funds to meet
operational needs and capital requirements for clinical trials and other research and development activities. We currently have no credit facility or committed sources of capital. Because of the numerous risks and uncertainties associated with the
development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated product development programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table summarizes our cash flows for the periods indicated: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,933</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,663</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(31,215</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,216</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(336</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,620</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,461</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,990</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Operating Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash used in operating activities of $16.9 million during the six months ended June 30, 2020 was attributable to our net loss of $13.7 million
and an increase of $3.8 million in our working capital, offset by non-cash charges of $0.6&nbsp;million principally with respect to equity-based compensation and depreciation expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash used in operating activities of $10.7 million during the six months ended June 30, 2019 was attributable to our net loss of $16.6 million
off-set by a decrease of $5.5 million in our working capital and non-cash charges of $0.4&nbsp;million with respect to equity-based compensation and depreciation expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash used in operating activities of $31.2&nbsp;million during the year ended December&nbsp;31, 2019 was attributable to our net loss of
$37.0&nbsp;million, offset by a $4.9&nbsp;million net increase in our working capital and <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $0.9&nbsp;million principally with respect to stock-based compensation and depreciation expense.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash used in operating activities of $28.2&nbsp;million during the year ended December&nbsp;31, 2018 was attributable to our net loss of
$28.4&nbsp;million, offset by <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $0.5&nbsp;million principally with respect to stock-based compensation and depreciation expense, and increased $0.4&nbsp;million due to a net decrease in our
working capital. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Investing Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash provided by investing activities during the six months ended June 30, 2020 consisted of $0.2&nbsp;million of purchases of property and
equipment and $20.1 million provided on maturity of short-term investments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash provided by investing activities during the six months
ended June 30, 2019 consisted of $0.3&nbsp;million of purchases of property and equipment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2019, our
investing activities consisted of a $20.0&nbsp;million net increase of our investments and $0.6&nbsp;million in purchases of property and equipment. For the year-ended December&nbsp;31, 2018, our investing activities consisted $1.5&nbsp;million in
purchases of property and equipment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Financing Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash used in financing activities for the six months ended June 30, 2020 of $1.3 million was principally related to the payment of offering
costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash provided by financing activities for the six months ended June 30, 2019 relates to proceeds received on the exercise of stock
options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash provided by financing activities for the year ended December&nbsp;31, 2019 amounted to $54.9&nbsp;million comprised of
$54.8&nbsp;million net proceeds upon the issuance of our Series C preferred in July and August 2019, and $0.1&nbsp;million received from the exercise of stock options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash provided by financing activities for the year ended December&nbsp;31, 2018 amounted to $42.0&nbsp;million comprised of $41.9&nbsp;million
net proceeds upon the issuance of our Series B preferred in January and May 2018, and $0.1&nbsp;million received from the exercise of stock options. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Significant Judgments and Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management&#146;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which
have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and
the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis
for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies
relate to the more significant areas involving management&#146;s judgments and estimates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expense and
Accruals </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We record research and development expenses to operations as incurred. Research and development expenses represent costs
incurred by us for the discovery and development of our product candidates and the development of our technology and include: employee-related expenses, including salaries, benefits, travel and <FONT STYLE="white-space:nowrap">non-cash</FONT>
stock-based compensation expense; external research and development expenses incurred under arrangements with third parties, such as CROs, preclinical testing organizations, CMOs, academic and <FONT STYLE="white-space:nowrap">non-profit</FONT>
institutions and consultants; license fees; and other expenses, which include direct and allocated expenses for laboratory, facilities and other costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the process of preparing financial statements, we are required to estimate and accrue expenses We estimate costs of research and
development activities conducted by service providers, which include, the conduct of sponsored research, preclinical studies and contract manufacturing activities. Payments made prior to the receipt of goods or services to be used in research and
development are deferred and recognized as expense in the period in which the related goods are received or services are rendered. If the costs have been prepaid, this expense reduces the prepaid expenses in the balance sheet, and if not yet
invoiced, the costs are included in accrued liabilities in the balance sheet. We classify such prepaid assets as current or <FONT STYLE="white-space:nowrap">non-current</FONT> assets based on our estimates of the timing of when the goods or services
will be realized or consumed. These costs are a significant component of our research and development expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate these costs
based on factors such as estimates of the work completed and budget provided and in accordance with agreements established with our collaboration partners and third-party service providers. We estimate the amount of work completed through
discussions with internal personnel and external service providers as to the progress or stage of completion of the services and the agreed-upon fee to be paid for such services. We make significant judgments and estimates in determining the accrued
balance in each reporting period. As actual costs become known, we adjust our accrued estimates. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of
services performed may vary from our estimates and could result in us reporting amounts that are too high or too low in any particular period. Our accrued expenses are dependent, in part, upon the receipt of timely and accurate reporting from
external CROs and other third-party service providers. Amounts ultimately incurred in relation to amounts accrued for these services at a reporting date may be substantially higher or lower than our estimates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our expenses related to clinical trials are based on estimates of patient enrollment and related expenses at clinical investigator sites as
well as estimates for the services received and efforts expended pursuant to contracts with multiple research institutions and contract research organizations that may be used to conduct and manage clinical trials on our behalf. We generally accrue
expenses related to clinical trials based on contracted amounts applied to the level of patient enrollment and activity. If timelines or contracts are modified based upon changes in the clinical trial protocol or scope of work to be performed, we
modify our estimates of accrued expenses accordingly on a prospective basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have and may continue to enter into license agreements to
access and utilize certain technology. We evaluate if the license agreement is an acquisition of an asset or a business. To date none of our license agreements have been considered to be an acquisition of a business. For asset acquisitions, the
upfront payments to acquire such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
licenses, as well as any future milestone payments made before product approval, are immediately recognized as research and development expense when due, provided there is no alternative future
use of the rights in other research and development projects. These license agreements may also include contingent consideration in the form of cash. We assess whether such contingent consideration meets the definition of a derivative. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Stock Tranche Obligation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Convertible preferred stock that includes features we have determined are not clearly and closely related to the equity host are bifurcated and
accounted for separately as freestanding derivative assets or liabilities on the balance sheet at their estimated fair value. This derivative liability is a result of certain investors&#146; rights to purchase from us, on the same terms as the
Series C Preferred Stock Purchase Agreement executed in July 2019, additional shares of Series C preferred in subsequent tranches based on the achievement of certain development milestones. At initial recognition, we recorded these derivatives as an
asset or liability on the balance sheets at their estimated fair value. The derivatives are subject to remeasurement at each balance sheet date, with changes in fair value recognized in our statements of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our preferred stock tranche obligation is measured at fair value using an option pricing valuation methodology. The fair value of preferred
stock tranche obligation includes inputs not observable in the market and thus represents a Level&nbsp;3 measurement. The option pricing valuation methodology utilized requires inputs based on certain subjective assumptions, including
(a)&nbsp;expected stock price volatility, (b)&nbsp;calculation of an expected term, (c)&nbsp;a risk-free interest rate, and (d)&nbsp;expected dividends. The assumptions utilized to value the preferred stock tranche obligation as of December&nbsp;31,
2019 were (a)&nbsp;expected stock price volatility of 30%; (b) expected term of 0.7 years: (c)&nbsp;a risk-free interest rate of 1.6%; and (d)&nbsp;an expectation of no dividends. The assumptions utilized to value the preferred stock tranche
obligation as of June 30, 2020 were (a) expected stock price volatility of 50%; (b) expected term of 0.3 years; (c) a risk-free interest rate of 0.16%; (d) an expectation of no dividends; and (e) a 51% probability of being settled. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant judgment is used in determining these assumptions at initial recognition and at each subsequent reporting period. Updates to
assumptions could have a significant impact on our results of operations in any given period. In the IPO, all of our outstanding convertible preferred stock will automatically convert into shares of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Stock-based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize compensation costs related to stock-based awards to employees and <FONT STYLE="white-space:nowrap">non-employees</FONT> based on
the estimated fair value of the awards on the date of grant. We estimate the grant date fair value, and the resulting stock-based compensation, using the Black-Scholes option-pricing model, or Black-Scholes. The grant date fair value of the
stock-based awards is generally recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Black-Scholes requires the use of subjective assumptions to determine the fair value of stock-based awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These assumptions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Fair Value of Common Stock</I>&#151;Historically, for all periods prior to this IPO, the fair value of the
shares of common stock underlying our stock-based awards was estimated on each grant date by our board of directors. In order to determine the fair value of our common stock underlying option grants, our board of directors considered, among other
things, contemporaneous valuations of our common stock. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Expected Term</I>&#151;The expected term represents the period that stock-based awards are expected to be
outstanding. The expected term for option grants is determined using the simplified method. The simplified method deems the expected term to be the midpoint between the vesting date and the contractual life of the stock-based awards.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Expected Volatility</I>&#151;Since we have been a privately held company and do not have any trading history
for our common stock, the expected volatility is estimated based on the average volatility for comparable publicly traded biotechnology companies over a period equal to the expected term of the stock option grants. The comparable companies were
chosen based on their similar size, stage in the life cycle or area of specialty. We will continue to apply this process until a sufficient amount of historical information regarding the volatility of our own stock price becomes available.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Risk-Free Interest Rate</I>&#151;The risk-free interest rate is based on the U.S. Treasury zero coupon issues
in effect at the time of grant for periods corresponding with the expected term of option. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Expected Dividend</I>&#151;We have never paid dividends on our common stock and have no plans to pay dividends
on our common stock. Therefore, we used an expected dividend yield of zero. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of each of our awards have
been estimated using Black-Scholes based on the following assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.1&#150;6.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.1&#150;6.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.8%&#150;2.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.6%&#150;3.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will continue to use judgment in evaluating the assumptions utilized for our stock-based compensation
expense calculations on a prospective basis. In addition to the assumptions used in Black-Scholes, the amount of stock-based compensation expense we recognize in our financial statements includes stock option forfeitures as they occurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense for employees and <FONT STYLE="white-space:nowrap">non-employees</FONT> is reflected in the statement of
operations as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Determination of Fair Value of Common Stock on Grant Dates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically, for all periods prior to this IPO, the fair values of the shares of common stock underlying our stock-based awards were estimated
on each grant date by our board of directors with the assistance of management. In order to determine the fair value of our common stock, our board of directors considered, among other things, contemporaneous valuations of our common stock. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="12%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Date of Grant</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares&nbsp;Subject&nbsp;to<BR>Stock-Based<BR>Awards&nbsp;Granted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercise&nbsp;Price</B><br><B>Per Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;Value</B><br><B>Per Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Valuation&nbsp;Date</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February 1, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">568,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">June&nbsp;14,&nbsp;2018</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March 19, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">June 14, 2018</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November 7, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">709,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July 31, 2019</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July 7, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">231,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">June 15, 2020</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the stock-based awards listed above, on September 11, 2020, our board of
directors granted options to purchase 197,111 shares of our common stock with an exercise price equal to the midpoint of the price range set forth on the cover of this prospectus. On September 11, 2020, our board of directors also approved options
to purchase 116,624 shares of our common stock with an exercise price equal to the initial public offering price, as well as restricted stock units covering 80,000 shares of our common stock, in each case to be granted as of the effective date of
the registration statement of which this prospectus forms a part. Finally, on September 16, 2020, our board of directors approved options to purchase 50,000 shares of our common stock with an exercise price equal to the initial public offering
price, to be granted as of the effective date of the registration statement of which this prospectus forms a part. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given the absence
of a public trading market for our common stock, our board of directors exercised their judgment and considered a number of objective and subjective factors to determine the best estimate of the fair value of our common stock, including
contemporaneous valuations, our stage of development, important developments in our operations, the prices at which we sold shares of our preferred stock, the rights, preferences and privileges of our preferred stock relative to those of our common
stock, actual operating results and financial performance, the conditions in the biotechnology industry and the economy in general, the stock price performance and volatility of comparable public companies, and the lack of liquidity of our common
stock, among other factors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining the fair value of our common stock, the methodologies used to estimate our enterprise value
were performed using methodologies, approaches, and assumptions consistent with the guidance outlined in the American Institute of Certified Public Accountants Technical Practice Aid,<I>&nbsp;Valuation of Privately Held Company Equity Securities
Issued as Compensation</I>. The grant date fair value of our common stock was determined using valuation methodologies incorporating a number of assumptions including probability weighting of events, volatility, time to liquidation, a risk-free
interest rate and an assumption for a discount for lack of marketability (Level 3 inputs). The methodology to determine the fair value of our common stock included estimating the fair value of the enterprise using a hybrid-method market approach,
which estimates the fair value of the company by including an estimation of the value of the business based on scenarios in a probability weighted expected return method, or PWERM framework. Under the hybrid-method market approach, the per share
value calculated under the scenarios are weighted based on expected exit outcomes and the quality of the information specific to each allocation methodology to arrive at a final estimated fair value per share value of the common stock before a
discount for lack of marketability is applied. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The scenarios for inferring equity value in determining the fair value of our common stock for the July&nbsp;7,
2020 grants of stock options included: (i)&nbsp;a market-based approach combining (a)&nbsp;a comparison of the company to a selection of similar firms whose stock is publicly-traded, and (b)&nbsp;utilizing transactions of similar companies and
allocating the resultant equity value using an option pricing method, or OPM; and (ii)&nbsp;an IPO scenario based recent IPOs of firms similar to the company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The scenarios for inferring equity value in determining the fair value of our common stock for the
November&nbsp;7, 2019 grants of stock options included: (i)&nbsp;a market-based approach back-solve OPM with reference to our Series C preferred financing; and (ii)&nbsp;an IPO scenario based recent IPOs of firms similar to the company.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The scenarios for inferring equity value in determining the fair value of our common stock for the
February&nbsp;1 and March&nbsp;19, 2019 grants of stock options included: (i)&nbsp;a market-based approach combining (a)&nbsp;a comparison of the company to a selection of similar firms whose stock is publicly-traded, and (b)&nbsp;utilizing
transactions of similar companies and allocating the resultant equity value using an OPM; (ii)&nbsp;an IPO scenario based recent IPOs of firms similar to the company; and (iii)&nbsp;a liquidation scenario. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimates of fair value of our common stock are highly complex and subjective. There are significant judgments and estimates inherent in
the determination of the fair value of our common stock. These judgments and estimates include assumptions regarding our future operating performance, the time to completing an IPO or other liquidity event, the related valuations associated with
these events, and the determinations of the appropriate valuation methods at each valuation date. The assumptions underlying these valuations represent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
management&#146;s best estimates, which involve inherent uncertainties and the application of management judgment. If we had made different assumptions, our stock-based compensation expense, net
loss and net loss per share applicable to common stockholders could have been materially different. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The intrinsic value of all
outstanding options as of June 30, 2020 was approximately $27.8 million, based on the assumed initial public offering price of $16.00&nbsp;per share, which is the midpoint of the estimated initial public offering price range set forth on the cover
page of this prospectus, of which approximately $12.3 million is related to vested options and approximately $15.5 million is related to unvested options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the completion of this offering, our board of directors intends to determine the fair value of our common stock based on the closing
price of our common stock on the date of grant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Emerging Growth Company and Smaller Reporting Company Status </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an emerging growth company, as defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised
accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that
have different effective dates for public and private companies until the earlier of the date we (i)&nbsp;are no longer an emerging growth company or (ii)&nbsp;affirmatively and irrevocably opt out of the extended transition period provided in the
JOBS Act. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also a &#147;smaller reporting company,&#148; meaning that the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT>
plus the proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700.0&nbsp;million and our annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal year. We may continue to be a
smaller reporting company after this offering if either (i)&nbsp;the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million or (ii)&nbsp;our annual revenue is less than
$100.0&nbsp;million during the most recently completed fiscal year and the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million. If we are a smaller reporting company at the time
we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the
two most recent fiscal years of audited financial statements in our Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations
regarding executive compensation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recently Adopted Accounting Pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Refer to Note&nbsp;2, &#147;Summary of Significant Accounting Policies,&#148; in the accompanying notes to our financial statements appearing
elsewhere in this prospectus for a discussion of recent accounting pronouncements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations and Commitments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Contractual Obligations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our contractual obligations as of December&nbsp;31, 2019: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Payments due by period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;Than</B><br><B>1 Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1 to 3</B><br><B>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>3 to 5</B><br><B>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More&nbsp;than</B><br><B>5 Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease commitments<SUP STYLE="font-size:85%; vertical-align:top">(1) </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We lease a facility in Redwood City, California under an operating lease that extends through August 2021. We
also lease a facility in Baltimore, Maryland under an operating lease which, as of December&nbsp;31, 2019, extended through December 2020. However, in June 2020, we extended the Baltimore lease 30 months through June 2023, with rent payments of
$32,000 monthly in the first 12 months, $33,000 monthly in the second 12 months, and $34,000 monthly in the last 6 months. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are party to license agreements pursuant to which we have <FONT STYLE="white-space:nowrap">in-licensed</FONT> various intellectual property
rights. The license agreements obligate us to make certain milestone payments related to achievement of specified events, as well as royalties in the <FONT STYLE="white-space:nowrap">low-single</FONT> digits based on sales of licensed products. None
of these events had occurred as of December&nbsp;31, 2019, and no royalties were due from the sales of licensed products. The table above does not include any milestone or royalty payments to the counterparties to these agreements as the amounts,
timing and likelihood of such payments are not known. See &#147;<I>Business&#151;License Agreements</I>&#148; as well as Note&nbsp;7 to our financial statements for additional information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We enter into contracts in the normal course of business with CROs for clinical trials and clinical supply manufacturing and with vendors for
preclinical research studies, research supplies and other services and products for operating purposes. As of December&nbsp;31, 2019, we had commitments of approximately $18.8&nbsp;million with CROs for the clinical trial services due within 12 to
21 months.&nbsp;These contracts generally provide for termination on notice of 60 to 90 days, and therefore we believe that our <FONT STYLE="white-space:nowrap">non-cancelable</FONT> obligations under these agreements are not material. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the periods presented, we did not have, nor do we currently have, any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet
arrangements as defined under SEC rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosures about Market Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Interest Rate Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities. We held cash
and cash equivalents of $17.5&nbsp;million as of June&nbsp;30,&nbsp;2020. We generally hold our cash equivalents in interest-bearing, U.S. government backed money market funds corporate debt securities, commercial paper and government agency bonds
held in a custodial account. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Due to the short-term maturities of our cash equivalents and the low risk
profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc796801_12"></A>BUSINESS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage
biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve. Our novel proprietary technologies are designed to release drugs in ocular tissue at a controlled rate for up to 12
months in order to improve patient compliance, reduce healthcare burdens and, ultimately, deliver better clinical outcomes. Our lead product candidate, <FONT STYLE="white-space:nowrap">GB-102,</FONT> is an intravitreal injection of a microparticle
depot formulation of sunitinib, a potent inhibitor of neovascular growth and permeability, which are leading causes of retinal disease. We are developing <FONT STYLE="white-space:nowrap">GB-102</FONT> as a
<FONT STYLE="white-space:nowrap">once-every-six</FONT> months intravitreal injection for the treatment of wet <FONT STYLE="white-space:nowrap">age-related</FONT> macular degeneration, or wet AMD, and diabetic macular edema, or DME. In our Phase 1/2a
clinical trial, <FONT STYLE="white-space:nowrap">GB-102</FONT> administered as a single 1 mg dose was well-tolerated in wet AMD patients and demonstrated durable clinical evidence of disease control of at least six months in approximately 88% of
patients in this cohort. <FONT STYLE="white-space:nowrap">GB-102</FONT> is currently in a dose-ranging, controlled and masked safety and efficacy Phase 2b clinical trial in patients with wet AMD. We expect to report topline data from this trial in
the first half of 2021. We are also using our proprietary technologies to develop <FONT STYLE="white-space:nowrap">GB-103,</FONT> a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">once-a-year</FONT></FONT> formulation of <FONT
STYLE="white-space:nowrap">GB-102,</FONT> for the treatment of diabetic retinopathy, or DR, as well as <FONT STYLE="white-space:nowrap">GB-401,</FONT> an intravitreally injectable depot formulation of a beta-adrenergic blocking agent prodrug with a
dosing regimen of once every six months or longer for the treatment of primary open-angle glaucoma, or POAG. We believe that our product candidates could significantly improve clinical outcomes versus the respective standards of care for several
ocular diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Age-related macular degeneration, or AMD, is a chronic, progressive disease, a leading cause of vision loss in the
elderly and estimated to affect approximately 15&nbsp;million people in North America. The disease prevalence is approximately 85 to 90% nonexudative, or dry, AMD and 10 to 15% wet AMD. The therapeutic market for wet AMD in 2019 was estimated to be
$7.9&nbsp;billion worldwide and has historically grown by approximately 8% as a consequence of an aging population and the lack of preventative measures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no cure for wet AMD. To maintain vision, patients must receive frequent intravitreal injections, up to 12 times per year, with
short-acting anti-vascular endothelial growth factor, or VEGF, agents. Although the use of anti-VEGF treatments has revolutionized visual outcomes for patients, the need for frequent injection visits combined with the increasing prevalence of this
disease puts an enormous pressure on healthcare systems and represents a severe burden for patients, caregivers and physicians. These dynamics often lead to a reduced frequency of treatment and result in suboptimal visual outcomes in real-world
practice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Damage to the retina as a result of DR includes a number of vision-threatening complications such as DME, and has been an
important cause of acquired vision loss in the young and middle-age adult population. It is estimated that the number of patients with DR will increase globally to over 190&nbsp;million by 2030. One-third of DR patients over 40 years of age in the
United States are at risk of developing vision-threatening complications, including DME. DME is the second largest market for anti-VEGF therapies, accounting for approximately $3.7&nbsp;billion of sales worldwide and approximately $1.8 billion in
the United States in 2019. Multiple clinical trials have shown that anti-VEGFs are also beneficial for the treatment of patients with DR but without DME; however, the need for frequent injections and follow-up for this often asymptomatic population
leads to inadequate compliance and suboptimal clinical benefit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">GB-102</FONT> is designed to provide <FONT
STYLE="white-space:nowrap">pan-VEGF</FONT> inhibition for six months or longer while minimizing fluctuations in retinal thickness in between treatments, which is emerging as predictive of visual outcomes. We believe durable and sustained drug
delivery of a single dose offered by <FONT STYLE="white-space:nowrap">GB-102</FONT> could provide improved visual outcomes for patients with wet AMD and DME, better patient
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">quality-of-life</FONT></FONT> and reduced disease-monitoring requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">GB-103,</FONT> a longer-acting formulation of sunitinib, is designed to maintain therapeutic drug levels in
the retinal tissue for up to 12 months following a single intravitreal injection. This potentially longer duration of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
clinical benefit and consequently less frequent need for intravitreal injections may be more conducive to maintaining a typically asymptomatic patient with DR on an effective anti-VEGF therapy
regimen. If approved, <FONT STYLE="white-space:nowrap">GB-103</FONT> could provide a paradigm shift in the treatment of patients with DR who are currently managed either by observation alone, <FONT STYLE="white-space:nowrap">pan-retinal</FONT> laser
photocoagulation or, in rare instances, with short-acting anti-VEGF injections. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Glaucoma is an optic neuropathy that is characterized
by the progressive degeneration of the optic nerve that leads to visual impairment. It is a leading cause of irreversible vision loss that is projected to affect approximately 76&nbsp;million people worldwide in 2020, including approximately
2.7&nbsp;million people in the United States. The most common type of glaucoma is POAG, which is characterized by an increase in intraocular pressure, or IOP, because fluid, which is continuously generated by cells inside the front of the eye,
cannot drain properly<I>. </I>The global POAG therapeutics market is estimated to reach approximately $3.8&nbsp;billion in 2026, of which the United States represents approximately $2.9&nbsp;billion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The most common treatment options for glaucoma are topical eye drops, which must be administered daily, or invasive medical procedures.
Topical eye drops can lower IOP and have been shown to both delay and prevent the progressive degeneration associated with POAG. However, these medications must be administered up to four times per day, and approximately 30% of patients often
require more than one class of drug to control IOP. It is estimated that approximately&nbsp;50%&nbsp;of patients stop using their glaucoma medications in the first six months post-diagnosis due to various reasons, including forgetfulness, lack of
disease awareness and/or cost, thus leading to uncontrolled IOP and progressive loss of peripheral vision. Laser-based or surgical treatments to permanently reduce IOP are invasive and achievement of IOP targets may require multiple surgeries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our third product candidate, <FONT STYLE="white-space:nowrap">GB-401,</FONT> is an intravitreally administered, proprietary formulation of a
beta-adrenergic beta-blocker prodrug designed to provide a controlled release of the active drug to maintain a reduced IOP for six months or longer after a single injection, thus addressing the patient compliance problem and improving outcomes. If
approved, <FONT STYLE="white-space:nowrap">GB-401</FONT> could represent a significant paradigm shift in the way physicians treat POAG. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our pipeline
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following chart summarizes the status and development plan for the product candidates in our pipeline. We own worldwide rights to
each of our programs. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g796801g93b67.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our proprietary technologies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our proprietary technologies are designed to allow sustained delivery of pharmacologic agents to the eye in a well-tolerated and controlled
manner to achieve extended duration of effectiveness. Our proprietary technologies utilize depot formulations of microparticles containing biodegradable polymers such as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">poly(lactic-co-glycolic</FONT></FONT> acid), or PLGA. The microparticles are engineered to carry a hydrophilic coating such as
polyethylene glycol, or PEG, that helps eliminate or minimize inflammation typically associated with intraocular administration of conventional PLGA microparticles. Our preclinical studies and Phase 1/2a clinical trial provided preliminary evidence
that our microparticles are well-tolerated in the eye. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, our microparticles are designed to aggregate after intravitreal
injection upon exposure to the vitreous fluid at body temperature to form a depot near the bottom of the eye, outside of the visual axis. Our biodegradable microparticles then gradually release the active ingredient at a rate dependent on the
composition of the polymers and biodegrade into lactic acid, glycolic acid and PEG that are naturally cleared from the body. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g796801g56d66.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some molecules, due to their physicochemical properties, are difficult to encapsulate and deliver in a
controlled manner. For that purpose, we have developed a proprietary prodrug technology to enable sustained delivery of these therapeutics. Our research and development team has developed our product candidates with different pharmacologic agents
using these prodrug technologies. For example, <FONT STYLE="white-space:nowrap">GB-401</FONT> has been developed using this approach. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our lead program
<FONT STYLE="white-space:nowrap">GB-102</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing our lead product candidate,
<FONT STYLE="white-space:nowrap">GB-102,</FONT> as a <FONT STYLE="white-space:nowrap">once-every-six</FONT> months intravitreally delivered microparticle depot formulation of sunitinib for the treatment of wet AMD and DME. Sunitinib is a <FONT
STYLE="white-space:nowrap">pan-VEGF</FONT> inhibitor <FONT STYLE="white-space:nowrap">(VEGF-A,</FONT> B, C and D). We believe that <FONT STYLE="white-space:nowrap">GB-102</FONT> is differentiated from the current standard of care, which requires
more frequent dosing, up to 12 times per year, and primarily targets one neovascular pathway <FONT STYLE="white-space:nowrap">(VEGF-A).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Phase 1/2a and 2b clinical trials of <FONT STYLE="white-space:nowrap">GB-102</FONT> in wet AMD.
</I><FONT STYLE="white-space:nowrap">GB-102</FONT> has been evaluated in multiple Phase 1/2 trials to assess its safety, tolerability, durability and pharmacodynamic effects, as well as to identify the optimal dose. In January 2019, we completed our
Phase 1/2a ADAGIO clinical trial of <FONT STYLE="white-space:nowrap">GB-102</FONT> in 32 patients with wet AMD that previously received at least three anti-VEGF injections, which we refer to as our ADAGIO trial. This trial met its primary endpoint
of safety and tolerability. No ocular serious adverse event, or SAE, or dose-limiting toxicity was reported, and the majority of patients had no drug-related adverse events, or AEs. The most common AE was the presence of medication in the anterior
chamber. These AEs were reversible and with no long-term consequences. In this trial, 88% of patients who were previously treated with an average of eight injections annually were able to maintain stable central retinal thickness and visual acuity
for six months or more with a single injection of 1 mg of <FONT STYLE="white-space:nowrap">GB-102.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the data from the
ADAGIO trial, we initiated the Phase 2b ALTISSIMO clinical trial in September 2019 to evaluate an improved product that would minimize the presence of medication within the anterior </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
chamber. This trial compares two doses of <FONT STYLE="white-space:nowrap">GB-102</FONT> (1 or 2 mg) administered every six months to aflibercept administered every two months in up to 56
patients with anti-VEGF-responsive wet AMD. On the basis of a safety analysis of the Phase 2a clinical trial of GB-102 in ME, described below, and the interim safety data in the ALTISSIMO trial, we terminated the development of the GB-102 2 mg dose
in all of our clinical trial programs. The primary endpoint of the ALTISSIMO trial is to determine <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-additional</FONT></FONT> anti-VEGF supportive therapy. ALTISSIMO topline
results are expected in the first half of 2021. If successful, we plan to advance two pivotal clinical trials in wet AMD in the second half of 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Phase 2a clinical trial of <FONT STYLE="white-space:nowrap">GB-102</FONT> in ME secondary to various diseases, including DME and central or
branch Retinal Vein Occlusion, or RVO</I>. In September 2019, we initiated a Phase 2a clinical trial of <FONT STYLE="white-space:nowrap">GB-102</FONT> in 21 patients with ME secondary to DME and branch or central RVO. This trial was designed to be a
<FONT STYLE="white-space:nowrap">six-month,</FONT> single injection, multicenter, open-label, parallel arm trial with a primary <FONT STYLE="white-space:nowrap">end-point</FONT> of safety and tolerability of two dose levels of <FONT
STYLE="white-space:nowrap">GB-102</FONT> (1 and 2 mg) in patients with ME secondary to DME or RVO who had been previously treated with anti-VEGFs. All patients have completed the study and the final safety analysis has been performed. An interim
data analysis from the ALTISSIMO and ME trials identified 1 mg of <FONT STYLE="white-space:nowrap">GB-102</FONT> as the optimal dose for future clinical trials. We intend to conduct a Phase 2b trial in patients with DME in the second half of 2021.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional pipeline programs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">GB-103</FONT> is designed to be a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">once-a-year</FONT></FONT> intravitreally delivered formulation of sunitinib, and has the potential to become an important
therapy for patients with DR. Our Phase 1/2a clinical trial with <FONT STYLE="white-space:nowrap">GB-103</FONT> in patients with DR is planned to initiate in the first half of 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also applying our proprietary technologies to develop <FONT STYLE="white-space:nowrap">GB-401,</FONT> a depot formulation of a
beta-adrenergic receptor inhibitor, designed to be injected once every six months to reduce IOP in POAG patients. We expect to submit an investigational new drug application, or IND, for <FONT STYLE="white-space:nowrap">GB-401</FONT> and initiate a
dose-escalating Phase 1/2a clinical trial of <FONT STYLE="white-space:nowrap">GB-401</FONT> in patients with POAG in the second half of 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our proprietary technologies will allow us to develop other novel therapeutics, either alone or in combination, that can achieve
extended durations of effectiveness and, thus improve the care and quality of life for patients with chronic diseases and disorders of the eye. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our
executive leadership team </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are led by a team of experienced pharmaceutical industry executives with significant experience in
ophthalmology: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Frederic Guerard, Pharm.D., our Chief Executive Officer, has 20 years of leadership, strategic and commercial
pharmaceutical experience, including as Worldwide Business Franchise Head of Ophthalmology at Novartis AG and Global Franchise Head of Pharmaceuticals at Alcon Laboratories, Inc. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Parisa Zamiri, M.D., Ph.D., our Chief Medical Officer, is an ophthalmologist and was previously Vice President,
Global Head of Clinical Development and Therapeutic Area Head for Ophthalmology at Novartis AG. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Daniel Salain, our Chief Technical Operations Officer, has 30 years of global pharmaceutical experience in
manufacturing, operations and business development, and previously served as Senior Vice President of Technical Operations at Ophthotech Corporation (now IVERIC bio, Inc.). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Robert S. Breuil, our Chief Financial Officer, has over 20 years of experience in the biopharmaceutical and drug
delivery industries, and previously served as Chief Financial Officer of Corium, Inc. and Codexis, Inc. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have raised approximately $134&nbsp;million of capital in gross proceeds from a group of
leading life sciences investors, including Deerfield Management, OrbiMed Advisors, a fund managed by Blackstone Life Sciences, Hatteras Venture Partners, CBC Group (formerly known as <FONT STYLE="white-space:nowrap">C-Bridge</FONT> Capital) and
Crown Venture Fund. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our goal is to become a leading biopharmaceutical company focused on developing and commercializing transformative medicines for the treatment
of chronic vision-threatening diseases of the retina and optic nerve. To achieve this goal, the key elements of our strategy are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Advance <FONT STYLE="white-space:nowrap">GB-102</FONT> through clinical development in patients with wet
AMD and DME.</I></B> We believe <FONT STYLE="white-space:nowrap">GB-102</FONT> injected every six months will address compliance and undertreatment issues associated with approved anti-VEGF agents. In addition, treatment with <FONT
STYLE="white-space:nowrap">GB-102</FONT> could lead to greater preservation of visual acuity by reducing fluctuations of retina thickness. We are conducting a Phase 2b clinical trial in patients with wet AMD and expect to report topline data in the
first half of 2021. We intend to initiate our global pivotal clinical program in wet AMD in the second half of 2021. We are also planning to initiate a Phase 2b trial in DME in the second half of 2021. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Advance development of <FONT STYLE="white-space:nowrap">GB-103</FONT> to offer patients a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">once-a-year</FONT></FONT> treatment for DR.</I></B> <FONT STYLE="white-space:nowrap">GB-103</FONT> is a formulation of sunitinib in a longer-acting polymer with the potential to maintain
therapeutic drug levels in the retinal tissue for up to 12 months from a single intravitreal injection. We believe <FONT STYLE="white-space:nowrap">GB-103</FONT> could significantly improve the standard of care for patients with DR. We are currently
conducting <FONT STYLE="white-space:nowrap">IND-enabling</FONT> activities and plan to initiate a Phase 1/2a trial in the first half of 2022. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Develop <FONT STYLE="white-space:nowrap">GB-401</FONT> for the treatment of elevated IOP in patients with
POAG.</I></B> <FONT STYLE="white-space:nowrap">GB-401</FONT> may provide a sustained reduction in IOP for up to six months, thus avoiding fluctuations observed with the chronic use of topical therapies and potentially leading to better
neuroprotection. If approved, <FONT STYLE="white-space:nowrap">GB-401</FONT> would eliminate the need for patient-administered <FONT STYLE="white-space:nowrap">IOP-lowering</FONT> eye drops, reduce redness of the eye and eliminate systemic drug
exposure. We expect to begin the clinical development of <FONT STYLE="white-space:nowrap">GB-401</FONT> with a dose-escalating Phase 1/2a trial to evaluate its safety, tolerability and pharmacodynamics in the second half of 2021.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Leverage our ocular delivery technologies to expand our pipeline into other vision-threatening
conditions.</I></B> We will continue to explore other development opportunities with additional small molecule candidates for potential long-duration delivery in other vision-threatening conditions, such as dry AMD, geographic atrophy and retinitis
pigmentosa. Our proprietary technologies have the potential to deliver combination therapies by either <FONT STYLE="white-space:nowrap">co-delivering</FONT> two therapeutic compounds or <FONT STYLE="white-space:nowrap">co-administering</FONT> our
product with another approved drug. We may also consider licensing or acquiring the rights to complementary products, product candidates and technologies for the treatment of ophthalmic diseases to expand our pipeline. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Commercialize our approved product candidates with our own specialty sales force and through
partnerships.</I></B> We have retained worldwide commercialization rights to all of our product candidates. Considering the number of ophthalmologists who perform most of the medical treatments and procedures for retinal diseases and glaucoma, we
expect to commercialize our product candidates, if approved, in the United States with our own focused specialty sales force. We intend to build our own manufacturing capabilities for the commercial drug supply, but could also decide to keep
contracting with third parties if it is more advantageous. We also intend to maximize the commercial value of our product candidates through potential partnerships or collaborations outside of the United States. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Differentiation of our product candidates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our proprietary technologies will allow us to develop therapeutics that may provide superior results to patients compared to
existing ocular treatments, which present several critical limitations. We believe our product candidates present a number of competitive advantages over existing therapeutics: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Extended durability and sustained drug delivery to improve visual outcomes in clinical practice</I></B>:
Currently approved anti-VEGF therapies work effectively but have limited durability. Most patients need to be injected every four to 12 weeks to experience positive visual outcomes. It has emerged that higher fluctuation in retinal thickness is
associated with poorer visual outcomes. If approved, we believe that <FONT STYLE="white-space:nowrap">GB-102</FONT> would be an important intravitreal injection offering a <FONT STYLE="white-space:nowrap">six-month</FONT> duration of action.
Controlled and sustained drug delivery could limit the fluctuation in retina thickness associated with poorer visual outcomes. We believe <FONT STYLE="white-space:nowrap">GB-102,</FONT> with only two injections a year, could provide a better balance
between patient quality of life and disease-monitoring requirements, and deliver, in a real-world setting, increased compliance and ultimately improved visual outcomes. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Differentiated mechanism of action</B>: Our retina programs, <FONT STYLE="white-space:nowrap">GB-102</FONT>
and <FONT STYLE="white-space:nowrap">GB-103,</FONT> use sunitinib, a <FONT STYLE="white-space:nowrap">pan-VEGF</FONT> inhibitor, which blocks all VEGF receptor types associated with angiogenesis, vascular permeability, cellular proliferation and
fibrosis. <FONT STYLE="white-space:nowrap">GB-102</FONT> and <FONT STYLE="white-space:nowrap">GB-103</FONT> could potentially provide additional benefits over traditional anti-VEGF A inhibitors, as supported by an emerging body of evidence
highlighting the mechanistic and clinical benefit of blocking the effect of <FONT STYLE="white-space:nowrap">VEGF-C</FONT> and <FONT STYLE="white-space:nowrap">VEGF-D,</FONT> in addition to <FONT STYLE="white-space:nowrap">VEGF-A.</FONT> Moreover,
sunitinib is a dual leucine zipper kinase, or DLK, inhibitor, which may result in a neuroprotective effect. Sunitinib&#146;s broader mechanism of action has the potential to provide visual outcome benefits superior to the traditional <FONT
STYLE="white-space:nowrap">anti-VEGF-A</FONT> treatments. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Versatile proprietary technologies</B>: Our proprietary technologies can be tailored for different
pharmacokinetic profiles. Our polymers can be tuned to provide varying drug elution profiles for a significant number of small molecules. Our proprietary technologies have the potential to deliver combination therapies by either <FONT
STYLE="white-space:nowrap">co-delivering</FONT> two therapeutic compounds or <FONT STYLE="white-space:nowrap">co-administering</FONT> our product with another approved drug. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Designed for Safety</B>: Our polymers are biodegradable and bioabsorbable. They are designed to hydrolyze over
a determined period of time and leave no residue in the eye. In preclinical studies, our proprietary technologies have not been associated with inflammation typically observed with the intraocular administration of conventional PLGA microparticles.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Wet AMD </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Wet AMD
is a common ocular disease caused by the growth of abnormal blood vessels under the central portion of the retina, or macula. This growth is triggered by VEGF, a protein produced by cells that stimulates the formation of new abnormal blood vessels,
a process called neovascularization, and induces vascular permeability, leading to leakage and swelling of the retina. Anti-VEGF treatment has been shown to improve vision in patients with wet AMD when compared to either no treatment or laser alone.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to the American Academy of Ophthalmology, it is estimated that 15&nbsp;million
people in North America have AMD. The prevalence of the disease is approximately 85 to 90% nonexudative, or dry, AMD and 10 to 15% wet AMD. As a greater percentage of Americans are living well beyond 60 years of age, more patients will become
visually impaired from AMD than from glaucoma and diabetic retinopathy combined. Early intervention is essential to treat wet AMD; without treatment, vision rapidly declines. The figure below illustrates the primary effects of wet AMD. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g796801g63c22.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our market opportunity in wet AMD </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2019, annual anti-VEGF sales reported for the treatment of retinal diseases exceeded $11&nbsp;billion in 2019 globally. We believe a
substantial majority of these sales were in connection with the treatment of wet AMD and DR. Avastin is also used <FONT STYLE="white-space:nowrap">off-label</FONT> in approximately 60% of the wet AMD patients in the United States, therefore the
potential therapeutic market is greater than reported. The wet AMD market has historically grown by approximately 8% as a consequence of an aging population and lack of preventative procedures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the significant benefits of existing therapeutic options, the need for frequent intravitreal injections is burdensome for both
patients and retinal specialists. Retinal practitioners surveyed by the American Society of Retinal Specialists responded that their three greatest unmet needs are availability of long-acting sustained drug delivery, therapies that reduce treatment
burden and new treatment mechanisms of action. According to a 2019 study of patient interviews in the United States, France and Australia, the factors affecting adherence from the patient perspective included the psychological burden of repeated
intravitreal injections, the time burden of both treatment and monitoring visits for both patients and caregivers, which could take up to 12 hours per visit including travel time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In clinical trials, intravitreal injections of anti-VEGF drugs resulted in significant gains in visual acuity for patients with retinal
diseases. However, in settings outside of clinical trials, patients often receive less frequent injections than in clinical trial settings. Long-term observational studies in the United States, Europe and Japan have demonstrated that many patients
with wet AMD lose visual acuity due to the challenges associated with receiving anti-VEGF injections at an optimal frequency. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The diagram below shows the declining visual acuity, or VA, results over four years after
the first anti-VEGF injection in patients with wet AMD in the United States. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g796801g70u41.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Most recently, it was shown that fluctuations between injections in retinal thickness in eyes receiving
treatment for wet AMD is adversely associated with visual outcomes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Diabetic retinopathy and diabetic macular edema </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">DR, which includes DME, is the leading cause of acquired vision loss in the young and <FONT STYLE="white-space:nowrap">middle-age</FONT> adult
population. Of an estimated 463&nbsp;million people with diabetes mellitus, or DM, worldwide, approximately <FONT STYLE="white-space:nowrap">one-third</FONT> have signs of DR and of these, a further <FONT STYLE="white-space:nowrap">one-third</FONT>
of DR is vision-threatening DR, including DME. Approximately 30&nbsp;million people in the United States have diabetes, 10&nbsp;million of whom suffer from DR, including 1.5&nbsp;million with DME. DME affects central vision and can lead to a decline
in vision ranging from slight visual blurring to blindness, substantially affecting independence and quality of life. If left untreated, DME is the most common cause of vision loss in patients with DR. The graph below illustrates the primary effects
of DME compared to a healthy eye. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g796801g92g85.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our market opportunity in DR and DME </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">DME is the second largest market for anti-VEGF therapies, accounting for approximately $3.7&nbsp;billion of sales worldwide and approximately
$1.8&nbsp;billion in the United States in 2019. It is estimated that there are three times as many DR patients as there are DME patients, which illustrates the commercial attractiveness of the DR indication for which short-acting anti-VEGFs have
been recently approved. Multiple trials have shown that anti-VEGFs are also beneficial for the treatment of DR without DME; however, the need for frequent injections and <FONT STYLE="white-space:nowrap">follow-up</FONT> in this often asymptomatic
population leads to inadequate compliance and subsequent vision loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our product candidates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">GB-102</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">GB-102</FONT> is a potent small molecule multiple receptor tyrosine kinase inhibitor sunitinib malate, or
sunitinib, formulated in our proprietary microparticles designed to be administered intravitreally every six months. Prior to administration, <FONT STYLE="white-space:nowrap">GB-102</FONT> is suspended in a buffered diluent and injected
intravitreally similar to the standard in clinical practice with anti-VEGFs. Sunitinib is gradually released from the microparticle formulation into the vitreous chamber and is designed to sustain therapeutic drug levels in the ocular tissues for up
to six months. Sunitinib also has a high binding affinity to the natural melanin pigment granules in the retina that allows the retinal pigmented epithelium, or RPE, to serve as a potential secondary drug reservoir and extend duration of action.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sunitinib is an orally administered treatment for advanced renal, gastric and pancreatic malignancies that was originally approved in
2006. Oral sunitinib has demonstrated efficacy in murine laser choroidal neovascularization, or CNV, models and in wet AMD patients for the treatment of their cancers. However, because of a boxed warning related to hepatotoxicity for cancer
indications, oral sunitinib has not been used for retinal indications. There are no reported cases of retinal toxicities in patients receiving continuous oral sunitinib for up to six years for the management of primary malignancies. In our
preclinical and clinical studies, we have demonstrated that there are no detectable levels of sunitinib in the plasma after intravitreal injections of <FONT STYLE="white-space:nowrap">GB-102.</FONT> Sunitinib&#146;s mechanism of action is the
inhibition of receptor tyrosine kinases, specifically of VEGF receptors 1, 2 and 3, blocking all VEGF signals, including <FONT STYLE="white-space:nowrap">VEGF-A,</FONT> <FONT STYLE="white-space:nowrap">-B,</FONT>
<FONT STYLE="white-space:nowrap">-C</FONT> and <FONT STYLE="white-space:nowrap">-D</FONT> and placental growth factor, or PlGF, which are ligands implicated in pathologic neovascularization in patients with wet AMD. Moreover, sunitinib is a <FONT
STYLE="white-space:nowrap">DLK-inhibitor,</FONT> which may result in a neuroprotective effect. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g796801g39q79.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preclinical toxicology profile of <FONT STYLE="white-space:nowrap">GB-102</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preclinical toxicology results indicated that two intravitreal injections of <FONT STYLE="white-space:nowrap">GB-102</FONT> with a five-month
interval and up to a <FONT STYLE="white-space:nowrap">10-month</FONT> observation period were well-tolerated in the eyes of rabbits and minipigs and supported intravitreal administration of up to 2 mg of
<FONT STYLE="white-space:nowrap">GB-102</FONT> every six months in clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specifically, in the repeat dosing minipig study, <FONT
STYLE="white-space:nowrap">GB-102</FONT> was well-tolerated based on all endpoint assessments, including no drug-related findings on histology of any localized tissue reaction or inflammatory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
response. There were no observations of adverse events and no drug-related effects on hematology, coagulation or clinical chemistry parameters, which is consistent with a lack of detectable
systemic exposure. The ocular examination observations were limited to a transient, yellow discoloration of the vitreous humor and lens in some animals caused by the release of sunitinib, which has a natural yellow-orange color. The main findings in
the repeat dose rabbit study include transient ocular inflammation not related to the investigational drug, and focal, peripheral and inferior lens opacities in some eyes due to the proximity of the depot to the lens. No additional toxicology
studies are planned. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our clinical trials </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase
1/2a trial of <FONT STYLE="white-space:nowrap">GB-102</FONT> in patients with wet AMD </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2019, we completed our Phase 1/2a
clinical trial of <FONT STYLE="white-space:nowrap">GB-102</FONT> in patients with wet AMD, or our ADAGIO trial. This trial enrolled patients with wet AMD diagnosed less than 18 months prior to enrollment who had received at least three prior
injections of any anti-VEGF treatment and demonstrated a response to anti-VEGF treatment, defined as physician-reported improvement in vision or reduction in macular thickness. Eligible patients received a single injection of <FONT
STYLE="white-space:nowrap">GB-102</FONT> and were followed for eight months. Monthly assessments included adverse events, best-corrected visual acuity, or BCVA, using the Early Treatment of Diabetic Retinopathy Study, or ETDRS, protocol letter
score, central <FONT STYLE="white-space:nowrap">sub-field</FONT> thickness, or CST, slit-lamp biomicroscopy, dilated fundoscopy and plasma blood samples to detect systemic levels of sunitinib. Patients were eligible for supportive anti-VEGF
treatment if any of the following criteria were met: <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 10 letter loss in BCVA (ETDRS) with new or increasing intra- or <FONT STYLE="white-space:nowrap">sub-retinal</FONT> fluid judged to be the cause in
the reduction in BCVA; an increase of <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 75 &micro;m in CST from baseline; new onset vitreous hemorrhage. Baseline demographics are summarized in the table below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>0.25&nbsp;mg</B><br><B>N=8</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>0.5&nbsp;mg</B><br><B>N=8</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1 mg</B><br><B>N=8</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2 mg</B><br><B>N=8</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>N=32</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Mean BCVA, ETDRS letters</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>(Standard Deviation)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B>Estimated Snellen equivalent<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">56.5&nbsp;(11.1)<BR>20/80</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">65.1&nbsp;(9.9)<BR>20/50</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">67.9&nbsp;(7.5)<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20/50</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">63.8&nbsp;(14.3)<BR>20/50</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">63.3 (11.3)<BR>20/50</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Mean CST, &micro;m</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>(Standard Deviation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">279 (84.3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">313&nbsp;(78.4)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">276&nbsp;(57.4)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">308&nbsp;(53.2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">294 (68.7)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Mean number of prior anti-VEGF</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>injections (Standard Deviation)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B>Range<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3.5 (0.9)<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3&#150;5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4.5 (1.1)<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3&#150;6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5.0 (3.4)<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3&#150;11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">6.3 (3.1)<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3&#150;13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4.8 (2.6)<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3&#150;13</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Mean days since last anti-VEGF injection</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>(Standard Deviation)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B>Range<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">45.3 (20.1)<BR>19&#150;82</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">74.9&nbsp;(65.7)<BR>30&#150;218</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">62.4&nbsp;(42.8)<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30&#150;163</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">54.6&nbsp;(28.8)<BR>27&#150;112</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">59.3&nbsp;(42.3)<BR>19&#150;218</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Safety results</I>. The trial met its primary endpoint of safety and tolerability with no ocular serious
adverse events, dose-limiting toxicities or endophthalmitis. No patients discontinued treatment as a result of any drug-related adverse event. Four patients discontinued due to reasons unrelated to the drug. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Out of 32 patients enrolled in the trial, no <FONT STYLE="white-space:nowrap">GB-102</FONT> related
<FONT STYLE="white-space:nowrap">non-ocular</FONT> AEs and no ocular SAEs or dose limiting toxicities were reported. There were no detectable plasma levels of sunitinib in any patient. All drug related AEs were mild or moderate: In five patients,
the only AE observed was vitreous floaters. In nine patients enrolled in the higher dose cohorts, medication presence was observed in the anterior chamber. All nine of those patients completed the trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The lowest dose had no cases of medication presence in the anterior chamber. For the three other doses, the median time to the observation of
medication presence in the anterior chamber was 65 days post-injection (range 27 to 108 days). The management of medication presence in the anterior chamber consisted of topical corticosteroid drops, followed by either
<FONT STYLE="white-space:nowrap">out-patient</FONT> anterior chamber lavage (n=3) or observation alone (n=6). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Mild, transient elevations in IOP were observed in five of nine patients and managed with topical <FONT STYLE="white-space:nowrap">IOP-lowering</FONT> medication. Medication presence in the
anterior chamber was no longer detectable after one to two months due to biodegradation of the polymers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Overall, the medication presence
in the anterior chamber appeared to be self-limited and reversible, with no long-term consequences. Since then, we have revised the manufacturing process of <FONT STYLE="white-space:nowrap">GB-102</FONT> to significantly enhance the rapidity and
firmness of particle aggregation. This optimized version of <FONT STYLE="white-space:nowrap">GB-102</FONT> is being used in both Phase 2 studies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Table below shows AEs per patient and events in all doses of ADAGIO trial. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g796801g94a22.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Pharmacodynamic responses. </I>All dose cohorts demonstrated maintenance of visual acuity and macular
stability, while maintaining retinal thickness. Even in the 2 mg dose group, where the BCVA was confounded by presence of vitreous floaters and medication in the anterior chamber, there was a consistent maintenance of macular thickness similar to
the other dose groups, indicating disease control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The figure below illustrates the mean BCVA at all visits and historic average during
anti-VEGF induction (open circle) in our Phase 1/2a trial of <FONT STYLE="white-space:nowrap">GB-102</FONT> in patients with wet AMD. A single injection of <FONT STYLE="white-space:nowrap">GB-102</FONT> was able to maintain visual acuity,
represented by BCVA for six months or more in wet AMD patients who previously required eight injections of short-acting anti-VEGF per year to achieve similar functional control. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g796801g53h17.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The figure below illustrates the mean CST at all visits and historic baseline during
anti-VEGF induction (open circle) in our Phase 1/2a trial of <FONT STYLE="white-space:nowrap">GB-102</FONT> in patients with wet AMD. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g796801g45d96.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A single injection of <FONT STYLE="white-space:nowrap">GB-102</FONT> was able to control CST for six months
or more in wet AMD patients who previously required eight injections of short-acting anti-VEGF per year to achieve similar anatomical control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Duration of response. </I>A general dose-duration response at six months was observed across the first dosing cohorts. The graph below
demonstrates that patients enrolled into the trials required between seven and nine injections a year to control their disease. Upon receiving a single injection of <FONT STYLE="white-space:nowrap">GB-102,</FONT> the retinal thickness and visual
acuity was controlled in majority of patients for six months or more. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g796801g48j28.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">GB-102</FONT> appeared to reduce the overall number of
anti-VEGF injections through six months. An analysis of the frequency of anti-VEGF treatment shows over 80% reduction of anti-VEGF injections observed in all dose groups. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The figure below illustrates that the need for additional anti-VEGF supportive therapy in the eight-month observation period. Following <FONT
STYLE="white-space:nowrap">GB-102</FONT> administration was significantly lower than the number of anti-VEGF injections prior to receiving <FONT STYLE="white-space:nowrap">GB-102</FONT> (mean anti-VEGF injections per month, plus or minus standard
error of measurement, or SEM). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All four patients receiving 2 mg of <FONT STYLE="white-space:nowrap">GB-102</FONT> that received
additional anti-VEGF supportive therapy before six months did so because they qualified for the visual acuity criterion due to the presence of vitreous floaters and/or medication in the anterior chamber confounding BCVA measurement. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g796801g42b49.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The graph below shows the proportion of patients free from additional anti-VEGF supportive therapy at <FONT
STYLE="white-space:nowrap">six-month</FONT> following a single injection of <FONT STYLE="white-space:nowrap">GB-102</FONT> was 63%, 75%, 88% and 50% for the 0.25, 0.5, 1 and 2 mg doses, respectively. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g796801g42a77.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ADAGIO trial, <FONT STYLE="white-space:nowrap">GB-102</FONT> met its primary endpoint
of safety and tolerability with no ocular SAEs or dose limiting toxicities. Our data demonstrated that for patients who required an average of eight injections per year to control their disease, a single injection of
<FONT STYLE="white-space:nowrap">GB-102</FONT> at various doses was able to maintain their central retinal thickness and visual acuity for six months or more, while significantly reducing the frequency of injection. The overall best performing dose
was the 1 mg, which controlled the disease in seven out of eight patients for six months, and in four out of eight patients beyond eight months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since the most commonly reported ocular AE was presence of medication in the anterior chamber, we optimized the manufacturing process for <FONT
STYLE="white-space:nowrap">GB-102</FONT> to enhance its binding affinity thus improving its ability to aggregate post injection. This optimized version is being used for subsequent trials. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase 2 clinical trials </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Phase 2a
trial of <FONT STYLE="white-space:nowrap">GB-102</FONT> in ME secondary to DME or RVO</I>. In September 2019, we initiated a Phase 2a clinical trial of <FONT STYLE="white-space:nowrap">GB-102</FONT> in 21 patients with ME secondary to DME and RVO.
This trial was designed to be a <FONT STYLE="white-space:nowrap">six-month,</FONT> single injection, multicenter, open-label, parallel arm trial with a primary endpoint of safety and tolerability of two dose levels of
<FONT STYLE="white-space:nowrap">GB-102</FONT> (1 and 2 mg). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g796801g57c49.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Six centers in the United States enrolled 21 patients (n=10 DME; n=5 BRVO; n=6 CRVO) who had received
at least three prior injections of anti-VEGF and shown at least some response within the last 24 months. In addition to the primary safety and tolerability endpoints noted above, secondary endpoints of the ME study were pharmacodynamics measures
including mean change from baseline in BCVA (ETDRS), mean change from baseline in CST (SD-OCT), and time to rescue treatment. As the focus of the ME trial was safety, disease control was not a requirement at enrollment, and patient eligibility was
not verified by independent third parties. On average, at enrollment, patients required eight injections per year to control their disease. Eligible patients received <FONT STYLE="white-space:nowrap">GB-102</FONT> (1 or 2 mg) at day 1 and were
followed monthly. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Table below represents the baseline demographic of patients in the ME study. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g796801g94n52.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were no drug related <FONT STYLE="white-space:nowrap">non-ocular</FONT> AEs in the trial. The 1
mg dose met its primary endpoint of safety and tolerability with seven out of ten patients demonstrating no adverse events. One patient had only vitreous floaters and one patient had vitreous floaters, medication present in the vitreous, and
reduction in vision. The other AEs occurred in a single patient with medication present in the anterior chamber. The 2 mg dose was associated with medication present in the anterior chamber of five out of 11 patients. The majority of AEs occurred in
these patients. Two SAEs were reported in a single patient (severe vision loss due to presence of medication in the anterior chamber and corneal edema as a result of <FONT STYLE="white-space:nowrap">wash-out</FONT> of the anterior chamber). On the
basis of an interim analysis performed at month 3 in the ME trial, it was determined that the 1 mg dose was well-tolerated. We believe that the number of microparticles injected in the 2&nbsp;mg dose (approximately 2&nbsp;million) were too many to
allow adequate aggregation. The graphic below, photographed using wide field color fundus photography, represents an example of progression of the GB-102 1 mg depot throughout the six-month observation period. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g796801g45e85.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Table below represents the drug-related adverse events reported in the ME trial. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g796801g57t95.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These results provided additional support for the potential advancement of
<FONT STYLE="white-space:nowrap">GB-102</FONT> 1 mg dose into pivotal trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Phase 2b trial of
<FONT STYLE="white-space:nowrap">GB-102</FONT> in patients with wet AMD</I>. We initiated the Phase 2b ALTISSIMO trial in September 2019 and expect to report topline data in the first half of 2021. ALTISSIMO is a
<FONT STYLE="white-space:nowrap">12-month,</FONT> multicenter, prospective, double-masked, randomized (3:3:2), <FONT STYLE="white-space:nowrap">3-parallel</FONT> arm trial comparing two doses of <FONT STYLE="white-space:nowrap">GB-102</FONT> (1 and
2 mg) administered every six months to aflibercept administered every two months in patients with anti-VEGF-responsive wet AMD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar
to the population in the ADAGIO trial, key eligibility criteria include patients with wet AMD diagnosed less than 18 months prior to enrollment, who had received at least&nbsp;three prior injections of any anti-VEGF and demonstrated response to
anti-VEGF treatment, defined as physician-reported reduction in macular thickness. In addition, those patients received an anti-VEGF injection within 21 days of screening. Eligible patients will receive either
<FONT STYLE="white-space:nowrap">GB-102</FONT> (1 or 2 mg) or aflibercept at day one and will be followed monthly for 12 consecutive months. Monthly assessments include adverse events, BCVA, CST, complete ophthalmic examination, wide-field fundus
photography and plasma blood samples to detect systemic levels of sunitinib. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients will be eligible for additional anti-VEGF supportive therapy (aflibercept) if they
meet the following prespecified criteria: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Decrease in BCVA (any of the following criteria): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 5 ETDRS letter decrease compared with the average of last 2 visit
BCVA ETDRS letter scores, and/or, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 10 ETDRS letter decrease compared with best <FONT
STYLE="white-space:nowrap">on-study</FONT> BCVA ETDRS letter score. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Increase in CST (any of the following criteria): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 75&nbsp;&micro;m compared with the average of the last 2 visit CST
measurements (&micro;m), and/or, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 100&nbsp;&micro;m compared with the lowest <FONT
STYLE="white-space:nowrap">on-study</FONT> CST measurement (&micro;m). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We initially designed the ALTISSIMO trial to
enroll 160 patients and initiated the trial in September 2019. In December 2019, we voluntarily paused enrollment as a precautionary measure following the report of a single patient experiencing SAEs with the 2&nbsp;mg dose in the Phase&nbsp;2a
trial of <FONT STYLE="white-space:nowrap">GB-102</FONT> in ME patients, as noted in the table above. Interim safety analyses of the macular edema trial demonstrated that five out of 11 patients in the 2&nbsp;mg dose had medication in the anterior
chamber as compared to one patient in the 1&nbsp;mg dose. We then performed an ad-hoc interim safety analysis of ALTISSIMO in February 2020. In order to preserve data integrity, trial personnel including investigators, patients, study technicians
and reading center remained masked at all times. No drug related SAEs were reported in ALTISSIMO. Presence of medication in the anterior chamber was reported in four patients in the <FONT STYLE="white-space:nowrap">GB-102</FONT> 2&nbsp;mg dose group
and one patient in the 1 mg dose group. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the number of patients in the 2&nbsp;mg dose group who had medication in the anterior
chamber in our ME and the ALTISSIMO trials, we decided to terminate the development of the GB-102 2&nbsp;mg dose in all of our clinical trial programs. In addition, we capped enrollment in the ALTISSIMO trial at 56 patients as we had sufficient
patients to explore repeat dosing with the GB-102 1&nbsp;mg dose. We amended the protocol of the ALTISSIMO trial to ensure the GB-102 1&nbsp;mg dose is used for re-dosing of all patients on GB-102 at month six, regardless of their original dose
assignment. Finally, following discussions with the FDA, we shifted the primary endpoint&#151;median time to first additional anti-VEGF supportive therapy&#151;from month ten to month 12. On the basis of a safety analysis of the ME trial and interim
safety data in the ALTISSIMO trial, we terminated the development of the <FONT STYLE="white-space:nowrap">GB-102</FONT> 2 mg dose in all of our clinical trial programs and amended the protocol of the ALTISSIMO trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The revised ALTISSIMO trial design is provided in the figure below: </P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g796801g34j05.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The results of the ADAGIO and ALTISSIMO trials, together with published clinical data in wet AMD, will
inform the trial design of pivotal Phase 3 trials. We plan to initiate a Phase 2b trial in DME in the second half of 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT
STYLE="white-space:nowrap">GB-103:</FONT> Potential for <FONT STYLE="white-space:nowrap">once-per</FONT> year dosing of sunitinib in DR </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">GB-103</FONT> is intended to be a longer-acting version of <FONT STYLE="white-space:nowrap">GB-102</FONT> with
the potential to maintain therapeutic drug levels in the retinal tissue for up to 12 months from a single intravitreal injection. We believe that <FONT STYLE="white-space:nowrap">GB-103&#146;s</FONT>
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
potential <FONT STYLE="white-space:nowrap">12-month</FONT> durability and reduction in frequency of injections could significantly improve the standard of care for DR patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are in the process of optimizing our <FONT STYLE="white-space:nowrap">GB-103</FONT> formulation, which will inform the timing and design of
the clinical development program to explore indications in DR. The development of <FONT STYLE="white-space:nowrap">GB-103</FONT> will also be informed by the extended duration of treatment that is achievable through
<FONT STYLE="white-space:nowrap">GB-102.</FONT> We are currently conducting IND enabling activities and plan to initiate a Phase 1/2a trial in the first half of 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In preclinical models, <FONT STYLE="white-space:nowrap">GB-103</FONT> demonstrated longer sustained drug levels of sunitinib in ocular tissues
in comparison to <FONT STYLE="white-space:nowrap">GB-102.</FONT> The figure below illustrates the <I>in vivo</I> correlation of drug release kinetics in a rabbit vitreous comparing <FONT STYLE="white-space:nowrap">GB-102</FONT> (blue, circles) with <FONT
STYLE="white-space:nowrap">GB-103</FONT> (pink squares). The estimated <FONT STYLE="white-space:nowrap">12-month</FONT> duration of <FONT STYLE="white-space:nowrap">GB-103</FONT> results from 10 months release from our proprietary microparticles
plus an estimated additional two months in which sunitinib is released from the RPE melanin, extending drug presence in target tissues<I>.</I> The longer duration is accomplished through adjusting the properties of our biodegradable polymer. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g796801g82t16.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The figure below illustrates <I>in vivo</I> tissue drug levels of sunitinib from a single injection of
either <FONT STYLE="white-space:nowrap">GB-103</FONT> (red, squares) or <FONT STYLE="white-space:nowrap">GB-102</FONT> (blue, circles) in a rabbit eye. High levels of sunitinib that are many folds above the Ki<SUB
STYLE="font-size:85%; vertical-align:bottom">VEGF </SUB>are observed in the retina (left) and RPE/choroid (right) throughout the entire studies. Ki is the inhibitory constant and reflects how much drug is required to block the receptor. Drug tissue
levels that are higher than the Ki indicate that there is theoretically sufficient drug concentration available to block the action of the receptor. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g796801g87s26.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preclinical toxicology profile of <FONT STYLE="white-space:nowrap">GB-103</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As <FONT STYLE="white-space:nowrap">GB-103</FONT> has the same active ingredient and a similar polymer composition as <FONT
STYLE="white-space:nowrap">GB-102,</FONT> we expect that <FONT STYLE="white-space:nowrap">GB-103</FONT> will be well tolerated in the eye. Since the ocular drug exposure is the same or lower with <FONT STYLE="white-space:nowrap">GB-103</FONT> than
with <FONT STYLE="white-space:nowrap">GB-102</FONT> in preclinical pharmacokinetics studies, we plan to use the completed <FONT STYLE="white-space:nowrap">GB-102</FONT> preclinical toxicology studies to support clinical trials of <FONT
STYLE="white-space:nowrap">GB-103.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">GB-401</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Disease overview </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Glaucoma is an optic
neuropathy that is characterized by the progressive degeneration of the optic nerve, leading to visual impairment, and is a leading cause of irreversible vision loss worldwide. POAG is the most common type of glaucoma. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Though the specific mechanism of neuronal damage in POAG has not been fully identified, progressive visual field loss is associated with
increased IOP. Chronically elevated IOP can lead to neuronal degeneration and retinal ganglion cell death with resulting disruption of the visual pathway. Increased IOP is caused by the over-production of the clear fluid in the eye behind the
cornea, or aqueous humor, and/or decreased drainage of the aqueous humor from the eye. Currently approved topical eye drops can lower IOP by either decreasing aqueous humor production and/or enhancing aqueous humor drainage when used as directed by
a physician. These medications must be administered up to four times per day, and it is estimated that approximately 30% of patients often require more than one medication<I>.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As shown in the figure below, in the healthy eye, the ciliary body produces fluid that circulates through the pupil and drains in the corner,
or the angle, of the eye where the cornea and iris meet. In POAG, pressure in the eye can increase if there is increased fluid production and/or decreased drainage in the angle leading to elevated IOP. Chronically elevated IOP can lead to neuronal
degeneration and retinal ganglion cell death with resulting disruption of the visual pathway. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g796801g65f35.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Market overview </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Glaucoma is a leading cause of irreversible vision loss affecting approximately 76&nbsp;million people worldwide in 2020, including
approximately 2.7&nbsp;million people in the United States. The global POAG therapeutics market is estimated to reach approximately $3.8&nbsp;billion in 2026, of which the United States represents approximately $2.9&nbsp;billion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Various drug classes for glaucoma therapy include prostaglandin analogs, or PGAs, beta-blockers, alpha-adrenergic agonists, carbonic anhydrase
inhibitors, <FONT STYLE="white-space:nowrap">rho-kinase</FONT> inhibitors, combination drugs and others. PGAs are preferred as first-line therapy for glaucoma due to their effectiveness in reducing IOP, once-daily dosing and reduced side effects as
compared to other therapies. The PGA segment accounted for a market share of approximately 50% in the United States in 2018 and is expected to remain dominant until meaningfully superior agents are developed and approved. The second most prescribed
class of drops is beta-blockers, however with a less favorable systemic side effect profile, including decreased heart rate, slowed breathing rate and decreased blood pressure. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A number of procedures have been developed to treat patients whose disease has significantly
progressed. These include laser or surgical treatments reserved for patients for whom other measures have failed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Unmet need </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Importance of greater compliance in glaucoma is considered a large unmet need</I>. It is estimated that approximately 50% of patients stop
taking their glaucoma medications within the first six months of treatment initiation due to various reasons, including forgetfulness, lack of disease awareness and/or cost. Poor adherence to glaucoma medication regimens has been documented in
numerous independent studies, particularly in patients on two or more prescription eye drops. Additionally, studies show that more than 30% of patients often require more than one medication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, because glaucoma progresses slowly and causes few symptoms, patients often do not adhere to their medication regimens as
prescribed until the disease has progressed to the point of significant vision loss. As a result, despite the availability of medication to treat glaucoma, progressive visual loss and blindness still often occur. According to a 2015 analysis
published in the Translational Vision Science &amp; Technology Journal, 15% to 20% of glaucoma patients progress to blindness within 15 to 20 years of diagnosis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our goal is to provide sustained reduction of elevated IOP associated with POAG to increase compliance for patients and improve the medical
management of glaucoma. For patients, our goal is to eliminate the need for daily eye drops required to manage elevated IOP. For physicians, our goal is to design a long-acting <FONT STYLE="white-space:nowrap">IOP-lowering</FONT> treatment that can
be administered in the office through intravitreal injections, ensuring patient compliance for up to six months. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our solution </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">GB-401</FONT> has the potential to reduce elevated IOP for at least six months</I>. <FONT
STYLE="white-space:nowrap">GB-401</FONT> is an inactive new chemical entity, or NCE, prodrug of a beta-adrenergic receptor inhibitor, or beta-blocker, formulated with our proprietary microparticle technologies for controlled release and is designed
to be administered intravitreally once every six months. Upon exposure to water under physiologic conditions, the prodrug is released from the polymer and is converted into the active beta-blocker by hydrolysis. The polymer biodegrades into normal
metabolic <FONT STYLE="white-space:nowrap">by-products</FONT> of lactic and glycolic acid and is naturally cleared from the eye. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g796801g60v33.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">GB-401</FONT> is designed to provide controlled drug
release with minimal burst effects that can result in potential systemic exposure of the beta-blocker. The figure below illustrates sustained <I>in vitro</I> drug release from <FONT STYLE="white-space:nowrap">GB-401</FONT> for 180 days at 37&deg; C
without a burst effect. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g796801g13q22.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beta-blockers have been used as the comparative control for the approval of topical agents for IOP
reduction, including PGAs, carbonic anhydrase inhibitors, <FONT STYLE="white-space:nowrap">rho-kinase</FONT> inhibitors and alpha-adrenergic receptor agonists. Beta-blockers must be administered twice daily and often produce systemic exposure which
can lead to decreases in heart rate, blood pressure and respiratory function<I>.</I> Though prostaglandins are the leading class of agents used to reduce IOP, evidence suggests that continuous exposure may lead to loss of IOP reduction effects that
may be due to receptor fatigue from continuous stimulation, as well as poor compliance due to topical side effects<I>.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe
that <FONT STYLE="white-space:nowrap">GB-401</FONT> has the potential to provide sustained reduction in IOP for at least six months, thus eliminating the need for frequent patient-instilled eye drops. <FONT STYLE="white-space:nowrap">GB-401</FONT>
could also improve tolerability by reducing ocular hyperemia (red eyes due to irritation) and sunken eye (reduction in peri-orbital fat), which are common side effects for PGAs and <FONT STYLE="white-space:nowrap">rho-kinase</FONT> inhibitors, while
eliminating systemic drug exposure. Therefore, we believe our proprietary beta-blocker technology represents a validated but differentiated pharmacological approach. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our preclinical study results </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Set forth
below is a summary of data from our preclinical studies to date: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In a rat model for ocular hypertension, we observed sustained IOP reduction from a single intravitreal injection
that appeared to be at least as potent as twice daily administration of topical timolol 0.5% ophthalmic solution for 28 days. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In pigmented rabbit eyes, we observed sustained therapeutic tissue drug levels for at least six months from a
single intravitreal injection. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In a <FONT STYLE="white-space:nowrap">six-month</FONT> good laboratory practice, or GLP, toxicity study in
minipigs, no active beta-blocker was detected in the plasma at any dose or time point. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The figure below illustrates the proof of concept study<B> </B>in a rat ocular hypertension,
or OHT, model. The control group received no drug (black dotted lined). The active control group (gray bar) received twice daily topical timolol 0.5% and demonstrated 10 to 15% relative reduction in IOP. Following a single administration of <FONT
STYLE="white-space:nowrap">GB-401</FONT> intravitreally, the low dose (green circles) and high dose (pink squares) groups demonstrated statistically significant reductions in IOP compared to baseline (p&lt;0.05). The results suggest that
intravitreal administration of <FONT STYLE="white-space:nowrap">GB-401</FONT> may be at least as potent in reducing IOP as traditional timolol eye drops. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g796801g10v99.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The figure below illustrates tissue drug levels of the <FONT STYLE="white-space:nowrap">GB-401</FONT>
beta-blocker from a single intravitreal injection at day one comparing low (pink squares) and high dose (green circles) in the iris-ciliary body of pigmented rabbit eyes. The levels of the beta-blocker are above the Ki required to inhibit the
beta-adrenergic receptors at all recorded time points out through six months. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g796801g03h66.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preclinical toxicology profile of <FONT STYLE="white-space:nowrap">GB-401</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The toxicology profile of <FONT STYLE="white-space:nowrap">GB-401</FONT> has been evaluated in a
<FONT STYLE="white-space:nowrap">six-month</FONT> GLP toxicology study in minipigs following a single intravitreal injection. <FONT STYLE="white-space:nowrap">GB-401</FONT> was shown to be well tolerated in this study. There were no observations of
adverse events and no test article-related effects on mortality, body weight, hematology, coagulation or chemistry parameters. In addition, there were no significant ocular observations associated with <FONT STYLE="white-space:nowrap">GB-401</FONT>
based on ophthalmoscopic examinations, IOP and electroretinogram.&nbsp;There were no test article-related macroscopic or microscopic findings, either.&nbsp;Systemic levels of the <FONT STYLE="white-space:nowrap">GB-401</FONT> active beta-blocker
were not detected in the plasma at any dose or time point. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our future development plans </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to pursue clinical development for <FONT STYLE="white-space:nowrap">GB-401</FONT> under a 505(b)(2) regulatory pathway, which obviates
the need to conduct repeat preclinical toxicology and safety studies. We intend to rely in part on the FDA&#146;s prior findings for the previously approved active pharmaceutical ingredient, or API, as well as relevant publications, and to conduct
additional GLP toxicology studies with GB-401, to support the GB-401 IND and any future 505(b)(2) NDA. At the time of NDA submission, we expect to provide the FDA with all required nonclinical elements in the NDA either directly through original
studies, published literature, and the FDA&#146;s prior findings as reflected in the approved labeling for the previously approved API which contains the same API as GB-401. We plan to initiate a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-human,</FONT></FONT> multicenter, open-label, sequential escalating dose-cohorts Phase 1/2a clinical trial evaluating the safety, tolerability and pharmacodynamic effects of a single intravitreal injection of <FONT
STYLE="white-space:nowrap">GB-401</FONT> with POAG in the second half of 2021. The primary endpoint will be the occurrence of ocular and <FONT STYLE="white-space:nowrap">non-ocular</FONT> adverse events. Secondary endpoints will include
pharmacodynamic evaluation of IOP. In pursuing the 505(b)(2) pathway, we expect to rely upon this Phase 1/2 clinical trial, as well as two Phase&nbsp;3 trials, which we currently envision as multi-center, randomized, double-blind trials with dosing
once every 6 months in patients with POAG or ocular hypertension, with approximately 350 to 600 participants per trial. The final Phase&nbsp;3 trial designs and sample sizes will be determined based upon our ongoing discussions with the FDA and the
results of the Phase 1/2a trial. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commercialization </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have no sales, marketing or commercial product distribution capabilities. We intend to start developing commercialization
capabilities after the data <FONT STYLE="white-space:nowrap">read-out</FONT> from the ALTISSIMO trial in patients with wet AMD in the first half of 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If <FONT STYLE="white-space:nowrap">GB-102</FONT> receives regulatory approval, we plan to commercialize it in the United States with our own
specialty sales force. We believe that retinal specialists in the United States, who perform most of the medical procedures involving diseases of the back of the eye, are sufficiently concentrated that we expect to be able to effectively promote <FONT
STYLE="white-space:nowrap">GB-102</FONT> to these specialists with our own sales and marketing group. We expect to use a variety of types of collaboration, distribution and other marketing arrangements with one or more parties to commercialize <FONT
STYLE="white-space:nowrap">GB-102</FONT> in markets outside the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If <FONT STYLE="white-space:nowrap">GB-401</FONT> receives
marketing approval, we plan to commercialize it in the United States with our own specialty sales force. Similar to <FONT STYLE="white-space:nowrap">GB-102,</FONT> we will explore a variety of types of collaboration, distribution and other marketing
arrangements with one or more third parties in markets outside the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis
on proprietary products. While we believe that our technologies, knowledge, experience and scientific resources provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical,
specialty pharmaceutical and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
biotechnology companies, generic drug companies, academic institutions and governmental agencies and public and private research institutions. Any product candidates that we successfully develop
and commercialize will compete with existing therapies and new therapies that may become available in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our competitors
have significantly greater financial and human resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Smaller
and other early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These organizations compete with us for recruiting and retaining qualified scientific
and management personnel, establishing clinical trial sites and patient enrollment for clinical trials, as well as in acquiring products, product candidates or other technologies complementary to our programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The key competitive factors affecting the success of <FONT STYLE="white-space:nowrap">GB-102,</FONT> if approved, are likely to be its
efficacy, safety, method and frequency of administration, <FONT STYLE="white-space:nowrap">on-mechanism</FONT> durability of therapeutic effect, convenience, price, level of generic competition and availability of coverage and reimbursement from
government and other third-party payors. The method of administration of <FONT STYLE="white-space:nowrap">GB-102,</FONT> intravitreal injection, is commonly used to administer ophthalmic drugs for the treatment of severe disease and is generally
accepted by patients facing the prospect of severe visual loss or blindness. However, a therapy that offers a less invasive method of administration might have a competitive advantage over one administered by intravitreal injection, depending on the
relative efficacy, safety and durability of the other method of administration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current standard of care for wet AMD and DME is
monotherapy administration of anti-VEGF drugs, principally Avastin, Lucentis and Eylea, which are well-established therapies and are widely accepted by physicians, patients and third-party payors, as well as Beovu, the most recently approved
anti-VEGF drug. There are also several product candidates in late-stage development, including those being developed by F. <FONT STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche AG, Kodiak Sciences Inc., Chengdu Kanghong Pharmaceutical Group Co.,
Ltd. and Opthea Limited. Physicians, patients and third-party payors may not accept the addition of <FONT STYLE="white-space:nowrap">GB-102</FONT> to their current treatment regimens for a variety of potential reasons, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if they do not wish to incur the additional cost, if any, of <FONT STYLE="white-space:nowrap">GB-102;</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if they perceive the addition of <FONT STYLE="white-space:nowrap">GB-102</FONT> to be of limited benefit to
patients compared to existing treatment options; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if sufficient coverage and reimbursement are not available; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if they do not perceive <FONT STYLE="white-space:nowrap">GB-102</FONT> to have a favorable risk-benefit profile.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <FONT STYLE="white-space:nowrap">GB-102</FONT> as an alternative to existing anti-VEGF drugs,
including Avastin, Lucentis, Eylea and Beovu. Accordingly, <FONT STYLE="white-space:nowrap">GB-102</FONT> would directly compete with these therapies. While we believe <FONT STYLE="white-space:nowrap">GB-102</FONT> will compete favorably with
existing anti-VEGF drugs, future approved standalone or combination therapies for wet AMD with demonstrated improved efficacy over <FONT STYLE="white-space:nowrap">GB-102</FONT> or currently marketed therapies with a favorable safety profile and any
of the following characteristics might pose a significant competitive threat to us: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a mechanism of action that does not involve VEGF; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a duration of action that obviates the need for twice-yearly intravitreal injection; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a method of administration that effectively avoids intravitreal injection; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant cost savings or reimbursement advantages compared to <FONT STYLE="white-space:nowrap">GB-102</FONT>
and other anti-VEGF therapies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial opportunity could be reduced or eliminated if one or more of our
competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. An anti-VEGF gene therapy product might
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
substantially reduce the number and frequency of intravitreal injections when treating wet AMD and DME, making <FONT STYLE="white-space:nowrap">GBV-102</FONT> unattractive to physicians and
patients. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter
the market. In addition, our ability to compete may be affected because in many cases insurers or other third-party payors seek to encourage the use of generic products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that product candidates currently in clinical development, or that could enter clinical development in the near future, could
represent competition, if approved. These product candidates may provide efficacy, safety, convenience and other benefits that are not provided by currently marketed therapies. Because there are a variety of means to treat wet AMD and DME, our
patents and other proprietary protections for <FONT STYLE="white-space:nowrap">GB-102</FONT> will not prevent development or commercialization of product candidates that are different from <FONT STYLE="white-space:nowrap">GB-102.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have any
manufacturing facilities or personnel, other than personnel who manage our CMO relationships. We currently rely, and expect to continue to rely, for the next few years, on third parties for the manufacture of our product candidates undergoing
preclinical testing and clinical testing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of our drug candidates include small molecules and are manufactured in synthetic processes
from base materials. We purchase the active pharmaceutical ingredient, or API, from a reliable source and we believe that our manufacturing process is amenable to <FONT STYLE="white-space:nowrap">scale-up</FONT> and does not currently require
unusual equipment. We expect to continue to develop product candidates that can be produced cost-effectively at contract manufacturing facilities. We anticipate that these arrangements will be sufficient for the manufacture of our product candidates
until our planned manufacturing facility is established and operational. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we plan to establish our own manufacturing facility, we
may continue to rely on CMOs for parts of the process, such as filling and labelling of our products for commercial sale. By establishing our own manufacturing facility, we expect to minimize or eliminate our reliance on CMOs. We believe that having
control over the whole manufacturing process will allow us to reduce cycle times, increase the robustness and consistency of the process and reduce cost of goods for commercial production. We also believe that having a dedicated manufacturing
facility will allow us to optimize commercial-scale processes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends in part on our ability to obtain and maintain proprietary protection for our therapeutic products for ocular
diseases, which include our novel microparticle aggregation technology, to deliver known active agents such as sunitinib as well as our novel prodrugs such as that in <FONT STYLE="white-space:nowrap">GB-401.</FONT> We also seek to protect our
proprietary methods of treatment using our microparticles for ocular disease, alone and in combination with other therapeutic agents. In addition, we seek protection on processes for the production of our aggregating microparticles, and dosing
regimens and formulations for the ocular administration of our microparticles. Our success also depends on our ability to operate without infringing on the proprietary rights of others and to prevent others from infringing our proprietary rights.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our policy is to seek to protect our proprietary position by filing or exclusively licensing U.S. and foreign patent applications
covering our proprietary technologies, inventions and improvements that are important to the development and implementation of our business. In addition, we currently plan to seek patent term adjustments, restorations and/or patent term extensions
where applicable in the United States, Europe and other jurisdictions. We also rely on trade secrets, <FONT STYLE="white-space:nowrap">know-how,</FONT> continuing technological innovation and potential
<FONT STYLE="white-space:nowrap">in-licensing</FONT> opportunities to develop and maintain our proprietary position. Additionally, we expect to benefit, where appropriate, from statutory frameworks in the United States, Europe and other countries
that provide a period of regulatory data exclusivity to compensate for the time required for regulatory approval of our drug products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are the sole owner of ten patent families covering our products and proprietary
aggregating microparticle technology, which include composition of matter, methods of use and processes of manufacture, as described in more detail below. Our owned patent estate as of July&nbsp;17, 2020, on a worldwide basis, includes 83 granted or
pending patent applications with eight granted U.S. patents, six pending U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> applications, one pending U.S. provisional application, four pending international patent applications filed under
the Patent Cooperation Treaty and 64 pending patent applications that have entered the national phase of prosecution in countries outside the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have exclusively licensed five patent families from Johns Hopkins University, or JHU, described below, and have granted an exclusive
sublicense to Kala Pharmaceuticals, Inc., or Kala, solely in the area of delivery through a mucosal barrier for the five families licensed from JHU only. Our patent estate exclusively licensed from JHU as of July&nbsp;17, 2020, on a worldwide basis,
includes 50 granted or pending patent applications with eight granted U.S. patents, five pending U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> applications and 37 pending or granted patents that have entered the national phase of
prosecution in countries outside the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We continually assess and refine our intellectual property strategies as we develop
new technologies and product candidates. We plan to file additional patent applications based on our intellectual property strategies where appropriate, including where we seek to adapt to competition or to improve business opportunities. Further,
we plan to file patent applications, as we consider appropriate under the circumstances, to protect new technologies that we develop. Our patent filing strategy generally includes seeking patent protection in the United States, the European Union
and China (which may include Macau and Hong Kong) and may in addition seek protection in countries where we believe such protection is likely to be useful, including one or more of Argentina, Australia, Brazil, Canada, countries of the Gulf
Cooperation Council, India, Israel, Japan, Mexico, Russia and Taiwan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exclusivity terms of our patents depend upon the laws of the
countries in which they are obtained. In the countries in which we currently file, the patent term is 20 years from the earliest date of filing of a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application. The term of a U.S.
patent may be extended to compensate for the time required to obtain regulatory approval to sell a drug, referred to as a patent term extension, or by delays encountered during patent prosecution that are caused by the PTO, referred to as patent
term adjustment. For example, the Hatch-Waxman Act permits a patent term extension for <FONT STYLE="white-space:nowrap">FDA-approved</FONT> new chemical entity drugs of up to five years beyond the expiration of the patent. The length of the patent
term extension is related to the length of time the drug is under regulatory review and diligence during the review process. Patent term extensions in the United States cannot extend the term of a patent beyond a total of 14 years from the date of
product approval, and only one patent covering an approved drug or its method of use may be extended. A similar kind of patent extension, referred to as a Supplementary Protection Certificate, is available in Europe. Legal frameworks are also
available in certain other jurisdictions to extend the term of a patent. We currently intend to seek patent term extensions on any of our issued patents in any jurisdiction where we have a qualifying patent and the extension is available; however,
there is no guarantee that the applicable regulatory authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions. Further, even
if our patent is extended, the patent, including the extended portion of the patent, may be held invalid or unenforceable by a court of final jurisdiction in the United States or a foreign country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Current issued patents and patent applications covering the composition of matter for our present clinical candidates <FONT
STYLE="white-space:nowrap">GB-102</FONT> and <FONT STYLE="white-space:nowrap">GB-103</FONT> will expire on dates ranging from 2031 to 2039, if the applications are issued and held valid by a court of final jurisdiction if challenged. Current issued
patents and patent applications covering our clinical candidate <FONT STYLE="white-space:nowrap">GB-401</FONT> will also expire on dates ranging from 2031 to 2041, if the applications are issued and held valid if challenged. Our pending applications
on additional methods of use of our clinical candidates, should they issue, will expire in 2039. We plan to file additional applications on aspects of our innovations that may have patent terms that extend beyond these dates. However, any of our
patents, including patents that we may rely on to protect our market for approved products, may be held invalid or unenforceable by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a court of final jurisdiction. Alternatively, we may decide that it is in our interest to settle a litigation in a manner that affects the term or enforceability of our patent. Changes in either
the patent laws or in interpretations of patent laws in the United States and other countries may diminish our ability to protect our inventions and enforce our intellectual property rights. Accordingly, we cannot predict the breadth or
enforceability of claims that have been or may be granted on our patents or on third-party patents. The biotechnology and pharmaceutical industries are characterized by extensive litigation regarding patents and other intellectual property rights.
Our ability to obtain and maintain our proprietary position for our microparticle technologies and novel prodrugs will depend on our success in enforcing the claims that have been granted or may grant. We do not know whether any of the pending
patent applications that we have filed or may file or license from third parties will result in the issuance of any additional patents. The issued patents that we own or may receive in the future may be challenged, invalidated or circumvented, and
the rights granted under any issued patents may not provide us with sufficient protection or competitive advantages against competitors with similar technology. Furthermore, our competitors may be able to independently develop and commercialize
drugs with similar mechanisms of action and/or duplicate our methods of treatments or strategies without infringing our patents. Because of the extensive time required for clinical development and regulatory review of a drug we may develop, it is
possible that, before any of our drugs can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby reducing any advantage of any such patent. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">GB-102</FONT> and <FONT STYLE="white-space:nowrap">GB-103</FONT> patent coverage </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Patents solely owned by us </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own a first
patent family that generally describes our proprietary surface modifying microparticle technology that allows the microparticles to remain separate prior to <I>in vivo</I> administration and then aggregate <I>in vivo</I> into at least one
microparticle of at least 500 microns that provides controlled drug delivery. Alternatively, the microparticle can be aggregated into an implant that is used in the eye. This family consists of one issued U.S. Patent (US 10,441,548) and two pending
U.S. applications (US 2020/0000734 and US 2020/0000735) covering the <FONT STYLE="white-space:nowrap">GB-102</FONT> and <FONT STYLE="white-space:nowrap">GB-103</FONT> aggregating microparticle <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">composition-of-matter</FONT></FONT> and their pharmaceutical compositions. Several pending corresponding patent applications cover methods of use of these aggregated microparticles and their processes of manufacture. This
patent family is now also in the national stage of prosecution in Australia, Brazil, Canada, China, Eurasia, Europe, Hong Kong, Israel, India, Japan and Mexico. The expected year of expiration for these <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">composition-of-matter</FONT></FONT> patents, where issued, valid and enforceable, is 2036, without regard to any extensions, adjustments or restorations of term that may be available under national law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also own a second patent family that cover additional microparticle formulations and methods of manufacture, including for example
suspensions of <FONT STYLE="white-space:nowrap">GB-102</FONT> or <FONT STYLE="white-space:nowrap">GB-103</FONT> and lyophilized solid <FONT STYLE="white-space:nowrap">GB-102</FONT> or <FONT STYLE="white-space:nowrap">GB-103</FONT> that have been
treated to remove adhered air or gas. It consists of two U.S. applications, US 2018/0326078 and USSN 16/821,738, and is currently in the national phase of prosecution in Australia, Bahrain, Brazil, Canada, China, Europe, Israel, India, Japan,
Kuwait, Mexico, Oman, Russia, Qatar, Saudi Arabia and the United Arab Emirates, that The expected year of expiration for this patent family, if issued, valid and enforceable, is 2038, without regard to any extensions, adjustments or restorations of
term that may be available under U.S. or other national laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own a third patent family that discloses coordinated control of a number
of processing factors that result in a significantly harder or more durable aggregated microparticle, and which may be used in the process of manufacture of our <FONT STYLE="white-space:nowrap">GB-102</FONT> or
<FONT STYLE="white-space:nowrap">GB-103</FONT> products. This family includes one international application filed under the Patent Cooperation Treaty, PCT/US19/61859 (which we intend to file in the United States and other selected foreign countries
on or before the deadline to do so), one patent application filed in Taiwan and one patent application filed in Argentina. The expected year of expiration for this patent family, if issued, valid and enforceable, is 2039, without regard to any
extensions, adjustments or restorations of term that may be available under U.S. or other national laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we own a fourth patent family that discloses various processes for the
manufacture of our aggregating microparticles that can be used to manufacture <FONT STYLE="white-space:nowrap">GB-102</FONT> or <FONT STYLE="white-space:nowrap">GB-103.</FONT> The family includes one international application filed under the Patent
Cooperation Treaty, PCT/US2019/028803 (which we intend to file in the United States and other selected foreign countries on or before the deadline to do so). The expected year of expiration for this patent family, if issued, valid and enforceable,
is 2039, without regard to any extensions, adjustments or restorations of term that may be available under U.S. or other national laws. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Patent Filings
Exclusively Licensed from JHU </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have exclusively licensed from JHU a first patent family that claims microparticles with a
hydrophobic polymeric core (such as PLGA or PLA or a combination of both PLGA and PLA) and a hydrophilic coating (such as PLGA permanently linked to polyethylene glycol) to reduce inflammation for intraocular injections and their methods of use.
This patent family includes four U.S. Patents (US 8,889,193; US 9,566,242; US 9,937,130; and US 10,369,107). This patent family also currently includes one pending U.S. application, US&nbsp;2019/0321297, as well as corresponding patent applications
Europe and Canada. The expected year of expiration for this patent family, where issued, valid and enforceable, is 2031, without regard to any extensions, adjustments or restorations of term that may be available under national law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have also exclusively licensed from JHU a second patent family, which covers sunitinib-encapsulated polymeric microparticles, including <FONT
STYLE="white-space:nowrap">GB-102</FONT> and <FONT STYLE="white-space:nowrap">GB-103,</FONT> and their use as therapeutic compositions to treat disorders of the eye. This patent family currently includes two U.S. pending applications, US
2017/0273901 and US 2019/0275001 and is also pending in Australia, Brazil, Canada, China, Europe, Hong Kong, India, Israel, Japan, Mexico, Oman, Qatar, Russia, Saudi Arabia and United Arab Emirates. The expected year of expiration for this patent
family, where issued, valid and enforceable, is 2035, without regard to any extensions, adjustments or restorations of term that may be available under national law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A third patent family exclusively licensed from JHU discloses method for reducing neuronal damage in the eye that includes administration of a
sustained release formulation of dual leucine kinase inhibitor in a polymeric particle, and wherein the dual leucine kinase inhibitor may be sunitinib. This family consists of one issued U.S. Patent, US 10,525,034, one pending U.S. application, US
2020/0147044, and corresponding applications in Europe, China, Japan and Hong Kong. The expected year of expiration for this patent family, where issued, valid and enforceable, is 2035, without regard to any extensions, adjustments or restorations
of term that may be available under national law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">GB-401</FONT> patent coverage </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own a fifth patent family that describes the composition of matter of a range of proprietary prodrugs, one of which is a prodrug of a
beta-adrenergic receptor inhibitor that is in <FONT STYLE="white-space:nowrap">GB-401.</FONT> This patent family provides the basis for compound (new chemical entity), pharmaceutical compositions and methods of use of these prodrugs. The family
includes one pending U.S. patent application, US 2020/0031783, and corresponding applications in Australia, Bahrain, Brazil, Canada, China, Europe, Hong Kong, Israel, India, Japan, Kuwait, Mexico, Oman, Russia, Qatar, Saudi Arabia and the United
Arab Emirates. The expected year of expiration for these <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">composition-of-matter</FONT></FONT> patents, where issued, valid and enforceable, is 2038, without regard to any extensions,
adjustments or restorations of term that may be available under national law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own a sixth patent family that describes microparticles
and implants with high-drug loadings of <FONT STYLE="white-space:nowrap">GB-401.</FONT> This family includes one provisional application and the expected year of expiration for this patent family, if issued, valid and enforceable, is 2041, without
regard to any extensions, adjustments or restorations of terms that may be available under U.S. or other national laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The four patent
families that we solely own described above covering <FONT STYLE="white-space:nowrap">GB-102</FONT> and <FONT STYLE="white-space:nowrap">GB-103</FONT> also cover aggregating microparticles that encapsulate
<FONT STYLE="white-space:nowrap">GB-401,</FONT> pharmaceutical compositions of these aggregating </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
microparticles, and methods of use. Therefore, we have six patent families that cover <FONT STYLE="white-space:nowrap">GB-401</FONT> as a compound and in an aggregating microparticle, and their
uses and manufacture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the first patent family exclusively licensed from JHU described above that describes polymeric
microparticles has claims that cover <FONT STYLE="white-space:nowrap">GB-401,</FONT> pharmaceutical compositions of these microparticles, and methods of use. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent filings that cover additional novel prodrugs, compositions, uses and manufacture </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Patent filings solely owned by us </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also
own several patent families that cover additional novel prodrugs, pharmaceutical compositions and methods of use in the area of ocular therapy. We may or may not develop these inventions to commercial products, and we have the possibility to license
undeveloped technologies to other entities where advantageous to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The seventh patent family owned by us covers an extensive number of
novel prodrugs, including prodrugs of sunitinib, timolol, brinzolamide and dorzolamide, pharmaceutical compositions, and methods of use for ocular therapy. The family includes seven granted U.S. Patents (US 9,808,531; US 9,956,302; US 10,098,965; US
10,111,964; US 10,117,950; US 10,159,747; and US 10,485,876) and is currently pending in Australia, Brazil, Canada, China, Eurasia, Europe, Hong Kong, Israel, India, Japan and Mexico. The expected year of expiration for these <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">composition-of-matter</FONT></FONT> patents, where issued, valid and enforceable, is 2036, without regard to any extensions, adjustments or restorations of term that may be available under
national law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The eighth patent family covers prodrug derivatives of ethacrynic acid, timolol, brinzolamide and pharmaceutical
compositions, and methods of use for ocular disorders, including the lowering of intraocular pressure. The patent family includes one U.S. pending application and corresponding applications in Australia, Canada, China, Europe, Japan and Russia. The
expected year of expiration for these <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">composition-of-matter</FONT></FONT> patents, where issued, valid and enforceable, is 2038, without regard to any extensions, adjustments or
restorations of term that may be available under national law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ninth patent family covers novel prodrugs of loop diuretics,
pharmaceutical compositions, and methods of use for ocular disorders, including the lowering of intraocular pressure. This family includes one international application filed under the Patent Cooperation Treaty, PCT US 2019/029416 (which we intend
to file in the United States and other selected foreign countries on or before the deadline to do so). The expected year of expiration for these <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">composition-of-matter</FONT></FONT>
patents, where issued, valid and enforceable, is 2039, without regard to any extensions, adjustments or restorations of term that may be available under national law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our tenth patent family includes one international application filed under the Patent Cooperation Treaty, PCT/US19/53513 (which we intend to
file in the United States and other selected foreign countries on or before the deadline to do so), and one patent application filed in Taiwan that covers additional novel prodrugs of sunitinib, brinzolamide, and dorzolamide, pharmaceutical
compositions, and methods of use for ocular disorders. The expected year of expiration for these <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">composition-of-matter</FONT></FONT> patents, where issued, valid and enforceable, is
2039, without regard to any extensions, adjustments or restorations of term that may be available under national law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Patent filings exclusively
licensed from JHU </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have exclusively licensed a fourth patent family from JHU that covers hydrophobic-hydrophilic copolymers of <FONT
STYLE="white-space:nowrap">HIF-1</FONT> inhibitors, pharmaceutical compositions, and method of use for ocular therapeutics. This patent family includes two granted U.S. Patents (US 8,962,577 and US 9,950,072) and corresponding applications in
Australia, Canada, China, Eurasia, Europe, Hong Kong and Japan. The expected year of expiration for these <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">composition-of-matter</FONT></FONT> patents, where issued, valid and
enforceable, is 2033, without regard to any extensions, adjustments or restorations of term that may be available under national law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have in addition exclusively licensed from JHU a fifth patent family that covers
hydrophobic-hydrophilic copolymers of <FONT STYLE="white-space:nowrap">non-HIF</FONT> active agents for ocular therapy, pharmaceutical compositions, and method of use. The family includes one granted U.S. Patent (US 10,159,743) and one pending U.S.
application (US 2019/0070302) as well as corresponding applications in Australia, Canada, China, Eurasia, Europe, Hong Kong and Japan. The expected year of expiration for these
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">composition-of-matter</FONT></FONT> patents, where issued, valid and enforceable, is 2033, without regard to any extensions, adjustments or restorations of term that may be available
under national law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>License agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Johns
Hopkins University </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2011, we entered into an Exclusive License Agreement with JHU, which has been amended from time to time,
which we refer to as the JHU Agreement. Pursuant to the JHU Agreement, JHU granted us an exclusive, worldwide, sublicensable license to three patent families to research, develop, make, use and sell products and provide services in any field, and a <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> license to use specified <FONT STYLE="white-space:nowrap">know-how</FONT> and materials with a provision that JHU will not grant a license to know how and materials to any other commercial entity. The
JHU first patent family describes microparticles with a hydrophobic polymeric core (such as PLGA or PLA or a combination of both PLGA and PLA) and a hydrophilic coating (such as PLGA permanently linked to polyethylene glycol) to reduce inflammation
for intraocular injections and their methods of use, which technology is incorporated into our <FONT STYLE="white-space:nowrap">GB-102,</FONT> <FONT STYLE="white-space:nowrap">GB-103</FONT> and <FONT STYLE="white-space:nowrap">GB-401</FONT> product
candidates. The JHU licensed fourth and fifth patent families cover potential future technologies. See &#147;Intellectual Property&#148; above for additional description of the JHU patent families. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2015, the JHU Agreement was amended to include the JHU second patent family which covers sunitinib-encapsulated polymeric
microparticles, including <FONT STYLE="white-space:nowrap">GB-102</FONT> and <FONT STYLE="white-space:nowrap">GB-103,</FONT> and their use as therapeutic compositions to treat disorders of the eye. Under the terms of the amended JHU Agreement, we
paid a <FONT STYLE="white-space:nowrap">one-time,</FONT> <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront fee, with a remaining amount to be paid upon the occurrence of certain events. We also agreed to pay an additional <FONT
STYLE="white-space:nowrap">one-time,</FONT> <FONT STYLE="white-space:nowrap">non-refundable</FONT> fee of $100,000 on the occurrence of the first commercial sale of a product falling under the claims of a patent in the second patent family. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2016, the JHU Agreement was further amended to include a third patent family which discloses a method for reducing neuronal damage in
the eye that includes administration of a sustained release formulation of a dual leucine kinase inhibitor in a polymeric particle, and wherein the dual leucine kinase inhibitor may be sunitinib, and thus is relevant to both our <FONT
STYLE="white-space:nowrap">GB-102</FONT> and <FONT STYLE="white-space:nowrap">GB-103</FONT> product candidates. Under the terms of the amended JHU Agreement, we paid a <FONT STYLE="white-space:nowrap">one-time,</FONT>
<FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront fee, and a milestone payment for the grant of the first patent. We also agreed to use our best efforts to develop a licensed product under the third patent family and enter into a Phase
I clinical trial on or before April 2019, and to have cumulatively spent several million dollars on research and development within six years of execution of the amendment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon execution of the JHU Agreement in 2011, we paid JHU an upfront license fee in the low tens of thousands of dollars and issued to JHU a
low single digit percentage of our equity interests as of such date. We have also reimbursed JHU for the prosecution and maintenance costs incurred by JHU for the licensed patent rights prior to our entering into the JHU Agreement, and we are
responsible for all of the ongoing costs relating to the prosecution and maintenance of the JHU patent rights licensed to us. We also agreed to pay minimum annual royalties in the tens of thousands of dollars per year until the first commercial sale
of a licensed product or service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The JHU Agreement further requires single digit running royalties on our annual net sales, which may be
reduced by 50% of any payments we make to third parties for freedom to operate, up to a maximum credit of 50% of the running royalty rate otherwise due to JHU. Royalties must be paid on products that fall within a patent claim of an issued and
unexpired patent or a pending patent application that has not been finally rejected </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or is pending for less than seven years. We also must pay developmental milestones for achieving certain clinical progression events, ranging from tens of thousands to hundreds of thousand
dollars per event, which in the aggregate, total less than $2&nbsp;million per product. Under the JHU Agreement, prior to the Kala Agreement renegotiation described below, we were responsible for paying each developmental milestone payment for the
first three products to achieve such milestone, and milestones for the second and third products are reduced by 50%. We further agreed to pay a percentage of any sublicense consideration we receive. Once commercial, we expect ongoing royalties on
sales to be in the low single digits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The JHU Agreement will remain effective until (i)&nbsp;the later of the expiration date of the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> patents covered under the JHU Agreement or 20 years from the effective date; (ii)&nbsp;the termination by either party upon the bankruptcy or uncured breach of
the other party or (iii)&nbsp;if we terminate the JHU Agreement, with a <FONT STYLE="white-space:nowrap">90-day</FONT> notification period. We may terminate the entire agreement or on a patent by patent basis if desired, subject to the <FONT
STYLE="white-space:nowrap">90-day</FONT> notification period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Kala Pharmaceuticals </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A dispute arose between us, JHU and Kala, over rights licensed to us and Kala by JHU. In October 2014, we entered into a Settlement and License
Agreement, or the Kala Agreement, with Kala and JHU, which settled all pending disputes and amended our and Kala&#146;s existing license agreements with JHU and created new rights and obligations among the parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Kala Agreement, each of Kala and us provided the other with a royalty-free, exclusive sublicense with respect to certain
intellectual property rights granted by JHU in limited fields of use. Specifically, we provided Kala with an exclusive sublicense for the use of a particle with specific characteristics for delivery of a biologically active material through mucus,
mucin or a mucosal barrier (provided that such delivery does not involve administration via injection to the eye), or the Kala Field of Use, and Kala provided us with an exclusive sublicense to the use of a particle with specific characteristics for
delivery of a biologically active material to the eye via injection (excluding such use of any particle comprising or consisting of loteprednol etabonate). Kala also agreed not to use a particle with those specific characteristics that include
sunitinib in the Kala Field of Use under the license from us or JHU. Neither we nor Kala owe JHU any payments under its existing JHU agreement with respect to the sublicenses granted to the other. Both we and Kala hold rights to sublicense our
respective rights in connection with a future collaboration arrangement and subject to any such sublicensee being bound by the applicable terms of the Kala Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Kala Agreement, JHU agreed to a number of financial concessions to both us and Kala. The payments under the existing JHU agreements
were modified by reducing all milestones and minimum annual royalties by 25%, including the development milestone payments due for the first licensed product; the development milestone payments due for the first license product were each extended by
one year; development milestone payments for the second and third licensed products were eliminated; and the commercial milestone payments for the first commercial sale of a licensed product were reduced by 50% in the United States. New sales-based
milestones were added for the second and third licensed products. Upon the second licensed product under the JHU Agreement reaching a certain level of sales or receiving sublicense royalty income, we are required to pay $100,000 plus the amounts of
the eliminated development milestones and reduced first commercial sale milestone. For the third licensed product, on reaching the same level of sales or receiving sublicense royalty income, we are required to pay $150,000 plus the amounts of the
eliminated development milestones and reduced first commercial sale milestone. In addition, we, Kala and JHU released each other from any liability or claims known to Kala and us as of the Kala Agreement and arising out of the actions leading to,
and related to the subject of, the Kala Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Kala Agreement will expire upon the expiration of all the patent rights that are
the subject of the Kala Agreement. We may terminate one or more of the licenses or sublicenses granted to us in the Kala Agreement on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis for
convenience upon 30 days&#146; prior written notice to Kala. We or Kala may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
terminate one or more the sublicenses granted to the other party under the JHU patent rights if the other party, or its employees, officers, directors, agents or representatives, takes certain
steps to oppose, attempt to invalidate or prevent the issuance of any of the patent rights directly licensed to the terminating party by JHU. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>AffaMed
Therapeutics </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2019, we entered into a letter agreement with AffaMed Project Limited, or AffaMed, in connection with their
purchase of our Series C preferred, which we refer to as the AffaMed Letter. Under the AffaMed Letter, we granted AffaMed a right of first negotiation, or the Option, to enter into a license agreement to exclusively develop, register and
commercialize <FONT STYLE="white-space:nowrap">GB-102</FONT> solely in the territories of China, Hong Kong, Taiwan, Macau and South Korea. The Option expires upon the earlier of (i)&nbsp;July&nbsp;31, 2021 and (ii) 60 days after we provide top line
data from the Phase 2b trial for <FONT STYLE="white-space:nowrap">GB-102.</FONT> If AffaMed does not exercise the Option, we will have no further obligation to AffaMed to license rights to <FONT STYLE="white-space:nowrap">GB-102.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The AffaMed Letter provides AffaMed with an initial <FONT STYLE="white-space:nowrap">30-day</FONT> period to propose terms for such a license
which, if such terms are approved by a majority of our board of directors (excluding the director appointed by AffaMed), shall lead to a <FONT STYLE="white-space:nowrap">60-day</FONT> exclusive negotiation period. During this period of up to 90
days, we are prohibited from soliciting, initiating, encouraging or assisting the submission of any other proposal, negotiation or offer for the development, registration and commercialization of <FONT STYLE="white-space:nowrap">GB-102</FONT> in
China, Hong Kong, Taiwan, Macau or South Korea. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will enter into a license agreement for such services with AffaMed if approved by a
majority of the members of our board of directors, excluding the director appointed by AffaMed, during the exclusive negotiation period. If our board of directors does not approve AffaMed&#146;s proposed terms under the Option following good faith
negotiations and following a further 10 business day period of discussion if requested by AffaMed, we have the right to enter into an alternative license agreement with any third party for such services. If AffaMed does not exercise its Option, we
have the right to enter into an alternative license agreement with a different party. The AffaMed Letter does not limit our ability to develop, register and commercialize <FONT STYLE="white-space:nowrap">GB-102</FONT> in territories other than
China, Hong Kong, Taiwan, Macau and South Korea. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trade secrets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to patents, we rely upon unpatented trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> and continuing technological
innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, using confidentiality agreements with our commercial partners, collaborators, employees and consultants, and invention assignment
agreements with our employees. These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed through a relationship with a third
party. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our commercial partners,
collaborators, employees and consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting <FONT STYLE="white-space:nowrap">know-how</FONT> and inventions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government regulation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government
authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging,
storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and import and export of pharmaceutical products. The processes for obtaining regulatory approvals in the United States and in
foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FDA approval process </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, pharmaceutical products are subject to extensive regulation by FDA under the FDCA, and other federal and state statutes
and regulations. The failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending NDAs, warning or untitled letters, product recalls, product
seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties and criminal prosecution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pharmaceutical product development for a new product or certain changes to an approved product in the U.S. typically involves preclinical
laboratory and animal tests, the submission to FDA of an IND, which must become effective before clinical testing may commence, and adequate and well-controlled clinical trials to establish the safety and effectiveness of the drug for each
indication for which FDA approval is sought. Satisfaction of FDA <FONT STYLE="white-space:nowrap">pre-market</FONT> approval requirements typically takes many years and the actual time required may vary substantially based upon the type, complexity
and novelty of the product or disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preclinical tests include laboratory evaluation of product chemistry, formulation and toxicity, as
well as animal trials to assess the characteristics and potential safety and efficacy of the product. The conduct of the preclinical tests must comply with federal regulations and requirements, including good laboratory practices. The results of
preclinical testing are submitted to FDA as part of an IND along with other information, including information about product chemistry, manufacturing and controls, and a proposed clinical trial protocol. Long-term preclinical tests, such as animal
tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted. A <FONT STYLE="white-space:nowrap">30-day</FONT> waiting period after the submission of each IND is required prior to the commencement of clinical testing
in humans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If FDA has neither commented on nor questioned the IND within this <FONT STYLE="white-space:nowrap">30-day</FONT> period, the
clinical trial proposed in the IND may begin. Clinical trials involve the administration of the investigational new drug to healthy volunteers or patients under the supervision of a qualified investigator. Clinical trials must be conducted:
(i)&nbsp;in compliance with federal regulations; (ii)&nbsp;in compliance with good clinical practice, or GCP, an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors,
administrators and monitors; as well as (iii)&nbsp;under protocols detailing the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. Each protocol involving testing on U.S. patients
and subsequent protocol amendments must be submitted to FDA as part of the IND. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FDA may order the temporary, or permanent,
discontinuation of a clinical trial at any time, or impose other sanctions, if it believes that the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. The
study protocol and informed consent information for patients in clinical trials must also be submitted to an institutional review board, or IRB, for approval. An IRB may also require the clinical trial at the site to be halted, either temporarily or
permanently, for failure to comply with the IRB&#146;s requirements, or may impose other conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials to support NDAs for
marketing approval are typically conducted in three sequential phases, but the phases may overlap. In Phase 1, the initial introduction of the drug into healthy human subjects or patients, the drug is tested to assess metabolism, pharmacokinetics,
pharmacological actions, side effects associated with increasing doses, and, if possible, early evidence of effectiveness. Phase 2 usually involves trials in a limited patient population to determine the effectiveness of the drug for a particular
indication, dosage tolerance and optimum dosage, and to identify common adverse effects and safety risks. If a drug demonstrates evidence of effectiveness and an acceptable safety profile in Phase 2 evaluations, Phase 3 trials are undertaken to
obtain the additional information about clinical efficacy and safety in a larger number of patients, typically at geographically dispersed clinical trial sites, to permit FDA to evaluate the overall benefit-risk relationship of the drug and to
provide adequate information for the labeling of the drug. In most cases, FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the efficacy of the drug. A single Phase 3 trial with other confirmatory evidence may be
sufficient in rare instances, such as where the study is a large multicenter </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
trial demonstrating internal consistency and a statistically very persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity or prevention of a disease with a
potentially serious outcome, and confirmation of the result in a second trial would be practically or ethically impossible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
manufacturer of an investigational drug in a Phase 2 or 3 clinical trial for a serious or life-threatening disease is required to disclose, such as by posting on its website, its policy on evaluating and responding to requests for expanded access to
such investigational drug. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After completion of the required clinical testing, an NDA is prepared and submitted to FDA. FDA approval of
the NDA is required before marketing of the product may begin in the U.S. The NDA must include the results of all preclinical, clinical and other testing and a compilation of data relating to the product&#146;s pharmacology, chemistry, manufacture
and controls. The cost of preparing and submitting an NDA is substantial. Furthermore, under the Prescription Drug User Fee Act, or PDUFA, the submission of most NDAs is additionally subject to a substantial application user fee, and the applicant
under an approved NDA is also subject to an annual program fee for each prescription product. These fees are typically increased annually. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FDA has 60 days from its receipt of an NDA to determine whether the application will be accepted for filing based on the agency&#146;s
threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, FDA begins an <FONT STYLE="white-space:nowrap">in-depth</FONT> review. Under PDUFA, FDA has agreed to certain
performance goals in the review of NDAs to encourage timeliness. NDAs for most standard review drug products are reviewed within twelve months from submission of NDAs for new molecular entities, or NMEs, and ten months from submission of NDAs for <FONT
STYLE="white-space:nowrap">non-NMEs.</FONT> Priority review can be applied to drugs that FDA determines offer major advances in treatment or provide a treatment where no adequate therapy exists. NDAs for most priority review drug products are
reviewed within eight months from submission of NDAs for NMEs and six months from submission of NDAs for <FONT STYLE="white-space:nowrap">non-NMEs.</FONT> The review process for both standard and priority review may be extended by FDA for three
additional months to consider certain late-submitted information or information intended to clarify information already provided in the submission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FDA may also refer applications for novel drug products, or drug products that present difficult questions of safety or efficacy, to an
outside advisory committee&#151;typically a panel that includes clinicians and other experts&#151;for review, evaluation and a recommendation as to whether the application should be approved. FDA is not bound by the recommendation of an advisory
committee, but it generally follows such recommendations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before approving an NDA, FDA will typically inspect one or more clinical sites
to assure compliance with GCP. Additionally, FDA will inspect the facility or the facilities at which the drug is manufactured. FDA will not approve the product unless compliance with current good manufacturing practices is satisfactory and the NDA
contains data that provide substantial evidence that the drug is safe and effective in the indication studied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After FDA evaluates the
NDA and the manufacturing facilities, it issues either an approval letter or a complete response letter. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing, or information,
in order for FDA to reconsider the application. The applicant may either resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. If, or when, those deficiencies have been addressed to FDA&#146;s
satisfaction in a resubmission of the NDA, FDA will issue an approval letter. FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. An approval letter authorizes commercial marketing of
the drug with specific prescribing information for specific indications. As a condition of NDA approval, FDA may require a risk evaluation and mitigation strategy, or REMS, to help ensure that the benefits of the drug outweigh the potential risks.
REMS can include medication guides, communication plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing
only under certain circumstances, special monitoring and the use of patient registries. The requirement for a REMS can materially affect the potential market and profitability of the drug. Moreover, product approval may require substantial
post-approval testing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and surveillance to monitor the drug&#146;s safety or efficacy. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are
identified following initial marketing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once granted, product approvals may be withdrawn if compliance with regulatory standards is not
maintained or problems are identified following initial marketing. Changes to some of the conditions established in an approved application, including changes in indications, labeling or manufacturing processes or facilities, require submission and
FDA approval of a new NDA or NDA supplement before the change can be implemented. An NDA supplement for a new indication typically requires clinical data similar to that in the original application, and FDA uses the same procedures and actions in
reviewing NDA supplements as it does in reviewing NDAs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Disclosure of clinical trial information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sponsors of clinical trials of FDA regulated products, including drugs, are required to register and disclose certain clinical trial
information in the ClinicalTrials.gov database. Information related to the product, patient population, phase of investigation, study sites and investigators, and other aspects of the clinical trial is then made public as part of the registration.
Sponsors are also obligated to discuss the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed in certain circumstances for up to two years after the date of completion of the trial.
Competitors may use this publicly available information to gain knowledge regarding the progress of development programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pediatric information
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Pediatric Research Equity Act, or PREA, NDAs or supplements to NDAs must contain data to assess the safety and
effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the drug is safe and effective. FDA may grant full or partial waivers,
or deferrals, for submission of data. With certain exceptions, PREA does not apply to any drug for an indication for which orphan designation has been granted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Best Pharmaceuticals for Children Act, or BPCA, provides NDA holders a <FONT STYLE="white-space:nowrap">six-month</FONT> extension of any
exclusivity&#151;patent or nonpatent&#151;for a drug if certain conditions are met. Conditions for exclusivity include FDA&#146;s determination that information relating to the use of a new drug in the pediatric population may produce health
benefits in that population, FDA making a written request for pediatric studies, and the applicant agreeing to perform, and reporting on, the requested studies within the statutory timeframe. Applications under the BPCA are treated as priority
applications, with all of the benefits that designation confers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Post-approval requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once an NDA is approved, a product will be subject to certain post-approval requirements, including, among other things, record-keeping
requirements, providing the FDA with updated safety information, product sampling and distribution requirements, and promotion and advertising requirements. For instance, FDA closely regulates the post-approval marketing and promotion of drugs,
including standards and regulations for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising, <FONT STYLE="white-space:nowrap">off-label</FONT> promotion, industry-sponsored scientific and
educational activities and promotional activities involving the internet. Drugs may be marketed or promoted only for the approved indications and in accordance with the provisions of the approved labeling. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adverse event reporting and submission of periodic reports are required following FDA approval of an NDA. FDA also may require post-marketing
testing, known as Phase 4 testing, REMS and surveillance to monitor the effects of an approved product, or FDA may place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control, drug
manufacture, packaging and labeling procedures must continue to conform to current good manufacturing practices after approval. Drug manufacturers and certain of their subcontractors are required to register their establishments with FDA and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
certain state agencies. Registration with FDA subjects entities to periodic unannounced inspections by FDA, during which the Agency inspects manufacturing facilities to assess compliance with
current good manufacturing practices. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality-control to maintain compliance with current good manufacturing practices. Regulatory authorities
may withdraw product approvals, request product recalls or take other administrative or judicial enforcement actions if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously
unrecognized problems are subsequently discovered. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Hatch-Waxman Amendments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Orange Book listing </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In seeking approval
for a drug through an NDA, applicants are required to list with the FDA each patent whose claims cover the applicant&#146;s product. Upon approval of a drug, each of the patents listed in the application for the drug is then published in the
FDA&#146;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange Book can, in turn, be referenced by potential generic competitors in support of approval of an abbreviated new
drug application, or ANDA. An ANDA provides for marketing of a drug product that has the same active ingredients in the same strengths and dosage form as the listed drug and has been shown through bioequivalence testing to be therapeutically
equivalent to the listed drug. Other than the requirement for bioequivalence testing, ANDA applicants are not required to conduct, or submit results of, preclinical or clinical tests to prove the safety or effectiveness of their drug product. Drugs
approved in this way are commonly referred to as &#147;generic equivalents&#148; to the listed drug and can often be substituted by pharmacists under prescriptions written for the original listed drug. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ANDA applicant is required to certify to the FDA concerning any patents listed for the approved product in the FDA&#146;s Orange Book.
Specifically, the applicant must certify that (i)&nbsp;the required patent information has not been filed; (ii)&nbsp;the listed patent has expired; (iii)&nbsp;the listed patent has not expired but will expire on a particular date and approval is
sought after patent expiration; or (iv)&nbsp;the listed patent is invalid or will not be infringed by the new product. The ANDA applicant may also elect to submit a section viii statement certifying that its proposed ANDA label does not contain (or
carve out) any language regarding the patented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">method-of-use</FONT></FONT> rather than certify to a listed
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">method-of-use</FONT></FONT> patent. If the applicant does not challenge the listed patents, the ANDA application will not be approved until all the listed patents claiming the
referenced product have expired. A certification that the new product will not infringe the already approved product&#146;s listed patents, or that such patents are invalid, is called a Paragraph IV certification. If the ANDA applicant has provided
a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent
infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days of the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until
the earlier of 30 months, expiration of the patent, settlement of the lawsuit or a decision in the infringement case that is favorable to the ANDA applicant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ANDA application also will not be approved until any applicable <FONT STYLE="white-space:nowrap">non-patent</FONT> exclusivity listed in
the Orange Book for the referenced product has expired. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Exclusivity </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon NDA approval of a new chemical entity, or NCE, which is a drug that contains no active moiety that has been approved by FDA in any other
NDA, that drug receives five years of exclusivity during which FDA may not receive any ANDA seeking approval of a generic version of that drug. An ANDA may be submitted one year before NCE exclusivity expires if a Paragraph IV certification is
filed. If there is no listed patent in the Orange Book, there may not be a Paragraph IV certification, and, thus, no ANDA may be filed before the expiration of the exclusivity period. Certain changes to a drug, such as the addition of a new
indication to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
package insert, can be the subject of a three-year period of exclusivity if the application contains reports of new clinical investigations (other than bioavailability studies) conducted or
sponsored by the sponsor that were essential to approval of the application. FDA cannot approve an ANDA for a generic drug that includes the change during the period of exclusivity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Patent term extension </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After NDA
approval, owners of relevant drug patents may apply for up to a five-year patent extension. The allowable patent term extension is calculated as half of the drug&#146;s testing phase (the time between IND application and NDA submission) and all of
the review phase (the time between NDA submission and approval up to a maximum of five years). The time can be shortened if FDA determines that the applicant did not pursue approval with due diligence. The total patent term after the extension may
not exceed 14 years, and only one patent can be extended. For patents that might expire during the application phase, the patent owner may request an interim patent extension. An interim patent extension increases the patent term by one year and may
be renewed up to four times. For each interim patent extension granted, the post-approval patent extension is reduced by one year. The director of the United States Patent and Trademark Office must determine that approval of the drug covered by the
patent for which a patent extension is being sought is likely. Interim patent extensions are not available for a drug for which an NDA has not been submitted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Hatch-Waxman patent certification and the <FONT STYLE="white-space:nowrap">30-month</FONT> stay </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon approval of an NDA or a supplement thereto, NDA sponsors are required to list with the FDA each patent with claims that cover the
applicant&#146;s product or an approved method of using the product. Each of the patents listed by the NDA sponsor is published in the Orange Book. When an ANDA applicant files its application with the FDA, the applicant is required to certify to
the FDA concerning any patents listed for the reference product in the Orange Book, except for patents covering methods of use for which the ANDA applicant is not seeking approval. To the extent that the Section&nbsp;505(b)(2) applicant is relying
on studies conducted for an already approved product, the applicant is required to certify to the FDA concerning any patents listed for the approved product in the Orange Book to the same extent that an ANDA applicant would. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specifically, the applicant must certify with respect to each patent that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the required patent information has not been filed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the listed patent has expired; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the listed patent has not expired, but will expire on a particular date and approval is sought after patent
expiration; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the listed patent is invalid, unenforceable or will not be infringed by the new product. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A certification that the new product will not infringe the already approved product&#146;s listed patents or that such patents are invalid or
unenforceable is called a Paragraph IV certification. If the applicant does not challenge the listed patents or indicates that it is not seeking approval of a patented method of use, the application will not be approved until all the listed patents
claiming the referenced product have expired (other than method of use patents involving indications for which the applicant is not seeking approval). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the ANDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV
certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of
a patent infringement lawsuit within 45 days after the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months after the receipt of the Paragraph IV notice, expiration of the
patent or a decision in the infringement case that is favorable to the ANDA applicant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that the Section&nbsp;505(b)(2) applicant is relying on studies conducted for
an already approved product, the applicant is required to certify to the FDA concerning any patents listed for the approved product in the Orange Book to the same extent that an ANDA applicant would. As a result, approval of a Section&nbsp;505(b)(2)
NDA can be stalled until all the listed patents claiming the referenced product have expired, until any <FONT STYLE="white-space:nowrap">non-patent</FONT> exclusivity, such as exclusivity for obtaining approval of a new chemical entity, listed in
the Orange Book for the referenced product has expired, and, in the case of a Paragraph IV certification and subsequent patent infringement suit, until the earlier of 30 months, settlement of the lawsuit or a decision in the infringement case that
is favorable to the Section&nbsp;505(b)(2) applicant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;505(b)(2) NDAs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NDAs for most new drug products are based on two full clinical studies which must contain substantial evidence of the safety and efficacy of
the proposed new product for the proposed use. These applications are submitted under Section&nbsp;505(b)(1) of the FDCA. The FDA is, however, authorized to approve an alternative type of NDA under Section&nbsp;505(b)(2) of the FDCA. This type of
application enables the applicant in certain circumstances to rely, in part, on the FDA&#146;s prior findings in approving a similar product or published literature in support of its application. A Section&nbsp;505(b)(2) NDA may provide an alternate
path to FDA approval for a new or improved formulation, a new route of administration or a new use of a previously approved product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specifically, Section&nbsp;505(b)(2) applies to NDAs for a drug for which the investigations made to show whether or not the drug is safe for
use and effective in use and relied upon by the applicant for approval of the application &#147;were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the
investigations were conducted.&#148; If the Section&nbsp;505(b)(2) applicant can establish that reliance on the FDA&#146;s prior findings of safety and/or effectiveness is scientifically appropriate, it may eliminate the need to conduct certain
preclinical or clinical studies of the new product. The FDA may also require companies to perform additional studies or measurements to support the change from the approved product. The FDA may then approve the new product candidate for all, or
some, of the indications for which the referenced product has been approved, as well as for any new indication sought by the Section&nbsp;505(b)(2) applicant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Thus, Section&nbsp;505(b)(2) authorizes the FDA to approve an NDA based on safety and effectiveness data that were not developed by the
applicant. NDAs filed under Section&nbsp;505(b)(2) may provide an alternate and potentially more expeditious pathway to FDA approval for new or improved formulations or new uses of previously approved products. If the 505(b)(2) applicant can
establish that reliance on the FDA&#146;s previous approval is scientifically appropriate, the applicant may eliminate the need to conduct certain preclinical or clinical studies of the new product. The FDA may also require companies to perform
additional studies or measurements to support the change from the approved product. The FDA may then approve the new drug candidate for all or some of the label indications for which the referenced product has been approved, as well as for any new
indication sought by the Section&nbsp;505(b)(2) applicant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that the Section&nbsp;505(b)(2) applicant is relying on the
FDA&#146;s prior findings of safety or effectiveness for an already approved product, the applicant is required to certify to the FDA concerning any patents listed for the approved product in the Orange Book to the same extent that an ANDA applicant
would. Thus, approval of a Section&nbsp;505(b)(2) NDA can be stalled until all the listed patents claiming the referenced product have expired, until any <FONT STYLE="white-space:nowrap">non-patent</FONT> exclusivity, such as exclusivity for
obtaining approval of a new chemical entity, listed in the Orange Book for the referenced product has expired, and, in the case of a Paragraph IV certification and subsequent patent infringement suit, until the earlier of 30 months, settlement of
the lawsuit or a decision in the infringement case that is favorable to the Section&nbsp;505(b)(2) applicant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other U.S. healthcare laws and
compliance requirements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, pharmaceutical company activities are potentially subject to regulation by various
federal, state and local authorities in addition to the FDA, including but not limited to, the Centers for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Medicare&nbsp;&amp; Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human Services (e.g., the Office of Inspector General), the U.S. Department of Justice, or DOJ,
and individual U.S. Attorney offices within the DOJ, and state and local governments. For example, sales, marketing and scientific/educational grant programs may have to comply with the anti-fraud and abuse provisions of the Social Security Act, the
federal false claims laws, the privacy and security provisions of the Health Insurance Portability and Accountability Act, or HIPAA, and similar state laws, each as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying,
soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering, recommending or arranging for the purchase, lease or order of any item or service
reimbursable under Medicare, Medicaid or other federal healthcare programs. The term remuneration has been interpreted broadly to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between
pharmaceutical manufacturers on one hand and prescribers, purchasers, and/or formulary managers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. The exceptions
and safe harbors are drawn narrowly and practices that involve remuneration that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor.
Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on
a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis based on a cumulative review of all of its facts and circumstances. Practices may not in all cases meet all of the criteria for protection under a
statutory exception or regulatory safe harbor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the intent standard under the Anti-Kickback Statute was amended by the
Patient Protection and Affordable Care Act, or ACA, to a stricter standard such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the
ACA codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act (discussed below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The civil monetary penalties statute imposes penalties against any person or entity who, among other things, is determined to have presented
or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Federal false claims laws, including the federal civil False Claims Act, prohibit, among other things, any person or entity from knowingly
presenting, or causing to be presented, a false claim for payment to, or approval by, the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal
government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#147;any request or demand&#148; for money or property presented to the U.S. government. In addition, manufacturers can be held
liable under the civil False Claims Act even when they do not submit claims directly to government payors if they are deemed to &#147;cause&#148; the submission of false or fraudulent claims. Pharmaceutical and other healthcare companies have been
prosecuted under these laws for, among other things, allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to
be submitted because of the companies&#146; marketing of the product for unapproved, and thus generally <FONT STYLE="white-space:nowrap">non-reimbursable,</FONT> uses and purportedly concealing price concessions in the pricing information submitted
to the government for government priced reporting purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">HIPAA created additional federal criminal statutes that prohibit knowingly
and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit
program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or
services. Similar to the Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also, many states have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other
state programs, or, in several states, apply regardless of the payor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Data privacy and security regulations by both the federal
government and the states in which business is conducted may also be applicable. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, imposes requirements on
certain types of people and entities relating to the privacy, security and transmission of individually identifiable health information. HIPAA requires covered entities to limit the use and transmission of individually identifiable health
information. HIPAA requires covered entities to limit the use and disclosure of protected health information to specifically authorized situations and requires covered entities to implement security measures to protect health information that they
maintain in electronic form. Among other things, HITECH made HIPAA&#146;s security standards directly applicable to business associates, independent contractors or agents of covered entities that receive or obtain protected health information in
connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state
attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#146; fees and costs associated with pursuing federal civil actions. In addition, state laws
govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the federal Physician Payments Sunshine Act within the ACA, and its implementing regulations, require that certain manufacturers
of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) report annually information related to certain payments or other
transfers of value made or distributed to physicians and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals and to report annually certain ownership and investment
interests held by physicians and their immediate family members. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Commercial distribution of products requires compliance with state laws
that require the registration of manufacturers and wholesale distributors of drug products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no
place of business within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new
technology capable of tracking and tracing product as it moves through the distribution chain. Several states have enacted legislation requiring pharmaceutical and biotechnology companies to establish marketing compliance programs, file periodic
reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing
certain physician prescribing data to pharmaceutical and biotechnology companies for use in sales and marketing, and to prohibit certain other sales and marketing practices. Sales and marketing activities are also potentially subject to federal and
state consumer protection and unfair competition laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Violation of any of the federal and state healthcare laws described above or any
other governmental regulations may result in penalties, including without limitation, civil, criminal and/or administrative penalties, damages, fines, disgorgement, exclusion from participation in government programs, such as Medicare and Medicaid,
injunctions, private &#147;qui tam&#148; actions brought by individual whistleblowers in the name of the government, refusal to enter into government contracts, contractual damages, reputational harm, administrative burdens, diminished profits and
future earnings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pharmaceutical insurance coverage and health care reform </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the
prescribed services generally rely on third-party payors to reimburse all or part of the associated health care costs. Significant uncertainty exists as to the coverage and reimbursement status of products approved by the FDA and other government
authorities. Thus, even if a product candidate is approved, sales of the product will depend, in part, on the extent to which third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial
health insurers and managed care organizations, provide coverage and establish adequate reimbursement levels for, the product. The process for determining whether a payor will provide coverage for a product may be separate from the process for
setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity and reviewing the cost-effectiveness of
medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular
indication. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct
expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable marketing approvals. Nonetheless, product candidates may not
be considered medically necessary or cost effective. A decision by a third-party payor not to cover a product could reduce physician utilization once the product is approved and have a material adverse effect on sales, results of operations and
financial condition. Additionally, a payor&#146;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#146;s determination to provide coverage for a product does not
assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The containment of health care costs also has become a priority of federal, state and foreign governments and the prices of products have been
a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls
and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#146;s revenue generated from the sale of any approved products. Coverage policies and
third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive marketing approval, less favorable coverage policies
and reimbursement rates may be implemented in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been a number of federal and state proposals during the last few
years regarding the pricing of pharmaceutical and biopharmaceutical products, limiting coverage and reimbursement for drugs and biologics and other medical products, government control and other changes to the health care system in the United
States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2010, the United States Congress enacted the ACA, which, among other things, includes changes to the coverage and
payment for drug products under government health care programs. Among the provisions of the ACA of importance to our potential product candidates are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and
biologic agents, apportioned among these entities according to their market share in certain government healthcare programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid
coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#146;s Medicaid rebate liability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expanded manufacturers&#146; rebate liability under the Medicaid Drug Rebate Program by increasing the minimum
rebate for both branded and generic drugs and revising the definition of &#147;average </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
manufacturer price,&#148; or AMP, for calculating and reporting Medicaid drug rebates on outpatient prescription drug prices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are
calculated for drugs that are inhaled, infused, instilled, implanted or injected; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expanded the types of entities eligible for the 340B drug discount program; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">established the Medicare Part D coverage gap discount program by requiring manufacturers to provide a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale-discount</FONT></FONT> (now 70%) off the negotiated price of applicable brand drugs to eligible beneficiaries during their coverage gap period as a condition for the
manufacturers&#146; outpatient drugs to be covered under Medicare Part D; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative
clinical effectiveness research, along with funding for such research. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of the provisions of the ACA have yet to be
implemented, and there have been judicial and Congressional challenges to certain aspects of the ACA, as well as recent efforts by the Trump administration to repeal or replace certain aspects of the ACA. Since January 2017, President Trump has
signed two Executive Orders and other directives designed to delay the implementation of certain provisions of the ACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress
has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA such as removing penalties, starting January&nbsp;1, 2019, for not complying with the ACA&#146;s individual mandate to carry health
insurance, and delaying the implementation of certain <FONT STYLE="white-space:nowrap">ACA-mandated</FONT> fees, and increasing the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discount that is owed
by pharmaceutical manufacturers who participate in Medicare Part D. On December&nbsp;14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the &#147;individual mandate&#148; was repealed by
Congress as part of the Tax Cuts and Jobs Act of 2017. This decision was appealed to the U.S. Court of Appeals for the Fifth Circuit. On December&nbsp;18, 2019, that court affirmed the lower court&#146;s ruling that the individual mandate portion of
the ACA is unconstitutional and it remanded the case to the district court for reconsideration of the severability question and additional analysis of the provisions of the ACA. On January&nbsp;21, 2020, the U.S. Supreme Court declined to review
this decision on an expedited basis. On March&nbsp;3, 2020, the U.S. Supreme Court agreed to hear this case. Subsequently, on June&nbsp;25, 2020, the Trump Administration and a coalition of 18 states asked the court to strike down the entirety of
the ACA. It is unclear how such litigation and other efforts to repeal and replace the ACA will impact the ACA and our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There
has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent congressional inquiries and proposed and
enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies
for products. At the federal level, the Trump administration&#146;s budget proposals for fiscal year 2020 contains further drug price control measures that could be enacted during the 2020 budget process or in other future legislation. For example,
proposals would create a new <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> spending cap for Medicare Part D, allow some states to negotiate drug prices directly with manufacturers under Medicaid, and
eliminate cost sharing for generic drugs for <FONT STYLE="white-space:nowrap">low-income</FONT> patients. Further, the Trump administration released a &#147;Blueprint&#148; to lower drug prices and reduce out of pocket costs of drugs that contains
additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out of pocket costs of drug
products paid by consumers. HHS has already started soliciting feedback on some of these measures and, at the same, is immediately implementing others under its existing authority. At the state level, legislatures have increasingly passed
legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and
transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other
healthcare reforms may prevent the generation revenue, attainment of profitability or commercialization of products. In addition, it is possible that there will be further legislation or regulation that could harm the business, financial condition
and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In
August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for
the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#146;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers up to 2% per fiscal
year, which went into effect in April 2013 and, due to subsequent legislative amendments, will remain in effect through 2029 unless additional Congressional action is taken, with the exception of a temporary suspension from May&nbsp;1, 2020 through
December&nbsp;31, 2020 implemented under the CARES Act. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several providers, including
hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since enactment of the ACA, there have been numerous legal challenges and Congressional actions to repeal and replace provisions of the law.
For example, with enactment of the Tax Cuts and Jobs Act of 2017, which was signed by the President on December&nbsp;22, 2017, Congress repealed the &#147;individual mandate.&#148; The repeal of this provision, which requires most Americans to carry
a minimal level of health insurance, will become effective in 2019. According to the Congressional Budget Office, the repeal of the individual mandate will cause 13&nbsp;million fewer Americans to be insured in 2027 and premiums in insurance markets
may rise. Additionally, on January&nbsp;22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain <FONT STYLE="white-space:nowrap">ACA-mandated</FONT> fees, including
the <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;Cadillac&#148; tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share, and the medical device excise
tax on <FONT STYLE="white-space:nowrap">non-exempt</FONT> medical devices. The Congress will likely consider other legislation to replace elements of the ACA during the next Congressional session. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Trump Administration has also taken executive actions to undermine or delay implementation of the ACA. Since January 2017, President Trump
has signed two Executive Orders designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. One Executive Order directs federal agencies with
authorities and responsibilities under the ACA to waive, defer, grant exemptions from or delay the implementation of any provision of the ACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health
insurers or manufacturers of pharmaceuticals or medical devices. The second Executive Order terminates the cost-sharing subsidies that reimburse insurers under the ACA. Several state Attorneys General filed suit to stop the administration from
terminating the subsidies, but their request for a restraining order was denied by a federal judge in California on October&nbsp;25, 2017. In addition, CMS has recently proposed regulations that would give states greater flexibility in setting
benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces. Further, on June&nbsp;14, 2018, U.S. Court
of Appeals for the Federal Circuit ruled that the federal government was not required to pay more than $12&nbsp;billion in ACA risk corridor payments to third-party payors who argued were owed to them. That decision, however, was overturned by the
U.S. Supreme Court on April&nbsp;27, 2020 . Further, there have been several recent U.S. congressional inquiries and proposed federal and proposed and enacted state legislation designed to, among other things, bring more transparency to drug
pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products. At the federal level, Congress and the Trump
administration have each indicated that it will continue to seek new legislative and/or administrative </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
measures to control drug costs. For example, on May&nbsp;11, 2018, the Administration issued a plan to lower drug prices. Under this blueprint for action, the Administration indicated that the
Department of Health and Human Services will: take steps to end the gaming of regulatory and patent processes by drug makers to unfairly protect monopolies; advance biosimilars and generics to boost price competition; evaluate the inclusion of
prices in drug makers&#146; ads to enhance price competition; speed access to and lower the cost of new drugs by clarifying policies for sharing information between insurers and drug makers; avoid excessive pricing by relying more on value-based
pricing by expanding outcome-based payments in Medicare and Medicaid; work to give Part D plan sponsors more negotiation power with drug makers; examine which Medicare Part B drugs could be negotiated for a lower price by Part D plans, and improving
the design of the Part B Competitive Acquisition Program; update Medicare&#146;s drug-pricing dashboard to increase transparency; prohibit Part D contracts that include &#147;gag rules&#148; that prevent pharmacists from informing patients when they
could pay less <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> by not using insurance; and require that Part D plan members be provided with an annual statement of plan payments, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> spending, and drug price increases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">More
recently, President Trump has issued five executive orders that are intended to lower the costs of prescription drug products. The first order would require all federally qualified health centers, or FQHCs, to pass on to patients the discounts the
health centers receive on insulin and epinephrine through Medicare&#146;s&nbsp;340B Drug Discount Program. The second order would establish an international pricing index that would set the price Medicare Part&nbsp;B pays for the costliest
medications covered under the program to the lowest price in other economically advanced countries. The President has indicated that this order will be held because the administration may not implement it. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The third order is intended to reduce the costs of drugs by supporting the safe importation of prescription drugs. Specifically, the order
calls upon the Department of Health and Human Services, or HHS, to facilitate grants to individuals of waivers of the prohibition of importation of prescription drugs that would allow patients to import FDA approved drug products from abroad, so
long as doing so would result in lower costs. In addition, the order would allow wholesalers and pharmacies to <FONT STYLE="white-space:nowrap">re-import</FONT> both biological drugs and insulin that were originally manufactured in the United States
and then exported for international sale. This action follows the publication of a proposed rulemaking on December&nbsp;23, 2019, that, if finalized, would allow states or certain other <FONT STYLE="white-space:nowrap">non-federal</FONT> government
entities to submit importation program proposals to the FDA for review and approval. Applicants would be required to demonstrate that their importation plans pose no additional risk to public health and safety and will result in significant cost
savings for consumers. At the same time, the FDA issued draft guidance that would allow manufacturers to import their own <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drugs that are authorized for sale in other countries (multi-market
approved products). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fourth executive order would end drug rebates used by health plan sponsors, pharmacies or pharmacy benefit
managers, or PBMs, in operating the Medicare Part&nbsp;D program. Specifically, the order directs HHS to exclude from safe harbor protections under the federal anti-kickback statute retroactive price reductions that are not applied at the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale.</FONT></FONT> Instead, the order requires HHS to establish new safe harbors that would allow health plan sponsors, pharmacies, and PBMs to pass on those discounts to
consumers at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;point-of-sale</FONT></FONT> in order to lower the patient&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT>
costs&#148; and &#147;permit the use of certain bona fide PBM service fees.&#148; Each of these orders directs the federal government to implement the initiatives outlined in the orders, meaning they will not have immediate effects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finally, the fifth order instructs the federal government to develop a list of &#147;essential&#148; medicines and then buy those and other
medical supplies that are manufactured, including the manufacture of the API, in the United States. The order is meant to reduce regulatory barriers to domestic pharmaceutical manufacturing and catalyze manufacturing technologies needed to keep drug
prices low and the production of drug products in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the state level, individual states are increasingly aggressive in
passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure
and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are
increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for drug products, once
approved, or put pressure on product pricing. Additional state and federal healthcare reform measures will likely be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and
services, which could result in reduced demand for such product candidates or additional pricing pressures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finally, in the European
Union, similar political, economic and regulatory developments may affect our ability to profitably commercialize our product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative
developments at the European Union or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the European Union, including the establishment and
operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than European Union, law and policy. National governments and health service providers have different priorities and
approaches to the delivery of healthcare and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most European Union member states have resulted in restrictions on the pricing and
reimbursement of medicines by relevant health service providers. Coupled with ever-increasing European Union and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our
product candidates, restrict or regulate post-approval activities and affect our ability to commercialize our product candidates, if approved. In markets outside of the United States and the European Union, reimbursement and healthcare payment
systems vary significantly by country, and many countries have instituted price ceilings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June 30, 2020, we had 24 full time employees, eight of whom have an M.D. or Ph.D. None of our employees are represented by a labor union
or covered by collective bargaining agreements, and we believe our relationship with our employees is good. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Properties and facilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive office is located in Redwood City, California, and consists of approximately 6,000 square feet of office space under a
lease which expires in August 2021. We use this facility for operations and administrative purposes. We also have facilities located in Baltimore, Maryland. The Maryland facility consists of approximately 8,500 square feet of office and laboratory
space under a lease which expires in June 2023. We use the Maryland facility for our internal research and development activities. We believe that our facilities are adequate to meet our needs for the foreseeable future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal proceedings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we
may be involved in legal proceedings arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, in the opinion of management, would have a material adverse effect on our business. Regardless of
outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity and reputational harm, and other factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc796801_13"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers and Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table provides information regarding our executive officers and directors as of September&nbsp;4, 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Executive Officers:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Frederic Guerard, Pharm.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President, Chief Executive Officer and Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert S. Breuil</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Parisa Zamiri, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Medical Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel Salain</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Technical Operations Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="4"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-employee</FONT> Directors:</B></P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christy Shaffer, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chairperson, Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christina Ackermann(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Bjerkholt(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gerald Cagle, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Emmett Cunningham, Jr., M.D., Ph.D.(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Julie Eastland(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hansoo Michael Keyoung, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chau Khuong(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cameron Wheeler, Ph.D.(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ms. Ackermann&#146;s appointment as a director will be effective upon the effectiveness of the registration
statement of which this prospectus is a part. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr. Bjerkholt&#146;s appointment as a director will be effective upon the effectiveness of the registration
statement of which this prospectus is a part. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr. Cunningham has notified us that he will resign from our board of directors contingent upon and effective
immediately prior to the effectiveness of this registration statement of which this prospectus forms a part. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ms. Eastland&#146;s appointment as a director will be effective upon the effectiveness of the registration
statement of which this prospectus is a part. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr. Khuong has notified us that he will resign from our board of directors contingent upon and effective
immediately prior to the effectiveness of this registration statement of which this prospectus forms a part. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr. Wheeler has notified us that he will resign from our board of directors contingent upon and effective
immediately prior to the effectiveness of this registration statement of which this prospectus forms a part. </P></TD></TR></TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive
Officers </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Frederic Guerard, Pharm.D.</I>, has served as our President and Chief Executive Officer and a member of our board of
directors, since February 2019. From 1999 to February 2019, Dr.&nbsp;Guerard held key leadership roles at Novartis AG, a multinational pharmaceutical company, including Worldwide Business Franchise Head of Ophthalmology from April 2016 to February
2019, Global Franchise Head of Pharmaceuticals at Alcon Vision LLC, a Novartis company, from May 2015 to April 2016, Managing Director of the United Kingdom and Ireland from July 2012 to April 2015, and Country President and Managing Director of
Australia and New Zealand from April 2009 to July 2012, among others. Dr.&nbsp;Guerard holds a Pharm.D. and a Master of Biological and Medical Sciences from the University of Rouen, France and a Master of Marketing from HEC Paris. We believe that
Dr.&nbsp;Guerard is qualified to serve on our board of directors because of his extensive experience serving in leadership positions in biotechnology companies, as well as the operational expertise and continuity that he brings to our board of
directors as our President and Chief Executive Officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Robert S. Breuil</I> has served as our Chief Financial Officer since September 2020. From
September 2012 to August 2019, Mr. Breuil served as Chief Financial Officer of Corium, Inc., a commercial-stage biopharmaceutical company. Prior to that, he served as the Chief Financial Officer of Codexis, Inc., a developer of biocatalysts for the
pharmaceutical and fine chemical production industries, from 2006 to September 2009. From 2002 to 2005, Mr. Breuil was the Chief Financial Officer of Aerogen, Inc., a specialty pharmaceutical company focusing on the field of aerosolized drug
delivery, which was acquired by Nektar Therapeutics in October 2005. Prior to Aerogen, Mr. Breuil worked at ALZA Corporation, where he held numerous positions including Director of Corporate Planning and Analysis and Controller. In 2001, ALZA was
acquired by Johnson &amp; Johnson and Mr. Breuil stayed on as Controller until joining Aerogen in 2002. Before his industry experience, he served for eight years as a naval officer and aviator. Mr. Breuil holds a B.S. from the United States Naval
Academy and an M.B.A. from the Stanford Graduate School of Business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Parisa Zamiri, M.D., Ph.D.</I>, has served as our Chief Medical
Officer since June 2020. From April 2012 to June 2020, Dr.&nbsp;Zamiri held key leadership roles at Novartis, a multinational pharmaceutical company, including Vice President, Global Head of Clinical Development and Therapeutic Area Head for
Ophthalmology. From February 2007 to November 2011, Dr.&nbsp;Zamiri served as a Director of <FONT STYLE="white-space:nowrap">Pre-clinical</FONT> Sciences at Arsenal Medical Inc., an early stage combination medical device company, where she led teams
across cardiovascular, ophthalmology and pain programs using innovative drug/device combination technologies. Dr.&nbsp;Zamiri received her medical degree from the King&#146;s College Hospital, University of London, and did her ophthalmology
residency at the North Thames Rotation, London, England. She earned her Ph.D. in ocular immunology for her research on the immune privilege of the subretinal space conducted at the Schepen&#146;s Eye Research Institute of Massachusetts Eye and Ear,
a Harvard Medical School affiliated institute. The Ph.D. institution is University College London, London, England. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Daniel Salain</I>
has served as our Chief Technical Operations Officer since November 2019, and prior to that, as our Chief Operating Officer since December 2017. From April 2015 to November 2017, Mr.&nbsp;Salain served as Senior Vice President of Technical
Operations of Ophthotech Corporation (now known as Iveric bio, Inc.), a biopharmaceutical company specializing in the development of therapies to treat ophthalmic diseases, and as Global Head of Manufacturing&nbsp;&amp; Supply Chain and Senior Vice
President from April 2015 to November 2017. Prior to that, Mr.&nbsp;Salain served as Vice President, Global Supply Chain and Manufacturing at Aptalis Pharma, Inc., a pharmaceutical company focused on gastroenterology and cystic fibrosis, from July
1999 to November 2014. Mr.&nbsp;Salain holds a B.S. in Chemistry from the University of Indianapolis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Christina Ackermann </I>has been elected to become a member of our Board of Directors upon the effectiveness of the registration statement
of which this prospectus is a part. Ms. Ackermann currently serves as Executive Vice President and General Counsel of Bausch Health Companies Inc., a specialty pharmaceutical company, since August 2016. Prior to joining Bausch Health, Ms. Ackermann
was part of the Novartis group of companies for the 14 years, most recently serving as Senior Vice President, General Counsel for Alcon, where she was responsible for the Legal, Intellectual Property and Compliance functions. She previously served
as Global Head, Legal and General Counsel at Sandoz, the generics division of Novartis, from 2007 to 2012. She joined Novartis Pharma in 2002 as Head, Legal Technical Operations and Ophthalmics and assumed the role of Head Legal General Medicine in
July 2005. Before Novartis, Ms. Ackermann served in Associate General Counsel roles with Bristol Myers Squibb and DuPont Pharmaceuticals, as well as in private practice, where she focused on securities and mergers &amp; acquisitions. Ms. Ackermann
has a Post Graduate Diploma in EC Competition Law from King&#146;s College, the University of London, U.K., a Bachelor of Laws from Queen&#146;s University, Kingston, Canada, and attended York University, Toronto, Ontario, for her undergraduate
studies in Math, Political Sciences and Fine Arts. We believe that Ms.&nbsp;Ackermann is qualified to serve on our board of directors due to her expertise in compliance and regulatory matters, public company experience and industry knowledge. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Eric Bjerkholt </I>has been elected to become a member of our Board of Directors upon the effectiveness of the registration statement of
which this prospectus is a part. Since April 2017, Mr. Bjerkholt has been the Chief </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Financial Officer of Aimmune Therapeutics, Inc., a biotechnology company developing treatments for food allergies. From 2004 until April 2017, Mr. Bjerkholt held various roles at Sunesis
Pharmaceuticals, Inc., a biopharmaceutical company developing oncology therapeutics, including as Executive Vice President, Corporate Development and Finance and Chief Financial Officer. From 2002 to 2004, he was Senior Vice President and Chief
Financial Officer at IntraBiotics Pharmaceuticals, Inc., a biopharmaceutical company that was acquired by Ardea Biosciences, Inc. in 2006. Mr. Bjerkholt was a co-founder of LifeSpring Nutrition, Inc., a nutraceutical company, and from 1999 to 2002
served at various times as its Chief Executive Officer, President, and Chief Financial Officer. From 1990 to 1997, he also served as a vice president in the healthcare banking group at J.P. Morgan &amp; Co. Incorporated, an international banking
firm. He has served on the boards of directors of several publicly traded companies, including as a member of the board of directors and chair of the audit committee of Corium, Inc. until its acquisition by Gurnet Point Capital in November 2018, and
as a member of the board of directors and as chair of the audit committee of StemCells, a biotechnology company, until its November 2016 acquisition by Microbot Medical Ltd. He currently is a member of the board of directors and chair of the audit
committee of Cerus Corporation, a biotechnology company. He holds a Cand. Oecon degree in Economics from the University of Oslo and an M.B.A. from Harvard Business School. We believe that Mr.&nbsp;Bjerkholt&#146;s financial experience and expertise
and industry knowledge provide him with the qualifications and skills to serve on our board of directors. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Gerald Cagle, Ph.D.,
</I>has served as a member of our board of directors since April 2014 and is also our Senior Advisor and Head of Business Development. Dr.&nbsp;Cagle also served as our interim CEO from October 2018 to February 2019. From 2008 to 2013,
Dr.&nbsp;Cagle served as Chief Operating Officer at Cognoptix, lnc., a biotechnology company focused on the diagnosis of Alzheimer&#146;s disease. Previously, Dr.&nbsp;Cagle held various roles with Alcon Vision LLC, from 1996 to 2008, including
Senior Vice President of Research&nbsp;&amp; Development and Chief Scientific Officer. Dr.&nbsp;Cagle has also served on the board of directors of Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, since September 2013 and
previously served on the board of directors of Clearside Biomedical, Inc., a clinical biopharmaceutical company, from July 2013 to June 2018. Dr.&nbsp;Cagle also currently serves on the boards of directors of two private pharmaceutical companies.
Dr.&nbsp;Cagle received a B.S. from Wayland Baptist University and a M.S. and a Ph.D. from the University of North Texas. We believe that Dr.&nbsp;Cagle is qualified to serve on our board of directors due to his strong scientific background,
particularly in ocular therapies, and his board experience. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Emmett Cunningham, Jr., M.D., Ph.D., </I>has served as a member of our
board of directors since April 2016. Dr.&nbsp;Cunningham is Senior Managing Director at The Blackstone Group Inc., a life sciences private investment platform, having joined Blackstone as part of its acquisition of Clarus Ventures, LLC, a venture
capital and asset management firm, in December 2018. Dr.&nbsp;Cunningham joined Clarus in 2006 as a Principal. Dr.&nbsp;Cunningham has also served as Adjunct Clinical Professor of Ophthalmology at Stanford University School of Medicine since July
2008 and as <FONT STYLE="white-space:nowrap">co-founder</FONT> and Chairman of the Ophthalmology Innovation Summit since October 2009. From 2004 to 2005, Dr.&nbsp;Cunningham served as Senior Vice President, Medical Strategy at Eyetech
Pharmaceuticals, Inc., and prior to that, as Vice President of Clinical Research Development and Licensing from 2002 to 2004. Prior to joining Eyetech, Dr.&nbsp;Cunningham served as Early Clinical Leader at Pfizer Inc., a multinational
pharmaceutical corporation, from August 2001 to April 2002. Dr.&nbsp;Cunningham serves on the boards of directors of a number of private companies and on the Scientific Advisory Board of Aerie Pharmaceuticals, Inc. Dr.&nbsp;Cunningham previously
served on the board of directors at Restoration Robotics, Inc., a medical device company, from 2011 to 2018. Dr.&nbsp;Cunningham holds a B.S. from Drexel University, a M.D. and M.P.H. from Johns Hopkins University, and a Ph.D. in neuroscience from
the University of California, San Diego. We believe that Dr.&nbsp;Cunningham is qualified to serve on our board of directors due to his experience in research and investing in medical companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Julie Eastland </I>has been elected to become a member of our Board of Directors upon the effectiveness of the registration statement of
which this prospectus is a part. Ms. Eastland is a consultant with Eastland Advisory Services since February 2020. Prior to consulting, Ms. Eastland was the Chief Financial and Business Officer of Rainier Therapeutics, Inc., a biotechnology company,
since August 2018. Prior to Rainier Therapeutics, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Ms.&nbsp;Eastland served as Chief Business Officer and Chief Financial Officer for Cascadian Therapeutics, Inc., a biotechnology company, from September 2010 through its acquisition by Seattle
Genetics in March 2018. Prior to Cascadian, Ms. Eastland served as the Chief Financial Officer and Vice President of Finance and Administration for VLST Corporation, a biotechnology company, from January 2006 to September 2010. Prior to VLST
Corporation, Ms. Eastland was the Vice President of Strategic Planning at Dendreon Corporation, a biotechnology company, from October 2000 to October 2005. Prior to Dendreon, Ms. Eastland was the Controller at Amgen, a biopharmaceutical company,
from March 1996 to April 1998. Ms.&nbsp;Eastland currently serves on the board of the TSX-listed company Pascal Biosciences Inc. and on the boards of Harpoon Therapeutics, Inc., and Dynavax Technologies, both Nasdaq listed companies. Ms. Eastland
holds a B.S. in Finance from Colorado State University and an M.B.A. from Heriot-Watt University of the Edinburgh University in Scotland. We believe that Ms.&nbsp;Eastland&#146;s extensive professional experience and expertise provide her with the
qualifications and skills to serve on our board of directors. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Hansoo Michael Keyoung, M.D., Ph.D.,</I> has served as a member of
our board of directors since July 2019. Since August 2017, Dr.&nbsp;Keyoung has served as Managing Director and Head of North America at CBC Group, formerly known as <FONT STYLE="white-space:nowrap">C-Bridge</FONT> Capital, a healthcare-dedicated
private equity firm with over $2&nbsp;billion assets under management. Dr.&nbsp;Keyoung is Founding Managing Partner of Portola Capital Partners LLC, a healthcare-dedicated investment and advisory firm, since November 2013. Dr.&nbsp;Keyoung was
previously President and CEO of Genexine Inc., a clinical stage biotechnology company, from July 2015 to August 2017. Prior to that, Dr.&nbsp;Keyoung served as President, Asia of Catalyst Biosciences Inc., a hemophilia and ophthalmology-focused
clinical stage company, from December 2013 to June 2015, and as Managing Director and Head of <FONT STYLE="white-space:nowrap">Pan-Asia</FONT> at Burrill&nbsp;&amp; Company LLC, a venture capital firm, where he oversaw investments in private and
public biotechnology and medtech companies from 2008 to 2013. Dr.&nbsp;Keyoung received both a M.D. and a Ph.D. in Neuroscience and Neurology as a <FONT STYLE="white-space:nowrap">Tri-Institutional</FONT>
<FONT STYLE="white-space:nowrap">MD-PHD</FONT> Program Scholarship recipient from Cornell University Weill Medical College, Memorial Sloan Kettering Cancer Center and The Rockefeller University. Currently, Dr.&nbsp;Keyoung serves as Chairman and
Member of the Board of Directors at AffaMed Therapeutics, member of the Board of Directors at InxMed, and served as founding board member of Everest Medicines Ltd. and <FONT STYLE="white-space:nowrap">I-Mab</FONT> biopharma US Ltd. We believe that
Dr.&nbsp;Keyoung is qualified to serve on our board of directors due to his extensive experience in research and investing in biomedical companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Chau Q. Khuong</I><I> </I>has served as a member of our board of directors since April 2016. Mr.&nbsp;Khuong is a Private Equity Partner at
OrbiMed Advisors, LLC, an investment firm. Mr.&nbsp;Khuong currently serves on the boards of directors of Fusion Pharmaceuticals, Inc., a biopharmaceutical company, Inspire Medical Systems, Inc., a medical technology company, NextCure, Inc., a
biopharmaceutical company, and Synlogic, Inc., a clinical stage company. Mr.&nbsp;Khuong previously served as a member of the boards of directors of Aerpio Therapeutics Inc., a biopharmaceutical company, BELLUS Health Inc., a biopharmaceutical
company, Nabriva Therapeutics plc (formerly Nabriva Therapeutics AG), a commercial-stage biotechnology company, Pieris, Inc., a clinical stage biotechnology company, and Otonomy, Inc., a biopharmaceutical company. Mr.&nbsp;Khuong holds a B.S. in
molecular, cellular and development biology and a M.P.H. with a concentration in infectious diseases, both from Yale University. We believe that Mr.&nbsp;Khuong is qualified to serve on our board of directors based on his roles on several public and
private boards of directors as well as his extensive experience in investing in healthcare companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Christy Shaffer, Ph.D.,</I> has
served as a member of our board of directors since February 2015 and as Chairperson of the board since March 2015. Since August 2015, Dr.&nbsp;Shaffer has served as a General Partner at Hatteras Venture Partners, a venture capital firm, where she
has also served as Managing Director of Hatteras Discovery since August 2011. Prior to that, Dr.&nbsp;Shaffer was President and Chief Executive Officer of Inspire Pharmaceuticals, Inc., a biopharmaceutical company, from 1995 to March 2010.
Dr.&nbsp;Shaffer serves as Chair of the board of directors of Clearside Biomedical, Inc., a biopharmaceutical company, and on the boards of directors for a number of private biotechnology companies. Dr.&nbsp;Shaffer holds a Ph.D. in Pharmacology
from the University of Tennessee Health Science Center. We believe Dr.&nbsp;Shaffer is qualified to serve on our board of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
directors because of her experience in the ophthalmology, pharmaceutical and biotechnology businesses, and because of her training as a pharmacologist. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Cameron Wheeler, Ph.D.,</I> has served as a member of our board of directors since April 2016. Dr.&nbsp;Wheeler is a Partner in the
Biotherapeutics group at Deerfield Management Company, L.P., a healthcare-focused investment firm, which he joined in 2014. Dr.&nbsp;Wheeler has served as a Principal on the Private Transactions team at Deerfield. Prior to Deerfield,
Dr.&nbsp;Wheeler worked for and on behalf of Eleven Biotherapeutics, Inc., as a director since 2009. Previous to Eleven Biotherapeutics, Dr.&nbsp;Wheeler was the manager of the Business Development and Operations team at Constellation
Pharmaceuticals, Inc. and a Senior Associate at Third Rock Ventures, LLC from 2008 to 2009. Dr.&nbsp;Wheeler holds a Ph.D. and S.M. in Biological Engineering and a S.B. in Mechanical Engineering from the Massachusetts Institute of Technology. We
believe Dr.&nbsp;Wheeler is qualified to serve on our board of directors because of his scientific background and longtime involvement with biotechnology companies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Election of Officers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our executive
officers are appointed by, and serve at the discretion of, our board of directors. There are no family relationships among any of our directors or executive officers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Composition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors
currently consists of seven members. Pursuant to our current voting agreement and certificate of incorporation, Christy Shaffer, Cameron Wheeler, Chau Khuong, Emmett Cunningham, Jr., Frederic Guerard, Hansoo Michael Keyoung and Gerald Cagle have
been designated to serve as members of our board. Christy Shaffer was elected by the holders of our Series <FONT STYLE="white-space:nowrap">A-2</FONT> convertible preferred stock, or Series A-2 preferred. Cameron Wheeler, Chau Khuong and Emmett
Cunningham, Jr. were elected by the holders of our Series B preferred. Hansoo Michael Keyoung was elected by the holders of our Series C preferred. Frederic Guerard was elected by the holders of our common stock. Gerald Cagle was elected by the
holders of our common stock and convertible preferred stock, voting together as a single class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The voting agreement and the provisions of our current certificate of incorporation that govern the election and designation of our directors
will terminate in connection with this offering, after which no contractual obligations will concern the election of our directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Classified Board
of Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, our board of directors will be divided into three staggered classes of directors.
At each annual meeting of stockholders, a class of directors will be subject to <FONT STYLE="white-space:nowrap">re-election</FONT> for a three-year term. As a result, only one class of directors will be elected at each annual meeting of our
stockholders, with the other classes continuing for the remainder of their respective three-year terms. Our directors will be divided among the three classes as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;I directors will be Christy Shaffer and Michael Hansoo Keyoung and their terms will expire at the
first annual meeting of stockholders held following the completion of the offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;II directors will be Gerald Cagle and Eric Bjerkholt and their terms will expire at the second
annual meeting of stockholders held following the completion of the offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;III directors will be Christina Ackermann, Julie Eastland and Frederic Guerard and their terms
will expire at the third annual meeting of stockholders held following the completion of the offering. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each
director&#146;s term continues until the election and qualification of his or her successor, or his or her earlier death, resignation or removal. Our restated certificate of incorporation and restated bylaws that will be in effect upon the
completion of this offering authorize only our board of directors to fill vacancies on our board of directors. Any increase or decrease in the number of directors will be distributed among the three classes so that,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
as nearly as possible, each class will consist of <FONT STYLE="white-space:nowrap">one-third</FONT> of the directors. This classification of our board of directors may have the effect of delaying
or preventing changes in control of our company. See the section entitled &#147;Description of Capital Stock&#151;Anti-Takeover Provisions&#151;Restated Certificate of Incorporation and Restated Bylaw Provisions.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Independence </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with
this offering, we have applied to list our common stock on the Nasdaq Global Market, or The Nasdaq. Under the rules of The Nasdaq, independent directors must comprise a majority of a listed company&#146;s board of directors within a specified period
following the completion of this offering. In addition, the rules of The Nasdaq require that, subject to specified exceptions, each member of a listed company&#146;s audit, compensation and nominating and governance committees be independent. Under
the rules of The Nasdaq, a director will only qualify as an &#147;independent director&#148; if, in the opinion of that company&#146;s board of directors, that person does not have a relationship that would interfere with the exercise of independent
judgment in carrying out the responsibilities of a director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Audit committee members must also satisfy the independence criteria set
forth in Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act. In order to be considered independent for purposes of Rule <FONT STYLE="white-space:nowrap">10A-3,</FONT> a member of an audit committee of a listed company may not,
other than in his or her capacity as a member of the audit committee, the board of directors or any other board committee: (i)&nbsp;accept, directly or indirectly, any consulting, advisory or other compensatory fee from the listed company or any of
its subsidiaries; or (ii)&nbsp;be an affiliated person of the listed company or any of its subsidiaries. We intend to satisfy the audit committee independence requirements of Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> as of the completion of
this offering. Additionally, compensation committee members must not have a relationship with us that is material to the director&#146;s ability to be independent from management in connection with the duties of a compensation committee member. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has undertaken a review of the independence of each director and considered whether each director has a material
relationship with us that could compromise his ability to exercise independent judgment in carrying out his responsibilities. As a result of this review, our board of directors determined that all of our directors, except for Frederic Guerard, are
&#147;independent directors&#148; as defined under the applicable rules and regulations of the SEC, and the listing requirements and rules of The Nasdaq. In making these determinations, our board of directors reviewed and discussed information
provided by the directors and us with regard to each director&#146;s business and personal activities and relationships as the may relate to us and our management, including the beneficial ownership of our capital stock by each <FONT
STYLE="white-space:nowrap">non-employee</FONT> director and then transactions involving them described in the section entitled &#147;Certain Relationships and Related Party Transactions.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Committees of the Board of Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
board of directors has an audit committee, a compensation committee and a nominating and governance committee, each of which will have the composition and responsibilities described below as of the completion of this offering. Each of the below
committees has a written charter approved by our board of directors. Upon completion of this offering, copies of each charter will be posted on the investor relations section of our website. Members serve on these committees until their resignation
or until otherwise determined by our board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our audit committee is composed of Julie Eastland,Eric Bjerkholt and Christy Shaffer, with Ms. Eastland as the chairman of our audit committee.
The composition of our audit committee meets the requirements for independence under the current Nasdaq and SEC rules and regulations. Each member of our audit committee is financially literate. In addition, our board of directors has determined
that Ms.&nbsp;Eastland is an &#147;audit committee </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
financial expert,&#148; as defined in Item 407(d)(5)(ii) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> promulgated under the Securities Act of 1933, as amended. This designation does
not impose any duties, obligations or liabilities that are greater than are generally imposed on members of our audit committee and our board of directors. Our audit committee is directly responsible for, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">selecting and hiring our independent registered public accounting firm; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the qualifications, independence and performance of our independent auditors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the preparation of the audit committee report to be included in our annual proxy statement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our compliance with legal and regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our accounting and financial reporting processes, including our financial statement audits and the integrity of
our financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the oversight of our cybersecurity measures; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving related-party transactions. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
compensation committee is comprised of Eric Bjerkholt, Christina Ackermann, and Hansoo Michael Keyoung with Mr. Bjerkholt as the chairman of our compensation committee. Each member of our compensation committee is a
<FONT STYLE="white-space:nowrap">non-employee</FONT> director, as defined by Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act and meets the requirements for independence under the current Nasdaq listing standards
and SEC rules and regulations. Our compensation committee is responsible for, among other things: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating, recommending, approving and reviewing executive officer compensation arrangements, plans, policies
and programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating and recommending <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation
arrangements for determination by our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">administering our cash-based and equity-based compensation plans; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing our compliance with regulatory requirements associated with the compensation of directors, officers
and employees. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Governance Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our nominating and governance committee is comprised of Christina Ackermann, Christy Shaffer and Gerald Cagle, with Ms.&nbsp;Ackermann as the
chairman of our nominating and governance committee. Each member of our nominating and governance committee meets the requirements for independence under the current Nasdaq listing standards. Our nominating and governance committee is responsible
for, among other things: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying, considering and recommending candidates for membership on our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing the process of evaluating the performance of our board of directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advising our board of directors on other corporate governance matters. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the members of our compensation committee has at any time been one of our officers or employees, and none of our executive officers has
served as a member of the board of directors, or as a member of the compensation or similar committee, of any entity that has one or more executive officers who served on our board of directors or compensation committee during the year ended
December&nbsp;31, 2019. Prior to establishing the compensation committee, our full board of directors made decisions relating to the compensation of our officers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct and Ethics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the completion of this offering, our board of directors will adopt a code of business conduct and ethics that applies to all of our
employees, officers and directors, including our Chief Executive Officer, Chief Financial Officer and other executive and senior officers. The full text of our business code of conduct and ethics will be posted on the investor relations section of
our website. The reference to our website address in this prospectus does not include or incorporate by reference the information on our website into this prospectus. We intend to disclose future amendments to certain provisions of our business code
of conduct and ethics, or waivers of these provisions, on our website or in public filings to the extent required by the applicable rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No compensation was paid to our <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors during the year ended December&nbsp;31, 2019. All compensation paid to Frederic Guerard, our only employee director, is set forth below in the section titled &#147;Executive
Compensation&#151;Summary Compensation Table.&#148; No compensation was paid to Dr.&nbsp;Guerard in his capacity as a director in 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019, Gerald Cagle held outstanding options to purchase 81,817&nbsp;shares of common stock with a weighted-average
exercise price of $1.89 per share. As of December&nbsp;31, 2019, 81,817&nbsp;shares subject to the stock options were vested and no share was unvested. No other <FONT STYLE="white-space:nowrap">non-employee</FONT> director held equity awards as of
December&nbsp;31, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2020, our board of directors approved compensation for our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors, to be effective upon completion of this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Cash Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beginning after this offering, our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors will receive annual cash compensation of
$40,000 for service on the board of directors, or a General Board Service Fee, and additional cash compensation for the chairperson and committee members as set forth below. All cash payments will be made quarterly in arrears and will be <FONT
STYLE="white-space:nowrap">pro-rated</FONT> for any partial quarters of service. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">General Board Service Fee: $40,000 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Chairman of the Board Fee (in addition to General Board
Service Fee): $30,000 </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Lead Director Fee (if named, in addition to General Board Service Fee): $25,000 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Committee Chair Service Fee (in addition to General Board Service Fee; in lieu of
<FONT STYLE="white-space:nowrap">Non-Chair</FONT> Committee Member Service Fee set forth below): </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Audit Committee chair: $15,000 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Compensation Committee chair: $10,000 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nominating and Corporate Governance Committee chair: $8,000 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">Non-Chair</FONT> Committee Member Service Fee (in addition to General Board
Service Fee; in lieu of Committee Chair Service Fee): </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Audit Committee member: $7,500 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Compensation Committee member: $5,000 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nominating and Corporate Governance Committee member: $4,000 </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Equity Grants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Initial appointment option grant </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each <FONT
STYLE="white-space:nowrap">non-employee</FONT> director who is elected or appointed to our board of directors after completion of this offering will, unless the board of directors determines that such grant will not be made automatically, be
automatically granted an option to purchase 25,000 shares of our common stock upon the director&#146;s initial appointment to our board of directors, referred to as the Initial Grant. The Initial Grant will vest in 36 substantially equal monthly
installments on each monthly anniversary of the date of grant, such that the Initial Grant will become fully vested and exercisable on the three-year anniversary of the date of grant, subject to the director&#146;s continued service on each
applicable vesting date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Annual option grant </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each <FONT STYLE="white-space:nowrap">non-employee</FONT> director who is serving on our board of directors immediately prior to, and will
continue to service on the Board following, our annual meeting of stockholders, will, unless the board of directors determines that such grant will not be made automatically, be automatically granted an option to purchase 12,500 shares of our common
stock on the date of such annual meeting of stockholders, referred to as the Annual Grant. Each Annual Grant will vest on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the date of grant, such that the Annual Grant will become
fully vested and exercisable on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the date of grant, or if earlier, the next annual meeting of stockholders, subject to the director&#146;s continued service on the applicable vesting
date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Initial Grants and the Annual Grants will be subject to the terms and conditions of the 2020 Equity Incentive Plan and will
fully vest and become exercisable upon the consummation of a corporate transaction (as defined in our 2020 Equity Incentive Plan and pursuant to the terms of our 2020 Equity Incentive Plan). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Contingent upon the appointment of Christina Ackermann, Julie Eastland and Eric Bjerkholt to our board of directors and effective upon the
effective date of the registration statement of which this prospectus forms a part, each of Ms.&nbsp;Ackermann, Ms.&nbsp;Eastland and Mr.&nbsp;Bjerkholt will receive an Initial Grant with an exercise price equal to the initial public offering price.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in September our board of directors approved a stock option award to Gerald Cagle, Ph.D. to purchase 25,000 shares of our
common stock with an exercise price equal to the midpoint of the price range set forth on the cover of this prospectus, which will vest in full upon completion of this offering, as well as a stock option award on the same terms as an Initial Grant,
to be granted as of the effective date of the registration statement of which this prospectus forms a part and with an exercise price equal to the initial public offering price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc796801_14"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables and accompanying narrative disclosure set forth information about the compensation earned by our named executive officers
during the year ended December&nbsp;31, 2019. Our named executive officers, who are our principal executive officer, our prior interim principal executive officer, our prior chief financial officer and the two most highly compensated executive
officers (other than our principal executive officer) serving as executive officers as of December&nbsp;31, 2019, were: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Frederic Guerard, President, Chief Executive Officer, Secretary and Treasurer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Gerald Cagle, Former Interim Chief Executive Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pamela Wapnick, Former Chief Financial Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Daniel Salain, Chief Technical Operations Officer; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Charles Semba, Former Chief Medical Officer </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Compensation Table </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
table presents summary information regarding the total compensation for services rendered in all capacities that was awarded to and earned by our named executive officers during the year ended December&nbsp;31, 2019. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-equity</FONT><BR>Incentive Plan<BR>Compensation</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Frederic Guerard</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Executive Officer<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">433,617</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">233,054</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">223,992</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">98,560</TD>
<TD NOWRAP VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">989,223</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gerald Cagle</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Former Interim Chief Executive Officer<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">54,712</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">54,712</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pamela Wapnick</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Former Chief Financial Officer<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">224,943</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">159,159</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">64,179</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">428,145</TD>
<TD NOWRAP VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">876,426</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel Salain</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Technical Operations Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">345,050</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">56,358</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">134,570</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">29,800</TD>
<TD NOWRAP VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">565,778</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Charles Semba</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Former Chief Medical Officer<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">351,117</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">63,159</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">136,936</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">551,212</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts reported in this column represent the aggregate grant-date fair value of the awards granted under
our 2015 Stock Incentive Plan to our named executive officers during the year ended December&nbsp;31, 2019 as computed in accordance with FASB ASC Topic 718. The assumptions used in calculating the grant date fair value of the awards reported in the
All Other Compensation column are set forth in Note 10 to our financial statements included elsewhere in this prospectus. Note that the amounts reported in this column reflect the aggregate accounting cost for these awards, and do not necessarily
correspond to the actual economic value that may be received by the named executive officers from the awards. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Guerard was hired as our Chief Executive Officer in February 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amount reported includes travel reimbursement and income tax <FONT STYLE="white-space:nowrap">gross-up.</FONT>
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Cagle served as our Interim Chief Executive Officer until February 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ms.&nbsp;Wapnick served as our Chief Financial Officer until September 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts reported in this column represent 12 months&#146; severance, 18 months COBRA benefits, travel
reimbursement and an income tax <FONT STYLE="white-space:nowrap">gross-up.</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Semba served as our Chief Medical Officer until March 2020. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we grant equity awards in the form of stock options to our named executive officers, which are generally subject to vesting
based on each named executive officer&#146;s continued service with us. Each of our named executive officers currently holds outstanding options to purchase shares of our common stock that were granted under the 2015 Plan, as set forth in the table
below titled &#147;Outstanding Equity Awards at 2019 Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT> Table.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at
2019 Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT> Table </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Vesting<BR>Commencement<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options</B><br><B>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options</B><br><B>Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Frederic Guerard</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2019</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">544,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/31/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/7/2019</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/1/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">361,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/6/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Gerald Cagle</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/2/2015</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/2/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/1/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/18/2015</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/1/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/17/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/24/2016</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/24/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/23/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/15/2018</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/6/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/14/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2019</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/1/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/31/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Pamela Wapnick</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/20/2017</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/11/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/19/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/6/2018</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/9/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/5/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/18/2018</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/18/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/17/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Daniel Salain</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/20/2017</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/11/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/19/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/6/2018</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/9/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/5/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/18/2018</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/18/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/17/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/7/2019</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/1/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,759</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/6/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Charles Semba<SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/15/2016</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/20/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/14/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/24/2017</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/24/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/23/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/6/2018</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/9/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/5/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/18/2018</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/18/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/17/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/7/2019</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/1/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/6/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All of the outstanding equity awards were granted under our 2015 Stock Incentive Plan. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This stock option vests at a rate of 1/4th of the shares of our common stock underlying the stock option on
February&nbsp;1, 2020 and 1/48th of the shares of our common stock underlying the stock option monthly thereafter. This stock option contains an early-exercise provision and is exercisable as to the unvested shares, subject to our right of
repurchase. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This stock option vests at a rate of 1/4th of the shares of our common stock underlying the stock option on
November&nbsp;1, 2020, and 1/48th of the shares of our common stock underlying the stock option monthly thereafter. This stock option contains an early-exercise provision and is exercisable as to the unvested shares, subject to our right of
repurchase. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This stock option was fully vested as of December&nbsp;31, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to the terms of the Separation Agreement, dated September&nbsp;11, 2019, by and between us and
Ms.&nbsp;Wapnick, or the Separation Agreement, the stock option was vested as to 65,131 of the shares of our common stock underlying the stock option as of December&nbsp;31, 2019, and 12,054 of the shares of our common stock underlying the stock
option were unvested and canceled as of December&nbsp;31, 2019. Ms.&nbsp;Wapnick has until December&nbsp;31, 2020 to exercise the vested shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to the terms of the Separation Agreement, the stock option was vested as to 15,559 of the shares of
our common stock underlying the stock option as of December&nbsp;31, 2019, and 5,779 of the shares of our </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
common stock underlying the stock option were unvested and canceled as of December&nbsp;31, 2019. Ms.&nbsp;Wapnick has until December&nbsp;31, 2020 to exercise the vested shares.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to the terms of the Separation Agreement, the stock option was vested as to 21,727 of the shares of
our common stock underlying the stock option as of December&nbsp;31, 2019, and 2,203 of the shares of our common stock underlying the stock option were unvested and canceled as of December&nbsp;31, 2019. Ms.&nbsp;Wapnick has until December&nbsp;31,
2020 to exercise the vested shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This stock option vests at a rate of 1/4th of the shares of our common stock underlying the stock option on
December&nbsp;11, 2018 and 1/48th of the shares of our common stock underlying the stock option monthly thereafter. This stock option contains an early-exercise provision and is exercisable as to the unvested shares, subject to our right of
repurchase. The stock option is subject to acceleration upon certain events. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This stock option vests at a rate of 1/4th of the shares of our common stock underlying the stock option on
January&nbsp;9, 2019 and 1/48th of the shares of our common stock underlying the stock option monthly thereafter. This stock option contains an early-exercise provision and is exercisable as to the unvested shares, subject to our right of
repurchase. The stock option is subject to acceleration upon certain events. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This stock option vests at a rate of 1/4th of the shares of our common stock underlying the stock option on
December&nbsp;18, 2019 and 1/48th of the shares of our common stock underlying the stock option monthly thereafter. This stock option contains an early-exercise provision and is exercisable as to the unvested shares, subject to our right of
repurchase. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to the terms of the Master Consulting Agreement, dated March 20, 2020, by and between us and Dr.
Semba, Dr. Semba&#146;s outstanding stock options continue to vest so long as he is providing consulting services to us. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This stock option vests at a rate of 1/4th of the shares of our common stock underlying the stock option on
June&nbsp;20, 2017 and 1/48th of the shares of our common stock underlying the stock option monthly thereafter. This stock option contains an early-exercise provision and is exercisable as to the unvested shares, subject to our right of repurchase.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This stock option vests at a rate of 1/4th of the shares of our common stock underlying the stock option on
August&nbsp;24, 2018 and 1/48th of the shares of our common stock underlying the stock option monthly thereafter. This stock option contains an early-exercise provision and is exercisable as to the unvested shares, subject to our right of
repurchase. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Arrangements with Our Named Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than as described below, each of our current named executive officers is employed at-will and their compensation is reviewed periodically
and subject to the discretion of our board of directors and compensation committee. Any potential payments and benefits due upon a termination of employment or in connection with a change in control of us are described below in &#147;&#151;Potential
Payments upon Termination or Change in Control.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Potential Payments upon Termination or Change in Control</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Outside of a Change in Control. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of his offer letter, in the event that Dr. Guerard is terminated without &#147;cause&#148; (as such term is defined his
offer letter) not in connection with a change in control, he will be entitled to receive a cash amount, payable in a lump sum, equal to 12 months of his annual base salary and will be entitled to continued coverage under our group-healthcare plans
for a period ending on the earlier of (x) 12 months following the termination date and (y) the date that he and his covered dependents become eligible for coverage under another employer&#146;s plans. In addition, Dr. Guerard would receive nine
months of accelerated vesting with respect to his stock option grant, dated February&nbsp;1, 2019, and his option grant, dated November&nbsp;7, 2019. All such severance payments and benefits are subject to Dr. Guerard&#146;s execution of a general
release of claims against us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of his offer letter, in the event that Mr. Salain is terminated without
&#147;cause&#148; (other than due to &#147;permanent disability&#148; (as such term is defined in his offer letter)), he will be entitled to six months </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of annual base salary continuation. Mr. Salain will also be entitled to the same portion of the monthly premium as we pay for active employees for coverage under our group-healthcare plans for a
period ending on the earlier of (x) six months following the termination date and (y) the date he commences new employment or substantial self-employment. All such severance payments and benefits are subject to Mr. Salain&#146;s execution of a
general release of claims against us. Additionally, Mr. Salain would receive 12 months of accelerated vesting with respect to his stock option grants dated December 20, 2017, February&nbsp;6, 2018, December&nbsp;18, 2018 and November&nbsp;7, 2019.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of her separation agreement entered into in connection with the termination of Ms. Wapnick&#146;s employment
with us on September 6, 2019, Ms. Wapnick received the following severance payments and benefits in consideration of her execution of a general release of claims against us: (i) 12 months of annual base salary continuation in the gross amount of
$319,300 (ii) pro rata target annual bonus of $64,179 and (iii) continued coverage under our group-healthcare plans for a period ending on the earlier of (x) 18 months following her termination date and (y) the date she commences new full time
employment or full time self-employment, whichever occurs first. Ms. Wapnick also received accelerated vesting of 42,738 shares subject to her stock option awards dated December 20, 2017, February 6, 2018 and December 18, 2018 (constituting 12
months of acceleration under each such stock option award) and an extension of the deadline to exercise such stock options to December 31, 2020. In addition, the Company engaged Ms. Wapnick as a consultant following the termination of her employment
through December 31, 2019 and during such period her then-outstanding stock option awards continued to vest pursuant to their terms, and as noted above, the deadline to exercise such stock options was extended to December 31, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr. Semba entered into a consulting agreement with us pursuant to which we have engaged Dr. Semba&#146;s services for the period beginning on
March 20, 2020, the date of his termination of employment, until December 31, 2020. Compensation for services provided under such consulting agreement is $500 per hour, with total compensation and expense reimbursements not to exceed $100,000.
Additionally, Dr. Semba is entitled to continued vesting of stock options granted to him prior to March 20, 2020 until the earlier of (i) the termination of his consulting agreement and (ii) December 31, 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>In Connection with a Change in Control.</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named executive officers who are current officers of the company participate in our Change in Control Severance Policy, which has been
amended and restated as of the date of this prospectus. Pursuant to the Change in Control Severance Policy, in the event that Dr. Guerard is terminated without &#147;cause&#148; (as defined in the Change in Control Severance Policy) or resigns for
&#147;good reason&#148; (as defined in the Change in Control Severance Policy) within 3 months prior to or 12 months following a &#147;change in control&#148; of us (as defined in the Change in Control Severance Policy), he will be entitled to
receive a cash amount, payable in a lump sum, equal to (i)&nbsp;18 months&#146; annual base salary and (ii)&nbsp;1.5 times his target bonus for the fiscal year in which the termination occurs. Dr. Guerard will also be entitled to continued coverage
under our group-healthcare plans for a period ending on the earlier of (x) 18 months following the termination date and (y) the date that Dr. Guerard and his covered dependents become eligible for coverage under another employer&#146;s plans. In
addition, each then-outstanding equity award that is granted after the date of this prospectus that vests subject to Dr. Guerard&#146;s continued service will automatically become vested and exercisable in full pursuant to the terms of the Change in
Control Severance Policy. Grant agreements for equity awards subject to performance-based vesting criteria may provide for alternative treatment upon a termination described above. Absent any such treatment in such grant agreement, the acceleration
of equity awards subject to performance-based vesting criteria shall be deemed to have been met based on the achievement of such award at the greater of target or, if determinable, actual performance. Plus, each then-outstanding equity award that
was granted before the date of this prospectus pursuant to the Company&#146;s 2015 Stock Incentive Plan that vests subject to Dr. Guerard&#146;s continued service will automatically become vested and exercisable in full in the event that Dr. Guerard
is terminated without &#147;cause&#148; (as defined in our 2015 Stock Incentive Plan) or resigns for &#147;good reason&#148; (as defined in our 2015 Stock Incentive Plan) following a &#147;change in control&#148; of us (as defined in our 2015 Stock
Incentive Plan), pursuant to the terms of the 2015 Stock Incentive Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Change in Control Severance Policy, in the event that Mr. Salain is
terminated without &#147;cause&#148; (as defined in the Change in Control Severance Policy) or resigns for &#147;good reason&#148; (as defined in the Change in Control Severance Policy) within 12&nbsp;months following a &#147;change in control&#148;
of us (as defined in the Change in Control Severance Policy), Mr. Salain will be entitled to receive a cash amount, payable in a lump sum, equal to (i)&nbsp;15 months&#146; annual base salary and (ii)&nbsp;1.25 times his target bonus for the fiscal
year in which the termination occurs. Mr. Salain will also be entitled to continued coverage under our group-healthcare plans for a period ending on the earlier of (x) 15 months following the termination date and (y) the date that Mr. Salain and his
covered dependents become eligible for coverage under another employer&#146;s plans. In addition, each then-outstanding equity award that is granted after the date of this prospectus that vests subject to Mr. Salain&#146;s continued service will
automatically become vested and exercisable in full pursuant to the terms of the Change in Control Severance Policy. Grant agreements for equity awards subject to performance-based vesting criteria may provide for alternative treatment upon a
termination described above. Absent any such treatment in such grant agreement, the acceleration of equity awards subject to performance-based vesting criteria shall be deemed to have been met based on the achievement of such award at the greater of
target or, if determinable, actual performance. Plus, each then-outstanding equity award that was granted before the date of this prospectus pursuant to the Company&#146;s 2015 Stock Incentive Plan that vests subject to Mr. Salain&#146;s continued
service will automatically become vested and exercisable in full in the event that Mr. Salain is terminated without &#147;cause&#148; (as defined in our 2015 Stock Incentive Plan) or resigns for &#147;good reason&#148; (as defined in our 2015 Stock
Incentive Plan) following a &#147;change in control&#148; of us (as defined in our 2015 Stock Incentive Plan), pursuant to the terms of the 2015 Stock Incentive Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The vesting of any outstanding equity award that is not assumed by a successor company following a change in control of us will automatically
accelerate in full without regard to Dr. Guerard&#146;s or Mr. Salain&#146;s termination of service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All such severance payments and
benefits are subject to each named executive officer&#146;s execution of a general release of claims against us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Compensation Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2015 Stock Incentive Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
board of directors originally adopted our 2015 Stock Incentive Plan, or 2015 Plan, which was also approved by our stockholders, in February 2015. Our board of directors, or a committee thereof appointed by our board of directors, administers the
2015 Plan and the awards granted thereunder. Awards under our 2015 Plan apply to shares of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2015 Plan provides for
the grant of both incentive stock options, which qualify for favorable tax treatment to their recipients under Section&nbsp;422 of the Code, and nonqualified stock options, as well as for the issuance of restricted stock units, or RSUs, stock
appreciation rights, or SARs, restricted stock awards, or RSAs, and performance awards. We may grant incentive stock options only to our employees. We may grant nonqualified stock options, phantom stock unit awards, RSUs, SARs, RSAs and performance
awards to our employees, directors, and consultants. Only stock options and RSAs have been granted under the 2015 Plan. We refer to such employees, directors or consultants who receive an award under our 2015 Plan as participants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exercise price of each stock option intended to qualify as incentive stock options must be at least equal to the fair market value of our
common stock on the date of grant. The maximum permitted term of options granted under our 2015 Plan is ten years. Options generally vest over a four-year period, and will cease to vest on the date a participant ceases to provide services to us and
all then unvested options will be forfeited. Our board of directors, or a committee thereof, may provide for options to be exercised only as they vest or to be immediately exercisable with any shares issued on exercise being subject to our right of
repurchase that lapses as the shares vest. Our board of directors has discretion to accelerate, in whole or part, the vesting and exercisability of an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
award, such as in connection with an award holder&#146;s termination of service. Stock options granted under the 2015 Plan generally may be exercised, to the extent vested as of the date of
termination, for a period of thirty days after the termination of the optionee&#146;s service to us, for a period of twelve months in the case of disability, for a period of twelve months in the case of death or such longer or shorter period as our
compensation committee may provide, but in any event no later than the expiration date of the stock option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All RSAs granted under the
2015 Plan are fully vested. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event there is a specified type of change in our capital structure without our receipt of
consideration, such as a stock split, appropriate adjustments will be made as set forth in the 2015 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a merger or
consolidation, or in the event of a liquidation, dissolution or sale of all or substantially all of our assets, each, a corporate transaction, outstanding awards under our 2015 Plan shall terminate upon such corporate transaction, unless
continuation or assumption of such awards is provided in connection with the corporate transaction. Our board of directors has discretion to provide that, upon a corporate transaction, awards shall be cancelled in exchange for a payment equal to the
value of the per share consideration payable to holders of our common stock in the transaction and, in respect of awards, less the awards exercise price or purchase price, as applicable (this payment may be zero if the award has no value). Stock
options granted under the 2015 Plan shall accelerate in full if they are not continued, assumed or substituted in connection with a corporate transaction. In addition, to the extent stock options are continued, assumed or substituted in connection
with a corporate transaction, and the award holder&#146;s service to the company is involuntarily terminated (without &#147;cause&#148; or for &#147;good reason&#148;, as defined under the 2015 Plan) within one year following such corporate
transaction, the stock options shall accelerate in full. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June 30, 2020, we had reserved 648,587 shares of our common stock for
issuance under our 2015 Plan. As of June 30, 2020, options to purchase 2,066,076 shares of these reserved shares remained outstanding and 648,587 of these reserved shares remained available for future grant. The stock options outstanding as of June
30, 2020 had a weighted-average exercise price of $2.52 per share. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our 2020 Plan (described below) will be effective upon the date
immediately prior to the date of this prospectus. As a result, we will not grant any additional equity awards under the 2015 Plan following that date, and the 2015 Plan will terminate at that time. However, any outstanding stock options granted
under the 2015 Plan will remain outstanding, subject to the terms of our 2015 Plan and the applicable stock option agreements evidencing such awards, until such outstanding awards are exercised, or until they terminate or expire by their terms. Upon
the effectiveness of our 2020 Plan, the shares reserved but not issued or subject to outstanding awards under our 2015 Plan on the date immediately prior to the date of this prospectus will become available for grant and issuance under our 2020 Plan
as common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2020 Equity Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2020, our board of directors adopted our 2020 Equity Incentive Plan, or 2020 Plan, that will become effective on the date immediately
prior to the date of the effectiveness of the registration of which this prospectus forms a part and will serve as the successor to our 2015 Plan. Our 2020 Plan authorizes the award of stock options, RSAs, SARs, RSUs, performance awards and stock
bonus awards. We have initially reserved 1,850,000 shares of our common stock, plus any reserved shares not issued or subject to outstanding grants under the 2015 Plan on the effective date of the 2020 Plan, for issuance pursuant to awards granted
under our 2020 Plan. The number of shares reserved for issuance under our 2020 Plan will increase automatically on January&nbsp;1 of each of 2021 through 2030 by the number of shares equal to the lesser of 5% of the aggregate number of outstanding
shares of our common stock as of the immediately preceding December&nbsp;31, or a number as may be determined by our board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the following shares will again be available for issuance pursuant to awards
granted under our 2020 Plan: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shares subject to options or SARs granted under our 2020 Plan that cease to be subject to the option or SAR for
any reason other than exercise of the option or SAR; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shares subject to awards granted under our 2020 Plan that are subsequently forfeited or repurchased by us at the
original issue price; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shares subject to awards granted under our 2020 Plan that otherwise terminate without such shares being issued;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shares subject to awards granted under our 2020 Plan that are surrendered, cancelled or exchanged for cash or a
different award (or combination thereof); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shares issuable upon the exercise of options granted under our 2015 Plan that cease to be subject to such
options, by forfeiture after the effective date of the 2020 Plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shares subject to awards granted under our 2015 Plan that are forfeited or repurchased by us at the original
price after the termination of the 2015 Plan; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shares subject to awards under our 2015 Plan or our 2020 Plan that are used to pay the exercise price of an
option or withheld to satisfy the tax withholding obligations related to any award. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Administration. </I>Our 2020
Plan is expected to be administered by our compensation committee, all of the members of which are outside directors as defined under applicable federal tax laws, or by our board of directors acting in place of our compensation committee. Subject to
the terms and conditions of the 2020 Plan, the compensation committee will have the authority, among other things, to select the persons to whom awards may be granted, construe and interpret our 2020 Plan as well as to determine the terms of such
awards and prescribe, amend and rescind the rules and regulations relating to the plan or any award granted thereunder. The 2020 Plan provides that the board or compensation committee may delegate its authority, including the authority to grant
awards, to one or more executive officers to the extent permitted by applicable law, provided that awards granted to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors may only be determined by our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Eligibility. </I>Our 2020 Plan provides for the grant of awards to our employees, directors, consultants, independent contractors and
advisors. No <FONT STYLE="white-space:nowrap">non-employee</FONT> director may receive awards under our 2020 Plan that, when combined with cash compensation received for service as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director,
exceeds $750,000 in a calendar year or $1,000,000 in the calendar year of his or her initial services as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director with us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Options. </I>The 2020 Plan provides for the grant of both incentive stock options intended to qualify under Section&nbsp;422 of the Code,
and <FONT STYLE="white-space:nowrap">non-statutory</FONT> stock options to purchase shares of our common stock. Incentive stock options may only be granted to employees, including officers and directors who are also employees. The exercise price of
stock options granted under the 2020 Plan must be at least equal to the fair market value of our common stock on the date of grant. Incentive stock options granted to an individual who holds, directly or by attribution, more than ten percent of the
total combined voting power of all classes of our capital stock must have an exercise price of at least 110% the fair market value of our common stock on the date of grant. Subject to stock splits, dividends, recapitalizations or similar events, no
more than 5,550,000 shares may be issued pursuant to the exercise of incentive stock options granted under the 2020 Plan. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Options
may vest based on service or achievement of performance conditions. Our compensation committee may provide for options to be exercised only as they vest or to be immediately exercisable, with any shares issued on exercise being subject to our right
of repurchase that lapses as the shares vest. The maximum term of options granted under our 2020 Plan is ten years from the date of grant, except that the maximum permitted term of incentive stock options granted to an individual who holds, directly
or by attribution, more than ten percent of the total combined voting power of all classes of our capital stock is five years from the date of grant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Awards. </I>An RSA is an offer by us to sell shares of our common stock
subject to restrictions, which may lapse based on the satisfaction of service or achievement of performance conditions. The price, if any, of an RSA will be determined by the compensation committee. Holders of RSAs will have the right to vote and
any dividends or stock distributions paid pursuant to unvested RSAs will be accrued and paid when the restrictions on such shares lapse. Unless otherwise determined by the compensation committee at the time of award, vesting will cease on the date
the participant no longer provides services to us and unvested shares will be forfeited to or repurchased by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Appreciation
Rights. </I>An SAR provides for a payment, in cash or shares of our common stock (up to a specified maximum of shares, if determined by our compensation committee), to the holder based upon the difference between the fair market value of our common
stock on the date of exercise and a predetermined exercise price, multiplied by the number of shares. The exercise price of a SAR must be at least the fair market value of a share of our common stock on the date of grant. SARs may vest based on
service or achievement of performance conditions, and may not have a term that is longer than ten years from the date of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Units. </I>RSUs represent the right to receive shares of our common stock at a specified date in the future, and may be
subject to vesting based on service or achievement of performance conditions. Payment of earned RSUs will be made as soon as practicable following vesting as provided in the applicable award agreement, and may be settled in cash, shares of our
common stock or a combination of both. No RSU may have a term that is longer than ten years from the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Performance
Awards</I>. Performance awards granted to pursuant to the 2020 Plan may be in the form of a cash bonus, or an award of performance shares or performance units denominated in shares of our common stock, that may be settled in cash, property or by
issuance of those shares subject to the satisfaction of achievement of specified performance conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Bonus Awards</I>. A
stock bonus award provides for payment in the form of cash, shares of our common stock or a combination thereof, based on the fair market value of shares subject such award as determined by our compensation committee. The awards may be granted as
consideration for services already rendered, or at the discretion of the compensation committee, may be subject to vesting restrictions based on continued service or performance conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Dividend Equivalents</I> <I>Rights</I>. Dividend equivalent rights may be granted at the discretion of our compensation committee, and
represent the right to receive the value of dividends, if any, paid by us in respect of the number of shares of our common stock underlying an award. Dividend equivalent rights will be subject to the same vesting or performance conditions as the
underlying award and will be paid only at such time as the underlying award has become fully vested. Dividend equivalent rights may be settled in cash, shares or other property, or a combination of thereof as determined by the compensation
committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Change of Control. </I>Our 2020 Plan provides that, in the event of a corporate transaction, as defined in the 2020 Plan,
outstanding awards under our 2020 Plan shall be subject to the agreement evidencing the corporate transaction, any or all outstanding awards may be (a)&nbsp;continued by us, if we are the successor entity; or (b)&nbsp;assumed or substituted by the
successor corporation, or a parent or subsidiary of the successor corporation, for substantially equivalent awards (including, but not limited to, a payment in cash or the right to acquire the same consideration paid to the stockholders of the
company pursuant to the corporate transaction), in each case after taking into account appropriate adjustments for the number and kind of shares and exercise prices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The successor corporation may also issue, as replacement of outstanding shares of the company held by a participant, substantially similar
shares or other property subject to repurchase restrictions no less favorable to the participant. In the event such successor corporation refuses to assume, substitute or replace any award, then each such award shall become fully vested and, as
applicable, exercisable and any rights of repurchase or forfeiture restrictions thereon shall lapse, immediately prior to the consummation of the corporation transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Performance awards not assumed pursuant to the foregoing shall be deemed earned and vested at 100% of target level, unless otherwise indicated pursuant to the terms and conditions of the
applicable award agreement. If an award vests in lieu of assumption or substitution in connection with a corporate transaction as provided above, the board or committee will notify the holder of such award in writing or electronically that such
award will be exercisable for a period of time determined by the board or committee in its sole discretion, and such award will terminate upon the expiration of such period without consideration. Any determinations by the board or committee need not
treat all outstanding awards in an identical manner, and shall be final and binding on each applicable participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Adjustment. </I>In
the event of a change in the number of outstanding shares of our common stock without consideration by reason of a stock dividend, extraordinary dividend or distribution, recapitalization, stock split, reverse stock split, subdivision, combination,
consolidation reclassification, <FONT STYLE="white-space:nowrap">spin-off</FONT> or similar change in our capital structure, appropriate proportional adjustments will be made to the number of shares reserved for issuance under our 2020 Plan; the
exercise prices, number and class of shares subject to outstanding options or SARs; the number and class of shares subject to other outstanding awards; and any applicable maximum award limits with respect to incentive stock options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Clawback; Transferability. </I>All awards will be subject to clawback or recoupment pursuant to any compensation clawback or recoupment
policy adopted by our board of directors (or a committee thereof) or required by law during the term of service of the award holder, to the extent set forth in such policy or applicable agreement. Except in limited circumstances, awards granted
under our 2020 Plan may generally not be transferred in any manner prior to vesting other than by will or by the laws of descent and distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment and Termination. </I>Our board of directors may amend our 2020 Plan at any time, subject to stockholder approval as may be
required. Our 2020 Plan will terminate ten years from the date our board of directors adopts the plan, unless it is terminated earlier by our board of directors. No termination or amendment of the 2020 Plan may adversely affect any then-outstanding
award without the consent of the affected participant, except as is necessary to comply with applicable laws. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2020 Employee Stock Purchase Plan
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2020 our board of directors adopted our 2020 Employee Stock Purchase Plan, or ESPP, that will become effective upon the
effectiveness of the registration statement of which this prospectus forms a part in order to enable eligible employees to purchase shares of our common stock with accumulated payroll deductions. Our ESPP is intended to qualify under
Section&nbsp;423 of the Code. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Shares Available</I>. We have initially reserved 210,000 shares of our common stock for sale under
our ESPP. The aggregate number of shares reserved for sale under our ESPP will increase automatically on January 1st of each of the first ten calendar years after the first offering date under the ESPP by the number of shares equal to the lesser of
1% of the total outstanding shares of our common stock as of the immediately preceding December&nbsp;31 (rounded to the nearest whole share) or a number of shares as may be determined by our board of directors in any particular year. The aggregate
number of shares issued over the term of our ESPP, subject to stock-splits, recapitalizations or similar events, may not exceed 2,100,000 shares of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Administration. </I>Our compensation committee will administer our ESPP subject to the terms and conditions of the ESPP. Among other
things, the compensation committee will have the authority to determine eligibility for participation in the ESPP, designate separate offerings under the plan, and construe, interpret and apply the terms of the plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Eligibility. </I>Employees eligible to participate in any offering pursuant to the ESPP generally include any employee that is employed by
us (employees of subsidiaries if so designated in the future) at the beginning of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
offering period. However, our compensation committee may determine that employees who are customarily employed for 20 hours or less per week or for five months or less in a calendar year are not
eligible to participate in the ESPP. In addition, any employee who owns (or is deemed to own as a result of attribution) 5% or more of the total combined voting power or value of all classes of our capital stock, or the capital stock of one of our
qualifying subsidiaries, or who will own such amount as a result of participation in the ESPP, will not be eligible to participate in the ESPP. The compensation committee may impose additional restrictions on eligibility from time to time subject to
compliance with applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Offerings. </I>Under our ESPP, eligible employees will be offered the option to purchase shares of our
common stock at a discount over a series of offering periods. Each offering period may itself consist of one or more purchase periods. No offering period may be longer than 27 months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Participation. </I>Participating employees will be able to purchase the offered shares of our common stock by accumulating funds through
payroll deductions. Participants may select a rate of payroll deduction between 1% and 15% of their compensation. However, a participant may not purchase more than 3,000 shares during any one purchase period, and may not subscribe for more than
$25,000 in fair market value of shares of our common stock (determined as of the date the offering period commences) in any calendar year in which the offering is in effect. Our compensation committee, in its discretion, may set a lower maximum
amount of shares which may be purchased. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purchase price for shares of our common stock purchased under the ESPP will be 85% of the
lesser of the fair market value of our common stock on (i)&nbsp;the first trading day of the applicable offering period or (ii)&nbsp;the last trading day of each purchase period in the applicable offering period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once an employee becomes a participant in an offering period, the participant will be automatically enrolled in each subsequent offering
period at the same contribution level. A participant may reduce his or her contribution in accordance with procedures set forth by the compensation committee and may withdraw from participation in the ESPP at any time prior the end of an offering
period, or such other time as may be specified by the compensation committee. Upon withdrawal, the accumulated payroll deductions will be returned to the participant without interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Adjustments upon Recapitalization. </I>If the number of outstanding shares of our common stock is changed by stock dividend,
recapitalization, stock split, reverse stock split, subdivision, combination, reclassification or similar change in our capital structure without consideration, then our compensation committee will proportionately adjust the number and class of
common stock that is available under the ESPP, the purchase price and number of shares any participant has elected to purchase as well as the maximum number of shares which may be purchased by participants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Corporate Transaction</I>. If we experience a corporate transaction (as defined in the ESPP), each outstanding right to purchase shares or
our common stock will be assumed or an equivalent option substituted by the successor corporation or a parent or a subsidiary of the successor corporate. In the event that the successor corporation refuses to assume or substitute the purchase right,
the offering period with respect to which such purchase right relates will be shortened and terminated on a new purchase date. The new purchase date will occur on or prior to the closing of the proposed corporate transaction, and our ESPP will then
terminate on the closing of the proposed corporate transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Transferability. </I>A participant may not assign, transfer, pledge or
otherwise dispose of payroll deductions credited to his or her account, or any rights with regard to an election to purchase shares pursuant to the ESPP other than by will or the laws of descent or distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment; Termination. </I>The compensation committee may amend, suspend or terminate the ESPP at any time without stockholder consent,
except as required by law. Our ESPP will continue until the earlier to occur of (a)&nbsp;termination of the ESPP by the Board, (b)&nbsp;issuance of all of the shares reserved for issuance under the ESPP or (c)&nbsp;the tenth anniversary of the first
purchase date under the ESPP. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>401(k) Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We sponsor a broad-based 401(k) plan intended to provide eligible U.S. employees with an opportunity to defer eligible compensation up to
certain annual limits. As a tax-qualified retirement plan, contributions (if any) made by us are deductible by us when made, and contributions and earnings on those amounts are generally not taxable to employees until withdrawn or distributed from
the 401(k) plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Benefits </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named executive officers are eligible to participate in our employee benefit plans on the same basis as our other employees, including our
health and welfare plans. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations on Liability and Indemnification Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our restated certificate of incorporation that will become effective in connection with the completion of this offering contains provisions
that limit the liability of our directors for monetary damages to the fullest extent permitted by the Delaware General Corporation Law, or DGCL. Consequently, our directors will not be personally liable to us or our stockholders for monetary damages
for any breach of fiduciary duties as directors, except liability for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of the director&#146;s duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section&nbsp;174 of
the DGCL; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our restated certificate of incorporation and our restated bylaws that will become effective in connection with the completion of this
offering require us to indemnify our directors and officers to the maximum extent not prohibited by the DGCL and allow us to indemnify other employees and agents as set forth in the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered, and intend to continue to enter, into separate indemnification agreements with our directors, officers and certain of our key
employees, in addition to the indemnification provided for in our restated certificate of incorporation and restated bylaws. These agreements, among other things, require us to indemnify our directors, officers and key employees for certain
expenses, including attorneys&#146; fees, judgments, penalties, fines and settlement amounts actually incurred by these individuals in any action or proceeding arising out of their service to us or any of our subsidiaries or any other company or
enterprise to which these individuals provide services at our request. Subject to certain limitations, our indemnification agreements also require us to advance expenses incurred by our directors, officers and key employees for the defense of any
action for which indemnification is required or permitted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that these indemnification provisions and agreements are necessary
to attract and retain qualified directors, officers and key employees. We also maintain directors&#146; and officers&#146; liability insurance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The limitation of liability and indemnification provisions in our restated certificate of incorporation and restated bylaws may discourage
stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might
benefit us and other stockholders. Further, a stockholder&#146;s investment may be adversely affected to the extent that we pay the costs of settlement and damage awards against directors and officers as required by these indemnification provisions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At present, there is no pending litigation or proceeding involving any of our directors or executive officers as to which indemnification
is required or permitted, and we are not aware of any threatened litigation or proceeding that may result in a claim for indemnification. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act, may be
permitted to directors, executive officers or persons controlling us, we have been informed that, in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act and is
therefore unenforceable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc796801_15"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a description of each transaction since January&nbsp;1, 2017 and each currently proposed transaction to which we have been or
are to be a participant, in which: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amounts involved exceeded or will exceed $120,000; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any of our directors, executive officers or holders of more than 5% of our capital stock, or an affiliate or
immediate family member of the foregoing persons, had or will have a direct or indirect material interest. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than
as described below, there have not been, nor are there any currently proposed, transactions or series of similar transactions to which we have been or will be a party other than compensation arrangements, which are described where required under
&#147;Executive Compensation.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Danforth Advisors Consulting Agreement and Warrant </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;3, 2019, we entered into a Consulting Agreement with Danforth Advisors, LLC, or Danforth. A Founding Managing Director of
Danforth is Daniel Geffken, our former Interim Chief Financial Officer. The agreement provides for Danforth to provide business consulting and advisory services to us. The agreement remains in effect until such time as either party has given notice
of termination and may be terminated by either party upon 60 days prior written notice to the other party. As consideration under the agreement, we compensate Danforth with consulting fees based on hourly rates as enumerated in the agreement. In
connection with the agreement, we also granted Danforth a warrant to purchase 27,759&nbsp;shares of our common stock at a price per share of $3.88, of which warrant 1/12 of the shares become vested and exercisable on October&nbsp;3, 2019, and an
additional 1/12 of the shares become vested on the same day of each full succeeding calendar month thereafter. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Series C Convertible Preferred
Stock Financing </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between July and August 2019, we sold an aggregate of 37,432,787 shares of our Series C preferred at a purchase
price of $1.4693 per share, for an aggregate purchase price of approximately $55.0&nbsp;million. Each share of our Series C preferred will convert automatically into common stock upon the completion of this offering at a ratio of 9.0058:1. The
Series C Financing further allowed certain purchasers of Series C preferred the option to purchase up to an additional 17,014,902 shares of Series C preferred at a price per share of $1.4693 for a period of up to 30 days after we notify them of the
three month readout from the Phase 2a clinical trial of GB-102 in patients with ME secondary to DME and RVO. In August 2020, our board of directors and the Series&nbsp;C preferred holders amended the Series&nbsp;C stock purchase agreement such that
this option is no longer exercisable and will terminate upon the effectiveness of this registration statement of which this prospectus forms a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the Series C preferred purchased by members of our board of directors or their affiliates and holders of more
than 5% of our outstanding capital stock: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;C<BR>Preferred</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Purchase<BR>Price&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AffaMed Project Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,208,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CVF 2018, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,805,962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hatteras Venture Partners IV SBIC, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(1)
</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,361,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with
Deerfield<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,874,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,570,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OrbiMed Private Investments VI, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(3)
</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,624,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,202,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clarus Lifesciences III, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,557,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,227,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Christy Shaffer, a member of our board of directors, is a general partner at Hatteras. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of shares held by Deerfield Healthcare Innovations Fund, L.P., Deerfield Private Design Fund III, L.P.
and Deerfield Partners, L.P. Cameron Wheeler, a member of our board of directors, is a Principal at Deerfield. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Chau Khuong, a member of our board of directors, is a Private Equity Partner at OrbiMed. </P></TD></TR></TABLE>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Emmett Cunningham, Jr., a member of our board of directors, is a Senior Managing Director at Clarus, a fund
managed by Blackstone Life Sciences. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also in<B> </B>connection with our Series C preferred financing, we granted a right of first
negotiation and first refusal to AffaMed Project Limited with regards to a potential exclusive license to <FONT STYLE="white-space:nowrap">GB-102</FONT> solely with regards to certain territories. Under the terms of the right of first negotiation
and first refusal, the option period for such license will run from the initial closing of the Series C preferred financing until the earlier of July&nbsp;31, 2021 or 60 days following the date that we provide them with a top line data package of
the <FONT STYLE="white-space:nowrap">GB-102</FONT> Phase 2b clinical trial results. See &#147;Business&#151;License Agreements&#151;AffaMed&#148; for addition detail. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Series B Convertible Preferred Stock Financing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between April 2016 and May 2018, we sold an aggregate of 76,078,535 shares of our Series B preferred at a purchase price of $0.991 per share,
or $0.842 per share for shares issued upon conversion and/or cancellation of outstanding convertible promissory notes, for an aggregate purchase consideration of approximately $74.9&nbsp;million. Each share of our Series B preferred will convert
automatically into common stock upon the completion of this offering at a ratio of 9.0058:1. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the
Series B preferred purchased by members of our board of directors or their affiliates and holders of more than 5% of our outstanding capital stock: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;B<BR>Preferred</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Purchase</B><br><B>Price&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hatteras Venture Partners IV SBIC, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(1)
</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,186,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,734,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with
Deerfield<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,619,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,389,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OrbiMed Private Investments VI, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(3)
</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,804,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,581,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clarus Lifesciences III, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,575,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,471,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gerald D. Cagle, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Christy Shaffer, a member of our board of directors, is a general partner at Hatteras. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of shares held by Deerfield Healthcare Innovations Fund, L.P. and Deerfield Private Design Fund III,
L.P. Cameron Wheeler, a member of our board of directors, is a Principal at Deerfield. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Chau Khuong, a member of our board of directors, is a Private Equity Partner at OrbiMed. </P></TD></TR></TABLE>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Emmett Cunningham, Jr., a member of our board of directors, is a Senior Managing Director at Clarus, a fund
managed by Blackstone Life Sciences. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Gerald Cagle is a member of our board of directors. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amended and Restated Investors&#146; Rights Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into an amended and restated investors&#146; rights agreement with certain holders of our convertible preferred stock,
including entities with which certain of our directors are affiliated. These stockholders are entitled to rights with respect to the registration of their shares following this offering under the Securities Act of 1933, as amended. For a description
of these registration rights, see the section entitled &#147;Description of Capital Stock&#151;Registration Rights.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this offering, we intend to enter into new indemnification agreements with each of our directors and executive
officers. The indemnification agreements, our restated certificate of incorporation and our restated bylaws will require us to indemnify our directors to the fullest extent not prohibited by Delaware law. Subject to certain limitations, our restated
bylaws also require us to advance expenses incurred by our directors and officers. For more information regarding these agreements, see the section entitled &#147;Executive Compensation&#151;Limitations on Liability and Indemnification Matters&#148;
for information on our indemnification arrangements with our directors and executive officers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policies and Procedures for Related Party Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this offering, we intend to adopt a written related person transactions policy that provides that our executive officers,
directors, nominees for election as a director, beneficial owners of more than 5% of our common stock, and any members of the immediate family of and any entity affiliated with any of the foregoing persons, are not permitted to enter into a material
related person transaction with us without the review and approval of our audit committee, or a committee composed solely of independent directors in the event it is inappropriate for our audit committee to review such transaction due to a conflict
of interest. We expect the policy to provide that any request for us to enter into a transaction with an executive officer, director, nominee for election as a director, beneficial owner of more than 5% of our common stock or with any of their
immediate family members or affiliates in which the amount involved exceeds $120,000 will be presented to our audit committee (or the committee composed solely of independent directors, if applicable) for review, consideration and approval. In
approving or rejecting any such proposal, we expect that our audit committee (or the committee composed solely of independent directors, if applicable) will consider the relevant facts and circumstances available and deemed relevant to the audit
committee (or the committee composed solely of independent directors, if applicable), including, but not limited to, whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same
or similar circumstances and the extent of the related person&#146;s interest in the transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc796801_16"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table and accompanying footnotes set forth certain information with respect to the beneficial ownership of our common stock at
August&nbsp;31, 2020, and as adjusted to reflect the shares of common stock to be issued and sold in this offering, for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our named executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our current directors and executive officers as a group; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person, or group of affiliated persons, who beneficially owned more than 5% of our outstanding shares of
common stock. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have determined beneficial ownership in accordance with the rules of the Securities and Exchange
Commission, and the information is not necessarily indicative of beneficial ownership for any other purpose. Except as indicated by the footnotes below, we believe, based on information furnished to us, that the persons and entities named in the
table below have sole voting and sole investment power with respect to all shares of common stock that they beneficially owned, subject to applicable community property laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership prior to this offering is based on 14,468,113 shares of common stock outstanding as of August&nbsp;31, 2020, assuming the
automatic conversion of all outstanding shares of our convertible preferred stock into common stock in connection with this offering. Beneficial ownership after this offering is based on 19,155,613 shares of common stock outstanding, assuming
(i)&nbsp;the automatic conversion of all outstanding shares of our convertible preferred stock into common stock as described above and (ii)&nbsp;the issuance of 4,687,500 shares of common stock in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In computing the number of shares of common stock beneficially owned by a person and the percentage ownership of that person, we deemed to be
outstanding all shares of common stock subject to options held by that person or entity that are currently exercisable or that will become exercisable within 60&nbsp;days of August&nbsp;31, 2020. We did not deem these shares outstanding, however,
for the purpose of computing the percentage ownership of any other person. Unless otherwise indicated, the address of each beneficial owner listed in the table below is c/o Graybug Vision, Inc., 275 Shoreline Drive, Suite 450, Redwood City, CA
94065. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of&nbsp;Shares<BR>Beneficially&nbsp;Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Before<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Directors and Named Executive Officers:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Frederic Guerard, Pharm.D.<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">906,123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gerald Cagle, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel Geffken<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,759</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pamela
Wapnick<SUP STYLE="font-size:85%; vertical-align:top">(4)<FONT STYLE="font-size:6.5pt">&#134;</FONT></SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel Salain<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">181,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Charles Semba, M.D., FACC, FACR<SUP STYLE="font-size:85%; vertical-align:top">(6)<FONT
STYLE="font-size:6.5pt">&#134;</FONT></SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">236,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Emmett Cunningham, Jr., M.D., Ph.D.,
M.P.H.<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hansoo Michael Keyoung, M.D.,
Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,133,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chau Khuong, M.P.H.<SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,600,847</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christy Shaffer, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,644,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cameron Wheeler, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,719,213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All executive officers and directors as a group (10&nbsp;persons)<SUP
STYLE="font-size:85%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,521,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5% Stockholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with
Deerfield<SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,719,213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OrbiMed Private Investments VI,
L.P.<SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,600,847</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clarus Lifesciences III, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,680,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hatteras Venture Partners IV SBIC,
L.P.<SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,644,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AffaMed Project Limited<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,133,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CVF 2018, LLC<SUP STYLE="font-size:85%; vertical-align:top">(14)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">755,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents beneficial ownership of less than one percent. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Former executive officer. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 906,123 shares of our common stock subject to options that are exercisable within 60 days of
August&nbsp;31, 2020, of which 679,400 shares are unvested, but early exercisable within 60&nbsp;days of August&nbsp;31, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i)&nbsp;3,322 shares of our common stock and (ii)&nbsp;81,815 shares of our common stock subject
to options that are exercisable within 60 days of August&nbsp;31, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 27,759 shares of our common stock subject to a warrant held by SG DAN Equity Holdings LLC that is
exercisable within 60 days of August&nbsp;31, 2020. SG DAN Equity Holdings LLC is wholly owned by Danforth Advisors, LLC, or Danforth. Daniel Geffken, our former interim chief financial officer, is a member of the board of directors of Danforth.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 102,417 shares of our common stock subject to options that are exercisable within 60 days of
August&nbsp;31, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 181,096 shares of our common stock subject to options that are exercisable within 60 days of
August&nbsp;31, 2020, of which 84,694 shares are unvested, but early exercisable within 60 days of August&nbsp;31, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 236,996 shares of our common stock subject to options that are exercisable within 60 days of
August&nbsp;31, 2020, of which 107,906 shares are unvested, but early exercisable within 60 days of August&nbsp;31, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Emmett Cunningham, a member of our board of directors, is an employee of The Blackstone Group Inc. or one of
its affiliates. Dr.&nbsp;Cunningham disclaims beneficial ownership of any shares of common stock owned directly or indirectly by The Blackstone Group Inc. or its affiliates. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 1,133,596 shares of our common stock held of record by AffaMed Project Limited, or AffaMed.
Mengjiao Jiang and Hansoo Michael Keyoung, a member of our board of directors, are the directors of AffaMed and each of them may be deemed to hold shared voting and dispositive power with respect to the shares held by AffaMed. The address of AffaMed
is Trinity Chambers, P.O. Box 4301, Road Town, Tortola, British Virgin Islands. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 3,600,847 shares of our common stock held of record by OrbiMed Private Investments VI, L.P., or OPI
IV. OrbiMed Capital GP VI LLC, or GP VI, is the general partner of OPI VI, and OrbiMed Advisors LLC, or Advisors, is the managing member of GP VI. By virtue of such relationships, GP VI and Advisors may be deemed to have voting power and investment
power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho and
Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VI. The address of OPI IV is 601 Lexington Avenue, New York, NY 10022-4629. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 1,586,490 shares of our common stock held of record by Hatteras Venture Partners IV SBIC, L.P.,
or HVP IV SBIC, and (ii)&nbsp;57,727 shares of our common stock subject to options held of record by HVP IV SBIC that are exercisable within 60 days of August&nbsp;31, 2020. Hatteras Venture Advisors IV SBIC, L.L.C., or HVA IV SBIC, is the general
partner of HVP IV SBIC. The managing members of HVA IV SBIC include: Robert Ingram, Douglas Reed, Clay Thorp, John Crumpler and Kenneth Lee. These managing members share voting and dispositive power over the securities directly held by HVP IV SBIC.
The address of HVP IV SBIC is 280 S. Mangum Street, Suite 350, Durham, NC 27701. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 1,713,873 shares of our common stock held of record by Deerfield Healthcare Innovations Fund,
L.P., (ii) 1,713,873 shares of our common stock held of record by Deerfield Private Design Fund III, L.P. and (iii) 291,467 shares of our common stock held of record by Deerfield Special Situations Fund, L.P. Deerfield Mgmt III, L.P. is the general
partner of Deerfield Private Design Fund III, L.P., Deerfield Mgmt. HIF, L.P. is the general partner of Deerfield Healthcare Innovations Fund, L.P. and Deerfield Mgmt, L.P. is the general partner of Deerfield Special Situations Fund, L.P. Deerfield
Management Company, L.P. is the investment manager of each of Deerfield Private Design Fund III, L.P., Deerfield Healthcare Innovations Fund, L.P. and Deerfield Special Situations Fund, L.P. Mr.&nbsp;James&nbsp;E. Flynn is the sole member of the
general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt HIF, L.P., Deerfield Mgmt, L.P. and Deerfield Management Company, L.P. and Mr.&nbsp;James&nbsp;E. Flynn may be deemed to beneficially own the securities held by Deerfield Private
Design Fund III, L.P., Deerfield Mgmt HIF, L.P., Deerfield Management Company, L.P. The address of each of Deerfield Private Design Fund III, L.P., Deerfield Healthcare Innovations Fund, L.P. and Deerfield Special Situations Fund, L.P. is c/o
Deerfield Management Company, L.P., 780 Third Avenue, 37<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor, New York, NY 10017. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 10,043,468 shares of our common stock, (ii)&nbsp;1,450,497 shares of our common stock subject
to options that are exercisable within 60 days of June&nbsp;30, 2020, and (iii)&nbsp;27,759 shares of our common stock subject to warrants that are exercisable within 60 days of August&nbsp;31, 2020 held by all our executive officers and directors,
as a group, of which 987,830 shares subject to stock options are unvested as of such date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 1,680,395 shares of our common stock held of record by Clarus Lifesciences III, L.P., or Clarus.
Clarus Ventures III GP, L.P. is the sole general partner of Clarus. Blackstone Clarus III L.L.C. is the sole general partner of Clarus Ventures III GP, L.P. The sole member of Blackstone Clarus III L.L.C. is Blackstone Holdings II L.P. The sole
general partner of Blackstone Holdings II L.P. is Blackstone Holdings&nbsp;I/II GP L.L.C. The sole member of Blackstone Holdings I/II GP L.L.C. is The Blackstone Group Inc. The sole holder of the Class&nbsp;C common stock of The Blackstone Group
Inc. is Blackstone Group Management L.L.C. Blackstone Group Management L.L.C. is wholly-owned by The Blackstone Group Inc.&#146;s senior managing directors and controlled by its founder, Stephen&nbsp;A. Schwarzman. The address of Clarus is
101&nbsp;Main Street, Cambridge, MA 02142. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 755,730 shares of our common stock held of record by CVF 2018, LLC, or CVF. The address of CVF is
222 North LaSalle Street, Suite 2000, Chicago, IL 60601. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc796801_17"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description summarizes the most important terms of our capital stock, as they will be in effect following this offering. Because
it is only a summary, it does not contain all the information that may be important to you. We expect to adopt a restated certificate of incorporation and restated bylaws that will become effective upon the completion of this offering, and this
description summarizes provisions that are expected to be included in these documents. For a complete description, you should refer to our restated certificate of incorporation and restated bylaws, which are included as exhibits to the registration
statement of which this prospectus forms a part, and to the applicable provisions of Delaware law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, our authorized capital stock will consist of 500,000,000&nbsp;shares of common stock, $0.0001 par value
per share, and 10,000,000 shares of undesignated preferred stock, $0.0001 par value per share. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the provisions of our
current certificate of incorporation all of the outstanding convertible preferred stock will automatically convert into common stock in connection with the completion of this offering. Our Series A convertible preferred stock, or Series A preferred,
will convert at a ratio of 8.8527:1, our Series A-2 convertible preferred stock, or Series <FONT STYLE="white-space:nowrap">A-2</FONT> preferred, will convert at a ratio of 9.0058:1, our Series B convertible preferred stock, or Series B preferred,
will convert at a ratio of 9.0058:1 and our Series C preferred will convert at a ratio of 9.0058:1. Assuming the effectiveness of the conversion of preferred stock into shares of common stock as of June&nbsp;30, 2020, there were 14,468,113 shares of
our common stock issued and outstanding, held by approximately 58&nbsp;stockholders of record, and no shares of our convertible preferred stock outstanding. Our board of directors is authorized, without stockholder approval, to issue additional
shares of our capital stock not in excess of our total authorized shares.<B> </B> </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with our Series C preferred
financing, certain purchasers of Series C preferred had the option to purchase up to an additional 17,014,902 shares of Series C preferred at a price per share of $1.4693 for a period of up to 30 days after we notify them of the three month readout
from the Phase 2a clinical trial of <FONT STYLE="white-space:nowrap">GB-102</FONT> in patients with ME secondary to DME and RVO. In August 2020, our board of directors and the Series&nbsp;C preferred holders amended the Series&nbsp;C stock purchase
agreement such that this option is no longer exercisable and will terminate upon the effectiveness of this registration statement of which this prospectus forms a part. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividend Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of our common stock are entitled to
receive dividends out of funds legally available if our board of directors, in its discretion, determines to issue dividends and then only at the times and in the amounts that our board of directors may determine. See the section entitled
&#147;Dividend Policy.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders. We have not
provided for cumulative voting for the election of directors in our restated certificate of incorporation, which means that holders of a majority of the shares of our common stock will be able to elect all of our directors. Our restated certificate
of incorporation will establish a classified board of directors, to be divided into three classes with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes
continuing for the remainder of their respective three-year terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No Preemptive or Similar Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is not entitled to preemptive rights, and is not subject to conversion, redemption or sinking fund provisions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Right to Receive Liquidation Distributions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon our liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up,</FONT> the assets legally available for distribution to our
stockholders would be distributable ratably among the holders of our common stock and any participating preferred stock outstanding at that time, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights of
and the payment of liquidation preferences, if any, on any outstanding shares of preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately prior to the completion of this offering, each outstanding share of preferred stock will be converted into common stock. Our Series
A preferred will convert at a ratio of 8.8527:1, our Series <FONT STYLE="white-space:nowrap">A-2</FONT> preferred will convert at a ratio of 9.0058:1, our Series B preferred will convert at a ratio of 9.0058:1 and our Series C preferred will convert
at a ratio of 9.0058:1. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the completion of this offering, our board of directors will be authorized, subject to limitations
prescribed by Delaware law, to issue preferred stock in one or more series, to establish from time to time the number of shares to be included in each series and to fix the designation, powers, preferences and rights of the shares of each series and
any of their qualifications, limitations or restrictions, in each case without further vote or action by our stockholders. Our board of directors will also be able to increase or decrease the number of shares of any series of preferred stock, but
not below the number of shares of that series then outstanding and not above the number of shares of that series authorized, without any further vote or action by our stockholders. Our board of directors may authorize the issuance of preferred stock
with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other
corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control of our company and might adversely affect the market price of our common stock and the voting and other rights of the holders of
our common stock. We have no current plan to issue any shares of preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2020, we had one outstanding warrant to purchase 27,759 shares of our common stock, issued on December&nbsp;11, 2019, with
an exercise price per share of $3.88. Upon issuance, 1/12<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> of the shares issuable upon exercise of such warrant became vested and exercisable, and an additional 1/12<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> of the shares become vested on the same day of each full succeeding calendar month thereafter </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Options </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30,
2020, we had outstanding options to purchase an aggregate 2,066,076 shares of our common stock, with a weighted-average exercise price of $2.52. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the
terms of our amended and restated investors&#146; rights agreement, immediately following this offering, the holders of 13,145,104 shares of our common stock will be entitled to rights with respect to the registration of these shares under the
Securities Act, as described below. We refer to these shares collectively as registrable securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Demand Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beginning 180 days after the completion of this offering, the holders of at least a majority of the then-outstanding registrable securities may
make a written request to us for the registration under the Securities Act of registrable securities representing at least twenty five percent (25%) of the then outstanding registrable securities (or a lesser percent if the anticipated aggregate
offering price, net of selling expenses, would exceed $20.0 million). Within 10 days after the date such request is given, we are obligated to provide notice of such request to all holders of registrable securities and as soon as practicable, and in
any event within 60 days after the date such request is given, to file a registration statement under the Securities Act covering all registrable securities that the initiating holders requested to be registered and any additional registrable
securities requested to be included in such registration by any other holders. We are only required to file two registration statements that are declared effective upon exercise of these demand registration rights. We may postpone taking action with
respect to such filing not more than once during any <FONT STYLE="white-space:nowrap">12-month</FONT> period for a total period of not more than 90 days, if after receiving a request for registration, we furnish to the holders requesting such
registration a certificate signed by our Chief Executive Officer stating that, in the good faith judgment of our board of directors, it would be materially detrimental to us and our stockholders for such registration statement to be effected at such
time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Form <FONT STYLE="white-space:nowrap">S-3</FONT> Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of at least fifteen percent (15%) of the then-outstanding registrable securities can request that we register their shares on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> if we are eligible to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and if the anticipated aggregate price to the public of the shares offered is at least $5.0&nbsp;million.
Within ten (10)&nbsp;days after the date such request is given, we are obligated to provide notice of such request to all holders of registrable securities and as soon as practicable, and in any event within 45 days after the date such request is
given, to file a Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration statement under the Securities Act covering all registrable securities that the initiating holders requested to be registered and any additional registrable securities
requested to be included in such registration by any other holders. We are only required to file two registration statements that are declared effective upon exercise of these demand registration rights. We may postpone taking action with respect to
such filing not more than once during any <FONT STYLE="white-space:nowrap">12-month</FONT> period for a total period of not more than 90 days, if after receiving a request for registration, we furnish to the holders requesting such registration a
certificate signed by our Chief Executive Officer stating that, in the good faith judgment of our board of directors, it would be materially detrimental to us and our stockholders for such registration statement to be effected at such time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Piggyback Registration Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
we register any of our securities for public sale, holders of then-outstanding registrable securities or their permitted transferees will have the right to include their registrable securities in the registration statement. However, this right does
not apply to a registration relating to this offering, a Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration as described above, employee benefit plans or a registration relating to a corporate reorganization. The underwriters of any
underwritten offering will have the right to limit the number of shares registered by these holders if they determine that marketing factors require limitation, in which case the number of shares to be registered will be apportioned pro rata among
these holders, according to the total number of registrable securities originally requested by such holders to be included in the registration statement. However, the number of shares to be registered by these holders cannot be reduced below 30% of
the registrable securities such holders requested to be included in such offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expenses of Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We generally will pay all expenses, including expenses of one counsel for the selling holders, other than underwriting discounts and
commissions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expiration of Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registration rights described above will expire, with respect to any particular holder of these rights, on the earlier of (i)&nbsp;a deemed
liquidation event, as defined in our restated certificate of incorporation, (ii)&nbsp;such time after this offering as the registrable securities held by such holder may be sold within any ninety day period without restriction pursuant to Rule 144
promulgated under the Securities Act and (iii)&nbsp;the third anniversary of this public offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Provisions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions of the DGCL, our restated certificate of incorporation and our restated bylaws, as we expect they will be in effect upon the
completion of this offering, could have the effect of delaying, deferring or discouraging another person from acquiring control of our company. These provisions, which are summarized below, may have the effect of discouraging takeover bids. They are
also designed, in part, to encourage persons seeking to acquire control of us to negotiate first with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with an unfriendly or
unsolicited acquirer outweigh the disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could result in an improvement of their terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delaware Law </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to
the provisions of Section&nbsp;203 of the DGCL regulating corporate takeovers. In general, Section&nbsp;203 prohibits a publicly held Delaware corporation from engaging in a &#147;business combination&#148; with an &#147;interested stockholder&#148;
for a period of three years following the date on which the person became an interested stockholder unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prior to the date of the transaction, the board of directors of the corporation approved either the business
combination or the transaction which resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the
transaction commenced, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the interested stockholder, (i)&nbsp;shares owned by persons who are directors and also officers and
(ii)&nbsp;shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at or subsequent to the date of the transaction, the business combination is approved by the board of directors
of the corporation and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66.67% of the outstanding voting stock that is not owned by the interested stockholder.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, a business combination includes a merger, asset or stock sale, or other transaction or series of
transactions together resulting in a financial benefit to the interested stockholder. An interested stockholder is a person who, together with affiliates and associates, owns or, within three years prior to the determination of interested
stockholder status, did own 15% or more of a corporation&#146;s outstanding voting stock. We expect the existence of this provision to have an anti-takeover effect with respect to transactions our board of directors does not approve in advance. We
also anticipate that Section&nbsp;203 may also discourage attempts that might result in a premium over the market price for the shares of common stock held by stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restated Certificate of Incorporation and Restated Bylaw Provisions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our restated certificate of incorporation and our restated bylaws, as we expect they will be in effect upon the completion of this offering,
include a number of provisions that could deter hostile takeovers or delay or prevent changes in control of our company, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Board of Directors Vacancies.</I> Our restated certificate of incorporation and restated bylaws will authorize
only our board of directors to fill vacant directorships, including newly created seats. In addition, the number of directors constituting our board of directors is permitted to be set only by a resolution adopted by a majority vote of our entire
board of directors. These provisions would prevent a stockholder from increasing the size of our board of directors and then gaining control of our board of directors by filling the resulting vacancies with its own nominees. This makes it more
difficult to change the composition of our board of directors but promotes continuity of management. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Classified Board.</I> Our restated certificate of incorporation and restated bylaws will provide that our
board of directors is classified into three classes of directors, each with staggered three-year terms. A third party may be discouraged from making a tender offer or otherwise attempting to obtain control of us as it is more difficult and time
consuming for stockholders to replace a majority of the directors on a classified board of directors. See the section entitled &#147;Management&#151;Board Composition.&#148; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Stockholder Action; Special Meetings of Stockholders.</I> Our restated certificate of incorporation will
provide that our stockholders may not take action by written consent, but may only take action at annual or special meetings of our stockholders. As a result, a holder controlling a majority of our capital stock would not be able to amend our
restated bylaws or remove directors without holding a meeting of our stockholders called in accordance with our restated bylaws. Further, our restated bylaws will provide that special meetings of our stockholders may be called only by a majority of
our board of directors, the chairman of our board of directors, our Chief Executive Officer or our President, thus prohibiting a stockholder from calling a special meeting. These provisions might delay the ability of our stockholders to force
consideration of a proposal or for stockholders controlling a majority of our capital stock to take any action, including the removal of directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Advance Notice Requirements for Stockholder Proposals and Director Nominations.</I> Our restated bylaws will
provide advance notice procedures for stockholders seeking to bring business before our annual meeting of stockholders or to nominate candidates for election as directors at our annual meeting of stockholders. Our restated bylaws also will specify
certain requirements regarding the form and content of a stockholder&#146;s notice. These provisions might preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our
annual meeting of stockholders if the proper procedures are not followed. We expect that these provisions might also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#146;s own slate of
directors or otherwise attempting to obtain control of our company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>No Cumulative Voting.</I> The DGCL provides that stockholders are not entitled to the right to cumulate votes
in the election of directors unless a corporation&#146;s certificate of incorporation provides otherwise. Our restated certificate of incorporation and restated bylaws will not provide for cumulative voting. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Directors Removed Only for Cause.</I> Our restated certificate of incorporation will provide that stockholders
may remove directors only for cause and only by the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of our outstanding common stock. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Amendment of Charter Provisions.</I> Any amendment of the above expected provisions in our restated
certificate of incorporation would require approval by holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of our outstanding common stock. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Issuance of Undesignated Preferred Stock.</I> Our board of directors has the authority, without further action
by the stockholders, to issue up to 10,000,000 shares of undesignated preferred stock with rights and preferences, including voting rights, designated from time to time by our board of directors. The
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
existence of authorized but unissued shares of preferred stock would enable our board of directors to render more difficult or to discourage an attempt to obtain control of us by merger, tender
offer, proxy contest or other means. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Choice of Forum.</I> Our restated certificate of incorporation will provide that, to the fullest extent
permitted by law, the Court of Chancery of the State of Delaware will be the exclusive forum for any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us
arising pursuant to the DGCL, our restated certificate of incorporation or our restated bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. Our restated bylaws will provide that the federal district
courts of the United States of America will, to the fullest extent permitted by law, be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, which we refer to as a Federal Forum Provision. Our
decision to adopt a Federal Forum Provision followed a decision by the Supreme Court of the State of Delaware holding that such provisions are facially valid under Delaware law. While there can be no assurance that federal courts or state courts
will follow the holding of the Delaware Supreme Court or determine that the Federal Forum Provision should be enforced in a particular case, application of the Federal Forum Provision means that suits brought by our stockholders to enforce any duty
or liability created by the Securities Act must be brought in federal court and cannot be brought in state court. While neither the exclusive forum provision nor the Federal Forum Provision applies to suits brought to enforce any duty or liability
created by the Exchange Act, Section&nbsp;27 of the Exchange Act creates exclusive federal jurisdiction over all claims brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. Accordingly,
actions by our stockholders to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder also must be brought in federal court. Our stockholders will not be deemed to have waived our compliance with the
federal securities laws and the regulations promulgated thereunder. Any person or entity purchasing or otherwise acquiring or holding any interest in any of our securities shall be deemed to have notice of and consented to our exclusive forum
provisions, including the Federal Forum Provision. These provisions may limit a stockholder&#146;s ability to bring a claim in a judicial forum of their choosing for disputes with us or our directors, officers or other employees, which may
discourage lawsuits against us and our directors, officers, and other employees. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, the transfer agent and registrar for our common stock will be
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. The transfer agent&#146;s address is American Stock Transfer &amp; Trust Company, LLC, 6201 15th Avenue, Brooklyn, New York 11219. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Nasdaq Global Market Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
applied to list our common stock on the Nasdaq Global Market under the symbol &#147;GRAY.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc796801_18"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no public market for our common stock, and we cannot predict the effect, if any, that market sales of
shares of our common stock or the availability of shares of our common stock for sale will have on the market price of our common stock prevailing from time to time. Nevertheless, sales of substantial amounts of our common stock, including shares
issued upon exercise of outstanding options and warrants, in the public market following this offering could adversely affect market prices prevailing from time to time and could impair our ability to raise capital through the sale of our equity
securities. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, we will have a total of 19,155,613 shares of our common stock outstanding, assuming
(i)&nbsp;the automatic conversion of all outstanding shares of our convertible preferred stock into an aggregate of 13,085,913 shares of our common stock and (ii)&nbsp;the issuance of 4,687,500 shares of common stock in this offering. Of these
outstanding shares, all of the shares of common stock sold in this offering will be freely tradable, except that any shares purchased in this offering by our affiliates, as that term is defined in Rule 144 under the Securities Act, can only be sold
in compliance with the Rule 144 limitations described below. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The remaining outstanding shares of our common stock will be deemed
&#147;restricted securities&#148; as defined in Rule 144. Restricted securities may be sold in the public market only if they are registered under the Securities Act or if they qualify for an exemption from registration under Rule 144 or Rule 701
promulgated under the Securities Act, which rules are summarized below. In addition, substantially all of our security holders have, or will have, entered into market standoff agreements with us or <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements with the underwriters under which they have agreed, subject to specific exceptions, not to sell any of our stock for at least 180 days following the date of this prospectus, as described below. As a result of these agreements and the
provisions of our amended and restated investors&#146; rights agreement described above under &#147;Description of Capital Stock&#151;Registration Rights,&#148; subject to the provisions of Rule 144 or Rule 701, shares will be available for sale in
the public market as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">beginning on the date of this prospectus, all of the shares sold in this offering will be immediately available
for sale in the public market; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">beginning 181 days after the date of this prospectus, 14,468,113 additional shares will become eligible for sale
in the public market, of which 11,521,724 shares will be held by affiliates and subject to the volume and other restrictions of Rule 144, as described below. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-Up/Market</FONT> Standoff Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of our directors and officers and substantially all of our security holders are, or will be, subject to
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements or market standoff provisions that prohibit them from offering for sale, selling, contracting to sell, granting any option for the sale of, transferring or otherwise disposing of any shares
of our common stock, options or warrants to acquire shares of our common stock or any security or instrument related to our common stock, or entering into any swap, hedge or other arrangement that transfers any of the economic consequences of
ownership of our common stock, for a period of 180 days following the date of this prospectus without the prior written consent of SVB Leerink LLC and Piper Sandler&nbsp;&amp; Co., subject to certain exceptions. See the section entitled
&#147;Underwriting&#148; appearing elsewhere in this prospectus for more information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 144 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, under Rule 144 as currently in effect, once we have been subject to public company reporting requirements for at least 90 days, a
person who is not deemed to have been one of our affiliates for purposes of the Securities Act at any time during the three months preceding a sale and who has beneficially owned the shares proposed to be sold for at least six months, including the
holding period of any prior owner other than our affiliates, is entitled to sell those shares without complying with the manner of sale, volume limitation or notice provisions of Rule 144, subject to compliance with the public information
requirements of Rule 144. If such a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
person has beneficially owned the shares proposed to be sold for at least one year, including the holding period of any prior owner other than our affiliates, then that person would be entitled
to sell those shares without complying with any of the requirements of Rule 144. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, under Rule 144, as currently in effect, our
affiliates or persons selling shares on behalf of our affiliates are entitled to sell upon expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> and market standoff agreements described above, within any three-month period, a number of
shares that does not exceed the greater of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1% of the number of shares of our common stock then outstanding, which will equal approximately 191,556 shares
immediately after this offering; or </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average reported weekly trading volume of our common stock during the four calendar weeks preceding the
filing of a notice on Form 144 with respect to that sale. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales under Rule 144 by our affiliates or persons selling
shares on behalf of our affiliates are also subject to certain manner of sale provisions and notice requirements and to the availability of current public information about us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 701 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rule 701 generally allows a
stockholder who purchased shares of our common stock pursuant to a written compensatory plan or contract and who is not deemed to have been an affiliate of our company during the immediately preceding three months to sell these shares in reliance
upon Rule 144, but without being required to comply with the public information, holding period, volume limitation or notice provisions of Rule 144. Rule 701 also permits affiliates of our company to sell their Rule 701 shares under Rule 144 without
complying with the holding period requirements of Rule 144. All holders of Rule 701 shares, however, are required by that rule to wait until 90 days after the date of this prospectus before selling those shares pursuant to Rule 701 and are subject
to the <FONT STYLE="white-space:nowrap">lock-up</FONT> and market standoff agreements described above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form
<FONT STYLE="white-space:nowrap">S-8</FONT> Registration Statement </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this offering, we intend to file a
registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Securities Act covering all of the shares of our common stock subject to outstanding options and the shares of our common stock reserved for issuance under our
stock plans. We expect to file this registration statement as soon as permitted under the Securities Act. However, the shares registered on Form <FONT STYLE="white-space:nowrap">S-8</FONT> may be subject to the volume limitations and the manner of
sale, notice and public information requirements of Rule 144 and will not be eligible for resale until expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> and market standoff agreements to which they are subject. Of the 2,066,076
shares of our common stock that were subject to options outstanding as of June&nbsp;30, 2020, options to purchase 872,853 shares of common stock were vested as of June&nbsp;30, 2020. Shares of our common stock underlying outstanding options will not
be eligible for sale until expiration of the <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> and market standoff agreements to which they are subject. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted
demand, piggyback and Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration rights to certain of our stockholders to sell our common stock. Registration of the sale of these shares under the Securities Act would result in these shares
becoming freely tradable without restriction under the Securities Act immediately upon the effectiveness of the registration, except for shares purchased by affiliates. For a further description of these rights, see the section entitled
&#147;Description of Capital Stock&#151;Registration Rights.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc796801_19"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary describes the material U.S. federal income tax consequences
of the acquisition, ownership and disposition of our common stock acquired in this offering by <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders (as defined below). This discussion does not address all aspects of U.S. federal income taxes,
does not discuss the potential application of the alternative minimum tax or Medicare Contribution tax on net investment income and does not deal with state or local taxes, U.S. federal gift and estate tax laws, except to the limited extent provided
below, or any <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences that may be relevant to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders in light of their particular circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Special rules different from those described below may apply to certain <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders that are
subject to special treatment under the Internal Revenue Code of 1986, as amended, or Code, such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insurance companies, banks and other financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations (including private foundations) and <FONT
STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign governments and international organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">broker-dealers and traders in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. expatriates and certain former citizens or long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that own, or are deemed to own, more than 5% of our capital stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies&#148; and corporations
that accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that hold our common stock as part of a &#147;straddle,&#148; &#147;hedge,&#148; &#147;conversion
transaction,&#148; &#147;synthetic security&#148; or integrated investment or other risk reduction strategy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons required for U.S. federal income tax purposes to conform the timing of income accruals to their financial
statements under Section&nbsp;451(b) of the Code; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who do not hold our common stock as a capital asset within the meaning of Section&nbsp;1221 of the Code
(generally, for investment purposes); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partnerships and other pass-through entities, and investors in such pass-through entities (regardless of their
places of organization or formation). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders are urged to
consult their own tax advisors to determine the U.S. federal, state, local and other tax consequences that may be relevant to them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, the discussion below is based upon the provisions of the Code, and U.S. Treasury Regulations, rulings and judicial decisions
thereunder as of the date hereof, and such authorities may be repealed, revoked or modified, possibly retroactively, and are subject to differing interpretations which could result in U.S. federal income tax consequences different from those
discussed below. We have not requested a ruling from the Internal Revenue Service, or IRS, with respect to the statements made and the conclusions reached in the following summary, and there can be no assurance that the IRS will agree with such
statements and conclusions or will not take a contrary position regarding the tax consequences described herein, or that any such contrary position would not be sustained by a court. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PERSONS CONSIDERING THE PURCHASE OF OUR COMMON STOCK PURSUANT TO THIS OFFERING SHOULD CONSULT THEIR OWN TAX ADVISORS CONCERNING THE U.S.
FEDERAL INCOME TAX CONSEQUENCES OF ACQUIRING, OWNING AND DISPOSING OF OUR COMMON STOCK IN LIGHT OF THEIR PARTICULAR SITUATIONS AS WELL AS ANY CONSEQUENCES ARISING UNDER THE LAWS OF ANY OTHER TAXING JURISDICTION, INCLUDING ANY STATE, LOCAL OR <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> TAX CONSEQUENCES OR ANY U.S. FEDERAL <FONT STYLE="white-space:nowrap">NON-INCOME</FONT> TAX CONSEQUENCES, AND THE POSSIBLE APPLICATION OF TAX TREATIES. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this discussion, a
<FONT STYLE="white-space:nowrap">&#147;Non-U.S.</FONT> Holder&#148; is a beneficial owner of common stock that is not a U.S. Holder or a partnership or other pass-through entity for U.S. federal income tax purposes. A &#147;U.S. Holder&#148; means a
beneficial owner of our common stock that is, for U.S. federal income tax purposes, (a)&nbsp;an individual citizen or resident of the United States, (b)&nbsp;a corporation (or other entity taxable as a corporation for U.S. federal income tax
purposes), created or organized in or under the laws of the United States, any state thereof or the District of Columbia, (c)&nbsp;an estate the income of which is subject to U.S. federal income taxation regardless of its source or (d)&nbsp;a trust
if it (1)&nbsp;is subject to the primary supervision of a court within the United States and one or more U.S. persons (within the meaning of Section&nbsp;7701(a)(30) of the Code) have the authority to control all substantial decisions of the trust
or (2)&nbsp;has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a U.S. person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are an
individual <FONT STYLE="white-space:nowrap">non-U.S.</FONT> citizen, you may, in some cases, be deemed to be a resident alien (as opposed to a nonresident alien) by virtue of being present in the United States for at least 31 days in the calendar
year and for an aggregate of at least 183 days during a three-year period ending in the current calendar year. Generally, for this purpose, all the days present in the current year, <FONT STYLE="white-space:nowrap">one-third</FONT> of the days
present in the immediately preceding year, and <FONT STYLE="white-space:nowrap">one-sixth</FONT> of the days present in the second preceding year, are counted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Resident aliens are generally subject to U.S. federal income tax as if they were U.S. citizens. Individuals who are uncertain of their status
as resident or nonresident aliens for U.S. federal income tax purposes are urged to consult their own tax advisors regarding the U.S. federal income tax consequences of the ownership or disposition of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Distributions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not expect to
make any distributions on our common stock in the foreseeable future. If we do make distributions on our common stock, however, such distributions made to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of our common stock will constitute
dividends for U.S. tax purposes to the extent paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). Distributions in excess of our current and accumulated earnings and profits will
constitute a return of capital that is applied against and reduces, but not below zero, a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s adjusted tax basis in our common stock. Any remaining excess will be treated as gain realized on
the sale or exchange of our common stock as described below under the section entitled &#147;&#151;Gain on Disposition of Our Common Stock.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any distribution on our common stock that is treated as a dividend paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is
not effectively connected with the holder&#146;s conduct of a trade or business in the United States will generally be subject to withholding tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty between the
United States and the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s country of residence. To obtain a reduced rate of withholding under a treaty, a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder generally will be required
to provide the applicable withholding agent with a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8BEN,</FONT> IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or other appropriate
form, certifying the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s entitlement to benefits under that treaty. Such form must be provided prior to the payment of dividends and must be updated periodically. If a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder holds stock through a financial institution or other agent acting on the holder&#146;s behalf, the holder will be required to provide appropriate documentation to such agent. The holder&#146;s agent
may then be required to provide certification to the applicable withholding agent, either directly or through other intermediaries. If you are eligible for a reduced rate of U.S. withholding tax under an income tax treaty, you should consult with
your own tax advisor to determine if you are able to obtain a refund of any excess amounts withheld by timely filing an appropriate claim for a refund with the IRS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We generally are not required to withhold tax on dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that are
effectively connected with the holder&#146;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, are attributable to a permanent establishment that the holder maintains in the United States)
if a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> stating that the dividends are so connected, is furnished to us (or, if stock is held through a financial institution or other agent, to the applicable withholding
agent). In general, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such effectively connected dividends will be subject to U.S. federal income tax on a net income basis at the regular graduated rates applicable to U.S. persons. A corporate <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder receiving effectively connected dividends may also be subject to an additional &#147;branch profits tax,&#148; which is imposed, under certain circumstances, at a rate of 30% (or such lower rate as
may be specified by an applicable treaty) on the corporate <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s effectively connected earnings and profits, subject to certain adjustments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See also the section below entitled &#147;&#151;Foreign Accounts&#148; for additional withholding rules that may apply to dividends paid to
certain foreign financial institutions or <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Gain on Disposition of Our Common
Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussions below under the sections entitled &#147;&#151;Backup Withholding and Information Reporting&#148;
and &#147;&#151;Foreign Accounts,&#148; a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder generally will not be subject to U.S. federal income or withholding tax with respect to gain realized on a sale or other disposition of our common
stock unless (a)&nbsp;the gain is effectively connected with a trade or business of the holder in the United States (and, if required by an applicable income tax treaty, is attributable to a permanent establishment that the holder maintains in the
United States), (b) the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a nonresident alien individual and is present in the United States for 183 or more days in the taxable year of the disposition and certain other conditions are met or
(c)&nbsp;we are or have been a &#147;United States real property holding corporation&#148; within the meaning of Code Section&nbsp;897(c)(2) at any time within the shorter of the five-year period preceding such disposition or the holder&#146;s
holding period in the common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder described in (a)&nbsp;above, you
will be required to pay tax on the net gain derived from the sale at the regular graduated U.S. federal income tax rates applicable to U.S. persons. Corporate <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders described in (a)&nbsp;above may
also be subject to the additional branch profits tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty. If you are an individual <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder described in
(b)&nbsp;above, you will be required to pay a flat 30% tax on the gain derived from the sale, which gain may be offset by certain U.S. source capital losses (even though you are not considered a resident of the United States), provided you have
timely filed U.S. federal income tax returns with respect to such losses. With respect to (c)&nbsp;above, in general, we would be a United States real property holding corporation if U.S. real property interests as defined in the Code and the U.S.
Treasury Regulations comprised (by fair market value) at least half of our worldwide real property interests plus our other assets used or held for use in a trade or business. We believe that we are not, and do not anticipate becoming, a United
States real property holding corporation. However, there can be no assurance that we will not become a United States real property holding corporation in the future. Even if we were treated as a U.S. real property holding corporation, gain realized
by a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder on a disposition of our common stock will not be subject to U.S. federal income tax so long as (1)&nbsp;the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder owned, directly,
indirectly or constructively, no more than five percent of our common stock at all times within the shorter of (i)&nbsp;the five-year period preceding the disposition or (ii)&nbsp;the holder&#146;s holding period and (2)&nbsp;our common stock is
regularly traded on an established securities market. There can be no assurance that our common stock will qualify as regularly traded on an established securities market. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Federal Estate Tax </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
estates of nonresident alien individuals generally are subject to U.S. federal estate tax on property with a U.S. situs. Because we are a U.S. corporation, our common stock will be U.S. situs property and, therefore, will be included in the taxable
estate of a nonresident alien decedent, unless an applicable estate tax treaty between the United States and the decedent&#146;s country of residence provides otherwise. The terms &#147;resident&#148; and &#147;nonresident&#148; are defined
differently for U.S. federal estate tax purposes than for U.S. federal income tax purposes. Investors are urged to consult their own tax advisors regarding the U.S. federal estate tax consequences of the ownership or disposition of our common stock.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Backup Withholding and Information Reporting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, we or certain financial middlemen must report information to the IRS with respect to any dividends we pay on our common stock
including the amount of any such dividends, the name and address of the recipient, and the amount, if any, of tax withheld. A similar report is sent to the holder to whom any such dividends are paid. Pursuant to tax treaties or certain other
agreements, the IRS may make its reports available to tax authorities in the recipient&#146;s country of residence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends paid by us
(or our paying agents) to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder may also be subject to U.S. backup withholding. U.S. backup withholding generally will not apply to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder who
provides a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E,</FONT></FONT> as applicable, or otherwise establishes an exemption, provided
that the applicable withholding agent does not have actual knowledge or reason to know the holder is a U.S. person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under current U.S.
federal income tax law, U.S. information reporting and backup withholding requirements generally will apply to the proceeds of a disposition of our common stock effected by or through a U.S. office of any broker, U.S. or <FONT
STYLE="white-space:nowrap">non-U.S.,</FONT> unless the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder provides a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or IRS Form <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">W-8BEN-E,</FONT></FONT> as applicable, or otherwise meets documentary evidence requirements for establishing <FONT STYLE="white-space:nowrap">non-U.S.</FONT> person status or otherwise establishes an exemption. Generally,
U.S. information reporting and backup withholding requirements will not apply to a payment of disposition proceeds to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder where the transaction is effected outside the United States through a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> office of a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> broker. Information reporting and backup withholding requirements may, however, apply to a payment of disposition proceeds if the broker has
actual knowledge, or reason to know, that the holder is, in fact, a U.S. person. For information reporting purposes, certain brokers with substantial U.S. ownership or operations will generally be treated in a manner similar to U.S. brokers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax. If backup withholding is applied to you, you should consult with your own tax advisor to
determine whether you have overpaid your U.S. federal income tax, and whether you are able to obtain a tax refund or credit of the overpaid amount. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Accounts </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition,
U.S. federal withholding taxes may apply under legislation commonly known as the Foreign Account Tax Compliance Act, or FATCA, on certain types of payments, including dividends paid to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> financial
institutions and certain other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entities. Specifically, a 30% withholding tax may be imposed on dividends on our common stock paid to a &#147;foreign financial institution&#148; or a <FONT
STYLE="white-space:nowrap">&#147;non-financial</FONT> foreign entity&#148; (each as defined in the Code), unless (1)&nbsp;the foreign financial institution agrees to undertake certain diligence and reporting obligations, (2)&nbsp;the <FONT
STYLE="white-space:nowrap">non-financial</FONT> foreign entity either certifies it does not have any &#147;substantial United States owners&#148; (as defined in the Code) or furnishes identifying information regarding each substantial United States
owner or (3)&nbsp;the foreign financial institution or <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity otherwise qualifies for an exemption from these rules. The 30% federal withholding tax described in this paragraph cannot be
reduced under an income tax treaty with the United States. If the payee is a foreign financial institution and is subject to the diligence and reporting requirements in (1)&nbsp;above, it must enter into an agreement with the U.S. Department of the
Treasury requiring, among other things, that it undertake to identify accounts held by certain &#147;specified United States persons&#148; or &#147;United States-owned foreign entities&#148; (each as defined in the Code), annually report certain
information about such accounts, and withhold 30% on certain payments to <FONT STYLE="white-space:nowrap">non-compliant</FONT> foreign financial institutions and certain other account holders. Under proposed U.S. Treasury Regulations promulgated by
the Treasury Department on December&nbsp;13, 2018, which state that taxpayers may rely on the proposed Treasury Regulations until final Treasury Regulations are issued, this withholding tax will not apply to the gross proceeds from any sale or
disposition of our common stock. Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing FATCA may be subject to different rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prospective investors should consult their tax advisors regarding the potential application
of withholding under FATCA to their investment in our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS OWN TAX ADVISOR
REGARDING THE TAX CONSEQUENCES OF PURCHASING, HOLDING AND DISPOSING OF OUR COMMON STOCK, INCLUDING THE CONSEQUENCES OF ANY PROPOSED CHANGE IN APPLICABLE LAW, AS WELL AS TAX CONSEQUENCES ARISING UNDER ANY STATE, LOCAL,
<FONT STYLE="white-space:nowrap">NON-U.S.</FONT> OR U.S. FEDERAL <FONT STYLE="white-space:nowrap">NON-INCOME</FONT> TAX LAWS SUCH AS ESTATE AND GIFT TAX. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc796801_20"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SVB Leerink LLC and Piper Sandler&nbsp;&amp; Co. are acting as representatives of each of the underwriters named below and as joint
bookrunning managers for this offering. Subject to the terms and conditions set forth in the underwriting agreement among us and the underwriters, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not
jointly, to purchase from us, the number of shares of common stock set forth opposite its name below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SVB Leerink LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Piper Sandler&nbsp;&amp; Co.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Needham&nbsp;&amp; Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wedbush Securities Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,687,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions set forth in the underwriting agreement, the underwriters have
agreed, severally and not jointly, to purchase all of the shares sold under the underwriting agreement if any of the shares are purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> underwriters may be increased or the underwriting agreement may be terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, or to contribute to payments the underwriters may be required to make in respect of those liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters are offering the shares, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal
matters by their counsel, including the validity of the shares, and subject to other conditions contained in the underwriting agreement, such as the receipt by the underwriters of officers&#146; certificates and legal opinions. The underwriters
reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Discounts and Commissions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The representatives have advised us that the underwriters propose initially to offer the shares to the public at the initial public offering
price set forth on the cover page of this prospectus and to dealers at that price less a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. After the initial offering of the shares, the
public offering price, concession or any other term of this offering may be changed by the representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the
initial public offering price, underwriting discounts and commissions and proceeds, before expenses, to us. The information assumes either no exercise or full exercise by the underwriters of their option to purchase additional shares of our common
stock. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per</B><br><B>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without<BR>Option</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>With<BR>Option</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate expenses payable by us in connection with this offering, other than the underwriting discounts
and commissions referred to above, will be approximately $4.0&nbsp;million. We also have agreed to reimburse the underwriters for up to $40,000 for their FINRA counsel fee. In accordance with FINRA Rule 5110, this reimbursed fee is deemed
underwriting compensation for this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Option to Purchase Additional Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted an option to the underwriters, exercisable for 30 days after the date of this prospectus, to purchase up to 703,125 additional
shares at the initial public offering price, less underwriting discounts and commissions. If the underwriters exercise this option, each underwriter will be obligated, subject to the conditions contained in the underwriting agreement, to purchase a
number of additional shares proportionate to that underwriter&#146;s initial amount reflected in the above table. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Sales of Similar Securities
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, our executive officers and directors and all of our other existing security holders have agreed not to sell or transfer any common
stock or securities convertible into or exchangeable or exercisable for common stock, for 180 days after the date of this prospectus without first obtaining the written consent of SVB Leerink LLC and Piper Sandler&nbsp;&amp; Co. on behalf of the
underwriters. Specifically, we and these other persons have agreed, with certain limited exceptions, not to directly or indirectly: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">offer, pledge, sell or contract to sell any common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sell any option or contract to purchase any common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchase any option or contract to sell any common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">grant any option, right or warrant for the sale of any common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">otherwise dispose of or transfer any common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">request or demand that we file a registration statement related to the common stock; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any swap or other agreement or any transaction that transfers, in whole or in part, the economic
consequence of ownership of any common stock, whether any such swap, agreement or transaction is to be settled by delivery of shares or other securities, in cash or otherwise. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">lock-up</FONT> provisions apply to common stock and to securities convertible into or exchangeable or
exercisable for common stock. They also apply to common stock owned now or acquired later by the person executing the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement or for which the person executing the
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreement later acquires the power of disposition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Global Market Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have applied to list our common stock on the Nasdaq Global Market, subject to notice of issuance, under the symbol &#147;GRAY.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Determination of Offering Price </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to
this offering, there has been no public market for our common stock. The initial public offering price for our common stock will be determined through negotiations between us and the representatives. In addition to prevailing market conditions, the
factors to be considered in determining the initial public offering price are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the valuation multiples of publicly traded companies that the representatives believe to be comparable to us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial information; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the history of, and the prospects for, our company and the industry in which we compete; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an assessment of our management, its past and present operations, and the prospects for, and timing of, our
future revenues; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the present state of our development; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the above factors in relation to market values and various valuation measures of other companies engaged in
activities similar to ours. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An active trading market for the shares may not develop. It is also possible that after
this offering, our common stock will not trade in the public market at or above the initial public offering price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters do
not expect to sell more than 5% of the shares in the aggregate to accounts over which they exercise discretionary authority. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Price Stabilization,
Short Positions and Penalty Bids </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until the distribution of the shares is completed, SEC rules may limit underwriters and selling group
members from bidding for and purchasing our common stock. However, the representatives may engage in transactions that stabilize the price of the common stock, such as bids or purchases to peg, fix or maintain that price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this offering, the underwriters may purchase and sell our common stock in the open market. These transactions may include
short sales, purchases on the open market to cover positions created by short sales and stabilizing transactions. Short sales involve the sale by the underwriters of a greater number of shares than they are required to purchase in this offering.
&#147;Covered&#148; short sales are sales made in an amount not greater than the underwriters&#146; option to purchase additional shares described above. The underwriters may close out any covered short position by either exercising their option to
purchase additional shares or purchasing shares in the open market. In determining the source of shares to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the
open market as compared to the price at which they may purchase shares through the option to purchase additional shares granted to them under the underwriting agreement described above. &#147;Naked&#148; short sales are sales in excess of such
option. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of our
common stock in the open market after pricing that could adversely affect investors who purchase in this offering. Stabilizing transactions consist of various bids for or purchases of shares of common stock made by the underwriters in the open
market prior to the closing of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters may also impose a penalty bid. This occurs when a particular underwriter
repays to the underwriters a portion of the underwriting discount received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar to other purchase transactions, the underwriters&#146; purchases to cover the syndicate short sales may have the effect of raising or
maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. The
underwriters may conduct these transactions on the Nasdaq Global Market, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the
transactions described above may have on the price of our common stock. In addition, neither we nor any of the underwriters make any representation that the representatives will engage in these transactions or that these transactions, once
commenced, will not be discontinued without notice. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic Distribution </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this offering, certain of the underwriters or securities dealers may distribute prospectuses by electronic means, such as <FONT
STYLE="white-space:nowrap">e-mail.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters and certain of their affiliates are full service financial institutions engaged in various activities, which may include
securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. Some of the underwriters and certain of their affiliates may in
the future engage in investment banking and other commercial dealings in the ordinary course of business with us and our affiliates, for which they may in the future receive customary fees, commissions and expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the ordinary course of their business activities, the underwriters and their affiliates may make or hold a broad array of
investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers. Such investments and securities activities
may involve securities and/or instruments of ours or our affiliates. The underwriters and their affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial
instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selling
Restrictions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>European Economic Area and the United Kingdom </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation to each Member State of the European Economic Area and the United Kingdom, each, a &#147;Relevant State&#148;, no shares have been
offered or will be offered pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the shares which has been approved by the competent authority in that Relevant State or, where
appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that offers of shares may be made to the public in that Relevant State at any
time under the following exemptions under the Prospectus Regulation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any legal entity which is a qualified investor as defined under the Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus
Regulation), subject to obtaining the prior consent of the underwriters for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided</I> that no such offer of shares shall require us or any of the underwriters to publish a prospectus pursuant to Article 3 of the Prospectus
Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each person in a Relevant State who initially
acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with us and the underwriters that it is a qualified investor within the meaning of the Prospectus Regulation and each person who
initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with each of the underwriters and us that it is a &#147;qualified investor&#148; within the meaning of Article 2(e) of the
Prospectus Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of any shares being offered to a financial intermediary as that term is used in Article 5(1) of the
Prospectus Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a <FONT STYLE="white-space:nowrap">non-discretionary</FONT>
basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer to the public other than their offer or resale in a Relevant State to qualified investors, in
circumstances in which the prior consent of the representatives has been obtained to each such proposed offer or resale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, the
underwriters and each of our and the underwriters&#146; respective affiliates will rely upon the truth and accuracy of the foregoing representations, acknowledgements and agreements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an &#147;offer to the public&#148; in
relation to any shares in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any
shares, and the expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">References to the Prospectus
Regulation include, in relation to the United Kingdom, the Prospectus Regulation as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above selling restriction is in addition to any other selling restrictions set out below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective Investors in the United Kingdom </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may
only be directed at persons who are &#147;qualified investors&#148; (as defined in the Prospectus Regulation)&nbsp;(i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and
Markets Act 2000 (Financial Promotion) Order 2005, as amended, or the Order, and/or (ii)&nbsp;who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d)&nbsp;of the Order,
all such persons together being referred to as relevant persons, or otherwise in circumstances which have not resulted and will not result in an offer to the public of the shares in the United Kingdom within the meaning of the Financial Services and
Markets Act 2000, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any person in the United Kingdom that is not a relevant person should not act or rely on the information
included in this document or use it as basis for taking any action. In the United Kingdom, any investment or investment activity that this document relates to may be made or taken exclusively by relevant persons. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice to Prospective Investors in Canada </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in
National <FONT STYLE="white-space:nowrap">Instrument&nbsp;45-106&nbsp;Prospectus</FONT> Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National
<FONT STYLE="white-space:nowrap">Instrument&nbsp;31-103&nbsp;Registration</FONT> Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares must be made in accordance with an exemption from, or in a transaction not subject
to, the prospectus requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may
provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit
prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these
rights or consult with a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 of National
<FONT STYLE="white-space:nowrap">Instrument&nbsp;33-105&nbsp;Underwriting</FONT> Conflicts, or <FONT STYLE="white-space:nowrap">NI&nbsp;33-105,&nbsp;the</FONT> underwriters are not required to comply with the disclosure requirements of <FONT
STYLE="white-space:nowrap">NI&nbsp;33-105&nbsp;regarding</FONT> underwriter conflicts of interest in connection with this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc796801_21"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the shares of common stock offered by this prospectus will be passed upon for us by Fenwick&nbsp;&amp; West LLP, San
Francisco, California. Certain legal matters relating to the offering will be passed upon for the underwriters by Wilmer Cutler Pickering Hale and Dorr LLP, New York, New York. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc796801_22"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our financial statements at December&nbsp;31, 2018 and
2019, and for the years then ended, as set forth in their report thereon (which contains an explanatory paragraph describing conditions that raise substantial doubt about the company&#146;s ability to continue as a going concern as described in Note
1 to the financial statements) appearing elsewhere herein. We have included our financial statements in this prospectus and elsewhere in the registration statement in reliance on Ernst&nbsp;&amp; Young LLP&#146;s report, given on their authority as
experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc796801_23"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the Securities and Exchange Commission, or SEC, a registration statement on Form
<FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities Act of 1933, as amended, with respect to the shares of common stock offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the
information set forth in the registration statement or the exhibits filed therewith. For further information about us and the common stock offered hereby, reference is made to the registration statement and the exhibits filed therewith. Statements
contained in this prospectus regarding the contents of any contract or any other document that is filed as an exhibit to the registration statement are not necessarily complete, and in each instance we refer you to the copy of such contract or other
document filed as an exhibit to the registration statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently do not file periodic reports with the SEC. Upon the completion
of this offering, we will be required to file periodic reports, proxy statements and other information with the SEC pursuant to the Securities Exchange Act of 1934, as amended. The SEC maintains a website that contains reports, proxy and information
statements and other information regarding registrants that file electronically with the SEC. The address of the website is www.sec.gov. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also maintain a website at www.graybug.com. Upon completion of this offering, you may access these materials at our website free of charge
as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. Information contained on our website is not a part of this prospectus and the inclusion of our website address in this prospectus is an inactive
textual reference only. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc796801_24"></A>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEX TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Audited Financial Statements</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin796801_1">Report of Independent Registered Public Accounting Firm </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin796801_2">Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin796801_3">Statements of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin796801_4">Statements of Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin796801_5">Statements of Convertible Preferred Stock and Stockholders&#146;
Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin796801_6">Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin796801_7">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-8</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Unaudited Interim Financial Statements</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin796801_8">Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-33</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin796801_9">Statements of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-34</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin796801_10">Statements of Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-35</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin796801_11">Statements of Convertible Preferred Stock and Stockholders&#146;
Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-36</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin796801_12">Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-37</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin796801_13">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-38</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin796801_1"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Stockholders and Board of Directors of Graybug Vision, Inc. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the
accompanying balance sheets of Graybug Vision, Inc. (the Company) as of December&nbsp;31, 2019 and 2018, the related statements of operations, comprehensive loss, convertible preferred stock and stockholders&#146; deficit and cash flows for the
years then ended, and the related notes (collectively referred to as the &#147;financial statements&#148;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December&nbsp;31,
2019 and 2018, and the results of its operations and its cash flows for the years then ended in conformity with U.S. generally accepted accounting principles. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Company&#146;s Ability to Continue as a Going Concern </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note&nbsp;1 to the
financial statements, the Company has suffered recurring losses and negative cash flows from operations, and has stated that substantial doubt exists about the Company&#146;s ability to continue as a going concern. Management&#146;s evaluation of
the events and conditions and management&#146;s plans regarding these matters are also described in Note&nbsp;1 to the financial statements. The financial statements do not include any adjustments that might result from the outcome of this
uncertainty. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial
statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial statements based on our audits. We are a public accounting firm registered with the Public Company
Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission
and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial
reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial
reporting. Accordingly, we express no such opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audits included performing procedures to assess the risks of material misstatement of the
financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits
also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:68%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/ Ernst&nbsp;&amp; Young LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s auditor since 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Redwood City, California </P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&nbsp;21, 2020, except for
the third paragraph of Note 1, as to which the date is September 18, 2020 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin796801_2"></A>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Balance Sheets </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in
thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities, convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock tranche obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock, $0.0001 par value; 142,150,096 and 87,898,561 shares authorized,
117,809,883 and 80,377,096 shares issued and outstanding as of December&nbsp;31, 2019 and 2018, respectively; aggregate liquidation value of $148,592 as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value; 188,000,000 and 120,000,000 shares authorized, 1,371,467 and
1,292,858 shares issued and outstanding as of December&nbsp;31, 2019 and 2018, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(105,836</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(68,799</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102,954</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(66,792</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to the financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin796801_3"></A>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statements of Operations </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,971</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,502</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,570</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of preferred stock tranche obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,037</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,378</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cumulative dividends on convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,055</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,317</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(44,092</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,695</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per common share&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(33.41</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25.77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares outstanding used in computing net loss per common
share&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,319,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,268,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per common share&#151;basic and diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.09</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used in computing pro forma net loss per common share&#151;basic
and diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,001,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to the financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin796801_4"></A>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statements of Comprehensive Loss </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(37,037</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,378</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized gain on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(37,034</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,378</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to the financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin796801_5"></A>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statements of Convertible Preferred Stock and Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Convertible</B><br><B>Preferred Stock</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">Paid-in</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Other<BR>Comprehensive</B><br><B>Income</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>Stockholders&#146;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance&#151;December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,995,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,916</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,207,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(40,421</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(38,886</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series B convertible preferred stock, net of issuance costs of $105</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,381,433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,895</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock issued on exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,378</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,378</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance&#151;December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,377,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,811</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,292,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(68,799</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(66,792</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series C convertible preferred stock, net of issuance costs of $217 and discount on
allocation of proceeds to preferred stock tranche obligation of $2,230</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,432,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,552</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock issued on exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,037</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,037</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Unrealized gain on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance&#151;December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117,809,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">131,363</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,371,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(105,836</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(102,954</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to the financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin796801_6"></A>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statements of Cash Flows </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Operating activities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(37,037</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,378</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of preferred stock tranche obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of premium and discounts on short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on disposal of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current and noncurrent assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,721</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,215</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,216</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investing activities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(605</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,461</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,515</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Maturity of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,620</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,461</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Financing activities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of convertible preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents&#151;beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents&#151;end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Supplemental disclosure of noncash items</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment purchases included in accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs included in accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">849</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to the financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin796801_7"></A>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Organization, Description of Business and Going Concern Considerations </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Graybug Vision, Inc., the Company or Graybug, is a clinical stage biopharmaceutical company developing medicines for the treatment of diseases
of the retina and optic nerve. The Company presently devotes substantially all of its resources to conducting research and development and raising capital. The Company was founded in May&nbsp;2011 and maintains facilities in Redwood City, California
and Baltimore, Maryland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to risks common to clinical stage companies in the biopharmaceutical industry, including
dependence on the clinical success of its product candidates, ability to obtain regulatory approvals of its product candidates, compliance with regulatory requirements, the need for substantial additional financing and protection of its proprietary
technology. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Reverse Stock Split </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;18, 2020, the Company effected a 9.0058:1 reverse stock split of the Company&#146;s issued and outstanding common stock. Upon
the effectiveness of the reverse stock split, (i)&nbsp;all shares of outstanding common stock were adjusted; (ii)&nbsp;the conversion prices of the convertible preferred stock were adjusted; (iii)&nbsp;the number of shares of common stock for which
each outstanding option and warrant to purchase common stock is exercisable were adjusted; and (iv) the exercise price of each outstanding option and warrant to purchase common stock were adjusted. All of the outstanding common stock share numbers
(including shares of common stock subject to the Company&#146;s options and as converted for the outstanding convertible preferred stock), share prices, exercise prices and per share amounts contained in the financial statements have been
retroactively adjusted in the financial statements to reflect this reverse stock split for all periods presented. The par value per share and the authorized number of shares of common stock were not adjusted as a result of the reverse stock split.
</P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Going Concern Considerations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company incurred losses from operations and had negative cash flows from operating activities for the years ended December&nbsp;31, 2019
and 2018. The Company&#146;s current operating plan indicates it will continue to incur losses from operations and generate negative cash flows from operating activities, given ongoing expenditures related to extensive research and development and
the Company&#146;s lack of revenue generating activities at this point in the Company&#146;s lifecycle. These events and conditions raise substantial doubt about the Company&#146;s ability to continue as a going concern. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will need to raise additional funds in order to further advance its research and development programs, operate its business and
meet its obligations as they come due. The Company is pursuing financing alternatives, similar to what the Company has previously executed, which include preferred equity financing. However, financing may not be available to the Company in the
necessary time frame, in the amounts that the Company requires, on terms that are acceptable to the Company, or at all. If the Company is unable to raise the necessary funds when needed or reduce spending on currently planned activities, it may not
be able to continue the development of its products or the Company could be required to delay, scale back, or eliminate some or all of its research and development programs and other operations and will materially harm its business, financial
position and results of operations. Based on the Company&#146;s current plans, it is anticipated that the existing cash will allow the Company to conduct planned operations into the fourth quarter of 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern and do not include
adjustments that might result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Company&#146;s assets and the satisfaction of liabilities in the normal course of business. The financial statements do not
include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might be necessary should the Company be unable to continue as a going concern. Based on the Company&#146;s current
cash position and current financial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements&nbsp;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
position as of the date of the financial statements, there is a substantial doubt about the Company&#146;s ability to continue as a going concern. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Summary of Significant Accounting Policies </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of
America, or GAAP, and stated in U.S. dollars. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification and Accounting Standards Updates, or ASUs, of the
Financial Accounting Standards Board, or FASB. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting periods. Actual results could differ from those estimates. On an
ongoing basis, the Company evaluates its estimates, including those related to accrued research and development expenses, other long-lived assets, the fair values of the Company&#146;s preferred stock tranche obligation, or Preferred Stock Tranche
Obligation, common stock, stock-based compensation and the valuation of deferred tax assets. The Company bases its estimates using historical experience, Company forecasts and future plans, current economic conditions, and information from
third-party professionals that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities and recorded amounts of expenses that are not
readily apparent from other sources and adjusts those estimates and assumptions when facts and circumstances dictate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
utilizes estimates and assumptions in determining the fair value of its common stock, including stock-based awards. The Company has granted stock options at exercise prices that represented the fair value of its common stock on the specific grant
dates. The Company utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, <I>Valuation of Privately Held Company Equity Securities Issued as
Compensation</I>, or AICPA TPA, to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company&#146;s judgment. These estimates and assumptions include a number of objective and
subjective factors, including external market conditions, the prices at which the Company sold shares of convertible preferred stock, the superior rights and preferences of the convertible preferred stock senior to the Company&#146;s common stock at
the time, and a probability analysis of various liquidity events, such as a public offering or sale of the Company, under differing scenarios. Changes to the key assumptions used in the valuations could result in different fair values of common
stock at each valuation date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s results can also be affected by economic, political, legislative, regulatory and legal
actions. Economic conditions, such as recessionary trends, inflation, interest, changes in regulatory laws and monetary exchange rates, and government fiscal policies, can have a significant effect on operations. While the Company maintains reserves
for anticipated liabilities, the Company could be affected by civil, criminal, regulatory or administrative actions, claims or proceedings. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash Equivalents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash
equivalents. Cash and cash equivalents are stated at fair value and may include </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements&nbsp;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
money market funds, U.S. Treasury and U.S. government-sponsored agency securities, corporate debt, commercial paper and certificates of deposit. The Company&#146;s cash equivalents at
December&nbsp;31, 2019 and 2018 consist of money market fund investments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Investments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company invests its excess cash balances in marketable government agency bonds, corporate debt securities and commercial paper. The Company
classifies its investments as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> and report <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT>
investments at fair value at each balance sheet date and include any unrealized holding gains and losses (the adjustment to fair value) in accumulated other comprehensive loss, a component of stockholders&#146; deficit. Realized gains and losses are
determined using the specific-identification method, and are included in other expense, net in the statements of operations. Should any adjustment to fair value reflect a decline in the value of the investment, the Company considers all available
evidence to evaluate the extent to which the decline is &#147;other than temporary&#148; and, if so, recognizes the associated unrealized loss through a charge to the statements of operations. The Company did&nbsp;not record any impairment charges
related to its marketable securities during the&nbsp;years ended&nbsp;December&nbsp;31, 2019 and&nbsp;2018. The Company classifies its <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable
securities as current or <FONT STYLE="white-space:nowrap">non-current</FONT> based on each instrument&#146;s underlying effective maturity date and for which the Company has the intent and ability to hold the investment for a period of greater than
12 months. Marketable securities with maturities of less than 12&nbsp;months are classified as current and are included in investments in the balance sheets. Marketable securities with maturities greater than 12&nbsp;months for which the Company has
the intent and ability to hold the investment for greater than 12 months are classified as <FONT STYLE="white-space:nowrap">non-current</FONT> and are included in investments, <FONT STYLE="white-space:nowrap">non-current</FONT> in the balance
sheets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Concentrations of Credit Risk and <FONT STYLE="white-space:nowrap">Off-balance</FONT> Sheet Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> investment securities. The Company&#146;s investment policy includes guidelines regarding the quality of the financial institutions and financial
instruments and defines allowable investments that the Company believes minimizes the exposure to concentration of credit risk. The Company may invest in money market funds, U.S. Treasury securities, corporate debt, U.S. government-related agency
securities, commercial paper and certificates of deposit. At December&nbsp;31, 2019 and 2018, the Company&#146;s cash and cash equivalents are held in financial institutions that management believes are creditworthy. These deposits may exceed
federally insured limits The Company has not experienced any losses historically in these accounts and believes it in not exposed to significant credit risk in its cash and cash equivalents. The Company has no significant <FONT
STYLE="white-space:nowrap">off-balance</FONT> sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other hedging arrangements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Financial Instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment
associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market
for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The
authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 1&#151;Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements&nbsp;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 2&#151;Inputs (other than quoted prices included in Level&nbsp;1) that are either
directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level&nbsp;3&#151;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the
assets or liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the
market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&nbsp;3. A financial instrument&#146;s level
within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value instrument. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Deferred Offering Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly
<FONT STYLE="white-space:nowrap">associated&nbsp;with&nbsp;in-process&nbsp;equity</FONT> financings as deferred offering costs until such financings are consummated. Capitalized deferred offering costs are included in prepaid and other non-current
assets in the Company&#146;s balance sheet at December&nbsp;31, 2019. After consummation of the equity financing, these costs are recorded in stockholders&#146; deficit as a reduction
<FONT STYLE="white-space:nowrap">of&nbsp;additional&nbsp;paid-in&nbsp;capital&nbsp;generated</FONT> as a result of the offering. Should <FONT STYLE="white-space:nowrap">the&nbsp;in-process&nbsp;equity</FONT> financing be abandoned, the deferred
offering costs will be expensed immediately as a charge to operating expenses in the statements of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Property and
Equipment </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment are stated at cost, subject to adjustments for impairments, less accumulated depreciation and
amortization. Depreciation is calculated using the <FONT STYLE="white-space:nowrap">straight-line</FONT> method over the useful life of the asset as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Asset</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated useful life</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Manufacturing and laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Three&nbsp;to&nbsp;five&nbsp;years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer hardware</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Three to five years</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office furniture and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Three to five years</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Maintenance and repairs that do not improve or extend the life of the respective asset are expensed to
operations as incurred. Manufacturing and laboratory equipment received is classified as construction in progress until placed into service, at which time depreciation commences. Upon disposal of an asset, the related cost and accumulated
depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of
Long-lived Assets </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates whether current facts or circumstances indicate that the carrying values of its <FONT
STYLE="white-space:nowrap">long-lived</FONT> assets may not be recoverable. If such facts or circumstances are determined to exist, an estimate of the undiscounted future cash flows of these assets is compared to the carrying value the assets to
determine whether impairment exists. If the assets are determined to be impaired, the loss is measured based on the difference between the fair value and carrying value of the assets. No impairment losses were recorded during the years ended
December&nbsp;31, 2019 or 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements&nbsp;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development costs are expensed as incurred. The Company&#146;s research and development expenses consist primarily of costs
incurred for the development of its product candidates and include&nbsp;expenses incurred under agreements with contract manufacturing organizations, or CMOs, contract research organizations, or CROs, investigative sites and consultants to conduct
clinical trials and preclinical and <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies,&nbsp;costs to acquire, develop and manufacture supplies for clinical trials and other studies,&nbsp;salaries and related costs, including stock-based
compensation, depreciation and other allocated facility-related and overhead expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Research and Development Costs
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records accruals for estimated costs of preclinical and clinical studies and manufacturing development. A portion of
the Company&#146;s clinical and manufacturing development activities are conducted by third-party service providers, including CROs and CMOs. The financial terms of these contracts are subject to negotiation, which vary by contract and may result in
payments that do not match the periods over which materials or services are provided. The Company accrues the costs incurred under the agreements based on an estimate of actual work completed in accordance with the agreements. In the event the
Company makes advance payments for goods or services that will be used or rendered for future research and development activities, the payments are deferred and capitalized as a prepaid expense and recognized as expense as the goods are received or
the related services are rendered. Such payments are evaluated for current or long-term classification based on when they are expected to be realized. If the Company does not identify costs that have begun to be incurred or if the Company
underestimates or overestimates the level of services performed or the costs of these services, actual expenses could differ from the Company&#146;s estimates. To date, the Company has not experienced significant changes in its estimates of
preclinical studies, clinical trial and contract manufacturing accruals. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Patent Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Costs to secure and maintain patents covering the Company&#146;s technology and product candidates are expensed as incurred and are classified
as general and administrative expenses in the statements of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company classifies convertible preferred stock outside of stockholders&#146; deficit on its balance sheets as the requirements of
triggering a deemed liquidation event are not within the Company&#146;s control. In the event of a deemed liquidation event, the proceeds from the event are distributed in accordance with liquidation preferences (see Note&nbsp;8). The Company
adjusts the carrying value of the convertible preferred stock to their redemption values when it becomes probable a redemption event will occur. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Stock Tranche Obligation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Series C convertible preferred stock includes features the Company has determined are not clearly and closely related to the
equity host are therefore bifurcated and accounted for separately as freestanding derivative liability on the balance sheet at its estimated fair value. This derivative liability is a result of certain investors&#146; rights to purchase from the
Company, on the same terms as the Series C Preferred Stock Purchase Agreement executed in July 2019, additional shares of Series C convertible preferred stock in subsequent tranches based on the achievement of certain development milestones. At
initial recognition, the Company recorded this derivative as a liability on the balance sheets at its estimated fair value. The derivative is subject to remeasurement at each balance sheet date, with changes in fair value recognized in change in
fair value of Preferred Stock Tranche Obligation on the Company&#146;s statements of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements&nbsp;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Stock-based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense related to stock options and warrants granted to employees, directors and
<FONT STYLE="white-space:nowrap">non-employees</FONT> is recognized based on the <FONT STYLE="white-space:nowrap">grant-date</FONT> estimated fair values of the awards using the <FONT STYLE="white-space:nowrap">Black-Scholes</FONT> option pricing
model, or Black-Scholes. The value is recognized as expense ratably over the requisite service period, which is generally the vesting term of the award. The Company adjusts the expense for actual forfeitures as they occur. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The grant date fair value of the Company&#146;s common stock utilized in Black-Scholes is determined by the Company&#146;s board of directors
with the assistance of management. The grant date fair value of the Company&#146;s common stock is determined using valuation methodologies which utilizes certain assumptions including probability weighting of events, volatility, time to
liquidation, a risk-free interest rate and an assumption for a discount for lack of marketability. In determining the fair value of the Company&#146;s common stock, the methodologies used to estimate the enterprise value of the Company were
performed using methodologies, approaches, and assumptions consistent with the AICPA TPA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company uses the liability method to account for income taxes. Under this method, deferred tax assets and liabilities are determined based
on differences between the financial statement carrying amounts of existing assets and liabilities and their tax bases. Deferred tax assets and liabilities are measured using enacted tax rates applied to taxable income in the years in which those
temporary differences are expected to be recovered or settled. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company assesses the likelihood of deferred tax assets being realized. A valuation allowance is provided when it is more likely than not
that some portion or all of a deferred tax asset will not be realized. In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be
realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which the temporary differences representing net future deductible amounts become deductible. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company files U.S. federal and state income tax returns. The Company&#146;s tax positions are subject to audit. Financial statement
effects of uncertain tax positions are recognized when it is more likely than not, based on the technical merits of the position, that it will be sustained upon examination. The Company evaluates uncertain tax positions on a regular basis. The
evaluations are based on a number of factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of the audit, and effective settlement of audit issues. Interest and penalties
related to unrecognized tax benefits are included within the provision for income tax. To date, the Company has not been subject to any interest and penalties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss Per Share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company calculates basic and diluted net loss per share attributable to common stockholders in conformity with the <FONT
STYLE="white-space:nowrap">two-class</FONT> method required for participating securities. The Company considers its convertible preferred stock to be participating securities as, in the event a dividend is paid on common stock, the holders of
convertible preferred stock and unvested shares of common stock would be entitled to receive dividends on a basis consistent with the common stockholders. The net loss attributable to common stockholders is not allocated to the convertible preferred
stock as the holders of those securities do not have a contractual obligation to share in losses. Cumulative dividends on preferred stock are added to net loss to arrive at net loss available to common stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements&nbsp;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the <FONT STYLE="white-space:nowrap">two-class</FONT> method, basic net loss per share
attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period, without consideration of potential dilutive securities.
Diluted net loss per share is calculated by dividing net loss by the weighted average number of shares of common stock and potential dilutive common stock equivalents outstanding during the period if the effect is dilutive. Potentially dilutive
securities include warrants, stock options and convertible preferred stock. Upon achievement of certain development milestones, the calculation of diluted loss per share also requires that, to the extent issuance of additional shares from the
Preferred Stock Tranche Obligation&nbsp;is dilutive to loss per share for the period, adjustments to net loss used in the calculation are required to remove the change in fair value of the Preferred Stock Tranche Obligation for the period. Likewise,
adjustments to the denominator are required to reflect the related dilutive shares. In all periods presented, the Company&#146;s outstanding stock options, convertible preferred stock, common stock&nbsp;warrants and issuance of additional preferred
shares from the&nbsp;preferred stock tranche were excluded from the calculation of diluted net loss per share because their effects were antidilutive and the development milestones for the issuance of additional shares from the preferred stock
tranche were not achieved. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Pro Forma Net Loss Per Share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma basic and diluted net loss per share has been computed to give effect to the conversion of all outstanding convertible
preferred stock into 13,085,913&nbsp;shares of common stock immediately prior to the completion of the Company&#146;s planned initial public offering, or IPO. The unaudited pro forma net loss per share for the year ended December&nbsp;31, 2019, was
computed using the weighted-average number of shares of common stock outstanding, including the pro forma effect of the conversion of all outstanding shares of convertible preferred stock into shares of common stock, as if such conversion had
occurred at January&nbsp;1, 2019, or their issuance dates, if later. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Related Party Transactions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2019, the Company engaged a firm managed by the acting chief financial officer of the Company for professional services related to
accounting, finance and other administrative functions. For the year ended December&nbsp;31, 2019, the costs incurred under this arrangement totaled $468,000 which were recorded as general and administrative expense in the accompanying statement of
operations. As of December&nbsp;31, 2019, amounts owed under this arrangement totaled $104,000 are included in accounts payable in the accompanying balance sheet. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuance of Series C Preferred in 2019 (see Note 8) included 20,417,882 shares to and proceeds of $30.0&nbsp;million from certain
stockholders considered to be related parties. The issuance of Series B Preferred in 2018 included 41,097,259 shares to and proceeds of $40.7&nbsp;million from certain stockholders considered to be related parties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Segments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed
by the chief operating decision maker, or CODM, in deciding how to allocate resources to an individual segment and in assessing performance. The Company&#146;s CODM is its chief executive officer. The Company has determined it operates in one
segment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive Loss </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and
circumstances from <FONT STYLE="white-space:nowrap">non-owner</FONT> sources. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements&nbsp;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Emerging Growth Company Status </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS&nbsp;Act. Under the
JOBS&nbsp;Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS&nbsp;Act, until such time as those standards apply to private companies. The Company has elected to use
this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&nbsp;is no longer an emerging growth company or
(ii)&nbsp;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS&nbsp;Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting
pronouncements as of public company effective dates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Recently Adopted Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June&nbsp;2018, the FASB issued <FONT STYLE="white-space:nowrap">ASU&nbsp;2018-07,</FONT> <I>Compensation&#151;Stock Compensation (Topic
718): Improvements to Employee Share-based Payment Accounting.</I> ASU <FONT STYLE="white-space:nowrap">2018-07</FONT> aligns the measurement and classification guidance for share-based payments to nonemployees with the guidance under Topic 718 for
share-based payments to employees. Under ASU <FONT STYLE="white-space:nowrap">2018-07,</FONT> the measurement of equity-classified nonemployee awards is fixed at the grant date at the fair value of the award. ASU
<FONT STYLE="white-space:nowrap">2018-07</FONT> permits an entity to make an entity-wide policy election for all nonemployee awards to either (1)&nbsp;estimate forfeitures or (2)&nbsp;recognize forfeitures when they occur. Nonemployee awards that
contain a performance condition that affects the quantity or other terms of the award are measured based on the outcome that is probable. Under ASU <FONT STYLE="white-space:nowrap">2018-07,</FONT> nonpublic entities that measure liability-classified
employee awards using intrinsic value must also measure liability-classified nonemployee awards using intrinsic value. The Company early-adopted ASU <FONT STYLE="white-space:nowrap">2018-07</FONT> effective January&nbsp;1, 2019 with no material
impact on its financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Recently Issued Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-02,</FONT> <I>Leases (Topic 842)</I>, as amended, or ASU <FONT
STYLE="white-space:nowrap">2016-02,</FONT> with guidance regarding the accounting for and disclosure of leases. The update requires lessees to recognize the liabilities related all leases, including operating leases, with a term greater than 12
months on the balance sheet. This update also requires lessees and lessors to disclose key information about their leasing transactions. This guidance became effective for public companies for annual and interim periods beginning after
December&nbsp;15, 2018. For all other entities, including emerging growth companies, this standard is effective for annual reporting periods beginning after December&nbsp;15, 2020, and interim periods within annual periods beginning after
December&nbsp;15, 2021. Early adoption is permitted. The Company is currently assessing the potential impact of adopting ASU <FONT STYLE="white-space:nowrap">2016-02</FONT> on its financial statements and financial statement disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued Accounting Standards Update No. <FONT STYLE="white-space:nowrap">2016-13,</FONT><I>&nbsp;Financial
Instruments-Credit Losses: </I><I>Measurement of Credit Losses on Financial Instruments</I>. ASU <FONT STYLE="white-space:nowrap">2016-13</FONT> requires measurement and recognition of expected credit losses for financial assets. In April 2019, the
FASB issued clarification to ASU <FONT STYLE="white-space:nowrap">2016-13</FONT> within ASU <FONT STYLE="white-space:nowrap">2019-04,</FONT><I></I><I>&nbsp;Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815,
Derivatives and Hedging</I>,<I>&nbsp;and Topic 825, Financial Instruments</I>, or ASU <FONT STYLE="white-space:nowrap">2016-13.</FONT> The guidance will become effective as of January&nbsp;1, 2020, and must be adopted using a modified retrospective
approach, with certain exceptions. This guidance is effective for public business entities that meet the definition of a Securities and Exchange Commission filer, excluding eligible smaller reporting companies for fiscal years beginning after
December&nbsp;15, 2021. For all other entities, including emerging growth companies, it is effective for fiscal years beginning after December&nbsp;15, 2022. The Company is currently assessing the potential impact of adopting ASU <FONT
STYLE="white-space:nowrap">2016-13</FONT> on its financial statements and financial statement disclosures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements&nbsp;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2017, the FASB issued ASU <FONT STYLE="white-space:nowrap">2017-11,</FONT>
<I>Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for
Mandatorily Redeemable</I> <I>Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception</I>, or ASU <FONT STYLE="white-space:nowrap">2017-11</FONT><I>.</I> Part I of this
update addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on
the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair
value measurement of the entire instrument or conversion option. Part II of this update addresses the difficulty of navigating Topic 480, <I>Distinguishing Liabilities from Equity</I>, because of the existence of extensive pending content in the
FASB Accounting Standards Codification. This pending content is the result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable
noncontrolling interests. The amendments in Part II of this update do not have an accounting effect. For public business entities, the amendments in Part I of ASU <FONT STYLE="white-space:nowrap">2017-11</FONT> became effective for fiscal years and
interim periods within those years beginning after December&nbsp;15, 2018. For all other entities, the amendments in Part I of this update are effective for fiscal years beginning after December&nbsp;15, 2019, and interim periods within fiscal years
beginning after December&nbsp;15, 2020. Early adoption is permitted for all entities, including adoption in an interim period. The Company is currently assessing the potential impact of adopting ASU <FONT STYLE="white-space:nowrap">2017-11</FONT> on
its financial statements and financial statement disclosures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2018, the FASB issued ASU No.
<FONT STYLE="white-space:nowrap">2018-13,</FONT><I>&nbsp;Fair Value Measurement (Topic 820), Disclosure Framework&#151;Changes to the Disclosure Requirements for Fair Value Measurement</I>, or ASU
<FONT STYLE="white-space:nowrap">2018-13</FONT><I>.</I><I></I>&nbsp;This ASU removed the following disclosure requirements: (1)&nbsp;the amount of and reasons for transfers between Level&nbsp;1 and Level&nbsp;2 of the fair value hierarchy;
(2)&nbsp;the policy for timing of transfers between levels; and (3)&nbsp;the valuation processes for Level&nbsp;3 fair value measurements. Additionally, this update added the following disclosure requirements: (1)&nbsp;the changes in unrealized
gains and losses for the period included in other comprehensive income and loss for recurring Level&nbsp;3 fair value measurements held at the end of the reporting period; (2)&nbsp;the range and weighted average of significant unobservable inputs
used to develop Level&nbsp;3 fair value measurements. For certain unobservable inputs, an entity may disclose other quantitative information (such as the median or arithmetic average) in lieu of the weighted average if the entity determines that
other quantitative information would be a more reasonable and rational method to reflect the distribution of unobservable inputs used to develop Level&nbsp;3 fair value measurements. ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-13</FONT> will
be effective for fiscal years beginning after December&nbsp;15, 2019 with early adoption permitted. As of December&nbsp;31, 2019, the Company has not elected to early adopt this guidance but does not expect that the adoption of ASU <FONT
STYLE="white-space:nowrap">2018-13</FONT> will have a material effect on its financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2019, the FASB issued ASU <FONT
STYLE="white-space:nowrap">2019-12,</FONT> <I>Simplifying the Accounting for Income Taxes</I>, or ASU <FONT STYLE="white-space:nowrap">2019-12.</FONT> ASU <FONT STYLE="white-space:nowrap">2019-12</FONT> eliminates certain exceptions related to the
approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other aspects of the
accounting for income taxes. This guidance is effective for public business entities for fiscal years beginning after December&nbsp;15, 2020, and interim periods within those fiscal years. For all other entities, including emerging growth companies,
it is effective for fiscal years beginning after December&nbsp;15, 2021, and interim periods within fiscal years beginning after December&nbsp;15, 2022. Early adoption is permitted. The Company is currently evaluating the impact adoption of ASU <FONT
STYLE="white-space:nowrap">2019-12</FONT> will have on the financial statements and disclosures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements&nbsp;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Fair Value Measurements </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables present information about the Company&#146;s financial assets and liabilities measured at fair value on a recurring basis
and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government agency bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock tranche obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables present information as to cost, unrealized holding gains and losses and fair value
determination of the company&#146;s financial assets measured at fair value on a recurring basis (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized<BR>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized<BR>Gains</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized<BR>Losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated<BR>Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government agency bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements&nbsp;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized<BR>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized<BR>Gains</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized<BR>Losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated<BR>Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Money market funds are highly liquid investments and are actively traded. The pricing information on the
Company&#146;s money market funds are based on quoted prices in active markets for identical securities. This approach results in the classification of these securities as Level&nbsp;1 of the fair value hierarchy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of short-term investments is determined from market pricing and other observable market inputs for similar securities obtained
from various third-party data providers. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate
fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads; benchmark securities; prepayment/default projections based on historical data; and other observable inputs. This
approach results in the classification of these securities as Level&nbsp;2 of the fair value hierarchy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Preferred
Stock Tranche Obligation is measured at fair value using an option pricing valuation methodology. The fair value of Preferred Stock Tranche Obligation includes inputs not observable in the market and thus represents a Level&nbsp;3 measurement. The
option pricing valuation methodology utilized requires inputs based on certain subjective assumptions, including (a)&nbsp;expected stock price volatility, (b)&nbsp;calculation of an expected term, (c)&nbsp;a risk-free interest rate, and
(d)&nbsp;expected dividends. The assumptions utilized to value the Preferred Stock Tranche Obligation as of December&nbsp;31, 2019 were (a)&nbsp;expected stock price volatility of 30%; (b) expected term of 0.7 years; (c)&nbsp;a risk-free interest
rate of 1.6%; and (d)&nbsp;an expectation of no dividends. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides a reconciliation of assets and liabilities
measured at fair value on a recurring basis using significant unobservable inputs (Level 3) (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="93%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were no transfers among Level&nbsp;1, Level&nbsp;2 or Level&nbsp;3 categories in the years ended
December&nbsp;31, 2019 or 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements&nbsp;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Property and Equipment, net </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment, net, consist of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Manufacturing and laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer hardware</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office furniture and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Construction in progress</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property and equipment, at cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(739</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(443</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation expense for the years ended December&nbsp;31, 2019 and 2018 was $303,000 and $175,000,
respectively. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Prepaid Expenses and Other <FONT STYLE="white-space:nowrap">Non-current</FONT> Assets
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other <FONT STYLE="white-space:nowrap">non-current</FONT> assets consist of the following (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid clinical and research expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total prepaid expenses and other <FONT STYLE="white-space:nowrap">non-current</FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other Current Liabilities </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other current liabilities consist of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Salaries and benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Commitments and Contingencies </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Operating Lease Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company leases facilities in Redwood City, California under an operating lease through August 2021 and in Baltimore, Maryland under an
operating lease through June 2023. Rent expense for the years ended </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements&nbsp;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
December&nbsp;31, 2019 and 2018 was $696,000 and $682,000, respectively. Future minimum lease payments under the Company&#146;s non&#150;cancelable operating leases as of December&nbsp;31, 2019
were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total future minimum lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>License Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Johns Hopkins University </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2011, the Company entered into an Exclusive License Agreement with Johns Hopkins University, or JHU, which has been amended from time
to time, such agreement as amended is referred to as the JHU Agreement. Pursuant to the JHU Agreement, JHU granted the Company an exclusive, worldwide, sublicensable license to three patent families to research, develop, make, use and sell products
and provide services in any field, and a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license to use specified <FONT STYLE="white-space:nowrap">know-how</FONT> and materials with a provision that JHU will not grant a license to know how and
materials to any other commercial entity. The JHU first patent family describes microparticles with a hydrophobic polymeric core (such as PLGA or PLA or a combination of both PLGA and PLA) and a hydrophilic coating (such as PLGA permanently linked
to polyethylene glycol) to reduce inflammation for intraocular injections and their methods of use, which technology is incorporated into the Company&#146;s <FONT STYLE="white-space:nowrap">GB-102,</FONT>
<FONT STYLE="white-space:nowrap">GB-103</FONT> and <FONT STYLE="white-space:nowrap">GB-401</FONT> product candidates. The JHU licensed fourth and fifth patent families cover potential future technologies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2015, the JHU Agreement was amended to include the JHU second patent family which covers sunitinib-encapsulated polymeric
microparticles, including <FONT STYLE="white-space:nowrap">GB-102</FONT> and <FONT STYLE="white-space:nowrap">GB-103,</FONT> and their use as therapeutic compositions to treat disorders of the eye. Under the terms of the amended JHU Agreement, the
Company paid a <FONT STYLE="white-space:nowrap">one-time,</FONT> <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront fee, with a remaining amount to be paid upon the occurrence of certain events. The Company also agreed to pay an
additional <FONT STYLE="white-space:nowrap">one-time,</FONT> <FONT STYLE="white-space:nowrap">non-refundable</FONT> fee of $100,000 on the occurrence of the first commercial sale of a product falling under the claims of a patent in the second patent
family. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2016, the JHU Agreement was further amended to include a third patent family which discloses a method for reducing
neuronal damage in the eye that includes administration of a sustained release formulation of a dual leucine kinase inhibitor in a polymeric particle, and wherein the dual leucine kinase inhibitor may be sunitinib, and thus is relevant to both the
Company&#146;s <FONT STYLE="white-space:nowrap">GB-102</FONT> and <FONT STYLE="white-space:nowrap">GB-103</FONT> product candidates. Under the terms of the amended JHU Agreement, the Company paid a <FONT STYLE="white-space:nowrap">one-time,</FONT> <FONT
STYLE="white-space:nowrap">non-refundable</FONT> upfront fee, and a milestone payment for the grant of the first patent. The Company also agreed to use its best efforts to develop a licensed product under the third patent family and enter into a
Phase I clinical trial on or before April 2019, and to have cumulatively spent several million dollars on research and development within six years of execution of the amendment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon execution of the JHU Agreement in 2011, the Company paid JHU an upfront license fee in the low tens of thousands of dollars and issued to
JHU a low single digit percentage of the Company&#146;s equity interests as of such date. The Company also reimbursed JHU for the prosecution and maintenance costs incurred by JHU for the licensed patent rights prior to the Company entering into the
JHU Agreement, and the Company is responsible for all of the ongoing costs relating to the prosecution and maintenance of the JHU patent rights licensed to the Company. The Company also agreed to pay minimum annual royalties in the tens of thousands
of dollars per year until the first commercial sale of a licensed product or service. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements&nbsp;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The JHU Agreement further requires single-digit running royalties on the Company&#146;s
annual net sales, which may be reduced by 50% of any payments the Company makes to third parties for freedom to operate, up to a maximum credit of 50% of the running royalty rate otherwise due to JHU. Royalties must be paid on products that fall
within a patent claim of an issued and unexpired patent or a pending patent application that has not been finally rejected or is pending for less than seven years. The Company also must pay developmental milestones for achieving certain clinical
progression events, ranging from tens of thousands to hundreds of thousand dollars per event, which in the aggregate, total less than $2.0&nbsp;million per product. Under the JHU Agreement, prior to the Kala Agreement renegotiation described below,
the Company was responsible for paying each developmental milestone payment for the first three products to achieve such milestone, and milestones for the second and third products are reduced by 50%. The Company further agreed to pay a percentage
of any sublicense consideration the Company receives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The JHU Agreement will remain effective until (i)&nbsp;the later of the expiration
date of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> patents covered under the JHU Agreement or 20 years from the effective date; (ii)&nbsp;the termination by either party upon the bankruptcy or
uncured breach of the other party, or (iii)&nbsp;if the Company terminates the JHU Agreement, with a <FONT STYLE="white-space:nowrap">90-day</FONT> notification period. The Company may terminate the entire agreement or on a patent by patent basis if
desired, subject to the <FONT STYLE="white-space:nowrap">90-day</FONT> notification period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Milestone and royalty expenses under the JHU
Agreement are classified as research and development expense and reimbursement of patent-related expenditures are classified as general and administrative expense in the statements of operations. Expense under the JHU Agreement is as follows (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total JHU Agreement expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Kala Pharmaceuticals, Inc. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A dispute arose between the Company, JHU, and Kala Pharmaceuticals, Inc., or Kala, over rights licensed to the Company and Kala by JHU. In
October 2014, the Company entered into a Settlement and License Agreement, or the Kala Agreement, with Kala and JHU, which settled all pending disputes and amended the Company&#146;s and Kala&#146;s existing license agreements with JHU and created
new rights and obligations among the parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Kala Agreement, each of Kala and the Company provided the other with a
royalty-free, exclusive sublicense with respect to certain intellectual property rights granted by JHU in limited fields of use. Specifically, the Company provided Kala with an exclusive sublicense for the use of a particle with specific
characteristics for delivery of a biologically active material through mucus, mucin, or a mucosal barrier (provided that such delivery does not involve administration via injection to the eye), or the Kala Field of Use, and Kala provided the Company
with an exclusive sublicense to the use of a particle with specific characteristics for delivery of a biologically active material to the eye via injection (excluding such use of any particle comprising or consisting of loteprednol etabonate). Kala
also agreed not to use a particle with those specific characteristics that include sunitinib in any technology licensed the Kala Field of Use under the license from the Company or JHU. Neither the Company nor Kala owe JHU any payments under its
existing JHU agreement with respect to the sublicenses granted to the other. Both the Company and Kala hold rights to sublicense the Company&#146;s respective rights in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements&nbsp;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
connection with a future collaboration arrangement and subject to any such sublicensee being bound by the applicable terms of the Kala Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Kala Agreement, JHU agreed to a number of financial concessions to both the Company and Kala. The payments under the existing JHU
agreements were modified by reducing all milestones and minimum annual royalties by 25%, including the development milestone payments due for the first licensed product; the development milestone payments due for the first license product were each
extended by one year; development milestone payments for the second and third licensed products were eliminated; and the commercial milestone payments for the first commercial sale of a licensed product were reduced by 50% in the United States. New
sales-based milestones were added for the second and third licensed products. Upon the second licensed product under the JHU Agreement reaching a certain level of sales or receiving sublicense royalty income, the Company is required to pay $100,000
plus the amounts of the eliminated development milestones and reduced first commercial sale milestone. For the third licensed product, on reaching the same level of sales or receiving sublicense royalty income, the Company is required to pay
$150,000 plus the amounts of the eliminated development milestones and reduced first commercial sale milestone. In addition, the Company, Kala and JHU released each other from any liability or claims known to Kala and the Company as of the Kala
Agreement and arising out of the actions leading to, and related to the subject of, the Kala Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Kala Agreement will expire
upon the expiration of all the patent rights that are the subject of the agreement. The Company may terminate one or more of the licenses or sublicenses granted to the Company in the Kala Agreement on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis for convenience upon 30 days&#146; prior written notice to Kala. The Company or Kala may terminate one or more the sublicenses granted to the other party under the JHU patent rights
if the other party, or its employees, officers, directors, agents or representatives, takes certain steps to oppose, attempt to invalidate or prevent the issuance of any of the patent rights directly licensed to the terminating party by JHU. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been no expenses under the Kala Agreement in the years ended December&nbsp;31, 2019 or 2018 and no amounts payable at
December&nbsp;31, 2019 or 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>AffaMed Project Limited </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2019, the Company entered into a letter agreement with AffaMed Project Limited, or AffaMed, in connection with their purchase of the
Company&#146;s Series C convertible preferred stock, or the AffaMed Letter. Under the AffaMed Letter, the Company granted AffaMed a right of first negotiation, or the Option, to exclusively develop, register, and commercialize <FONT
STYLE="white-space:nowrap">GB-102</FONT> solely in the territories of China, Hong Kong, Taiwan, Macau and South Korea. The Option expires upon the earlier of (i)&nbsp;July&nbsp;31, 2021 and (ii) 60 days after the Company provides top line data from
the Phase 2b trial for <FONT STYLE="white-space:nowrap">GB-102.</FONT> If AffaMed does not exercise the Option, the Company will have no further obligation to AffaMed to license rights to <FONT STYLE="white-space:nowrap">GB-102.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The AffaMed Letter provides AffaMed with an initial <FONT STYLE="white-space:nowrap">30-day</FONT> period to propose terms for such a license
which, if such terms are approved by a majority of the Company&#146;s board of directors (excluding the director appointed by AffaMed), shall lead to a <FONT STYLE="white-space:nowrap">60-day</FONT> exclusive negotiation period. During this period
of up to 90 days, the Company is prohibited from soliciting, initiating, encouraging or assisting the submission of any other proposal, negotiation or offer for the development, registration and commercialization<STRIKE>,</STRIKE> of <FONT
STYLE="white-space:nowrap">GB-102</FONT> in China, Hong Kong, Taiwan, Macau or South Korea. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may enter into a license
agreement for such services with AffaMed if approved by a majority of the members of the Company&#146;s board of directors, excluding the director appointed by AffaMed, during the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements&nbsp;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exclusive negotiation period. If the Company&#146;s board of directors does not approve AffaMed&#146;s proposed terms under the Option following good faith negotiations and, following a further
10 business day period of discussion if requested by AffaMed, the Company has the right to enter into an alternative license agreement with any third party for such services. If AffaMed does not exercise its Option, the Company has the right to
enter into an alternative license agreement with a different party. The AffaMed Letter does not limit the Company&#146;s ability to develop, register and commercialize <FONT STYLE="white-space:nowrap">GB-102</FONT> in territories other than China,
Hong Kong, Taiwan, Macau and South Korea. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been no expenses under the Affamed Letter in the years ended December&nbsp;31, 2019
or 2018 and no amounts payable at December&nbsp;31, 2019 or 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Indemnification </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company, as permitted under Delaware law and in accordance with its certification of incorporation and bylaws and pursuant to
indemnification agreements with certain of its officers and directors, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, which the officer or director is or was serving at the Company&#146;s request
in such capacity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company enters into certain types of contracts that contingently requires the Company to indemnify various parties
against claims from third parties. These contracts primarily relate to (i)&nbsp;the Company&#146;s bylaws, under which the Company must indemnify directors and executive officers, and may indemnify other officers and employees, for liabilities
arising out of their relationship, (ii)&nbsp;contracts under which the Company must indemnify directors and certain officers and consultants for liabilities arising out of their relationship, and (iii)&nbsp;procurement, service or license agreements
under which the Company may be required to indemnify vendors, service providers or licensees for certain claims, including claims that may be brought against them arising from the Company&#146;s acts or omissions with respect to the Company&#146;s
products, technology, intellectual property or services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, the Company may receive indemnification claims under these
contracts in the normal course of business. In the event that one or more of these matters were to result in a claim against the Company, an adverse outcome, including a judgment or settlement, may cause a material adverse effect on the
Company&#146;s future business, operating results or financial condition. It is not possible to determine the maximum potential amount potentially payable under these contracts since the Company has no history of prior indemnification claims and the
unique facts and circumstances involved in each particular claim will be determinative. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Convertible Preferred Stock </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019, the Company had 142,150,096 shares of $0.0001 par value convertible preferred stock, or Convertible Preferred
Stock, authorized, of which 2,280,000&nbsp;shares are designated as Series A convertible preferred stock, or Series A Preferred; 2,018,561&nbsp;shares are designated as <FONT STYLE="white-space:nowrap">Series&nbsp;A-2</FONT> convertible preferred
stock, or Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred; 76,078,535 shares are designated as Series&nbsp;B convertible preferred stock, or Series B Preferred; and 61,773,000 are designated Series C convertible preferred stock, or
Series C Preferred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements&nbsp;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes outstanding Convertible Preferred Stock (in thousands, except
share and per share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A</B><br><B>Preferred</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series <FONT STYLE="white-space:nowrap">A-2</FONT><BR>Preferred</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B</B><br><B>Preferred</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series C</B><br><B>Preferred</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total Convertible</B><br><B>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance&#151;December 31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,280,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,018,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,697,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,995,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,381,433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,381,433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(105</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(105</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance&#151;December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,280,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,018,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,078,535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,377,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,432,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,432,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Allocation of proceeds to preferred stock tranche obligation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,230</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,230</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance&#151;December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,280,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,018,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,078,535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">74,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,432,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">52,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117,809,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">131,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Original issue price per share</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.4693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Liquidation value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">87,729</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">56,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">148,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2019, the Company authorized the sale of up to 61,773,000 shares of its Series C Preferred at a price
of $1.4693 per share, or Series C Financing. In initial closings in July and August 2019, the Company issued 37,432,787 shares of Series C Preferred for aggregate gross proceeds of $55.0&nbsp;million. The Series C Financing further allowed certain
purchasers of Series C Preferred the option, or the Preferred Stock Tranche Obligation, to purchase up to an additional 17,014,902 shares of Series C Preferred at a price per share of $1.4693 for a period of up to 30&nbsp;days after the Company
notifies them of the three month readout from the Phase&nbsp;2a clinical trial of <FONT STYLE="white-space:nowrap">GB-102</FONT> in patients with macular edema secondary to diabetic macular edema and retinal vein occlusion, for potential aggregate
gross proceeds of up to $25.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company concluded that the Preferred Stock Tranche Obligation met the definition of a
freestanding financial instrument, as they were legally detachable and separately exercisable from the Series&nbsp;C Preferred. Therefore, the Company allocated the proceeds received from the issuance of shares under the Series C Preferred Stock
Purchase Agreement between the Preferred Stock Tranche Obligation and the Series C Preferred.&nbsp;The fair value of the Preferred Stock Tranche Obligation of $2.2&nbsp;million on issuance was allocated from the $55.0&nbsp;million proceeds of the
Series C Preferred financing and is classified as a current liability on the balance sheet as of December&nbsp;31, 2019 as the Series C Preferred would become redeemable upon a deemed liquidation event, the occurrence of which is not within the
Company&#146;s control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rights and preferences and privileges of Convertible Preferred Stock are described below: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dividend Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of Series C Preferred, in preference to holders of Series&nbsp;B Preferred, Series <FONT STYLE="white-space:nowrap">A-2</FONT>
Preferred, Series A Preferred and common stock, are entitled to receive cumulative dividends on each outstanding share payable when declared by the board of directors of $0.117544 per share. After payment of such dividends on the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements&nbsp;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Series C Preferred, the holders of Series B Preferred, in preference to holders of <FONT STYLE="white-space:nowrap">Series&nbsp;A-2</FONT> Preferred, Series&nbsp;A Preferred and common stock, are
entitled to receive cumulative dividends on each outstanding share payable when declared by the board of directors of $0.06937 per share. After payment of such dividends on the Series&nbsp;B Preferred, the holders of Series <FONT
STYLE="white-space:nowrap">A-2</FONT> Preferred, in preference to the holders of Series A Preferred and common stock, are entitled to receive <FONT STYLE="white-space:nowrap">non-cumulative</FONT> dividends on each outstanding share payable when
declared by the board of directors of $0.06034 per share. After payment of such dividends on the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred, the holders of Series A Preferred, in preference to the holders of common stock, are
entitled to receive <FONT STYLE="white-space:nowrap">non-cumulative</FONT> dividends on each outstanding share payable when declared by the board of directors of $0.08 per share. The board of directors has not declared any dividends <FONT
STYLE="white-space:nowrap">to-date.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Conversion Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of Convertible Preferred Stock is convertible at the option of the holder, at any time after the date of issuance, into a fully paid
and <FONT STYLE="white-space:nowrap">non-assessable</FONT> share of common stock. Each share of Convertible Preferred Stock is convertible into that number of common shares as is determined by dividing the applicable original purchase price of such
share by the applicable conversion price. The conversion rate is subject to adjustment upon the occurrence of certain events. The conversion rates for the Series C Preferred, Series B Preferred and Series <FONT STYLE="white-space:nowrap">A-2</FONT>
Preferred is 9.0058:1 and for the Series A Preferred is 8.8527:1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All shares of the Convertible Preferred Stock automatically convert
upon the closing of a firm commitment underwritten initial public offering of common stock, in which the price per share is at least $14.56 per share, subject to adjustment, resulting in gross proceeds of at least $40.0&nbsp;million. The conversion
price for each series of Convertible Preferred Stock is subject to adjustment in the event of stock split, combination, common stock dividend or distribution, reclassification, exchange, substitution, reorganization, and certain antidilution
adjustments. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of any liquidation, dissolution, or winding up of the Company or a deemed liquidation event, the holders of Series C Preferred are
entitled to receive, prior to any distribution made to any other class of security, an amount equal to $1.4693 per share, plus any dividends accrued and declared but unpaid. Upon distribution to holders of Series C Preferred, the holders of Series B
Preferred are entitled to receive, prior to distribution to holders of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred, Series A Preferred and common stock, an amount equal to $0.991 per share, plus any dividends accrued and declared
but unpaid. Upon distribution to holders of Series C Preferred and Series B Preferred, the holders of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred are entitled to receive, prior to distribution to holders of Series A Preferred and
common stock, an amount equal to $0.862 per share, plus any dividends declared but unpaid. Upon distributions to the holders of Series C Preferred, Series B Preferred and Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred, the holders of
Series A Preferred are entitled to receive, prior to any distribution or payment to the holders of common stock, an amount equal to $1.00 per share, plus any dividends declared but unpaid. Upon the completion of the distribution to the holders of
Series C Preferred, Series B Preferred, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred and Series A Preferred, any remaining assets available for distribution will be distributed among the holders of the shares of Series C Preferred,
Series B Preferred, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred, Series A Preferred and common stock, on a pro rata basis on the number of shares held by each such holder, treating each share as if they had been converted to common
stock immediately prior to such liquidation, dissolution or winding up of the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of Series A Preferred has voting rights equal to the number of common shares into which the Series A Preferred can be converted.
Shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred, Series B Preferred and Series C Preferred do not have voting rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements&nbsp;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of Series C Preferred are entitled to elect one director of the Company; the
holders of Series B Preferred are entitled to elect three directors of the Company; the holders of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred, are entitled to elect one director; the holders of common stock are entitled to elect
one director; and holders of common stock and any other class or series of voting stock, exclusively and voting together as a single class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, are entitled to elect one director. Holders
of Series A Preferred are not entitled to a director of the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Redemption Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares of Series C Preferred, Series B Preferred and Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred may be redeemed at the
greater of the fair market value or the original issue price for the applicable series of convertible preferred stock plus any dividends accrued but unpaid with respect to the Series C Preferred and the Series B Preferred and any dividend declared
by unpaid with respect to the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred. A redemption will occur upon a written request from the holders of a majority of the then outstanding shares of Series C Preferred, voting exclusively as a
separate series, and the holders of a majority of the Series B Preferred and Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred, voting together on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, which request can be made at
any time after July 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cumulative dividends and accretion of discount on Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred,
Series B Preferred and Series C Preferred, together the Contingently Redeemable Preferred, is not recorded until the Contingently Redeemable Preferred is probable of becoming redeemable. As of December&nbsp;31, 2019, the Company has determined that
the Contingently Redeemable Preferred are not currently probable of becoming redeemable and, as such, the cumulative dividend and accretion of discount on the Contingently Redeemable Preferred has not been recorded. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Common Stock </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of common stock are entitled to dividends when and if declared by the board of directors, subject to the preferences applicable to
outstanding shares of Convertible Preferred Stock. The board of directors has not declared any dividends and the Company has not paid any dividends. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of common stock are entitled to one vote per share on all matters to be voted upon by the stockholders. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Stock-based Compensation </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2015 Stock Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February&nbsp;2015, the Company adopted the 2015 Stock Incentive Plan, or 2015 Plan. Under the terms of the 2015 Plan, the Company may issue
stock options, restricted stock and other stock awards, to employees, <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, and consultants. As of December&nbsp;31, 2019, there were 2,891,777&nbsp;shares of common stock reserved for future
issuance under the 2015 Plan. Awards granted under the 2015 Plan expire no later than&nbsp;10&nbsp;years from the date of grant. For incentive stock options and <FONT STYLE="white-space:nowrap">non-statutory</FONT> stock options, the option exercise
price will not be less than&nbsp;100%&nbsp;of the estimated fair value on the date of grant. Options granted to employees typically vest over a&nbsp;four-year period but may be granted with different vesting terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019, 608,290&nbsp;shares remained available for grant under the 2015 Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements&nbsp;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Stock Option Activity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summarizes stock option activity: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of</B><br><B>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average</B><br><B>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average</B><br><B>Remaining</B><br><B>Contractual</B><br><B>Term<BR>(years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate</B><br><B>Intrinsic</B><br><B>Value</B><br><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding&#151;December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,189,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,254,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(78,609</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(248,055</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding&#151;December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,117,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and expected to vest&#151;December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,117,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options Exercisable&#151;December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">740,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate intrinsic value of options granted is calculated as the difference between the exercise
price of the options and the estimated fair value of the Company&#146;s common stock. The aggregate intrinsic value of options exercised in the years ended December&nbsp;31, 2019 and 2018 was $157,000 and $61,000, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate fair value of options that vested during the year ended December&nbsp;31, 2019 was $659,000. The weighted average grant date
fair value of options that vested during the year ended December&nbsp;31, 2019 was $1.44. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Stock Option Awards
</I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company estimates the fair value of stock option awards on the grant date using Black-Scholes. The weighted-average grant
date fair value per option granted to during the years ended December&nbsp;31, 2019 and 2018 was $2.16 and $1.53, respectively. The fair value of each award is estimated using Black-Scholes based on the following assumptions: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.1&nbsp;&#150;&nbsp;6.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.1&nbsp;&#150;&nbsp;6.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80%</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.8%&nbsp;&#150;&nbsp;2.5%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.6%&nbsp;&#150;&nbsp;3.1%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Black-Scholes requires the use of subjective assumptions which determine the fair value of stock-based awards.
These assumptions include: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Expected Term</I>: The Company&#146;s expected term represents the period that options are expected to be
outstanding and is determined using the simplified method, based on the <FONT STYLE="white-space:nowrap">mid-point</FONT> between the vesting date and the end of the contractual term as the Company does not have sufficient historical data to use any
other method to estimate expected term. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements&nbsp;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Expected Volatility</I>: The Company is a private company without any trading history in
its common stock. The expected volatility the Company uses in Black-Scholes is estimated based on the average volatility for comparable publicly-traded biopharmaceutical companies over a period equal to the expected term of the stock option grants.
The comparable companies are chosen based on their similarities to the Company, including life cycle stage, therapeutic focus and size. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Risk-free Interest Rate</I>. The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant
for periods corresponding with the expected term of the stock option grants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Expected Dividend</I>: The Company has never paid
dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Stock-based Compensation Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense is classified as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019, total unrecognized stock&#150;based compensation cost related to unvested stock
options was $2.7&nbsp;million. As of December&nbsp;31, 2019, the weighted&#150;average period over which such stock-based compensation was expected to be recognized was approximately 3.4 years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2019, the Company accelerated the vesting of 61,812 unvested stock options and extended the exercise
period related to the awards. The modification resulted in additional stock-based compensation of $128,000. During the year ended December&nbsp;31, 2018, the Company accelerated the vesting of 77,061 unvested stock options and extended the exercise
period related to the awards. The modification resulted in additional stock-based compensation of $70,000. </P>  <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Income Taxes </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has incurred net operating losses for all the periods presented. The Company has not reflected the benefit of any such net
operating loss carryforwards in the accompanying financial statements.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2017, the U.S. government signed into law the Tax Cuts
and Jobs Act, or Tax Act, that significantly reforms the Internal Revenue Code of 1986, as amended. The Tax Act, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top
marginal rate of 35% to a flat rate of 21%, effective as of January&nbsp;1, 2018; limitation of the tax deduction for interest expense; limitation of the deduction for net operating losses to 80% of annual taxable income and elimination of net
operating loss carrybacks, in each case, for losses arising in taxable years beginning after December&nbsp;31, 2017 (though any such tax losses may be carried forward indefinitely); and modifying or repealing many business deductions and credits,
including reducing the business tax credit for certain clinical testing expenses incurred in the testing of certain drugs for rare diseases or conditions generally referred to as orphan drugs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements&nbsp;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The effective tax rate for the years ended December&nbsp;31, 2019 and 2018 is different from
the federal statutory rate primarily due to the valuation allowance against deferred tax assets as a result of insufficient sources of income.&nbsp;The reconciliation of the federal statutory income tax rate to the Company&#146;s effective income
tax rate is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax benefit at the federal statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State income taxes, net of federal benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24.6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets
and liabilities for financial reporting purposes and the amounts used for income tax purposes. The principal components of the Company&#146;s deferred tax assets consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal and state net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,841</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,719</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has incurred annual net operating losses in each year since inception. The Company has not
reflected the benefit of any such net operating loss carryforwards in the financial statements. Due to the Company&#146;s history of losses, and lack of other positive evidence, the Company has determined that it is more likely than not that its net
deferred tax assets will not be realized, and therefore, the net deferred tax assets are fully offset by a valuation allowance at December&nbsp;31, 2019 and 2018. The Company increased its valuation allowance by $9.1&nbsp;million for the year ended
December&nbsp;31, 2019 in order to maintain a full valuation allowance against its deferred tax assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019, the
Company had federal net operating loss carryforwards, or NOLs, of $97.6&nbsp;million and federal tax credits of $4.5&nbsp;million available to offset tax liabilities. The Company&#146;s federal NOLs and federal tax credit carryforwards begin to
expire in 2035 and 2036, respectively. Of the federal NOLs, $63.5&nbsp;million have an infinite life. The Company also had gross state NOLs of $12.3&nbsp;million and state tax credits of $1.3&nbsp;million which are available to offset state tax
liabilities. The state NOLs begin to expire in 2036 and the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements&nbsp;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
state tax credit carryforwards can be carried forward indefinitely. Federal and state NOLs and tax credit carryforwards are also subject to annual limitations in the event that cumulative changes
in the ownership interests of significant stockholders exceed 50% over a three-year period, as defined under Sections 382 and 383 of the Internal Revenue Code of 1986. The Company has not completed an analysis to determine if the NOLs and tax
credits are limited due to a change in ownership. Should there be ownership changes that occurred, the Company&#146;s ability to utilize existing carryforwards could be substantially restricted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determines its uncertain tax positions based on whether and how much of a tax benefit taken by the Company in its tax filings is
more likely than not to be sustained upon examination by the relevant income tax authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A reconciliation of the unrecognized tax
benefit is as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance&#151;beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">873</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Addition based on tax position related to current year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Addition based on tax position related to prior year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance&#151;end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">873</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unrecognized tax benefits, if recognized, would not have an impact on the Company&#146;s effective tax
rate assuming the Company continues to maintain a full valuation allowance position. Based on prior year&#146;s operations and experience, the Company does not expect a significant change to its unrecognized tax benefits over the next twelve months.
The unrecognized tax benefits may increase or change during the next year for unexpected or unusual items for items that arise in the ordinary course of business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company files income tax returns in the U.S., California, Florida, Illinois, Indiana, Texas and Maryland. The Company is not currently
under examination by any taxing authority for any open tax year. Due to net operating loss carryforwards, all years remain open for income tax examination. To the extent the Company has tax attribute carryforwards, the tax years in which the
attribute was generated may still be adjusted upon examination by the Internal Revenue Service, or IRS, or state tax authorities to the extent utilized in a future period. No federal or state tax audits are currently in process. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Employee Retirement Plan </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company maintains a 401(k) retirement savings plan, or 401(k) Plan. The 401(k) Plan allows employees to make
<FONT STYLE="white-space:nowrap">pre-</FONT> and <FONT STYLE="white-space:nowrap">post-tax</FONT> contributions up to the maximum allowable by the IRS. The Company did not make any contributions to the 401(k) Plan on behalf of its employees in the
years ended December&nbsp;31, 2019 or 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements&nbsp;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Net Loss Per Common Share </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share attributable to common stockholders is calculated as follows (in thousands except share and per share
amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(37,037</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,378</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cumulative dividends on convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,055</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,317</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(44,092</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,695</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per common share&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(33.41</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25.77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of common shares used in computing net loss per share&#151;basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,319,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,268,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following outstanding potentially dilutive securities have been excluded from the calculation of
diluted net loss per common share, as their effect is anti-dilutive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117,809,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,377,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,117,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,189,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,759</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Series C Financing, up to 17,014,902 shares of convertible preferred stock may be contingently
issued upon achievement of certain development milestones. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Unaudited Pro Forma Net Loss per Common Share </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the computation of unaudited pro forma basic and diluted net loss per share attributable to common shareholders
for the year ended December&nbsp;31, 2019 was calculated as follows (in thousands except share and per share data): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Numerator</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(44,092</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cumulative dividends on convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(37,037</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Denominator</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used in computing net loss per common share&#151;basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,319,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma adjustment to reflect automatic conversion of convertible preferred stock to common
stock upon completion of the proposed initial public offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,682,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used in computing pro forma net loss per common share&#151;basic
and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,001,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per common share&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.09</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements&nbsp;(continued) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Subsequent Events </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated subsequent events through April&nbsp;21, 2020 (except for the impact of the reverse stock split as discussed in the
third paragraph of Note 1, as to which the date is September 18, 2020), the date these financial statements were issued, and has determined that there have been no events that have occurred that would require adjustments to the Company&#146;s
disclosures in the condensed financial statements. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Coronavirus Outbreak </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2020 the World Health Organization declared the global novel coronavirus disease 2019, or
<FONT STYLE="white-space:nowrap">COVID-19,</FONT> outbreak a pandemic. As of April&nbsp;21, 2020, the Company&#146;s operations have not been significantly impacted by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak. However, the
Company cannot at this time predict the specific extent, duration, or full impact that the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak will have on its financial condition and operations, including ongoing and planned clinical trials.
The impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak on the financial performance of the Company will depend on future developments, including the duration and spread of the outbreak and related governmental advisories and
restrictions. These developments and the impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> on the financial markets and the overall economy are highly uncertain and cannot be predicted. If the financial markets and/or the overall economy
are impacted for an extended period, the Company&#146;s results may be materially adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2020, the U.S. government
enacted the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, which includes modifications to the limitation on business interest expense and net operating loss provisions and provides a payment delay of employer payroll taxes during
2020 after the date of enactment. The Company does not expect the CARES Act to have a material impact on the Company&#146;s financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin796801_8"></A>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Balance Sheets </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,&nbsp;2020</B><br><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B><br><B>2019</B><br><B>(see Note&nbsp;1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro forma</B><br><B>June&nbsp;30,&nbsp;2020</B><br><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities, convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock tranche obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock, $0.0001 par value; 142,150,096 shares authorized at June&nbsp;30,
2020 and December&nbsp;31, 2019, actual; 117,809,883 shares issued and outstanding as of June&nbsp;30, 2020 and December&nbsp;31, 2019, actual; no shares authorized, issued or outstanding pro forma as of June&nbsp;30, 2020; aggregate liquidation
value of $153,385 as of June&nbsp;30, 2020 and December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value; 188,000,000 shares authorized at June&nbsp;30, 2020 and
December&nbsp;31, 2019, actual; 1,382,200 and 1,371,467 shares issued and outstanding as of June&nbsp;30, 2020 and December&nbsp;31, 2019, actual, respectively; 14,468,113 shares issued and outstanding, pro forma as of June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(119,499</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(105,836</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(119,499</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(116,157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102,954</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to the condensed financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin796801_9"></A>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Statements of Operations </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share amounts) </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,836</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,609</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of preferred stock tranche obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,663</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,558</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cumulative dividends on convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,793</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,585</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,456</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19,143</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per common share&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13.40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14.78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares outstanding used in computing net loss per common
share&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,377,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,295,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per common share&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.94</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of shares used in computing pro forma net loss per common share&#151;basic
and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,463,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to the condensed financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin796801_10"></A>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Statements of Comprehensive Loss </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,663</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,558</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in unrealized gains on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities, net of income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,666</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,558</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to the condensed financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin796801_11"></A>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Statements of Convertible Preferred Stock and Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share amounts) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Convertible</B><br><B>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">Paid-in</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Other</B><br><B>Comprehensive</B><br><B>Income</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>Stockholders&#146;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Amount&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance&#151;January&nbsp;1, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,377,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">78,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,292,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(68,799</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(66,792</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock issued on exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,558</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,558</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance&#151;June 30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,377,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">78,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,296,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(85,357</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(83,043</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance&#151;January&nbsp;1, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117,809,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">131,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,371,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(105,836</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(102,954</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock issued on exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,663</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,663</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Changes in unrealized gains on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities, net of income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance&#151;June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117,809,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">131,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,382,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(119,499</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(116,157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to the condensed financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin796801_12"></A>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Statements of Cash Flows </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,663</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,558</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of preferred stock tranche obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of premium and discounts on short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current and noncurrent assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,705</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,108</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,205</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(332</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,933</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,663</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(154</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(336</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Maturities of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(336</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,364</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,341</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,990</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents&#151;beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents&#151;end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,844</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Supplemental disclosure of noncash items</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment purchases included in accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs included in accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to the condensed financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin796801_13"></A>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Condensed Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Organization, Description of Business and Going Concern Considerations </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Graybug Vision, Inc., the Company or Graybug, is a clinical stage biopharmaceutical company developing medicines for the treatment of diseases
of the retina and optic nerve. The Company presently devotes substantially all of its resources to conducting research and development and raising capital. The Company was founded in May&nbsp;2011 and maintains facilities in Redwood City, California
and Baltimore, Maryland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to risks common to clinical stage companies in the biopharmaceutical industry, including
dependence on the clinical success of its product candidates, ability to obtain regulatory approvals of its product candidates, compliance with regulatory requirements, the need for substantial additional financing and protection of its proprietary
technology. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Reverse Stock Split </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September 18, 2020, the Company effected a 9.0058:1 reverse stock split of the Company&#146;s issued and outstanding common stock. Upon the
effectiveness of the reverse stock split, (i)&nbsp;all shares of outstanding common stock were adjusted; (ii)&nbsp;the conversion prices of the convertible preferred stock were adjusted; (iii)&nbsp;the number of shares of common stock for which each
outstanding option and warrant to purchase common stock is exercisable were adjusted; and (iv)&nbsp;the exercise price of each outstanding option and warrant to purchase common stock were adjusted. All of the outstanding common stock share numbers
(including shares of common stock subject to the Company&#146;s options and as converted for the outstanding convertible preferred stock), share prices, exercise prices and per share amounts contained in the financial statements have been
retroactively adjusted in the financial statements to reflect this reverse stock split for all periods presented. The par value per share and the authorized number of shares of common stock were not adjusted as a result of the reverse stock split.
</P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Going Concern Considerations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company incurred losses from operations and had negative cash flows from operating activities for the six months ended June&nbsp;30, 2020
and 2019, and the Company&#146;s accumulated deficit at June&nbsp;30, 2020 is $119.5&nbsp;million. The Company&#146;s current operating plan indicates it will continue to incur losses from operations and generate negative cash flows from operating
activities, given ongoing expenditures related to extensive research and development and the Company&#146;s lack of revenue generating activities at this point in the Company&#146;s lifecycle. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will need to raise additional funds in order to further advance its research and development programs, operate its business and
meet its obligations as they come due. The Company is pursuing financing alternatives, similar to what the Company has previously executed, which include equity financing. However, financing may not be available to the Company in the necessary time
frame, in the amounts that the Company requires, on terms that are acceptable to the Company, or at all. If the Company is unable to raise the necessary funds when needed or reduce spending on currently planned activities, it may not be able to
continue the development of its products or the Company could be required to delay, scale back, or eliminate some or all of its research and development programs and other operations and will materially harm its business, financial position and
results of operations. Based on the Company&#146;s current plans, it is anticipated that the existing cash will allow the Company to conduct planned operations into the fourth quarter of 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern and do not include
adjustments that might result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Company&#146;s assets and the satisfaction of liabilities in the normal course of business. The financial statements do not
include any adjustments relating to the recoverability and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Condensed Financial Statements&nbsp;(continued) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
classification of recorded asset amounts or amounts of liabilities that might be necessary should the Company be unable to continue as a going concern. Based on the Company&#146;s current cash
position and current financial position as of the date of the financial statements, there is a substantial doubt about the Company&#146;s ability to continue as a going concern. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Coronavirus Outbreak </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2020 the World Health Organization declared the global novel coronavirus disease 2019, or
<FONT STYLE="white-space:nowrap">COVID-19,</FONT> outbreak a pandemic. As of September&nbsp;4, 2020, the Company&#146;s operations have not been significantly impacted by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak. However, the
Company cannot at this time predict the specific extent, duration, or full impact that the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak will have on its financial condition and operations, including ongoing and planned clinical trials.
The impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> coronavirus outbreak on the financial performance of the Company will depend on future developments, including the duration and spread of the outbreak and related governmental
advisories and restrictions. These developments and the impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> on the financial markets and the overall economy are highly uncertain and cannot be predicted. If the financial markets and/or the
overall economy are impacted for an extended period, the Company&#146;s results may be materially adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2020, the
Families First Coronavirus Response Act, or FFCR Act, and the Coronavirus Aid, Relief and Economic Security Act, or CARES Act, were signed into law in response to the COVID-19 pandemic. The FFCR Act and CARES Act include provisions related to
refundable payroll tax credits, deferment of employer side social security payments, retroactively and temporarily (for taxable years beginning before January&nbsp;1, 2021) suspending the application of the 80%-of-income limitation on the use of net
operating losses, which was enacted as part of the Tax Cuts and Jobs Act of 2017. The CARES Act also provides that net operating losses arising in any taxable year beginning after December&nbsp;31, 2017, and before January&nbsp;1, 2021 are generally
eligible to be carried back up to five years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2020, Assembly Bill 85, or A.B. 85, was signed into California law. A.B.&nbsp;85
provides for a three-year suspension of the use of net operating losses for medium and large businesses and a three-year cap on the use of business incentive tax credits to offset no more than $5.0&nbsp;million of tax per year. A.B.&nbsp;85 suspends
the use of net operating losses for taxable years 2020, 2021 and 2022 for certain taxpayers with taxable income of $1.0 million or more. The carryover period for any net operating losses that are suspended under this provision will be extended.
A.B.&nbsp;85 also requires that business incentive tax credits including carryovers may not reduce the applicable tax by more than $5.0&nbsp;million for taxable years 2020, 2021 and 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The enactment of the FFCR Act, CARES Act and A.B.&nbsp;85 did not result in any material adjustments to the Company&#146;s income tax
provision for the six months ended June&nbsp;30, 2020 or to the Company&#146;s net deferred tax assets as of June&nbsp;30, 2020. Given the Company&#146;s history of losses, the Company does not expect the provisions of the FFCR Act, CARES Act and
A.B. 85 to have a material impact on the Company&#146;s annual effective tax rate or condensed consolidated financial statements in 2020; however, the Company will continue to evaluate the impact of tax legislation and will update its disclosures as
additional information and interpretive guidance becomes available. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Summary of Significant Accounting Policies </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than with respect to the adoption of ASU2018-13 discussed below, there have been no changes to the significant accounting policies as
disclosed in Note 2 to our annual financial statements for the years ended December&nbsp;31, 2019 and 2018 included elsewhere in this registration statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Condensed Financial Statements&nbsp;(continued) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2018, the FASB issued ASU No. 2018-13, <I>Fair Value Measurement
</I>(Topic&nbsp;820), Disclosure Framework&#151;Changes to the Disclosure Requirements for Fair Value Measurement, or ASU 2018-13. ASU&nbsp;2018-13 removed the following disclosure requirements: (1)&nbsp;the amount of and reasons for transfers
between Level&nbsp;1 and Level&nbsp;2 of the fair value hierarchy; (2)&nbsp;the policy for timing of transfers between levels; and (3)&nbsp;the valuation processes for Level&nbsp;3 fair value measurements. Additionally, this update added the
following disclosure requirements: (1)&nbsp;the changes in unrealized gains and losses for the period included in other comprehensive income and loss for recurring Level&nbsp;3 fair value measurements held at the end of the reporting period;
(2)&nbsp;the range and weighted average of significant unobservable inputs used to develop Level&nbsp;3 fair value measurements. For certain unobservable inputs, an entity may disclose other quantitative information (such as the median or arithmetic
average) in lieu of the weighted average if the entity determines that other quantitative information would be a more reasonable and rational method to reflect the distribution of unobservable inputs used to develop Level&nbsp;3 fair value
measurements. ASU 2018-13 became effective for the Company beginning January&nbsp;1, 2020 and the adoption of ASU 2018-13 did not have a material impact on the Company&#146;s condensed financial statements. For the disclosures regarding the
Company&#146;s Level&nbsp;3 fair value measurements, see Note&nbsp;3, Fair Value Measurements to these condensed financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Interim Condensed Financial Statements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s condensed financial statements included herein have been prepared in conformity with accounting principles generally
accepted in the United States and pursuant to the rules and regulations of the Securities and Exchange Commission. The unaudited interim condensed financial statements have been prepared on the same basis as the annual financial statements, and in
the Company&#146;s opinion, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of the financial position and results of operations for the reported interim
periods. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional
disclosure. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The interim condensed balance sheet as of June&nbsp;30, 2020, and the condensed statements of operations, comprehensive loss, convertible
preferred stock and stockholders&#146; deficit, and cash flows for the six months ended June&nbsp;30, 2020 and 2019 are unaudited. The financial data and the other financial information disclosed in these notes to the condensed financial statements
related to the <FONT STYLE="white-space:nowrap">six-month</FONT> periods are also unaudited. The condensed results of operations for the six months ended June&nbsp;30, 2020 are not necessarily indicative of the results to be expected for the year
ended December&nbsp;31, 2020 or for any other future annual or interim period. The balance sheet as of December&nbsp;31, 2019 included herein was derived from the audited financial statements as of that date. These interim condensed financial
statements should be read in conjunction with the Company&#146;s audited financial statements included elsewhere in this registration statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Pro Forma Financial Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed stockholders&#146; equity as of June&nbsp;30, 2020 and the unaudited pro forma basic and diluted net loss per
common share for the six months ended June&nbsp;30, 2020 have been prepared to give effect to the conversion of all outstanding shares of redeemable convertible preferred stock into 13,085,913 shares of common stock upon the closing of our initial
public offering, or IPO. The shares of common stock and any related estimated proceeds from the IPO are excluded from the pro forma information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma basic and diluted net loss per share for the six months ended June&nbsp;30, 2020 was computed using the
weighted-average number of shares of common stock outstanding, including the pro forma </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Condensed Financial Statements&nbsp;(continued) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
effect of the conversion of all outstanding shares of convertible preferred stock into shares of common stock, as if such conversion on IPO had occurred on January&nbsp;1, 2020, or their issuance
dates, if later. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Related Party Transactions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2019, the Company engaged a consulting firm managed by the acting chief financial officer of the Company for professional services
related to accounting, finance and other administrative functions. For the six months ended June&nbsp;30, 2020, the costs incurred under this arrangement totaled $444,000 which were recorded as general and administrative expense in the accompanying
statement of operations. As of June&nbsp;30, 2020, amounts owed under this arrangement totaled $40,000 and are included in accounts payable in the accompanying balance sheet. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Fair Value Measurements </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables present information about the Company&#146;s financial assets and liabilities measured at fair value on a recurring basis
and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June&nbsp;30, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock tranche obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:11pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government agency bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock tranche obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Condensed Financial Statements&nbsp;(continued) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables present information as to cost, unrealized gains and losses and fair
value determination of the Company&#146;s financial assets measured at fair value on a recurring basis (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June&nbsp;30, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized</B><br><B>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized</B><br><B>Gains</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized</B><br><B>Losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate</B><br><B>Fair</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized</B><br><B>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized</B><br><B>Gains</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized</B><br><B>Losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate</B><br><B>Fair</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government agency bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate debt securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Money market funds are highly liquid investments which are actively traded. The pricing information on the
Company&#146;s money market funds are based on quoted prices in active markets for identical securities. This approach results in the classification of these securities as Level&nbsp;1 of the fair value hierarchy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of short-term investments is determined from market pricing and other observable market inputs for similar securities obtained
from various third-party data providers. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate
fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads; benchmark securities; prepayment/default projections based on historical data; and other observable inputs. This
approach results in the classification of these securities as Level&nbsp;2 of the fair value hierarchy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s preferred
stock tranche obligation is measured at fair value using an option pricing valuation methodology. The fair value of preferred stock tranche obligation includes inputs not observable in the market and thus represents a Level&nbsp;3 measurement. The
option methodology utilized requires inputs based on certain subjective assumptions, including (a)&nbsp;expected stock price volatility, (b)&nbsp;calculation of an expected term, (c)&nbsp;a risk-free interest rate, and (d)&nbsp;expected dividends.
This approach results in the classification of these securities as Level&nbsp;3 of the fair value hierarchy. The assumptions utilized to value the preferred stock tranche obligation as of June&nbsp;30, 2020 were (a)&nbsp;expected stock price
volatility of 50%; (b) expected term of 0.3 years: (c)&nbsp;a risk-free interest rate of 0.16%; (d)&nbsp;an expectation of no dividends; and (e)&nbsp;a 51% probability of being settled. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Condensed Financial Statements&nbsp;(continued) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides a reconciliation of assets and liabilities measured at fair
value on a recurring basis using significant unobservable inputs (Level 3) (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="93%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at January&nbsp;1, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were no transfers among Level&nbsp;1, Level&nbsp;2 or Level&nbsp;3 categories in the six months ended
June&nbsp;30, 2020 or 2019. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Prepaid Expenses and Other <FONT STYLE="white-space:nowrap">Non-current</FONT> Assets
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other <FONT STYLE="white-space:nowrap">non-current</FONT> assets consist of the following (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,</B><br><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B><br><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid clinical and research expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total prepaid expenses and other <FONT STYLE="white-space:nowrap">non-current</FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other Current Liabilities </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other current liabilities consist of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,</B><br><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B><br><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Salaries and benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Commitments and Contingencies </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Operating Lease Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company leases facilities in Redwood City, California under an operating lease with a term through August 2021 and in Baltimore, Maryland
under an operating lease with a term through June 2023. Rent expense for the six months ended June&nbsp;30, 2020 and 2019 was $352,000 and $344,000, respectively. Future minimum lease payments under the Company&#146;s non&#150;cancelable operating
leases as of June&nbsp;30, 2020 were as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="93%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020 (July 1 through December 31)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total future minimum lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Condensed Financial Statements&nbsp;(continued) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Convertible Preferred Stock </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2020, the Company had 142,150,096 shares of $0.0001 par value convertible preferred stock, or Convertible Preferred Stock,
authorized, of which 2,280,000 shares are designated as Series A convertible preferred stock, or Series A Preferred; 2,018,561 shares are designated as Series <FONT STYLE="white-space:nowrap">A-2</FONT> convertible preferred stock, or Series <FONT
STYLE="white-space:nowrap">A-2</FONT> Preferred; 76,078,535 shares are designated as Series B convertible preferred stock, or Series B Preferred; and 61,773,000 are designated Series C convertible preferred stock, or Series C Preferred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes outstanding Convertible Preferred Stock (in thousands, except share and per share amounts): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A Preferred</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series <FONT STYLE="white-space:nowrap">A-2</FONT><BR>Preferred</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B Preferred</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series C Preferred</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total Convertible</B><br><B>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Balance&#151;January&nbsp;1 and June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,280,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,018,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,078,535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">74,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,377,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">78,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Balance&#151;January&nbsp;1 and June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,280,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,018,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,078,535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">74,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,432,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">52,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117,809,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">131,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Original issue price per share</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.4693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Liquidation value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">90,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">153,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with our Series&nbsp;C Financing in July 2019, certain purchasers of Series C preferred stock
had the option to purchase up to an additional 17,014,902 shares of Series C preferred stock at a price per share of $1.4693 for a period of up to 30&nbsp;days after the Company notified them of the three month readout from the Phase&nbsp;2a
clinical trial of GB-102 in patients with macular edema secondary to diabetic macular edema and retinal vein occlusion, or Preferred Stock Tranche Obligation. Subsequent to June 30, 2020, the Board and the Series&nbsp;C investors amended the Series
C stock purchase agreement such that the Preferred Stock Tranche Obligation is no longer exercisable and will terminate upon the effectiveness of this registration statement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Stock-based Compensation </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2020, 648,587 shares remained available for grant under the Company&#146;s 2015 Stock Incentive Plan. However, on
July&nbsp;7, 2020 a further 231,510 options were granted to employees with a weighted average exercise price of $3.51. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Condensed Financial Statements&nbsp;(continued) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Stock Option Activity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summarizes stock option activity: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average</B><br><B>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Remaining<BR>Contractual<BR>Term&nbsp;(years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic<BR>Value<BR>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding&#151;January&nbsp;1, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,117,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,733</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,297</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding&#151;June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,066,076</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and expected to vest&#151;June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom" ALIGN="right">2,066,076<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options Exercisable&#151;June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">872,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate intrinsic value of options granted is calculated as the difference between the exercise
price of the options and the estimated fair value of the Company&#146;s common stock. The aggregate intrinsic value of options exercised in the six month ended June&nbsp;30, 2020 was $18,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate fair value of options that vested during the six months ended June&nbsp;30, 2020 was $400,000. The weighted average grant date
fair value of options that vested during the six months ended June&nbsp;30, 2020 was $1.53. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Stock-based Compensation Expense
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense is classified as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2020, total unrecognized stock&#150;based compensation cost related to unvested stock
options was $2.2&nbsp;million. As of June&nbsp;30, 2020, the weighted&#150;average period over which such stock-based compensation was expected to be recognized was approximately 2.8 years. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Income Taxes </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company did not record a provision or benefit for income taxes during the six months ended June&nbsp;30, 2020 and 2019. The Company
continues to maintain a full valuation allowance against all of its deferred tax assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated the positive and
negative evidence involving its ability to realize our deferred tax assets.&nbsp;The Company has considered our history of cumulative net losses incurred since inception and its lack of any commercially ready products.&nbsp;The Company has concluded
that it is more likely than not that it will not realize the benefits of its deferred tax assets. The Company reevaluates the positive and negative evidence at each reporting period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Condensed Financial Statements&nbsp;(continued) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Net Loss Per Common Share </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per common share is calculated as follows (in thousands except share and per share amounts): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,663</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,558</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cumulative dividends on convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,793</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,585</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,456</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19,143</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per common share&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13.40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14.78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used in computing net loss per common share&#151;basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,377,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,295,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following outstanding potentially dilutive securities have been excluded from the calculation of
diluted net loss per common share, as their effect is anti-dilutive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117,809,883</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,377,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,066,076</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,746,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,759</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Series C Financing, up to 17,014,902 shares of convertible preferred stock could have been
contingently issued upon achievement of certain development milestones. However, subsequent to June&nbsp;30, 2020, the Board and the Series C investors amended the Series C stock purchase agreement such that the option to purchase additional shares
is no longer exercisable and will terminate upon the effectiveness of this registration statement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B><B><I></I></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><I></I></B><B>Pro Forma Net Loss Per Common Share </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the computation of pro forma basic and diluted net loss per common share (in thousands, except share and per
share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended<BR>June 30, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,456</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cumulative dividends on convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,663</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used in computing net loss per share&#151;basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,377,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma adjustment to reflect automatic conversion of convertible preferred stock to common
stock upon completion of the proposed initial public offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,085,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of shares used in computing pro forma net loss per common share&#151;basic
and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,463,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per common share&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.94</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Unaudited Condensed Financial Statements&nbsp;(continued) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Subsequent Events </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated subsequent events through September&nbsp;4, 2020 (except for the impact of the reverse stock split as discussed in
the third paragraph of Note 1, as to which the date is September 18, 2020), which is the date these condensed financial statements were available to be issued, and has determined that there have been no events that have occurred that would require
adjustments to the Company&#146;s disclosures in the condensed financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>4,687,500
Shares </B></P>  <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g796801g02e22.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:16pt">
<TD VALIGN="top"><B>SVB Leerink</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Piper Sandler</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top" NOWRAP><B>Needham&nbsp;&amp;&nbsp;Company</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right"><B>Wedbush&nbsp;PacGrow</B></TD></TR>
</TABLE>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until and including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2020 (25 days after the
date of this prospectus), all dealers that buy, sell or trade our common stock, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the obligation of dealers to deliver
a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;13. </B><B><I>OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION.</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth all costs and expenses, other than underwriting discounts and commissions, paid or payable by the Registrant in
connection with the sale of the common stock being registered. All amounts shown are estimates except for the Securities and Exchange Commission, or SEC, registration fee, the Financial Industry Regulatory Approval, or FINRA, filing fee and the
Nasdaq Global Market listing fee: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount<BR>Paid or<BR>to&nbsp;be&nbsp;Paid</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Nasdaq Global Market listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">475,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,725,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,640,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Blue Sky, qualification fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer agent and registrar fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>    <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;14. </B><B><I>INDEMNIFICATION OF DIRECTORS AND OFFICERS.</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the Delaware General Corporation Law, or DGCL, authorizes a court to award, or a corporation&#146;s board of directors to
grant, indemnity to directors and officers under certain circumstances and subject to certain limitations. The terms of Section&nbsp;145 of the DGCL are sufficiently broad to permit indemnification under certain circumstances for liabilities,
including reimbursement of expenses incurred, arising under the Securities Act of 1933, as amended, or Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As permitted by
the DGCL, the Registrant&#146;s restated certificate of incorporation to be effective in connection with the completion of this offering contains provisions that eliminate the personal liability of its directors for monetary damages for any breach
of fiduciary duties as a director, except liability for the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of the director&#146;s duty of loyalty to the Registrant or its stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">under Section&nbsp;174 of the DGCL (regarding unlawful dividends and stock purchases); or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As permitted by the DGCL, the Registrant&#146;s restated bylaws to be effective in connection with the completion of this offering, provide
that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Registrant is required to indemnify its directors and executive officers to the fullest extent permitted by
the DGCL, subject to limited exceptions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Registrant may indemnify its other employees and agents as set forth in the DGCL; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Registrant is required to advance expenses, as incurred, to its directors and executive officers in
connection with a legal proceeding to the fullest extent permitted by the DGCL, subject to limited exceptions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rights conferred in the restated bylaws are not exclusive. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the completion of this offering, the Registrant intends to enter into
indemnification agreements with each of its current directors and executive officers to provide these directors and executive officers additional contractual assurances regarding the scope of the indemnification set forth in the Registrant&#146;s
restated certificate of incorporation and restated bylaws and to provide additional procedural protections. There is no pending litigation or proceeding involving a director or executive officer of the Registrant for which indemnification is sought.
Reference is also made to the underwriting agreement to be filed as Exhibit 1.1 to this registration statement, which provides for the indemnification of executive officers, directors and controlling persons of the Registrant against certain
liabilities. The indemnification provisions in the Registrant&#146;s restated certificate of incorporation, restated bylaws and the indemnification agreements entered into or to be entered into between the Registrant and each of its directors and
executive officers may be sufficiently broad to permit indemnification of the Registrant&#146;s directors and executive officers for liabilities arising under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Registrant has directors&#146; and officers&#146; liability insurance for securities matters. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;15. </B><B><I>RECENT SALES OF UNREGISTERED SECURITIES.</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following lists set forth information regarding all securities sold or granted by the Registrant from July&nbsp;31, 2017 through the date
of the prospectus that is a part of this registration statement that were not registered under the Securities Act, and the consideration, if any, received by the Registrant for such securities: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Option Grants</I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From
July&nbsp;31, 2017 through September&nbsp;18, 2020, the Registrant has granted to its employees, directors, consultants and other service providers options to purchase an aggregate of 2,708,505 shares of common stock under its 2015 Plan, with
exercise prices ranging from $1.00 to $16.00 per share. In addition, during this period the Registrant issued options outside the 2015 Stock Plan to purchase an aggregate of 7,825 shares of common stock to two individuals with an exercise price of
$1.00 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From July&nbsp;31, 2017 through September&nbsp;18, 2020, employees, directors, consultants and other service providers
of the Registrant exercised options granted under the 2015 Plan aggregating 209,570 shares of common stock with exercise prices ranging from $1.00 to $2.26 per share for an aggregate exercise price of $327,284. In addition, during this period the
Registrant issued 7,825 shares of its common stock to two individuals upon exercise of options outside the 2015 Stock Plan with an exercise price of $1.00 per share for an aggregate exercise price of $7,752. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between July and
August 2019, the Registrant issued and sold to eight accredited investors an aggregate of 37,432,787 shares of Series C convertible preferred stock, at a purchase price of $1.4693 per share, for aggregate consideration of approximately
$55.0&nbsp;million. In connection with the completion of this offering, these shares of Series C convertible preferred stock will convert into 37,432,787 shares of the Registrant&#146;s common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Between April 2016 and May 2018, the Registrant issued and sold to 17 accredited investors an aggregate of 76,078,535 shares of Series B
convertible preferred stock, at a purchase price of $0.991 per share, or $0.842 per share for shares issued upon conversion and/or cancellation of outstanding convertible promissory notes, for aggregate purchase consideration of approximately
$74.9&nbsp;million. In connection with the completion of this offering, these shares of Series B convertible preferred stock will convert into 76,078,535 shares of the Registrant&#146;s common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Warrants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2019, the
Registrant issued to Danforth Advisors, LLC a warrant to purchase an aggregate of 27,759 shares of common stock at a purchase price of $3.88 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise stated, the sales of the above securities were deemed to be exempt from registration under the Securities Act in reliance on
Section&nbsp;4(a)(2) of the Securities Act (or Regulation D or Regulation S promulgated thereunder), or Rule 701 promulgated under Section&nbsp;3(b) of the Securities Act, as transactions by an issuer not involving any public offering or pursuant to
benefit plans and contracts relating to compensation as provided under Rule 701. The recipients of the securities in each of these transactions represented their intentions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed on the stock certificates issued
in each of the foregoing transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the foregoing transactions involved any underwriters, underwriting discounts or
commissions or any public offering, and the Registrant believes each transaction was exempt from the registration requirements of the Securities Act as stated above. All recipients of the foregoing transactions either received adequate information
about the Registrant or had access, through their relationships with the Registrant, to such information. Furthermore, the Registrant affixed appropriate legends to the share certificates and instruments issued in each foregoing transaction setting
forth that the securities had not been registered and the applicable restrictions on transfer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;16. </B><B><I>EXHIBITS AND FINANCIAL
STATEMENT SCHEDULES.</I></B><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Exhibits. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description of
Document</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001534133/000119312520240042/d796801dex11.htm">Form of Underwriting Agreement. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d796801dex31.htm">Amended and Restated Certificate of Incorporation, as amended to date, as currently in effect.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001534133/000119312520240042/d796801dex32.htm">Form of Restated Certificate of Incorporation to be effective upon the completion of this offering.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001534133/000119312520240042/d796801dex33.htm">Amended and Restated Bylaws, as currently in effect.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.4*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001534133/000119312520240042/d796801dex34.htm">Form of Restated Bylaws to be effective upon the completion of this offering.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d796801dex41.htm">Form of Common Stock Certificate. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001534133/000119312520240042/d796801dex42.htm">Amended and Restated Investors&#146; Rights Agreement, dated July&nbsp;
31, 2019, by and among the Registrant and certain of its stockholders.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001534133/000119312520240042/d796801dex43.htm">Warrant to Purchase Common Stock, dated December&nbsp;11, 2019, by and between the Registrant and SG DAN Equity Holdings,
LLC.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d796801dex51.htm">Opinion of Fenwick&nbsp;&amp; West LLP. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001534133/000119312520240042/d796801dex101.htm">Form of Indemnification Agreement.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001534133/000119312520240042/d796801dex102.htm">2015 Stock Incentive Plan, as amended, and forms of award agreements thereunder.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d796801dex103.htm">2020 Equity Incentive Plan, to become effective on the date immediately prior to the date the registration statement is declared effective, and forms of award agreements.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d796801dex104.htm">2020 Employee Stock Purchase Plan, to become effective on the date the registration statement is declared effective, and forms of award agreements.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001534133/000119312520240042/d796801dex105.htm">Separation Agreement, dated September&nbsp;11, 2019, by and between the Registrant and Pamela Wapnick.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001534133/000119312520240042/d796801dex106.htm">Employment Agreement, effective as of February&nbsp;1, 2019, by and between the Registrant and Frederic Guerard.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001534133/000119312520240042/d796801dex107.htm">Offer Letter, effective as of October&nbsp;23, 2017, by and between the Registrant and Daniel Salain.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001534133/000119312520240042/d796801dex108.htm">Offer Letter, effective as of May&nbsp;7, 2020, by and between the Registrant and Parisa Zamiri.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001534133/000119312520240042/d796801dex109.htm">Offer Letter, effective as of September&nbsp;4, 2020, by and between the Registrant and Robert S. Breuil.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001534133/000119312520240042/d796801dex1010.htm">Master Consulting Agreement, dated March&nbsp;20, 2020, by and between the Registrant and Charles
Semba.</A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description of
Document</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001534133/000119312520240042/d796801dex1011.htm">Change in Control and Severance Policy</A>.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001534133/000119312520240042/d796801dex1012.htm">Office Lease, dated May&nbsp;
17, 2016, by and between the Registrant and Hudson Shorebreeze, LLC, as amended by that certain First Amendment, dated April&nbsp;1, 2019.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001534133/000119312520240042/d796801dex1013.htm">Lease, dated October&nbsp;
8, 2019, by and between the Registrant and Ventas Beckley, LLC, as amended by that certain First Amendment to Lease, dated December&nbsp;5, 2019, and that certain Second Amendment to Lease, dated June&nbsp;26, 2020.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.14&#134;*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001534133/000119312520240042/d796801dex1014.htm">Exclusive License Agreement, dated June&nbsp;
23, 2011, by and between the Registrant and Johns Hopkins University School of Medicine, as amended.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.15&#134;*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001534133/000119312520240042/d796801dex1015.htm">Settlement and License Agreement, dated October&nbsp;
24, 2014, by and among the Registrant, Johns Hopkins University School of Medicine, and Kala Pharmaceuticals, Inc.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.16*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001534133/000119312520240042/d796801dex1016.htm">Letter Agreement, dated July&nbsp;31, 2019, by and between the Registrant and AffaMed Project Limited.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.17*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001534133/000119312520240042/d796801dex1017.htm">Consulting Agreement, dated September&nbsp;3, 2019, by and between the Registrant and Danforth Advisors, LLC.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d796801dex231.htm">Consent of Independent Registered Public Accounting Firm.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d796801dex51.htm">Consent of Fenwick&nbsp;&amp; West LLP (included in Exhibit&nbsp;5.1). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1534133/000119312520240042/d796801dex233.htm">Consent of Christina Ackermann. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d796801dex234.htm">Consent of Julie Eastland.</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d796801dex235.htm">Consent of Eric Bjerkholt. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1534133/000119312520240042/d796801ds1.htm#ii796801_poa">Power of Attorney. </A></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Previously filed. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Registrant has omitted portions of the exhibit as permitted under Item&nbsp;601(b)(10)&nbsp;of&nbsp;Regulation <FONT
STYLE="white-space:nowrap">S-K.</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Financial Statement Schedules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No financial statement schedules are provided because the information called for is not required or is shown either in the financial
statements or notes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;17. </B><B><I>UNDERTAKINGS.</I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned Registrant hereby undertakes to provide to the underwriter at the completion specified in the underwriting agreements,
certificates in such denominations and registered in such names as required by the underwriter to permit prompt delivery to each purchaser. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of
the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In
the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit
or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to
a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned Registrant hereby undertakes that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For purposes of determining any liability under the Securities Act, the information omitted from the form of
prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of
this registration statement as of the time it was declared effective. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purpose of determining any liability under the Securities Act, each post-effective amendment that
contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant has duly caused this registration statement on Form <FONT
STYLE="white-space:nowrap">S-1</FONT> to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Redwood City, State of California, on the 21st day of September, 2020. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">GRAYBUG VISION, INC.</TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Frederic Guerard, Pharm.D.</P></TD></TR></TABLE></DIV>
<DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Frederic Guerard, Pharm.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ii796801_poa"></A>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement on Form
<FONT STYLE="white-space:nowrap">S-1</FONT> has been signed by the following persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Frederic Guerard, Pharm.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Frederic Guerard, Pharm.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Principal Executive
Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>September&nbsp;21, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Robert S. Breuil</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Robert S. Breuil</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Principal Accounting
and Financial Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>September&nbsp;21, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Christy
Shaffer, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>September&nbsp;21, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Gerald
Cagle, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>September&nbsp;21, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Emmett
Cunningham, Jr., M.D., Ph.D., M.P.H.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>September&nbsp;21, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Hansoo
Michael Keyoung, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>September&nbsp;21, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chau Khuong,
M.P.H.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>September&nbsp;21, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">*</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Cameron
Wheeler, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>September&nbsp;21, 2020</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">*By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Frederic Guerard, Pharm.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Frederic Guerard, Pharm.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attorney-in-Fact</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>d796801dex31.htm
<DESCRIPTION>EX-3.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AMENDED AND RESTATED </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTIFICATE
OF INCORPORATION </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">OF </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">GRAYBUG
VISION, INC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Pursuant to Sections 242 and 245 of the </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">General Corporation Law of the State of Delaware) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Graybug Vision, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State
of Delaware (the &#147;<B>General Corporation Law</B>&#148;), </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>DOES HEREBY CERTIFY: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1. </B>That the name of this corporation is Graybug Vision, Inc., and that this corporation was originally incorporated pursuant to the
General Corporation Law on February&nbsp;19, 2015 under the name Graybug, Inc. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2. </B>That the Board of Directors duly adopted
resolutions proposing to amend and restate the Certificate of Incorporation of this corporation, declaring said amendment and restatement to be advisable and in the best interests of this corporation and its stockholders, and authorizing the
appropriate officers of this corporation to solicit the consent of the stockholders therefor, which resolution setting forth the proposed amendment and restatement is as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>RESOLVED</B>, that the Certificate of Incorporation of this corporation be amended and restated in its entirety to read as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>FIRST: </B>The name of this corporation is Graybug Vision, Inc. (the &#147;<B>Corporation</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>SECOND: </B>The address of the registered office of the Corporation in the State of Delaware is 1209 Orange Street, in the City of
Wilmington, County of New Castle, 19801. The name of its registered agent at such address is The Corporation Trust Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>THIRD:
</B>The nature of the business or purposes to be conducted or promoted is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>FOURTH: </B>The total number of shares of all classes of stock which the Corporation shall have authority to issue is (i) 188,000,000
shares of Common Stock, $0.0001 par value per share (&#147;<B>Common Stock</B>&#148;) and (ii) 142,150,096 shares of Preferred Stock, $0.0001 par value per share (&#147;<B>Preferred Stock</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a statement of the designations and the powers, privileges and rights, and the qualifications, limitations or restrictions
thereof in respect of each class of capital stock of the Corporation. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. COMMON STOCK </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1. <U>General</U>. The voting, dividend and liquidation rights of the holders of the Common Stock are subject to and qualified by the rights,
powers and preferences of the holders of the Preferred Stock set forth herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2. <U>Voting</U>. The holders of the Common Stock are
entitled to one vote for each share of Common Stock held at all meetings of stockholders (and written actions in lieu of meetings); <U>provided</U>, <U>however</U>, that, except as otherwise required by law, holders of Common Stock, as such, shall
not be entitled to vote on any amendment to the Certificate of Incorporation that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together
with the holders of one or more other such series, to vote thereon pursuant to the Certificate of Incorporation or pursuant to the General Corporation Law. There shall be no cumulative voting. The number of authorized shares of Common Stock may be
increased or decreased (but not below the number of shares thereof then outstanding) by (in addition to any vote of the holders of one or more series of Preferred Stock that may be required by the terms of the Certificate of Incorporation) the
affirmative vote of the holders of shares of capital stock of the Corporation representing a majority of the votes represented by all outstanding shares of capital stock of the Corporation entitled to vote, irrespective of the provisions of
Section&nbsp;242(b)(2) of the General Corporation Law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. PREFERRED STOCK </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2,280,000 shares of the authorized Preferred Stock of the Corporation are hereby designated &#147;<B>Series A Preferred Stock</B>&#148;
2,018,561 shares of the authorized Preferred Stock of the Corporation are hereby designated &#147;<B>Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock</B>&#148;. 76,078,535 shares of the authorized Preferred Stock of the Corporation
are hereby designated &#147;<B>Series B Preferred Stock</B>&#148;. 61,773,000 shares of the authorized Preferred Stock of the Corporation are hereby designated &#147;<B>Series C Preferred Stock</B>.&#148; The Preferred Stock shall have the following
rights, preferences, powers, privileges and restrictions, qualifications and limitations. Unless otherwise indicated, references to &#147;sections&#148; or &#147;subsections&#148; in this Part B of this Article Fourth refer to sections and
subsections of Part B of this Article Fourth. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1. <U>Dividends</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.1 <U>Series C Preferred Stock.</U> From and after the date of the issuance of any shares of Series C Preferred Stock, dividends at the rate
per annum of eight percent (8%) of the Applicable Original Issue Price (as defined in <U>Section</U><U></U><U>&nbsp;4.4</U> below) per share shall accrue on such shares of Series C Preferred Stock (the &#147;<B>Series C</B> <B>Accruing
Dividends</B>&#148;). Accruing Dividends shall accrue from day to day, whether or not declared, and shall be cumulative; provided, however, that such Series C Accruing Dividends shall be payable only when, as, and if declared by the Board of
Directors and the Corporation shall be under no obligation to pay such Series C Accruing Dividends unless declared by the Board of Directors. The Corporation shall not declare, pay or set aside any dividends on shares of any other class or series of
capital stock of the Corporation (other than dividends on shares of Common Stock payable in shares of Common Stock) unless (in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
addition to the obtaining of any consents required elsewhere in the Certificate of Incorporation) the holders of the Series C Preferred Stock then outstanding shall first receive, or
simultaneously receive, a dividend on each outstanding share of Series C Preferred Stock in an amount at least equal to the sum of (i)&nbsp;the amount of the aggregate Series C Accruing Dividends then accrued on such share of Series C Preferred
Stock and not previously paid and (ii)&nbsp;(A) in the case of a dividend on Common Stock or any class or series that is convertible into Common Stock, that dividend per share of Series C Preferred Stock as would equal the product of (1)&nbsp;the
dividend payable on each share of such class or series determined, if applicable, as if all shares of such class or series had been converted into Common Stock and (2)&nbsp;the number of shares of Common Stock issuable upon conversion of a share of
Series C Preferred Stock, in each case calculated on the record date for determination of holders entitled to receive such dividend or (B)&nbsp;in the case of a dividend on any class or series that is not convertible into Common Stock, at a rate per
share of Series C Preferred Stock determined by (1)&nbsp;dividing the amount of the dividend payable on each share of such class or series of capital stock by the original issuance price of such class or series of capital stock (subject to
appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to such class or series) and (2)&nbsp;multiplying such fraction by an amount equal to the Applicable Original Issue
Price; provided that if the Corporation declares, pays or sets aside, on the same date, a dividend on shares of more than one class or series of capital stock of the Corporation, the dividend payable to the holders of Series C Preferred Stock
pursuant to this <U>Section</U><U></U><U>&nbsp;1.1 </U>shall be calculated based upon the dividend on the class or series of capital stock that would result in the highest Series C Preferred Stock dividend. The &#147;<B>Series C Original Issue
Price</B>&#148; shall mean $1.4693 per share, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series C Preferred Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.2 <U>Series B Preferred Stock</U>. From and after the date of the issuance of any shares of Series B Preferred Stock, dividends at the rate
per annum of seven percent (7%) of the Applicable Original Issue Price per share shall accrue on such shares of Series B Preferred Stock (the &#147;<B>Series B</B> <B>Accruing Dividends</B>&#148;). Accruing Dividends shall accrue from day to day,
whether or not declared, and shall be cumulative; provided, however, that such Series B Accruing Dividends shall be payable only when, as, and if declared by the Board of Directors and the Corporation shall be under no obligation to pay such Series
B Accruing Dividends unless declared by the Board of Directors. Except as set forth in <U>Section</U><U></U><U>&nbsp;1.1</U> above, the Corporation shall not declare, pay or set aside any dividends on shares of any other class or series of capital
stock of the Corporation (other than dividends on shares of Common Stock payable in shares of Common Stock) unless (in addition to the obtaining of any consents required elsewhere in the Certificate of Incorporation) the holders of the Series B
Preferred Stock then outstanding shall first receive, or simultaneously receive, a dividend on each outstanding share of Series B Preferred Stock in an amount at least equal to the sum of (i)&nbsp;the amount of the aggregate Series B Accruing
Dividends then accrued on such share of Series B Preferred Stock and not previously paid and (ii)&nbsp;(A) in the case of a dividend on Common Stock or any class or series that is convertible into Common Stock, that dividend per share of Series B
Preferred Stock as would equal the product of (1)&nbsp;the dividend payable on each share of such class or series determined, if applicable, as if all shares of such class or series had been converted into Common Stock and (2)&nbsp;the number of
shares of Common Stock </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
issuable upon conversion of a share of Series B Preferred Stock, in each case calculated on the record date for determination of holders entitled to receive such dividend or (B)&nbsp;in the case
of a dividend on any class or series that is not convertible into Common Stock, at a rate per share of Series B Preferred Stock determined by (1)&nbsp;dividing the amount of the dividend payable on each share of such class or series of capital stock
by the original issuance price of such class or series of capital stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to such class or series) and
(2)&nbsp;multiplying such fraction by an amount equal to the Applicable Original Issue Price; provided that if the Corporation declares, pays or sets aside, on the same date, a dividend on shares of more than one class or series of capital stock of
the Corporation, the dividend payable to the holders of Series B Preferred Stock pursuant to this <U>Section</U><U></U><U>&nbsp;1.2 </U>shall be calculated based upon the dividend on the class or series of capital stock that would result in the
highest Series B Preferred Stock dividend. The &#147;<B>Series B Original Issue Price</B>&#148; shall mean $0.991 per share, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar
recapitalization with respect to the Series B Preferred Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.3 <U>Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred
Stock</U>. From and after the date of the issuance of any shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, when, as and if declared by the Board of Directors and out of funds of the Corporation legally available for that
purpose, the holder of each share of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock shall be entitled to receive <FONT STYLE="white-space:nowrap">non-cumulative,</FONT> <FONT STYLE="white-space:nowrap">non-compounding</FONT>
dividends at the rate per annum of seven percent (7%) of the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Original Issue Price (the &#147;<B>Series <FONT STYLE="white-space:nowrap">A-2</FONT> Dividends</B>&#148;). The Series <FONT
STYLE="white-space:nowrap">A-2</FONT> Dividends shall be payable only when, as, and if declared by the Board of Directors and the Corporation shall be under no obligation to pay such Series <FONT STYLE="white-space:nowrap">A-2</FONT> Dividends
unless declared by the Board of Directors. Except as set forth in <U>Section</U><U></U><U>&nbsp;1.1</U> and<U> Section</U><U></U><U>&nbsp;1.2</U> above, the Corporation shall not declare, pay or set aside any dividends on shares of any other class
or series of capital stock of the Corporation (other than dividends on shares of Common Stock payable in shares of Common Stock) unless (in addition to the obtaining of any consents required elsewhere in the Certificate of Incorporation) the holders
of the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock then outstanding shall first receive, or simultaneously receive, a dividend on each outstanding share of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock in
an amount at least equal to the sum of (i)&nbsp;the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Dividends that would have then been accrued if such dividends had been cumulative and accruing daily from and after the date of issuance of such
Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock and (ii)&nbsp;(A) in the case of a dividend on Common Stock or any class or series that is convertible into Common Stock, that dividend per share of Series <FONT
STYLE="white-space:nowrap">A-2</FONT> Preferred Stock as would equal the product of (1)&nbsp;the dividend payable on each share of such class or series determined, if applicable, as if all shares of such class or series had been converted into
Common Stock and (2)&nbsp;the number of shares of Common Stock issuable upon conversion of a share of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, in each case calculated on the record date for determination of holders
entitled to receive such dividend or (B)&nbsp;in the case of a dividend on any class or series that is not convertible into Common Stock, at a rate per share of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock determined by
(1)&nbsp;dividing the amount of the dividend payable on each share of such class or series of capital stock by the original issuance price of such class or series of capital stock (subject to appropriate adjustment in the event of any stock
dividend, stock split, combination or other similar recapitalization with respect to such class or series) and (2)&nbsp;multiplying such fraction by an amount equal to the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Original Issue Price
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 4 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(as defined below); provided that if the Corporation declares, pays or sets aside, on the same date, a dividend on shares of more than one class or series of capital stock of the Corporation, the
dividend payable to the holders of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock pursuant to this <U>Section</U><U></U><U>&nbsp;1.3</U> shall be calculated based upon the dividend on the class or series of capital stock that
would result in the highest Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock dividend. The &#147;<B>Series <FONT STYLE="white-space:nowrap">A-2</FONT> Original Issue Price</B>&#148; shall mean $0.862 per share, subject to
appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.4 <U>Series A Preferred Stock</U>. From and after the date of the issuance of any shares of Series A Preferred Stock, when, as and if
declared by the Board of Directors and out of funds of the Corporation legally available for that purpose, the holder of each share of Series A Preferred Stock shall be entitled to receive <FONT STYLE="white-space:nowrap">non-cumulative,</FONT> <FONT
STYLE="white-space:nowrap">non-compounding</FONT> dividends at the rate per annum of eight percent (8%) of the Series A Original Issue Price (the &#147;<B>Series A Dividends</B>&#148;). The Series A Dividends shall be payable only when, as, and if
declared by the Board of Directors and the Corporation shall be under no obligation to pay such Series A Dividends unless declared by the Board of Directors. Except as set forth in <U>Section</U><U></U><U>&nbsp;1.1,
Section</U><U></U><U>&nbsp;1.2</U>and <U>Section</U><U></U><U>&nbsp;1.3</U> above, the Corporation shall not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Corporation (other than dividends on
shares of Common Stock payable in shares of Common Stock) unless (in addition to the obtaining of any consents required elsewhere in the Certificate of Incorporation) the holders of the Series A Preferred Stock then outstanding shall first receive,
or simultaneously receive, a dividend on each outstanding share of Series A Preferred Stock in an amount at least equal to the sum of (i)&nbsp;the Series A Dividends that would have then been accrued if such dividends had been cumulative and
accruing daily from and after the date of issuance of such Series A Preferred Stock and (ii)&nbsp;(A) in the case of a dividend on Common Stock or any class or series that is convertible into Common Stock, that dividend per share of Series A
Preferred Stock as would equal the product of (1)&nbsp;the dividend payable on each share of such class or series determined, if applicable, as if all shares of such class or series had been converted into Common Stock and (2)&nbsp;the number of
shares of Common Stock issuable upon conversion of a share of Series A Preferred Stock, in each case calculated on the record date for determination of holders entitled to receive such dividend or (B)&nbsp;in the case of a dividend on any class or
series that is not convertible into Common Stock, at a rate per share of Series A Preferred Stock determined by (1)&nbsp;dividing the amount of the dividend payable on each share of such class or series of capital stock by the original issuance
price of such class or series of capital stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to such class or series) and (2)&nbsp;multiplying such
fraction by an amount equal to the Series A Original Issue Price (as defined below); provided that if the Corporation declares, pays or sets aside, on the same date, a dividend on shares of more than one class or series of capital stock of the
Corporation, the dividend payable to the holders of Series A Preferred Stock pursuant to this <U>Section</U><U></U><U>&nbsp;1.4</U> shall be calculated based upon the dividend on the class or series of capital stock that would result in the highest
Series A Preferred Stock dividend. The &#147;<B>Series A Original Issue Price</B>&#148; shall mean <B>$</B>1.00 per share, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar
recapitalization with respect to the Series A Preferred Stock. The issuance date of any shares of Series A Preferred Stock that was issued upon the conversion of a Series A Preferred Unit pursuant to the Corporation&#146;s Plan of Conversion, dated
on or about February&nbsp;19, 2015, shall be the date of issuance of such Series A Preferred Unit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 5 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2. <U>Liquidation, Dissolution or Winding Up; Certain Mergers, Consolidations and Asset
Sales</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.1 <U>Preferential Payments to Holders of Preferred Stock</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.1.1 <U>Series C Preferred Stock</U>. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation
or Deemed Liquidation Event, the holders of shares of Series C Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Corporation available for distribution to its stockholders or, in the case of a Deemed Liquidation
Event, be entitled to be paid out of the consideration payable to stockholders in such Deemed Liquidation Event or out of the Available Proceeds (as defined below), as applicable, before any payment shall be made to the holders of Series B Preferred
Stock, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, Series A Preferred Stock, or Common Stock by reason of their ownership thereof, an amount per share equal to the Series C Original Issue Price, plus any declared Series C
Accruing Dividends accrued but unpaid thereon, together with any other dividends declared but unpaid thereon (the amount payable pursuant to this sentence is hereinafter referred to as the &#147;<B>Series C Preferred</B><B> Liquidation
Amoun</B>t&#148;). If upon any such liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, the assets of the Corporation available for distribution to its stockholders shall be insufficient to pay the holders of
shares of Series C Preferred Stock the full amount to which they shall be entitled under this <U>Section</U><U></U><U>&nbsp;2.1.1</U>, the holders of shares of Series C Preferred Stock shall share ratably in any distribution of the assets available
for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares of Series C Preferred Stock held by them upon such distribution if all amounts payable on or with respect to such shares were paid in
full. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.1.2 <U>Series B Preferred Stock</U>. Subject to payment or setting aside for payment the amounts referenced in
<U>Section</U><U></U><U>&nbsp;2.1.1</U>,in the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, the holders of shares of Series B Preferred Stock then outstanding shall be
entitled to be paid out of the assets of the Corporation available for distribution to its stockholders before any payment shall be made to the holders of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, Series A Preferred Stock,
or Common Stock by reason of their ownership thereof, an amount per share equal to the Series B Original Issue Price, plus any declared Series B Accruing Dividends accrued but unpaid thereon, together with any other dividends declared but unpaid
thereon (the amount payable pursuant to this sentence is hereinafter referred to as the &#147;<B>Series B Preferred</B><B> Liquidation Amoun</B>t&#148;). If upon any such liquidation, dissolution or winding up of the Corporation or Deemed
Liquidation Event, the assets of the Corporation available for distribution to its stockholders shall be insufficient to pay the holders of shares of Series B Preferred Stock the full amount to which they shall be entitled under this
<U>Section</U><U></U><U>&nbsp;2.1.2</U>, the holders of shares of Series B Preferred Stock shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in
respect of the shares of Series B Preferred Stock held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 6 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.1.3 <U>Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock</U>. Subject to
payment or setting aside for payment the amounts referenced in <U>Section</U><U></U><U>&nbsp;2.1.1 and Section</U><U></U><U>&nbsp;2.1.2</U>, in the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation or
Deemed Liquidation Event, the holders of shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Corporation available for distribution to its stockholders
before any payment shall be made to the holders of Series A Preferred Stock or Common Stock by reason of their ownership thereof, an amount per share equal to the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Original Issue Price, plus any
dividends declared but unpaid thereon (the amount payable pursuant to this sentence is hereinafter referred to as the &#147;<B>Series <FONT STYLE="white-space:nowrap">A-2</FONT> Liquidation Amoun</B>t&#148;). If upon any such liquidation,
dissolution or winding up of the Corporation or Deemed Liquidation Event, the assets of the Corporation available for distribution to its stockholders shall be insufficient to pay the holders of shares of Series
<FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock the full amount to which they shall be entitled under this <U>Section</U><U></U><U>&nbsp;2.1.3</U>, the holders of shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred
Stock shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred
Stock held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.1.4 <U>Series A
Preferred Stock</U>. Subject to payment or setting aside for payment the amounts referenced in <U>Section</U><U></U><U>&nbsp;2.1.1</U>, <U>Section</U><U></U><U>&nbsp;2.1.2</U> and<U> Section</U><U></U><U>&nbsp;2.1.3</U>, in the event of any
voluntary or involuntary liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, the holders of shares of Series A Preferred Stock then outstanding shall be entitled to be paid out of the assets of the Corporation
available for distribution to its stockholders before any payment shall be made to the holders of Common Stock by reason of their ownership thereof, an amount per share equal to the Series A Original Issue Price, plus any dividends declared but
unpaid thereon (the amount payable pursuant to this sentence is hereinafter referred to as the &#147;<B>S</B><B>eries A Liquidation Amoun</B>t&#148;). If upon any such liquidation, dissolution or winding up of the Corporation or Deemed Liquidation
Event, the assets of the Corporation available for distribution to its stockholders shall be insufficient to pay the holders of shares of Series A Preferred Stock the full amount to which they shall be entitled under this
<U>Section</U><U></U><U>&nbsp;2.1.4</U>, the holders of shares of Series A Preferred Stock shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in
respect of the shares of Series A Preferred Stock held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.2 <U>Distribution of Remaining Assets</U>. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the
Corporation or Deemed Liquidation Event, after the payment of all preferential amounts required to be paid to the holders of shares of Series C Preferred Stock, Series B Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred
Stock and Series A Preferred Stock the remaining assets of the Corporation available for distribution to its stockholders or, in the case of a Deemed Liquidation Event, the consideration not payable to the holders of shares of Preferred Stock
pursuant to Section&nbsp;2.1<B> </B>or the remaining Available Proceeds, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 7 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
as the case may be, shall be distributed among the holders of the shares of Series C Preferred Stock, Series B Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock,
Series A Preferred Stock and Common Stock, pro rata based on the number of shares held by each such holder, treating for this purpose all such securities as if they had been converted to Common Stock pursuant to the terms of the Certificate of
Incorporation immediately prior to such liquidation, dissolution or winding up of the Corporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.3 <U>Deemed Liquidation Events</U>.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.3.1 <U>Definition</U>. Each of the following events shall be considered a &#147;<B>Deemed Liquidation Event</B>&#148; unless the
holders of (x)&nbsp;a majority of the votes represented by all outstanding shares of Preferred Stock (voting together as a single class on an <FONT STYLE="white-space:nowrap">as-if</FONT> converted to Common Stock basis), (y) a majority of the
outstanding shares of Series B Preferred Stock (voting together as a single class) <U>and</U> (z)&nbsp;if and only if, such Deemed Liquidation Event would result in holders of Series C Preferred Stock receiving less than the Series C Original Issue
Price for each share of Series C Preferred Stock held by them upon the consummation of such Deemed Liquidation Event pursuant to <U>Section</U><U></U><U>&nbsp;2</U> hereunder, a majority of the outstanding shares of Series C Preferred Stock (voting
together as a single class) ((x), (y) and as applicable pursuant to this Section&nbsp;2.3.1(z), the holders of a majority of the outstanding shares of Series C Preferred Stock (voting together as a single class) collectively, the &#147;<B>Requisite
Investors</B>&#148;) elect otherwise by written notice sent to the Corporation at least 10 days prior to the effective date of any such event: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) a merger, consolidation, sale or reorganization in which </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Corporation is a constituent party or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a subsidiary of the Corporation is a constituent party and the Corporation issues shares of its capital stock
pursuant to such merger or consolidation, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">except any such merger, consolidation, sale or reorganization involving the Corporation or a
subsidiary in which the shares of capital stock of the Corporation outstanding immediately prior to such merger, consolidation, sale or reorganization continue to represent, or are converted into or exchanged for shares of capital stock that
represent, immediately following such merger or consolidation, a majority, by voting power, in substantially the same relative proportions as among such stockholders prior to such transaction, of the capital stock of (1)&nbsp;the surviving or
resulting corporation; or (2)&nbsp;if the surviving or resulting corporation is a wholly owned subsidiary of another corporation immediately following such merger or consolidation, the parent corporation of such surviving or resulting corporation;
or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) the transfer by one or more stockholder(s) of the Corporation of outstanding securities of the Corporation representing a majority
of the combined voting power of the then-outstanding securities of the Corporation; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 8 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c) the sale, lease, transfer, exclusive license or other disposition, in a single
transaction or series of related transactions, by the Corporation or any subsidiary of the Corporation of all or substantially all the assets of the Corporation and its subsidiaries taken as a whole or the sale or disposition (whether by merger,
consolidation or otherwise) of one or more subsidiaries of the Corporation if substantially all of the assets of the Corporation and its subsidiaries taken as a whole are held by such subsidiary or subsidiaries, except where such sale, lease,
transfer, exclusive license or other disposition is to a wholly owned subsidiary of the Corporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.3.2 <U>Effecting a Deemed
Liquidation Event</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) The Corporation shall not have the power to effect a Deemed Liquidation Event referred to in
<U>Subsection&nbsp;2.3.1(a)(i)</U> unless the agreement or plan of merger or consolidation for such transaction (the &#147;<B>Merger Agreement</B>&#148;) provides that the consideration payable to the stockholders of the Corporation shall be
allocated among the holders of capital stock of the Corporation in accordance with <U>Section</U><U></U><U>&nbsp;2.1</U> and <U>Section</U><U></U><U>&nbsp;2.2</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) In the event of a Deemed Liquidation Event referred to in <U>Subsection 2.3.1(a)(ii)</U>, <U>Subsection&nbsp;2.3.1(b)</U> or
<U>Subsection&nbsp;2.3.1(c)</U>, if the Corporation does not effect a dissolution of the Corporation under the General Corporation Law within ninety (90)&nbsp;days after such Deemed Liquidation Event, then (i)&nbsp;the Corporation shall send a
written notice to each holder of Preferred Stock no later than the ninetieth (90<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day after the Deemed Liquidation Event advising such holders of their right (and the requirements to be met to
secure such right) pursuant to the terms of the following clause; (ii)&nbsp;to require the redemption of such shares of Preferred Stock, and (iii)&nbsp;if the Requisite Investors so request in a written instrument delivered to the Corporation not
later than one hundred twenty (120)&nbsp;days after such Deemed Liquidation Event, the Corporation shall use the consideration received by the Corporation for such Deemed Liquidation Event, if any, (net of any retained liabilities associated with
the assets sold or technology licensed, as determined in good faith by the Board of Directors of the Corporation)<B>, </B>together with any other assets of the Corporation available for distribution to its stockholders, all to the extent permitted
by Delaware law governing distributions to stockholders (the &#147;<B>Available</B><B> Proceeds</B>&#148;), on the one hundred fiftieth (150<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day after such Deemed Liquidation Event, to redeem
all outstanding shares of Preferred Stock at a price per share equal to the Series C Preferred Liquidation Amount, Series B Preferred Liquidation Amount, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Liquidation Amount, or Series A Liquidation
Amount, as applicable. Notwithstanding the foregoing, in the event of a redemption pursuant to the preceding sentence, if the Available Proceeds are not sufficient to redeem all outstanding shares of Preferred Stock, the Corporation shall ratably
redeem each holder&#146;s shares of Preferred Stock to the fullest extent of such Available Proceeds, and shall redeem the remaining shares as soon as it may lawfully do so under Delaware law governing distributions to stockholders; <I>provided
however</I> that (i)&nbsp;no shares of Series B Preferred Stock may be redeemed until all shares of Series C Preferred Stock have been redeemed (or the payment therefor has been set aside), (ii) no shares of Series
<FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock may be redeemed until all shares of Series C Preferred Stock and Series B Preferred Stock have been redeemed (or the payment therefor has been set aside) and (iii)&nbsp;no shares of Series
A Preferred Stock may be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 9 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
redeemed until all outstanding shares of Series C Preferred Stock, Series B Preferred Stock and Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock have been redeemed (or the
payment therefor has been set aside). The provisions of <U>Section</U><U></U><U>&nbsp;6</U> shall apply, with such necessary changes in the details thereof as are necessitated by the context, to the redemption of the Preferred Stock pursuant to this
<U>Subsection 2.3.2(b)</U>. Prior to the distribution or redemption provided for in this <U>Subsection 2.3.2(b)</U>, the Corporation shall not expend or dissipate the consideration received for such Deemed Liquidation Event, except to discharge
expenses incurred in connection with such Deemed Liquidation Event. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.3.3 <U>Amount Deemed Paid or Distributed</U>. The amount deemed
paid or distributed to the holders of capital stock of the Corporation upon any such merger, consolidation, sale, transfer, exclusive license, other disposition or redemption shall be the cash or the value of the property, rights or securities paid
or distributed to such holders by the Corporation or the acquiring person, firm or other entity. The value of such property, rights or securities shall be determined in good faith by the Board of Directors of the Corporation, including a majority of
the Preferred Directors (defined below). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.3.4 <U>Allocation of Escrow and Contingent Consideration</U>. In the event of a Deemed
Liquidation Event pursuant to <U>Subsection 2.3.1(a)(i)</U>, if any portion of the consideration payable to the stockholders of the Corporation is payable only upon satisfaction of contingencies (the &#147;<B>Additional Consideration</B>&#148;), the
Merger Agreement shall provide that (a)&nbsp;the portion of such consideration that is not Additional Consideration (such portion, the &#147;<B>Initial Consideration</B>&#148;) shall be allocated among the holders of capital stock of the Corporation
in accordance with <U>Sections 2.1</U> and <U>Section</U><U></U><U>&nbsp;2.2</U> as if the Initial Consideration were the only consideration payable in connection with such Deemed Liquidation Event; and (b)&nbsp;any Additional Consideration which
becomes payable to the stockholders of the Corporation upon satisfaction of such contingencies shall be allocated among the holders of capital stock of the Corporation in accordance with <U>Sections 2.1</U> and <U>Section</U><U></U><U>&nbsp;2.2</U>
after taking into account the previous payment of the Initial Consideration as part of the same transaction. For the purposes of this <U>Section</U><U></U><U>&nbsp;2.3.4</U>, consideration placed into escrow or retained as holdback to be available
for satisfaction of indemnification or similar obligations in connection with such Deemed Liquidation Event shall be deemed to be Additional Consideration. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3. <U>Voting</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.1
<U>General</U>. On any matter presented to the stockholders of the Corporation for their action or consideration at any meeting of stockholders of the Corporation (or by written consent of stockholders in lieu of meeting), each holder of outstanding
shares of Series A Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Preferred Stock held by such holder are convertible as of the record date for determining
stockholders entitled to vote on such matter. Except as provided by law or by the other provisions of the Certificate of Incorporation, holders of Series A Preferred Stock shall vote together with the holders of Common Stock as a single class. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 10 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.2 <U>Election of Directors</U>. The holders of record of the shares of Series C Preferred
Stock, exclusively and as a separate class shall be entitled to elect one (1)&nbsp;director of the Corporation (the &#147;<B>Series C Director</B>&#148;). The holders of record of the shares of Series B Preferred Stock, exclusively and as a separate
class, shall be entitled to elect three (3)&nbsp;directors of the Corporation (the &#147;<B>Series B Directors</B>&#148;). The holders of record of the shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, exclusively and as
a separate class, shall be entitled to elect one (1)&nbsp;director of the Corporation (together with the Series C Director and the Series B Directors, the &#147;<B>Preferred Directors</B>&#148;). The holders of record of the shares of Common Stock,
exclusively and as a separate class, shall be entitled to elect one (1)&nbsp;director of the Corporation (the &#147;<B>Common Director</B>&#148;). Any director elected as provided in the preceding sentences of this
<U>Section</U><U></U><U>&nbsp;3.2</U> may be removed without cause by, and only by, the affirmative vote of the holders of the shares of the class or series of capital stock entitled to elect such director or directors, given either at a special
meeting of such stockholders duly called for that purpose or pursuant to a written consent of stockholders. If the holders of shares of Series C Preferred Stock, Series B Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred
Stock or Common Stock, as the case may be, fail to elect a sufficient number of directors to fill all directorships for which they are entitled to elect directors, voting exclusively and as a separate class, pursuant to the first sentence of this
<U>Section</U><U></U><U>&nbsp;3.2</U>, then any directorship not so filled shall remain vacant until such time as the holders of the Series C Preferred Stock, Series B Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred
Stock or Common Stock, as the case may be, elect a person to fill such directorship by vote or written consent in lieu of a meeting; and no such directorship may be filled by stockholders of the Corporation other than by the stockholders of the
Corporation that are entitled to elect a person to fill such directorship, voting exclusively and as a separate<B> </B>class. The holders of record of the shares of Common Stock and of any other class or series of voting stock (including the
Preferred Stock), exclusively and voting together as a single class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, shall be entitled to elect the balance of the total number of directors of the Corporation. At any meeting held for
the purpose of electing a director, the presence in person or by proxy of the holders of a majority of the outstanding shares of the class or series entitled to elect such director shall constitute a quorum for the purpose of electing such director.
Except as otherwise provided in this <U>Section</U><U></U><U>&nbsp;3.2</U>,<B> </B>a vacancy in any directorship filled by the holders of any class or series shall be filled only by vote or written consent in lieu of a meeting of the holders of such
class or series or by any remaining director or directors elected by the holders of such class or series pursuant to this <U>Section</U><U></U><U>&nbsp;3.2</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.3 <U>Preferred Stock Protective Provisions</U>. At any time when shares of Preferred Stock are outstanding, the Corporation shall not,
either directly or indirectly by amendment, merger, consolidation or otherwise, do any of the following without (in addition to any other vote required by law or the Certificate of Incorporation) the written consent or affirmative vote of the
Requisite Investors, given in writing or by vote at a meeting, consenting or voting (as the case may be) separately as a class (except (i)&nbsp;as required under General Corporation Law Section&nbsp;242(b)(2) for amendments that alter or change the
powers, preferences or special rights of the Series A Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, Series B Preferred Stock or Series C Preferred Stock adversely but not all series of Preferred Stock or
(ii)&nbsp;for increases or decreases in the authorized number of shares of Series A Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, Series B Preferred Stock or Series C Preferred Stock, wherein, in each such case
described in (i)&nbsp;or (ii), the written consent or affirmative vote of the holders of a majority of the outstanding shares of Series A Preferred Stock, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, Series B Preferred Stock
or Series C Preferred Stock, as applicable, shall also be required), and any such act or transaction entered into without such consent or vote shall be null and void <I>ab initio</I>, and of no force or effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 11 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.1 amend, alter or repeal any provision of the Certificate of Incorporation or Bylaws of
the Corporation; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.2 alter or change the rights, preferences or privileges of the Preferred Stock, or any series thereof; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.3 take an action, including without limitation, by way of merger, consolidation or otherwise that would adversely affect the powers,
preferences of privileges of the Preferred Stock; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.4 increase or decrease the authorized number of shares of Common Stock or Preferred
Stock or any series thereof (except as provided for pursuant to <U>Section</U><U></U><U>&nbsp;4.3.3</U>, <U>Section</U><U></U><U>&nbsp;5.1</U>, and <U>Section</U><U></U><U>&nbsp;7</U>); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.5 create (by reclassification or otherwise), or authorize the creation of, or issue or obligate itself to issue shares of, any additional
class or series of capital stock unless the same ranks junior to each series of Preferred Stock with respect to the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends and rights of
redemption; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.6 purchase or redeem (or permit any subsidiary to purchase or redeem) or pay or declare any dividend or make any
distribution on, any shares of capital stock of the Corporation other than (i)&nbsp;redemptions of or dividends or distributions on the Preferred Stock as expressly authorized herein, (ii)&nbsp;stock splits, dividends or other distributions payable
on the Common Stock solely in the form of additional shares of Common Stock for which adjustments are made to the Preferred Stock pursuant to <U>Section</U><U></U><U>&nbsp;4.5</U>, <U>Section</U><U></U><U>&nbsp;4.6</U> or
<U>Section</U><U></U><U>&nbsp;4.7,</U> (iii)&nbsp;repurchases of stock from former employees, officers, directors, consultants or other persons who performed services for the Corporation or any subsidiary in connection with the cessation of such
employment or service at the lower of the original purchase price or the then-current fair market value thereof and (iv)&nbsp;repurchases pursuant to the MVF Documents (as defined in that certain Series C Preferred Stock Purchase Agreement, dated as
of the Original Issue Date by and among the Corporation and the purchasers listed therein); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.7 liquidate, dissolve or <FONT
STYLE="white-space:nowrap">wind-up</FONT> the business and affairs of the Corporation, effect any merger or consolidation or any other Deemed Liquidation Event, sell, exclusively license or otherwise dispose of a majority of its assets, or consent
to any of the foregoing (in each case referenced in this <U>Section</U><U></U><U>&nbsp;3.3.7</U>, in a single transaction or series of related transactions); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.8 increase or decrease the authorized number of directors constituting the Board of Directors; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 12 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.9 (i) reclassify, alter or amend any existing security of the Corporation that is pari
passu with the Preferred Stock (or any series thereof) in respect of the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends or rights of redemption, if such reclassification, alteration
or amendment would render such other security senior to the Preferred Stock (or any series thereof) in respect of any such right, preference, or privilege or (ii)&nbsp;reclassify, alter or amend any existing security of the Corporation that is
junior to the Preferred Stock (or any series thereof) in respect of the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends or rights of redemption, if such reclassification, alteration
or amendment would render such other security senior to or pari passu with the Preferred Stock (or any series thereof) in respect of any such right, preference or privilege; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.10 create, or authorize the creation of, or issue, or authorize the issuance of any debt security, or permit any subsidiary to take any
such action with respect to any debt security, if the aggregate indebtedness of the Corporation and its subsidiaries for borrowed money following such action would exceed $250,000, unless such debt security has received the prior approval of the
Board of Directors, including a majority of the Preferred Directors; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.11 create, or hold capital stock in, any subsidiary, or sell,
transfer or otherwise dispose of any capital stock of any direct or indirect subsidiary of the Corporation, or permit any direct or indirect subsidiary to sell, lease, transfer, exclusively license or otherwise dispose (in a single transaction or
series of related transactions) of all or a material part of the assets of such subsidiary, in each case unless approved by the Board of Directors, including a majority of the Preferred Directors; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.12 make any change in the principal business of the Corporation or its material subsidiary, enter new lines of business or exit the
current line of business; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.13 adopt or amend any equity incentive plan including form agreements thereto or increase the number of
shares of Common Stock reserved for issuance under any equity incentive plan; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.14 sell, assign, exclusively license, pledge, or
encumber material technology or intellectual property of the Corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 13 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4. <U>Optional</U><U> Conversion</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of the Preferred Stock shall have conversion rights as follows (the &#147;<B>Conversion Rights</B>&#148;): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.1 <U>Right to Convert</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.1.1 <U>Conversion Ratio</U>. Each share of Preferred Stock shall be convertible, at the option of the holder thereof, at any time and from
time to time, and without the payment of additional consideration by the holder thereof, into such number of fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock as is determined by dividing the Applicable
Original Issue Price by the Applicable Series Conversion Price (as defined below) in effect at the time of conversion. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.1.2
<U>Termination of Conversion Rights</U>. In the event of a notice of redemption of any shares of Preferred Stock pursuant to <U>Section</U><U></U><U>&nbsp;6</U>, the Conversion Rights of the shares designated for redemption shall terminate at the
close of business on the last full day preceding the date fixed for redemption, unless the redemption price is not fully paid on such redemption date, in which case the Conversion Rights for such shares shall continue until such price is paid in
full. In the event of a liquidation, dissolution or winding up of the Corporation or a Deemed Liquidation Event, the Conversion Rights for a given series of Preferred Stock shall terminate at the close of business on the last full day preceding the
date fixed for the payment of any such amounts distributable on such event to the holders of the applicable series of Preferred Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.2 <U>Fractional Shares</U>. No fractional shares of Common Stock shall be issued upon conversion of the any series of Preferred Stock. In
lieu of any fractional shares to which the holder would otherwise be entitled, the Corporation shall pay cash equal to such fraction multiplied by the fair market value of a share of Common Stock as determined in good faith by the Board of Directors
of the Corporation. Whether or not fractional shares would be issuable upon such conversion shall be determined on the basis of the total number of shares of Preferred Stock the holder is at the time converting into Common Stock and the aggregate
number of shares of Common Stock issuable upon such conversion. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.3 <U>Mechanics of Conversion</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.1 <U>Notice of Conversion</U>. In order for a holder of shares of Preferred Stock to voluntarily convert shares of Preferred Stock into
shares of Common Stock, such holder shall (a)&nbsp;provide written notice to the Corporation&#146;s transfer agent at the office of the transfer agent for the Preferred Stock (or at the principal office of the Corporation if the Corporation serves
as its own transfer agent) that such holder elects to convert all or any number of such holder&#146;s shares of Preferred Stock and, if applicable, any event on which such conversion is contingent and (b), if such holder&#146;s shares are
certificated, surrender the certificate or certificates for such shares of Preferred Stock (or, if such registered holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably
acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate), at the office of the transfer agent for the Preferred
Stock (or at the principal office of the Corporation if the Corporation serves as its own transfer agent). Such notice shall state such holder&#146;s name or the names of the nominees in which such holder wishes the shares of Common Stock to be
issued. If </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 14 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
required by the Corporation, any certificates surrendered for conversion shall be endorsed or accompanied by a written instrument or instruments of transfer, in form satisfactory to the
Corporation, duly executed by the registered holder or his, her or its attorney duly authorized in writing. The close of business on the date of receipt by the transfer agent (or by the Corporation if the Corporation serves as its own transfer
agent) of such notice and, if applicable, certificates (or lost certificate affidavit and agreement) shall be the time of conversion (the &#147;<B>Conversion Time</B>&#148;), and the shares of Common Stock issuable upon conversion of the specified
shares shall be deemed to be outstanding of record as of such date. The Corporation shall, as soon as practicable after the Conversion Time (i)&nbsp;issue and deliver to such holder of Preferred Stock, or to his, her or its nominees, a certificate
or certificates for the number of full shares of Common Stock issuable upon such conversion in accordance with the provisions hereof and a certificate for the number (if any) of the shares of Preferred Stock represented by the surrendered
certificate that were not converted into Common Stock, (ii)&nbsp;pay in cash such amount as provided in <U>Section</U><U></U><U>&nbsp;4.2</U> in lieu of any fraction of a share of Common Stock otherwise issuable upon such conversion and
(iii)&nbsp;pay all declared but unpaid dividends on the shares of Preferred Stock converted. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.2 <U>Reservation of Shares</U>. The
Corporation shall at all times when the Preferred Stock shall be outstanding, reserve and keep available out of its authorized but unissued capital stock, for the purpose of effecting the conversion of the Preferred Stock, such number of its duly
authorized shares of Common Stock as shall from time to time be sufficient to effect the conversion of all outstanding Preferred Stock; and if at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect
the conversion of all then outstanding shares of the Preferred Stock, the Corporation shall take such corporate action as may be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient
for such purposes, including, without limitation, engaging in best efforts to obtain the requisite stockholder approval of any necessary amendment to the Certificate of Incorporation. Before taking any action which would cause an adjustment reducing
the Applicable Series Conversion Price below the then par value of the shares of Common Stock issuable upon conversion of the Preferred Stock, the Corporation will take any corporate action which may, in the opinion of its counsel, be necessary in
order that the Corporation may validly and legally issue fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock at such adjusted Applicable Series Conversion Price. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.3 <U>Effect of Conversion</U>. All shares of Preferred Stock which shall have been surrendered for conversion as herein provided shall no
longer be deemed to be outstanding and all rights with respect to such shares shall immediately cease and terminate at the Conversion Time, except only the right of the holders thereof to receive shares of Common Stock in exchange therefor, to
receive payment in lieu of any fraction of a share otherwise issuable upon such conversion as provided in <U>Section</U><U></U><U>&nbsp;4.2</U> and to receive payment of any dividends declared but unpaid thereon. Any shares of Preferred Stock so
converted shall be retired and cancelled and may not be reissued as shares of such series, and the Corporation may thereafter take such appropriate action (without the need for stockholder action) as may be necessary to reduce the authorized number
of shares of Preferred Stock and the associated series of Preferred Stock accordingly. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 15 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.4 <U>No Further Adjustment</U>. Upon any such conversion, no adjustment to the
Applicable Series Conversion Price shall be made for any declared but unpaid dividends on the Preferred Stock surrendered for conversion or on the Common Stock delivered upon conversion. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.5 <U>Taxes</U>. The Corporation shall pay any and all issue and other similar taxes that may be payable in respect of any issuance or
delivery of shares of Common Stock upon conversion of shares of Preferred Stock pursuant to this <U>Section</U><U></U><U>&nbsp;4</U>. The Corporation shall not, however, be required to pay any tax which may be payable in respect of any transfer
involved in the issuance and delivery of shares of Common Stock in a name other than that in which the shares of Preferred Stock so converted were registered, and no such issuance or delivery shall be made unless and until the person or entity
requesting such issuance has paid to the Corporation the amount of any such tax or has established, to the satisfaction of the Corporation, that such tax has been paid. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.4 <U>Adjustments</U><U> to Applicable Series Conversion Price for Diluting Issues</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.1 <U>Special Definitions</U>. For purposes of this Article Fourth, the following definitions shall apply: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) &#147;<B>Applicable Series Conversion Price</B>&#148; for the Series A Preferred Stock will initially equal $0.9830, for the Series <FONT
STYLE="white-space:nowrap">A-2</FONT> Preferred Stock will initially equal the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Original Issue Price, for the Series B Preferred Stock will initially equal the Series B Original Issue Price and for
the Series C Preferred Stock will initially equal the Series C Original Issue Price; provided however that such initial Applicable Series Conversion Price, and the rate at which shares of a series of Preferred Stock may be converted into shares of
Common Stock, shall be subject to adjustment as provided below. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B>Original Issue Date</B>&#148; shall mean the date on which
the first share of Series C Preferred Stock was issued. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B>Applicable Original Issue Price</B>&#148; for the Series A Preferred
Stock, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, Series B Preferred Stock and Series C Preferred Stock will equal the Series A Original Issue Price, Series <FONT STYLE="white-space:nowrap">A-2</FONT> Original Issue Price,
Series B Original Issue Price and Series C Original Issue Price, respectively, plus, in each case, any declared but unpaid dividends thereon. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(d) &#147;<B>Option</B>&#148; shall mean rights, options or warrants to subscribe for, purchase or otherwise acquire Common Stock or
Convertible Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(e) &#147;<B>Convertible Securities</B>&#148; shall mean any evidences of indebtedness, shares or other
securities directly or indirectly convertible into or exchangeable for Common Stock, but excluding Options. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 16 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(f) &#147;<B>Additional Shares of Common Stock</B>&#148; shall mean for a given series of
Preferred Stock, all shares of Common Stock issued (or, pursuant to <U>Subsection</U><U></U><U>&nbsp;4.4.3</U> below, deemed to be issued) by the Corporation after the Original Issue Date, other than (1)&nbsp;the following shares of Common Stock and
(2)&nbsp;shares of Common Stock deemed issued pursuant to the following Options and Convertible Securities (clauses (1)&nbsp;and (2), collectively, &#147;<B>Exempted Securities</B>&#148;): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued as a dividend or distribution on Preferred
Stock or any series thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued by reason of a dividend, stock split, <FONT
STYLE="white-space:nowrap">split-up</FONT> or other distribution on shares of Common Stock that is covered by <U>Section</U><U></U><U>&nbsp;4.5</U> <U>Section</U><U></U><U>&nbsp;4.6</U>, <U>Section</U><U></U><U>&nbsp;4.7</U>, or
<U>Section</U><U></U><U>&nbsp;4.8</U>; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock or Options issued to employees or directors of, or consultants or advisors to, the
Corporation or any of its subsidiaries pursuant to a plan, agreement or arrangement approved by the Board of Directors of the Corporation, including a majority of the Preferred Directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock or Convertible Securities actually issued upon the exercise of Options or shares of
Common Stock actually issued upon the conversion or exchange of Convertible Securities, in each case provided such issuance is pursuant to the terms of such Option or Convertible Security; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued to banks, equipment lessors or other financial
institutions, or to real property lessors, in each such case pursuant to a debt financing for the purposes of equipment leasing or real property leasing transaction approved by the Board of Directors of the Corporation, including a majority of the
Preferred Directors; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 17 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock, Options or Convertible Securities issued in connection with sponsored research,
collaboration, technology license, development, OEM, marketing or other similar agreements or strategic partnerships approved by the Board of Directors of the Corporation, including a majority of the Preferred Directors; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">shares of Common Stock issued in connection with a firm commitment underwritten public offering pursuant to an
effective registration statement under the Securities Act of 1933, as amended, pursuant to which all shares of Preferred Stock convert into shares of Common Stock. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.2 <U>No Adjustment of Conversion Price</U>. No adjustment in the Applicable Series Conversion Price for any series shall be made as the
result of the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from the Requisite Investors, provided however, that any such waiver by the Requisite Investors must apply to all series that
would otherwise be entitled to adjustment in the Applicable Series Conversion Price as the result of such issuance or deemed issuance of Additional Shares of Common Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.3 <U>Deemed Issue of Additional Shares of Common Stock</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) If the Corporation at any time or from time to time after the Original Issue Date shall issue any Options or Convertible Securities
(excluding Options or Convertible Securities which are themselves Exempted Securities) or shall fix a record date for the determination of holders of any class of securities entitled to receive any such Options or Convertible Securities, then the
maximum number of shares of Common Stock (as set forth in the instrument relating thereto, assuming the satisfaction of any conditions to exercisability, convertibility or exchangeability but without regard to any provision contained therein for a
subsequent adjustment of such number) issuable upon the exercise of such Options or, in the case of Convertible Securities and Options therefor, the conversion or exchange of such Convertible Securities, shall be deemed to be Additional Shares of
Common Stock issued as of the time of such issue or, in case such a record date shall have been fixed, as of the close of business on such record date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 18 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) If the terms of any Option or Convertible Security, the issuance of which resulted in
an adjustment to the Applicable Series Conversion Price for a series of Preferred Stock pursuant to the terms of <U>Section</U><U></U><U>&nbsp;4.4.4</U>, are revised as a result of an amendment to such terms or any other adjustment pursuant to the
provisions of such Option or Convertible Security (but excluding automatic adjustments to such terms pursuant to anti-dilution or similar provisions of such Option or Convertible Security) to provide for either (1)&nbsp;any increase or decrease in
the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any such Option or Convertible Security or (2)&nbsp;any increase or decrease in the consideration payable to the Corporation upon such exercise,
conversion and/or exchange, then, effective upon such increase or decrease becoming effective, the Applicable Series Conversion Price for such series computed upon the original issue of such Option or Convertible Security (or upon the occurrence of
a record date with respect thereto) shall be readjusted to such Applicable Series Conversion Price as would have been obtained had such revised terms been in effect upon the original date of issuance of such Option or Convertible Security.
Notwithstanding the foregoing, no readjustment pursuant to this clause&nbsp;(b) shall have the effect of increasing the Applicable Series Conversion Price for such series to an amount which exceeds the lower of (i)&nbsp;the Applicable Series
Conversion Price in effect for such series immediately prior to the original adjustment made as a result of the issuance of such Option or Convertible Security, or (ii)&nbsp;the Applicable Series Conversion Price for such series that would have
resulted from any issuances of Additional Shares of Common Stock (other than deemed issuances of Additional Shares of Common Stock as a result of the issuance of such Option or Convertible Security) between the original adjustment date and such
readjustment date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c) If the terms of any Option or Convertible Security (excluding Options or Convertible Securities which are
themselves Exempted Securities), the issuance of which did not result in an adjustment to the Applicable Series Conversion Price for a series of Preferred Stock pursuant to the terms of <U>Section</U><U></U><U>&nbsp;4.4.4</U> (either because the
consideration per share (determined pursuant to <U>Section</U><U></U><U>&nbsp;4.4.5</U>) of the Additional Shares of Common Stock subject thereto was equal to or greater than the Applicable Series Conversion Price for such series then in effect, or
because such Option or Convertible Security was issued before the Original Issue Date), are revised after the Original Issue Date as a result of an amendment to such terms or any other adjustment pursuant to the provisions of such Option or
Convertible Security (but excluding automatic adjustments to such terms pursuant to anti-dilution or similar provisions of such Option or Convertible Security) to provide for either (1)&nbsp;any increase in the number of shares of Common Stock
issuable upon the exercise, conversion or exchange of any such Option or Convertible Security or (2)&nbsp;any decrease in the consideration payable to the Corporation upon such exercise, conversion or exchange, then such Option or Convertible
Security, as so amended or adjusted, and the Additional Shares of Common Stock subject thereto (determined in the manner provided in <U>Subsection (a)</U>&nbsp;of this<U> Section</U><U></U><U>&nbsp;4.4.3</U> shall be deemed to have been issued
effective upon such increase or decrease becoming effective. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(d) Upon the expiration or termination of any unexercised Option or
unconverted or unexchanged Convertible Security (or portion thereof) which resulted (either upon its original issuance or upon a revision of its terms) in an adjustment to the Applicable Series Conversion Price for a series of Preferred Stock
pursuant to the terms of <U>Subsection</U><U></U><U>&nbsp;4.4.4</U>, the Applicable Series Conversion Price for such series shall be readjusted to such Applicable Series Conversion Price as would have obtained had such Option or Convertible Security
(or portion thereof) never been issued. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 19 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(e) If the number of shares of Common Stock issuable upon the exercise, conversion and/or
exchange of any Option or Convertible Security, or the consideration payable to the Corporation upon such exercise, conversion and/or exchange, is calculable at the time such Option or Convertible Security is issued or amended but is subject to
adjustment based upon subsequent events, any adjustment to the Applicable Series Conversion Price for a series of Preferred Stock provided for in this <U>Subsection</U><U></U><U>&nbsp;4.4.3</U> shall be effected at the time of such issuance or
amendment based on such number of shares or amount of consideration without regard to any provisions for subsequent adjustments (and any subsequent adjustments shall be treated as provided in <U>Subsection (b)</U>&nbsp;and <U>Subsection
(c)</U>&nbsp;of this <U>Section</U><U></U><U>&nbsp;4.4.3</U>). If the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any Option or Convertible Security, or the consideration payable to the Corporation upon
such exercise, conversion and/or exchange, cannot be calculated at all at the time such Option or Convertible Security is issued or amended, any adjustment to the Applicable Series Conversion Price for a series of Preferred Stock that would result
under the terms of this <U>Section</U><U></U><U>&nbsp;4.4.3</U> at the time of such issuance or amendment shall instead be effected at the time such number of shares and/or amount of consideration is first calculable (even if subject to subsequent
adjustments), assuming for purposes of calculating such adjustment to the Applicable Series Conversion Price that such issuance or amendment took place at the time such calculation can first be made. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.4 <U>Adjustment of Applicable Series Conversion Price Upon Issuance of Additional Shares of Common Stock</U>. In the event the Corporation
shall, at any time after the Original Issue Date, issue Additional Shares of Common Stock (including Additional Shares of Common Stock deemed to be issued pursuant to <U>Subsection</U><U></U><U>&nbsp;4.4.3</U>), without consideration or for a
consideration per share less than the Applicable Series Conversion Price for such series in effect immediately prior to such issue, then such Applicable Series Conversion Price shall be reduced, concurrently with such issue, to a price (calculated
to the nearest <FONT STYLE="white-space:nowrap">one-hundredth</FONT> of a cent) determined in accordance with the following formula: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CP<SUB
STYLE="font-size:85%; vertical-align:bottom">2</SUB> = CP<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB>* (A + B) &divide; (A + C). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For
purposes of the foregoing formula, the following definitions shall apply: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) &#147;<B>CP</B><B><SUB
STYLE="font-size:85%; vertical-align:bottom">2</SUB></B>&#148; shall mean such Applicable Series Conversion Price in effect immediately after such issue of Additional Shares of Common Stock </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B>CP</B><B><SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB></B>&#148; shall mean such Applicable Series Conversion Price
in effect immediately prior to such issue of Additional Shares of Common Stock; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B>A</B>&#148; shall mean the number of shares
of Common Stock outstanding immediately prior to such issue of Additional Shares of Common Stock (treating for this purpose as outstanding all shares of Common Stock issuable upon exercise of Options outstanding immediately prior to such issue or
upon conversion or exchange of Convertible Securities (including the Preferred Stock) outstanding (assuming exercise of any outstanding Options therefor) immediately prior to such issue); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 20 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(d) &#147;<B>B</B>&#148; shall mean the number of shares of Common Stock that would have
been issued if such Additional Shares of Common Stock had been issued at a price per share equal to CP<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB> (determined by dividing the aggregate consideration received by the Corporation in
respect of such issue by CP<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB>); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(e) &#147;<B>C</B>&#148; shall mean the number
of such Additional Shares of Common Stock issued in such transaction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.5 <U>Determination of Consideration</U>. For purposes of this
<U>Section</U><U></U><U>&nbsp;4.4</U>, the consideration received by the Corporation for the issue of any Additional Shares of Common Stock shall be computed as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) <U>Cash and Property</U>: Such consideration shall: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">insofar as it consists of cash, be computed at the aggregate amount of cash received by the Corporation,
excluding amounts paid or payable for accrued interest; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">insofar as it consists of property other than cash, be computed at the fair market value thereof at the time of
such issue, as determined in good faith by the Board of Directors of the Corporation; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the event Additional Shares of Common Stock are issued together with other shares or securities or other
assets of the Corporation for consideration which covers both, be the proportion of such consideration so received, computed as provided in clauses (i)&nbsp;and (ii) above, as determined in good faith by the Board of Directors of the Corporation.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 21 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) <U>Options and Convertible Securities</U>. The consideration per share received by the
Corporation for Additional Shares of Common Stock deemed to have been issued pursuant to <U>Subsection</U><U></U><U>&nbsp;4.4.3</U>, relating to Options and Convertible Securities, shall be determined by dividing: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The total amount, if any, received or receivable by the Corporation as consideration for the issue of such
Options or Convertible Securities, plus the minimum aggregate amount of additional consideration (as set forth in the instruments relating thereto, without regard to any provision contained therein for a subsequent adjustment of such consideration)
payable to the Corporation upon the exercise of such Options or the conversion or exchange of such Convertible Securities, or in the case of Options for Convertible Securities, the exercise of such Options for Convertible Securities and the
conversion or exchange of such Convertible Securities, by </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the maximum number of shares of Common Stock (as set forth in the instruments relating thereto, without regard
to any provision contained therein for a subsequent adjustment of such number) issuable upon the exercise of such Options or the conversion or exchange of such Convertible Securities, or in the case of Options for Convertible Securities, the
exercise of such Options for Convertible Securities and the conversion or exchange of such Convertible Securities. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.6 <U>Multiple Closing Dates</U>. In the event the Corporation shall issue on more than one date Additional Shares of Common Stock that are
a part of one transaction or a series of related transactions and that would result in an adjustment to the Applicable Series Conversion Price for one or more series of Preferred Stock pursuant to the terms of <U>Subsection 4.4.4</U>, and such
issuance dates occur within a period of no more than ninety (90)&nbsp;days from the first such issuance to the final such issuance, then, upon the final such issuance, each affected Applicable Series Conversion Price shall be readjusted to give
effect to all such issuances as if they occurred on the date of the first such issuance (and without giving effect to any additional adjustments as a result of any such subsequent issuances within such period). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.5 <U>Adjustment for Stock Splits and Combinations</U>. If the Corporation shall at any time or from time to time after the Original Issue
Date effect a subdivision of the outstanding Common Stock, the Applicable Series Conversion Price for such series in effect immediately before that subdivision shall be proportionately decreased so that the number of shares of Common Stock issuable
on conversion of each share of such series shall be increased in proportion to such increase in the aggregate number of shares of Common Stock outstanding. If the Corporation shall at any time or from time to time after the Original Issue Date
combine the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 22 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outstanding shares of Common Stock, the Applicable Series Conversion Price for such series in effect immediately before the combination shall be proportionately increased so that the number of
shares of Common Stock issuable on conversion of each share of such series shall be decreased in proportion to such decrease in the aggregate number of shares of Common Stock outstanding. Any adjustment under this subsection shall become effective
at the close of business on the date the subdivision or combination becomes effective. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.6 <U>Adjustment for Certain Dividends and
Distributions</U>. In the event the Corporation at any time or from time to time after the Original Issue Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other
distribution payable on the Common Stock in additional shares of Common Stock, then and in each such event the Applicable Series Conversion Price for such series in effect immediately before such event shall be decreased as of the time of such
issuance or, in the event such a record date shall have been fixed, as of the close of business on such record date, by multiplying the Applicable Series Conversion Price for such series then in effect by a fraction: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(1) the numerator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such
issuance or the close of business on such record date, and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(2) the denominator of which shall be the total number of shares of Common
Stock issued and outstanding immediately prior to the time of such issuance or the close of business on such record date plus the number of shares of Common Stock issuable in payment of such dividend or distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing (a)&nbsp;if such record date shall have been fixed and such dividend is not fully paid or if such distribution is not fully made
on the date fixed therefor, the Applicable Series Conversion Price for such series shall be recomputed accordingly as of the close of business on such record date and thereafter the Applicable Series Conversion Price for such series shall be
adjusted pursuant to this subsection as of the time of actual payment of such dividends or distributions; and (b)&nbsp;that no such adjustment shall be made if the holders of such series of Preferred Stock simultaneously receive a dividend or other
distribution of shares of Common Stock in a number equal to the number of shares of Common Stock as they would have received if all outstanding shares of such series of Preferred Stock had been converted into Common Stock on the date of such event.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.7 <U>Adjustments for Other Dividends and Distributions</U>. In the event the Corporation at any time or from time to time after the
Original Issue Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable in securities of the Corporation (other than a distribution of shares of
Common Stock in respect of outstanding shares of Common Stock) or in other property and the provisions of <U>Section</U><U></U><U>&nbsp;1</U> do not apply to such dividend or distribution, then and in each such event the holders of such series of
Preferred Stock shall receive, simultaneously with the distribution to the holders of Common Stock, a dividend or other distribution of such securities or other property in an amount equal to the amount of such securities or other property as they
would have received if all outstanding shares of such series of Preferred Stock had been converted into Common Stock on the date of such event. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 23 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.8 <U>Adjustment for Merger or Reorganization, etc</U>. Subject to the provisions of
<U>Subsection 2.3</U>, if there shall occur any reorganization, recapitalization, reclassification, consolidation or merger involving the Corporation in which the Common Stock (but not a given series of Preferred Stock) is converted into or
exchanged for securities, cash or other property (other than a transaction covered by <U>Section</U><U></U><U>&nbsp;4.4</U>, <U>Section</U><U></U><U>&nbsp;4.6</U> or <U>Section</U><U></U><U>&nbsp;4.7</U>), then, following any such reorganization,
recapitalization, reclassification, consolidation or merger, each share of such series of Preferred Stock shall thereafter be convertible in lieu of the Common Stock into which it was convertible prior to such event into the kind and amount of
securities, cash or other property which a holder of the number of shares of Common Stock of the Corporation issuable upon conversion of one share of such series of Preferred Stock immediately prior to such reorganization, recapitalization,
reclassification, consolidation or merger would have been entitled to receive pursuant to such transaction; and, in such case, appropriate adjustment (as determined in good faith by the Board of Directors of the Corporation) shall be made in the
application of the provisions in this <U>Section</U><U></U><U>&nbsp;4</U> with respect to the rights and interests thereafter of the holders of such series of Preferred Stock, to the end that the provisions set forth in this
<U>Section</U><U></U><U>&nbsp;4</U> (including provisions with respect to changes in and other adjustments of the Applicable Series Conversion Price for such series) shall thereafter be applicable, as nearly as reasonably may be, in relation to any
securities or other property thereafter deliverable upon the conversion of such series of Preferred Stock. For the avoidance of doubt, nothing in this <U>Subsection 4.8</U> shall be construed as preventing the holders of Preferred Stock from seeking
any appraisal rights to which they are otherwise entitled under the DGCL in connection with a merger triggering an adjustment hereunder, nor shall this <U>Subsection 4.8</U> be deemed conclusive evidence of the fair value of the shares of Preferred
Stock in any such appraisal proceeding. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.9 <U>Certificate as to Adjustments</U>. Upon the occurrence of each adjustment or readjustment
of the Applicable Series Conversion Price pursuant to this <U>Section</U><U></U><U>&nbsp;4</U>, the Corporation at its expense shall, as promptly as reasonably practicable but in any event not later than ten (10)&nbsp;days thereafter, compute such
adjustment or readjustment in accordance with the terms hereof and furnish to each holder of such effected series of Preferred Stock a certificate setting forth such adjustment or readjustment (including the kind and amount of securities, cash or
other property into which such series of Preferred Stock is convertible) and showing in detail the facts upon which such adjustment or readjustment is based. The Corporation shall, as promptly as reasonably practicable after the written request at
any time of any holder of Preferred Stock (but in any event not later than ten (10)&nbsp;days thereafter), furnish or cause to be furnished to such holder a certificate setting forth (i)&nbsp;the Applicable Series Conversion Price then in effect for
the series of Preferred Stock held by such holder, and (ii)&nbsp;the number of shares of Common Stock and the amount, if any, of other securities, cash or property which then would be received upon the conversion of the series of Preferred Stock
held by such holder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 24 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.10 <U>Notice of Record Date</U>. In the event: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) the Corporation shall take a record of the holders of its Common Stock (or other capital stock or securities at the time issuable upon
conversion of the Preferred Stock) for the purpose of entitling or enabling them to receive any dividend or other distribution, or to receive any right to subscribe for or purchase any shares of capital stock of any class or any other securities, or
to receive any other security; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) of any capital reorganization of the Corporation, any reclassification of the Common Stock of the
Corporation, or any Deemed Liquidation Event; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c) of the voluntary or involuntary dissolution, liquidation or <FONT
STYLE="white-space:nowrap">winding-up</FONT> of the Corporation, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">then, and in each such case, the Corporation will send or cause to be sent to the
holders of the Preferred Stock a notice specifying, as the case may be, (i)&nbsp;the record date for such dividend, distribution or right, and the amount and character of such dividend, distribution or right, or (ii)&nbsp;the effective date on which
such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or <FONT STYLE="white-space:nowrap">winding-up</FONT> is proposed to take place, and the time, if any is to be fixed, as of which the holders of record
of Common Stock (or such other capital stock or securities at the time issuable upon the conversion of the Preferred Stock) shall be entitled to exchange their shares of Common Stock (or such other capital stock or securities) for securities or
other property deliverable upon such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or <FONT STYLE="white-space:nowrap">winding-up,</FONT> and the amount per share and character of such exchange
applicable to the Preferred Stock and the Common Stock. Such notice shall be sent at least ten (10)&nbsp;days prior to the record date or effective date for the event specified in such notice. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5. <U>Mandatory Conversion</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.1 <U>Trigger Events</U>. Upon either (a)&nbsp;the closing of the sale of shares of Common Stock to the public at a price of at least 1.1
times the Series C Original Issue Price per share then in effect, in a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in at least $40,000,000 of
gross proceeds to the Corporation and following which the Common Stock of the Corporation shall be listed or quoted on The Nasdaq Global Market or New York Stock Exchange (a &#147;<B>Qualified IPO</B>&#148;) or (b)&nbsp;the date and time, or the
occurrence of an event, specified by vote or written consent of the Applicable Requisite Investors (the time of such closing or the date and time specified or the time of the event specified in such vote or written consent is referred to herein as
the &#147;<B>Mandatory Conversion Time</B>&#148;), then (i)&nbsp;all outstanding shares of Series C Preferred Stock shall automatically be converted into shares of Common Stock, at the then effective conversion rate as calculated pursuant to
<U>Subsection 4.1.1</U> provided that such conversion is approved by written consent of holders of a majority of shares of Series C Preferred Stock(the &#147;<B>Series C Majority</B>&#148;), (ii) all outstanding shares of Series B Preferred Stock
shall automatically be converted into shares of Common Stock, at the then effective conversion rate as calculated pursuant to <U>Subsection 4.1.1</U> provided that such conversion is approved by written consent of holders of a majority of shares of
Series B Preferred Stock (the &#147;<B>Series B Majority</B>&#148;) and (iii)&nbsp;all outstanding shares of Series A Preferred Stock and Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock shall automatically
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 25 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be converted into shares of Common Stock, at the then effective conversion rate as calculated pursuant to <U>Subsection 4.1.1</U> provided that such conversion is approved by written consent of
holders of a majority of shares of Preferred Stock voting together as a single class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis (the &#147;<B>Preferred Majority</B>&#148;) (collectively, such conversion the &#147;<B>Mandatory
Conversion</B>&#148;). Such shares shall be retired and canceled pursuant to the Mandatory Conversion and may not be reissued by the Corporation. For this <U>Section</U><U></U><U>&nbsp;5.1</U>, the &#147;<B>Applicable Requisite Investors</B>&#148;
shall mean the Series C Majority with respect to <U>Subsection 5.1(b)(i)</U>, the Series B Majority with respect to <U>Subsection 5.1(b)(ii)</U> and the Preferred Majority with respect to <U>Subsection 5.1(b)(iii)</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.2 <U>Procedural Requirements</U>. All holders of record of shares of Preferred Stock shall be sent written notice of the Mandatory
Conversion Time and the place designated for mandatory conversion of all such shares of Preferred Stock pursuant to this <U>Section</U><U></U><U>&nbsp;5</U>. Such notice need not be sent in advance of the occurrence of the Mandatory Conversion Time.
Upon receipt of such notice, each holder of shares of Preferred Stock in certificated form shall surrender his, her or its certificate or certificates for all such shares (or, if such holder alleges that such certificate has been lost, stolen or
destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such
certificate) to the Corporation at the place designated in such notice. If so required by the Corporation, any certificates surrendered for conversion shall be endorsed or accompanied by written instrument or instruments of transfer, in form
satisfactory to the Corporation, duly executed by the registered holder or by his, her or its attorney duly authorized in writing. All rights with respect to the Preferred Stock converted pursuant to <U>Section</U><U></U><U>&nbsp;5.1</U>, including
the rights, if any, to receive notices and vote (other than as a holder of Common Stock), will terminate at the Mandatory Conversion Time (notwithstanding the failure of the holder or holders thereof to surrender any certificates at or prior to such
time), except only the rights of the holders thereof, upon surrender of any certificate or certificates of such holders (or lost certificate affidavit and agreement) therefor, to receive the items provided for in the next sentence of this
<U>Section</U><U></U><U>&nbsp;5.2</U>. As soon as practicable after the Mandatory Conversion Time and, if applicable, the surrender of any certificate or certificates (or lost certificate affidavit and agreement) for Preferred Stock, the Corporation
shall (a)&nbsp;issue and deliver to such holder, or to his, her or its nominees, a certificate or certificates for the number of full shares of Common Stock issuable on such conversion in accordance with the provisions hereof and (b)&nbsp;pay cash
as provided in <U>Subsection</U><U></U><U>&nbsp;4.2</U> in lieu of any fraction of a share of Common Stock otherwise issuable upon such conversion and the payment of any declared but unpaid dividends on the shares of Preferred Stock converted. Such
converted Preferred Stock shall be retired and cancelled and may not be reissued as shares of such series, and the Corporation may thereafter take such appropriate action (without the need for stockholder action) as may be necessary to reduce the
authorized number of shares of Preferred Stock accordingly. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 26 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6. <U>Redemption</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.1 <U>General</U>. Unless prohibited by Delaware law governing distributions to stockholders, shares of Series C Preferred Stock, Series B
Preferred Stock and Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock shall be redeemed by the Corporation at a price per share equal to the greater of (A)&nbsp;the Series C Preferred Liquidation Amount, Series B Preferred
Liquidation Amount and Series <FONT STYLE="white-space:nowrap">A-2</FONT> Liquidation Amount, respectively and (B)&nbsp;the Fair Market Value (determined in the manner set forth below) of a single share of Series C Preferred Stock, Series B
Preferred Stock and Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, respectively, as of the date of the Company&#146;s receipt of the Redemption Request<B> </B>(the &#147;<B>Redemption Price</B>&#148;), in three (3)&nbsp;annual
installments commencing not more than ninety (90)&nbsp;days after receipt by the Corporation at any time on or after the fifth anniversary of the Original Issue Date from the holders of (i)&nbsp;with respect to the shares of Series B Preferred Stock
and Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, the holders of a majority of the shares of Series B Preferred Stock and Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock voting together on an <FONT
STYLE="white-space:nowrap">as-if</FONT> converted basis or (ii)&nbsp;with respect to the shares of Series C Preferred Stock, the Series C Majority, ((i) and (ii)&nbsp;the &#147;<B>Redemption Requisite Investors</B>&#148;) of written notice
requesting redemption of all shares of Series C Preferred Stock, Series B Preferred Stock and Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock (the &#147;<B>Redemption Request</B>&#148;). Upon receipt of a Redemption Request, the
Corporation shall apply all of its assets to any such redemption, and to no other corporate purpose, except to the extent prohibited by Delaware law governing distributions to stockholders. For purposes of this <U>Section</U><U></U><U>&nbsp;6.1</U>,
the Fair Market Value of a single share of Series C Preferred Stock, Series B Preferred Stock and Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock shall be the value of a single share of Series C Preferred Stock, Series B Preferred
Stock and Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, respectively, as mutually agreed upon by the Company and the Redemption Requisite Investors, and, in the event that they are unable to reach agreement, as determined by a
third-party appraiser agreed to by the Company and the Redemption Requisite Investors. The date of each such installment shall be referred to as a &#147;<B>Redemption Date.</B>&#148; On each Redemption Date, the Corporation shall redeem, in total,
that number of shares that is equal to (i)&nbsp;the total number of shares of Series C Preferred Stock, Series B Preferred Stock and Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock outstanding, respectively, immediately prior to
such Redemption Date divided by (ii)&nbsp;the number of remaining Redemption Dates (including the Redemption Date to which such calculation applies). Prior to the redemption of any shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT>
Preferred Stock, all shares of Series B Preferred Stock shall be redeemed on a pro rata basis in accordance with the number of shares of Series B Preferred Stock then outstanding and prior to the redemption of any shares of Series B Preferred Stock,
all shares of Series C Preferred Stock shall be redeemed on a pro rata basis in accordance with the number of shares of Series C Preferred Stock then outstanding. After all shares of Series C Preferred Stock have been redeemed, all shares of Series
B Preferred Stock shall be redeemed on a pro rata basis in accordance with the number of shares of Series B Preferred Stock then outstanding. After all shares of Series B Preferred Stock have been redeemed, all shares of Series <FONT
STYLE="white-space:nowrap">A-2</FONT> Preferred Stock shall be redeemed on a pro rata basis in accordance with the number of shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock then outstanding. If on any Redemption Date
Delaware law governing distributions to stockholders prevents the Corporation from redeeming all shares to be redeemed pursuant to this <U>Section</U><U></U><U>&nbsp;6.1</U>, the Corporation shall redeem the maximum number of shares that it may
redeem consistent with such law, and shall ratably redeem the remaining shares as soon as it may lawfully do so under such law, in each case, consistent with the preferences set forth in this <U>Section</U><U></U><U>&nbsp;6.1</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 27 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.2 <U>Redemption Notice</U>. The Corporation shall send written notice of the mandatory
redemption (the &#147;<B>Redemption Notice</B>&#148;) to each holder of record of Preferred Stock not less than forty (40)&nbsp;days prior to each Redemption Date. Each Redemption Notice shall state: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) the number of shares of Preferred Stock held by the holder that the Corporation shall redeem on the Redemption Date specified in the
Redemption Notice; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) the Redemption Date and the Redemption Price; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c) the date upon which the holder&#146;s right to convert such shares terminates (as determined in accordance with Subsection 4.1); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(d) for holders of shares in certificated form, that the holder is to surrender to the Corporation, in the manner and at the place designated,
his, her or its certificate or certificates representing the shares of Preferred Stock to be redeemed. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.3 <U>Surrender of Certificates;
Payment</U>. On or before the applicable Redemption Date, each holder of shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, Series B Preferred Stock and Series C Preferred Stock to be redeemed on such Redemption Date,
unless such holder has exercised his, her or its right to convert such shares as provided in <U>Section</U><U></U><U>&nbsp;4</U>, shall, if a holder of shares in certificated form, surrender the certificate or certificates representing such shares
(or, if such registered holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made
against the Corporation on account of the alleged loss, theft or destruction of such certificate) to the Corporation, in the manner and at the place designated in the Redemption Notice, and thereupon the Redemption Price for such shares shall be
payable to the order of the person whose name appears on such certificate or certificates as the owner thereof. In the event less than all of the shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, Series B Preferred Stock
or Series C Preferred Stock represented by a certificate are redeemed, a new certificate, instrument, or book entry representing the unredeemed shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, Series B Preferred Stock or
Series C Preferred Stock, as applicable, shall promptly be issued to such holder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.4 <U>Rights Subsequent to Redemption</U>. If the
Redemption Notice shall have been duly given, and if on the applicable Redemption Date the Redemption Price payable upon redemption of the shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, Series B Preferred Stock and/or
Series C Preferred Stock to be redeemed on such Redemption Date is paid or tendered for payment or deposited with an independent payment agent so as to be available therefor in a timely manner, then notwithstanding that any certificates evidencing
any of the shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, Series B Preferred Stock and/or Series C Preferred Stock so called for redemption shall not have been surrendered, dividends with respect to such shares of
Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, Series B Preferred Stock or Series C Preferred Stock shall cease to accrue after such Redemption Date and all rights with respect to such shares shall forthwith after the Redemption
Date terminate, except only the right of the holders to receive the Redemption Price without interest upon surrender of any such certificate or certificates therefor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 28 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7. <U>Redeemed or Otherwise Acquired Shares</U>. Any shares of Preferred Stock that are
redeemed or otherwise acquired by the Corporation or any of its subsidiaries shall be automatically and immediately cancelled and retired and shall not be reissued, sold or transferred. Neither the Corporation nor any of its subsidiaries may
exercise any voting or other rights granted to the holders of Preferred Stock following redemption. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8. <U>Waiver</U>. Any of the rights,
powers, preferences and other terms applicable to the Preferred Stock set forth herein may be waived on behalf of all holders of Preferred Stock by the affirmative written consent or vote of the Requisite Investors. Any of the rights, powers,
preferences and other terms unique to the Series A Preferred Stock set forth herein may be waived on behalf of all holders of Series A Preferred Stock by the affirmative written consent or vote of the holders of a majority of the shares of Series A
Preferred Stock then outstanding. Any of the rights, powers, preferences and other terms unique to the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock set forth herein may be waived on behalf of all holders of Series <FONT
STYLE="white-space:nowrap">A-2</FONT> Preferred Stock by the affirmative written consent or vote of the holders of a majority of the shares of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock then outstanding. Any of the rights,
powers, preferences and other terms unique to the Series B Preferred Stock set forth herein may be waived on behalf of all holders of Series B Preferred Stock by the affirmative written consent or vote of the holders of a majority of the shares of
Series B Preferred Stock then outstanding. Any of the rights, powers, preferences and other terms unique to the Series C Preferred Stock set forth herein may be waived on behalf of all holders of Series C Preferred Stock by the affirmative written
consent or vote of the holders of a majority of the shares of Series C Preferred Stock then outstanding. Any of the rights, powers, preferences and other terms unique to the Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, Series
B Preferred Stock and Series C Preferred Stock together set forth herein may be waived on behalf of all holders of Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Stock, Series B Preferred Stock and Series C Preferred Stock, as
applicable, by the affirmative written consent or vote of the Redemption Requisite Investors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9. <U>Notices</U>. Any notice required or
permitted by the provisions of this Article Fourth to be given to a holder of shares of Preferred Stock shall be mailed, postage prepaid, to the post office address last shown on the records of the Corporation, or given by electronic communication
in compliance with the provisions of the General Corporation Law, and shall be deemed sent upon such mailing or electronic transmission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>FIFTH: </B>Subject to any additional vote required by the Certificate of Incorporation or Bylaws, in furtherance and not in limitation of
the powers conferred by statute, the Board of Directors is expressly authorized to make, repeal, alter, amend and rescind any or all of the Bylaws of the Corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 29 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>SIXTH: </B>Subject to any additional vote required by the Certificate of Incorporation,
the number of directors of the Corporation shall be determined in the manner set forth in the Bylaws of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>SEVENTH:
</B>Elections of directors need not be by written ballot unless the Bylaws of the Corporation shall so provide. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>EIGHTH: </B>Meetings
of stockholders may be held within or without the State of Delaware, as the Bylaws of the Corporation may provide. The books of the Corporation may be kept outside the State of Delaware at such place or places as may be designated from time to time
by the Board of Directors or in the Bylaws of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>NINTH: </B>To the fullest extent permitted by law, a director of the
Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director. If the General Corporation Law or any other law of the State of Delaware is amended after approval by
the stockholders of this Article Ninth to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent
permitted by the General Corporation Law as so amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any repeal or modification of the foregoing provisions of this Article Ninth by
the stockholders of the Corporation shall not adversely affect any right or protection of a director of the Corporation existing at the time of, or increase the liability of any director of the Corporation with respect to any acts or omissions of
such director occurring prior to, such repeal or modification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>TENTH: </B><B></B>To the fullest extent permitted by applicable law,
the Corporation is authorized to provide indemnification of (and advancement of expenses to) directors, officers and agents of the Corporation (and any other persons to which General Corporation Law permits the Corporation to provide
indemnification) through Bylaw provisions, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise, in excess of the indemnification and advancement otherwise permitted by
<U>Section</U><U></U><U>&nbsp;145</U> of the General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Any amendment, repeal or modification of the foregoing provisions
of this Article Tenth shall not adversely affect any right or protection of any director, officer or other agent of the Corporation existing at the time of such amendment, repeal or modification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>ELEVENTH: </B>The Corporation renounces, to the fullest extent permitted by law, any interest or expectancy of the Corporation in, or in
being offered an opportunity to participate in, any Excluded Opportunity. An &#147;<B>Excluded Opportunity</B>&#148; is any matter, transaction or interest that is presented to, or acquired, created or developed by, or which otherwise comes into the
possession of (i)&nbsp;any director of the Corporation who is not an employee of the Corporation or any of its subsidiaries, or (ii)&nbsp;any holder of Preferred Stock or any partner, member, director, stockholder, employee or agent of any such
holder, other than someone who is an employee of the Corporation or any of its subsidiaries (collectively, &#147;<B>Covered Persons</B>&#148;), unless such matter, transaction or interest is presented to, or acquired, created or developed by, or
otherwise comes into the possession of, a Covered Person expressly and solely in such Covered Person&#146;s capacity as a director of the Corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 30 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>TWELFTH: </B>Unless the Corporation consents in writing to the selection of an
alternative forum, the Court of Chancery in the State of Delaware shall be the sole and exclusive forum for any stockholder (including a beneficial owner) to bring (i)&nbsp;any derivative action or proceeding brought on behalf of the Corporation,
(ii)&nbsp;any action asserting a claim of breach of fiduciary duty owed by any director, officer or other employee of the Corporation to the Corporation or the Corporation&#146;s stockholders, (iii)&nbsp;any action asserting a claim against the
Corporation, its directors, officers or employees arising pursuant to any provision of the Delaware General Corporation Law or the Corporation&#146;s certificate of incorporation or bylaws or (iv)&nbsp;any action asserting a claim against the
Corporation, its directors, officers or employees governed by the internal affairs doctrine, except for, as to each of (i)&nbsp;through (iv) above, any claim as to which the Court of Chancery determines that there is an indispensable party not
subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten days following such determination), which is vested in the exclusive jurisdiction of
a court or forum other than the Court of Chancery, or for which the Court of Chancery does not have subject matter jurisdiction. If any provision or provisions of this Article Twelfth shall be held to be invalid, illegal or unenforceable as applied
to any person or entity or circumstance for any reason whatsoever, then, to the fullest extent permitted by law, the validity, legality and enforceability of such provisions in any other circumstance and of the remaining provisions of this Article
Twelfth (including, without limitation, each portion of any sentence of this Article Twelfth containing any such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) and the
application of such provision to other persons or entities and circumstances shall not in any way be affected or impaired thereby. Notwithstanding the foregoing, Maryland Venture Fund InvestMaryland II, LLC (&#147;<B>MVF</B>&#148;), Maryland Venture
Partners, L.P. (&#147;<B>MVP</B>&#148;), Maryland Innovation Opportunity Fund I, LLC (&#147;<B>MIOF</B>&#148;), Maryland Innovation Venture Fund Enterprise Fund, LLC (&#147;<B>MVFEIF</B>&#148;) and the Maryland Technology Development Corporation
(&#147;<B>TEDCO</B>&#148; and together with MVP, MVF, MIOF and MVFEIF and any of their successors and assigns that are controlled by TEDCO, the &#147;<B>MVF Parties</B>&#148;), each of which are or may become stockholders of the Company, do not
consent to the selection of the Court of Chancery of the State of Delaware as to the actions set forth in this Article TWELFTH, and this Article TWELFTH shall not govern with respect to any actions brought by, on behalf of or against the MVF Parties
or the State of Maryland. The appropriate forum for such actions with respect to the MVF Parties or the State of Maryland shall be a court in the state of Maryland (or in the event of exclusive federal jurisdiction, the federal courts for the
District of Maryland). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>THIRTEENTH: </B>For purposes of Section&nbsp;500 of the California Corporations Code (to the extent
applicable), in connection with any repurchase of shares of Common Stock permitted under this Certificate of Incorporation from employees, officers, directors or consultants of the Company in connection with a termination of employment or services
pursuant to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 31 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreements or arrangements approved by the Board of Directors (in addition to any other consent required under this Certificate of Incorporation), such repurchase may be made without regard to
any &#147;preferential dividends arrears amount&#148; or &#147;preferential rights amount&#148; (as those terms are defined in Section&nbsp;500 of the California Corporations Code). Accordingly, for purposes of making any calculation under
California Corporations Code Section&nbsp;500 in connection with such repurchase, the amount of any &#147;preferential dividends arrears amount&#148; or &#147;preferential rights amount&#148; (as those terms are defined therein) shall be deemed to
be zero (0). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;* </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3. </B>That the foregoing amendment and restatement was approved by the holders of the requisite number of shares of this corporation in
accordance with Section&nbsp;228 of the General Corporation Law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4. </B>That this Amended and Restated Certificate of Incorporation,
which restates and integrates and further amends the provisions of this Corporation&#146;s Certificate of Incorporation, has been duly adopted in accordance with Sections 242 and 245 of the General Corporation Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 32 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, this Amended and Restated Certificate of Incorporation has been
executed by a duly authorized officer of this corporation on this 30<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day of July, 2019. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Fr&eacute;d&eacute;ric Guerard</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Fr&eacute;d&eacute;ric Guerard</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE PAGE TO GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF AMENDMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO THE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESTATED
CERTIFICATE OF INCORPORATION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Graybug Vision, Inc. (the &#147;<B><I>Corporation</I></B>&#148;), a corporation duly organized and existing under the General Corporation Law
of the State of Delaware (the &#147;<B><I>DGCL</I></B>&#148;), does hereby certify that the following amendment to the Corporation&#146;s Restated Certificate of Incorporation, filed with the Delaware Secretary of State on July&nbsp;30, 2019 (the
&#147;<B><I>Current Certificate</I></B>&#148;), has been duly adopted in accordance with the provisions of Section&nbsp;242 of the Delaware General Corporation Law, with the approval of such amendment by the Corporation&#146;s stockholders having
been given by written consent without a meeting in accordance with Sections 228(d) and 242 of the DGCL: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The following two paragraphs
are hereby added to precede the first paragraph of Article FOURTH of the Current Certificate: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Contingent and effective upon the
filing of this Certificate of Amendment to the Restated Certificate of Incorporation (the &#147;<B><I>Certificate of Amendment</I></B>&#148;), every 9.0058 outstanding shares of Common Stock will be combined into and automatically, without any
further action by the Corporation or the stockholders thereof, become one outstanding share of Common Stock, of the Corporation (the &#147;<B><I>Reverse</I></B><B><I>&nbsp;Stock Split</I></B>&#148;). No fractional share shall be issued in connection
with the foregoing combination of the shares pursuant to the Reverse Stock Split. The Corporation will pay in cash the fair value of such fractional shares, without interest and as determined in good faith by the Board of Directors of the
Corporation when those entitled to receive such fractional shares are determined. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Reverse Stock Split shall occur automatically
without any further action by the holders of Common Stock or Preferred Stock, and whether or not the certificates representing such shares have been surrendered to the Corporation;<I>&nbsp;provided, however</I>, that the Corporation shall not be
obligated to issue certificates evidencing the shares of Common Stock issuable as a result of the Reverse Stock Split unless the existing certificates evidencing the applicable shares of stock prior to the Reverse Stock Split are either delivered to
the Corporation, or the holder notifies the Corporation that such certificates have been lost, stolen or destroyed, and executes an agreement satisfactory to the Corporation to indemnify the Corporation from any loss incurred by it in connection
with such certificates.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. The foregoing amendment to the Current Certificate has been duly approved by the Corporation&#146;s
Board of Directors in accordance with Sections 141 and 242 of the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. The foregoing amendment to Current Certificate has been duly
approved by the Corporation&#146;s stockholders in accordance with Sections 228 and 242 of the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. This Certificate of Amendment
shall be effective upon filing with the Delaware Secretary of State. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[SIGNATURE PAGE FOLLOWS] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be signed by
its duly authorized officer this 18th day of September, 2020 and the foregoing facts stated herein are true and correct. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>GRAYBUG VISION, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Frederic Guerard</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Frederic Guerard</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>d796801dex41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.1 </B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g69361page001.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">GB INCORPORATED UNDER THE CUSIP 38942Q 10 3 LAWS OF THE STATE SEE REVERSE FOR CERTAIN OF DELAWARE DEFINITIONS AND LEGENDS This certifies
that is the record holder of FULLY PAID AND NONASSESSABLE SHARES OF COMMON STOCK, $0.0001 PAR VALUE PER SHARE, OF GRAYBUG VISION, INC. transferable on the books of the Corporation in person or by duly authorized attorney upon surrender of this
Certificate properly endorsed. This Certificate is not valid until countersigned by the Transfer Agent and registered by the Registrar. WITNESS the facsimile seal of the Corporation and the facsimile signatures of its duly authorized officers.
Dated: AUTHORIZED BUG VISIO Y N, A RPORA I N R O TE G CSEAL C . SIGNATURE CHIEF EXECUTIVE OFFICER CHIEF FINANCIAL OFFICER COUNTERSIGNED AND REGISTERED: AMERICAN STOCK TRANSFER TRUST&amp; COMPANY, LLC (BROOKLYN, NY) TRANSFER AGENT AND REGISTRAR BY:
CHIEF EXECUTIVE OFFICER CHIEF FINANCIAL OFFICER </FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g69361page002.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">The Corporation shall furnish without charge to each stockholder who so requests a statement of the powers, designations, preferences
and relative, participating, optional or other special rights of each class of stock of the Corporation or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. Such requests shall be made to the
Corporation&#146;s Secretary at the principal office of the Corporation. KEEP THIS CERTIFICATE IN A SAFE PLACE. IF IT IS LOST, STOLEN, OR DESTROYED THE CORPORATION WILL REQUIRE A BOND INDEMNITY AS A CONDITION TO THE ISSUANCE OF A REPLACEMENT
CERTIFICATE. The following abbreviations, when used in the inscription on the face of this certificate, shall be construed as though they were written out in full according to applicable laws or regulations: TEN COM &#150; as tenants in common UNIF
GIFT MIN ACT &#150; . Custodian TEN ENT &#150; as tenants by the entireties (Cust) (Minor) JT TEN &#150; as joint tenants with right of under Uniform Gifts to Minors survivorship and not as tenants Act (State) in common COM PROP &#150; as community
property UNIF TRF MIN ACT &#150;Custodian (until age) (Cust) (Minor) under Uniform Transfers to Minors Act (State) Additional abbreviations may also be used though not in the above list. FOR VALUE RECEIVED, hereby sell(s), assign(s) and transfer(s)
unto PLEASE INSERT SOCIAL SECURITY OR OTHER IDENTIFYING NUMBER OF ASSIGNEE (PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING ZIP CODE, OF ASSIGNEE) shares of the capital stock represented by within Certificate, and do hereby irrevocably
constitute and appoint <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> to transfer the said stock on the books of the within named Corporation with full power of the substitution in the premises.
Dated X X Signature(s) Guaranteed: NOTICE: THE SIGNATURE TO THIS ASSIGNMENT MUST CORRESPOND WITH THE NAME AS WRITTEN UPON THE FACE OF THE CERTIFICATE IN EVERY PARTICULAR, WITHOUT ALTERATION OR ENLARGEMENT OR ANY CHANGE WHATSOEVER. By THE
SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION, (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM), PURSUANT TO S.E.C. RULE <FONT
STYLE="white-space:nowrap">17Ad-15.</FONT> GUARANTEES BY A NOTARY PUBLIC ARE NOT ACCEPTABLE. SIGNATURE GUARANTEES MUST NOT BE DATED. </FONT></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>d796801dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g69361fw001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">September&nbsp;21, 2020 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Graybug Vision, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">275 Shoreline Drive, Suite 450 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Redwood City, CA 94065 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At your request, we have examined the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File Number <FONT
STYLE="white-space:nowrap">333-248611)</FONT> (the &#147;<B><I>Registration Statement</I></B>&#148;) initially filed by Graybug Vision, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), with the Securities and Exchange Commission
(the &#147;<B><I>Commission</I></B>&#148;) on or about September&nbsp;4, 2020 as subsequently amended on September&nbsp;21, 2020, in connection with the registration under the Securities Act of 1933, as amended (&#147;<B><I>Securities
Act</I></B>&#148;), of the issuance of an aggregate of up to 5,390,625 shares of the Company&#146;s Common Stock (the &#147;<B><I>Stock</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with our opinion expressed below we have examined originals or copies of the underwriting agreement pursuant to which the Stock
will be sold to the underwriters, the Registration Statement, the prospectus prepared in connection with the Registration Statement (the &#147;<B><I>Prospectus</I></B>&#148;), the Company&#146;s certificate of incorporation, as amended (the
&#147;<B><I>Amended and Restated</I></B> <B><I>Certificate</I></B>&#148;), and the Company&#146;s bylaws (the &#147;<B><I>Amended and Restated</I></B> <B><I>Bylaws</I></B>&#148;), certain minutes and consents of the Company&#146;s board of directors
(the &#147;<B><I>Board</I></B>&#148;) or a committee or committees thereof and the Company&#146;s stockholders relating to the Registration Statement, the Amended and Restated Certificate and the Amended and Restated Bylaws, and such other
agreements, documents, certificates and statements of the Company, its transfer agent and public or government officials, as we have deemed advisable, and have examined such questions of law as we have considered necessary. In giving our opinion, we
have also relied upon a good standing certificate regarding the Company issued by the Delaware Secretary of State and a management certificate addressed to us and dated of even date herewith executed by the Company containing certain factual
representations by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our examination of documents for purposes of this opinion, we have assumed, and express no opinion as
to, the genuineness of all signatures on original documents, the authenticity and completeness of all documents submitted to us as originals, the conformity to originals and completeness of all documents submitted to us as copies, the legal capacity
of all persons or entities executing the same (other than the Company), the lack of any undisclosed termination, modification, waiver or amendment to any document reviewed by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We render this opinion only with respect to, and express no opinion herein concerning the application or effect of the laws of any
jurisdiction other than, the existing Delaware General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with our opinion expressed below, we have assumed
that, at or prior to the time of the delivery of any shares of Stock, the Registration Statement will have been declared effective under the Securities Act that the registration will apply to the offer and sale of such shares of Stock and will not
have been modified or rescinded and that there will not have occurred any change in law affecting the validity of the issuance of such shares of Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon the foregoing, we are of the opinion that the up to 5,390,625 shares of Stock that may be issued and sold by the Company, when
issued, sold and delivered in the manner and for the consideration stated in the Registration Statement and the Prospectus and in accordance with the resolutions adopted by the Board and to be adopted by the pricing committee of the Board, will be
validly issued, fully paid and nonassessable. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We consent to the use of this opinion as an exhibit to the Registration Statement and
further consent to all references to us, if any, in the Registration Statement, the Prospectus constituting a part thereof and any amendments thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion is intended solely for use in connection with issuance and sale of shares of Stock subject to the Registration Statement and is
not to be relied upon for any other purpose. This opinion is rendered as of the date first written above and is based solely on our understanding of facts in existence as of such date after the aforementioned examination. In rendering the opinions
above, we are opining only as to the specific legal issues expressly set forth therein, and no opinion shall be inferred as to any other matter or matters. We assume no obligation to advise you of any fact, circumstance, event or change in the law
or the facts that may hereafter be brought to our attention whether or not such occurrence would affect or modify any of the opinions expressed herein. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Fenwick&nbsp;&amp; West LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>FENWICK&nbsp;&amp; WEST LLP</B></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>5
<FILENAME>d796801dex103.htm
<DESCRIPTION>EX-10.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2020 EQUITY INCENTIVE PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.</B><B><U> PURPOSE</U></B>. The purpose of this Plan is to provide incentives to attract, retain and motivate eligible persons whose present and
potential contributions are important to the success of the Company, and any Parents, Subsidiaries and Affiliates that exist now or in the future, by offering them an opportunity to participate in the Company&#146;s future performance through the
grant of Awards. Capitalized terms not defined elsewhere in the text are defined in Section&nbsp;28. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.</B> <B><U>SHARES SUBJECT TO THE PLAN</U></B>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.1.</B> <U>Number of Shares Available</U>. Subject to Section&nbsp;2.4, Section&nbsp;2.6 and Section&nbsp;21 and any other applicable
provisions hereof, the total number of Shares reserved and available for grant and issuance pursuant to this Plan as of the date of adoption of the Plan by the Board, is 1,850,000 Shares, plus (a)&nbsp;any reserved shares not issued or subject to
outstanding grants under the Company&#146;s 2015 Stock Incentive Plan (the &#147;<B><I>Prior Plan</I></B>&#148;) on the Effective Date, (b)&nbsp;shares that are subject to stock options or other awards granted under the Prior Plan that cease to be
subject to such stock options or other awards by forfeiture or otherwise after the Effective Date, (c)&nbsp;shares issued under the Prior Plan before or after the Effective Date pursuant to the exercise of stock options that are, after the Effective
Date, forfeited, (d)&nbsp;shares issued under the Prior Plan that are repurchased by the Company at the original issue price and (e)&nbsp;shares that are subject to stock options or other awards under the Prior Plan that are used to pay the exercise
price of an option or withheld to satisfy the tax withholding obligations related to any award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.2.</B> <U>Lapsed, Returned
Awards</U>. Shares subject to Awards, and Shares issued under the Plan under any Award, will again be available for grant and issuance in connection with subsequent Awards under this Plan to the extent such Shares: (a)&nbsp;are subject to issuance
upon exercise of an Option or SAR granted under this Plan but which cease to be subject to the Option or SAR for any reason other than exercise of the Option or SAR; (b)&nbsp;are subject to Awards granted under this Plan that are forfeited or are
repurchased by the Company at the original issue price; (c)&nbsp;are subject to Awards granted under this Plan that otherwise terminate without such Shares being issued; or (d)&nbsp;are surrendered pursuant to an Exchange Program. To the extent an
Award under the Plan is paid out in cash rather than Shares, such cash payment will not result in reducing the number of Shares available for issuance under the Plan. Shares used to pay the exercise price of an Award or withheld to satisfy the tax
withholding obligations related to an Award will become available for future grant or sale under the Plan. For the avoidance of doubt, Shares that otherwise become available for grant and issuance because of the provisions of this Section&nbsp;2.2
shall not include Shares subject to Awards that initially became available because of the substitution clause in Section&nbsp;21.2 hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.3.</B> <U>Minimum Share Reserve</U>. At all times the Company will reserve and keep available a sufficient number of Shares as will be
required to satisfy the requirements of all outstanding Awards granted under this Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.4.</B> <U>Automatic Share Reserve
Increase</U>. The number of Shares available for grant and issuance under the Plan will be increased on January&nbsp;1 for each of the first ten (10)&nbsp;calendar years during the term of the Plan by the lesser of (a)&nbsp;Five percent (5%) of all
classes of the Company&#146;s common stock outstanding on each December&nbsp;31 immediately prior to the date of increase or (b)&nbsp;such number of Shares determined by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.5.</B> <U>ISO Limitation</U>. No more than 5,550,000 Shares shall be issued pursuant to the exercise of ISOs (as defined below) under the
Plan. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.6.</B> <U>Adjustment of Shares</U>. If the number of outstanding Shares is changed by a
stock dividend, extraordinary dividend or distribution (whether in cash, shares or other property, other than a regular cash dividend), recapitalization, stock split, reverse stock split, subdivision, combination, consolidation, reclassification, <FONT
STYLE="white-space:nowrap">spin-off</FONT> or similar change in the capital structure of the Company, without consideration, then (a)&nbsp;the number and class of Shares reserved for issuance and future grant under the Plan set forth in
Section&nbsp;2.1, including shares reserved under <FONT STYLE="white-space:nowrap">sub-clauses</FONT> (a)-(e) of Section&nbsp;2.1, (b)&nbsp;the Exercise Prices of and number and class of Shares subject to outstanding Options and SARs, (c)&nbsp;the
number and class of Shares subject to other outstanding Awards and (d)&nbsp;the maximum number and class of Shares that may be issued as ISOs set forth in Section&nbsp;2.5 will be proportionately adjusted, subject to any required action by the Board
or the stockholders of the Company and in compliance with applicable securities laws; provided that fractions of a Share will not be issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, by reason of an adjustment pursuant to this Section&nbsp;2.6, a Participant&#146;s Award Agreement or other agreement related to any Award
or the Shares subject to such Award covers additional or different shares of stock or securities, then such additional or different shares, and the Award Agreement or such other agreement in respect thereof, will be subject to all of the terms,
conditions and restrictions that were applicable to the Award or the Shares subject to such Award prior to such adjustment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.</B>
<B><U>ELIGIBILITY</U></B>. ISOs may be granted only to Employees. All other Awards may be granted to Employees, Consultants and <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors; <U>provided</U> such Consultants and <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Directors render bona fide services not in connection with the offer and sale of securities in a capital-raising transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B><U>ADMINISTRATION</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.1.</B> <U>Committee Composition; Authority</U>. This Plan will be administered by the Committee or by the Board acting as the Committee.
Subject to the general purposes, terms and conditions of this Plan, and to the direction of the Board, the Committee will have full power to implement and carry out this Plan, except, however, the Board will establish the terms for the grant of an
Award to <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors. The Committee will have the authority to: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) construe and
interpret this Plan, any Award Agreement and any other agreement or document executed pursuant to this Plan; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) prescribe, amend and
rescind rules and regulations relating to this Plan or any Award; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) select persons to receive Awards; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) determine the form and terms and conditions, not inconsistent with the terms of the Plan, of any Award granted hereunder. Such terms and
conditions include, but are not limited to, the Exercise Price, the time or times when Awards may vest and be exercised (which may be based on performance criteria) or settled, any vesting acceleration or waiver of forfeiture restrictions, the
method to satisfy tax withholding obligations or any other tax liability legally due and any restriction or limitation regarding any Award or the Shares relating thereto, based in each case on such factors as the Committee will determine; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) determine the number of Shares or other consideration subject to Awards; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) determine the Fair Market Value in good faith and interpret the applicable provisions of this Plan and the definition of Fair Market Value
in connection with circumstances that impact the Fair Market Value, if necessary; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) determine whether Awards will be granted singly, in combination with, in tandem with, in
replacement of, or as alternatives to, other Awards under this Plan or any other incentive or compensation plan of the Company or any Parent, Subsidiary or Affiliate; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) grant waivers of Plan or Award conditions; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) determine the vesting, exercisability and payment of Awards; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) correct any defect, supply any omission or reconcile any inconsistency in this Plan, any Award or any Award Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) determine whether an Award has been vested and/or earned; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) determine the terms and conditions of, and institute, any Exchange Program; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) reduce, waive or modify any criteria with respect to Performance Factors; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) adjust Performance Factors; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) adopt terms and conditions, rules and/or procedures (including the adoption of any subplan under this Plan) relating to the operation and
administration of the Plan to accommodate requirements of local law and procedures outside of the United States or to qualify Awards for special tax treatment under laws of jurisdictions other than the United States; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) exercise discretion with respect to Performance Awards; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(q) make all other determinations necessary or advisable for the administration of this Plan; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(r) delegate any of the foregoing to a subcommittee or to one or more executive officers pursuant to a specific delegation as permitted by
applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.2.</B> <U>Committee</U><U></U><U>&nbsp;Interpretation and Discretion</U>. Any determination made by the Committee
with respect to any Award will be made in its sole discretion at the time of grant of the Award or, unless in contravention of any express term of the Plan or Award, at any later time, and such determination will be final and binding on the Company
and all persons having an interest in any Award under the Plan. Any dispute regarding the interpretation of the Plan or any Award Agreement will be submitted by the Participant or Company to the Committee for review. The resolution of such a dispute
by the Committee will be final and binding on the Company and the Participant. The Committee may delegate to one or more executive officers the authority to review and resolve disputes with respect to Awards held by Participants who are not
Insiders, and such resolution will be final and binding on the Company and the Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.3.</B> <U>Section 16 of the Exchange
Act</U>. Awards granted to Participants who are subject to Section&nbsp;16 of the Exchange Act must be approved by two or more <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> directors&#148; (as defined in the regulations promulgated
under Section&nbsp;16 of the Exchange Act). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.4.</B> <U>Documentation</U>. The Award Agreement for a given Award, the Plan and any
other documents may be delivered to, and accepted by, a Participant or any other person in any manner (including electronic distribution or posting) that meets applicable legal requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.5.</B> <U>Foreign Award Recipients</U>. Notwithstanding any provision of the Plan to the contrary, in order to comply with the laws and
practices in other countries in which the Company and its Subsidiaries or Affiliates operate or have Employees or other individuals eligible for Awards, the Committee, in its sole discretion, will have the power and authority to: (a)&nbsp;determine
which Subsidiaries and Affiliates will </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be covered by the Plan; (b)&nbsp;determine which individuals outside the United States are eligible to participate in the Plan; (c)&nbsp;modify the terms and conditions of any Award granted to
individuals outside the United States or foreign nationals to comply with applicable foreign laws, policies, customs and practices; (d)&nbsp;establish subplans and modify exercise procedures, vesting conditions, and other terms and procedures, to
the extent the Committee determines such actions to be necessary or advisable (and such subplans and/or modifications will be attached to this Plan as appendices, if necessary); provided, however, that no such subplans and/or modifications will
increase the share limitations contained in Section&nbsp;2.1 hereof; and (e)&nbsp;take any action, before or after an Award is made, that the Committee determines to be necessary or advisable to obtain approval or comply with any local governmental
regulatory exemptions or approvals. Notwithstanding the foregoing, the Committee may not take any actions hereunder, and no Awards will be granted, that would violate the Exchange Act or any other applicable United States securities law, the Code,
or any other applicable United States governing statute or law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B><U>OPTIONS</U></B>. An Option is the right but not the obligation to
purchase a Share, subject to certain conditions, if applicable. The Committee may grant Options to eligible Employees, Consultants and Directors and will determine whether such Options will be Incentive Stock Options within the meaning of the Code
(&#147;<B><I>ISOs</I></B>&#148;) or Nonqualified Stock Options (&#147;<B><I>NSOs</I></B>&#148;), the number of Shares subject to the Option, the Exercise Price of the Option, the period during which the Option may vest and be exercised, and all
other terms and conditions of the Option, subject to the following terms of this section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.1.</B> <U>Option Grant</U>. Each Option
granted under this Plan will identify the Option as an ISO or an NSO. An Option may be, but need not be, awarded upon satisfaction of such Performance Factors during any Performance Period as are set out in advance in the Participant&#146;s
individual Award Agreement. If the Option is being earned upon the satisfaction of Performance Factors, then the Committee will: (a)&nbsp;determine the nature, length and starting date of any Performance Period for each Option; and (b)&nbsp;select
from among the Performance Factors to be used to measure the performance, if any. Performance Periods may overlap and Participants may participate simultaneously with respect to Options that are subject to different performance goals and other
criteria. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.2.</B> <U>Date of Grant</U>. The date of grant of an Option will be the date on which the Committee makes the
determination to grant such Option, or a specified future date. The Award Agreement will be delivered to the Participant within a reasonable time after the granting of the Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.3.</B> <U>Exercise Period</U>. Options may be vested and exercisable within the times or upon the conditions as set forth in the Award
Agreement governing such Option; <U>provided</U>, <U>however</U>, that no Option will be exercisable after the expiration of ten (10)&nbsp;years from the date the Option is granted; and <U>provided further</U> that no ISO granted to a person who, at
the time the ISO is granted, directly or by attribution owns more than ten percent (10%) of the total combined voting power of all classes of stock of the Company or of any Parent or Subsidiary (&#147;<B><I>Ten Percent Stockholder</I></B>&#148;)
will be exercisable after the expiration of five (5)&nbsp;years from the date the ISO is granted. The Committee also may provide for Options to become exercisable at one time or from time to time, periodically or otherwise, in such number of Shares
or percentage of Shares as the Committee determines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.4.</B> <U>Exercise Price</U>. The Exercise Price of an Option will be
determined by the Committee when the Option is granted; provided that: (a)&nbsp;the Exercise Price of an Option will be not less than one hundred percent (100%) of the Fair Market Value of the Shares on the date of grant and (b)&nbsp;the Exercise
Price of any ISO granted to a Ten Percent Stockholder will not be less than one hundred ten percent (110%) of the Fair Market Value of the Shares on the date of grant. Payment for the Shares purchased may be made in accordance with Section&nbsp;11
and the Award Agreement and in accordance with any procedures established by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.5.</B> <U>Method of Exercise</U>. Any
Option granted hereunder will be vested and exercisable according to the terms of the Plan and at such times and under such conditions as determined by the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Committee and set forth in the Award Agreement. An Option may not be exercised for a fraction of a Share. An Option will be deemed exercised when the Company receives: (a)&nbsp;notice of exercise
(in such form as the Committee may specify from time to time) from the person entitled to exercise the Option (and/or via electronic execution through the authorized third-party administrator), and (b)&nbsp;full payment for the Shares with respect
to which the Option is exercised (together with applicable withholding taxes). Full payment may consist of any consideration and method of payment authorized by the Committee and permitted by the Award Agreement and the Plan. Shares issued upon
exercise of an Option will be issued in the name of the Participant. Until the Shares are issued (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), no right to vote or receive
dividends or any other rights as a stockholder will exist with respect to the Shares, notwithstanding the exercise of the Option. The Company will issue (or cause to be issued) such Shares promptly after the Option is exercised. No adjustment will
be made for a dividend or other right for which the record date is prior to the date the Shares are issued, except as provided in Section&nbsp;2.6 of the Plan. Exercising an Option in any manner will decrease the number of Shares thereafter
available, both for purposes of the Plan and for sale under the Option, by the number of Shares as to which the Option is exercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.6.</B> <U>Termination of Service</U>. If the Participant&#146;s Service terminates for any reason except for Cause or the
Participant&#146;s death or Disability, then the Participant may exercise such Participant&#146;s Options only to the extent that such Options would have been exercisable by the Participant on the date Participant&#146;s Service terminates. Such
Options must be exercised by the Participant on the earlier of the expiration date of the Options or three (3)&nbsp;months after the date Participant&#146;s Service terminates unless the Committee determines a shorter or longer time period, provided
that such time period is no later than the expiration date of the Options and that any exercise beyond three (3)&nbsp;months after the date Participant&#146;s employment terminates is deemed to be the exercise of an NSO. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Death</U>. If the Participant&#146;s Service terminates because of the Participant&#146;s death (or if the Participant dies within
three (3)&nbsp;months after Participant&#146;s Service terminates other than for Cause or because of the Participant&#146;s Disability), then the Participant&#146;s Options may be exercised only to the extent that such Options would have been
exercisable by the Participant on the date Participant&#146;s Service terminates. Such Options must be exercised by the Participant&#146;s legal representative, or authorized assignee, on the earlier of the expiration date of the Options or twelve
(12)&nbsp;months after the date Participant&#146;s Service terminates, unless the Committee determines a shorter or longer time period, provided that such time period is no later than the expiration date of the Options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Disability</U>. If the Participant&#146;s Service terminates because of the Participant&#146;s Disability, then the Participant&#146;s
Options may be exercised only to the extent that such Options would have been exercisable by the Participant on the date Participant&#146;s Service terminates. Such Options must be exercised by the Participant (or the Participant&#146;s legal
representative or authorized assignee) on the earlier of the expiration date of the Options or twelve (12)&nbsp;months after the date Participant&#146;s Service terminates, unless the Committee determines a shorter or longer time period, provided
that such time period is no later than the expiration date of the Options, with (a)&nbsp;any exercise beyond three (3)&nbsp;months after the date Participant&#146;s employment terminates when the termination of Service is for a Disability that is
not a &#147;permanent and total disability&#148; as defined in Section&nbsp;22(e)(3) of the Code, or (b)&nbsp;any exercise beyond twelve (12)&nbsp;months after the date Participant&#146;s employment terminates when the termination of Service is for
a Disability that is a &#147;permanent and total disability&#148; as defined in Section&nbsp;22(e)(3) of the Code, deemed to be exercise of an NSO. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Cause</U>. If the Participant&#146;s Service terminates for Cause, then Participant&#146;s Options (whether or not vested) will expire
on the date of termination of Participant&#146;s Service if the Committee has reasonably determined in good faith that such cessation of Services has resulted in connection with an act or failure to act constituting Cause (or such Participant&#146;s
Services could have been terminated for Cause (without regard to the lapsing of any required notice or cure periods in connection therewith) at the time such Participant terminated Services), or at such later time and on such conditions
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
as are determined by the Committee, but in any event no later than the expiration date of the Options. Unless otherwise provided in an employment agreement, Award Agreement, or other applicable
agreement, Cause will have the meaning set forth in the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.7.</B> <U>Limitations on Exercise</U>. The Committee may specify a
minimum number of Shares that may be purchased on any exercise of an Option, provided that such minimum number will not prevent any Participant from exercising the Option for the full number of Shares for which it is then exercisable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.8.</B> <U>Limitations on ISOs</U>. With respect to Awards granted as ISOs, to the extent that the aggregate Fair Market Value of the
Shares with respect to which such ISOs are exercisable for the first time by the Participant during any calendar year (under all plans of the Company and any Parent or Subsidiary) exceeds one hundred thousand dollars ($100,000), such Options will be
treated as NSOs. For purposes of this Section&nbsp;5.8, ISOs will be taken into account in the order in which they were granted. The Fair Market Value of the Shares will be determined as of the time the Option with respect to such Shares is granted.
In the event that the Code or the regulations promulgated thereunder are amended after the Effective Date to provide for a different limit on the Fair Market Value of Shares permitted to be subject to ISOs, such different limit will be automatically
incorporated herein and will apply to any Options granted after the effective date of such amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.9.</B> <U>Modification,
Extension or Renewal</U>. The Committee may modify, extend or renew outstanding Options and authorize the grant of new Options in substitution therefor, provided that any such action may not, without the written consent of a Participant, impair any
of such Participant&#146;s rights under any Option previously granted. Any outstanding ISO that is modified, extended, renewed or otherwise altered will be treated in accordance with Section&nbsp;424(h) of the Code. Subject to Section&nbsp;18 of
this Plan, by written notice to affected Participants, the Committee may reduce the Exercise Price of outstanding Options without the consent of such Participants; <U>provided</U>, <U>however</U>, that the Exercise Price may not be reduced below the
Fair Market Value on the date the action is taken to reduce the Exercise Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.10.</B> <U>No Disqualification</U>. Notwithstanding
any other provision in this Plan, no term of this Plan relating to ISOs will be interpreted, amended or altered, nor will any discretion or authority granted under this Plan be exercised, so as to disqualify this Plan under Section&nbsp;422 of the
Code or, without the consent of the Participant affected, to disqualify any ISO under Section&nbsp;422 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.</B> <B><U>RESTRICTED STOCK
AWARDS</U></B>. A Restricted Stock Award is an offer by the Company to sell to an eligible Employee, Consultant, or Director Shares that are subject to restrictions (&#147;<B><I>Restricted Stock</I></B>&#148;). The Committee will determine to whom
an offer will be made, the number of Shares the Participant may purchase, the Purchase&nbsp;Price, the restrictions under which the Shares will be subject and all other terms and conditions of the Restricted Stock Award, subject to the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.1.</B> <U>Restricted</U><U></U><U>&nbsp;Stock</U><U></U><U>&nbsp;Purchase Agreement</U>. All purchases under a Restricted Stock Award
will be evidenced by an Award Agreement. Except as may otherwise be provided in an Award Agreement, a Participant accepts a Restricted Stock Award by signing and delivering to the Company an Award Agreement with full payment of the Purchase Price,
within thirty (30)&nbsp;days from the date the Award Agreement was delivered to the Participant. If the Participant does not accept such Award within thirty (30)&nbsp;days, then the offer of such Restricted Stock Award will terminate, unless the
Committee determines otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.2.</B> <U>Purchase</U><U></U><U>&nbsp;Price</U>. The Purchase Price for a Restricted Stock Award
will be determined by the Committee and may be less than Fair Market Value on the date the Restricted Stock Award is granted. Payment of the Purchase Price must be made in accordance with Section&nbsp;11 of the Plan, the Award Agreement and any
procedures established by the Company. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.3.</B> <U>Terms of Restricted Stock Awards</U>. Restricted Stock Awards will be subject
to such restrictions as the Committee may impose or are required by law. These restrictions may be based on completion of a specified number of years of service with the Company or upon completion of Performance Factors, if any, during any
Performance Period as set out in advance in the Participant&#146;s Award Agreement. Prior to the grant of a Restricted Stock Award, the Committee shall: (a)&nbsp;determine the nature, length and starting date of any Performance Period for the
Restricted Stock Award; (b)&nbsp;select from among the Performance Factors to be used to measure performance goals, if any; and (c)&nbsp;determine the number of Shares that may be awarded to the Participant. Performance Periods may overlap and a
Participant may participate simultaneously with respect to Restricted Stock Awards that are subject to different Performance Periods and having different performance goals and other criteria. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.4.</B> <U>Termination of Service</U>. Except as may be set forth in the Participant&#146;s Award Agreement, vesting ceases on such date
Participant&#146;s Service terminates (unless determined otherwise by the Committee). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.</B> <B><U>STOCK BONUS AWARDS</U></B>. A Stock Bonus Award is
an award to an eligible Employee, Consultant, or Director of Shares for Services to be rendered or for past Services already rendered to the Company or any Parent, Subsidiary or Affiliate. All Stock Bonus Awards shall be made pursuant to an Award
Agreement. No payment from the Participant will be required for Shares awarded pursuant to a Stock Bonus Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.1.</B> <U>Terms of
Stock Bonus Awards</U>. The Committee will determine the number of Shares to be awarded to the Participant under a Stock Bonus Award and any restrictions thereon. These restrictions may be based upon completion of a specified number of years of
service with the Company or upon satisfaction of performance goals based on Performance Factors during any Performance Period as set out in advance in the Participant&#146;s Stock Bonus Agreement. Prior to the grant of any Stock Bonus Award the
Committee shall: (a)&nbsp;determine the nature, length and starting date of any Performance Period for the Stock Bonus Award; (b)&nbsp;select from among the Performance Factors to be used to measure performance goals; and (c)&nbsp;determine the
number of Shares that may be awarded to the Participant. Performance Periods may overlap and a Participant may participate simultaneously with respect to Stock Bonus Awards that are subject to different Performance Periods and different performance
goals and other criteria. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.2.</B> <U>Form of Payment to Participant</U>. Payment may be made in the form of cash, whole Shares, or a
combination thereof, based on the Fair Market Value of the Shares earned under a Stock Bonus Award on the date of payment, as determined in the sole discretion of the Committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.3.</B> <U>Termination of Service</U>. Except as may be set forth in the Participant&#146;s Award Agreement, vesting ceases on such date
Participant&#146;s Service terminates (unless determined otherwise by the Committee). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.</B> <B><U>STOCK APPRECIATION RIGHTS</U></B>. A Stock
Appreciation Right (&#147;<B><I>SAR</I></B>&#148;) is an award to an eligible Employee, Consultant, or Director that may be settled in cash, or Shares (which may consist of Restricted Stock), having a value equal to (a)&nbsp;the difference between
the Fair Market Value on the date of exercise over the Exercise Price multiplied by (b)&nbsp;the number of Shares with respect to which the SAR is being settled (subject to any maximum number of Shares that may be issuable as specified in an Award
Agreement). All SARs shall be made pursuant to an Award Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.1.</B> <U>Terms of SARs</U>. The Committee will determine the
terms of each SAR including, without limitation: (a)&nbsp;the number of Shares subject to the SAR; (b)&nbsp;the Exercise Price and the time or times during which the SAR may be settled; (c)&nbsp;the consideration to be distributed on settlement of
the SAR; and (d)&nbsp;the effect of the Participant&#146;s termination of Service on each SAR. The Exercise Price of the SAR will be determined by the Committee when the SAR is granted, and may not be less than Fair Market Value. A SAR may be
awarded upon satisfaction of Performance Factors, if any, during any </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Performance Period as are set out in advance in the Participant&#146;s individual Award Agreement. If the SAR is being earned upon the satisfaction of Performance Factors, then the Committee
will: (x)&nbsp;determine the nature, length and starting date of any Performance Period for each SAR; and (y)&nbsp;select from among the Performance Factors to be used to measure the performance, if any. Performance Periods may overlap and
Participants may participate simultaneously with respect to SARs that are subject to different Performance Factors and other criteria. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.2.</B> <U>Exercise Period and Expiration Date</U>. A SAR will be exercisable within the times or upon the occurrence of events determined
by the Committee and set forth in the Award Agreement governing such SAR. The SAR Agreement shall set forth the expiration date; provided that no SAR will be exercisable after the expiration of ten (10)&nbsp;years from the date the SAR is granted.
The Committee may also provide for SARs to become exercisable at one time or from time to time, periodically or otherwise (including, without limitation, upon the attainment during a Performance Period of performance goals based on Performance
Factors), in such number of Shares or percentage of the Shares subject to the SAR as the Committee determines. Except as may be set forth in the Participant&#146;s Award Agreement, vesting ceases on the date Participant&#146;s Service terminates
(unless determined otherwise by the Committee). Notwithstanding the foregoing, the rules of Section&nbsp;5.6 also will apply to SARs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.3.</B> <U>Form of Settlement</U>. Upon exercise of a SAR, a Participant will be entitled to receive payment from the Company in an amount
determined by multiplying (a)&nbsp;the difference between the Fair Market Value of a Share on the date of exercise over the Exercise Price; times (b)&nbsp;the number of Shares with respect to which the SAR is exercised. At the discretion of the
Committee, the payment from the Company for the SAR exercise may be in cash, in Shares of equivalent value, or in some combination thereof. The portion of a SAR being settled may be paid currently or on a deferred basis with such interest, if any,
as the Committee determines, provided that the terms of the SAR and any deferral satisfy the requirements of Section&nbsp;409A of the Code to the extent applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.4.</B> <U>Termination of Service</U>. Except as may be set forth in the Participant&#146;s Award Agreement, vesting ceases on such date
Participant&#146;s Service terminates (unless determined otherwise by the Committee). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.</B> <B><U>RESTRICTED STOCK UNITS</U></B>. A Restricted Stock
Unit (&#147;<B><I>RSU</I></B>&#148;) is an award to an eligible Employee, Consultant, or Director covering a number of Shares that may be settled in cash, or by issuance of those Shares (which may consist of Restricted Stock). All RSUs shall be made
pursuant to an Award Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.1.</B> <U>Terms of RSUs</U>. The Committee will determine the terms of an RSU including, without
limitation: (a)&nbsp;the number of Shares subject to the RSU; (b)&nbsp;the time or times during which the RSU may be settled; (c)&nbsp;the consideration to be distributed on settlement; and (d)&nbsp;the effect of the Participant&#146;s termination
of Service on each RSU; provided that no RSU shall have a term longer than ten (10)&nbsp;years. An RSU may be awarded upon satisfaction of such performance goals based on Performance Factors during any Performance Period as are set out in advance in
the Participant&#146;s Award Agreement. If the RSU is being earned upon satisfaction of Performance Factors, then the Committee will: (x)&nbsp;determine the nature, length and starting date of any Performance Period for the RSU; (y)&nbsp;select from
among the Performance Factors to be used to measure the performance, if any; and (z)&nbsp;determine the number of Shares deemed subject to the RSU. Performance Periods may overlap and Participants may participate simultaneously with respect to RSUs
that are subject to different Performance Periods and different performance goals and other criteria. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.2.</B> <U>Form and Timing of
Settlement</U>. Payment of earned RSUs shall be made as soon as practicable after the date(s) determined by the Committee and set forth in the Award Agreement. The Committee, in its sole discretion, may settle earned RSUs in cash, Shares, or a
combination of both. The Committee may also permit a Participant to defer payment under a RSU to a date or dates after the RSU is earned provided that the terms of the RSU and any deferral satisfy the requirements of Section&nbsp;409A of the Code to
the extent applicable. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.3.</B> <U>Termination of Service</U>. Except as may be set forth in the
Participant&#146;s Award Agreement, vesting ceases on such date Participant&#146;s Service terminates (unless determined otherwise by the Committee). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.</B> <B><U>PERFORMANCE AWARDS</U></B>. A Performance Award is an award to an eligible Employee, Consultant, or Director of the Company or any Parent,
Subsidiary or Affiliate that is based upon the attainment of performance goals, as established by the Committee, and other terms and conditions specified by the Committee, and may be settled in cash, Shares (which may consist of, without limitation,
Restricted Stock), other property, or any combination thereof. Grants of Performance Awards shall be made pursuant to an Award Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.1.</B> Performance Awards shall include Performance Shares, Performance Units, and cash-based Awards as set forth in Sections 10.1(a),
10.1(b), and 10.1(c) below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Performance Shares</U>. The Committee may grant Awards of Performance Shares, designate the
Participants to whom Performance Shares are to be awarded and determine the number of Performance Shares and the terms and conditions of each such Award. Performance Shares shall consist of a unit valued by reference to a designated number of
Shares, the value of which may be paid to the Participant by delivery of Shares or, if set forth in the instrument evidencing the Award, of such property as the Committee shall determine, including, without limitation, cash, Shares, other property,
or any combination thereof, upon the attainment of performance goals, as established by the Committee, and other terms and conditions specified by the Committee. The amount to be paid under an Award of Performance Shares may be adjusted on the basis
of such further consideration as the Committee shall determine in its sole discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Performance Units</U>. The Committee may
grant Awards of Performance Units, designate the Participants to whom Performance Units are to be awarded and determine the number of Performance Units and the terms and conditions of each such Award. Performance Units shall consist of a unit valued
by reference to a designated amount of property other than Shares, which value may be paid to the Participant by delivery of such property as the Committee shall determine, including, without limitation, cash, Shares, other property, or any
combination thereof, upon the attainment of performance goals, as established by the Committee, and other terms and conditions specified by the Committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Cash-Settled Performance Awards</U>. The Committee may grant cash-settled Performance Awards to Participants under the terms of this
Plan. Such awards will be based on the attainment of performance goals using the Performance Factors within this Plan that are established by the Committee for the relevant performance period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.2.</B> <U>Terms of Performance Awards</U>. Performance Awards will be based on the attainment of performance goals using the Performance
Factors within this Plan that are established by the Committee for the relevant Performance Period. The Committee will determine, and each Award Agreement shall set forth, the terms of each Performance Award including, without limitation:
(a)&nbsp;the amount of any cash bonus, (b)&nbsp;the number of Shares deemed subject to an award of Performance Shares; (c)&nbsp;the Performance Factors and Performance Period that shall determine the time and extent to which each award of
Performance Shares shall be settled; (d)&nbsp;the consideration to be distributed on settlement, and (e)&nbsp;the effect of the Participant&#146;s termination of Service on each Performance Award. In establishing Performance Factors and the
Performance Period the Committee will: (x)&nbsp;determine the nature, length and starting date of any Performance Period; (y)&nbsp;select from among the Performance Factors to be used; and (z)&nbsp;determine the number of Shares deemed subject to
the award of Performance Shares. Prior to settlement the Committee shall determine the extent to which Performance Awards have been earned. Performance Periods may overlap and Participants may participate simultaneously with respect to Performance
Awards that are subject to different Performance Periods and different performance goals and other criteria. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.3.</B><U> Termination of Service</U>. Except as may be set forth in the
Participant&#146;s Award Agreement, vesting ceases on the date Participant&#146;s Service terminates (unless determined otherwise by the Committee). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.</B> <B><U>PAYMENT FOR SHARE PURCHASES</U></B>. Payment from a Participant for Shares purchased pursuant to this Plan may be made in cash or by check
or, where approved for the Participant by the Committee and where permitted by law (and to the extent not otherwise set forth in the applicable Award Agreement): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) by cancellation of indebtedness of the Company to the Participant; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) by surrender of shares of the Company held by the Participant that have a Fair Market Value on the date of surrender equal to the
aggregate exercise price of the Shares as to which said Award will be exercised or settled; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) by waiver of compensation due or accrued
to the Participant for services rendered or to be rendered to the Company or a Parent or Subsidiary; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) by consideration received by the
Company pursuant to a broker-assisted or other form of cashless exercise program implemented by the Company in connection with the Plan; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) by any combination of the foregoing; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) by any other method of payment as is permitted by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.</B> <B><U>GRANTS TO <FONT STYLE="white-space:nowrap">NON-EMPLOYEE</FONT> DIRECTORS</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.1.</B> <U>Grant and Eligibility</U>. <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors are eligible to receive any type of
Award offered under this Plan except ISOs. Awards under the Plan may be granted to <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors automatically pursuant to a policy adopted by the Board, or made from time to time as determined in the
discretion of the Board. No <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director may receive Awards under the Plan that, when combined with cash compensation received for service as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT>
Director, exceeds $750,000.00 in value (as described below) in any calendar year, increased to $1,000,000.00 in value (as described below) in the calendar year of his or her initial services as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT>
Director. The value of Awards for purposes of complying with this maximum shall be determined as follows: (a)&nbsp;for Options and SARs, grant date fair value will be calculated using the Black-Scholes valuation methodology on the date of grant of
such Option or SAR, and (b)&nbsp;for all other Awards other than Options and SARs, grant date fair value will be determined by either (i)&nbsp;calculating the product of the Fair Market Value per Share on the date of grant and the aggregate number
of Shares subject to the Award, or (ii)&nbsp;calculating the product using an average of the Fair Market Value over a number of trading days and the aggregate number of Shares subject to the Award as determined by the Committee. Awards granted, or
cash compensation paid, to an individual while he or she was serving in the capacity as an Employee or while he or she was a Consultant but not a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director will not count for purposes of the
limitations set forth in this Section&nbsp;12.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.2.</B> <U>Vesting, Exercisability and Settlement</U>. Except as set forth in
Section&nbsp;21, Awards will vest, become exercisable and be settled as determined by the Board. With respect to Options and SARs, the exercise price granted to <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors will not be less than the
Fair Market Value of the Shares at the time that such Option or SAR is granted. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.3.</B> <U>Election to Receive Awards in Lieu of Cash</U>. A <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director may elect to receive his or her annual retainer payments and/or meeting fees from the Company in the form of cash or Awards or a combination thereof, if permitted, and as determined, by the
Committee. Such Awards shall be issued under the Plan. An election under this Section&nbsp;12.3 shall be filed with the Company on the form prescribed by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.</B> <B><U>WITHHOLDING TAXES</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.1.</B> <U>Withholding Generally</U>. Whenever Shares are to be issued in satisfaction of Awards granted under this Plan or a tax event
occurs, the Company may require the Participant to remit to the Company, or to the Parent, Subsidiary or Affiliate, as applicable, employing the Participant, an amount sufficient to satisfy applicable U.S.&nbsp;federal, state, local and
international tax or any other tax or social insurance liability (the &#147;<B><I><FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items</I></B>&#148;) required to be withheld from the Participant prior to the delivery of Shares pursuant to
exercise or settlement of any Award. Whenever payments in satisfaction of Awards granted under this Plan are to be made in cash, such payment will be net of an amount sufficient to satisfy applicable withholding obligations for <FONT
STYLE="white-space:nowrap">Tax-Related</FONT> Items. Unless otherwise determined by the Committee, the Fair Market Value of the Shares will be determined as of the date that the taxes are required to be withheld and such Shares will be valued based
on the value of the actual trade or, if there is none, the Fair Market Value of the Shares as of the previous trading day. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.2.</B>
<U>Stock Withholding</U>. The Committee, or its delegate(s), as permitted by applicable law, in its sole discretion and pursuant to such procedures as it may specify from time to time and to limitations of local law, may require or permit a
Participant to satisfy such Tax Related Items legally due from the Participant, in whole or in part by (without limitation) (a)&nbsp;paying cash, (b)&nbsp;having the Company withhold otherwise deliverable cash or Shares having a Fair Market Value
equal to the <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items to be withheld, (c)&nbsp;delivering to the Company already-owned shares having a Fair Market Value equal to the <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items to be
withheld or (d)&nbsp;withholding from the proceeds of the sale of otherwise deliverable Shares acquired pursuant to an Award either through a voluntary sale or through a mandatory sale arranged by the Company. The Company may withhold or account for
these <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items by considering applicable statutory withholding rates or other applicable withholding rates, including up to (but not in excess of) the maximum permissible statutory tax rate for the
applicable tax jurisdiction, to the extent consistent with applicable laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.</B> <B><U>TRANSFERABILITY</U></B>. Unless determined otherwise by the
Committee, an Award may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent or distribution. If the Committee makes an Award transferable, including, without
limitation, by instrument to an inter vivos or testamentary trust in which the Awards are to be passed to beneficiaries upon the death of the trustor (settlor) or by gift or by domestic relations order to a Permitted Transferee, such Award will
contain such additional terms and conditions as the Committee deems appropriate. All Awards will be exercisable: (a)&nbsp;during the Participant&#146;s lifetime only by the Participant, or the Participant&#146;s guardian or legal representative;
(b)&nbsp;after the Participant&#146;s death, by the legal representative of the Participant&#146;s heirs or legatees; and (c)&nbsp;in the case of all awards except ISOs, by a Permitted Transferee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15.</B> <B><U>PRIVILEGES OF STOCK OWNERSHIP; RESTRICTIONS ON SHARES</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.1.</B> <U>Voting and Dividends</U>. No Participant will have any of the rights of a stockholder with respect to any Shares until the
Shares are issued to the Participant, except for any Dividend Equivalent Rights permitted by an applicable Award Agreement. Any Dividend Equivalent Rights will be subject to the same vesting or performance conditions as the underlying Award. In
addition, the Committee may provide that any Dividend Equivalent Rights permitted by an applicable Award Agreement will be deemed to have been reinvested in additional Shares or otherwise reinvested. After Shares are issued to the Participant, the
Participant will be a stockholder and have all the rights of a stockholder with respect to such Shares, including the right to vote and receive all dividends or other distributions made or paid </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with respect to such Shares; <U>provided</U>, that if such Shares are Restricted Stock, then any new, additional or different securities the Participant may become entitled to receive with
respect to such Shares by virtue of a stock dividend, stock split or any other change in the corporate or capital structure of the Company will be subject to the same restrictions as the Restricted Stock; <U>provided</U>, <U>further</U>, that the
Participant will have no right to such stock dividends or stock distributions with respect to Unvested Shares, and any such dividends or stock distributions will be accrued and paid only at such time, if any, as such Unvested Shares become vested
Shares. The Committee, in its discretion, may provide in the Award Agreement evidencing any Award that the Participant will be entitled to Dividend Equivalent Rights with respect to the payment of cash dividends on Shares underlying an Award during
the period beginning on the date the Award is granted and ending, with respect to each Share subject to the Award, on the earlier of the date on which the Award is exercised or settled or the date on which it is forfeited<U> provided</U>, that no
Dividend Equivalent Right will be paid with respect to the Unvested Shares, and such dividends or stock distributions will be accrued and paid only at such time, if any, as such Unvested Shares become vested Shares. Such Dividend Equivalent Rights,
if any, will be credited to the Participant in the form of additional whole Shares as of the date of payment of such cash dividends on Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.2.</B> <U>Restrictions on Shares</U>. At the discretion of the Committee, the Company may reserve to itself and/or its assignee(s) a
right to repurchase (a &#147;<B><I>Right of Repurchase</I></B>&#148;) a portion of any or all Unvested Shares held by a Participant following such Participant&#146;s termination of Service at any time within ninety (90)&nbsp;days (or such longer or
shorter time determined by the Committee) after the later of the date Participant&#146;s Service terminates and the date the Participant purchases Shares under this Plan, for cash and/or cancellation of purchase money indebtedness, at the
Participant&#146;s Purchase Price or Exercise Price, as the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.</B> <B><U>CERTIFICATES</U></B>. All Shares or other securities whether or
not certificated, delivered under this Plan will be subject to such stock transfer orders, legends and other restrictions as the Committee may deem necessary or advisable, including restrictions under any applicable U.S. federal, state or foreign
securities law, or any rules, regulations and other requirements of the SEC or any stock exchange or automated quotation system upon which the Shares may be listed or quoted and any <FONT STYLE="white-space:nowrap">non-U.S.</FONT> exchange controls
or securities law restrictions to which the Shares are subject. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17.</B> <B><U>ESCROW; PLEDGE OF SHARES</U></B>. To enforce any restrictions on a
Participant&#146;s Shares, the Committee may require the Participant to deposit all certificates representing Shares, together with stock powers or other instruments of transfer approved by the Committee, appropriately endorsed in blank, with the
Company or an agent designated by the Company to hold in escrow until such restrictions have lapsed or terminated. The Committee may cause a legend or legends referencing such restrictions to be placed on the certificates. Any Participant who is
permitted to execute a promissory note as partial or full consideration for the purchase of Shares under this Plan will be required to pledge and deposit with the Company all or part of the Shares so purchased as collateral to secure the payment of
the Participant&#146;s obligation to the Company under the promissory note; <U>provided</U>, <U>however</U>, that the Committee may require or accept other or additional forms of collateral to secure the payment of such obligation and, in any event,
the Company will have full recourse against the Participant under the promissory note notwithstanding any pledge of the Participant&#146;s Shares or other collateral. In connection with any pledge of the Shares, the Participant will be required to
execute and deliver a written pledge agreement in such form as the Committee will from time to time approve. The Shares purchased with the promissory note may be released from the pledge on a pro rata basis as the promissory note is paid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18.</B> <B><U>REPRICING</U></B><B><U>;</U></B><B><U> EXCHANGE AND BUYOUT OF AWARDS</U></B>. Without prior stockholder approval, the Committee may
(a)&nbsp;reprice Options or SARs (and where such repricing is a reduction in the Exercise Price of outstanding Options or SARs, the consent of the affected Participants is not required provided written notice is provided to them, notwithstanding any
adverse tax consequences to them arising from the repricing), and (b)&nbsp;with the consent of the respective Participants (unless not required pursuant to Section&nbsp;5.9 of the Plan), pay cash or issue new Awards in exchange for the surrender and
cancellation of any, or all, outstanding Awards. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19.</B> <B><U>SECURITIES LAW AND OTHER REGULATORY COMPLIANCE</U></B>. An Award will not be effective
unless such Award is in compliance with all applicable U.S. and foreign federal and state securities and exchange control laws, rules and regulations of any governmental body, and with the requirements of any stock exchange or automated quotation
system upon which the Shares may then be listed or quoted, as they are in effect on the date of grant of the Award and also on the date of exercise or other issuance. Notwithstanding any other provision in this Plan, the Company will have no
obligation to issue or deliver certificates for Shares under this Plan prior to: (a)&nbsp;obtaining any approvals from governmental agencies that the Company determines are necessary or advisable; and/or (b)&nbsp;completion of any registration or
other qualification of such Shares under any state or federal or foreign law or ruling of any governmental body that the Company determines to be necessary or advisable. The Company will be under no obligation to register the Shares with the SEC or
to effect compliance with the registration, qualification or listing requirements of any foreign or state securities laws, exchange control laws, stock exchange or automated quotation system, and the Company will have no liability for any inability
or failure to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20.</B> <B><U>NO OBLIGATION TO EMPLOY</U></B>. Nothing in this Plan or any Award granted under this Plan will confer or be deemed
to confer on any Participant any right to continue in the employ of, or to continue any other relationship with, the Company or any Parent, Subsidiary or Affiliate or limit in any way the right of the Company or any Parent, Subsidiary or Affiliate
to terminate Participant&#146;s employment or other relationship at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.</B> <B><U>CORPORATE TRANSACTIONS</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.1.</B>
<U>Assumption</U><U></U><U>&nbsp;or</U><U></U><U>&nbsp;Replacement</U><U></U><U>&nbsp;of</U><U></U><U>&nbsp;Awards</U><U></U><U>&nbsp;by Successor</U>. In the event of a Corporate Transaction any or all outstanding Awards may be (a)&nbsp;continued
by the Company, if the Company is the successor entity; or (b)&nbsp;assumed or substituted by the successor corporation, or a parent or subsidiary of the successor corporation, for substantially equivalent Awards (including, but not limited to, an
award to acquire the same consideration paid to the stockholders of the Company pursuant to the Corporate Transaction), in each case after taking into account appropriate adjustments for the number and kind of shares and exercise prices. The
successor corporation may also issue, as replacement of outstanding Shares of the Company held by the Participant, substantially similar shares or other property subject to repurchase restrictions no less favorable to the Participant. In the event
such successor corporation refuses to assume, substitute or replace any Award in accordance with this Section&nbsp;21, then notwithstanding any other provision in this Plan to the contrary, each such Award shall become fully vested and, as
applicable, exercisable and any rights of repurchase or forfeiture restrictions thereon shall lapse, immediately prior to the consummation of the Corporate Transaction. Performance Awards not assumed or substituted pursuant to the foregoing shall be
deemed earned and vested at 100% of target level, unless otherwise indicated pursuant to the terms and conditions of the applicable Award Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an Award vests in lieu of assumption or substitution in connection with a Corporate Transaction as provided above, the Committee will
notify the holder of such Award in writing or electronically that such Award will be exercisable for a period of time determined by the Committee in its sole discretion, and such Award will terminate upon the expiration of such period without
consideration. Any determinations by the Committee need not treat all outstanding Awards in an identical manner, and shall be final and binding on each applicable Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.2.</B> <U>Assumption of Awards by the Company</U>. The Company, from time to time, also may substitute or assume outstanding awards
granted by another company, whether in connection with an acquisition of such other company or otherwise, by either; (a)&nbsp;granting an Award under this Plan in substitution of such other company&#146;s award; or (b)&nbsp;assuming such award as if
it had been granted under this Plan if the terms of such assumed award could be applied to an Award granted under this Plan. Such substitution or assumption will be permissible if the holder of the substituted or assumed award would have been
eligible to be granted an Award under this Plan if the other company had applied the rules of </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
this Plan to such grant. In the event the Company assumes an award granted by another company, the terms and conditions of such award will remain unchanged (<U>except</U> that the Purchase Price
or the Exercise Price, as the case may be, and the number and nature of Shares issuable upon exercise or settlement of any such Award will be adjusted appropriately pursuant to Section&nbsp;424(a) of the Code). In the event the Company elects to
grant a new Option in substitution rather than assuming an existing option, such new Option may be granted with a similarly adjusted Exercise Price. Substitute Awards will not reduce the number of Shares authorized for grant under the Plan or
authorized for grant to a Participant in a calendar year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.3.</B> <U><FONT STYLE="white-space:nowrap">Non-Employee</FONT>
Directors&#146; Awards</U>. Notwithstanding any provision to the contrary herein, in the event of a Corporate Transaction, the vesting of all Awards granted to <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors will accelerate and such
Awards will become exercisable (as applicable) in full prior to the consummation of such event at such times and on such conditions as the Committee determines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>22.</B> <B><U>ADOPTION AND STOCKHOLDER APPROVAL</U></B>. This Plan will be submitted for the approval of the Company&#146;s stockholders, consistent with
applicable laws, within twelve (12)&nbsp;months before or after the date this Plan is adopted by the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>23.</B> <B><U>TERM OF PLAN/GOVERNING
LAW</U></B>. Unless earlier terminated as provided herein, this Plan will become effective on the Effective Date and will terminate ten (10)&nbsp;years from the date this Plan is adopted by the Board. This Plan and all Awards granted hereunder will
be governed by and construed in accordance with the laws of the State of Delaware (excluding its conflict of laws rules). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>24.</B> <B><U>AMENDMENT OR
TERMINATION OF PLAN</U></B>. The Board may at any time terminate or amend this Plan in any respect, including, without limitation, amendment of any form of Award Agreement or instrument to be executed pursuant to this Plan; <U>provided</U>,
<U>however</U>, that the Board will not, without the approval of the stockholders of the Company, amend this Plan in any manner that requires such stockholder approval; <U>provided further</U>, that a Participant&#146;s Award will be governed by the
version of this Plan then in effect at the time such Award was granted. No termination or amendment of the Plan or any outstanding Award may adversely affect any then outstanding Award without the consent of the Participant, unless such termination
or amendment is necessary to comply with applicable law, regulation or rule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>25.</B> <B><U>NONEXCLUSIVITY OF THE PLAN</U></B>. Neither the adoption of
this Plan by the Board, the submission of this Plan to the stockholders of the Company for approval, nor any provision of this Plan will be construed as creating any limitations on the power of the Board to adopt such additional compensation
arrangements as it may deem desirable, including, without limitation, the granting of stock awards and bonuses otherwise than under this Plan, and such arrangements may be either generally applicable or applicable only in specific cases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>26.</B> <B><U>INSIDER TRADING POLICY</U></B>. Each Participant who receives an Award will comply with any policy adopted by the Company from time to time
covering transactions in the Company&#146;s securities by Employees, officers and/or Directors of the Company, as applicable, as well as with any insider trading or market abuse laws to which the Participant may be subject. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>27.</B> <B><U>ALL AWARDS SUBJECT TO COMPANY CLAWBACK OR RECOUPMENT POLICY</U></B>.&nbsp;All Awards, subject to applicable law, shall be subject to clawback
or recoupment pursuant to any compensation clawback or recoupment policy adopted by the Board or required by law during the term of Participant&#146;s employment or other service with the Company that is applicable to Employees, Directors or other
service providers of the Company, and in addition to any other remedies available under such policy and applicable law, may require the cancellation of outstanding Awards and the recoupment of any gains realized with respect to Awards. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>28.</B> <B><U>DEFINITIONS</U></B>. As used in this Plan, and except as elsewhere defined herein, the
following terms will have the following meanings: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.1.</B> &#147;<B><I>Affiliate</I></B>&#148; means any person or entity that
directly or indirectly through one or more intermediaries controls, or is controlled by, or is under common control with, the Company, including any general partner, managing member, officer or director of the Company, in each case as of the date on
which, or at any time during the period for which, the determination of affiliation is being made. For purposes of this definition, the term &#147;control&#148; (including the correlative meanings of the terms &#147;controlled by&#148; and
&#147;under common control with&#148;), as used with respect to any person or entity, means the possession, directly or indirectly, of the power to direct or cause the direction of the management policies of such person or entity, whether through
the ownership of voting securities or by contract or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.2.</B> &#147;<B><I>Award</I></B>&#148; means any award under the
Plan, including any Option, Restricted Stock, Stock Bonus, Stock Appreciation Right, Restricted Stock Unit or Performance Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.3.</B> &#147;<B><I>Award Agreement</I></B>&#148; means, with respect to each Award, the written or electronic agreement between the
Company and the Participant setting forth the terms and conditions of the Award, together with any country-specific appendix thereto for grants to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Participants, which will be in substantially a form
(that need not be the same for each Participant) that the Committee (or in the case of Award Agreements that are not used for Insiders, the Committee&#146;s delegate(s)) has from time to time approved, and will comply with and be subject to the
terms and conditions of this Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.4.</B> &#147;<B><I>Board</I></B>&#148; means the Board of Directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.5.</B> &#147;<B><I>Cause</I></B>&#148; means a determination by the Company (and in the case of Participant who is subject to
Section&nbsp;16 of the Exchange Act, the Committee) that the Participant has committed an act or acts constituting any of the following: (a)&nbsp;conviction of, or plea of nolo contendere to, a felony or crime involving moral turpitude;
(b)&nbsp;fraud on or misappropriation of any funds or property of the Company, any affiliate, customer or vendor; (c)&nbsp;personal dishonesty, incompetence, willful misconduct, willful violation of any law, rule or regulation (other than minor
traffic violations or similar offenses) or breach of fiduciary duty which involves personal profit; (d)&nbsp;willful misconduct in connection with Participant&#146;s duties or material failure to perform Participant&#146;s responsibilities in the
best interests of the Company; (e)&nbsp;illegal use or distribution of drugs; (f)&nbsp;violation of any Company rule, regulation, procedure or policy; (g)&nbsp;breach of any provision of any employment,
<FONT STYLE="white-space:nowrap">non-disclosure,</FONT> <FONT STYLE="white-space:nowrap">non-competition,</FONT> <FONT STYLE="white-space:nowrap">non-solicitation</FONT> or other similar agreement executed by Participant&#146;s for the benefit of
the Company or (h)&nbsp;other conduct by such Participant that could be expected to be harmful to the business, interests or reputation of the Company. The determination as to whether Cause for a Participant&#146;s termination exists will be made in
good faith by the Company and will be final and binding on the Participant. This definition does not in any way limit the Company&#146;s or any Parent&#146;s or Subsidiary&#146;s ability to terminate a Participant&#146;s employment or services at
any time as provided in Section&nbsp;20 above. Notwithstanding the foregoing, the foregoing definition of &#147;Cause&#148; may, in part or in whole, be modified or replaced in each individual employment agreement, Award Agreement, or other
applicable agreement with any Participant provided that such document specifically supersedes this definition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.6.</B>
&#147;<B><I>Code</I></B>&#148; means the United States Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.7.</B> &#147;<B><I>Committee</I></B>&#148; means the Compensation Committee of the Board or those persons to whom administration of the
Plan, or part of the Plan, has been delegated as permitted by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.8.</B> &#147;<B><I>Company</I></B>&#148; means Graybug Vision,
Inc., a Delaware corporation, or any successor corporation. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.9.</B> &#147;<B><I>Consultant</I></B>&#148; means any natural person, including an
advisor or independent contractor, engaged by the Company or a Parent, Subsidiary or Affiliate to render services to such entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.10.</B> &#147;<B><I>Corporate Transaction</I></B>&#148; means the occurrence of any of the following events: (a)&nbsp;any
&#147;Person&#148; (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becomes the &#147;beneficial owner&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> of the Exchange Act), directly or indirectly, of
securities of the Company representing more than fifty percent (50%) of the total voting power represented by the Company&#146;s then-outstanding voting securities; provided, however, that for purposes of this subclause (a)&nbsp;the acquisition of
additional securities by any one Person who is considered to own more than fifty percent (50%) of the total voting power of the securities of the Company will not be considered a Corporate Transaction; (b)&nbsp;the consummation of the sale or
disposition by the Company of all or substantially all of the Company&#146;s assets; (c)&nbsp;the consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the
voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%)&nbsp;of
the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation; (d)&nbsp;any other transaction which qualifies as a &#147;corporate
transaction&#148; under Section&nbsp;424(a) of the Code wherein the stockholders of the Company give up all of their equity interest in the Company (except for the acquisition, sale or transfer of all or substantially all of the outstanding shares
of the Company) or (e)&nbsp;a change in the effective control of the Company that occurs on the date that a majority of members of the Board is replaced during any twelve (12)&nbsp;month period by members of the Board whose appointment or election
is not endorsed by a majority of the members of the Board prior to the date of the appointment or election. For purpose of this subclause (e), if any Person is considered to be in effective control of the Company, the acquisition of additional
control of the Company by the same Person will not be considered a Corporate Transaction. For purposes of this definition, Persons will be considered to be acting as a group if they are owners of a corporation that enters into a merger,
consolidation, purchase or acquisition of stock, or similar business transaction with the Company. Notwithstanding the foregoing, to the extent that any amount constituting deferred compensation (as defined in Section&nbsp;409A of the Code) would
become payable under this Plan by reason of a Corporate Transaction, such amount will become payable only if the event constituting a Corporate Transaction would also qualify as a change in ownership or effective control of the Company or a change
in the ownership of a substantial portion of the assets of the Company, each as defined within the meaning of Code Section&nbsp;409A, as it has been and may be amended from time to time, and any proposed or final Treasury Regulations and IRS
guidance that has been promulgated or may be promulgated thereunder from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.11.</B> &#147;<B><I>Director</I></B>&#148;
means a member of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.12.</B> &#147;<B><I>Disability</I></B>&#148; means in the case of incentive stock options, total and
permanent disability as defined in Section&nbsp;22(e)(3) of the Code and in the case of other Awards, that the Participant is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment
that can be expected to result in death or can be expected to last for a continuous period of not less than 12 months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.13.</B>
&#147;<B><I>Dividend Equivalent Right</I></B>&#148; means the right of a Participant, granted at the discretion of the Committee or as otherwise provided by the Plan, to receive a credit for the account of such Participant in an amount equal to the
cash, stock or other property dividends in amounts equivalent to cash, stock or other property dividends for each Share represented by an Award held by such Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.14.</B> &#147;<B><I>Effective Date</I></B>&#148; means the day immediately prior to the Company&#146;s IPO Registration Date, subject to
approval of the Plan by the Company&#146;s stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.15.</B> &#147;<B><I>Employee</I></B>&#148; means any person, including
officers and Directors, providing services as an employee to the Company or any Parent, Subsidiary or Affiliate. Neither service as a Director nor payment of a director&#146;s fee by the Company will be sufficient to constitute
&#147;employment&#148; by the Company. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.16.</B> &#147;<B><I>Exchange Act</I></B>&#148; means the United States Securities
Exchange Act of 1934, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.17.</B> &#147;<B><I>Exchange Program</I></B>&#148; means a program pursuant to which
(a)&nbsp;outstanding Awards are surrendered, cancelled or exchanged for cash, the same type of Award or a different Award (or combination thereof) or (b)&nbsp;the exercise price of an outstanding Award is increased or reduced, each as described in
<U>Section</U><U></U><U>&nbsp;18</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.18.</B> &#147;<B><I>Exercise Price</I></B>&#148; means, with respect to an Option, the price
at which a holder may purchase the Shares issuable upon exercise of an Option and with respect to a SAR, the price at which the SAR is granted to the holder thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.19.</B> &#147;<B><I>Fair Market Value</I></B>&#148; means, as of any date, the value of a share of the Company&#146;s common stock
determined as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) if such common stock is publicly traded and is then listed on a national securities exchange, its closing
price on the date of determination on the principal national securities exchange on which the common stock is listed or admitted to trading as reported in <I>The Wall Street </I>Journal or such other source as the Committee deems reliable; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) if such common stock is publicly traded but is neither listed nor admitted to trading on a national securities exchange, the average of
the closing bid and asked prices on the date of determination as reported in <I>The Wall Street Journal</I> or such other source as the Committee deems reliable; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) in the case of an Option or SAR grant made on the IPO Registration Date, the price per share at which Shares are initially offered for
sale to the public by the Company&#146;s underwriters in the initial public offering of Shares as set forth in the Company&#146;s final prospectus included within the registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> filed
with the SEC under the Securities Act; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) by the Board or the Committee in good faith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.20.</B> &#147;<B><I>Insider</I></B>&#148; means an officer or Director of the Company or any other person whose transactions in the
Company&#146;s common stock are subject to Section&nbsp;16 of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.21.</B> &#147;<B><I>IPO Registration
Date</I></B>&#148; means the date on which the Company&#146;s registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> in connection with its initial public offering of common stock is declared effective by the SEC under the
Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.22.</B> &#147;<B><I>IRS</I></B>&#148; means the United States Internal Revenue Service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.23.</B> &#147;<B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director</I></B>&#148; means a Director who is not an Employee
of the Company or any Parent or Subsidiary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.24.</B> &#147;<B><I>Option</I></B>&#148; means an Award as defined in Section&nbsp;5
and granted under the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.25.</B> &#147;<B><I>Parent</I></B>&#148; means any corporation (other than the Company) in an unbroken
chain of corporations ending with the Company if each of such corporations other than the Company owns stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such
chain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.26.</B> &#147;<B><I>Participant</I></B>&#148; means a person who holds an Award under this Plan. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.27.</B> <I>&#147;</I><B><I>Performance Award</I></B><I>&#148;</I> means an Award as
defined in Section&nbsp;10 and granted under the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.28.</B> <I>&#147;</I><B><I>Performance Factors</I></B><I>&#148;</I> means
any of the factors selected by the Committee and specified in an Award Agreement, from among the following objective or subjective measures, either individually, alternatively or in any combination applied to the Participant, the Company, any
business unit or Subsidiary, either individually, alternatively, or in any combination, on a GAAP or <FONT STYLE="white-space:nowrap">non-GAAP</FONT> basis, and measured, to the extent applicable on an absolute basis or relative to a <FONT
STYLE="white-space:nowrap">pre-established</FONT> target, to determine whether the performance goals established by the Committee with respect to applicable Awards have been satisfied: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(a) Profit Before Tax; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(b)
Sales; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(c) Expenses; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(d)
Billings; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(e) Revenue; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(f)
Net revenue; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(g) Earnings (which may include earnings before interest and taxes, earnings before taxes, net earnings, stock-based
compensation expenses, depreciation and amortization); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(h) Operating income; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(i) Operating margin; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(j)
Operating profit; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(k) Controllable operating profit, or net operating profit; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(l) Net Profit; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(m) Gross
margin; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(n) Operating expenses or operating expenses as a percentage of revenue; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(o) Net income; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(p) Earnings per
share; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(q) Total stockholder return; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(r) Market share; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(s) Return on
assets or net assets; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(t) The Company&#146;s stock price; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(u) Growth in stockholder value relative to a
<FONT STYLE="white-space:nowrap">pre-determined</FONT> index; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(v) Return on equity; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(w) Return on invested capital; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(x) Cash Flow (including free cash flow or operating cash flows); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(y) Balance of cash, cash equivalents and marketable securities; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(z) Cash conversion cycle; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(aa)
Economic value added; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(bb) Individual confidential business objectives; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(cc) Contract awards or backlog; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(dd) Overhead or other expense reduction; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(ee) Credit rating; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(ff)
Completion of an identified special project; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(gg) Completion of a joint venture or other corporate transaction; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(hh) Strategic plan development and implementation; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(ii) Succession plan development and implementation; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(jj) Improvement in workforce diversity; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(kk) Employee satisfaction; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(ll)
Employee retention; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(mm) Customer indicators and/or satisfaction; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(nn) New product invention or innovation; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(oo) Research and development expenses; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(pp) Attainment of research and development milestones; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(qq) Improvements in productivity; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(rr) Bookings; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(ss)
Working-capital targets and changes in working capital; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(tt) Attainment of operating goals and employee metrics; and </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(uu) Any other metric as determined by the Committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee may provide for one or more equitable adjustments to the Performance Factors, including, but not limited to, to preserve the
Committee&#146;s original intent regarding the Performance Factors at the time of the initial award grant, such as but not limited to, adjustments in recognition of unusual or <FONT STYLE="white-space:nowrap">non-recurring</FONT> items such as
acquisition related activities or changes in applicable accounting rules. It is within the sole discretion of the Committee to make or not make any such equitable adjustments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.29.</B> &#147;<B><I>Performance Period</I></B>&#148; means one or more periods of time, which may be of varying and overlapping
durations, as the Committee may select, over which the attainment of one or more Performance Factors will be measured for the purpose of determining a Participant&#146;s right to, and the payment of, a Performance Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.30.</B> &#147;<B><I>Performance Share</I></B>&#148; means an Award as defined in Section&nbsp;10 and granted under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.31.</B> &#147;<B><I>Permitted Transferee</I></B>&#148; means any child, stepchild, grandchild, parent, stepparent, grandparent, spouse,
former spouse, sibling, niece, nephew, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mother-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">father-in-law,</FONT></FONT> <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">son-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">daughter-in-law,</FONT></FONT>
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">brother-in-law,</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">sister-in-law</FONT></FONT> (including adoptive relationships) of the Employee, any
person sharing the Employee&#146;s household (other than a tenant or employee), a trust in which these persons (or the Employee) have more than 50% of the beneficial interest, a foundation in which these persons (or the Employee) control the
management of assets, and any other entity in which these persons (or the Employee) own more than 50% of the voting interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.32.</B> <I>&#147;</I><B><I>Performance Unit</I></B><I>&#148;</I> means an Award as defined in Section&nbsp;10 and granted under the
Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.33.</B> &#147;<B><I>Plan</I></B>&#148; means this Graybug Vision, Inc. 2020 Equity Incentive Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.34.</B> &#147;<B><I>Purchase Price</I></B>&#148; means the price to be paid for Shares acquired under the Plan, other than Shares
acquired upon exercise of an Option or SAR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.35.</B>
&#147;<B><I>Restricted</I></B><B><I></I></B><B><I>&nbsp;Stock</I></B><B><I></I></B><B><I>&nbsp;Award</I></B>&#148; means an Award as defined in Section&nbsp;6 and granted under the Plan (or issued pursuant to the early exercise of an Option). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.36.</B> &#147;<B><I>Restricted Stock Unit</I></B>&#148; means an Award as defined in Section&nbsp;9 and granted under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.37.</B> &#147;<B><I>SEC</I></B>&#148; means the United States Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.38.</B> &#147;<B><I>Securities Act</I></B>&#148; means the United States Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.39.</B> &#147;<B><I>Service</I></B>&#148; means service as an Employee, Consultant, Director or
<FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director, to the Company or a Parent, Subsidiary or Affiliate, subject to such further limitations as may be set forth in the Plan or the applicable Award Agreement. An Employee will not be deemed
to have ceased to provide Service in the case of (a)&nbsp;sick leave, (b)&nbsp;military leave, or (c)&nbsp;any other leave of absence approved by the Company; <U>provided</U>, that such leave is for a period of not more than 90 days unless
reemployment upon the expiration of such leave is guaranteed by contract or statute. Notwithstanding anything to the contrary, an Employee will not be deemed to have ceased to provide Service if a formal policy adopted from time to time by the
Company and issued and promulgated to employees in writing provides otherwise. In the case of any Employee on an approved leave of absence or a reduction in hours worked (for illustrative purposes only, a change in schedule from that of full-time to
part-time), the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Committee may make such provisions respecting suspension or modification of vesting of the Award while on leave from the employ of the Company or a Parent, Subsidiary or Affiliate or during such
change in working hours as it may deem appropriate, except that in no event may an Award be exercised after the expiration of the term set forth in the applicable Award Agreement. In the event of military or other protected leave, if required by
applicable laws, vesting will continue for the longest period that vesting continues under any other statutory or Company approved leave of absence and, upon a Participant&#146;s returning from military leave, he or she will be given vesting credit
with respect to Awards to the same extent as would have applied had the Participant continued to provide Service to the Company throughout the leave on the same terms as he or she was providing Service immediately prior to such leave. An Employee
will have terminated employment as of the date he or she ceases to provide Service (regardless of whether the termination is in breach of local employment laws or is later found to be invalid) and employment will not be extended by any notice period
or garden leave mandated by local law, <I>provided however</I>, a change in status from an Employee to a Consultant or a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director (or vice versa) will not terminate a Participant&#146;s Service,
unless determined by the Committee, in its discretion or to the extent set forth in the applicable Award Agreement. The Committee will have sole discretion to determine whether a Participant has ceased to provide Service and the effective date on
which the Participant ceased to provide Service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.40.</B> &#147;<B><I>Shares</I></B>&#148; means shares of the common stock of the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.41.</B> &#147;<B><I>Stock Appreciation Right</I></B>&#148; means an Award as defined in Section&nbsp;8 and granted under
the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.42.</B> &#147;<B><I>Stock</I></B><B><I></I></B><B><I>&nbsp;Bonus</I></B>&#148; means an Award granted pursuant to
Section&nbsp;7 of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.43.</B> &#147;<B><I>Subsidiary</I></B>&#148; means any corporation (other than the Company) in an
unbroken chain of corporations beginning with the Company if each of the corporations other than the last corporation in the unbroken chain owns stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock
in one of the other corporations in such chain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.44.</B> &#147;<B><I>Treasury Regulations</I></B>&#148; means regulations
promulgated by the United States Treasury Department. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>28.45.</B> &#147;<B><I>Unvested Shares</I></B>&#148; means Shares that have not
yet vested or are subject to a right of repurchase in favor of the Company (or any successor thereto). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2020 EQUITY INCENTIVE PLAN </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GLOBAL NOTICE OF STOCK OPTION GRANT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise defined herein, the terms defined in the Graybug Vision, Inc. (the &#147;<B><I>Company</I></B>&#148;) 2020 Equity Incentive Plan (the
&#147;<B><I>Plan</I></B>&#148;) will have the same meanings in this Global Notice of Stock Option Grant and the electronic representation of this Global Notice of Stock Option Grant established and maintained by the Company or a third party
designated by the Company (this &#147;<B><I>Notice</I></B>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B>Name: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B>Address: </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You
(&#147;<B><I>Participant</I></B>&#148;) have been granted an option to purchase shares of common stock of the Company (the &#147;<B><I>Option</I></B>&#148;) under the Plan subject to the terms and conditions of the Plan, this Notice and the attached
Global Stock Option Award Agreement (the &#147;<B><I>Option Agreement</I></B>&#148;), including any applicable country-specific provisions in the appendix attached hereto (the &#147;<B><I>Appendix</I></B>&#148;), which constitutes part of the Option
Agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="75%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Grant Number:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Date of Grant:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Vesting&nbsp;Commencement&nbsp;Date:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Exercise Price per Share:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Total Number of Shares:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Type of Option:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> <FONT STYLE="white-space:nowrap">Non-Qualified</FONT> Stock Option</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> Incentive Stock Option</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Expiration Date:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> <U>&nbsp;&nbsp;&nbsp;&nbsp;</U>, 20<U>&nbsp;&nbsp;&nbsp;&nbsp;</U>; This Option expires earlier if
Participant&#146;s Service terminates earlier, as described in the Option Agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Vesting Schedule:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Subject to the limitations set forth in this Notice, the Plan and the Option Agreement, the Option will vest in accordance with the following schedule: <I>[insert applicable vesting schedule, which may be time-based,
performance-based or a combination of both]</I></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By accepting (whether in writing, electronically or otherwise) the Option, Participant acknowledges and agrees to the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Participant understands that Participant&#146;s Service with the Company or a Parent or Subsidiary or Affiliate
is for an unspecified duration, can be terminated at any time (<I>i.e.</I>, is <FONT STYLE="white-space:nowrap">&#147;at-will&#148;),</FONT> except where otherwise prohibited by applicable law, and that nothing in this Notice, the Option Agreement
or the Plan changes the nature of that relationship. Participant acknowledges that the vesting of the Option pursuant to this Notice is subject to Participant&#146;s continuing Service as an Employee, Director or Consultant. To the extent permitted
by applicable law, Participant agrees and acknowledges that the Vesting Schedule may change prospectively in the event that Participant&#146;s Service status changes between full- and part-time and/or in the event Participant is on a leave of
absence, in accordance with Company policies relating to work schedules and vesting of Awards or as determined by the Committee to the extent permitted by applicable law. Furthermore, the period during which Participant may exercise the Option after
termination of Service, if any, will commence on the Termination Date (as defined in the Option Agreement). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This grant is made under and governed by the Plan, the Option Agreement and this Notice, and this Notice is
subject to the terms and conditions of the Option Agreement and the Plan, both of which are incorporated herein by reference. Participant has read the Notice, the Option Agreement and the Plan. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Participant has read the Company&#146;s Insider Trading Policy, and agrees to comply with such policy, as it
may be amended from time to time, whenever Participant acquires or disposes of the Company&#146;s securities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">By accepting the Option, Participant consents to electronic delivery and participation as set forth in the
Option Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2020 EQUITY INCENTIVE PLAN </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GLOBAL STOCK OPTION AWARD AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise defined in this Global Stock Option Award Agreement (this &#147;<B><I>Option Agreement</I></B>&#148;), any capitalized terms
used herein will have the meaning ascribed to them in the Graybug Vision, Inc. 2020 Equity Incentive Plan (the &#147;<B><I>Plan</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Participant has been granted an option to purchase Shares (the &#147;<B><I>Option</I></B>&#148;) of Graybug Vision, Inc. (the
&#147;<B><I>Company</I></B>&#148;), subject to the terms, restrictions and conditions of the Plan, the Global Notice of Stock Option Grant (the &#147;<B><I>Notice</I></B>&#148;) and this Option Agreement, including any applicable country-specific
provisions in the appendix attached hereto (the &#147;<B><I>Appendix</I></B>&#148;), which constitutes part of this Option Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B><U>Vesting Rights</U></B><B>.</B> Subject to the applicable provisions of the Plan and this Option Agreement, this Option may be
exercised, in whole or in part, in accordance with the Vesting Schedule set forth in the Notice. Participant acknowledges that the vesting of the Option pursuant to this Notice and Agreement is subject to Participant&#146;s continuing Service as an
Employee, Director or Consultant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B> <B><U>Grant of Option</U></B><B>.</B> Participant has been granted an Option for the number
of Shares set forth in the Notice at the exercise price per Share in U.S. Dollars set forth in the Notice (the &#147;<B><I>Exercise Price</I></B>&#148;). In the event of a conflict between the terms and conditions of the Plan and the terms and
conditions of this Option Agreement, the terms and conditions of the Plan shall prevail. If designated in the Notice as an Incentive Stock Option (&#147;<B><I>ISO</I></B>&#148;), this Option is intended to qualify as an Incentive Stock Option under
Section&nbsp;422 of the Code. However, if this Option is intended to be an ISO, to the extent that it exceeds the U.S. $100,000 rule of Code Section&nbsp;422(d) it shall be treated as a Nonqualified Stock Option (&#147;<B><I>NSO</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3. <U>Termination Period</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>General Rule</U>. If Participant&#146;s Service terminates for any reason except death or Disability, and other than for Cause, then
this Option will expire at the close of business at Company headquarters on the date three (3)&nbsp;months after Participant&#146;s Termination Date (as defined below) (or such shorter time period not less than thirty (30)&nbsp;days or longer time
period as may be determined by the Committee, with any exercise beyond three (3)&nbsp;months after the date Participant&#146;s Service terminates deemed to be the exercise of an NSO). The Company determines when Participant&#146;s Service terminates
for all purposes under this Option Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Death; Disability</U>. If Participant dies before Participant&#146;s Service
terminates (or Participant dies within three months of Participant&#146;s termination of Service other than for Cause), then this Option will expire at the close of business at Company headquarters on the date twelve (12)&nbsp;months after the date
of death (or such shorter time period not less than six (6)&nbsp;months or longer time period as may be determined by the Committee, subject to the expiration details in Section&nbsp;7). If Participant&#146;s Service terminates because of
Participant&#146;s Disability, then this Option will expire at the close of business at Company headquarters on the date twelve (12)&nbsp;months after Participant&#146;s Termination Date (or such shorter time period not less than six (6)&nbsp;months
or longer time period as may be determined by the Committee, subject to the expiration details in Section&nbsp;7). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <U>Cause</U>.
Unless otherwise determined by the Committee, the Option (whether or not vested) will terminate immediately upon the Participant&#146;s cessation of Services if the Company reasonably determines in good faith that such cessation of Services has
resulted in connection with an act or failure to act constituting Cause (or the Participant&#146;s Services could have been terminated for Cause (without regard to the lapsing of any required notice or cure periods in connection therewith) at the
time the Participant terminated Services). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) <U>No Notification of Exercise Periods</U>. Participant is responsible for keeping
track of these exercise periods following Participant&#146;s termination of Service for any reason. The Company will not provide further notice of such periods. In no event shall this Option be exercised later than the Expiration Date set forth in
the Notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) <U>Termination</U>. For purposes of this Option, Participant&#146;s Service will be considered terminated (regardless of
the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where Participant is employed or the terms of Participant&#146;s employment agreement, if any) as of the date
Participant is no longer actively providing services to the Company, its Parent or one of its Subsidiaries or Affiliates (<I>i.e.</I>, Participant&#146;s period of Service would not include any contractual notice period or any period of &#147;garden
leave&#148; or similar period mandated under employment laws in the jurisdiction where Participant is employed or the terms of Participant&#146;s employment agreement, if any) (the &#147;<B><I>Termination Date</I></B>&#148;). Unless otherwise
provided in this Option Agreement or determined by the Company, Participant&#146;s right to vest in the Option under the Plan, if any, will terminate as of the Termination Date and Participant&#146;s right to exercise the Option after termination of
Service, if any, will be measured from the Termination Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In case of any dispute as to whether and when a termination of Service has occurred, the
Committee will have sole discretion to determine whether such termination of Service has occurred and the effective date of such termination (including whether Participant may still be considered to be actively providing Services while on a leave of
absence). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Participant does not exercise this Option within the termination period set forth in the Notice or the termination periods set forth above,
the Option shall terminate in its entirety. In no event, may any Option be exercised after the Expiration Date of the Option as set forth in the Notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4. <U>Exercise of Option</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Right to Exercise</U>. This Option is exercisable during its term in accordance with the Vesting Schedule set forth in the Notice and
the applicable provisions of the Plan and this Option Agreement. In the event of Participant&#146;s death, Disability, termination for Cause or other cessation of Service, the exercisability of the Option is governed by the applicable provisions of
the Plan, the Notice and this Option Agreement. This Option may not be exercised for a fraction of a Share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Method of
Exercise</U>. This Option is exercisable by delivery of an exercise notice in a form specified by the Company (the &#147;<B><I>Exercise Notice</I></B>&#148;), which will state the election to exercise the Option, the number of Shares in respect of
which the Option is being exercised (the &#147;<B><I>Exercised Shares</I></B>&#148;), and such other representations and agreements as may be required by the Company pursuant to the provisions of the Plan. The Exercise Notice will be delivered in
person, by mail, via electronic mail or facsimile or by other authorized method to the Secretary of the Company or other person designated by the Company. The Exercise Notice will be accompanied by payment of the aggregate Exercise Price as to all
Exercised Shares together with any applicable <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items (as defined in Section&nbsp;8 below). This Option will be deemed to be exercised upon receipt by the Company of such fully executed Exercise
Notice accompanied by such aggregate Exercise Price and payment of any applicable <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items (as defined below). No Shares will be issued pursuant to the exercise of this Option unless such issuance and
exercise complies with all relevant provisions of law and the requirements of any stock exchange or quotation service upon which the Shares are then listed and any exchange control registrations. Assuming such compliance, for United States income
tax purposes the Exercised Shares will be considered transferred to Participant on the date the Option is exercised with respect to such Exercised Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <U>Exercise by Another</U>. If another person wants to exercise this Option after it
has been transferred to him or her in compliance with this Option Agreement, that person must prove to the Company&#146;s satisfaction that he or she is entitled to exercise this Option. That person must also complete the proper Exercise Notice form
(as described above) and pay the Exercise Price (as described below) and any applicable <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items (as described below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B><U>Method of Payment</U></B><B>.</B> Payment of the aggregate Exercise Price, and any
<FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items withholding, will be by any of the following, or a combination thereof, at the election of Participant: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Participant&#146;s personal check (representing readily available funds), wire transfer, or a cashier&#146;s check; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) if permitted by the Committee, certificates for shares of Company stock that Participant owns, along with any forms needed to effect a
transfer of those shares to the Company; the value of the shares, determined as of the effective date of the Option exercise, will be applied to the Exercise Price. Instead of surrendering shares of Company stock, Participant may attest to the
ownership of those shares on a form provided by the Company and have the same number of shares subtracted from the Option shares issued to Participant. However, Participant may not surrender, or attest to the ownership of, shares of Company stock in
payment of the Exercise Price of Participant&#146;s Option if Participant&#146;s action would cause the Company to recognize compensation expense (or additional compensation expense) with respect to this Option for financial reporting purposes; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) cashless exercise through irrevocable directions to a securities broker approved by the Company to sell all or part of the Shares covered
by this Option and to deliver to the Company from the sale proceeds an amount sufficient to pay the Exercise Price and any applicable <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items withholding. The balance of the sale proceeds, if any,
will be delivered to Participant unless otherwise provided in this Option Agreement. The directions must be given by signing a special notice of exercise form provided by the Company; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) other method authorized by the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided, however, that the Company may restrict the available methods of payment due to facilitate compliance with applicable law or administration of the
Plan. In particular, if Participant is located outside the United States, Participant should review the applicable provisions of the Appendix for any such restrictions that may currently apply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.</B> <B><U><FONT STYLE="white-space:nowrap">Non-Transferability</FONT> of Option</U></B><B>.</B> This Option may not be sold, assigned,
transferred, pledged, hypothecated, or otherwise disposed of other than by will or by the laws of descent or distribution or by court order and may be exercised during the lifetime of Participant only by Participant or unless otherwise permitted by
the Committee on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis. The terms of the Plan and this Option Agreement will be binding upon the executors, administrators, heirs, successors and assigns
of Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B> <B><U>Term of Option</U></B><B>.</B> This Option will in any event expire on the expiration date set forth in
the Notice, which date is 10 years after the Date of Grant (five years after the Date of Grant if this option is designated as an ISO in the Notice of Stock Option Grant and Section&nbsp;5.3 of the Plan applies). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8. <U>Taxes</U>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)
<U>Responsibility for Taxes</U>. Participant acknowledges that, to the extent permitted by applicable law, regardless of any action taken by the Company or a Parent, Subsidiary or Affiliate employing or retaining Participant (the
&#147;<B><I>Employer</I></B>&#148;), the ultimate liability for all income tax, social insurance, payroll tax, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
fringe benefits tax, payment on account or other tax related items related to Participant&#146;s participation in the Plan and legally applicable to Participant (&#147;<B><I><FONT
STYLE="white-space:nowrap">Tax-Related</FONT> Items</I></B>&#148;) is and remains Participant&#146;s responsibility and may exceed the amount actually withheld by the Company or the Employer, if any. Participant further acknowledges that the Company
and/or the Employer (i)&nbsp;make no representations or undertakings regarding the treatment of any <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items in connection with any aspect of this Option, including, but not limited to, the grant,
vesting or exercise of this Option, the subsequent sale of Shares acquired pursuant to such exercise and the receipt of any dividends; and (ii)&nbsp;do not commit to and are under no obligation to structure the terms of the grant or any aspect of
this Option to reduce or eliminate Participant&#146;s liability for <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items or achieve any particular tax result. Further, if Participant is subject to
<FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items in more than one jurisdiction, Participant acknowledges that the Company and/or the Employer (or former employer, as applicable) may be required to withhold or account for <FONT
STYLE="white-space:nowrap">Tax-Related</FONT> Items in more than one jurisdiction. <I>PARTICIPANT SHOULD CONSULT A TAX ADVISER APPROPRIATELY QUALIFIED IN EACH OF THE JURISDICTIONS, INCLUDING THE COUNTRY OR COUNTRIES IN WHICH PARTICIPANT RESIDES OR
IS SUBJECT TO TAXATION BEFORE EXERCISING THE OPTION OR DISPOSING OF THE SHARES.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Withholding</U>.<I> </I>Prior to any relevant
taxable or tax withholding event, as applicable, to the extent permitted by applicable law Participant agrees to make arrangements satisfactory to the Company and/or the Employer to fulfill all <FONT STYLE="white-space:nowrap">Tax-Related</FONT>
Items. In this regard, Participant authorizes the Company and/or the Employer, or their respective agents, at their discretion, to satisfy any withholding obligations for <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items by one or a
combination of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">withholding from Participant&#146;s wages or other cash compensation paid to Participant by the Company and/or
the Employer or any Parent, Subsidiary or Affiliate; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">withholding from proceeds of the sale of Shares acquired at exercise of this Option either through a voluntary
sale or through a mandatory sale arranged by the Company (on Participant&#146;s behalf pursuant to this authorization and without further consent); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">withholding Shares to be issued upon exercise of the Option, provided the Company only withholds the number of
Shares necessary to satisfy no more than the maximum statutory withholding amounts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Participant&#146;s payment of a cash amount (including by check representing readily available funds or a wire
transfer); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other arrangement approved by the Committee and permitted under applicable law; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">all under such rules as may be established by the Committee and in compliance with the Company&#146;s Insider Trading Policy and <FONT
STYLE="white-space:nowrap">10b5-1</FONT> Trading Plan Policy, if applicable; provided however, that if Participant is a Section&nbsp;16 officer of the Company under the Exchange Act, then the Committee (as constituted in accordance with Rule <FONT
STYLE="white-space:nowrap">16b-3</FONT> under the Exchange Act) shall establish the method of withholding from alternatives (i)-(v) above, and the Committee shall establish the method prior to the <FONT STYLE="white-space:nowrap">Tax-Related</FONT>
Items withholding event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Depending on the withholding method, the Company may withhold or account for
<FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items by considering applicable statutory withholding rates or other applicable withholding rates, including up to the maximum permissible statutory rate for Participant&#146;s tax jurisdiction(s)
in which case Participant will have no entitlement to the equivalent amount in Shares and may receive a refund of any over-withheld amount in cash in accordance with applicable law. If the obligation for
<FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items is satisfied by withholding in Shares, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
then for tax purposes, Participant is deemed to have been issued the full number of Exercised Shares; notwithstanding that a number of the Shares are held back solely for the purpose of
satisfying the withholding obligation for <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Finally, Participant agrees to pay
to the Company or the Employer any amount of <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items that the Company or the Employer may be required to withhold or account for as a result of Participant&#146;s participation in the Plan that
cannot be satisfied by the means previously described. The Company may refuse to issue or deliver the Shares or the proceeds of the sale of Shares, if Participant fails to comply with Participant&#146;s obligations in connection with the <FONT
STYLE="white-space:nowrap">Tax-Related</FONT> Items. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) <U>Notice of Disqualifying Disposition of ISO Shares</U>. If Participant is
subject to <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items in the United States and sells or otherwise disposes of any of the Shares acquired pursuant to an ISO on or before the later of (i)&nbsp;two years after the grant date, or
(ii)&nbsp;one year after the exercise date, Participant will immediately notify the Company in writing of such disposition. Participant agrees that he or she may be subject to income tax withholding by the Company on the compensation income
recognized from such early disposition of ISO Shares by payment in cash or out any wages or other cash compensation paid to Participant by the Company and/or the Employer or any Parent, Subsidiary or Affiliate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.</B> <B><U>Nature of Grant</U></B><B>.</B> By accepting the Option, Participant acknowledges, understands and agrees that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) the Plan is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended or terminated
by the Company at any time, to the extent permitted by the Plan; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) the grant of the Option is exceptional, voluntary and occasional and
does not create any contractual or other right to receive future grants of options, or benefits in lieu of options, even if options have been granted in the past; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) all decisions with respect to future options or other grants, if any, will be at the sole discretion of the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Participant is voluntarily participating in the Plan; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) the Option and Participant&#146;s participation in the Plan will not create a right to employment or be interpreted as forming or amending
an employment or service contract with the Company, the Employer or any Parent, Subsidiary or Affiliate, and shall not interfere with the ability of the Company, the Employer or any Parent, Subsidiary or Affiliate, as applicable, to terminate
Participant&#146;s employment or service relationship (if any); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) the Option and the Shares subject to the Option, and the income from
and value of same, are not intended to replace any pension rights or compensation; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) the Option and the Shares subject to the Option,
and the income from and value of same, are not part of normal or expected compensation for any purpose, including, but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">end-of-service</FONT></FONT> payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) unless otherwise agreed with the Company, the Option and the Shares subject to the Option, and the income from and value of same, are not
granted as consideration for, or in connection with, the service Participant may provide as a director of a Parent, Subsidiary or Affiliate; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) the future value of the Shares underlying the Option is unknown, indeterminable and
cannot be predicted with certainty; if the underlying Shares do not increase in value, the Option will have no value; if Participant exercises the Option and acquires Shares, the value of such Shares may increase or decrease, even below the Exercise
Price; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) no claim or entitlement to compensation or damages will arise from forfeiture of the Option resulting from Participant&#146;s
termination of Service (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where Participant is employed or the terms of Participant&#146;s employment
agreement, if any); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) neither the Company, the Employer nor any Parent, Subsidiary or Affiliate will be liable for any foreign
exchange rate fluctuation between Participant&#146;s local currency and the United States Dollar that may affect the value of the Option or of any amounts due to Participant pursuant to the exercise of the Option or the subsequent sale of any Shares
acquired upon exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.</B> <B><U>No Advice Regarding Grant</U></B><B>.</B> The Company is not providing any tax, legal or
financial advice, nor is the Company making any recommendations regarding Participant&#146;s participation in the Plan, or Participant&#146;s acquisition or sale of the underlying Shares. Participant acknowledges, understands and agrees that he or
she should consult with his or her own personal tax, legal and financial advisors regarding his or her participation in the Plan before taking any action related to the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.</B> <B><I><U>Data Privacy</U></I></B><B><I>. Participant hereby explicitly and unambiguously consents to the collection, use and
transfer, in electronic or other form, of Participant&#146;s personal data as described in this Option Agreement and any other Option grant materials by and among, as applicable, the Employer, the Company and any Parent, Subsidiary or
Affiliate</I></B><I> </I><B><I>for the exclusive purpose of implementing, administering and managing Participant&#146;s participation in the Plan.</I></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Participant understands that the Company and the Employer may hold certain personal information about Participant, including, but not
limited to, Participant&#146;s name, home address, email address and telephone number, date of birth, social insurance number, passport number or other identification number (e.g., resident registration number), salary, nationality, job title, any
shares of stock or directorships held in the Company, details of all Options or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in Participant&#146;s favor (&#147;Data&#148;), for the exclusive
purpose of implementing, administering and managing the Plan. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Participant understands that Data will be transferred to
[Name of Broker/Platform], or other third party (&#147;Online Administrator&#148;) and its affiliated companies or such other stock plan service provider as may be designated by the Company from time to time that is assisting the Company with the
implementation, administration and management of the Plan. Participant understands that the recipients of Data may be located in the United States or elsewhere, and that the recipients&#146; country may have different data privacy laws and
protections than Participant&#146;s country. Participant understands that if he or she resides outside the United States, he or she may request a list with the names and addresses of any potential recipients of Data by contacting his or her local
human resources representative. Participant authorizes the Company, [Name of Broker/Platform], or such other stock plan service provider as may be designated by the Company from time to time, and any other possible recipients that may assist the
Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer Data, in electronic or other form, for the sole purpose of implementing, administering and managing his or her
participation in the Plan. Participant understands that Data will be held only as long as is necessary to implement, administer and manage Participant&#146;s participation in the Plan. Participant understands if he or she resides outside the United
States, he or she may, at any time, view Data, request information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>
herein, in any case without cost, by contacting his or her local human resources representative. Further, Participant understands that he or she is providing the consents herein on a purely
voluntary basis. If Participant does not consent, or if Participant later seeks to revoke his or her consent, his or her employment status or service with the Employer will not be affected; the only consequence of refusing or withdrawing
Participant&#146;s consent is that the Company would not be able to grant Options or other equity awards to Participant or administer or maintain such awards. Therefore, Participant understands that refusing or withdrawing his or her consent may
affect Participant&#146;s ability to participate in the Plan. For more information on the consequences of Participant&#146;s refusal to consent or withdrawal of consent, Participant understands that he or she may contact his or her local human
resources representative. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Finally, upon request of the Company or the Employer, Participant agrees to provide an executed
data privacy consent form (or any other agreements or consents) that the Company or the Employer may deem necessary to obtain from Participant for the purpose of administering Participant&#146;s participation in the Plan in compliance with the data
privacy laws in Participant&#146;s country, either now or in the future. Participant understands and agrees that Participant will not be able to participate in the Plan if Participant fails to provide any such consent or agreement requested by the
Company and/or the Employer. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.</B> <B><U>Language</U></B><B>.</B> Participant acknowledges that he or she is sufficiently
proficient in English to understand the terms and conditions of this Option Agreement. Furthermore, if Participant has received this Option Agreement, or any other document related to the Option and/or the Plan translated into a language other than
English and if the meaning of the translated version is different than the English version, the English version will control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.</B>
<B><U>Appendix</U></B><B>.</B> Notwithstanding any provisions in this Option Agreement, the Option will be subject to any special terms and conditions set forth in any appendix to this Option Agreement for Participant&#146;s country. Moreover, if
Participant relocates to one of the countries included in the Appendix, the special terms and conditions for such country will apply to Participant, to the extent the Company determines that the application of such terms and conditions is necessary
or advisable for legal or administrative reasons. The Appendix constitutes part of this Option Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.</B> <B><U>Imposition of
Other Requirements</U></B><B>.</B> The Company reserves the right to impose other requirements on Participant&#146;s participation in the Plan, on the Option and on any Shares purchased upon exercise of the Option, to the extent the Company
determines it is necessary or advisable for legal or administrative reasons, and to require Participant to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.</B> <B><U>Acknowledgement</U></B><B>.</B> The Company and Participant agree that the Option is granted under and governed by the
Notice, this Option Agreement and the provisions of the Plan (incorporated herein by reference). Participant: (a)&nbsp;acknowledges receipt of a copy of the Plan and the Plan prospectus, (b)&nbsp;represents that Participant has carefully read and is
familiar with their provisions, and (c)&nbsp;hereby accepts the Option subject to all of the terms and conditions set forth herein and those set forth in the Plan and the Notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.</B> <B><U>Entire Agreement; Enforcement of Rights</U></B><B>.</B> This Option Agreement, the Plan and the Notice constitute the entire
agreement and understanding of the parties relating to the subject matter herein and supersede all prior discussions between them. Any prior agreements, commitments or negotiations concerning the purchase of the Shares hereunder are superseded. No
adverse modification of, or adverse amendment to, this Option Agreement, nor any waiver of any rights under this Option Agreement, will be effective unless in writing and signed by the parties to this Option Agreement (which writing and signing may
be electronic). The failure by either party to enforce any rights under this Option Agreement will not be construed as a waiver of any rights of such party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.</B> <B><U>Compliance with Laws and Regulations</U></B><B>.</B> The issuance of Shares
will be subject to and conditioned upon compliance by the Company and Participant with all applicable state, federal and foreign laws and regulations and with all applicable requirements of any stock exchange or automated quotation system on which
the Company&#146;s Shares may be listed or quoted at the time of such issuance or transfer. Participant understands that the Company is under no obligation to register or qualify the Shares with any state, federal or foreign securities commission or
to seek approval or clearance from any governmental authority for the issuance or sale of the Shares. Further, Participant agrees that the Company shall have unilateral authority to amend the Plan and this Option Agreement without Participant&#146;s
consent to the extent necessary to comply with securities or other laws applicable to issuance of Shares. Finally, the Shares issued pursuant to this Option Agreement shall be endorsed with appropriate legends, if any, determined by the Company.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>18.</B> <B><U>Severability</U></B><B>.</B> If one or more provisions of this Option Agreement are held to be unenforceable under
applicable law, then such provision will be enforced to the maximum extent possible given the intent of the parties hereto. If such clause or provision cannot be so enforced, then (a)&nbsp;such provision will be excluded from this Option Agreement,
(b)&nbsp;the balance of this Option Agreement will be interpreted as if such provision were so excluded and (c)&nbsp;the balance of this Option Agreement will be enforceable in accordance with its terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>19.</B> <B><U>Governing Law and Venue</U></B><B>.</B> This Option Agreement and all acts and transactions pursuant hereto and the rights
and obligations of the parties hereto will be governed, construed and interpreted in accordance with the laws of the State of Delaware, without giving effect to such state&#146;s conflict of laws rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any and all disputes relating to, concerning or arising from this Option Agreement, or relating to, concerning or arising from the
relationship between the parties evidenced by the Plan or this Option Agreement, will be brought and heard exclusively in courts of San Mateo County, California, or the federal courts for the United States for the Northern District of California or
the Superior Court of California, County of San Mateo. Each of the parties hereby represents and agrees that such party is subject to the personal jurisdiction of said courts; hereby irrevocably consents to the jurisdiction of such courts in any
legal or equitable proceedings related to, concerning or arising from such dispute, and waives, to the fullest extent permitted by law, any objection which such party may now or hereafter have that the laying of the venue of any legal or equitable
proceedings related to, concerning or arising from such dispute which is brought in such courts is improper or that such proceedings have been brought in an inconvenient forum. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>20.</B> <B><U>No Rights as Employee, Director or Consultant</U></B><B>.</B> Nothing in this Option Agreement will affect in any manner
whatsoever any right or power of the Company, or a Parent, Subsidiary or Affiliate, to terminate Participant&#146;s Service, for any reason, with or without Cause. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.</B> <B><U>Consent to Electronic Delivery of All Plan Documents and Disclosures</U></B><B>.</B> By Participant&#146;s acceptance of the
Notice (whether in writing or electronically), Participant and the Company agree that this Option is granted under and governed by the terms and conditions of the Plan, the Notice and this Option Agreement. Participant has reviewed the Plan, the
Notice and this Option Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing the Notice and Agreement, and fully understands all provisions of the Plan, the Notice and this Option Agreement.
Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions relating to the Plan, the Notice and this Option Agreement. Participant further agrees to notify the Company
upon any change in the residence address. By acceptance of this Option, Participant agrees to participate in the Plan through an <FONT STYLE="white-space:nowrap">on-line</FONT> or electronic system established and maintained by the Company or a
third party designated by the Company and consents to the electronic delivery of the Notice, this Option Agreement, the Plan, account statements, Plan prospectuses required by the SEC, U.S. financial reports of the Company, and all other documents
that the Company is required to deliver to its security holders (including, without limitation, annual reports and proxy statements) or other communications or information related to the Option and current or future participation in the Plan.
Electronic delivery may include the delivery of a link to the Company intranet or the internet site of a third </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
party involved in administering the Plan, the delivery of the document via <FONT STYLE="white-space:nowrap">e-mail</FONT> or such other delivery determined at the Company&#146;s discretion.
Participant acknowledges that Participant may receive from the Company a paper copy of any documents delivered electronically at no cost if Participant contacts the Company by telephone, through a postal service or electronic mail to Stock
Administration. Participant further acknowledges that Participant will be provided with a paper copy of any documents delivered electronically if electronic delivery fails; similarly, Participant understands that Participant must provide on request
to the Company or any designated third party a paper copy of any documents delivered electronically if electronic delivery fails. Also, Participant understands that Participant&#146;s consent may be revoked or changed, including any change in the
electronic mail address to which documents are delivered (if Participant has provided an electronic mail address), at any time by notifying the Company of such revised or revoked consent by telephone, postal service or electronic mail to Stock
Administration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>22.</B> <B><U>Insider Trading Restrictions/Market Abuse Laws</U></B><B>.</B> Participant acknowledges that, depending
on Participant&#146;s country of residence, the broker&#146;s country, or the country in which the Shares are listed, Participant may be subject to insider trading restrictions and/or market abuse laws in applicable jurisdictions that may affect
Participant&#146;s ability to directly or indirectly, accept, acquire, sell or attempt to sell or otherwise dispose of Shares, or rights to Shares (<I>e.g.,</I> Options), or rights linked to the value of Shares, during such times as Participant is
considered to have &#147;inside information&#148; regarding the Company (as defined by the laws or regulations in the applicable jurisdiction). Local insider trading laws and regulations may prohibit the cancellation or amendment of orders
Participant placed before possessing the inside information. Furthermore, Participant may be prohibited from (i)&nbsp;disclosing the inside information to any third party, including fellow employees (other than on a &#147;need to know&#148; basis)
and (ii) &#147;tipping&#148; third parties or causing them to otherwise buy or sell securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company
insider trading policy. Participant acknowledges that it is Participant&#146;s responsibility to comply with any applicable restrictions and understands that Participant should consult his or her personal legal advisor on such matters. In addition,
Participant acknowledges that he or she read the Company&#146;s Insider Trading Policy, and agrees to comply with such policy, as it may be amended from time to time, whenever Participant acquires or disposes of the Company&#146;s securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>23.</B> <B><U>Foreign Asset/Account, Exchange Control and Tax Reporting</U></B>. Participant may be subject to foreign asset/account,
exchange control and/or tax reporting requirements as a result of the acquisition, holding and/or transfer of Shares or cash resulting from his or her participation in the Plan. Participant may be required to report such accounts, assets, the
balances therein, the value thereof and/or the transactions related thereto to the applicable authorities in Participant&#146;s country and/or repatriate funds received in connection with the Plan within certain time limits or according to specified
procedures. Participant acknowledges that he or she is responsible for ensuring compliance with any applicable foreign asset/account, exchange control and tax reporting requirements and should consult his or her personal legal and tax advisors on
such matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>24.</B> <B><U>Award Subject to Company Clawback or Recoupment</U></B><B>.</B> The Option shall be subject to clawback or
recoupment pursuant to any compensation clawback or recoupment policy adopted by the Board or required by law during the term of Participant&#146;s employment or other Service that is applicable to Participant. In addition to any other remedies
available under such policy, applicable law may require the cancellation of Participant&#146;s Option (whether vested or unvested) and the recoupment of any gains realized with respect to Participant&#146;s Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BY ACCEPTING THIS OPTION, PARTICIPANT AGREES TO ALL OF THE TERMS AND CONDITIONS DESCRIBED ABOVE AND IN THE PLAN. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPENDIX </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2020 EQUITY INCENTIVE PLAN </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GLOBAL STOCK OPTION AWARD AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COUNTRY SPECIFIC PROVISIONS FOR EMPLOYEES OUTSIDE THE U.S. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Terms and Conditions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At such time as the
Committee or Board issue an Option under the Plan to a Participant who resides and/or works outside of the United States, the Committee may adopt and include in this Appendix additional terms and conditions that govern such Option. This Appendix
forms part of the Option Agreement. Any capitalized term used in this Appendix without definition will have the meaning ascribed to it in the Notice, the Option Agreement or the Plan, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Participant is a citizen or resident of a country, or is considered resident of a country, other than the one in which Participant is currently working, or
Participant transfers employment and/or residency between countries after the Date of Grant, the Company will, in its sole discretion, determine to what extent the additional terms and conditions included herein will apply to Participant under these
circumstances. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notifications </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Appendix
also includes information relating to exchange control, securities laws, foreign asset/account reporting and other issues of which Participant should be aware with respect to Participant&#146;s participation in the Plan. The information is based on
the securities, exchange control, foreign asset/account reporting and other laws in effect in the respective countries as of [&#9679;]. Such laws are complex and change frequently. As a result, Participant should not rely on the information herein
as the only source of information relating to the consequences of Participant&#146;s participation in the Plan because the information may be out of date at the time that Participant exercises the Option, sells Shares acquired under the Plan or
takes any other action in connection with the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the information is general in nature and may not apply to Participant&#146;s particular
situation, and the Company is not in a position to assure Participant of any particular result. Accordingly, Participant should seek appropriate professional advice as to how the relevant laws in Participant&#146;s country may apply to
Participant&#146;s situation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Finally, if Participant is a citizen or resident of a country, or is considered resident of a country, other than the one
in which Participant is currently working and/or residing, or Participant transfers employment and/or residency after the Date of Grant, the information contained herein may not apply to Participant in the same manner. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Country-Specific Terms </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2020 EQUITY INCENTIVE PLAN </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GLOBAL NOTICE OF RESTRICTED STOCK UNIT AWARD </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise defined herein, the terms defined in the Graybug Vision, Inc.<B> </B>(the &#147;<B><I>Company</I></B>&#148;) 2020 Equity Incentive Plan (the
&#147;<B><I>Plan</I></B>&#148;) will have the same meanings in this Global Notice of Restricted Stock Unit Award and the electronic representation of this Global Notice of Restricted Stock Unit Award established and maintained by the Company or a
third party designated by the Company (this &#147;<B><I>Notice</I></B>&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Name: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Address: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You
(&#147;<B><I>Participant</I></B>&#148;) have been granted an award of Restricted Stock Units (&#147;<B><I>RSUs</I></B>&#148;) under the Plan subject to the terms and conditions of the Plan, this Notice and the attached Global Restricted Stock Unit
Award Agreement (the &#147;<B><I>Agreement</I></B>&#148;), including any applicable country-specific provisions in the appendix attached hereto (the &#147;<B><I>Appendix</I></B>&#148;), which constitutes part of the Agreement. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="75%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Grant Number:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Number of RSUs:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Date of Grant:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Vesting&nbsp;Commencement&nbsp;Date:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Expiration Date:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The earlier to occur of: (a)&nbsp;the date on which settlement of all RSUs granted hereunder occurs and (b)&nbsp;the tenth anniversary of the Date of Grant. This RSU expires earlier if Participant&#146;s Service terminates earlier,
as described in the Agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Vesting Schedule:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Subject to the limitations set forth in this Notice, the Plan and the Agreement, the RSUs will vest in accordance with the following schedule: <I></I>[<I>insert applicable vesting schedule</I>]<I></I></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By accepting (whether in writing, electronically or otherwise) the RSUs, Participant acknowledges and agrees to the following:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Participant understands that Participant&#146;s Service with the Company or a Parent or Subsidiary or Affiliate
is for an unspecified duration, can be terminated at any time (<I>i.e.</I>, is <FONT STYLE="white-space:nowrap">&#147;at-will&#148;),</FONT> except where otherwise prohibited by applicable law, and that nothing in this Notice, the Agreement or the
Plan changes the nature of that relationship. Participant acknowledges that the vesting of the RSUs pursuant to this Notice is subject to Participant&#146;s continuing Service as an Employee, Director or Consultant. To the extent permitted by
applicable law, Participant agrees and acknowledges that the Vesting Schedule may change prospectively in the event that Participant&#146;s Service status changes between full- and part-time and/or in the event Participant is on a leave of absence,
in accordance with Company policies relating to work schedules and vesting of Awards or as determined by the Committee. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This grant is made under and governed by the Plan, the Agreement and this Notice, and this Notice is subject to
the terms and conditions of the Agreement and the Plan, both of which are incorporated herein by reference. Participant has read the Notice, the Agreement and the Plan. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Participant has read the Company&#146;s Insider Trading Policy, and agrees to comply with such policy, as it
may be amended from time to time, whenever Participant acquires or disposes of the Company&#146;s securities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">By accepting the RSUs, Participant consents to electronic delivery and participation as set forth in the
Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2020 EQUITY INCENTIVE PLAN </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GLOBAL RESTRICTED STOCK UNIT AWARD AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise defined in this Global Restricted Stock Unit Award Agreement (this &#147;<B><I>Agreement</I></B>&#148;), any capitalized
terms used herein will have the same meaning ascribed to them in the Graybug Vision, Inc.<B> </B>2020 Equity Incentive Plan (the &#147;<B><I>Plan</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Participant has been granted Restricted Stock Units (&#147;<B><I>RSUs</I></B>&#148;) subject to the terms, restrictions and conditions of the
Plan, the Global Notice of Restricted Stock Unit Award (the &#147;<B><I>Notice</I></B>&#148;) and this Agreement, including any applicable country-specific provisions in the appendix attached hereto (the &#147;<B><I>Appendix</I></B>&#148;), which
constitutes part of this Agreement. In the event of a conflict between the terms and conditions of the Plan and the terms and conditions of the Notice or this Agreement, the terms and conditions of the Plan shall prevail. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B><U>Settlement</U></B><B>.</B> Settlement of RSUs will be made within 30&nbsp;days following the applicable date of vesting under the Vesting
Schedule set forth in the Notice. Settlement of RSUs will be in Shares. No fractional RSUs or rights for fractional Shares shall be created pursuant to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.</B> <B><U>No Stockholder Rights</U></B><B>.</B> Unless and until such time as Shares are issued in settlement of vested RSUs, Participant will have no
ownership of the Shares allocated to the RSUs and will have no rights to dividends or to vote such Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.</B> <B><U>Dividend
Equivalents</U></B><B>.</B> Dividends, if any (whether in cash or Shares), will not be credited to Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B><U><FONT
STYLE="white-space:nowrap">Non-Transferability</FONT> of RSUs</U></B><B>.</B> The RSUs and any interest therein will not be sold, assigned, transferred, pledged, hypothecated, or otherwise disposed of in any manner other than by will or by the laws
of descent or distribution or court order or unless otherwise permitted by the Committee on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B><U>Termination</U></B><B>.</B> If Participant&#146;s Service terminates for any reason, all unvested RSUs will be forfeited to the Company
forthwith, and all rights of Participant to such RSUs will immediately terminate without payment of any consideration to Participant. Participant&#146;s Service will be considered terminated (regardless of the reason for such termination and whether
or not later found to be invalid or in breach of employment laws in the jurisdiction where Participant is employed or the terms of Participant&#146;s employment agreement, if any) as of the date Participant is no longer actively providing services
and Participant&#146;s Service will not be extended by any notice period (e.g., Participant&#146;s Service would not include a period of &#147;garden leave&#148; or similar period mandated under employment laws in the jurisdiction where Participant
is employed or the terms of Participant&#146;s employment agreement, if any). Participant acknowledges and agrees that the Vesting Schedule may change prospectively in the event Participant&#146;s service status changes between full- and part-time
and/or in the event Participant is on a leave of absence, in accordance with Company policies relating to work schedules and vesting of awards or as determined by the Committee. In case of any dispute as to whether and when a termination of Service
has occurred, the Committee will have sole discretion to determine whether such termination of Service has occurred and the effective date of such termination (including whether Participant may still be considered to be actively providing Services
while on a leave of absence). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. <U>Taxes</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Responsibility for Taxes</U>. Participant acknowledges that, to the extent permitted by applicable law, regardless of any action taken
by the Company or a Parent, Subsidiary or Affiliate employing or retaining Participant (the &#147;<B><I>Employer</I></B>&#148;), the ultimate liability for all income tax, social insurance, payroll tax, fringe benefits tax, payment on account or
other <FONT STYLE="white-space:nowrap">tax-related</FONT> items related to Participant&#146;s participation in the Plan and legally applicable to Participant (&#147;<B><I><FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items</I></B>&#148;) is
and remains Participant&#146;s responsibility and may exceed the amount actually withheld by the Company or the Employer, if any. Participant further acknowledges that the Company and/or the Employer (i)&nbsp;make no representations or undertakings
regarding the treatment of any <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items in connection with any aspect of the RSUs, including, but not limited to, the grant, vesting or settlement of the RSUs and the subsequent sale of Shares
acquired pursuant to such settlement and the receipt of any dividends, and (ii)&nbsp;do not commit to and are under no obligation to structure the terms of the grant or any aspect of the RSUs to reduce or eliminate Participant&#146;s liability for <FONT
STYLE="white-space:nowrap">Tax-Related</FONT> Items or achieve any particular tax result. Further, if Participant is subject to <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items in more than one jurisdiction, Participant acknowledges that
the Company and/or the Employer (or former employer, as applicable) may be required to withhold or account for <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items in more than one jurisdiction. <I>PARTICIPANT SHOULD CONSULT A TAX ADVISER
APPROPRIATELY QUALIFIED IN EACH OF THE JURISDICTIONS, INCLUDING THE COUNTRY OR COUNTRIES IN WHICH PARTICIPANT RESIDES OR IS SUBJECT TO TAXATION.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Withholding</U>. Prior to any relevant taxable or tax withholding event, as applicable, to the extent permitted by applicable law,
Participant agrees to make arrangements satisfactory to the Company and/or the Employer to fulfill all <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items. In this regard, Participant authorizes the Company and/or the Employer, or their
respective agents, at their discretion, to satisfy any withholding obligations for <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items by one or a combination of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">withholding from Participant&#146;s wages or other cash compensation paid to Participant by the Company and/or
the Employer or any Parent, Subsidiary or Affiliate; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">withholding from proceeds of the sale of Shares acquired upon settlement of the RSUs either through a voluntary
sale or through a mandatory sale arranged by the Company<B> </B>(on Participant&#146;s behalf pursuant to this authorization and without further consent); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">withholding Shares to be issued upon settlement of the RSUs, provided the Company only withholds the number of
Shares necessary to satisfy no more than the maximum statutory withholding amounts; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Participant&#146;s payment of a cash amount (including by check representing readily available funds or a wire
transfer); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other arrangement approved by the Committee and permitted under applicable law; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">all under such rules as may be established by the Committee and in compliance with the Company&#146;s Insider Trading Policy and <FONT
STYLE="white-space:nowrap">10b5-1</FONT> Trading Plan Policy, if applicable; provided however, that if Participant is a Section&nbsp;16 officer of the Company under the Exchange Act, then the Committee (as constituted in accordance with Rule <FONT
STYLE="white-space:nowrap">16b-3</FONT> under the Exchange Act) shall establish the method of withholding from alternatives (i) &#150; (v) above, and the Committee shall establish such method prior to the
<FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items withholding event. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending on the withholding method, the Company may withhold or account for <FONT
STYLE="white-space:nowrap">Tax-Related</FONT> Items by considering applicable statutory withholding rates or other applicable withholding rates, including up to the maximum permissible statutory rate for Participant&#146;s tax jurisdiction(s) in
which case Participant will have no entitlement to the equivalent amount in Shares and may receive a refund of any over-withheld amount in cash in accordance with applicable law. If the obligation for
<FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items is satisfied by withholding in Shares, then for tax purposes, Participant is deemed to have been issued the full number of Shares subject to the vested RSUs, notwithstanding that a number of
the Shares are held back solely for the purpose of satisfying the withholding obligation for <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finally, Participant agrees to pay to the Company or the Employer any amount of <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items that
the Company or the Employer may be required to withhold or account for as a result of Participant&#146;s participation in the Plan that cannot be satisfied by the means previously described. The Company may refuse to issue or deliver the Shares or
the proceeds of the sale of Shares, if Participant fails to comply with Participant&#146;s obligations in connection with the <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.</B> <B><U>Nature of Grant</U></B><B>.</B> By accepting the RSUs, Participant acknowledges, understands and agrees that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) the Plan is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended or terminated
by the Company at any time, to the extent permitted by the Plan; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) the grant of the RSUs is exceptional, voluntary and occasional and
does not create any contractual or other right to receive future grants of RSUs, or benefits in lieu of RSUs, even if RSUs have been granted in the past; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) all decisions with respect to future RSUs or other grants, if any, will be at the sole discretion of the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Participant is voluntarily participating in the Plan; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) the RSUs and Participant&#146;s participation in the Plan will not create a right to employment or be interpreted as forming or amending
an employment or service contract with the Company, the Employer or any Parent, Subsidiary or Affiliate and shall not interfere with the ability of the Company, the Employer or any Parent, Subsidiary or Affiliate, as applicable, to terminate
Participant&#146;s employment or service relationship (if any); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) the RSUs and the Shares subject to the RSUs, and the income from and
value of same, are not intended to replace any pension rights or compensation; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) the RSUs and the Shares subject to the RSUs, and the
income from and value of same, are not part of normal or expected compensation for any purpose, including, but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">end-of-service</FONT></FONT> payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) unless otherwise agreed with the Company, the RSUs and the Shares subject to the RSUs, and the income from and value of same, are not
granted as consideration for, or in connection with, the service Participant may provide as a director of a Parent, Subsidiary or Affiliate; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) no claim or entitlement to compensation or damages will arise from forfeiture of the
RSUs resulting from Participant&#146;s termination of Service (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where Participant is employed or the terms
of Participant&#146;s employment agreement, if any); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) neither the Company, the Employer nor any Parent, Subsidiary or Affiliate
will be liable for any foreign exchange rate fluctuation between Participant&#146;s local currency and the United States Dollar that may affect the value of the RSUs or of any amounts due to Participant pursuant to the settlement of the RSUs or the
subsequent sale of any Shares acquired upon settlement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.</B> <B><U>No Advice Regarding Grant</U></B><B>.</B> The Company is not providing any tax,
legal or financial advice, nor is the Company making any recommendations regarding Participant&#146;s participation in the Plan, or Participant&#146;s acquisition or sale of the underlying Shares. Participant acknowledges, understands and agrees
that he or she should consult with his or her own personal tax, legal and financial advisors regarding his or her participation in the Plan before taking any action related to the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. </B><B><I><U>Data Privacy</U></I></B><B></B><B><I>. Participant hereby explicitly and unambiguously consents to the collection, use and transfer, in
electronic or other form, of Participant&#146;s personal data as described in this Agreement and any other RSU grant materials by and among, as applicable, the Employer, the Company and any Parent, Subsidiary or Affiliate</I></B><B></B><I>
</I><B></B><B><I>for the exclusive purpose of implementing, administering and managing Participant&#146;s participation in the Plan.</I></B><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Participant understands that the Company and the Employer may hold certain personal information about Participant, including, but not
limited to, Participant&#146;s name, home address, email address and telephone number, date of birth, social insurance number, passport number or other identification number (e.g., resident registration number), salary, nationality, job title, any
shares of stock or directorships held in the Company, details of all RSUs or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in Participant&#146;s favor (&#147;Data&#148;), for the exclusive
purpose of implementing, administering and managing the Plan. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Participant understands that Data will be transferred to
[Name of Broker/Platform], or other third party (&#147;Online Administrator&#148;) and its affiliated companies or such other stock plan service provider as may be designated by the Company from time to time that is assisting the Company with the
implementation, administration and management of the Plan. Participant understands that the recipients of Data may be located in the United States or elsewhere, and that the recipients&#146; country may have different data privacy laws and
protections than Participant&#146;s country. Participant understands that if he or she resides outside the United States, he or she may request a list with the names and addresses of any potential recipients of Data by contacting his or her local
human resources representative. Participant authorizes the Company, [Name of Broker/Platform], or such other stock plan service provider as may be designated by the Company from time to time, and any other possible recipients that may assist the
Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer Data, in electronic or other form, for the sole purpose of implementing, administering and managing his or her
participation in the Plan. Participant understands that Data will be held only as long as is necessary to implement, administer and manage Participant&#146;s participation in the Plan. Participant understands if he or she resides outside the United
States, he or she may, at any time, view Data, request information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting his or her local
human resources representative. Further, Participant understands that he or she is providing the consents herein on a purely voluntary basis. If Participant does not consent, or if Participant later seeks to revoke his or her consent, his or her
employment status or service with the Employer will not be affected; the only </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>
consequence of refusing or withdrawing Participant&#146;s consent is that the Company would not be able to grant RSUs or other equity awards to Participant or administer or maintain such awards.
Therefore, Participant understands that refusing or withdrawing his or her consent may affect Participant&#146;s ability to participate in the Plan. For more information on the consequences of Participant&#146;s refusal to consent or withdrawal of
consent, Participant understands that he or she may contact his or her local human resources representative. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Finally, upon
request of the Company or the Employer, Participant agrees to provide an executed data privacy consent form (or any other agreements or consents) that the Company or the Employer may deem necessary to obtain from Participant for the purpose of
administering Participant&#146;s participation in the Plan in compliance with the data privacy laws in Participant&#146;s country, either now or in the future. Participant understands and agrees that Participant will not be able to participate in
the Plan if Participant fails to provide any such consent or agreement requested by the Company and/or the Employer. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.</B>
<B><U>Language</U></B><B>.</B> Participant acknowledges that he or she is sufficiently proficient in English to understand the terms and conditions of this Agreement. Furthermore, if Participant has received this Agreement or any other document
related to the RSU and/or the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.</B> <B><U>Appendix</U></B><B>.</B> Notwithstanding any provisions in this Agreement, the RSUs will be subject to any special terms and conditions set
forth in any appendix to this Agreement for Participant&#146;s country. Moreover, if Participant relocates to one of the countries included in the Appendix, the special terms and conditions for such country will apply to Participant, to the extent
the Company determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons. The Appendix constitutes part of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.</B> <B><U>Imposition of Other Requirements</U></B><B>.</B> The Company reserves the right to impose other requirements on Participant&#146;s
participation in the Plan, on the RSUs and on any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require Participant to sign any additional agreements or
undertakings that may be necessary to accomplish the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.</B> <B><U>Acknowledgement</U></B><B>.</B> The Company and Participant agree that
the RSUs are granted under and governed by the Notice, this Agreement and the provisions of the Plan (incorporated herein by reference). Participant: (a)&nbsp;acknowledges receipt of a copy of the Plan and the Plan prospectus, (b)&nbsp;represents
that Participant has carefully read and is familiar with their provisions, and (c)&nbsp;hereby accepts the RSUs subject to all of the terms and conditions set forth herein and those set forth in the Plan and the Notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.</B> <B><U>Entire Agreement; Enforcement of Rights</U></B><B>.</B> This Agreement, the Plan and the Notice constitute the entire agreement and
understanding of the parties relating to the subject matter herein and supersede all prior discussions between them. Any prior agreements, commitments or negotiations concerning the purchase of the Shares hereunder are superseded. No adverse
modification of or adverse amendment to this Agreement, nor any waiver of any rights under this Agreement, will be effective unless in writing and signed by the parties to this Agreement (which writing and signing may be electronic). The failure by
either party to enforce any rights under this Agreement will not be construed as a waiver of any rights of such party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15.</B>
<B><U>Compliance</U></B><B><U></U></B><B><U>&nbsp;with</U></B><B><U></U></B><B><U>&nbsp;Laws</U></B><B><U></U></B><B><U>&nbsp;and</U></B><B><U></U></B><B><U>&nbsp;Regulations</U></B><B>.</B> The issuance of Shares will be subject to and conditioned
upon compliance by the Company and Participant with all applicable state, federal and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
foreign laws and regulations and with all applicable requirements of any stock exchange or automated quotation system on which the Company&#146;s Shares may be listed or quoted at the time of
such issuance or transfer. Participant understands that the Company is under no obligation to register or qualify the Shares with any state, federal or foreign securities commission or to seek approval or clearance from any governmental authority
for the issuance or sale of the Shares. Further, Participant agrees that the Company<B> </B>shall have unilateral authority to amend the Plan and this RSU Agreement without Participant&#146;s consent to the extent necessary to comply with securities
or other laws applicable to issuance of Shares. Finally, the Shares issued pursuant to this RSU Agreement shall be endorsed with appropriate legends, if any, determined by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.</B> <B><U>Severability</U></B><B>.</B> If one or more provisions of this Agreement are held to be unenforceable under applicable law, then such
provision will be enforced to the maximum extent possible given the intent of the parties hereto. If such clause or provision cannot be so enforced, then (a)&nbsp;such provision will be excluded from this Agreement, (b)&nbsp;the balance of this
Agreement will be interpreted as if such provision were so excluded and (c)&nbsp;the balance of this Agreement will be enforceable in accordance with its terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17.</B> <B><U>Governing Law and Venue</U></B><B>.</B> This Agreement and all acts and transactions pursuant hereto and the rights and obligations of the
parties hereto will be governed, construed and interpreted in accordance with the laws of the State of Delaware, without giving effect to such state&#146;s conflict of laws rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any and all disputes relating to, concerning or arising from this Agreement, or relating to, concerning or arising from the relationship
between the parties evidenced by the Plan or this Agreement, will be brought and heard exclusively in courts of San Mateo County, California, or the federal courts for the United States for the Northern District of California or the Superior Court
of California, County of San Mateo. Each of the parties hereby represents and agrees that such party is subject to the personal jurisdiction of said courts; hereby irrevocably consents to the jurisdiction of such courts in any legal or equitable
proceedings related to, concerning or arising from such dispute, and waives, to the fullest extent permitted by law, any objection which such party may now or hereafter have that the laying of the venue of any legal or equitable proceedings related
to, concerning or arising from such dispute which is brought in such courts is improper or that such proceedings have been brought in an inconvenient forum. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18.</B> <B><U>No Rights as Employee, Director or Consultant</U></B><B>.</B> Nothing in this Agreement will affect in any manner whatsoever any right or
power of the Company, or a Parent, Subsidiary or Affiliate, to terminate Participant&#146;s Service, for any reason, with or without Cause. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19.</B>
<B><U>Consent to Electronic Delivery of All Plan Documents and Disclosures</U></B><B>.</B> By Participant&#146;s acceptance of the Notice (whether in writing or electronically), Participant and the Company agree that the RSUs are granted under and
governed by the terms and conditions of the Plan, the Notice and this Agreement. Participant has reviewed the Plan, the Notice and this Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this
Notice and Agreement, and fully understands all provisions of the Plan, the Notice and this Agreement. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions relating
to the Plan, the Notice and this Agreement. Participant further agrees to notify the Company upon any change in Participant&#146;s residence address. By acceptance of the RSUs, Participant agrees to participate in the Plan through an <FONT
STYLE="white-space:nowrap">on-line</FONT> or electronic system established and maintained by the Company or a third party designated by the Company and consents to the electronic delivery of the Notice, this Agreement, the Plan, account statements,
Plan prospectuses required by the SEC, U.S. financial reports of the Company, and all other documents that the Company is required to deliver to its security holders (including, without limitation, annual reports and proxy statements) or other
communications or information related to the RSUs and current or future participation in the Plan. Electronic delivery may include the delivery of a link to the Company intranet or the internet site of a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
third party involved in administering the Plan, the delivery of the document via <FONT STYLE="white-space:nowrap">e-mail</FONT> or such other delivery determined at the Company&#146;s discretion.
Participant acknowledges that Participant may receive from the Company a paper copy of any documents delivered electronically at no cost if Participant contacts the Company by telephone, through a postal service or electronic mail to Stock
Administration. Participant further acknowledges that Participant will be provided with a paper copy of any documents delivered electronically if electronic delivery fails; similarly, Participant understands that Participant must provide on request
to the Company or any designated third party a paper copy of any documents delivered electronically if electronic delivery fails. Also, Participant understands that Participant&#146;s consent may be revoked or changed, including any change in the
electronic mail address to which documents are delivered (if Participant has provided an electronic mail address), at any time by notifying the Company of such revised or revoked consent by telephone, postal service or electronic mail to Stock
Administration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20.</B> <B><U>Insider Trading Restrictions/Market Abuse Laws</U></B><B>.</B> Participant acknowledges that, depending on
Participant&#146;s country of residence, the broker&#146;s country, or the country in which the Shares are listed, Participant may be subject to insider trading restrictions and/or market abuse laws in applicable jurisdictions that may affect
Participant&#146;s ability to directly or indirectly, accept, acquire, sell or attempt to sell or otherwise dispose of Shares, or rights to Shares (<I>e.g.</I>, RSUs), or rights linked to the value of Shares, during such times as Participant is
considered to have &#147;inside information&#148; regarding the Company (as defined by the laws or regulations in the applicable jurisdiction). Local insider trading laws and regulations may prohibit the cancellation or amendment of orders
Participant placed before possessing the inside information. Furthermore, Participant may be prohibited from (i)&nbsp;disclosing the inside information to any third party, including fellow employees (other than on a &#147;need to know&#148; basis)
and (ii) &#147;tipping&#148; third parties or causing them to otherwise buy or sell securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company
insider trading policy. Participant acknowledges that it is Participant&#146;s responsibility to comply with any applicable restrictions and understands that Participant should consult his or her personal legal advisor on such matters. In addition,
Participant acknowledges that he or she read the Company&#146;s Insider Trading Policy, and agrees to comply with such policy, as it may be amended from time to time, whenever Participant acquires or disposes of the Company&#146;s securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.</B> <B><U>Foreign Asset/Account, Exchange Control and Tax Reporting</U></B>. Participant may be subject to foreign asset/account, exchange control
and/or tax reporting requirements as a result of the acquisition, holding and/or transfer of Shares or cash resulting from his or her participation in the Plan. Participant may be required to report such accounts, assets, the balances therein, the
value thereof and/or the transactions related thereto to the applicable authorities in Participant&#146;s country and/or repatriate funds received in connection with the Plan within certain time limits or according to specified procedures.
Participant acknowledges that he or she is responsible for ensuring compliance with any applicable foreign asset/account, exchange control and tax reporting requirements and should consult his or her personal legal and tax advisors on such matters.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>22.</B> <B><U>Code Section</U></B><B><U></U></B><B><U>&nbsp;409A</U></B><B>.</B> For purposes of this Agreement, a termination of employment will be
determined consistent with the rules relating to a &#147;separation from service&#148; as defined in Section&nbsp;409A of the Internal Revenue Code and the regulations thereunder
(&#147;<B><I>Section</I></B><B><I></I></B><B><I>&nbsp;409A</I></B>&#148;). Notwithstanding anything else provided herein, to the extent any payments provided under this RSU Agreement in connection with Participant&#146;s termination of employment
constitute deferred compensation subject to Section&nbsp;409A, and Participant is deemed at the time of such termination of employment to be a &#147;specified employee&#148; under Section&nbsp;409A, then such payment shall not be made or commence
until the earlier of (i)&nbsp;the expiration of the <FONT STYLE="white-space:nowrap">six-month</FONT> period measured from Participant&#146;s separation from service from the Company or (ii)&nbsp;the date of Participant&#146;s death following such a
separation from service; provided, however, that such deferral shall only be effected to the extent required to avoid adverse tax treatment to Participant including, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
without limitation, the additional tax for which Participant would otherwise be liable under Section&nbsp;409A(a)(1)(B) in the absence of such a deferral. To the extent any payment under this RSU
Agreement may be classified as a &#147;short-term deferral&#148; within the meaning of Section&nbsp;409A, such payment shall be deemed a short-term deferral, even if it may also qualify for an exemption from Section&nbsp;409A under another provision
of Section&nbsp;409A. Payments pursuant to this section are intended to constitute separate payments for purposes of <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2)</FONT> of the Treasury Regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>23.</B> <B><U>Award Subject to Company Clawback or Recoupment</U></B><B>.</B> The RSUs shall be subject to clawback or recoupment pursuant to any
compensation clawback or recoupment policy adopted by the Board or required by law during the term of Participant&#146;s employment or other Service that is applicable to Participant. In addition to any other remedies available under such policy,
applicable law may require the cancellation of Participant&#146;s RSUs (whether vested or unvested) and the recoupment of any gains realized with respect to Participant&#146;s RSUs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>BY ACCEPTING THIS AWARD OF RSUS, PARTICIPANT AGREES TO ALL OF THE TERMS AND CONDITIONS DESCRIBED ABOVE AND IN THE PLAN. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPENDIX </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2020 EQUITY INCENTIVE PLAN </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GLOBAL RESTRICTED STOCK UNIT AWARD AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COUNTRY SPECIFIC PROVISIONS FOR EMPLOYEES OUTSIDE THE U.S. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Terms and Conditions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At such time as the
Committee or Board issue an RSU under the Plan to a Participant who resides and/or works outside of the United States, the Committee may adopt and include in this Appendix additional terms and conditions that govern such RSU. This Appendix forms
part of the Agreement. Any capitalized term used in this Appendix without definition will have the meaning ascribed to it in the Notice, the Agreement or the Plan, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Participant is a citizen or resident of a country, or is considered resident of a country, other than the one in which Participant is currently working, or
Participant transfers employment and/or residency between countries after the Date of Grant, the Company will, in its sole discretion, determine to what extent the additional terms and conditions included herein will apply to Participant under these
circumstances. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notifications </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Appendix
also includes information relating to exchange control, securities laws, foreign asset/account reporting and other issues of which Participant should be aware with respect to Participant&#146;s participation in the Plan. The information is based on
the securities, exchange control, foreign asset/account reporting and other laws in effect in the respective countries as of [&#9679;]. Such laws are complex and change frequently. As a result, Participant should not rely on the information herein
as the only source of information relating to the consequences of Participant&#146;s participation in the Plan because the information may be out of date at the time that Participant vests in the RSUs, sells Shares acquired under the Plan or takes
any other action in connection with the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the information is general in nature and may not apply to Participant&#146;s particular
situation, and the Company is not in a position to assure Participant of any particular result. Accordingly, Participant should seek appropriate professional advice as to how the relevant laws in Participant&#146;s country may apply to
Participant&#146;s situation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Finally, if Participant is a citizen or resident of a country, or is considered resident of a country, other than the one
in which Participant is currently working and/or residing, or Participant transfers employment and/or residency after the Date of Grant, the information contained herein may not apply to Participant in the same manner. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Country-Specific Terms </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2020 EQUITY INCENTIVE PLAN </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GLOBAL NOTICE OF PERFORMANCE STOCK UNIT AWARD </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise defined herein, the terms defined in the Graybug Vision, Inc.<B> </B>(the &#147;<B><I>Company</I></B>&#148;) 2020 Equity Incentive Plan (the
&#147;<B><I>Plan</I></B>&#148;) will have the same meanings in this Global Notice of Performance Stock Unit Award and the electronic representation of this Global Notice of Performance Stock Unit Award established and maintained by the Company or a
third party designated by the Company (this &#147;<B><I>Notice</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Name: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Address: </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You
(&#147;<B><I>Participant</I></B>&#148;) have been granted an award of Performance Stock Units (&#147;<B><I>PSUs</I></B>&#148;) under the Plan subject to the terms and conditions of the Plan, this Notice and the attached Global Performance Stock Unit
Award Agreement (the &#147;<B><I>Agreement</I></B>&#148;), including any applicable country-specific provisions in the appendix attached hereto (the &#147;<B><I>Appendix</I></B>&#148;), which constitutes part of the Agreement. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="75%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Grant Number:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Number of PSUs:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Date of Grant:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Vesting&nbsp;Commencement&nbsp;Date:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Expiration Date:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The earlier to occur of: (a)&nbsp;the date on which settlement of all PSUs granted hereunder occurs and (b)&nbsp;the tenth anniversary of the Date of Grant. This PSU expires earlier if Participant&#146;s Service terminates earlier,
as described in the Agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Vesting Schedule:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Subject to the limitations set forth in this Notice, the Plan and the Agreement, the PSUs will vest in accordance with the following schedule<I>: </I>[<I>insert applicable performance metrics and vesting
schedule</I>]<I></I></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By accepting (whether in writing, electronically or otherwise) the PSUs, Participant acknowledges and agrees to the following:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Participant understands that Participant&#146;s Service with the Company or a Parent or Subsidiary or Affiliate
is for an unspecified duration, can be terminated at any time (<I>i.e.</I>, is <FONT STYLE="white-space:nowrap">&#147;at-will&#148;),</FONT> except where otherwise prohibited by applicable law, and that nothing in this Notice, the Agreement or the
Plan changes the nature of that relationship. Participant acknowledges that the vesting of the PSUs pursuant to this Notice is subject to Participant&#146;s continuing Service as an Employee, Director or Consultant. To the extent permitted by
applicable law, Participant agrees and acknowledges that the Vesting Schedule may change prospectively in the event that Participant&#146;s Service status changes between full- and part-time and/or in the event Participant is on a leave of absence,
in accordance with Company policies relating to work schedules and vesting of Awards or as determined by the Committee. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This grant is made under and governed by the Plan, the Agreement and this Notice, and this Notice is subject to
the terms and conditions of the Agreement and the Plan, both of which are incorporated herein by reference. Participant has read the Notice, the Agreement and the Plan. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Participant has read the Company&#146;s Insider Trading Policy, and agrees to comply with such policy, as it
may be amended from time to time, whenever Participant acquires or disposes of the Company&#146;s securities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">By accepting the PSUs, Participant consents to electronic delivery and participation as set forth in the
Agreement. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2020 EQUITY INCENTIVE PLAN </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GLOBAL PERFORMANCE STOCK UNIT AWARD AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise defined in this Global Performance Stock Unit Award Agreement (this &#147;<B><I>Agreement</I></B>&#148;), any capitalized
terms used herein will have the same meaning ascribed to them in the Graybug Vision, Inc.<B> </B>2020 Equity Incentive Plan (the &#147;<B><I>Plan</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Participant has been granted Performance Stock Units (&#147;<B><I>PSUs</I></B>&#148;) subject to the terms, restrictions and conditions of the
Plan, the Global Notice of Performance Stock Unit Award (the &#147;<B><I>Notice</I></B>&#148;) and this Agreement, including any applicable country-specific provisions in the appendix attached hereto (the &#147;<B><I>Appendix</I></B>&#148;), which
constitutes part of this Agreement. In the event of a conflict between the terms and conditions of the Plan and the terms and conditions of the Notice or this Agreement, the terms and conditions of the Plan shall prevail. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B><U>Settlement</U></B><B>.</B> Settlement of PSUs will be made within 30&nbsp;days following the applicable date of vesting under the Vesting
Schedule set forth in the Notice. Settlement of PSUs will be in Shares. No fractional PSUs or rights for fractional Shares shall be created pursuant to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.</B> <B><U>No Stockholder Rights</U></B><B>.</B> Unless and until such time as Shares are issued in settlement of vested PSUs, Participant will have no
ownership of the Shares allocated to the PSUs and will have no rights to dividends or to vote such Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.</B> <B><U>Dividend
Equivalents</U></B><B>.</B> Dividends, if any (whether in cash or Shares), will not be credited to Participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B><U><FONT
STYLE="white-space:nowrap">Non-Transferability</FONT> of PSUs</U></B><B>.</B> The PSUs and any interest therein will not be sold, assigned, transferred, pledged, hypothecated, or otherwise disposed of in any manner other than by will or by the laws
of descent or distribution or court order or unless otherwise permitted by the Committee on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B><U>Termination</U></B><B>.</B> If Participant&#146;s Service terminates for any reason, all unvested PSUs will be forfeited to the Company
forthwith, and all rights of Participant to such PSUs will immediately terminate without payment of any consideration to Participant. Participant&#146;s Service will be considered terminated (regardless of the reason for such termination and whether
or not later found to be invalid or in breach of employment laws in the jurisdiction where Participant is employed or the terms of Participant&#146;s employment agreement, if any) as of the date Participant is no longer actively providing services
and Participant&#146;s Service will not be extended by any notice period (e.g., Participant&#146;s Service would not include a period of &#147;garden leave&#148; or similar period mandated under employment laws in the jurisdiction where Participant
is employed or the terms of Participant&#146;s employment agreement, if any). Participant acknowledges and agrees that the Vesting Schedule may change prospectively in the event Participant&#146;s service status changes between full- and part-time
and/or in the event Participant is on a leave of absence, in accordance with Company policies relating to work schedules and vesting of awards or as determined by the Committee. In case of any dispute as to whether and when a termination of Service
has occurred, the Committee will have sole discretion to determine whether such termination of Service has occurred and the effective date of such termination (including whether Participant may still be considered to be actively providing Services
while on a leave of absence). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. <U>Taxes</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Responsibility for Taxes</U>. Participant acknowledges that, to the extent permitted by applicable law, regardless of any action taken
by the Company or a Parent, Subsidiary or Affiliate employing or retaining Participant (the &#147;<B><I>Employer</I></B>&#148;), the ultimate liability for all income tax, social insurance, payroll tax, fringe benefits tax, payment on account or
other <FONT STYLE="white-space:nowrap">tax-related</FONT> items related to Participant&#146;s participation in the Plan and legally applicable to Participant (&#147;<B><I><FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items</I></B>&#148;) is
and remains Participant&#146;s responsibility and may exceed the amount actually withheld by the Company or the Employer, if any. Participant further acknowledges that the Company and/or the Employer (i)&nbsp;make no representations or undertakings
regarding the treatment of any <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items in connection with any aspect of the PSUs, including, but not limited to, the grant, vesting or settlement of the PSUs and the subsequent sale of Shares
acquired pursuant to such settlement and the receipt of any dividends, and (ii)&nbsp;do not commit to and are under no obligation to structure the terms of the grant or any aspect of the PSUs to reduce or eliminate Participant&#146;s liability for <FONT
STYLE="white-space:nowrap">Tax-Related</FONT> Items or achieve any particular tax result. Further, if Participant is subject to <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items in more than one jurisdiction, Participant acknowledges that
the Company and/or the Employer (or former employer, as applicable) may be required to withhold or account for <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items in more than one jurisdiction. <I>PARTICIPANT SHOULD CONSULT A TAX ADVISER
APPROPRIATELY QUALIFIED IN EACH OF THE JURISDICTIONS, INCLUDING THE COUNTRY OR COUNTRIES IN WHICH PARTICIPANT RESIDES OR IS SUBJECT TO TAXATION.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Withholding</U>. Prior to any relevant taxable or tax withholding event, as applicable, to the extent permitted by applicable law,
Participant agrees to make arrangements satisfactory to the Company and/or the Employer to fulfill all <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items. In this regard, Participant authorizes the Company and/or the Employer, or their
respective agents, at their discretion, to satisfy any withholding obligations for <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items by one or a combination of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">withholding from Participant&#146;s wages or other cash compensation paid to Participant by the Company and/or
the Employer or any Parent, Subsidiary or Affiliate; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">withholding from proceeds of the sale of Shares acquired upon settlement of the PSUs either through a voluntary
sale or through a mandatory sale arranged by the Company<B> </B>(on Participant&#146;s behalf pursuant to this authorization and without further consent); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">withholding Shares to be issued upon settlement of the PSUs, provided the Company only withholds the number of
Shares necessary to satisfy no more than the maximum statutory withholding amounts; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Participant&#146;s payment of a cash amount (including by check representing readily available funds or a wire
transfer); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other arrangement approved by the Committee and permitted under applicable law; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">all under such rules as may be established by the Committee and in compliance with the Company&#146;s Insider Trading Policy and <FONT
STYLE="white-space:nowrap">10b5-1</FONT> Trading Plan Policy, if applicable; provided however, that if Participant is a Section&nbsp;16 officer of the Company under the Exchange Act, then the Committee (as constituted in accordance with Rule <FONT
STYLE="white-space:nowrap">16b-3</FONT> under the Exchange Act) shall establish the method of withholding from alternatives (i) &#150; (v) above, and the Committee shall establish such method prior to the
<FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items withholding event. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending on the withholding method, the Company may withhold or account for <FONT
STYLE="white-space:nowrap">Tax-Related</FONT> Items by considering applicable statutory withholding rates or other applicable withholding rates, including up to the maximum permissible statutory rate for Participant&#146;s tax jurisdiction(s) in
which case Participant will have no entitlement to the equivalent amount in Shares and may receive a refund of any over-withheld amount in cash in accordance with applicable law. If the obligation for
<FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items is satisfied by withholding in Shares, then for tax purposes, Participant is deemed to have been issued the full number of Shares subject to the vested PSUs, notwithstanding that a number of
the Shares are held back solely for the purpose of satisfying the withholding obligation for <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finally, Participant agrees to pay to the Company or the Employer any amount of <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items that
the Company or the Employer may be required to withhold or account for as a result of Participant&#146;s participation in the Plan that cannot be satisfied by the means previously described. The Company may refuse to issue or deliver the Shares or
the proceeds of the sale of Shares, if Participant fails to comply with Participant&#146;s obligations in connection with the <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.</B> <B><U>Nature of Grant</U></B><B>.</B> By accepting the PSUs, Participant acknowledges, understands and agrees that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) the Plan is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended or terminated
by the Company at any time, to the extent permitted by the Plan; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) the grant of the PSUs is exceptional, voluntary and occasional and
does not create any contractual or other right to receive future grants of PSUs, or benefits in lieu of PSUs, even if PSUs have been granted in the past; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) all decisions with respect to future PSUs or other grants, if any, will be at the sole discretion of the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Participant is voluntarily participating in the Plan; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) the PSUs and Participant&#146;s participation in the Plan will not create a right to employment or be interpreted as forming or amending
an employment or service contract with the Company, the Employer or any Parent, Subsidiary or Affiliate and shall not interfere with the ability of the Company, the Employer or any Parent, Subsidiary or Affiliate, as applicable, to terminate
Participant&#146;s employment or service relationship (if any); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) the PSUs and the Shares subject to the PSUs, and the income from and
value of same, are not intended to replace any pension rights or compensation; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) the PSUs and the Shares subject to the PSUs, and the
income from and value of same, are not part of normal or expected compensation for any purpose, including, but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">end-of-service</FONT></FONT> payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) unless otherwise agreed with the Company, the PSUs and the Shares subject to the PSUs, and the income from and value of same, are not
granted as consideration for, or in connection with, the service Participant may provide as a director of a Parent, Subsidiary or Affiliate; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the future value of the underlying Shares is unknown, indeterminable and cannot be
predicted with certainty; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) no claim or entitlement to compensation or damages will arise from forfeiture of the PSUs resulting from
Participant&#146;s termination of Service (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where Participant is employed or the terms of
Participant&#146;s employment agreement, if any); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) neither the Company, the Employer nor any Parent, Subsidiary or Affiliate will
be liable for any foreign exchange rate fluctuation between Participant&#146;s local currency and the United States Dollar that may affect the value of the PSUs or of any amounts due to Participant pursuant to the settlement of the PSUs or the
subsequent sale of any Shares acquired upon settlement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.</B> <B><U>No Advice Regarding Grant</U></B><B>.</B> The Company is not providing any tax,
legal or financial advice, nor is the Company making any recommendations regarding Participant&#146;s participation in the Plan, or Participant&#146;s acquisition or sale of the underlying Shares. Participant acknowledges, understands and agrees
that he or she should consult with his or her own personal tax, legal and financial advisors regarding his or her participation in the Plan before taking any action related to the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. </B><B><I><U>Data Privacy</U></I></B><B></B><B><I>. Participant hereby explicitly and unambiguously consents to the collection, use and transfer, in
electronic or other form, of Participant&#146;s personal data as described in this Agreement and any other PSU grant materials by and among, as applicable, the Employer, the Company and any Parent, Subsidiary or Affiliate</I></B><B></B><I>
</I><B></B><B><I>for the exclusive purpose of implementing, administering and managing Participant&#146;s participation in the Plan.</I></B><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Participant understands that the Company and the Employer may hold certain personal information about Participant, including, but not
limited to, Participant&#146;s name, home address, email address and telephone number, date of birth, social insurance number, passport number or other identification number (e.g., resident registration number), salary, nationality, job title, any
shares of stock or directorships held in the Company, details of all PSUs or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in Participant&#146;s favor (&#147;Data&#148;), for the exclusive
purpose of implementing, administering and managing the Plan. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Participant understands that Data will be transferred to
[Name of Broker/Platform], or other third party (&#147;Online Administrator&#148;) and its affiliated companies or such other stock plan service provider as may be designated by the Company from time to time that is assisting the Company with the
implementation, administration and management of the Plan. Participant understands that the recipients of Data may be located in the United States or elsewhere, and that the recipients&#146; country may have different data privacy laws and
protections than Participant&#146;s country. Participant understands that if he or she resides outside the United States, he or she may request a list with the names and addresses of any potential recipients of Data by contacting his or her local
human resources representative. Participant authorizes the Company, [Name of Broker/Platform], or such other stock plan service provider as may be designated by the Company from time to time, and any other possible recipients that may assist the
Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer Data, in electronic or other form, for the sole purpose of implementing, administering and managing his or her
participation in the Plan. Participant understands that Data will be held only as long as is necessary to implement, administer and manage Participant&#146;s participation in the Plan. Participant understands if he or she resides outside the United
States, he or she may, at any time, view Data, request information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting his or her local
human resources </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>
representative. Further, Participant understands that he or she is providing the consents herein on a purely voluntary basis. If Participant does not consent, or if Participant later seeks to
revoke his or her consent, his or her employment status or service with the Employer will not be affected; the only consequence of refusing or withdrawing Participant&#146;s consent is that the Company would not be able to grant PSUs or other equity
awards to Participant or administer or maintain such awards. Therefore, Participant understands that refusing or withdrawing his or her consent may affect Participant&#146;s ability to participate in the Plan. For more information on the
consequences of Participant&#146;s refusal to consent or withdrawal of consent, Participant understands that he or she may contact his or her local human resources representative. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Finally, upon request of the Company or the Employer, Participant agrees to provide an executed data privacy consent form (or any other
agreements or consents) that the Company or the Employer may deem necessary to obtain from Participant for the purpose of administering Participant&#146;s participation in the Plan in compliance with the data privacy laws in Participant&#146;s
country, either now or in the future. Participant understands and agrees that Participant will not be able to participate in the Plan if Participant fails to provide any such consent or agreement requested by the Company and/or the Employer.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.</B> <B><U>Language</U></B><B>.</B> Participant acknowledges that he or she is sufficiently proficient in English to understand the terms
and conditions of this Agreement. Furthermore, if Participant has received this Agreement or any other document related to the PSU and/or the Plan translated into a language other than English and if the meaning of the translated version is
different than the English version, the English version will control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.</B> <B><U>Appendix</U></B><B>.</B> Notwithstanding any provisions in this
Agreement, the PSUs will be subject to any special terms and conditions set forth in any appendix to this Agreement for Participant&#146;s country. Moreover, if Participant relocates to one of the countries included in the Appendix, the special
terms and conditions for such country will apply to Participant, to the extent the Company determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons. The Appendix constitutes part of
this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12.</B> <B><U>Imposition of Other Requirements</U></B><B>.</B> The Company reserves the right to impose other requirements on
Participant&#146;s participation in the Plan, on the PSUs and on any Shares acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require Participant to sign any
additional agreements or undertakings that may be necessary to accomplish the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.</B> <B><U>Acknowledgement</U></B><B>.</B> The Company and
Participant agree that the PSUs are granted under and governed by the Notice, this Agreement and the provisions of the Plan (incorporated herein by reference). Participant: (a)&nbsp;acknowledges receipt of a copy of the Plan and the Plan prospectus,
(b)&nbsp;represents that Participant has carefully read and is familiar with their provisions, and (c)&nbsp;hereby accepts the PSUs subject to all of the terms and conditions set forth herein and those set forth in the Plan and the Notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.</B> <B><U>Entire Agreement; Enforcement of Rights</U></B><B>.</B> This Agreement, the Plan and the Notice constitute the entire agreement and
understanding of the parties relating to the subject matter herein and supersede all prior discussions between them. Any prior agreements, commitments or negotiations concerning the purchase of the Shares hereunder are superseded. No adverse
modification of or adverse amendment to this Agreement, nor any waiver of any rights under this Agreement, will be effective unless in writing and signed by the parties to this Agreement (which writing and signing may be electronic). The failure by
either party to enforce any rights under this Agreement will not be construed as a waiver of any rights of such party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15.</B>
<B><U>Compliance</U></B><B><U></U></B><B><U>&nbsp;with</U></B><B><U></U></B><B><U>&nbsp;Laws</U></B><B><U></U></B><B><U>&nbsp;and</U></B><B><U></U></B><B><U>&nbsp;Regulations</U></B>. The issuance of Shares will be subject to and conditioned upon
compliance by the Company and Participant with all applicable state, federal and foreign laws and regulations and with all applicable requirements of any stock exchange or automated quotation system on which the Company&#146;s Shares may be listed
or quoted at the time of such issuance or transfer. Participant understands that the Company is under no obligation to register or qualify the Shares with any state, federal or foreign securities commission or to seek approval or clearance from any
governmental authority for the issuance or sale of the Shares. Further, Participant agrees that the Company shall have unilateral authority to amend the Plan and this PSU Agreement without Participant&#146;s consent to the extent necessary to comply
with securities or other laws applicable to issuance of Shares. Finally, the Shares issued pursuant to this PSU Agreement shall be endorsed with appropriate legends, if any, determined by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.</B> <B><U>Severability</U></B><B>.</B> If one or more provisions of this Agreement are held to be unenforceable under applicable law, then such
provision will be enforced to the maximum extent possible given the intent of the parties hereto. If such clause or provision cannot be so enforced, then (a)&nbsp;such provision will be excluded from this Agreement, (b)&nbsp;the balance of this
Agreement will be interpreted as if such provision were so excluded and (c)&nbsp;the balance of this Agreement will be enforceable in accordance with its terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17.</B> <B><U>Governing Law and Venue</U></B><B>.</B> This Agreement and all acts and transactions pursuant hereto and the rights and obligations of the
parties hereto will be governed, construed and interpreted in accordance with the laws of the State of Delaware, without giving effect to such state&#146;s conflict of laws rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any and all disputes relating to, concerning or arising from this Agreement, or relating to, concerning or arising from the relationship
between the parties evidenced by the Plan or this Agreement, will be brought and heard exclusively in the courts of San Mateo County, California, or the federal courts for the United States for the Northern District of California or the Superior
Court of California, County of San Mateo. Each of the parties hereby represents and agrees that such party is subject to the personal jurisdiction of said courts; hereby irrevocably consents to the jurisdiction of such courts in any legal or
equitable proceedings related to, concerning or arising from such dispute, and waives, to the fullest extent permitted by law, any objection which such party may now or hereafter have that the laying of the venue of any legal or equitable
proceedings related to, concerning or arising from such dispute which is brought in such courts is improper or that such proceedings have been brought in an inconvenient forum. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18.</B> <B><U>No Rights as Employee, Director or Consultant</U></B><B>.</B> Nothing in this Agreement will affect in any manner whatsoever any right or
power of the Company, or a Parent, Subsidiary or Affiliate, to terminate Participant&#146;s Service, for any reason, with or without Cause. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19.</B>
<B><U>Consent to Electronic Delivery of All Plan Documents and Disclosures</U></B><B>.</B> By Participant&#146;s acceptance of the Notice (whether in writing or electronically), Participant and the Company agree that the PSUs are granted under and
governed by the terms and conditions of the Plan, the Notice and this Agreement. Participant has reviewed the Plan, the Notice and this Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this
Notice and Agreement, and fully understands all provisions of the Plan, the Notice and this Agreement. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions relating
to the Plan, the Notice and this Agreement. Participant further agrees to notify the Company upon any change in Participant&#146;s residence address. By acceptance of the PSUs, Participant agrees to participate in the Plan through an <FONT
STYLE="white-space:nowrap">on-line</FONT> or electronic system established and maintained by the Company or a third party designated by the Company and consents to the electronic delivery of the Notice, this Agreement, the Plan, account statements,
Plan prospectuses required by the SEC, U.S. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
financial reports of the Company, and all other documents that the Company is required to deliver to its security holders (including, without limitation, annual reports and proxy statements) or
other communications or information related to the PSUs and current or future participation in the Plan. Electronic delivery may include the delivery of a link to the Company intranet or the internet site of a third party involved in administering
the Plan, the delivery of the document via <FONT STYLE="white-space:nowrap">e-mail</FONT> or such other delivery determined at the Company&#146;s discretion. Participant acknowledges that Participant may receive from the Company a paper copy of any
documents delivered electronically at no cost if Participant contacts the Company by telephone, through a postal service or electronic mail to Stock Administration. Participant further acknowledges that Participant will be provided with a paper copy
of any documents delivered electronically if electronic delivery fails; similarly, Participant understands that Participant must provide on request to the Company or any designated third party a paper copy of any documents delivered electronically
if electronic delivery fails. Also, Participant understands that Participant&#146;s consent may be revoked or changed, including any change in the electronic mail address to which documents are delivered (if Participant has provided an electronic
mail address), at any time by notifying the Company of such revised or revoked consent by telephone, postal service or electronic mail to Stock Administration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20.</B> <B><U>Insider Trading Restrictions/Market Abuse Laws</U></B><B>.</B> Participant acknowledges that, depending on Participant&#146;s country of
residence, the broker&#146;s country, or the country in which the Shares are listed, Participant may be subject to insider trading restrictions and/or market abuse laws in applicable jurisdictions that may affect Participant&#146;s ability to
directly or indirectly, accept, acquire, sell or attempt to sell or otherwise dispose of Shares, or rights to Shares (<I>e.g.</I>, PSUs), or rights linked to the value of Shares, during such times as Participant is considered to have &#147;inside
information&#148; regarding the Company (as defined by the laws or regulations in the applicable jurisdiction). Local insider trading laws and regulations may prohibit the cancellation or amendment of orders Participant placed before possessing the
inside information. Furthermore, Participant may be prohibited from (i)&nbsp;disclosing the inside information to any third party, including fellow employees (other than on a &#147;need to know&#148; basis) and (ii) &#147;tipping&#148; third parties
or causing them to otherwise buy or sell securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. Participant
acknowledges that it is Participant&#146;s responsibility to comply with any applicable restrictions and understands that Participant should consult his or her personal legal advisor on such matters. In addition, Participant acknowledges that he or
she read the Company&#146;s Insider Trading Policy, and agrees to comply with such policy, as it may be amended from time to time, whenever Participant acquires or disposes of the Company&#146;s securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.</B> <B><U>Foreign Asset/Account, Exchange Control and Tax Reporting</U></B>. Participant may be subject to foreign asset/account, exchange control
and/or tax reporting requirements as a result of the acquisition, holding and/or transfer of Shares or cash resulting from his or her participation in the Plan. Participant may be required to report such accounts, assets, the balances therein, the
value thereof and/or the transactions related thereto to the applicable authorities in Participant&#146;s country and/or repatriate funds received in connection with the Plan within certain time limits or according to specified procedures.
Participant acknowledges that he or she is responsible for ensuring compliance with any applicable foreign asset/account, exchange control and tax reporting requirements and should consult his or her personal legal and tax advisors on such matters.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>22.</B> <B><U>Code Section</U></B><B><U></U></B><B><U>&nbsp;409A</U></B><B>.</B> For purposes of this Agreement, a termination of employment will be
determined consistent with the rules relating to a &#147;separation from service&#148; as defined in Section&nbsp;409A of the Internal Revenue Code and the regulations thereunder
(&#147;<B><I>Section</I></B><B><I></I></B><B><I>&nbsp;409A</I></B>&#148;). Notwithstanding anything else provided herein, to the extent any payments provided under this PSU Agreement in connection with Participant&#146;s termination of employment
constitute deferred compensation subject to Section&nbsp;409A, and Participant is deemed at the time of such termination of employment to be a &#147;specified employee&#148; under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Section&nbsp;409A, then such payment shall not be made or commence until the earlier of (i)&nbsp;the expiration of the <FONT STYLE="white-space:nowrap">six-month</FONT> period measured from
Participant&#146;s separation from service from the Company or (ii)&nbsp;the date of Participant&#146;s death following such a separation from service; provided, however, that such deferral shall only be effected to the extent required to avoid
adverse tax treatment to Participant including, without limitation, the additional tax for which Participant would otherwise be liable under Section&nbsp;409A(a)(1)(B) in the absence of such a deferral. To the extent any payment under this PSU
Agreement may be classified as a &#147;short-term deferral&#148; within the meaning of Section&nbsp;409A, such payment shall be deemed a short-term deferral, even if it may also qualify for an exemption from Section&nbsp;409A under another provision
of Section&nbsp;409A. Payments pursuant to this section are intended to constitute separate payments for purposes of <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2)</FONT> of the Treasury Regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>23.</B> <B><U>Award Subject to Company Clawback or Recoupment</U></B><B>.</B> The PSUs shall be subject to clawback or recoupment pursuant to any
compensation clawback or recoupment policy adopted by the Board or required by law during the term of Participant&#146;s employment or other Service that is applicable to Participant. In addition to any other remedies available under such policy,
applicable law may require the cancellation of Participant&#146;s PSUs (whether vested or unvested) and the recoupment of any gains realized with respect to Participant&#146;s PSUs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BY ACCEPTING THIS AWARD OF PSUS, PARTICIPANT AGREES TO ALL OF THE TERMS AND CONDITIONS DESCRIBED ABOVE AND IN THE PLAN. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPENDIX </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2020 EQUITY INCENTIVE PLAN </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GLOBAL PERFORMANCE STOCK UNIT AWARD AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COUNTRY SPECIFIC PROVISIONS FOR EMPLOYEES OUTSIDE THE U.S. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Terms and Conditions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At such time as the
Committee or Board issue a PSU under the Plan to a Participant who resides and/or works outside of the United States, the Committee may adopt and include in this Appendix additional terms and conditions that govern such PSU. This Appendix forms part
of the Agreement. Any capitalized term used in this Appendix without definition will have the meaning ascribed to it in the Notice, the Agreement or the Plan, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Participant is a citizen or resident of a country, or is considered resident of a country, other than the one in which Participant is currently working, or
Participant transfers employment and/or residency between countries after the Date of Grant, the Company will, in its sole discretion, determine to what extent the additional terms and conditions included herein will apply to Participant under these
circumstances. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notifications </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Appendix
also includes information relating to exchange control, securities laws, foreign asset/account reporting and other issues of which Participant should be aware with respect to Participant&#146;s participation in the Plan. The information is based on
the securities, exchange control, foreign asset/account reporting and other laws in effect in the respective countries as of [&#9679;]. Such laws are complex and change frequently. As a result, Participant should not rely on the information herein
as the only source of information relating to the consequences of Participant&#146;s participation in the Plan because the information may be out of date at the time that Participant vests in the PSUs, sells Shares acquired under the Plan or takes
any other action in connection with the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the information is general in nature and may not apply to Participant&#146;s particular
situation, and the Company is not in a position to assure Participant of any particular result. Accordingly, Participant should seek appropriate professional advice as to how the relevant laws in Participant&#146;s country may apply to
Participant&#146;s situation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Finally, if Participant is a citizen or resident of a country, or is considered resident of a country, other than the one
in which Participant is currently working and/or residing, or Participant transfers employment and/or residency after the Date of Grant, the information contained herein may not apply to Participant in the same manner. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Country-Specific Terms </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>6
<FILENAME>d796801dex104.htm
<DESCRIPTION>EX-10.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2020 EMPLOYEE STOCK PURCHASE PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B>Establishment of Plan</B>. Graybug Vision, Inc. a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), proposes to grant
options to purchase shares of Common Stock to eligible employees of the Company and its Participating Corporations pursuant to this Plan. The Company intends this Plan to qualify as an &#147;employee stock purchase plan&#148; under Code
Section&nbsp;423 and this Plan will be so construed; provided that the Company may adopt <FONT STYLE="white-space:nowrap">sub-plans</FONT> applicable to particular Participating Corporations which <FONT STYLE="white-space:nowrap">sub-plans</FONT>
may be designed to be outside the scope of Section&nbsp;423 of the Code.&nbsp;Subject to Section&nbsp;14, a total of 210,000 shares of Common Stock is reserved for issuance under this Plan. In addition, on each January&nbsp;1 for the ten
(10)&nbsp;calendar years immediately after the first Offering Date, the aggregate number of shares of Common Stock reserved for issuance under the Plan will be increased automatically by the number of shares equal to one percent (1%) of the total
number of outstanding shares of all classes of the Company&#146;s common stock on the immediately preceding December 31st (rounded down to the nearest whole share); provided that the Board or the Committee may in its sole discretion reduce the
amount of the increase in any particular year; and provided, further, that the aggregate number of shares of Common Stock issued over the term of this Plan will not exceed 2,100,000. The number of shares reserved for issuance under this Plan and the
maximum number of shares that may be issued under this Plan will be subject to adjustments effected in accordance with Section&nbsp;14 of this Plan. Capitalized terms not defined elsewhere in the text are defined in Section&nbsp;27. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B> <B>Purpose</B>. The purpose of this Plan is to provide eligible employees of the Company and Participating Corporations with a means
of acquiring an equity interest in the Company through payroll deductions, to enhance such employees&#146; sense of participation in the affairs of the Company and Participating Corporations, and to provide an incentive for continued employment.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.</B> <B>Administration</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Plan will be administered by the Compensation Committee of the Board or by the Board (as applicable, the
&#147;<B><I>Committee</I></B>&#148;). Subject to the provisions of this Plan and the limitations of Section&nbsp;423 of the Code or any successor provision in the Code, all questions of interpretation or application of this Plan will be determined
by the Committee and its decisions will be final and binding upon all Participants. The Committee will have full and exclusive discretionary authority to construe, interpret, and apply the terms of the Plan, to determine eligibility and determine
which entities will be Participating Corporations and whether an offer to Participating Corporations is intended to meet Code Section&nbsp;423 requirements and to decide upon any and all claims filed under the Plan. Every finding, decision, and
determination made by the Committee will, to the full extent permitted by law, be final and binding upon all parties. The Committee will have the authority to determine the Fair Market Value (which determination will be final, binding, and
conclusive for all purposes) in accordance with Section&nbsp;8 below and to interpret Section&nbsp;8 of the Plan in connection with circumstances that impact the Fair Market Value. Members of the Committee will receive no compensation for their
services in connection with the administration of this Plan, other than standard fees as established from time to time by the Board for services rendered by Board members serving on the Board or its committees. All expenses incurred in connection
with the administration of this Plan will be paid by the Company. For purposes of this Plan, the Committee may designate separate offerings under the Plan (the terms of which need not be identical) in which eligible employees of one or more
Participating Corporations will participate, even if the dates of the applicable Offering Periods of each such offering are identical. The Committee may also establish rules to govern transfers of employment among the Company and any Participating
Corporation, consistent with the applicable requirements of Code Section&nbsp;423 and the terms of the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Committee may adopt such rules, procedures, and
<FONT STYLE="white-space:nowrap">sub-plans</FONT> as are necessary or appropriate to permit the participation in the Plan by eligible employees who are citizens or residents of a jurisdiction and/or employed outside the United States, the terms of
which <FONT STYLE="white-space:nowrap">sub-plans</FONT> may take precedence over other provisions of this Plan, with the exception of the provisions in Section&nbsp;1 above setting forth the number of shares of Common Stock reserved for issuance
under the Plan; provided that unless otherwise superseded by the terms of such <FONT STYLE="white-space:nowrap">sub-plan,</FONT> the provisions of this Plan will govern the operation of such <FONT STYLE="white-space:nowrap">sub-plan.</FONT> Further,
the Committee is specifically authorized to adopt rules and procedures regarding the application of the definition of Compensation (as defined below) to Participants on payrolls outside of the United States, handling of payroll deductions and other
contributions, taking of payroll deductions and making of other contributions to the Plan, establishment of bank or trust accounts to hold contributions, payment of interest, establishment of the exchange rate applicable to payroll deductions taken
and other contributions made in a currency other than U.S. dollars, obligations to pay payroll tax, determination of beneficiary designation requirements, tax withholding procedures, and handling of stock certificates that vary with applicable local
requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B>Eligibility</B>. Any employee of the Company or the Participating Corporations is eligible to participate in
an Offering Period under this Plan, except that the Committee may exclude any or all of the following (other than where exclusion of such employees is prohibited by applicable law): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) employees who are not employed by the Company or a Participating Corporation prior to the beginning of such Offering Period or prior to
such other time period as specified by the Committee; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) employees who are customarily employed for twenty (20)&nbsp;or less hours per
week; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) employees who are customarily employed for five (5)&nbsp;months or less in a calendar year; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) (i) employees who are &#147;highly compensated employees&#148; of the Company or any Participating Corporation (within the meaning of
Section&nbsp;414(q)&nbsp;of the Code), or (ii)&nbsp;any employee who are &#147;highly compensated employees&#148; with compensation above a specified level, who is an officer and/or is subject to the disclosure requirements of
Section&nbsp;16(a)&nbsp;of the Exchange Act; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) employees who are citizens or residents of a foreign jurisdiction (without regard to
whether any such employee is also a citizen of the United States or a resident alien (within the meaning of Section&nbsp;7701(b)(1)(A)&nbsp;of the Code)) if either (i)&nbsp;such employee&#146;s participation is prohibited under the laws of the
jurisdiction governing such employee, or (ii)&nbsp;compliance with the laws of the foreign jurisdiction would violate the requirements of Section&nbsp;423 of the Code;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) individuals who provide services to the Company or any of its Participating Corporations as independent contractors who are reclassified
as common law employees for any reason <U>except</U> <U>for</U> federal income and employment tax purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing notwithstanding, employees who,
together with any other person whose stock would be attributed to such employee pursuant to Section&nbsp;424(d) of the Code, own stock or hold options to purchase stock possessing five percent (5%) or more of the total combined voting power or value
of all classes of stock of the Company or any of its Participating Corporations or who, as a result of being granted an option under this Plan with respect to such Offering Period, would own stock or hold options to purchase stock possessing five
percent (5%) or more of the total combined voting power or value of all classes of stock of the Company or any of its Participating Corporations may not participate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B>Offering Dates</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While the Plan is in effect, the Committee will determine the duration and commencement date of each Offering Period and Purchase Period, <U>provided</U> that
an Offering Period will in no event be longer than twenty-seven (27)&nbsp;months, except as otherwise provided by an applicable subplan and no Purchase Period will end later that the last day of the Offering Period in which it begins. Offering
Periods may be consecutive or overlapping. Each Offering Period may consist of one or more Purchase Periods during which payroll deductions of Participants are accumulated under this Plan. Purchase Periods will be consecutive. The Committee shall
have the power to change these terms as provided in Section&nbsp;25 below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.</B> <B>Participation in this Plan</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <B>Enrollment</B>. An eligible employee (as determined in accordance with Section&nbsp;4) may elect to become a Participant by submitting
a subscription agreement, or electronic representation thereof, to the Company and/or via an authorized third party administrator&#146;s (the &#147;<B><I>Third Party Administrator</I></B>&#148;) standard process, prior to the commencement of the
Offering Period to which such agreement relates in accordance with such rules as the Committee may determine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <B>Continued Enrollment
in Offering Periods</B>. Once an employee becomes a Participant in an Offering Period, then such Participant will automatically participate in each subsequent Offering Period, which commences immediately following the last day of such prior Offering
Period. The Participant will be enrolled in each subsequent Offering Period at the same contribution level unless the Participant (i)&nbsp;withdraws or is deemed to withdraw from this Plan, (ii)&nbsp;terminates further participation in the Offering
Period as set forth in Section&nbsp;11 below, or (iii)&nbsp;otherwise notifies the Company of a change in the Participant&#146;s contribution level by filing an additional subscription agreement or electronic representation thereof with the Company
and/or the Third Party Administrator, prior to the next Offering Period. A Participant who is automatically enrolled in a subsequent Offering Period pursuant to this section (x)&nbsp;is not required to file any additional subscription agreement in
order to continue participation in this Plan, and (y)&nbsp;will be deemed to have accepted the terms and conditions of the Plan, any <FONT STYLE="white-space:nowrap">sub-plan,</FONT> and the subscription agreement in effect at the time each
subsequent Offering Period begins, subject to Participant&#146;s right to withdraw from the Plan in accordance with the withdrawal procedures in effect at the time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B> <B>Grant of Option on Enrollment</B>. Becoming a Participant with respect to an Offering Period will constitute the grant (as of the
Offering Date) by the Company to such Participant of an option to purchase on the Purchase Date up to that number of shares of Common Stock determined by a fraction the numerator of which is the amount of the contribution level for such Participant
multiplied by such Participant&#146;s Compensation (as defined in Section&nbsp;9 below) during such Purchase Period and the denominator of which is eighty-five percent (85%) of the lower of (a)&nbsp;the Fair Market Value on the Offering Date or
(b)&nbsp;the Fair Market Value on the Purchase Date, but in no event less than the par value of a share. Notwithstanding the foregoing, the number of shares of Common Stock subject to any option granted pursuant to this Plan will not exceed the
lesser of (x)&nbsp;the maximum number of shares set by the Committee pursuant to Section&nbsp;10(b) below with respect to the applicable Purchase Date or (y)&nbsp;the maximum number of shares that may be purchased pursuant to Section&nbsp;10(a)
below with respect to the applicable Purchase Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.</B> <B>Purchase Price</B>. The Purchase Price in any Offering Period will be
eighty-five percent (85%) of the lesser of: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) the Fair Market Value on the Offering Date or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) the Fair Market Value on the Purchase Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.</B> <B>Payment of Purchase Price; Payroll Deduction Changes; Share Issuances</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Purchase Price of the shares is accumulated by regular payroll deductions made during each Offering Period, unless the Committee
determines that contributions may be, or are required to be, made in another form (due to local law requirements, in another form with respect to categories of Participants outside the United States). The deductions are made as a percentage of the
Participant&#146;s Compensation in one percent (1%) increments not less than one percent (1%) or greater than fifteen percent (15%) or such lower limit set by the Committee. &#147;<B><I>Compensation</I></B>&#148; means base salary and regular hourly
wages (including overtime and holiday pay), bonuses, cash incentive compensation and sales or other commissions, and in foreign jurisdictions, in each case, equivalent cash compensation; however, the Committee may at any time prior to the beginning
of an Offering Period determine that for that and future Offering Periods, Compensation means any or all of base salary and regular hourly wages (including overtime and holiday pay), bonuses, cash incentive compensation and sales or other
commissions, shift premiums and/or draws against commissions (or in foreign jurisdictions, in each case, equivalent cash compensation) or other cash compensation reported on the employees&#146; form <FONT STYLE="white-space:nowrap">W-2</FONT> or
corresponding local country tax return. For purposes of determining a Participant&#146;s Compensation, any election by such Participant to reduce his or her regular cash remuneration under Sections 125 or 401(k) of the Code (or in foreign
jurisdictions, equivalent salary deductions) will be treated as if the Participant did not make such election. Payroll deductions shall commence on the first payday following the beginning of any Offering Period and shall continue to the end of the
applicable Offering Period unless sooner altered or terminated as provided in this Plan. Notwithstanding the foregoing, the terms of any subplan may permit matching shares without the payment of any purchase price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Subject to Section&nbsp;25 below and to the rules of the Committee, a Participant may decrease the rate of payroll deductions during an <FONT
STYLE="white-space:nowrap">on-going</FONT> Offering Period by filing with the Company and/or the Third Party Administrator a new authorization for payroll deductions, with the new rate to become effective as soon as reasonably practicable and
continuing for the remainder of the Offering Period unless changed as described below. A decrease in the rate of payroll deductions may be made once during an <FONT STYLE="white-space:nowrap">on-going</FONT> Offering Period or more or less
frequently under rules determined by the Committee. An increase in the rate of payroll deductions may not be made with respect to an <FONT STYLE="white-space:nowrap">on-going</FONT> Offering Period unless otherwise determined by the Committee. A
Participant may increase or decrease the rate of payroll deductions for any subsequent Offering Period by filing with the Company and/or the Third Party Administrator a new authorization for payroll deductions prior to the beginning of such Offering
Period or such other time period as may be specified by the Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Subject to Section&nbsp;25 below and to the rules of the
Committee, a Participant may reduce his or her payroll deduction percentage to zero during an Offering Period by filing with the Company a request for cessation of payroll deductions, with such reduction to become effective as soon as reasonably
practicable, and after such reduction becomes effective, no further payroll deductions will be made for the duration of the Offering Period. Payroll deductions credited to the Participant&#146;s account prior to the effective date of the request
will be used to purchase shares of Common Stock in accordance with Section&nbsp;(e) below. A reduction of the payroll deduction percentage to zero will be treated as such Participant&#146;s withdrawal from such Offering Period and the Plan,
effective as of the day after the next Purchase Date following the filing date of such request with the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) All payroll
deductions made for a Participant are credited to his or her account under this Plan and are deposited with the general funds of the Company. The Company will not be obligated to segregate such payroll deductions, except to the extent required to be
segregated due to local legal restrictions outside the United States. No interest accrues on the payroll deductions, except to the extent required due to local legal requirements outside the United States. All payroll deductions received or held by
the Company may be used by the Company for any corporate purpose, except to the extent necessary to comply with local legal requirements outside the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) On each Purchase Date, so long as this Plan remains in effect and provided that the
Participant has not submitted a signed and completed withdrawal form before that date notifying the Company and/or the Third Party Administrator that the Participant wishes to withdraw from that Offering Period and have all payroll deductions
accumulated in the account maintained on behalf of the Participant as of that date returned to the Participant, the Company will apply the funds then in the Participant&#146;s account to the purchase of whole shares of Common Stock reserved under
the option granted to such Participant with respect to the Offering Period to the extent that such option is exercisable on the Purchase Date. The Purchase Price will be as specified in Section&nbsp;8 of this Plan. Any amount remaining in a
Participant&#146;s account on a Purchase Date that is less than the amount necessary to purchase a full share of Common Stock will be carried forward into the next Purchase Period or Offering Period, as the case may be (except to the extent required
by local legal requirements outside the United States), or otherwise treated as determined by the Committee. In the event that this Plan has been oversubscribed, all funds not used to purchase shares on the Purchase Date will be refunded to the
Participant without interest (except to the extent required by local legal requirements outside the United States). No Common Stock will be purchased on a Purchase Date on behalf of any employee whose participation in this Plan has terminated prior
to such Purchase Date (except to the extent required by local legal requirements outside the United States). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) As promptly as
practicable after the Purchase Date, the Company will issue shares for the Participant&#146;s benefit representing the shares purchased upon exercise of his or her option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) During a Participant&#146;s lifetime, his or her option to purchase shares hereunder is exercisable only by him or her. The Participant
will have no interest or voting right in shares covered by his or her option until such option has been exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) To the extent
required by applicable federal, state, local, or foreign law, a Participant will make arrangements satisfactory to the Company and, if applicable, the Participating Corporation employing the Participant for the satisfaction of any withholding tax
obligations that arise in connection with the Plan. The Company or any Participating Corporation, as applicable, may withhold, by any method permissible under applicable law, the amount necessary for the Company or any Participating Corporation, as
applicable, to meet applicable withholding obligations, including up to the maximum permissible statutory rates and including any withholding required to make available to the Company or any Participating Corporation, as applicable, any tax
deductions or benefits attributable to the sale or early disposition of shares of Common Stock by a Participant. The Company will not be required to issue any shares of Common Stock under the Plan until such obligations are satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.</B> <B>Limitations on Shares to be Purchased</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) No Participant will be entitled to purchase stock under any Offering Period at a rate which, when aggregated with such Participant&#146;s
rights to purchase stock under all other employee stock purchase plans of a Participating Company intended to meet the requirements of Section&nbsp;423 of the Code, that are also outstanding in the same calendar year(s) (whether under other Offering
Periods or other employee stock purchase plans of the Company, its Parent, and its Subsidiaries), exceeds $25,000 in Fair Market Value, determined as of the Offering Date (or such other limit as may be imposed by the Code) for each calendar year in
which such Offering Period is in effect (the &#147;<B><I>Maximum Share Amount</I></B>&#148;). The Company may automatically suspend the payroll deductions of any Participant as necessary to enforce such limit provided that when the Company
automatically resumes such payroll deductions, the Company must apply the rate in effect immediately prior to such suspension. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Committee may, in its sole discretion, set a lower maximum number of shares that may
be purchased by any Participant during any Offering Period than that determined under Section&nbsp;10(a) above, which will then be the Maximum Share Amount for subsequent Offering Periods; provided, however, that in no event will a Participant be
permitted to purchase more than three thousand (3,000) shares during any one Purchase Period or such greater or lesser number as the Committee may determine, irrespective of the Maximum Share Amount set forth in (a)&nbsp;and (b) hereof. If a new
Maximum Share Amount is set, then all Participants will be notified of such Maximum Share Amount prior to the commencement of the next Offering Period for which it is to be effective. The Maximum Share Amount will continue to apply with respect to
all succeeding Offering Periods unless revised by the Committee as set forth above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) If the number of shares to be purchased on a
Purchase Date by all Participants exceeds the number of shares then available for issuance under this Plan, then the Company will make a pro rata allocation of the remaining shares in as uniform a manner as will be reasonably practicable and as the
Committee will determine to be equitable. In such event, the Company will give written notice of such reduction of the number of shares to be purchased under a Participant&#146;s option to each Participant affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Any payroll deductions accumulated in a Participant&#146;s account that are not used to purchase stock due to the limitations in this
Section&nbsp;10, and that are not covered by Section&nbsp;9(e), will be returned to the Participant as soon as administratively practicable after the end of the applicable Purchase Period, without interest (except to the extent required due to local
legal requirements outside the United States). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.</B> <B>Withdrawal</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each Participant may withdraw from an Offering Period under this Plan pursuant to a method specified by the Company. Such withdrawal may
be elected at any time prior to the end of an Offering Period, or such other time period as specified by the Committee. The Committee may set forth a deadline of when a withdrawal must occur to be effective prior to a given Purchase Date in
accordance with policies it may approve from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Upon withdrawal from this Plan, the accumulated payroll deductions will be
returned to the withdrawn Participant, without interest (except to the extent required due to local legal requirements outside the United States), and his or her interest in this Plan will terminate. In the event a Participant voluntarily elects to
withdraw from this Plan, he or she may not resume his or her participation in this Plan during the same Offering Period, but he or she may participate in any Offering Period under this Plan that commences on a date subsequent to such withdrawal by
filing a new authorization for payroll deductions in the same manner as set forth in Section&nbsp;6 above for initial participation in this Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) To the extent applicable, if the Fair Market Value on the first day of the current Offering Period in which a Participant is enrolled is
higher than the Fair Market Value on the first day of any subsequent Offering Period, the Company will automatically enroll such Participant in the subsequent Offering Period. Any funds accumulated in a Participant&#146;s account prior to the first
day of such subsequent Offering Period will be applied to the purchase of shares on the Purchase Date immediately prior to the first day of such subsequent Offering Period, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.</B> <B>Termination of Employment</B>. Termination of a Participant&#146;s employment for any reason, including (but not limited to)
retirement, death, disability, or the failure of a Participant to remain an eligible employee of the Company or of a Participating Corporation, or Participant&#146;s employer no longer being a Participating Corporation, immediately terminates his or
her participation in this Plan (except to the extent required due to local legal requirements outside the United States). In such event, accumulated payroll </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
deductions credited to the Participant&#146;s account will be returned to him or her or, in the case of his or her death, to his or her legal representative, without interest (except to the
extent required due to local legal requirements outside the United States). For purposes of this Section&nbsp;12, an employee will not be deemed to have terminated employment or failed to remain in the continuous employ of the Company or of a
Participating Corporation in the case of sick leave, military leave, or any other leave of absence approved by the Company; provided that such leave is for a period of not more than ninety (90)&nbsp;days or reemployment upon the expiration of such
leave is guaranteed by contract or statute. The Company will have sole discretion to determine whether a Participant has terminated employment and the effective date on which the Participant terminated employment, regardless of any notice period or
garden leave required under local law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.</B> <B>Return of Payroll Deductions</B>. In the event a Participant&#146;s interest in this
Plan is terminated by withdrawal, termination of employment, or otherwise, or in the event this Plan is terminated by the Board, the Company will deliver to the Participant all accumulated payroll deductions credited to such Participant&#146;s
account. No interest will accrue on the payroll deductions of a Participant in this Plan (except to the extent required due to local legal requirements outside the United States). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.</B> <B>Capital Changes</B>. If the number of outstanding shares is changed by a stock dividend, recapitalization, stock split, reverse
stock split, subdivision, combination, reclassification, or similar change in the capital structure of the Company, without consideration, then the Committee will adjust the number and class of Common Stock that may be delivered under the Plan, the
Purchase Price, and the number of shares of Common Stock covered by each option under the Plan that has not yet been exercised, and the numerical limits of Sections 1 and 10 will be proportionately adjusted, subject to any required action by the
Board or the stockholders of the Company and in compliance with applicable securities laws; provided that fractions of a share will not be issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.</B> <B>Nonassignability</B>. Neither payroll deductions credited to a Participant&#146;s account nor any rights with regard to the
exercise of an option or to receive shares under this Plan may be assigned, transferred, pledged, or otherwise disposed of in any way (other than by will, pursuant to the laws of descent and distribution, or as provided in Section&nbsp;22 below) by
the Participant. Any such attempt at assignment, transfer, pledge, or other disposition will be void and without effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.</B>
<B>Use of Participant Funds and Reports</B>. The Company may use all payroll deductions received or held by it under the Plan for any corporate purpose, and the Company will not be required to segregate Participant payroll deductions (except to the
extent required due to local legal requirements outside the United States). Until shares are issued, Participants will only have the rights of an unsecured creditor (except to the extent required due to local legal requirements outside the United
States). Each Participant will receive, or have access to, promptly after the end of each Purchase Period a report of his or her account setting forth the total payroll deductions accumulated, the number of shares purchased, the Purchase Price
thereof, and the remaining cash balance, if any, carried forward or refunded, as determined by the Committee, to the next Purchase Period or Offering Period, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.</B> <B>Notice of Disposition</B>. If a Participant is subject to tax in the United States, that Participant will notify the Company in
writing if the Participant disposes of any of the shares purchased in any Offering Period pursuant to this Plan. If such disposition occurs within two (2)&nbsp;years from the Offering Date or within one (1)&nbsp;year from the Purchase Date on which
such shares were purchased, the Company may place a legend or legends on any certificate representing shares acquired pursuant to this Plan requesting the Company&#146;s transfer agent to notify the Company of any transfer of the shares. The
obligation of the Participant to provide such notice will continue notwithstanding the placement of any such legend on the certificates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>18.</B> <B>No Rights to Continued Employment</B>. Neither this Plan nor the grant of any
option hereunder will confer any right on any employee to remain in the employ of the Company or any Participating Corporation, or restrict the right of the Company or any Participating Corporation to terminate such employee&#146;s employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>19.</B> <B>Equal Rights And Privileges</B>. All eligible employees granted an option under this Plan that is intended to meet the Code
Section&nbsp;423 requirements will have equal rights and privileges with respect to this Plan or within any separate offering under the Plan so that this Plan qualifies as an &#147;employee stock purchase plan&#148; within the meaning of
Section&nbsp;423 or any successor provision of the Code and the related regulations. Any provision of this Plan that is inconsistent with Section&nbsp;423 or any successor provision of the Code will, without further act or amendment by the Company
or the Committee, be reformed to comply with the requirements of Section&nbsp;423 (unless such provision applies exclusively to options granted under the Plan that are not intended to comply with the Code Section&nbsp;423 requirements). This
Section&nbsp;19 will take precedence over all other provisions in this Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>20.</B> <B>Notices</B>. All notices or other
communications by a Participant to the Company under or in connection with this Plan will be deemed to have been duly given when received in the form specified by the Company at the location, or by the person, designated by the Company for the
receipt thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>21.</B> <B>Term; Stockholder Approval</B>. This Plan will become effective on the Effective Date. This Plan will be
approved by the stockholders of the Company within twelve (12)&nbsp;months before or after the date this Plan is adopted by the Board. No purchase of shares that are subject to such stockholder approval before becoming available under this Plan will
occur prior to stockholder approval of such shares, and the Committee may delay any Purchase Date and postpone the commencement of any Offering Period subsequent to such Purchase Date as deemed necessary or desirable to obtain such approval
(provided that if a Purchase Date would occur more than twenty-four (24)&nbsp;months after commencement of the Offering Period to which it relates, then such Purchase Date will not occur, and instead such Offering Period will terminate without the
purchase of such shares and Participants in such Offering Period will be refunded their contributions without interest, unless the payment of interest is required under local laws). This Plan will continue until the earlier to occur of
(a)&nbsp;termination of this Plan by the Board (which termination may be effected by the Board at any time pursuant to Section&nbsp;25 below), (b) issuance of all of the shares of Common Stock reserved for issuance under this Plan, or (c)&nbsp;the
tenth anniversary of the first Purchase Date under the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>22. Designation of Beneficiary.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Unless otherwise determined by the Committee, a Participant may file a written designation of a beneficiary who is to receive any cash
from the Participant&#146;s account under this Plan in the event of such Participant&#146;s death prior to a Purchase Date. Such form shall be valid only if it was filed with the Company (or the Third Party Administrator) at the prescribed location
before the Participant&#146;s death. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If authorized by the Company, such designation of beneficiary may be changed by the Participant
at any time by written notice filed with the Company (or the Third Party Administrator) at the prescribed location before the Participant&#146;s death. In the event of the death of a Participant and in the absence of a beneficiary validly designated
under this Plan who is living at the time of such Participant&#146;s death, the Company shall deliver such cash to the executor or administrator of the estate of the Participant or to the legal heirs of the Participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>23.</B> <B>Conditions Upon Issuance of Shares; Limitation on Sale of Shares</B>. Shares will not be issued with respect to an option unless
the exercise of such option and the issuance and delivery of such shares pursuant thereto will comply with all applicable provisions of law, domestic or foreign, including, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
without limitation, the Securities Act, the Exchange Act, the rules and regulations promulgated thereunder, and the requirements of any stock exchange or automated quotation system upon which the
shares may then be listed, exchange control restrictions, securities law restrictions, or other applicable laws outside the United States, and will be further subject to the approval of counsel for the Company with respect to such compliance. Shares
may be held in trust or subject to further restrictions as permitted by any subplan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>24.</B> <B>Applicable Law</B>. The Plan will be
governed by the substantive laws (excluding the conflict of laws rules) of the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>25.</B> <B>Amendment or
Termination</B>. The Committee, in its sole discretion, may amend, suspend, or terminate the Plan, or any part thereof, at any time and for any reason. If the Plan is terminated, the Committee, in its discretion, may elect to terminate all
outstanding Offering Periods either immediately or upon completion of the purchase of shares of Common Stock on the next Purchase Date (which may be sooner than originally scheduled, if determined by the Committee in its discretion), or may elect to
permit Offering Periods to expire in accordance with their terms (and subject to any adjustment pursuant to Section&nbsp;14). If an Offering Period is terminated prior to its previously-scheduled expiration, all amounts then credited to
Participants&#146; accounts for such Offering Period, that have not been used to purchase shares of Common Stock, will be returned to those Participants (without interest thereon, except as otherwise required under local laws) as soon as
administratively practicable. Further, the Committee will be entitled to establish rules to change the Purchase Periods and Offering Periods, limit the frequency and/or number of changes in the amount contributed during a Purchase Period or an
Offering Period, permit payroll withholding in excess of the amount designated by a Participant in order to adjust for delays or mistakes in the administration of the Plan, establish reasonable waiting and adjustment periods and/or accounting and
crediting procedures to ensure that amounts applied toward the purchase of Common Stock for each Participant properly correspond with amounts contributed from the Participant&#146;s Compensation, and establish such other limitations or procedures as
the Committee determines in its sole discretion are advisable and consistent with the Plan. Such actions will not require stockholder approval or the consent of any Participants. However, no amendment will be made without approval of the
stockholders of the Company (obtained in accordance with Section&nbsp;21 above) within twelve (12)&nbsp;months of the adoption of such amendment (or earlier if required by Section&nbsp;21) if such amendment would (a)&nbsp;increase the number of
shares that may be issued under this Plan or (b)&nbsp;change the designation of the employees (or class of employees) eligible to participate in this Plan. In addition, in the event the Committee determines that the ongoing operation of the Plan may
result in unfavorable financial accounting consequences, the Committee may, in its discretion and, to the extent necessary or desirable, modify, amend, or terminate the Plan to reduce or eliminate such accounting consequences including, but not
limited to: (a)&nbsp;amending the definition of compensation, including with respect to an Offering Period underway at the time; (b)&nbsp;altering the Purchase Price for any Offering Period including an Offering Period underway at the time of the
change in Purchase Price; (c)&nbsp;shortening any Offering Period by setting a Purchase Date, including an Offering Period underway at the time of the Committee action; (d)&nbsp;reducing the maximum percentage of compensation a Participant may elect
to set aside as payroll deductions; and (e)&nbsp;reducing the maximum number of shares of Common Stock a Participant may purchase during any Offering Period. Such modifications or amendments will not require approval of the stockholders of the
Company or the consent of any Participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>26.</B> <B>Corporate Transactions</B>. In the event of a Corporate Transaction (as defined
below), each outstanding right to purchase Common Stock will be assumed or an equivalent option substituted by the successor corporation or a parent or a subsidiary of the successor corporation. In the event that the successor corporation refuses to
assume or substitute for the purchase right, the Offering Period with respect to which such purchase right relates will be shortened by setting a new Purchase Date (the &#147;<B><I>New Purchase Date</I></B>&#148;) and will end on the New Purchase
Date. The New Purchase Date will occur on or prior to the consummation of the Corporate Transaction, and the Plan will terminate on the consummation of the Corporate Transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>27. Definitions.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) &#147;<B><I>Affiliate</I></B>&#148; means any entity, other than a Subsidiary or Parent, (i)&nbsp;that, directly or indirectly, is
controlled by, controls or is under common control with, the Company and (ii)&nbsp;in which the Company has a significant equity interest, in either case as determined by the Committee, whether now or hereafter existing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B><I>Board</I></B>&#148; means the Board of Directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B><I>Code</I></B>&#148; means the U.S. Internal Revenue Code of 1986, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) &#147;<B><I>Common Stock</I></B>&#148; means the common stock of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) &#147;<B><I>Corporate Transaction</I></B>&#148; means the occurrence of any of the following events: (i)&nbsp;any &#147;person&#148; (as
such term is used in Sections&nbsp;13(d) and 14(d) of the Exchange Act) becomes the &#147;beneficial owner&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> of the Exchange Act), directly or indirectly, of securities of the
Company representing fifty percent (50%)&nbsp;or more of the total voting power represented by the Company&#146;s then outstanding voting securities; (ii)&nbsp;the consummation of the sale or disposition by the Company of all or substantially all of
the Company&#146;s assets; or (iii)&nbsp;the consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation that would result in the voting securities of the Company outstanding immediately
prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%)&nbsp;of the total voting power represented by the voting
securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)
&#147;<B><I>Effective Date</I></B>&#148; means the date on which the Registration Statement covering the initial public offering of shares of Common Stock is declared effective by the U.S. Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) &#147;<B><I>Exchange Act</I></B>&#148;<I> </I>means the U.S. Securities Exchange Act of 1934, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) &#147;<B><I>Fair Market Value</I></B>&#148; means, as of any date, the value of a share of Common Stock, determined as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) if such Common Stock is publicly traded and is then listed on a national securities exchange, its closing price on the date of
determination on the principal national securities exchange on which the Common Stock is listed or admitted to trading as reported in <I>The Wall Street </I>Journal or such other source as the Committee deems reliable; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) if such Common Stock is publicly traded but is neither listed nor admitted to trading on a national securities exchange, the average of
the closing bid and asked prices on the date of determination as reported in <I>The Wall Street Journal</I> or such other source as the Committee deems reliable; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) if such Common Stock is publicly traded but is neither quoted on the Nasdaq Market nor listed or admitted to trading on a national
securities exchange, the average of the closing bid and asked prices on the date of determination as reported in <I>The Wall Street Journal </I>or such other source as the Committee deems reliable; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) if none of the foregoing is applicable, by the Committee in good faith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) &#147;<B><I>Offering Date</I></B>&#148; means the first Trading Day of each Offering Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) &#147;<B><I>Offering Period</I></B>&#148; means a period with respect to which the right to purchase Common Stock may be granted under the
Plan, as determined by the Committee pursuant to Section&nbsp;5(a). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) &#147;<B><I>Parent</I></B>&#148; will have the same meaning as
&#147;parent corporation&#148; in Sections&nbsp;424(e) and 424(f) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) &#147;<B><I>Participant</I></B>&#148; means an
eligible employee who meets the eligibility requirements set forth in Section&nbsp;4 and who elects to participate in this Plan, subject and pursuant to Section&nbsp;6. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) &#147;<B><I>Participating Corporation</I></B>&#148; means any Parent, Subsidiary or Affiliate that the Board designates from time to time
as a corporation that will participate in this Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) &#147;<B><I>Plan</I></B>&#148; means this Graybug Vision, Inc., 2020 Employee
Stock Purchase Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) &#147;<B><I>Purchase Date</I></B>&#148; means the last Trading Day of each Purchase Period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) &#147;<B><I>Purchase Period</I></B>&#148; means a period during which contributions may be made toward the purchase of Common Stock under
the Plan, as determined by the Committee pursuant to Section&nbsp;5(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(q) &#147;<B><I>Purchase Price</I></B>&#148; means the price at
which Participants may purchase a share of Common Stock under the Plan, as determined pursuant to Section&nbsp;8. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(r)
&#147;<B><I>Securities Act</I></B>&#148; means the U.S. Securities Act of 1933, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(s) &#147;<B><I>Subsidiary</I></B>&#148; will
have the same meaning as &#147;subsidiary corporation&#148; in Sections 424(e) and 424(f) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(t) &#147;<B><I>Trading
Day</I></B>&#148; means a day on which the national stock exchange upon which the Common Stock is listed is open for trading. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>G<SMALL>RAYBUG</SMALL> V<SMALL>ISION</SMALL>, I<SMALL>NC</SMALL>. (<SMALL>THE</SMALL> &#147;C<SMALL>OMPANY</SMALL>&#148;)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>2020 E<SMALL>MPLOYEE</SMALL> S<SMALL>TOCK</SMALL> P<SMALL>URCHASE</SMALL> P<SMALL>LAN</SMALL> (&#147;ESPP&#148;)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>G<SMALL>LOBAL</SMALL> E<SMALL>NROLLMENT</SMALL>/C<SMALL>HANGE</SMALL></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>F<SMALL>ORM</SMALL> <SMALL>AND</SMALL> A<SMALL>GREEMENT</SMALL> (<SMALL>THE</SMALL></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>&#147;A<SMALL>GREEMENT</SMALL>&#148;)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Capitalized terms used but not otherwise defined herein shall have the meanings given to them in the ESPP.</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">S<SMALL>ECTION</SMALL>&nbsp;1:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>C<SMALL>HECK</SMALL> D<SMALL>ESIRED</SMALL> A<SMALL>CTION</SMALL></B><SMALL></SMALL>:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B><SMALL>AND</SMALL> C<SMALL>OMPLETE</SMALL> S<SMALL>ECTIONS</SMALL></B><SMALL></SMALL>:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>A<SMALL>CTIONS</SMALL></B><SMALL></SMALL></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#9744;&nbsp;&nbsp;Enroll in the ESPP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2 + 3 + 4 + 19</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#9744;&nbsp;&nbsp;Change Contribution Percentage</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2 + 4 + 19</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>(for next Offering Period)</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#9744;&nbsp;&nbsp;Withdraw from ESPP</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2 + 5 + 19</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">S<SMALL>ECTION</SMALL>&nbsp;2:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name:
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>P<SMALL>ERSONAL</SMALL> D<SMALL>ATA</SMALL></B><SMALL></SMALL></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Home Address:
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Social Security No. or Employee ID
No.:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">S<SMALL>ECTION</SMALL>&nbsp;3:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>E<SMALL>NROLL</SMALL></B><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">&#9744;&nbsp;&nbsp;I hereby elect to participate in the ESPP, effective at the beginning of the next Offering Period. I elect to purchase shares of the common stock of the Company pursuant to the ESPP. I understand that
the stock certificate(s) for the Shares purchased on my behalf will be issued in &#147;street name&#148; meaning that the shares will be held in the name of the brokerage firm and deposited directly into my brokerage account at the Company&#146;s
captive broker. I hereby agree to take all steps, and sign all forms, required to establish an account with the Company&#146;s captive broker for this purpose.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">My participation will continue as long as the Company offers the ESPP and I remain eligible, unless I withdraw from the ESPP by filing a new Enrollment/Change Form with the Company. I understand that I must notify the
Company of any disposition of Shares purchased under the ESPP.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">S<SMALL>ECTION</SMALL>&nbsp;4:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>E<SMALL>LECT</SMALL>/C<SMALL>HANGE</SMALL></B><SMALL></SMALL></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>C<SMALL>ONTRIBUTION</SMALL></B><SMALL></SMALL></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>ERCENTAGE</SMALL></B><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I hereby authorize the Company to withhold from my paychecks such amount as is necessary to equal at the end of the applicable
Offering Period the percentage of my Compensation (as the term is defined in the ESPP) paid to me during such Offering Period as indicated below, so long as I continue to participate in the ESPP. I understand that my contribution level <B>percentage
must be a whole number (from 1% up to a maximum of 15%). This change will be effective for the Next Offering Period.</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Designated contribution percentage: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;%</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If this is a change to my current enrollment, this represents an
&#9744;&nbsp;&nbsp;increase &#9744;&nbsp;&nbsp;decrease to my contribution percentage.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Note:</B> You may not increase your contributions during any ongoing Offering Period. A request to increase your contribution percentage that is received
during an ongoing Offering Period will be construed to take effect during the next Offering Period. You may decrease your Contribution percentage to a percentage other than 0% only once within an ongoing Offering Period to be effective during that
Offering Period. If you decrease your percentage to 0%, any previously accumulated contributions will be used to purchase shares on the next Purchase Date pursuant to Section&nbsp;9 of the ESPP. If more than one decrease is received during an
Offering Period, the second decrease will not have any effect during this Offering Period and will be construed to take effect during the next Offering Period. A change will become effective as soon as reasonably practicable after the form is
received by the Company.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">S<SMALL>ECTION</SMALL>&nbsp;5:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B></B><B><I>DO NOT CHECK ANY OF THE BOXES BELOW IF YOU WISH TO CONTINUE TO PARTICIPATE IN THE ESPP </I></B><B></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>W<SMALL>ITHDRAW</SMALL>&nbsp;<SMALL>FROM</SMALL> P<SMALL>LAN</SMALL></B><SMALL></SMALL></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#9744;<B>&#8194;&#8201;&#8201;I hereby elect to withdraw from, and discontinue my
participation in, the ESPP</B>, effective as soon as reasonably practicable after this form is received by the Company. I understand that accumulated contributions will be returned to me without interest (except to the extent required due to local
legal requirements outside the United States), pursuant to Section&nbsp;11 of the ESPP.&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>Note: I understand that I cannot resume participation until the start of the next Offering Period and that I must timely file a new enrollment form to do so.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">S<SMALL>ECTION</SMALL>&nbsp;6: </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>E<SMALL>LECTRONIC</SMALL></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>D<SMALL>ELIVERY</SMALL>
<SMALL>AND</SMALL></B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>CCEPTANCE</SMALL></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the ESPP by electronic means. I hereby consent to receive such documents by electronic delivery and
agree to participate in the ESPP through an <FONT STYLE="white-space:nowrap">on-line</FONT> or electronic system established and maintained by the Company or a third party designated by the Company.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">S<SMALL>ECTION</SMALL>&nbsp;7: </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>N<SMALL>O</SMALL> A<SMALL>DVICE</SMALL></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>R<SMALL>EGARDING</SMALL></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>ARTICIPATION</SMALL></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding my participation in the ESPP or my acquisition or sale of Shares. I acknowledge, understand and
agree that I should consult with my own personal tax, legal and financial advisors regarding my participation in the ESPP before taking any action related to the ESPP.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">S<SMALL>ECTION</SMALL>&nbsp;8: </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>PPENDIX</SMALL></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Notwithstanding any provisions of the Agreement, my participation in the ESPP will be subject to any special terms and conditions set forth in the appendix to this Agreement for employees outside the United States (if
any) (the &#147;<B><I>Appendix</I></B>&#148;). Moreover, if I relocate to one of the countries included in the Appendix, the special terms and conditions for such country will apply to me, to the extent the Company determines that the application of
such terms and conditions is necessary or advisable for legal or administrative reasons. The Appendix constitutes part of the Agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">S<SMALL>ECTION</SMALL>&nbsp;9: </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>T<SMALL>ERMINATION</SMALL>,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>M<SMALL>ODIFICATION</SMALL>&nbsp;<SMALL>AND</SMALL></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>MPOSITION</SMALL>&nbsp;<SMALL>OF</SMALL>&nbsp;O<SMALL>THER</SMALL></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>R<SMALL>EQUIREMENTS</SMALL></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">The Company, at its option, may elect to terminate, suspend or modify the terms of the ESPP at any time, to the extent permitted by the ESPP. I agree to be bound by such termination, suspension or modification regardless
of whether notice is given to me of such event, subject in any case to my right to timely withdraw from the ESPP in accordance with the ESPP withdrawal procedures then in effect. The Company reserves the right to impose other requirements on my
participation in the ESPP, to the extent the Company determines it is necessary or advisable for legal or administrative reasons and to require me to sign any additional agreements or undertakings that may be necessary to accomplish the
foregoing.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">S<SMALL>ECTION</SMALL>&nbsp;10: </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>S<SMALL>EVERABILITY</SMALL></B><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">If one or more provisions of this Agreement are held to be unenforceable under applicable law, then such provision will be enforced to the maximum extent possible given the intent of the parties hereto. If such clause or
provision cannot be so enforced, then (i)&nbsp;such provision will be excluded from the Agreement, (ii)&nbsp;the balance of the Agreement will be interpreted as if such provision were so excluded and (iii)&nbsp;the balance of the Agreement will be
enforceable in accordance with its terms.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">S<SMALL>ECTION</SMALL>&nbsp;11: </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>AIVER</SMALL></B><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">I acknowledge that a waiver by the Company of breach of any provision of the Agreement shall not operate or be construed as a waiver of any other provision of the Agreement, or any subsequent breach by any
Participant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">S<SMALL>ECTION</SMALL>&nbsp;12: </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>G<SMALL>OVERNING</SMALL> L<SMALL>AW</SMALL> <SMALL>AND</SMALL></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>V<SMALL>ENUE</SMALL></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">The Agreement and all acts and transactions pursuant hereto and the rights and obligations of the parties hereto shall be governed, construed, interpreted, and enforced in accordance with the substantive laws of the
State of Delaware, without giving effect to such state&#146;s conflict of laws rules. Any and all disputes relating to, concerning or arising from the Agreement, or relating to, concerning or arising from the relationship between the parties
evidenced by the ESPP or this Agreement, will be brought and heard exclusively in the courts of San Mateo County, California, or the federal courts for the United States for the Northern District of California. Each of the parties hereby
(i)&nbsp;represents and agrees that such party is subject to the personal jurisdiction of said courts; (ii)&nbsp;irrevocably consents to the jurisdiction of such courts in any legal or equitable proceedings related to, concerning or arising from
such dispute, and (iii)&nbsp;waives, to the fullest extent permitted by law, any objection which such party may now or hereafter have that the laying of the venue of any legal or equitable proceedings related to, concerning or arising from such
dispute which is brought in such courts is improper or that such proceedings have been brought in an inconvenient forum.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">S<SMALL>ECTION</SMALL>&nbsp;13: </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>R<SMALL>ESPONSIBILITY</SMALL> <SMALL>FOR</SMALL></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>T<SMALL>AXES</SMALL></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">I acknowledge that, regardless of any action taken by the Company or the Parent or Subsidiary employing me (the &#147;<B><I>Employer</I></B>&#148;), the ultimate liability for all income tax, social insurance, payroll
tax, fringe benefits tax, payment on account or other tax related items related to my participation in the ESPP and legally applicable to me (&#147;<B><I><FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items</I></B>&#148;) is and remains my
responsibility and may exceed the amount withheld by the Company or the Employer, if any. I</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">further acknowledge that the Company and/or the Employer (i)&nbsp;make no representations or undertakings regarding the treatment
of any <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items in connection with any aspect of the purchase rights granted pursuant to the ESPP, including, but not limited to, the purchase of Shares, the subsequent sale of Shares acquired
pursuant to such purchase and the receipt of any dividends (if any); and (ii)&nbsp;do not commit to and are under no obligation to structure the terms of the grant or any aspect of my participation to reduce or eliminate my liability for <FONT
STYLE="white-space:nowrap">Tax-Related</FONT> Items or achieve any particular tax result. Further, if I am subject to <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items in more than one jurisdiction, I acknowledge that the Company and/or the
Employer (or former employer, as applicable) may be required to withhold or account for <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items in more than one jurisdiction.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to any relevant taxable or tax withholding event, as applicable, I agree to make
arrangements satisfactory to the Company and/or the Employer to fulfill all <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items. In this regard, I authorize the Company and/or the Employer, or their respective agents, at their discretion, to
satisfy any withholding obligations for <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items by one or a combination of the following:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">a.&#8195;&#8201;&#8202;withholding from my wages or other cash compensation paid to me by the Company and/or the
Employer or any Parent or Subsidiary;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">b.&#8195;&#8201;withholding from proceeds of the sale of Shares acquired upon purchase either through a voluntary sale
or through a mandatory sale arranged by the Company (on my behalf pursuant to this authorization and without further consent);</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">c.&#8195;&#8201;&#8202;my payment of a cash amount (including by check representing readily available funds or a wire
transfer) to the Company or Employer; or</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">d.&#8195;&#8201;any other arrangement approved by the Committee and permitted under applicable law,</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">all under such rules as may be established by the Committee and in compliance with the
Company&#146;s Insider Trading Policy and <FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plan Policy, if applicable.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depending on the withholding method, the Company may withhold or account for <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items by considering
applicable statutory withholding rates or other applicable withholding rates, including up to the maximum permissible statutory rate for my tax jurisdiction(s) in which case I will have no entitlement to the equivalent amount in Shares and may
receive a refund of any over-withheld amount in cash in accordance with applicable law.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Finally, I agree to pay to the Company or the Employer any amount of <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items that the Company or the Employer
may be required to withhold or account for as a result of my participation in the ESPP that cannot be satisfied by the means previously described. The Company may refuse to issue or deliver the Shares or the proceeds of the sale of Shares, if I fail
to comply with my obligations in connection with the <FONT STYLE="white-space:nowrap">Tax-Related</FONT> Items.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">S<SMALL>ECTION</SMALL>&nbsp;14: </TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">By enrolling and participating in the ESPP, I acknowledge, understand and agree that:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>N<SMALL>ATURE</SMALL> <SMALL>OF</SMALL> G<SMALL>RANT</SMALL></B><SMALL></SMALL></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">a.&#8195;&#8201;&#8202;the ESPP is established voluntarily by the Company and it is
discretionary in nature;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">b.&#8195;&#8201;all
decisions with respect to future offers to participate in the ESPP, if any, will be at the sole discretion of the Committee;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">c.&#8195;&#8201;&#8202;I am voluntarily participating in the ESPP;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">d.&#8195;&#8201;the purchase rights and Shares
subject to the purchase rights, and the income from and value of same, are not intended to replace any pension rights or compensation;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">e.&#8195;&#8201;&#8202;the purchase rights and the Shares subject to the purchase rights, and the income from and
value of same, are not part of normal or expected compensation for any purpose, including, but not limited to calculating any severance, resignation, termination, redundancy, dismissal,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-service</FONT></FONT> payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar
payments;</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">f.&#8195;&#8201;&#8201;unless otherwise agreed with the Company, the purchase rights and
the Shares subject to the purchase rights, and the income from and value of same, are not granted as consideration for or in connection with the service I may provide as a director of any parent or Subsidiary; and</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">g.&#8195;&#8201;neither the Company, the Employer
nor any Parent or Subsidiary will be liable for any foreign exchange rate fluctuation between my local currency and the United States Dollar that may affect the value of the purchase rights or of any amounts due to me pursuant to purchase or sale of
Shares under the ESPP.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">S<SMALL>ECTION</SMALL>&nbsp;15: </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B><I></I></B><B>D<SMALL>ATA</SMALL> P<SMALL>RIVACY</SMALL></B><B><I><SMALL></SMALL></I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>I hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of my
personal data as described in the Agreement and any other grant materials by and among, as applicable, the Employer, the Company and any Parent or Subsidiary for the exclusive purpose of implementing, administering and managing my participation in
the ESPP.</I></B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>I understand that the Company and the Employer may hold
certain personal information about me, including, but not limited to, my name, home address, email address and telephone number, date of birth, social insurance number, passport number or other identification number (e.g., resident registration
number), salary, nationality, job title, any shares of stock or directorships held in the Company, details of all purchase rights or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in my favor
(&#147;Data&#148;), for the exclusive purpose of implementing, administering and managing the ESPP.</I></B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>I understand that Data will be transferred to [Name of Broker/Platform], or other third party (&#147;Online Administrator&#148;) and its affiliated
companies or such other stock plan service provider as may be designated by the Company from time to time, which is assisting the Company with the implementation, administration and management of the ESPP. I understand that the recipients of Data
may be located in the United States or elsewhere, and that the recipients&#146; country may have different data privacy laws and protections than my country. I understand that if I reside outside the United States, I may request a list with the
names and addresses of any potential recipients of Data by contacting my local human resources representative. I authorize the Company, Online Administrator, or such other stock plan service provider as may be designated by the Company from time to
time, and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the ESPP to receive, possess, use, retain and transfer Data, in electronic or other form, for the sole
purpose of implementing, administering and managing my participation in the ESPP. I understand that Data will be held only as long as is necessary to implement, administer and manage my participation in the ESPP. I understand if I reside outside the
United States, I may, at any time, view Data, request information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting my local human
resources representative. Further, I understand that I am providing the consents herein on a purely voluntary basis. If I do not consent, or if I later seek to revoke my consent, my employment status or service with the Employer will not be
affected; the only consequence of refusing or withdrawing my consent is that the Company would not be able to grant purchase rights or other equity awards to me or administer or maintain such awards. Therefore, I understand that refusing or
withdrawing my consent may affect my ability to participate in the ESPP. For more information on the consequences of my refusal to consent or withdrawal of consent, I understand that I may contact my local human resources representative.</I></B></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B><I>Finally, upon request of the Company or the Employer, I agree to provide an
executed data privacy consent form (or any other agreements or consents) that the Company or the Employer may deem necessary to obtain from me for the purpose of administering my participation in the ESPP in compliance with the data privacy laws in
my country, either now or in the future. I understand and agree that I will not be able to participate in the ESPP if I fail to provide any such consent or agreement requested by the Company and/or the
Employer.</I></B></P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">S<SMALL>ECTION</SMALL>&nbsp;16: </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>NSIDER</SMALL> T<SMALL>RADING</SMALL> R<SMALL>ESTRICTIONS</SMALL>/M<SMALL>ARKET</SMALL> A<SMALL>BUSE</SMALL>
L<SMALL>AWS</SMALL></B><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">I acknowledge that, depending on my country of residence, the broker&#146;s country, or the country in which the Shares are listed, I may be subject to insider trading restrictions and/or market abuse laws in applicable
jurisdictions, which may affect my ability to directly or indirectly, accept, acquire, sell or attempt to sell or otherwise dispose of Shares, or rights to Shares (<I>e.g.,</I> purchase rights), or rights linked to the value of Shares, during such
times as I am considered to have &#147;inside information&#148; regarding the Company (as defined by the laws or regulations in the applicable jurisdiction). Local insider trading laws and regulations may prohibit the cancellation or amendment of
orders I placed before possessing the inside information. Furthermore, I may be prohibited from (i)&nbsp;disclosing the inside information to any third party, including fellow employees (other than on a &#147;need to know&#148; basis) and (ii)
&#147;tipping&#148; third parties or causing them to otherwise buy or sell securities. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider
trading policy. I acknowledge that it is my responsibility to comply with any applicable restrictions and understand that I should consult my personal legal advisor on such matters. In addition, I acknowledge having read the Company&#146;s Insider
Trading Policy, and agree to comply with such policy, as it may be amended from time to time, whenever I acquire or dispose of the Company&#146;s securities.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">S<SMALL>ECTION</SMALL>&nbsp;17: </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>F<SMALL>OREIGN</SMALL></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>SSET</SMALL>/A<SMALL>CCOUNT</SMALL>, E<SMALL>XCHANGE</SMALL> C<SMALL>ONTROL</SMALL> <SMALL>AND</SMALL> T<SMALL>AX</SMALL> R<SMALL>EPORTING</SMALL>
</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">I may be subject to foreign asset/account, exchange control and/or tax reporting requirements as a result of the acquisition, holding and/or transfer of Shares or cash resulting from my participation in the ESPP. I may
be required to report such accounts, assets, the balances therein, the value thereof and/or the transactions related thereto to the applicable authorities in my country and/or to repatriate funds received in connection with the ESPP within certain
time limits or according to specified procedures. I acknowledge that I am responsible for ensuring compliance with any applicable foreign asset/account, exchange control and tax reporting requirements and should consult my personal legal and tax
advisors on such matters.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">S<SMALL>ECTION</SMALL>&nbsp;18: </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>L<SMALL>ANGUAGE</SMALL></B><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">I acknowledge that I am sufficiently proficient in English to understand the terms and conditions of the Agreement and the ESPP. Furthermore, if I have received this Agreement, or any other document related to the
purchase rights and/or the ESPP translated into a language other than English and if the meaning of the translated version is different from the English version, the English version will control.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">S<SMALL>ECTION</SMALL>&nbsp;19:<B></B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>CKNOWLEDGMENT</SMALL> <SMALL>AND</SMALL> S<SMALL>IGNATURE</SMALL></B><SMALL></SMALL></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">I acknowledge that I have received and read a copy of the ESPP Prospectus (which summarizes the features of the ESPP). My signature below (or my clicking on the Accept box if this is an electronic form) indicates that I
hereby agree to be bound by the terms of the ESPP.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Signature:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Date: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>APPENDIX </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GRAYBUG VISION, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GLOBAL ENROLLMENT/CHANGE FORM AND AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COUNTRY SPECIFIC PROVISIONS FOR EMPLOYEES OUTSIDE THE U.S. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>7
<FILENAME>d796801dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the reference to our firm under the caption &#147;Experts&#148; and to the use of our report dated April&nbsp;21, 2020 (except for the third
paragraph of Note 1, as to which the date is September 18, 2020) in Amendment No. 1 to the Registration Statement (Form S-1 No. 333-248611) and related Prospectus of Graybug Vision, Inc. for the registration of shares of its common stock. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Ernst&nbsp;&amp; Young LLP</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Redwood City, California </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September&nbsp;21, 2020 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.4
<SEQUENCE>8
<FILENAME>d796801dex234.htm
<DESCRIPTION>EX-23.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF PROPOSED DIRECTOR NOMINEE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I hereby consent to the inclusion in the Registration Statement on Form S-1 of Graybug Vision, Inc., any amendments thereto, and in the
related Prospectus, of (i) a reference naming me as a person about to become a member of the Board of Directors of Graybug Vision, Inc. and (ii) such other information regarding me as is required to be included therein under the Securities Act of
1933, as amended, and the rules and regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated September 21, 2020 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Julie Eastland</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Julie Eastland</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.5
<SEQUENCE>9
<FILENAME>d796801dex235.htm
<DESCRIPTION>EX-23.5
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF PROPOSED DIRECTOR NOMINEE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I hereby consent to the inclusion in the Registration Statement on Form S-1 of Graybug Vision, Inc., any amendments thereto, and in the
related Prospectus, of (i) a reference naming me as a person about to become a member of the Board of Directors of Graybug Vision, Inc. and (ii) such other information regarding me as is required to be included therein under the Securities Act of
1933, as amended, and the rules and regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated September 21, 2020 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Eric Bjerkholt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Eric Bjerkholt</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g69361fw001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g69361fw001.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M T +_:5M_?/_ 'R:8#X;R&9]D;$GZ4@+% !0 4 % !0 4 % !0 4 % !0 4
M1S2B&-I&Z** *]K?K<R%-A4]LT 7* "@ H @NYVMH#(J@XH 2SN#<0!V !R1
M@4VA)EBD,* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H BN>+:4_[!_E0!DZ=;QSNXD4D*..33$:']FVO_/,_P#?1H DALX8&W1I
M@XQG-(9-TH * %H * "@!,\T &: #\* %H * "@ H CFB6:)HVZ&@"O:V"6T
MA?<6;H..E %R@!,T % %74?^/)_P_G0@(]*_X]"?]H_RILE%^D4% !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 0W7_'K+_N'^5
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M0,CTK_CT/^]_04$H2^O3'^ZB/S]R.WM2*)[1)ECW3N68_P )[4 61Q0 4 %
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M;D>N^'F:STRTTV>;S9((EC$IXWX&*YI;FR3-P=*DH* "@ H * "@ H * "@
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M0 9H 7- !0 E !F@ S0 M $,EK'(Y=C("?[LK ?D#0 S[%#_ 'IO^_S_ .-
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M57QR <9'Z#\J '[!S[]?>@ "@=* #8,8' ]J #;[F@ V@ #' Z4 !4#N1]*
M#:"../I0 X# Q0 TJ#UH%87:/?\ .BX6$* T7'87:*6P6$V =*=PL&P>I_.B
MX6%Q1<+";0.G% !M Z<4 ,FMXKB%X9D5XG!5D89# \$$=QBBX#U144*HP ,
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4*')L$K&L.*D84 % !0 4 % '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g69361page001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g69361page001.jpg
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M46'P<8&AL<$B$Y'1X08R<C0'\4*"% AB(S,54D,)4__:  P# 0 "$0,1 #\
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MKS!PRVL,=RQIM;D==A.0[RXI+L*UI;^L$FA-'?4S0K$]$^*5._T5.@W)] =
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M78<OG5)3UG#W/L+IV./5JM9.)F(A1V]FN<WH-Q_[@6 HI_13BO70"!;+C['
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M"%S_  \:G0M&6<:S/XBWY&1)!F9Y*TZ"DNG9^=/F3LK4195[K_'H(FUO(VW
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M_"TWFIA@%;::30FBJUQS3"AD0>)7(R.%?!6KT&<<?U^GJXB0XS'T,-X+-6E
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M%K^:2:15<Y?HGT1$Z#,V,:C47Q1>[T<O=?+L[Z?F17?@O^SH/?H/-8T7^/\
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M_;T GI]A$[__  Q?8'LJ(B__  Z-AW^G]R%=^@Y7T]P:(G;D/GY?[DYHV/\
M9]/_ ,*_@J=!Q_W/,%]6_P"H?/\ V[I_^.?8?54[]E[_ '7?Z)_X^@$]/<(G
M9/\ 4+G[Z*JI_P##HV"]^_XHO^:_!>@Y_P"Y]@T3_P"N'S_]>_\ ^.?8]T[_
M /R7^']G0'_<^PCD[+R'S\O;Z(KN:-@CD_'\/\U_#OT OI]A$[]N1.?_ ,?Q
M3F?8?^4BHO;_ #7X)WZ#C_N?81>W_P ,3G_Z)V1/]:-@G?LGT[HA7X_1.@Y;
MZ>X+OW7D/GY5_#\W,VP^G9/Q_P#.OQZ#E?3_  ?T7_43V __ .S['Z=OX?\
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M"UXT+L;.JU'')N92AUV!UN5+_3==DM V,90;*QQ5TQ\+HI&.0P98IV+X2(Y
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MOUZ"9N2^1_53B7ACE?CW'DF^Q'(L<59FA];?!"3Y;-D6CG_!+F /ED,JRZV
M=S6S1,2-\SFJUZHO0:_\9I"=-G=/G#K204VZ8'""2P1D$U7 O?[02P?'(Z.8
M5A#.TO;N]&=^_?\ #H,7RG&6RNKZ&F9E+&[%MBQ!R:: ']1!(BK)8YFW(9R*
MW[2!DS_EC?YL\&_1/K].@D3E;#9>XJ<]7#T-?74O$]D=GKC],#2ML;?:V8WR
MV(MS:N?,A,$<GFK)WJKVKV[KT#C2<66^CHH:AH5G>.JZ1AU HHI!YE'G@G(-
M$^]#&<V$M@".<KOA:]R1^+G=N_0/FVXTU%IA6VN/*BMQZQ0H[H.O*_G!0A"Q
M.@,BKE56,KYIF*CE1J^+E7NB+]5"K7..5U<H?'BP5\PF?M8*J$="8B81C)[8
MV(.^>66K)XRX:A[E>KI(U;"J=^[51'($=^U-Q<@;Z/C<>JCDP7$]8'59'/CD
M/G4EZL'71:QQ*%)))<VQ7=T9;GJ2H_=GS>"N:H>7%16IP&%W/,_'^4Y<DU6,
MY+X@].^++[B_CZGY(Y"R>[]CJV/<^P_*G'W&^H-KZW3:L3C(NBQPS7S>5= >
M7)&YZR.8X/IOX*%0/UZ]7@_![9!N4?7R)\,XL8TT+8N6>1V+$2(Q$B#(B<SM
M)#'_ "X)&JQBJB(Y0W3= = = =!HOU60O-]Z?'8?/5@]OH-93^WU!2U%B4RM
MKK4XOE^TGC$L+&1\25]6HT$CRYT<BP",DD14\>_0:(X>.>-.2*:OXL];:#+<
M=>M%.=ILAQ?44VCTQ]9N=C<Z.;0^PO.M>=HS[.])XNTFZAD%H339GR25-;\\
M?BQ[44+9^OK?2+@2ML.. SX=S5E^-IR5=A"R0?UT10P)8#PM+>U3ZS 5Y4L;
M%8R3O.U'32?1$3H&BQYIFL-Z'KKJFAG I+)0<AC<[71A9F@J7R+$')E*Z")D
M144J.8L<\_E/.Y5D1RIT$@Z""+-6'];5PYNGT^A5C9:ZYF)/=G[,Q\:165G*
MQ9)"S(9I&^(TJ^,+NW;LG08'RP;F8XQ,]N+]R:B0: JW^V+CBBSMS8S,<TBP
MGB21J6Q+?S(DCOY;4\?Q3H,CJXS.(:*@W DK$C7%S4PMD;.PL,V0PF2/[H2)
MR?\ G;HD:YZ_^F[]!7K?<@W4< Q<M95CPW['-%L$$-:38%RRPQ/LE<UC(#WB
MD+(Y49W8SMV7^SH(=K((;$F[T^A,>/CJ&<2\W&@65T(U6$ H\;@F/(2-KS3U
M<Q(QX_D=W^O9/KT'CZY>^F@L?9V($6UB(R6LTI_']M6M*?\ :'T.@!EK:T4P
M21B!NL:F<&)JK*WR1WYD7LJ=!*=]<Y'ES.#5^&,IN+>4=I[2<4^NKM@(*)9W
MG'6=Y%O[L+=<@Y:LLF35QVH^VR'VH,,\;Q8C#6S*B^"(H?3KZ@?M\>OOJ_D%
M%P>2"AET2B7&FM+ PW3:O?6Z2.(_J7EC?W4L^HY,ORYY'3(PV9M4$YZQB!QL
M8WH-@<36(UL;&M:R-$:QD;&QM8Q$[(UK4_*U/[D^B(G0*4[_ (KW[K_!51>W
M_)T'/0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0:^.>N6;R
MZTUKDJ>P(K\[1DR5I,8<SX'VU@.[XSI#)8G-?(+ 0CHXXN_@OAYJBJJ>/^;;
M_P#1'_F3^_OWS_=3NW]G/V3W+D]M_MIV'E7\+?LXVY=M7]PY>S.CE7\F^R8N
MOV-K>B_9V=C5.U,;?WKXNOOMC;_6G]J_V%VSMO9=COW<-JS>[QR;(W+9OB+H
MVK+L;(LB<(NFVEUUU-6.F*1$U@"GO;G/FQ65):&U9T+T>P@,B2%ZJB]_&1&K
MX31N_P#*8]'-<GT5%3K_ )Q?LG^X7[X_MOW[:_='[#[KSNT]^V;XNMWN-NW[
M=TS$UI?$3IW+)ROV]R+K+XK;?;=;,P_J_<.U]N[MQKN'W+8VM_BW12;;[8F/
M9UB?"8F)CI+9KP_OG\B8P2Y+9'';"$2U5PR%/&)QPK(I/N(F=U\(RQIXY/'\
M&N<K4^B=?ZL/^%7_ "*W_P#DO_8[B?O?O%FUM?O#A\G<X'<K=N-.W/*V+-N_
M[VW;_DLY&SN[6]H_ALOOOV[:VV1,_BS^X7[5M_:/[CW.W<>;IX&Y9&[LS.,Z
M+IF-,SUFRZVZVO6(B9QE*/7ZV?#CH#H#H#H#H#H#H#H#H#H(CYYY%L>)>(=U
MR-4UP5M992H98B5UC)/$$7(XX03XR)!E2=C$82J]V_7NB==CB[,<CD6[-TS$
M731P<K=G8X]V];$3-L*G^H_N1LO8GD#0X_18_,YX.GR$^CA+I3+4@F8F*YJ:
MU!Y6'.=$D"Q6#G=T_-Y-3^'?KO<_MVWQ-F-RRZ9F;J8T\)ET>!W#<Y>[.W?;
M;$1;7"OC$-AG7DO5'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0
M'0'0'0'0'0'0'0'0'0'0<*G^WZ?7Z=O^GH/![%54_BJIV[_3^"?5?X=D[_PZ
M#1S^^SQ_D;KT2YN20"('2R4>1TV>T(X$,A6;W=7S7P_497?T;YG?'4:_-37<
MBM-B\)9A9)(9WOA<K>@T[VWNQ?6.S]CZSCZ6"N)XQX(WESFZ.NJ&5L*Z0:82
MC/<.3 ^48BTNJ4HDF9J*LCF>3_HC4[!K"]=^;FLTY=-MHC;7,ZFO!%V5Q2N?
M<765 ?&V:CO1 XF2/;/4W?9Y+7N5)!O/Q^J=!=<:CU^?.#MP&V,PUI 4?0:/
M(QQWE?HZV5G<8P:.-DKHY'PN19H7-:^-SE^B]!9C.WW*'&&0JM5H:/79FIN;
M(N?-%24+ZUUB&# Q+5!9YXVQE/:Y.SAU:QKVJJM3Z=^@F#1X  #C.@W&LT\)
MM%LM?8:@4%JD""6-B340H&EK Q$8^-&->YS$<JHYW;\4Z!HP1-K=YV<CB&]L
MP=7CSR+<?/"2^-E'.:JQE/"(D5LI.<FAB5Q DJRQ^+N_C].@RR1])FY9>1P8
M%KM2?32';?%0*\FFCCE_->DUPS9(H81[@A4<C6^2Q=E7MVZ"-.*^:<SG+B7.
M<N8B':>OUU<1IH,I8!O_ %G(_P!3&Q "Z'+6K)'6(UT 7-&](AIDC(A15<Q?
M%4Z"9>;>"/7OG@\^+AV^'L>2,A65%2*#8,B@-WV:KV$*/\DLZCQB[3- R.B;
MVD=^H-_%$=VZ#7)I.*]BRHVWJE*O'NM V'.O$'O9AL]R]O=EQEB;O&<4YO-X
M[VEP _)^*=%LLOL^,(<;1:]D-<]IKZ$HA1VR+%(B!] 7KVH[O7'U7>(^-0G[
M_P!=90'CF/LAGUK^5>17U\@-E*GSV5>X-\?VY$G\R>!6R/\ S*O0;KN@.@.@
M.@^;[V\O)<A^W%OMD/86HY^<Q?NBV.2F^\?9#YK3\MF9;?V80P2.*(GIL/;&
MR*K$[PPJ^15:U%5 T19[DFBIN2-3QA:6%7B,IJ^$V\-X.]!<L-?B,_'7 196
MWAC%3L'6V]6/%$^:-4^**9WU7R5>@CCBW@;VWR?(=.DO&=EN0Q)@QQ;;)=M;
ME+^NL&3 #FT4HCB([&K/@1&SCS)V5'*UR(WH-SN;XZX^]3<EH=-\\>BYZT:T
MN>V?$E_H9]-B. ZK4))"_89%#19IA-743MBC=62DRBU\<BHB-[?4(7XW)WYE
MC<YW+V!,Y)T4MU?D) XT&BI96H\K9%V*N6&)L;'*OPJYO\Q.R?@G01K:6? 1
M>B(SEGI-D!#,KVR\@V, )]'=&))VB)L\\]6F/$4KZ*Y)5E8G^'NOTZ"5^1:/
M3P9?CCBO5,9VI=.^0*>"27].M,]:QL?37=80BM?/63#3J]CG+V:J>+NRIT&P
MC"3C^P'K#R/PYG<QC[6]X4_27\1:$^I&G+MZMLK5LLZV9GQ%I;VZI(C?!Z?(
MY_?ZJG0?,C[7[?G&ET<&"Y$I+O',K6A$46= S!XU/!8/)8/$$370P)">6D4G
M9\KUD=)V\>_EVZ#!N*PYO6T;2>TW-M:+FRX<YH1.)L5]E%3W6XY$LH7P-T#<
M\7XR-JZ<-Z3L(E:U6R_1%[]!.O[=^4T_,_L3ZJ9ZX(DN2=SS2G-!4\<" SYO
M'>OM7>ZW6[2^&B<Y\HY.RTE33P1N^CG%?1RR=V]!^AAG191**G$F^'Y1JX2&
M7[?R2#S9"Q'MA[_F2-'?1$7Z]DZ![[(U>Z?V*G;\?[_^CH#S9_Z)OXHGU5$^
MJ_1$^O\ %5Z 5[4[]U[=OQ[]_HG]O^SZ?C^'0<(]CD[HJ=D[=_[N_P"'_+T!
MYM5.Z+_'M_M5>W9/]J]T_P"7H!)&+V[.3ZJK?][?\2?_ */\>@Y\V]^W?\W9
M%\?X]E^B+V_L5>@/-BIW1R*BKV147OW5._T3M^/X+T!YIW1/JJK^'9/[.@$>
MU4[HO=._;O\ P[]^WX_AT''R,^OYF_1.Z]U[=D_M7^SH#Y&=^WDGX(O^Q%^B
M=_[.Z_3^WH!7M14;W^JIW1.R_5/I]?\ GZ#LKD3\5_'H./-G?MY)W1._X_P_
MZ>@X^6/Z_F3Z?C]?P_CW7^Q.W0'R,^OYD^GX_P"S\>_]R+V_W] ?(WZ_7\/]
MWT5%5%^O]J)T'9%14145%1?P5/JB_P"]/IT'/0'0'0'0'0'0'0:M^9LK897D
M+11%PR-%M[$R[JBG-7XBP[(B0I?CD[=GO%FE=%(GXHYO]BHJ_P"2/_G'_9_]
MQ_V@_P"2/[EXO>-C=M[/WGN?)[IP-^8G[?(XW-WK]_Z+\KKMC<W+^/NQG;?M
MS,QINLF[]P_VZ[[Q.^_M+B;G'NB=_C[-FSNV];;]NV+<8Z1=$1=;XQ/C$HLZ
M_(C[EL6]>L[/C>-I[2_<VK2W+*T<RGO:+&!41AP10DF/G5C!HW#".G<YZHC8
MGHKNW9>W^G__ /,'^S_[D_M7_P <HY_[JV-WB]W_ '+W3<[E9L;D3;N;?%NV
M=C8XVNR<;;MZS9GD6Q./V]W;K$36(_'?]X^_</O/[KG;X=UM_'X>S&S-T36)
MOBZZZ^D]8MF[37QMGHJ#RE^YICL_;ET_%V+(WD(<SX':BUM'9^A,?&YS725
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ME,\O%>[>_P#3=YW\5_BG?\.OH^X?T6Y_+\X?/=O_ *W;]?RE]+/7QKZ\= =
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MWT_Q>4/Y8^_0:[,%[ISWEQF:4SUDXESN-AMF31@YD(_.Z3+5,C$8D]7I'/\
MU*62NE1LO9['HKO\2?5J(&U+WDYCT5]QIQ-RO27-%I1+7BZV$KN0DS%>W1P7
MM#$T.6"QLX!Y"*73"3/_ )I<C_.2)&O9^*=!2+T-]AMWZRE<S^PMK,8;B\13
M#Y&FL9[N1:_?;/260<M_#;3FN5MH+"KGQ^,35(8B^7;H+4^S/^GGLQR[%6<%
M\2^R/)MRG$F$YPW>1H;C!3<*8!NUMM#4U]):['>ZZDBJ@[.USY,L8[("$;''
MY^'9$[A5W:YPWTYFRW,WL%K.)!--2<L8&#C#CH(?5<B^OG%7*VJ^]9Q_RU[1
M\RT%-$FW)X^FE4K/Y#(!.##N8XRC'RJU'M#Z(^"E,D]=_5LBTLEN;,KD_P!>
MR[.X^2>5+@XOE;D0DNXB>2U"I(K(B5T['O1K^ST[M;W\4#=/T!T!T!T&ACEA
M'.]([ID7WJROH?<)!TK8X)['YUY@);#^GQ$JHLIGS=OC;)^17HGDGCWZ#YWN
M*X>0J/9<_P!5J,M[#B<I:+V,M=.@_L%QL)7<SLQ -'3&T^JGI\/GI<!)7$$L
MBBK2:6,X2<3Q16Q.5ZJ&0>R]D1#R&O*P_P!X_!>Z&CX_6FUQ4!]/C\[[88')
M5_%W+_"'(UO=AUL&?GY;S%$!H\Y.8.*/:G(8(/(XB%&*&?<;<A:*/.#.YQS>
M 2BX]H+!I7+'+#X<\_-92N&NAY'7EY9/AK2J<46H&<&V1RJ[NU6I([Q:H>?(
MT?,OLY.!R9E<T(-B-%2Q?TQRM[&[6ZX3H^3LY3P#PAD\+<9@X[9\AEXF)\2L
M;:V=?3C3L7S@9+$[R4*R;KA_<<99PGE#D3*+C>."BXJHKDK!WL/,G P4<C_M
MIX]/LLU6T^MXJ;-)*K4*O:$("-SU1Q;57H-T7HI94^P]4N?>(][90M;G,UE-
M=56JR"SUUED\U9Q6%/7U1@:OKB*R2.6.$*5'R?R)4_.[^ :^ *WE'V'YVJ^%
M>.;*W Y.YPL[&2._!9&K.&>&\^\$;E;F9 XG210GY^G)2CS+5=',9I#X&1+X
MPO[!]7'$_P"W[ZVX;BC$\9C<69<#.8ZC!J:3-345#9"5E>(OSC-LGGUY<M]I
M2)IG$VEF6Z4L^RFFG>]?-O8++9[@WB_+"# 5&1IPQ1#&6$0@H 8->ID:>,9,
MM97PB5TLT;?HCG1*O\?[.@EAD;&JB,1&(UBL8UG9K$3\?\#%[)^'T^GTZ#JY
M51WC]/Q_^)T'LB=D_#NJ]E3\/P[M_'OVZ#77^[%EB-W^WA[4X426N@)V/'P.
M7'EM9"8*J(G0:_.U43K242<4IE:CRNTZQ2-D^-5\5[]!JN_;+X/YFX&]U_8C
M/\B5W#&?RMKP1D2>,<IP+<V.DQF6!I]Q85=UGSSC6O-;?+*.TMPK9G1C13_5
MJ.554-]39S&J]S5>SN]7?2 M?)?%/RIY.\?!R?14[+WZ#E"#4[*R61B>7GXM
M&(8U'JU&_5&*G=415_W*O]O0=4E*3Q[.[*U>[502?NWLY/%&N[^2-[?BG?\
M#Z=!YK\SG2R/\WNE[)*JBD*Z5C9/D1JHWMY,8YWT;_9].@TFZ_\ ;O\ ;:[]
MJ-5S-D^?F5/$O(7N^G.^\X:L-#H#:A_'M3Q'>8;#ZK%L>.B97D42^N967U)\
MKZN[KV"RI\,PJ>80FG[=GO=R_P >Y[CGEZWH>#'\:^NOK?Z^T.\XLYYTFSU%
MWH^&^>(.4;CFZLG=0U;\R7)6UHK(P"W$E6#WR#32+#W=T&.<Q?M:^ZVIR%R)
MJ.1J/V2T6A]M=5S]M;X[:UO%LFC$V?J>SA@F6OJM'D]-EZ&ISO(_QS@T+Q7M
M'K1V213(0C7-!1P)^UE[+\2^P'^HW(6$XQY>4GU-XWX2Q?*1G+T\=QP9N\AP
MMI,#8:G*U>CR)>W+0F^LXF)(':#BRPN>0D*/8SL%K_VIOV]N=/1?2\QD\L;C
M-;I-UQIPMDL?:8BJ"RE.'!@1+@C35FOQ-*)$/>[X?07,GEM'3.FO0%A9+% ^
M%W<-R"3F-1KD>YSHU[L=*.5+(B_3Q_XKW-<J=OHJHJ?V)_'H.6DF-<J^?DKE
M5[GO#F<KG*B(O=._T\D1._94_#H/)[BGO5[Y'*Y6-9]!RD8C47R1&Q([P:K5
M^B?W+VZ#JOSN<YZN<KW*JJY!9VJG?Q[>/CV1K6JU%3LG?Z= HAG/=-%V?,YW
MDQ/K$<[R[O;]%8KW,[KV^O9/IT'RM'+Q$=[4\L:#(4^JI^6(/W!<[1<R6!^7
MG?4W4L?M'BW9(G)Z^Y'=5RU\]38K!8B5;E) GA1Y'UFC[A]CB(G_ )+OIY/1
M?K^#NZIV3OW^J+].@]>@.@.@.@.@.@.@.@.@KQ[2<-3<Z\-:/$5TL,&ACD#T
M&5F)?\8W]0TSWS"#$R+](A[(>281TGX1)/Y_7Q[+V^#R(XW(MW;OX,I]4_EF
MZG-X\\GCSMQ_'G'KCTHT7\.<U\J>I'(-^,VB<,7.D57M<#JH2@&F?823.#(1
M\7\X,X-9Y%&+B2:&2.5WTD8Y%3Z;D<;8Y^U$UPSBZ/3W/F^/R=[@[LQ3'*;9
M6!Y:]^^3>:\Q8\:8; PY---7&!WDU79FZC1FTR#2R6XE>D59615H,P#)$*F6
M.5S1_/LZ-.[NNKL=JV>-?&]NW:J3A7"*]/&OD[6_W3>Y-D[.W9IU1C3&9CKT
MA%OH)V7VFX\5O96K6[14[?AV_H^X[*G;^';KG[I_0W^N/BX>U_UMGJGX2RO]
MQ[_[9,C_ .Q]DO\ ^/>]<?:/Z/\ US\F^[?UG^B/FW'^M7_VOG"O_P!C+&__
M $""Z^>YG]7N?SS\7O\ #_I-O^2/@UT_NF,T7ZAP]([[C^D$&U3&*WR^S;IW
M/JU_G]OR(6^H:[X/+Z^"3>/T\^O7[)HIN?\ ],/PQ^;R>]:Z[?\ _/'\</D8
MO5+=^D6>XD"'Y6J\=#R.,1:/TQ&UR).D,M/*P*EK):(A:FV@4!M6Z&-((?C>
MV5C_ "8JKYNUSMKN5^_78F[[.%*33UUQCJSP=SMMFQ3?BW[V-:Q6OJPGHHQ[
M#[+!;WE33Z/C',"Y+#21 U]%5B58E+%/%6!,%(MEJPHXH 9+0IKY/C[?(C?'
MS[/\D3U.)M[NUL6V;UVK=ZS6N?2OD\WE;FUN[\W[-NG:Z12GMIYOHSX:'@,X
M0XK$*AC(%*XLQ Y(\S$DBG@GR=9%-#*QR*U\<L;E:Y%^BHO7R'(F8Y-\QGKN
M^,OK./$3QK(G+1;\(?/SR11:GU1]CKD?*DOKC\9>S7&*/EC^:,C,WHA#JKYF
M*J,*B2J/>'.U5[++$]%_#KZK9NV^=PXUXQ=%)]<9^_%\MO6W\'ES%F$VS6/5
M.7NP6'_;CXHDVW+5QRC<Q/+J^.!7O#()[2_>;;1QD103/=)W66:NJW$D/=]5
M;--"[\>W74[OO_:V(V+?XK_A'ZT][M]IV/N;\[UW\-GQELV]S_\ [5[F3_\
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M2I&_Z1>@$N+'M])?^2I@_P"@;H.%N;#O]9/P_'_LD;Z_\H_?H.GZQ8_^O?\
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M?I]?_-2^_P#XO[^@X0OO]?MHO]XI:?\ BZ#E"O\ VEA7^[[8S_H3H.5(7O\
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M[=D[(BKW3^WMV_L3^_Z]![= = = = = = = = = = = = = = = = = = =
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MTJR(R9K(X7$UF8B(\VP)4_'LJI^/X?W_ %[_ .WHR.WU[_\ @G0<] = = =
M= = = = = = = = = = = = = = = = = = = = = = = = = = = = = =
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M+]53\TC)5[N0-^?!GB[AKAQ_B]G?BCCY6L>J>347)U"^*^*-3NU/HJ=D^O\
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M;%3&\I_M_7-G=6P[PP+RPO5V-C*3D@E<D0-#&PAGPQ1.6)C51J-;V5J!O1Z
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MDWV$]6N5N7L;QI6X6>JPDV']=.>,L-5W0M$Z>OY3UD/%+>.)JT?)6 >=REN
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MCK#A_(9BKXOHI2"]*.EY4[X-]@AMM5@@HE7+"PAL5K/*VPE8;&/6+([[#\3
M9SD8>,2Z$T>S(K1$LB;$D3+6&HM#\P)812Z385]*<-3DQ,?6UMH=55Z(D ;V
M#LCBC,SFL'T0= = = = = = = =!B^U_^H_6?5$7^FK[LJIW:B_I)??NG_H4
M_'H/E$_;9RW+$O&'!J6=E3V%B9+H"PJRJ/K!JRYM:^_OIZ<.HIA8Q70&Q4GQ
MHR5['S1E^3I7.C5.@V23ZKC+!C9U_)@NA.N./\ALMGS1G=[CX>3>2+*INC#G
M5N&*W <,8LU>B3>2,2*5XD2,1\G9J=!'5+J^%\Y1;.NL\@F5V.<?CP;.6;"G
M\DUU9PGH6QW-'D\+%%9$5\<THA;5.%^6*5K)GM<WP:Y$#).;JR[G$V&US453
MQWFM]LLKE<Y)!KG_ &]Y@H:2.FJHJNC8K4P$\;S'L-KV,8V1(T8QWU[]!7GT
M7"T]=H^>9M'H'VTME[@^G!50#\!4@V?J5*U([*P<LGQ(((()BD(E?](62/5(
M^[$3H/IFZ Z Z Z#0AILT7IL;Z?AUDV-@MZKFGV_OQV<@ESPTJB5&DUQEK,(
M\1KB%O@ZUKYA&M15[IV5.W083?-IKNUN>4<W5PP\*YVZ!Y"SE!2ZF,/3[.KJ
M55NT@MN-U(@6\I-*56OE%(1KGO6)CNR*G90IIR=[L5G'UMH<9-JRJBK?L0^0
MZ,;=TUAL+2C(O&,8/QV;/7AI^A#:*K$8D+%\8G?%X/:JR.7H)9XLY[I?8P79
M4>H;9SKR_P N4<XQUDI%9C,_:XD>O=+4%2,<EQC?UN:2%9PF-A:X=6,:Y8E1
M%"9;HJGM>&.5<+H]!@:ZTKJ3DK;Z'DVCJ[BTR>QXPIZV81F:J]3/"TRMN<X5
M$Z")T\;EE^-4;^16]!O<X5?')Q%Q"^!46"3B_"20=^[N\3LM5NC7R_'S^)4[
MJO02MT!T!T!T!T!T!T!T!T&';#;56*'!+MTG:+8&QU\9,<?D,,5/^49ATWDC
M0HC9U;!'*_M$A$D;'N;YHO081%SSQ]*G?[\R-&-B?,LU>1$Z!J&R5MDDT+V_
M-&_.V$2Q6;?%7A(K9'I\3D?T"J;FS$PJ]LA!Z2QQ'ROB0"9\GE5RQML1(T9Y
M)(>*+(A;8D7O.%_.B\VHO8$\G.F'C=(QDYQ,D4T@[FC".D;),V!A8T8LJ.^,
MI;<)_P P"L56F-8YK%^1OAT"F#FW!$3010V,TL9$HK(28QGJ,^.Q'?/4EI,Y
M6L:'92QO&;([Q;$8WX)?"143H$;N><$V..9T]E'#)&+-\LM;/$D,!$\@9,A,
M;^T\"TE@Q(;%CF^82N:^1$C<C^@\I>?L'"Q7SR6<#6^;94DKYG2P2C2_'9#3
M0Q*^1I=3&K2)H^RN<&]"(ODC[J@./^M>)7\K2B))$FD&=' -(0[[IHR'C01?
M&GA-^KUJ_."]J_&8Q')&Y7HK>@1_Z\X/[EHS"3)?/X_$B,1R#/0R-'U$Z2O<
MQ&AW<_D,/,O9GWC%@D6.3LBA[Q<Y<?RR=OU.2*%/@59Y19XV-@DD:-.6]KF)
M)&)66+E$/<Y$<#.B),C6N1_0</YQP\:]GRVK71H1]Q ^I*83!($3]O8BO@7N
M]QU;%V)EA;W>H2_/&CXT5>@\I>><% ^>-Y%DYT2S,8V"K)(?--%VEA%B9#YI
M-/9 +]V%XJK#1VN6%SGM<Q 6LYIPTB-6(\F?Y'I&.L(4TD9B3"N*KI@IOI$0
M/=HQT0<B+X3$M6!59+^7H$S.=<!)+"C; IH\S0I/NY@"8H(ACE= ADOFQ)8Q
MP;-GV)GDUK@C'-9,UC'(_H._^N.%^*:9Q%E$P:-LA'G6$+(,L131+> B%B.E
MB-S;GME/A[*^$5[9T1\3D=T'>;FS$PPI(DY\TJK81M%' FG(D)K?"68.!(^[
M""RP'_=AL:O8T5%?"KU16] D;SMAWO2..<N9RO5D:1#.5I'RP_<5,T$JJD3A
M=%$U[0)%5&SD1N@7PE3Q4%T?-F$D=&BV$T44S@OC)F%EC%6"Q3XQ37RN3M"&
MP_\ R9+W]OLS$^*9&=T<H>9/-V$#@4DLTP>%D+9ITEKBFRB,C+8%:*7%XK)$
M[/2O:\]B(YX\#DF[+%^?H$W^N^%1A'G-8MF&:9\@K0)9BGR@(R8@:"*!9$)*
MEK'H<,R-7?>!HLD"O\7-0%K.:L-(QTD1\TR,>YG:"!9'2.>(IU:L/YFMDAOQ
MD5 'HOB1,U8>Z2IX] F3G3!(QDCSR&QR?9O9*HKTA^WL&.^T+>][V?")]ZU0
MIY'HUH9O:*?P547H.8^<\$]D4JF&00R0?/)(0!/%]K'&3]H>I<:HLT$E&3XH
M?&K?,5DC9'(L:^?0<S\XX<=DZRRV7RP(<BCMKIGD.FK)'??"Q1,5RSDQ@M^]
MB:SO]R%_-A\T140/.+G;!RI&U#"G3S3N%'AC%=*I13Q5.KHAI$<D<J7X;5?7
MO[M86YJQM7Y45G0>[.;\+(C58:2Y'R#M8Y1)$C6,Z)S@BGRJK61!2EQN$DE?
MV; 8GPR^#E3N"&;GS"0N8DDMG QT4$\DI-;/"P2![W0&SEHO=T+:(UJ0V+51
M7A*]CY&_$[S0/9G.V'<R1SI+&-889Y9HE E<0Q0I%99#L@9YOF+KH?$ET3>[
MI0GH1#\D?=4#UDYQP\<OP,).)E<^5D2#@2/;.](5* 9!(CECE=?AM66N5%\3
M/%S&+\B>/0>#>>,'+^8<LJ:)?!6S?:R0Q?&3"DE=.]T_Q?"-:3>0T,C_ !:P
MQBP2_&_MW!1'SE@9'?\ GQ;(4'$->3)7DLAC )(4$DQ_=GR-CI;%/M[%JIYA
M2*BR(D:^?0=)N<<4.K5G?9Q-5I"R,?6S+/$\(ET-D.L,2R.>56"HTR6)O=[P
M'?<1)(Q%[!S_ *Y83[APJ$V+I^\[(F,K9I?NIHHONA81'1N5I$EU7]RJ_P 5
M\386N^)72-5G0>R<W8-S&.8<4]))(&(YH4J1>!H[YZHE9GK'$T2XEC<,/*JH
MQ3$^!ZLD^G0)DYVP:-;*\LR(96#/D((!G@8.PF1!I)B$D:CX8:JR>T,]7(C@
M2'-25$8Y']![_P"MV%\?/[H]&M;,^=%KB%E'4$G[6W@EB8BO0VC>J2%P)WE8
M,Y)VH^+\W0=".<,0*Z2.2:Q?+'*8+\,%?)/*0<)_-B"$;$YR3SW-=_G*[LJL
M/&1RQ.5Z*SH.B<YX9\D<49)4SR'.0581UDA*9*.I-5/!.CDB<+>LC?&)*JM8
MXICAW^$R(Q04-YMP;HON/U E!44!9"Y0IHH((+!70M,(\T22$0,]/M"WN:GV
MA2HR5&HJ.Z!,WG;!(WS(*.&1(YYY6S5\[9!802FB6[2XT170F43GME,@[++$
M,Y)D1T?=R!V9SCBG>;/E/?-&D[?MX1/N)WE#>,T@,4<,COE*(KE^\$1O=IPJ
M*^%7JBH@*7<U8A)'0M,)ED1_QQ_"-YQ3_,(XRKE'F5[8Y![UK'1!R=T9(4U8
M%5LO9O0-L//N E2!7%F0-(<(L4I(;X!_MC56&(V>:5S&ABPV#5")67Q40SM'
M,C4<UR@M=SA@XX/N)C#H6-B2>9LE<0DPT41?V5A]U"B.D@EIIO%YD:HKX('M
MF[+&OET'G/SGAQY)(7RV3IF*=$V&&NEGEE)KWQJ0+$V)SEF(>#(AL#6]U*!1
MTL/FC51 ZLYTPTC4^(HF>1Q#QHXX1W2)/,HRF5ZC3(OPRCWP[7+7S=TB*E:Z
M%'),GAT'K)SCA&N8UAAKV21@3I.M?/".@UE$]12G23>#6#M,C42=SNWVI:MC
MF1BJB] E9SW@7L21Q%B,SM$^;[VM)&<)%\KASY2HGM^:/]#)1K+!OBKQ&O;(
MY%B=Y]!ZP<Z8@AB/C(-\W(9XC?8D.,4BL5LEI6_;,:YRVH8;VE-@154@14FA
M\V=^P<E<YX<9&^)!A4CW21PQ#!R.<5+\#2P(A'/5L<RWPCE?7.\DC*>QT2.2
M9/#H._\ KIQ\_P"!T5HKX2%B=$2Z)T(WP$L_R)4DTR,; *<8C@TDD\6Q'-^"
M7P>K>X>CN;L(B,7[L^-'Q03><]69"R*-Y+PSU*^1C9!GT1+4;8,5JR!M<V1[
M?C7RZ!+/SMAA^WRR6S51I"RQ)4%2SL>$]%L!VQQ>;I2P E0UT3$5\H#DGA21
MB+V#W@YQP9"O2(PZ16O,A:V,"5ZR3CP_=AQ1*U5:_P#7P$6>L?W2.PC[I$Y9
M&JSH"7G#"L[-B-(G<^4%D;FBR1PR0V@ZS5)R32=F-KK0AJB13K^1AR?!+\;^
M@$YPPJN%:I9K&D-'D=).#*/\$,L[PRIIXYE22.*EL6_;6/=$<#(K72(D;D?T
M'=O-N%\)WRF&CJ-#-/-%/6DI/$@9:"V<#H&(YZE5#7M(GC1%7[-4G9YQKWZ!
M(_G7%L?/'Y'O?#(5 Q(A5E0HL:-2H1 GQO5ADMU6(I=8YBK'80M<V)RRM5G0
M>\?..&E<B1EE/:^9D<4K1E6&6,N%9ZDILODC4"NE:HX\R]HT,11Y%9)]%#V3
MFS".:R5+"9@\D8DS2)A)XHVPE3O$DEF1[4D@966#$&.\T10Y7-^1&L7RZ!NC
MY^X_>YR.)L8DC4AI'RUTK)!'@$?;VT!,/=9(C:='-G)A[>:!O2>/SC[J@+X^
M;</*^6%"3?N8GGPM%01SYB2:^-"7#!M:JH3-85_^: 1J]CX$5T*N5JM0.%YM
MPZR/9&65.SY8X8I81O)A#RQ%,K'P/<]D<@UPB+ +*JHQYC5'<K9?R] E@YXP
M4S5=]X7'](94?*'+!"HA,GV[3GR2^*PBA&_Y4U7HC@2OR3-8BHY04OYRP,;4
M?(8?&SXG33.DK"6J&T<G[2RC*8K5?$53O5LA,7;Y&#N29J.C_-T"?_7?"(XA
MCY;)CAT*[QI7RR323!(DLXD,4?DZ<N4!R&#,9Y*8)WDA\^RH@*&\W89Z_P L
MPJ=CW-:+*.*Z6$Y"14-JI0Y4<UD\%[$JL"D149,2BP*K94\>@\9.=,0QK'_)
M8I'(@SVRR@30PL@+C<L)1$DG;[4:(U$")?(C?LC'-CF1GDCE#I%SSA).RO(.
M';XQR3?< SQ.#8DB0V"&QN;\D$U%.YJ'1]E</$]LW9T*^?0*).<<-%&][Y[+
MY(T*8\5E81(2A83V*17-C9Y+*<H3OO(6-[_<AHLL*O1%3H,ASO)&=U9985%-
M(80$V*4A%C6)J"$I#(!8PND[*556L,JJ.3$CXW.8YKO%[5:@9W#)\L;7^+F^
M2(OBY.SD7ZHJ*G^U/]Z=!Z] = = = = = = =!C&S\$R.K615:S^FKWS=V^B
M,_2BE?W5/JO9K>@^<7A2K?G_ %LX'QN=%XO3DD'-TG(8-K3Z*;/YF#A?2:"Q
MK[F8S7FM?)5[.XGD6$AX\G=BM\/RIT#!RKS/!ZQ#53*1=,'J.'] 8FHN[.V7
M0Y/>A<@%$'A8\Z>139-C)+4EJ./+YO8C$;Y,\D1$"%.//=RJU>DX_P A5W1-
M_1Q\G&\@/&S^6/R-TPBN'()LL$?$>@@6I+K(Q4%F&G<LGPJ]T3.SU[!<;!E8
M;*V]5RH2S(:/%;4OD_DO7<;V;KRUY7^XN+!H ;G4(3?T^$#":6O\1QX?"919
M5:G?Q<O02QQI7#5&\T8O]3YW579O,WI!>Z6SSM5+15WQ:*TV%AF@YJ:=/EJK
M4>G2)7CN5RL<Y4^G;H-YO0'0'0'0:&K1\X.*]5+,;'Q[.QI^0O>6T%0^'[N#
M.2LL]FS^IYAW/^(IM9$_NL+TD9(Q%:B>2IT%2>81J^3@_"[4H0&^BM9+S.'^
MQ\59/D:VQ!$J#[6F_3,?*4-=5T0MTV0&:,/M+(CV_)_+5'-# /V<O7;UI]A(
M.2]3['5-#IN0B;/&ZVCP.JW%395-D-E999).9JG.M(9>5IDUM<M%*87),.U[
M(FM3M]5"GUWGN/N._=#E?%<.:&*\X@AL-_'27-%M[O5V7(^LH+"H:;D]X78P
M -H[:HU?F#\P[GR,%BCBA<YS6]!MQV,>JK!/Z:I\M#2/3UMY! !X]SHE5;\-
M662.RY-KL"]C=&K]\FHJ[U@Z2QR/^1TB)\CX'*YJAO1X/[MX=X>:J1M[\58!
M$;$U4B14RM2JMC_,Y$C3\&IW7LG\5Z"6>@.@.@.@.@.@.@.@X5>R*O05S]A6
MLDK,VU8X732''#P-</),40I C6R5X22.;4V#S8N[9*POM^HQ(YD+F$-C7H-)
M?N)[>\L>I]QQE+F/5PWFC!<B\A<5\7Y7D"MY]X_PAPO)O*UQ>93&9EE)K:6R
MN)*X8BOACBT9?QCQBDR5MJUSH$53=ML7=:2QK/\ [E_&V/YGUO OM149?U0Y
M!QV&X+NR@--RO7:^@FT_+Q&G&@Q<6@RV;8+G*O$6](-"EX7+&/4'VL(ZN09Z
M,<-$TK;C":M+[G<(8>ZY@I^8-ID>+QN,N7 N$ZPF?4NVMYJ+XGCZGY4,"(X[
MP%#9Z7,6%?7V3C+*C;$20")$S0!31C3?'T33,Y)O"YJXL(XL9S7)R+D">&YL
MP_?S\FRW]1+CF9$VNEN2]--=R2ATQX)=.,^<SNZ(70!QOEB^&SA?&I*36G5#
M8'OWZ:6W&U_R_5>R''IN%RVPH\5=7<%O?/T(&[N0'&9K*,SY^?BW-KJ]!G$=
M/02_I$BW]4CQ2V/8UI"%T71-*8C2^\GJ%B:; ZF^]AN):Z@Y:SL.KXU.#TUI
M*/M,K67R9YMWD(:VNMKE:[-:"5XKGK#+8Y.P248UCJY7.C&FZ>B#./OW2_7S
MD/COCSEO/2L'XGV6)]C-3:G:#5T5+L\G7>M;!;N_H2.,@G&VFD;I0+,,\H:I
M.=_2,QX9L3W0SRPQ%T3$TG/#WDOK-^YYQG[#8Z+>[>FX\X'X[DX'T/L-8W.L
MYZQ^TO*#$KR!'A'P\B8H#.YTJO*LR6K^K,CG=7V%A%\ ?R6;8WO%UDQA&,U3
MG+[W^H$/'</+<OL-BEQ!NTM\(%<!DZ*YTTO(P=1]_9Y('(+0?UV;JQ,J.XOQ
M*J(_U6F1X]LR%6Q%*31=6E,6;<M>WG"?$?JUJ/<:SU(^QX7S^%AY)H-%QJ4Z
M]7<T+"8:W*!X,PF<=)'V]T;&#2$E2M*SMG,X"Q[A.1Z"+9F[3U5BSG[J_J@;
MRSI>.M1R'D.-*8+%^MU_A-OI;T]E#R3#[!U%CIZ>N$K *)DF(J<G>Q#!V!)1
MC! ;DR$JND9%(H\A=%U*PLJ1[@^LU;RS9<!VO-V#$Y3I"+(&WQY3K8HVMM@<
MX;O=AGBR@:Y,E;:T;)A/M[?/!V"&V-<U+4"&$IKHW$TW4K3![>HWM5Q+[Q\*
MUG-?#IEG)1W&@T>;FK;9T3-A7:.NN3Z .&^<]_Z6S1Z*@"@*"65[Q;^H)C"/
M6.Q9Y="ZV;9I.:P,L;1G-<CHQY1XF%P%!$E"Q.A')95UI8!)S_FKF5Y"_9AE
MD^9-(0YU99M>$^*5#);"6QTA<4D8L+8U/4D>5A@(_:KE8L\*@CR/*KH*8YWR
M%CQ.^YS)KVE"NEKY%3H.Y0B/C<_[-$F^<F.7YQD+*F=+!^HFPSUHDS0RS"XV
M?=68,#DAMQVMLJM["6.8H(D<1YPRQL?)":@DK&,FB,D+EMQW)%) 5-X#VQ=J
M)&YL+IFQBZ4)OVQ'PV,:.4'9DT4D<1+%;\K$&E'^,M\(\L2.=6UI0]@=Y2C,
M:BO# -*9\@4JOJ[5'1.8]08#XOM&M8R*-@,#/.-Q3" (:Z*I,\YAS((G.-K*
MFIL)6K+!$JE9@IR$#_-7RN:@+FR32D2PD"1_=*V466&4<>2)\:M4\P:80-4:
MZ4A%0D\,?Z$,1MI5N1_G'T'+HGD-9(Y)2'32-:Y%DKK$U\UP.Z/R5W9H=L19
M 1JC$?XB:<%/%Z1GQIW!N0B:+Q>*C9DCBC)@:-8_ DC$\Z^I)#L;)'_"CG*X
M:NL26_RG(ZHM6=ECD0'!I@BC12M8R(>)LO:52IJV,6"E(1K8WL?&ZPI!**S?
MV<Q/([*EN54^:OD^@=; 5D4L[UA5\;6FC%!SH_NV/P;86,;@@6^:,9+V++!'
M^J+VM:MWT?'T'H 4V5T<:N>KBIH&-G^:$\DHFR%=)(/-&D+ +4ZWKV=^R*@6
MK#3S9\5A$J=![-:U1O.$K^5WKY!IH;*1T\#YWOKJXT*R.B5DCU[J*!8$-\9T
M5:NV8CO!_0-<:3P+%#(D$+HH%DB? 696#QCT<CX5F%6:-3:D:E.(^*-S^YF4
M,=\<B35DJ*T'>&?Y&3@$M[_4D69_V!@ZPI%''96BD5@B_*)! [PGLZH=SG#2
M._5JE[H7.8@=# 9W&1M>B2E$.=%)$^-]C^J):11D22.@:K1KRPLJ]B/DC:J"
M:85ORQ?%81*BAYAD3HPF:%'>!,D9*3#$K*5$40J5-<4&><U(#ICH8_MPBIVL
M@L8$?5VB,*:R506M&9&%Y,D''9!#&<JPS%! LKZHJ4,4P F?RL:8"HLI'M'G
ME13,L:KA2FR@/\D!O6&065&S,&8Z*.41'2#E0P1#!)+:%A3A 2*17)6F/:0=
M7C*Z2OG>EM5.<,LL70>X\SY)!1#8W32$O;%$TB)AC#Y#A7F60Q0@;E$M;&S#
M8DY<$+FBZ(5$/!^,R-\:AS(!(=\1->K7NE9"2GP'1F3$3VB*(&W[XM(PSB;(
M.!T0%A*UHMT,QU;8MC):R3H&]9&IVE9/%X1M<9*WY2JN-(J\W]-@-'()=(35
MLICY'CAED-<51%.4 ]) )8Y4!S1!9X)HT8,V-$-%F%F%G'AACK"&$6%:77#.
M>?6BUIKU(-$A>XFA*5M@ L@4BMZ!HE!D&>YBQR$1.()84V=HII#""1&F$"N%
M$EC#.-LX&?.6)!XBWXC4/ =&>Q[' K&)D)? WRDF<]@Q S_N(#FE*?"L 4D!
M4J1BV3SQ>\0Y$S607HR*&6D9T2.4#MY-?,C6L8QHA$;XC90T'0>5]=6F!&$-
M?,,/%-*Z *P*1TU5*KJZR:\=S7H"!8W!1^,T<+((F2M<CX) 8OM:HKYIX9AQ
M_,ZI"IBY?D*%B60K-%>)8?RU\CV(#NUK"'-CG:]7(Z0.<<I@4\S)3(DL#(GA
MAJT8^>RB5""P8?Y-E"UEE7.:0DD?0(C()&O(?'\1BE^,RL;*-83'+9CN@&F2
M6=&A6ED<(Q612N1@>C%9]N0D1[&N4.HQ$K5B="YB(V 6<4F"Q4-BPP/6NJY(
M"RQWS!.CE1PP1Q7DX-_E5VC5B=%)T#C(C'13>;86(/\ /&K%)*KAAV4LOGY*
MP:)]A4C4MF[R?%&LAF7-<D\7S5\JIT"&%TH,DL<TBR(Z4D9T1<<<RO;(U;:P
MK3JX%K&S,2)SB3@151AC$;;53VS-DB4'""9A$$+V/DF;++ CHY25L9&$6L,C
M8)1_.-@5D39A,5&2JJ!ZBO;\;DBL(^@\2%DD0:>)(5?$X(@,L:U,1DG9TE97
M%0V9<:JY&^3A*\TAO=G=:FV8K5CDZ!/$3]HCWO1@CAHG23BP+9 1"0U#5CC^
M)7,<53#4UB]K6/[J=E#W]I/FJI45 =/S/^5LPSGOFC($(^\"E4@A%C;:6PKJ
ML1ZQH:-W:9:54#OP5MM4.5%<SH&R<5Z/:R.)"W32N$=&YBV2EEVGC/(R2.1T
M8EQ86X,:N\D7[+5BQHYOPV4/U!8(2Y_QKW6<9KF$_)&7-,]LALKJVN>)8V';
MYBE1KAJVQF[(3'YU5JULC62*'=X\S88YXE&^&-%(B/8AE<+!'GYGP#MD1RN-
MI0J2RD1C)'>1N6.>C)DFKG_0$;DGC(E;*D".;'- 7#."\;N*! EK<0DUX<KY
M8XH"&(2?7C_S 9>UO3N="LL2!W'DCE<U)D=)]TV)D4SXX+.5Y=F*XVP@6&%&
MB6A=K6,20F.+P!U(G^8%6(^-[5!*4 R)B21J^6,N0.<4B Z.:6*6R<X&LGBM
M3'?;EP64**, 80UK#HD6KM4;,V.7H/& Q1FP1.<U&PCJ\29YDM;&-&(<@,+T
M*F^<RLKZPU70"D3HI% 8JAF)*#(Q_0+R(8I&RPN'&5(X#XDCG'G$@C0)\1ID
M4M6&[[T<($N1"+$"!?N*F;M95CG#O<SH&Y\9'\U&L=\[)WP*Z1@UF]\MJ(TZ
M:"08.1@EM+;AJV4B.!R#:,)J%"_#91/8H+@2_E5D3VDJV=L$R2P&Q&RNF,C<
M(#+&>2R**R=:BQN'$+E:D5O B@6#8RF,>H>4S?**0D:-BR(@79L)<P@DPX4S
M@ZXH8PB)Y5>H)#OMQ3"6O(HR.X)J/$>UR D%F4<<<>2"%!X7SPHCH) 60OJI
MGS3B'!PJ\ZMBJC'K,;# YY% 4Y#@?D!D>QH.JQS%3O'FB9*Z7Y&SP3,$*^Y>
M?']\=$X$)K1""C1FK,:#!V@NAVML:YT93'LZ!$]Y$2M*@621L[XB&NBEAL)7
M&64#@AGCE$-:'9D684:1BD3HP:_$:X(Y(SHV/Z!P#L8I(9I?C8GV[!RHW16,
MX8_81Z5U6<(66.^4*(0I[QPRR4?-3SJZLLFN@<R1 ZD"P2Q,<US1D#^X8JND
M,!%'953++/ 1! W[VI@JCI%?-%"KS<T2[[L590)'-0$P\D;IY89QU_ES2B$#
M%13$RBOG&=9V\,=;7-2$Q9XV-*L:P=S66,*-MJER3M?%T#S"U2Y898Y(B92H
MQ9%D2PELE-?;0.8*]I4[(P;(FU#:Z&">1/L]*&Q1BTBL(F*H,LC$B68I)17!
MJHQ#2(3SATA'C\JH*9AY\;GBCP$N^TKSR6J^OE\ZJU:X=T<B JAF6L1&2QCJ
M/ TAS6R06-<,./531.?!*C9)#*ZJ .<BHK54W*G.^1OS5LOY0G_@\.>/2VTO
MB2^!@1$/F0!#]Q5V1!,!IE>8]LWE1&R_<-EG'A\ZVR61#15;\KV]!;*#_AM_
M#_"W\/HG?M]4:B_7Q1?PZ#VZ Z Z Z Z Z Z Z#%=NG?&:]/Q[Y?0)V1/X+4
M%_1>WU[+T'SI<(U[]%A>(./++CH0RHA]=Z,8;@UXSJJR_3X!K/1MY,,V?DU6
M5L]LG=09)%5S9%\E1O9$#4WHZS+;'VPXAQ>^M3,[Q>TRET7(=K6:P'/!<*$
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M(A <$D]G2 U![VR2PL[FYHUWW0BRUTCV]!X13.;*1#+'-W22=AP$@(+W1O\
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M'0'0'0'0'0'0<+_#_;_?_8J_P_'Z]!7;V 5/L<R^0=9XF'D*KT@'8^ F5@\
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M%(I44<!#E@!-(19:R3RKK%KAW->@('QH!)%%)\#8_%T:/E@)#%:*"0TN:&:
M5[BZT.L-5LD\,7D7G"G(0+\@,CD0'=KXB/E;-%\Z.2P:7!. \IS9Y/$BSCE#
M$D\94/8B%% P*L!C.UE5O2=KF= A+%D1[)&2$3K(4QZ2=Q2ICWDC(T<J M_@
M!86-F''XME=XAZ@-%&(2,]B+T'0,AC)(^Q+/RH)/!/!\K&R1C->&(0PXV1TT
M2L)<HP1I7\P1_>LM&NB6.3H%ZQ,E$1%CA:Q8H4G:P5P$<<0<\CGHL3)5/J(J
MPEW=6QJIN9,7Y8ED D7L#:]) 42%!E5TL9 C8IJZ)5D67L2: :"$]8_C<R%2
M3@8%[/3M;5+O/Y85!Z27[CR=$V:19I)GR,CBJK.=Q9@J-9,V-[VUUT5=5[4:
MZ3\H6L#_ "JD-E']0\)HRY9(I(36)(K19X3&S KXLB:\.OF996*.7Q:BO$ -
M(;Y,=Y5-NU46.3H$K'K$Q$^W@CBB^UBE;),E1$+  >Z1DC(VND.IAZ8N3^4]
M4<7EBG>,GRULR*@.?9TZ/A(1KFR?>LEBD$9$U[8YONC&.!%19HBX)%2>PKHE
M=\*O;;5+E:CF= AGBE0ES^[Y%(^X=)'-^GV$YY=B"K919&0HRMN;"S%A59$:
MY@>K$[2M^&TB1%#V#(1.RMEEG:4X#XHX3HOF1(Q?LJHF*V+C1DADC(W"5MB2
MUOWD?>LMT;*D3U#UF&A;]NYI,*,1H?Z?*/+/5LB' +[M'DE?'*;4C4QO>-CY
M/(O,FN\)?DKY?H#0]C8OFBD=V?$V:,H"<-6QL:AZ6-B[[ )4>%"$JH04*,JR
M5\J_JM6YT#I(D!T21)4? 3%,0R1YST7[<>P<LMO"DA@98L?@#;FV=:GS&#P]
M@],)_FA%B.C<SH$9H_Q(QS?*>!KX)8IF3-+E;(0&@%>^"T-C:PJ"UA[C5QY3
M$B/'\JJV\9V1R]!U&(G'G:/*B#P#_;NBD@^<"&)E<Y8!/@--[FU@5,9*L0Q4
MR.)HBE40M) 9(W] H='(L9$;EC@[M?&YC@Y88F#P2J380$BAN<?  .3(A)X$
M#ONJB?M8UJN'<YG0(91RFI CWJTN5L[?C=$.>0]]BGS3PF!BO8#<.M@V?*1!
M$Z."^@C::"L9\;V*"\,R65)FN>OR++!*V2"9AI#9BQ_M!9XRR48)9S6$#%C$
M)F:V"Z&1P)Z,-B:]03FA3_!&^#XAWQL1\K8)Y0H)(@95:,6,5-YG!*%*GQ!%
MRH^>C(50#6O#>UZ FAF\%CB(GC=&Z*6)KYA2 ?MF!3L*,#G"&E6:N8 2Y)B8
M(7*31E*A@2R!2/:@.;H73?=H_P#FS*IL+X)Z]D[2WDJP@F&8"&5("2"X4;.:
M% OPVL+4L:Y6$M>Q0;GM</,PJ!\DZ3DQR->R4>RF60P=8(Y4(*1@EF3:"-^"
M*67Q$TP3/LS/BL(VO4' $U[QXO#[-)8W SR1BN;'"Z,15%K3(+ N3[H.$<A5
M%".):L]5(GZ79,<.YDG0>I ;?%DL;((9HQ46.1P:5T:0BS?-)$4.*Z4BHAK3
MG*Y\,2N,SI3D(%60&1S>@1PS21QS,(&D9XH;&<#^GAOE9*5(PJQ\ZP.1$G4B
M#L185HSOC,C[6E4])6R1]!8C@QK7Z2\?YRO=+6PD2K]Y7$1$?-..V$^=L#5>
M<\H>-J16PRI%:0M;]TQA44G<+7C?2%J>+F=NZ>#U17IV<[\>W]O\$_@G0>_0
M'0'0'0'0'0'0'08QLV^62U;4:JN=F[QJ(GT[N6I+3MW3M]53LG?H/F@]1DS/
M&'K-P;RFE]B"J02_DQ.G%O*>6GKB]+K"[00>CN#5A'+@I@Y'I]Z5$V:*7Z)W
M1R]^@E;1WU*E/16?(Y-CQ]Q[R52:CC2RS7%>QEHZWB*G#MCH:*\J*/N\BP#M
M"5C+GF3PB(AE1)')XKT&-U&AXQN;2+.TMGN1M)RIO<K@M)2 6MEQQ75^3Q]?
M##4[W,0Q+)#:W%G'"XRP,\F/GB5/S*DR=!,0-_<\D:8/A[5VO'^+/N-EK+C.
MWE9FR#KS69KC;],GH3.0K](B*FX/V-=%\C4BD^1/A<WOYL=T#9ZZYROH-5NY
MJB._CK-'[(>F]R"S3!$UMO*VON=I5'>587%!^FC0FQ.;"SQ171M15[K]>@^@
M7H#H#H#H-&$%G/19WU+,9J:7*U\/(/O.^[(MA&FS'U?ZGMY)!L\-)V:S20S*
MR45Z.1Z2-[)W[]N@JKN]A=9WA@&*F-SQ%#N\Y?UI>0WF=(%YKL+D.(^UNK>_
ML%@BT@9A(Y,!%<.,CD5&>7QM_P 2A2#U7]8/8;]Q:XVFWX\W57Q;A<L9@ZT:
M[IM3:24\F<(<3-L^-"Z@ F+0LV)$$4$YLQZ(,]SFM:B]E7H,:XFO^3/7?V+T
M/"VHGR]IR?Q'>:73/_2],7<E<?502TIKJ[DR[+9&+<415,4TQ2$A?,.\GX&N
M<]B)T&TK0V)-;4[JVFWNTO+#5>O/)U5NN=LHR$'&U>HT=+/?9RG(RTTS";.P
M%JAW01$(.DBHR-1^[47L&]G@QSEX:X<\I73+_I3Q^JSO8K'3N7)U"K*]KOS,
M=(J]^R_Q54_'H):Z Z Z Z Z Z Z Z#A?X?[?[%_Z/P_W]!6CV-8Y*S,/B3_
M ##[ H0=6@N(FG<7!&R2O%D>]M8=,? CF.K#O""TA1\4;V$_ O05A@G'D:PB
M%ODQ4B*[PF2K\3HT=75)X5G8(SLD4GF-7VA3>T*=ZFU:J?')T'E+!#\*+X?"
MV!(D&F?&360-%K)%<K)?)ZV%/!3V#U56=E,S!C_-ORUTG0)8Y/@:\<H9ZM^"
M<8L0@9[T\D>VR*9/45\JI\K/'[H\ 1W=S>UM6*O\R- =Y&N.>UKV,*D<DR1S
MI'%:*6ZS&;Y1/>YS1; RS$1'?&[Q#TX:=V+'8,Z!@DB<.L;U'7R@6"46=#(U
M2-RH^MJ'I:&KX/&>Y[AJZS):Y%:JU5LU%\).@4CSQ1.^- VC11101.B^ T&&
M&.N,G1CFR/DDL*X.J.7NU51Q6:+=XR?)7S(J!W*%\H'M^&2-S8R!VQOK?":-
MRDH;9P3UP,KDA:QZM)-"'<KH7*VTK'*WS9T">%Y$7RQSQ+*XB4IDD+8!;65Y
M%A$CYD@@9X"VY%P"/\DS&^ ND'19Q_BL(G-4'98UF=\C40A9OC+'*%E!<^9S
MQ&! DCGF/0<N0R#O !83]H;&-%J[-J3(Q_0-3HX@_C4=?@B8T9\SH6K7Q,BJ
MT1K"8)9U4RE%IC5^*"1[7'9DIWVQ22UTGD@>T<T$$3F'/^/QCF@?]^,Z**.-
MLJ6%@ ;6!))*&.%,_P"<T$=ZRU$[DLZQ[Q'/8@.4[&&-2+SG?+(DT#FSP G%
M?=6$7R&0$QQHP6Y)O*U$?) Q6AZ$5&EAN8:Q44&][U@D559+(V.9)8(HBAS)
M%G-$DK@B8[ AOVUG):C,>,,9,B#WD#5J[%L9C(Y%!R'('>UJ$*BM'^&<<QA)
M-9$+'5O^T&;%8D1O*KZX4IWP!%3I]YFC'?8'M>&]CU!*9$L2>#X(VN8Q6%@S
M03!CQP0F)8V,<H0D?SAP5Y2M),%@7YJ>=?U&M5XKWQH"=4>CI_/Y%=+,9X.0
M-]HYDEFC3;&,D&O5(+>:Q#8DQ0\#D&NX&I85BL,CDC4'7NEDR2-?GD+=)\[)
M1GM)+(FL E&#+#+G:RO./+"18827^(>E"\P3$C/8B] TS1.B?$U"5'GC^ H2
M<22P''^UK!_L0R@3C6NGIXA"540<HIJD4DKEJ[-KPY8Y4!7&X9J00S0Q)]JC
M8G#?9&@"-@JYFO*8T""5UC6!4!TB2E0L\R\R:YI0JR5\BH@=2!($?/VB,GE\
M9AY!9*[YWS%V,[#+&*<0.9@TY\@;4)/!&58;J)&V5:K2FN:H-T<J]OGA81,Z
M2?Y_\LC"Y2"3V/@')#)G^$6W,MP8G,8YR,%T@S7"D)%91-50>1Y8IDDDC(5K
MU9 4U8IW0QSP,:\"M*ALSO\ "X$GS% .)1)09'+66K5C<QZ@Q$B#@C>3&I )
M"C&1S?$17_I3ZB922H9QHY'V=4!3V3_ED@C5Y.7*=]Q LM?,K4!3'(UZLBF$
M?$1\9<1 Y@K)G3OF2(ZSAF! F= :LK.Q1@8B^)+/&TK%1Z21]!Z3L;.\CQBG
MD2>7Y7M\!3YU)L1_")4;+XB64]Q7M[-\O$/2B-\)%C/C^H-C/$.<8P95[+('
M(CH"/R30M8\"J,'LCW)\?\UZB@GDM[([RJ;5/K'+T#N#*-]FDK7-C'BA%\>X
MY-;% VM+(26.5DCI;2G$I["9'N1$<7EBU[_S:^9.P)C1/#RD6/Y8I(C!S090
M8E5J.)0P]KZT.3M\3_C:66$,Y'*OC;53O^)'T"X8E97/9)YDOFE-2.?[>OL)
MS)+*!CD')_/&)9V%N#'_  1HFI#:CF+&?&J*"B>%LCT>D3D:CHBAI!7"?/'(
MV%H 4P9IG?Y&RO:HH1Y#?A(C\JJU:BHR3H&B/N*T>">-HJP.A<LHZRUP445*
M0_[<L5TJ3'TL-+83K$DOYC,J6]8I4FJY45H.89(KH'"V,:11QMG9*DPB1-'_
M )ZV%S&H S%=!&-)VGM*<=RS#/5MK5.=#Y,0$Y@4KGR.?#-.7-(1(]R*'8,M
M5L8421(XX$:%<EW%="USX45HFG':DD*Q6,2]P![!L!*RC_*L2/@)'DB+<67"
M61"VN!+&L26(TLLYBN%$,(3X+&%KJJS1I#8WJ#C_ "BVS/1(&M9&))&L<]A7
M,F'I9',&L #)8U.JA:X[^7 1+_GLN>JC$)(!(B] S.@CB8D)D;6P_$\16SBF
MA^4+25L[04D.M\IQ%JBGH857C+\]?*Y+2J>\9TL2 I'G<JL&E;-.42IH<ZDU
M;;%Y\EJ/]X9 2$'(E?8G'UL;92!H'('H1>QH"QFQR,4%1PZ/@>56QDJY9/E6
M1)9IV3DD M"K6K9%)]J:24&U8 +"5%&N!VK6V*-):Q_0-S'R"RH4(L4;A_MG
M^,2%UT2B5S4!A(2<]%)J&5I+U'&*F12Z$E?L#VR R,E0%[6130M:D3/CBB05
M\9 ,X4$4-<0TLVN.!'F4NL"K"7I.6(QREY\I&'@N>'(YO0,I S!.T+1REB(<
MX7[>2O:49]S9R?>%#E#BSQB61)PT;B"QQE0/0C,:> K#HWM4%;)?D8SZOG(>
MK9H)62Q'2FRV [H!Y6$SI&+8368C5A&GF\(+X=K@BVQG1M<H>KFP(_R8CHX&
MLAG;)%+]F@C T4.M-%/,5THL(9:O@$-G19ZJ975]DUP[F/Z!M1D@,CUCC2%8
M!VQ12/;*#&+'6DM)F@G%'?(77A51:MD*%9YDYLEZ&B+*!(YB [MD^8>:-HG\
MM\ID$P\@,1$T<A/B<8R6J'E4>QEGC1A1P8COBL(/"SK5;*Q\?0)2A96SN<R!
M2E+\)5;%*+8R%$F0*/#)!)+\8EI9V C7,BGE\0](*U1B/ Z-KE!,).QL8[H8
M&-1DX,HI([EBC6$=L@-=,EB6B* \1R.@$,*:YX4G>KM$6)S).@<WM@<Q5=!%
M!&R 5DOS#3UX\0M<6^>2-S(GOL:X.G.>DLD;/(S,&.;-$LE?*J(#=\9,$\B2
M1>7T/A2,L&#M*A$S";4(^K#7PF<YC&%E "KX&(UMO4N;*DL:@[QRL)9+*Q'S
M^4I9"0_&"<6Z6UACBC=$:Y& 69-T)^9LCD0+5!-^-R1V,2JH>$\;(4=-$Y(Y
MHGL<,1#*UK48P=0PBAK,QKI'+(]WV@!Q/TB_-4V[?!8Y.@3Q210RJ]TCXVCP
MB121RR&58XK*?M)*^-L3)S:6+/G/\&.[N+RASU:[YJR1'(#FR44J%\2I\S))
M"X9AW5SG1EJQ\1]X)+3#L8L)2,;&5;5@CO+RC;;U"JU7,Z!#/ Y9E[?(0\J4
MCQF18[7[];6.-J#HL:1"6IUW70M1ZJC!-9!'V:L-E"O</44]B?F8Q[X'.CDC
M@BFG>\E'HM:"6/9%L;XDR(U1J\\A%:2C75-JC96L>H*I8(88TD9(R""-HS!2
M/E-"'9'4R/6.22=(GF4X=)82^$;E\S,P8Y8I6R5\GT!G="D;'?,(U/&"88P'
M].+:][6*MQ:#RUM?(L@R1RO0LVO$7Y0Y');5+G#K+%T"\,E\KVQD13RN*<?"
MGR5Z&DOFLQG3S02LA<T&YFN 6]R(FJ@6I#3[@58SV.9T"2<9!V.F:V1@TC_N
MHY&.D*EC<2.@%9(AIK_@*')3N, ?,G@8/_V5:-;,D<G0> B(&U(YW(UJ((YA
M3UDK5@97/^S#G4DMR%TX]6<_X!99T4F@+=]F8D@4C'] KG"">R*&8?X/^&-)
M"M1/ D(HI,9EG!/5C$(5&&'(Y)SP8G?<5)+FV=:KAU>WH&R5ORSO_D$H]4(B
M2(@2&QE?+;1M)+'GC&E:):/N@V(3*/"[[71#HI8;HK&-[%!P%+2=(&ND(9(R
M5BQ2MEA-EA*+A46I)$MB42 YMD.CH S9O\M;C(M?8(PMC7=!P4)#\SRH^RRL
M46=6(7'7#S"5WD,+*&<2CWU[*HQ5A',E3[BCF<H)K9!)&N0&\4F'X)X9H%2&
M%DD$4Q LH8X< 1*%EC$0CO4RI@I3%20J!GD113JTX)T@+WM0'F1$D3XU&D?-
M,X^$B&04<A"Y#(VDGPRAB*@UF26 U"C0!E2"Z@:EC7N:4QS.@:YX'0SME@6:
M=LDHTD#HG!EE(48.\<*9AI"1"VA5F*U81RID:+HAF*"<V,Z-C^@=@2H9)()6
M3,A2-*U[/MIFQQ_; NE!"-&.*1KA( #%= *80U9Z:?O6V*/'<Q_0!0T4L:OB
M6,7X(VL1\D$X4;(P#D)(&FCA1UE505IW:>2&-'$YTMR%#+)7R.;T$W\!?<IH
M[B)RRQ?"%+]V/)7@1-&LB[*(B>1"!N[:4LYKVRD00>59;*]IHO@LTK$"WHJJ
MZ)OE_B1$1W=$14=_Y351JJWZ*O\ #Z= IZ Z Z Z Z Z Z Z#%-QW3&[!4=X
M*F6OU1R?XFK^DE]G_1%7\JI]/Q^O0?.]Q3-?6W&W!H(N]S16GJ_6/+0IH];E
M@R^$8K@6UL]!+##%-!]A)R0F=8U)(GQI),L/U3LOET&L_G'>\A<X\WU?%F/K
M<Q)M>:+C'_<EU%I-DI=-F%LEH):; 06IC*(8HEPDEA9QBK*BP1>,*>7X!D/M
MCZA^PG[>X7&?)?)/*>,Y%RAEOH:&PM--J]#'6)',EI)EN,J:IL9)["*U%S,"
MO;9QSL1DT+8FM<KFIT%VN(.1M%O.'SLUHC+N"GQ&,(HL)P!5$L$Y1T5ELB67
M6;)?HID@@IS21[=&@RNG^=XCU8B?(Q_<+=8#1NTW)6ALB-=<7JC\F_M_5I%)
M>-'G-P=G6KMP[7,S6(CGCW!?ZC&YQ<R*YZD([R7OT&\?H#H#H#H-%D5 [54'
MJ3GUQ;MH(5RC[Q//24R :3.US++9=M,,]W860D4E&QP0/^CY7M[JU?J@5LW6
M0UFZXGAK:VL/%@XYJ3=5I.5]H56+S\?</(FS\N=$#(M)BP)F9FP^3Y&0O;]E
M'^>61JM1 U^^N_L#[9>A-EO<YP'2Y_DK&Z"KSQE;5RX!TXI-P5.(3:[';2!%
M4.K?LJ7/#S"1U[)$'+8GS,=V^G0(^*<GRY[&\X77+/)&J=+I-]J]F)7%Z;-&
MF-KJ Z:>R6@Y"N*7_LH"MKBZ^"OH62/D^V%?'\KGROZ#:%>U1MG7ZF[*K.&=
M-J<;ZY\M5 FDSNG#_P!(JJP!K"*O+9W3E,/:);:]]>V=B3R0*Y97>,R>?9>@
MWM<'ME;P[P\DS8V3-XKP+98X?I"R5,I4)*D?XHL;7(J-[?3MT$L= = = = =
M = = =!P[\/]Z?[?]W;H*Y^PT:3U>>'='%.DIQCYAU^Z(FF 'AAG/62EB<R+
M2U@T#/E+":YIR1L^X$7YX&HH5-8D\94+)(W3'RI!'"@<,5C(6VSCD42-ID[W
MU=N9>5$*-CGE\ =6$U()O@M(&N<"D>?Y1F.B1'?*T8IC896))%W62K!-K[.Q
M17PQQ.:X:ML"F?) _P JFW;V6*3H."Q'.;#]88?A':@LB0+6#N@KYD5%>B22
M6%0!4'?^A\CLQ8.[HDM=)V0$R.<-,0/,SNQ'GQFP2"*US98AVG6T$];62JBR
M*UJ$V-:,JJYRMMZARM22- 6I$A43V?-(203*Q(I'(&>29-9A?,UDS%<VKM["
MYJV=G>+F@ZD-G=%BL8NR@UN^2.2":,M'(GVA QD)C?-C7^=?6.2V/B\GQ>*O
M%K;(AB=U5U3;-7\DB!S#.D$#V/<(,D'C(L'B360#LKS/BC<QLKGV=,'3D2=F
MO=Y&9HZ3PD^2NE1>@]CA8W1JR3X(TA8:Q[)Q9U7Q9,TPX,FO <CX60/5"K*M
M&=\@CFLM:MRL^1G0)8R5@(4>9CB'RND;+!(/!93S3VT*NDEC''B@!LY+8.+R
MDBC5@>J#:LX_QV<3V*#FUS)%@EBD21K)@R!9_N(R?)"AW TTPMJ4SX9Y)T22
M &R+_EGQ(ZJM&MF2.50;5C?$LDK60I%#]G)(Y%*KF0CUDTT$$\)A#7EU0X%C
M*L<#W(\O,%*HQ"35TS7("V(B>.2.&8=L+&PE-?*9"4-#". [[VR#,J!8WD A
M F(R<L,973TI"MM*YSPWR,0%DD<I37M;$_[O^; UJ016DS2+>-AIP4X(SF!7
M!ED$QI!$4+OL],$W[L)T9T2HH-KWO:BNB?(B?<_(OP&-,ED+,5M=7SB''Q-%
MLW68T+H SB?&"Z&\JFS^,V..10=H2X^T4<L[(XXFH1%-!+8@C"AUQ#1 F.,+
MCDM*FMKK*1(0R9?(K,DN4$]'AO8Y 3DB^$LC94^'X8Y(2A5B,&@9!72J<8^8
M !9#*\2N)>V8D(5SB:8ER65:KA7R1H"*-))',:]8IHW_ "0-9-7DFSLD-&:?
M8PE!!RQ@G264,;23A8'-AO!V-LJIS3(Y(E!X1'VC(XYE=*>J".AE&<XF8L^U
M#6$(P"Y)<T*SL[JM5T0A<[$ U <;@#DB/C:O0,Z,;&1Y^$+9X6C/$*"4H-LH
MM?+^G5AP9UAY2UPU<0Y1@YYO,BB)<^OM6O"EBD:"L25J12_/#%"X=A$3XR0"
M:V%T%68GR/>-#/(93@U9CVNF&9W.S1?8L7Y*^7Z!R2&9(Q8WCPN5\A,14$E1
M]U,47*[]2N(C:X(A8CC)16MFL:X9&P74*-LZM[2HWL4$:Q%03L3M)*I'V\KX
MXD%L'N?<#NA&F@E*[#V%A:AQ+%%+.C0M0&Q1B4ALX6JH.4,[9H!IHHX?+Q$F
M9/!+_E9&CR_85<XED;W(#5%:X8 TM'RUI#75=JUT*L>H,Y@L@DD'PM0<03Y/
M#Y!7"PUPX,WR2P2P"?*4!6UAC_(EC%4S,'+]S!\E?(K4#W@D(D<7#*L/S-:5
M"6V<=KXY5EB;86$,]>%([Y_E'1I!P8Z^)+?&UJG>:21] /CDDC;,CWR_++"B
M-^0,\YQ%K KXUB[,^PMS+0!BHG?L%J 41C_BL6(J@W,=)!,I<'PR*[]/*[P%
M(C9O@?\ I]=.);&M\OY2N<-6V)#4=$_RJ+AOC\4B \C&0O@@9#%%$-'%(C4;
M =6PC-KSE8UD\"HIE6'2G2*CFN7[[,&.[I\M=(G8$)X+8$)["1OB7[J P*<,
MA61,5[3K..4 !'3Q>#D:38 #*KD7QMJI>WR1] N&-DE5&=WS?>/F2&1P[#I2
MB#@D1PY2-:@=R=8U[%_*QS =:$WSB^*QB5.@[SCP>#7-F5&NF"+"(A)D<0/(
MHTE91FB6I;58Y9'1N% L3$1KV=ZBV9W6.1 ;&NECF\9W0L2* 8N.1'ET[%'J
M'K&R0>26)Q%##4G/[-^3Y#<D:[XY%EK)T\0=("7S1K7&1M^-&S1KY SBP0?;
M+%8V#GU(SGEQ0-E5"K.J'?W%?XVU4]T+G,0/26$I"G-<Z0@TF.=DGR1,/99_
MJ34FF5C(/"NM#+42)'R1-<T34!M26%8K.'Z@D&*)9 V> A_QSS1$Q3B&S3DA
M$ES.KJTP"R,:@AD\[(WCAV!GC!8P^51:,86V*107RLBC&A7YQXTB;$5VA(L0
M@7@UY+Q!BQ296OLZ,*HLW.;!*J2&Y,UZCDI(!)] 9YH'11O!F9$Z-KI&.:37
MG,:Y*]/U,V*6K F>96/"GE;,:"*Y90)?&WJU<,Z6+H' *8A250R-L\T[2?"2
M05MBM@\P!#3X2A I65QQIHL;9BQ!T:-?AM0\!6',DC4.[Q'GSLL(B/DD5XI*
MOC(?(^0RP#^UK5BL+%6BV=F4!WAK+,A&AW0?G6V36E-9(@-37Q0RR%B(QC1H
M8%?%''/51+$$:H(4C#3^Y-.E27+\(TY+7%YHAR@V*2@2LE0'1$@E'16+$UD3
M21Y1RZD@2,8>O+0@\*Q!@G<77!U);VS%!"JI=(4[]1KW/"D<Q 9R1'#22MDC
M62-9IQY(% C.,F/*C0ZPB(##F6&S)+#8V<L6%&P: 9&V->Z,V-\:@J&FFDD:
M[R5\LKH)(I6O!LI"G6H[AA9(23$C%L3[42/XAB)D:'?!L<&8D=A&UW0>[O-P
M\CTDCA'1T$S982&AL&:*YX=<6/:&M4D$,29/@ -G:L]21WKK-KQ5:] :I8I
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MLH'MC[-WT0X$7W(QCZW5;-_VUX%V<V>B?!.KIE<YK(WM:]>_BB*$T<;)D>.
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M(B(B+P8_S2T^=)QX))7(L$9=@.H 34B(88WL5950KO$E6MMJIR2M>SH&KN3
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M5Z_LE@TEXD<DTL!%9 >0Y+.(WY9)IHVCE&12M22SD-A1J#6XR-4^*-(S&H3
MYRA<.%55C5=Y(OBWNCT1')]$^CD15_,G\?JO0>W0'0'0'0'0'0'0'08MM?\
MZD-;^*?_  ,7R=T1.Z?]E%*GU7^Q>_0?*;^W7P]1X;A[@HBXO;FLK;!NO/'V
M%[2=QJ1MA=W5VME?6:?+-*5,6](HV.8B$C11PIW^G0;#ZCD^UB=A*CB.@X]Y
M$T.$SFVL^-M%4W[^+<3RARH\PY]Q9UN%'E' MR0!E<V&21DDA9;7,16JG;H&
MYF\Y-'RE[0'9;-ZJJO>1<D?AK2UU%MQ_)R%R7,)#8;+''J"8TXVOS9KV10S>
M;6$S1L8K?YG= 9N43\]S W1$5NDU&WW<G, OZSBJG,J&SC\BCB"K=#11W7Q!
MMV=-F(9)_*:5TDXSY>R*OBBJ$4^G'&S>-=?SA"2':#6VI]N_3"^M9K<IIMD:
M1)-JPQU(=$D< L(X8\4;(6)YPM:B/553OT'TF= = = =!H5LZJGL\OZ>U-F?
MLZ]9N9_<LJLL,&YC+U;JHT&PNAJHTA\4_P!O0W+1U&*?X*C$D;Y*B=!%6JY0
MK@3M)RIM[JSS_)9S<WR!FN/R\I"7QMC;_..L@LHL.M%:I=?H#QPT86T=7"N?
M)\J)_B:H:N-Q[0ZS7;W8"\99BTY!=/L<<->5W&<MQ1@5O*-^5/)6:JOJJ>J)
M.-I:E8)("RIHXPB/)Z?*J]E:$[>LWMI7:NTNJ[97-(T$[D,.?D_[=Y16K;#C
MEKJK/:/&:FPA2LU--3%E21R.BC4^ B*5'=U:Y5"\DQ4QG%6QS!N9WVGX\?A.
M9O8# 4%UI(Z[D\_0B5KPYX;:DC''AT>3MY9&D11NA;'!%*WXV.5BNZ#>KPA.
MXGA[A\A\:PNGXLP<[H5^BQ.ERU3(Z->_9W>)7>/;M].W02OT!T!T!T!T!T!T
M!T'"_@O^Q>@KG[!-1!\A+\;EF_4#QAIH1T0N*8L1D7@(82JU$\A#$5CJLUOP
M6\:N@:YLWQKT%5"VLK%@^W=!+&R,%S9 #HPQQHQYY1@9!K@Z-\H5<)),\82U
M(:Z:HD\JRT:\:2-Z!YP%H$H\,G:(1B_;1)))/6K7L!E?.])(612D5-?3FO\
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M5KU[6U6[M\D?0.\T<1;86/9*3-.LRQO5L%C(9-9#(V6)RL>RMMC;D!C7JQ?
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M9?O"PPW?$:SM:5;FO^2- ]I(TDDC=$Z>9LKVN7N@]C.PJP&6.*1KW.8':$7
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M<A3EG:D?RO:[Y1IHYHRD)+B0N)1@9X#2DC&L9#86K$&9,C1[<=' GHPQC7=
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MX:%S[ *EK;%6RSB1]SLJ=_FPU>%(K>@9'QH]>[A',,BG(BD@=6_.]KY!5,M
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MG1P'RV$#%&&+E[0WL#5K+!K"XV2*#D(3\T:,E56?"R,R$R,HJN8,\8EP=?\
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M\+U>:'&MK*LM;0:.DQ,5<R ^TIV1TIQL31_&281K!'N:JPM;%XHA)QFKY?\
M]N0;E$WB;A<RZQ@=>VMLM%=15(%3&3'7/ O;O[0JCN32"S2[HVL%:5.L?@PC
MY?@B:GT52-EYQ7%5ZW';?G'65%U:6..VFEY>T>\==\9[?/<<V91X.?IF\?@/
M*%"NRE1(@C'20$2MC:JL3R5%".LY5>OL&<O_ -1N:IVHS5!D>-Y,URG?WN?$
MPO!]X0XFBO\ XZVNB-OVZ*%Z(PI6R.3Y8U8Y.@S/EZ3:UM5K@L!7;6EXR_J#
M/XG'56B:$_)C8\2A@%@T/%J>2H8+I"BODFE)[F,>UTCOSKV0*S^C,VS,U?/L
M^L(&[$^YOIQ/0AQJ(18"4KY]7-.EO-7M:,XPVP=+*Q53YF0N:V1RO15Z#Z;>
M@.@.@.@^?S9Y6VU6$].&U&7GUYU+SM[<W_Z+!<@YR%( -=K7$W)91:MCE#H1
MD<3-#_ZU8SH$=L41'/KY<?9;^J]9:3455UM=,&]L^*Y*SK&I+R#1&/DD)MJX
MVCL ?(7XVJ/+ QZM58W/1 J[KO:O!Y*0K'.AXRM&B$&W..N]:ZMP5I+Q!H)H
M!+WC]\5?\9!P%P(&DL8;^ZE-;(C7,:K&J$B\<\O8OF=VG%RMPRAT&OW^:BX7
M%P\ M%94--G(14T^>R.ZAA& K::R69@T4,KW$0L>]RM^2150,XV.<I]GQARW
ME[Z@S]?S 3%O3N19=?N0#)!^)*6CG6OV]3:B*^GO[^G(>Z*>-)6_%(DC>WFC
MU4-\7"K8F\0\2-B>DL3>,<*V&5%;_-B3+U38Y/R?E\9&(B_3Z=_PZ"4N@.@.
M@.@.@.@.@.@X7^'^W_H7H*W>Q@_W%/FVH.Z57VKXVOBKOG)9YQ-\X0[&21H"
M$%1(YBUQJ*);Q*\;R;,Z%>@JT+--%) ]A$;RDB&)$.AGE!&>/"<HPW<\URDB
MQ!3N4<4\A/GJI%?56C70.CEZ#U+#81"07'\8SAHB6$BSCE!"AQA'?).U0H7_
M *F#5#G2^4\$3E+S12H6*KP9%;T#<Y)WN1$^+Y6.LPI(YP8".[2 VED!EQ!/
M8.:T]C4E*$'5&F,\;6L<TALD?0/ !3GIX(DD,KC(8IE8D5J2P@JG5K9HYY'J
M%=NN1F>#)7HT'4C)\,J1V,:] V2@L @86CV) Z&L(1PT[HH1XH2'15A45G9>
M9 =.*]ZP!'D(Z:KF5U5;(\96/:'F(1 $.V.5S8QD9-V7[6>N_28!+-9)8OLV
M/E/J :PR1LBQQJXS,$O^>%9:R7\H.E@)"3#/'.SR8Z6R6>-P#7>3U\"CX?TT
M)R.G8\?P*L*Z!WQD)VMJIR2(]G0(/Y\9*1N193'O>K$AD%L7D?=@(X=DDOA]
MC<DVP"HC97>(.K'3XWI#9P]U!2,6Y\:303,;Y(*3XPF-9) YC75X)X5O8QJZ
M)K6>8H%B2SR^BU=LWLK']!Y$#2/CA17P1.0=B#2QM*K!&1 %*[XO@3SL*P:F
M)[/5G=3LH8Y')\M=(J= G9+(.^6.5%5S4.^YA(B?"[RE_G6+90@T>Q958C23
M*X=?![D;:U3NWR1] Y.8PILL3IUF(FE<D4SI&6,A,AH+7-CFC:C*VZ+N@8_Y
MO@J":09OE'\9\?U!E5)(IXW1E.:G^4FA)A-=\D4DT30Z]Z69[%:^-8FN&K[&
M=B-E1755LGE\4G0=A9DC&<U9!H(H((5?#\EC7PC1AGHD/9\BNLJT.H(E[->_
MN9ERG>$GRU\C5Z#W,$8^.3NB0M8M@QWD(;&K7L(B,/"+#!=Y-B1?$BP '5'0
MO5+*K=X.>SH$T9*0$*-(/),]\Y+IH7-0Z=SCQ/D(G2")T0EC^JC(BRQ1*P?0
MCHDXZ1V$3FJ#HQ?K"^"3R<LX,@DR+(5\C2QI1J]X]F8OP$O(8BC!FEI\-E#W
MK;-&SM8_H&MXY,7E)\8S!XFBS2JW[ZM9#$%// +..9*^4RL'K#GNBAFD:\G-
MD.40I):Z1CD!8V;P?_-%D;&QEDQJEARA#Q1B+&0:&55CR/F'$%F1)RPH%=/2
MS.;9UCGB/>Q 6NA<0Y_>&1TT3YH%2(."P>YY\+"2@RJ\>9@MK-9#(V>9L#D&
MOQ4^[#6,YCD4&Z)CXG.:OFK$* 1%B?!822$DHZ" B,@I[1K%3XHU&'G(\8;L
M='5Y_@:R-Z@X02QO@@BG(CA6.,*:(B":84<0: R083S/*\SP*NN->D0I<R*3
MG2'+7V"/%>QW0>!0#XON6+''%,D5E 6#]O\ ;0Q#@NBE)^0(69QM6+7$.^<H
M4=SB*0CQLJU7"221] G;^:1B2.80V9UA' D@D91**17QEDP$!!/:&4^W3Q(+
M%@5(;J%J6-:YAC)8U!T8R.R=''(][S_F#;',R0<QY1,X;F0$@FE(T&T-MPT=
M!!/,B!Z49JAF)&;&CN@8V,9'/#(Q&LGC95R03B%J"QXXTLPX18YYR/E#BKI6
MN''+G1TE3*KJRU:\9\4B X!F+/%-"^.")8!IHY(7#%5L2"A'_<%H^&/S-IP:
MF=R.?"SO89<I4*%62OE[=!R5 0V"1$@9YR26B$"H!'/,25.R,LV FM'58C+&
M89J2'5XZMANX_&TK',*:YJ@E>LD)3T3^8LTC)'C,EAM)G?>"-BAECEF;&-8$
MV,#?B:^9&BZ,9OP$?%81(Y0<XB6S0C21-8Z1'!2))$8YL4K(?(,"<:U*C645
M[&JHP1Q#5<&_O5VC5C5C^@9BQI1%A2-K1@(VQM&;(PH*&NC@E[.'EC;\IM;7
M5IK565L:N/RICON(?DKI'-Z!5',4^4F.1&H0S[Z&=L[$=&2Z2)I9([P /I(D
MT+6DF CN^,O_ -VE4Y'))'T L;I$CD1\LOS$=WN;)%8E-DL D6)45[6@7!ED
M)&C6N7L)HQ&_&_XSXT50;H_N(GK/!XO>]:\G^49-$LKDD^S!-&/+16_+$U70
M!'$)]%[U=JWM\<G0.T1,3H1OAB'9"@T?BJ?JH40\8MBV-C9D=YG5@E.:_MW5
M5.S13^SODKI/H"(T)!6'.^T18W1V,!]:0(4U&,=,RPL()ZL"1TK&Q/<A)U>*
M[O&_M:5+D198U!>*6LDK89%GG4HB5L<LT#;&<R<FL14@(^&1H5G86HK/JL:M
M"U(K%<Q(["-44.TP;7#-6*25%?+72C21.?\ -!+)!()5F16)CEBE<]/(80XE
M$;.SO56;?+P?T#9\<C'JR98H7-&86D[6DU2?:@&M'1\$Y*R$4T503W\7/\SL
MP4J03_+6S(J [ME;.V0 R-$^-;%BMEK%%6)@\T9ABMJ R/N(X6/D0JSJ1GJ\
M%ZI:U3UA5R('4@4J.Q1J/=*5*KUF1!@[!+",J!RN?&QDK +4VW@\7R,C5@6D
M$;\L21V4?U!&'/*@P\BS)'$LP$H\XY4,I T\S)0PIPCC52 [YVM4<<TQJ1V4
M*+6636DMCD4%JPC.#;XD01OBA&G>L1,H0SAX3%AA,")G\CJ@:K->L<4SO,O-
MDN44M) )$7H&LL?PC+#F0>2)8SV-8X.0.!R"S0DSC2UP+W'U<H<J?.4&*]9J
M:566M8KQ'RQ("^ B2,I87QI+/.\]4DEB@L4L/N:]LIX<XU>YM:=960S$E)&@
M[": =GWU=X&QO9T'O,'*;-"<--Y+Y5LC9$DBF)E)E!<P:7[X]C1+ TN+N.!8
MD(P:Z@\JZQ:TEC'= R#2,A[2#210OC97H^)9Y@45HI$D RH<0U9ZJ:K*=\,$
MQ#7$44SE L/D"DCD0'A70$#J]B-\&"E031R"D5\4$<!CB+ (NO'\BJD2I*>V
M:4<=7&9TGL<$YX<BM0&DD5X[I?ROD'66Q9(/(,RQ-6P+9]X;"17C)]K9%'B1
MH02(/XC:")&V%<L9K'L4%<)$SY6(CG)(BQNCG=-"?]V\^!!1I4-)CB&LS+,5
MKH8")D:-?"HH9B1G1M<H<JCTC_+X)$Q17]X"B(E%9 YXH4\%@2GR #@/[PAE
M3M=+63.6OLD>.YCN@02-E!C:UZI$,D$D;?-"Z\9D$!'RE-=!"KC:P6K(5)IX
MHE<7FRO\T-\@$BM0'ALL<[W,F1%1)CQ9QIDD)E^1XD)A<31@/&$IAH:-).#B
M5([!B):5;FS(YG0-I8\GDYT,TA"RS0RM5CH2B3%LA/" H6>7XZ^SM#P>\4,\
MB('IAF_ 2D9\;7*'(A#TEA<TL?LK0)!"$++C8^.">04*2 XW\PJ ^2C"&3M5
MX<G>LM$=$K).@6-'CD@<Y&#=DBDCD8L5J!#! !8HYZ+&R3[^J&JRE1ST8KB\
MT6[Y8_D E5$!!X-K_D8Y/-[TLQ'*<%*0LRN:XTL*PK@WL83.2CXR#:\94;+W
M;:T[D>V2+H'F!8YT;X+*]296QSQ? RW,0T\!'12?29 +8JV":K5<SP U@C%:
M]([&-.X))8Y)5$D':,YZM">'-!\J(YBI]G6RPFFR(UC&N1XXE@8WS9]:JV:K
M5CDZ!(V9H\$C&#^+1V?SF0MGIH(D$L&-61A+W2FTPU,6OT>JJ7EBG>#UEK94
M5 >59'.CXGQ0JLJ6 \K)0HHWRM'=$4:TD$&5/B4.=S2;&LA5'L3_ +5J'JQ7
MLZ!&1#.DZ21I)+//+V>LP@11!#B Y&S1RQH]H5H;=#M8YS8_$+6"-\X_ALX5
M[AV!(1B->V1/AD_3W,^,J*4B65R/@ ,@LCV_$08QR_;@V1342>)JU%LU)D8]
M0]" T^ >1A(L<,4+)1C/-]<Z%HQJ0^,_S)][6)4V#G1L>Y%*RY+OCD22OD^@
M-A#$C0\>9K$:D5FA@)0LL$;FQ3M-)@( J5<4'!%,OW9@ KEF E5MI5.<.Z6-
M <(Y_D:H\OR3,(E)6)KAX+621Q8*2%Q$@P(T"QEO!$^0@6-6A:85GW0BQGQJ
MWH$18+&)%^=DP\CZ^6,EMA]RL3R!)!:XAEF4S[>Q87 BC@V134A.C:M5:(D[
M8I>@\H2W0?%!X-AAB97?%/\ (2&@\ T[V0^!A".-KOL)E^,<F;S)ST[E#-\P
MI6/Z!=)#(OW#NPT+VP%P=W E0I!%"8TVRA6N$7Y0PQYNTY@$'D34DJEC7*\=
MSV=!.7KXPB*^OW$#SIV%E1\KF!D?SYBH'^<Y$2,= 98,7Y%)#3],NHO$EJ1S
M_,WH+@P]OC;V_#Q;V[*O;\/P3R_-V1/[>@]>@.@.@.@.@.@^?+]\#E;FGB6]
M]=[KA3D:_P",[4^CY2!TUYQYIN-LMRY/FV$8J>03C\WEEX6 (.0MK'NBMRHJ
M]7(Q9&N[(J27)MQ$UJL![;938<Q\ >I-96U-_IUT''M7;Z7D?=\B^N%9NLFA
MF)Q\LVHGQ.U)'XNY*Y7O'%RL6:M/ASE:2^<AS317P!STBD3+8CQV5G[#UDQ)
M>7,.,RY/!=!)0'VKZ.:R(I'8(1*XNRES =?FICI O!TSJV"$![U51V,A\&H8
MG-H8]>:2]X\]>/7UU%B-A#R[6K4VU1FLU?A6>I*XOT-K:!V/*PDRS(#6RS*6
MU!!C6N1OAW9^=O;HCQY$Y9SG#4\9FWNG<@[W/%7 /L!6<@YL,PK29#0'D.I:
MJPL2OC2MM@Z(IGQPC-573Q_+$]O=>@C3(>V'']_>YG-238(M]IN!=-JM)F)(
M-S/HN**JO>X"DV(DP9=JU*"GB; R$/Z!S2N\OI&Q4"TV?2K'?0:_DJVO=CZW
MZZ^Y Y$AT5QN18P\56A2#/X\&HL5\Y%I05F.O:^80B=L;^ZN8YZ=WHG09AQ3
MECLGL] AXF>!M-)SUZ6:4^JR-M#=4 %?96>N_IHH.QB:R=TEE3L:2L<K$=VD
M[K]>Z]!O>Z Z Z Z#0A;G453B_4:[MJ.]T#*CE+WC(K1*>8A!VVDUEMPV2Z%
MHZQ3DYM&S.0MK7,[1=U^O;LH5;Y'7]-XHQ]D&6;5:2R#N\9:W/'^EF.]?:@<
M .UO1!:6T5K:UH-RZ:40J<B*562(D;&_XNX0I^UYZ-\;^^XO*G+7L-><AVP0
M6HP!%?CYXVT!2:>@$F/-MJO3023$7W'E@.6/ RLCBB&'>Q5[N<[Z!70_$VOK
MC[<<N<)Y3>Z*YQN?/UNPCUAQ>:/K-?8C251TC^/ \Q.2%FM<'.K*DM9F0) \
M7Y)D\G*BAL\U:U]  =AZ[#I^@6/K3OP5XFT]3:G[_<A:S-FZ.RWJ;<=8Q1Z\
M,R+\T+&)V61[(F/:[RZ#?EP8UC.&^'&,C^-K.*./F,8G?M&QN2J$;&BN[/<C
M4^GU3O\ 3H);Z Z Z Z Z Z Z Z#AR=^W\?K_P!"]!7;V 7O6T$2(V199;"-
MT#&E3$3P+$.V:)*SNVOT('=6J6"Y[#'P(LP:_-"B*%420V?<+(U%F5LXY<S
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MOMB72SUD<8XI[I&(R5(YK"G'IS7]EF<CB\L8KF2I+72_0&E6_&KEG'^-6*7
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M;<5*L*CEC4'4&PD?'\CTG>2V<=K&S6,5I- 3:I(*"3$04.VNMIKD!KT@G>C
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M=8L@;Y&H#C-_F99%?'(A2?J'=DL0MI-+/:BLD.%L !6H'9$6P,3)I!H5:#J
MFH8&L1\:] VJ\CM-X22(]SXI))8SQS)ED*!:%6DBGF11CV:GC+]N"82C8KZ)
MCJJT1I<<<B@X#&-=# DLT([8E%^R(85-#"*+7.:./X6)D"&558 >YT8ID[7%
M9TQS@#D>%(QR!Y$PRPR2M15&;"DPLX[F$AQ)! 4AY[&C!(A5=#7E2H0? .LD
M]'.K;&M5XCY(^@2LD(>](IG?/$^>0=LDDSBB'363)CK04D"O9&VW?8!1).4
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MQ)8$,)+B::2)**-*T.P)/%;]R8*.^,:^%:VQKU8=&]B@J&)666-[4=++(L!
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M/$@7XE=(Z.18)5DA/$?#XHBQ+^I6(L@0/DDB-14+.KQ7><#^UK4/[++'T"H
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M0)51 ;VH4!*GRHOEYRQ.83 LKE:]/U.P *JZ[^7*00CFE'ABJGFB):U#D?\
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M-Q KDD;-$\F=LY [45'QDR&O,&5@<\!\R(%965D&GA'(OB+I!6*,4D9T;7*
M&0K'M\"$3RB$G&F'EE9\D4+Y !"(BR466.2,M5&"-*3S"?WK+-KHECDZ!P=
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MOI^&:RRL.-LM2ZKB#E7DFHY0YI]F^?\ UWXRNZ>IAPKW<89LC@G7YL;8\E[
M+0QGB?J"G/KZX&>40(_Y)HV&K:I*3C?0F\4>D,.&H]\174?JS1Y<3A*7V#L/
M7CF(22/*\0FT%YH[/--H)=,N!BH7A7P[&1)7G&1DCBR2(V-HKC-?%>O*YG2X
M/UWH,?J[F+0:W(\-5^>T=_#+//!<:&BQC +6SB(+@%*)B-L!WRI-+''+*CD<
M]K7*J(9G&:M#'%]87;\2<,8,;&\7Z#1)Z[9+DDK@J%7U>3DU4.C.,EY*M+8>
M4<4RYEH6I++'\SI6.\E8O=/'HB@'LMS9K>0.0B.,<#D-7'I-=;Y. 3)YJT?K
M*O"Y@VTASQQV1H'0QV-M+9VSG2N?*C'5\#%>]5:B]P;^8.*_=7T_N.,MM[#U
M5K<TWW&E;)H<[H\I55E!2 2657EQH]57#UA$_*Q5)&I[A4'6*05CVR/\T1>@
MO]Q3R ;O.)B-@]]3GLSQEE-+'7\B!9X6U]BM%<2R)8TY5/6(V2^/>^EMH@WL
M5$'F&D;+VD:K4:%KL=;'77(5A9SF9XVN,Y%_;[,JTK:N&B/!D+EVK[R74T@\
M<$==K;"[^22:/P:C5D_#Z=!NYZ Z Z Z#0M:5=7H<GZ@TMK6:@T>TY2]XAA)
M\]%*7)1V45GMB8KVW':L3RZ4%L"NEB\D1R=F]E[^*A6[DBENMWQE0V^>!O=9
MI<:(=LMESC+4%5N K0CV38N<<#!5XX84QJ@FQJ^":-%<D?RLB:YJ.4*4>FON
MEMOVRX^3, _B3.\AY"_%H]>$M-H;UA6VU!I%4''LAKN.'04V9SU70+.XZO\
MM5-0AG?Q_*[H,+QD?)7L[[0;CG8JNX]J-#S'I.0,D)^E.CQAW)V.<*I#1+.N
M*$CD%LJ+/TB5[2Y7I^KRIYN1K4^-P;6]3E+!:S35)O&FFSYU;Z[\I77^B]1?
MLDRNF.QN<GILWH;XX9\X(^B_2)9IF,^1K9'-1L*QHG90WH\'*Y>&N'/)CH7?
MZ5\?^<+F]EC=_252JQK]55'1KW1?JOX=!+/0'0'0'0'0'0'0'0<+^"_WHO\
MXEZ"M_L7-"E/2Q2O<D;IC2"&I-.Z% AF#/G).K!VH876B/<R20H-R'U;T85$
MUS&2IT&E;VJ]%8_8SDRUY(=K:8$N?A[+<6#9[2X"WUPC;?,<WU?.D.R^;)\A
M8*WAUY7V+6"/H3:DTIJI;U1\9['CJ;MNI%/-Z7'ICI]?Z23>HNIYTM]=LC;R
MCT@7,NJSDVQD_6JKEBLY8R-4^HO-K^O:3.C-S\%%63V&AEL+^IB42S-2TC:]
M1J^K51$O(?[7%1RQ7ZBKW/*BCU6V]B/;GGO5R8_'$Y^98O;'@,O@J>DHSKC9
M6B506'*+<8)9'Q$/&)8VG/@A&>A*B+Z91C2/<D;BOT4CXIX']F.'R-EF"M3[
M)XZ]Q-YO:S ZZGKQ*P7BB/BJG.TE)O.6N4=/=$8H-K2SAOU:*2EEDC?6-;4,
M:QHFZMT3TAA%Q^V!D='R#PEK2-N#(-A.(_6+A7?930X73V-?K@?5"V?K\B;C
MZ+)<OY/,9S1WIDKRBQ+,/4 %C,BN:+X[&*3S+&Y-)]<^\O#_ &[=O4\8Y[AD
M#V%J9<#P]M\!R1ZZUSN$,C:WV9V&)YKM.:LI?\FZ:RVCF<R#67W[Z*) '9<#
M3 HOW;8+V.&=A-<5K3&<WG@OVYZ.IY'*Y+V/)O\ 45QNL7[G57*Q=3E/Z%$O
MM'[JWV%CTFDXVM2-+<$\49_&4.'925D1J6)PUE/)%<$?SG22#7-*1Y>Y*OJM
MZ:ZOU]W=MR%KN9JODJ</UNX-]6J*DK^,BN+*[/<>>N5WJ)\Y<7P,&PV15GH)
M(-)&V\45@;\W8QM,KX$K7_$A+KJX>:L+/VG:A_'.$XVM>:;Z.3C;UOTG!U<:
M!B8'RS;"7VIRWMW1;BUR<VKM*_0UE3H<L)#99A)YQ]14OFM "VD?(.TU]S&M
M.ORHRK6_M@0\T7/(>LYGYV/O-ES>+[,IS ;QMAX\Q2$W'LGPMQ!P[FR^-J@S
M8Z(8*LR&9X;"*&ELC;9O(4A! YDXI;?B41N4RC*C$M_^UCM.1-=>\N[CV(H[
MKEVPTN$U53857&.VPO#]=59_@"T]<):\G+9KG&@VD]5;9@P><>X?I!)::W&=
M46@\M65\;1%\1A3!<GU ]4J+U*O.7K&@O:JSI>26\ P @#9<S,"XBL]>^(<]
MQ2#4.9^M:(X"HB)HG'I#"D<N+();\;C*]SIW&;KM2L%M^U87<X;1<5'>P-A)
MQQ0\6^YG&OK[5)Q2 W9X&7W6LGWG(UMRI?#:HV+F>RQC7R*)45PE&APDC+J-
MY9L:.0U]RDUB,</<V>T($M'49^BF)(/*H*>IK6&0MA*CMO"H%HQI86O>\"R.
MT@@+DAE>K0=4&BP3+%:P-53C91!)"O:9O\R.+[5_<(I[81I!TD JBPCK&*)T
M44$JN' /):U\#T=46S53XW]!XR0C>">3&L;#&QD!#F'5HD8]?,Y[VR2)W.J8
M:NS=Y*U&O+RAB^;?DKY?H"6-[H63"2C]D>PF*88@0E44E[DL#HIJ:O<O=\"K
M]U85X;U56N2WJ7?5\70.LG<^5B]FD/D6=(ITC_5GERV0K&NAD[MC$/+LQF>3
M6.\ M8!V5/CL&(O0,,D3QW,\XE;]O(#,+.A/FV)8_D!J)(K0[S9]J^21T%;9
ME,5K4\JFW8G\N3H%,$C&/\$$6!D,$$2M^VL0HXHJ\Y[FN:YR*76AUI[N[>R.
M*S)B^,GR5TB.0.9Q&NB=XP.C3X38$C?3SQN8C2T*LH"ZX.9)6MBD=]S8!#/\
MQG>-I5*K%>SH$\*D1.FC(9)(^64YDH_V\%K*XBQ'665@\#G0B6Y5P$/\LS&^
M(>H$:X@?X;*-S' Y+ DSHYHV_.Z912A2Q%&?\SE$0.O('LCI70%2EP-^WK+&
M=/B.B1:JU1)D8_H&Y\(P?QO'B<*WP&?+X,<#%"P%[8V%03SDJ74"TQ3DBBD?
MW,S13E&);)72([H%#70Q0N:2]J11-/A>EF(HD$4?W,19X9M<$^0@,425R$'B
M0.6>FE<VSK'/$>]J O*A85Y12+--,KIQ6LG'KSIGDGP(0:(2V%S1[<J_KV><
MHK58%I@T:6(^,YBHH(NZ03Q.^.69&D5\XT;"03I'SSA2 B$0'DJH]JZP@8HH
M)TOB-=Q-6KM&QELCDZ!P%FBFC8PE[.P\(,L)L1#ZX<> "9T(OC:$L>165@)2
MH.,60GW>9L.]>:CPWL>H(C1T8CVS#(V7XBHC02!T$':/$4P\Z)@HZ(17C!$.
M0@\<?^?3D*VQKE>*^2/H/%[E19T=%V=YW"M\0X+-8Y[!(BK"(NIK^T-H39#-
M;*0% J07HS4M*Q6%QRQ= \J_]1\VJU\AR%PRMEBF%,*F<2 D()(I9$;:ZU/*
M#\H13)$:%J!?, ]L9S$Z!CE:^%(6.G;!-&M=.-+ 20&*T<!)A!C CS62ST\0
M!C_MQS2V_<T4SUJ[)L@4L<B N&>,^.&*5(FO@B;&HS13:X*.$(O[DSN$/Y'5
M(=,8Y)"8H_(S,F/:6*Y]?*J('<@:&1Y:NA)E[M+AE$6O2:::>PEC).AE"#?&
M.18RB,0D^N$<D%Q"UMK6N0IKF*#;%-XN:2/\TSYBGDH\5S#Y")R8D#%(#*GB
MA#OC;4!BQPRN\!=0(QXA;8K.)JJ#O"Z$CR>R?ZOB%G8Z(F4>.4>%7!UQ0]@>
MU'PJ(2]1@#R$^YKYU6JM6K$K'] Q$ACU\2N[)"-&U(XWJ.=6NJ&@2?<$0D#Q
M.?8T]?56;DDD@C1Q.6)?]U Z6NE5J JCE:Y[(IA_$E(C(YARQGR?=)-X&FBS
M 5SOB.65$0LL,1RH5'XVU8OFDD?0=YV?*^=\,,\KE(DFE\61V4_WE@'\3>RR
M.8';DW 3$1JJD8&J#7P<L5C&G<&UJ?9RBEC,5Z-973(X<MSH9AXF3"TY@MF>
M]'0.CFD>+6V)+>\;E=46[?%8IN@=@WB-#>[RBBAB9"UOF#85\0[*\]_S,D8K
MY+*FKZJP?W<SLI>7-7R_/7RIT"8T!T7RO2)CX9HCHC09ZYJM>U26&V+"  I4
M\6JUC2S0A7(]%1MM5._XD2@M%G^=RQ.60E)9SF-E00*RG,D/$B>H\S?DB"M+
M2V!C[HWLT+5@-21BQV$2IT'M,,D\C9E@<J=Q2HYA'CME@5!FB"$"61\B/6.2
M1/MZZRG;\4[4=4VS6]F2= SM9]O%$/-#]DX=H[DD9"^O&;#4G-? 5 CW3V%$
M'4'3+'\C5<?EC7K%*D]3*BM!W'(AE'E&.B<UJ*>KUD&'3X/(M"+-L@ ;OY+1
MY52>VIQW(\17-M:ISH7.:@>)0<OT5T#YRVSE$2^,=:>EE^H!.;.]C&.:'<&7
M ,2*^/NT/3BM^6!8;*)44/(6RBCG:Z!KEC8H9,#QBHR2H"'A.#K#!3RHNQ<M
ME]1@C9N\%NU'5-JV,F..107_ !,,B>JQ@M^*$/XU9.57#_#6$K\9M>;(S[ZI
M#K#%^.*:1/U#*V'D*2DE?(CD!I(8V-JM-A1(YHCX')*.X)7,<:RRL12Q@4=*
M)/73N0PP ;^962*VTJ7/&?)%T"R"=ROD@)7YB99+0=_W->RSE.?:P1S3P%B
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M0?;#3,EGB8-8S6 K71#22]H-$,QP9:1GQM7H/1T8WDQS&.2%B"R,:/+,*@C
ME4:M)#/)_FA0!F><(=@1_/IYU?6V;5'>QR @<R0.17+$V)L<?Q1ND0NK@@C
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M(:1Q1+^9@EN?;@QHB-<C!-4-'W3XK.'ZA[B&QHL2^#I1U>%(R 8M)Y)6_ X
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M1ELD;'YH6DFK8UOK=QSH(*+D#GCC_CF])A#.&S6MY$Q&5O%KGLF'I2*L*^N
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MO7Y[-YG":756_#>4V>ZT&7XKMA=9@]WJK&4^0RD&OM#]_H+,*G%D^Y.&AF;
MYSORQN^O08K1<A&5>9WM0+Q=J?U)NFQ-V_:<4OSH!&[K[F".[?Q=7G6M5%]I
M98]RL4P:"*2"-8I.R]W(G0,W.?Z7LX]IL!]M@U-V7(N:%(IL=#-+L J\<(*K
M&SO+(@ZEQ1%T/SR?*]K&1]T;YL1CNRA"OI'@[/$:KGIEN9;DGZ3W%]--"L5M
M!(&*)#([3B104U;\DD@->L(J/1?I]P]RRJB>?0?3!T!T!T!T&A"ZK@+3&>H
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M*:C3.:20$S%96WH:#17G]315+\L.RINM56C202FL*64Z'QC<CE5!2:5Z,/\
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M /FLU/4\FBX:3(DYW1:$Z(<2]^Y2C*?.Q\9CHY&O4NF5O^C(Z Z Z Z Z Z
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M=V]FM^B_AT$L] = = = = = = = = = = = = = = = = = = = = = = =
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M879^^OK+4Y/<;+=:]^;XYR]X9G;+16N.WYHL(0V!QFYMC=Q1QXMUMQT*RIW
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MW._7&K+Y69"FUF X8#L;/9SVN-TV3MK&NK^"])STKL'F-33U5]L;%<QFY8I
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M7D5;EL9HK@MH^/Y")M]M=TXAXWZE\BW#X_LI"X1)8#,3,848?2^OM?Q3R)Q
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M&/X8-U4-74<FV&+NK+9ZB[L)=1")9W#FUX#)*V"3]-89-//(6ZZ>L9MI',?
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MVN_J#>SZM>/>'O9U?7J]S3C4%@IW['9UT\5T&>D3 :<B-X$PQS7M.8--OFQ
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M6(J"-D\8\$<;7(QC6H*RS<;"X@,\:T$QV5%LPKN\TP=B-GJB \31Z8>832:
M8R(-I$%WH!")(CBV.2<N-[FRN>BJBDK+$+#@/@JVT5YK[7A;B:SUFFC)ATFH
ML..<>;HM!";2D9LR*\NB::2RMHR\Z7*!*V>61) I7P.[Q.5JEK)?K.&>'][
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M_P!.R?7HRYZ Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z
MZ Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z
MZ Z Z Z Z Z Z Z Z Z Z Z#6S[,\'<W;/DO=6&&"WYX&[PF4H,1=8_D3C['
M8C!:X*+6T5[=<P9?3 RW^RI/TG1Q2(E>->2G5_W-:X8:.19)S43%&R;HR.@.
M@UU^X?"NDY"VX-V&'3ZNML.,3L734=M[$;K@9F!US[BR,@Y'E@Q[)H]I4D0V
M4,)<;VN+#_3HD'CF0F7XC5LTA6/]P*C'-EX)XGV=WB=L)G>)5)TN,Y X\P%U
M4\[7:VV4S  %EH]7R3Q]HX<<&T&TO]2$&?#3"TP;R+N2<=T A!JWK,(+_=KQ
MN YEXB]1C7:;)5)MQEZV3*<,DY;D>DY-U&6V$6!&MKCAS"\9<\\571.LXY!,
M'EDS-6597$8LC_M96,&D=(+)I,MX?KQ6Z.FX X,I]C23YG757#W&5;J<X5:V
M5Z5G]&#BJ06\I";RYM;ZXN9ZJSBE@>66<:20Z-9)9YGN=(XQ.<LYVDBQ8_62
M-15='FKY[4[=T5[*DES4[=OKW[?A]>B/G#XNST*>O/"F*@XUV@M$1QCD><R^
M+<KLE@Y5*Y/_ *JL8TU4Y$LTI5-0?I4/W,#($C9'#,JO16(O04O]J_:&Q?83
M8G)GZX0$[49@+#9BRJV/?Q^1H;"$,O5Z.UII95-+GU,B0#SQ,>L\CT\T3ZN0
M(L/U?L_Z_P"XXQO.;^+-3Q<VXLM/H)&Y? E1SA+GY#J,#E.Z@+.M,Y9_K%B[
M[F0&61#7,(6>)J?F[!LVX_Y#;ML<SF#.AUU1=<3XG7%Z7VDM#+EN5)T5A+^G
M*$F;>5")>06.>6& QD4'FI,,:>36_50L9Q^( W9SAT><S%!EV\G^A%[G&XHN
M4VCM_P"I"=E<7VE8/-(^2MC.N'O\&.[>+%1O;Z=^@WB] = = =!H0NQ*^RQO
MJ3266EM\G-<<E>\HE58U<9*#&6"6NSG;47;!F3S0T)P[7(1)XN;\?DBM[*BH
M%5>4$CFXDPN;SSZJ;54D%YIK7"81\H?KEE<C<1DY8R(PETA9*AOL"87SLA[L
M^Z5'?([MXM""_P!NGWCS?[<5'R9QGSEQ]R4>"<N9O@;F"WSMA=%7EG^GUE-F
M<1G[*:N<1AIZLF6Q=9R6"C0?X'(CU[=!!46@W?L_[>\M\_97C.T!$W=[M\?X
MTNA=IZPH%U>/ #I./ZJVLGS5U_%DJ5773:]D;("U[#S.15=T&S75B4I^>TDA
MO^H5)20>O7)M]<\>7]!"9RCHK'$9\BA6YH[)K)+D#,&N+4J<23LOT\I&2KW<
M@;\N#'([AKAM4:YJ+Q3Q\J(].SV^62J51KE3LB.1/Q3MV[]!+?0'0'0'0'0'
M0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'
M0'0'0'0'0'08]J=508J@NM/IK%E;2Y^EM]!:$?"29/%4T-?/:6Q(]<!"596#
MPP!GR+$/#+,Y$[-:YRHBAK,Y+_<XP]3JZJBP-:RZRPV\]7A]IOW3P&5C/7WW
M)J;7/\+^SW'<X,Q5?IN.P>:/LL_=+/\ &H2-(E>C6_ Z0NF:>G3HI=_JC^Y'
MS%BDL&5>KH]HG$G$95Y25$296FJO9SU)]ZUQGL5EZY\S@VCYSV+X5:MD$)+*
M\0VI%<V%59YJ]CT6=%<_\)C#\";?>M'OA:P^R@F;V=ND>OPON[B>*2UY!^W)
M$7F?W0X^Y'X@N!Y%LD?52T'!R70XDRJR2MBA:(U6*]C%J1=;A7R^"2]KL?>+
MAS;<D\F0A;K2\>T_-/NY[!+E*4R:\30<2\5^NF.XM]3^$*H -YI G^L/*94N
ME97CL9.Z8.6:5&.61'"-,X1GA"4N(OW#>2\]J\]PWS;E!=AM(-YP)ZMOTN<B
M%HB=][)-X77FGW/VL$2O@SE)PKZWY4H=3"XXE1;" D3Y/D= U(M.L99_DV<<
M/<X\7<\XG+<A\6ZL+2Y7;43]5E#$9/7E7N3_ %4VG#UE?5V,0MG/F+@H![P#
MTB^U-@<R6%[XWM<IG+!+/0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0
M'0'0'0'0'0'0'0'0'0'0'0'0'0:9?>)L\7L?6YT[;Z"E%Y$R&!90/I=+D*:Y
MSFDJ[C99K+2ARW/L1Q<M5EA-)J_ZAA0JLC;:[&FJ(D*.A&D!B-VY-S71@= =
M!IR_<IKV;3>87-1<;U6T*QF>I]+ 65QMP?L42XWUIMLE05&F-Y:W>4MR\<X+
M/VQ/Z=3. 5MK$(42:^&)0IY+DLPBI_\ 8J^XJ?A_6BA%G]IH[.NXZXPMLY8\
M.3WD5@N"UQ&>QXF<U[<WR#BZL70<B/\ "M4J%270?S?JV!?S5(K$S6BCG[K/
M(?'C>&?0FKY@FS_L*#M<%+:U'#N\YVU/K73<T:FSXVSN:M^0^1-V#P]K?Z>Q
M(.0VEJEL^YUF8@B_5_C8/9FO@BB2U96LTP][Z"^'H:P?B3BV"EKLW3T\''.(
MAJ:C&WA.GR%7619FL8!7972F!5I>AS8(K61 G2C#R%BM9*Z-CGJU#CG,][=4
M3':]57Z?TM?]U_@B-J2U[+V5%1WU54_NZ(^<S@TC-T7&W$^R-V93\PGK=5Z2
M#6UK7-YN+F(=9Y5,2""7(U_]&#F^4C)7/6-K(_J[ZHU0UF;:/=< ^P7&OL07
MD-):5?$)U+7_ */5Z(2B+U1TVCL;.OAYEN+*N*!%I+44Q7RS-C8Q)H&-1$[I
MT%G/W(_W!<%[^Y+C[@[@S :ZY>)R+HQK:X70.S5Z!HZ;.",KKG,+57485IQX
M*5<3QV1-BHZ_'$B0QJY_;H)6X(KS:WB^T-O*?;8XD[(41F9Y%DJHYN'LO-@:
M@(4\BXSK8)J*[ TRH,C8&0JXJ)6R2,G3Q1 N+Q;755%NM&)73VYA5CRI^W[<
M7-S;#3!5UR?HW[6U()R@K%:T?/=B6H/&Q5@C;^5K6(WQZ#>UT!T!T!T&A'1[
M]_'N ]5[ .ZJLG;7W*?N+EZ/3WH@EK!0E66MU*SEK6'MFA/0@2)\2L:BO<R3
MQ3MT""_ M)"M9)PP%R#H>&K4?'XK387.9JF%S5-8_J*2\C:F]=- ^XJLX$R%
M3!'"2D1Q3)XHQ)%5>@K'K?7CBNZO-O/GK?%U\1^N2DX:H"1*CDMVQPU2 1/J
M3PXWP7MF.T$2&>:9SHHHAYI?!.SXWIT&88/C+ <:+.)Q4'G.5=!?U@EOZR:>
MDT,,VE)L[>R%@TL!84HG;--KAS2A939WQM@E1&NC6.1.P9GR_?6G%7#WL367
MNPY2J^4@Z@ZZ@V>AF U.FS.(OJESXN,QKI6B2%U-@28C"4"C22!DB,5943LT
M-\7"K_EXAXBF5K46;B_"/_*BHU//*U4BHWNUO9.[E_@B]!*G0'0'0'0'0'0'
M0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'
M0'0'0'01-S7S7QSZ_P"!.Y(Y5U=3A\<#84U.7J]']]!EJ2PT=F-1TA>KN PS
M(<SG'W!T$15F7\0(39$?/+&WZ]#&<(S:-[W1^T/N9RT7$*ZUX6TW$&NHM! !
M<I56&A]+/:3C>D,GI;"(T#]!$]F/07WJX?/-"4\7YRHW%2]V03.DAJS7TVQ6
M<:^^/SAQ_K7Z(^HQ6PXZXPR_^HVVX7KN61),H2(<M7FN'&<Q8+E;V>X#XCUU
MM1+4\@Q^MHVM;KP,6R(\BN &008F%62LBN"3%]V,Y3Z1^*.[WV3]U^9;:/><
M*56RY>I..MOHN.,-/ZS7=,+ZZ<T<DX/G@LBVN>5MO(+M"&<8[CUGOLTE80^P
M9G0;T?1#D&16 XB-E9739&$Y^?IXI7]P>-O;:[Y?Y<AX-Y7GK>*=-P[LN4,T
MP'G*JRFJR_LWE>-+CU_$XZHZL[2U9-7QU'7;BLY L7H^&KK]+1,?.C"3(?.X
MLVS92-48U]V:$[WG?WO]=.6>;^0MGC_8N[X8"U&GW\[-A74&CQ><XCXDKN5.
M2MCC>/R 9;JD',TF(P%%29_6!3U 9$6P;^J5;KVK))DF+419=$1A5-@7L?P'
M[ W&@]=O;F#A;+<I;?\ 5N!<AKO7/D6WV6:TV=YOX6AYSYOQ63Y6=05-GBC\
M]QSDA1M[;HL0+A3ZN1"QWV,8\-S9FV;?JMK3,FW/'G+GJSR"WFSBV32<@9C;
MZ;&6\]+PI753>0>80<JTG'^D_P"W=Z_TD*VF>X8]7<%0.ETN\V!L\ A\<Q9#
MGLA*+;"6)U83A/I6?7Y-MGJ?[-T'LABK$H:US%[L,!;QX#E&\XW;?67#,O+=
M170$<@Y+B;?WH84/)E5Q_<2OK#[(%)!XSH)(7JR>.:&*$Q25K.B#H#H#H#H#
MH#H#H#H#H#H#H#H#H#H#H#H#H#H#H#H#H#H#H#H#H#H#H#H#H#H#H-,ONSHF
MY[V0(P&>U5%<&\_\79W+<B<-0<[8'C2^-R$UI>Y$SDG42;?BC4A9;(4^:N;$
M(!9KADMK:2/6G"=:#N>XW;E7P;FD^GT_LZ,#H#H-77N]M3LIRMEPK+56F;H+
MSBK2/S1F5YRQO"=A1[VCAUUC7W^O2]MJNRWU=/;K35U)7$0V><'>9;3V8W;X
M5<;MR/'LGQMSMK:GA2XXNIM5=Z^KR.2=RIH>*+CU[SU%<T%075VKZC$B<T9'
M026&IET;I#\^WY*6HKQ(YYY3$*046<1,=3MREP#[.<J\8\?<.Y?F79^M_P#3
MG!6:K]+LN,B..),5L=\%#EP+7C^]SP&3H>7<QFW#59D;+/#ZG(DP %O:+/"2
MT>2 D3$8YXKT<>T1>6P.'S)XU6$=G,AFJ(P.C,N;&D$+J*4*O(&I[#1S$:$Z
MK@F'5H\Q\CS)84:Z=SI%<JF9*-DB?TEJ_)/)BYJ]\D[(BJGZ65W1%7^*HB]!
M\['!FZI.0O7+B:RK=7)7<J35N;QW#1V0S>?G,R]'5GF0Z'$&6[QI*FSL3?LI
M"H&%IX122)Y+Y(G0>?)F$$Y(?7C\GTUAB^02^3;(+>%\BV517:9W%N>%8F=U
MUQ0NG%KIXB)'2$%-:Q'R0M[,[/5.@BFJ]<^-:J9][3ZCCO2DX\D:2MSEJ$SC
MFMUG!-@YTW]5!F15+8M!7,-'>U\WB3/%"]OFU$8JN"UE?4R5C,YIXLYR'5^L
ME!M8[G*8VBN(),1R#BC@Y@XA+3+Q*.>UU;<"I-Y/5@[HV1O1CH51B Z<.:@O
M2<C\IQ/U5QK8*'V9],Z()]L" -'F:H:WV+!\I4K7RNK5KJ+X_A8L'T7Q7R[N
M5>@WT= = = =!\P_MY7ZJVX2]'1<B52P/D]K/9N.[FLA!GE_H+]3M8SX*)Q\
M,\$%J^1[&^:IW\//Q_-VZ"RG"X.M!S><O-@;L7X+.<AKI-O?9S35\06-I:<,
MDC]%U$9,9BZ',6DYB12@=U)=*K4:J(OT!!:<@\,D9ZJ_1<<%>W[I-SS?CCJ+
MCBQX\APO$M6/*)H:NID>="87H+D&1[WANE?Y32J[XVJ].@S:NT7$VBJK_#\5
M9BK>FVXFK:KA#'SYJ;C$^MJ+=T)FP4_E0I'&5^T-_P P^1CFQ?<M8UZN1')T
M&NG]P'-[Z?C;E_,Y3?CUA='DX\J,8,6;9666''KT>,4?4"JY]C80B5,PXL\J
MJ/.QZ.[=E3H/IWX*1[.&.&V/<Z56\3\>HZ16(Q5>F2J$5ZL:U/#S5._;Z(G]
MG02YT!T!T!T!T!T!T!T!T!T!T!T!T!T!T!T!T!T!T!T!T!T!T!T!T!T!T!T!
MT!T!T!T!T!T!T!T!T!T!T'5SD:USE_!K5<O^Q$[K_P W0?/CR9RCL_=3V3-S
M_$-_'#58&RM./3KO/!6A-OQD/=U[!]WZW_N5^AG,AN>L-WP5R[^ES+1[:AC9
M,'-/&X91X_,HLUA;%9]/5+$O9WF"CXMSO#/I+ZUX_E2RX;Y7QW('&."Y#]3M
M;Q7SUI*JYQI6CH^3?6R#C_F(?05=[E^.,5?OLC 7:NCMJ:G&=" Z- )(NJEL
M5F;[L_/XL#FX:QG&N\R.D.K<CHO='BWA_AX_FZ]N+]N)]6>)+WCKC#EO(^IW
MNY[-":F#*;G2$VM901T5OF\[HK5]99%)\HQ3PP[%8M9F/^G_  K"*.</8OB:
MQGY:XXU!6^]JY@.)>5CLGDLSN&<6^F]Y5\E<1\7<F#<(<<9;A VFL>5L;:CY
M"X(XVM["Q39/NXK6OA1S8#"H"VVSGE\>J6=CA;<:QHJ?E#]NKU[FL^3:FVN=
MMG*;A#=<H.YT7V-YZ%R//E%'R9E-+HLEP+HH>#./LON-7%H+"^%L#?C$C)FC
M!EG<3SBZ<//P1=EO8;C/.T'+VSY:DY5_;DY(+NBC<<)Q;JM!L=/O]=[619GD
M;2Z>7U%Y(+W-1L=#E>&\+0ED7Y0#,_FQ[2V%A%KC@RA^BS$S2(^J/R\V?\Y\
M$<;[G68C#<C<>\*YNWJO9#,X#*[SU]L'X7U^Y,L#N2N::H'T3Y%QE!'J>0.+
M-A><7[ G3\DV(E)4U&OEB'#<7\$@SH21=,16/#K\5RM7^X#Q@SVD(]0[W$VU
M9@[QFDXEM;@^NMZ"S)M8,Q?7^GT5E5P?HM/Q1ZR9+CW*6\<FKNSJ\C0EL\LX
M&56AD6*UF+)TZHG'T]Z">5J6?TIYYX\Y*S]W09[$%P5G'_%-D7FS.0;'!\<.
M)CG&]./VX?13A>+RM=_KJ>L@EUO(=\CY&0$,E>LX[4'%-1.J*3GZ8S+Z#,5I
MUV64H=-)17>6)N:H"P.RFG96PZ?+FF"0E$9[2BU%E<5P=]4NF^(J&(J=D<K5
M1'N3LJQEE/0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'0'
M0'0'0'0'0'0:A/>F5,KS;6\GCZJRXQK\)Q.?;[2[I.+N2^:[#D0<"VCM\]0?
MT69@3N J":A%J+46&XMKIA8ZWKII8QHQ()GF[<J-O?1@= =!K!][Z]T&H"O;
M/D[59?+NXET<%OGZ'!>Q6GF;'G#3]5!^D7?"4HM71P;72BTT6B<:0+:/J**,
M<*>*(PQRF[4:>SHMYR:GJA!AS-P3I\YQ0+R?><D8FPS>1]BG9:_QD^<#JZ;:
M7_(.,R3KO8'ED6\=*YMZ*?<T+))QFCP>4Q;<*U-_LY08_FKF#UC4/@SE3W)K
MK/U-V^RS^4AY,S'$U:VAM-1PM]KR;J;>\WW&XQ^UM(#X1F"P!/2.,LE_^71$
MC>(PB>F+;AA@65>)Q]9'G9LA'79;/@QY,BQ@N)\NP2I$';G9[<8L\:TFI&Q_
M;.)CGF9.Z)7MD>CD<IQR-K_]1^M[.\57,WR(J_5$5*DM>ZHO\$[]_P"_H/E%
M_;8RG*S^+N#FVEE3'V)DM^8'5U!]:/6W5N#?WQ%2)54XT0SX#F4R1^,KV+-&
M4KG2JL:M3H-DI&LXSP8^;=R:+H3[CC_([+8\SYW?8Z#D[DBQJ+DTY];ABMN'
M#$%-7HZ;S2-(99!(D8CG]D3H(XI=3PQG*+:5UCCTRFPS4F/!LI9<*?R36UG"
MF@;%<4F2P<,5D0#%/,(4U; ;Y8I49+(US?!CDZ#)>;:R\($V&WS455QWFMYL
M\IE<Y(/L)6CWV!@I(:BHAKJ.-6MX_F:\YS"Z]D;?F^)K&.^O?H*\^BX>FKM%
MSO)I= ^ZFL?<+TY+IPE'+?!15*D:D>*K@,(5)RB)B(I"9'?2".214C[L1O0?
M3-T!T!T!T&A#3Y@O3XWU #K)<=#;5?-7M_?C-Y!+FAIE$J-)KC;68201KB'7
MPE<U\HC6HJ]V]E3MWZ#";Y*.YM+?E+.5<$/"F>O .0LU0TVI8)IME55"^.T'
MM.-7$0?KE+HS*U\HLZ,5[UA:[LBIV4*:\G>Z]9Q_::#'2ZDBGJW;$+D:C%W=
M18;"TI)[Y(HQ^/"YP T_1!-'6AM2*-?&%?B\'M57N7H)7XMYYH_8L794FG99
MS_ZN\N4<PQ]BI-7C:"QQ$->]]44]BI<8Q;V:6'YPV,A8X96,:Y8E[*$SW)%/
M:<,\JX70Z# 5UO6TG).WT7)M)5W-GD]AQA3ULPD>:J]21&TRKN<X2QX\3B8W
M.F^-4;^16]!O=X4DBDXAXB? JK _B_"O@555>\+\O5.A[JOU\OB5.ZK^/02I
MT!T!T!T!T!T!T!T!T!T!T!T!T!T!T!T!T!T!T!T!T!T!T!T!T!T!T!T!T!T!
MT!T!T!T!T!T!T!T!T%#_ -Q+FS+<.>O-S!I=1POFEY$*3$AQ>P&_WW$'&6C@
ML()'6^:L>9N/JNTL^*;FUK$>VMN949$,6C5[]_JTL16:0UI9*V3A/UGI^1=X
M-O-'HN=]70^M6 T?+GL1PUM]5Q#Q]RE%:,,7*_N$<;4%EJ-EP^3!6/,R!>@<
M1H'Z1*X!RQ$$1217H3]5U(Z>F2JOIQ@:'CCBV/7X.+13>Q?+//N\X>]5J76[
M/BUNTXFM<9D0>&>1N=(>#Q.3*[U#YLO_ %AX]IHG65WB*L"\T&>%-$.B0Z0V
M2:0U=.-)RI6?RKGCYKDE^L?,E?J)O7#-TFOSO"S^1N+^9<SS%CR..(..,YNZ
MFW9S=RSSC;9W:$;#D&TYZTOLU6.0/%%#F<>KD[5&PQP2P230UG5;35.>5&P/
MA'@?"<#T)U=DQ&FZ+16MSHMSO3ZRBK]3N=)H-KK^1+.SN/Z=JZ>I"!@V6]N"
MZZM"&' JFGR1C1L1SU><<W3*:T>]/)$<Y$=V\D1RIY=E[IY=E^O9>B(VY.X@
MXNYHSEOD^5<'FMS1WM8E-917=8/+8NK$M +MHH-[$R*]J$9<U8Q37"$PO81
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MXYG&JO& "S-O[B[;*95,S3X?U1X)XZQ.<XVQFOXQ(RF,V',IEUJ2K OA"JQ
MVUX9UP6$HAA*VUAN(JR^HK&>%H:+"YZNK4UTXYS*Y-M,2-46Y(1%8&</4VA
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M6Z/SB=&OGV54C14\E3NG01]GOWK/23565G341G.9=I5/1Y8DWK]R8')]BLY
MK;05#*,9IU3(2,^-L\2O:KF_CV_$)QK?W&>$K:G/NZO(<^VP535B7=M#5\)[
M(ZXK:L^3P$+-HA@)+6*"5?P?\79>@R#_ +^'&3;?^GG<>>P:WSJ-^CBIDX0V
MC;)]0V!I'S-#4-9W$?'W[P=OF:Y%:K45.@Q:V_<BX-HHLM+<8_V(KI-S$>3E
M0R>!MXP^S&JI/B.GC!6L^X@AC<BN594:KF_5/IT$-Z+]ZGTAR9U57:"RYMKB
M[8Q:^)LO 7);HA"7$QA0+;$Q44@]3$2;,V&)Y#F,DD3LB]!*N4_<]];]O+\&
M:K.:BW_J(E4R4OAS8U8\]@:^6,0,0FQ!&@-)*?"Y&1Q.<]R]NR=!E=E^X#Q-
M4 WEI:<?^Q=56YN[;G+DJTX'W0$8]O)X?&/"A-?'(:BJ]J>4+7M17M[_ .).
MX>=K^X%Q70QZ&6ZXX]D@!LIGTU=]93\#;C]*%H9(HY8C8K)E>\(ADC).[6QO
M<_Z*BI_% BK0?N[^I66IVWU\)SL#6/ 2R@G;P/R(5(8&Z9889 11*><HN0F5
M$1D<;'.7OW[=OKT#?C_WBO3S>15<F33G.X2W>9$(UG W(HLWR5I:@V41$1=/
M!(-, 2GC,Q[4='W[JG;Z]!.HGOEQ;:?TW^C8+V NA]>^RBH;.DX4V-I4D2U/
MG^H12VHP;P!)!61N<[Y7M1$:O\>@:F?N$<2$5\EJ%Q_['6 $&BBR4\U5P%O+
M5\6@EE\(A)8@J^26**=6*U)G-2%'+_BZ#%]!^Y[Z\9>UT=)>9[GT.TR),0.D
M$9P3NRG59\T,1,(<[X*Z2-I$T$S?'ZJU5=]%7\.@B>M_>S]'K;0V&7 L><);
MNH!)LS1)_7SE ".4,20<<V0$LZ@@%-6NG*8V9L+Y',<O9>@G6H_<8X5T@EB1
MF\=S]=R5=4MZ;75W">QEO8J6)T:26H]$\-EE8!?S6]WPQN;V7\>Z+T#_  ^^
MW%TUIG:9..?8:.TUE0MUG02.$]B.7: M\W]XQY1&2QD*/&LB1.:CU8J=D^J=
M!C=K^X]PM1 4%I=X7V*IPM3<G9[/?J/ F]%*MKJK@=/8 A@RU["Y%BB8KFO\
M/"1$7Q5>W?H(7VG[TOI?Q\/ 7KG<]5$1*2.\?^[SR<;((/!\:&FV$85+.\,2
MMDE:PA\B-2-[D:OUZ"1Z/]TWUDTGWR4PG,Y/Z28,'8D3\-;2M!BF,BBE!CD.
ML*^ ./\ 4(R&+"GGW>J]D^O09\9[^\55BZ=;7CGV-K(\;%73Z0@_@C<BB Q6
MSG,KWP%2U[8+%T[F_1L#I'*B]^W;H.__ '\N-5)&'7CCV-\#,H3LX2X^"MK)
M7+G!622RV2V3 I!6*U(7M2)7?(JM7LG01!8_NY>J577P71X?.HM1/1KHXBW<
M#<A30D4K$E^<^&6&K?YJ,L*^<34=*OT[-[JG0,F+_>6]-^1!VS8W_7:U?^KK
MGYAY/7[DRN.%NTB@(_3BZZSI BQB'#$LD3R;X^*]!.,?[@7$90M>?58CV!T(
M5K>,S Q&<X,V]W"/HE\6.J+*0 &5*XMKWIY),K$9]>Z] 3?N \4QQ:B5G'OL
M24N+.%KM,/7\&[*R+JR3)4@'\Q@PY928'S.1/.)%:G\7?7H,?U/[EW &+M[:
MATV;Y\J;>@JJFZO YN"]Y-+4U=^YOZ06<D%9(V+[A')^7OW3O]>W01$O[TGI
M.FMAQ#[#FR+23QD.% ?P%R4@YTPH3+.<$6U6C2LEL(JYR3+ DOR>+T^G?Z=!
M,^1_<?X+W<0TF.S7.VAD*$N# @!.%=DEK9CT+E2VEK*Z4*,LYX3FJUS(V.>J
M_5$Z!Z9[^\5/3,>7'_L$')M"I!<P+9<*:^O.M%A>L9$K1"QH9H!QWIW621&M
M[?V] UZ#]QCA;*59MSIL)[&T-8'K&8=Q5KP!R$$D^ME[)%0@,GJV2'$2_562
M,:L;NWT<OX=!$.W_ 'DO3KC9I_\ 6D'/]7-6&K7'BM]>.4#2QR6PSDRN48"B
M)E=!"*,^621$5D3&+Y*G09-FOW9?5+7_  S9R+FFT"(JEN(;&/A7<05SJQ(H
MB/U!2R*V*-@ZCSM=W<J=OP5.Z=!*R^]_&Z$V O\ IK[&2.J\^S5EE1\&;3],
M=G)T:Z"V&LW!?9DCRHOY$8]7/[+V3Z= G ]^N,+=V7;5\:^QY\.R$-,SE@%P
M1N":T^*M<[[Y9;"(!XE<Z&)OR^,[F.=$J.1.@C"7]U_U?& AMRZ_G06H(LS:
MB"RFX,W7V+S*]SVG(AD=>Z+XPG0N1[OP1R=O[$Z#"<G^])Z6;;]39FR^<;*>
MF-@"LQ'\ <DU]@-,6,XP'O7GTHY;QK,1/D'F8QT<C51$7NO;H*V>_P#S#PI[
M%<;U>^C#S%?G.-CPJW36GM7RY[7>OO$]7/K(HS*.L_TM]?TAN>?.0SY('-&S
MI'VY<<2.6-SFOD:AJW/](7Z]9M+%K>!>,+D8&8(-,R)5!=N).2N#:<L.E;^F
MB&Y/C3E^<OD>AQTHL#$K7VLLI!0[4F\E1Z(E<5V$^DHLYIT#N%?87A7F>WO)
MZSB_DJ"+UFY%;9[&MI,I4;37: 8W@2]!PM9QY>[/DKD;7;HJ3+C2/NZ^KHJL
MR:>2-?D<_HL8Q,=<TC^T/ T7LAQ'8<.V%]-F*VXW'%UYH#X P#C)*#!<EY?:
MZ"E$%MZZYI7G7U9GY08OO@C06R3HI \T2.C<2V=,U45L/1?VX@T+K^E]V["H
M91'\NUN)M'Q:.L)PO%NSEPQ>7RX-)1NJ<A]IFZ_#,KYZ^:%]."V1+*N:.7&D
M?3%R:[:4HQ!O&//F@G@=Q[^Z/QR3BZ.R$UU*8WE"VU>G=QI:ZWD*@SQ>INF;
M VMT#+2\UL&::04R84HJA"=#.TZ-85%;8SMQ3)QUP+R#RQPA[.\::CV.LN3*
M6XY,K,5PUIR.4">02\94\3E9^]MG[?08_2365EI;GE,FY0VJL#%,BH!:@"R@
M18)85)JB)B:=$Z>K?K[OO7S0\[#76MJ-=B.6.5M9RYG61$W+[G(&WI5> /FY
MTLXD2UDL*D%UA:6,DCR)K.5&?).UKIE,W3$TIG$.F@O)N6/<')\=Y^[*3,^J
M]#)R1S '3;$6O>O)_*6>DK^&L-O^,]!QW8)KLT5B";+3U5[2Z *>GM@HXIF.
M^9&J,K?.5O2C!*X>4X\H8(,5J23E&%P C0M\FL:LI9,L,$'G(Y&M5SFHKW(G
MXJG1EH[X.Y+]9.)_;O1\L;>YX8W7)XMMJ!VYP3]O'=>N/[@&9L[D*TD?9WS:
M"2FI^7,"^K0B(K0IGUA(=) YI3I)6HZ.::Z8SIZZPOGI?WH_2O($ BZ4CG*F
M?93LA&G(]?N3)18FSDP BSG$CTLHX TYI#8FOF<QKI$5J=E1>C*3,]^Z)ZW:
MJ2"&CJN:IGDGOJAWF<.;"L$)M&$((E=%8'AP!(;.0Y&Q1J_O(JHC>_09B9[^
M\8U(=^==<9^R=0'F+0>GOB;7@K9@1 'DN[LB:I 4?W<;(NSW/B\VI&J.[_QZ
M#ULO?KC"L;<S&\;>QHH6?SBZ^VM'\$[A:D;,I%\JV[;+['[6>)L;VO\ CC<Z
M16]U[?1>P1+??NX^J.9JVW=^#SS5U7Z4/=,,DX#Y$FC,K"Q8BA"1&#U4\T["
MDE;&WP:[^<Y(_HY4Z!+D/W@?4#>0!S9'_7&[4XNSK8XH>!^18"1[:IF;%8U)
MHA-- 0&>$KT\FR-1O;NO?Z+T$R@>_G%%JW/OI^/_ &#NQM38&5=#9TG"6RMZ
MHTZN8KSX)+($.4,%X?BJ2I,YGQJB]^@1_P#Y0GB&>MLKBOP'L1;5U/="9ZPF
MI^#-O9O@N3)T&@"4<8%\[VRSJK$E1/C[M54<J)T&*:+]T'USR=KI:>^H.? ;
M''$5@NE&=P7O)?TB:U'<6&TR2&L>R#Y!VN<JK]$1O]W01D+^])Z5FZ$G*CE\
MX+>BK8M<'/P#R2,R>:HA@(MH BB*:$6QEJ8RX_G2!S_%>Z=^Z+V";:#]Q?A'
M50?+G<QSM;3MJ9M VJ!X3VD]V71#-_S%H'3H&IY D+O\3F,=_=T#D)[^\6%D
MY8-O'OL- 9M19CLL&?P?LJXRX&C5R)X"EB13B3O5J^#)FL=(B=T3LJ= U6_[
MC'"]!5U5O?8?V+I1+[43XVF2QX$W@Y5AI!U7Y:P4-];]Q+)^541_BC%[+V55
MZ"'=;^\SZ9X6*.;4S<Z5C)9[&%ZKZ^\FE/"6J':79..C$HY7AP5PSD?+)(C6
MHUR=OQ3H,TH/W7/5C3H4ZF@YFF@!'$,,/)X8VP->.+8QQR5LTIA=?$.R*R^1
M$A<KD1RKT$E&^^W&59+HXK+C7V.KX\I6!6]X>5P5MFU8=?8Q)-7D06*!(+8?
M?QKWB;"YRO\ P3H.T/OIQF1/510<:>R4R6^?-U()4/ F[DK9:&M^E@?+8L <
M*,HG95?#(]LR=T_*O010=^[5ZI5E*)HCP>=AZ.P L;,"V=P/R$H18-6R=QA
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M(E) ;09ORH]89/* AB>#N['+T9:PL1^U?QMFG: O4<IZ?D*ZTN? $L[JTP>
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M?P_5S/K^"]_^%W3Z]!Q\R*[O]Y5JG]GZP8OX?A]/C5%Z#LLZ]E[%U:=U^O\
MVN7]?I_^R_NZ ;,OU[F52?BOTMRT557\?JD2+]>@/G_(B?>5?U157_M<M/JO
MXJO:)/KW^O01SRY&RSXNWU')95\#=%DKS/R%,LC2'B1W04E9(<V!L2?*H32O
MD5J*CE1J]OKT'R1#5?*7I][16? &LASNHV^=U@^OX^JZ[5V-MK*JNKJXL^AT
ME]:$I"-)D-AG8)2)@I6R."<Q(T=W<O0;C<AR221I.+N4+C?7^KMKM=)?[;D;
MC8NOI\EQ9DM/#%1TL=Q5V+AOZF$=>O9$'X02*C>[6(LG?H'7:6>CNMWA\T7R
M12[_ ','%E@+#R5H,*D?$3-!)=$W(I6F'E&^TDY%*S@Z^2DQK)(YGA\?;LY
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M$7N@;2,OR/=WU;QSROI=;=;G05&VJ2&4W'A==02<-83(AA46JL-$?9.KVW0
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MG9 P/4>_OOS?>OE+Z\V8-IGP?M,UC1N:P,O_ $CI++5#:2.V%SQ$U=9-J*S
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M<<L=L$1K'-0D=455\T15!FH=75\TU>\P4F+JYH>;]#K<GR5;[NP5+B'+78D
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M(+TXH*H""KJO2;E2KKA[Y=0T2M]WMN#%)HWIV==$*+RC$\VP5/KY3*]/+Z]
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8'0'0'0'0'0'0'0'0'0'0'0'0'0'0?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g69361page002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g69361page002.jpg
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M5D%1(U36F'$R)"4F)V&!D;$S-#:ADE-W0G(U155&MJ>W.#?'&1$!  (!! ,
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MP</QN.Z?U <EZ=4[&]QMY*G5-#&47I_ZF7,;=(Y)&5RCM%7UUB[RZ)&(W,"
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MCR8T>3N1\/I\1UOSX2OR=\JNB>.HBL>XY5$NQ@AP7N'5[)+B'QXD<#L7&PM
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MUNEKMX6W?:7X$<#3#JUVY=QBB0[RS=NE+A,<FC.!I4'EE3(0[I=[+, U>8)
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M<66EQ3;;#B179$^?V;],'G H++ /<R+ZX5R*'T0%?R7.9UAG47D73G95RK$
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M M4D,'ZI0.>%YZR[+L2KH@-5[E8>-[Q/LIT_&=?<4N2_(=<$S,Z3Y:01QOQ
MOG;NNQ@UOL%AO- G4WI=UJD>[VI^A\F+="NE2[R@X ;7Z5*OE.J6+EHLZ789
ME.NN14>]]U&8(N[E#6N%P=8Y/P7R7BU,O8+F],@-!2P&.1Y[TYT#"O7..G$@
MXRR\]/RZX42S9^?]'+U.#&D1DJTJ3(@I:8>0KWJ5DB9A52>6>&PFY)$2K_!E
M'>JWJ?90XF;T;XP//L_+N]2^N&*>&=;?^4QW!'9.V.K=!./;F.Z*;BH:4PSM
M#);[>4BY)XJ^+OC8=HX&FSV*]8*]/L]@HE>,W,>R32-(TW[)RH$$-ZCY1T%7
MJB#6VRZ^W)DMI8=?D2'7=..X)F95GY.^//BSW-5YZL;["(K%U*^//3P(N[1>
MA19H6JT#[/GZS=.CC! \W!FO#ZP*)S&Y;D::T+9E(1)=;U/CL2&BQ/:-.6-2
M/'SP=N:>7]V$71VP%*D&']@W?+O=5-6ZU5KH1R/T&MVKK#%XB0[#!$D3"&I0
MU;T<3M,=&HB/^Q^U&V+[1HV1;Q%\.UTXO4CW33TBN4H)#'Q$V+ODLHQR6DV3
M5.(T>LB&+ 8FBJW1XC%&'*$0IK#L0C'2XF5J<V\YI1+[+PX9QSQY\=8?V8YO
M8XL=4SF0A?PQV_,G"4GFU>MW1KE#M"$S9NWE V[%UDNIPDA.HVT/-->WI#3>
MM$F9GRYD[AX:\DZU1^64[BG<A'+;6YS&H<RYY<(EE(VRP'N)<^H_3J6J'17
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M+F7R2-'>G54?IC<N4E[V"+$>7)CN#/VWW/?TW1G/+]X\= #]/:'$^)+L[IQ
M.G'$.WM-GN%\NLT,S.N'3;R^%K4@K?Y?O626K"18]%+'3ASDB2MX3W\QN_'3
M?TVQ_5>[]1[%9NM*F">E5LG5GJ1,Y]%GM0@AF=Q4A.#$9CMK;KAX.A[C+26D
MJ!QYKK9-Y$R5,0S&TU*([U%-A-_3J&1KQ7;=3NB@ZU'!7J7>F1LSCU:/RP4F
M!W?L7=J6*YL8=-CU<X&"2O998XLB*Q(T:ACXOIJ'_MTO4RW:JV_IF56SRK-!
M1T.,/J%@H<ZL(@+YH (W5@J0\<QGC)(;(=#?+MD#/+W*0,T274UQ6V';$YN8
MY,6VEN,B&3I/N7BA4>UO;=D3!]<3#\=>Z^/=;:C5022;JD+N".>QIEG I>=B
MZ'2:^.H*8K<1C33<F/+4A3B$HTE59B:_MQ+2/T_+N;\@NH6?IX[G(OE#%VC6
M&E;C@J]:KCTIC^:N/Y0N-]%+K@#Y1\>W,@-CHZ2;2'1.G=M,(F:8W/F&\HK3
MRW9_]*P.1HPZDA>O1Z^H.:Y6>"V=CEL!=E!$N<\CD<:D2A4N#<1,5S<^K-0]
MP8A!F>(A*:?9F0BD20F,P3-WIV?CYKL?+#7.R5JK#,HB?AE&)1_F06\5">)%
M6-HN-K5QHEA*K0?AN#X[<>5*@$ I#4I"9D%\>\AO2#,34VY5B^ 1R/)YMM7?
M2T@;6F^=M7J'+I3A(A9XG*NWW3M]#!4BQF;N4/<XK5:(7R6&AL/OGY<<-#'M
MHE:=C.NR2Y(R'_3)KC5(&4VR7RJ&=UB@6OGM+*!N#T&HN5Z.9UP2,#NSK8V9
M)E%^HBX'"&-33SLE+\U\BO<9 ^-'9B:+GK:Z_)3PFK'D:0Z"<(6A5<L-RI7"
M:B+*L@GI,@&GA?6[IUZ"S+)!K#5;21J]R,6QJ.6&0R@I;C4!IQN4A[V%M$CM
M3F8]^F*F,1Y.+K-P RJ4/K\VB=%^/I455Y#")7BWWK@6CO-;[8#UHL(BMI=Z
MA%>^RLM9!KXC;LC<_P!E3[+Y<_Y^V^+_ *93EQM-(O?1.W?:NW5_I):^6)<"
MAG:76#$8JQPAM$&O5RJ]9'NUX\*7P(;\*2(3#S&FY3^G83RTL.-C.M/3]#OT
MO@<&'<Q;G4!\T':ND7VZQ*U+Y8/FUT$(Z-R?LW*K0(APB=N(S&C!B'V!4N1)
MB2809#@MIN('AZ?DJ<&:?3O !LIX=C_%,KU3YR^)NB[N)O)6GE'HH:<FYSK=
M 'B0\+H8^\M1 FYZF8DN1;9)E2DZ<E3I25NM.$R^LFA*?IM!I8ZRNC^LRX=X
ML]<L5=*]#E<YJCUA,1SW+?'[FFVK%L/(KZ9XQ*.",RW(L-0[2-E'$PEP78L6
M2@N:1\-_3^'\87S%_749M@>YO8HMB;;;JJQL,DY'NOEK=-CV_F5KLI:)#2_Y
M6R8S:Y$R=)TR#94XZZY(=6DD]K_GX_X0B]_IEB+\?[0:(]6;&(Z:?MEJ!)K_
M #F-738HQ;^H<EZK/@]$MU>MXBR=3JT(OQH7"B0]/A),<=*F-IE^VN*Y#+'>
MER3?!FD%O'KC_CX8*C2('D\ZY%VGYM56>%%C%RYAV/GSTI@)<[':YHYD,0["
M\4@ZD$2#[*X#+/OM^U[U),M9E1=U_2[#6!VA1JQUAJE5VD]!J_0OLT-YG!;&
MOEJN/\=([,@6FOVVJH'$24[Q]2]+5+03@/?/)#FX?QK$>:DL=VKLGZ58FQ![
M4)<ZY"CHFG^?DJIN'S)T"G8V@$^_2HL?KTVC]%IUF[!8BD/R#(ID%M$@;JY@
MZ)*4TM2I2) S=$]9\(P/2ZGRRI0[?'KT/EW#K-P^$_.ID*WO$PQ:3QXP(E/J
M-F=.*@PSO%1J"8^2N8P<#S)T!]2-R-26R1VIDC_#:-"XG4N6*NHAPW6>^0_(
M=1]GG R+3D6U759O3BX2L\U0>7'J56=V4E01[+1-^3 ]M,EQ^4]IWWPRUOAS
M+;/TD>?'J/5:0*Z%L$,K3%%B/#HU/GBZV=:K?"Q'"[*4+!*'?J#,DVFSB S4
MYF<N<MN$^I;3S$YE6TY%SGR[0ZEX^W*QWL'TOD/8%\@NL7FA+C]@*SJ(.Z2R
M5H\PM#.C9HB$7.!6P=ZJI=A]X<0?41'J^,=3.'34Z9TU4B=]7/\ *_3FK96^
M6"T'[]".@R=R:N,4,0YA5W+ 9>*^0''_ "$N0SJ]O^-].JC9=@X_'&@FI ^"
MW7QDYUKV)FFH^FAEH@XG].<T7E](L]DN=!KEC+]DZA?.>B1G'J\:K:!1_P I
MS?> &NX1]'!$CNS4J"P-;C1)#@9=?TZ^B,\Y(TF7A<F26_2\KSO$[#R*O]32
M)EVFR\^-GK;-YP.?DE!%&XW&Y.BGR&*U9J::A5EN2ETP(BCRL%@.OW4#W<D=
MJ3'EC/6VU_\ ^:HO4"1#3U2.XM%:J8\>[+Y>$FLS;'4J1XGU1DG>H#]@5"O=
M6,3/$L7(GA'T1TR8AF?#5*]G;3J!G_/[_P"4HHOZ=U/I]CJ=UDVT<3N-:LG/
M+4DO!YP !,0)E1ZMY#]9L-?H\1@C,DT.B6<EY#S1\<3'DOI'#1[3:W9:G7E[
M)/;TM7D7B7'Y)Y)=O\@!UY5)A=H;==F\_A5E(N!$,RYXJ?+L14O(/&$$##>Q
MFV&=C(0)EYF0M9!LA+2U*;$]KB(=AX9,!@,!@,!@,#^>GF/XS],[3=:3:N;
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MN[>??B;J3,53^E6&3 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M\.>(7,Y.1%ETBPD[36VE:>D;=GQH!@Q)5_VI;[BV5I8VO;#++;9<I9EM\%>
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M1AP.- 4-!S96XR6@D$U LEF;L3VUZFJE+4ZTN+[EC7L>R\EUT37IU5[MO_\
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M$)2"C7L-N-I3_64^Z6^NR7<KYIYK S74]W;IU;(1G*K<A]$>^.A[KA*YV,0
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M&E*?5J ^U,D-R?AWY;L73[$D92TQK]-[BY6W#ST4U9Q %MZP;)U8=#I\5MV
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M6O7=MKFM>FM_M-#OZ-ZUO6__ )C_ $ZWA$ ZAW2E\PI\B[2Y#=@##C-<%FW
M4V%*^11;*30*BFBJ]/*3%%L27->VM7]/]"?7>%B+<;E_U$9<8*((Q?'_ *!!
MDG2]<>$13,B$N08J1#I#W/RB0PZ!I<XETI:Q!&8.K2-:DR1\?XQ3J6D.(2:Q
MY3JD>;!#I/-K?T4%QNU50;3 ](.$W[I+A.QW(-DOY.MG'H+5;61?E0:M504L
MK,E;VWJ/M.FG&_ZCBM$GK4U*$V_SWM(<5=7:SQ$Q:71Y"ZP>=VB).5NE7M0D
MW.^R$K3C33AB%6[%450YVS#34F,XMQ>HS;S>VU*&,>Y9X[SY-2V-P(_C[=SE
MB%I^'L6AY8,+$PB+=AK-0='.KGNRGQ5C;.G]R)8=]2Y0P4EJ0\XO;[:-EPY6
M.6\C.DFJ'S>^TVE1*FDQTD_3KY5;R#*6@Y $ P%GL>B%>F56QA1Z9,Z%6=--
MK?T]']_.0G>];:WIXE1=*PA_J)M2;.3J&_'WI:C->%UP_9M0YHN5"#AB5>)V
M&P-IFO,0F2=BKC Y+:8$?V]3G)+6VWDI5[6BXZ>47@?J2$Y-B#2'?'Z^.40Z
M_7JQ&6*]Q.LH^\D+7T$2;A$Y<MP94WX8T)3XKT-L?+G;)RICS33^OA=^\&'.
MKJCQ\\FV^ZV"[5>9SFR<[-TL'SZPOQ3DR(5:(#>A5_5@'J9GB65C8LL>RM++
M\5YY,Q+NE*VREKW;CAF8IU-A# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8',GD1S;M'0Y-
M%^Z3HZ^=[K9!=AFS/CBT>%..!;%3SP"!81@B1%=LM4+P@Y$82@N.):=BSU^N
MM[WI2#43$>7/5:\=/-^G5UD,*\N6S3L%YF%#=M0>,<DR!3#;"F"I,\=K5A/R
M[)LFG<B9IQYV+.AH5";U#4_\<P+Z[.NN,U7IU3&FX?3KJ]>B+S];5%-2$Q6E
MS)L:E5R%;"<:#!BPH0,46M\>:[$'--Z1&8]%;WM;J\)->ES80P& P& P& P&
M P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
M P& P& P& P& P& P& P& P&!QM:>$=ME]_?Z94.QR@-"+GJ 5,TUTS:7&F6
M*J@!$.L0P7OGZW,CV$ &G#51%ICQ=.'7"2]*FCXNW#5Q5>W/]A\%^UN6NPVB
ME]^9JSSEP[-;:2E,$Y)D5&3W&_PKS<?8=DSY<:2]\5716X>_<IT/=3)]Q[*'
MO31<HV6"GQE\GM6=G6_*6S)H\,T5D1XZ3-C79Y51T5FRZE2Y\M[;D=V;7O1B
M1+L.UN%#&G'($I*H;3>UDN-GF_XO^2QJL<!4<\CF&>A\&=L)^+8F!)$]&O-N
M/&WAC,F\+-/M22T(9RF;.#[4RW$U(EE9#^F6&VV&4ERC73RLW@W'NX<L)VTO
M<[T/Z--M@2E#U[-W;H)5 J=4EV=F7*@MV".4C,_:1!EN7(W&:B:0[_V?V'&8
M[#FR3,2Z2]]>_77H-J7IZ?M_[\,>OKZ[_HU]GOZ/3#)[^]__ +,J7]'_ .W#
M/]/KOT__ '>_H],![^]^F_\ NRI>O[/3_OPSZ?T_M]=_9[U_HP*XZ5U_?) Z
M35WW7(,9QJ:^Q''/6LV1DLCD,KFNL#Q55E2-1XVY+27'W--QV5/(]ZXA*O:P
ML1:I'_-SB</4;YEU;DP1V5+G1$Q+ =M(*>PL6IULI(FPBM0BR((T8\PMN1-=
M2B$RY[*5.ZVM.MEQE>5*Z-(Z,+<.4:?0;.&;>AMZ*"K"9DP'T$@8BRBY$.6F
MN_#SH9( >ARV'V5+9=8D(4E6_7>M$JO*7^_OGI_^C*CZ^N__ ->&?3T_9Z?M
M^SVOV_TX1]]_>_37_=E2]KUWZ_\ ?ACT]G]GIO6_L]Z[W@/?WO\ 9_W94OZ=
M^O\ WX9_9K]GIZ?^'OV[]?7 V QRS+D*T9A@H\7W+FT+&$B$R1M_2V?=)4U*
M%06],J;VYM2M+VK2M)UK6];WO0;W 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# @5YYE2>D-CFKD&26;%Z(IB:U+FP7$-%(R(\QGX@?(BR4I4XPQ(1M"TK:EQ
M6'D*2XTA6BW2FI7A3XH39:YTK@W/7Y+@;5>VI8??NTA/^R;4,:CZ>U'9BN*@
MM*6E"4^VI&E*]=[WO8RE=](Y]4N=#I8FGB6PXZ9)ARG8K3KSK:-C0(:L#6&?
M?N.*:C#Z_7X<5I&M^B6V-;WZJVI6R>4SP& P& P& P& P& P& P& P& P& P
M& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P
M& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P
M& P.?O)2?WB/SI [QO%BY?4CE@%PQQ4_)@1*W6Q0]$JPFB!UX@+-M?#&(878
M9G2(CSJ911I>O=Z0IYLL5>OAQ?9.Y^?I.;89-:X5/K0N<[0T5\1*J0\F6 O)
MOAK=CKT@PY<GAQ.:>YLY%FS+'[A0<0_'T.9@N37=R<-5U; ;V[]0(5 (,3N
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M=?3;!'9"+DJ&S,=3J1"A;]XI#2D+-9Q/F$ANW@E=N@![Y3[!VNNHHUJE=WO
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MIG4W;*)4J3K*S,WJOO"& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M 8# 8# 8# 8%%5?_ /N.[+_^*C@7_P#$G?,+Z_:]<(8# 8# 8# 8# 8# 8#
M8# 8%%>0G_T?3_\ \>OCI_\ UUY]A87KA# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# HJK_\ ]QW9
M?_Q4<"__ (D[YA?7[7KA# 8# 8# 8# 8# 8# 8# 8# HKR$_^CZ?_P#CU\=/
M_P"NO/L+"]<(8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M_ON"HW/O,[E^6DK]5^<_WW!4;GWF=R_+25^J_.?[[@J-S[S.Y?EI*_5?G/\
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M1:(>_>TJ/&@!.:72-(A:C:;5IY4EI>UJ4GW>M)TI1=/:)?./)C^'7"_K1?\
M\!<&A\X\F/X=<+^M%_\ P%P:'SCR8_AUPOZT7_\  7!H?./)C^'7"_K1?_P%
MP:'SCR8_AUPOZT7_ / 7!H?./)C^'7"_K1?_ ,!<&A\X\F/X=<+^M%__  %P
M:'SCR8_AUPOZT7_\!<&A\X\F/X=<+^M%_P#P%P:'SCR8_AUPOZT7_P# 7!H?
M./)C^'7"_K1?_P !<&A\X\F/X=<+^M%__ 7!H?./)C^'7"_K1?\ \!<&A\X\
MF/X=<+^M%_\ P%P:'SCR8_AUPOZT7_\  7!H?./)C^'7"_K1?_P%P:'SCR8_
MAUPOZT7_ / 7!H?./)C^'7"_K1?_ ,!<&A\X\F/X=<+^M%__  %P:'SCR8_A
MUPOZT7_\!<&A\X\F/X=<+^M%_P#P%P:'SCR8_AUPOZT7_P# 7!H?./)C^'7"
M_K1?_P !<&A\X\F/X=<+^M%__ 7!H?./)C^'7"_K1?\ \!<&A\X\F/X=<+^M
M%_\ P%P:'SCR8_AUPOZT7_\  7!H?./)C^'7"_K1?_P%P:'SCR8_AUPOZT7_
M / 7!H?./)C^'7"_K1?_ ,!<&A\X\F/X=<+^M%__  %P:'SCR8_AUPOZT7_\
M!<&A\X\F/X=<+^M%_P#P%P:'SCR8_AUPOZT7_P# 7!H?./)C^'7"_K1?_P !
M<&A\X\F/X=<+^M%__ 7!H?./)C^'7"_K1?\ \!<&A\X\F/X=<+^M%_\ P%P:
M'SCR8_AUPOZT7_\  7!H?./)C^'7"_K1?_P%P:'SCR8_AUPOZT7_ / 7!H?.
M/)C^'7"_K1?_ ,!<&A\X\F/X=<+^M%__  %P:'SCR8_AUPOZT7_\!<&A\X\F
M/X=<+^M%_P#P%P:'SCR8_AUPOZT7_P# 7!H?./)C^'7"_K1?_P !<&A\X\F/
MX=<+^M%__ 7!H?./)C^'7"_K1?\ \!<&A\X\F/X=<+^M%_\ P%P:'SCR8_AU
MPOZT7_\  7!H?./)C^'7"_K1?_P%P:'SCR8_AUPOZT7_ / 7!H?./)C^'7"_
MK1?_ ,!<&A\X\F/X=<+^M%__  %P:'SCR8_AUPOZT7_\!<&A\X\F/X=<+^M%
M_P#P%P:'SCR8_AUPOZT7_P# 7!H?./)C^'7"_K1?_P !<&A\X\F/X=<+^M%_
M_ 7!HE-0(=BE%'&[]4N: PNH;JV9E0Z':+4460TZQIAAP:9YA38C<-;&W%+>
MU+4M*TI3IM6E;4D:>EEX0P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M@,!@,!@,!@,!@,!@,!@,!@?-JTGT]K>M>N])UZ[UKUVK?IK6O7_3O>_V8'W
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M\?Z+TN;9Y[5&YI=[-1R;?W1&4Z"LBS<=CXB)M1+X?4N1$C6$;Z.K.M^<;',
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M*^OF%PYCT_K#5TD$K)RX;.(V036^62VI H1#*"7I<Z)J*;D,[D/QA/2O;?\
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M14E:8E?ML8I(K!PS')4RI0=1#?R27J)/"/GZV1U'<6.+S4-N*028IV!ADP&
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M=:O_ )_[]_S"=A_XQP7^#^76K_Y_[]_S"=A_XQP7^#^76K_Y_P"_?\PG8?\
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M-*^AF_Q1P7UV/L5Y$_QYI7T,W^*."^NQ]BO(G^/-*^AF_P 4<%]=C[%>1/\
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M.XZ\RZA#0_3:/] =A62S5,GY=WP*9J) B*.)/\!! 1C1 54YM[G11]@,<RA
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MFZJOG8*3QKQ_Y\Z)D';2$#SS<NVV#FLZ4IM"=QAD=AA+:M^^4E!GM-N_L,F
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MZB%*T2I7GA# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MW^"X-.3WOE1_N'C_ /O;HW^"X-.3WOE1_N'C_P#O;HW^"X-.3WOE1_N'C_\
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MX$@O\EKFB$B+'VE#CFH,76UZWZ-IUAB?*R,(8# 8# 8# 8# 8# 8# 8# 8#
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@ 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g796801g01e22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g796801g01e22.jpg
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M P$1  (1 0,1 ?_$ !X   $% 0$! 0$            &!P@)"@0% P$"_\0
M31   00" 0," P()!@H)!0$  P$"! 4&!P ($1(3(0D4,15!%A<B(S<X=G>V
M,C-"45=A&&)Q=8&5EK*TM1DT-59T@[/2U20F0Y'4UO_$ !X!  $% 0$! 0$
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MGBQT3QHT>.&XR@ICLW2,=E<_(5.4<**.%%.CI09R[:U\V.CE(F45A'>/?OZ
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M+D%T)$[M:%BN1[8LVSH) 2@,3<BOHY[4.F/9*U*AVC/&1OGI5YAL!O!@,_W
MU<]I7>6!;XQ5N3X18/<^,X4>\H9Z#!>8].(QSVQ;.(PA6^F9&$=#G1R&@SF#
M+\N=Q021 I)X)+=]R0<=58:JP','LY@X(TR,$9NX)X[A=Z,^TIT93U$?Y!(/
M73P\9IZJ4>M[?&X\!W[=8YAFQLHQNB!08S)#5U=@^/#&>56L+)*P2-5$>8GY
M9%[_ )3O?EY8V\$ENKO&K,6<$G.=&('.J2^N)X[@K'(RKNJ< Z9(UJ(W^%7U
M&_VQYS_K=_\ [.2_J=K_ $4]Q_6H?URZ_K/[Q^E:78+W$A0R/<KGOBQWO<OU
M<YPF.<Y?[U555?[^9DZ$]YK3#@.X5U<Y7:KV^(7LK/=:X1KZ?@65W.*3;+*K
M"'/DTTIT4LN*.H>88#.1%\QL*B$:W[G)WY8[.BCE>02(' 4$ \CFJ_:,LD4<
M;1N4)<@D<QNDX]XJJ'_"KZC?[8\Y_P!;O_\ 9RV^IVO]%/<?UJH^N77]9_>/
MTJ[CHIS'*,\Z?<8R3,;RPR.^EVV4!DVMH=9$PPHE_.C1AD*J(KF@ -@AIV_)
M8U$^[E'?1I'<,B*%4*I '#5035Y8R/);J[L68LX)/'1B!4K^1*EU7_U+==^*
MZ@GS\*P"%#SC/H;B1K,QCO3%L8EL[M?%L31'LDV]H!Z>$FJ@'BLB/\Q3+./,
M 2$MC:[/>8!Y"8XSJ!_.XZP/Y1VG4\AC6J^YOTA)2,"20:'7S4/:>9', CM(
MX551FO5UU%9U),:RVCDE1'*YRLK<1ENQ&  2K[1VMH/D9,D34]D=82IAWI_.
MF(OORUCL[:,#$2L>MQOD]OG9 \ *J9+RYD.LK*.I#N#_ *<$^)--W"W7N.ND
M)*@[8V3%D-<CO5#G&3,<Y47O^7VL^Q&K_2:]'-<BJCD5%5..F"$Z&&(]\:_I
M30GG!R)I0?Q&_7M-2^TM\0[:N%V,*NV>3\9&).(,4J24$2'E];'54:Z1 LH[
M(L:V<%%<5\6Z&4\QS6A9;P&KZB0Y]FPN"8OX3\M24/>#DC/6O#CNFID&T94(
M$O\ $3.IT#@9U((T.G(^^O&ZD.K+9$K<N62]3;=R6/KV;%Q*;CD>GL2QH 13
M<*QV5/$V*]B$BRAVQ9[;&*9K#QK%)0#L88;V-[;6<0A030J9 7#$\3AV .<Z
MC=Q@\Q@URYO)>F<PS,(R$*@<!F-2=,:').1R.13)"ZJ^HQ7M1=QYRJ>_LMN]
M4^B_XG'_ *G;?T4]W_FF5N[DD S/[QU=U:.,SPK'L^H96.Y+"29 D=B#>U4'
M+@RF-<@9T"1XN='E@\W>!$1S'L<0!QECE*)_XE]*OT4^1'TS>1NT?(;R^V2N
MU-BWQ6:&2-A!M'9.T8E=;3:^Q[T([V.T[/I'Z*95>*6*2:SO(+JQN;JUFW>Q
M=M;1V!?Q;1V9.8;B/*L"-Z*>)B"\$\>0)(9,#>7(8$*Z,DBHZUYYUTG; H))
MSXGZ&84_DYP4":/ N0"[JJ,E0991 .]B*C4? DG>945_RL=%]-/B)]+_ /PV
MOII\C+^[N_HV^I_2?Y,&222U%K=66QO*JSM\EECVCLG:=S;6=Y+&I6,3;&O[
MN2[96F_=UD&$"^A]A?2SY/[0C1-K=)L>\P Y=)+BR=NN*>%'DC#:G=N(D5/1
MZ60^<6E'I7;)3_+MU]E*$[^/D2J.('?OV_ZT5&1NW^-ZWCV]^_;WYYJ@_91_
M:2N;P6,?T)_2(LQ?<WY_)V\M;/.<9.T+I(; )G_W#<A,>=O8UK6-Y:^2:1](
M?*'997&<+=1O)_\ $A:7/9N9[*?S772+D=C*CS]B214-6QS2$I:^2&;<S&HJ
M+Z)94=35]>)Z*B.*,\V3V1XT"!ZM,SV;]!O_  R_+K;FT++;/TXW]MY&^3L+
MI--Y*;%VA:;5\JMIA6#?5;G:-DUUL38EM,I&_<V]WM:_W1) +2RE9+J/ ^4?
MTN[.MXI+?R=B>_NF!5;VXB>&RA)TWTBD"7%PZG@CI!'G#;\@RAL#IZ>KQ^K@
MTM+"!75=<!D:%"C-\! "SOV1.ZJY[WN5Q"E(YY3%>\IGO*][W?:KR6\E_)[R
M*\GMD^2GDILFSV%Y/;"LX[#96RK"/H[:TMH\G=7):26661GGN;F=Y+F[N99K
MJYEEN)I97\_7EY=;0NI[V]GDN;JYD,LTTIR\CGF>    554!44*B*JJ (6]=
MN^YVG=8QL?Q>:^#FVQ23:JNF@>K)=-0PQ"^W[>*1B^8)RMEPZRO,BL($L\TZ
M*1LBO;S76%N)I2SC,<>"0>#,<[J]VA)[@.!JGO[@PQ;JG$DF0#S51Z3#MU '
M:<\JS^*JJJJJJJJJJJJO=55?=555]U55^J\T-9ZGPTGT\[-WY;2*_!:H/V?7
M/$VYR:W,^#CU.ID\ACE3&!D&D2R-3S'7UT6;.</\^Z.R.UYF,3W,5N 9"<GT
M575CW#(T[20.6<T_!;2W!Q&- <,[:*.\X.3V $U/6)\+*S?":^=NJ#'L58BN
MC1,"D3(32=O=C9QLM@G>SR]D(M>-W;W]+O[<KSM89T@)'69 #[MP_G5@-E'&
MLXWNR/3YP>NHD[YZ.MKZ'ANR"S%!RK"VE8(F58Y\R0-:\SVBCLOJZ2(<RI4Y
M7-$.2GS=8IB!CK8I*.(#IEO>PW!W1E'^XV->O=(T./ ]E1+BRFMQO'#IG&\N
M=,_>!U'5S';43^2ZAT_72Y^L3IK]X&/?\:SD>[]6G_#;\JDV?K4/MC\C6F[F
M7K3UE3VG^D_8_P"WF7_Q#8\UD/V47X:?**R<WVLOXC_,:0?'*;IZ]3]/&WMU
MN,37^(3+*KC&]"7D$TT:IQ^,9$17A6UL2QP2I(D<QQ85?\Y-$P@R/C-&]KE8
MFN88/M' )&0HR6/@,D#M.!VT_#;33_9H2!Q8Z+W9/$]@S5AW3%T2;EU#N_!-
MBY7(PPE#0IDOVB&IO)LRR']K8?D%)%0<<U/$ 54G649"^$M48+U"(K_!&NKK
MJ^AF@DB02;S;N"R@#S75CJ&)X \JLK2QF@G21RFZ V0K$G56 T*@<3UU:W>4
MM9D=-;8_=0Q6%/>5LVIM()T[AEU]C&)$F1B(BHO@:.4@U5JHY/+NU4<B*E0K
M%6#*<,I!!'(@Y!JV90RE6&0P((ZP=#6>.TZ,]RR-PYAJ_$,9FV\/&[3L+*[!
M65N/)03VMF4EC-MSM9#65)K3!?(KH'S<]LH<P (AEBE5NC%[ (4E=PI<>@-6
MWAHP"C)P"#@G Q@DZBLZUC/TSQ(A(4Z.=$W3J"6.F<'4#)SG32I7XO\ "XL2
MQA&S3;4*%+5K?6K\8QD]E'8]4[N0=O:V=60C6K[(KJ4:N3\K\GZ<B/M49\R$
MD<B[@'^T!OFJ6FROZDW@B_Y8CY:_,P^%W81ZX\G ]J1[*S$-[@5.48\ZLCRW
MM:KFC^V:VQL%C.>J>#4?3E&KG(KRC:BKP3:H) DB('-D;..W=('S>^N/LH@$
MQRY/4RXSV9!/Y?\ BKO+<3R'!<DN,1RNKD4V0T,Q\"TK9/@I(YV(U[7-(-SP
MGCG"\<F)*CD+&EQ3!DQBE 49'6J.LBAT(96&01S_ -\"#J#H=:JG1HV*."K*
M<$'_ 'J#R/ C6EII+:-KIS9^)Y_5F,UE19A9<Q!.5&VF/2WM!=UA6=T81)4!
MY?E_41[031Q9;&^M&$YJ)XA-$\9_F!W3U,-5/@<>&1SIR"5H)4D'(^<.M3Z0
M]W#MP:TW9!1T>>8E;X]9L'8X[EM#,K):#<BMDU=S!>!Y0$5'(U[HY_5CF1/(
M9/3*SLYK53+*S1N&71D8$=A4_KQK4,JR(RG574@]H85EOV-@]KK7.LKP.[:J
M66+7<ZH,7P4;)8HY5^3L L555(UE"='L(O=>ZQY(G+[KS5QR"6-)%X.H8=F>
M([P<@]HK*RQF*1XVXHQ'>.1\1@COI\>CC;'XI-[XG9S)/R^.Y.1<+R97/\ L
MKKXX!Q)IG*O@P=7="K+$Y517-AQY0V]O5<O(][#TUNX RR?Q$Z\KG('7E<@=
MI%/V4W0W"$G"OYC=6&(P3W'!SR&:TA\S5:6DSF>5U."XEDF9WA?1J,8I;&[G
MN16H]X*Z*22X 4=[/DR7#;'C"3NXT@HA,1SWM15HC2.J*,L[!1WG_ XGLI+N
M(T9V]%5+'N S663-<MML\R_)<TO"^K;91=6-W.5'.<P9K"221\N'R]VQHK'M
MC11IV:*.(0F(UK$1-6B+&BHOHHH4=P&,GM/$GF=:RDCF1WD;B[%CXGAW#@.R
MIR_#HU+^&FVYFPK*+ZE'K*$V5$<1G<)\LNAR(=0Q$<B-(M?"99V:N8KGQ9@:
MLCD;ZHW<@;2FW(1&/2E.#UA%P3[S@=H)J?LV'?F,I'FQ#3M=M![AD]^*M[ZA
MOT![L_=-L3^$K?E-;^L0?C1?.M6]UZM/^$_RFLO'-566K^F,>1[1C:Y[WN:Q
MC&-5SWO<J-:UK6HJN<Y51&M1%555$1.Z\**L0U1\./:><T\2^S>_K=91)XAR
M(E5-K)%[D[0$:CV$L*@4RJBUCB,<US8LFU6P"JN'-A1"L4:UTVTHHV*HIE(T
M)!"IGJ!()/:0N.HFK*'9DLBAG<1 C(4J6;':,J!W9SU@4H\_^&5L.AJY-C@6
M=TF>2HPG&6EGU)<1LIB,15]"N*6UNZPTER]O!DZ?6!=[I\PCO%KT1[4B9@)(
MVC!_F#;X'?HIQW GLYTJ39<B@F.19"-=TKN$]@.6&>6I [JK9M*NRH[*=3W$
M"75VM7+/!L:Z?'+%FP9L4C@R(LJ,9K"@.$K',(,C6N:Y%14Y9@A@&4@J0""#
MD$'@0>8-5A!4D$$$'!!T((X@BG;T!NB^T5LFDS:I*<M<TPX&4TXWJ@KW&Y!A
M_:,$C%<T:R1,:DRL,_VC64>,9WD)"C(S<0+<1-&<9XHWW7' ]W(]8)IZVG:W
ME5P3NY <?>0G4=_,=1 K3?56D"[JZVZJI(YM7;P(=I6S JJBEP+"..7#DB54
M15&>.896*J(JM>GMS+D%25(P5)!'40<$>!K4 A@&!R& (/6",@^ZJ!OB&?K+
MW_[,XC_REG-#L[U5/:?YC6?VEZT?83\C4'^3J@5K<KO^SX/_ (.+_P"@SF0;
MB>\_G6O7@.X?E79SE=JK[XH?Z/-8_MG9_P#(R<M=E?:2^POS55[5^RB_$/RF
MJ6.7=4=:%/A^?JPX?_GK,?XEL>9W:/K3^RGRBM%L[U5/:?YC73UN[YF:3U2D
M;&Y:Q,XSV1)H,>E#=XR*F"$#"7]_'^BI(@1I$6'"(U4?&L;2%,:CDC.8O+&W
M$\V6&8XP&8<B<^:I[#@DCF 17;ZX,$/FG#R$JIZACSF':!@#J)!Y8.>1[WD>
M\A'N(0CG/(1[E>][WJKG/>YRJYSG.55<Y555555555YHZSE/)IC0>R=\7AJ?
M :=AH\'TG7.0697P<>HQG5R!6QGH([U,;Q>H($&/,L3L84H8CP@.03,UQ%;K
MF1L$^BHU9NX=0YDD#MR13\%O+<-NQKD#TF.BKWG_  ,GLJ?\#X6=H2$U]GNF
M!$L58BOC0,$D6$)A.WNULZ1E=8<C._LA%KQ.[>_II].5QVL,Z0$CK,@!]P0C
MXU8#91QK. >R/(]Y<'X"HK;WZ+MLZ,KC9+*;7YCA0'M;*R3'$DJZI0CVC$^^
MJ9(VRZX12.1C9@'V%:-[A"/."<X0OEV][#<'=&4DY(V/.]DC0]VAXZ$#-1+B
MQF@&_HZ#BRY\WV@> [02.LBHA\F5#KZ"_G&_Z?\ =7A2D](>/Y&M<G,?6NHX
M44<**.%%'"BJ&_B2WTFSW_ J'D=\KCF!T40 >Z^FT]C,MK:2=&_1"&9+C"(Y
M/=S(H47^0G+_ &8H%N6YM(Q/@  /@3XU0;38FX"YT6-=.HDL3[]/=5??+&JZ
MM0/3WKRIU?IS <3JHP@N%CU;97!QL:U]CD%M#!/NK [T3S(\TTQ!@]1SW A!
MBQ&.]&.)K<M<R-+/(['/G$+KG"@D*!W#JXG)YUJK>-8H8T7DH)/6Q&6)[S[A
M@<J>?C%/5YMS3UF0U-E174&/95%Q!E5EG7RF(6--@S0OCRHQF+_*&8)'L<GL
MJ(O=JHJ(J=5BI#*2&4@@C0@C4$5P@,"K $$$$'@0>(K+!LO%&8+L7/,*&1Y@
MXGF&28Z Y%12'C4]O,@1CO5$1/(X #*[LB>[U]D^G-9$_211O]]$8]A902/#
M-925.CEDCSG<=E!ZP"0*</I<_6)TU^\#'O\ C6<:N_5I_P -ORIVS]:A]L?D
M:TW<R]:>LJ>T_P!)^Q_V\R_^(;'FLA^RB_#3Y163F^UE_$?YC7\:RPP^Q=AX
M5@L<K@/RS)J:C))8B.=$BSYP03)J-<BH[Y*(X\I6JB^2!5.R]^R]E<1QO(?Y
M$9L=9 R!XG3QHB3I98X_ONJ^!.I\!DUJ/Q7%J'"<<I\3QBMCU-#0P 5U9 C,
M1HPQP-\4<]?Y1I!G^1Y4DJO/*DD+)D$(8I'NRCNSLSN268DDGF3_ (Y < -!
MI6J151510%51@ <A_O4GF=32@XFE4<**:/9>^-1:@8W\86<TU#,()#!I_,]E
M?'$[NC#"HJH,ZV6.1R*QDIT-L7R[HX[>SE1Z*WFF^SC9APWL87^XX7PSFF9;
MB&'[215/'=SEO[1EO'&*BI:_$JZ?H!G"A5.RKMJ*J-DU^/4L>,]$7^4GVOD]
M9*1%3W3RBH[[E1/NEC9ER1DF)>PLV?\ I1A\:B-M.W' 2-W*!\S _#]*\;_I
M.M(_]R]J?ZKQ'_\ V7%?NN?^I%[W_P"RD_O2#^G+[D_[ZK=ZN=TX+OG9-;G6
M#TF048TQ6!2W8\ABU<65.LJ^?9D#.8E7:6HRM^S94.$I"F&5&PAC07@QKG6=
MG!);Q&-V5O/++NDD $#34#F"?&JV\GCN)%D167S K;P )()(.A/(X\*BSR54
M2M2^CYAK'2VH9\AROD3=88#*.]R]U>:1BM44KE7[U<]SG*O]_,I< ">8#@)9
M .X.U:N YAA)XF*,G^P55[\3+4GV??8IN:KB^,:_$S$,J>-G9K;FN 63C\XS
MD15<6?4BF5[WN5K!BHX0T17%][79<V5> G53OI[)T8#L#8/>QJJVI" R3#^;
MS&[2-5)\-/ 555]/IRVJIK2STG[7_'#H[#LEE2?F;^LB_@ME3G/\S+?T PQC
M2I"]U_/6T%T"[<GLB?:2-1$\>R9B\AZ&=U'HD[Z>RVN!V*<KX5I[2;IH$<GS
M@-U_:73/B,-XU%KXE6V/P?P''=35LGQLLZFMN;]@W]GBQB@D#)$ 9J*CFLM;
MYL<@'IW:YM%-$].ST[R]F0[TC3$:1C=7VV&I'LKQ]H5$VG-NQK"#K(<M["GA
MXMCW&J2^7E4=:2.C[4OXH-%XI438ORV1Y&+\,<I1[/ [+6]" @()VJGDPM34
M"K:LP_)S$E1))6=O6=S,WDW37#L#E5\Q.K=4G7Q8D]Q%::SAZ&!%/I-Y[]>\
MP&G@ !X<,TO^H;] >[/W3;$_A*WXW;^L0?C1?.M+NO5I_P )_E-9>.:JLM4Z
MOA[ZUK,]WLRXNXHYE=KRBD99'C'8T@"WZ385;1J4;D[*L(TR1;QW?T)M9&<J
M*G=.0-HRF.WW5.#(VX2..[@EO?@*>PD5/V=$)+C>89$:EL'[V<+ISQDGO J_
M[F>K0T<**I@^)MK6LILKP79U7&''DYA%LJ#)5$QHVRK''QP"5-@;LG<LN363
M#0#$5>_RU1"9V545>7>RY69)(B<A"&3L#9WAV $ ][&J3:D05XY0,%P5;M*X
M(/?@D'7D*JVY:U55HWZ'\DD9-TR:V-+(XLJGC7.-O<Y57M'HKZR@U8T[]U1H
M:<=>%$^B>GV;V;V1,W?J%NI<# ;=;Q902?%LFM+8L7M8B?Y05\%8@? "JJ/B
M&?K+W_[,XC_REG+;9WJJ>T_S&JG:7K1]A/R-0?Y.J!6MRN_[/@_^#B_^@SF0
M;B>\_G6O7@.X?E79SE=JK[XH?Z/-8_MG9_\ (R<M=E?:2^POS55[5^RB_$/R
MFJ6.7=4=:%/A^?JPX?\ YZS'^);'F=VCZT_LI\HK1;.]53VG^8U GXFE])F[
MJQ*@4CE@T6O(,D057NUD^ZO;Q\TK4^B*6+ JQN^]?03O[=NUALM0(';FTA'@
MJKCXD^^J_:C$SHO)8P?%F;/P JN'EE5;6F?I<UY4ZTT5KJDK8P@RK+'*K)[^
M0QC4+/R#(X$:SLI$@J(CCK'<<==%>3NYE?!A@1&L$UJ9>[D,MQ*Q.@8HO8J$
M@8ZLXR>TFM1:Q+%!&H R5#,<:EF&23SYX[@!IPJ0/(]2*X["O@VT";5V<2//
MK;*)(@6$&6)AXLR%+"^/*BR0D1PS D (\11/:K7C>YKD5%5.=!((()!!!!'$
M$:@CM!KA (((!!!!!X$'0@]A%9;MR89'UWM?8>$0G/= QG+[RKK'$<KRK5@G
M&6K]9[NZN-]GNC>LY57N7S7NOUYJH7,D,<AQET4G'#)&OQS65G01S2H."NP'
M=G3X8IN!?SC?]/\ NKQVD)Z0\?R-:Y.8^M=1PHHX44<**.%%44?$KQF55[RH
M\B4;OD,IP6L4)U148ZPI+"R@3HS5[=E<"(^J,_LOLDQG+[9C P,O-)#IV, 1
M\<^ZJ':B$3J_)XQKVJ2#\"/>*KNY956UIAZ7-LTNWM,X==5\P);FFIZW',MK
MT(U95;D%1"##E*</=7C!9M"VTKWKY-)#EC;YJ81V#S%W"T,[J1YI8LAY%6)(
MQW>B>T&M/:S":%&!\X *XZF P? \14A^1JDTF<RS#'L!Q>[S'*K$-708_ -8
M6,PSFIXB$G9@ ,5461,EF<.+!B#[FES#!C :\I6-5:(TCJB#+,< ?[X #4GD
M 2:0[K&K.Y"JHR2?R[2> ',UEHSO*3YQFV89G*%Z$C+,GOLD-'\O-([[NTE6
M2QVN[(BM!\SZ351$3Q8G9$3VYJHT$<:(."(J]^Z ,^.*RLCF21Y#H7=FQU;Q
M)QX4Y_2Y^L3IK]X&/?\ &LXU=^K3_AM^5/6?K4/MC\C6F[F7K3UE3VG^D_8_
M[>9?_$-CS60_91?AI\HK)S?:R_B/\QIV>CQ$7J8U"BHBI^$I5[+[^[:BS<U?
M\J*B*G]2HB\9O?59O9'S"GK+UJ'VC\K5I3YF:TU'"BHL=7V]I6AM2RKNC4*Y
MCDDYF-8FIF,,.#-DQI$F9=ECD1PSLJ(,<I0#*P@"61JX4D1(Q"L=+L[<7$P5
MO00;[]H! "Y_U'CSQG&M1+R<V\)9?38[B=A()+<#P )[\5G0N+BVR"TGW=[9
M3;BXM)))EC9V4DTR=-E&7R(>3).]Y3$>OU<]RJB(C4[-1$32*H4!5 50,  8
M  Y "LVS,[%F)9B<DDY)/::D%I?I.W)O6 2[P^HKJ_&AR"PVY-DT]U542)0%
M1IP0F@C3[.P]!W<9SP:V1%"9KXY3LD,<)(\]W!;G==B6QG=49(!YG4 =>"0<
M:@5)@LYK@%D "\-YS@$CD-"3W@8SIG-2)3X8V\NR=\RU0B]O=/MC+U[+_5W_
M  )3O_E[<C?O2W^Y-_:G_P#2I/[KG_J1>]_^RHK[ZZ?\OZ><BIL:S&UQNUFW
ME+]N138U*LY4447YZ5 ]*0^TJ:@S9'K1".\1A*/TW,7U?)7,;+M[A+E2Z!@%
M;=.^ #G .F&88P>NHEQ;/;,JNRL67>!7.,9(UR!U4Q7'ZCUJ,T!^@C2W[I]=
M_P (U',K<>L3_C2_.U:N#["'\*/Y%HWOK")N+4^::_.T22KFI*^DD%[(V%D5
M>YL^BEJ]?RAB'9QX[):L5KB0B20*Y&%<BEO*89DD'!3YPZU.C#W$X[<&N3Q"
M:&2,_P RG'8PU4^! _\ /"LODV'*KIDNOG1RQ)L&2>',BG8HSQI44KP2(YAN
M[.84)F/&1BIW:]JM7W3FI!! (.00"".!!U!\:RQ!!((P02"#Q!&A![JL<^&Y
MMEN+;)O=86DI!5&P*]9]3ZQ$:(&48Z \KP9YJ@Q?:=&M@T[U<CC'K*T"(YRM
M[5NTX=^)95'G1G#8XE&T\<-C'4"QJRV9,$D:)C@2#*YX;Z_JN?[0*BUU0;6=
MN3=F9Y>"0IZ,4U<?Q7L[R$W&J-SX=>8*+W5C+0B2;L@U5?"19G1%\>R)+M8>
MA@C0C#8WGZ]]M2#W:+W 5%NYNFG=P<J#NIU;JZ CVM6\:]SI"U+^.#>>)TLR
M-\SCF/E7+\J:]GF!]11& 44$[53Q<*WM25M29GDU_P M-D$8O<2\3>3=#;NP
M/G,-Q/:;.O\ RC+=XUI5E#TUP@(RJ>>W5A2, ]YP.[-:3.9FM+3/=0WZ ]V?
MNFV)_"5OQZW]8@_&B^=:8NO5I_PG^4UEXYJJRU6/_#-R>#5[DRO&Y91AD95A
M!UJ_-R(Z3.H[.%.)#$B^[B.K"V,U43Z"@%<OT3E;M1"8$8<$D&>P,",^_ \:
ML]EN!,Z'BZ:=I4YQVZ$GP-7D\H:O:.%%5*_%'R>"D'4^&C*Q]DZ5D63RPHY/
M4C06!@U5>4C?JC)TA]FP3OHKJ\R?5J<M]E*<S/RPJCM.I/NT]]5&U7&(4YDL
MY'4  ![\GW54#RYJFK0YT"59ZWIAPDLACF+;666V@F.14=Z#\FLX07]E]T:5
ML+UAK]'#(QZ>SDYG-H$&ZDQR" ]^X#_FM'L\$6L>>9<CN+']*K&^(<-[.I:[
M<YJHA<6Q(@U7^DQ*U1*Y/ZT\QO;_ )6JGW<M=G'-JO8[@^_/Y&JO:7K)[43_
M "*@YR=4"M96*VD6\QC'+J"1I85Q0T]I#*QR.82+85\>7'(QR>SFO$9CFN3V
M5%14YD7!5W4\0S ]X)%:Y"&16' JI'<0"*][B:5537Q1\CAMJ]38DPK'V!9^
M29'("UR*^/#CQZ^LAE(W^4C)AY,Y@7=NSE@R$^K.6^RE.9GY811U$G)/NP/>
M*J=JL-V).99F\  /CD^ZJ?.7-4M:%/A^?JPX?_GK,?XEL>9W:/K3^RGRBM%L
M[U5/:?YC4%OB<XS)@[:P?*_3<D#(<$;4C+V7Q?98Y=V1IK4=].[(5]4JK?JG
MEW7V5.3]EL##(G-9-X]S* /BIJ#M1")HWY-'NY[58D_!A5:G+.JNM(_2!MFE
MVMH_#20Y@7W^'TM5B&5UWFWYR%94D(5?'F&#W\DCW<***SBG:B@>II$9CO7A
MR1!S5["T-P^1YKLSH>1#') [5)P1QT!X$5IK.99H$(/G(H1QU,H ]Q&HY<1R
M-2AY$J57AY-DM'AV/V^4Y+91JBAHH![*TL93T8&-%CL5[U^]Q"D7Q%'CB:\\
MF0\4< R&*-CE(C.RH@)9B  .9/\ CF3P U.E)9E16=B J@DD\@/]^)TK+?M'
M-'[%V/G&=/"^.W+,INKP$4BHKXD.?/,:#$>K55KGQ(;@1W.151SA*[NO?OS5
M1)T44<><[B*I/60,$^)K*S/TLLDGWW9AV G0> P*0XOYQO\ I_W5XY24](>/
MY&M<G,?6NHX44<**.%%'"BHC]9.@#;XU:X%$$;\ZPT\B^Q)'JQCK'S @[;'%
M,148%+J.$#HSWN&/[5@5B',&*L@B3+*X^KS98_PW&Z_9KHW_ "GO\TMSQ4.]
MM_K$6%^T3+)V]:^('O Y5G7EQ)=?+DP)\:1"G0I!HDR'+"2/*B2HY'!D1I,<
MS6% <!6/$8)6-(,C7,>UKD5$T@((!!!!&01J"#P(/,&LX002"""#@@\0:76M
M]J[ U'?)D>O<FGXY9N8T4KY91'@V,=KO-(MI62QGK[*,CE5S!3(QD"1?5 HC
M(TB-RQ1S+NR(&'+/$'K!&H/<12XII(6WHW*G3..! Y,#H1W^%31B?$RWQ'@I
M'/C6L)TMK$8E@>DR017KV[*4T>)ED>*XBK^5^9%'%W]O2[>RP3LNWSG>E ZM
MY?S*$X]Y[:G#:D^,%(B>O##_ /;%1=W!U&;;WD8*9]DQ)-5$-\Q QNK .JQV
M$?Q<UIV5T;_K<IC7D8*;9FGSA#*0(I+ O4?)<-M# #T:8)XL3ECV9/ =@P-,
MD9UJ)-<S7!_B-H#D(NB@]>.9[221KCB:8[C],4_72Y^L3IK]X&/?\:SD>[]6
MG_#;\JDV?K4/MC\C6F[F7K3UE3VG^D_8_P"WF7_Q#8\UD/V47X:?**R<WVLO
MXC_,:=KH[_68U#^TAO\ D]GQF]]5F]D?,M/67K4/M'Y6K2ES,UIJ.%%54_%)
M@SB8QJ"S&UZUD2^RV#+<G?TTG6-?2R*YKU_D^;H]7:*/O[^+"]O;RY;;*(WY
MAS*H1W L#\2*J=J@[D)Y!F![R!CX!JIMY=52UH&Z%=MX!D^D<,P6NMZN!F&'
M0YE5<8N>2"+9$=]I39C+>#$(X9;"%8BE,E'EQ6%8"<63&D.:5B.)G;^&1)Y)
M"I*.05?!(X ;I/(C&,'D,C2M%831O!'&&4.@(9,@'B?. XD-G)(YG%2[RS-<
M1P2J/>9EDM+C-5'8\A)MU81H G>"=_3 TY&DE2'KV:*-&8:0<CFB"(A'-:L1
M(WD(5$9R=,*"?RX=I.@&IJ6\B1@L[*H&N6('_P!^%9YNK_>]?OS:Y+_'P%#B
M>.50<9QHLD*@EV<.-+F39-Q)"]$+'^T)LTRQ8Q?$@8 8GKB!+?)&FCL[<V\.
MZQ!=F+MC@"0!N@\\ #)Z\XTQ6=O+@7$N\H(11NKG0D9))\2= =0..M17Y*J)
M6HS0'Z"-+?NGUW_"-1S*W'K$_P"-+\[5JX/L(?PH_D6G<XS3M4!_$#U)^+S=
MA\KKHOHX]M",7) .&SQ +)([QQ\IBM7M[E-)+$O3.55[OO'-;[#5$T.SIND@
M"$Y:+"GV3G</N!4>S6>VC#T<^^!YLHWNY^##QT;O)J#L*=-K98)U=+DP9L9_
MJ1Y<0Q(\@#^RM\A&$YA&.5KG-56N3NURM7NBJG)Q (P0"#Q!&0? U!!*D%20
M1P(XBN7G:Y5[/PYM2_@;J:=L2RB^G=[,G(>&XC.Q@8G2$D1*IB(Y/,:6,]]G
M9.<Q6LE0WU151R"&[E!M*;?F$8/FQ#!]ML%O< !V'/;5_LV'<A,A'G2G(]@:
M+[SD]V*L/Y758TSW4-^@/=G[IMB?PE;\>M_6(/QHOG6F+KU:?\)_E-9>.:JL
MM2BQ+*[[!LFI,OQ>P+5W^/6 +.KG"[*H9('=_$@W(HSQSC5\>7&,UX)44IHQ
MV/"5[')=%=61P"K @@\P?\\P>(.HUI2.T;JZ'#*<@]OZ'@>L5=GJGXC>H<DI
MX@=H-GZ]R806#L"AJ[.]QF;(:U&ND5AZ@%C;11G<BD6'80.T-'M"EC.1CI#J
M.;9LRL>BQ(G++*KCOWB%..L'7C@<*O(=I0LHZ7,;\_-+*3U@J"1W$#'6>-*/
M/_B'Z QBKD&Q&QM]B7?I/2%655/;4D%9'BJC2PMLBKZYL>*J]D(:!$M3M[IX
MQ7KW\4Q[-N'8;X$:\R65CCL52<GL)7OI<FT;= =PF1N0"L!GM+ :=>,GLJD_
M;.T\JW+G5QGV82!EM+1[!@B1D>ROJ*R,BL@5%8$CR.#"AC54;Y/>60<DB9*(
M67)D&)>0Q)#&L:#11J>;'FQZR?AH!H *HYI7FD:1SJ> Y #@!V#\\FDYAN)7
MF>9508;C4-\Z]R2TBU5;':CO%3R2(U3'>UKO1B11>I*FR')Z<:($T@JM&)[D
M4[K&C.QPJ@DGN_R> [:0B-(ZHHRS$ #O_P #B>RM2>OL-K]>8/B>#52J^!BF
M/U=& RM1CY2U\00#32M151#SCM++/V544QR+]_,I(YDD>0\78L>S)SCN' =@
MK5QH(XTC'!%"CMP,9[SQ/;517Q.\$E0<[P+8P0.6MR#&RXK-,QJJ,5OC\Z58
M1_7?V[,+.KKE&1VJOYP=3(5J?FGJMQLN0&.2+FK;X]E@ <=Q77VA5/M6/#QR
M@:,I0GM4DCW@GW55YRUJJJSGI;Z]X.L<0K-;[5I[FVHZ$?R>-9+0-C3+*!5^
M3G J+6MF2H22HE?Y**#-B2UD A-#!6 9H!EY5W>SS*YEA*JS:NK: G[RD X)
MXD$:G)S5I:;0$2"*96*KHKK@D#DK D9 X @\,#&F:D_E?Q*=(5568V+4^999
M<*)RPX!*V/0U_K]N[6S[.;*,>,'O[.)#K+)Z+]!*B^214V9.Q\]D1>9R6/@
M #XL*EOM. #S [MR&[NCAS)/#.AP#5.VX-M99NS.K3/,P.)UA.:.+"@1$>RN
MI:B*I/D:BM$1Y'LBQO5*1SGO<63+/)F'>^1)*Y;F&%((Q&@T&I)XLQXL>T_
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M$:($:-'&XQSG*]6L$$(F/(0CU1K&-<YRHB*O.@$D :DG '637"0 2= !DGJ
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ME@=4).N[IJ-T:9&02.&M5'[S"S."N]#G"E=&  QG70@G7E@?&;6$]7W3IG8
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M.FR5MRLE5&B<TVG;8KD\+8$W%:B.<U-E$W&[>S/BV:RZ_P"6*2JLY5G,?9S
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M59"H+.OKD3^ICH;AM^YB<DK>W2\)F/M!6^+ GXU&:RM6XPJ/9)7Y2!_O'"D
M[X>730I/-*')VM[]_2;EMKZ?^3NYSB]O_-[_ -_'/WC=?>7^Q:;_ '=:_<;^
M]OUI>8QT6],^*''*AZMJK.4-6N]7)I]SDXGJWZ*^NO+&=5*G?W5J0$:[^DBH
MB=D/?73C!E('^@*A]Z@-\:<2RM4P1$I(YL6?X,2/A4F(%? JH<>NJX,.MKX@
MT#%@P(P8<.,)O\D4>+'8, 1IW7LP;&M3O[)R*222222>))R3WDU)      '
+ 8 [@*[.<KM?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g796801g02e22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g796801g02e22.jpg
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M 0$! 0'_P  1" !D ;@# 1$  A$! Q$!_\0 '@   @(# 0$! 0
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M*OL R/U&JQ]J3D]!(T'406/M) _TCMS6IUWJ)]24([32;/$+@;7<K%L<4BB
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M]C[C57;_ &B#\Z+XUJTN/L\_Y,OP-57;755RM>V-8SX<>PB1)DF-%MHXHEF
M!GB%8102X]@&-,8QR)(CCG1(DQH2HX:2HL<_;Y0"<WP@$@D D'()&H.",CJ.
M"1IR)'.O0Q (!(### <QG.#V9 ..L"O&UKG.1K45SG*C6M:BJYSE7A$1$]U5
M5]D1/=5]DU[7E3'Z)<?OH/4]M1,FTEO#AK(RI4E2JV;'C*C\%R=K50Y0L%PY
MSFM:O=PJN1$Y54U#OF4VLP# G"Z @_?6IMDCBZA)5@,MJ5('H-S(I_N7XM49
MQBV0X??@632Y-3V%)9":J-(L2QC$C%>$G"^*0%">:,9$[@G&,K?M,1=<ZCF-
MU=?21@P[P<UT+H)$9&]%E*GN(Q57;<_;ZZVKS_*MO[]JI98Q;'@*?L48Y\->
MT]9:1V.57-C6M::+8QD<JN:&2QK^'HY$ZJ*198TD7@XSW'@1WJ00>T5RLL;0
MR/&W%3CO'$'Q!!K=,*Z:]^-PHP9V)[795/KY#6OC6<V&.BJY0W)RTD6SR U7
M E#5/\X"01B?17(NL'NK>,X>5 >8!WB.\+DCQK-+6XD&4B<CK(W0>XM@'PK?
M+7HBZHJ>(^;)VJG2 C8KWLJLAQ"YE\(G*M9 J<@F3S/X^C 1BN5?9$551%UB
M^M&.!,-=-5=1[64 =Y.*VM872C/FL^JR,?8&S_>HQ6E59T=A+J;JNGU%K ,Z
M/.K+.)(@6$*0SCO!+ARABD1S-Y17#,-CT1454]TU*!# %2"#J"""".L$:&HC
M*RDJP*D<0001X&O107USBUU5Y%CUE+I[RFF@L*NS@E4,J',C/1XC">GYE3M>
MQR.&4;GB*QXWO8XRJZE6 96&"#P(KU69&#*2K*001Q!'_>X\#5EWIOWA#OEM
M%C.=N8$%P49:C*(4?V%#R6J5@+%HF<N\4><UT>VA!5[WA@6,49'N(UZZY>YA
M,$SQ_=&J'K5M1WXU4GK!KIK:;S\*R:;W!@.3#CW9T(["*4GZBFTGX$[O1MP*
MV-XZ+<^&^=(4;.!1\KIV1XEV)4:BM9\PBDK+;O>Y'R9DNS<UJH%RZN-FS;\)
MC)Z41P.U&U7V'*]@"U4;2AW)A(/1E&3U!UP#[1@]I)I>^K&JZK)71_NQ^Z[L
M3B5Q,D_$9#CH5P[*'.?WF?;4(0!#,.Y5[G&MJ@M9:F?VM:LB:=C>4&JZYF\A
M\S<.H&%;IIU;K$Z># CN KIK.;SUNC$Y9>@_>O/Q&#WDU)[46I51SZK-UTV=
MV/S')XLGX:_L(OX,8HK7]AOPAOAEBQY4=55.35$-LZ\1J\HYM8]O"\HBR;2'
MS\Z(1E0=]^K=74@]A.%\:C7<WF8'<>D1N)ZS: ^ RWA5:-555557E5]U5?JJ
M_G773US%-.],[:7YIDV5;QV<7NB8R!^)XN0C.6NO;6.P][,"[A%::NI"QX*J
MBJUXL@,G'<-%2JVI-A$A!U<[[^J#A1W%LGO2K;9<.6><C1>@GK'5CPX@8&GX
MC4TNOG^2WN!_;L+_ &UH-0=G_:X^Y_@:INT/LDG>GQK5=_71USE?>5X5.5X5
M454Y]E5.4153Z<HBKPOW<K^==*5T7!-H=S]S7%_ '!,ERD('^*1-JZPY*R,;
MA'>&3:D:*MC&5KD<T)Y8R.:O<UJM1537)-%%]9(B=0)&3W+Q/@*VQP2R_5QL
MX&A(&@/5DZ?O6S9CTX;Z8#7&M\KVORRLJ8S%++LQ0$M*^$)J<J:=-J"3XT$*
M?12RR!&BJC5=W*B+@ES;R'=25"QT S@D]0#8)\,UD]K<1C>>)P.9QD#OW2<>
M-<3UOK17:MA]\LMV%SJ#EN-R"GKR$#&R?'7G>.OR2F0G)X<EGVACF!:XA:NP
M\;S5\M4(UI8Y)4:1HN($N(RCC74HW-6Y$=G6.!';@C?;W#V\@=>!P'7DR]1[
M>H\CXU98PS+J//<4Q_,\:E?&T62U<2VK3JB-)\/+&C_#(&CG>"7%)WQID=SE
M?&EA, G#QN37,NC1NR.,,I(([1U=8/$'F-:Z='61%=3E6 (/8:@'ZG?Y%,)_
MO2KOV3R_5ALOZ^3\H_&E5VU/J(_S1\#TCG5[5%3JO2]_)QN9^FU?^HH^J/:O
MUL7Y9^(U>;*^JE_,'PBF?:JZM*-*55]ZC/R_[U_WJ9[^T]GKJK?[/!^3%\"U
MRUU]IG_-?XC7.L1_C7C'Z0TOZRC:V/Z#>JWN-:D]-?67WBK8^N1KKJ@=UQ]3
M4O97%(>&89,0&XV;1#D!.&J*;%L;:]\61=C1>5;93Y#30*1ZM5H21["=W--
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M*F \G/P]57$%%")&>;XJ5YI9N:GNI9V)9B%Y1@D*!RR/O'K)U[N%=+!:Q0*
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MY55?JNIZJJC"JJCJ4 #V#%06=WU9F8];,3[R:PNO:QHTI1I2FS>EE_E+>O\
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M%RX(WP@/X% /@QRP\"#X5FFS[5#G<+D?C8L/$#"GQ%<J]1?,*##MC:+;&J'
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M G';@59S*7BE1<9>-U&>&64@9[,FDF?O<749_1P3_F@W_E.KSZ3MO_)^@?\
M*J/Z,N?_ !_K/_&I-](_1WO!LMO'!SG-$Q9*./0WM<3Y3=DGS/B;&.,4?MCN
M@1T4?<U?([R)VI[\+]-1;R]AGA,:;^\64])<# .NN34JSLIH)A(^YNA6'1;)
MR1II@4UC535M1I2A4145%1%14X5%]T5%^J*GWHNE*6AOYZ=>-9Q:3\KVCN(&
M"W4\I94W%[*.9V'RY955Y#5QH(S3L<0I%<\L8$*SK^7(V'#KQ,['VEOM)HP$
MF!D4<'&-\#J(. W8<@]9/*LN-FI(2\+"-CJ5.J$]8YJ2>/$=0%0/N.@;J@JY
M#PQL$@7H6N5J3:?+L42.3A51',%;6]5/1KD]T\D)BHGXR-7VU/7:%J1K(5/4
MR/D=Y"D?O5>VS[H<(PW:KI_<@_M64QKT]^I:]E"#:8Y08?&>YJ/FY!E5-*$-
MBK]I_@QB1D,QSD3GABQV*J\(JM15<GC[1M5&C,YZE1A^[A1^YKU-G7+<55.U
MF'_QWC_WOJ=N/]!%-@&SNXU/2SHF8;O9EBDNBB9);#^54]0DL@'F@4L?_#25
MX3M&HIEH=TB=,&WQL;!BG/#? ;:#231LP*0H^\5&K'&0"QTR1G0# ':0#5@E
M@L4,JJ=^9T90S: 9QH!K@=9U)[M*A5^]Q=1G]'!/^:#?^4ZF_2=M_P"3] _Y
M5!^C+G_Q_K/_ !J>'0_TU[D]/\S<@^?I0(S*8V*BJ_DMJ^R=WTY<@?,^)1\2
M+X4XLHWB5%?WKY.>WL]X%]=17 C\WO= OG>&/2W<8U/4<U/L;66W,OG-WIA,
M;ISZ.]G.@ZQ3 ]5U6-&E*3;ZGV#T<#(=NMP8LF*"^R"!:8Y;5J*C94^+0NCR
MZZW8-J<$2*EH:MFG(J/['5(1][!.0=ULJ1BLL9!*J593U%L@CQP"!WU3;5C4
M&.0$!FRI',@8(;PS@]XI5.K:JBG3>FCM+\FP[)MX+.+VS\PDOQO&B$9P]F-T
MLGNM90'\(OBM;X:1"M55X?CHW-X:3EU)M2;>=80=$Z3^LPZ(\%.?ZJO-F0[L
M;3$:N=U?47B?%LC^FFA:JJM*-*5'GJGVRR;=_9'*\ Q!*];^YDXX6'\TENA0
MNRKR2JM)7EDM"=6+\+#-XT03N\G:S[/=W))M)4AG21\[JALX&3JI TTYFHUW
M$\T#QIC>8KC)P-&!.3KR%*2_>XNHS^C@G_-!O_*=6_TG;?\ D_0/^55'T9<_
M^/\ 6?\ C4N.G[H7-7;?;DX+OU54DP.36>/66-6.-VJR;:BF5<.XC'L:^P)!
M$L&4U9P6^$@I4.<'O#.C' BB=$N+\&2*2W+ H'#!A@,&*G!&3D:'M!U&#K4R
MWL2(I8[@*=\J5*G)4@,,@X&",]QYYJ..XGIJ[MT4R0;;N\Q[.Z=7O=$CS93<
M9R)C%57,%(CSU?2%5C50?Q(KH7G>U2+#BM<@VR(]IPL )%:-N9 WE\,=+PW3
MWFHTNS)E),3+(O($[K?OT?'>'=7&1]"?500_@7:Y1_:X<8F8X$@&I_3\C<H=
MW-^_@;7O_,Q5]M;_ )_:8SYW_1)GV;GOJ/\ ,+O./-']:8^*I [;^F9N!:RH
M\K=#+J3$ZE',>>LQQS\@R$S$5%(!9)0Q:6N>Y%X9+&>Z:Q4570WIQS'EVI&
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M:4HTI1I2D']>^_)-R-UF89CE@_\ !3:V3(KXYXAW-'89CY&-O+49!.;WI6%
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M8L8 T<0QY!R,$(;&JY[WM:U%5=9D@ DD  $DG@ -23V 5@ 6(50220 !Q)/
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M16RJTK%0[K&N%9B7;) PH.- 3DZ:=>!4A=:*WU'SJ!ZHMFNF"'MY/WBR*=0
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M!!&A&#U&@$<\HK 1@&D'(Y&C" ;S%(Y?HU@QM<][E^Y&M55T) U)P.LT )X
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MPESYTJU'$KX\A9%DT+;5K03VFSY+>,":666WEP6.](&S&S9)"_RPS-@  9/
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M[LAR+=*:N ^LK'24A1F$C 9W4;E6=F1-Q"Q*IO%MQ220N\>DVZ,#>.IQFKE
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M1ER4^6S*RLM(\RPJWR$LK.992YED>ZB=+B""]F@@DN=]$\XROKNN$#,H<*S
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E1]IKS=7\(]@K)(B(B(B(B(G"(GLB(GT1$^Y$UY7M&E*-*5__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g796801g03h66.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g796801g03h66.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X5NB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX
M;7 Z0W)E871E1&%T93XR,#(P+3 W+3,Q5#$U.C(T.C$R*S U.C,P/"]X;7 Z
M0W)E871E1&%T93X*(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P,C M,#<M
M,S%4,34Z,C0Z,3,K,#4Z,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \
M>&UP.D-R96%T;W)4;V]L/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W
M<RD\+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @(" @/'AM<#I-971A9&%T841A
M=&4^,C R,"TP-RTS,50Q-3HR-#HQ,RLP-3HS,#PO>&UP.DUE=&%D871A1&%T
M93X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F
M.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U
M-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M:&5I9VAT/C$W,CPO>&UP1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @(" @
M(#QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @(" @
M(" @(" @(" @(" @/'AM<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G
M14%304))04%$+S=107-51VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!
M04%"04%304%!04%%028C>$$[05%"24%!04%!44%"+RLT041K1FMB,DIL04=4
M04%!04%!9B]B04E104)G445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+
M0W=O2R8C>$$[1$)!341!=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C
M2'@X9DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[
M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF+SA!04519T%R045!07=%4B8C>$$[04%)4D%135)!
M9B]%06%)04%!04A!445"05%%04%!04%!04%!04%11D%W24=!44%(0T%K2T-W
M14%!9TE$05%%0D%114%!04%!04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!
M04-!44U$06=10T)G8T1"04E'06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%
M54UP1VA">%=X46E00B8C>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-0
M0TY546YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y
M-"]0128C>$$[,4]4,%I85T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N
M9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[
M<6)N2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#
M04U$8E%%04%H141"0T53355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T
M4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H
M9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&19
M5U9P8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H
M66%(:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ
M2VUQ<39Y=')Q*W8O84%!=T1!44%#15%-4D%$.$$Y531Q-T9867$W1EA9<3=&
M6&HK<28C>$$[95EV>E%S=GI$,6)68D11.5-V=$%-1GAP;6Y75&EL<3%X8E%#
M94LT-$(O55@Q6FQK:CE1>#A757!2=6Q&55!D*UIF>F9U=&(T>#)B>28C>$$[
M,DUO,#AA95 P9'%&;$(V=C92.4]A-&TT>G)-9U-.9WIX4W9X6DYY=D98-495
M,%AZ,2MB,#%P;SEZ2#59:'0O,&I02TQI0S5I=2]5:"8C>$$[:FEA2TI9,T50
M<2MK.&I'5U):6DM2.$%+-SE1<5AA:F,K9F]0>FMU5W1,6%9:.4I';U=N<#!K
M=FA9=%IV<'EP2VEX=$5D4$-,8W1Z928C>$$[5#%!-$E)0VLT<7-S+T\O-3)Z
M86IA,VPY;S97=&MT<G%"97=T=%!V6F5D>DA#:W-%57I38T=$2S-*5F5-*VTU
M1$%%;&QO5E)M;RM:+R8C>$$[>E4Q9CAV-4QS84Q*<#DV3'$S2')W3&0R.3EX
M:3%/245J5%%K:W9P=F)$;$HO<$(R3$1P=F=61#)V;3,X,4ET4C%,55@P<31-
M5GET<"8C>$$[1$4P;&QF4U<X85).<4$Y84=W1&E:5W5F5'0O55AL5U!M<&99
M659D<G9M,S@S3"MZ:E<S,$-E,'9O3#9X;49H0DAC>"]#;#%&5T]7*R8C>$$[
M1$Y$3$1/:&(Q3T,P:E5(;FEQ='%8-6<O;D-T>F%R<'9L>4=A,FQI<U,X:SEL
M<4M3.#=H;S%U2D1'2W!'<TQ/>4=.<&5E,U!D8T-S:"8C>$$[,7)79&4P:GHW
M<%4Q>D)F,W5N4S9.4$)/=6XR,3-.6B]P1G)I06]Z<$5S=VDK0EI+33E3<3DX
M5E-/=S@X+VY.3EHR,#%X-6)T:VQU-R8C>$$[>$Q)>'!B,VQB8WI+<DQ,3W-P
M:5!P5SE'5U=22V]X<'AB>$MP6F4K8R]W035*8FUZ=C4Y065%,D8S9&-,1WEI
M,4%X=4=S8G!9-#=W1B8C>$$[0C9Y4GI#2G5C5E99:V-F:4%X5DYD5S@U+VU2
M+VA,461B9SAU5%-A-WHQ03-D:W-&.&E$,&)A-"MR=3%T2$ER.%IM5D]+5&<P
M2C)(4"8C>$$[:3)"560U9S%F>C=D954W5S13>75)=&%S+TU53G9-;&Q&8U),
M8U=D=&8X1$XV9DIP4'$X,$LX;7%X57%E=$U663-C964O=T$V3%,X="8C>$$[
M3&E0>7E*-4PK># V93A#,G5P4U)P3$XV<G9B2D4P,W!14TE'0WE/85599DA8
M-&5+<69E9'!V3S R<%=X,4MZ,4<P,%998GA953AS6"8C>$$[13%X8U!E0F]V
M<6(S1$I&039)5CE8-%-':D15-7-2:7)'3$174'I3="]--C--*VHV<$IA>'E/
M:E%32%58:')&3'%J97922F936G!!:R8C>$$[04MJ.7I2:S1)0C9F17%J=$PO
M33<X,TIR8E<W+T%&1%%).5 P>E$W84LY85<W,"LX=%I,;4E.>G5&:5=39&Q6
M,&A"+V%B-&AV,31G2R8C>$$[<BME=%4X.#9L-5@X;V%P1&$S,&,Q.# X*V\R
M=6Q0<4U!:FIM=%I'=%)/,FYP9'HO04%-,%I)-&M--' X24]Y<F1V-38O3FUY
M,&E'2R8C>$$[5%%*6G)I,W-90DY*8U=D>$I,55=K5%-8:VMK5&E+4G976C%.
M<D="2CA.83168CAQ*V50>D-46'1.,&)53&8V>DAR="]F4&$S;'IA>B8C>$$[
M,GIP85=L>DDP>D-+5C%:23)T,FA%05E%9VYF;&ER,2]!<G-69&ER<U9D:7)S
M5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5B8C>$$[9&ER<U9D:7)S
M5F1I<G-69&ER<U9D:7)S5E5,-G=S9%%T6'1,*S)I=3=35VYQ,C@V3$I',T5H
M:'E2=U9.0T%C5E9W06]!06]"<T%/;"8C>$$[359D:7%(3VXV96(X86=B84DS
M-G@K9TQZ9W9R0TQL>3E0,4MC=5!,9FI7;&-64D=+=7A6,DMU>%8R2W5X5C)+
M=7A6,DMU>%8R2W5X5B8C>$$[,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+
M=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W9(+T\O
M-7DK828C>$$[.4(Q3%4W87DP3T]D9%!V1W1O65I!-WDS2W)$6GE+<V9O=7<U
M>4QE4$UU>"]D>&M&43%E2W%75T@U-BMB-VE054]7;C)14S!"5F(P4B8C>$$[
M>FE%4G)E,C%S="MW36TY=$Q(8W4V9TU0-W!V:DER>$MV6$Y(.'=#-C!B4F)Y
M+VAE,'4Y5W0T6E1B.$I'16-S<U-Y3D5Z9T9524Q52"8C>$$[26EU0E4S>%8R
M2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R
M2W5X5DPY4S%U1W=L5TM3,74U>7DX9R8C>$$[,71B4WIQ3C953%)Q=T(Y<TE$
M8FIW;5%U=U!E445N,')Z+UDV;&)'-&HP<E9O5D1S;D=3>6Q*<79F.3,V:3 K
M;DI'1D]4;#!-;T=U2R8C>$$[0B]Z9S@W.'AF;G0U;#!H-VQJ;W%T8E=D-W%-
M1%1'36QB;4=Y,6$R<U9&='AN3"MQ25HR-3@P03E4:G@R<4UG-$M.,#,X.#E1
M=G9-1B8C>$$[:%IP<&QL2G X.7HY4G5P-U,Y8398;DI.<#!553!%=VAJ5C%6
M=%0T=D=52%-O9F)I5E8U+U!X5%DV:'%53VME=&%7,7A$8G=21V15:R8C>$$[
M2'%7.#%W5FU:0DU%;6(P0DA(1%-P:UE)4TLQ=W%V=69Z.&AT=DYF*T@U=$5F
M,41Q6#9/4U-+6C5724UO:4)+<$%55UEH=E4Y1G!.:R8C>$$[53%93GA69W(Q
M;D9867$W1EA9<6QU="\X94@O35I$+TA&57EX5C)+=7A6,DMU>%8R2W5X5C)+
M=7A6,DMU>%8R2W5X5C)+=7A6,DMU>"8C>$$[5C)+=7A6,DMU>%8R2W5X5E-U
M-U<S=3=783!U545L=F-),%4P6C9-:F=Q>6UN:41I<4,P2'DW<$=G,FML<G!K
M5'AX4WE'85IP6EIB:28C>$$[5U-1<7%C<$I:,VMK8SA%5E)Y8EE!1&]-5E1"
M26]O>7A21E5S87-604935%=P<#@X5EA9<3AI.&]E9%8X=RMF,#!F4B]/3B]Q
M8E=T="8C>$$[3F0V=D)06E$R<TM',W5)669Q,V]3,FM%-D9V5V8T:$U3<$<Y
M8U9E=31Q-T9867%L=70O.&5(+TU:1"](1E5Y>%8R2W5X5C)+=7A6,B8C>$$[
M2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A63&17=&1F
M;D)45$PK,W-56D-P85<Q931K1&UV>&]W;FA553=!;R8C>$$[8VE196I4;&IK
M4#!K1#18*VM*8G!7:V5E3$MW:'1P=&1T3'53355-.7A9>79)9CA!5UIB<4E.
M5'@T,7=!4T$U=$]01FYJ1VI/2CDX9B8C>$$[*U!":#DR,S5Y=S9D<49J<%9J
M8TIE<G$Y.6-7,G!45#)->5,R53!L=SEP2$=S,'-J2D5J1T@Q1EI1=VDU0E!I
M07EB;4PO3%,O;G=L-R8C>$$[<5DQ=#=E5S%T8F5E6%-74#%59E=R;$5E0T-'
M65)!1E5L6E9U5UEC4T,S2'!65E910V8X04LK2DY+:&MT4%5H=DIR=35E8C9Y
M=&M84R8C>$$[36TS15!/3C5(45)E;#8O1EEN-65P=S556&QH5D8K5F)N."M'
M.'=A3D9R9&MQ84I'2D4Q3S5M;'-05FM!.54K<$Q&8D)U36A,4D--428C>$$[
M=GA!5G5D95$T:%8S-6)72#%8>GIR53@Q-TI$3F5T9EA#-DIC>%AK13!F<C-A
M,T1K8W)M8E0U4%0Y54MZ5S96<6%L=#(U2W95.%93+R8C>$$[5W9-3VDV2D1&
M3G%T,FQP1DUZ<$<X;&%&;S1N;F9O1%1J2$4W12LR2W!$1"MB4#5F5%)Z4$AQ
M-G0Y6%1N2VYO>FAW9E9317AH1$AZ328C>$$[;VQL4E=I035G<W16,T=+<'1F
M,V1T95=M:S-L<DE*8F$U=6)E84-69G-V1S9L;%EE>$)R:7%C67$W1EA9<3=&
M6%EQ-T9867$W1E9+-"8C>$$[=3=3,S1F5TIO-&954$9055E,>5!G2VM6>%I2
M:51Y0W)I>&1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER
M<U9D:28C>$$[<C5T.&Q76&Q,579Z979R*RMV;UE$*VMR;34P94-"8D%4=F-0
M<4-Y>#AP635:3#EV5D$U37-S2SA&3$IY5D]3=7$K:W-64T1Z8C5),"8C>$$[
M2'I62&%2-G1'>F95,FU-5'@X5F-R8S(X;'1,1U=+<S-",&QQ44MF17%N=&ER
M1V)B.&EV2CEV.$%76%,U=GIC6%1'6G)H<%EY-C-4,R8C>$$[14YY.7EG.4QG
M2DAK=$EQ:FIW;W1!;W%A<7-L=61&,"]48DA13$LQ:DMW85A,8C)T;4-34W-3
M2C992'8X2T1&5U%9<3=&6%EQ-T98628C>$$[<3=&5VU:555S-4-Q3GEX3D%"
M:71*3F-E8R]+<TUH:$]P=U14:G)"8G0Y66M(>FIH.5)V=WE80UA*:G!-<$8X
M2G)Z,BLY2U!-6&TK-28C>$$[*W%7+S%$4613=D5E-W1G6&%(-G-!0DUR03AB
M9WAV5FEO56-L03,S27=I4&TU1VXP9W,X5312.4HV,S X<E14+T%"538P.692
M3E5H-B8C>$$[5B]C2DQ3=B]!0F=K;#9E,D-M:CAT,U1G9FI8,V=/+WAR;U,O
M,S1V3%EI;&9R1FIE4D%63E!T4$-&4'I"<&IW;&9Y8RMN0V9D2THO4R8C>$$[
M=51Z>#506F=R87IA4D]X;W%45$I#>$YA54-Y1E182&=08VHX;&TO;5,K5F\K
M,S%N4TQM;C%A*W0U-CE05&Q2-CEV,E-C1DY5<U4T."8C>$$[=U(X148U9G9)
M-VDW,6%.4%8O,&$V15A'5UE3.&8S4TU61DI*3U!X368Q9'%#249-1&E-9698
M,R]!2U4U=V]D:7)S5F1I<G-69&ER<R8C>$$[5F1I<G-69&ER<U9D:7)S5EEH
M-5@X*S)U<RMA9%@X=GE74#%B5DY,96-3>DIC5V-Y4$)&4#9C2DMX5$YC27IO
M=UEQ.%%#-VET85966B8C>$$[9FER<U9D:7%7-C,O04UE2"]-6D0O2$95>7A6
M3')F6'10:VAU2EIP1G1%='!79VU-.&M39T]V545Q-T%F5&AP=6QH:T-!3C<W
M<E%J928C>$$[9"],0EIK=#<P6'IR<U5S235,=S$X4#A!4C%L=SA*8E!Y95AQ
M3T@K=%5F=G!R+T5M<%0W5T]G6#!V+T9L>#9.<6XS4U-E<B]Y5'AR>B8C>$$[
M6#AV16963U!W<R]C2RLQ2G9,>65E2DI.5$,R,FUA4D5B=5%)+T=3-F-R6"M6
M2&=";U!%:C595%1K6GIG2$1V3V9P.3,V,#4O=S=Q="8C>$$[>"]V9G(Y-#10
M5TLQ5T<Q:BMG<6I49CA!2E1"9FLT+S5I02MM169J6B]:.6IA95-F3%!*6'5,
M4#8O274T:W8U2DPQ<6IE=&)H<&-E228C>$$[<61:;#9(:"]Q,4@W<51I,W1R
M93)J159V16M-639*1V]69G5&36DT,'!%-VQ#-GHO04QX>"]W1$U6868Y4DUE
M14YM3&XX1#EX4C)"<28C>$$[9&ER5$MR<59C0FQ/>%5I;TEX5S),83-&;VQZ
M9%!P96XV3EIA;G%H2#<O,6]9,G0W8TU0=%A$.%0Q-U)J-&TY:'9K5&M.,$]A
M1')C<R8C>$$[5'=W:V5,,VUH-R\Q35HP6#AS8FY45&-Y-F)C,T-3<$EV-W%7
M4U=Z4U9E04HY2U,R8U!(4BM106-/=$MB9#A!16\X:F9V6$=-=4%E;28C>$$[
M9FEC5FU1;C9H6C=R1FIP,W Q6C-E;W@S83)2,7DV,#(O8F%/=S%I0T,T:F,O
M=T1&33!F;T=997=L3&5.36M-9S5%53)X,75+4G%C3R8C>$$[1UAK4TPY,T]0
M>51J-C$U,71V-S9W<W116'4Q=$\Y=DHY155Y3W8X07E6>65Z9'<T5'E-;RLX
M6#EO+U4W+T9S54$O,TIA6G%';C R6B8C>$$[;G1Z8TE08W9A1S151#-.365&
M9GEP4#!Y:DPT,2]U<55R>GIP;V)W4G1P*W-74')'94=&-'!8575"3$EQ53E0
M,4EN5F='-6(K1U!#5R8C>$$[54Y(:W8Q4FQ62#=09WE0275'-T9867$W1E9'
M0SAS-V@U16=N:FUE23!L5TXQ67%D.6U!3S-1-'-J06IM1F)&:3=&54)F-B]O
M5VXQ*R8C>$$[=C9J83)H6'%*-6\T+W=$:5)'14%L='@T36LO<&E4-V=X>GI&
M*UEM:U=T<D$K;C-%,7<X='A&0UAT<EHU:S1U,4=R27=736)6<#A6828C>$$[
M-4M-0UA-,"MG;DEN:4%'>$\U<CER0U!Y=# R+T@U<C8U<3)O<&%W5%AD=G%%
M5G1$8E1Z>C Y3%5683=11U,S:&E94C-%:%5M27!V=28C>$$[-G4W1CAG-C4W
M5&ER<U9D:7%7-C,O=T%E2"]-6D0O2$96*W5A=$9P3VQZ,S!I1U9O=T9H9U@W
M57-R:TQ(171F,FYC:%)H071T=S1J:R8C>$$[:TDO9T1Q9F=X-WEJ-4%S3E!3
M-79.6'-,3S4Q=3EN935U<C!$,6EZ>6YM+T@Q14AP:FM4.$LW6DM5>69C-6UR
M,3AP,4=%<$-%4E%(3"8C>$$[;#=U8DPQ5E952V]#<6]O04YG04UG-C5V1E5.
M6E=)=&97<$Y*3#8P:&Q0<6-.;6)R5&=Q9FII>FY0:7):131S2%EQ-T960S=S
M<F4W0R8C>$$[3$]'2WAS2%5+-V]/4VM-<%!!<E=H1E)81FQ'6FIY5CA73%1U
M:4EZ=7=61D),3511041Q4V-6638R;V%J-6=9=S9023%P<$<V>F%U0B8C>$$[
M4U-59$-T;T=(5"]I,#=F>6<Y8W)S>35C;D<T>FLK;F%09CA!<2]8.&LU,'I3
M-TA43%)B4WEI155+:VMG5DQ->"LP-W-A<WI.,UDW;B8C>$$[2F=!8VTV14)%
M5456:%IQ1C=9,E8Y8E!B6'-%9'IB=CEU2U91-FXV1&=)0C5S6E)%:%)&:$HO
M,%)R3VMR6%),:C9Z87)V*VDW-3)9028C>$$[945.>%)P13EG+TIF;&M/16IK
M,65(2U P;7@S2#EF.$%A:4Y0.'I75GAC<EDS8V-M;39M4G1:6%%#<SE/<&EC
M17AY:B]!1D=0=E1#2B8C>$$[:FQY2UE:9U12,FPS2#AB;TQZ=F$K6$IR1S%/
M=%<X37DO5S=94F5T2#9N*S=L-41O9'5"8F),0DMN4# R965-:WA*1W@U6#-F
M<E)(*R8C>$$[0G9+62]U9$UI=&%D4'%V2S)P,S(Y17@T94EP+T\U5'IK5#<Y
M+W9D+VA#>%0O96$K,4LS2%E,9C--9TAY5UHU45!K365*9GIC:GI%5"8C>$$[
M+VUJ.4%$6"M(=%EJ+W="-2]-9#A00DHT-T]69BM40U O=T%0:EDW;#AE0C5W
M:B]S=BM+<C='+W%0;DM,*S8Q97IN2#AT>%EV>5 X028C>$$[<S1R:4U$+V=$
M:EE8:G=N;D=8=VPK=5 V57 P5E!Z1&YV.5A3-75.37-O,75W1FQJ=#5P,F-E
M:D=!44101T8K1&HQ<G980V5&=GI(5"8C>$$[:4UA17HV93A$<69*3F8X041U
M<GIF-S)E66(Q>"]V=3-3,G0P-BM+>$Y*+W<K0R]*;SAE0351:CAB4#9A*W@S
M*T-D069E-U,T=FHS*R8C>$$[=5A6>F-!+S=#4U)K2#!,:GA&9GIM5'!59F-!
M4'5#4'-.03!,5#9F54Y/=')4:C Y0T=/3VXO06=90U-7<65E8R]Q:U0W>78Q
M3WIU8B8C>$$[=4));TIK:$MY>'EL;FI-9U!P3W-G1D$X9F129T--8VA%,E$X
M<"]+-U@Y33%8.#!V33<R5CEA5'9):S!K.$UD:$IA,U%68FA&:45R4R8C>$$[
M5TYO-DY%:#133$I02UAB-&=&04EX83-S3TMU24I"04Y#930V:C<X5F5(5W8U
M1BMC65<Q4G Y66=V5&535%-$,35*83-+4V%J0F1I,R8C>$$[=75-4W%)+U1T
M,W)X56IL33E&-"]A2W93,# S54Y.,&)Y>G X,3!T=SEI8E,S=35M56PU<$EO
M9VYQ0G51-#%:4U165%@R=TML,VQT3"8C>$$[3%=.66LK<4Q(*VE.0G4W:R]U
M9V]36%5*2D@T+UHK1FA"8G-T4&1H+TQK>G-093=,56-73T<O,7II4#A!4R]T
M4#-E8DM.2C$O4F185R8C>$$[5G1-=DER=%E(84M8,&UR>%I442]2-$AO93)6
M0U%02C%/4$Y#9C!M-E(K4V)(67%P5SDS85A(4#9V3DA.-EHT>65M=V)I9D$P
M2F]C028C>$$[24M!4653<FA3-T9867$W1E5*<6UQ,D=L,G!U<C)8,#0V:%5!
M0EHS9'1L4TY&<7IS>#9+;W)G36='1U1)24-Y;$-A6G%'=D]S*W1X;28C>$$[
M,S!S14Y";W!)2FLX2'9#3FTO-'A$-%(K,7EY1D=84&LQ8T)Y8GDK;BMB*W8Y
M6#-S:%965E%Q9T)12T%$64%$3$A)8GA6,DMU>%8R2R8C>$$[<48Y<#EJ9C(W
M5S$W06QX03(U:FM534MJ;U)8;U(R3T%G2&UX;$531DAD:5AM1%-F3F5M43)O
M,$<Y5S=S9G)D=C9T;'%,1C)10UIE028C>$$[:G5+1U1J>6]$>35%9'9$2W!2
M235/2&UX-5EG94=B1FIA6#9$*W4P-%!M3%5B9CA!-#9':5AK42\S-V$X3'50
M-V]M.6(O:VYK*TTY428C>$$[,RM+4GII9G8O8CEI=&)E8E!,;'A,-DLS.%56
M>"]W07,Y=U1B>2\X04EU65)V*T=);4\Y;$A006UR,RM2*U)4645%06<Q0C9(
M2G1R<R8C>$$[5E%L;&%8144Y,TI,2VMG=5I"2W%Q:%1J4D9J;U-8979W;W9H
M=E@V1G-N245!06-K6&DQ=7A6,DMU>%8U9#5"="])=&XK62MQ-F9O="8C>$$[
M-V-83C=:,F-W5T\V;3%+9&QL92MB.4M%4&16=&E';E-#<E)K<U@U.'$T<3E2
M>%8R2W5X5DQD8B]!3U!$+VU-:"]J:7%3*U-$<&UM*R8C>$$[53=Z53!J5T,S
M;75T4G8W:V]+07%,;5=H<"]K>%)Q=C!:3$I,-T$U;F%753AF<5 P=VHY:U(K
M,79Y-S5,.'9T;V1T2F8V5&%.93-.8B8C>$$[=31:;U4U<$QC35I754YX1$%*
M>31#;EE:4D=!<F-/;G<V6$AW9VU)<S<X=7!41"]"*VIO4#E'83=S>B]Y-S-L
M,4=V.$%W06LT2#96>28C>$$[6&AH=$]N:C5J-&XY8G8X040K<%)F-WDV.69*
M+VM3:3)N6"]H-'5F+T%!*U!!93E0:%,V4U R9G%3<GDO<%AN4S)3*T(Q>3)U
M4S$S328C>$$[=TYZ6DTU,TEP47A4=V-F;%$P-UI'06QV=3!9<V596#9W9'IZ
M:BMO:$YQ961&4#)T3FU(6#=-.%@P9F%L*R\X041*97)Y8VHY-35F828C>$$[
M-S8S-7A4-U=M,D5W.%DW,E97+S1&<F%N+T19,TQU63A75R]P:E@Y62]W1$4O
M<&0K;'9-:2]W0C5O2F)S9E)U;U<O-&XV5S)01DQU6B8C>$$[8V,O-78R<% U
M:CAZ*UHT23=*8DA18C9+86$U:FED;FMS+U-O-T%56C!A-DMH:CA027%V6#9-
M:D]2-D)X<S)O>4-Q:$QN+U(O5U4U,"8C>$$[=E%*175X<6UR4VDY,5EG:$A!
M<$1B<65Q5S9(-TDX5U!X3C-08DI2:C%03GE)670K2U<X=G4Y>6,U3G5D:7)S
M5F1I<G-69&ER<U93-R8C>$$[6')M,V=S-&I.2VM1835T9W!D9W1A6$5:3DLK
M=WE->G-W>45!8CDT*SE-8VMZ57)M,'1,<4EX6%5-8SA2-GAY<4A8-VU"1T%I
M,$=)4"8C>$$[3DM4-4XP2TTX<D9*9$UB=#E1;6MT;"\U1E)S26HY2S5(=W@P
M,F%F>3A">3E0=3(K>FLP9$LX>E<S*SAE<VDT461).5%T,&M*.795="8C>$$[
M>F)%9DUQ8V5'6%%R=U1(2U8K.&9Q<$I03&5R96)K=4Y65SAS271184\V2V=7
M9#1(-$IX0E5+;'=W04)Q9"M1-V=G57E%2E,S-G1/2"8C>$$[2FPY6$5!9"MH
M+U=N;BM,3&50.$$S=# O54Q,>$UL<3AQ:C5V8F5U9RLO2CAF94,S94]">D5H
M.$PK-C%A,3@Q*U=R<"]4:#%/,DUO3B8C>$$[1$,P:7!)4#EG>%9V=W=I8U0Q
M6E)Z=TIO15=M;TE)0D)Q1#!/4V)54&98,&1N17-K:5-/<D]S63E.95(U3U%Q
M+V5X07=%,'AL2VYJ2"8C>$$[-5101$8K8U!M9E1'931V3'94-$QP6DPK9#=5
M=BLY=F=3<W%W5W1U>&58:7-O-'E/<6<P4$9I5E5S;G0K2W5X5C)+<%(U;'5%
M=')7,B8C>$$[=4@K>$1C<$DS>55-5"MR0T5X:EI!67!O8TQ395%V3'5H4VYL
M3G%5;VEU4C!R1D1).#EY9'5Z3$=5+S)74GIB;74Y<S=826QM24A+528C>$$[
M=G,U+V1S.4-W=%1S5F1I<6AA,E9V82MP-DE997%X9"M4=3E74%4O1U=P.4=!
M0VM#3DLK1DQS5F1I<48Q1S!U3'%+3T]'5DEG<W-C<B8C>$$[;#!-;&93:U=1
M055D2U9+*RM!:3)-9U-I<TQ*,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+
M=7A6,DMU>%92=7)+>74P.4\W=#0W:"8C>$$[4#5*559X=C=-1&=)0E%99S@P
M<5!K>GDR<#57.7 Y4F)S,6I*3&%%9"]W1&HS85!)*T=';CAT0W%!<C-B9F-L
M=75E5C<X43)J5W5V6"8C>$$[.%5-5C=A=DQ$23!C=UIF5U5!8VU4,4YI=U!X
M35(T9S5'55!.<GDT2D=Q;$EB:C<O04IS5R],=5AY4D(K6D=S84QP1G)Q;S%8
M5$QE-B8C>$$[.5,V=C=Y5S9H-'I8:2]7=4M35%-M2C5P-'A*5C%$4TPX9C)3
M0V)83&5R67$W1EAN=C5I9FU,<FYL=E9K<TQ(5#0R=#-S4')B-FQC,28C>$$[
M84=.:F8R=&]Z37-B<2]#0T\U85-3=D=U,4<R8D964'HW-6AL;B],2WDQ1S9T
M2EEB>E5R84=:;T52;45%<SA'-&1U:3A(:W!1;7!W1R8C>$$[5F)O3V-9:4IM
M2FM):T=H>C5O+WE*3EIA<F5.93)D5%EA6DA*83)F2VQ1.7I/,#AL86)65TE1
M:F)X3U%"-'!7=VQK1UA+6D$R04%0:B8C>$$[478X05%Z9DQ'>#)+=7A6,DMU
M>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU
M>%8R2W5X5D0S,6PY8B8C>$$[:5=->E-1:%A34W-F0W!-8D(Q<GI6*VI+1&=)
M=&I+3G9)+WEG;79B;GHQ<G5O5#9:93)$6#8S53@V=3DS2%IO-74Q;V=T<'10
M,"M->28C>$$[3CA2.5%U,&UZ8V=+;6A:4%I-5F1I<G-663,U+W1O<FY14D)*
M1SAW:VQ64D5G9&U::7)C4GA48S<T2D=G9S5$05=/8G9)5VDR96LV3"8C>$$[
M3D1A,C1T:VQV3&U49W)Y4#!L6D9R-FEQ=S1Q9U=L3S%4=51K65)O3F5(5%)W
M:6=+=F8U-W-K>6)A-T9867$W1EA9<3=&6%EQ-T98628C>$$[<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EAL;FMB>78U,7-0
M>E0Q=E4Y5'1W;FPV95!54#!C+W=#-B8C>$$[<6HS1BMK;TA.6$US;G%O=G%F
M=D8O9"]96&E.:7$Y5'A6,DMU>%9,9&(O-#A0*UEY2"M/2W%M:F8W>'EF.'A6
M,R]W0E)-;45T=5AN."8C>$$[0CEW4C)"<61I<G-69&ER<U9D:7)S5F1I<G-6
M9&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<GE4
M.&XW,B8C>$$[,6LX=S,Y<75L86YA,TUC13!R,T]O86AQ1C-W:FMU455G94LW
M4TM$:W8R565%>69#:'))83%D5C8S:7)S5E%U<39R<"MK-F)C-FYQ328C>$$[
M>3(Y:EIX=$YC>G15:$515DIO05-F:T)I<4@Q=B]J=R\U:DEF-#1Q:7)+=W0W
M2T9O<F9M15HR:U!Q4U-3;FLU-4UE56I-9'IV:7IN328C>$$[>4YL15ES2%EQ
M-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ
M-T9867$W1EA9<7@O>C=Q6&U(5&9,128C>$$[.3,U9'1V<F5R<E!:<&(R,T1N
M>E=7-VEJ;$)(665K-U9B.6MB.7-65RM39%,Q5%5,0S9M=C)M8TQ/:3)K;'IB
M+T%&5U(T5&%W4'I-6"8C>$$[1D]02U(S3D]X,C=9<7=V.'(W8CAS2690971Z
M*U1L=#!7.3 K,F5+2DQE94HP-%13=F1'2G!O:TAO=71X87921TY15DY/4$1&
M6'$R2R8C>$$[=7A62W9.4&QR4R]-,F=8=6AA;VAE>79O>DA+5D,X,3=Q-D8Q
M9%$V34%Y;6UX>%92.# K;$9(63-V,5$S9'AA,U-'1DDQ47IF141Y5R8C>$$[
M375604Q5+VU'2V\R>#%/839T;UIN,"LU=%=L:TU::&Y%46M1044X,S133W9%
M.&%B16YF<&EQ;F)A>&-46'0Q8DYP9#5#;'-(2UA59R8C>$$[:$55,T4P06E+
M>7,S>&12>55E.4U65S-M=#-&=DIA;W5K,W1X.5I65V0T4D%6:$Q%0VMV2U9.
M>#,T,7A65W9D4VUT;TQM5DY0=6)K,B8C>$$[-W%I>%%I279+1T-K=$=(:U%5
M6&Q1.&E/:'A69&%A:$QC4E=S:E=6>$%B:FQZ:FQ%66%(:40O93A88C=63G5.
M8U91.6QR9'AC<&1S*R8C>$$[:UAT<6)64WE,34E!6GE++T1$=VQE<"M(.7)J
M,4=+<6QZ<3 X1W!W,E,V6F1Z>'EH4V(V25%M,VIQ4U!J3%-+*S%.-DEC5F1F
M8710828C>$$[,FIZ<G!T,V1-<W!I1G9!26I)=T9F,V<U4TEV03 W;79T:7%R
M1F9Y>5)W=6)+94UY=T=C;R]P.&M98V8S3#!C+W9$>3)P5F1J=FEQ2"8C>$$[
M<V1A=4QQ,6QN8E-B,C%E3FQ55S@V=VE2=WA!-4QW;&1A3%AE<D1&5B]W0VQP
M+S!X*VIV,&)D*VQ3=C92<$8Y5RMX>38K<#9N6#1F<R8C>$$[9&9B9D96=6\V
M>&-79'-K>6%695AJ3S=)66)C46PQ0VMG3S-/5D8T=%-O;V-64D5L.4MI4W0Y
M5&YB,&]"3T954FMU>#5F=54K4"LX2"8C>$$[2'8X041U3CA654Q(5C4W<3%7
M9#E-=3=6;6U%4F=N14EK0VUN-S!H2EA89TLK3F9B1EA7,G)Z>F%N3EET<&PS
M0DA&>30S,&]I*W)V>"8C>$$[24AW1EI'9F5U,55'2W%D,W)L>F)X,FIR;SDY
M8T<V5W)P0TE#,$(R,FTU5$M!9FDO6DQD35925C-F>3(X3GA)=&Y08T=!2U9J
M:$5:828C>$$[6&PR:C5/9W%V9FM2:7%Y>3%+835G='!8,"LU=&IC3WE.1DU)
M9SA154U1,&=34GA2=4Y">$HV:D962S(Q<31M;G4T;3!M.6=&<4A+4R8C>$$[
M>4-!2D]53D%)94UR16QU;S5"8U9B=71:=4E,>3)T;#!Q.6Y7-$-&<FU)46U+
M174Q0TI3,'%T5F5P-'%D=DA&5CDW<6LY<F)Z>DIP,28C>$$[,61.1$E),6AG
M15)E44964'%2.#5%2$5C<4=P0G%$=&EQ<F$S<VLX9'4W5VLX0FY1=7E3:$]5
M4D909VLT=3-X1W4S1V\R>%9#,D=T,R8C>$$[3C%$8WEV<$8Y84YB,#1X5&E!
M4$Q7=CA!9#A*6$<Q4#)I35962G17;FHQ5T]W1VU88W-C9T).*V=H*W)R5W8R
M:5I"2G14<VU+<F(O5R8C>$$[3&DP=%)/;6Q8;#)X;6%,,$E"0UI+2U=!;&\X
M<4QW8FI58C$S1E%-5E)!=G!39V(V;E!V0C8O1VMD43(S-VLO2"]E8B]!3W(O
M04I72R8C>$$[<DY*,4MB54E(;&QS3&Y4>7(X0D9D:4E/,G=0265L2DM+8C V
M-'$X:"]*9CAU=DY8;#=Z:&,V:'%S5C5"87@R16QP-DYX3W-T<6MZ;28C>$$[
M,%)266HQ<FE6;VA(6F-E8VY&9V=J4V@T-'$Y<GA6,DMU>%9*=DTV6&IX865T
M<DES36AV;T]5:DQY;W9X5F]02$969C9H<E O049D4"8C>$$[*U-%9CEC5F0Y
M43%N+W$V9CAK22\V-'$W-FAR4"]6,"\U25(O,7A6,S%$5V8K<G O>5%J+T%+
M-'%P=S)0;4@T+U<Q3D(X6CE0:$%V,B8C>$$[3S-+=F9&5E0V:')0+U8P+S5)
M4B\Q>%8S,4179BMR<"]Y46HO04LT<3<V:')0+U8P+W=#4T5F.$%81E9/97@X
M=SA"-D=P;U@U<%AN028C>$$[;TA$:T]F5'9W<G@Y.%964'%'<R\Y6%0O04I)
M4B]W0F-69#E1,6XO<39F.$%*0U K=4MU*V]A>B]!3EA4+VMH2"]81EAF54Y:
M+W=#<B8C>$$[<"]Y46HO<FEQ;DA9*UEE8W9Q-FUN1&U0431W3%AH>%=V3W9F
M;GDV9'%9<7%F54Y:+W=#<G O>5%J+W)I<G9Q1W,O.$%6,"\U25(O,28C>$$[
M>%8S,4179BMR<"]Y46HO<FEQ;E!9*UEE03E$53!,.#!R>F=51&AY2%!P,S16
M-"LK2W%N,4179BMR<"]Y46HO<FER=G%'<R\Y6%0O:R8C>$$[:$@O6$989E5.
M6B\V=6XO2D-0.$%R:7)V<4=S+SE85"]!2DE2+W="8U95-#=(>D1Z;#E853 T
M8W@V2$="83A/2S$U,3<X*UA4=%1&5B8C>$$[5#9H<E O5C O=T-3168X05A&
M6&953EHO-G5N+T%#46HO<FER=G%'<R]W1%8P+S5)4B\Q>%9O,F5U;S!B2G%#
M4V=32C9K8VM+<41(>B8C>$$[2'%B<G9Y-%8T*RM+<&YI<G-69&ER<U992"M:
M9FQ0571A,6IY<F4R;#)T=$AP="MJ5$)I=V(T<&]*9E5J0V=G=45T,VHS22M'
M4G9K5B8C>$$[5V59<3=&6%EQ-T959SAQ95@Y43!I-3AW4S-L,F)W87)Q:C,Y
M<3='<G!#.71"17-455-.4G=A1F=O1F9H<%5K,7A64#A69&ER<U999B8C>$$[
M*UHO;%!69DTK:E=L:'!Y44TP9#-(3D\Q>&-4,GA72E9:5TU,47AZ:C%F:2M"
M;E%H1#A1*TE+47%Z1$9867$W1EA9<7=Z>4(U4#%R428C>$$[=%0Q-B]W0E1L
M9UHY66QI;#E+,FMM:U0Q13E1>7DO=F=R3#9J4S=+5V-Q048Y47%%5E976C1Q
M-T9867%X3#AX=DME=2M:8DA48F93="8C>$$[4VIS0EHV:&$S='I&3$=Z3$]T
M=DUK;D%U:DM6-#A3,4]*-45!9D0Y;TMS='A6,DMU>%8R2W-0.$%)4&LO5E!,
M=#DU9VQU-6)E5T16<B8C>$$[-E,Y:&%*53EC=DY*2DI),#!I>%%%:CDT;U)'
M-3A+2#1Y0T965FU'2W5X5C)+<T\O33=Y8G)0;7)3-T,Q,'4K4WEE,75X8WER
M2GE%8R8C>$$[:6E+4D9$8U%X*T(S1#!&0V%B36IC6%96;4]+=7A6,DMS9"]-
M1'DU9F59=DQ%*VPR57-A5%!,8GEM3V-S<TUY451P2SA%<%%/,T-6528C>$$[
M2TXX2C8Y1&EQ=G!N;"LW=#E',$MW=6(Q<'!.2FAG4S5L-&=M-&QG:4-C>7@S
M1E="8D95-WA6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2R8C>$$[=7A6038W<3ET
M;W5I86AR1C!R=F$V8F)46&LV4D%'47AW4FU29V=9<4-X0S=627A6:&5M+VYV
M.$%L-6935&HV,4YB>%<X3G!/.#AK4B8C>$$[6D0Y8V=A-$-!46U6-G=X>'-:
M:58T<%$Q3WAO<74Q<C@X+TE/;5)Y<W-T,V9M0U-E2V1,5S%L2E9R94]D,DY:
M4D5R2U1:>6](56QE4R8C>$$[;F-+<D5+<#4U9"]-6'ED-6HQ1UA49$AV>F-8
M,$-'4V5";TQI1FM#='=:5SEA3TU",6)::U!X1'5-5EI*:7)S5F1I<G-69&ER
M<U9D:28C>$$[<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER
M<U9D:7)S5F1I<G-69&ER<U93,WI0*VAF.$XV="MN9BM/2CE4=5 P<"8C>$$[
M+V5F-WDK:S-R+S-8-WHK-W(Y:C1V1&9&6&QX+S9&>#E+-G V6$1M9G)0<"]8
M-B\S=#=Z*WAV=R\S<3E3;G<K;%AL*S8T-'%Q86XO,"8C>$$[3#,Y5W90<F10
M4S53+U=V4R]36$MV4%5V5W V6'AC82]8=5A(-&50*U0V94MP<#5C+W=#5DYF
M-#!T+S!.-FXK2797=G9Q;DPY22MJ-B8C>$$[+T]B-C<V9G)F-DQZ-65R5VTO
M2' X3DU696PT<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1E@O.6L]/"]X
M;7!'26UG.FEM86=E/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+WAM<#I4:'5M8FYA:6QS/@H@
M(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O
M;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @(" @/'!D9CI0<F]D=6-E
M<CY!9&]B92!01$8@;&EB<F%R>2 Q,"XP,3PO<&1F.E!R;V1U8V5R/@H@(" @
M(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R
M9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L
M+F]R9R]D8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YA
M<'!L:6-A=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B @(" @(" @(#QD
M8SIT:71L93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^,SPO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @
M(" @(#QD8SID97-C<FEP=&EO;CX*(" @(" @(" @(" @/')D9CI!;'0^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M<F5P86ER(CY&:6QE
M($YA;64Z(" @(" @(" @(" @(" @,RYA:28C>$$[57-E<FYA;64Z(" @(" @
M(" @(" @("!R<C(S,#<R."8C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @
M,S$M2G5L+3(P,C @,3 Z-3$Z,S,F(WA!.T535"!4:6UE.B @(" @(" @(" @
M(" @,S$M2G5L+3(P,C @,#$Z,C$Z,S,F(WA!.U-C<FEP="!697)S:6]N.B @
M(" @(" @(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP
M)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($%R='=O<FLF(WA!.R8C>$$[
MXH"B(#$P(&AA:7)L:6YE(')U;&5S(&-H86YG960@=&\@,"XR-2XF(WA!.R8C
M>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C
M=6UE;G0Z)B-X03L@(" @(" @(" @0V%L:6)R:28C>$$[(" @(" @(" @($AE
M;'9E=&EC84YE=64M0F]L9"8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&-O;&]R
M<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @
M0FQA8VLF(WA!.R @(" @(" @("!#35E+)B-X03LF(WA!.RTM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[1FEL
M92!.86UE.B @(" @(" @(" @(" @(&<P,V@V-BYA:28C>$$[57-E<FYA;64Z
M(" @(" @(" @(" @("!R<C(S,#<R."8C>$$[3&]C86P@5&EM93H@(" @(" @
M(" @(" @,S$M2G5L+3(P,C @,34Z,C0Z,#<F(WA!.T535"!4:6UE.B @(" @
M(" @(" @(" @,S$M2G5L+3(P,C @,#4Z-30Z,#<F(WA!.U-C<FEP="!697)S
M:6]N.B @(" @(" @(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @
M,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($%R='=O<FLF(WA!
M.R8C>$$[*BHJ5&AE('!R969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE
M87-E(&5N<W5R92!M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R('!R
M;V-E<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R
M97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @($-A;&EB<FDF
M(WA!.R @(" @(" @("!(96QV971I8V%.975E+4)O;&0F(WA!.R8C>$$[5&AE
M(&9O;&QO=VEN9R!C;VQO<G,@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT
M.B8C>$$[(" @(" @(" @($)L86-K)B-X03L@(" @(" @(" @0TU92R8C>$$[
M)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TF(WA!.SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^
M"B @(" @(" @(#PO9&,Z9&5S8W)I<'1I;VX^"B @(" @(#PO<F1F.D1E<V-R
M:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@
M(" @(" @(" @("!X;6QN<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]T+W!G+R(*(" @(" @(" @(" @>&UL;G,Z<W1$:6T](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS(R(*(" @
M(" @(" @(" @>&UL;G,Z<W1&;G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]S5'EP92]&;VYT(R(*(" @(" @(" @(" @>&UL;G,Z>&UP1STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O(CX*(" @(" @(" @/'AM<%10
M9SI.4&%G97,^,3PO>&UP5%!G.DY086=E<SX*(" @(" @(" @/'AM<%109SI(
M87-6:7-I8FQE5')A;G-P87)E;F-Y/D9A;'-E/"]X;7!44&<Z2&%S5FES:6)L
M951R86YS<&%R96YC>3X*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE3W9E
M<G!R:6YT/E1R=64\+WAM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/@H@(" @
M(" @(" \>&UP5%!G.DUA>%!A9V53:7IE(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @/'-T1&EM.G<^.38P+C P,# P,#PO<W1$:6TZ
M=SX*(" @(" @(" @(" @/'-T1&EM.F@^-30P+C P,# P,#PO<W1$:6TZ:#X*
M(" @(" @(" @(" @/'-T1&EM.G5N:70^4&]I;G1S/"]S=$1I;3IU;FET/@H@
M(" @(" @(" \+WAM<%109SI-87A086=E4VEZ93X*(" @(" @(" @/'AM<%10
M9SI&;VYT<SX*(" @(" @(" @(" @/')D9CI"86<^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \<W1&;G0Z9F]N=$YA;64^2&5L=F5T:6-A3F5U92U";VQD/"]S
M=$9N=#IF;VYT3F%M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&
M86UI;'D^2&5L=F5T:6-A($YE=64\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%C93XW-2!";VQD/"]S=$9N=#IF
M;VYT1F%C93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/E1Y
M<&4@,3PO<W1&;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N
M=#IV97)S:6]N4W1R:6YG/C P,2XQ,#(\+W-T1FYT.G9E<G-I;VY3=')I;F<^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T
M1FYT.F-O;7!O<VET93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&
M:6QE3F%M93Y(3$)?7U]?7S N4$9".R!(3$)?7U]?7S N4$9-/"]S=$9N=#IF
M;VYT1FEL94YA;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1.86UE/D-A;&EB<FD\+W-T1FYT
M.F9O;G1.86UE/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A;6EL
M>3Y#86QI8G)I/"]S=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @(" @(" @(" @
M(" \<W1&;G0Z9F]N=$9A8V4^4F5G=6QA<CPO<W1&;G0Z9F]N=$9A8V4^"B @
M(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT5'EP93Y/<&5N(%1Y<&4\+W-T
M1FYT.F9O;G14>7!E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z=F5R<VEO
M;E-T<FEN9SY697)S:6]N(#8N,C,\+W-T1FYT.G9E<G-I;VY3=')I;F<^"B @
M(" @(" @(" @(" @(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT
M.F-O;7!O<VET93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&:6QE
M3F%M93YC86QI8G)I+G1T9CPO<W1&;G0Z9F]N=$9I;&5.86UE/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z0F%G/@H@(" @
M(" @(" \+WAM<%109SI&;VYT<SX*(" @(" @(" @/'AM<%109SI0;&%T94YA
M;65S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D
M9CIL:3Y#>6%N/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^36%G
M96YT83PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/EEE;&QO=SPO
M<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/D)L86-K/"]R9&8Z;&D^
M"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!44&<Z4&QA
M=&5.86UE<SX*(" @(" @(" @/'AM<%109SI3=V%T8VA'<F]U<',^"B @(" @
M(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$<Z
M9W)O=7!.86UE/D1E9F%U;'0@4W=A=&-H($=R;W5P/"]X;7!'.F=R;W5P3F%M
M93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!4>7!E/C \+WAM<$<Z
M9W)O=7!4>7!E/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI3=V%T8VA'<F]U<',^
M"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL
M;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]2
M97-O=7)C95)E9B,B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B/@H@
M(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.C@T-T,U-#E#,$%$
M,T5!,3$X,3-&048T,C@U1D(Q13!&/"]X;7!-33I$;V-U;65N=$E$/@H@(" @
M(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.C@T-T,U-#E#,$%$,T5!
M,3$X,3-&048T,C@U1D(Q13!&/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @
M(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z-T)%-34Q,$)%
M.40R14$Q,3@Q,T9!1C0R.#5&0C%%,$8\+WAM<$U-.D]R:6=I;F%L1&]C=6UE
M;G1)1#X*(" @(" @(" @/'AM<$U-.E)E;F1I=&EO;D-L87-S/F1E9F%U;'0\
M+WAM<$U-.E)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \>&UP34TZ1&5R:79E
M9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \
M<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.C@S-T,U-#E#,$%$,T5!,3$X,3-&
M048T,C@U1D(Q13!&/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \
M<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.C@S-T,U-#E#,$%$,T5!,3$X,3-&
M048T,C@U1D(Q13!&/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \
M<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z-T)%-34Q,$)%.40R
M14$Q,3@Q,T9!1C0R.#5&0C%%,$8\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)
M1#X*(" @(" @(" @(" @/'-T4F5F.G)E;F1I=&EO;D-L87-S/F1E9F%U;'0\
M+W-T4F5F.G)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \+WAM<$U-.D1E<FEV
M961&<F]M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @
M/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N
M/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#II;G-T86YC94E$/GAM<"YI:60Z-T)%-34Q,$)%.40R14$Q,3@Q,T9!1C0R
M.#5&0C%%,$8\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IW:&5N/C(P,C M,#<M,S%4,3 Z-3 Z,S(K,#4Z,S \+W-T179T
M.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT
M/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W
M87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\
M+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z
M86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX
M;7 N:6ED.C@T-T,U-#E#,$%$,T5!,3$X,3-&048T,C@U1D(Q13!&/"]S=$5V
M=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR
M,#(P+3 W+3,Q5#$U.C(T.C$S*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R
M871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z
M4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(#PO<F1F.D1E
M<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  $! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $I
M ;L# 1$  A$! Q$!_\0 '@ !  (" P$! 0            <(!@D$!0H# 0+_
MQ !'$   !@,   0#!@0$ P0(!P " P0%!@<  0@)$1(3%!4A%A@B5YC7%R,Q
M,C=!>+@9)#,T.$)1)2<U-D-B=[<*4F%R@9&V_\0 ' $!  $% 0$
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M#/+.^V>BP4OQH8JDZ%E'0+A-96+@I%X15>=DMM9%PR'BG!=N2SJ1ZIW3>!>
M@#V;-%JP+76'V?.G8Z^)?@?,BS2R1FOXRG@. ,>MQEO/R!]W56=</&+AM0(K
MX0]E<X6[RE8=)<[LO5":O'E^KNSEUET[))P@JUF.AK[ Y&H8TTX_BB\L$!>(
M;)E#(-G>Y U*#'50T;7.*$J>'.,$$$X\,'SS]NX^.R@+O#Q+.M8!P1UO8:3F
M>\^$[YI]AYSFL#GD];*PMRMGN*6E?U;PA]1L\Y0I9G6(I^U1YX>FF:5W)&_4
MABY#LC>FW:KVPNC>536@N R' AW+(.P.-N?/E]GC/;UXTE%-_.DSZP:J_E;S
M0ZN^V?FGFJ9J)5 XJ7U'9[DZND?6N$7%+WQD9JTK%F>&&1&K;"M9\C";4<CC
MY(Q-12=*0F5E' 0<$[XR1OL, CWDYY#/OYXC$KQYJ='639)DU#V)+K3#U]7W
M&DBI6I9Y4MNN(;"MB!2^?UH_0"Q(5*UU;61%IJDB2A@:%;?(6D]/)1+D#V2T
M)VI0M-)W9\0/5XLGR(!]VYZ_;LI-\5GKCI:@/"EF/4%<MSKS'T.F44*,^./
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MC8D#<8SG?P4H(?&"CZ-JEL6G_-UD5_TU$>K.>>2%?,JZ6PI\EBN=]*Q5JFT
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MP!EP=MGF 1MDGQS[U%5?>!KS37/&B7D-GL6W%:ABZ C'4$+O=W/ACO:<3N>
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MK&HS8U8UD?536S*(#-XB]Q6711;'U:E>:DDR)8XHGW9"Q Y$) *6]64<9QC
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M/OAYZSE,AA.K@BEK<T$*DE#R"$MS/!FROVE!7Z!P=6M.SK(DY <6IX<$"E4
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MA><"T^Q.B6^"\Y2)?TU8<)M5#X;GAH73S37Z*4-J OL/H^[;1(C%]MLKCBQ
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MI3"&',U/6L@IJ9C<4"@J;.->-MGIR&X@9@E[=J+.SY'T9AB\.RP!7#</6CT
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M,M=UN5M94:0U[-.R@KJJC;/-0:!U34T$TS:>6,2RT51^OI)'ASZ:;];"6/\
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MS4\"NUD8UBL_8/K\$EEQQFC->T28K\]#ROT2Q3[P72IHR>4=?1F09Z9FI'O
M'F8@.9..2SOS9[$[UZUE[2=1Z4E=M'1:XTF:Z-SCR#[OI:JJHHF9V[V2W-:1
MZSVQ8PG_ !,Z;BN_;ONI^G^9! \BSG*XJ$F8HG[VOH/:6:UVGGL74(PCUO6E
MXW).F"#R&HVG_$$(V"JDWHJFWW 'DVEK8>]QTS#.89 X_P (:2>F4_07J:X;
MZ0U#H/78(XFP::U=;!< WF!):[T^T5[)<;F$0O>2"&!^V;+5AUCS'=/PX*JO
MVI)TL4^GVVAAGD=4R .Q^7H HC@EY;\D,%YZ]):IN),W_D'-?46VX4F?2:*I
MA _>?"\,^$F"P_!Q7#7[L\UWICC=J#2&H[3$S.:FKM%:RB..997"%U'(!U,<
M[@.I5@\PEQR815[C-OSQ\N^65$XU,4S-L08F"5KYKJ?MCD4?&IFZ6,SPM<GC
MQ+*0MVM=UU:NX7%M&MUMD)5HC1J5OF8 .=)2PLI(JIM3Q.E>^-L/<N:1)$V!
MTH+RXMPT5#>%V/7(( &Q795VF[32Z5MVHX=0NJ9[E5UENAM?T1/"YE=;*>R5
M-TB?6.JGQ=U3Q7RF,$XB/I3HY6B.+U2;"9@KC4PB81,(F$3")A$PB81,(F$3
M")A$PBP>R'*6LT)D#O"-1K<C:T(W%(&7?,],(R$6]*5Y:O;0,M<$PQ$6H D$
M4+0 JQ$B.T(G0P[O0-B=,QLW>=VX\)[KAX\G9N.(%N.(C.1RSC=;6R06ZINE
M'377T[T*HE$,AMO<>EA\OJ1.C%2'1%K97,,@<,F,.#2'8*A.LI?T985<P2>B
M+H]!J;1&/2TM 4&=* H29$U)7<A$,_:D/O')"5A:=08$(0C/*,$ (0;"'674
M14$$\T/_ -8[N97Q<1,(XC&XM)QC8$C(\B%U-]MNB;->[M9^+54QM5RK;<9G
M&TL[YU%424SI0SNSPME=&7L:22&.:"2<E:=?&D=X@'I/B1H5/4]KR:^XI1ZM
MMBZ[FG*"&(UI:E_\\41-D\45P=N/=IW+BG*RXO+I<0:[L3-#ZUB+M(7K3V$3
M>W!UWX_'R7",!/%[N6 <X!(Y\N73W+;7X?D\;[/XJYIG[7N>B12FJHZYEFV;
M8;E;<V4&B+-)5*G>TW<E.YV,2K5%'*6:<+$J0Z4,1K8];1I-+0IBBI.Q(\#C
MECZE</"A,(F$3")A$PBJ'Q+_ (1S[_5YWM_O>Z"PI//X-^P*WF%"U#^,+;5.
MT92U63VS*)BMS.:Z\JP8F43RSQ98[M#)'Y:U6I,V="X2!C>5!+5.8W7KA"7E
MO2>RD7$2 .G4E<@+/1*.FTO2U595U,-/624K6T=0]_"Z0-<]\3J:)Y:Q[070
MR3MF:XY+2SU2'8(^C?R;-/:EU5JB_P!HL6K+AIB"+2E^JZH4M37Q4]355EMJ
M-/VRIEAHZNE8ZHM-;>8KK332<4D3Z,^CNBF<V5DAQ;IWLB<QF.?P,\.\R&1%
M4Q-&HT]79>E<5RQ-30)O3[;"D<#@K?.)-II3(MD%HDQ:1G"!($H!)17H^'!9
MDM]JADD],O@EE#W=XRDHYYWN=D\1=-,88^(G.3E_K9SXK35^A.S2U5U<=5]L
MXN=RCK*GTZETOI.]WJKJ*@3/[]TMWNTUJH/29)>-TKS)5$R<1<YV>,][J!^*
M)/\ \,FO[E;GM&/ZA!3M/S&XW\DO?U]HQWMJ21QB,5:U^'X@N*Z3 %^+X10'
M7D.WWVGH?V=%<:T__*JHJ5A.W)M-'(_'/;O,GQ'3%^E^P6SG-#H_M UE(.?Y
MRZDMFF:-Q&W$VGT[0UM6V/KP.N'>.Y=Y'GU7W 9++_YUX=O]D6>8=_[09(U8
MK-1T'7AW]3"C8Q44;C:OV![WO7L"D!A00^G00:$'0\?34<6U):+53XW:^2!]
M9,WW254D@^/ "H_3!0VT<&E>ROLTL36G,-5766IU7=H2/9<ROU'6UL?$/XQ1
MM<3G)P<+,(?X:'"T,7:=T_.$%ECV(033GRT]O5P.ZE0'Z_$GK;2=I>8(_P!?
MX]##Z EC^I(2]:#K5N6_WB5O":^:)G1E/P4K0/ "F;$,?;U6NN7;EVL7.+T=
M^MKM;Z4 M92V#T73=/&P[=VR*P4]M 9CU<')</:+B238Z3P^ P^K)FQLT6A\
M6C0HL^%"9VQD961CWO34J]DO;>D2I4&]Z&$/M V3]!!#Z->>M9@1RS2U$3W2
M2R2=XP\3GO>_VAD\1)=[]UQ-!<KO<M06RKJJ^Y5]<+A2.%34555558'I$?$[
MOI)))@,9XCQ<LYV75<T%MA//%'%-($)20%2UYO9;<%.!,!2;$F@Y9O8$VM%!
M/,4FFG*=^6C!GF&&&^9@Q;W57\1K:LOXB[TF;=V<X[QP'/?&, >6,+(UT9W:
MTU6ZH,KI#J*]>M,7EY8VXU+(MY/6+&QM:QG0,:UK?5 "F_,1<JF$3")A$PB8
M15,[ EB%B@4/:36><O3@X73SU)B4T*K6Q+"&2QUST74$RF+@XB@D7D9;06U1
MEO<'8LMV&B/=24*PIF*<%24\@O96R)SYI7!T+&MI*Z,F6>"'+YZ&JBB:WOI&
M<1=(YK?5R&D@O+005Z'V;VZ6KNUSJ&U-II88=+:SH'272^66S!]7>]%:DMEL
MA@^EZ^A-2ZHKYH:=QIQ*RG=+$ZJ=#'(QYM$T.B1\:6M[0!6A0O#<B=$07)L<
MF5Q"D<$Q2M.%>S/21 \-*W1)P-*FQV0(G) ?HQ*N2)E11I(->]I8YS'8XF.+
M3PN:]N6D@\+V%S7#(V<UQ:X;M)!!7!5-/)25%12S&(RTTTM/*8)X*J$R0R.C
M>8:FEDFIJF(N:>[GIYI8)F8DBD?&YKCV.4JRF$3")A%22_>NS8C,04!SS$07
MKU$[(RU (.B6"30RK&I5H&BYO>,L3^I/#XXD+-+5IV()NI5)=C1H&I(G^;(7
M#>!45O _T:F9Z15D?LP<1P@C:2H>/88.?#[;^30,Y'F&K>T-UON0TCHZW#5>
MNJB(/%KBEX+988),!MTU3<&99;:*,.;(REXA7UV8H::-GI$4R^_/W(A4"EJF
M^+UEP[VZC?T0DKE93NB"GCU?M1^C-B@U*Q4SU)(+$403STQBQ,6"0R(1JU>\
MJP:<CFXF::B[IYJ*A_I%6X8,SAAL;3G]7 SE&P9()'K/R2X[X%>D.SP6FX/U
M7JJXNU7KNKB,<]ZJ8PRCM%._)-JTQ0',=JMT8<YCI& 5E872RU,@$[X6SA+:
M"K&<39HL21MTG4RY@V5ME<&^R;+8$;;[82P#TD8H_+FN/EA6EDE$NH=-?I>"
M !(==+"?P9N(ZRHBB= QT8B?[3700/+MR1E[XG//"22WUO4)RW!7N5NU??K5
M:JFRT4U RW5G%Z5#-8['62S\1<1WE766VHK'&)SG.ISZ1FF>2^G[IVZF XDI
M04:0>46>0>6,DXDX 3"CBC [ 84:6/0@&%F %L P##L(P[V$6MZWO68O/FN8
M<UKVN8]H<UP+7-< YKFN&"UP.0002""""#@J@<RX+C\?D;G9O(L_?.2;1<C]
MKW=+!D25VI.>+ _^&P:2<!EQ):,X'K("\QH$<>48E!Z\*A6KT'SULEN:U[IJ
M*5U%,XY<(P'4\I_^[3GU"3RXF<#ADG)*\DN79124E;/?.SR[U79]?9W&6I9:
MXHZC3%VD Y7?3$Q%OD+AEOI-"**JC+W2A\DF%CZ3M"RZ#5)HYWA40ZW;MGDH
M472M1E/4\YS?#C1@((/D>P)CYM4*E:H,+3D(IBW+6X8PJ%6WTA"7HS5(KIJ;
M#;C!W0Y"J@#I*5W@7<Y(,[ "0$$Y/%A8D?:7>])2,H^U;3QLL!>V*+6VGFU-
MUT95.<0UCJW#'7/3LDKB&LBN4,L!(>_TML;<C8#&)3&)NP-DIATA8Y9&'M*%
M8T2&..J%[9'5&9YZ"I;W1M/4HEA MZ$'W"#C >K0@[WZM;UK9,>R1H?&YKV.
M&6N:0YI'B""0?@5ZY0U]#<Z2"OMM92W"AJ6"2FK**HBJJ6>,\GPSP/?%(P[C
MB8\C((RH'L_C3D^Y_B#;.YVJ"6KU7KV<^+8*PI9-YC\_7LN4MB-#(R!"W^(0
MB'0O>QZ"/>_4$.];&GNMRI<>CUU5$!R8)GF/I_DW$QGEU:?!>B6'M-[0M,<#
M;%K34ENACQP4D5VJY*$8Y9M\\LM$\#EA].X8R.1(5??^&O741_'0%\]7\W!)
M_&C8JYO632&"EG:^I?Q4&M;5@LJI*'?]$I>DGI!O91!I!>]AS.^GYY-JVCMM
M?XOGHHV2XY;2TW<.!\]^0R"5V/Z<+U<<C6&DNSW6Y?M+5WO2=#1W8MY$Q773
M_P!#5,<A'.1W>9/K.:YP#A^?PJ\3"N?Q0?J>A.@40/H4T="TBOKEV 0#Z!(W
M,J1>@IE"K8=:#\P4P@0?5O8SD9PO,0GI%@G_ &UNK:(_Q4-6VH;GQ[JL9D#/
M[HF]S@GYP=AEZ.+MH#5VCI"/6J=&ZJBO=.Z0[E_T;JJE+XX^(D]S'=!AH 9(
MW8"DE?\ 7'B&L?;UU,4WX0-F@$=55HQ2$JHGQ4A;2V2)O]EN4+ED<G]HK8M%
MY W2ATFL_0 1?"(G%S,BPTC01H^.2(X_;SVRR/M%(^&\"'-34/C-4P%Q?*R!
MLT<D%.))&.C;#"[.2&B0%YQ)&%ZE>.SKL:JNRO2]7:^UEMK,FH+[5T3M14L<
MT[JJXT=B@NENKK/8(J^OHYZ"GM=GF,O>2PP"O$E0\LKJ)K+P?\0)\9O,N=<(
M=ZQ@TO\ [2I9:59+*9RM:_O&%=74ZD2LTL'UV(S36$/IUZM>?]-:?Z%8\_J;
MQ9I!T#ZM].\_W9X8P/\ >*\L_0]25(XK3VM=D5<T^Q'5:HJK'5/\ 8;U::.)
MKCL TU!<2<8V)7[_ ,4[C]L_ESQ]MFIU.O[TUG\\7K%O9WK^[2A:.OU;4G]'
MU]0CG L&O+^['YNW1W[%E-4C;!IJZCESGP:)P\\OX5 [ >TFHWM%)I[4+-L/
ML.LM)U_%GD61"\1U#\] V$GR4AQ?Q&>$9?[>F?K.BB1G>6BRI#8#'$#Q"%_0
M'L2U2R':,WOZ:+V7H>]_3T^?TRQ)8KQ%[=MK" <99 ^4?.(/V\^7FM-7]BO:
MU;>+TGL\U8\-YFBL]5<FCSXK<RK:1_:!(ZY5BXQ<-23?V_L9:5<R[WO+VOLQ
M-XR_^[Y_T]OY4YJ_7Y_Y>GS\_P#+,&2EJ8?VM//%_I(9&?\ ,T+BJ_36H[5G
MZ4L%ZMO#[7I]JKJ/A]_I$$>.1YJ1LL+2IA%Q%^UP4*T366D-<PI%.VXI><<G
M0F+M$CVD+6GIR5*@E(-1[85)Q"=0<63L8RB31A"6*6\/$WBR&Y'$6@%P;G?A
M!(!.,X!(!/,A7(1$98A.9&P&1@F="UKY6Q<0[PQ,>YC'2!F2QKWL:YV YS02
M1 E!6+:ED)IFOL&+U_&T4;FTQ@C?J&RF1R)4N=8-*7:,/*Q8![BD<*2-ZHUM
M J;-D&JE(BSA 5$D"!KU9M;!3TYB;#)-(9(8ICWL<; &31MD8 62/)< [#L@
M#;8E=?K"RZ?L;[9#9J^\UTM;:[9=YC<[?144<5/=K?35]+%$:6X5KI)HVSF.
M?C;&P.;F-SP=K#9@KC%BTIG,)@R/;C-IC%H>WZ"(>UTID#3'T>@!_N%M2[*T
MA&@A_P#$+U^6O\]ZRY'#+,>&&*25W\,;'//R:"5GV^U72[2]Q:[;7W*;('<V
M^CJ*R7)Y#NZ>.1^3T&,GHJC3#Q*^#X0IVB=.H*N>5_KV4%N@#JKM)Q-.UY^9
M!*"M$,M5G*//6P^P42,W0];#L&A:WK-G%8+S,,MMU0P<^*=HIF@>)=4.B 'F
M2 O1K;V']K5U9WM/H*_TT6.(S7BGCL$+6_QNEOLMNC:SKQN<&XWSA85_Q'HG
M(OI4/+W:MT%'?A1/,5YWD,5BB@0O^F(R36JN@").0+7D+8]@,-"#>A;(WKS\
MKWT%)'_2KC::0]6R5S)9!Y=W3"9Q/R'GG"VGZ$[A1[ZCU[V7:8<S>6EN&LZ.
MON+ /:#:&P17>61XW &6M)VXP<+]^\'X@DQ_EP7@:/0%*H^J207OTO"T/M@%
M_:8LA]8,,[>"O+S\QDF.J<\/EL.BQ;WH6/0K)%^VO4DY'-E';Y3\I:A\+3[P
MTCS3\SNQVV^M=NUZMN\C#B6BTGH:Z2Y(W(BN=^J[33.SR:YM,]AYEPP0OS[$
M>*3-_P"7(+VY%HI*/R\AU53U@V\\IP;^NPB76?+XJT*3P^?I":%@3D^>O5M.
M/6O(4=]IV+]G1W.L/_R:J"E:?A3Q2N \N,GS3Z5[ [40ZBTEVC:M>WFW4.I;
M/INFD/B(K#;;A4QL//A],>[IQCI%UV>'I;EQU+8,=N[Q >C9N6ZQERVI9XY&
MZGK6O5^TA7QX$S["8K$0'O+9L:4&O@#)*F\S-%'&J#ME[ 9DTE[IJ6J@?266
M@AX9!ASWU-1.WB]7+)I92&N&?:[L[9  SE;_ $MVRZ<TUJ*SUNENQ[15J=!7
M0!E36UVH;Y>(>\/<F2CNEPN)92U $A_7"ADV+FM8W(+9PX#YQ9Z5XXY_@+?)
M7)]2DP8J7:<5B)*D/$?9CJYV6K1[((,-+T4U*Y<>UIC?7ZU"9$4H-" TT8 X
M=ZKGU=UKIG,#"9C%PM<2,4[6TX.XSEPB#CX$D#9<IVOZUJ=3]I>L;O-0P4CW
M79UM[F.621G!8H(+''+Q.:T\51';F5#VXPQ\KF-+FM#CJ@\7CHJVI3-V>KZJ
MX L_J=JA+XMADN:;S\,^Q.CZ48'1\4L1[9TI1\T0-A[7+WZNVKYVUK82%8UL
M,^2.OLG/J%5'@H'C3+R9C>O$!S_?#3UV\L^.#[MUO&X]"\%\O447(7*PG=[*
MKF/%.CC:M5)*,GZE:4F]L[<CII 0F05<>6(/LHX(B( CC+:6B:4WJ(2@&(J#
MS/OZ'/U]59'"A,(F$3")A$PBJ'Q+_A'/O]7G>W^][H+"D\_@W[ K>84+1Q-(
MO</>742RZ:QCM=2:D.0K-B<%I558%CR:#-DAMRN[6KJ?W?8T?(CM5V2"0)E3
M?$E-)Q][-4(FM 6:[/K<6ZJ-K$A/7124MGMPI*B2>.KNE/+-5B"".8LI9Z:>
M"C@>9*FG+"#**M[ '.=ZK'%HP5]66NOTUV1Z"CTQ?JV]4.JNTBPW&[:G99K+
M07:>BTY>M/7NSZ6LE8ZMU!8S121S7&/5%92M9+43.;3TD[J=G=2.W=MPW UO
M0&NR5&A=#$:4;DB;UQSF@1N R "6)4+DH;VE0X(TZC9A29<>U-ARLD %!K>B
M&8),5R3N$.<&DEN3PES0UQ;G8N:'.#21@EH<X [!QYGY8F$+9I6T\DLM.V60
M02S1-@FDA#R(I)8&35+(97LX721,J)VQO)8V:4-#W<S(5I,(F$6.2J'1&=-!
MD>F\5CDR8#CB%)S'*F-LD+0:H2C]Q,>8VNZ58B,.3F?S"#1$;&2/\18@B^N7
M(Y987A\,DD3P" ^-[F/ .Q <T@X(YC.ZS;?<[E::EM9:KA6VRL:U[&U5OJYZ
M*I:R0<,C&STTD<H:\;/:'@.&Q!"_(I#8A V@$?@\4C<-82SSU1;)%&)KCK06
MJ4BT)2I VM"5&C">H$$(CS@DZ,-%K6S!"WK6\2RRS.XYI))7X XY7ND=@<AQ
M.).!T&=E-PN=RN]2:RZW"NN=6YC(W55PJZBMJ3'&"&,,]3)+*6,!(8TNX6@D
M !9)EM8*81,(F$3")A$PB81,(F$7P5*DR%,H6K5!"1&D(.5*U:HXM.F2IDY8
MC3U"@\T0"B"""@#-..-&$LLL(AC$$(=[U!( ))  &23L !S)/0!422,B8^65
M[(XXV.DDDD<&,C8P%SWO>XAK6-:"YSG$!H!)( 6M&0= VYV,^.U9<6.>X94#
M8O4L=F]GN#=\8U;&F-$F=HIS>U*O;)G$IT()J-581V]1*-^@Y2V'+UYK(M.U
M3JF:N<8J!W! #PS5Y&1M[3*5IVD?S!E]AG[I)X2O$ZS5VHNT>JJ+'V9SFV:=
M@E?2WSM+F@[RG)8XLJ*#1<$F&76O!#HY+P[_ ,/HL.? ^69U+*ZX=!<Z59S7
M#1PZL60Y-MR6&/,NECVK,>YS8,G4B&8X2N=RI9K;E(W]P4&GGFJ%(PIDFCAI
M6M(@0!*2%YU-2PTK.")IW/$][CQ22O/-\CSN]QYDG8<F@#9>C:2T;8=%6TVZ
MQTKF=](:FX7"JE=576[USR737"ZW"7,];5S/<Y[GO(CCXBR".&(-C;.69"ZE
M,(F$3"+X*DJ5<E4HER9.L1+"#4JM(J)+4)528\L11Z=2G.",H\@XH8BS230"
M+,+$( PB#O>MP0""" 01@@[@@\P1U!5$D<<L;XI6,EBD8Z.2.1K7QR,>"U['
ML<"US'-):YK@0X$@@@K7[)^#DD'?G.Q.+[(=^5)XXJA.3S$&)$"1\\SQ;Y!]
M8)A3*\XMD:U"HHL* M_@QL<<6E.:H5)DRM6+6]ZY]N$;C+0RNHY"<N8T<5-(
M?[<!(:"=AQ1\):-\$\_(Z[LHCM=7/>>S2]5&@;M,\S5-NI8A6Z.NTO47+3,K
MVTL#WM'=-K+4ZBGIVN=(QDDAWZUN[=F5)+T<3[PJ8^DS3U1#:W= 0 3I.N9)
M2K.& A.:IDA28<FJI4XJ1^VC9;#;BRRRBCE:A^ G#H64BX/@(9<(33Y.!4QY
MDI'D\LOQQPD]&R# P2785B'M/N6F)H[?VK:?=IASGM@@U?:3/==#U\CCP,<^
MM;&:ZP23/.(J:\0-:&M=(^K:P G8*PO[%*6=ND48>FF1Q]X2EKFE\8G%&[L[
MHB.UYDJVYS;SE"):E-U]2U"8\TH>OJ$>\V37->T.8YKFN&6N:0YI!Y$$9!!\
M05Z]25=+7TT-90U-/64E3&V6GJJ6:.HIIXG;MDAGB<^*6-P]E['.:>A7;94L
MA5?A[XR*.N[P1)WAK/6"H?FM(%(2X)#5(E3?/NL#%Z8) #A&[4(@&%C5DZ!L
MQ, 8!'!!H0=[S9'L-NHVAS2X5MQRT.'$/U-MYC.1R/R/@NKK:ZADT'I:ECK*
M62J9K'7I?3,J(75#1]#]GPRZ%KS(W>*4;M&\<@YL=BT&82Y1,(H[D]0U--]&
M:F=7UW+M'>?NZD\*C3_HWU?W>Y\U;%?K]7^?J\_/_/+\=54P_LJB>+'+NY9&
M8QR]EPY+=4&I-16K'T7?KU;>''#Z!=*ZCX<<L>CSQXQTQR5=)1X=/"4P]S;S
MR91)0SO/W#H_7K#$5 Q"_J/:B)I60_W-[^NS-&:,WOZ^KS^N9T=\O$7L7*L]
MSYY)1\I"\?!=I0=M':S;>'T;M#U:X-]EM9>:NY-&.0X+C)5-X1_#CAQMC"CG
M_A7\>-G\R"1VU:H4Z_Z:FL.A+UBGL;U_;M.A*L%2TI_1_4.B6\ =?36P[UK6
MLO\ YQ71W[9]-4CPJ*&CDS[W& //+JY;H]O_ &E5&!=ZW3^H8^L=^T;I.X<7
MB'RFSQU#\]2Z8GP(3_A^/+/_ #(-W;WM%C"_^S)7>[F:R&<G6O[ "06-!I(K
M-*!]-!+^9@#Z=>G?G_73Z::[]M9[-)XEM(^!Q\\T\T8!\^%3^F*FJ1PW;LF[
M(J]I_:24VE:FR53^63WUENM%&UQW)=Z.7$G.>A?=E[N8_I$_$B='-,5]4[?:
M'+-.RSUZ#_0M2\199 '4?K^FAGB,-'KZB"7Y_3'I]G?^UL36DY]:GN-5%\0V
M43MV\, */SZ[)JH?^(=B5/#([9\UBU_J6W8\7,IJ^*\4XQT9AH/(NZJC_$5
M^*!)H[:Q%I=JIZH:2;;G"(9,+JBIK%D#]*DTLD2:R7%)('YD;TD43J).4>H2
M@*87?:T*L*A$-I)2A2G;B[UNGHY*8T]I-2XTL)!EJ:J!C(C'&:<%C'N,A$>
M<R-QC#@XG*]5[4]7]@]!6Z?=8>RY^H:EVG+5*U]SU#J*RTE';Y+=0OL<,E'2
M54TEQ>R@<QCRZLI^Z,99**ETAD9=_P#X=C?(_P =N]=]MVT$[ZKV5POA97\/
M5[W]!@#&*G98,240+7GK19BU2,&A"T X.MZUK4?3AC_HMLM--CV7BC$\H_\
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M4J/)3)4Q)JA2I4&@)3ITY(!&''GG&""64246$1AII@@@+ $0QBT'6]ZD D@
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M&AF,K<=G+3CS"0.4A>G%:6B)$!$A >%(A((2DE% F]5,M7=*Z68@N%1+$,
M".%YBB;@ 9X8V-:2=W8R2225/;!J"YZE[3-:7&ZRLFJ(M07.UPF.**%L=#9Z
MN6VV^'AB8P.,%'2PQ.E>#+*YIDE>^1SG&GOB!\Y5%UEUCQC2LKC G5[T19EB
M62^MKL[-KHV45#6]*5J-J]-ZP@LM%.;'>F)K1NH2@NK6)$Z_*W!#M6I"JY"Y
M4L%96T$#V<3OULDK@2"*>,#U#@@8DE<T ^TW#L$9.?BGM=T9IWM [0.S33-P
MH34509?+S>JN&HJ()X=*VR&-OH,G<R,:(KI>JJDACJ T5$'=3]Q-%WCQ)/V_
M"VXF0^@V(U:_ULXE%E%DN]9VU;T(<"_9 $L!H]L<Y3HU:GR"'8U2](K4&CUL
MPPP8Q#$+(^B* 8+(71. P'133QNVZ^K( 3YD$KK?T$=F,0!MUAJ[+,UK0VHL
M>H=16J9O",-<?1+K''(_J7S1R/)]9Q)))_/N$O3#OW:X[<[=AAA?_9&]YMYI
MM&.)0Z^H"PM%E1"1JA$@^F@DZ=RR_3YZ$'>]^>I^CG-_95]PC\ Z=LK!_=EC
M>2,].+=#V35-)ZUE[3^U"V.;^SBJ=107ZC8 ,!OH][M];(6C;#14-&-L<L?F
MJ)\02,;V;%^[8=/2BOHG:+>Y>B!7K"'R] %4BK.4Q!69]->D9GR?9POJ,1@A
M;QZ/<F>Q<(Y,<A/2,^MT3XS[SPY^*?FKVNT/K4':K;;J&^Q3ZBT+;FY Y!]9
M9*^VO=T!=Z-Q'<EV5^Z?O%%BW\QSK[BRW$A?TT5#IQ;U5O:K0?\ ,2>6QZ;L
MR<PS7E^(+L87H>]_RP UK6.*[LYQ4$P'\$D\+CYX>R1H\3ZQ^]Z7VZT'K3V?
MLSU#&W]VVW745@JI /[%PH[K3,<?'TES<G/"!LJF=L]U=S4ISY*G]?P_JM5:
MH]%'UEC'VQ#[K@,?:WD*E(O7JFJ'ZCDI2J3M;*0M:Y^:6]B2K5I EQRD[X5M
M7X5PN-PIZ:1QM_=9PTRF9D\30[8DB/@>,\FEP:T$CBWPT^?=I_:IVIZ8T?<*
MN7LN^A9)'1T<MZ=J"W:FM-'!4A\<TTE/;O0J^-[LMB@EJZ>&DCEE:97O=W<,
MW=<;^(M(1\SU!NVN4.KP.S;$6]D+E]6<]3:9UG(H^PAVS1V1,[LB4+7 .G)E
M0HCG$(TPTNW+XLYM/,;SDH 54-S=Z)!WU%6@MC#>.&FDDA<UOJM<UPR=V@9R
M,9S@D865V;]LE8=$:<.H= :_;40VZ&E;<;#H^Z7.R5M)2#T:CK::>)\LP[ZF
MBB?,"PQ]]WCH'.A<P-LWOQ-^6T'_ +V_QR@.]?\ 4U,N:KZ0>SO_ ,C1(*^<
MRP>6_IL6Q^@/EO>Q:UK>\R_I:D'M^D18Y]Y25(Q[\1.7;_IPT)%_6'YTV@]1
M<M$ZMAX2.8<8;/.!CKO@>*YK?XHG S@=I/KI.'-A^_+6R)&TS**' \_Z>Z5)
MXRT#)_\ U]T(/+^F_+>2+O;B<>E,!_MMD9_SL;\U=B[=>R69W!^>MM@?R+:V
MGN5O<#X.;74-.6_W@%*#-W/Q@_\ HTV=6\]&&&>7H(56]!6Q4/>_Z:"E<WQ&
MI$+_ ,PZ*WO7^>M9=;<*%W*LIO<9XP?D7 K>TW:IV:5>!!K_ $>YSN3'ZBM4
M,A]T<]5')_PJ6&:\*5D?H^SUOU<_>YY>CY-8$3=/7Y_T]'P+L?ZO/SUY>7GY
M^?TR^VH@?C@FB=GEPR,=GW8<<KH*;5&F:W'H>HK%5\7L^C7>WSY]W=5#\_!2
M2E5I%I(5"-2G5D#_ +#DIQ:@D7_[3"A# +_^!;RX"#R(/NW6Z9(R5H?&]DC#
MR<QP>T^YS20?@5R,E5JJO5%]N5!,<(>6]]IEK%+)S$X.!!;$R41)2Y*9A-8C
M$P+XSH@(]NB>)H) Y2R7%Z#LQ%'V<U7K99.CSRL.LJ33-C<'0-XY&1XFD+">
M.1C,LQ[08'%[_!HRN"UYJR;25+:ZF&JTW ;A=;?:Q%?[D^WOGDN-SMUO$M#P
M ]^RWPU<]PN(P3%24[I,M:'O; TSZKM6XG]50'&Z**RJSF4E&T7=T2<4J=N?
MJ#>!I2M/:%D5G@ .T;$2G".VPPI#L:1 <)(=+U!9*1[;TF/)633N--0ACY6X
M;45.[J>F<0.(-) [Z4?NQC8;&0[.:.3N6OK]J.L?I'LWBH*^^4S8Z?5&LG-D
MJ-(:2J3&WTJ*EE>UOT]>8W%WHELBS'"_NW7%[6QU4,=B.<N5J_YT1OCJ@6/,
M_MJ=&EN%IW?.U&G>Q[$=]:!O8G%T,]?RJ/(A  4Q1%HVG9&5&2G++)4K GN"
MG)I:..E#G NEFDWFJ)3Q2RGS/[K!R:QN&M&.9R3V.C-!6C1L55/#+4W?4%U<
MV:_:HNS_ $F\WFH &3-.[/H]'&6AM+;Z?@I::-K &OD#YGV;S+7<)A$PB81,
M(F$3")A$PB81,(F$3"*O,7_[U=V__07F?_\ WW5>8S/Z9/\ ZM2?]6M7'T/_
M *]U/_LGHC_NVOE8;,E=@F$6#3FL*UL]N^4657L(L%J](@:;9O%&*5(=!'_=
MH*1]0+B ^K?UWZ0:WY_7S\]>>6Y(HIAPRQ1RM_AD8UX^3@0M5=;'9+[#Z->[
M/:[Q3X([BZ4%+7Q8//$=5%*P? *G+EX9_+29<I>JJ;;(YQDJHS9IDAYUM>=5
M>=H?T].PL+>[JX9Z0^7EZ!1@19@/Y1P3"?(O6";51@ET+9:5YYNI9I(?^$.+
M-O\ ,]^1LO.)^Q'0C)7U-@@O6C*UY)-9HV_W6Q.R?"DAJ)+9MCD:$@CU7!S0
M&K@_=X[BKC\=0]NI[$:TFO)##>HJ?CLLV?K6OPA<+,K55 I>9O>@A":,UL6C
M%Y[,+]D6A!,CT:X1?L;@)6CE'5P-?GWRQ&)__"?+"M?F?VI6;)T[VH,O,$9)
MBMNNM.4=PXO!LU[LDEIN)!QASG02G?+0TYR_CMWO7'D7:?&<4MEM3?B7R_F&
MYFM29LH/]1HJTMMOB$D5#'Y>82$L@6':%O1>PB#K9^/2+C%^VH63 <Y*2<'Y
M0S!CSMT#CNGYU]K-E]6_=FM!J"!F\MQT-J6GD<6CF8K)J&*VUKR>89'62N'(
MY XETTC\43GB'1U^/M-KN[G25HF1V5M4?O2@;":%2YR2-ZA0D2MQC2 ^*2 X
M]0666D;TL\:PO(A@3HW9-H[2PF'W:FC:[OA44KPUQ:VHII6Y(!(QPY8[/1HD
M!=R!',8U;VZ:/MM'5OOU/JC1M?%2U$L%)JK2-XIWRS1PO?&R%U.'V^L<Y[6M
MCACNT J20R*I8'"5O1>'%WR7VJALE0[2R'@>X:]IT"2$HZP=*UD8&-R4NYD?
MDQRAPN^W$#^2\MK:8!>UM.D1L8=T2U,I7.J%4U."NFUW(5XER]G%&['=B%T3
M^$EW"_)J)@X.:-PW!8X$$D%I.+V,=K3>TZ*]/GN%N%5;*ED3+7%8I[)6BEG?
M4.I*YSYM4:ABJV5,,!$L%.(G4%3%*R26>*2GFEVAYME[HF$3")A$PB81,(F$
M6BCQBNEIW7$@H6HH]#^9U,<V^UYT:\37J6?6M 8@PO\ 4W3U QJ#R)B75:8W
MG*&VH9K/8W;-P'2)U$QM-8LRUQ7LSPWE+T*@JVCF=^1&V#S!SL?'EGSVW6S7
MBF\9!TKRG1E[2LN(DR:S((@D;^7 !.AD&"[F*%21?J'JWE4M<7*-;4I#-LKP
M>J/ \M^T[JF'\*L(UHJ2,$CP*M%A0F$3")A$PB81:*NBW!4F\*OJ]E;S-@=9
MWU_U=6[6 /\ >>JG_B:69%3B@:U]1;^7.:XT0->?K 4,/E]<WNFF@WJC>[V8
M?2*AW+E!332=?-H&>F<]%[7^3U#&_M>TI4S@&GM3;U>J@GDQEHT[=*]CCX?K
MH(F@]"X'HMK/*?\ W7>;?_H'3O\ ]O([FNN/]85W^N57_7>N#[0?_7VM_P#:
M_4O_ 'JM59^6O_7!U;V-TJ?_ ,RRQN1L?(]5J3->>R([3I8WJT5*$WZ@4-K]
M:DB5Z*4$[]D8H[H&A&B*$/-!1_KZRMJSNUCFT4)S^Y!ETQ&-B'S/._\ 8QT7
MS9H/_P QZ^[2-;/]>FHJVE[/+"\[\-'IL&JOLD3O9=!5WZME#7M]4FCP"2TD
M[%,V:]D3")A$PBP>RG1J:(#,%;RXM[6BW&WQ/M2YJTR)+LT]K5EE$[.5&%%;
M,.%OT%E[%ZC!;](0[WORRW*0V*0N( X';D@#V3U*U5[G@I[1<I*F:&",T-4S
MCGD9$PN?3R!K>*0M;Q..P;G).P!6'<XN;:ZT#2RAK<$3D055=>I#3T"LA826
MJ31!F+4)C#$YA@ *"#-; <2(6C"AZ](PA%],MTA!I:?!!_41#8YW$;<C;JM=
MHR:&?26F7P313,;8;/&YT4C)&A[+=3!["YA(#V'9S2<M.Q *FG,A=,N"O;&U
MU)^'<VY"XD;\_,E>D3K"=^?]?Y:@LP'U_P _P_7((!V(!'@0#]JM2P0SMX)X
M8IF;^I+&R1N_/U7APWZ[*,'GGZA9'Z_M#2-1/WN>?K^<UM#'3U^?]?7\<RG^
MKS\]^?GY^?G]<M.IJ=WM4\+O\Z*,_:TK15.D-)UF?3-,:=J^+GZ39;;/GW][
M3/SS/-1.\\$\3/WKVX<H<_A$9Y^LQLJN',9HM[_J+9S(TMYOJWOZ['H?JWOS
MWY^>\L.MU [G1TWPAC:?FUH/Q7/U/9-V85>>^T!I $\S!8+;2N/3/%2T\+L^
M><]<Y4:JO"UX(4G"4$\[L+,H'OSV?%I;8T/.UO\ ^0V*S%F&7Y>?T]L0?3_E
MY9:-HMQ.12M:1U8^5A_X'M6ED[".R9[B]FCJ2F><^M07"\VYPSU!H+E3%IWV
M+<8Z8POA_P ,_G%!_P"Z,@Z+K_T_]+[&].WFB]CR_I[7S*;NV@^G_P /GH6M
M>6/HJE'L/JH_]'5U QXD9D=SZJC]".C(OZNK-9VC'L_1NN=51<!W]GO[I4 8
MZ<^0\\Z\>^O"12SEIK:7LG3MY/.VB?5[6ZU%?$O>[M&WM=Q6G!:Z3N$.<'=R
M:5[()C7R0MW<V<]0K2R$A*00!:SG) G*M9<;*)&PO;5U#N&6*(BH>ZHPV>:.
M++"XM+>$NXBW<.QC+<;^/=K?Y/4=VI[)<:77&J:GT>[V>RRQ:KN-5J<PT^H[
M]:K.V:VS5$T$U,:66M%1-3/?(RL;&UO>TSXP^3>+3%10NAZNA-2U^U(VF,0B
M/MK&C"D0HD!KD>C2%$KGYT @(3D*7U^6 .=GMPV7[S@YJU2L\8S31"WT$$,=
M/%'#&T-9&T-& !G W<<<W..[CS)))7U)IK3ULTI8K9I^T4\=/06ND@I8A'%'
M$Z9T4;6RU4XB:QKZJKD#JBJF(XYIY'R/)<XE2?EU;Q,(F$3")A$PB81,(F$3
M")A$PB81,(JK0U;8 ^H+-?7.E;%883)Z]K*"-,]='>HCX^:OK&3WP].#J:VL
MMI.\T(9I"EGL<+C0QQ/3H-0H4 D#5'RTIINL1AE]+E<8)6QNBAC;(YT!:3$^
MI<3PMF=(&N$K.'+,Y)X@W"X*VRW<ZYOE5/IF\TEKKK/8[53W:>HTZ^D=-8Z[
M5=3-.Z"EOU3<VTU9'=J(41-O[\O>\5<%&(W.5J<RUWJ81,(F$3")A%B,_BS%
M.(/+H?)XRAF<>DT<>61XB3D,LM#)$#B@/3*&90<;L($P' !FTVE>QEB2","I
M 86,H(PT2,;)&]CV"1CVN:YAY.!!!:?#/+/3FM==Z"DNMKN-MKJ&*YT==15-
M+4V^<M;%6Q31/8^F>YQ 8)@>#O,@QDAX<TM!&J_GKPO>:6^,2^)6QQY$64HZ
M:261QJ1+;"7S&3:8G5[5CC<=(E#8]$REH%%X\2U(AB(="4RI: ]P#L]P4+%J
MC44UII Q[)J%C?UCWL<9>\?PEQX&AX<'MX&X'M8SDY)))\'T?V%Z(AH;C;[_
M -G%NI6NN=;6459+=Y;E7>B5%3(:*C97P5+:^F-#1M@B/!.V-\H=,"Z5\DKY
MTWX=,&C?ENFNA.O*+))_$C981T!*)#$R1A_Z03XO:)<_;U9!?]NBA[ 9Z/,
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MMB"-EC55'25T)IZVEIJR!SFN,%5!%40ES3EKC%,U["YIW:2W(.XPC%'8_%T
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MP[M+VG."TDN&1@CD1YMVE]A-TNVDJZW:9U]J]X8^*K-BU7J.KNUAJ(*0NE,
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MS:I8EVZ]Z;L.(Y SC9H.<@^)'3/CGD01E;7/#N?X3*>'.6W^N*U-I^$.=-Q
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M=CX$J\LSDTP8':O$,7K=TGC=*9IJ/S5Z;Y%%V(BL8MN-R%UW/'1'(7) NDR
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M"/MVD"UG6-+9(9"\"9'-F:W$KH]8 <)]G&>(-!P=SN#C<XYX)\UZ&?"ZAS=
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MRSN2GV](J7KH%UPD1(4QZQ8J4<*]G%$)DJ8H1RA0>8*B=!+))) ,PP8MZ"
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*(F$3")A$PB__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g796801g10v99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g796801g10v99.jpg
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M051XMR,D83-1UR<U0E)78G&!&24F*"E3<I&ATM7_Q  = 0$  @(# 0$
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M<D91Q@1' #K*SN">$QU?@=;=/:G0)VE)(5TJ+WB5K8;*I!%'^9BGV#%3P)8
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MWXB,^IGPT=>J%D0N*2SL+F5,9\#L>@))<=D!K<!K1)NQG S! %[*$$A$8AG
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MZ[P^DVU3=0!LVZQ0D:"'0XON*D,S8R-H\,6W$-STJCCIT5;DFC/30R64.(+
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M%D0/R&;^S+ZNFWJ!>6_L*7L[G75PAZM#7U2^NJJ?HJ8QMPB^GL:CA%F@.(
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MX3PJX61;I^DLJGIL14QFGB?=((!!*<LN1W,YUA-\5\K;M>F0]8V[)-OLB:J
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M,/I4Z.V>%VXJX_A=%@8W'[.D UV-X=18 /;J3=W[1M:;?ULBM2:'EE.M>+G
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M1SJJFH5;;.FN72R/(KTF.8+F@/U3B!4I\:%0ZM/^8XYL=$1ED5VC:? L/O+
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M9_E?[$?]N+C_ ((GWDX1^HCXLOR_E?\ XW<?8;?Z:P+_ %ZI_NR?Q*,_RO\
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MX"0X4**^GO\ =(ZM?Z<Z1_VSC'"*QG")PB<(G")PB<(G"*N\![8]=;1N*PJ
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MULSU/GY?&%-S8/[1Z/\ ^;]ELY*^AG;_ !]FQMC_ -3SYC..;&./OTKRA_\
M;XA2KQX=[;_,_A&IK?I#?H4UI]M=M#@TZ_8&WF&8UN<]SV_!';\<-[7C"PY;
MQ@KGCBF=7L_\/JT\:9\LH5GOW)$$%LX_KQJW?TU+VJ.^_EGT,:OW>N//&<[Y
M\OQI]J[$/D-Q'%Z)U]^THW('G0W2?^J/!:Y_;G^@S=.W+7M,[5<.J'+^4;(V
M>T--IZ'!*-*K4 )&8HTR[@U=D%\<JTUGNC%?H?+YFC^'F=K2:SMZR7_'&/\
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MB5G8[HITK%^CEIU-ZZYVU_L[NZ<@)%37./\ '"I$"Z4QG_WO2\_^OX\R##[
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MNW:J3MYE:8VP&<C4KDU3,G)5O;-D54K8=+20G@Q(*?L?%?R4!I,J]+DLK.G
M0MJKNAN])Z,';-(J23=E(<1I'F 8/,<C]< NF@?AR]3JRO1AV A$$. 94$,G
M)9%H>VG\YVIR&S^40AG6LHLJ'TVJ?WKJ.6#)( Q1BAF3C(^@^=#%'JF,ID"1
M%Z[)O$B)^4ZS!.I$YP3RY!6ML[]&UA?L/+/X"0X4**^GO]TCJU_ISI'_ &SC
M'"*QG")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(
MG")PB<(G")PB<(G")PB<(G")PB@WL9U]@/9VII)4=B-G&!9G5!\%/BU,-9)"
M9:+VV<QN;Q,EC'K1<DCA#T'C!TEMC19/VD<]T<#7SUJOS+&]K8?<T[F@1O,E
MKV.SIU:3LJE*HW]IE1N1' PX0YH([7L5MCB^PFT5CM'@KV&XM2^E=6=PWO++
M%,.K@,OL*Q&A]VO97M&:=5CA+';E>D65Z-*HRMG3CL%/G$@E/4/LZY;H=HZ5
M&MG>LBU3]C$]@ZEW6RPC-W1#13.-5EWNNB0Z?"V^RFP*4:K85PUW=K#!7/Q2
MRH[E/$\/!^SKMQ'=S+K*YC>J6E7D&SO47'[].-8!=WCM+V.P=EGA_:/L)3>[
M8':BL^F;(N[VXV.VB#>]O]EL2<!+64B75\(KO#?:[ MW>\;39<7.P7FD7CB<
M(G")PBI%VTZ:CNQA^O+2C=_71U<N&I0DVC("X*1-14<6<UY83B+$9S!9@*F\
M9E<7D,5)$H/%) UU?#4G@*01X>6&OV_D\0=E(,< 1R,]1P(YE33UJH.#]8Z5
MA=*UX2DQZ-Q?$@)J2F:G,269S233B4FY[.)U+I!HW9HEY/-YK)Y!*SKYJR8L
M521=S@>Q8L=6[1$A,F?K+(#R"G3A0G")PB<(L'L[]&UA?L/+/X"0X117T]_N
MD=6O].=(_P"V<8X16,X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$
MX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%3'N/UB*WG'XM8%3G&\
M [04:2<3&A;(SIY(MS&4?0+P&78TUSN2KNP6.F04G&K8612T60(Y;.TVSD<0
MVN%X@VS?4HW+#6P^\:*5[0XED^[6I?NUZ!._2=D9ELB0X>G=FFW=OLI>8A@V
MT-J_%]@MJZ#,-VNP0&7/M@Z;;%\.D@4<9P:L1=V%=I:YQ:^B'TW/IUZ.3=2.
MSPKLY73PJ]!N(%;=?F7$#O2I"N_D>K*R1'I(EA#A/?;*CL"2425)10ZGZ;4R
M'WUSJK@@S)M&>/$\/=A]P&->*UM6:*UG=-^Y<6[\VO!&0>W[M5FK'C3=+2>#
MVB["7&PF-4K>E=LQ?9W&+5F+[)[16X_DF.X'<P^WN&. #:=Y0:YM#$;0Q4MK
MD'W31JT*M6U'-<O/TX1.$6@;O?.R5XSN8=/ DO(WV!.VG'7>M>&NMY%1A&['
MKH.VN9_2T>LR?PX'TK[3M_@X([DQ7K7:-@UK83$<U)D];;/R ".C#"/K\?/A
M^:NW+WN77,9@ P"'#/CGK$'CLTZ#0"&5=U4K:!0(K*RD? O; 4SI,ZN>TB8!
M&CUDRZ3R2'M*>>A@/V91:%'S1*)P:$L!^0L>A0>/C@1 R'19&'TJI,DS^?G(
MU)XGB95Q>%"<(G")PBP>SOT;6%^P\L_@)#A%%?3W^Z1U:_TYTC_MG&.$5C.$
M3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%2.V#OB(LY^?;TE7
M?4<U6*>['$7)V/8MK")HZ2V&,]B6QP9'X0_#LU=#&2"31-B^=Z;#]&BJJWM"
MBJ:>VMF8&:+#=U\3;<'>[QMO0MG4@=X[NXZI6:\^[NDDM'O$@" "O4MGK3L9
MJ8/9OVIQGM%ML=<*WM]#!,%V?N<+IN%>J* M:]YBE*YJ--L*+JCJM*F16-1K
M6[C6N-%KCT\=(S:=:%:^']<XI"1K@/M,8W Y@!,0R0)(R/5R0TEQ2U(4A8XU
M)V(])@_VK]%9=$5G9P*QL=QKKG<6IV0;;7#:YOZE9P?W52M2>RK3)IPTTVVU
M8T'0[WF]\0"[)WN+UC9H_HH6VS^.6^,5MM+_ !6NRZ&&WN+X;=VV*6;G6191
M.&T-G\3?@E9U.Y_74?MA[6NN(9<1:25:3XF\6?\ ]D_1#YKW=_X?<UW=[-_\
MXQG_ %:S_P#/70?8?T>?^D':U_L_LK_QA5_[6SCO2C<73O>#BX($FE,T9VO[
M0=AA31Y<AOK\?=1J.1"K817Z+J,,0)R;R DC9,RE,1B1QIE1$Y%-3;9D[4#-
M'^FGKB@*U06SJKJ&]^J=7:UE4MR^^UCGL!F='&1GEF!Y5C3,$9BE^S9ZOB5Q
M@HKAN&U\7M[:VQ.I;[H.]=T+2O<V].H'[S8HUG!S-QY#'$TVZT*Z['=P.N\!
MA4GL=U9<*?.*[ZRUE;G9&5U);U[GJZ=FNM]Y=^KR0:0!R3=AY$?+6-9%9]>H
MR:?CDA4.=,C  R55^'PPX+B^OKY<_):R 20"").[F!JX-$\C GC.1B)4M4+=
M'B$6-V&ZW=CSKM-DXL&'>'5U]M2(MJ=.+Q ^QN:$VUW#O\\ (J%_=\!'UY7D
MMB,1=R9HB=4?3B.QF/E#S/9B0&2,A#8CEO$&1T S @R1\?!2;WEOSM98_;E7
MK=$ =AYK"M^S'6@BE5,0HZ;N,W;7M5U>EW:F$]+=B=$M8M&1<EL.O!/7>,PH
M4Z<.#[\5,F1,80=/,[@2@ 1.N1G3(DANFI@'>RXP9X*+D_$1\0G:EY99#%TX
ME[8D ZLFD<!^J=A0><,+7F[>R)-V;ZO=;(Y*(Y(AME3&KHZSJT1%CMLMVPPO
M*2DKC#F1[R/5)I'B0V8XYC7*!$.F-#F>.@($$3?+J3V/[H79W1N*%V K$H32
M=/R&WH,]K>0UY,@ECGQ,(+1>(UK:C SF':Q-!2S2B<DL'*B=G$@;Z!2"-AX?
M"'CL%)9F@4$  =<_GEY?#CJ *!-+PMS/9A_,K,K_ +*6!>\6OKN!)YO#49MW
M(K6(=;J*ZY#+2F/7I" P&OF(;K9;E:71"(!7P@F2-NI,:N.>6_N-<Z$FK%NR
M%E:!&K0(;^Z22=W>DS((DF. '#59'X0Y#NT 3GLH(1NT[Z;O*HZB1XR^M:XN
MQ$$KQ]91QC;LI["S-@U[-165/W-LPM^\@47F ^E182H20AQ'AH[9"0 "RJY0
M^)@1J=(RC32 1\>/C -BV?X@D@[&7U85XP/N9UT@<@&=4JCM9(#+!9ZO* IB
MUNUOM]@9I]+KO:%C.G\MUZ\P<6+/7I'P>;! RR?V>6-[5:!S3X%W'U_9]$_)
M3[L#,$YD"#),:$P..G3+65.E2G;%93CPT:UD4\[>PQC)>YW96[]*]D#KL(2:
MQ+J-(S?8 EU+KJ]#A,63*&R)M_FF63*.V[,7[B!1SV]G)0P?"*B^DH0"'$!L
M -&4#WLI(&768@'73)>FSA8TX1.$3A%K4[;U#/ZCL5IWRZR@7!NRHB&;A>P]
M0"O-%/L=2@SR4<HH-D]=DU;8KQHGN4@1?"6Y%\R;*1K?WFVU'@7N_P ,NJ-U
M0.#8@\,MZKR^QNG9FPNW9 DG2VKD[M9D[K214&Z=YX]Q[.MI,'VCP6IV2;=7
MC+7 \1N7W6QFTEQ#CL3M17EK'/J.(<W9[&:CA0Q>V+A0I57MO@*#S6O*-WZ=
MMZ 7U6</MRKSR$C@\X$(EPA)'RT5UUVVW1>#2+7.VR@\R(?).19D8X\G(THT
M=,G&NJJ&V.:BZM:]E<5;6X8:=:BXM>TZ<PYIT<QS2',<,G-(<,BO*]IMF\8V
M0QW$MG,?LWV.+85<NMKJ@_-I( =3KT*D!M:UN:3J=Q:W#)IU[>I3JL):\%29
MSCK1)PBKFAU(ZXMKVW[+MZICZ5V[N5R.9MHX,XVU-NHKO!G4H2CWO/X41F+J
M%**Q%U,T@6DJ<1I9<&L8W&KJMMRF3$<%8SA0G")PBUS=_>U'9[JH&B<MI6A*
M<NR.R8[#J\8A9I>LGK&R)3;]B3!K$H/7M=Q0/3=A"I&X,JOD'KDJ7D\98A&#
M8P7-;L  4B80*S0"8)(ZQ/C.8/H"H;J/Q,)99/>,WU3-PFD8#%P5ES6HVYV0
MVC<"=ESV:UU4 F=3%M5P'/7%.E95@3,"+V/[@7]_@9YM$(W(IUB'9:MAXXH3
M=&[,GT$:QF=Z1Z:D#C*VBV=^C:POV'EG\!(<*JK#X?=N02TNI]"-X6_-/585
M1U*QZ18+PV:1+1L52K8 GNBP5ET?!)'6V-FRV,$@.Y,;MC&FVKS;55'.Y21!
M@_,'Y*>[=O6IZ''1<M;,R'PQA-9D!KZ*KD47RWOZ:R=UJS 1H:FQ:NE7)@JO
MG;#%@GILY=:(N-T$E-6Z^="B)^:E;==!-1-'=9+19;;T44MU--5%=O5JJ^BG
MIG;&V^WJD%U/+7&<^K15W\O13WS@BB>TKXJ6EV*9"R9DS );J+:[-FS S(BK
M=LS#%9&2+/0D8'&3+"/!8Z#,R"025ZP;Q^/ A;\P<)CQK19SH35)O?-25R:A
MT?F,S9BB<\W8XCFB3 P69J-BAT%%A14R5"CB(J*@"LHE$;C(J1RIZ% DI&=$
M@F)%P5?MFBA%V%:7! ;?&$S< )%RP0406&J&B$/F<7#D%VZR[=9>.E)9'P;&
M5B]%VJZ6348<%P^5-/0U?9SMIC8D?7Q_%2/[0WPMJWRNCAQOJIMHAZW3UV^J
M/JO7;:I>EZ>VJ7KT/69QKG&GKDO2SCUFGF1?6RR6BB26ZJ>BJV=\(I[;ZZJ*
MY3U]-3"6F<XV4SII_2W]'&?1U_I;>6/QX1?CJ^9;IIK:/&NR2JGJDE=7".R:
MJOM&K7U2>^-\Z[J>U;:MO0USG;VC;5'R]9G&N2+JPDJC,D:*OH_( QIDB:/Q
MM5T+)-'S=.010Z0C$F";JMU5--2@"1BB8(NQSGVD>58.V#I--RW43U(NO<SN
M)M);&H,L72S)Y>&EQ^.CT6[QRF0%01[&ATK<^\6S=48UW$O9?'V^[5Z\;.W.
M[[?V)!SAD_RU(LNX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$416_0-']@!0<'
M>525W;H6/D]S(818T1"2\:.)*M56+ARW8G&;UMK[6R659OD=DMF[YHILV>)+
MHY]#A2"1H2)U@PI8000:H(MFR*3=LW230;MT$]$4$$$=,)I(HI)XU32223UU
MT33TUUTTTUQKKC&N,8X4+]>$3A$X1.$3A$X1.$3A$X1.$3A$X1:D9^R>>&[=
MA6\8TT=;=(+]EK97L%$QR"J[3KG;<@<H#V=YQT>WTW]DKN:/%&HVRA;5+342
M3V8F&.'">1@-'LM MQVT;9U' 8O94S[%5<0#?VS 2;-YU->DT%UNXR7MWF.C
MWGGZ*P>K2[;=EK?92^JL':KLAA]1NQV(UWL8_;79RSIOK5=D[VL\M[S&L,IM
MJ5\#N*CG>T4!6MZW=D7%X[;*S>LR+-J1'.VS\>_;(/6+YDNDZ9O6;I+1=L[:
M.4-]T'+9R@IHL@NCONDLEOHHGOMIMC.>MD%I+7 M<TD.:00008((.8(.1!S!
M7SS5I5:%6I1K4ZE&M1J/I5:55CJ=6E5IN+*E.I3> ]E1CP6O8X!S7 M< 00M
M?71#OQMW:(7BQVH6TJ4^QR4A@**]BL4FB4L:FVY-5%T*SIC3.ZC382JHXV1P
MNR79/QCEJZWV5711A4(B,P9Y<-->N>8X+8=PH3A$X1.$5?K?ZYQ&ZK(ZWV-+
M#<H14ZRV8?MJ(Q,8Y%)Q.2S0Q6DRK 80F3-Z(?$'OPB*G1PS&-@Y((NS/[(.
M7:[UGJJQ6*08GJ(/J#^"@)/P_P"//>QT=OJ8]A.R%DQJ!V[,+^J^@+!F49DE
M45G<4WBAN%%9+%2+J&XM72.A@$DD*4%K4E8[^O("Y.$U(O'![3=HQ9E.]E$#
M,03&9$@^' 9Q)XDJXUG?HVL+]AY9_ 2'"JHKZ>_W2.K7^G.D?]LXQPBF&602
M%3QLR93:)1N7,QSYN28-9(%'&F[-^U62<-W;9(BW<:(KIK((J8WTUQG.R6GI
M>EC7&.$5&KKZDRJZ.U3>RE](*#@X.)=35F$U(QO8S:+0]2'86U+DE,<K"2CY
M0')UTC*1BT0B$Y**#7:<BC4L53&NO:8R]'/RL" .N?Q ')=25Z$'(V&;C*?M
M4*.<MV-LQS!NT*X9S&4$H]=D-81B7DIQ*XJ<@9>T9V&(QZ)FP,ZG/O&9G!XL
MP GTHE!&18EX<HG.2.(.66G+D.@B,HR$+))OTXFDI>B&#&R8J,AZ\#@],2X>
MXA)H@?=5)5MFCIY!\1XQF:H-AT_<A]9%%94?>#7@9Z]."I8, #LQ;X</DGC&
M<DZGCUU^//FLB@'3U,9&^Q,'FYP'I7%]PIO -JNK1E+8Y!8BS4:6"REDWCPV
M4S.89!3FP4)TST/YCFH8.Q3@\0V0;D"S8@;?DG2,H^?IZ3*C>O>DUH5W-(-;
M;*U:Z-W2/B5D9M.Q#U6$G^MJ3Z;*VL;#ZJ %ILIM"H)$);8@181I"S8:P%('
M"M:Q,30U'C;):*E,C/* 8X\H]?.=9YS)783J04NV>2J5-95#1"4TH(I2&AB1
M0!>53RGGKE&RM=+*H:1IR<+K"9@<VL9%"6N,MU%":,"@BFCO&0^6ZA0#'S\=
M->8_-5\(^&8PDPJQ,'R5.A2,P@O8$1#H] Z>T!UU3%A6S6G6RN8;9%91Q[)"
M*X$[!U>OSJ9JD!CH48<GYV]T&$A:@M4H9*0Z-)U!.>L$Z^,_!9>GX<\<<.I4
MDY)P0*T=M>]F8,?B%;,A$TALI[GV#!Y\.LUL44)KMDK(IM()(H9&I,,1'OWL
M9<@4V[D)JT?LG1-[_P#74S]WAX=%GO7_ *;/Z>L]O:#DU6XG&R=A:+5Q45=.
M*]K8/M,(7UTA396+A%I(;R.6V3H10X=5V\\OW4H:CM-?_LYN7/%!,\_,SQ)5
M]>%"<(G")PB<(G")PB<(G")PBP\K8<  OEA9R<P\,3;X3RX'%9,%'/D,+):+
M(Y6:/'J+A+"J*B:J>=T]?32WT4U\]-M<YH:E-I(=48TC4%S01QS!,Z9K75\8
MPFUJNH76*8=;5V;N_1KWUM1JLWFAS=ZG4JM>W>:X.;($M((R(*UQO/%VZL,N
MUJ/5;?>4J/E9.U@F]JI) =JS2FSW=)N@)V(^_/>FPS!-9,$M(M1GNY$QMG.W
MF$TW-ZZLXU9B\%G[\[XI]]#>Z[PY!L[V]$D-WMV [_-&\O&*GZ0^P=+;]NP)
M-^:SKZGA1Q]K;0X&W%*NZUEN:WM7?FCW[FVCKP4.Y;<DS_)0;H;"_M:JK_VF
M5]^^<<__ -+FS[ZE_C:?_7;^:]A_A!@/]-X1_P!Y67_G+"Y?V(KV'V=U\JA;
M8J>D?90A8+2OGL82&%0#5A6<"(6!)I'(B>Q9MLTCVC)H/!,GHEL:7<261Q]D
MHT09.G1)E<$$ @@@Y@@R".8(U6SI5:5>FRM0JTZU&HT/IU:3VU*=1AT=3>PN
M:]IU!:2"-"L?%]R^I9R326&!NR=(E99#I7&(+*(\.LN)/"P28S.:(UO%XR^9
M-RBBR9DU8;A&!LV&NNR^9EO\,*:)FL;,L2LL'D>>ATB9],_#-9U"+\I&RRHX
M'7EM5Y.#!<5-3HL;%):$//" 6N)QK6<]+-$!CQRHN.B-A;XA9]ZGC9N-DOI!
MW"FCW3='4A!&H(\1Y_+-59:>)QTV)6K-J\$7C5Y>+U=6KR?VK<8^R(0YJ^NR
MN;'$UG'ZYDAY(WOJWG4L./26X$3IKML^U#;M&V7#X@/;K$W3$P<S&AX9\E.@
M;N!U5D3Z"# /8JF#+^SH>1L& -1EBQ9\K*H.)0D#DE+16&Y-3"L?9)1&6^T%
M%,IM$U(I*$,J^OCQA-D2#R/+3CR7%0[D]6G]*V3V*!WM6\JI:HF9EY8D_ATE
M8R\-&L@PS&0NV+OX<4)NEB[H*6#$@H9FW<%)"U.@5@30CH;%9=D@S$&2J_'?
M$:!0ZOUK#L#JEV]KID3E]0P6M8_-XC3023V_)KLF"$,AHJ',<WFNPC)%J]<:
M%94)N,I5IJ* -%R9D:VPW61T(!)B1QYP($\ ?A*GRH.W%/6_UD:=MT'Y6O:=
MV!SJ1&R5FM6$=?1,56TADD8F+P_[O*&PVS$:2B9E5H7!FC8,\+39F8^4*BR+
M!TX(008XY?'/Z"I"Y\:3K&C4PRX&]8=EWP)49=,PE8%*NXDQF%9U/0%J)TO9
M5R6&$-V,*3#P@=8FR\?%"![TQ9Q]T-.)!Z\=N(\=0'%.Z9C+AQ&I$@3] '(G
M17CK'M3 +9O^^^N<9C=F,9AUS%5X4GA^5PEW%(:0Q9CN;LXXWAKXXY:')-IG
M>OY$NH:;1Y*+OV.C$C'SQM@_0<9*(( / R->4?F%9?A0G")PB<(G"+I9'' ,
MPCYN*2D0/D$:DHH@"/@BS5)Z,,!RK55D1&D&B^NZ+EF]:+*MW"*FN=%$E-M<
MX\L\O3J/I/94IN<RI3<U['M)#FN:9:YI&8((!!7*L;Z\PR\M,1P^YK6=]8W%
M&[L[NVJ.I7%M<V]1M6A7HU&$.95I5&->QS2"UP!"U>4)(S_1&Y0?2^TRY KU
MXLL@\STIM8\Z6=;Q]UG?9T\ZO38RZVVS@R#U4RI5+]^MZ4@"8U M7"KY)F##
M]AO6,QBT?BUNQK;ZW ^UK9@ [P')N(TF#]E\1<M:/<>=\B"Y[O>MK[*S[6MF
M;OM.P"VH6^V>!4:7\:.SUI3;3%Y3@4Z>WN%6M, >RW1&[M!1HM_D=U-W4IMH
MFK>7.U5!HU:Y7RU;-VV73C=VYR@BFCEPZ5UTU4<KY3UU]<X4U3TUW64])3?7
M33&VV<:X\NMKY[7(X1.$3A$X1.$3A%@]G?HVL+]AY9_ 2'"**^GO]TCJU_IS
MI'_;.,<(HA[DG^P4;DW7LW0NTF([QF4SV<3R" QJ+YA:\2AT#?DR-7DUG#51
M$>9EXW<LPKA\J0%-V=G_  >_?N7(MD_'NRD1Q_\ 3K]<%!4'LONU+NLE=Y:"
M"$26EG2\))"%[SV* F)J(6V5Z]*G<'Y<->6<ZL<:3%6-LSP:&9ZQ21ZQ=Y<-
M%H^1227<)E/NR?'GJ)X9<NJBUI>MW"*QE+L@H5W%TXIV4[7@$CTVGDJTDU)T
M76S!*KX3)Y[(HI7UDR*/3KL=(#$@B9\_'F>\QK:G#0]@]ET:68'#!!!/C T&
M<G7B!ERT*SZ,=M^X,AA\BD[&)P J_A5?=C)G(X=BB+.%6 W.P,C#F-2UQ(88
M,O":N87/2<=EZ%HR2+M24YD$NB> XF%"1;T^D79%$"0-)C.1'4Y:CS\5W:O=
M*^@6<MGT+"S466>S8+6MD16E;C$1ZV2(&;]=A8P@*B>TBEA6)BD@-G6TT=*&
MI"]92':GC-E@C+2"LRS)L2!\).?CEYY>$P9*SWKKVNMNT3%T+R0,%.Q6!@+0
M)L-X!3UF!B\6D5?V]9<"#P1\I)YB48W#)9G$X<.EPU&#:1'V??&4]DEA<QB1
M'0A&G7J#,_+K)URU!591W8;M%<Q^MC3@7.XP+%3YE&G+F%1":5X"F48<]G_"
MP/I'3\82G%DCD7#*"V3?4#(.F\ZDH=]% MFJMGJ =U*A[0I@ =8XQK#O[,N!
MA39=]Q=HX7V)F8B./A<CKP$1@$@A]?ZU)8>AC8,^I6X2!4IFR(G8(@3) ^]G
MQ$8.- C<7,-\9)B!C9$0218EGQ,H' DD$^8S^?+Q6,ONT?>F(@)W(3%;5]8B
ML?3E8*/1>$4C;4;,E9 VZA0OLL"E&%WUL3/<K'1TSD)JE7T2%BDC,J/@\[!Y
M.&DBV\12) ,</$Z9QR'0^$J4"W:.Y@'66&6C(G55@97*KTCU;;RY" SV60=G
M!9'.5@"$S6K\#.]9#J0&A_+)1%E8I6/MG3!X><&&879RR$E&4Y3H>7 ?+T4*
MK=Q.V1R/M&[ZKQP@Z6KO5RK &E1W6&ETI%D^O,RL!W>,8FVDQ:H5I%F%BC!,
M(TK"0BB-B BNGPX_FC:9RR&I\*8'E.LC28S$<L^4+L9WV)[K(1>P_A\;%HHS
M9P6W#$--I4?8TKDT37I><==6.KZ2J%;$=L)SB?PJQK+=,F30#'W[9:'8,,',
M@U9%V>I !EQS''F/P\?17%Z\W-85BV+>4+G#<*Z'U^]B+F&2:'P.31N*&8_)
MLRE!)%Q(I1,3+XG-TL1Q$M)(GB*QMO#A9R,NQL@L(+*1<A2*/QGT^N/'R5L^
M%"<(G")PB<(G")PBJ]/^E'4NU)<8GMB]>JLF,SD&[54W)3D58.RQ55DR;#6J
MKYWMIC=PJBP9M6NBBGGOZE!+7.V?1QSB5+&SK/=4JVU&I4=&\]U-I<Z  ))&
M<  >2Z+B_9CV?8]B-SBV,['X#B6)7AINNKVZL*-2XN'4J3*%-U6H1+W-I4J=
M,.,G=8T$F%!*GA.= U+#3L;/7R.:O4V7LOPJF0-Z5XHMAKEE@@I!M2. &[W#
M;/EZ/LF&.SK&"F[+8OC#_G'^QL-[T5?9F2!&Y+NZ)YFG.[,9:1QB<UU0_H_]
MDAQAN-?P/LA5;2[OV 5;H8.7=V:7?.PH5O8S5%,Q'=]T:D5S2-R!64B__1S]
M%?U5:7_<T?\ _P!>9?LS#_\ F=O_ -DW\EN?XFNRK_H#LS_W;1_)8M-.D+G>
M]^L%NTE90&D(IUH@5CUD(J5A4PR31TC$;=EE<2&P<Q]]F51[,+DI8=6PT"QD
M"0L]D:D4+/\ 9@]7<[I;<NG3928VG38UC&B&L: &M&L #(9Y^*[]A>&8=@F'
M6V$X38VV'8;9TQ2M+*TI-H6]O3#GOW:=)@#6@OJ.>[*7/<7.)<232IEX*B.E
M(NJL(=JI;F6Q*M:0I_K[:L?K"-QTW2\+H_L?&>S@T^X$ZR(BA/[;F=@1(&K-
M[!)$0S CL,9OAL.%.53.#-UL=_.8&<SKG((C4$  D #3F59KJ#X7M3].Q=_"
M8/-9:3;V\SD<*@:BJ+0:YH6F#$AG4V'UA7SA-5ZJID?8%GSJ:DY6]V3(R0N0
M"ZDF>C>,"D]"@N)B?/J=/D/F>*K7!_!L/P4379-CVOV)6G3:O4)G4DJ(T#&-
M8'%8GTX@]W0:!1 C6(^<L59"..?;G(Y^=?+39B5UM4:'ES1WHR8,(\Q*2Z>$
M3,P3F203K/(#J/5<@IX*T??1LI"1W9&:16,%NL%J]<SI&)1+ ">V5O<:LKD<
MND%WFF$T2A%G1EC:-AV/9\.@FE:Q=W$C4X-!Q<UQ'E/=^Q-\B,A(((G,"! C
MCH!Q.@Z*T&?#GB13IC:/4PY+1 ,K;11E*9/;-50-:(D5IU&BL/+027/0D[FU
MMF)0^C6:]A MVG-IU)MS4= HQO5T+!:#QXTJSG,9:0>7E'PA58D'@S;2W:92
M>47=5A:R[.[/P?LY:;K;J! TJ=L0Y7M36!60$)*J0S/E19Y5\6LN4VG*9#(I
M0<=R:QW*1D@Q]2CJVR5M[/C $#,R,YR/#EEP,*Q<;\)CK('H>O:-*FKG,)P&
M,0R-HS4?<$\AY4@E!IXSM !LWBT5.#:\CC$3/!PTL %QV)#TH^/$!@(Y?06-
M32W*-XYZ9\/$1XZ=57*)^"9'HJ#@D*QV;L,_ EJDAU0]C LFBS,\=O@!%NQL
MQ[1%=!,K+29Z\JAA8UCSR2CK'&#V<LW/0QYJ)8$ IK562+%.^<S F21P D1I
MQ@:<NLF;[]<>KEB4S>/9R[Y_=XNURG90Q 2SX0PJ="O4H<G6T2;0>,!QA#2=
M2Y<D&;1]IZ_=HX0:J[R,I(#>7&=2J8]B529 '*>,Z^05U.%"<(G")PB<(G"*
M$NQ% U_V:J:3U#9#)98(?12<#BX]3#601"3#M\N8],XJ2QC*HN21PCA-\.=I
M_P!!3&JS!ZFY&O7K1QR[&]K6%S3N:! >PD.8[-E6F[*I1JMT=3J-EK@>CA#@
MTCM.QFV&,;"[16&TF"56MNK-[F5[:L"^SQ*QK#<O,,Q"A(%>QO:.]2K4SFTE
ME:DZG7I4JK*.>&=87?J5M;6BG=R#.HZSKUE78.JI>5B^D>/6$GIB9,)6=.N4
M3!%J6)J("(H_=KMV@[31R565]!7+KR2V^/T,%I&VJ836%0US7?<TFU-]E#^:
M=38P%C2ULNJ- +G9-'+/U7MSP;LAP^IL_B'99BM.\J8S5QJ[Q_#;>_-[:8,2
M<,K8=:6M-UM1J6U .N<0HTV5*E8EENULM[OWMJ'.NKP%.$3A$X1.$3A%@]G?
MHVL+]AY9_ 2'"**^GO\ =(ZM?Z<Z1_VSC'"*QG")PBZ(M%XR>;G69R.@C324
M LQ>3-2P@>1;R*,[:$TMHZ=0>-UDBX+9,V93R((:N!^="Y/3+?T7[O"I%PX=
M!83781.-5_#HM!8XDY=/4@$.CXF,A4WCU3USUWH*"M&3'1R[6SE5TOJAA5PI
MG*BN^^WX\(LIX1=8("AH^QU%@1(P(-T<OWF@X0P:C6.CLJ_<E2CK5HS21;ZN
M"11Z\)/U\)X4=OW;EXXV4<+JJ;D79\(G")PBZPF%#FM6.AD2,+:C";(T-U)L
M&K_4>8&J>N'%F.'22N&A,>M_Q63]#";IJI_Q$%4]OQX1=GPB<(G")PB<(G")
MPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(
MG")PB<(J'=U>\+SI:)92HKU;["79!%6@GWK-:<4IE8:#D$CE+*'1>%*![!MN
M!2X],92>*"!\<"1&.R%P9?%AXQCE8HYU9<*0)X@>,_@#IUA81 _$UK*==@Q%
M&YJ*YXP"DEP3WK;&KQD3* IU<9[*U5!'5@V12FB0R>DIVQ-QH4*D89&2D(:V
MA4@ET3DT=C\@(+,&Z[Z)^OKEUA3NY$R,H,9S!R!_]8U'-7NM';&E9V)OGSSC
M2"R[;.,?UYQJ (9SY?\ 7\.2JC,@<U7OI_8M?I]2^KR*LXAZ*Z/7:DTET%9,
M%3606TK6,ZJ(K)[/L;I*I[XVT43WQC;3?7.NV,9QG'"'(D<E8O[1Z\_/D,_>
M@'_/<(GVCUY^?(9^] /^>X1/M'KS\^0S]Z ?\]PB?:/7GY\AG[T _P">X11W
M;W8ZJZ=J:T+=,R<(=$597<UL<J$CTBCCD^8&P>-$Y,^% VSHLT:N#!!J+5:#
M$'+IL@J]6036<(I[;*:E($D <3'JI 1LNNUD4EM9W#M=54]%<:[2@'C;7"FN
M-\8VQA_G&-L8SY9QC.<>?G^.>%"_3[1Z\_/D,_>@'_/<(GVCUY^?(9^] /\
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MZ\_/D,_>@'_/<(GVCUY^?(9^] /^>X1/M'KS\^0S]Z ?\]PB?:/7GY\AG[T
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M=<@!F,SU *O;UDM$1=_7&A;C 'CLI#6E3M;3X=)90#%1F3'VLKB @TF8D4=
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M9TF-6-5 NHHQAAV<G-]]EK'I>V LO?247B60 O$VL"W@K!G43\0#3N!M(W3
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g796801g13q22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g796801g13q22.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1LX4&AO=&]S:&]P(#,N,  X0DE-! 0
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M<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M      IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O
M;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I
M;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M     %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB
M;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!O
MX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M      !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M          !2<VQT56YT1B-0>&Q <L            IV96-T;W)$871A8F]O
M; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L
M=                %1O<"!5;G1&(U)L=                %-C;"!5;G1&
M(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P
M4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M#6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M        /X   #A"24T$#0      !    '@X0DE-!!D       0    >.$))
M30/S       )           ! #A"24TG$       "@ !          (X0DE-
M _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $
M,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M '   /____________________________\#Z     #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z   .$))300(       0     0   D
M  )      #A"24T$'@      !      X0DE-!!H      S4    &
M      *P   "Y          !                          $
M     N0   *P                      $
M$     $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   *P     %)G:'1L;VYG   "Y     9S;&EC97-6;$QS     4]B
M:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G
M<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X
M   -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "L     !2
M9VAT;&]N9P   N0    #=7)L5$585     $       !N=6QL5$585     $
M      !-<V=E5$585     $       9A;'1486=415A4     0      #F-E
M;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO
M<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )
M=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=
M  MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N
M90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M   ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M   X0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$
M%       !     ,X0DE-! P     $*<    !    H    )4   '@  $78
M$(L &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(
M" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,
M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( )4
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M^RQW4<Z[)JL:&@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
M$0@ W #M P$1  (1 0,1 ?_$ !X  0 " @,! 0$            ("08' P0%
M @$*_\0 .1   00# 0   P8% P(%!0  !0(#! 8  0<($1(5"1,4%E:7(3AV
MM=<7(B11E1DC)7'!-6&!D?#_Q  ; 0$  @,! 0              ! 4" P<&
M ?_$ #H1  (" @(! P,$ 0,!!@8#  $"  ,$$042(083,0<B010C,E$5,V'P
M<4)24V)R@0@D)4."D:&QX?_:  P# 0 "$0,1 #\ _OXQ$8B,1&(C$1B)UILR
M,/ARY\QU#$2#&?F2GW%:2AF-&:6\^ZM2MZ2E#;2%+4I6]:UK6][WK6/G0_L@
M#_J? _\ YGPG0)/P 3_^I5SYR^T'M73'>,UZW<I>D$.G6*G5LC= !.*)#ASG
M4>5W'T)4PD6HSUDC$Y56XZ-JDBZDE%8[#1"P1Y,9E*W'!<>TR<!:O>9+="M7
M8(P)8K5:F.S%M  /<7Z#7PNO(^Z5]&:]GM*U>R[("P( !LK:]0!\GK5T['QY
M/^^AU.N^Z>B<VZ#Z+YDT(KDHYPTV3ZP4G_1I[D<5Y4 <3J%^65EM;-L,$;]=
M.HE2'):C\LJ#%6\]+-[%2T54E&EJL*NRO'LVP6\"H L/.4USUZ&E)")6!:X.
MSK0V.XU\MS'KLOKTI:DFTZ'QC+2K[.V +O836OD#P200#OJ"_M$[Y6R_01E]
MXQNR0*/.Z:ZX7HA^ Q,AT+SS4><2^Y=$LPDJM26-0[==9@:NUL%))3)9&!^7
M&G9;D:0>='CT8(R7 =UK\,I.[+VL]FM"/G:ILNQ T>WC>@&<REPU8;JU@VK
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M;GO;V[,0_ 6F4YO:W]+5_'/IMM+BPVV&Q==;"[%QU^-.3V&OQH^(%=80UBM
MAWM BA#OYVNM'?Y\3ZK?*N7TV&$'5#F]"JH^M2"LNN0:W3Z\#AU^6=C[B&Y(
M2,+'1614@Q%4J,5>@(8<(1U;9EJ>;WM.'MM<L7LL<N '+.S%@I)7L223U))&
M_@DD3XM52]>M:*%V5"JJ@%AIB   -CP?['B:=Z#XX\[=#IJ*(]SD+2JZFQC;
M8Y&Y?#A\Y5,."&"\<=+)ZJL4?'+;A)/%GX22<>7]/(2_JP[<0LQ&G,[:\S(K
M?N+6=NI0&PFS2DJ2%[D]=]5!ZZVHZG:^)K?%H=0GMA5#!M5_M^0& WUUO79B
M/Z8]AIO,W.%YI0*^(JX074 #8^E4_P#T_JR9(V,0E!J4J$+'R*S$($&Y,](>
M=$"B&B<)<E;)/Z;"603)<C-+3I:VQF9B[=G?W&(.NS[)[$#0V"3HZ\;.M3:*
MZU"@*ND3HNP"0F@.NSYT0!O^_P SQV>(<7C[D*8Y#S!E4NN"Z?+4U0:HVJ54
M@:XC@6K2-H$ZV_7 [D""L6$=VH8/7"B*B16=QF=HR]^[P/>MT&+ >X_AFWV8
M>?#-L[/R=G9\F?/9I!V*JP2H4_8OE1K2GQY T-#X&O&I]S.*<:(13\*?R3F4
MZ':[!%MEHB3*%59,6R6J"O[R%93\=X4MHQ8(:_\ ?%,D422,=?\ N9DHW_'
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MW'EZ_P!1;[1I! K*JA 4?"L7^?[+$EC\G>MZ\3/]/7[@M/8N&+=BQ^2H3X^
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MN]+O_P!1.O-GC_5/[G_FD?\ 28__ (2_R[#RWCY\ ;UT\G]O^'G?69P4\_\
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M]/=;1,J^J>X?T+Y3_=?KO^&,1'U3W#^A?*?[K]=_PQB(^J>X?T+Y3_=?KO\
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1(C$1B(Q$8B,1&(C$1B)__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g796801g34j05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g796801g34j05.jpg
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M:[-L>6VE6,*L%6PMRR,S58K0,RF6LCN<UHE2S.5:E*A&00>ISD\TL1O^GR"
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M8W>TJM@]@.C,R9UWK!TRSM+A+&)W5MS5ES<%[CEO1G$I,KERQ7DGOA2<8.,
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M"U%VY#GKQ_$*CL9_\N.@7/9#^-VGZ^IZ;!_KOQ6Z_4TFTNVX21[8:P;?IIS
MZLECU73L%=&>TM8][6!V:'2JI'<SQA<WG1C7%[1KD#PEM4DKN5 DJE*>TF_Z
M!I:@ @.@7/9#^-6OZZAO;<<3,#\MM<\.K]I\=7+/2'6KC.,"0U4'NL]6,CHK
MI#P8S_2/57&,?Q]>?%QT"Y[(?QJU_75'3K?ME_%KG]369ZS[9TS5->/C79$J
MF2V8RNU[CM%[]A>K^W9D7;C;2LN33HAG;%3]2")T5EM*5](0&JU:-()0H)-,
M 0 O(.N.@W'Q8OQFV_6U)OK<]<O ?Y-<]0 ^Y4PON@>KWVP6K_9DV?\ \G.3
MT"Z^)'^,6WZVG3;?XTGXO<?JJCQM^^61SV&F]QT_.F-0PSRMJKAK@SV7KUN@
MT/#6Z5L[V<M$K1CC="NZ16@=$T_("'M\IE"<]O.QD!A9H!XR6QNQG"1;^VYM
MOUPK%KRV( +2[B3NM[CKQ_JCV5C'MF9YUY#F54N 6.KKP93>]Q>?'];Q#UN#
MU_T<RZ%=_$A_&;;]?6/2K8_;3?B]P/7#3.:E;1T31M1&0ZP[%>'28/%F7+8[
MP?$->]GPQI*;:=JRZQ"6IL/?JA1N:DMH220AN-5*TJ82A0G-, 2 L8,9P-A=
M;SIB\ES;?KJL-[;#'?2#<!O@GZ@!]RIF1=(-JF''="FLY#C'U\BH+87&,=?U
MO'FK,8Y'<^Z/!(S_ .8M_P!;4=.MOCOZ"?\ 5TFDGV\8XQ?MEVQ3<\K]YC]G
M02IXVXM=FU'MRR/#,Z5FKL88CT8XM1[ZB6H'5-.",XR>-*H3GH309*,+, 9R
M>Y]W]S3T]O\ K:GIUMC&M]Q/[3/UX_U?R5<\=(I/Q8Z\/FN'5G^&%;M!S_!X
M\"UTQG']./X_K<CN?=_<U]-!^LJ.G6OW0^BF_5UFNL6W- 516;C'[$M0E=,Y
M#:UXVB^YA].["^QI"HN&XYQ:!+.TGO\ 5Z%V6$LJ26$-9JQ6C2C5*$AIX4Y9
M9A>..@77W-?30?K*&_M,_9&X#]JF/  =4?:*8//2$ZDAS@(K*>P9SU]7:5'=
M)>,]7U_&.NPX_P#/Z_B^OR>Y]V>$2G_Q8?UE1T^U/[8WHIAZXZ@IWL@E?[*;
M.R.]JTV:K:/1^20"OHF>R3VG=EL.R-QA8Y,$Y24H8*S5HCD2XI\($5@>2CRC
M"30#!D.0#%ZI[GWN@;6Y 6>T;2WV';;2&T+F&Y9YK];<Q&&)H@BK&LNH,#DD
MD$'<!7SG[M_N"[$]VO:>PMI7O*N^V VP["ZL4BM=DK?+<+<W"7!D=I9[<QE"
MND* P(.21PI2O:L&>=IKS\E&UG^5?/0?[H';O^:%C_Q9_P!17A_]PSR7_P!)
M6V/^6X/Z_4X&@%[ZV:DZLPBC)Q?K)+)3'Y3;\G=GN*UA="-@.,LZXY[9R=&W
M$O,$+<L@:DDP3M9QRHHH2A2C./ 6 HPL./ -OSWVWMM[5VU)9K;/M2_N;YX$
MFCD2%KF5I3&KLREPA; 8J"0,D"OMCD9LFPY'<DN3?)2&_EOHN3NQ=G;&CO);
M9X)+I-GVL=LL[PH)%B:41ZRBNX4G 8XS3E8Z0W3W.<XS;_<YQGJS@< M &<9
M^\.%!S_Y<XCH%W]R_P#4B^G79>FVI_;#Y8Y1ZTI,'W<2(Q&]K7LRGKDH5XCM
MK,59IE;=9\?V(8'ME<Z_;9 U&][#C55O;>N0.)+N0>68::F4$FE&E")&#N#!
M.@7?W+_U(OIU)OK4;C*!Q/O).O'WOR5>!=(W*@]616)IR#&<XQUC/VG#CKS]
M;'6*D<8Q_3GCN?>?<2?$\9]3U'3K3[L/Y+_1K-M8MP-9JBJ<<6L&_8(XS%WM
M/8*TG\Z'1BT11A(KO"_[.NH#.T'/<-2.BE-'TT_(8AK5J5*8M/;C5F$Y!9P"
M@.Y]Y]P;SI]*I-_:']N' #WK]0 /VM,%CI#M-,XQG%Y,GC\?CCTWQG^G&8QC
M./O9QC/'<^\^X-YT^E4=.M/NP_DO]&HZ+.V!@)M^VC:E2;%ZW*XY9;17292U
MV0ENQG?&=S@S*X,A^"<QVOG=$L0KBE1*@HP9B<\HS!I(RA!"$P4BRO%S]9/E
M9/IT-Y:-CZ\!C(X,.)SUK5B]M(X]UW(K[TH +JZ^HQUV'+\7UNOK,JH./O>/
MQ^/J^MGF0LKX[Q;DCM!4_P#OK#I=F.,ZCS_1IHM3-L=6:*I)N@,_V6JIVERB
MQKWL-\611)-01HE7=%\65<@&EI,>X\E<CT[$GGA+()6L3IC%AS<:KPG(+."4
M#$[.O22>COO^5?I5GT^SW?7TW #KZ@!V?)3(YZ1/2C&,YSL/!\8QX\YR!]QC
M&/X<YRS^+CN=?>#OYU^E3IUI]W3_ /E[*2]UW)K^'7;<%C4]L9J4]QFW"J[5
MJ$%EO]JL3\R.4)BV8P>25B,0A\0+$*XH!*PHTPU,I),$:081D( FC=SK[P67
MS#VTZ?:8QSZ=?QNO'R?)5Z#TC[J+K_\ C;H!CJSG&<#L6\@9QG'U_P#1'6 <
M_P#EU?\ #CN=?>"R_P G_P#NG3[,_P"4Q?RL>L5G6LNXNIM152&)3S:>CU\P
M=++OBSW\V+.[T"-I5UV7M9%S#9V<U\;4;FJ2, )Z!C M6)DQZX3<-9E,G"=@
MD$=S[T<;:0>0>VIZ=:'>+B/J'OL\ !6_<](IHZ'J[K9RJ0=UGJQD;_D&,Y^^
M)/C'W_'XN.Y][X/)YA[:=.M!QN(Q_P#NI1+ VEUE>K'ELSBFW>M*5MDI,>+R
MED4A>3%A F-H*;LBZVU.60$)IO;#QCM#LY!V6<Y +N@<E;*]'"VEW_>GVU@;
MVR;&;F+=]\/96.8V=HW..OVXFHGC\?CD<DQG^G&1=>/O9\?,NA7_ (++_(;V
MU'2[+PF/^6/93%TIN]I57%:1R&O>V]"+W1G\*X5JVR:I0H#A+7EP<"QIPK0D
M*@8[%47W99I>>R-[LH)IX !/,P[GWO@LW\@U9TZS\)A_ECVUM/'2,:)YSD.=
ML*.#G'5UX,GC,7GQ_6_^8>'K_A\7^KQ\&PO1_DL_HV/J%1TZS'&Z@'_B+[:2
MQQW0JR"W/=,]J/;30]ZB]Q.D%?AI++MV1,#\QN42K]B@JE&7[&F5[;5J%6!A
M)<25(CTYY8E1B8Q/U% --=S[X\+2X/\ X3^RG3[+PJ#TB^VKUGI)PXQUYV6Z
M,G&,?7SG8"P,8_XYAG'<^^\$N/1/[*=/LO"H/2+[:S[6?<K3:H:E2Q";[G:M
MN<M76!=5B/Y\5M!FS'4[A<5U6#;IK2SF.ZM,YJ43%B<!92UBU,F/79;Q+!)D
M_;X) &SKX?Y)<<2?L3]9SV5)O[(GX5!P'[8O4,=M;\#TC6A(L8SC</7/&,_]
M:V8<'/BSU>,(G7 L?TXQUX\>/%QW/OO!+CT3^RHZ?9>%0>E7VTERK<VJ81<E
MX3JH-P^CW?(M<;]").-)95\*V"0,;E%JUBU>J4( QM$]MRY$J#%BG,A3VY!X
M,K1IC4^,$@.-=S[[P2X]$_LJ>GV1Q_?4&[ME0=9/61608Z1X(L]6-H>BTZ\_
MP[,RD./X?'D4:QC'].?XOK\=S[[P2X]$_LITZS\*M_3)]*M@ZS[?Z;U!4#7"
MYKNOJ4Z2PR86S-WY3%[GB/L>)<;3MR<VB<VM!CL\)W(]$S>S'#04K6ITQZSO
M'*H:=/VV"01T"^\#N?02?1H;ZS/^56_ #[-'U#'QJW][H3HCYX^LORVUW^L'
M'0+[P.Y]!)]&G3K/PJW]-']*O0/2":)BQC.-R-8>K/\ UKRK8.?Z0BD>,X_I
MQCCH%]X'<^@D^C3IUGX5;^FC^E7H'I -%1]?<[DZO>+Z_7>]9!^O_O2;'7_1
MQT"^\#N?02?1ITZS\*M_31_2INN:E;5+7,=Q]6*^LU+3<VORL8S9RM4U(,0]
MWE#>E<T;@_8 )C;7<8C,HV-R>@&D&-+<\JD"UQ+4)C$9!Q:D@1EZVUP\9E2&
M1HP"=04XP.)'6P'60"!UU2UQ CB-I45SCO2P!R> /4">H$@GJ%,IRBKJ.*4<
M4K4%P7_2>O[6T/5UVC"JQ;']>:V,BJ8/J-GP[+4R?*M84WE*#,'JPH$F.^W(
M\DH:=M2=2E>:G(S@S-L4,LQ(BC>0J,G2"<#JSV9X <2=PR:KDEBB ,CJ@)P-
M1 SCCCMQU]G76TFQS;GIM;WAG<$3LT.R)(YM3HVJB%S<Y-R\@M4A<$"U*8:F
M6(EB8TI0E5)S3"%!!A9Q)@RQA%FL@@D$$$$@@C!!&X@@[P0>(K,$$ @@@@$$
M'((.\$$;B".!JMY%31Q2CBE'%*5!-O+J:LM<JDTMW1,^QCY:; $[864]Y9%,
M])[H)L%2S?P3B"J9J6< :,43(DAD@PXA$V^#N_\ &4W-GHER(S*8F"!=9.[4
M$^.4SKT8WZM.G&_.-]:_2K<R<USJZ]6C&_&OXFK&C5U:=6<[L9JEC^^&I$HL
M-/53-=3 ;.EDU<ZX0M*UIE3.D7SUG7K&I=$&^0/# @C:^0!<V]8WIFQ([G*E
MZPG*9O+5'#+ ,UG<K'SAB;1H$A(*DA",ABH8L%QO)( '7B@NK=GYL2C66* $
M,,L"1I!("DY!  .\\*WG:UN5K1T(=+'MJ9,T$A+,8B(7O[X<86F J<E92!N1
M)R4Y1ZQ>O7+#RDZ1 @3*5B@P7420/ 19#3'%),X2-2[G) '8!DG?N  ZR:MD
MD2)2\C!5&,D]IW  <23U  FL0DVS5"0VVXW1,GM&,,ULRT+9EAABL]3A<J-?
M<N08^B4K"TQC2UN<C$SN@(VU.S@A<I"- I RI%PB\XYFL$SQM,L;&-<ZF' 8
MQJ.,Y(7(U$ A<[R*Q:>)9%B:11(V,+OR<\!G& 3@X!()P< U1UWM5KQ;-A2.
MJJYMB+2R?Q0MX.=XZV&K.U$GCKP"/2)2S+E*,AKDR6/OII3.^JHVN=D[,YFE
M(G(Q,H, 6*9+:>)%DDC94;&&..)&H!@"2I(W@, 2.%0EQ#([1I(K.N<J,]1P
M<$C# '<2I(!W&F!Y15U'%*.*4@W2B6?8%,Z#;*695<J<H18$5AK6IC4K9P(A
MNC(K73&--)ZM#AQ2+D>%'>*]426,](=@O)O: #@P(!!V+2-9KJVB?)26XAC<
M X.EY%5L'J."<'JKG^2FS[;:_*CDWLJ]5VL]I[>V1L^Z6-S&[6UYM"WMYPD@
MWHYBD8*XWJ<$<*XI?=,ND4\]*[_ZS"OU-YZM_8;L3[G<?C#^ROTX_N2?<<_<
M_;O_ !VZ^A4B'1/[X[IVST@FOE8VMLU9MCU[,LVNEDD0E(HL>TN062DK'E;2
M8/+?&FY:4>@?F!K7DF)U96<B3Y*,P82::6/K7*C8.SME6,$]FDJR272PL7E9
MQH,,SD $;CJ1=_9D==?/GU2'N'\@O<SY%;)VYR6M=I07]YRGM-E3/>;2FO(S
M:3;*VQ=NJQ2*%5S-90$.-X4,O!C7:'SHU?%=(,?#Y?<NSNPL>6WM=\"C-;L5
M)IXQ&JSE+'&F@DV5QZ3.SZN6%JXJ\*UJY:K2INLXY7W)1)!9118 X\:L@<#@
M#O/$9X8]M;"]JBO\Z?;?Y3XY^H/%-7WJ^:JW3)[E+W2*X,PET@G3O&+]V[KE
M-*96>B52-RC55[:7=6D*+>%;<@;$BU:VPV)L+4:M A(,6=XX4J<&*33C1JAN
M/#&X' ^4"ONY;Y*6*DD6(?+'^#N\GOO4>MU,HBQR)-(FV-6OME2=930+,K<$
M+DE1+W"&RU^;"%PT)YB(2WOI/@"DDDP"@X^0GS FJ'VJ*_SI]M_E/CGZ@\5.
MK[U?-6N_8;+Z8V5UQ8T%[WC/(W91-QMLJC5F2IBDK,I#&8.G?V18D*2Q5H5H
MEZ)Q!D85!*S&#"C#232Q@'G'%"<C@!O' 8XY]E/WQ6-147NJLN9;B61!&V]+
MAKB&0K7S7F3,\;K9^8F%O-D,\GNR[=)GAQ$NC+RL6+%J"!19&#NE0"$Y+:'!
M)(1G'C,S50V<YW8^>L7.D#&-Y/'Y,>VK%]3.Q/.PVH^4&,?J'S+0.T_D]E8:
MSV#\OMIHM#I+,Y)2DB!.9K);!=HO>M^P=#)Y>>@5R-7'8?:\G8X\E<UC:W-:
M98<WM*1,A IRC+.,)(+[40QXR+-9W$CL)JWL^55/G ITN12D,D$4EUO[<7+"
MC[PNFO8A7E&:XOT?CE82=DC3<-]L"8;)I)0[N7?L8>5:Y:M202,)2\C5 )3$
M-V DDA$<<(:I!QU ^,9K//:HK_.GVW^4^.?J#Q4ZOO5\U5&G#K*5]83)MELS
MDT_70S8+8ZOVV3S%2A7257&H-=4UC493.R]N;FI.N4-S(WHF\*K*(HXXI,7D
M[(S.L>50>/9N'#Y0*:_BHJ*2[%5F37;NUH4@O:XJZA\'INA7ADC=;O["P-N7
MB:OUWER)U7]_1AX5K%JTF*L2<(AJ@E$$H0 **#D9F19JH;.<[L?/6+L5 QC>
M6X_)I]M6;ZF=B>=AM1\H,8_4/F6@=I_)[*PUGL'Y?;33:&2:92>AG <ZFDCL
M!ZCMX[(P9-*9:>@52)='H+?-A12,)W16W-[6F6'MK TMS<%3A$4:<4E+$=D9
MO=#%6=Q([":M[/E"GS@$TYW(I2%.L2E]Q;67G$U5Y797\4KFL=?UL<C=8RAC
MC37ARFZVY#)&YN&%D7>5:Y<M#&F4D)ABK!9!"(!910<"'G*L@<#@#DGB,\,>
MVL^]JBO\Z?;?Y3XY^H/%-7WJ^:JG31WE+I4,B1R^8R2>N42V!VDKU#*)>I0K
M9*NC5=[&VA"HDG=UK<WM:9:J;(RQM39WWA"2:H+1EF'Y,.$,P2H;CPQN!P/E
M IKN*BN7GI/=G-GX-NY-:]K78FT:R@\?JBHW1NB\)61Q"V8=9&.:FO+D?EQC
M;HK/5K<MZ( QF*L@ 6G++++ ''C]^]QWW.^3?+79VVKG;D5X\MC>VT$!MKMK
M=1'+ TC!U56#'4!@[L#=7Q7]5-[N7+WW)MN\E+#DA<;+AM]K[)OKR\%_LV.^
M=IK>\CAC,;.Z&-0C$%1D$[Z0[VW>ZOGE;!_^.0_]2>>Q_P!H7W/_  ?:O_$Y
M/U=?+']V9[MOAW)S_E^#]=72YT3]GV/<.C=;3FV9L^6).%$]V(CSA+Y)E )[
M=&V%;&VM#(T6X&-B%M1G&ML:86AK <!&4,TE$68?DPX1A@_D#E=LRUV-RHV_
MLFR#K9[.VM?6=L)',D@A@G>.,.Y +L%498@$G?7ZA^YGM[:'*GW/.17*3:S1
M/M/;O)C8VU;]H(A#"UW>V,-Q.T4()$49D=BJ D*, '=4C?.NUWBD&40^7W+L
M]L''5MZW? 8Q6\=I$F,1JLY2Q1IH).EC%+'5^7K0*XJ\*UJY:J1I<9..5]R4
M206246 .,]:L@<#@#DGB,\,>VMA>U17^=/MO\I\<_4'BFK[U?-57I@\REYI!
M<"82^13QXC%_;>UTFE4M4(5<D<8U5NVUWUM"BGA8W(&M(L6-<-BC"T#6 0D&
MJPH J%/:*C3CC%0>/F/G&::SBHJ)FU#[.GFU5\1A-?=SU_%8 QTZ1'(S74A8
M&!H(,DT7=7A[6J@+(L[JU:U:M 6(1QRO."RBBR2BP #C',U4-G.=V/GK%VTA
M< ;P<YSVX[:H?J9V)YV&U'R@QC]0^9:!VG\GLK#6>P?E]M-?H;*)A+=<$2Z=
MS!_GLA9KHVM@F)7*34*B0N;!6>UEU5U#RW92W(&Q(J5ML0BS$TC5@0D&*@H0
MJ%/:*33C3*SN)'835O9\H4^< FG%Y%*00,-E]T;)[(,KA?%XP.-UK]1]JBL9
MK25,4:94Q<D@7LA>E:HI5%7=6M7K7,\1@U!ZS. % *(*+ 6#&.*R!P. .\\1
MGACVUL3VJ*_SI]M_E/CGZ@\4U?>KYJK]-'V4OU(*/9A+'Z</$:O3;"NB)1*#
MD2F1.4<JS:NZ*UAH7A6WH6U*L7H(?$V)M/6@1$&+1(^^E&!J3C3!J@\?(#YP
M#34<5%1*V8=9T^VCV#CI%^W3 8O7P:F;8S&:[D3 PLR4$@KU%(GA4H+619V5
MJURUT6&FF*#E@NY+P626 !98<<S50V<YW8^>L7;2%P!O!SG/;CMJE^IG8GG8
M;4?*#&/U#YEH':?R>RL-9[!^7VTVVBDIE\OUQ:7&<RQ\G,A:;8V8A I3)3$1
MS^Z,E;;-6_7D3\+*&Y"VI%2Y%%(NRMQZPM$0-6))WR?@:@TTP=9W$CL)JWL^
M4*?. 33?<BE($DA,ONO8C9UM<[YO.#1^LY'5L;B49K65,,;8T2)\J&)RYV4*
M"%44=U:Q>N>WI<H-5*%HLA*R2G* 642 /%2#CJ!\8S6Q?:GK?.FVV^4Z-_J!
MQ4ZOO5\U7'31]D\AHL!DQE+W-GJ/W%L[ 2Y/)C$2B0.;!66S5OUU$LO"IO0M
MR58X(XG%F5 I6@1$#6F)<JCPB4'&F#@?.?R$U!X^0'S@&FFZL?P8_P"&.345
M'Z@@<INW87:-"ZWK>$(8JSF-91:(QJMY/'HVQHFYXI. S-T./)51)W5K7!:_
MR)S4FJU"T><%#)3% +)(+#A66< ;@<C.\9ZR*V(+44P?5W6SVUXNKZW=63%\
M]7WNNO\ /)R1P)%"0>*H?&M5^FKB]26@VQ1,GQPFSVSV9L)"LR:2EMJA^=6>
MO-AK3@48&[J$#>WI%:]-&8VT(E"PM$0)68FRI.#D\TP8F3VGSFL2JYX#@#P'
M6 ::/P:W9^NWHOZJ1_\ CXR>T^<U&!V#S"O+P,S_ /93;_44O_XN,GM/G-,#
ML'F%>>6!B%G.1,K2+.?KYRW(\YS]_.2>O/)U-\9O.?;3 [!YA5VYC4USWVK6
M.V]=P?:#7VN*"E\YG=P[661>D,L8-84+;E$W#$+&>TT@B[%="RX)"05 UU=*
M2T;<LRMBZP]/[$60R+B4-:T)B?FHY+9WMYI)E5(K>.%DYR:*:)T4AFB$0[\/
MOX,,ZCJ /'B'2X19X4B9FDGDE5PD4D4BN05$AE)TE#C[7[4:2:V7,]?-JE<9
MW#LA,??BVP7C9Z,,C!&(O<$H85LAU +S0L@MEKHEE-F35"XM*I.-JGC<S2-(
M2Q2GL$#E'V-U0A=,)UM2S6^JVC(A""!B7:)2%N3SRQF8Z"[*N4+*=2Y(8@XR
M,VAN"MP_UTN9P JRLI,'ULR<T-056;#!2,-C(!W[Z" 1W:^N)755E--=;1K=
M<(OMQ8CE%*1?YBHF=X,U(RW7!QA;2&9-\HL1P6ND+)O12LD$<8)G+G1SA;6<
MC=UN$2<"0:>7:WD62,R6XG:W0-,JZ(C*DX8A2(P QA #,B@,>]&:()T:-Q'.
M81<.5C9M4HC>$H-09R=(E)8!VRHWGJPHJMEV?$.$4_8\>W!D]P@T LZ0,<+K
M2Y9(S2*(WZY;/66AJ.PIZI:[-C29X;&-$L8D8WM<OE#*UMF&DQV8UK:B1FM>
MWFW&N6,VJQ=,169XE*M"+>(RQQYC8@DAC@!23G!!.#KD3$K&PN#)T1R$CD8,
MLO/R"-W(=00N0,DE<8W$ 5)1N?[8A)26OL)8Z)D5N71*X&KK^YK[KR!02>3&
MDHW((;'&6[%M:I)<^1%"*66FJR:U,Q 7UNCH$S8<\OJ==X'9FQ7H6O,F69S,
ML42N'BAD=T64JS-%SA56[V/B>])R<#&2:W;@3<U"@B,DC)HDE149HPRJLNC4
M5RTG ;PN[)S@"I$Z,CS'$J4J&*1B,2>$QJ,5C X]'H;-L(\3.*,C+%FMM:HY
M+<-[@ZH/9*RH4Q#<^=Y.CBERYIU64ZY45W)X]&8EI969E=FD=F=,Z&8L267(
M!TDG(W#=U"MN(!8HU561515"MC4H   ;!(U#&_!.3UFMI\KJRCBE'%*^9QUX
MSCKSCKQG'7CZ^.O_ %XZ^O'7C_5XL\4KG_AM*[W5K76MVJ$%JZ5LQU%78>YR
MJWA%:O2W7FVZW76YB9G6<\CL8J2W-&[-21Q4\DH6J(1ECD:>3O3@[G/"XHML
M$BYAY;222:X>13ST0 CS<+-&XCT\V.;TQ-'J R6)72 ,<<\2L5TB0P)&PYJ4
MDR?66AD0R:^<.O,@<#.  #J).3NK7D*U-VV03Z,-::I]A4ZB,]('(K_2JIK:
M5$J]/TM>K;KDDJ#,!5\CEBZTUDP!#W@UU82TC00XM\S-0NA6$YB(( YM<VY1
MCSD)U68A.F.47.L1*N@/I$>C4,')(*Y' U@MO.'7$<V1=F7OGB-N$YQFU:-1
M?5I.1N!#8(P13W;E:G77=6K]Z,$Y6U_LE:^%V7/6]*T5:SUNYUPE<I R@=&]
M(YR&>2)L<9$*.ICDATORIC*D: "]&0F* YGD&:EM<117$3)K@CQB?,A<.0IQ
MN5 0NK!"]]OP2=U;5Q!++#*'T329!AP@0H"PU %F()T[M61NR,;ZU3?FLE_R
M;;F?BC5;.CU ;NV$T*NU-<:-^B*:/5G'=6!&_5%8I$@<I"BF0)(LRU(U$(2Q
MZ./#:\'2Q=WTYM8F]PP*R&XA6V3+@210WD/-E6+.;C!C92 4TC)#:B" NX'(
MJN6"5KA\(2DLMI)SFI0$$&0X8$AM1P-.D$'/$8-; U<B]X2;;F3VC>&K$UIF
M.1"/V%7^MK>TKJ4)J*MZZD<B:)#)GAS10R?NLO>;<N-X:T+J_K@Q5%'H^C0Y
M:4YJ@]6M=5>%PT*VRQPW"RLQ1YR1+SDCJ"% +(%$40.%&K+'?@8 JR!93.7E
M@:-5#K" 8N;1&(9B0K%C)(1ECC2.'629;.<=6_1Q2CBE1E],C\&;MG_,>/\
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M^>L)."^-O4M9SRRJJRGH_/>>L;TH]H_SV2_E#<3XSZZV.I?WJ_FBGGY%*4>
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M2N'/;Q$G=Y8FFT-DK:LJ+)79="I%*XL8YCBLM95*\EFD;NE1JCS4>5AAR<W
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MV_H8_HU1+] .C]:RBSW/4O6%N(-4$)"CE]45^C*-5*1]FF3%F*&DL U"@S.
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MCGM7 >FA@>U4P=6-.^)H<0\#:%DID!C<>N-28=EQ9(#QNZ%]X7<>E?VT-C9
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M<E?D.ZK!!"%51%&%5M:J$7 <?; 8P&^7C6^.4U;1Q2HQ>F9^#%VZ_F"R?/\
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M0HX!!>G<.DD\LD88(\C,NHDM@G.222<GCO)QG&36W C1PQ(^-:(JMI  R!C
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M+;M!#)*%B96**6 .LG!QP.#FH:?85.?M"GWY#2SZ'YSO=&P\+@](M<+W.O\
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M,!:C,5G("U:4:Y,22H4(@*"A*R"% C ISSDP1Y.*)/$4:$DP8 @-$49@ A9
M+JG!QG!QV]7GJ,C.,C/9U^:J(;^Q%D@4F/;06G,/4IBSQN2,!(U*,T1"M. T
M1V "/2G@&2I*"+)A!H1%FA",.<88/8?,>OA3([1YQ5UQG L8$'.,ASC&<9QG
M&<9QG'7C.,X\6<9QX\9QXLXY%37WBE4H%J(Q6>@+5I1KDQ1*A2B H*$K3D*,
MF!3G'I@CR<44>(HT))A@ @-R69@ A9 +JG!QG!QV]7GJ,C.,C/9U^:J03ZR
M((4C>&H*92ORU)E G!($A0Z8/,39;2#<G8+-7X4DFI\HRQ"4=N485V?: $'#
M!SC!R!DC!SCM\5,C&<C!. <C&>SQU=>14T<4JF M1F*ST!:M*8N3%$GJ40%!
M0E:<A1DP*<X],$>3BBCQ%&X),, $!N2C, $+(!=4X.,X..WJ\]1D9QD9[.OS
M5;AR2.EA",;^R@ ,9Y8!#=4(0C&E/,2J0!%D_&!#3J234YX<9SDH\HPDS 3
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M8$;:_.JD:QS>T"9J2$HW=Q5F *,5+W). M8L4C++&>H.,-$  A9#CB')+L2
MI+,2HW $DY '4!P%<J@ 50#J 50">)  P2?EXUD_,:RJ(B]5LZJ+=&S=CX/$
M7N5.#;2M+4H:RH6YQ5))!BU#[\.A ,A1D&!/,0WM%J=CJ]?G'9QB.3N1.ZQ0
MD1"4X4<E"$EM8H&95!EFER2 1S?,ZO/"TK ?;,B@?)Q\Q>.X>9%+$11QX SG
MG#,5\TJQ G[57).ZE\/J:M8'J_8M/S,:9OLE$^[D1.M;0LNL9#82!_ROGY)<
MJ10U(2YIF]NO.T7(AD?X<[I6I\E"PPIP<8PR2A.V.C3BX22-<)*N=!%J[QQN
ML>,1]Z6R"3#&-0<$A1P9ER#5)CC6%HVP)/[Y5)'1G!R_?!=XQ*YP5."QWZ0V
M"*G0@BUS<H1#7%Z9E\<>%\5CRUVCSJNRYNC"YJFA&>O9G)R$$(G!>UJC#4*Q
M=D(<JU!!A^0XR9U8XEP [ $, S ,!@, 3@@=0(W@=7"N43)5205.E<J3DJ<#
M()ZR.!/765<QK*HA[T6SNH=T+/V.@T1>Y2XH::IBD3&9$VN*I&_BM05ZGP3N
M\)"3 G"07K%J@C:]?U=G&8Y/I&[+#TJ+*C!_)PA);6*!V"YEFEU$C*\V(=>[
MY86E8#[9D4#?PX^8M%<23JI8B..+ ''G!)H_]98U)^U#$G=2KRJK;LA6J\TI
MQ@K:P9W5%>6W=3^^2-AD,49WZ?V,U7TH*C"J6-,ADS#(7",%#3*K)7886]Z*
ME<O=(PJ.4HVF,/"&07K)$UPLK2(DKQQ  AB$C,(UA2JLH8YYOOB-*AAO+ K0
MT<JP&(([QI)(2P907<2D#6&8,1D!^]!U,03@*0>A1N4*5C>@5K&\]I5JD:50
MJ:U1R10I;5)Y #3V]0H;U"M >>C-$).<<B5*4AIA8AIE!Q(@&"X8[B0#D G!
M&<'Y=^#OX[P#VURPW@9&#C>.SY-V[=\E5G(J:B"NE78%1[E6YL!7T5>I&[N%
M;U30!;8E;'%6V.CK9S%9"^KW5?WJ0<$Q&Q7;%8!$7%QP$9$;8;/D+LO&2C+.
M%GDH1'):QPR,J@2R39)&0(^:$@'[Z)I& W:FC51OKCI"\=S+*BLQ*1Q8 W$N
MKF,GMQ*J*3]J'8G=2Q)J8AM<UPR,<KDJ9,OIAPWW9JCCEK:]MUR1BVY:MV1(
M5H"ACD@7 +I/9<&%,6$,8C38DL.5,TG?G*%2A.5X;"9>)7>1F4'$O1#(8YS$
MT:"#&<+@A%UG+,>;4JH9<XJH1HB*&;!B-TL8DB$BR,9MWOLY=@HW* [*Q*L-
M]3[PY4[+HC%5K\R$QI\61MC5/4<3F .(C[LH;$ISBR$FE8P6:2U+!G("S"\8
M ,"<(@8[G..<0^-38)8:CACQ89."?E(WURBYTKD:3I&5'!3C>/(=U9'S&LJB
M!NA5851[DV]?U?15ZD3PZ5W5>OQ;:E:W%8UN;O9L>L%PJMX<>]2#@F(6"[(K
M!8@Y.(0&$QQBM"0NS@(I&4<+')Q!);6.%V50'DGR2 0(V02*/E:)G8#/?-&H
M&\UQTA>.YEE12Q*1Q 8."75]!..($JJI(]Z'8G=2<)JB55I&'&$2M4Q!KF$1
MC=Z+5<&UJE<[2*L>S$FT,Y"JBB%+W\D.23"VXR3$5"<]@,+LN8(RUXJW>4@T
M<@/-V>=UMJ4'6[6K2<W((]"&W3#$X(*1MKW$<VAQK!R *-&@:6*Z$6Y5.<0O
MKDY]@5QG.J1=)[WOV&=!]]71)$3W%5%(PI=VDQA=E$>93W1C.6C<CF5Q.;4Q
MBUI-<31F&+S&Y2(U&-:8,8U0B<GC&(1F<YX5L:FP=0U'#8QD9W''5GCCJKEE
MSI7(P=(R,YP<<,]>.&:R'F-95$!<RJPJDW)N"_*\BSS(7EXK^K=?"6Y,UN*Q
MK<7JS(S.G&J'MR[U(."8WQZZXK"H>Y.(0&$1QCM*0NSADI&2<,/)PA);:.%V
M"J'DGR2 0(V02 ?*T3.P'VS1J!OKCI"\=S+*BDDI'%C!QEU<H3NX+(J*3]J'
M8G=6 0'5NOWFGJAUGD-8,4L [[7;10V26#-(.UO$R;Z*K2ZK@F[[A'*'9L5.
MC4?;3BW1>(JG!"X(U1[58DBD3*O+=DZ5;S)KAUEEG61D_O:W98T<A#+)%$@R
MH(!$8+L 1@%%4C!Q4+ ACC@9 V9YD9V4%A$DDCGOB"07(49!&YRP.<5-NE2I
MD*9.B1)R$B-(02E2)$I):=,E3)RPE$)TY!00%$$$%  4224 )9980@ $(0XQ
MCBB2223DG>2>)/::Y+APKWXI4/-M'V/4^X5Y7;7$;>W=[F\>KC7!(0F:%ZYH
M-E%@UVL=:9F+W@@@P H_#;9C:*(O#D'NDK&V6H\N+IW"1*8>EY.+1);0Q2,
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M2H*E8SDA:W28)9:[$C5'KU2Y7KW.K$ D),HA(DU'+@\[+H#\3J$>G<3D+I!
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MY; *QE&&4N,*Y.D-I)("DKI((;4!IP<XP:O]0;?U7=UY7+1D&$ZKW6G&*OI
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M3G#(<NZC3BB\_P"F8#&:!#,2P$4A*>_ C8E/WP RO \<5<98@%)EC ?WA+J
MW5WN_OMY'#/&OT\W_1$<>UT:D-V5(PR-L\,>$F!YLB&M;VW^QYK(>W_OYJ7/
M)"Y)X#9E25W>.W(+\&-:DA>M[!(<6:*5AF8!EAE93C#+&Y!R=(P0,'+ @=I&
M!OH98E)#21@C.074$8&3D$Y&!O/8-YK8,<DL<F+$URB(O[)*8T]I"U[+(HXZ
MH7QB=T)O7V2UK=VP]4WN"0SN<]FI2*#B1]6>Y'GJSRME92592K X*L""#V$'
M!!\=9JRL RD,IW@J001V@C<:O7(J:.*4<4HXI1Q2CBE'%*.*4<4HXI1Q2CBE
M'%*.*4<4HXI1Q2CBE'%*.*4<4HXI1Q2CBE'%*.*4<4HXI7'-OC$Y6HW+V,5)
MXQ(STRJP"U"520QNAR=20.+QW #DYY:411Q0LA%@)A8A SD(L8%G.,]7V1[C
MG*SDQLGD)L^RVIR@V/L^\CN]I.]K>;0M;>=%DO97C9HI95<!U(921AE((W5^
M5WU4ON9^Z)RF]V/;>UN3O(?E5MO9<VS=A1Q;0V5L+:-]9RR0;+@CF2.YM[>2
M)VBD4I(%8E'!5L$$4I?L.E_VIR?\GW?_  ?/4O[/^0_^=O)W_B]C^NKYW_M)
M^[!_HQY=_P#*^V/ZI4V_1 5B;+8;NC!9NR/S7&[%B%9PIQ,4(5C4<K;'QJNI
MG?"FU2L3! )6G0/!8A"+"=E*-2E,-!U&EX'\L^[KMS96U^4^Q;O8VT[':<-O
ML:.-YK&YANHXYTVA>2B-WA=U5PK(^DD'2P.,$5^C7U'')+E-R4]S_E1L[E5L
M#;')V[N^5L]S!:[9V?=;.N)K5]B;)@Z1%%=1Q.\)EBEC$B@KKC=<Y4@,9 ="
M]G45@ZGYGMI5("#:AAB<?C\Z@)]RM=EVY6M=M;NT0V!SVNE,I3T^Q 4D.*19
M*I"D+E;TX.+2ARB/2-V%#:H\>>[@T7&A)-=SJ9D<1<W')(07='"F4XP0J]Z
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MBXN=:S]N;D-ZUVK7+U\-D:-$C2D2%&8>I5JE#:60G3DEA$8:<<8 LL <B&+
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M?"LP&<K6UO->6I0L95,C$:[,3<]EHE@FDPHA6#OD)5BW<>I R/H-D+233IU
M@EM: G!P0NXE<C/EP:U?#%636+SI2!M07@%TL0"0<9W@'?BM)NO1][9M]<Z[
MT^P3S7R:U36;C,+5MBNK#S9S/$K<O6<6E+;1[N0HHFA-7/M5UZ[R!(=$(DZ.
MB5'('5$6Z31F<"T3>@*M%Y;&2:5DG21PL<3IS9:*)(TC[TL0!(X4ZF )4'"$
M9)JHVER$BC#PO&FIY$<N%DE:1G[X*I+1KD:5)&3O8' %-/O)KULUL@FK"'5U
M):;35 UK3'Z[*VL5?83:VW&XH\IC(]$7Q9!T W8VMD"XHUU>X[AT0XEBC"%
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MD.H(JMC(4-8MAP3%DA*G.#9 VM2@P$<&A%X2.=DSL,2#%'3E":!SH_O)[8<
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+XI1Q2CBE'%*__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g796801g39q79.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g796801g39q79.jpg
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M 0$! 0$! 0$! 0$!_\  $0@ O )= P$1  (1 0,1 ?_$ !X  0 " @,! 0$
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M3BL]T2;\Q][WL]V<2,?\9I1VE9O5I!_"$E_XU;3" (HPIY*$71"\01KX+_$
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M'\DS+Q$:,JK)QYC94@D')WDPBAK8_BRS<V\SORD>1^:^<(F#%W5B8]\#H$$
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M&AF%$/CA"(4Z?)E@Q@AIH\T0NP4:'J68^BJ.[,WV =SK9/H 20#%V"*2=GX
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M;&SNHUQLK-&/.:-&6^3R+><O[.B2!FD1O)25IT=941JVK=<8F2@=!:;B)>\
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MV;D58JZ'4)RZS<O;&H2S.M1\E3W)_?$N% E41JE!@'3IKU]UR<U84SH94:7
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M:[E"Q<A*C,PE,%*F)L(G$BT<B;6@=P L,G+PM\,ZPP7"JK>=.%B#]N*PG9D
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MAQU2W7/5#,-HRXZM;CF4Y6XM2U*5F#,69F/<L2Q/S).S_MJ:J%55'8* H'R
M&A_LKM^:5K41[!AY2#E ]JU$ F1G8(!,7;:['MY<+O5!:(?-?C!&$>'M5JJI
M!)M@HV'$K4041/5-IR/9NILJ#;&0P,3D!6.T8^B2:T"?DKZ"R?8%<[X &MP0
M?,4;*C3*!W=!WT/\9=DI\R67MS+"2H:8B[#$1<]!GC2D--1XDK%20;F'13XX
M]ALH,L=S'R6R0.ZVZVKY>*58\<8SXXY605)5@05)!!]00=$'[0>U3!# ,#L$
M @CT((V"/O%87;]@)A)%BIUF+5;]A2(B3 :N,7@(6,CW771VK%=)KV<QJJ5;
M!#!"$GOB&RLNL0X*JP=BE1'H],T3D"S'A&#HMK9)]>*+L<VT1VV -@NRJ=U%
MGT>*CDY&PH.M#TY.>_%=_'1)T>"L1JOG4=?*BY-RX6Z43;]A%BNAN3[@F0HN
MOQI*VGB*[1819!B:U ./,L+-5DLZ?L#@H+UGG)A4=%)CS/L<$'",'?'>RQ'8
M,Y[<FT3KL%79XJNSO14T2S'FY[<B-!1_)1=GBOS[EFT.3-H:DKE=64XI42:K
M_P!6E[0J/_X=9VC8C0E+^3Q(6Q!8S:KY.4Y_*RPU/WB>AQW<>*%XB'&TYPIE
M:$6R]Q$_\J)0?L,9,0'W\44G[ZKC[>8NB LC$$_'S-2D_=R=E'^3\P:EOE56
M4XI3BE.*4XI3BE.*5:?4'T03_:9W^#'*7^L?R?U"K4]#]_ZA41;9^F9?]3 _
MRZ>33T/W_J%1?U'W?K-1KR=0IQ2G%*<4IQ2G%*U.]^_5IV9 *I"MD9V$O2EL
M;V4BE ZZ-#;T+F?;R:^UC8\A'"(N^)K,JFGMP[A.'\8EOB 58[45G'GSZ0D?
M@3)8>&W[^D\\%HOB3AVZ&-L^?5I.KO+?R4O1@8Y7&(,7#\(RW8CCC'D^5/'(
MQ#;_ -.'J87&6/2ZEIOP)<C*[6S(&,+ N8_;"J^T\P?($6V)Y\U("ZK?:<=6
M&UZ>5T-D;,=N1NC6!O#5.(@YU2-5YCJ;\1.7X;;TL)#1T\F214<5U,.Z,6Y8
M5%L'"NPB3TLYOTI(_!B7PT@3Z1LMW;]!#K+ FTDLCG$N3U,(\F+)(CTY%+>M
M;MC#F?;O,0Q+8B>2)EOTLF&/T6<XN9'[B@K9<XR[\Q6]E9/P?NW\XR"^98@X
MG%KY(4\_-T&!A,HK;MU830$=<=)HU8Y.NZ^3KBKXJSEH2VBRKCL1K/CFQ('Q
M@1$[[3Z_WNV!C$:B0]H1&X]@P/SOA]<CQX%-#@8R3&8]#RRA;WBG#CQ+>\5T
M6[[K9(>/E1\>6N(USUS^WEKMRWOEKMO>NVJKUZ0WZ&=:O_6WUB_]ZN\SL=]>
MZ_\  W7_ *=8M_\ 4M__ !EM_P"I6P'FWUG4XI3BE=+9+!%U.O3MHFWG!X:N
M0\E.2K[([Y;S4=%!O'&+9$&;=)*>2.PYED49IT@ASRLL-N.K0C.JJ695'JQ"
MC9 &R=#9/8=SZGL*T8A5+'L%!).B= #9[#9/;X ;JMU_W+)(9 ;>;V+J8&-F
MQ(R\/ATV#O=]BC;,P,/K,2-A*\SLZ&/A;U.DOP_O:*!L!C$U'LU=QB&D9%Z0
MC,F.$$G7ERDJ2@+F.,A-F4LS&(JR*-Z8J-'EL@ &AY3VWSB (#^ZKN.7:, +
MYBD.VUV QV..@3L*]V01.1.NJU&HILCNJP58J6NM$LMJ?ULNF258B(]VZ"3<
M:;"VJUPYC$L;Y(2)(KY*9*(8D)QF7=A8U<F2:WXF1CS\E7"I(J^9S#EN!!!1
M""![QY#3$+QY'0T6?D(U' S,NW1F,? J!R!!#N#L^Z"IV 6WH;-:]Z;;KFS8
M1-K;AJQ"0B^N-RL*(S?T&L/-DAKIFO.K_!#'$N(#LEJCF8W(,LZ,;D0HJ<H
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M9: :W,%7C71XM:NY"6<S I:'E5&_LB,H88!NL>+C+J)!L1IH.)N\6W\30*&
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M'AA;\H-MR*:2O/F<RS X1G.$-(QRWUA_[N7\_FIV_-Y)_P#BJOTF/K[\8[?
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M*2<SC\*."@.*'DW-J76<:,D.[B272B*UF(;C@7:S9,IL"IZ&@]O:'B^IM<5
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M 8(W#A#.0REB!)HR0<" JDS#W S(1$2A'+877(&1]4]?RK,16+/LR&CIX$R
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M)3)9DA*$YCJ[7(<?WA9+1+Y:6\B)@(M+C:BR<,MN$F$O.BQ4-',E34](Q4(
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MC3]8OUC=#_WO:^_B'F+[+<_T>?\ 0R?LUD^T6_\ /P_I4_:I^-/UB_6-T/\
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MSER//?#=!+,BLD**(C5DBD$BJRR4I[(9#HKK[S:W//A[(V 2 >Q&_4;! .M
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M(,TE@8449E*&1QQV4(:88:0AMII"6VTI2G&,5$DDDDDD[)/<DGU)/Q)JP
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M#NORF23B,H&8*DD1T4A]:4$R#'CX\OAM)Y^Z(0@&VE?W(E7XLSGMH>NALZ]
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M^*_;OKX.!O:DD*75-5NI[.@VZ_#^6F]LG?MOXH21IM#85G!SJN6&'MD%%62
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M.'<;;MV;X\=ML^[&  :5_@:V_P#T4[)_<:T?_*^9OGP?ST7Z1/\ ?6'Y$_\
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MQT$N.K"YT8<$J6B(.)>FO>,R@V6.W"S_  =8QO#!>0K 9&>.$W$)CMP^BT<
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M!^0+<D)&,K 9\L\X4I#\J2:\PT,.XT,SG0X'+0H(UQ63(#2,-V%R->9(TA
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ME;TZ!/"UM)7T"=:%9&/L\GF&X87%9'+'?$O9VLKVZ-O6I;IE6WB'VO(!\ZP
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M22XMXR03P259IB%!8\(T)!.@3W8?9NH2Y%50O'!<. 0.;1M%$"Q '*1QV&R
M=*:F;176F_.[*QV:[36B#OF]U11</1:S56BF]6Z&K,JG.)"#U\/(>)DG899E
M?L]CN\BG$F<.I<4*M0&'23Z)[F/R_9K562WV&=GUYL[CT:378*I^J@[#U/?L
M+8;=_,]HN65Y]$(J;\N%6]5C![ECZ,Y[D=O3UO)S"K,IQ2H8W9V%TWUVK6+3
MN"]PU/ (RXU% DN.&6"Q%HPG_0*U6X]LJ<GS<J6VE3,6 3@?#B72EL,>9U-B
M1/('90 D2-)+([*D4,:@LTDLKE4CC5069W8* "2>U52S1P@&1@.1TB]R[MV
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MIK>Y(X326:HKW,:]T61"O,K*(Y*U?LB!VY1H+857%G1*_8VRB8C%BARH*2*
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M\-#MDO92RDR2?;6T*EU;:%N8\OGQG.,9BB.Y(12Q52Y"C9"KW9C]@'K4F=$
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M7LE5)?URP$K0OO\ ;]M;;SL@8D15WS-XE<T]4.EK#>,RWQ [@9<5SSY](1O
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MEKB-<_K?;RUVY;WRUVWO7;58OV\U=I[:FK8T'?5M@J=JRI7RJWBT&V:1CHB
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M$*6TZWE+K2UM+0M7T)L+^SREE:Y''W$5W97L,=Q:W,+<HYH9%#(ZGU'8Z96
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M&]?]L3[[ITCJN:*=5EN-U]<RU$25+.>6T-$22BPBTY;]\S?#C\(0^:H!O($
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M)^\!X[_X%/%K_5SUA_R>K/W4=-?WPX3_ #K8_P#'I^"O9W]'5Y_=.=^X<?O
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MA1QL6(]!Q_NY!L8P&4_&,"MB1Y+KP@>$BM--H\S^*/@3U_?]?=2Y#PW\&OI
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M[E[K76B+>/L!^Z7YR[@I.7&6C+M*3*1QDJ+% RAS66Z2@4M18$:^"S&RHTA
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D1]<,@27(@; '?M\==M:UW[>OW5IQ[Z^6CZ#???V?9]_SK__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g796801g42a77.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g796801g42a77.jpg
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M,E9Q=I>XU=?8)SE">8&QM"4F*$-$56)H<G-UD;6R_\0 '@$!  (" P$! 0
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M2E*4I2E*4I2E*4I53>>OF.\Q/5?WQ[KY15NP\.L_28/:+56^\#NO1YO9M7'
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MK_\ TQ3^Z)N$?YN.3O\ 4C6'^^2GW#ZO\?I_UUQ^:T_28]*7[=\!_P!*Z_\
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MZ1;MB/+(R@%V)Q+Q3^,/H^::_P!'$3_V55[[N.,_W5<0_P!,7_Y>M/\ H/\
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M6L[BYC"F:WFCVLZOE"=NTJ3LZX$>8SPT]5;C[[IXG7B]]X;>>E7'MGKZNLO
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MPQQ<WRRRRRO:V.-K7O>][6M:][TZR,]CI_.7\=9&H6!( O;0DD  7,)))Y
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MDXY';OXR[5>Q>8&!\;E9? R.>]_,C,9%1(8 "CC;V[4R9G)E!G$H$?56N6T
MEBN)2\D?51DY5<I\!V"NVX'OV0(%4,<,TC )&V>_<(\,IK&C\5ZM)?ZKIZZ+
MILK=?96?6V,C26&HW,-EJ%P+F&0G4KFQM]/@L[6&ZE*7-SJERL6GZ3=L\G1;
MA+M784,C,J8[=UTH_DL,9/0\1,F=AMS*0+YH278(P [)N(3G$6""<6@LH)XH
M9R3Y&8+"F33-RFY?H8I3)I\TL:2+/%ET&$9I0V.K>0)GJRGP(W.-VT8 SDX&
M]T_HOX@UC3;&_AXCT8S7VF12V^G7-SK"7*VOVMO=8@LY)WTPZ?$HL-*OIPAO
M>YHF@BC+AY4"P3R-T=--$3(.$G4B92@M*XXXEJ!5JVFC)SFS;3.8017 JSGT
M;BTD0?9%803<(W<#,F[H2N,?M':Z+NW>5KJW>WD"R.'9U+[@'!($CQ\Q(JMG
M=&3S&"I!!(-=3XTX5U/A/4[>UU6]BO[C4+)]16X1-3BD,::GJ6DL+B/5K*PO
M4E-QI<[J7@*26[P2QR.L@QB>BOQW:<_6IKW]KA%<+?PB#_;1?^=:U_"GZZ>&
MOX?T?^\;:O\ 24KU*OVII2E*4J/-2M<&.LX.S2ARVO4VT;&(X0AP_<%%XOC@
MAC:P94B[P3=/5&?\GDX<88K*7MWREK9=:DF.97._K,L3U@& _P#K8\6?)4<7
M*-!LZOO1WF<[?DR>9Q4AU'4E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E5-YZ^8
M[S$]5_?'NOE%6[#PZS])@]HM5;[P.Z]'F]FU<<"/,9X:>JMQ]]T\3K%]X;>>
ME7'MGK-EX':>C0>R2IUVL 0E6KMDQ=U$$=A-9) 9@ <P%P;O&F\X0,1XB.6B
M"\CM?&\?1DJ;G(*J;MEC<5@]R?VO:Z'6H8FV2QL'ZLK(C"0+N*88'?M_SMN-
MVWQXQXZFD7='(I7>&1U*$[0^5(VEO\W=G&?%G-4VX!2+31Z/;$QU-JN0ZD>-
M2@-Q.X\?W@!W-?.4%\I"2(JM%1&VMF.!7>F5CER!9^QBN<L)*NG5D"3T:2P%
MW+]9E:/K95F!4]6RP-#A0% !#11@][MPH+[!@9 (S4LFB97ZN)HB""ZF99N^
M.XD@K+)CGG)(4L?$<'&P>M?5ZE*4I2HMWE^)3</ZK=@_LF7I2H^X9^9_Q2]6
MS1?NOBU*RW:?G/X:LG2L4I2E*5@VT(<IL/6FQ-?I/\!2LY@TMAR911OD[3&J
M28 0"X/\VF*S?)U@SR>V<9-\7"&2^*=T[+)7R[_&.5.LBDCSCK(W3.,XWJ5S
MC(SC.<9&?+6JUS3CK&B:QI"RBW;5-*U#3EG*&00F^M)K82F,,AD$9EWE Z%@
MNW<N<CS1_P!SGROTKH]_H@)?[PZZK]S#^>+]0?RM?$GZ334/W?V?]79_\9KN
MAO[GSV:'9D!PCF:@*'ED\D2K$;K60,69-'))1#)(@U:[+20>)Y(*JHY8.<%,
M;I*J)WM?#/*U^2\-S*"%O]H;X06)@#XN8$V#RY<ZM0?8A:[;130VW26MO#<*
M5N(H-$O(HIU*E"LT<>MJDJE&92'# JQ7L)%<M?W/ILUE="[7F6U0LUQPP;X)
MZR.XIHIIMW#/!+!+]\GL[(V:.W;3L>][.[5TY;7PNBNKAF'#4HQB_P 8Y#[R
MW9C&/U;LP2,>0D4C^Q"UV+9U?24B", (%T.["J CQA0OV[V[>KDDCVXVF-W0
MC:[ Y!L+N#6XMJ&V\AG?,F/FR;,=@)8Y)Z0P#L1XS!Z_)W9#1 .:C! YNL5*
ME"SK!DQ0L\+%"11WVS]^[<+<I>'9YF#27RL0-H_]GV@#). JR!0"S,QP!EF+
M')))MZQ]B?Q)K]TEYJW239W4\<(MXB.%Q;10P"6:?JH;>UU."WA1KBXGN)!%
M$G67$\T\FZ661V^"!?N?240N=0N8J<H@!!.)RR.291AAJ8BVS?8 C#,IDSP<
M93];%#)SBUNCBM=%6R5\[9W24MCWM\1\-/')')W8IV.CXZ@C.U@V,]:<9QC.
M*BTC[$&_TS5=,U)N.[29=/U"ROC".'YD,HM+F*X,8<ZNP0N(]H8JP4G.TXQ7
MIIKM=?<%*4I2E1CI=P(=:GU\Y &#\A"K184H,-RF]\I&49Y-\;HO#-[WOU?J
MX_A+^6]N^^B][>6\L^[KI-P56W'*I\$'R+\GDJ*':8DVEF7:,%OA$>4_+4G5
M%4M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E5-YZ^8[S$]5_?'NOE%6[#PZS])@
M]HM5;[P.Z]'F]FU<<"/,9X:>JMQ]]T\3K%]X;>>E7'MGK-EX':>C0>R2K9U5
MJS6O[@G+M(S9#9I;3@!X!29Y0X$\8F=\B-QG0,:'*S!:'0=2-#M@3MQI<%$\
MGLCN$ULXL"9B%BY9H.'_ -XNTVVPODG0Q"8J<[V!6 PJS'9O?<8XQ,SX7=)W
MQ. 2>8S2LWA?K#$",; 0TPE95&_:FT._5*O?8CY8)( Y8&P&M?5VJL<N])RC
M>^M@\4BS>&&%Q4P1D1.'[%(EA4&FHZT3ET<1%R%^&CLM>HXQ\W(P^P0UK1PG
M@K)86$1O<;FHF8'6K298)&=BZY3:'C ,B'>C$J"R#OE5HSWP[UV[>PUKJ%IH
MPJ[3AMQ1R0CC8ZX8A6/>EA(.]/?(O9VB&P_&S<:W(#06RID.U@8%:9@S:(/-
M@,]FS[]]B2O0@O8\4&DWH8MK(A'<(](P,Q1DTRAL?DT0=G)VNP6ELSG@36D)
M9N9C<P=1<1H909GWK&8TZI-QC<@,)0VY60JCLCXCR%2-I'(B%O+U\$C"(B)-
MA<22=:V!(H.&1EVLK!G4,I9SWSN(TS*',K7.S)UJ29N]?\@YOI)H!UMLU61"
MHE"]22QK.4'$945;-2Z^RX),'XC!@DS?-D58P[#++)EW.;K-99J/4:Z^KX./
M$#\^?^1%91PS\S_BEZMFB_=?%J4;M/SG\-63I6*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I6#:S=E'^OX>]-28+,RSD"/6(2N.>#6!'W6:.-U28JS1!JULR=9=<T;
M(-T$[8WZ8I86_!M)*%$CA59%#'"-\)1GD#V\Q\Y^<UPC),:%F5R5&67X+'RC
MY/HK.:CKG2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I53>>OF.\Q/5?WQ[KY15NP
M\.L_28/:+56^\#NO1YO9M7' CS&>&GJK<??=/$ZQ?>&WGI5Q[9ZS9>!VGHT'
MLDJRLJ/MXI%Y)*7:::K6- #!]RDL2$ADE&X8<X(K)JES[\6"%)YIMLL<R1HF
M.$L<;W=$G[-FDLX3KJI=E4=K,%'(MS8@#DH+'M[%!)[ ">53LVU68]BJ6/,#
ML!/:Q"CL[6( [20.=:SNYISMI.G.\GH_9F>QA^&>NG;1ZVG ><LGB)1;8;A*
M9GW(;?6\FH3:$R;I(?/T BEJYFR:@HIFQUK'T5[HVV.HIL$ ,75G[X""C(00
M(QL :W@)B0YZMLRY+/F1L50T]]_7'K.L'WL@[PXP=^&8B>8"1_\ /4=7C:OW
ML9K:?6LK8UBDTGD'UN <2O8DRBL#B[1=JV=2.9R$3& +9P]6Q;,V[@N;=L1Z
M*SMQG@@V24<8YKK98II8Y9WM:N2(\C;8T9V.2%12S$#M.%!/+Q\JXNZ(I9V5
M%&,L[!5&>0R20.9[*[/.11],F)"J'0R9@^Q?$P0G,FRP)FAHNS*Y,@)89+V=
M$6(ZQ(==\[9I+(-+/V5W"B?A2':-K8)VMA2 QP<*3G )[ 3@X![<&L[ER!N&
M6!*C(R0,9(':0,C)'(9'EK!=Y?B4W#^JW8/[)EZXUFH^X9^9_P 4O5LT7[KX
MM2LMVGYS^&K)TK%85/\ 8T%U9'LY5L.4"(D Q?,1:9 NYLCB[*$UK-QPH>WP
MLH[)%7ZW5-F,'H.7SF^.=T6^=D\[X\XXY)6VQHSM@G"C. .9)\@ [2< >,UP
M>1(UW.P1<@98XYGL \I/B YU@@7DMH"22J.0@!MZ!F)3,!PDK%1 Z0,G:LB8
M'H\\E@58*NCGFT(Y%HP.('Q[=JX5<NQ#!Z_01S;M5U$Y&MKA49VAD5$)#$J1
MM*L$;=GF,,0IR.1(!YD5P%Q SJBRH6< J P.X%2PVGL.5!88/, GQ5WDOWCI
MR *21":;.A$9<P]I&7TI9EI&,:OH^UF;Q^PB2Q5CFX\+9VDCL431"8K(XYDK
MCWF37%5-LMEAQ2":3;LB=M^X(0I(;8 7P<8.T$%N?+(S7)IHDW;Y$7;M+ L
M5WDA<C.1N(./+@X[*^R&[BU3L0Y((U ]BPV8GHJDQ<2$5&I",,NQ38E=;%DY
M<X,'"]O!EU6[AO9PG=1'!VW79J*8.D5$<</#+&JL\;HK$A2RE02,$@9 YX(/
MS$'LHDL;LRI(CLN"P5@2 <X)P?'@_P H(J2*CJ2E*4I2E*4I2E*4I2L"U<S>
M#]=0QD0B3*!O6L?'(NH:-<).V$;6P1QMF):.455DET6E_P #!3!92V5O^GE?
MK>I)2#(Y#F0%CAR,%OE(\IJ.($1H"@0[1E <A?D!^2L]J.I*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*J;SU\QWF)ZK^^/=?**MV'AUGZ3![1:JWW@=UZ/-[-J
MXX$>8SPT]5;C[[IXG6+[PV\]*N/;/6;+P.T]&@]DE6SJK5FM<?<]2T^R&[5A
M\H=[!<1J!$HR BPB;LLV3?7#Q)66)'M/"7#K5^NG$I6U\S:QK%_.0KR6P&0,
MS81E"B:*(,IX7L;]8\Q.@C#2!F8H23(,(5F;[[($ZPEL1D(Z[277+#%"Q,F)
M$;?M0JJ!QC8>_P!T0^]QEMF%RX+HV0$/>DG8Y6NJ_4!<A])N]X12/AQ4M0A4
M@B<J4E8 V_C6,P$8.WL-F&ORC8O&;FHY<JW7C$Z/786Q-,OD\[@(+*8OD&"H
MUY8MYA S%D+JZ;&4-L. Z2*0VUL8>-<]Z<KN7(SD0SPF95 ;8RMN5BN\ E'C
M.5RN>]=L<^38/,#!QZ'<:1D6F6F9NX.L2IS2NO)QJ4&4QB;)@=-:\/N8O\T0
MAX]8B[?.EH8/BZ>"Z^/>L3YDJ7.(B@&;S-E?+W)=)DVD":1)6&XE1(N_>RK@
M ;RW9VJ%"Y;&:XI;A7B<L"T4;Q*=@#&-BFU2V2>]"<_$Q).%[*Z'F5H>);DU
M),B4EE6ZHXO"];;-=#$=3\@-V:5'D\WT94<*IRX7J:>PT;-VR68IOBS:RYJ:
M08(.";=FF@@7)INZU60<>3^4 _A!K*>&?F?\4O5LT7[KXM2C=I^<_AJR=*Q4
M(;TTOAN<-#T6DL*0>4:\FZ&P(5)QC1N2Q''K12605^F2%.%6ORB.)1"<R@4I
M@T(B2;!R^:F!!8>4&LW.$\$W4L^4#K(AC=22,KN1Q@\\$.BGF&!P00034,T/
M7!1N*,C[T8#.&VLAR.605=AR((R"""!50(9W-F.1>=Q2:DMW[4DR\:2#]N^=
M/U14[,N@D'F^OD%EMD""+:2"[.X_.B:;UP%\ -IN&K%<0<$Y(VJV^I,T;H((
MEW;L<MR*&D23]38%20R#&[*X)!4YJJM@JNKF:5L8).2')".@^^*0P[USV<\@
M$$5,.P>&<9ELF<S6-S610Z7IQK3H(0><((S=\F\TZIM1F,/RE_+7+XU/2YJ,
M[9-QTJ_E!AV3SQ&AR=R2SQMGVD,=XRJ$9%=-TQ*CO!B7JB50* L8#Q*P"*!S
M88P:F>U5F+JQ1ML0#$;SF(R89BY)<E9&4EB3C!SRKL^-O$]CQR,R!ZPG3^9B
MWD= PN*,CD?&,2,+A<7RS^0XP.)BUT62K+')9T3.N&P,8_ELI?D97)W14RYQ
M61Q<W1N N4"-N9W*L2KN_P )MIY@^)068(H"(%48.8+80%B'+ JJ*"H!5$SM
M4$<N6220H+,2S9/9;JJE6:4I2E*4I2E*4I2E*C'2]@F.J(!A&T9,W X1@9@)
M1F5D;2E-E@C;%'$[X/>Z%R-L;?Q]T;W3ROTOA^#>U2S;C+(6*EBQ+%/@Y\>W
MY*CAV]5'MW!=HP'^%CQ;OE\N.7DY5)U15)2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I53>>OF.\Q/5?WQ[KY15NP\.L_28/:+56^\#NO1YO9M7' CS&>&GJK<??
M=/$ZQ?>&WGI5Q[9ZS9>!VGHT'LDJV=5:LUJ7[FU!"@>4[9E">>P L<4B\#C0
M\ 9C4,$1EVW:&9T0#BBQACQETA(9;L_6K9R_1DTT%2_9L4E@[88M=>:3)X,&
M%V6UU%U*0IF-FW.Y979F!*H&('=,ZK'(<;4*1.IC/WM 2#K+!"&D;[XJ[47:
MRH%/?.0"PMX6:2/)W,'D5A("9'(!&VBM56SK&Y9,HA @CB33J5QN%QQHJU0=
MR"6'!<<"-5WSA-HR1<%3#IFP15>.UDFK5-1QCFX<*IHI6S4SQQOR1'D;:B,[
M')"HI9B ,DX )Y#F?(*XLRH"SLJ*,99B% R<#)) YD@#RGE7YN)Q"VDG$0EU
M+XNVF9\8Z- 8BX/B49.;#,>^\-+" "CO$J2&,^\S\*?LVBS5OWN7:JX=[?ID
M1N4+A'**0K.%.Q6/8I;& 3X@3DTWIN";EWL"57<-Q [2%SD@>,@8K%=Y?B4W
M#^JW8/[)EZX5RJ/N&?F?\4O5LT7[KXM2LMVGYS^&K)TK%*4I2E*4I2E*4I2E
M*4I2E*4I2E*4K -6.UW^NH<\=2]"?.'(-FJM,FS2S%O(\\L;]2:3/''"S?%?
MZOO<;VOC>^6-LKWM4DH D<!"@W'O#VK\G\E1Q',:$OUF0._ QN^7'BSY/%6?
MU'4E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E5-YZ^8[S$]5_?'NOE%6[#PZS])
M@]HM5;[P.Z]'F]FU<<"/,9X:>JMQ]]T\3K%]X;>>E7'MGK-EX':>C0>R2IPV
MZ0GHG5&SRNJQ*![9XS7DU(:X!.L6N38U/64;)N8>)<8OB(AED@1D*8YFMB\+
M"VMTULK."+)&^;E*&(1F6(2G;$9$$C#.5C+ .1@,>2Y/)2?D/94TI<1R&,;I
M CF-3C!<*=@.2HYM@<V \I';53^ L,DT%UY)P,SU/MW6DE:R4MBJ0V7*11<9
M,X_E+)BYAA2,Q@#NS<(&$%&\3=",IZ( (Q($M)GV>09H1'-V_P G6K]U>1&2
M:&5=B\HD*E"$3>'8PQ&0;]VQF+MM'?8)YU;%62-E>*6-@Q&9&!#KN<H5432A
M#M(WA0J[CRR!ROG5&KM5\Y'Z0(;TB,?"A98-AI^*RM25!2IR)YSF/*KO87,H
M 29G(JE)(BJ5;J1Z=&7 [LY Q\ /M0Y17!\@Q5'.[%O.(&8E"ZN@0A7V,,2)
M("K[7P=T8![TY4L.6<B">$S*H#!2K%@2N]3E'C(9=RY&USC### 'F!@PM&N&
MI<'M?5^P7VU&!4-K0= !: '" .F9\HSU!&-]0?6&%Y@XGI/%CFC$]]%D]@98
M1UPE,CX) L&0A(XV8 JS/>*T4L8A*F4N=W694&5X))>\$8SW\ ZL;AU:L0>L
M(#5$MH1+&YD!$>P8ZO#$1+,D8W;CCO9COPO?,,KL#%:S_EMQ[9[YUO(F]YAN
M^.&@D$V"U B=/[CV'J]O)R)P#WC4=)QD)/!V<NPR=L&S8<U.)/$VV#XBW0M@
MD2=XJT:NYQY/Y0#^&JO\;N7P[7'';0FO)7QJYOLY1 ]+:MADD:-^(&[7J#4_
M%X,"!F&R#QM&,V[M% BQ<I)N4,\T5\,<54LLL,\;W5DC))&.9)[1^.II\?&'
M^CESD]C?>?PK2L8/R?2/QUB\;[I+J>7.Y:QC>C>:9AU!I2M"Y6BPXA[J=J Y
M0W"A)"N$)8-XVKFR(I!Y&%?J,W>*#G%L0:N+I=@X0554P?D^D?CK*/'QA_HY
M<Y/8WWG\*TI@_)](_'6+C>Z2ZG,2N40@;HWFF\E4+91PC* C?B'NI4B$9R[
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M$3,=12=3L\TA;F01J.?/A(+.7@10L/BN;N\[0%8$GWH5=MFT;MP;!..:A6P
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MXOC^]Y&Y.#UP):&9F&4C379[T=+]WB1\G:@G)(-?:4VQ+H(2T8-N;@(1P+*
M&#PP,LV6W4FI6\@<-"_WQU:1B$.[J\K 2I8!NJ3!*$[9#E6(5LC4)I\\94B9
M?O:L(QEAM$A#S ,!E>M;(W@;D4@KS&#,,JX<<NYE#)&#/\AUGS@X+-AT .6U
M-J-X^SC[B*EE(W&71=B%:$BQ #.$H>@^V:Z$XR^21\*6+%&EW,D.1<C$MY:(
MZE;< *5.[JHBY8.NYP"<*&CWD1!BBL5 ;O0XE:UN71@TY)8,NWK9=H4J=JY
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AE*4I2E*4I2E*4I2E*4I2E*4K]4/Y='_[J?\ _O&E*__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g796801g42b49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g796801g42b49.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!/@)= P$1  (1 0,1 ?_$ !\
M 0 " @,! 0$!           '"@8(! 4)"P," ?_$ %<0  $$ P !  0'# 8$
M"@@' 04#! 8'  $"" D3%#@*$1(5=[2W%A<A-C=7=79XE[;2(C,Y<[*S&#%R
MN!DC)#5!45AQM=8F,F%T@9&2DR4H0E64H=/P_\0 '@$!   ' 0$!
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M4:9=2G5=W+1+,E4\"I)RH7:?$R@P&IU-96IM2GH-+ 7:EM.P[VW>SU]&<^#
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M&W 51@ =W/0  2W;A^B=F=M/669BS$[LEF.23U\23F9];O@IX@WU8(RU+?\
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MZ8N(S!BH[Z;PED?;Z.+U12M/IU=>EJ;F:&JY43T@[PS@$<MF2VH$J;.4<NA
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MH7SVE(GHV/)NZMC6IO)E 4D9/EXF&U+YD=8-W:H8VV<=MOG^3&!9-HZ4'/\
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M7Q"GQK6'QRP[5(.H76:$JE D2V30EDO?G.H^P=H)D' Q&4L$Y"\"CY0P5(7
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M^['2T WD<=)J)0^5RU(,L\9JN&K^+2A<#.XV4&OA\HB@5;37VI!&/6#GV?\
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M%Y%AB4B )\O)!)>.W@.0-77!B00Y>,5'*GSO92K:Y@@/3D6J@X]7^?\ D/\
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MN!,S:6TLQ8^D-XDG_LZ_;+4V8"9N,1&(C$1B(Q$8B,1&(C$1B(Q$Z61R 7%
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M;UY<3;8Q$8B,1&(C$1B(Q$8B,1&(FL'F[[E_EW^S!?OV4RS)D^.OZR_:)!O
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M$HP1;J''3<)%F;D-*QH"=1&9.)JDE$"04:'V2BW5W:73XNNY1IU"765K0*Z
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M<?"?Y#3RR;\&_P#>%\BOH9 ?QNTS0>WOQ^%_JZS[=+/$'GO_ -)Y-/U.U_\
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MOBCRA.-2*WWR=>2$78,H%<5Q:9('$9 ,C1!C7148Z(;R^FIJ%=%=BZ<66G4
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M!]<K4T_ .EJL/^L:BP $AOE-EM3J5.<_%9<'.< ^L33-[X\77"(R#L^.QZY
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MM;1:N 0Z@:8:84@ 8Y8_I =WCW=O]:;^Y82]C$1B(Q$8B,1*\?PC'W<?'/\
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M#5M195;9NIJ%*;5 0,6^*,9))\2,9P /;DY9J5%=E=>VVTVON8[R O1CG
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M3Y,378'Y91Q9D+RRK!]Q\%VXW9.1@8R<R L0IS Z&O!.\,"F!XG=G;@8.3G
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MV?F3\P;\X_L]]7NU?X/=+7RY?-[K_?\ A?\ -I+ F=Z9X>C$1B) MZ>1=?\
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M%B;AWMO&M-PK;2(]FT;H5&U%SYW6,=RA#UZ;%<6!0!T #@/@8[W7Q)DBT4H
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M]Z=C/Y3M'/,GG'_*^R7N_&?O.&SU\SJ1/,\8B,1&(C$1B(Q$8B,1&(D(1/\
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M>KB-1,?ECZY+.T^]L"%J)[=)]I]_%VR=[[^6P<Z_H.D^.^^-?%SO$>H?2?\
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M+E0Q96 @FF_#_P NXC=E&3([XQW UC\)O2EIM(G? <,X[9QR&VC$Y-('B;9
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MLG_!.>DA_P"Q_:?_ -^%_P#FS-K_ --\._WS?]S;_P"2:S_H;B'^Z7_O:_\
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M7KD3'F#I*"+/NU2K63.R2R&VS-\LX3XY:*\*>O[3Y1WO?J]=[[UOG/>WF/\
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M'#./1TZ<?NE4^&C 2(($'JZ#5JJKS4KJLM)6M2Y5=Q QT&X+GKCQ9E4#Q+,
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MVRO6N.%%.]<II]]\SI6]A*HNX@%CU P!XDDD #^W]$INZ5@,YP"0HZ$Y)\
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M<(*,Q8Q@2E4:'NRA5PR'(/3HIJHZY7>M^.ZB566!BB%@N,X\<D,0 /$DA&(
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M;@6*6BWN]01GE;0!@$$J 2Q,2^&REQ2B6U6=L=O;3F7#&D](S613L9+6\;9
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;&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B)__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g796801g45d96.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g796801g45d96.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
M$0@!/P)> P$1  (1 0,1 ?_$ !X  0 #  ,! 0$!           &!P@$!0D#
M 0(*_\0 7!   00" 0$% @D'"0,'"08'!0(#! 8!!P ($1(3%!47EPD6&"%7
M6);4UC$W5973U=<B(T%14W9WMK<D87$R-#96@9&3)28S-4)2<W2U.%1B>)*R
M&4-G=8*AT?_$ !X! 0 " P$! 0$!           ! @,$!@4'" H)_\0 7!$
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M/&Q=XFXEO/OUZ41'K"IJ*G6&X!A#15V5%C2&X+;<F0\ &TGR@\OP^KRT).X
M=GESY>T\O+_?7])V%L1'4ZW2')<-S7\P65'QPZ/)8<CD0U;K=G?L#TO->]35
M(D8LD80R&295![K$@FN0VO#4!Q@;,^7R]OG(Y<\?'9Y:9._&>7FY>;/MK4O*
M5>G%*PMU2;=VYKW;_3K7*#,A1*W<;/%B6F(]+&(7869MQIM42*DJ(4JPR0\6
M/(M0Z3@J((-RY$1TO#S"CRFQI)OYUQEK.OZ9KG"5OI4D,=A=WZC58WEA5[R"
M;4-+TM+<=;I5\T(CN-4M[@S03PR20QW-OM622"XA^I<":#PUJW#O&USK,5Q)
MJ5CIKMHLL<,[QV-S!IFKZP]R_4ZQIZ3];:Z-=6JP7%M/''<S6=R7>*.XM9]T
M\^BU\MIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*
M<4IQ2G%*<4IQ2G%*<4J(&K>V%L]1K"P9N>[;W"[48K R$P*$J#0?4'\E\3S4
M$KC#\?"L1<BA97.7$*2_B/C*%*4J7\4IQ2G%*J+<XX>2 5-!&!#GHC[8U+)C
MHFQ6)26).-@@&,2&4OH<PT_AE]]G#J,)<PT\ZWA7<<7C,CM^H_D:@_J/S%6[
MR*FG%*\K_A:/S&:]_P 6(7^3[=S-!\\_U3^8JC]@]OZ&O5#F&KTXI3BE.*56
M^V=KTW2M'(W^]2Y\<+"G PT6&&$D+!83]CM)L?6:K5JS7Q$>44.V.S6,J,"!
M1<&.X])G36L+RS'2\^UDBB>9Q&@!8AF))"JJHI9V9F("JJ@L23V#EDX%8Y9$
MB0NY( *J, LQ9F"JJJ 269B  !VGS<ZST3ZX=;"(58P1UUOV):K7=;/01^N9
M6I#<.^MGZC48]\,+6(FOQH4\(FI2F#$6P@BA<+,;4]#8G*(PYT.-L"RE8OB2
M HB+(9!,ICVN^Q>8R0=X*E6"L#Y,$9P&\C 7,<X9G9!&8B'W*N\\B0"NWF&4
ME3Y\@@3X]U8Z.K73C#ZK#%K>BZ;)TJ#>Q)=P,50:+"B@S)4; '5EV*V;D'IK
M&%-MB/*(D-N-ON2? B1I$EK&MK,UP;4*#,',9&X;00<$EL[0H/ESCS<R!5VN
M85@%RS$1% X.TY((R %QG)\Q'MQ47.];6AZY>YNO"1&X*.#ZL]9)#PNAVDX,
M7/9UI-W)BB0904=/=*;&DZL'3+Q"IXN-,(S@[241/&(OQX#MULKAH^L 3:6"
M\Y$4XZP0[SN( C$I"%V( ;MY<ZJUY"KF,E]P7)(1F&>K,NP;029.K!<( 21V
M9/*NYB]7&I']0VS<DINZB U(N[.LK+5#%,,0MA#]ESK'7ZF&H2:EEMR5,LA\
M_;:L.#,PGI$*4X?'K7.8;Q*7&@VDW7)"-A9TZU75U,9B"LYDWYP%548MG!&T
M\LXS8741B:4[U5'ZME9"'$FY5";>TL690,9!R.>*Y4WJKUBSIBJ[S$P-@VRI
M7.8\-"B:C0+&=N22@])]5@'%ZW'B)DU]ZJJJME8LCYQT? &S0T@?F8[/DCHT
MV!:RF9H"8T=!N)>153!V[2K$^-OWJ5"Y)!SC ) W,?5+, [JY(4(C,^1NW J
M!D;2K!LX (QG)&>!KCK TUMS9,366NI%LM!.51:GL55@A5$NW3X-9O--#7ZJ
MO%#LMJ.D9-,5>P@I[ ^;&9DMK+P(DA#4I]+/)DM)H8S+($4"1XMI=2Q='9&P
MH)R RL,C(.TD9 )I'=12R"-"S$HLF=C;=KHKKEB, E64X//GBK!D=1/3]%//
MU65O33D:T13K-6DUN1LVE,GH]FDEIP"/77P[AM)!HZ^=&$@K(AR.D@Z6'SAJ
M(ZID20RWC\'N-N[J)MNW?NZI]NS ;=G;C;M(.[.,$'."*N9X VTS1!L[=ID3
M=NR5VXSG.01C&<@CM!J2U_:NK[;93M+JNR*%9KC5W9[%EJ=?N%>-66NO"I,.
M&39.@AI&24$NCIA"!$GMD(L=<.3.AL2,-NR64+JT4J*KO'(B-@JS(RJP.2"K
M$ '(!(P3G!QV599(V8HLB,RYW*KJ67&,Y4$D8R,Y'+(\XJ#UKJ7T79L5]MG9
MU+"D;@>+U^E@K1:*_7K'=7QEPL]&BSZE7R11DN>$V4[3SZ:C.@1'4V6%!7-&
M(>9[<XNUM.F[,;D( 7959E3**Y#L!A2JNN\$^*3@U1;B%L?O$!9BJ*S*&?#L
M@*J3E@S(VP@>-C(J!W'K@Z8*K6WK&(VW3]I99."*Y\7]-6.O;0LV2YQHI)'Q
MWA-5+S<C6G(8,U,S,+O#H66A<IEN0Y,RQ%>NEE<N^QHGBY%MTRM$N%(!YLHS
MS8# R<D9Y<ZH]W;JNX2+)XP7$3+(V6R0,*3C(4G)P.7GY5:NJMWZ]W,V7=H9
M.7.;$#:(=7YX;+%.SJYLND!;_2K) BSD,S%AC80SF,R_(CQGV#0<^'E1F9@B
M2C&.:"2 @2  DR+R(.&BD:-U)'+<K+Y"05*L"0162*:.7.PDX"-S!&5D0.C
M'GA@?5S# C(-6YS#66G%*<4IQ2G%*<4IQ2G%*<4IQ2L_]3_YFC'][M3?ZN4;
MEX_GCV-_9-5?YI^K\Q7<7KJ UAKJX1J!9#,_%RFU!-VA@!0$T9ER0TJ^T_6
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MSMOQWG&EX^=*L\,K*2K JPY$,""#YB#S% 0P!4@@\P0001YP1R-=ER*FL_\
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M589P1R(*Y!5N1S5O]-]"N&OM=S8%[FKDV:Q[!V9?YT9:A*E"6[[>CMIBC',
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M]"F'@7B90W8;K2KFP!SZ[Y+< >LD"O+/4_PJH.U=32Y]SKP<%IZZ1K50*88
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MX?Y<=O;V]G^_LX_G'XIF_P DZ).-'SV>&3Z+IY^L2WTFWUYSCVU'\V?"4/\
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M%;3\J*ZZVN'%4A>,QV<H9/;DY\^:8'9@8\V*_HAJW6182$ E==40F#K7>S7
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MZ=9*U!(LOM/)J^Q+T/RRX^RZQYN$U)/SXD*<PAY:HLJ-&;=CNYPXUE*\=O/
MDZ,.&3J9UFWN.)['56ZL27]KQCQ.;B:.(H4@G:ZU6Y66W C1#;NIA**$*;>5
M=#%TK<5+I@T6YM^%;_25,K1Z?=<%\*"VADF#AYX%M-(M6AN"9'87$;+.KL76
M0-SK*6C/@O=:B;UL27?-F["N\B@6@;6*7D0[&H#<0=(JE+NWK!](1R8LS<\3
M"\>)ZZ.<KPR&R/4L'70BB9%+_.Z5T'\/:/'JL5IQ'QS%'K6H-J%^L'$MQ9M<
M,5N$6"YELHH)KJ,"YF:22YDEGN&96N)93&A'2ZMT\\2:S)I,MYPUP%+)H>G+
MIM@UQPO;7PMP&MW,]M%?2W$-I)FV@$4=M''!;*KK;Q1+(X.Q6.@3I8\TX0*Z
M^(V4F_E"I!&RWN_%94E2$I0E4GQ+*AA_.$(0G&76%=B4)2GL2G&,>V>B3@N6
MQ33+^#7=6T^.03)8:KQ9Q3>V"RAG<2BPDUCP$2;Y)'W^#;@SNP.6.?!'3'QS
M#J$FJZ?<:#H^I21F%]0TC@_A.QU!H2J(8CJ,>C&_,92.-"AN2I6- 1A%Q8 G
MI'Z9 O=\GHS6SO=[.S)6LP#N<]GY,JR<;(Y7G^GM5E6>WY^WM^?G3IPAPVMU
M87TFE0WE[I7_ )LO-2DN-4NM/^;SLKC49KJ:U)V)DPNF=JY[!7+/QIQ.UKJ%
MC'J\]G8ZM_YTLM,CMM)M-2Y,,7UMID-I#=@!VP)T<#<V/G',R5H?1RX+8Q>F
M=4+&M/>8:'JUW4%06W\8<3A]N)D/EA#V$O.I\1+>%]CKF.]V+5V^S'86,5W/
M?Q65I'?7*JEQ>QVT*7=PB+&J)/<J@FE55BB55D=@JQQ@ !% \.34=0ELX-/E
MO[R2PM7:2VL9+J=[.W=VD=W@MF<PQ.[RRLS1HI9I)&))=B85$U7K!G?TT\SK
MBAM'(U!KAF.9;I]>058+Q3Q49&*LD4CL3&B4<<.'CV)R'DRF84&'$;=2Q%8;
M1M*JID(H4'&0H"YP,#.,9P.0SV#D*U6=WQO9GQDC<Q;!)R2,DXR>9QVGF>=7
M#"HE'&6$G;AM-J@^UFV'8IFSPJZ(B6$O&>7'<>CDS3$-LE/8=7#B+=9ER76W
M%Q8ZEISEAK*;9/G-4P/,*ZV%JK5XP 5J@W6]"'U8Z\W(-UJ%3Z]$ &'V5,*9
M?*AV!S8X@\TJ-&4VY+C/+0J.QE*L9:;[K)[<G/GS3 \P[J3]5:O*@Q%8*:WH
M1*M %N. :]/I]>F PCCN5Y=<$"9 YR -6YEUS+BX<=E2\N+RK.>^KM9/;DY\
M^33 \P[JA5UJ-3E;CT]:)-8KTBS1U6Z''L3X4:\=8B1*W-?B162[D91!J-%?
MERGH[")"6F'9,AQI*5O.94R?.:8'F%6'!U]0A90Z<&4BH#C5H;DM68Q!K0:(
M4L34UW+TQLZ0CPFY9=N6]G+LE!!Z0E]W.7'<+5GMXR?.>79SI@>8<^WE7!CZ
MJU?$K4ZF1=;T&-3R<U!(E5(]/KS-:($6\Q%-SYP)L<D7+FMY@0<HE2(KCZ<P
MHF4N8S&9[C)\YY=G.F!V8&/-BOH0UAK0M  "BNO*,3%U-/=JPTA4@$V!6D]C
M&.Z AR1[D<,GLC1L=@YN-CLCL8__ )3?=9/G/?3 \P[JK_;M(I;LNIWAVH5=
MRZ1MDZGAQ[>X $KM$>(J^@(BHK-@5$R6:CJBR'XRF&Y:6LQWWF<I\-Q:52">
MS)QAN7D[#4$#MP,Y7GY>T5;H2L5JM9**KE>!@%'"DDV:R$$P!63!J9W?-ERF
M8,=C) I*[J?,SY?C2W^ZGQ75=F.RM6P/-7><4KRO^%H_,9KW_%B%_D^W<S0?
M//\ 5/YBJ/V#V_H:]4.8:O3BE.*4XI3BE5E;=D2:KL#5=#:UUL>T,;.EVZ+)
MO%6 1B5$UJFJ /76I.S#3I**_78UH7GT6JN1X)+U,VE4)S$7^;<<RI&'CE?K
M(U,00A';#R;FVXB&#N*_.89&%Y\ZQO(5>-.KD82%@75<I'M7.9#D;0W8O(Y-
M0+JLV'L75ND3=PU*-#F=B(N&H:U6 Y^,_*%EY=]W%0J')%OHC3(#S3Q =99D
M.#,3([H^>]&GN,3&XRXC^2TCCEG"2DK'LF=BO:!'#))D>PH"1Y1RY9JER\D<
M+-$ 9-T2J&!()>5$(Y$=H8@'R'!P<8.4X?7N1F[(M\>NU)6P-=V>-IIKI^57
M EQ?*6%=D ]1A;8YZTOU2N7X^V-'D]!6*N!(@BC3'&B(UN42>9!DIYP#LFP
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M!B,LQ8<.*RU'BQVFV&&T-(2G%22Q+,26))))))).223S))YDGF35@
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M_$:8;TOX13V;[N^L@3]U>O?NG&5]'^(TPWI?PBGLWW=]9 G[J]>_=.,KZ/\
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M2JMH7_3'=W^(P/\ T?U=R3V+[/U-0.UO;^@JTN14TXI3BE9JK6WM56KJ7N%
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M2B"AL9#L-4'&;^4J5V1^,26/[S+,1(-Q!<KN/6L6;&YC@D]N;^!1[@V]^0
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MH:6$UEJ2C$ 1DQH;7U>FAJO,(UV*4L8]S7UCU)4+9L9T&!>E.13P==P@),,
M_39TV2;F1!4U8]N$SA>65S)*X(6=V!8!B%/6+*Z1AFQXK;#C=D  $C.:RI%$
MHBB0J3 BD*<98;&B5GP.P@L,XP26P.6*I>H= NM&:=K$;;B?J5LH(:6'MTOT
M^D7N(;;+V 5<WP$HELJC6 NS' ,Q(%4K]E',U>TOT;#")BF)B0D@'G>_D+RE
M5 21@RC+QE=JE PZMU!W$EV4[EWYQR+;L*6,86,,<NB[7.$<-DAR"9$)Y<E5
MAM;9C/,#$9UQKWI%H%H"[NC=2\>SRH=H"1V+#8KCK)V.<-5BB;B8'N68\+K
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M4-G,27+HSOU9E&=JN4\('/=%*,*)(MN4)RA/BL%:N>[T7;XGVU9(O?JS/'R
M$"IV \Y;CF+/>0,";J%YARS/,:TC6IPNF)0#Z)>9VT+!7729U9.LURD()E("
M8\,@"8$;!LEE4(NR-B)OF RE,9D7LB5L+AF? )>"3%\EU(VA2=YW.H,1\;$8
M;.(R/Z5ERQ953)%:)(]-=@F:JK.L8%BC5J)6NHDELX7)K1,@-=KVN\[>M%ZK
M]8JSZA,C J>"JY@: &BFH;8$2F%D4-DMB(L-SFOX2O6M*5+%K<1MN .Z3J5C
M9FP1D,P+$YW-G+ L36P;=C&L8;:%G,@()&U.M9U53CD54A0,8&,#E5<["Z)9
M)#-X=U^?5#DE@>J_0R%HM),F?)V ;NZ][/WJFREK#5[V(CPMPUVP Z;.F.U2
MV#\B(LJMD*:_3(C%?(Y([W&SK%SAI2P1%"A3!'%!M56C.82K.!N0Y(8/O.X8
MWL\[S&Q!*QX+,2Q(FDDFW,RR#$H95/B,,#:5V>*;%'Z(V. U9H<>.* K%L+1
MNSC>R8(>W6B9\5#<:Q!ML5#-(>N(#70QX8)I]3VN\S32 G5$(?!DTZMP(]0%
MBL8;@XC/&TLY(98YHEC)11N!4Q-OV-(<EVB\<&4D[V)<GMN(9%BA *M)#(TF
M&8A#N$J[-RQC 19,(1$ -JC8!V0/9N@=_P!]9R:A1M.5:^&JY;PJSU+O^SZ2
MU0Y!^RER0_UP;%IQVG=4M=8'$8,DS5-J4.BBREA@'Y<3(N+=Y;8++%/;QG:>
MN>-61MKQQ.9 J@':Q=7M6)! >)Y"%*@Y,8+4D@F?QOW2N58;D>1-A+$C("%+
ME1D$K*B L&(P'(&K:Q1"H7;.T;]+ECWA=YK^LA(V,PJ1ZA'DTINXH)NSFG(Z
M(S3,I5BB9@^7E2EJPS)P^ECNM>+J,X,4<8!RCRL2<8P_5X ]8V'/(=HQ6RJ$
M2R.2,.L8&,YRF_.1Y =PQS/ES41UUT_PM:V>[6L3<S<\C<HQ)G#4\%2H\8*_
M/(*)-RHB@M<$SIZHC^4I0R6FS6GFT]K^%O*R[R\EP951&10$(YAG)( P0=S,
M!D>B!^E52 1L[!SE@1S5  2<Y&U03CZ1-9AJ/2'N#5\H\8KMQH6R2;FTRMY%
M0KLV5I3)Q%KZ>1^I;A9KD9!5^YR'[T7MT3-F(N,B9\4W#686^2&D;1(0'V7N
MXI0JLDD8ZH1DIA]NVX,J*@9D&Q4\0<U(.WD0N6UUM98R2K)(>LWC?E-P:#JF
M+$*YWEO&/([N>2,X&C=0:!:U+;XYH>Z$D0T:)U)JLJ6CP4P;):K'K/!H:JT6
M+PHOAS5RZ^\"@194HG.GM,CDCU81"A0U+UYI^M0J=V>OEE )RJK)M.U>?+#!
MB< #GGM)K/%!U3@C;CJ8HR0,,S1Y&YN7/*[1DDGECL J+Z;TIL.CVCJ$,F5P
MQ2=N'5V"OSL[LV1N1 B8FBU"C14D*??:75P;2VL5%DRJ7&)3W\PIL>E8_P#(
M(,?)7:::-UMU7)ZE=K#J8X<CK'?DR2.W^?C!QS&_.YC58HI$:<G ZUMP_>O+
M@[$095T4?YF<@GD=G8HK*\7H8W .I!$*!-5:L'2E.>UFN5'VW=K9(AU4UJP#
MKVW356J[ZF.$Y=>L+]4J4IG3XD+5(M19K,=[76TZ2Z6+QGMHWT)=259E5^L_
MH40%EE:1!L24 ,H9QUK,Y?>1)$X -:_@<H1E5E5BG5YZUVPIC",=SQL=K;4/
M5*$"[?$E0DUZIAAK84.*#M//26A(V"-;D2587(?;@16HJ'GUXQC"GG4M86ZK
M&,84M2LXQ\_/+8[F+=F23@=@R<UZ(& !Y@!W5V7(J:<4IQ2G%*<4IQ2L_P#4
M_P#F:,?WNU-_JY1N7C^>/8W]DU5_FGZOS%=KM7I^UKN<O3CE\@&)Q+7Y+!ZF
M/CK&:"9KMG80\D;:!WI4R)ELX'7(<DCI"LKCXF(@RYD69($AW(%*MG'Y5\]<
M].VJM4V!=FI04F/*9 HKK:IMFL9F-'A+"T"O$Y+,4P3FLX+6 5JS7C5A+.)<
MGEY56B$Y3ZB9 W,**9_'G7?TH.(;NVWCC8L<V:D705 D&$08R2C\%K6&M'6X
M3Q!+6);L1MQ.'$1EO*90O&%I1A6,9Y)[%'DQ^IJ!VGV_H*M#D5-.*4XI3BE.
M*4XI3BE.*4XI6:=T:@U3=MG]/%PN.MJ-:K4!V3,AAK%8:L%,&AT.!K':5G'Q
M(I&?"?E-Q1UF&#;(.C>+EF!8!\$W#0R3B,2F]::QLKF:WN;FSM;BYLF:2SN)
M[>&6>T=]JN]M+(C20.Z@*S1,A8  DBMN#4+^U@N;6UOKRVM;Y5CO;:"YFA@O
M(TW,B74,;K'<(A)*K*KA220!DUI;FS6I3BE.*54NYW)N*D,:'A#AZ3F_ZQ(+
MB 1CQ.4S KVQ*Q9RTQYIGLRW'BB0LYSO9SVNOX8BLI7(D--JD?H?R-*MKD4K
MH355K%D;RS8JX!/M93W<M&@X\HWE/Y.[E$Z.^G*>S^CL[/\ =S1O-+TS45V:
MAIUC?*1@K>6EO=*1YML\;C',\L8YUOV6JZIIC!].U*_T]P<A[*\N+1@?.&@D
MC.?7G-4N?Z2^FBR]_P!3TAKE"G.WQ'1%;A5U]><_E5E^O(%O97G\N7/$[^<_
M/WNWG&W_ $5=&^H[O">"N'06SN:TTV#3W)/:3)IZVSECZ6[=GGG-=MI_2YTF
MZ9M\%XYXD8+\U+S4Y]2C '8!'J+72!?H[=OJK%_4]\&IJ.S4-T]J@T7U)9Z!
M$/V,;F;)M6R*9.AI#25E!,ZFGKL-S'?F8BQ50308Z*GBG&5M8Q,%S20R;R&M
M= / FI:1<:3IRZKH,4\]K<CP35;^]@CEM>M"%;35+F\A"M'/,C+'U>-R,"#&
MH'::%\HGC_2]8M]7U-M(X@E@M[JU(O-(TZPN)(;OJ6<->Z3:V4Y99+>%PTG6
MYVNK B1C5FZ6^#KZ=Z;KNG"+4+.[0*Q(3QB:4M=FLS0ITW92$RS'7A51''&0
M(<2Z9,3UC1*F2"X$%3,:00(R4/SY/IP="'1Z([--1TZ^UQK&SLK*W.K:QJDT
M*16%I#9Q;;*"ZM[!"T<*LZK:B/K&=E10V*\FXZ>>D=Y+Q]-U.PT%=0O+Z^N%
MT?1=*@F>74+N:]E#7\]I<ZBX66=E1GNS)L5 S,5S6LJOHC2M+\-54U-KL$^U
MV=V8/IX%DAG*?R*<)>15/=5C^A3LE:L?T9YV>F<#\&Z-M.E\*\/V+KC$MOI%
MBDY(Q@M<=09V(P,%I"?77$ZIQ[QOK>X:MQ=Q'?HW;#<:S?O;CU+;=>+=!ZDC
M4>JK62E*4X2G&$I3C"4I3C&$I3C'9C&,8^;&,8^;&,?-C'S8YU       & !
MR  [ !Y *Y,DDDDDDG))YDD]I)\I-?"7);A19,QY,A;,2.])=1$B2I\I;;#:
MG5IC08+,F;-D*2C.&8D.._*DN92S'9=>6A"IJ*K#2+KCNM &7AQL4\A\ZER#
M80!NLE6>]8"CJ,OB+"/&%&$.M.-O,./0T(?96AUE2VU)5E2K7XI3BE5OL33^
ML-LUPS5-BT>O6H(>AKA$69\%#<WN*4EQJ2/,P\QC0<I"D-LS!9D.0@%Q)"/&
M(BYT2=&CR&_,O=%T?4EE34-+T^]6:*6&7PJSMYR\4\;PS1LTD;-MEBD>-QGQ
MD=E/(FO5L-=UK2WB?3=6U*P:"6*>$VE[<VXCF@D2:&15BD50T4J)(AQXKJK#
MF!6?.ECIAT3JFE&F:CKD'F:_LO:L>78;+B3=+7,C5O9-KJH&+)M5N?-'UPA(
M$*/@08"2"(,?+<B6W'Q.($),KR=+X'X/T2WAM-,X:T:UA@9WB_Q"WFE1YB'D
M;PB=);@LS!<EI2<(BC"HH'L:MQ[QKKUS-=ZKQ1K=U-.L<<O_ )0N((72 %(E
M\&MGAME5 6("Q*"SNYRSL3L9AAB,TAB,RU'8;QW6V6&T--(3C\B4-MI2A.,?
MU)QC'.F2-(E"1HD:+R5$4(H'F"J !]0KE9)))7+RN\CL<L\C,[L?.68DD^TU
M]>7JE.*55M"_Z8[N_P 1@?\ H_J[DGL7V?J:@=K>W]!5I<BIIQ2G%*II!X&U
MOR6$=,"VC,O5X?$42X0B()R<LV.Q3'L1X*G<2GO"B8S*=\-I7AQ\>,OL;_E<
M8/;CEYZ5<O%*<4IQ2JNMWYQ]2?\ S=V_RL]Q2K!*"11N$\--#!Y<=)3W9 \I
M#C3X3Z>S..Z]%EMNL.I[,YQV+;5CLSGYOGYKW-K:WL+VUY;6]W;R#$D%S#'/
M#(/,\4JNC#U,IK8M;N[L9TNK*YN+.YB.8[BUFDMYXSYTEB9)$/K5@:S/8^B_
MIY.3U&A%*<UU8\=[,>QZK-%M>DH:U9[<N1X]=E1 W?[W8OO/BGNQ6,9QCYU=
MOS?4>ASH_O9S>VFC-P]J(SU>H\+WEUH%S"2<EHX].EBL]V0#E[5^8S7T[3>F
MOI%L;<6-YK:\1Z;RZS3>*[*SXBMI@.Q99-2AFO=N,C"7:<CZAB/^P_J1HW\K
M5G4^3L@]CMRQ5]\58==42,X_Y"95Y#8$6EM.,8[BO#CNY7A65Y_EIQG.A_(K
MI%T3GPQTF76HP)\S3..=+M]:$A'8)=;L_ ]34>0E8W+=I.1S]#^7/1IKOB\5
M=%UKIEP_*35> =5N=$:(=A,.@WOAFDL3\X;I$ (VCQ2<>;G6AU.]>^L[_1*5
M/I%-&)814+92(^NZ\8N=:WUL<=<)DB!0\3SL')X:XQ."U=A53KDD+;5,6;)-
MTT]!D1&H'@:UQCTTZ+J'"]@_!.BZF=0U22VU:\T$:MJ.G-9!K-%D2=V@DT0E
M);R0S:FD\($"/XR1S(W1Z%P5T&:[IO%>H)QWKNE_L[2H[K2;+B$Z/INHI>E;
MUVC:"-9X]> >&SC6'2W@F)G:,@/) Z^\S*G%LM+>:\!Y;3:G6<.8=PRXI&,N
M->*G&$N>&K.4>(G&,+[.]C&,9[.??J_.U?7BE>5_PM'YC->_XL0O\GV[F:#Y
MY_JG\Q5'[![?T-63MW=9\!U4P=:*W$[2 :*KJ4O!J*-@=-E&P?F6NXWL46QD
M3MFE6K8MQ3.9 #8"L4@O74M=N!8MI!UY9-S:A@5K5I>IWMNE4OU=S)M"HC [
MHI$C3&XD;U;L)/BC%:DLS+<B/K2@VQ$+OMTR6=P>4J-(^=H!V%<=@YG-<3KJ
M;<F$=503L#6(6M>H&Y #9.R-Q"];A*]>(H0H7A13$2UZ0V96',1)82NV&LOQ
M#<2Q'"@LD#D"<4Q%K446/S9BO6LV%#1Q0F1FC+ '!2>)^8+*V5*J"&#=84PO
M/G1!A$%RQ$DDHC4.%) (:&1>1"LN&#$@C:4#9U+TU8:QT\Z/PS&EPV?930O"
MB39$67(C-_%D;W&,R8 >O#GVF4]C<9T8"#C%QDLJ&C84',>.WJW/^43<P3UK
MY(R,G<<\B6(/G!8G.<DG-;%O_00\L?NTP.W VC R%4$>;"@8Q@ 5=O,-9J<4
MJLK,.VW(V5K$A4K+2QNJ!S%V3MRN&:^2GW&R2)@B&U0%TL]&)QAP%L.;1-EV
M))(<0R2'N-18F&7L^.SD4Q".4.KF4[.J8, B@$]9O7&6RN N",')-8V$O61E
M601 /UJE278D#9L8$!<');(.1R'G%7]8%!N.S]&D:/02!L-:#FP-*)A'J\]*
M8)UR- W10296S)7$=9>5#K8F%-.$V<K4Q(&0);$II^*X\RYFLY(XYP\H5D6.
M;*L,AB87"IS!P7)"@^0GD0>=8KN-Y(=B%@QDA\9<@J!*A+C!'S1EB.P@'.1D
M5AJ60ZS8-UN6W1M0O](:W"+TO+MH&(SFS3]:Q*O#ZI*\W7JF*3KO=+691&0(
MTN;NJAFO3,B-*O;7G9(42N=9 >\!9&-(B\;]2T^P_-$N\VAW.QD@. #.$S(,
MB,X!.%.IF[#-*%=.M$.\ ;C&%\(7:HV2YSB(OB-B-_,@983,A?\ KH(7!L7%
M$74 W+%@@]AS$IE8G5ZNEI$+5;A"S5;SVM)HW*'Y#VQ7(C;FX]M0XS&)46Q
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M9)T)2,[%"##1QH%+!)#@*_684OLR,D\R V234.E6CJYO6QX04S5M@#Z+BY4
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M^ T3:8NT9"4,[F-UACV9R=L;8&S*QF664)(Y&,F4X0N>:Y0Q+O$"B1&E?=C
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M2GQA ?IP/^LX7[?BE/C" _3@?]9POV_%*?&$!^G _P"LX7[?BE/C" _3@?\
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MB7L=T\5PC2PRIOB6.!RMPT\@.U+81]>9/$ZO<"!TQ/X0&8&L4JL$MO6Q@I"
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M^<>%$DB69D[_ -&OM\A'E=WL_E=G:GM8/+U]G,4W#F<\AVGX[?JKR7ZR>O\
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M*XN.K_=B:RJX/]'UK37T3O3ES(VTZ?+?Q+[4I\-(Q U!5:.\K&/,)@^6^?\
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MBUXOZ(-$O++4-'Z/N(+^^L+VSO;5]>XH@DM7DM+F*XV7%E;Z8]O/',L9B9)
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M45'2!BSDCIL\/KTS6)B9KF8V,)Q" !Q!IWO9F1^V6Q$6SVK5E3_:T[W.8O\
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MQE/-1FE29<E:&\.293\>'#CHRJ1-FR(\*(T]*D,LKNB/(ZQQJSNQPJJ,DGU
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M#,L,]R8XS'A1(M=BRK%(;DO-2VJ_&D'%QTBF'9:+BVN&4.L,C*9.J!"DYD)
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M=F,8[>WLQC';G\N?]^?^//&KUZ_>*4XI3BE.*4XI3BE.*4XI3BE.*4XI6?\
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MSSDM4DY\@'?^IJV:Y%?]I&QYOJ4WRW@U2+Z1X8[T[Q_1TN^I>+Y#U;SN6_\
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M%(I5G,A#LLJ,/&165 BL2.KYAB0#N)'S=A.6.9WN9(R&5%0%%,;KV.ZLY=E
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M4C.&  41KUC,S8VJH+(.>[))(  /:2 9:7]V)$"E2229&V*JC.68@,3\T
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M%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4K/\ U/\
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M5R\5%>5_PM'YC->_XL0O\GV[F:#YY_JG\Q5'[![?T->J',-7IQ2G%*IK:6L
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M/X=<8/J[Q[Z9'K[C[JB!S;73-9RT,_9:<6L)T>,)!1YHYTT[7+%H(<S&D0C
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MK--)@0A%^M7:B3"C0P.N)"=2?09C>95,RTPI#KKLI0G)SYQ^E<;;G31N>][
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MM8TIR+)C!0U?KHB,^PL)EIV.+K]3JX(>RM.6H8>N AD=+<(3 8CJ9/G/?5A
MJ-2:LZV_6:=5JX\TP4C-/ J\)$.M1CAV5:#4=MP?$CK0P8LLZ;8BC2<X;('9
MDHM+2\0D/2%JBI3Q2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*
:<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g796801g45e85.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g796801g45e85.jpg
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MI::RU3555F9S='>#EJ2XPL/6XO_$ !T!  (" P$! 0            0% P8
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M;]VW&HS&KF/M51N=WG(%I_O3@PTK1OY38!Z(3'3< =\=AU<=6X!_Y:;J..X
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M8=)%)*SHP\ZM"VE@5*^H]B(Q4&?[B392CZ@1_<(B(6-0N#\IGTTS3J5!Y6E
M2H*7T"A,>ZM,3^4XS]_#S^)##5R8%R ZE,6$=1(*3!<@<V,1FCCBJI3IIJ#+
M6=*J5@?F"QC@PO,$A*RG33XM(I"U;_+G[6_V1/!-5XN\%,:EH*ZG-O#U.E14
M4"5OU^6MI&F2)4_2)C5=;"=9T&@9MX<;I0I]H:Z):G"\X;KI%J,M^9()53J_
MB&9_AD 0INR<V.8LJI(K?JE8%3NHU*ZO>S @$,&!!&YN#>Y''S_DWB @I"G"
M+BQD*0I,2F"9!!!F0(,B)D8YGG/A]*P5>6F=P4@7!DA22+1R"%7$$$BYSG]
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M1R I0 .XN+#8\;2#([@&P.!J:=*;<)GF;?#;?;OQA$M5.F(&FIXV5G<%%5;
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MU: ,#;PE!"6WL;;WOPO0_8G:9($00D1)MO)^H!X&):K)E)J$)M*4I2HS;5M
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M(DQ'M$6O;?N>V#E,..%I3:TD38:IV41M<@3)WM:XQWGI8V@62)[,%'BQ#L'
M[J!>PN -N_?UXB0Z08B038FQ@GK%_P  =MHPS>I1'F:I5 ) (5LF)"1<6'X;
MX9F1HW$BV(86=/6W8D$[ CO;U]['8L%+@*2(TFQX/-^TVGC?C J5AE*2+^=N
M8,B#IN+Q8=<;9OE]_P P62+=OT0RU_O-1<?4;']@S_U3?_<3CBSO]JY_UB_^
M\<8"ORDZF^;Z/>2\%].KJ3P7S6!"VY7\S[EK^EK@6]2!Z\<X_:DL(R2@41(_
M>S=N9^QUFP@SU/88M?@UMU[,*IMK=5"H*_Z/VBG-^T@2.>;3CQ72Q14<;Q*
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M'UO%MH_H\OF&OH2T=#20GQ5NSO$I((!!*VTV/>YN0=CW'&-I;6F77-,&(&T
MC>9WZ$6PH<R@.*25#[EYVWXZ1;L;\G=CK8ZRODUS$@R'4RJ0 #ZJJ@#M[WMZ
M 6O>5IYIO5I$D3ZB#?>Y)M'P!Y.^)5TVA*4Q(V %ND\B9M,#J+8:Y,)>Q9KV
M%S?8&Q^Y=SVX)%:DD :9[@[_ #_KCQ--,R%#XI$[SQA-^;V)8GS$@!4LH)[
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M8?$6N!W(@<1<85U5(12)!01K%A('$;6()OP1L1L,))J"861 !8:F8%9=SM<
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MP>TEN?*B%I405 3!V@1^4@[WOA[EPM5#* =(46)4@6L#NHL![>A]>YX'#D\
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M1T7SBQ4LUM[:NP[&Q/;CG$F A( F5 W F1$WN!>";Q>,7]EMI"U.K(40-"D
MWM,B^T3OV'Q'*I(9:G7'$00FCPW.P-V:X.P)-P?L]Q:Y%[,$%:&M*E R09$;
MG@CJ -B<8VA+[BE(94V HI"%)N0/YQ:"%; ]C8G#3B4,_@AU"HH0H5_:0G8+
MY2/,22;6(V[>O$U,ZWY@"R3Z@>((WO?8"; B_P!3GJ!T-E8;(&D[_>M,#803
MP9GXX'J9Z@,X(94OH0$V8L1;MML -R._L!W;/!D@$E!4$ZU=" )@QO/?"UEI
MY2M26W"D**0=,01M$$V -SQ&'JDU:BMW9D1W52+G86)[C:Q]OX CA6_I@*3I
M"5'23L)W(VL;B_?K&&C:5A6F#J !TF3"=IW,<\3;L</]/:LBC_5M=%.FP(5C
M87V[G[@186M;;@)?\)9.H7(D'<?../AUDS@XMJ?2408;3((V"CN-^MOA:^%M
M$%9O!EC_ %BKY20055#:WI]VW<;D\1NR!K0KTG< R)-Y'Q.VUO?"Y>@H*5M$
MK25)!(),#5'OM_3C!-14[AD9([Q26O\ [5@2!<;D DCO[WOP(5"3)N-^O7X_
MH8%#2HE#9".#$"?PWGG!GAM,(JA9 CG01XX'=@003'>VK2-[7O\ 9&QOP*ZL
ME,!0@FVTB(B8V)V_#:^].E'FJ"DZ%$05FQV $7W$_E@THU,,;)X-PFMHY'LR
M21ZM2JW?N25OZ$;$&PX"7ZCJ"MP)2F00=N+#;IL?C@NGJ!3K-.XGS$@DA9NE
M04=6F>8F^]][X=IGIOEJBG^716D5"%*W\Q!8:2-BRDGT]#L#>XZ4K\Q"M9(!
M5<6($$01T5QR+[8=KJ:49?F# 8"7'$ME"H^^2E)&F-RG:1T[QA@GI99Z!XSI
M@97U*4 \UE8K<C225=;@@VNM^VW!:%A#DP5 V(WY$G;D&\VC?KA$[3*?I1I4
M$N-H&E6Q)BX$7E)L>;;6PV**I:?5/)9@0JL'^VP6XLI[F_VMK@DFU^)B6]9"
M$2"+B+@;[CK;MMU(P TS4%L"L=TK05:=9@JA1*0#N21'O&V!^ID:6HF$T8#Q
MD(78:;K<BYW6]D?OZ6OL>)DD)2"DPE4$"9OS ]Q;K\\;!M3DE7J6++N9@0!,
M#IL>D'C#%7PAH'92-@P 2Q8FYTL23O8;=_P/$S:CKO-R-_8&T<$3C5UE*F00
M0001 )FY(/R(]]A[B,J-X=@EW&Y'V3<FVY!(O;?;U [G;@]+D."50#M%Q$<6
M!F]YFUQM 6"C2A(5I]=S'-C%_>T<WX.-LKR^_P"8+)'_ &H9:_WFHN/J=C^P
M9_ZIO_N)QPYW^U=_ZQ?_ 'CC 9^4EQS2](')5(=0)ZE,%U$&P _DPYG_ &MC
MY;^EN]O;CF_[4R@9'0E?_I1$;[_8ZSH1^N]\7'P-]H_>E3]F,*-"H+/'E_:*
M>9^,8\9-/2K31O+,&>=EMXS,"L2+LJJJGR B[7TDN6!8@\<"4O6H!/I0#(2!
MO.\]?C$"P! OV%+!:9<<69<<3I5QT58;[BUOF<"&(PS4D#,JED<,SRF]_ ?<
M(MR0'=@"?LV -N_!B5A:@"!:"+V*KB0;6CJ>>N 4TBVVBZ@$:U$$W!(@G\H^
M'!P%5$];4&TD0C@2(Z&>Q>]["PT]V.Y((W].W!R?*0 4J*EE5PF0F(F_)BPY
MFYFV!0PZZI27?N@6D29GVBXN/S$R.>(RU+*SJA4+=F)U:S<JMQW"KV]=R;;'
MA@""T#!,F8 $1L>]R>>!@<4B6UDS)-@/K:.TQ!OVOC[(\0>0B8/*Z^=RS%2Q
MVTC8FY4 +V%]B>_&DJ*4C3I3-@0)$&>#U%_AN<3H8N>T6N"9VM[].+CG"F.T
MD4NH*%15*D+I8D$7!M]#^!^_C0G2M"AR23>P!F".>"0"/K8RJ8AI\7DI@#X[
M=^#\-SB@Z@A@L-RI \]]P2#<6-_V+D;=P;@=R0J2)6+@FT<<&T<_,1QBO_9S
MH,[ST["Q![]R/QPLHHT$S:5TDJQ W(+-8V/:^JQ&_P#2O8]N(GEJ"!)D @38
M$"\'M$@]+&,0,TXUK$B8!%^9)O[BQM\N2N@B4R*CZ0KH66R:M#':P-QL1=2-
MK@WN+<+G%$^H7(,&\2;7^&_OQ?#!EEE)4' 84 !-[\QUXL/SP_C WFU/3B[Q
MJ8_##:2VX+Q D-N K:0>Y';?: U>GT+GU&0HB8WO^'7><%?N4.'[13#^QNL"
MQ(7.GW@I5( &^%%-@J2T\\LJ20.BJS:58BP+!G( ]/VB2.PV.W&JJE2%H2"E
M23MVVCY_'@'?&R<MIW6'UK0H+(2%>E5XU;[;?/B1;%2+"J=8/F-8B9"%<G64
MD5B%5X]%K"0L-7]&U]QQXI]94$P53T,$<P9F8BT_2<1LY?3-LD@:5':1:T\F
M\&0+WBPY(KI@X($52X9#V>%M5K#U^R=MK"^QOL=N,54$ J0FXWFQ,D1U[[1]
M<0HH@MT-U!]#L^61!!*?O^\@I/?:,,[T<=/-*EV=8V++J#"XN2"/<LNDFQV[
M$[7XG#BUI2?[PBT3WGXG??G$1IJ9EYUH P@IV&X,_P"(^O.&.K4)',5%E!#!
M?Q'K[GU-O2V_&R"5+3)Y[ W&-W4MML.EL1($B=[&/H3_ )7P+.0=)?18%M.L
MD6V!LMB!O8#MWMWX9)!!4 ";)!CF.OL#WL.INM_D1OL3?X?K;&PW^ );_!;\
MAK&X_2/G18V(_P"C)GCT/'>/!<_Z.4,V]=4/E5O8Y]GW_G-__HL_^Q1C,SQ:
ML)\:SKG5$XYO\VHFJXD$/,[/GB3S.OB(),V8J7T@D :AL@N>P]P>/B[,S.9Y
M@842NMJX2D&##[FD&_!Z==[''WAEH7^X<O\ M&8)0D4%& HP"E/V=L 1 N
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M4F^E@XO<@VWVXG"%:T09.H&3?H1(Z18_CA:X$FB?4) E9 [2JT<$G_+HU87
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MMQ,IL:B!]R21TVWL)Y]OACQ.H("BGKSU)/2#;O/M?&V7Y?&^0LD'WRAEH_\
MT-1<?5-.(88'1EL?]A./GY[^U=_ZQ?\ WCC E^4B3-#T?\FM*AO$ZD,&0C<&
MW\F/,YK@J0;C3?[A[<<V_:JG5D=!<B,V;N/_ *G6?*\=O;?%W\ +T9G71NK+
M7$]X^TTID=[#'C+B13&DK._G=;AA;4;=CL'97(!  47 \Q['@*B05  6!!C:
M)Z"UIB;[DX[72T[:VFEN)/\ :!0%]P#OM&Y$VZ3OADQV22-71X_U$C,I5@O<
MDM;;?S6 '<($M<WVF8 (D'U  F) /%O:>MYVQE8^ZE[01_"_E'>(X[6XCWN
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M6.O+#9YOSC,YQ:<(\:Q'GU!*></-R*NU1K+S0S_-(_9WOFK%VC4@7LEDLQ)
ML21VX^.*]0&9Y@I$$IK:H)' A]<W^/RM;;'V2VTM_*<NI:A12%T-*K4.].@@
M #M-NIL<1G#A]-XT35 *R(/#HS<*J1L#:8V)4ZQ?PPQ)8:F(4V!!+BB#I'I)
M)<FY)MZ1[<D;$VD8;4.64XJ&Q5$PD)2W>1 $ F.HG3-STD###75E;13'#$A
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MXA><4D6/,#<@ C>UKV.]O>Q=4="TM(+H,"QGW(&WJB,;87(  R)DH#L,I9;
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M? ($@^%QR$\5=,GY_P"<I86MN><6=][?7N?J>.W^!B@^&J'1]WS*R._^N/\
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MJ#.C%K&X=@B$ :KLIW L>)-9$ G>>3:+ <1O/2T839A5!]W+6D"$AY*=*;2
M4@2!O.VY/UBMA&')055?#,OBBJE+P@(Q*C45 ">IU$*%6Y:]@";<>.N%P-E-
MBD:57^\3<WBT6)^76 2NFH'\U753I*7='&DF8@#:.HV)GWR!\C^C'G)G_!ES
M;)@S97@KZ!TR>F+QS05E;7L7@H,4J,--/-(,-@EM(OCK&T[%&11&"_'-O$'[
M0O#>3ON4BZQ%4:9P*S!3*D+;9:"?,=9#WF)3YQ3(A!4$09]7I',?$7B=I]UN
MBHR5RA("1(5J@"2G> J=]OJ+_P#D=\)3QZ?",5YM9OQ#'Y8&E-=@&! T&'M6
M,YTPQULNJO-'$K*5=O!D:0$(!& &XGXO_P"$EE]"[44^1T3;!6D+:K*L^8L-
M$25%I/\ #+JB(*)6E(^\9V4U6?9XXRU3TB%!324,Q,C4A(2(DD@")N;S8VQ>
MI7?"MY(Y@99</CQ;*M>BTZ138+B]8/DWIZ=8(GI:>:22E(8AY*F.HBJ%FD=V
ML@+!N.J_X56=9:L)=I&LT943I2_3H27];A4I+BFP%DP4I;4C1H"0#JXCI:;Q
M*_3O-.YGI*U%2_4J6RHE12E,V"28@V.!_F)\-#+^ 8-0TF U&+5> 4<5*N(T
M4-7X&(5C1PU$%36>-#$(VFJ#4U-5+IAO'/*S1: YM;_"O_";&:5#E-FU(QEU
M?4EQ5(\ZT%4J4J4E;;!U*D:-"&KN>I(&J3$TO-?"V:43PS%-0JK;;TJ66UJU
MA4DE11*N25&+"8D"P8<[] 739F3(E'3X+#B.6LTU^&I38CF"CKJJHFIL3@?6
M<0JZ>:H%'43O(Q6I6GAA66%B(FIM*:=LF_;-X_I?$>9(S%JEKLHIWRNAI5--
MLJ>IEI@,M.(1YB$!(EM3JU$+$*#DDX?N5M53Y9ESC"G%.NN!3DDF%:I(/J@Q
M(!! F\''GLYY94FY5\P\U9&Q/PVFRQ6+!#44_C)'B=*E/#)3XG3B0'3#5+)'
M,($9Q!K$+L\@:1OL/(*Y&=9509K3Z@W7L!TMK*2ME2E'6RN(];:@I&LQK@JL
MFPZOX1\1JJ*1Y+H'G!1:4#NE:?2J)/I ,V$ "US.+9L<Q5*ADJ(O$IYG77')
MX8575M]$EQ8DJ39OM>]]7%G984"4*$Z3"D_S!0L2-]B"(%K8L+U02DDF"H!6
MUIW,GO>YN8N=\!WYRG:=BVZAR-)L"+$%M(%Q9B18VL !?VX,+*4I$'U1-IWX
MFUMN09XQ!1U51YI 3*02$@W](,COM\,%6%D%@0S)XA5[@W\Q&X+"P'VB2MNP
M]]N!EV!L#!N#>>.>OX8LS0"@"H"3<R J"8L;&+_'VFQ-(R+=602$JH+L3OI%
MK]NV]QN?OWX& Y!BY)2.)XOT[_XX$<%*EUP:E ^8J8L)!(,1:-0M'3K?#<)5
MIYP2B*#J(*:K =U4^1A<>H&_U%B#A!(($DS8&.NX^H'QC"NH<IFBI14;DF5Q
MUW&]HG\QMAHQ?&)9(FBU:+!K%2"2#ZD$+]PV!^@[<%TU/J<3(,$B9B!<VF\S
M\?IBFYYFB$H4ELC2"0"FT@$P=MHW^&_ 3\W/_LB7_<K_ ,+AU]F;_P"93_VO
MZ8I7[V[_ %_PQ=!AI2. 5$DJ0@"Y&H$MN;[VVL/P]M^*0\#JT@%5@(%OEU^L
M]<?0NMBF;#JJA#(%_5T (FWZZG"^FQKYNH,%-4O*X/96-E !)NY! %KBWK8@
M;WMHNG4VC4M, CGG8"Q-SMSWB,)AGAKJE=*PZ'+$%P60H1M.XYCW$<8)8V>.
MF8LJ,[AI$9I%#%!<EI&(^R[@$:3V4@[NUQ@$ZIVBQML=H'-N9^9@8LU"@)IU
M%>D*"5$+49"2 3)VD#<Q?ZX!\Q8K3R.R,0S$1Q^,K 1M(0 P"J#O&I"GU(%M
MK\&T[2AI.PN8B\7/N9(Z6Y,; 9A4TM0MMIPJ<4#!<2?2+1-IVDQ'!/; ;,:F
M:&58Y2:<ED9EO=5B!+$7%P&9PBW[%5'8G@Y(0"F1"S>#$W-OB(,^^"J>E<=8
M4TAQ/V<V)(,^CU),P/Y@+3WF\$>%/#315$CZI)U4@NYN2=P]K[[ZF .^Q(W%
MSP1)44QI O\ (_'@Q8B#Q.-&J)EMAYQ1"WDJT)4)L%&".HL?RCI4I4DQ"&DH
M8HV,]96T]+"K6-V=U"A!O:ZFP!"C[K;Y "E*)D)!*B!$1N3<;'IM?>;5K/:I
MO+LCS"H4H(*4 I,:K[@")N8)DR/CB;6Y09SK\;RWE; <M8UB>8L2G6GH*"GI
M6J:NJFBND[0"$-JBC99&+FRQPQL\C*BFR2HS;+Z*FK:ZMKJ5BBID:WZAQT-L
MM(-TZRM0 49$"94H@)!,31LH\0_OA&6H"G//)*=*DG44I"CJV$IM  DB1N(G
M(ADOX:O4#6K1IF;]#\MTE1)2RUM14XG4XGB%+ S+XD:4=!ATM+)B";EDBQ-8
M%",9)@C<<3S']N_@5GS#0O5^8.H#@:;:IT,-N*2#"B[4/(6ED_="E,ZRI0"4
MDXNKE6\I*V_LQ00LM^:I04%%.\  F8@D3M,G;%X]1\+K(%'EUY,,YC9C3,BT
MK?,U,N'4LF$558\<K1E*<TL4M*A;8JE?.3"A((9PW'+&/^$9FSV9AI[P]2?N
M]2Y0$U1%6VTE:0HJ4'7 X8(DEE$+4!L",>E=91TRE)=0"N\!%EGU1P-M47)Z
M\XCSE7\.^.HH,0I^9V.3Q9EGJIJ2DI,NU5-+24]+XLJT]2K5-'(]3//$BR.G
MZI8@[*067BX>(OVW,TBV*C(J1+^7!I+K[M:VXVLK 25H(2XD-I05:03J*B ?
MNF30WJFOS5U;3BPQ4I)2VH)U)TV)V$\3$"\3@:YE?#9SAEC L4Q3)&8HLU.D
MLDZ8/64BX;B(HQ%*BFFJ_FFHZBI29O+&XI_'(*JP8%>#_#7[?,@S.M8I,TI%
MY67 $"K2[]HI_-.E6EQ :#K:%($E7K" 0HV,X2YME>;(2'-0JFF6P764@I=5
M"U2M)40F "!>#8ST&.[#LP8YD\5V XD&BEPFHEP^KHZNA@%523T[>%44\R31
M-+'+&Z-&]K';8LH5F[2^TUF 0^TO6V\E+R'&W%%MQ"QJ2M!20DI4DA23<"=I
MD8Z5X7\+Y!4T]'F2TEQ_RTJ4I-@T1!+*@8_B-DDJ(M<$<'$98_CF7:AYO!G8
M3[?J]=B@50IV918-:]KD$G;OPQIV'TI3J$I@WB"9,\&+=Q\[''1'7/#A284
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MY>O&H?3]OFGSL0LPW 1=)+-:]K^W''?VA,ES.&%$0@9:P%*CE-36* !M*C,
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M@K%X8V5' # #4XVHJ;TI2E(2$:BI1TC3>0+7&Q,\GC#^E >;73U:2I.E2DN
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M$E(O!W(N>OZ][S #UFG>6$N*2E(5P%#:8N.-IL9_#&V R!_S"9*OW_1++?\
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M-N!U).JXDSOL.3SR(]]^I.-:FHIE2LJ(4HE2KR/49(F0+$F;CXX^/B<4.M'
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M6TI));! (A)*;DF8,&XZ3:8'JJEEEC=0A1Y6=M3;*44:=MO5B2-P?3UN"$J
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MCL#R-L/,NSORE*>4A)(22&U*Y$D?RR#/80+@X?X,PMBLJ>.QB$#$J!(!L;7
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MQ<'M>X%_KPIKZDK@) 2H)-R3'I%I!!V!&YYXVPOK7M20E"4H7I)),Q;>01:
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MNOEQ:GEJ<5"5%+B5R@Z5(1H0+:4 ZL=)RK)<JID(70TS32=$$(24CUQ, :E
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M/'6WY_/;;WN1Z,G_ .7!Z43ZGJ4Y%W\P_P"JAE:_K<_=;@AO^T;_ .FG_O#
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M5I%J8:M;!U+IJC(%@'4.SQ@->RN$9AN%*D'BJYMERVPL)38)M8P1-S)3"B0
M9$CK>9Z)E.8L5"DE2SJ,&RHN1/N!?:)]XO<1RXSIB^1,TY8S]E^LB7,&2L8H
ML=PHSJ9J=*FAG6HI_$CM9T+*1(+W*L1>XVH^9T;%=3UF6U3)-%F5.Y25"8"5
MK:>06W4SQ*20D@B(Q-F^6,9A2NT_F$*=N%DRI)F1I)Y!,W^<X]BO3GU19;YV
MY7Y5YK@KJ5*_%<L2+C=/3H7>''*>GB6KHR!&S*J5*2K''*9"8U  *DW_ #7_
M &D?LTK?"M1XJI665KIOMS3]"5+(2*1Y:CK!*HD)6)*='JE4R)#+P4VS54C-
M+5N0IJJ4PIP74M+!#8U6N2$S\Q&V#K.N;\'RQF)ZMJZO#U=.C BCD6&Y#!ED
MNL:V(+;J  ;Z1PB\.Y979KDZ&%4M,$LND$!\*7:/4DA2S-@(U$F+JFXZ/F65
M4M+4)(62 !I40>!  /  ["/;:-:KG30XLD^&4<S)'%K2<*C%*C4/-K)B4V [
M&YV&VQVM%/X*<I%HJG4!:SI4@J/J;TW&@:E#MM&^/7A3(0G2M0E(V-C %Y,&
M\_6\R#B#<U9KHTDJ96N\4:.(I"CV0L"6:X6VD; $[7O?<\7S*LM=*4)!TK)&
MI((N$@  R=^>OPOA-6I24"-@)!Z3$$W Z=IY.+7\Y9F:J1I:.=]2J40JTA62
M-GM(&LA &DD@[VM[&QZ+EE$&U:74B)D@@2E02(CU7N(CIOBOO)2!(%R;G^O(
MG@@[X@RJQ.MDQ)4&(2",U$8ECBB>3]4UE 4E?*VHG45WL1L;$\6YIEL-%1;!
M4$*TDJ ]0!,Q[; P+=\*WTC0;03),"(WVL+$[?X7-\>QV/!\"J8@[2B>(((5
M))0%"#>^ECJ !ON1]G;OP'0TAJ:M"X "%$E1_F@DP+=?AOWA!7OPG2)'$ Q?
MO%CQU@_'$"UO-KP:*<-*T4T5+-%&JS*'8*A3P%U&PL"++>POQ=J7( IU)"4J
M27 HE23$GU:K;GO\^II^9UA2D1(L!8Q;X;1O(L)Q']/U(XC'(,.665Z6GB$6
MIG!8C2!]K41?;?<@[V)XLJ?"E.1YI2G6HA1 28/%P)_J.1N<4BK>5*SK494K
MF;:C(!XVXL)N<11S3S_59^R?CN!2U32_->#+$DJRS!&CG1M<"Q/'*A L6\*0
M7DB!8$,RFP93EC675#+Z4 :"0=(2";0=6I)!' D$ *MP<*DJ4FL:<E4'>YV(
MM)F]XF(VD1C'_FC)>-#%*>;Y>N:)Z51XJTIC::2G0"1V3:RL5)NUCL+#VOM'
M64XIR"&P0LD!2B0$J)-C!)(!_4XL-/G'EI>:+DDG3]Z8@\= +1? ;'%AE;B&
M&X1B.,'#))YFCQ&JJ-4\-!&7*J3"FERR*-4BHW86#!M0X9!+K:'JAFG#R0 6
M4(3I6Z8&HZC(@D^DD GIL3)]K>#"G4A2TI')-Q?CFTW/7>,!^>Z>AP#%I<,I
M,9@Q5:5S"U53+*D3E2X+Q%G=9(V50VL$F[A>X)X9Y9YE0R'7&"QJNE*E F#!
MO8*3N8! , D;@8TI:EZJ:4O3&N50>-5_A!F>)VD7Q%N8,1HZ4Z8:CQ 0&9R=
MRS+=A8GN#<&W<[\.&&W%B5(TJF +[7$VL0?I@Q@$?>$0G:UCS^H'; C^>J?_
M %S^O^_@O[.OH?E_C@G%RM+7K/\ :;5V_"^W[C;O_F:"ZP6ON@"\B=B1:]^]
MCUQU%*D.R5$\[0.N\@]9'];%[6HTH #L5WTD6&UOKZ<"%)*C(N"+$&_,;C\,
M#+93I7N/28N(^[[3OW&'G#\2>-=B/*-N]V\HWW/J=K_^?@2IIDN&\S:>TVX&
MT=^L[#'M)K0("4[]#/8S($<[;#YJ_P ]S"4,Q<*FXTEA?ZG<[]NWMWWW'^PM
M!!2-U1)-R(C:WOQ?H,'%QU2VEDJ'E&4@&)$1!ZV/$7Z19:N8IIG4"Q"B^IP+
M@C8"W<V%@#WL!]_ YRUI(,*4)_NP -IX($D1ML=K8-16.:DRA"A.RP2#8@&
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M$787C&$T,Y628*YU1-42-I,@1RT8!O8L-P"HNR@6[#BQKHWW;Z9'W@@"=,@
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MMZ&R-E<"-ATWX%XD<'Y?'#5(! )B\1;Y>\[]YY$0Q>#1_P!/_P"SP1K7T/\
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ME4DI?90HJCU@"0>]MK=-YPQILZKF)2'%: !I$F-YB-C\)_K>?TE]12Y%FQ+
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M]#?_ +$[>G%QH<J@@% 2=()M! YN1R>TST%C2*VLDF"2-2M-^ 3&_P  (MM
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M8VOV.]^*OD_A1VII7PEK4XVA"E";F9 4 2),;VM!%L>9Y4/:VB'$Z2I02 E
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M1\"=P;XDO!L<CS!E:;":]U>K@4K%<V;Q(_LL6V_9!%KWMM].$=11JH\Q15,
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M\<&!Y9N%1[D3\MOF<?/SF-0%K$]B&N!];$[_ .?MQ[]F7!Y[1O\  G'HJ%R
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M)YG\Y\<Q+!GI,UYPP#$I)Z3"<R8'6O/%1O1NF(PQQ5,DT=1%$(^P7%A0$^D
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M,^KVV7F%R-4;?3^4[CT "PQYYB_[QQP?D]'QMQ_TCF?3]3S#Y'7_ (<SQQA
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M.#6XW3E4QI\AI* !TA(N(@[V-C,XK+SVZE68I'S]YZ%0+L[<U\_FPMYF!_2
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M?"DKQ4O"3='^_LX:H%4M13/Y?05##V6C11TS"5O-T])4-#7.8>6?,=>6X5K
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M03%P>"(WPC"RHYC<#8Z%U$V([W-P ;6L#<V[;\;2E0U)VY%K18Q%^8VO?$J
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M)V]ASMSB>F0L%1\L*]-@H2+FY Z]^DX?:2AJ)X[%2B@V#*I8F]M@+@&PV![
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M%</:GC69SFG!*:+!\?H*QZK#L5PHRX=6T<U)/40RFL>(W4(0$O*1Y:E*0 H
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MBQT^7K?0%J84H2"@?:D:3T44E8,WL"!])Q6_1EO]B/\ O7_A<:_:1_?'S/\
M7!?[I>_^:C_>I_\ QXEF7$%H6:JEW8$!8K*R!KVMI9@2I%]]^P.UK<)@V7/2
MFW55Q,=2 ?4#Q\]\#A\4Y^T&Z3;3_+/%I(X&X@@3;%&7,<E5- 8$6!8G#%*=
M  0+!SL22&M?N%W!'8\8*5* L*)65")5,;<<6G@6P#5U[ZW$A" VG4)"!ID2
M)! $$$0.>8 %L29@6.TK1)K%P27>%F6,D&0"-0;,S->]C=6%KBVQX45-*X%$
M"UH2H J&TDQ(X[$;VWP_H76U )4 4R)! (%^)$ P>(,]Q.'',24LE)/1EIO
MKBD< DM(K3:(FU!U.H-$2SN" &C3N6.DQTGF!:'/3K:DJBT)E0 (Z*  2=P2
M>DAU6993MM-NE4H>A(!N+WV((VG>W(. 1<8_-GCTNF.37((S/&++$?M%S&HU
M1ACN=!9%!TG8<,C3^:4KE0 !4$JDDVB).\<E0D[[DQS;-Z%D_:4LH07="M T
M@>K<6-H$D_X 8D#!9\/>(2U)BJ)3X8\*2*-[:]U99&D 5]-K[D6(6PL"5KX>
M!+:90B\K!(, 7$ 3$CI-IDR<4.IRU3,O+'\9 !2D_=)LF2GD!),';:;@'!6<
M.PVM5A2E=15BR/J!A(%B@0BZG8G?R"UU8K8\!>:XT?7JB1"A!"N\VG?N9W$R
M,#!3ZE)"D^D;R+@1  /%^^\=<)J7"*-TIY56.0HPUE(YIA;38:9(HWC)62PN
M2%N-S;C9;[FI:94 9@:@D_%)4#<;@\;],'M)&D$)3(%E0)[P>>N^^^/LD5ZH
M030R0Z8CK9XV"!@+J6,2R*$[A=1##8%0>V)5#>L*"@2($[B2;:B"3<;3-X.(
M%-!YW3 *H)"MR -Q)',$D?'"*II*81>([1L"Q42(P\TA!(5>UP NY!/[^T[;
M[A5I 4#$D'@;7/4]^))/& '\O!4;#?D?&.Q_4]1.HBB,B2/&FHML2&TG?20W
M==P3ON+C;N.&+;JKIDD1U$_^K(XZ"#U .%U3EVELJ0 %;2G>+[D08ZC8X3R8
M9*D?B$%H"Q1@JW"DDE1:X\C =U+,+CRB_&XJ4%91LHI$$D"=Y[@]NT3-L1IH
M'_L[3J?4&UE:Y)4=.D@3/4D<]/?"$8;"X#QQR(VK21X,H;4#^P-!':P(-[;^
MW&RGU(E)TD<*E.W>\VDF3O/?!=*PW4N!2%$$%(<3P(L"(,"X/X&^%PPQ%,4H
MA8Z20T;+8'218^'(A>]]5KJ!]XX%-2HA:"O[P@$'WY! Z;'M[VIG*Z)*Z5\+
MU%HJ+@43'JTD6(/142.XQ]2:'#)=(I@X*K,MFT*C *J(ZB.Q))(8 D[[V!WU
MT*>3.N+E-Q),F209Z73 Z],.::JIZ2M#J!*71<0-(*;)MQN>NXCB*M2M*MI9
MZ?1)*I<1QE_"T$=D874R']INQ.W8B^J/,,I0K4$F)(!5(W)Z)@P!TOOLV>J*
M5#P==46W';M)$I&D1.W,D?7>,#E?&M:(H7(8,=$$Q4!]"FXCG.D)L#HUDV8@
M%B;\%LE3>I21$ E2>)-@4@R;[D<3:\#$=4^P^E(6=*C]U0@$IDB\1\STV%\2
MQR PI*7J,Z?DIPJ?XY>59^VDA<#/.!G4"B:&#+NI(+^ER%!X=>'7RO.<IU^K
M_P JY?-BD#_6V0!<D@@V/SYLK\14_E9'F7D*/JR>O6H%1 )-,^"2 8F$Q) /
M!L,;%OC[BQ\2XQ_]5U5E[+>;:K/.:\2I<%RYE?EU'BN.8Q7R+#0X=A6%UN8Z
MZNK*B9R%6."G61V^TVRI&ADD4'\:/_Q@=-F6;_MY\(^'LI8<J:[-O 'AZEIF
M6 5NJJ*CQ/XK:9&A,JTJ5 $#U&0)@X[M^SFO>9\*U%(S*EN9U5+"$#4LE5'E
MZ1"4RH_=M:]R3"2,>.?J+Z@,8ZON;U?GZJ?&,.Y:9?GK, Y49;>*9:?#\MQ5
M;A\Q5])(H2+,6:Q%'7XF9(_%I*4T.#K)-!AJRR=5_9I^SNC_ &3>$F,B;2Q4
M>(*M+=9XFS$V>J\R4TD%A"E+6LTM#ZF6$A>E2P[4 )74* ^P/V;>#0G+DYI6
M4;_GOH_B!YA16DE2% ^I"2$Z1$D  Q*BHDX@O%*?!J>FJ::FIFCJI)/#CEDA
M5U4*2;J&4J!+?S6 [VW[#H#2ZE:VUK<26]&I24N$$DQ91!U$IMN>9@0#B\YN
M66*9VG8;"G'4J: 0D*4F1I^ZD2#O)(!F1;;$!8_@7S%7)-X:^$YM),PN+#8F
MYN%8D^IU;"WTL-._"$B84/Y9CCI:P@&VQXZ\6S6A#SREK0="9U*4+)ZA1,!/
M69W]K1Q7X'XQEB$+,A!"74 ,%-MF#'4;#TN;]]Q?A@V_ !)@R)OL3S/'0@[G
MI-JM44:I4$ D ^DQ90%@01O;8"?J!@+J\KZ0TCC4C;!G4D1LHOWML+=O:VQ!
M/!J*B0(,0.(O[WW$<6O>^!',L4:15:YZ4)*DJU>D)""!))@"3'(XZ8;#DYZO
MQ:J.(20J/"@,0#F1U4DVN6.E&4M*Y!TJ+DCB;[840@F%&Y!,0"8!N.=DQ<SR
M)PA"?M6M;+1<:9,EUM)4W8D&5I24R.03;D6P(XIA,4 :$4R,R7)D0J-6UR .
M_>YL;W%C['@MAU2B%EPIG@SWCM\3(M[3B:RG4"PVV%K58E"=9'O$V])V]L!<
MM(I?3'&0V]P;,>Y]%O\ Q/?:]K$,DO+%RN4R)N>F\QP-_;Y^>8P#I4A*5=#
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M?*+:B0I] "6 VX9MU*X 6HD'83L3,FUI@S)B8WFV&+="JHUAMM:5:%*NA0D
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M&)59%D*E'5!ZD@W0>P]2VV]Q<WX]?(2E4$$B93)Z<F ;^W3&98VWYY2Y U*
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M.UQ@A33BI+;:DP39*8!OU!!%K<R.8OB/<QT<$%Q$EHGU,$5M034;@ FS!4(
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M334C29@Q%G:1@?##+J8G4SMZ*$V _-G.GGGLYS9VJ7]GI4YIF (!EQP)JW@
MG^:#$ )COJW/[,>&LOR[+_#V1,9/3C,,Y<R7*UA;@*:6D\Z@I]9=<20DJ0%%
M03*I5Z50 1B)\6^1PV%8 T7YPF9A6U"J3+).QL8TT[%$-U1!I!()(]AZ<//J
M*S)9 EI), ( G49N";$F\;#?!->S34+26UN(57/:OM;X2$K=?DZ6T>7LT+@!
M,)5Z"1L3$6-P3A:OY@"*%IM,6I0E34N ?(AL=*HV[N"%46"ZVT@V*E*9;T2I
M03*X]3: 8DFUY&P-Y' VH==0/ OJ=2EBF6HC4IM/GU#B2J6V]:2H(1)E:2D$
MZ2"9G A5HU+3K,T):4K)'$"QNS*+E5(;4;7NSW(!LOVKD'H.M>D* 1(*H@P)
M[R-A8>\=,(ZEE;-,E]+21*"EA"BI*U$7(@$7'*MMH42,!%;35-2JO5SI"Z,M
M@\CR:!J&E+7 L&U!0+7%B"+6X/0I*3"$J4-[ "2-R9$1M,R1SOBJU]"]4ALO
MN!*T+^\I2UJ:! TB%3)"O2-R.HP9Y:K,3I75(BK-3LI><.(G:\B2R%.Q8LB@
MZ;-M<&W<@5C33@,BRQ9/WA9,)'M)L=YYC9ODS&8H?_@66V&PIXJ"% (<2HE$
M$!6I"9B""DD'>,/V.8K1U#/40,QA99CHD4!Y:FH+:IH@Q&E LQ2., :P#(J7
M +#TS#B0$*^^"D$I^ZE"(A*B+DRF2J;;&VUAS<TSJM;16DJ"]16D)<<J'#*E
M)B$Z4DD  "0+C>023"8Q%+4@34TXC4*S@A&#:QJ*$@,X*V'AE.Y:YLO#%+RI
M2B4K3)D R1]T\ P#WVB+;8J;F3K4PMY8<\Q*= <="DRE4RILI(!)M$$;6(PT
MST,\$2(T8J7.B9JA&9A&K*&NZEM6I.[(KD$F[,HV$P6E2B9\L04A!&Y!/;G@
MD [B"2<5NLR0H(A)>6H!>JYB20 29F%7WYOUQ4BIZ=U#!O$FN!&6(:(.!<@H
M%-R0I"%V\K:0"';C52G)B E&QZQ< BXCB8&T]+"*R?S6X1"74Q" /YA<$B8B
M1&\=IP0020U<9@:)(OU>B58UTRZE((D5#J!*$V*@!F56(!)MP(I"D*UA1/JE
M)5<09)3, P>L[]L,VLL:<(IU)!!0D+DJ^]RH;Q!@P(Z09.$-9AH\(R!%\81D
M1#06\9(VL)(M](+$LI!LRAB" 1M,V\0J#.F95<>DG^4B-1&T>V-UY/Y*%K\E
M1=#2DH2=0\Q((TJ0"8DC8#U1)B)PAHL%0"*J>)YH)F,CP"0-*L:W$H"K^L8(
M"#;8J;BQOO(X_!* 0E21&J+$G[MR--^9[?&&FR5+0;JR@O,NO*6XPDE3J)C4
M@(!*C$B9%OY8,G"K$,L".>GEP*20+-%=X"A6ZD_;T-I+*0;$"Y!V(%^-&:N0
MH5 2"#90,_,["-QQ!&)<S\//(?IU9(ZK^,@'RU-E,I5][4E0 3.PTWD3TP\T
M&7D6A/CTZJR%6=H8I%D6[-=U.DK961B0"5-[;'@9RJ5Y@T+,&0 5)"=A;?H;
M3!MTM@YC)0BA+E2RE+S*H6&DE#AF0IP)A(4$G81<\;X<VPB?1%+1B:H73I!L
MHD3225+*021IMJ!%P#:_H8@^)*5Z4F?<&1! /?8$;P>#AFUE]6I#+M,'JAI:
M%:5 'S4%!"85!]*2+P=K"QMBI'0O6-%3N6A(<!CH",CJ+:RQ]V/F!!-K?0C"
MZ&PI8A1(Z[B28,1?:"+$[W@8/IF'*IQ%.%%IV4I62F%)(3]]1(F#&TD208F(
MI)#B$255+/(:@0R, 2P*D$W4@"QW90=.FP+ @$$\;E;2BA:1ID=+CK<[1;N>
MQ P:RBK"7Z9T^:6%*("@DC4O8]PJ#"22D'8"^&2Q_P!9_P#FF_NX(@]OF/ZX
M7:7/[@_W$?TQ8]D>CCH\!DJ:E"U35,:J1]AH5F\J,3YRR@%=)9K=P3?B^YHX
M':PI:,-MPTD&\Z1<Q:RC>;3(M(G'S]D:A296*FI_B/*,Z1!4"H]!)@2...).
M%N/8E#14DM0X6(&,_P"5V;0;"P] 9 38"UN^XX@IVEO+2A()438)G?\ $00D
M\CXX:5-0EMA%6LP2H:TG>-5Y!VU '?B9XQ%&%\P,9S+C396RY(U/04\=J^OL
M&$<0(\32Q&E6(! &Y[;]P++49)3Y=0)K\P.I]X_P*<6E4&)Y4!;41 C8R<4]
MOQ%69OFC]!0DII6-1=42=/E@^L=/NDQ)%]\*L@9EAEYNUV$QU,\L5-120K63
ML':IF5HS,S,=B7)&H@:F (-K7X\S7+U(\,4M8I"4K<J0LMID!"5I7HL)B($2
M2)Q/D&:)'B]RF*@&VV-(<4H1JL#))TWU6,F9(N "+V*',E)A4G@U$@2Z1K'(
MS:=.L@1KI((MYCO<"WH=QQSAVF4\)2#>=0 W@7,]3!M ][X[$,VI*9:6W2 Z
M8#:B1 )LE6T0>3MUXP^TDCI41U:2AUD?6%OY% <W#?\ =>4;"YM<#L(%@%)0
M0H$ "1N3$@C>\;Q-ML 5Q\M2:M*I"S*2"(,F(!$S DVVWM8XD6BKHJV,65G,
MDH^80$:0HV%E'VBNY76?M,Q%B>$[K2FC<@0#I,&2?>WL1$Q'%\ EP.)\P&3V
MBQ40+_.Q]L%%.'C3PE8L) '$FD%=&E%VWN0NPWMW M8$\!K@J!-M,VG<R9VN
M>I@_&^!7:ARGTL-6+JDJU ^FQ"B)ZD".I)OSAXA035L4E.4B,9C64 DLL:(K
M/("UPKEK$  >(@*K=P 1U2EM25@D$$I!$"282D_[(ZDB#<B)P559@RPE"E$%
MZ #!!,&9/P._$6VOB65Q7#Z"JBCIZJ2K-3!XCA8T,2.C,4:.8HCN=*!R -6H
M^&P)N>*^JF>>;45MALMK*4^J%$* D*2%$ 2J!<B!JG!&4Y[4TU477C-*II2
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MC2.%=>3SUPT.].LHC!D<JJ H@)+@1KJW-Q8F]AV*BP)-@9@%$$PD75<VTW(
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MSA:E;H3K;]:E2U !"]*;>E0*I@&X.%DM-35U&M1!2^&T3115E.%U+JL#KC+
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M8G15G@X'B"HE5*QG2)G9IO!B:\9>-M+6<V\1#=;@=P;<,66W&M52R90D:"8
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M2Q44U0%#4"R^VX%)_F(TJZCYX^>ZS/1DF;"NRX.U*G*@+2IH%U+:BJ4E93J
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MKYUJL5QCPF%/%))#$-BTS%]8! +JB2RDEO*S&,AMB3P8ZMI)0PQ(UJ2DJC9
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M+=IH $.J1J)!!FX(D]QB2^7G+'&<6GCQ3&\0J8Y)52#P:63PQ'%(/5P-9(!
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M H)DQQQ>]MSLZXI5QQPZA=EB,FAM1(>1"2H)]@0#M?8=AWXCIT$J() *@)!
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M,RR'Y8R&WA*RL&"AFV.X(!*KMN%CHKJ9(=9*5@76DCUA-PJ+@V$$3()@DE4
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M+;6:-3L/.I&I1!*%$:8W(O$7F(L>09QR^LS!NCU4-(]-.R(0Z@*2Z3)$:MB
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M]MFU:AW-]]/;;8'B7[.M)U)'-R 1-]XVN09(VXYFQ,^(<N?02M]M"K0HK0%
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M2;-8J;ACI)M<V-B*D_D:5H<4M2A;4D:U 3$01,6^-_@#VN@\?/M5C#-,PRM
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M%!*]68B*<:GT1J!)IU.Y$:BY8BY( \/Y4YF?B&CHT'6PX\ARH+A4XV&$J)<
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M*) J@GS(;;7[#8CZ6_ VVXKG+E05$:UJ)5T5 OO/!O$\7(ZX(S(.-C0V8,\
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ML4['B\_*"Z<R=?G+>5J@+##TR9 D>G,(<2>'S.YQ2*&D+ (K.J:M(+'0+@[
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MMS\*8ZOAH=!C:=&KI.Y%G3>^F_+W CIO].W%PI;4S F89;OU](OA ]_:N?\
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M(_U-!3AGD*JRMX2@'20M[$; LQ N5 (OQ2*ZG=;J*B-1"W"0D P1,[W( F9
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MK6^'3!?1YP$J^#5H8KD!9(Q<%O=EL=/;:S;DG\85-)N0/?Z_'D];Q\"TU14
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M8<@[[8"?\0N5:"FHB3&QD;GDJ@*&XXZ'C"3\YT?^S)O_ (U_[^)_(7_S:/\
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MYPQS\R,3E+W\%5U$ +'J(W\NYD\WN?+OOOW/! R^F L@\7U'C B\_K%$G6D
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3 )AW_<5_3&0/^=3_ +Z?_%C_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g796801g48j28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g796801g48j28.jpg
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M?!!1N0G61:]+Y!JYIA_V<8#&&Q"HSC\>,@*I&]>?/>A>E?NP(H:561T"P2M
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MR"N\9Q)O8=#)&T5U*QR3==]%H8^RD,FQ1= )FRSUB3,*[EJDY* BW.LF0BP
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ME;3YKM$U'%E-1GIJGV%V:AIY,GI%HWJ,PIYIMF8XZJFBCS"AD9Z9I?L57!*
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M6QD?5?DRLI0=?;7!'+M0#8KM&N&.+SCVNR=QO_*%9AI%1AD2+2]EM-:V95R
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MB,2U6/W\8_\ *?\ ,W&MBWJ&]X?UEQ2+^,7[_P#5.):U@Q,QJ9Y9;^E/KO\
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M%NH@/2:S1P22@E#$ #8\2>&(WZ^0ED0D>Z 1[N,;RK&0&$AN+]I#+(/OF-&
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M]8N>BYX&15Z5NCK9LOGBD>,M =!M<U-.A(ZP=#RJZW!O9E!Q.CK(I$5[2C4
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M%]]O[AW,*&F&12)2CJ#2;("=TBG+ 59!OL:'*TJC)JJ4*H%_B=1:[7M?B1H
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M4O*I"W'4%47[AL#C8)YH^\^PZW3_ ,#MV_\ $1J!T=/95-\,_F,2^,_L:?\
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ME(X<K+%*?KC8.<4JAS !N B'. ./ 1#CP$=:3/8XTIX2D:(>-:ZHJFVAS:X
M-K@<O<QOMGY99*F</)(X$%P'=F /$7F 2;'&1Y_W!O[$W\0ZY?'68@G4C&OP
MTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPP
MTPQ9MXQSCW)T2C 9)HE,R%!-WR$FA"WBKPELB4))J!RMI!&.GF,@S3?-RJ*
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M,JI6HC4])D/:-()-*A %O=3$26+<BO\ & DD<NX839A4+5BGX">J5-&IBY+
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ME_=AP!X1^ 8=BV7IMU[B7Z&G$]SY?W8< >$?@&'8MEZ;=>XE^AIQ/<^7]V'
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M\[')MW,"9N:3IG3U2S"JQ;R<BS<L8UPOMH*RKRO5TVD4+. 8VA2FA[9+]J_
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M )*H051K\-6(5%PN=RNC$P$:VBHY)9RJ(J.%4V;1$BBZ@B=4X&4.(F,.KP+
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M3+K'KM+QU18*E5:LE>N73IU*@T\&2LTM*O3]?=/; \27$Z+9L(%73\  ]Q5
M 'WN9^_BCN7M?K[8GW69BQ/N=8%ARY>Z<3#J[%F&F&+QIG\W._[D_P#C):A5
MW\6G^'_V3C89=_&O_P &?ZRXD80 0$!#B @("'H@/<(:UF-QBT/%_2_4W%_P
M'_FU6Y[Y^$XMT+WOE/EP\7]+]3<7_ ?^;2Y[Y^$X:%[WRGRX>+^E^IN+_@/_
M #:7/?/PG#0O>^4^7#Q?TOU-Q?\  ?\ FTN>^?A.&A>]\I\N'B_I?J;B_P"
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MN>19./%':P9(YHE5P#?GS)![A*D$CO$7QFF7&G)"%*4I8W8> % "@'A_#(\
M . =XRPB/=YXB(CYXZA:\V[U=\2;YN)>C*_[S^/%\[#Q:<D$)@,,7L,,(" \
M33F%C>3R<0-*" A[0@("'<(<-5UYN.KIX_Z,WDQ31E?]Y?&B\N/OQ;\D(/DB
M-@_XUPA](:<3-^_7_%G\F'#RKO47QH?+C[-BWDAS\.? ;"3\./#G/\(FX<?+
MPXOAX<> <?N:IQ<V\*N^";R8KPLL\&C^&+RXC[*^V[D@\J8XN&.Q=;-J&:V0
MCB*0N>/;+A*MW6L.CB15G-5V:0<J&:2+!TDBN0JR3AH[3*HR?MG+)RX04OBJ
M,VBD22U8^A@Q219V1AW59>Z".7*Q'6+$ XLEI\LDC>/^"IJ4C6AA5U/<96[X
M//G>_4;C$';2MB')0;9J=88"UY>VT[CK!99I*4>6S,=KPG,JQ;1F@=O'PU:B
M59-VVA&"955G+]0CAR\E'RPK.7 -FT>R99ZNNS2I=2L-33JH("0K,MR;79V
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M#$=9/F#PE=0>$;).C&E6R'1K&5(0 .W>'Y_%(Q#<X.CX ''AP,/$.(!K9Y5
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ML/2O%B,I])E%74I([SF J=**27+&P/,JX"+S OVQO?M>7.#59I2T[HB0+-J
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M4UKTC5!J2L@5F6#43J"DW!E$FE6-B0+,O5J9;G3 ?-:5*I8!3AD)56FT@6+
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MX\4[B'#R\:!=/<_>/3Z[C="+ZH=YJ6Z]6YO>F+&]K&VR1L;]_%?2)GWA9/\
MC_)?IV'CWQ^'#B-M+Q]&@W4/^XOXM/KNMS0MJ?>,A/<;<[O6!Z[7Y;'D? 3\
M/+#TB;0=ST(/O9_DOT\8Y\>^._/7M!?[*A7CW.ZOCJGUWNY,7+5NWR =UMS^
M]@#WN6QA^7%/2)M%W$RL^]G^1_K#' YYQL @!GUC*(^<:AWD.[T?YW?)]SCI
M]=_N+%@V;[;(2+V;=#O;!'OVV(/R7P](>TG<@RT^Z,^R+]8X>/O&/VUG@^[1
M;W_U5L=4^O"W" $MM#M>@Y<WW1[W@#?O$;"GY;>YBIV"VF]C9>?_ /.Y%_IS
M(8I4YGZE)Q#Y2N23EQ.$0$\<VF*9D1M'++E,412=.&M5561*HF!RD4(0P%5%
M,3AT?.$.<VO[,K=13[-YO+L1M!5UFUL5+Q<DH=IMV&^R@R6JJDDC9J>OJZ#=
M[/54R30":.*:**14J#"THX(D(E4.P.=-5P#,::..A+VJ)*/.MG)*E$((#Q1R
MYJJ.5;265F%U# '5;%5Q-FFNY8;.R1S.1BYJ+(49:+=-UU6[<3'Z,%&TH1 C
M1PDH<!!(BX,WX@4QCL2$*)M=%V./93[$]D909A%DN69WL_M5D$4;[2;/YC15
M=11T1>3@K-0;0Q4D675M---J6GBJURO.6$<KS9/#%&9#$VLV+S'9.6$U,U/5
M4563T2JBD19)+#45EI2[2QNJD%F3C4_-0L[,=(F/7I[''8:88B'-?\Z+;_?Q
MG_FDAK<Y%_9K?\!)_6CQHMH?[!C_ .,Q_P"3FQK'+@1TKG&[Y??VF*5;6RG&
MI3&,C*K(5^TP,2M$1#)R@O;8:Y-82W$&4CW4W'.KG0IR?KZCX(NN3T3%(KM7
MO4\(\5I"PLRZ+!2& L!ZH/9N8N-2$K>RE1R/*<<"!(0ANDAD)+!D8ZF([0H6
M0V(5M$BJ]KLI;F,6X;D]Y1FG522>95GY:\Q7J;QN:O6*01F<9S5,Q_0+QC]1
MY9\A6*<9P=[AZ2ZF9%HG+K,H>QS31:+:F:5QD1W'%&1IO*3I!4@JQ!C9(XW2
M[2%@KJA)&H@,P(':B\ILP!U:80NHZP0RC3*)'DCELD2J6C+  Z;E0;D%KC8!
MCFIFH6/:)13/PE#4NFU>IFDRMA9%D35R$8PXORLQ7="T!X+,7 -A<N!0!3HA
M76YG2&F1KH1$O?0BK>UKZ0!>US:]NJY]_$"1^)))):VMV>U[VU,6M>PO:]KV
M%^]B\M78LPTPPTPPTPQ9&X#'SC*54L]):S!8)Q(R=7D49(R+]4$SUFSP%H!J
M"T1*P4Y&&DO W@TD[79R&LU=,["=K4M'3L='O$8J)Q*9$OIN%-^?\EPUN1!%
M[6NI#+>ZD$ XEO)PJMWMJMJ%N7\J,I>S!E-M5]+*RM;2P*DC&#U4V$)P;F?-
M/W:)N,9*462KC2$D8.WM8U*6<0.((Z(.^1+D9V1[&PDOAJO3#J>,F&5;DV48
MPMTR--,H$IY>Q:,"^IPP*%=)# 7TQ@=4G, Q*2Q'$?DKN0O/*]<6"Z4*%9 ^
MH,A-M4Q-OL0TDB=E"@\%.;)$"_:S'%8(O=9Q\\IIKXI>6\?FR@9%JR$JS;1C
MMM4*IE*JWI_ R;Y#FIR]D<LXA^N:7<=21G;8",[+J-UYB75#*(F":=>NTJ.M
MQ:RK(KE21ZHV!-S;4W,VN<83.C2!^'HO#)&VDD@NT3QA@#ZE 2.U%RJ75;A5
M&*3<MJ;ZUPZB!KTFG.*W"?OCV7-&3C%:9L$SFJ@Y28]<DZ];(2TQ0U2LXUJN
M,J;-0%CCK!6X&/9JM7RK-@C"J4:GU+;7VVLN38BY,J2#FK*PTB-8T(8%5 YF
MUL52JTL#P^U"+&%NI "P21&P9&0ZVD>5PRE68D6!);$B;?,02^'HN7@9&40D
MF+2&Q94X9PS:IQK>9:XZQ54:6ZMSF'2</$X:3GG\6YCQC"/7XM8&O5TAWSA3
MG@E?#&8@5)N (U6PL"$C52UN=B2"+7/)5YGN8ZB59F#!2"6E<@FY7B2NX35R
MU!00;V%V9N0QD/K-C!AIAB;,'?O_ "_^\_\ \ZUUHL__ +&A_P"''^3?'0[.
M_P!DS_\  ?\ >)C)S7*8Z_#3##3##3##3##3##3##3##3##3##3##3##3##3
M##3##3##3##3##3##3##3##3##3##3##3##3#&,F\S/DQM=VOYES[7Z:K?IK
M&E4\-QU6(HX20>N7$I'1!7TFJT34=)04"$D:P6%1N!%DX*+D3IKMS #A*31P
M+55,,#/PUD:Q;ER !:PORU-;2O\ ;$<CU&/5SFFIY9U368UN%Y\R2!<VYZ5O
MJ;^U!ZNO&M?DYN5>RSNWQ=<+-D+:MD&;L%1MY*^:?V\5QK(4*01=QJ$BDS60
MR#D-G(QE@C4U2&D6J$S-MU6CR.>B:/%R1J;8YAE45)(BQU4:JZ:M-0UI!8V)
M'#C(*GN$JO,$<['$"@S*2JC=GIG+(^G5 H*&XN!V[@AAW1<\B#RO;&PWS4UD
MX\"[0]VQ^[B(]D,4D /:_;<R)B(_< =0.BI[+I!_TIO]$!Q-Z2WL6J/_ $8O
M],HQ^>?>'OEQ]1N4_P 3R[[DWHJ0R+%O<7I.Y_)\9(-,_6>2FUF3.M3=(A:E
M>)+%CV=@$SLHRDR]D8W*7-*0S=@WFJJI'MTHK?4E#(^62@9@1&PE.F(@P*!?
M6KET$MF()<*46Q/:M<EM)55D:9C&30 N#'=I 1.Q-@I0*YC)6X"%@QN  5L+
M?H8\U#<A'@79INV-P !X^!L#D#OX]W[;GY,1'N[^ "'>'?K0BE0_[]I![YJ!
M_P#+XWG2']BU/P0>?Q\>:AO0@ EV5;N3"(@ !U';H00X^>/2[C4P*'H\1 ?:
MX:IT9/9E+\-1]'PZ0_L6I^"#S^-,?+![OX>AUO"%TN7)P-+#<"VV59U>Z;OZ
MC1K!5(5I%(,95Y7HMMA_+]AD)1W,*K$?%AK7-Q$ *<8Z>H0UC52>A%[G**1G
M:=$S JFE=:4C.KDG4 Q,T*@6MUH&;G:Z\KZG-*H(L+/0!FU$*]4B,H L2HX4
MI))O>S$+RO9NYL^P!OAR;E[">+<G*;&=S'37FEP5@4&I.MO 558[]D10SRLJ
M7K<!2+0I7'@AUN#7G*S#O5XQ=HL+8Z9R.%=9444<,TL73:?M'9>V%1JY'J;1
M3NFH=3:687OSQL8*N26&.3H=1VZ ]J8-/_1USHVD]:ZE!M;EBY<GY]LMDQU>
M82[<G;NAN]0?U6<2L53GPVD3$-8HLD<X6=13^)0W.S;]^@Z(ET8H1\'+R!CB
M48^->O 0;J6Q0*LD;)F%+&X==+#I:LIO8$$TRJ+>ZP'?(%SBLD[,CJ]#4NI4
MAE/12K"W,$=()(/N*3W@<:<^2 Y1B>N;[+&%<:\GW'15.KA!O\;$[34:E!.8
MH\G)MX8X90E,_9CI</9)QZV(T;1TVQM#29<-X19HSIHP[!9S"[?-LO5!%-)7
MDNWV,M5%B#8%OL8@A<JHYD@J0+W+W(!U>5U[,988Z$!%[<"E"@BY ^R&:5 S
M$6 8,"=-@FD=KO%'<EF ><*>PC=@(!Y.DMFR=(1'AYX#O!-P#CW<0YWH^7NU
MI>CQ=VNI?O+6G_Y3&WZ1+W**I^^U(/\ YK&B#E0=Z:^V/<'@S-K3DVZ?4LW2
MC9W+ERON9BL?VR=EVM56CXN/;4UYM_S5;Z\E9Z^U6133L=MFG5GKK5:"3B8-
M%@5F[4WF648J8)X?1%WA%EX5,9$52]R2XGA1M+&_:HH5CJU,3<8TV851IYX9
MN@(DINW$G",QTV%E,,KKJ /JF.I>5AU'&[JE[J,Y6VFU.UCL"W*-#6:LP-@Z
MH-\VD-"MS3,4TDA0!O8MR5>L38J(N12!&?KL#-I 3F2L'%/BKL$-*]+ CNG3
MZ8Z69;Z*L^I)'6M,RGJZU9E[S$6)VZ5,S*K=!J!J56MKI1U@'J:H5A_TE4]\
M \L=5XS_ ']S5I=K?]F65JG6G#<B*\SD.X[>9BJI/#N$08I/VF,,UWZV$.HX
MYIFCEI!$12=IHE5D8\RB2X>6NS(VSV?W>[@=K\]V@V,RK>9EL\^3Y0^R^:QU
MBY/)/F69014F8YM4+3":EILMJ5BJ8)J5X*QLQ6A@I:NBGF2L@[C=]15N;;4T
M%+35=3DDJI45 KHWIVG5886+PP(LSB229"R,KJT?"XC.KJI1K9IFZD]4K<=#
M5;:1GNV,TRK*K26%*I4YNDD>*.%2JME)2TWZM2PS14TT5WZ*K1\1-%PS$LFN
M8QT&W =A+O.R';;<?2U>S&ZB'=_19/M)F^1U&4;+1-/D=;704^75\^<4E3F5
M2,RJ'JH\QAIZEZ^HS"J2IHY86KIHXXUCX_?GM3FNP>VRY3)LIO'WA/6Y-19L
MN=9!E635E)3)/45U(N5U,M7GN6&*MIS0FH:&&D6 4U922*2\KJMT^;"ORG\S
M;'-WYN/DZS7<3L_0\O29;/S?O_\ UX>NO1FH/5D6<_?BI%_35]_Y.>/CGU6<
M\;^+W+[V#_PF7[+1?(VU1P\UIEM0?Y&V*;H# /D%RMAMF/G^4#Y1/P^^/W_1
MJ,WK#U9#FGWS1+^FK^3[V'U4]JF_B]R>\HWZN(^R$7PZMIC;[_RX>:FSPI_,
M^PS< ;CY.LV[![3W>?D@_-[_ +O=W^B&AS6O[F09@??FH%_^9-O_ *Y8?5,V
MW;^+W'[=D?W3-=BXN?O-M">7N_?[^'FE]RJG\S[!,PF]#K.5L!-/1\O/OY^'
M<'D[^_N] 1IZ)YGW-GZS[]9EX_\ F#_]>]A]4;>*W\7N+VM/>XFU&PT7PZL]
M-N7<[_+W< W$[LE/Y1R?F01#T7.?]O+7SO/ US4-Y1X=Q3#PXCP[A#3T2S>W
M+9ZH^_F.7#_OC^C%/3_O3;^+W#YZ1_=-N]@8OA!S=C[]@3[AQB)N>WM;_P#&
MMCP/'TK8Y*P;6[9(0@9AK)WBGY+5N"9FPBG3&LCC]X_8T%R^:G?2Y;'.J&(F
M$.+E)-2,C9U%>!69OG<34P&4-2\272$>:&K-4UN5,'IBRTY9=3AWYG3K4&.*
M8'YSMWO<WUY)7;)PT&Z*IRA,SSM:62"IS;*MIGSURG:Y)#49#--!D4DT;350
MKZUB0*;CHK4E'F*2;,FMDW +MFZR^)<7LEED$55F:V<+"JLT543*=1LJHVP<
MNV440.(I*';K+(',03)*J)B4X]BH@*J6>96*@LO!C;22.:W%18V/*XY&UQCU
M)!)5R0PR2TL=/*\4;RP-4\1H)&0,\+21PM&YC8E"\9*,5U*2I!QW^'\]^M=B
MOX[;1]1.JZ:?UV;Q"?2,9;S^MQ>.?S&'A_/?K78K^.VT?43III_79O$)](PO
M/ZW%XY_,8>'\]^M=BOX[;1]1.FFG]=F\0GTC"\_K<7CG\QAX?SWZUV*_CMM'
MU$Z::?UV;Q"?2,+S^MQ>.?S&'A_/?K78K^.VT?43III_79O$)](PO/ZW%XY_
M,8>'\]^M=BOX[;1]1.FFG]=F\0GTC"\_K<7CG\QAX?SWZUV*_CMM'U$Z::?U
MV;Q"?2,+S^MQ>.?S&'A_/?K78K^.VT?43III_79O$)](PO/ZW%XY_,8I,ZIF
MVQQ#Z#DL78UZA)(]7=@RSU<XYR=$3D.=,CQC@]!TD54"=&L"2I.E1,HB?G)J
M'*/-[7[)Y#MQLUF^R>?2YMZ#9[2]"S),KKJ[)*V6D,L<LL$>9Y1F5'F%/'4"
M/@5*T]3'TBEDFI9=<$TJ-+H*^NRVL@KJ6.EZ13/Q(3,$J8U?20&,,]+)$Y2^
MI"Z-H<*ZV95(O/&T;/0T0K$RU%I5#8LC(%B8^EVR0M+9R0Q#]:7?J2%&I1VS
MD#%1X*<R46>B=55PNB=,.GQ;)[%[(; 9%1;,;#Y#ENS>04"D4^695004%,KD
M*'GD$3N]55SZ0]56U3RU=3)>6HFFD9GQ?69AF.:5,E9F=1)554ANTTL[SN1<
MG2"Z((T6]DC0!$')54 #$BZZ/$;#3#$>Y+AR3=?09G=&: 64;+]*5N#D1$C=
MX3F=&+AL  /2"/.Z0>'-X<T>/$-CE<YIZDN$#GA,MBVCK9#>^E^]U6^_C59Q
M *BE5"Y2TR-<)KO9)!:Q9/"O>_<M;G<0/XO&_P!O%OQ23Z5UT/HF_L=?'GS.
M.:]#$]D-X@>>P\7C?[>+?BDGTKIZ)O['7QY\SAZ&)[(;Q \]AXO&_P!O%OQ2
M3Z5T]$W]CKX\^9P]#$]D-X@>>P\7C?[>+?BDGTKIZ)O['7QY\SAZ&)[(;Q \
M]AXO&_V\6_%)/I73T3?V.OCSYG#T,3V0WB!Y[#Q>-_MXM^*2?2NGHF_L=?'G
MS.'H8GLAO$#SV'B\;_;Q;\4D^E=/1-_8Z^//F</0Q/9#>('GL5"6H2"\BZ6&
M95()U $2A%D. <"%#]T,F3CY./[D/0UCAS%EB0<!39;7XQ'R<$_IQEFRY&E=
MN.PN1RX(/4 .OC#O=[%/\7C?[>+?BDGTKK)Z)O['7QY\SC%Z&)[(;Q \]AXO
M&_V\6_%)/I73T3?V.OCSYG#T,3V0WB!Y[#Q>-_MXM^*2?2NGHF_L=?'GS.'H
M8GLAO$#SV'B\;_;Q;\4D^E=/1-_8Z^//F</0Q/9#>('GL/%XW^WBWXI)]*Z>
MB;^QU\>?,X>AB>R&\0//8>+QO]O%OQ23Z5T]$W]CKX\^9P]#$]D-X@>>Q)F+
MZNE!2T@X)(*/!6CNA$AV16H$#K*!^>!P>N></V/#F\TOEX\[NX#J\UJVJ(8U
M,033+JN)"]^T86L8TMU]=S[V-QDU(M//*PE+EHK6,82W;J;W$CW]ZP]_$W:T
M..BPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPPTPQBB]RUND0>.T6>T
M5L^:(N5TFKWS05$;=;;IJG(@ZZLK F4;]82 JO0*&,=+G]&<1,41U*$5+87J
MR#87'1W-CW1?5SMW\1C+4@D"EN+FQX\8N._8BXOCS>-_=;[#MM^430?H#5>#
M2>S#^#O\_%.+4^Q/Z>/R8>-_=;[#MM^430?H#3@TGLP_@[_/PXM3[$_IX_)C
MX',.ZX!X!LW1,'HAN*Q[P_YT&4?S:<&D]F'\'?Y^'%J?8G]/'Y, S%NNXASM
MFR8!YXAN)QX(@'M ,,4!^YQ#[NG!I?9A_!W^=AQ:GV)_3Q^3'9XX=U'L.?\
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M90\&2&ECEE6*O(0.ZJ5CE:Z7( +I97%OY0[5NL<B,34EJ7BC,M%J?2K->2(
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MW_UW,/0;9'VZ-][9O,?],XQ\A<\N^LJD'MCDJO?]4<(_FT^JCV2W\U>E'_\
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MDIR:I<^C@R'+Z^-X!09*ZM+4)'V[R?9;*:X1[/9F]1*S$5>7J!4T]"P'-4S
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MSAXX2:-$"G4=%*99TZ71;-D@$3KN%DD4BF44(4:6)ZA?K/W@+D_>',^YBO\
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MF9L">M95?>BWR^G2:CUU_APX$7@#Y?+AYF; GK657WHM\OITFH]=?X<.!%X
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MYF; GK657WHM\OITFH]=?X<.!%X ^7RX>9FP)ZUE5]Z+?+Z=)J/77^'#@1>
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MWK3?A5+Y_%3V.N]D"_I0C^]M%LL3\ SPG -S/)3B/#PS5 'V\6Y@*'WQ-2@
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M]=AW[88U66/:%N#5I]DK99S']E5RC#6JZWCP<UE*BVBLUSE(R? S4MSI*=M
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M2S.W66/Z"2MMM>7V7=/4V%G;)3)DKJ_=6J")-$D$JI/'3DZJG#.V[=5*O'E
M8:^3!5;M5/)4X8 NO+M!I:UM:\FU8IPX;J;<U+$<WZV;6;\^?;]LM[Z6YK8C
M%?Q]MFK>+J([QE3*Q.,Z,[2>MA@)B^6VVI-&4@Q3CG<=$O+?:IV2A(H[9,>C
MBH=XQCF[E9T^;M4GKQTX6MDFDD?B.1KY=LJ(ER#<$A%4$W_E$$D6!-@+7(L2
M)H6X7GR)=K \B 6)('N @7N>LG'Q8MK],M==@*G8*$60K]7J4K1H*.-.R;<K
M"JS<(TKDI$E<M)QN\7*ZA6#1D+MTX7?I%1!=!TDY.HL>JS2*S,&LS,'8V4W8
M$L#8@CK)Y6L;V(MRQ0K$RA2+JJE .VY*0%([_,"USS]W$0V38? 363ZKD>*-
M/U9.!M#2ZS-;AY$O4+;9V&2)_+321F7#B44.Z3"\V>;D@822$HRB&\E(M*>C
M5?"LLL_R+5.L;1D*VI2@9@"54QK$=/>.A5%Q8FPUEP !C:&(NKAF6S!R!>S$
M.9!>X-QK8FQO:Y":;F^5SZ,MM;CY.PQU8<STC!Q<G+1\$V=-4W,T_CV#AVRB
M&Z@**BFO)N4DF22G1*<Q1<IA(8 X#@0!F4,=(+ %O!!(!/WASQED?M&*]LP!
M(7F+D<P.KN]6--W)W\IMO1W(Y'R_6,@;;7&18FILO"!4\8L:]CM_CV;&92CP
MJ,^]RM>Z]"/BKMCNSMF"\J:XH+Q#M91I(,!>KQ.]S#+:.GCB>.?AEC;[(6D$
M@M?4HC1B".5S8)8CJ-KZ2CKJF>217AUA1>T85"AO;2>(Z@@B_6=5QW1>VV<V
M=,Z 'V.RG- CZ!LF;7RA[H9S./YM:G@P^RXO%U'F<;'BR]RFE^/ /^]..OQZ
MYY]A-F3XT-L/UW:<&'V7%XNH\SBG%F]BR>,@\YC45:^5!WN1'*'PFW)IME5:
MTUY.UZ$##SQC%/,G2M=E8YF[D+LVR%'VU>@%,T!=W*H2*,L-$81;(\;.2B#M
MO(S3;;KEM$<O-0:B[Z6;C D1A@39.&5#\[!2+:R3=0;@'7M750K!#P+*2HX9
M +E3:[ZPQ7ES-[Z !8V()&WGQY9W]A9F#XS]LWUTZU'!A]EQ>+J/,XV'%F]B
MR>,@\YCH=9WSV@U<K([)LP+K(MUE4D/&AMJ+TRB:9CD2YR69'"H=(8 )Q2;K
MJ!QXD15-P(:H@@) Z9$+D"_#J.7N_P 4/TX&::Q_@LGC(/.']!][&I78#RGF
M];<3FC+M(ONVM2]1%7C'LF>&QXPA\>36,9AO/,XQ"KV&6RE<H"$>@NW7?)>#
M9&03N!WL6X=MFCB.;2H1VUK\MHZ>&)XZCAEB!JD+2"4:22RB-6(-[&X&BQMR
M-KZ^CKJF:216AUA039 J%"& TDNRJ>L\B=5P>5@;;<?'EG?V%F8/C/VS?73K
M4\&'V7%XNH\SC8<6;V+)XR#SF(HSENHW)8WQ!DJ^5W9-DQ69J5.G)V-/,WS"
M4[$-G4>Q57(^EX.BY3F;?*Q<=S1?2,?76"TH[9MED6RC4Q^M(9H*:FDFC1ZR
M.S. ;1S*2">H,\84$]0+<@3W<8Y:B=(W<4KW521=XF'+ND)(6('60HO;&&?)
MO<HQNVW14&_S5UVR2&3^RMFCXV+NV+9"BX\@W!9%F[=O(%^TRCD"$;24K""@
MV4.ZK+IZ"+&38I3;1BZ%J\F)F8Y?24SQA*@1:U)*2!Y#R(&H<-"0#>W;=9!L
M3S C45;43HY: R:6 #QE$',7L=;@$C^UZ@1<#D3LD\=^>?87Y7^-+;?];VM?
MP*?V=%XFI\UB;Q9O8LGC(/.8U$6[E3=YL)RAD)MK:[8R-ZD\L%<KOBF>-V3O
M*<M#S,<T>/+HTOS"V*X_33: L[ED'Y'1Z4RA&+AI.2S=PW?S;':KEE&:!J@U
M%V"LW&!(C!4FRF,KKY\A:VLDC2.8!U[5]2*P0""REE7AFQD((!+:PQ3ES(/J
M0.3&X)&W?QWYY]A?E?XTMM_UO:U7 I_9T7B:GS6-AQ9O8LGC(/.8U5<HARIV
MZS:E;,45ZK[96E!;VQH]F7SO+CJ(O);6#*228FKM8=XGOSN(C'#8ABJRH/I-
MU-_ZYQ*B$8R:B1>3V=!EE)4K(S5)ETD "(-'IN+W82QAC?N6&GD>9/5 K*^H
M@:-5@T:@6/$L^JQMI4QN0+=WGJYCD >>SNM[A,_3M=@9M;9+EMBO,0L7*JL5
MLF;?FJK-608H.SM%6\KD^,E&ZC<ZPHJ(R49'R")B"1XP:.2J-T]:U/3JS 5T
M1LQ%^%4'J-KW$1!^\2#W#;GB<LTQ53T607 -N)#W1?NR _" >^!BK^/#/OL+
M<J?&MMP^MK5.!3^SHO$U/FL5XLWL63QD'G,8M[S=Y>ZG!NW2_P"2Z7M"M]>G
M(%&+*2T7"U8KN];JS-_*-63^P2M:QSD.9LL@A'MECBF<K=**8N5$)":7\%M7
M2"\FDHZ6:HCC:K1PU^T1)49K D*&DC51>W?N1R OC!4U,\4+NM,RD =LS1LJ
MW(!8JCLQM[UAUDVQ:>P7?#NPW$;>HS(E[VJV*YRA['-PS*[4>?QO0*W;HJ.3
M8';R[. R->X24%5-RZ>13Q_#HN:Z[=QJW4'"+E-_',+JZBI:><HE4L8TAN&Z
MR2,A-^1:-"+'D0&.JQY\K$VTE5430AVIV<ZB Z-&BL!;G9W4]9() *W'(WN!
MFIX[<]^PSRA\:NW7ZU=0^#3^S(_$U'F\2>+-[%D\9!YS&N/E).4'W>[8\9TJ
MQ4/;7(XQ"Q6I>*F;YD5]1<C0L>FV9IN6,*U98ZNLVVBY.=5.MT3VRJ-T%&L>
M\;1+9V]4.YC=AEU!25,CJ]0)=*W5(P\;$D\VO(@+!>\O42">7(PJVLJ8$4K"
M8M36+N4<"PN  CL 3WV[@-N?,9?8!W2;FLE86QG?;3LOOQ+#:ZA$S,JI#7K$
M%;AW;EV@!ADHJOWG(T9;H:,E4P)),(V?:%D&C5VDBHN\*4CQQ%J*6FCFDC6L
M32K$"\<K$#O%D0HQ'42IL2.YU8DPU$[Q([4KZF4$D/$H)/="O(& /6 1< ]W
MKQ"N^_?'NHVZ;>IW)%-VG6*IRC>:A(=6Y7JRXWO-7J;*44<%7F9.OXWOLO-*
M"*B*$:Q=R ,H%K)2+,\DY6,+>,D<U#14M14"-ZI7&EFT(LD;.1;D&D0#JN2!
M=B ;6YD8JJJJ(82ZT[(;@:G:-U4'ND(Y/N FP!//O&K;*-ZVZ;<!MVI>3;9M
M%LUCEYA67:C:J9;<:4BK6IK&R*S1K.PU=R-?8RQ-$'"9.KN5B%=1+M^U=NHE
MT5FJFS:6UE'2P5#QI5JH !T.DCLA(N5+1H5/?[A (!%Q<UI:JHFA5VIF8DD:
MD:-%8#J(5W#?I!M<'$T9<ON2KKCVR1E]Y/&>RA!,HQ[.EI=TMVW&Z0LG)PS-
MP]CB'K[FZ6 SQV"Y 3:]0B)"2!142Q[9=R<B*F*&.))$,>8+&Q(76B5", Q
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M9''<ARSC9TH*37:>#E4"**"FAF:064!-(@J*J"1/&)C<Q,A3'4-PYI" )C"
M (ZM?L;H8QJ?;70MP-3Y JB[&RBYSL"Y)  ZR38<\9(^STJ9FT0[I3*^EFT1
M[:22-I12SMI79 G2J@LQM95!)L!CJ-RT<>4PE-M51*8HB4Q39J>@8I@'@("
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M !Q'B/  #CP -,,?6F&&F&..:7G ?FEYX%$H&X!S@*(@(E WE HB "(<> B
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M&3B]5Q;I!8G5W=&GGIMU_P GJT]W&U4R6]L0^Q?;5P'CY3166S!P^X$P7O\
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M=)E\0^]S0^[Z+CY!W:#,/PZ(_P#RPP]&]Q'M#W@CWMNLJ/Z=EO\ 3AV$Y1P
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M9JB.J26DDBB?HS-'4[#:W:K=1F&SV?T6S>S&8T6=5N:PU66UU=E>2PB*$QY
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M%JNCW"NK%39@K Z3WC8FQ]PXN[5F+L<&,4A3'.8I"%*)C&,(%*4I0XF,8P\
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MIP3W.[!R%^0)L+\KWQ-7F<;^ B(;S-U  /#NZ/;.8 X>AS]MAQ#CY1[_ ,P
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M#_A)CW_3*)U]1W&_[8V4_P#%,V_S=48\U]F#_M%;1?\ *FS?^>Z/&@;#F4\
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M3LGMSM%EF739K11YSF>4[*9GM9DM-G-;1Y0U;+3TXJ*J5)@D\>6YCPC2OO\
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M<[9"=AL8S1GS4BATSJ$*F^G7391);HRD6342XF3$P$.D?FJ%^.[]]S.0[_\
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MBG=HQ*&,3*=<BL+%T/4(UYW YW[_ "[TY:T&.DQ"=HQ >QSTC-!8"LP?J)*
MV&+%<4NC;HH<.F"01Y_'HN=QZ,O#G<W@/#B-X>P MU>[^[%A2Y)OU^Y^_% \
M0JGJI)^)C?2FJ\3W/E_=BG#]WY/WX>(53U4D_$QOI33B>Y\O[L.'[OR?OP\0
MJGJI)^)C?2FG$]SY?W8</W?D_?AXA5/523\3&^E-.)[GR_NPX?N_)^_#Q"J>
MJDGXF-]*:<3W/E_=AP_=^3]^+%F]F]!LEK@[Q/-Z[+VZM%;D@[ ^JR;B1CRL
MG+A[']$L>3$#C&/7;M]%&6*J:+?.G+V/%LZ755/>*AU4HI8(U[J&(!O8'E;N
M@ 'O@ &X Q88$9@Y ++U$K<BW,=WN'F.\>8YXE*OX:/!S49+C8B.0CW:3H6X
M10HBMT8\>9TOA%7F<?ZKHS\/ZD=6%[@BW6+=?[L7A+$&_4;]7[\3GK'C)AIA
MAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAC#[?QM_O^
MZ3:3F/!.,+LWH-VOL+%M(B=?.)!G$N2QEBAYN0K<X\B4',FT@K9&QKNMRZ[)
ML[.FQE%A<,))F+F-=RZ&>.FJHIY4,B(22H )%U(#*#8%D)# $CF.L&Q$6MAD
MJ*:6&)]#N  Q) Y,"5)',!P"I-CR)Y'JQ@%R;W)L[IMJ^"9.B7S>-D'&TE+W
M64LS6AX/885NE)@FCMA&,Q5-+9UP+?9<DU)KL57<DTK0PM>3 6ZG5W\FJ^?J
MS\QS&EJIPZ4D<@5 NN8S([$$GJ@G0:1>P+:FZ^8%AB%04%330E'JWC)<L$A$
M3H 0!US0NUR1S"V7WS<XR'R;C>XVE/(6WFJ\JGDEMN L..K0A7\=3:NRF-MK
M1:5K;T(R8DZW1-N=8RQ&P).L(/7<W4WT)/,8X#R4%,,'R35XG'BD1>'4-E<9
MIUD75(O3"G)A<!GJ&B+=P*X*D\F!%QC-)&[<2!,R?CM&VF-NB!N:D E4@60+
MWRI# <P0;8P;Y+GDR-[.V)AF F5MT%LPU&V^7AEH6JX9D,79(3G9*./+#+7"
M<-F;$F1H.$/()O&:#0U=81EAF2D5/:EB)QD0UU.S/,J*I,/"IDF*!M33"6/2
M#ITHO!EC9K&]]1*K_(ZR<1,NR^LIQ+Q*EH0Q!"Q&.341>[GBQ2*+\O4@,?Y7
M4!C9!8:Q(5*YUK'%JY47+%9R'="E-3Z'8$-@D-<K64ZRC8AJW6)':VVFYP#N
M$E4"#&,70'6242+Q4(8H:Y6#HTB97$T:>KD4U[(O=[9Q4E5Y=\C$YE976-LR
MD5W]0C"B#M_@J:<%OO X^,R;2=PM^Q-DJD5S?WN(;S]MH]GKL.K/5#:Q%P@2
M,O#NV+0DQ)X^VTU2\QL6LLN5%_(5&QPUB9-5%7,0^2>I(B*&KIXY8W:@I]*.
MK'2]46L"";"2I=">\'5E)ZQ;"6EG>*1%K9[LC*+I3 7((%RE.K@7ZRK!K=1O
MC5/R<VR3+FQE[;<4YUY0.L[=K]FJ?K[G&N%,6W;!MDF+H>+&8C'%F1@MP6++
M>NK(SCERVC(U*A0,>^DDXPJ-B>R;IK%1L+M,PK8JX)+!0-4)"K<2:5)U":K$
M+JIY4Y+8DZV(!-U N2VMH:.6C+QS5RP/*5X<43PL7M<%M,\3<S< :%!-NV)L
M -SGF=<Y>SXW,?%YLK_\*&M/TB#V!3>,K?I6-MP)O9M1XND^C8P<Y0##E^>8
M#MN&'O*>SU3R/F*.0@L>TK.DOM3Q1!Y+7;3<0O*50DO0<'X^R*"$VS*>".M6
MYPC15[*L8N?;R$-)/8M[-H)HQ.DPRQ6CA):1X!52M'VK6>TD\D=U/;=LM[ E
M2& (AUL+F!XCF+*\HTQI,::-9#J%UND*268=KVK6N0&NI(-L<FER>6[_ &U[
M?WE%RANVR)BI^\NDK.PF-\2ML(Y!K58B73&,;&Z:;S#A?(CMI)2C]H[D'$-4
MG[*L-2*I/NB<3<E+JEOS',*.HG#Q4D<H"!6DE,\;,03U+#-&" "!J<%SU<E4
M8MH*&JIX2DE5)%=RRQQ"&15! OSEAD()(O92%'7S))QL-\SQG#V>FY7XO=E_
M_A3UK^D0>P*;QE;]*Q.X$WLVH\72?1L6U<MOF6DJK.FF]XN5KQ&@R 7-?R=7
M]N55IC@A'""HJRDWC'!6/[.TZ(""* >'_!:JQBIR+%RB8!2\Q]F#L/F.\O<%
MMELQDVU.0; 3,<MS*LSK:#.*G)-G:C+<MKH:BLRK/LWEFFCR_+:U0I,\D4D)
MJH:6&H II9G7L]@*Y,EVIR^MJH*W-T'&ACI:>FIZBJ6::)DCGIH(X8WEFB-[
M('#:&=DNZJ,4"A[5)*?K$=).MRF;:Z14%BLXK"&5&D91$&H+',!D"+5^5(YD
MU'!G!Y!TW610$XIMRH"=N=PXKV!.39IN=['O*]F,US#==O.6NVCSW:#+,[R:
M:3:_)\NRW,.AP+D>6Y_'6PTM9#2UM%6UM0M'3P4M/7YA64Z"=XY*NHXG?AL=
M'O!VZESRGVNWJ;$<++*'+9LHR3/(=GZ:::E:HD.83Y;)EE7(E5/'41PM+).S
M2P4U.VE  BWAYCI?V6&\OXYH[]2]>T/3\OM(W?\ Y/R_K#'Q_P"HK)]U_?;^
M6]-^H\/,=+^RPWE_'-'?J7IZ?E]I&[_\GY?UAA]163[K^^W\MZ;]1X>8Z7]E
MAO+^.:._4O3T_+[2-W_Y/R_K##ZBLGW7]]OY;TWZCP\QTO[+#>7\<T=^I>GI
M^7VD;O\ \GY?UAA]163[K^^W\MZ;]1X>8Z7]EAO+^.:._4O3T_+[2-W_ .3\
MOZPP^HK)]U_?;^6]-^H\6],;9Z[7Y*N0T[O3W7PTO<)%Q$52+E,]P#"0LDHT
M8N)-U'P3-U44G$J\;QS5P]7;LDUE4FR1U3E*7@(XWWB01M&DFQF[M'F8I$CY
M#(K2LJEBL:G,07(4%B%!(',X@5>ZJ@H*C+Z2MWW;X*2JS:H>ERNFJ=X%!!/F
M%3%!)4R0444F3*]3+'!%),\<*NRQJ6( MBX?,=+^RPWE_'-'?J7K)Z?E]I&[
M_P#)^7]88G_45D^Z_OM_+>F_4>.2[.U@, CNNWE& ! 1*;,[ "F !XB41)3"
MF !\@B4Q3<![C / =#M\MC_^)&[\>Z-GY;CW>>8$?""/<P&Y9P03O>WVD7Y@
M[;TX!]PD9(#8]7(@]X@\\19M\Y.^$P1D'+%X9YDRG(#?901AD(ZQO(5\VA%E
M_"JX7&0(HZ[8V$)9PZ30F72#<4VA%'8) ]EWQ4-GMKO/J=L<FR'*),FRVB&5
M1!JB:*&-N)4HA@5:!="G+Z(P*C24T;,'ET(6X5/'JT6Z3L?*#=5M9MCM1!M3
MGF<':.=TH:2KJ9E$%#+,M;))G3\5QG>;I5O-'#F$Z)H@,LHCZ16S\/+L</%[
MN&4,Q%X>A>5!X_= T>8/S:^9<;^Y0_$_?CT+PAZY+\<X>)\0'B&4\Q!__>I#
M![AXHP:<;^Y0_$_?@8_[I*/^D/\ 2#CGQ0J /$,JYB#VNV#40_YT*;3C?W*'
MXG[\.$?79?C#YN./%"OW\,LYB !\[M9'#P^X)J^8?SZ&6_\ N4/Q"/T-BO#_
M +I)\;]V 8B= ' ,N9B^_9X<P^Z:M"/NB.@FM_N4/WT/SKXIPCZ[+\8?-P\4
M;WAP#+V8@]OM' B/_.JH_GXZ<8>LP_%?Y^'"/KLOQA\W <2OQ\F8<Q%'CQXA
M/UH?S&J!@X?>TXP]9A^*_P _#A'UV7XP^;BZZI37587=KN+Q=[65TBFD5O:W
M\.\0:"F<3],T+&P42HFLH \Q05%52&(  ! , &U8[A@+(B6[J!@3[]V.+E32
M3V[M?N,00/>L!B]]68OPTPQ;MJ_>5Q_;&_\ EB:DTG\>OO-_5.(E=_8S^^G]
M<8P8<X+G5]RC'.X7.-;P;*LFKXTR.J[F"E7ZAHIZQ!W8KC7+)#*WMHW<.P<Q
M5=R/#7*MUM0@R%6BH.R]%84MIH^R:[@BUM-K'[[ ]M[@8$#N"]CC3\0<(QZ3
M>]]1:X',<@I!T^ZRD,>HDKRQB$3D\;M'V*9L\9GMTZLSFXY#N$)=9:KM&]JC
MIC+E)V^XUR/8GAZ\K#1[RS3=+QMDQLS<((,HR(E;G7'T9'-&\ HQ4Q\$]8>Q
M[;GIN;L$!/6 20K<^X6%A86.85*V ,8TZ54J";61I&0"]R "R7YW(4]^^,^L
M'8U1PWAS&.)VRC!5MCBCUNEMCQ;08^-%M78MM%MRL&(F-U-F1%L0C9MSA!%$
MI$P'@4-9E&E57P5 ^ 6Q&=M;L_A,3\.)4U7%N&F&&F&&F&/';F\J[AYAK N&
M#2<<UTR$*[E&IGT8UEU84A(US(LB&(=VQ0>F05=MB'(== BB13E,8!"Q+Z3;
MKURVOU7XC=>,LEM:WYC1#<#D2.$E[8P<1V:-H^W4=:/DDBTNN4.KU:U"C<,G
M0UGR,:H1F0W4<SLK2*LI:FA*.,I7I#-9<M0D9%9*C;K$R*!EI<MH?2C*G#%Q
M?F+ 'FP+6N>8!L3J.K5:X/?ORNXUPU[ZBQ*\D(745O8V#$:5T:"2I%N0MCKK
MFVW*M$P[DO&2%NA[97%VN/G]!IK%@Q@T72E=D6]BR73W\BZ:(/$*_E$6W89D
MSL5CM+:NUHY4TI!A"*)5R)IH8*RWOU6%@+VM<$BQLUK6)( ZB ;"IE1I%?20
M;MJ8DGK%E:PY73U5U"W/<N+FSK%LLR)?YD;)9+]5:;+16:\79'@F%"@VJ].=
MU7$N7"Y%HE:D:I)5Z.+'25.;/[I(,),DM.]H,C9&M5PGC"WC:+#T^AC8]9 (
M96!47!"M=18@6MSMS/-B2.0&*B=5%@K,#&ZDL>V#.FEB&N>1(7E8650HYEBU
M4L&U#+17<-.4V?Q QMT)7WZZEFEZW,O1L=_ND[C:S7RY3E;E$['4 N\9<Z0Y
MO^.,G! /)6"DTJ14Y"J/:Q4Y,;6,;\B"MP";D$W8E22;W%P1J5K<C86L.=!,
MEB&#Z21R!')5#A5!Y-I(;2R7L068&[#3/N <22N*W5D9GCF5=K*%1Q#2:_7X
MR:=V!@\<X_IRC&8N@RDB1"6=O9<)6,I:[J<:-9I^SQS'2;M,4'K/A>JD7Y6%
ME'7>Y YG] [YTWQ9(X<#F6.IV)(L>V;DMA<6%BW(V!<CN8R3U?C%BY*O^^"W
M]QJ?Y=OJ-5?Q:_X8_JMB90_QK?\ !G^LF)4UJ,;S#3##3##3##3##3##3##3
M##3##3##3##3##3##3##3#'6JLB@4#KJIHD$0*!E5"IE$P@(@4#'$ $1 !$
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M\&DYF_\ 8L/^E2?A-\; 4B  <6IY #^R9NY[S@?  ,>SS'-3]>W=U^59FO\
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M2Z;7B?G "R2:)S\#$$YB@)=8Y'D<#B"P'5]C5/ZJK?%Z)&I)0W)'/MV?E?\
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MOY.4<)MR*OY-ZNJ\?NC*NG2JBZJAS:AILV9F8M7 L2Q $P4$DD@*!I Y\@
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M5"DD@[4Q38$AA*9LC66\PDT\'VJNO2INBO)DQS6B62BCE6:)E)68Z1(%D!U
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M=1) J 6+.SEF-[ !7  %N9+7%Q8'G;%5U]#3!-%.DQ<GD(U0*!:Y)9.9YBP
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MG)LQ,SE)9N1*4DVBBK9^[<(*J)GSM4U#0BG::0PK:T98Z18W MW@>8!Y V(
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M>KF3:;D%5'#Y\Z65=/G[M1=X^<J*N'+E98YCCJY8S-(TDM?3R.UKNQJ"386
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M0[5Q-C"1<H^DY*/BC2)W!H]D_D7[QLU%)%P[<*D.J?,A)52>LJ";=5R!?O\
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M2"UV5AI2P!Y7NR\QU'69I72T4<1BC5C(S NX)1=(! LK*=37)'.UE;K[DT8
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M;LWZ1"/F31PA@EWM;[9I89I>Q&VQDEIV+02/O,W1EHV86)4G:7EU VZ@RJX
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M,=)(.6:_1+$(JETJ)^C5(10O Q0$+E9D(9&96'4RDJ1[Q%CBC*K#2RA@>L,
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M(LW3F"63;\XT>J1*UF=A=F9@3UDDW*CND]9 ;WP"._BY41>2@"PL .X">]W
M2/OV]S%]:LQ?CH=.FK%JY?/G+=FR9MUG3QXZ63;M6K5NF99PY<N%C$20;H)$
M.JLLJ<J:293'.8I2B( "38"Y/( =9/>P) !)-@.9)Z@.^<<&>-"BT SIL47Y
M^B8 9=(!>J=66>=&T 3!UD_5&[AUS$>>;JR"R_#HDCF*L>?+JZ_<[G/[_+"X
MY<^OJ]WN\OO<\?*SYDV<,VCAXU;NI%19*/;+.$4G#Y5NW4=+I,T5#E4=*(-4
ME7*Q$"G,FW246.!4R&,"QY\NKK]SW\+CO]?5[N/5IAAIAAIAAIAAIAAIAAIA
MAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIAAIA
MAIAAIAAIAAIAAIAAIAAIAAIAC 7E+D=WB^T^WI[)E'Z>9QFJ\*W@!2,1N!Z2
M#E7M.2E+2YB,T['PZB8IB'))C$%EB09O#AHX!G9=T3I2=-MP=+>JOHUV[77I
MYZ>OW+VU=K?$+,.E=&?HE^+=?4VUZ+]MHORU=7NVOI[:V/1R;26[=#:;22;U
M3OE<UA)6$1";4BUK<%.%]_L6)=%8@QF"EEZMTXJF%0TB$8:++/'\/EE !F/1
M.E/T.W!LOJ;Z-=NVT:N>F_WKWT]K;"@Z3T9.EWXUV]5;7HOVNNW(M;[]K:NV
MOB@Q\5OEC(^SG00!N_MTE/Y3CN;<JA=%JG*2-&R4]C,(N27!!C&PU=B[E&X;
MKG^Q DS&+MWUXE6UUBA?^&60FD)%SR0+'ZADU@/&#,--R6*&4]O8^H!1K6Q4
M"J :W6Q:0=LK:25<B+MK!0&$:]K<$%CJ%]6+QJ]7W2J5+)4-+N'R<L2RV:;H
MMFLM\9MY]X[K-F?63';-!A34GT&I1K,\CXB#LT3).*@[5HCQ:-EXI^\=R;5&
MQFIM:,!RTJK*J=J RA7-W(.M06*D!NW ((%CBY5GTN"3?4Q5F8:NU8E!9>UT
ML0 0=-T/,$DXLY&B;GU\GL[6Z[>-V=DHD#,$:.+LXE*ACK(4W>,Q3CNM2\#"
M[CZ37W3+'E:G\7UR;D&>*\L0MP95GIXI!TY!X@[N+T_"*C1=78>ILSHJ1*&#
M&G9@799& ,D90MSQ;HG,@8ZP"@-M1*HY:0Z2JS*O: H"=$H8#EU8HC#%&Y*R
M2E6A6ILF8[JS>Q4&1M,O>LNW:TR3Q6-Q-FR+NG3JT'<VPGY:$D,@26.WK=*O
MRU"C5W2\$Z<4-VA59&1)<9(%#,>&[$.%"1(H ,D17U=.0"$#CM@QM>S]N!BG
M#F8JHXB+J4L7D=CRCD#"Z3ABI<H;*4%R.T[4XG?);;<5'Y!E'>.G"K+'<1C2
M+DFKEW)5A^E-W6O2DBJ-:DT[A)NW\?&2\0X($[/,F\3(.TDTA-:$GC5NJWP1
MF#1V_-RY%K,-*D#MAH N01R4D@7/:VOC*_'#G1Z@(""2INP/J3J-P"#S:P)\
M+D+0CCRQ[UYB#KLA(PDTC4I2BX[?&>0@XT=W &[RM8^=.7-5)D>9;OD[B=\Z
MN!+LURHG)M5$T5U8!5C(Q\6G;<SK2AF (+!W%CQ O(OR/#4@KR708R+<KW!.
MG&K5)4&QTE5YC06M9.:AR#JYMJ$@/5VMC;5[8=OO<AW,T8S&RR17#>UNXEU(
M2^)WYEK<ME/+DQ18>6CW-E&/B<0IT:7I+.Y.JVW)DYLW0@X>O/7I(AYX+H>B
MFW-18J" )1VO#C#D'229-8?2&^QFY+ 7%PZ4"W(GU14DQGMN)(5#"]A'H*ZB
MMG   O8VD!2:W-UG$G6;:-BDKW*VK S83U2)Q<^LD8WN2]"C\N0M?:*'3I)6
ME5E7ML0AY>TB^!LR(,@O*6%LV9K+6Z:=I.UL$"S'MC(%[368BQ';W8!;A;7)
MM9>8%^J=8QJOJ+0CM0A;MM(D _D]J2UB;V'.[ <[932WJ ZILS/)S!TWD5,L
M[]%T9?$@2=:_V/8C7C5:'&VB81JLS,RMV1OR<@]NKJ:1AJ@UET:\>+D7T2%C
MK_!;, 1U@H7$MCVT@.LJ"P 301I NQ&H$ Z;?X3VI8'U)#A#'<&T=B@8V)U:
M[ZB;*#IL2 UROF.[USA"(F'#H@9Y#(9IE]4X-S2&-,9P;&3FXN&@1>+'37?T
M*0;$K]EM!7,^ZO2D:O)M8UPVDDF\$G:#3<8BWV'18,VLOJ(!)L.IP;HO:Z.0
M)OZK%UJ@Q D_9M9.D:0H )"B_=0C2S<]=K@<^UQD%B);(:U>E/&*WF4'2=A>
M)UL]I+2T[BYK/4(LZ3BVHXZ=.Z0C*>'3SR# E?5!(]:0@5Y))*<5E"!ADT:A
MH((MVVG7I#7/)=8#VTZ2=0]46MVML98RY4ZP1S[75IU%;#FP0E0;WL!_)M?G
M?$J:QXR8:88PMWR[2T=V^)259C/NJ]<ZH]<6*CNEGKTE:=S1FAFJD;9XQ QT
M'#-^VYS5O,%:+RE>55.ZC^F:.)6*E?HF[7;I]A,]-=)2I5Y?71I29DBQQFL2
MF$@<2T4S69)(GL[0&18:H*$ETNL,T/PW?[N=CWR;&C*(,QERW/,HGDS/()GJ
M)URN6O,)B:FS6DC+1RP5$1:&.M$,E7EKN9J;7#)5TE7<NSC;#'[4<-Q^.D)]
M]9)U^]4L=OE573LT0I97[5J@\2KD6X/T,7#M4VJ#5 2H)/),4!D)+@NL5NUA
M[P-LYMN=H)LW>EBHZ:.,4E! J1BH6CB=VC:LG0:IZAR[.UV:.'5PH>T74^TW
M);J:;=!L33;,QYC49I7U$[YGG-6\TYHGS2HBBCG3+*21M%)11)%'%'IC2>J*
M&IJOLD@CBMRO;49NM5/*%8#+=CM;/(5S=71^PLD?"Q+2U/I"EX^KTD:]35#B
MZI<DY5Y-4V0L",W0['3P0>S9#2T78F#1:&?<BU2&:-N$JE%T@J2=(#NPT!RR
M@ .%*NK\EY%2;CZJ*<JLB\0L';400!J)1%.LH%:Y*ZKH5YGF".6*Y-;<K+9X
MO%S"Q9*FWXT7PJ:5*::N)AF$I?+V,+T$4M)FL@3,VWA\>TZTXB:S5J>2\_+U
M^W/GDV\<*RE@;REJSJID(C7M[6[5.1$4B7 TV6[NLA"V *@ <E(J8681@R$Z
M;WYMSO(C6OJN;(K1@L22&N3>][&KFTJ\,W=9;VC+DC8X*&CJ['V)-20NJ<E?
MVL4CC5/P=9#'M9FA&$(%%GVL-T*:QI1CD2PEG4COE)U_;,C5*G45B"EBQ%@E
MD)U\QVH))U@F_44&GE8)8*9NUU2%@ H;U0+@:.1[:UAH8#OAS?G?5;%3V16F
MN-K&[/E10;C+Q5>8(75@I<H^7=/DF%L)<YN=6C[;'OWTE97MN<$!RG*)R#5L
MP3>MI)I)OEED+FJU:PX?:!F.DZ2!<KI NI "Z;VZC>Q%ABBTK*#]D[8JHU#4
M"39M9)!!)8MUWO[H.+\F]L=\GL5TB@2F1&<JZKR=[:2AY1*63C%B6NV-;!7I
MENA6G-7:O9_'\,S6J$*@I#Q55>1L]-*$K<.P!I!%QB=!([A"NK1:UB>U0JPN
MVHA7)UGF6! &ICVV+S"YC5"X-M0-P;=LP*GM=(+(!I')5()[4<ABBCM9RN\:
MM#3680DG]?I2=-KX$5MB+1R+9IB."7LLPB\G9..7LMBK="NS9XZD86Q1L0[R
M5(%7B;4P;3#2T7=(CY@1V#/K;U-Q_&$*+ '2K.AL"I(C'-38K;P)#UR7(4*O
M-K<A&-1N?5$*W<8 N;AK'5;]6V;9'JYRKJY79V4RKM63LD?))VF+C\B+=G,*
M5./BK@I$3B;DL;"QF(UGL6LRZ0R;JP>"UV*\$VD&4U5JI&_W,KW%(*DIVTK$
MK=;7)EYW[UQ8D$46F=>9DU7-V!# /VL2C58_R1'RL.[;J'.>L&X(LN)G+)[/
MY+F[_)'KDO#6>5F'4\JXM,BI/,)"O3KIM*STRW9.8:,2E8\4FYCF44F':PN#
MB=4RN&659+Z8U0:@5 MVH"D,O)1<$V/WARQFBB:.UW+]J022Q+&X()!) (%_
MA//&3&L&,V&F&,!+-R=V,K39)^S.\Y[SXYU8IJ4G',?![N,T1,(Q7EGR[]9G
M#Q3>R=7C(MJHN9"/CVX @R:$1;(@"210">N82*JJ*>B(50H+4D)8V%KL2MR3
MUDGK//$)J&-F9C-5@L22!53 "YO8 -8 =P#J'+$VX"VR5/;PI9U*SD'.UY-:
MR1)'A<S9JON648P(<T@9$U?;W&6D&\&H[&14"268))+/RMV)'"AB-$BA@GJ6
MJ-.J."/3>W!ACBO>WJB@!:UN5^0YVZ\9H:=8-6EYGU6OQ9I);6OZD.2%O?G;
MF>5^K$4V/9^$S5Y9"NY#>-;?+7C+4HK9)49*SPT35<G9(M%]F*A 5&5F'U7B
MA8V%W4GLJX"*77EY&AM"HFKTBK'3->O6JLPN@TA(ETBRDM&BH'9@ S7&H 7
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ML,UDI=)57 8Z2&);M>3W!-B"+!3>P-R+JERBQ%:IN"RFPU @!>?J+&W(CF2
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M6P2PB*UG#F]C86 )1'&DW.H6>UR%Y@VN,9XI3)>Z%!:XN>VL'=#J&D:3=;@
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K:88:88:88:88:88:88:88:88:88:88:88:88:88:88:88:88:88:88__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g796801g53h17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g796801g53h17.jpg
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MW&,_#G+(()!Y$'!'8173!R,CJ/,54\BE.*4XI3BE.*4XI3BE.*4XI3BE.*5
M?4W^ALY_2;6']Z=+Y9/G#Z?N-5?YI^C[Q5OWSL+IMHDJK8W\W4ERR :]R*LY
M9Z',N:V 4> '"W_T9^)7#V \ C!LP,"69D.0F[%@S"!I;(N2D0U5JXSZ.O\
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M0!NP.9(&>KM-09$5&D+#8@+,P.[ 49/S<GJ] !)] K&F]\Z[71#&PG91Z&(
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M=3_E=H[YWWG\!>,)WF^J/Z]//_9^VGK[J?\ *[1WSOO/X"\83O-]4?UZ>?\
ML_;3U]U/^5VCOG?>?P%XPG>;ZH_KT\_]G[:>ONI_RNT=\[[S^ O&$[S?5']>
MGG_L_;3U]U/^5VCOG?>?P%XPG>;ZH_KT\_\ 9^VGK[J?\KM'?.^\_@+QA.\W
MU1_7IY_[/VT]?=3_ )7:.^=]Y_ 7C"=YOJC^O3S_ -G[:>ONI_RNT=\[[S^
MO&$[S?5']>GG_L_;3U]U/^5VCOG?>?P%XPG>;ZH_KT\_]G[:>ONI_P KM'?.
M^\_@+QA.\WU1_7IY_P"S]M/7W4_Y7:.^=]Y_ 7C"=YOJC^O3S_V?MIZ^ZG_*
M[1WSOO/X"\83O-]4?UZ>?^S]M/7W4_Y7:.^=]Y_ 7C"=YOJC^O3S_P!G[:>O
MNI_RNT=\[[S^ O&$[S?5']>GG_L_;3U]U/\ E=H[YWWG\!>,)WF^J/Z]//\
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MV+@T-F0;D.'6%YP".!T8L<-#$L\FW:H=9"YV# Y-NDMH@!R7+X7S>>4O,C
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M-&NX,.LH'R+>JPR(I/.V]'N!4.&#L",C+'"%MJ*YVD,,@/LR_4_6&#VV7HJ
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MS<D*G$F/.F,37LQE1LRG?1F7,+96E#65/84C&K'!TD;/O5=N[S2&R<*#R(!
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MDHC)E(RO.4NXPE.,=JV\I''%J1T7$FI. ,8NI([W/+T_+([C/TYKGS<)\.S
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MAF&4X=8QA]B*B5G,5/:[G#KN%<:>^N[HDW5U=7.?^/N9IN?:3([$UT([:"$
M0PPQ$>F.&-/L51BL;WC49)8?K\D2--SQM<VAI"0X#GURN362!M.VZ;#8L#1&
M2/<)!2,?,S+B,AI$1&4(7&[,1Y$A#FL,<^7H..OER-9L'ES]O(<_A4N0PEC8
M.ER4JZ3IP>='>:&5U84#'C@WG%L*;E1R,>"@G.6PEMY"&B#[[*\2%9=0M3;6
M4QRP.7/TGMISR>?L&.K\35LC5FY-5L@)?V44EG94QM^%:EUJJM2AD9"HF5P6
MA+(Q(B2VZEF2E3\J,Y(3Z8K*%IRPSW61GJY=F3]],''7S[<#[J]YU=MLF'7&
M(FPB0Z2*QC!R<W7JS(<M.<>C=[,IB2.<CBLY\)_&/5#<;&,2U_#.6F<H9'/E
MU]7,\OC3!Y<_;R'/X?QUU'NX@UA]#:,^V$WV>]L=4M>Q_J<'Z%X_UETQKTGU
MQZ'Z[[WC_P"M>%Z9X?B?P79X'\'R01U8YX;GS[#Z.JF#G.>79@??4A0:[;8T
M2QL2]A$B,DKC. 4UVO5F.Y5L]LGNYBL11S<<KG'C,8SZW;DXSB(CLPG+KV5Q
MD<N75U\SS^%,'GS]G+J^->$FLW)VMCQ+&RBD0[%F./S;4BM55V43C+5+RB"Z
M)>&*$1FVDO1DI?BQFY"O0TY6M67WN\R,YQR[,G[Z8.,9Y]N!]U7.8$L;YT.1
MBW2=!$0([+1.NMA0+\<X\VI]3DI\C(@K)P5OI<:0MH?(891B.G+2$*<<RID8
MZN?;D\OHI@Y'/EV8'/Z:BS<8.R1M6;ZG3+K.(C"&J]BI$A'0H",Q7UN5@JMI
MV/.BP6YY#,=&,M(22??0XG.5/86OL5B01E>6#D<^?/G_ !_93!Y\_9R'+XU-
M(."2'"H<(N:?L1%A+F))F3"@#GYREO..(6N&,8C06/":6B.E,=E&%(:2XOO.
MK6M53[,4&?2<^OJJ[<5-<L?I:/T$Z_\ ZVA_['7'F:#YY_=/WBJ/U#V_@:CT
MB8S"ZJFJ;="90WDAL?8:+G5(O50 $BKR;.[/"V#IHA&J+.N4:2-;H.JYDP;]
M549H"[=GIP%PM6;G#9&NM]$#^]2Z*%Q'$4<VK$HJQ,MR5D"\]\H!Z3S@GG89
M#7-+ 7.QF9LR2!T%PH5V:16@!0N#YD1QT0"[N65< 8V/Z]")(,"US/<=B&*Y
M*L%D$$:3*UIKRYH)>G:[NS!HV]8=A;"U[%JL 53W[$@JH)/F&YXIZ<UB)D'@
M^^Q@L &:4<U8*K!Q+*F,21[5VQ1R%R7V[=V%!P2<[:SWI*B,\BNY@4,<;C^;
M?<VYY(]H"9SM))&1C&ZMC>F7,+Z@M4H@-RF6&:@/CKC38E=@S8DR-EV.1A38
MU2D3:TB7"(-2HDE88D8A//LN/MG#F7%%YNM<YZ>7/I<GK8Y!Y@@OAL$8(R <
M'J'4-BW_ )F,<^2@8.W((ZP=I*Y!Y'!(Y<B>LSIS!6:K>6+"@ HF=.DQX4(%
M'S2QDR6F1APH2*&QG9A$F3(3'&8D ? B,O2ILR4\U&BQFG'WW$-(4K$@%B%4
M%F8@*H!)))P  .9)/( <R:@D*"S$!0"220  !DDD\@ .9)Y 5X5^P ;8"#VB
MK&Q-EK5A&0C0"P@",,P$-AR4=N6.*B"H]Z1!)#9\1UJ3#G0WWHTJ.XV\RZMM
M:59,K(S*ZE64E65@596!P0P.""#R((R#UT5E=0RD,K ,K*00P(R"".1!',$5
MH>;Z@.EZ(/V39B>G,23>O]Z$^GN6*72*8[:+47N^Q0YBT6>M*>(81-H16VU@
MK?K+/GSH$V?.U19"\@3+.U^ U)WEM[DF)1-A9(1<!M[A4$:,J*V!RD"L(T !
M'ZY1D!CC2,]N!(QARR3& C8FYB\@+.O/YA=2[$D',3'!*C.<./=#DENR/(K&
MH2+KMF&SBD<;KQ@J5L-@>=O+(PK71HVNR2MR8D.JVBAHM4HQD5(PO9??E.(7
M;^VG]^@J-THPN!F3 51T?)B6 0C]5R?!&(N7)*N?D?G>;$?.!.(\EF._!4!2
M7S^LYID?SG/Y]9GKNX=)\DW5Z3J]W5V"460 L=-'U(# C#(Q->D0T>KR:Z2'
MC&@;)]73L3#, X(^:DU]4:VVH47V4B/)8I(MWM9Y>EP0RN78DXZ=BP8$[MOR
M@,22-O2]9WFKQM;95(^CSD,@50!NZ$;=I V[N@(P =W1=0V@XP&+U":D+R]O
M:U^JV'BH";/L&K[&9(']*1Q-BGS+#[.W.:8H<B^XMLL7;C1MQJ:0.U1ADWDG
MEZ=E>)[>7LA@E7H9>E(<K&\9"S%E 7<@#A-@**N0%?(QRZJH)XV,L71C:&D6
M3+0@,=VU\IOWX8GF60 YYGG66#=G](TJUF-I!)5!G7YK(R!,M0:H29]Y,Y.1
M"H:!D(H<!?LEMS,@4$Z$?G5UDOW(5#,B)TAN/4)\4;0QW>P1'I!'SPC. @VE
M6(;+!5YR*P#8R9%8#+@FPDM=QE7HR_++JF7.01D87<V0C+E<_,92?-(&!2+K
MTH5NO;GZB:SJ&D&ETBPB!AR\UZL:Y8(WY6YZ3K#8"[$#MQ2:-@O@;8$W4#78
MC1XR'8)92;D$E21Z6)<S)LNF:"!IG'2(2L;-(1'T,DL05D )W(T+;0JMCECG
MD"A:V599UB0[& +A8\OTRQON5R0-K"8;B2 ?.)Y<SC&O]B].1FJF];ZJZ81I
M:1LF;=JG;-4UD5H]^M6NL:_KU)Q;"YFT#+G,U;:M?A(&U:736HT"R&WX!^R+
MI:J\-?#6AD%:2.X5UDENBO1A'65C/O1I&?:H4H)5D)B=R2JY5=^X[DW41X&4
MQQVP/2%U>)1"5945=Q+!S$R#I$3 8X9BNT;6Q*R]LZC* ]D1+'ILT'+&W-/:
M[N&MK;4*JQ9[Z'W+"%5.E"R8G!2<+,56(0L%MHA;!,@X%'JI.PI$7,RJPV3)
M3%T4H:,K,K!>FD21'8JA@W.Y!(!#$*KK@;COC'SCM&7I8B),PL">AC>-E4,X
MEPJ C)!4%F0Y.T;7QE1DRGK#>%.VC:-E4VN0S,*;J\W@-)>*1HD>#8QS1>R5
M%VRU=<:=+>DU^-?*)L*AN.D&!LW)ZC&G&X*P[X<F3Q2P/$D;M@B49&,Y4X5]
MKY PQC>.3D2-LB\\Y R1S)(TB+D&,[>>/.&2NY>9)7>CIDX.4)QM*DT0:;H7
M9MY7< 0>H7'9=&@X:CG\UICVJ$1V<EXD6-!.%Q\1QG+*RQV) 4B<E$))LRAE
MV,P7(JD2?E$4>QF=(I#S7<=AZB25!/7A2>7/:.O P'0N^\!&D0<FVC<!S'(D
M>C<P'/EN.,9.8'D=1%#(B[[0B'3#L5W";7:QUCH2X6D",*W%!U;^L_9I=AT9
MM,A5#*@."09BSNS"K<V;>[0. M(F%8EI77L_R>0&-UN8_FH5?]<"@+='$,&(
M.-V"4PN BEL@%-V#IT(>-K=_G,&3]20Y Z24\I-IVY7=DY+,%&2&VS0/OG3;
MJBL:Z##BFO->U3<#Z7:(&9:&5L58E':S.M*IWJ[+<1F-%G A3RI$\@U'BKE+
M@BWGO6)"#$D83'<RM(2))'A'ZP\V*X<)C/7D,>0'/K(Y D9@]O$L8!2-93^K
M PH8LI;JZN8'7U9P.LBL?LP'IZH>Y-/PWM(B%;$NS_LG3KZ&UC S%J\?7VO;
MA: 0J7=L0([,#,&M4PV-J]<%2YI:.WC"F!,01E^:W96N)(9CTQZ-!O>-I#EN
MDD16(3//+."S$ >LMRJ&6!)8OU0Z1O-1Q'\T)&S ;\<O-0A5!SZL4T]8-=;C
MG;\932+ '6=*@Z]N+7]Y]B3P6::FZ^%BI+)B+5SEO%,6.?0,UFIWZG&BZ" J
M+7@L<A7(+,]LK8THDB$'GJ=H9H9$WJ0!(S#:75"5$FYT=1@EFPQQA8B9)3/Y
MC+N*K*C[&!)C .0C.-Q3:CJS9 505&<M+YW3VJ+.@6BR:WI)Y 0J>."4F*R(
M(X'E;2:Q9++-BXEQ'?"=L-@2V<-I3_!E"S$8A-0_*BQW6L*S2KG;(Z[@JG#$
M9"C:H.#_ $5\U>P$@<B:RM%$V-T:-M+$94'!8[F(R.6X\V[2 3U5?*E31%-9
M.H%YEOR++:3UP.$2#K3Y B8/2_%5F0^TQ'2N,)&LC:X$:RWWH-="!QN7'O0\
M/.0[E]N< *JHH'4%4>CF>LY9NUF)]-2B! V,G<S.Q/62QSZN0&%'8H ]%97R
ME7IQ2G%*<4IQ2H#ZF_T-G/Z3:P_O3I?+)\X?3]QJK_-/T?>*H][#>G(Q( C]
M^0JN0S[+[ )#HMG9(/#L4H(U6BVPIQM,9.1F*H&DQ*4;)2+)V!AEC&TXU'4Q
M8A8"7&K5QGT9^BJZ;FB*Z=[CG6RX;M/S0MC>@N1'9C[CA'T6Q8LBC#Q-2S#M
MG59O7&;>L^M5D7:?7&;(K)W)#/)7K'M'WU5NH^P_=4\(0AM"6VT);0G'8E"$
MX0A./Y$I3C&,8_X8QC'(J:QFZ5RO6RK&P-I!!K*"FPEKF!; +@F1,M<-29T-
M4D<18DPWU19L:-,C*=97EB5'8D-90\TVM*E8IHX2*!Z:U8-"C!X@<S0*H\U
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MX^?$>>BS(<IEV/*C.N,/MK:6I.9!*D,I*LI!5@2""#D$$<P0>8(Y@U! 8%6
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M4;5S=R&3=6IMB5/4?%3B9>YOYF.656)#9):?YS%"77]=^J;S,?JM@(9UQM8
M4%C$HPK,H!7D%AP54. K_JOUB^?G]9O.Y4;.Y23)NKNDW76I1>OA-<-72;&U
MO;ZK= 2S1  ^[))T_I>@=)8J*4R.K0QIX<YK<;'+S&8;4&2Y=,N$69<<&I-=
M1CENY)2Y94'2(T9VAA@/=&[)&6.#TI('6-G+&[SJRQVT<00*7(C=77)4\UMQ
M; '"C(Z,9/4=_/./-K*'NG;7[U6O56SZU;:V%=#=Y.FVO4B+$T2/6^-=9<"
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MXA/%#9T\0X\\)FS(,63+%NR$H2^Z.DO-+>A./):;2\N,MI3B6T87E6$)QA3
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M.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE<L?I:/T$Z_\
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M#,XDED=00&8D XR<^EL<MS?.8#D&)QRQ6:%#'$B,02J@'&<<O0N>>T=2YYX
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M&KK4XI7-;K3_ $@5;^AS7_WLOS^$O^ZF_P#QKX#_ /M;9?\ FSBNOTKY%?\
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MOZ9::_$FI7^A6BT;C!(I$GN;JX:2>V6Z==5O$,VP:D9KO3XX]7M7@C>66RS
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MI)&3M)M$<+4HI@G<K:Q;;48:RV/%Q E1'2IQ!#DJ*'=;5ZO:GEV'U\_[/C0
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M.OM,+?BK<B2$Q76YF9= X < CR@W,)](GX0U _;!?2XQZ>39]%8SJ?$ZD_\
MY8AD';'KEK]TMO'GQ%8;L[JL^D:J^MIQ4)T'D&[L!KY6<45$/TO9 <Y.C1,.
ML+ UZF[78LL!+'<??R+BYO)<KGP8 V(Y,4AN2/"_!^5>+RA6$\8>/>C:+J]I
M,8BZB4QB>(H9%C+LBLRAF4+D%L@-8U[YK\+W,;E6VL-0L9XP^T[ QCD#!"V
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MZ9PUQ#Q_PO8Z!I4&@:1K/"/ 4D^F<'Q+K,EGJ%SPCID^J+;Q:WKUH;[4WO\
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M?\WIM@G[EG;K_HQBM;J3T\]/0CK,WL:&::U/!/D="]/Q.5*C4>KMRW)]EO\
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M /3&M?\ E+B"O#>4K_@1K_\ B+7_ ,?:5TOZB@?4=*OU2(Z>]K"U/DLU(7?
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MSB>[@AN91G#S1JY\X9JTYZ&3N5/N8T9"0X_.:(J=:P%9>9E,X+)1F&\T30[
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M;5(=).G3:U)IWYMAU5WU6"Q^2_)H=5=M3BB2^8W!Q'B7R8&W%M\LTL0BX-T
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MVKK"CV\.+8='"RV\ ,:X4]#%D9C7%]]W7=.?ST(E_P X'^\></\ N)ORIO\
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M[I_\A$O^<#_>7']Q-^5+_@?UW_*?#7^VZ?RB\%_\O6W_ &-Y_P"FI[NNZ?\
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M%?ZB^L.=55OVVF.5XX9*4"'): :FVH5?UY8C@':A>XU4O,):W;@MUP'.J=-
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M0V^"U)/DR10A !19!(5E@@ADB!9B)2S,>; +"ACW,J]"RR, 9&*],A(  !;
M;#---'(=J@QA5 Y*296WX5F,JL@)Z, ]&X!))(',5FC]L$=B^WUENM$S<;OI
MEX,+KEB$Z:.ZPN4J!L.D5*T6.O JEM(W+LX"0@CEMHAARPCQ]A"1:W-RW+0S
M&)D8GB$>Q4DV1S%BRF82H#&[HK,\2A&&.HA25.\<NH3#(9-[.F]XL!6$31N1
M(BLRJDAWKSZ^8# *>=>\_J2N)[I;H.ZZK0256O&RI&E((&D6B!$.S%R=I6.E
M022 4:/9:Q ..10=B,2ZQ)/V*DC)DL;&E6>37A?IN60MD6ZD@:0,D73%I%)
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M(((ZP1S!K0XYU&].<(?LL\3TA"DV*@[Y(: ]2NT^DNV&WOW388\G:;J"??\
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M(\C2;5"-B1')BDDR2HVJ'#$LH:L<D#(8X;=&$AD5D3HNB=45 [%@2CI^L1,
M$[B5*@*Q$N.[>UM/%;%&6C24T+9#C^F:%:-96JNTYRP;!"[IB#ZE4H9^+$EE
M@QRK#")"]TDZF=/*AH$#7U\FQ%3*LRS-FX>AD!C*SAE FD21&<+&826?:2%*
MNP6-U  8F2,'#G R]+&1)NA*LQBC9&5-T@E 50V"0R@LZ'.0 CD97F90U9O.
MJ[2M6RZ:"&%1DG6AGU8U((M0VH-J",&[/2G[/6\19+SF0L78.O\ 8=*RB8U$
MEYEU!TFW'R',!9DS'+ \21.Q!$JYY$DJV%?:V?Z71R1ORR,.!G(8#)',LC2(
MH(,9QSP R[F3<O[/2)(G/!\S.-I4FF#+T-M&[RK2Q2PIJ^U,:J Y;K1JDL(-
MCA64EAV8<"TV^J#7)$1#)8[&PP-(OMM0C!=*4HB%9F9(]/%&$WL(W.=BR@J3
MR.2B.>?)3S YJ/2HQ Z"1RVP%T&-S1$,!S& SJ,CFPY$\B?03G2H;U<]+83I
MZP='Z4H@?4ER*,(DT&.1TC!KTQDCK(OM!EVYA5&X]9$G352IK8VLUL_CUK9#
MJ0@:!A(^)))"]TVETUQCIY&E1<](1/N $HB\Q@I<J&?+LO)5))R2 =47-NL&
M1$@C8\TS%@YC,@W D+N*IA0>;-@# !(VGMI[I(U/5J5J^[C=-:WJ&VS#> .M
M["%I=1!$BS8V1;O6).I368 Z(Y">KL?Q"TN%CT.S-@X/I+9>0-0K507<K/*A
MFD>%?.D5G=E7.S <$DYW'D#S7<<8!K8=K6-4C<1(DI\U"$52<;LE3@#&T<R.
M3;1UXJYWQ_7%4LG3[I^/1#H>,1O/I&NB=&K\('3Z 8I-(O5V;&XFH9C#(N+3
M5*K<JE(KP&),FR:^:,,SD"(9&+.?B,2.MQ,9%.$Q()&+/('>./..9.QG1PS$
M ,HQN((J9-BM#$$89?*,B@+&41W R>7G*KIM )VD@[<@G&>GQ>D;DO8XJJ:%
MI^L2]0GKIUY 10&MI&$*N=;KYLI53TJB22P9!ML2R!&7FFS);KPB2.'0WDSP
MZ@I&9:X$R=&7G>57&]&+2 '8S*&42!6VYRR. ,@D\FW 5@Z%]X6%8V4['7$9
MQO525)0D9QM#H>:X P5()F8-I76=:(5275JB#J<&ES[$<!5VKB!-?K;-GLH=
MFMS+:^*%P(R'[+&K.2E;@$LN)RR$/F83K4C#T1<+"TTC!@SLQ<*I9B6;8IW!
M 2>2EL,1CYR@\N><RPQJ5*J%"%BJJ %W,-I; 'S@N5!["1V8E/F*LE.*4XI3
MBE.*4XI4!]3?Z&SG])M8?WITOED^</I^XU5_FGZ/O%8=O#;.EZC=P=-V3K9%
MQL5A!B0E6?GA-;RT6.1LNTJID#6U9=O5E!S3A>PEH3#EB#B(TH&$">A6&\D
M@+*"":U<9]'MY9]'I^BLZ+6ZNW#I\B7NMH6-J5HU_6[4#:F1V!:Q]=-0!94<
MS,B-N+C#EQ!LEIN3%0ZIB)EMQE+BFV\*RJ#Z<XY>'+TU-[+S4AIJ1'=;?8?;
M0\R\RM+K3S3J<+;=:<1E2'&W$*2M"T*RE:<X4G.<9QGBE:P=:4&%+Z7]TR,@
M+,?LPS75UF:Y11ZQ;K5?16RWZF;$THO1XM"&E+D-LL<P3:CPSE?9CRAL>7+<
MDS8HU<YSBI&?1_'M]7MY5L!4(-<&U:OPZ@'8K]8;$P5@@L<&_66QHV0PB1%B
MYKTN$.F!7D-NX](&S8$.=$D9=9FQF92'FTJBLCXI3BE.*4XI3BE.*4XI6O/2
M+_W4.F'_ -O.EO[MJUQ2MAN*4XI3BE:T]*,Y<W6MJPZ(M(1YKJ"ZI)7H=NIU
MKI)!Z!8NH[:%O %(8VWA@<^<'-5JQ!BXLS"C/BYT:;C$:6X\Q):94K9;BE.*
M4XI6O6@O^L-__P#N%N7[,TCBE3B6"!3\54$Z(%FH2NWO0RT"(1BJ[<=F>]'F
M-/-9[<?#/:CXX^&?AS+#//;OTD$TL#CJ>&1XW'_60J?MJDD4<HVRQI(O=D17
M'@P(J K1T==*%S\15DZ<-*$)#W;XDY&MZI *+[WY^TJ-%PR7\?;CLE8[%?E8
M[,_'GH+7C/BVRP+;B36XU7JC.I7<D0QV0RRO%[GJKES:!HEQGI=)TYB>MA:0
M*Y_ZZ(K^]ZZA61]&1T=,ON3:IKZRZW)N*ROUEK?:NTJB\A?Y\*:AP+?D0A2<
M]F4JP-[<=F,9SE.,)QVU\J'&;*L=WJ-KJ42\NBU+2=*NU(](9WLQ,<^G,M<X
M\'</@EH+2:T<_P!.TO;V CV*LYC'U*YW]//T0=5UMU-[98@=3.^@@G7]2JCU
M!FZO,XUCL)@-LZ7:$R0MYV!$EGY5S2.ATF(A]Z"'J<,X1DH+D1>)8Z#AOI77
ME5U.\T[2-.NM X9O8-(B6-(]0TY[RWE:.W^2PR_)7G6.%XX"RX0F,NY<(@6-
M4UH>"[."ZOKN#4]7MY;^1F9K6Z6"5 THGD3IEB9W5Y<'+>>%7:68LS'H7_H^
M@*_][ZL>O"?C\V<3.J*UKQG'\F?"@-9^/_KCG/\ Y0[@?,X2X"CQW.%K4??*
M:V1PO'GSM<XF?M#:S-@^W" _;7[_ *.[7CG^][]ZQY_\>?3.IB]K[<_RY\-Q
MK^3D?RBZB/F</\&1X& $X9L!CV9!^%/T5M3\[5-?;][6+D_<17[_ *.33#G^
M][*ZH)_\OIG4=LM?>_E[?#+-?G_C[.S\_'\I&M#YFF<+1_N<-Z8.?;YT3<Z?
MHEIY^=>:RW[VK79^YQ6D&N?H?.E07U<[0A6&7LN\T>JZZUULVJTFPW<G$;'V
MC<EGWO7+.Z5MM94!NMBA#85 _P#W?BD3W;CVE.>TCMF=:#/B\\GE6XO-E8V4
M,^GVBZ?/+/;RV^FVQD7I(YXEBZ*X6>T6&"&XDB@2*UC*)LRS,BL*+P7H0N+F
MXDBN9FNHTCE26[F"$(T3E]T31S&25X4>4O,X8YPJAB#T2KOT>71+5^YZMZ:=
M7RO#[.[[1A7+AV]GYO$]K9)OQ>WL_*\7O][X][M[<\Y=SY1>.+K/2\3:HF>O
MY-.+/P^1I!CZ,5MQ<*\.PXV:19MC_C8S/X].TF?IS4\US1NE*?W/9'3^K:MX
M79X?LYK^IA/#[/ACN>K!$7N=F,8QCN]G9V?#G N==UN]S\LUG5;O/7\IU&[G
MS[>EF?/TUTX=-TZWQT%A90XZNAM8(\>S9&N*E!*4H2E"$I0A"<)0A.,)2E*<
M=F$I3C&,)3C&,8QC&,8QCX8YRB2223DGF2>LGM-;O5U5KW9?^]?I;_V\]3W]
MY/2+Q2MAN*4XI5','#R+?A$(,.<U\<>',BL2F^S/Y\=Q]"T_'^/X<NDDD9S'
M(\9[4=D/BI!JK(CC#JK#L90P\"#6@^]NECIQM'4ATO7:PZ4UR6LDBV7(20F3
M*P.7%,P .KKS9*^S80^&DA;$JO6"+',U^0='D)((DTF6)>AO=J\]*+7=;@AE
MMX-8U2&"=XI9H8K^ZCBEDA*M#)(BRA6>)D0QL060HI4@JN-5].T^1TEDL;.2
M2-72.1[6!G1) 1(J,R%E5PS!P" P9@00QSL"1Z2>E8OWO6?33H*<I7;VN2=/
M:^=>QG/Y\I>57O&0K_\ $A:5?\>;L?%W%</\UQ-Q!&!Z%UG40OTK\IVD>H@B
MM9M#T1_GZ/I;>LV%J3X]%FL"(_1_]%13O8D],VHVN]V]OJZJPP_9V_\ AR(]
M!RC_ .GL[/XN;\7E!XVBQLXGU<X_XVZ>;QZ;I,_36L_"_#S_ #M'L1^Y"L?_
M '>VL(E?1@="4IS+WN_!H+O\3H:W[( N)^/;^0L)<AZD?'\W<RGL_BYO)Y4N
M/4  XAF<#T36>FS@^CF)[*3/TYK6;@WAISDZ7&I[8Y[N+_N[A*TEZN_HB>ER
M>QKZW4B=LS6TJ1LG46LK+"%7DQ<8QVGW_:=<JDI$5W9K]TEUXV 8M)B;7R(F
M0@=Z3/DX/!#V$#5#-RS\K7&=F]W*+G3YI;RV2V>632[.%H^B:9H9XULH[2,S
MQ&XFVF9)HR'P\3A4VX9^"= G6!##<HEO,TRHMY<.K%Q&)(W^4/,PC<1)N$;1
MN"N5=<MG<8=]%_TFC!\$4P+VRX.&PXH^%$>WWN3+,>'"81&BQT);NC78VRPV
MAM&.WX)3C'-./RE\4Q(D<3Z1&D:+&@70=')"HH5?.>S9F.  2Q)/6<FL[\):
M-(S.ZWS,[,S$ZE?C+,<DX6X ',\@  /0*K/]&%T:.?[WK^ZS_P"7TS>6\U]O
M;^?M\/8S7Y_X^SLY;^5'C4?,U&SC_<T/0A]^FGJ]%5_0WA\_.M;AOWM2U(_=
M=BF?HN>AA7^UTK,D?Q?ZWMK=LSMQ_(KTK9#W>_\ J[>/Y4^.QU:VB_N:1H:?
MZ.FBGZ&<-_\ )S']Z^U%O]*[-:M=5WT4?1;[%U$_4* ?UO8&=P:)I<HW3KO9
M)$TI5-H[TUKKVV!2+5TFW <XTZ%L4J4,GQH,4P)*QXTB"1:BND84^8_*IQW'
M/\H_/A>402VX+V&F[528QL2$6S1"Z/$C1LP8H0RCS))%<W!G#;1F+\W!4,J2
MD+<W>2\891YQG+!2KLK*" PP3YR(5Z_TRH5S7M/JE!IPMH)4:/6@50JP6.X^
MZP(KE:%Q0H,6R[*=?DNM0!D*+$;<D/O/K0TE3SKCF5+S\_=WD=Y)&9Y)&9W=
MB2SNQ+,S$\RS$DDGF22:].JJJJJ@*J@*J@ !5 P  .0  P .0%9+RM37+'Z6
MC]!.O_ZVA_['7'F:#YY_=/WBJ/U#V_@:ZG<PU>G%*<4IQ2J,B.'EQ\X26@PR
M@HI#E#B8PC%8FCR(^:PN--@SH4E#L:7#EQG7(\J+(;<8D,.+:=0MM:DYD$@@
M@D$$$$'!!',$$<P0>8(ZJ@@$$$ @@@@C((/(@@\B".L5XA@PBNB1@"OBAH($
M%@1!08*&@Q1@D2+@,-Q8 T8-A-,0X$"%&::CQ(<5EJ/&8;;99;0VA*<&9F8L
MS%F8DLS$EF).223DDD\R3S)H % 50%4      #J  Y #T 5K$6Z-=/F3Y&R3
M'+;ZQ*R+3-G8:-14PWB%GV61VBV2S#4*6SZQK!BPW,+5)N4Y?%U:^W$2\N:X
M7Q-C[*WDRJ%&S V@>:<@+&(\9SG#!49AU%XT/(#!US:1%BQW9)8GSN1+2&0'
M&.M2SJI]"NX.2<C"(/T?>CA,!0L-)/B1[14-.'08M?U ] BC 46WPQU9,#B&
MJYH_8@1ENXR)"']L1;]8HY8%5+!#/1K  AE.7-_,QRP4G#9):8$EBA+ B4&-
MO, _5=&NUF4J58BJ"QA P,@9! "PD8&X!2#$0X&[_P"H';*JV=R@U*.L^E76
M>J1E"$UB7:G8FN;75[A7L%2D"4XHG4>FF#TIB&""V!$3$F!C6(Z-(DM-ICOO
M6G"RN)+<)7JK&.6ZEE+E@F9$9&P".3W)NV(YG!Z4GU;>6,\ZR1VT<00*6Q&R
MLN2#S6W%L,X R.C _P"MS]59D_HVER*;<Z,MTU@/>KJ:OAIY,R)@BV:.VUFY
MS6H,G(_+; ])=A"&([L>0ZW"[65R'',X?Q3IGWH^%RB+&O(XVJFP9YYSCK.1
MS\*OT2[&3)P[LYYC.6;><<NK/TX]-12=Z,-6G1M7%N&+E%CU,/6 4%I2Z8>'
MDAE3=V$^,BV2MW&EV6I65G+^RCDQ<<V FQ8I4?63PE@;8*\.*-Y%O)%+':AW
MLS'YZD%^CSM9'5U_FU'FL#@LI)5B*QM:QD*-S@*%4#S&!";\!E=&5OYP_.!&
M0K##*#5VKO21KBI:<.Z2KAN[#*V<SK1S!E)$#+LPF3J:A:HUU398M\A6I813
MT8)IJGRIK94$4B3RF2S[T;T2:W!C&NY'F69EC++T@VX8*1+)-*X.'#?.F?&&
M! P/1DRMM&D1B4N%/1G.5+ Q)$B$97'(1)G*D$Y[<5^1.E8$/*R;D.VCM4?M
MF?8#9XIN**O6:;D4;L56HU.,U^:"<UDYJQ5=G ]8Z\2[ 8URP]ZSIX8YB7@T
MB5/E#=,0$,41B50JPGI=@VO(X8-TO2[@TLG,R'S7*XQ@"!:J"7$DHE+,QE!C
MWG<J(008S'@K&G(1CFH(YY-9+&Z;Z%%L^K[C@C<I5DU17"=?"%B=C=,3#S\\
M:7%P[+<Y!6--?LMDKS%HN[E<DRW4#A;]ZM*T"W4RX38^AN)"LJ80+*P9@%VA
M>8)5 I 56*IN &3T:<^1S;Y.@:-\ONB4@$MG<2" SY!W,NY]I/(;VY<QBDUE
MTL::TZ<J-DUQ6F*L=K%#):]*%A40-");'%DY%:GOF-I3X@EB;=[:T6K+1J+9
MR4C!5DH<M<C#ZD68NU)F6ZFF#K(Q<,XD )8B,C< L0)PB8;;L VX5!CS5PCM
MHHBK1KM*H4) 4&0,5):0@9=LKG<3G+-WC4CU;4FKJ+*,SZ/KVFTLC865,'"5
M1KHJM$BC:G''NR:1"Q84UY:7WG)#;BG\N-2%J?;6AW/?YC>:60*'D=POS0[%
M@/1R#$CJ&/95UBC3)1%4D8)4!21[1@U!4OH^JI A[2$-H[?(W](*)3F]D$B5
M )VW%!A!+,#8H[[9'74JKD1F6[C9"$@^6K4^_3"I65,EW%_"_"YG%XX!41Q"
M,MTG1@2!!(2I+C$FX'S%&T,(P  $%83:J2&,LI<*$#DQEM@5EV',94@[V))4
MN2<[JD6T:*@'8^KH &_7K7XS4/HBZ@.JT;7)9E$@?6Y]/@2Y\O8VO;X5?DQ:
MN6+!4KC$(:7XY.3(EHD$$19D;&DY4REHXY#-D.7Z0<BP<@".1!@L W,'F!C
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MMEF+4F3:*761^V]8F^I#5VSA= KUCJEPE7<J=L&H*A;]5-(VZ"JE=H\"[%A
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(*4XI3BE?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g796801g56d66.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g796801g56d66.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2($4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (>B^AH X0DE-!"4      !                      .$))300Z
M  $9    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
M     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y"
M:71B;V]L      MP<FEN=&5R3F%M951%6%0    ; $( <@!O '0 : !E '(
M( !- $8 0P M $P ,@ W #4 , !$ %< ( !S &4 <@!I &4 <P      #W!R
M:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M    "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O
M9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN
M=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M    4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L
M<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M     $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M     $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
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M8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M.$))30/M       0 [_^-0 "  $#O_XU  (  3A"24T$)@      #@
M       _@   .$))300-       $    'CA"24T$&0      !    !XX0DE-
M _,       D           $ .$))32<0       *  $          3A"24T#
M]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M     0!:    !@       0 U     0 M    !@       3A"24T#^
M<   _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H   X0DE-! @      !     !   "0
M D      .$))300>       $     #A"24T$&@     #-0    8
M     CL   9.          $                          0
M   &3@   CL                      0                         0
M     0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T
M,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M
M;&]N9P   CL     4F=H=&QO;F<   9.    !G-L:6-E<U9L3',    !3V)J
M8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R
M;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@
M  UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   ([     %)G
M:'1L;VYG   &3@    -U<FQ415A4     0       &YU;&Q415A4     0
M     $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L
M;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R
M>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV
M97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M"V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M  QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
M #A"24T$*       #     (_\        #A"24T$$0       0$ .$))3004
M       $    !CA"24T$#      7N@    $   "@    .0   >   &K@   7
MG@ 8  '_V/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN=')21T(@
M6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M   !  #VU@ !     -,M2% @(
M                            $6-P<G0   %0    ,V1E<V,   &$
M;'=T<'0   'P    %&)K<'0   ($    %')865H   (8    %&=865H   (L
M    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$    B'9U960
M  -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,   0,    )'1E
M8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)44D,   0\   (
M#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#
M;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0
M    $G-21T(@245#-C$Y-C8M,BXQ
M                                  !865H@        \U$  0    $6
MS%A96B                      6%E:(        &^B   X]0   Y!865H@
M        8ID  +>%   8VEA96B         DH   #X0  +;/9&5S8P
M   6245#(&AT=' Z+R]W=W<N:65C+F-H               6245#(&AT=' Z
M+R]W=W<N:65C+F-H
M                 &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L
M="!21T(@8V]L;W5R('-P86-E("T@<U)'0@              +DE%0R V,3DV
M-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M                  !D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#
M;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F97)E;F-E
M(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                    =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #
M7)X    !6%E:(       3 E6 %    !7'^=M96%S          $
M               "CP    )S:6<@     $-25"!C=7)V        !      %
M  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &, : !M '(
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M6 5G!7<%A@66!:8%M07%!=4%Y07V!@8&%@8G!C<&2 99!FH&>P:,!IT&KP;
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M,W\SN#/Q-"LT932>--@U$S5--8<UPC7]-@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M2%-B9&=T>(.'L?#_Q  = 0$  04! 0$              P$"! 4&!P@)_\0
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M%*<4IQ2H\TFKLGVZ8O%0AFZR06(RS//CF(H<55%.D8-;:",:8:<TTUT4_P!
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M3SSB(A @@Q8GSDEEE3OC@&&&A8^:>>:1D4,3'R2/:QJJD0!)  )). !R23V
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M#7-*W,=R]0V(D$::"IA0U;:*,.I]V6O;//X[G=>ZFTOIV.%;Y+EC.\ICL;?
MO+25-OBO%+(0BVL@8##$ELG"EXRYXKK'KO2^C4M6O5FO;Z^4M;06B12)=6D9
M"FXNQ++"D'A.5C1@6DDD!$4;1K-X/W@NR.G>X<-9VM^9VG<8VZU=='VP+0,%
M-]:OK5[]L:"&WDRV>KL%<.L>O>B.O:"/XH5+DKVD!2HI$I?FJ+/T]T_59&AZ
MW9=0P+?:>B++ 3"([E%6+2HP<C>S;UDEGR"L@+ARQ/,@*QY'2_4^A]8V)U*S
MBE$EM,8;N"ZBB&JBZ=!(J*T+R*MJR>>.2"78X1HV\-XIHQ.T'SF@L<*>#MLC
MOM%V!G9,9T1W[N@H']4^M'K!KRTL?2%ZP*KZ;*%3]W4#8K*LSNA+HW7I9]=;
M65;61W+-_@C]T<('!1XQ&P>XMT/WVSEXQ>6ASEH6)!8!MH#*"=NQQUOTBA#H
MY="D,S@>%=1<YMKKC E R%;&202!G?&=YH,2P APJ**"L(H\2A!.]X0:QPL8
MHHC_ )<3WBCJGPAW?*C>Z)C%^7A\_#;HSW/)//<]S\SWY^TUMQV' ''8=A\A
MVX^P5'O:TD:4&?&=]Y#>S.IHX&)[5<^0/LK+6\GM:Y4]WPQJTB9_M\N;%%)(
MB>&*J21#S-\HI3_^4X_I) JR0\+\Y(Q_GJ?ZA^2NMW1TMUUZ@.OK?K+M&B2^
MRUPX<AT49$X)]=8A/66OMZFP&<P@"S!E5SH)XW*R2-\PA<)())0LVOOK&UU&
MVDM+R(2P28W+DJ0P.596!!5E/((/R.02#J=?Z?TOJ;3)M)U>W]XM)BCC:[13
M0S1DF*XMY4(:.:(D[6&592T<BR1/)&T&>F'T)]!^DRQO;[K.NT-EJM $M29K
M-E;CW-Y!2.)A-?25R@UM/65]?,6,*06HU:PPZ003YXLA@@S(M=I/3VF:*9'L
MXY#+(NQIIG\23P\[MBX"JJYP3M4%B!N)P*Y_I+V=].]&S7%UIB7=Q?7$1MWO
M=0FCFN$MBZ2-;PB&"VABB>2.-Y"L/B2&.,22.L:!<R.;RNZIQ2G%*AGN+T\=
M)>H"L%J>X^M<SO!@%>M<1;"20V]6DO\ OS:J_K9@;VKCG^RSQ@6(\<[FL=,U
MZQL5N1!=7%L2T$KQD]PIRI^M2"I(]"02/2NLZ5ZZZOZ(N);GI77]0T9YP/>(
M[:17M;C;]$W-E<)-9W#)V1YH'9 6"$!F!QA_BL/03]_]P '[_P#X@=K_ /5_
MM[^W^3F7]V=2_9)_DH?]G7H7Z8[VT?MVF_F7IO\ N:OG^*N]!']  ?\ K"[9
M_KYQ]V-2_9)_DX?]G5?TQ_MI_;M+_,?3/]RU\N_"L]!#D\?P!"M^_GRWL/ME
M%_S_ )\7[<?=C4OV2?Y.'_9U4?FD/;2#G\^LA^O0NF2/R'1:X_XJCT$?T"P_
MZQ>V?Z]\?=G4OV2?Y*'_ &=7?IDO;3^W1OYAZ8_N6OA_X4OH(>J?[A#&^//V
M9V/VRU%\_P _^WM?T_=RHUG4A_[3GZXH3_\ ZZN'YI3VTKG_ .^><X[]/]+G
MMGMG1?RU!G??X6WI3RV1#WW6?195L5U_<0:?6]?B[CLHTGLG!C#D0:K-54I.
MQD.!U E=._19*2L*%=87],'1G).!:SM9DVVL7LDGA37 42C8DOA1#PI2049@
M$P4+ (X(X5BP(*UV/17YHSVDZEJDNB=0]8Q6L>MVDFGZ7KDFC=/0Q]/ZU(Z/
MINH7*1Z2D$^G2W""QU-+F.4065W+>0[)[9"9+RWX8WX=&ZS5#L\KU%'<YK45
M(%Y1VH'9_;+Q#ZNR&C*#)A5-UY1)(9&J]CT;)')[XY6MD:]J0OJ^J1NT;S;7
M1BK PP9!!P1^I_D/J.>:Y_4OS0WMWT;4+W2=2ZH-I?Z=<SV=Y;3=-]+"6&XM
MY&CEC;.B\X=3A@2K+AD)4@U7OXIOT$?T(3_ZS>V_Z]<M^[6I?L@?R,/^SK"_
M3,>VK]N$?^3G2O\ <E<?\4QZ"?Z%"_\ 6=VQ_7?C[M:E^R!_(P_[.GZ9CVT_
MMOC_ ,G>F/[FK\7\)?T$JGA.E3$_PIV=VOY3_/ME3_.G'W:U+]D#^1A_V=5_
M3,>VG.?SW1?5^=WIC'_<^?Z:^?XI7T%?T,'?ZS>U/ZY\?=K4OV0/Y&'_ &=5
M_3,^VC]MD/\ D]TU_=%2EU/^'MZ/>E-,)LL#TM2C:BNE:15W.AN-/LR*DEGA
M8BZF'7W=V%6G0N3WP6 0L!\#E58B6<AFU.^N$,<MPQ0C#*JI&&'P;PU4D'U!
M)!]17.]2^W'VI]6Z?+I.M=6W<FG7"F.YM;&TT[24N8V^E%<OI5G9S7$+CRO!
M+(\#CAHSSG1G^+[^,AO*_NK/?AG_ (?%U"1ZDNR=?GNL.Q.X:J2,MO5MOK[$
M:H;C,;/&DT+-T-&:A&IT:LE9A1$E&";^9XR",]?:VRC;)-W(WHA 8*@!)E<'
M@\#*(?I<,P*D!O&IYB0R1G@>5F!P6;.T1HP[>;RNX(VG*@@@E=RG4W053T5U
MQUQC^JK<NAT?6F0K,L+LCFSV\^W05[K"ZE[,$F+@EV<6JT)-QHK<@LZ"] N;
M^\MLW=TEI9&&3W2/XK,9!N5CG;G!7C *-CRL% &<$,%&]6  J-$,87P_*R@C
M<!Y6]2&7@,"V20""N6*%3S5_Z+L<CN",;JR>F.S1 D3#>\:<ALI0D=2DCXJ;
M'U%R^$,;09SLLN HU;D426(W"4NBS6AJ\[I+B4"GACA$3&3(8 XA.,9;@ER,
MG:T8(&TGZ;*ZEE&6DDF\0>%@H>\RGD8]$!(&Y)#GS $%0RL%8D+4'T\W9VGG
MZ[%EE'Q]) (7VC9A3/AF(@/B2>IZT!,&EBE L-$"YMKJYXG)85&*F!%@@$(W
M=%?U57?PDW\;VR(P?3'!D(]0I\JYX+Y/.QE)4,C&/\ 8,A'?UVQ@^A(Y8XRJ
M'  WJPRP%%&"&'##'@$#$@B&%%%BC'&&&@C;% ./!$UD4,$,36QQ11L;''&U
MK&-1J(B8!))))R3R2>Y/Q-9H  P!@#@ =@/A7/Q2G%*<4IQ2G%*_%\^%\>//
MA?'G]//[O/C[^/Y^*59%C#F;PX0'2@0U]_"KF5)#R9:ZS=Y]DLSLOHPI0;%6
MO1G@R&M*%-2#RRQ#B'(:V:4;U!9#N3\+@,H]/OB'*COQN!&>5)(XV\#ZA9PR
M36$SS63 &Y01K/;CNJ#4;"99H 1G,33QR0EQFWE=XR4H[L!94MC/>8W3F@FD
M.66PH[J(4_,WKD1W[=C&*,':06\K7)&[4Q&%7#_A!K;MO@PHZV09 PVNB\=F
M7(8?+DE2H_%P!WQM)S65]VH+N!+35-/AEBC&V&[M&D@O[,9'$#222V[VJX)&
MG-%':KND%J;*65IQ&MKCHMS+=P4K4QV_RQ?YHRCSV_&9G--;?'BU>?,8 Z%+
MKK?;()56=Z'&Y$L9[Q=+7NJ=G241V=E5_#",?,C91\<;E &QAGM(F64'L-FW
MS(S;H-<M&>TT^Y,B7!"/;P7\88"YMH5C-F;A6.]9XE,UA-"QS%'8PHA(CAN)
M([L/F=SFQ-+3TL8>XR\]R')EKZ6)C)#X%EI]WU5JI_@D"D9S6#0$T9I3Q;&H
M=[L[OZH.P(ILX6W(P!Y2V4;!#+^5)%&>&7(8#(;Z49(#,*Y7DX(7#+NRK9Y]
M'C;C!##C@%?HN,E5-3+Z=-L)K^O( H;(NUGQIGY8<=8M>VT+J&UX%SD"KCXB
MK([0/QMO00:SW?M#;$;15LJ-) (C9B7*%),X"[QOP.P))5]O[G>K%/W!4]B*
MRH'WQ]R=IVY/<C *EL_A;"N_X/N'I4\\@J:G%*<4IQ2G%*UZ^H[\,WTT>H_0
MF;6UKM#U[NK.5)[G3]='5]8Z_(1J-^9O:6VJ[FB+,D1/)-D)7@6QK_#C; A6
ML]O-:KTII&K2F>:.2"X8Y>:V81F0XQF5&5D8XQE@JN<#+$#%>9=4>R?I7J>Z
MDU!TN])U"=_$N;K2I(8A=/C!>XMKF"YM6D;O)-%%#/*WFEE<XK%G^([Z$_IA
M[D_[#?U3YI_T/M*X_P +ON/W4/QYY\('GG/V?"N1_0 Z?'_]0:__ !=+X_\
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MTQ1XQ(6BMEQF:50,/<E?-X,>?*K$%R2J@+N:L*5&DN,1!E?8%DG.<1QDDE(
M<J))/PF4>7 +<@ S+I?1]U#8=0Y/JC& %]9S=9&?F+J/?Y.9?SUUUO6_,3.W
M8=W8*23H+FY-*+(W$6EELQ.P8;"U#UT=I%9$*L*WDPF>5R)?%&V6-QY)(_Q"
MHP%"@#P]N#&0"N,5*UK$8EC0&,QG=%(OTT<9\^3G<22=X;(<%@V<FL$<UT[V
MM>=QZ6FJ.CF]+>H^W&F![M]7]) 3/U#'B[9@HEGV5Z8<U;&'T]7WMW=75E?7
M:^"2C&(PYV7G/V1^H8'GI==G--$L*EI_'MAS!:,<2[QDB*Y8 $P0$DIYL.&
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MX\<<36P5U0 DLK:NF!9$"$DQ!'LFL3K$\VC-NP,!5'T5'89[]^Y.!ECR<#T
M JJ[<\Y)[L>Y_P!0'H!P.?4DFY^6U=3BE.*4XI3BE1AU_P",\?I>NI4=&S.F
MNO,NLC_<A.*U)AI]>..GE60PY>Y;=Y$:OB^X%'3YZ>5L;+09'2R>8++^,-K_
M "=  2?B77:Y)[LS_ U&GE+1^BG<OS1B2 /WIW+CT4*?45)_(JDIQ2G%*<4I
MQ2G%*<4IQ2G%*<4J,<"Y=%:ZKL-7N>#HIPZ#*>8UC:_&Y.6QA#LV(J*V>/1:
M&RTE]6V,+W0V>7,S,R?[VU$ED\H2/U4%G_?O@X^6U0JD>CAA4:>8M)Z,=J?O
M%SS\PS%F!]5*U)W(JDIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*C#N+J^L[?P-O
MC#SBJ0Z60*XRNJK48ESB]I0E16N4V%)([Q\.SS]T,*=&SW-C,@817%>\(PF*
M2:WF:WE60 ,,%70_1DC<;71ODRDCY'!'(%=%TKU%<=+:W:ZM##'>0*LUKJ6F
MW!/NFK:3>QM;:GI5XHSNM[ZTDDA8X)B<QSQXEBC86YT'VA9]D9$T+8A"T?:W
M7EQ-A>V<T,Y_P*O8U@X\_P!3JTE1LLN7V%257:[)&JBM)H;D2-[_ )P8R**Z
MYA6)P8R6AE7Q('/=HR2-K>F^,@HX]&4\ $5G]:].6^@:G#-I4TEYTUKMHFL]
M,:A(!ON-*N))$]VN2N574=*N8Y]+U.'@QWEI(P4121,TY<QZXZG%*<4K^>7_
M &53Z@CNPO7AA^AQ3Y79OT^=/T*E5J2*L$>Z[1FDU]R<K$7V_&ER*8,=%5/<
MQL#_  OB14YM+==ENG_.L[GGN%/AJ"/D4<@Y/TOE6#*=TS_\V%C'UD"1B#\&
M#(#\TK,G^Q2,&+!@/6'VA+"GSMGL>K< $0K/VFBT=)J=#:0M?X\^R271U#W-
M1?NZ%JN:OM:O+Y#][0?%W)_@K'M__4W]-1K^J-SV1 ../,9,_P#Z1\>W;BO4
MWW&ADW66OJZXAPEEIZQF&JSHU<R0"SWIHN*K#XW)X<V0$^_&+8K?*H^!%3RJ
M>%CCQO4GLK!R/B$\Q'V@$5=)G8W(!(V*>1@MY!]N6';X'G@YD>&&(>*(<:-D
M \#(X1X8FM8R"*)J,BBB:GA&1QL:QC?:GAJ-:U/LB<LJ[Y=QQVQ]6!SP.PR.
M.P&1WK'0!$8N,L\6UR^_K777V,B@]SI& 43U$UN%JXI7_MR1U?7>JR ".>JO
M]P[FO<YS5<N/<C[YO_7%5\_%N4<^O>17-3VY^][?Q&*X^ .'0<]\(RBIQYCU
M/3BE.*4XI3BE.*4XI5J:,R[KVJ=75$]D.-$LDGTP[XMK^S^TYK: F$8*S'1$
M<LK8K6*U^&KFU8\Y;HXGR(%/!;!/H5P/EYQEE/P\NW.-W&2-E816DY\&>Y2!
MY&"K[Q#MM^>,F]C:26W?ML+6S6V[!N72(,PZS8I+P4#5Y@QE=8F!PNDB,@FD
MKK0=B/\ ]CKD3^YRH"!)7S1CGP? L*XEJMGB,#0FJ)9VDHX) )Q@X92<<J>0
M0<#(.01V(.&%Y9;22;3=0B,\$4C!6B=%GMW)4^/:R_?(WCE4*SP/OAGC.4:&
M4I<QQ=I#B::]KM ^G-SEU';UQMS3^]AF=V$C()::8[,W$,40A>P92%'U5;66
M;*"^TH*BP3U!,M/025\L8!#)N#*58!CD,G(8;QDX0L%+$;E4\[@"V>AL(8[J
MSGL1<Q7UJUK/%:W6&BOM+!=;M(=0M69I(M+-Y'#<W%Q;M>V5A+XLBW2+=7JS
MU?O]PB]0:'5(K)Q\.E'VA%/#X>^4# 7-=LK*(.9G[4:W%#4V50^6)[4E"LR(
M'N6">5KK8 1.J'@L3&<^A<%!G/XK$''Q KA;E"B2*ZE6B)+*00RM$V64CN#Y
M2K#X9!]:QX['F?G^Y_2AJVHSW,[AT771Z.1J*VI[#ZD[!55:]?NU5U&5R2>U
M//Q%5&?97>>9?#07*_\ -)(./5)H^_\  =S\N?G6%DK-;G_G&0\'@/%)\!ZL
MJ<YQSGXUGKS6UL:<4IQ2G%*P(]:_KXQ7HS3&5EGC;C?:W;1GV %'768U$$#1
MU<XXQ=E97!(=DZ.68DE(*T(:M)4IPYCB)P8X8G$<YK_4EMH(MUEADN)K@L4B
MC8)MC0@,[.0V.3A5"DL0>0!FO..O?:/9=#-86[Z?-J=[?K+,D$<ZVL,-M"Z1
MM+-<-%.P=W?;#$D#[_#E,CQ!4\3)3H#NW*>HOJ/']PXN"Q#H=>(9)'7V\<,5
MG5GU=D936]8:T>:<=\H-I7ECMG@FDA)A9$3$J,F:B;;3K^#4[*"^M]PBN%+*
M'&'4JQ1T8 D95U9<@D'&0<&NIZ9Z@L^J=$L=<L4FBM[U9?O,X430RP326T\,
MFQG1C'-%(H=&*NH5Q@-@3'S-K?4XI6*/3W_":]87_2'1'_=:WFLM?^$M5^JP
M_P"QDKA^G_\ CC[0/_>>FO\ N&+G_1]8-0UZT?Q$\-Z.M/DL0?AKSL#6:6IC
MTQ0-=;!T(%+F9+$RJA-FL"@[%Y=B8976+0JV$)D2QA2R&6 ?O&:1J]?ZHM="
MEMX)+>6YFG4R[(V5!'"&*[RS!LL2K;4 YVG++D9U'7?M.L>B;VRTXZ;/J=[<
MP+>2HEPEI%;V;S2P(YE:*=I)I)(9O#B6()B)C)-'N0-F9U#VEF.Z^L\7VMC5
M,_+>XI![JLCL8&#6(K9'20% 'P1RSPQG5QL!():03D#J0/(HY$\*QROWUG=P
MW]K!>6Y)AN(Q)&6&&P>X89.&4@JPR1D'!-=UH>L6G4&D6&LV/B"UU"W6>-)E
M"31DDI)#*JLRB6&57BDV.Z%T)1W0ACSVV@L[JP*R^*DC:8*]1M%JY(XB:W)J
M^-'J&)#(CX;G7/CDCD&J7M=7U$,C+31/]BUE'H<T*% =^QY5.07Y[Y_!3OYN
M['A0?,R[(L2=J=_PFXPOR'Q?X#L,Y;T5KEH,]69L%P5;')YG(E./-*F>596U
MB1[?F;*T.F5TYILZ,8Q997>V$>* ,6. (88:&UF+')^& !P !V 'H!_]3R2:
MN50HP/4DGU))[DD\D_\ EV JM\MJM.*4XI3BE.*4XI5@[BCLB%JM9F8&3ZW(
MO*FKQ%?!!^8:0]!_S%CIBIW1QCQWL081-?/+-"*'I:C/6)KW@A%#SR1L.4<X
M1\ G!.UA]%\#D[<D$#)*,P R14;J>'4>=<X[>93C<F3VW8!!R &"D\ YN3/:
M"KU-,%>TQ"D ',D]GOC? 2,2-/*(?76 DJ-G M:H^ FMMJTID1E99"% &PPE
M#31,M92K%6&"/M!]00>Q!&"".""""015RL'4,IR#]A!!P00>00000>000>15
M:Y;5U1R;VYUO6ZY<)8:^J"UB&5U>M.4Z>&5#[@6(VJ"4F2!H2%V(LT4H0RDI
M,3[VLB8Z3]CDH@F9/$$;%,,=P&1A3AC\< ]SCBHC-$'\,NH?(&T\<L,@9[9(
M/'/-4D3OGIXZ.ZE$[ H"(L^-\[:21S3.9&#]2BIW6 KO@>VSKV6D\($IU8I@
MD1,T44DS'2,\W&VG&W,3C<<#(]<;L'GRG'.&P<507$!W$2+A1D]^V<9''(SQ
MD9&:N&P[.P52;:5MCIZX.QIK3/TMC7S?'0Z&TU;?=G XQ$A4@J6Y;[E!42.=
MDR13^'I\O/\ #L$,K ,$)5@S ^A"?3.>PV^N<8JXS1 D%U!#*I![[G^@,>N[
MTQ5'A[MZH(K<Y<0;JCEK==86-5FR62S.2VL*EZQV0HT:0_&20)Z(D_Q8XVL]
M\:^Y6RQ*^[W>8%U,; Q@%P1]$$9!/U^E6B>$A6$BD.2J'/TB.X'U>M4>#U%]
M*D@?4Q]_5S ?-@ ,)C%MG,E,M(3B*\<=$KO>3(7!6G2Q) V1%8.]55/+/==[
MK<9QX39P3CCL,9/?TR,_75!=0$9$JD9 XSW.<#MZX.*DW-:?/[&E$T67M@[N
ME/\ CH+8@R?$@E>*1*(3$OE&OCF&*@F'(@E8R:">*2*5C'M5J0NCQL4=2K#&
M0>",C(_*#FI4=9%#(P93G!';@X/Y",&J]RVKJC#:G$Z*P9UI1$SP%6@C"]I;
MA32P39G&D/E@EC'+&?'.'I-8L)5/G7Q2CD@CQW6F'F6;/CB'RH H\1L$ X13
MSN<?+L53@MG@\+CS'$;DL?#7N1ER.-J'(X(Y#-R%QR.6_!P9'$$% %&!"'A$
M""'A$$$&C9".,*/&V$<>"&-&QQ0PQ,9'%&QK6,8UK6HB(B<B)))).2>23W)^
M)J0  8 P!P .P'PKL<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4K$;O,4KIS
M:U7JCSX\\E'6U@F.]0U,%%)*ZVZKC+G(K.PHA(&N4F^ZALS2+:>5(W$$X&QU
MH?NDE#J8HLZV(N(VLW/F)+VK$_1F(&8LGLLX 7' $@1O5L^H=&R1]5Z1<^SF
M^=%O+BXEU7H6ZE95]VZE:)$N-":5R!'9=46T*6R(6$<>MV^F3859KIFRR%*&
M.%&."(@+#,'A*$+&E9.,4,1&V: @>:-SHYH)HGLDBEC<YDD;FO8Y6JB\PB""
M00002"",$$<$$'D$'N*\RDCDADDAFC>*6)WCEBD5DDCD1BKQNC ,CHP*LK ,
MK @@$5S\I5E.*5_+G_L@E3E_%V]7?SWN]WU3JM!?=Y_^(_P']:_*^WW??V_#
M\>/'V\^53[>.;:/]1A^'AC'\9L_YV<_/-:]OU27X^(<_Q5QG[,8^6*]"7]BN
M_ _M/O4*L?CYK^V2F^/X1%=\#^#'!?+>?W^/>I/CS]OU\??SQ+]&/X9?\OES
M_HJBYWMC.<+VY..?].?_ "Q7I![,3_:Y6JOGS_"/TU[43QY]R=Q8)6_=5^_W
M\>?M^GGQ]_MR-/I?P)<_R3_[\\?;BKG'&3WWQC'?\-,XYR3M^6,U('[OM_D\
M>55?YO'V\^$5/*??PG[_ "O+:N]./J'<DX^' .,C/!P,=B<Y^>A_;]=[^]OG
MW?POT_QE7[^9?X".E?:OZ)]OEOEO'G]WC]WCD-SWA_Z$_P#;39_IS4MO_CO^
ME&><Y/A1<_DQCY8^LY#\Q:R*<4IQ2G%*<4IQ2J3#:Q2VIE*1&D!<(T9P['O:
M]EA6RN6!Y(_EK5<HI2*,? B/<(LP,DKDCL!5DNQA0P/&2#^Y(Y /UCD'UP?@
M:R6MV6VBNT;?$\C0R$ @P3J-ZQOR<"2,B2%R0)=DRJ-T$NVV ;JR$U4F*A!<
M?$*-%>R6I!4K(ZO-'_,BUHLTBP$2'W4]T#:"5XCE'B6BK9CC;-3AXQK.]E!0
M2DXR2F .6D7!8@9&%VLI)YP[ !<'(V$UK!+IRZJ\PA:61K-;=(U+7%_#X<D\
MBKO18;1+2:WEGE&]A>3I#%;^#(TEO4AV.+I3XV02DD17-^R(<:Q(JI/BI?6+
M8?>>-+&0+'\*1DL\D7Q)$@<YT(\[UC@?0\,O8#:G)4-^ N>",'Y#["1R:QW8
M1W<)9UC0VMD6>2!+E=ON<!;$,BLDC;E*J&VKO #.@#,MHNQ6VG^,Z79 ?3YX
M9&R8^PHY--GRTG;[9P[FTT%B1H;(=K%>V":M)ST:3*R<FN)@:ZODO,D?&(SN
M!_5 P1A\"JH H^W<?@1WK:#5M)38$TJ;QT8%=4AO!I]]$4.4EM+>Q@CLK=R0
M"ZSI?-MRB3HY$XM7L6%!/3?W%5VHC:]M3U?V=7F )826D(0*96Y)''@L9FQS
MEAQ51(S1)R81RGBI$I(PT_Q((ZKS<PL#NW21$$C;D[E!R!V.X'(!(^!(P:T^
MMLLLT]PDOCI=6_C"8P+;-*QC,<TDD"EHXI6GCE,J1L\8D+>')(FUV@?NE')8
M>G_X_L^=_MD^H?A^Y?NA'U(U#?9X^_N^1^>^W_H>[W?;W>,Q,%)CSCW>7M^]
MX^S./A^7BM#( 'A[?J\6.Q((?GMVXS]GVXS[YJZV-.*4XI3BE8G>J'T7]*>K
M@3-1]I!WXMKD9#$HM)D[6&HO!@;)P[[&JF>8!:UIM<7*(--\,RMGG$FB<^N(
M#4DSYC3ZOH6GZTL2WJ/NA),<L3^'(H8@LF2&4HQ4$AE.",J0<FN+ZNZ#T'K1
M;0ZLMW%<6/B+;W=C,D-PL4Q4RP.)8IX)8G9$<"2%I(V4F&2,22B2;^JNK<3T
MKU]F>L.NZGZ)C\D$\*H <1.9-_+E3GFEF&%/D(+.L+ LH\TF5ZNF*)E>B,8K
M8VY]I:6]C;16EK&(H(%V1H"3@9)))))+,Q+,2<DDFN@T71M/Z?TRTTC2X3!8
MV4;)"C.\CDO(\LLDDCDM)+--))+(Y/+NV JX46QW_P!^=>^FOK.W[4[+,.@S
MU80'7P!U(K#KJ[N+%[HZ^FI@Y2!()SROAS2_W26(*.*.2663 ,/+*V+4=1MM
M+M)+R[8K#'@84!G=F.%1%) +-Z D  $D@ FL3J7J33.E-)FUC56E%O&\<,<5
MNBR7-S<2DB.WMT=XT:1@KOF22.-(T>1W5$)%B>ECU>=3^KO*WNFZR_,%?/E[
M(:KTF;U8 =??5$I\,I%85+'6V5O7$ 6<0Y?R10EC,CI RX)F03COC3&T?6K+
M6X'GLS(/"<)+%*H26,L"5W!6=2' )4JQ[$'!!%:_H_K;1^M;2ZN=*6ZA>RE2
M*[M+V...XA,JLT$A\&:XA>*81R>&Z2L=T4BNJ,I%=7I[_A->L+_I#HC_ +K6
M\DM?^$]5^JP^O]1D_P!Q]M8O3_\ QQ]H/_O/37_<,-4CU.^ACHCU9VF9O^SP
MM(%HLJ*ZL"O\C<Q4]B91O*D-6BLT,K[4(NN89,02.] XK 20DKY0Z!A4[),?
M5NG]-UIH7O8Y/$A&U)(9#&YC)W&-^&#(22<8R"3M89-4ZM]GG3W6<]K=:J+R
M&[M(C ES87"0R26Q=I1;S+-#<0O&LCNZ-X2RH9) DBJ[ R;B,W3UN3S_ %=T
M^*F1ZGQ=:/G(KZNFF?.8%7M9$ZEQ9TTDTY4LKOF$T.\(GFEB+>1#226&@)-N
MLQNK>V@LH(H(HPB0QK'#".51%&%+DDDGU"G+,?,YP</U&FZ=::586FEZ9"+;
M3[&!+:!%9F*Q1C  =RSR.QRTL[NSN[,S,TC,ZS155-;1UPM34!P 5P4?PAA1
MV^V.-JN<][E555\DTTKWS$3RN?.1/))//))-(][KB2Q))R3ZG_?[ /0<5L0
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MGL@30P9XLES80W*F5:RB-RKD!)0$8GLC9!1S\E/#'T1FP"<"H)T+*'49:/+
M#NRGZ:CYD $#U95!.*\<W]CA]SS='_B,G]1:UI=$G>/76TZM)K+.-X,P.]R1
M8NVIP[ 0E(IH+%OY5T&?C'>QI,1UK\LK$<^1J[!E/AR(< H5?'J=N5('U*Q;
M^#6'GS1N.0P*\ XPX!!/UE57^%\<5_01<QLB.:]K'L<CFOCD:U['-5/#FO:[
MRU['(JHY'(K7)]G)X<O,6I1R2?MYP1]O//KSV)QGO4,8"I4SKB_ZH.L[$<W%
MQ77515F)*^"W&I654:8J[@-^R27)77MSE;D@X9RQC:"8\1'_ #->0UDC$AQ)
M@>;;)@\@G/G&/Q?$#  ]U /8U&H\C(<^0E,@[2 !Y#R.6,95LC&"2!V.,H.G
MM,W3X"CDG!"I[JAB=D]/0U[&0AT6DS2-JK, $9J^Z&FF=!%:9I[V1_/9>QI+
M2&-!3X'.P)EVR-R6#>=6/<JWF!)_&&=K_!PP[@UFPMNC4X (&UE'8,O! ^1[
MK\5(/8BI.Y%4M.*4XI3BE<,\\0T,D\[VQ0Q-]TDC_/LC:B^%>]41?:QOGW/>
MOAK&(KWJUK55*@$G [FKD1I&5$!9V.%4=V/H!\6/90.6.  20*MPFQO@XV6
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M*R<<D>=C989X)HG.CFAFC<V2*6-SF2,<U['*U45<#MWK-[]JYN*4XI7'+-%
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M61@H8\Y,[FI'#%)(YK5N1&D=4099V"J,@9). ,G '/Q-6NZHK.QPJ*68X)P
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M\%;%(^",A8FM1Q1:,5%(=.JK) DOF..!T:1L1[GR/_%3\U][;NO>H?:9U3T
MFJ:AH?2'2M_]R8=#L9YK)-5EBAB>?5-7:%HWU 7<DADL89BUI;V7N[0P^.\]
MQ/\ 0W0?3NF6FCV6IF*.YO[Z(7#W,B+(8%9B%AM]V5B$8&V4IAWE#[GV*B+!
M'Z+^_P#G\IX3[HJK_G\_JOZ(OC]///BT$@@@D$'((."".00>X(/.:]"';/V
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M6,$@@@D$$$$'!!'(((Y!![&I" 000"",$'D$'N"/4&L:+?KW6]:^\C$CG[K
MQ>7KBY3&3;?(0-8Y5CQUK:D1Q:ZBBD1CX\OH; 2^J!GG-H-!>#09_$#9:3(_
M$F$?\?'D;]^H'D./PE!4\953N<XSQ,G*9=<CR$^= .3L9CAAG\%B"!G:Q 5!
M9=<-F=2?9:WKW36>1V<$D=;H+?.HE3>0G1C#O'J.QL1H:^8,ZS# ^!&-7[W,
M/OZ, AZT<U,\OYA\S=@KJKJ1E0WF&,GE'5@0"<Y,;[6/?=C%1#&248JPX9E.
MTYX(#H006"CLZ;E'"D9&9& [1[+S_NAUF)K]T%%&WX=]UL<)274\J^7RN/P6
MXMQ:ZN#&C3X2$U?9>DLK&=/?#G062-A9 UNAY1RO[F0$@?4Z D_48U SW.":
ME6=Q]-0V/5,*?M1VP,=N)"3W"C.*L#?670?8KOKE_HK7JV\;$R.>WW&8T&#"
M(^"U6-A,)V572T5L^!$^&TJKMI'.CC8UADP\<:)\P>V_\R?T)[:[O[N737G3
MG5ZP16[=1:(D%R;Z&!-EO'K.F2,L6H>[IMCAG66SOEA2*W-VUO##"G:].=>:
MAT]$;9=ESIY9F%I=^)%X3NQ+FWGQF+>V69")8MQ9_##NS''*LK.I[7L:RQ(O
M?769-/7X^HU2;$31YLFJ))M+R]J)\[$D6D49+6NBIH+,IGU*21@UH(KAHFJR
M6;YE_P#LR]633X-7E]K5N+";5KG3!$G0]S[\%MK6TNVF*-U,(1XB7:QJ/%8*
MR,Q+ A:W">WJSDZENNF4Z=<3VN@6&NF\^Z\1@<7VH:EIZVH46&_?$=.,K/D!
MEF"[%P6;*7KN_P#3%UM/*M?W-UK=Z>:)P\Q3]WE#;;X2JCW"U]17V<Y$+9%8
MU71PPSE3JUK'S2(C&)]7>Q'\S)T/[#TGOM%@U#6^IKZW-K>]3ZO&OO7NKNDC
MV>G6T*+;:;9R21QO(J>-<S%$6XO)D2-$T'476E]U&4BN);>WLXW\2.RMG\GB
M %1)*S,7GD4,P4G:B G9&A+$R&7WU12RJ-E,=V/LB4:KG/$R)61JV,\^UD[;
MWLJ7$5-B,KO"JM 5=%+'YDA$F\(UWT0+9_PFC3MW;<?R1AR/X0%<H9USA5=C
M\EVCGX&0H"/WI-6&:9VCKW3.NKFKZXJCI'?4:'K@TRWT-E&R%!(8CNR[JLIB
MP121/"RB9+'9J]J3(T?6;<A%?//,L<:XX,A X+C"CG/$8)!(/XS,K \H*MDG
MGE1$9]L<8941#DJ&9F/G('TF8D[45L@ 2%0M6Q0$UXZ$XOI7+#::R#,,9;%"
M%R!8VDNFR1Q6A6_W[A[5Y&D?*UKK:O%CU?8AI4L!MK3-"F*NAI'8##RMM! P
M,9<KZ;$X\H],E(P,@-G ,"#/EB&2"<D$A5;C.]\$Y..?I2<@E<9)OMM''UD<
M'-%-!V;Z@ML$=69Z4R!U55U%/$0-/;E U4$]H[!=69\B:KGU%DPBRO="8S-T
MUE<:K5E9 !V.7,V<_>H$(+ '))YV@GCQ)6&=@P%4;V"HN\U.%$1&/OD[@A<\
M #.6( SX<0)&XC)8[%)9R@J:<-CA\52O!4Z:ZNK,V>[U>F,AA@L=1I3F0L/N
M3HX?,<+?A#BUU571.<)1T-?4T%<D=95!PQP2.7;.-J@;44=D09PH^/<DD\LQ
M+'DDU,B;!C.6)W,Q[LQ[D_#L !V50%' %7ERRKZ<4IQ2K<V&7K-OE-+C;J2T
MAI]716N=M):2WLJ"XCK[D&>O,?67=.2':5)[8")%%L*\H<L69&302L>Q%Y<C
M%&5UQE6##< PR#D95@01\000?6K64.K(<X92IP2IP1@X(((/P(((J(_3=Z9^
MH/2=UC6]6].YUE)0!.<;;6ICXR])J[J1B(9HM7<I#!+;6Q*-1GO6.$, 2."N
MJQ *P44.&6XN9;J0RS-D]E49"(OHJ+DX4?623R23DU%!!%;1B.,!5'+,<;F/
MJ[MZD_'L!P,  5A[U%^*MT1W+WV+T939G8UXVBMR\[C=U91UCZ326H[)UAC(
MK("I+&H NOEY8Z0J="I"7S!QV0=4\A[(.*M.KM*U'4&TH12D3%X8Y940P7!P
M0R%"20D@RJ[@0^<,JYQ7E.A^V/0-;ZCAT*"SU"".[N&MM.U.7P3%<3KGPO$A
M1S+;1W)4BUD)D=F:)9X[=G(3(;L?TSLL"B+C D"@R3/=+-GCG/B#][E5[UK3
M4211FN?]V!SQ_+L5RI&3!"UD*? WMO\ S",>L7][U-['KVPTJ6[D>YNNBM5=
M[;31*^6E;0-319A9+(_*:9?1"SC9W\'4+2W2*U7ZWZ=]I36\4=GKT<LZH L>
MH08:<   >\PDJ)2!G,R,)#C+1NY:0XH:_$ZG @'VVPI2L_2UC$E/O3OAQT0<
M2R,A9,7<MD?6CQ.E?'&U\Q+&.?(QO]^]J+\&=2^P+VS])2RQZU[->K8TA)#W
M=AI%SK&G<'&Y=1T=;ZQ93P01/R#G%>BIUCTLUL;N3J#2K:W10TLE]=PV B#$
M*/$]]>WV LRIEL>8A5)SBK.RY@FXE)'Q18VOG"9"\R'+D0W\HD93I6#2%153
MRW01SN@E9 Z5&-F='*C%5T;T3DK/V=^T#4)? L.ANL+V;(7PK7IK69Y S<*"
MD5DS D]L@9J>WZHZ9N@YMNH="N?#57D-OJ^GS;%.0K,8KABH<JVUS@$J0">:
MG+-] ]DZ)[%EIFT :^%<5?R*&J)^]& L;.>YZIY5OD:.-?LUTK/U3W7H+\QS
M[<>MKB$W739Z+TMG7QM3ZO=M-DCC)\YBT=5FUF:7:"8T>R@@=MJR7,*MO&HU
M/K[IW3D?P[O[H7 !V0V(,BLV.-]P=L*J3C)#NXP6"-R#KI]*G:OK0N/77GLP
M9@]-B<I5GVF?[,PQ-$8N;H\?' 5*7:W>@.KH6EV2G"ADYV^&D$AM2?DPJ>'Z
M;9EQE?HK^9^]B.G^QB^>STNUN+[6+Q#;]1=1W]HL5Q=V\9,BP6JYD33M/$PC
MEBM8)Y&GD$<EU/=M%$T?P)<^UKVI>T'VFZ?!?6%UHFBV-Q-;W72\44SZ=IUB
M8W\>ZU&\EAB-Y?$QI[KJ3+"DKB."PAAM[J=)O1_SZ]KVRG%*<4IQ2G%*<4J&
M,MV\'9Y[MG4:,4>BJ.K=ON,T81$0\GYFJQHHA<EH]LD</PRBHR)$0.-9$21L
M<<<DCI/',AX"&A1"6::.-P",8:3(QZ\ CO\ #DU DX*S.P"K#)(A.<Y$8!SS
MCDY[?94+Y_U93Z+$P&A92H?V)9;_ "W7];EV:J&>A@,W-4V^S5K;:04(E1@6
M5:%CVD X)!D5]5G4\47Q421L[66R0@NWA+$\K/LPV(FVNH0GONQ@D@;2&]"*
M@6\+("$'B-(D83>-H\095F89X SD 9+ J/4BZ=GVEWIBH,.RQPG5TINPV@.!
MC^6WNFE%CN[62Q?6V'G\CMD@IY! '.*1_P >Q&F<UJ"S(]R0V1PV\AEQ)-B.
M,R_J:9VKM!7]4^D"W'X)^([F^2:>,)F.++R"(??&QN8G:3Y,@8&3W/RYJGS^
MH?627)&'J\;GR-Z1VA8=:T[#=&<'E4?28JIU]W=V-FE--8_!@2PD$ KQ*QQ9
M[6,D189/?#RHM4P)"[B,0B9L*"^&D**H7<!GC)).!V^=6^]/O,813(93$N6*
MIY8U=F)P6X)P%"\]\U-%AN[#&=7V^][)KJFE/S=/;65U6T%S+=5TDE=*3$'!
M661==5332W'PQ6C03A1R#E&L"D=*^)TKX!&))ECB+,'90I==IYQDD GA><D'
MD#/%9!D*0M)*%4HK,P5MP\N< $A>3@<$<$XJ":/U16.ER6992Y?/S]G:3L(K
MK=^?DU;7Y*GM(*TF_BMB],!7GS%U4^?C&*&C! >48?*17#I\4.=Z9#681WW.
MPB2(2[MGG8$A2H0L &#9!R< 8)X(K'6[9T3"*96E,6W?Y 0"VXN <C8,X R2
M<55]=WUM\"AE?JL5FV7];U)O^R#(*;3'657*3C;H*K#!&,GI:^=HMP.6TV19
MA?F:YW@61LTK9'-M2VCDP4D<J9HXAN0*<.I8MC<?HXXYY^55>XDC!#QH&$,L
MAVN6&8V50,[1PP;/;(^!/%7=UUVUJ;S:18#=Y6CHKRRP(?9%$=EM$7H*DS/D
M6$%7,+8,LJ2B/J[44HD=6,^ 6&9$Z=82FO&5LEDL"+&98W9E64PL'4*VX L"
MI#,&4@'U!''&#Q?',[2>%(BJ3&)5*,6!4G:0V54J0<>A!YYXY[&(N;#3]G=M
MZR0\]V2QRUW6M !$02M839T8ZWVYN$KVR*,381VUF+G&&)$Z>)*(H2.1J/FC
M5(H2&"/ WR9F8D#(#';&,]PNT%\=CN!QQFD;%IIY"6V1@1*.<$J"TC8[$[B%
MSW&TCUJ(G^IW818:?LTG(X8/*7>1V.KP=1/N3W[6T@R+HT='9U<6:6L1Q4+T
M)-BK[69U+$Y(R9")T2-\WND?B>$'D+J\:2,(QX8,GP8MNX.<94;L< =Q%[VX
MC,I2((R2/&/$)=A'\5"XY'?#';GFK\W_ 'MHL+:YZK_(DMY)V)GJQ>M9:XHG
MX-GO"R X2\GH)5#DCIQ8 SX[V.Y5SXY*D"V11T($1LD<=LDBLWBA?"<^*& R
M(P"0Z<^8DC;M_&(YP:DDN&C*CP]QD4>%@GF0]T;C@8(;.>P;CBNK2]W[JX@U
M>PCQ69;UEAK384>A/=JCV;.<G"!FRW]K4YY*"8!X<AU?.)559MN-9DPO@-*D
M"A<](ZM;Q@HGB-XLBHRC8/#^^$! 7W YP02P4J#D9)JBW$C!W\-/"C9U8ER)
M#X8.\A=I&,@@ L&(Y.*M9_J6VM+5UMSKL#FP@]OU?M.S>O6T.O*NB/@Y#.1:
MA:76LEHZ^,.4ZL)'>VSJ)#Q(2%<(L;WK\1E_ND;,RI*^8YHX9=\84$NY3<GG
M)."/HGGUSVS9[TZA2\:@21/+'M<L?(N[#@J,9!'(R,\=^TDZ3O%<S5].7)M(
MR0+LFL/MKA(")9"*06MZ_,VY#:^+X*?49E^3<%%'*X;WHY)/*/5&<B2V\1IU
M5N8B N1@-F01C<?P>^3W^%2M.46%BO$@);'=0(S)P/7MCDCXU5.H]YV/V '5
M:B_R.1H<5JL[!I,S/5:\VYT8T!KAI:\*]K9,^#7_ #!0!/S<T]=9RQ5\T7R,
MT<LTGNCMGBBB+(KR-(C;'#1A4R,Y*G<3@$8 *\]QQ5T,DLFUF1%1UW+ARS#.
M,!AM S@\X/E(QS5FS>IFA%[JM>L"! $HZT>QJTT<-N/-8S[:II!M*=0MHFM2
M=!&U$I L%@DCDFOPB*AL?QD^TGNC&W$P)W'#;-N (RQ0-N[$Y ./Q2#VYJ,W
M2B<Q$#: PWA@3XBJ'*[1SC;D9Q](8JC0]^=E+U;=]SE=?XZ##.Q=CL,L/#MC
MRM*Z,8H:*N!T +,VP"*6R&G>5.^ML2&U+X5#)28A[4Y4VT0E6 2.9/$6-_O8
M"<CDJ=Q/!XY W=P .:M]YE$+3F)!'LWH!(2Q&1C< N.0<\,<=B:Z]_ZD-A0G
M]BVZX7.GX#JZUR%=J#6:LP/6O@U-/16CSJ>GFH9:FP6O6Z2- 9KH$@WX*,A5
MKY$5*I:HXB7Q'$DRR-&-@*91F&&8,&&=O<*0.Y[8HUS(AD;PU,<3(KG>5?#J
MARJE=IP6QC<"2.*R_8Y'L:]OGVO:US?**B^'(BIY1?"HOA?NBHBI^B\P>U9O
M>OKBE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE6SK<C1[6H=37H\K
MXF$0'UYP1,P%O26P;E>!=45J*^,VIMP)'*\4X26.5B.EAD^(-//!+<KLARI]
M""#R&![JP/!!]0?ZZM9%<88>H((."".Q!'((]"*CL'<7> ('SW;I$#J^26(.
MA[<A'B S-ZLKHH0P=N/$U@>"U\Y$GR2/>K<9IBU$GH+&IM[J+!T\A029:$'/
M=HN[+QDE#WD08S^.HX8,%,AC#M'A93QG"R\!6SV#C "-Z?B,<8(+;!-7(:FJ
M/]AU=B=P0/97=0Z*_"B; !JJ,X_.:T$=DCID"'TM$2!<+5OF<LI5*07/2GK^
MQ85Q<2NC61)7CX4\9R5(#*3\2K C/P;&X>A%6/&CD%AY@,!@2K =\;@0<9YP
M<@^H-1>9UCVE1-FDS6SH=X,QSGBT_85=^5[F5ST1/A3;S$5Q-0.(/X\PL3J<
MTV5%5I-B]_\ +<G%PAP'0H?5D.X?Q'()SZ_?0/@*@,#CZ+AP.RN-I]<C>G '
M;_%D\<GG-4>6?LJL;[;7J'4%DPL]Q1N.T6$OJ)%1/+OD)[K49'6'-:O][[\:
M(0]$3P-Y^R2!XF/$J@'\=9 ?X0",HR/@Y'I5NR49S&Q/Q5D([< %F5S@GN5]
M/JK'A-2))ZB=&3:X+LCXZ=+8L9U?)UAK+NSCDBW/84SBGBTM/;N0&9L\< ]F
MCE!)(@)%B(?,+-&SJI!CHJR(DCQ^>K5L'Q44?\#Z(,#<5YX)QW Y]17GD/\
MZU=6\KY_0]Z>&-C%L_GDZI.3@9(R?I8 .,>G,Z ::\,9\OG^I^U#HONJ1/S
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ML<?LJUU.VW=*QV,&' 'F7Z). -Q&."V?Z:H+:!=V(P-RE2,G&T]PO/E!SV7
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MG;D #'%2WR"IJ<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2N
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M#XJ01^456>6U6L=:_P#X6FN__3KUW_WE]H\ZV7_B)8?_ !;JW_<^BUYU;_\
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M('#]%Z%[#;5K2*;J+4[M;R1 [V>F&!(K4L,^$]U-%<>\2*,;VBCCB5]RH\R
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G*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g796801g57c49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g796801g57c49.jpg
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M/VKT[^!6W^ZI^,[A^=EE_7K3]JX^JEXF_=%Z[_E=U!^4*?0?2?M7IW\"MO\
M=4_&=P_.RR_KUI^U<?52\3?NB]=_RNZ@_*%/H/I/VKT[^!6W^ZI^,[A^=EE_
M7K3]JX^JEXF_=%Z[_E=U!^4*?0?2?M7IW\"MO]U3\9W#\[++^O6G[5Q]5+Q-
M^Z+UW_*[J#\H4^@^D_:O3OX%;?[JGXSN'YV67]>M/VKCZJ7B;]T7KO\ E=U!
M^4*?0?2?M7IW\"MO]U3\9W#\[++^O6G[5Q]5+Q-^Z+UW_*[J#\H4^@^D_:O3
MOX%;?[JGXSN'YV67]>M/VKCZJ7B;]T7KO^5W4'Y0I]!])^U>G?P*V_W5/QG<
M/SLLOZ]:?M7'U4O$W[HO7?\ *[J#\H4^@^D_:O3OX%;?[JGXSN'YV67]>M/V
MKCZJ7B;]T7KO^5W4'Y0I]!])^U>G?P*V_P!U3\9W#\[++^O6G[5Q]5+Q-^Z+
MUW_*[J#\H4^@^D_:O3OX%;?[JGXSN'YV67]>M/VKCZJ7B;]T7KO^5W4'Y0I]
M!])^U>G?P*V_W5/QG</SLLOZ]:?M7'U4O$W[HO7?\KNH/RA3Z#Z3]J]._@5M
M_NJ?C.X?G99?UZT_:N/JI>)OW1>N_P"5W4'Y0I]!])^U>G?P*V_W5/QG</SL
MLOZ]:?M7'U4O$W[HO7?\KNH/RA3Z#Z3]J]._@5M_NJ?C.X?G99?UZT_:N/JI
M>)OW1>N_Y7=0?E"GT'TG[5Z=_ K;_=4_&=P_.RR_KUI^U<?52\3?NB]=_P K
MNH/RA3Z#Z3]J]._@5M_NJ?C.X?G99?UZT_:N/JI>)OW1>N_Y7=0?E"GT'TG[
M5Z=_ K;_ '5/QG</SLLOZ]:?M7'U4O$W[HO7?\KNH/RA3Z#Z3]J]._@5M_NJ
M?C.X?G99?UZT_:N/JI>)OW1>N_Y7=0?E"GT'TG[5Z=_ K;_=5&N=$KD:<4IQ
M2G%*@(&U=:-,*C(MOM288W^9D/1_L;Y:3E;9D^4N#?"NX0D9YM_NO*";ICD#
MC-B%W%G]I[B^KWSNEYX<=?Z<_4Z:AT7U/8MT5%83=7^UZ+J%NO3$>JB)M+;7
M6E@1=+^B0FB-@MX86O.XOLZR$UQT>L:5,+(PZE8RC4FF73NW=0N;YK?=[0+0
M*Y-QV-K=[M!NU@[]N*GW.EUR-1^TVNLT="PM-Q?J*O6U6(^3-Z^8#*U(&)9<
M  V19YDD0P_1!I0PL7<LF/4A$\46/TYYX]=\WTYTUU#U?K5ETYTKHFJ=1:_J
M1G73]&T:RN-1U.]:VMIKVX%K96L<MQ.8+2VN+F41HQ2"&61L(C$:UY>VFGVT
MEY?7,%G:0[3+<W,J0P1!W6-#)+(RHFZ1T1=Q&695') J (O06C+/#]HKFWM<
MO(/O.!-\Y5;T9T7WN4M:N!EGUQS9,?MTZI&Y90B_3\Z0)6>3CAW$)-EAW76?
M!/Q@Z=E[&O>&'7>CS?0^;5>UJ72^L6<GT,M[_3=*GO\ 9/:(WL<.IZQI5A)<
M8[27>HV5NS"2YB5N-MNI.GKQ=UKKFE7*]U8-T%_:RCOO%-.D64E/UQH;:XE5
M/G&.&5P-J,19J9RIL2A8_0L@7*-T (T4-EA,1JYFM/@P)"/!+@SS@*$+'DCG
M'(ASSCEBSQSPRRQRZ[YY]JNE:GH6IZAHNM6%YI6KZ3>W.G:IIFH6\MI?:??V
M4SV]W97EK,J36]S;3QO#/#*BR1R(R.H8$5RT$\-U##<VTL<]O<1I-!/"ZR13
M12*'CDCD0E71T(964E64@@D&H^DV)0[*UR15^XUMTZP@=E9*EC@$UAB-6W>%
M:L$^0H\V<W426PR8)&>?>'U0FF70)'<9'?R^<WJW0W6>@Z:NLZWTMK^DZ2TV
MD6ZZEJ&E7MI8M/K^D-U!HD(N9X4A,NK:&K:OIR!]UWIRF\@#P O6M!J>G74Y
MMK:^M)[@+<.88;B*24+:7 M+IBB,6VV]T1;S'&(YCVWP_%>0_:>ME3$U.SO=
M3 :KF$JD]<6]70&AM(*W)<9EY(TA&,T)D53BDLD@\F&,N*2/-EWCT)CW+UL6
M7AUU[J5C::G8=&]2WNG7]C%J=E?6VBW\UI=Z=-U G2D5];W$<#12VLG4TD>@
M).C&-M7=; ,;EA'5)=7TJ&62";4;&*:*0PRQ/=0K)',MH;]HG0N&6060-V4(
M#"W!EQL!-9]'::S9H\9:[8$KW#):G<]=J68;#+I381,CT#// 6:7.,%T%AF6
MJ*DQQA8#X9S"YRQX99=<-J_3G4'3[M'KNAZMH[KJ&JZ41J>GW=B#J>AW*V>M
M:>K7,4:O>:3=NEMJ5LA::RG=(KE(W=5.Q;WEI=@&UNK>X!A@N/K$T<OUBZ0R
M6TQ",Q$5Q&"\+D!95!9"P!-90XX)8$6Q9&"KUX TYAQYQ$0@008T>4Q)194^
M<< PP\.&<L\\TF$44>&4DF>../??7'6EG=ZA=VUA86MQ>WU[<0VEG96D$MS=
MW=U<2+#;VUM;PJ\T]Q/*Z10PQ(\DLC*B*S, <TDD<4;RRND442-)))(RI''&
MBEG=W8A41%!9F8A54$D@"H-0-MZOVI&SFUML"HWG!-/&.V[J[Y<YR72S?,^S
M_;(PB)9((RODS=B3R8XP%=0R]CR2]1Y]X]QZU\,O$3PXDT^+K[HGJCHY]5B>
M?3?IBT6_TE;Z.+9W_97O((DFDM^[$+F%&,UL98A.D9D0-Q^FZUI&L"9M*U.Q
MU$0,%G]CN8;CM%L[>X(G8J'VML8@*^UBA;:<9ON\4W%N>@SM==C=JV29,Q4R
MN%\3 -Q8@LV2!5.)(1C/@Q=+XY#587>'VD\7#.8:*2/#++KB!TAU6=,LM:7I
MO77TC4;#5=5L=3CTJ]DL;O2]"NTL-:U&"Z2!H7L-)O9$M-1NP_L]E<ND-Q)'
M(P4Y_HA8">2V-[:BXBE@@E@-Q$)8Y[J,RVT+1E@PEN(E,D,9&^5 60%1FI1S
MKM;E8:"Q(27S"K#N5L]D5+E[=FBB,@S; *FLQ@ZQB6!CGV2.$?.N/A#)DCQB
M(E#)PBRRRADZQY6;0M9M]&LNHI]*U"'0=2OK[3-/UF2TF33;W4=-BM)]0L;6
M\9!!/=64-_92W4$;M)!'=V[2*HE0G MS;M<26BSPM=0Q13RVZR(9XX9FD2&6
M2('>D<K12K&[ *YC<*25.,SSBJSTXI3BE.*5U5\R_P "]4_^O8?[QM>?T)?(
M0_ZKWAY_VKK/_P!<=15\P>)'Y\-4_6:?_5UK5]\^OJZ-3BE.*4XI3BE.*4XI
M3BE.*5SI]_;7] ZLJ#BV:+OU;1?DWU3?-H6&D)Z.LVEMJY'I95@]7[FIS=FG
M@0Z07R??.>S;TJ*)M(&>:H6O"]3=$=3[MG'#(P69"W<D2-79S'$H.2WF4',I
M\O;0X4\Y/I6G=R2QJ6B=1LC>1E"AY&Q@#RD@"(<]QQEAQ@>M5-ZG][S=>0+_
M &+S5L=##Z115[SVUB.@I%F8419)MC:6HZD8P4,[S48ZU8T)@-_SC720RL6$
M8)D)_8L90LF4&2WL_P#I2+/&W89IQ@NH<B..1@"$;<K ISZ#(QG!K'/=?]'<
MPN.\JPG.QBH[CQJ2"Z;6!#^[)&?0$5JK4?BE;>N^]O)\>)@=<TTIUH\ ]E+,
M:PJ,==;^K>G]Y7N]4I/+,),Q6=T&;36+28-08OFGBLZH0N.6 F+Z-EM/B2*X
MXW2M(IM3N..RTL2(YP0#O[N,L#\TD<BL"WTC2P<A8A&?:1M&>Z(Y7=?3(V]O
M. 1ZX/NK; _XHY-<KJUI<O-=K2/+SKK2VX]0UA?L:HO";WK+=6VZ7J)06U98
M!@KJ7<TKC8%68,ZJ?*R62"L>HA[;EF*=(+K>P DA;A2%>6*5C&R[)(HWD( R
M2R$(P#C!X^9[JV#?%5RT)!9(Y8U#J=T<LBQ@DX 5@6!*G(^#>M88WX@N\K+M
M32] K&DT=-+,]'[_ //&[TCV^+[%* ZU+H_/;$+&DV,%&(,:OB1-%5MZ),40
M2M95AE*S! E/B?P3['"L<KM,6 @AFB(0C(EE[9#KN.#N!7AN,A^<%:@W<I>-
M5B"DS2PR@N&P4CW^5L#/!#9(YP5QSFIO\/[VYLK?2[3&N]U:]*47Z_>55?HI
M5LL=Y62%6PE0-I1T:TE$U"O@!848O)]859R9;C.PB.1D_:2<4Q\4RJ.MY:)"
M99(GRB7!@,>&RA*EU 9B2XV@@D@8(X+#FK6MR\O;25,,T F#Y4[P"%8E5 ">
M9@0,G(]<'BJWI?Q"-P*[OM;7!.LI-Y7,KUC[5UWJ\ *R5;6*RM:X\Q5O6%G@
M4OFQ"4SHZ8A?<V$0C;,1@V(8Q"C'=2C$9&K[O91%(W[G946UJ\A*M(6>X:12
M0-PQ@J. 0,9QSZT6[D#2)L[K&XN40;EC"I $8 G:<\,><$YP#P<C"P?%5L03
MV[[,=:JQ[\]#^4/,>\*2K#>!]['(N'HBXM:4@1M.^Q>UG0AUNS&JYF6$GRJ\
M#7C+;U,XC>#) 9^AZD)&)#WC<3Q-E?)M@4,Q'.<A>0#\XL%\NTDQ[<P+N8\P
MB&&10#Y]TS;0#QCYW!QZ $^;( MJI_$K?7BQZOUW5O,%R:[0V1<]KT_I%G=%
MR.H@PZHKVO;@QN:J\6NMU[\24IG6;YWF.?#7ESH>QH&%9DK\I,PQ66-K%4$C
MM<*(XTC?=L)8]QG0*45FVL&3TR05(;/J*NMZS&-%@8R.TB[=X"CMA6+!V4;E
M*L3G .1MP2:IQ/\ %8=U+5V%C8:<N.WL:GJ.Q[YV1;IK;0*8Q5Z]"]/[5T+(
M*!7P48:UW8E.5&&,4+0HU8SE5EE][.%[6#,EKE.GAGP)5CW2+"BA78&0V\<V
M22Q*J=Y#$DD'T4C@8Q?E4W&-I-L9E=MR*0G?DBP   6&T$ 8!'J0>3T/\\^D
MS]R,-Y5F\ZXGT_=] W=94KLC-MZ:XJ>@[!0ZYL9 \%LZL5:%WA/6[(+FU#S%
MZC4&03P8GGQ8]$<TIX!$(F23NI,A9"$*'AV0@J23\Y3@YY'N%;D,QD[H9.VT
M3!6!8,,%0X.X #E3R,<'WUR>T!\7PMXZ]<7"\6"C;(HB+5-]](>>J!26]:7W
M*NZXUAL2XT1MKS8,XD918%ZLM<#H6T%T+V @L=%9S<X\)!@9QP.0FTT*MLJ!
MT<R)!,[!BI>1%<2)S@HI+1G& 64 X)R="+4"6N&<JZA'FA52 P1&92CXY#L
MK\Y.&/X!N,;\1QJGCV,BLVAH*AL>C7K355$JMIW?1%B-NEWG3+!>J=8,[-@
M4T*;!J*PW%?T*@4_8]OA91QYI 'R.%J\5ZXL0W;*S%D=)6++"Y8&%U1EVYP
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M3X2?8SBGI[D6[J>+YVIV9M9#,@9W6J(Y42[7""KMV25#"F2G62X_*G>2 K&
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MXEU#48NGGM3))!')?0:S!=37%_LAB2../3A87INDBC*YA4)L[J@12G^YF>-
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MQ"LMPJ#&6N6+(/-_5&Y])L%<,L-0=Y@!YMJD_F9UMAG!AF4KER[R[RSPW,T
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M?A<7-Q$\A#LKNX:3<H),B/O!(93AE?)Q@>\$8R*H;>"1$!1614*IM) V,NW
M*D94K@<D@\'UP:R=T\;><;\^/M=CU^5U;&+N@V.6V5Z];%IEI$=ZPK+ZFTA@
MGLE-MJ!V@F3U:T6!%-TB.71N%S4J%Y@RZ[P[P+=3HH57\H#C:R(ZXD8,X*NK
M!LLH;D'!&5Q1K:%R6*'<2C;E9U;,:E5P58$85BO&,@G.:I_87P[M)-=.W/4V
MG%X&E,KQJYGH]I9X%S38A NH[%>;=L6RU96HN-GF7"L#+=?;8_3V7/N=K7F[
M.&</N4):O7#Y4OIA*LDI,NV02A<B/,@18U8E5S@*BJ5]& (/))K&]G$8VCC
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M/T99XW\.;2&QZ)N].N%TT7&CZGT]:6\5O9ZMI$MCJ;QJPNKN?N2%JMTMH#&
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MO45G;NO1U>UB@:=V2!^@<EV'SQ=]K17B-)=$UC<5[O )9+/:=AAF)F*R!F;
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MRGON57_\H>CO^(J?3_TA]NHOX-??X6G[G?<OYD%_K1#_ ,5X_,5?*>^Y5?\
M\H>CO^(J?3_TA]NHOX-??X6G[G?<OYD%_K1#_P 5X_,5?*>^Y5?_ ,H>CO\
MB*GT_P#2'VZB_@U]_A:?N=]R_F07^M$/_%>/S%7RGON57_\ *'H[_B*GT_\
M2'VZB_@U]_A:?N=]R_F07^M$/_%>/S%7RGON57_\H>CO^(J?3_TA]NHOX-??
MX6G[G?<OYD%_K1#_ ,5X_,5?*>^Y5?\ \H>CO^(J?3_TA]NHOX-??X6NA&B*
MV[J6KZ\AL0&:UN'*ZR)#DE'GSBQ*=L2H.^Y!9IX,OF#S12=?4ER[ZZSZZR^K
MEUWCU^S'R1^A^JO#CP#Z+Z/ZTTB30^H]+N.J'O\ 3);FRNWMUO\ JO6M1M";
MC3[F[M'[UG=6\X[5PY42!) LBLB^"=;ZC9:KU+J%]I\XN;29;,1S*DB!C%96
M\3X65$<;9$9>5&2,C(P:KB@^T_->SKLJH5+V >R;64RP+J.[.UYLZNZXV<QJ
MHK%A8E^H=NV2F*-4[@.3K4[EJ<'K"YVTF)0F<-NXNURI@4-])UU3'O\ [1_R
M*_C2WM?S7Z#;5E)JR^-VC"\4V38=!ZLVL]K:V#V)1H8DY,]JURSV71Z@LV E
M'#L"-@0;33'<4"UNN93=X &0$9J$$>ON.#R.#]_]RKO;;.U\BO52UBWN" '8
M=[$>L*A3)F$/XC?+JP'B?8&02K#O,KM:I&DBR,82QQ!QRSCC?/[)(AAD5%4\
M#[,\ML8-C%";OH^8NJ!LS;N7*?.*($#'9"J7VP3%%"PP7!=E=@R*1$PITC\.
M>ZQ]5"&>2QR1+,U3@\<>OI5JZNVWKG=-8RN&L;2#:D,#9G7SYAX3E[!+84LV
M,#>O6)$X$7OJW8%DF<7VY&^6KFHL<XTTPF$)(\DBHQC^>M'/81&VWFV:?4]2
M[OW5JN<!)3";0MH5R\\U*L,UMTL-\7@'Y=[>\\;I?$V&*2FL(#BP&2A&N7XJ
M.NU1III)$>I=7]C8]OVV]M+/N[A%[5<PV_<*;=_;[SIO*;EW;<[=R[O45L0V
MUQ<;NQ;S3[<;NU%)+MSG&[M@[=V#MSZD''H:W6T8Y[L>E=16/MU:;)^(=945
M_P!/[QG7)+FYQ=5A6SQ96O.GI:Y5,[$9B5U.YSK5?2HLF&9&2I6"%W -'M @
M@$'((!!'((/H<CCG[U:Y]3QC[WP^]5I\FE.*4XI3BE.*4XI3BE.*4XI3BE.*
M4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI7/GV5_P"\]-_^PG?VAS\:?_:=
M?G\\,/Q1U?\ KD5[UX0_^[=7_P"W0?T>M->?F+7KU.*4XI3BE.*5^<T,),,H
MY$44X\\4D,\$T>,L,T,N/>$L4L6?66$D4F&66$D>>.6.>.7>.77?7??7,D4L
ML$L<\$DD,T,B2PS1.T<L4L;!XY(Y$(=)$<!D=2&5@&4@@&H95965E#*P*LK
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MG;7-]'JYNYHVM;>XW3FWU2"$N&F9?K<2+M XSDFAO]-9Z(_FPTO_ /T+Q_\
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MZ'G2W['O_2[BOQ&^4C^CCXC?LW'_ %;8UIMST*O$*<4KZC?@U_Q3GW],]O\
M[LT;GQ5\H/\ /U;?B]I_],U*OUH^1)^@[>_CMK?]6Z'76/GAE?8%.*4XI3BE
M.*4XI3BE.*4XI3BE.*4XI7\X9X28XYQYXR89=?3CGAEUECEU_P#''+'OOKOK
M_P#GKOE(Y8YD66&1)8W&4DC=71Q\5=258??!(J2"I*L"K X((((/P(/(/X:Q
M3ZP(:JH-?V=VHKB)=A'(P=/F02=0!'+-&-%F:R83#ABX2D30P1Y3S1XYS2QQ
M8]]YR8X]Y%5F(506)] H))_ !R:J2%!+$*!ZDD #\)/ K\Z[9JW;U([ZIV!'
M:$9>4N(KFNM@':DG*"3*&;$=BM()#FRAEPSBEZCFR[CDQRPS^C+'OKHRLI(9
M2I'J&!!'X0>:*RL,JP8'T*D$']L<5F^14TXI3BE.*5Y0#P6@(;-88(Q6L11S
ME[  B$L$X(N+"<4P,L?.2 D4F"3"8<B"3.*:+/"2//+#+K+N2""0000<$'@@
MCU!'N(H"",@Y!Y!'H1\:BN.R-=Y6[/7^-]I>5\C^CYE)QM*/NW1_2#@TZ^O6
M^COOG'Z5DD;'KZP77T@YX%]?\GRQD[MVWV[]C[/L]IV^N/G8QZ\>OKQ5.XF[
M9O3>/5=PW?O<Y_T5Y1-KZM/<6&O [)H)K^HS##6M&)<:Z2XK!!AL*T2"PK86
M.9J68IB0.O&B90#9SFSPBQ8Y3RX1Y.W( I,;X;)4[&PP R2IQ@X')QGCGTIW
M(R64.FY?G#<N5R<#<,Y&3QSCFI"QM%93X.9&UB1*\*ZL&=6#-BW7A8(DYF1V
M ;9SD21%TL6%9*V>(QYO< L^2X[&*7+L0CJ.H5CC"D[B0N 3DC&0/B1D9 Y&
M1\:L649RP&T9;) P#G!/P!P>3\#\*SO_ #_\W(J:_$@@<,><LN>$446&4@DD
MB7" <<>##*6:>>:7+&.&&&/'*2663+'"/#'+//+K'KOOIZ^E/3UKPR/$L3,%
M+*X5Q.&8I!RU3(P$P9L A/J?:C 0,INBBQ1OF1_:"((I(H?F8?,SQ^MC],X.
M"<' ."<' )] 3[B:C(R!D9/(&1DCX@>^HH[VOJVLOQZI8]E4"OVDO(+$6M.[
MC753\G)C)U$OQ'3'L1V,V1\O?48748V794G?6$'S,N^NN6$<C#<L;LHSE@K$
M#'KR!CCW_"JF2-6VM(BL<84LH8Y]."<\^[XU@Q-_Z(88'2 ;LU(;&L"R9,I!
M-D4TG!>NPG'%S/.RA<YXB!8%%BC9%3]QP8SDCP]R=231XY6,,PQF*49.!F-N
M3\!QR>#4":$YQ+&<#)Q(IP/B>>!]^LN3M_4P5:!NAFT-=B4YH=DK66PF[5J"
MM,6>&!,F:X%[*SP5EG8QAF9Y"#E2$8X"DY=Q]8P2]XU[4A8H(W+@9*[&W <<
ME<9 Y'./>/C4F6,*&,B!2<!BZA2?@#G!/X#7]M=M:J1!5AF[V;KY,NNTV U,
M8-;G7%P5N(E^5\L>L%ELH8'\TGSX/J1*I"Y,_G1?5Q[^9A](1R$L!&Y*<N C
M$J/BPQY?V\4,B *2Z /PI+ !C\%R>?VLU8/*5>G%*<4IQ2G%*<4IQ2G%*<4I
MQ2G%*<4IQ2G%*<4KRB@A!?:/L08HGVPJ4XO[*/$/]J-(^K\\PCY6&'SRIOJ8
M?-(E^M+)]7'Z^>7U>OHDDGU).!@9]P^'X*@ #T &3DX]Y^/X:]7(J:<4IQ2G
M%*\IH(3&#[*P#%/&^>*3]G-'A*@^T@E0G D?*GPSC^>&:,.8++]7Y@Y4$)$.
M6$T6&>,@D'()!Y&0<'!&"/VP2#\1Q4$ \$ CX'GT.1^X>?PUZN14TXI3BE.*
M4XI56;4W;JC2 U&,VS>$M$#V3LBKZAI!CW,B$1]LBZ_;_P *U2$J$>: 0YYD
ML-B"F82" Y3Q8P2%QS301RJD G./<,_M5(T%^J%ILE[J*!V.RL>LFZ=#>E<4
M)<<U=;V"KIKHG"*DG'B'GD.K%@3MX\P9BHL(#HXII(R<)H(U17X6+95 J5JH
M-'LMO0IKCM-TUKVNZP<PAB>7!PCJ5EO;@1(M^MV45]V5&H61X<1U'B*,(JFZ
MEGQGD'AF4QZ_>]:A=-]&Z-V#L6SZEI>S:Q8MB5#[_P#OVL+RY<RX^ZBZ#K5R
MQ6DR0QKW^=(LK!?6KS@@,9YTJR'@H+3BI;ECAR*8JZ^*5\AGJ7V[[=4^N_5]
M*IOK#9=#I&NMVG4RFU*M5/1I"M*@$I-(;QC1EVG45E?%RYGN6$\D[!P7)W\W
M&/'O"./#'KZ.\*_"GICK+IAM8U>355NQJ=W9@6=W###VH([9T.R2UF;?F5MQ
MWX(Q@#'/PA\HWY2/B#X5>(4?2_3%OTY)IK=/Z;J9;5=-N[NZ]IN[B_CE'=AU
M*U3M!;:/8G:R#N)9L\4"S]_?$"KN2-K'[0VTTQPN5#")6M:9YXS7, &UU0*&
M(1G0&D%YO4)0!Q,&68API,?U^I(9XY,<<NNP=;>"W1_3W2FN:U82ZRUYIUD;
MBW%Q>P20F021I]<1;*-F7#'@.ISCFNF>$7RL/$_KCQ)Z1Z3UFVZ432]<U3V.
M]:RTF]@NUB]FN)<P2R:M.B/OB7EHI!C(V\Y'TH>YG.X6NY_"FC=6;ZV'YZ6[
MYVYN%!?[EJY-JUO<"4E"\X[-V@G6@=[:UWLRM!0S66I*^CIL:YD7*#D3!"1!
MG)A+'\HU^D8QR2 <#T.?B/@0:]/[B'T)_P!*C[J_JMX4_P#)GQ4[A]@O[K_[
M5:TUG>/H2C?#@^*%<VV\KAL;;GE5O[_K.JMQ7-!K4>XC8Z-HCICKALW44ZBU
M37S%FE9!P'2==TN)>?+A\LX @;+N#M4@ NHQ@$KD#/OQGU)/^FKUJ/CCT98*
MI6'Q?Q3?<D1;NO)6Y,0U4\,8CQ$,EHQDT<&,OC>63&'"2;+&+&263/K#K'K.
M3/+Z<NU1N'V"_NO_ +50U;6_0GG3V[Y%UR\]K>@_0NO=YUCTMG;Z?N6M^;0U
MXINL*;3W578IC]0Z$U6^&)B-?F9%X%-S!",(Q\.QL>L9.Y%"01\T#D>F[WY^
M)/PKK7Q5:Y<>A(-Y[:]ZT/SO0_5.Y/-NOXO(EUW0VZTVAT8S;6*XJ=RTNC@=
MM3-RZ?VQA"N@2V(W_DJB!7GF3&/+)-GUC)A(JPP%R5!.<<Y^'WB*E_[B'T)_
MTJ/NK^JWA3_R9\4W#[!?W7_VJGOPWMG; W-X8\S[0VK:"[ML2Y:U!:VVV' )
MEAC]MTP8B2LBE]>6IT8LY$8T7<L2M6 )UGUWW$-'UW]'%0V,G' R<#[V:^87
MXH[(U-Z1];-UL_8K%5*_9+R<<(Y,AS0:0(4)/U'-A)#)W#/%')UA+')'EWC]
M7/#+'OO'O[RZ%N)K3PBTVZMW,<]MTWJ5Q!( K&.:'VZ2)P&#*2CJK ,I4XP0
M1D5^,_C%96NI?*=U[3KZ(3V5_P!>Z!97<!9T$UK='2(+B(O&R2()(I'0M&Z.
MH.596 (YCTW7&P['4*I83/1VWH2WM;1N2H1E6F\1HB6BL4Z>,?&754LN,&$L
M^6,6,DLLG4?6/6<F>7TY=\CI.@:[?Z5IE]+U[U0DM[I]G=R)';]+B-9+FVCF
M=4#=.LP16<A0S,VT#+$\UPG4O6W1VB]1]0:/;>"WAS+;Z3K>JZ9!)/>^(QFD
MAL+^XM8GF,?7D:&5TB5I"D:(7)*HHP!YRE=]U]M/2R^?<E]NJ6[62WI7B2U+
MM=1A2#K-;6ZQA2P3UBBUUE#/"T4AR]=]'=Q9X1Y1R1989Y==UDMM:T/J/I*!
M^J]:U>TU?4-4M+RSU*#0UA:.WZ?U2_A9'T_2+&=72YMH6R)MI"E64@FLD.H=
M)=8=!^)MW%X:](],:GTQHG3NJ:7JF@7G6+W237O6W3NBW4<L6M]4ZQ920RV&
MHW,9!M0ZLX='5E!'V9?!K_BG/OZ9[?\ W9HW/G'Y0?Y^K;\7M/\ Z9J5?=WR
M)/T';W\=M;_JW0ZE'JV3=NP_:_E_SGKCTUMGS;2KCYS]5[:N#+3Z+2[6Q62Q
M:NOWEJL5 0TK<NJ-K+Q%00&U;9)-"H6KBBB9A,YB\HQL8LO#*^PA@*20#RHY
MS[PV?0CX"I'^XA]"?]*C[J_JMX4_\F?%-P^P7]U_]JIA\-G8>QMI>.-:6_;-
MX;;)OV5IWG6'5Y>KZVJ=60>@;_VC04)S0"H(ZU6H#\:Y65(Y7:="K$FE@RGZ
M%PDED[R48 ,<<#X?M??K<"\,#%-+M[1?-V,>MJ[]@"1UA')W 8&I+(&FZPEP
MDBS[BFCPSZPDPSCR[Q^C/#+'OOKM5:Y">/\ 0/J;T+Y+\O[\MWQ0?:*FU[N\
M\Z7VY9E5<J'B(>O++!LC7%;N+E>B'9^0FC*!,&Q<DCK(6#-B;$%'!@4<7/C(
M1(J[$!B B\$CU?W']=6;V51O2/EK=7AX[]WMZ9W=6-T>MEVDK]K[;E7\KQ59
MI46N@?0&Q,YX2]8><=;VT)L+8=:U[(8D6S1#_9<CH)Q9^YH\X8SZ??./]!/]
ME 00WE PI((+>O'Q8BNQ')JE<TO:!^YK1Z;\4Z!UAZ)V=YSKNWEWIIU?+'J9
M+J-M:7&6L*CK]Q5@,9=P:RVDD""A,=LLBOL20<LC CZN177RXOJ*D$#U /X<
M_N\$'_365_<0^A/^E1]U?U6\*?\ DSXJ=P^P7]U_]JI!\."\[-O/GVV];;V3
M8=N6V@>H_8>F8=@VQ94%-FL56TKZ=VGJVF%/@Z%6:=4^F^%5JBF)A.FK2@4H
MO"4GH.+N7O'I1@,\#'"G'/O4$^N3ZGXUOQQ5:Q;Q5"]2MTA$Q(P[A8<KG(#D
MZA+@A/%E%DF&E[QRZCGCPE[SBS[QRQQDZQ[RQRZ^GKO@.J^GK;JWI?J/I6]N
M;VRL^I="U;0+J\TV86VH6MMK%A<:?/<V-P5<0W<$=PTEO(T;JDJHS(Z@J=FR
MNGL;RTO8TCDDM+F"Y2.5=\3O!*LJI(H(+1L4 =002I(!!YJ+ZWH0.MJL-5E[
M YG .267V4?W'U)W(9+\S/"&*+KJ,>#'OZ.\8L/K?3)E)+EEEG+EWSH/@AX0
M:5X'= 6/0&CZSJVNV=G?:CJ!O]8>+O&;4KCORQ6]O JP6=I&0"EO%N!F:>X=
MVEN)">3ZBUV;J+4Y-3GMX+:22.*+MP!MNV%=JL[L2TDA'!<X\H5  JBJX]0U
M:SW#4!*JGU<RZO =BZ,MO557FUQ>>Z44+>6N;S9! 2K<ZKM;Z,_#==;2BP-W
M:T4N>+ 3[3C)/'UE[);LJ2@NP13',NXAB 7AD120H9L;F&<*2/7%=>G5FC(5
M2YW1MM!4$A9$8XW%5] ?4C/I6E6P-4>DG-@MU^UW1;EJ>F[ V&A-M&I:S8ZT
MOV0RPJ^J7-<'V"T.U9Z-U(A"G?V@A"K.7(=Y3&DJ:=2F]D!/#P;H%>TDD"A4
M=TD9$;;*RL8P6D#; )()6(50QYA'+N%(.UFU)(YR6=$>-7<%HU8!SMC(#MVY
MHQEFP"%E)PJD@C('NRUEZX)3V56[+W8QVH6J2@8;3KFYJY4M7EUS&K:S + 2
MZXBN10JB^8V(2W-3'051KAF!T#TK"_-Z^V3U=U DMLJ0(A&&)[;1,\H.]SEG
MV\IM*C:688VC9N!<6V7!# ]TR8 [BR*L9&U/FINX?=N).T'.<NRE0?&\UA[$
M1W+:?=9.V4[10+[PDJ&'Y06LZIYKPM,C2:^5IWMG]*YL(MDUT;#IL=99=9:W
MNUALJ*S9.]X1=VH&T,Y62V*Q[A&&)4MY!E7RQ<E5M\=MCQM$DB*K+MA.TH(,
M=P'DP9" &"^=L%, ( 3/GN#U+=N-F8-NE\VXXM71/:(^.O/GK-M$Y5;9MQG@
M6G[(C$4L*@TNU"?U\JV,H/5%@M,(RQ#U90!(;RS]+A0+A+'69:''D76#&EB]
MIY\&(;HTR=F2'"NK;1[,%Y.TG8+<DE6#X#8J%N?)Q+P[<%^-I9&!8^T%N!N
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MF95XQN!Y)6S3&PCMUPL(-=S,IV]_\QW-#N?%A3^AM:4W4.'7>P]?D]EO8+O
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M]&T6V:YL.TS8756J239-RUH-DX3-I73MM4]AFZP&S4UQ>O)>'$VJU!=B5I&
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M9C6W(G\.Y9,\;BWF)P$)X!R"I!#$JN&!VDEE90 <EP5QNXJAN(0-Q? R1RK
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MBH[9O7NV*^TN].$UOK-[<-;5S:=OM#(+8MAPI1R76VNM/;+B"0G848MG]_N
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M )E]6<5;])_XO[*Z+<56N=7PD_Y-[R'_ $4"?VTYXJ6]3^$_SU\V/Q6OX?\
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M&Y\DTTA.W:<Y69E R,,%8MC(K*\+;I)$8%F[F%(^SBBC W;N,-$&)P>"5"Y
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M[QZ[V[+K71K[4++2T@URUN]0>>.S&I].ZWI<,\EO:S7DL:W.H6%O!O6VMYI
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MJ>XKYAH-6RH$C];55<6Q"M*G 6(4&.2!O<R0DLFY3A+4@2,K09#6X<*%7<&
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M0UYPVS8^]GA+3T=T8$:7UG)6-?K:80%VJMI5*\[LVB\VR6G$DY?2Y3VF9XX
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MUZ9[%>9E5G G8TN4@15[)!\Q (93O3:,,P$TA#9^*1#)9=F5.,EN\S%N[D<
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M_P"N+RH!M#^%KS1^GE^_P9V!SA>HOSS>'_[-:U_Z3URNV]"?H?>-WXI=)_\
MU,Z/K[!_@U_Q3GW],]O_ +LT;GR]\H/\_5M^+VG_ -,U*OT/^1)^@[>_CMK?
M]6Z'5F;-_E5O'O\ N1>[_P#&+PCSPROL(?,;]<O\SUT7XJM<ZOA2?Q'=>?TG
M^J?\V>\>*L_SC^U_,*WAV1_!W??T+M/]AG<56M4/AB_R;/P^O]R3RK_@71.*
ML_SV_7-_.:A?O;^$SX9/_:+UG_*/[!Y!]5_#_8:+^F_6G^RNB_)JM<Z/1/\
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M<3=V+M0R._<3;N&Q:+;/=VJ7DCPVCW$*W4T:[Y(K9I%$\D:X;<Z1%F1=IRP
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M,2!'G],&"IO8@$ 9XK^ZI[DFMUUI]:4ZO*-4L2=9H[L_73[*)CK-IV4P8*,
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M\N7 >1>U$CXVP%W+LX+/G$>U=F"(RI]3N]!7ITYM[;.Z]NNVJYKNCK5J]EJ
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M#_8:+^F_6G^RNB_)JM<Z/1/\HE\-W]%/;W^'FJN*5T7XI7.CX8O\!V[?]_\
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M:?H0" <?J:;OKKN67Y?UY.^NN\\N^^NN5+,QRQ+'TR22<#T&35@ HPH 'P
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M0?SOA\M9)OLJX6(0?YTG7L[#K.7Y4.'S,^L,>LL_IRZQQZ[^CI4Y3[ _O_\
M\:]='\C>I#/26E=_^B_6^M]OAZ+1;:55.DT#RL5I>4HO;:%(A;'M;.5Z%VC\
MZ)= A"F$!C01]RYY38Y%Q]9]98J@E2,!2.0?G9],_>'Q^-='N*K6@N__ "IO
MN\>D*AZ6\]>E*3HVU(-(V'1CI1>_/)&\U;VOO[XAOV3(3(;=6I9$AXK*O B]
M8Y8-<)A\IN_K199]=8JL& &"N><^N/[#6"_(=\3?_I!?.G_A[-O_ #H<5.4^
MP/[_ /\ QK8CR'Y_D\K^:--^>9KCUL";4]-$JL]TZKW53QLD\!)14S3&M].K
M'TEPGD*R^H!]^M/DXX]=?;)?I^GI52<DD#&3G'KC]NOE)^)@DZLWJ?U%7.R?
ML75@:LDG9G4/VCL3IK45X'VG[/\ -@^?\C[1\WY/SH?F_4^I\V/ZWU^OOGPZ
ML_HAX5Z+8&3L^W:%>V?=V;^U[3)>0]S9N3?LW[MF]=V,;ESD?BWXYZI] _E&
M]6:T(/:?H1UCI6J>S=SL^T?0^'2[OL=[MR]KN]KM]SM2=O=N[;XVGF.DUOOR
MOI5"$#>5)^PI%:]0%\_2$\D_V1:)$&-\Z3K:V'4DOR8</F9]88=99_3EUCCU
MW]'7)6>@=:V-I:V4'6.C]FSMH+6'?T?(S]JWB6*/>WTS#<VQ!N.!DY.!Z5P.
MJ]:^$NL:GJ.K7?A9U1[7JE_>:C==KQ1A2+VB]N)+F;MH?#]BD?<E;8I9BJX!
M8XS7J"U7LT^\T"W7O:M=LH- 9O6X*5+K"2K3&&.ZD\J>7SVLE]L'4<(T#R0K
MJ/I=)W+)!C%]>/K/N3'+#TWU#-K.B:IK/4EAJ$.B7%[=0VEGTZVFO++>:9>:
M8=]RVMWVU(TO&DVB EF0+E<[AKW/7O0UITKU=T]TIT#K.BW75]CI6G76IZIU
MU'KT=M;:7U#I74 [6GITEH^^2>;2H[<N;Q1&DK/M<KL;[$/@U_Q3GW],]O\
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M)"A%N(V[FQGR2<L1A#&"NPX)+AR0P49#!0?)N-1*9S(NS>J8 &%SYQ(0Q<9
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MG '[9KS]/T79@*[ITI[8,XLYUH'3(/LQA!$/@7),"+\[YY<48LD9.<@^$F&
M^>$V674>6.7;!P3@X'J<' _":9&<9&3Z#(R??_-4'GW)K>)VTKL5G%/<)I-=
MQ,A%<);/ ;/:=UL.OJ;'T8%!,#/,7:JI8P68PY,Q-?@4%,'T*Y?W"3+?M28#
M;2 =^"<#/;19&X//"LI!QAL@+D\53N)DKNR1LSC)_P H[(O(X^<K _8XR<"I
MG#9JV2-$8/8$<XDS#M3"5"V E&E:8E8@Y+8I\",HI&&)N> ?8>.79'16>(_<
M?SLNL.ZE6!P58$#)!!SC&<_@QSGX<U?<N,[ACTSD8SZ8_=K-\K4TXI3BE.*4
MXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3B
ME.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4
MXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*54&Z=6#;>KM8K9^"<A:GV;K2]L@7H
M&+)<S!H=Q56B=;(')'+#+,7TMQC&[(CS'P(^7G-UWACWS+%)VV9AG)CD0$'!
M!=2N<_>S6.6/N!0<8#HY!&00C!L?MXK1P_X?[-<DK@U-;4A3)7!J'.=75Z[&
ML(;TQI=YW+9H1K&=#6K+"*,*/M89E7V1%4LTR>TU@ V-5G%\N6';%X"QW!R&
M+>8G<R!DB4E067DF,@@.N58C-:IM,* NP8VG:!M5RK2L WE;'^4!!VMAE'!K
M\!_#.S 76M)A;-K61908-?="YY"/5V:\.OJ[>E?52 18MBLKU*-#>7)M6,8[
M(6@+E,/=*2T^G1,Y+6N&[C(DRKY?N9Y!!+%6#9)(5LH,X0G=YR[XVE[+)N0[
MDVH$]Q& H8%0  2HWDKEP /*%7.X?BB\3;DK%2:*:Z]U.N*:5/9^MPT9/;<Y
M56:QLG6FOJ)G9.K<OI:"VWIJB,UXM,65V[PG-\:^1%6"=KE0IUYW1KJ)G4L)
M2%:.3/&69'=]NTN50'N$$IQGS=L9(H+:15(4Q@E9(P#DA5=$4-NV@LP* X;)
MP=I<X%9B]>#&[J ADE/H9KYC>;R_>@N NUBFRJ[AKFO4!66^9]5>U&GN*2.H
M:0J1,U?U#*[:[.@#>UK-Q,SP)>*#A@X4(B@@Y*E79R -RC:Y()YX958AL8HU
MH2."A)=BP(P&#*%!)VMR@! &/1F (W$UD6OP_E+4*Q1GR4%VX<KML@8V)Y5Y
M63>>2^:(I.GD)C ]MFX;D3)BJG*V)R*;,2NQ2X\(S23L9B9*B\(*XW@#MY56
MP/),TIP!@#(; P!SG@"I-F"#G:21( Q7)\\2Q@Y))X*Y]3^'/-1UAX"L[BQW
MB=W::J[56=I;'&3MQBR-?O1KU9J>\:4VQ*H5 ,$E<2+ZYV@"G;V6Y0.5:BEP
MQUVK25[$B6XO5"IM5E9=HP,!1L5P'4Y/F);<<*N"7\S;L5'LK%F)*D,6.>23
MO925(P. J@#);(51A<5);IX>8,7EI9UP;6,BUX3>"%Z0^&PU7M+ \VUIC:Z4
M-0UJ0OVE1-$TUU9I,S(X#E"RP6$1ZRJMY5YV"J.:)=@*H;N94)DC:V2(Y8F+
M!N#Q(N/0E5(#(=K++VI).T1X)<A3N4#,D4@P5'!RC'T(!;)5QE3;46EKS5=*
MZ9K1$ZRT6/5NXJUL!NOKBQ,E7,J[)L%R:Q7CC)D=35-6-+JUJS;XM!:O7R;S
M9:C&W_#ZAJ_["%QF5&FE;!59(F0$DDANV #EF8@,RXP6;8K8W$+DY.VZQ1J<
M,R2*Y   (WDD<!02@;.=J[RN< G%4-J[R=LZV*-4,MN 4%0JI*[5B^.BD0L[
M"Q. USL6U7CHNS8L%PR@1L?@[5C0I1(FH*TU1(Q[>G8,H@E.62XC7N"(N2Y<
ME^  714PN"21P?,2"0<;1C)Q) [",R! %V#802<(S-ELC&3D<<@8SDYXD";Q
MTSUN@K=:J0U;QZ;=>0ZVZEJZ>)&&OE\]^@[EO>U71GW'&/UEVS1,>J_7)/DE
M'=6F1?"5C&"3D1!!NA(69BW'M+#<2Q/>@6%$&<^A&6]!M!QS4BV*!57&#[.I
MVC '9F:9F/X0=H]^[&>#6PVWM>;.V_K&NJ)!Z<DLR[8(UB=(V$XTZMK7D;-]
M"G&760NK7G.JO)AY*[9,G %;:GAE!'(%QJJ0^.QK<$3QQ2,?,RE"JD#D,0,Y
M7<NX?.7&X Y!.<;3FE221%'E!$@8@^A52< ':VT_-;(4D8(!&=PUKHW@MJAI
MR92YL=2BN23#1Z9=>ZZM/QL"FNZA!L* GJOMV,.3=.2[1O)\@U^)I(RR4TU8
M4>U%Z[-+V'O 68@-M;O$HQ&TM*5;) X.".3@9P" #P,*6A50"5W#M . =P$8
M*\$\C(/ R0.02?4_W2O$=R"96")RVUIKU&STO4M:!YZ96-EC3"WT*@;<UC7]
MDDQ&@JQ,3246Y'CW%7C-.37FM;IRN!Z]P4R/B#W:$+M$CD2O(>\01M=XI#'P
M3GF)03P&#-Y1G%%M6&X$H@,:I]:R#N5)(P^,#DB0G&3@JHR<9J94'R >OV51
M]CVY5J%,-3GR1F-KN@("<J4&;4M6OM?([LGB:JUW0=W8DNAB22.EV&:"O5JI
M5X-PZ)1=.S*/<@QM&ID.Y6!=V\Q#R+(R'!/D&#[_ #,S,0,XJR6Y#J[",;2I
M"(OE\B,BL,@><Y'./*JJH)QFM^^:=;=.*4XI3BE.*4XI3BE.*4XI3BE.*4XI
M3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.
M*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI
M3BE.*5CVK5>C6G.&Q482U:+,:<7+];N. 8?#N263O'#'.3/OK''OZL<>&<DF
M7T81X9YY8X]\/U#U!HW2FAZMU+U#?PZ7H>AV%UJFJZC<"0Q6=C9Q--<3LD22
M32%8U.R*&.2>9RL4,<DKHC9[6UN+VY@M+6)IKFYE2&&)<;GDD8*J@L0HR3RS
M$*HRS$*"1X:S9T5P3"V"ML(V:DWN7H<K"*>#OO."7.":.2 J* F"2.6/+'*.
M:&//][K+KKO#+'++B>A>O.D_$OIC3NL>B-8AUWIS5/:!9ZA%!=VI9[2XEM+F
M&:TO[>UOK6>"XADCDANK:&48#A3&Z.V?4M-O=(O);#48&MKN'89(BT<F!(BN
MC+)$[QNK(P(9'8>XG(('L9N5"2$<ARU6J("S1%HL[,X4"$EB?+U "O'D*EBP
MF--G[ZA$%CRRG)E[ZCACSS[ZZYV\ GT!. 2< G@>IX]P]YK0) ]2!SCDXY/H
M.??4.VAM6AZ:J1-WV,_'KU>'+"78$RQSDD&LV,OR5ZQ<$+',6<>7)UE\H<>+
M/+J*.8B7N,:">:.T<;RMLC4LV"<<< >I)/  ^)JLDB1+N<X7(&?ODX  ]Y-0
M*S^G],TRS66L6BR'I<ZA&ZPL-A+K-E_!H#>N:[DVX]JWXNB52(BK8LU?#/>Y
MZ\(9.RRKXY<T,,I(98L&1;>5U5E4'=C:NY=Y#/VPVW.=AD\FXC&[]VJ-/&K,
MK$C;G+%6V@A.X5W8P6">; R< ^\$5,J/M^D7Q'8WRXQDB@IKC-#<E]X2-:,Z
MJ37%,GLD0MB4V@566LZ*KEB0O@R)\.AB53@$F.;OYF>.%'C=&52 =PW*4(<,
M,E<J5R#YE93]\$5=9%<,1E=IPP<%2IP#R&QCRD,#Z$$&LJ^VAK2JDBAVC8E%
MK99K;[A"%?6U G)+>?46R?<PL#!@/*0V^HY49_=T6.9GU&JW+Y/T'"]RP(W;
M)5'8 ;B0I.%YY.!P.#SZ<'X&AD12 SHI)P 6 )/' !/KR./7D?&O2'L.@,:A
M)L)?>:>?081#3Y;P'9DI50B!6S3CL39++ ;FEP$7D#$0&D9&]0BS#SQ3YQYQ
M28XP4<-L*,'R!L*D-D^@VXSDY&!CG-2'0KO#*4P3N# K@>IW9Q@8.>>,5XP]
MIZQ8G5=8OV-0SF5W52/*6O#M]?).MZ2&.6:9Q5Q(&.9#]5%#!/+(P4QEB81P
MRR93=8QY]]28Y &)C<!#AR58!3\&./*?O'!J.XF5&],L,J-PRP]<KSR,>\9%
M8I7O'2KLZ%6EV_JYNR)E;PCKE>P*FP.GF0+HG#Z&$01M,1+*D4$0-&\>$>6:
MU=-$<9U"-)A+E)BE R8Y !C)*,!YCA>2/>00/B1@<U EB)P)(R<D8#J3D#)&
M,^H')^ ]:_K/=VF(T!-KSV[K#"KAOLJL99,[]5,4 MGQB^?E7"7';;I= ^Q@
M_P!MDHE)P8=1?[3L?K#]_CM2Y"]N3<5W!=C9*_9 8R5^_P"E.[%@MW(]H.TG
M>N WV).< _>]:]CW;FJ*ODYQLNSM>5W*N8JL[#B]NE;49(<'O>/23-STP9#]
MJ\7'>>'2K([J#IAWEC]D[F^MU],"*1L;8W;=G;A&.=OKC YQ[\>GOJ3+&N=T
MB#;C=EU&W/IG)XS[L^M>)MN?6*:\TW6I%S0$WR]LNUZ*IKFRX]_U'^#K9>8F
M[%0,7FQ75\E#2W>8KLD7%<2;B&%#/G.9#CW(BD*/)L;8@RS$$+\Y4P">"VYU
MRHY R<8!H9(PRIN7>WHH()QM9LD9R 0IP?0^E2J6ZTV"22&>VUF&:&%V1-%*
M^51R1#UEB"HL<\D>9?64<-?;,UJMW+EUU@J8L 0C\AR2QXI*[6/HK'T]Q_3
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ME.%U5;,K&R)3A@+Q5U+0A/Y9J?F@Y::?1-@5:Z8=XPH6%H3GQ67ZL +0FI'
M%C&EMN1[8"2-AV&-H\91F -PTX(#HR?I@I!7D@,#D 5)M6VC#C<)!)D!E&1
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M+L)5?<.VJ(& *%<;FV-@&0E@57&25IP[!-^<KL4(#&R;<NS.5.'!SM4N,E4
M4AFSG=4D>J4^#):_.,V!#)5-4V8Y]LT!+5GJMQ8JDVSV*AHZRCT6NU^PEI+"
MK G#J]D-1_=Y+>0 ^X0!2B= Q*+<D%0$\TBA8RS*55AL9R[LPW G++GA<A"?
M68^^,@DOY8V+2 *P+*=X0(B@D$#"MC!/+8K4*-_[,;U8*QX,-]%W>GU[>X]5
M99Z]'7+KA?6OG'-C2<7-*L>A-=L4*\#9*F?M4,\6NJ0+:G$=:7;/N89"Y2LV
M2MJ&(Q $=H2Z]S+(@GP^UQ.X8E",E2K%1N,:$,QUP;DKNS+N42A3LP&<P^3*
MM$A4!QP,% QP)&! $H] WCT3LFN>@0:^)Z$0:OL5=WE7]1B5?1)^%PM%CET'
MYX&UU4W]=LNMC[K7Z%9K^]]"8SV=^OJ7>#<#$,Z^U<("K#F5A6"-H2>RTBM$
M9"TP**O>GWLK+($9U0084%N#D(Q+&K3/,XEQWA&PE$86)MQ;M0[%8&,NJ,YE
M\Q"\^KJ *VGT7:]R.]S[/H-N:DSTW2G1Z_[SD5U^&*]G;<FKNQ]?K^YUZ^$M
M:9HJB_;*$>+UF$38XK$JL5@Q='Y"M.]>98A%&Z@;Y<'&XG8(MT;G!//>?#@\
MA<%5P,BL\+2M*ZL?)%D9P/.9,.H.!P8E\A'!.0QR3FH5YY;7 &RDV%^@;'X.
MAMAJ;6V!J4C8N/;1GIR[UPU,?80%);Z&NUE;$K#&C*.RKM=HBI:XZC'3A1FX
MVG"E0H(!&PJ"V!VA;HP(4D+N8Y)P-S.2,DFJPD@DD$Y+AB%)/<,[J02 2%7@
M<\*@!]!7^>1+_P"CV73>;T,ON_VD]+K((I<?2W48]9VNWDMO>PU:(R'3>L(<
MZ"H^S(1\&@A>S:>JAC!)"V]:)7!TT:Y2 8[!3 ,A!##+1C;VRP[DGG/FR/K;
M'G,2X&8MWF.[O!^=@P4/ED.[>!];C\@XY!D4#&)&))J4[^W"9/6O+=AI%QVG
M3J9NK8<6#AKK;6?=PV292&?GK;VR$88U+;Z_OS]7/*^KM5+;_8Z24]5##%C&
MX+0NVA8M88ANG5DC=HHR0))-D8<31(27#Q@\,P&7"DD>IP*M-(<0%6D59'Y,
M:;I"IB=P A1V!R%)\N0,YP,U0*N\^U\P0<G_ 'L];M#*M+\S*LLU#6GFL(*M
MGY5B?-;GD\P2 J#ML">E<C4D&O(=JK<S2!0*^/5HZ(5->Y<Y2TSY>V8]Q\QE
M99-WM. F"21&;?!WF,@<L6W@)6(/<\9[@DVC*B,&/;V,ELXV]P39 3N#W#;M
M\U9'5+3U&\V-0[,RZV.?FII_H:IJH-D .ZQK>VL2CO+SZKM+:7'YPUU>JF.2
M-CMD:M3VS7"1A@]I1M>1N7]=:QNKC606XC=1L&6@8E-K2*,7"L%'?D1L'M%M
MLA&&#,%885$9RZ,>X<+,H#AE1CF J6^LHRY^N %D!RI"DKRW3L3LO(07(^,>
M([(>#LV(266<2,ON/'LF,6>:$::8?";Z^,$LH\$LD?6.<D,67?>&.B<9.,XS
MQGUQ[L^O/[=;XSCGU]^/3->CD4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ
M2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*
M<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ
M2G%*<4JG]V[-::HJM?L*FHFW(AUM'4>OIEP)RA?(")LO9-9HA#G.9PS5P2]K
M<7_4@@L,TDA+',*(C$9;D>Q"RQ1B1F4L%VQR/D@G.Q&?' /KCD_#.,G ..60
MQJI"[LR1IC('#NJ9Y(],\??]<#)&N&7Q M603U.%G3KTBRMPH#X*!ZTU.M:Q
MTAM:<J8GN@Z&39V;RQ M'P-B['K]0 L5S@455LS/K8?9U8$L.?V.0AB'0A25
M) D(WA=Y3<(]JD*5R6*KE@ QPQ7![7'Y<JZ[L$;C&#M+;0P'<R03GRKE@%)*
MC*AOZ.]S5LY@Y0T>@V"S/D&QM.T\^""SZN."D1[1W5UIPA[B4BV&U^ZF:<\<
MDKNK6/!/8H\FE<Z9+ 8I;#W7H]D8!6=U4-'*X\LF<QQ=W;R@!!'&Y2R\-@GR
MEANER55"Q$D2'S(1B27M;LJYP00?*<'D9 \VWVUKW/4K!+7RB]1[?K%7?I=.
M6GJXV#'6'2=34M^OW]2U586H:?9CBP=06.TUARKF"6IF3)(- .X=B@+31YLC
M6C+N^NQ,RF5=J]S):%5:103&%RJL#DL ?122,5*W:G:>W(JL(FW-V\!9B5C)
M D+>9E(( )7@G KPTWWWKS8L-?BU_KW8=S>7![55%2K]>;Z>8$-!KGK_ &OL
MI&W9.(=JY5JJ]1US35R[>UNSNE=WKYN: =E5H\7P$N9[-T+;Y$4*&+,PE !1
MXXV ';W-YI4PRJ4;G#>4U"W:/@(CLS%0J@QDD,CN"3W-J\1MN5B'4XRO(KUT
M?V%/?W29JJHC!1J]S=-)5Q=8WTJO%NV4;^TRMV+3&HJU4_93K62BSO*U5K"I
M:@Q09 V'%JM:3S)S@I3VVP$%P9 LS%1G ,,I1QD@9!4,P().5P0 0:E+@N00
MA$9:(!CC)$T>]3@$X(8JK C&&R"<$5++3M'<K>];C6ZS.T_6ZOH,>MQ6;#:J
MVR23WETVIX.Q&8\%Q46U"KU555E6;I@NKHSJNRNNW!#LLBO0 UKL9U58X@D1
MD$K--NV]LKY &,:G858RL6#'8'CX  ;+9%FDD+2!#&JQ;0W<!\Q*ASY@RA%"
MD#<5?G)QA<&#C;[W.PW*3KHLJ@Z_&L-VV)1Z$+<=.;99 '"UM#:F%4N"'<R:
MYC:EV@\<35C%F]TE 5K.Z)$15BBSL.36AF16&_9B$0DP[[51W*2Q C<5#*8B
MADC W8$Q$B,P'EPX(J)I#+L)1 S.J;HY,' 8JRRANW(3C)C&Q@"1G*'-B^4&
M]_L]4N]INDFI(,#MN[HK6"_5NKG6N\BGVK]R;!U0_N-F,;;,OW5B:7CJCK7W
M?T"*S$N4TRPUK9NHQV$>.X"*R*@EXCB;,D@DPLD22*J@1IM";R/4@^H"^E7@
M+E6+=O\ RDJX1"F2DCH6.7;);:#Z CT)/K6T4 8@N94@PHX\AQ'VPW.""*',
MPOY$ OVHK*/''(@C[,*,/\^7O.7Y \$/UOEQ1XXZ^2?4^G ^\/A6? 'H/7D_
M?/QKT<4KQD+EYDRXDL ,HA05(<I((%@GF5FR@F*Y3%TLN&6814BQBP72$#91
M2Y@G&"99]CDSQYSDC."1D8/WQD'!^(R ?P@'W5&!QP./3CTXQQ\."1Q[CBO9
MR*FG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G
M%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4
MIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2HM<:96[ZE
MQK]J!E/51NJS8H8QV35.2,[IUC56ZM,Q6:4U<S$)4V)(K9P9C&18R2"8PD8S
M"RSP2V1V0[E.#AE] 05=2K @@@@J2#D>_P"-595<;6&1E6X)!!5@RD$$$8(!
MX/WCQFJWG\YZ:F[JF6%6)!CI*X-,G@46ZZ) BD:YSA9%Z&UA)[$"'>T #OYC
M0)%>8+$I$),82#AQXLV'1-^_)YO,#N.3E$8@D;25)4E"1P2FTG R>!5##'Y3
MM(V@ 89E&T'(#88!U!R</D9)..36#7>3]#J<LOL%4=0_3!61A(LMC[.(A3@4
MF\+-C4Y;7!R;E-#65%1N:L-Q6E-=C6+$/4K!8K%$4N6P!UC<S'U8>K$^2/DN
MA1RWE\Q93ABV2W!.2 1 MXA^E/Z7&7<XVL'4*"V%"L,J%P%Y  !(,M"T)J$
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MW#K#N3J6NH'<%N]@-&Y;:"6,;NP7:\[[00YY$A4'YL8%%MID4A>T,K(FTM@
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4(J_>8:S4XI3BE.*4XI3BE.*5_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g796801g57t95.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g796801g57t95.jpg
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M$Q055%56T]77&I27F*8A(B0Q(T$E)C5"1%'_Q  8 0$! 0$!
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M"@EYO5CNO^C;\ F3;^M</<H4$O-ZL=U_T;?@$R;?UKA[E"@EYO5CNO\ HV_
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MA!?2IFD+,S#T/NA&F&2U].1GW!3'>#H;*C*4B-Z"%B%;DU\*#0'3G$TXM?\
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M'L\OF#!V"V>=AY+O-$MPOM\N'EQ\F/DQP\N'EQ\F/_W5.9]* 4 H!0"@% *
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M)*>D(A.U0.7&+E \H*YT4W986!U.J)Y*/+?.<R\5""@% * 4 H!0"@% * 4
MH"M>:7*%EYSI,!"C#,HPS,@LILOI#DQOIA)[R#'YU)?3:(+*:A.(DX8T=;.<
M@1M,)N!7L+@X*^)/ 4U8:O+7FRI,<N*FZ<5S4/!.4^33E$&M#HK<@S$BA\0J
MU\OB:084F/1@2#(=IA^2HKO-[.V*W,F/&.U)SRBLOI0E!:+M%QI!-11T<^\1
MT0#SCY.Y.O(*RJ5.BVJFYG&&EPP3F87!<69;,9T9^2[-@_U>3)UB=4=3L<L<
M!1(\!T:5)?CU*?,?%#Q]426^^6_'#]:2&[[&^J*9M4;IY?3SZFAJ7J)]-.%S
M:.C#)X*JI1#X.5@G#[2B@>97H3$G,%/3@>83QAMJ1.\EW+PJ+-@$-.L2>6ZB
M9>QFH(0:K:?R9,"/'+@47.3:)5N62K),3NZ36DS%99:2>LJR48PMN%5<+G*3
M2Q48S.$<,>"A3C\>P>8;+S#V:R'GA <^,_!^Q*_<$#!V-/%?<[8P5L&NZ$5Y
MH7_YQF+3=<I'U%RMU&4O_P :L$_6?4_4SGK! P:*CC*;3E&GRKDXRTS>_3TF
M2Q%*0^7BJP@\,MZJ=6E5RWIBM"C\5R2^Z6*JM<LMEVLI$U!:3B*H753R*.X$
M@Z6#'159/O\ +CB$M*$\)3^:X.>)"S6Z+O)*TT TW@(L<CB!./R(9&'6G[-4
MYR$\L7% 2S>O0N5L?3UDA<>(32C=3$%';C"#7+61;@8-V'V^>M.G<# MIX\%
M*:P22AX/!*,<^)_L?=%YDHB^2F5*[-B]TI[IC)^O^2XL(')OGA98,6NZ50%\
M"2#D<Q4L26>C%G$'M<Z%TTXT-$:)1$43IT(V*GXC)B1<G@ZJFFF^*2>"EI1$
MN)PA<_\ ;-3+=$-D%2V*U(Z;L2O%H-UAN)].%BF&9F!S$M)TLH*3BB,1D)H-
M-\H,JD'FWHR=Q9!3O:\5I2\5CJXW8852S9+*YPV?&!U-N7&*AX+'XJ(;[O'N
M9J2NBAR#RL&WBSI@JX@F-V&R&7S!%8,F2[%:(XX71[!\$./'VE1D_6D3D!"0
M#!D510\7F$N'TM5QM4BAP,Y9:-@"JJ6"?.<4GCFFU*?P+"/'*1EZD!JP R'C
M'MJZT<KKRCN0(.;QIT/4-+9SPB=%';\=+9PL5<8%KS':B68%#32[\ZSDL3>-
MJH:+&%0,([8)+Q[RGPY_Z^1$<]]&EDES..-^NR:H4M="[*#+8<?OXVDR++#"
M!<[9C!YX/]@@GTZ/'VU$RU8:[IP]=3G46)@.K C=>@#K0S?OO2[A554HA\&V
MN&#:A\>QMV6#(EEAR;GGBHY>F4[&D;?I5%).D1RS3.,L6'BS?&4ATFPH7E^1
MWX71+@!58_<,,A!)HQ[ 4.Q0$-6%2EH .IU1,89)+_21*C5R\0ZR9LE?,6V&
M?@F3)-Z$P6S*#Q]ON<YBZ$2,"2@G,8EBWU!:-M9&]ADU0^#ZRWD1)-J7I_2*
MXZ@*$#>&)+A+DICY\?\ 1@A,J.7LPYLR#N/QFDJRUF[;S3:F8W!<4%]>1I0;
M;'9:C'C:1E5LK*L>;240),U64$,R"VTA%P5P3-YE9Q4#]H9JP)>&/#AV*[(G
M14Y&$:-Y,B<6)7$YF7+J/'[8>X3ZFN=GVXS#,BET%'G&S"0'R[9*6'PS6&S'
M(1**:.SF>XD)OXBA>8>(' A!K! M/#MPA)<5#P2C&#=GOT=N4.1)P%S"NN+C
MIR1E!QLEYN8 A(LG(<=OQYQK:3LCUXR1#Z&\DZ*)%=++L3B%J NO1F+:B4M3
MT["\<7!,3O5!54TH3PQ7!3#XJ8G'XF<)Y#<J">S&='I2*;0F@P,RP.<%HI'7
M>1Q/9&8LN]%20@9%P/BN^]3/8V/!:4UCJFI'3C'NQ,^H7-G%,!+D@A+3SY6?
ME$1HH,')?1VY0Y=F8>>GW%QY2D%546*L/ --D63VTQ),5XP$+"QPJRW%;:>2
M1&4K*+'N)$PVZ<D%I.(8H5)$"-]XQ%/(%BP2XCE\%A\'Q4\XB>9J)WHLLC*A
M,5DZ&8=5<'V!.:+F;(E2<NS4EQZEYA$-5*K0,PID2I4B$HM)/E34B18=R*P+
M/PQ=%MID!PA*1=25 CHMIQ&'"."F,IB8^>'(L]/>7B'LSS""C&<F?@^&."ZV
M@]PT/%?=#;\UT,)?).AIJGM)HK: KX^R5U.)GO4KC^*>>]#ZLI%#A,04O>(F
MTY6#Q6JA^"'<Q.0#*IFH>)!_S/'JRK.\JT!(Y5%II2=*D7&'I&@JH,MBQI)
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MC1R&KV*PB/BHFI15(E*1^4:>)H.X>UY&7$$U[TW&Q5M5<4Z^PSB.5EQ.&?\
ME3.DS\HDJCE6S=9W90S3])A#DLQ-$J,Y,LT>Y:G! <)->3!E! 4E>5VI,Z^&
M7>,ZC1P14[!'P9:;4#45"V.#A%B%\1@T]#7!0#AA5?\ ?]_R--4JFEIO%U2X
M7*."GN^>/8J"W>D8SFE\I$D9H9<46:T'+EEZ7H3+7.4:L1*0G"T%#+V'+#)@
M-S1LE.=:;H2\J'FJX9*+.E D5/";#B75)KI^*F$"@J2DWQ1;-+J27.B4WFDW
M,)]HC%*>9^DBAS% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M55#GFJ6E'=-8XY-_.,#K'0R* 4 H!0"@% * 4 H!0"@/S$=8<U'CRS7_ +F
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M!*7%&=6JV%X^FGU?V'6'-1X\LU_[F OP)2XHSJU6PO'TT^K^PZPYJ/'EFO\
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MC.K5;"\?33ZO[#K#FH\>6:_]S 7X$I<49U:K87CZ:?5_8=8<U'CRS7_N8"_
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M$I<49U:K87CZ:?5_8=8<U'CRS7_N8"_ E+BC.K5;"\?33ZO[#K#FH\>6:_\
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M% * 4 H!0"@% 467LPDID%]W/LE8Q\(5868MBY>%=KF4!;&?ZQ@ZW(PF KR
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MLV7D;E$V>7%TK?*J9$R6L6E,4_S$X&(EU27T41-],3$Q](IF5,4%4]:Q'MQ
M##]4M+B>=?=;"_=#?[K,S[N"R^9%4U96'[6WKQ^Q'#AR9-)>3'*D!OEXIA)X
M-3-VRW(&6 ;H]Q]!S@O8Y(3O""$-HXPA$TSW,.4':1HM=9=>4(V$UVQ5#,#W
M7'1,XQ*K7#K;?AOYE7M&FG"E/V;7'_\ YJ%SYKCX@D6W+HU[2B@4]N+V-BC/
M;>S BW8XI_G6.1NCMHP510__  O)[#'N;!2TQA=A<?\ -,&?1G+,?18AK'?_
M .[?F8);?;_%T?)SWXX_8K/!T%S @RQ%%ZZFN]IQ1 K=DUOM)MN-R1<XV\7)
MN;!+1&HBL1599<L]G,BHR 5&"*+4FHS+5T1%(I2'@B+JF=5E_#-%-2:G!4II
M8KG\.,9M+#,W552U5P=533;2J^<S@L<FY<O(NNZXV2G:]XM?1T^H%E"*5AT+
M*.3*XEO4E(=U,Y79AP)3]* (/B$7(K YHMZJ*7O];""]+<(#YX=VW3-5-4_X
MS\Y4'--I-=43\G)$1[+ EG'2>.VOYVEX[5)529P4XGM*-L1NFY/1%5)<I!3Q
M6Q$?%U MZYZH22_3K9"5[0#3M*8CVG040T<0C$=&/'"U:B%_ERQ48<X?',U;
M<<%-ETVL9LO#.)AM3DXR9J17)2S"15SAEWX_KCDC ))R65$V:2#0TD/)!D8E
M(Z._E< 1,P*)KD3C(1]I%<$4$BEAL0VF-C AZFU&K<DR[XXO]R_=W<S:^/++
MMR%X\,%AA3QP3337'YXRYE\W/L4LH9-1;;YCO"7I*3XF=R1-*>0CA,O;Q%-0
M#4ZD'24=0XRJ CV*SI2D(T\W&K,EN.<PHI*"IG"9DP&IWH+=Q25WQ5IV?W12
ML(M)KYI2X6'>2JN'3595I6<<<;,1AR;A2UB\<V:O..6E>561+#;CP^Z5)8G2
M5(I>)=3"4&DBAP>Z&:CL9O&I3350W:16U(B618T;@QEME+'&IJ*K=>F$B15"
M6UHRGRJAPTI<M-<%9:Y\IF%@*:U*;A0JD^+M)RXC%<6^,*..*QNBVV\CM%NH
M#4;Q()-0&PBI;>0TX##R D$=%(@)J:2!P_\ H(J2+ @!X8__ -0\*ZI0DER4
M:'-N6V^+Q9FJ 4 H!0"@% * 4 H!0"@% * 4 H!0%757+ E*CW4EK!]N@K'S
M@E%JS8Y8F")M\1OK$GLS%NF417P6QDR]R$4.]=:#5=JJV2Q_ FH.E%L/X&"Y
M)16$U0Q8QF6E:537=<Y[OB;MX1"E4NE/'@YY<)Q:GN6BK9@4 H!0"@% * 4
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M4ZB:8>'+?^.,<(%U4,J9% _^$08*^\+_ *76T(\&UD2;0"@% * 4 H!0"@%
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M8H6$NN!L$>+;S;)RH04 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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MYM,JVD9<GT U5,N>B=TE7T\<I^51GF72FD1":Z&OLB>W::E-!..Q.- JB2X
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M8X?\X8X?\8X4!_M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M/AT*S&2 FL:RI%R([28A]4':C14#^"@8$<"DWTH@?<0^!859,'+B97T(TO\
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M2T0':+(/SV\MYUOCJ0LEH@.T60?GMY;SK?'4A9+1 =HL@_/;RWG6^.I"R6B
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M"PM.W+;%TDVIX":IG/4GW*TIQ;%Z2>N3P%\L9,LQ+-/\^L#(_KI115 4:\D
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M+K!+<N5[D*)& E^W,2/M.PFVDP((8)-72SG3R@(. &(1)/)N0D37BZ<1L+$
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MA]QN525A75,X<8SXKX\L7AW['3&AD4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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MQVVT3SC5';*[S%;1%UNBP0YBBQ*R2J8$;4A'BNE$PZ9"4#!(^$&(822:4AN
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MFGQX1.O'L67K9@4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MJD;B1JXD<;T6GV"FO(T95;0L4\@*0.28T RQ4X8!'4,#X]Y*P:TB;Q"#_O\
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MB&,'8*'CCACACC8);A?9CCACY,<,<;;L,?)CAY</_6- ?2@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H"JZWG3RYMZ7,(457FN O&U
M\-N+SRN!&<I'XN193>2>E*K1BYQ3:09AF'&Y)+F(KJ#>BL5<?1!S'C"^WD\)
M,Q47"AE% 6'$_/BIC..,*,7&!:BA!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M6V[#'#'R8XX?\?\ &-#F>R@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M90))()V$KE%_&+Y#S)M4^;%6P1R$@SPT6LDD8603!DP7*&EV*S]LWFDIIW&
M>JRBI1P( 6)88IIK"N\Q_P IAUIXO&J%9RP3J:7)QR6,_8FO\6I5+X<*6_W1
M[RLR_BL9,\Q6B^CBNCWH!>05J/R<Y97U@)+-QO.K=1$9:1UYZC/MRI^,[.AQ
MR%>-:C#-6R0S_LM+91$Z22S(2J>=!EYV$E*<X<+5/!5)3C,6I?Q^,B5S:FS[
M3&:9Q2A?MPXS'/%\H->CN/)F';L;LI319I;K9$0LC:2N$4JU_-+U$@7?.8[&
M62&)M+]G&D/S40PT0) &)CD#Q%+.-P15,D_2(P]LII<)--+_ /GFN%IM+A\X
MX%;IM5.:9_\ Z0W#G]M,?'G'>>Y(0S856J\2+7DM/G,;+@VI0S#DT-';0DU+
MRT$HFDZ'5>(3N-S&%/R.ML!-]?F4@V3X(J@VT9UG&X1M'+'2C<M*7FE4JG2J
MZUS<.59E+%\X[N3,IK"S:=-+<V5SJM<<)?[9G%J<'++=Y+U537,KT.*ZPHN%
M643[9&,&%%V'!U!RF\+EI4P %7#ID488RI8E\ K3(EXHF&(EN.%EV(>%M=/9
M_P"%/P\SB8K45U*$L>"X?(L_6S(H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M=S?+J[LA0X>DK-:H#JNYOEU=V0H</25FM4#](=> ] H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@/
MD."&8!&+BX8W!#A" BVVWWAW7!BV8V7X87AW6"68XVW8X87V76WVX_\ -MV%
MV&&. '"N&WO*#M=V6OH]%.0WR;D+*UF8EE9S"O$5UKMSS=N6K*V VGIEP&>*
M]B>P65<2;R,\Y2QW=<M*!X!\DT66T@[BM@%ES %D:C!N,&L)S?&(X1#B<8C,
MUN)<_D]HS#RSK B&P(_@D]$^7!7=;N<K#S"3VAGER4'6H)+R;+QG5N2P_7OE
MI,MQNW-XXS'9F C:3&Z]U5=*"+;^0$? \H)80L8Q:;PF,%SB,?@L>T%JP\_C
ML3V- CU=!&+4(E)&9?/]$SX.*YIPHJ&W8ZR@)&=150W6$HAGUTZD#CA9;&6)
M("V,DN4B5*+CF'2&X4&,(Q8@$?'@GK&^!39Z9WLR#]CZ2& _31-&406YD0FI
MHOUAPO-F5Y0!3Y*SHL*/'BT"2%+DA.>0'@T3::3Q*IS[4$**17&DJ*TD*T?
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M"BII0P*"&#A+GBDUPPQQ3P[8-0=H:&10"@% * 4 H!0"@% * 4 H!0"@% *
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MQV]9#8]S4=JHN/(4LUR02HA(TAHJDQ6\VV2H/Q*%M,HHZ:\G<GI1ZV](6C(
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M(XRVVDTL8Y-N'AC$+AQY70KJ8% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@(*S Q^X
M9&:['26T&4$-H,Z0&_U# Z:M*!VMZ.Y>9[S<@@5]UE_I38:(BGKR97##"XT9
MM"+VW68B8789J3:PQQI>E2;X]D:I:3;?36OG5152O+)UK1D4 H!0"@% * 4
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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MAELM0\<%:7;!S&&*Y).8J7#%J?W<RU#02YA>^9QHQ2;?\Y,.'4C-9G* ,(K
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M&IY3,9V(K 9(Q)*:9@J&6%</'";5??"*8PY\VIXN<9+%M2:'^^LO#KD+V3F
M-7Y1,N^99V-]3+/L667ZLR5+4@R;%41R##<RO"(DE8?S>C.'F+)9EAR7(D/+
M;V4HFE!G/1Y($@JQL95=HF$PHQ:XI+!0W*G"7R3XIKL17'\G34\'(]89:<UR
MD48:_F&R CH*Y&&8#,'.N/9O);ED]K9@1([S*3DUT*0'6SE;!KH20Y5QL@EV
M<Q''>>!:-S9<)4[ZI.?R7_OV+*XX<*HE)91@FU/^^<\]H=J!*S5F:/31%RSJ
M[G! .9?/?&>60>09*E9PAK:DH97FM(,(,1[.I97!C<C$%N1%);:B.K2,KKA]
M=;Y.]IJ"VI%"(@54F#3X*4ICLW.'98N((JCJ4\U*S#LJ&V/.DDFED[ELB\[)
MA]#F+,'.4AL7,6N3K#R0&LB%)B@>/6AERD#%IJLO%'QEX9%@[;+ED]('&CE!
M1D(0ZX PE>&Z52HAPWCCC''%\VRSLAJ3_B^=GE%<@2]F/;63%OYA8J;,FRU?
M)LJ!/%':(V3 9T-LFN3HC* <BLMB/"=KB 3X?[<<B (7<UK>9Y]RHB(XCQ T
M'>%+6"C"9:X9QP4.?CQW3*P-/$NSIE[3WQ*N8^V$FHRLXT@1X8/+[J92A-+)
MCO-U&S<RM.&;C-Q)(775:H0^J&S10FXL4Q2E1H7D7$^BBT$M+Q90$<8\)_;_
M *<QRXY?!8'OZ0+,L^H.7>D-;A5]22V%UU=&RP%3* CM4@[U \IS^GJ.==/?
MZK$P+>3SO_[XVPSD#K+Y,IEUBD@-DHU7.L^K(*5@H%CX/F$DX^./98<<IQ@]
M#Q=><9/S&2GEK82A)"W<PG#+V>!B/11&6<4)YQ8NP^(EPYEA4'4/<&1% OSA
M.9VB!,T-1OM+0U$:6BG0$]&52M@P81.:A\.,XM?_ .,8\;3?(HS%LN9H%"-7
M4JMN7'VYS@L+P,JS*G 3%F-FUX-Z>U7,Y ":9$6"4H0A&+<RTO$ZRE29TB0<
MOD<FPD8NE%B!P-CMM+;7M5>&H4J>$N)5*40\FYY8^3:$422HC2969L32;/;'
M/V3!TS1YZ+5A24IH6&*O7O5/685?&#,4S2DK+(MC5<!&24$% QO.NL975'8F
MV*[@530YH3!\4IBB.4\GL_)TEZ,F0UMXHLY(1Q6=#N0&D]&GU??EF822\T</
MN 1<9I,=:)1++LW,=IS#<*EG"(9V06$ZUI_)+"<JZ&F-9U^I&32,E"5?]A#7
MQ2P_]\'42AD4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H#CMTF"Y#)<O+;.75LE"$VR5E076.SYSD2(#\P,:1
M6&M*;Z+.7+S&""$Y@2QF8!%T1 <"LBDFV8<2PEN)DF$M-?\ :CCI;4&E.&$I
M/@L,>3G_ *(Y2=)LNURS=E^@NYQL]1CQPW0Y&-R\P%A1,K"NQUG%E(F*HSU1
M6.6V'%11;)[TZ*>43=EADZ9)"F1[;11;\,!E\7S[YDQT H!0"@% * 4 H!0"
M@% * 4!A>LC=^/HNU"/UZL/)Z,DK-:H=9&[\?1=J$?KTAY/1B5FM4.LC=^/H
MNU"/UZ0\GHQ*S6J'61N_'T7:A'Z](>3T8E9K5#K(W?CZ+M0C]>D/)Z,2LUJA
MUD;OQ]%VH1^O2'D]&)6:U0ZR-WX^B[4(_7I#R>C$K-:HT*4&W'$OL%SQH\G&
M<":SP3\$I>P9\E.*.W"83<3(!@R2)O%@N-MNY( 4+ /45/!'6R%RBE&#R4<O
M&3SQLL,AY/1BTES6J-F0!F&U4%$:[;-MA$;K;2$U!0$5-.II5.2$5')@IR6E
MD"H0UH18DGD2X!0J7#MP#! !##LPPMMPPI#R>C%I9K5&7ZR-WX^B[4(_7I#R
M>C$K-:H=9&[\?1=J$?KTAY/1B5FM4.LC=^/HNU"/UZ0\GHQ*S6J'61N_'T7:
MA'Z](>3T8E9K5#K(W?CZ+M0C]>D/)Z,2LUJAUD;OQ]%VH1^O2'D]&)6:U0ZR
M-WX^B[4(_7I#R>C$K-:H=9&[\?1=J$?KTAY/1B5FM4.LC=^/HNU"/UZ0\GHQ
M*S6J'61N_'T7:A'Z](>3T8E9K5#K(W?CZ+M0C]>D/)Z,2LUJAUD;OQ]%VH1^
MO2'D]&)6:U0ZR-WX^B[4(_7I#R>C$K-:H=9&[\?1=J$?KTAY/1B5FM4.LC=^
M/HNU"/UZ0\GHQ*S6J'61N_'T7:A'Z](>3T8E9K5#K(W?CZ+M0C]>D/)Z,2LU
MJAUD;OQ]%VH1^O2'D]&)6:U0ZR-WX^B[4(_7I#R>C$K-:H=9&[\?1=J$?KTA
MY/1B5FM4.LC=^/HNU"/UZ0\GHQ*S6J'61N_'T7:A'Z](>3T8E9K5#K(W?CZ+
MM0C]>D/)Z,2LUJAUD;OQ]%VH1^O2'D]&)6:U0ZR-WX^B[4(_7I#R>C$K-:H=
M9&[\?1=J$?KTAY/1B5FM4.LC=^/HNU"/UZ0\GHQ*S6J'61N_'T7:A'Z](>3T
M8E9K5#K(W?CZ+M0C]>D/)Z,2LUJAUD;OQ]%VH1^O2'D]&)6:U0ZR-WX^B[4(
M_7I#R>C$K-:H=9&[\?1=J$?KTAY/1B5FM4.LC=^/HNU"/UZ0\GHQ*S6J'61N
M_'T7:A'Z](>3T8E9K5#K(W?CZ+M0C]>D/)Z,2LUJAUD;OQ]%VH1^O2'D]&)6
M:U0ZR-WX^B[4(_7I#R>C$K-:H=9&[\?1=J$?KTAY/1B5FM4.LC=^/HNU"/UZ
M0\GHQ*S6J'61N_'T7:A'Z](>3T8E9K5#K(W?CZ+M0C]>D/)Z,2LUJAUD;OQ]
M%VH1^O2'D]&)6:U0ZR-WX^B[4(_7I#R>C$K-:H=9&[\?1=J$?KTAY/1B5FM4
M.LC=^/HNU"/UZ0\GHQ*S6J'61N_'T7:A'Z](>3T8E9K5#K(W?CZ+M0C]>D/)
MZ,2LUJAUD;OQ]%VH1^O2'D]&)6:U0ZR-WX^B[4(_7I#R>C$K-:H=9&[\?1=J
M$?KTAY/1B5FM4.LC=^/HNU"/UZ0\GHQ*S6J'61N_'T7:A'Z](>3T8E9K5#K(
MW?CZ+M0C]>D/)Z,2LUJAUD;OQ]%VH1^O2'D]&)6:U0ZR-WX^B[4(_7I#R>C$
MK-:H=9&[\?1=J$?KTAY/1B5FM4.LC=^/HNU"/UZ0\GHQ*S6J'61N_'T7:A'Z
M](>3T8E9K5#K(W?CZ+M0C]>D/)Z,2LUJAUD;OQ]%VH1^O2'D]&)6:U0ZR-WX
M^B[4(_7I#R>C$K-:H=9&[\?1=J$?KTAY/1B5FM4.LC=^/HNU"/UZ0\GHQ*S6
MJ'61N_'T7:A'Z](>3T8E9K5#K(W?CZ+M0C]>D/)Z,2LUJAUD;OQ]%VH1^O2'
MD]&)6:U0ZR-WX^B[4(_7I#R>C$K-:H_-S7O.!_'I0O2>A]('Z;S/2>B\^WTG
MH_.\WTGH_+YWF>=_U\[R>;YW_'E\M ?W0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@/YNQNPMNQLPPQ
MOPMQQMPNQ\VW&[R8^;AC=AACCAACCY,,<<,,?)A_SY,?_5 <H(;:^7$UE]BB
M;91#)AYB5A[M#KE)*'@4$S 89BC[\)I:_&Y57PL-NK$F3=EYQEGXXNQ$;A./
MRQM.,(P#>+B"A<4J;*J?^3?%/]UJ8P[R_A'8[5.JU533-B'"?^-B,&^7#&UQ
MG@V;0+F/E\B@-63.NK?5.TMZ9@F+=#0;:20S49!1:U)@6TE8+J@(N+D/KK4/
MQDCI\EAN:\PAFC#H&P2B+<O"2"B@MN$U5+;:A0[,)O*94<^/&(P)9IQ4/!4M
M59RZ5#Y0YPC%1C/+7W)+<Q)[602$@NELR,#(<5Y<Y@M)G6(CI*8TW"N9@(G;
M*TDHA8H*((H(?J;L!/(XCA&5%Q+64<%1#51 Q["96.JJ(;F::*\:4HFNE9QX
MX\&N BF6Z4U#K2QXI4U-3WY..61(*CFA?!=H1J9!7VYUJ<\QYU&@J)^)(A<:
M$;,"I&9HPUO1)WI/2EQ4<['D<V+1O"S"XUB8Q#-^;[8_[:MN%BDVZT^$JRJH
MP?P7%?'B2PL93PI]F^W[K+>LN%L:4HYA)^82*U;G _6TY#TMQ)!;Q 7U!D)J
M,@P^MR?,4<1>Y5H JFGBXJPS6VD2-BX@"KH4#9RU2;UGM!<#1U$R 1EJJF$W
M,TIIPE$M4OMS3QPF>"A&K%+;A-6:JE$_Y6::JER<-V8PSS/ZDEP242D1JHQR
M?DV0"3-&S((ZN6(-M"(6+=J5!;6>A9H2<F)Y8LW#KC3Q%HSACBWRQ0L&WCZ.
M((0(K]JH(+*F\9KF%4N"4_METO#&>W*&1)66[,2Z(XX354II?&,,^/-FP,&>
MY-+GXSA6P5")N602>7-^,(X20"I8@B0$IQOU@ET/!/#\I,4=O+$8O9I)Q[&R
M[%%'DZ- S)<:^XI><U:::IYNRZ7Q_;#M81RAQS<KYJJ5^Y\E;3__ -E4U3JF
MG'.S5\JZR9F,DQ\1++"0LKBLL,J7LD.928&X<6&_&S6*W%&^ R2S.6(W2V@\
M'%(::SU5"?*@&8#F(J3=!TXGDC1*T@*66TLOBJNJJERG#H;QC#APC&,8QYZ+
M5--*JIA+]OM?9TO%N9XVFU9F5RCBU'!G2/,.YY&2E*!&A&KJ3V6I2O,AYAK;
MC/MPHZ1$YNE(2F2030J4F'S!<G@LX*#$2\4TR;Q') &,,,3Y!2(7&D\UVJ;_
M &PXEPY4X0WKAAY.5*7[FU,*4IB7:I6/:&_MQ5,TK-;F(]=,/WJNH*S=/NO,
M:UBL?*G8FCHE@4.H<IG&^29PZ;*!V<5Z1<%2.TDN]TA88@2=<16W$?3$AODT
M5*-*7)5UN'R;JP_;R3CG,J,921TL4\)Q_:Y4S^YT\<+*4-M0YX3S-,=THR\U
M'RV'NF32SI#>:]E6:SB05+%HI *0WA)8S'Y?&T>ON0T%2+6*C*-$E(Y:TL3I
MGK)8&65L#;H4Q\"Y@GEU5)VK2;NT^"A373AQ>.?#D5*EIJRTE6TU+QLT5/B^
M#S_TB5WM.L^L9V*,*%5U5?BV<GAKL%-D1$:T5I+U*-EP0(HR\,D$$EYN1C1,
M8=(ZZB&T9#/K1H +%O&#6%J&XW(1)V*6W56G9F<4K223X3"3JC'ACWPF)RJ:
M6K4)*RW9;JB559Y)U1&+B/BI-05\S68@)HE%LXL%DDNPVO+"\^5-FE8(?3H"
M)L61G UD%ZR<Q )2,IXC'#16X;(OY(@YX*;M(/HFX4T@(DEP$TEA'74N.&#>
M%E\&U+QX<)AMRG\"JFE.,W2DFJTG*EJEPL<4U:A66OB3(V)[D4Y/J437')?C
M%KPE)P1RS+F^@,5Q1^K8)S%5UPDW#JJ0<A>9F++A)31C2DX;7@U#+$Q2RQQ(
M(A%#)M/60+374VI>#<0DH7'"9E/"7."Q^!ETJSP_<E+3;52QQ<-672UPAS./
M# Z"UV.8H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@*<9Q4I5$2(1<!!Y.Y"+H^9[+*3/ME$
M/)Y)NNL!<GN.D^X-U67)0RP? 3@[Q!R!(FLIR?<:$P'4BBCB 5P Q6IAR\*J
M<,(<U)8X3P>9OV?&I0G-'M,7Q445/#&-4^T%QZV8% * 4 H!0"@% * 4 H!0
M"@% * CX*)8J >XLF 1G'P,CC67!#2 $S&X&]A0[P?5KPQ'78FX+M]EY;_Q[
MK;C^-MP'_P 6.&(?_6I9IF84YPIQ[EEQ$N,I<:<#U QE&Q9Q+KP+Q\QP':Z2
M%Z4YG0"TT$)Q.-+%LL"$35U;L(6J:N0$"###O)J!HP7OL#LLN#QMLMPP0L<%
MCQP6/QS$N$I<+%*7">:1JLEPJUI*1$- 'ON;))'6V0=&&;:4W@% ^W6(Z4=Y
MIC&P/GD@\,E-8XOMY#,'RR+B0-X )]H!$V2N$Q%ME5*J4<.$M<83E*>6)54U
M/.4UC/-0W$\8?.5FF; %$D5%U]6=8$91\"Z5\P,:77($S&X&OK1HPFJ",.95
MEBQ-M45$P.CJJHE##'#(P@J:I*!&^ZXJ<,!"6S3,V5+XN%+GCCW):JB)<92X
MS_V9PTS&>>*WDCK3;1PF(WA&E>4-(268*WM0; + 9L7EQ2MX5S>%P!!P$1<;
M,4V_ (+"XMCZ.SR(7"%$1$+AE\.PEYOC/'GG\>Y@B<1Q0G(J&VD^,8\(-QL'
MC*FVD FRVV516\I' C(!M00TH!-L(I)XT =. F39  N8'"-F0Q1+K!Q<+UFG
MA94+%*%@\Q:JEN7+XN7+^+YFSEVRVRAU+4BK?1"RBB(XK=1CY=)( G4AOCWD
MA!D-+-!E[1R".,(F)MXJ84$")"7IY*Z\#&XH!B'86&"PX=O@27GQQ?QS\O4T
M8I!<(D+S@A"'(K)"* RR9/WE(]:1:\\8<9$9,<)@Y<"D67&1EY-,&$Y9%&QO
M$5"(XQ0]<.7%O#NEFGIIT1;574]7RQ6CQ)&-I:8H#IAH^G$3II%.WJ:.9-E"
MYD=)4A$\^DB*"8,,'>(0.B)2HIIEYLK<$/>GJ)\E<)B6-F A+"?%<,5V>9/_
M 'B:R1C>.TMW*<@)C"9:<_%HOZHL/8BUD,H[E8IY L/55-R%R(:R?+^0 ##T
M)HZ*'Y 0L/-\@=GFR%,PISA3J66U#;A<%+A?(Q2/#40-ZY0N0(IC9#N5S5YY
M5N1V,V$RY3.BJ*:KB'%#$DE@8G30BLC(ZI>8,^E%O44I-.W7XF2)44(J:4Y5
M*3S24Y_[Q#;?%M_%LS3@CU@NT@N)3J8[0<R6YQ"0SD37 VD5:(.$9,"! 3A5
MPFI$C)=6$3P2Y<$E>?#,7% @ 0P,0[ K,+32?%)SQE)S'#0)M0TVFN#3:CX9
M&$5(9A]<)M9.6HHC583V-A9:RB*HQ6NH$V?:'B%B'@UBQM+& ;^ >)<#&S!)
ML*86X@A8V^3T=GFK-+B::7'#!8? 6JL?W/'CB\?CF9,&,XW+/,>1R\?L@"0S
M1;$F:?H+400GF9*8@6E<2H[HL(6K@Q;$M986Q $/7!8@66@XV^CMPMP6:9FR
MISA3J)<1+C*7&G W>J04 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0'@44E+6 BX"LFIZH 54
M$Y6*@J),N="+*B0= 4DE2+AF0Q; 5!+42Q8^G' [;3!(Z7 -%A AP@Q+4)\5
M(_[7B>^@% * 4 H!0"@% * 4 H!0"@% =_\ 1]A#56R-@$?I5X;=?55]3W.U
MBG+R]QH^PAJK9&P"/TJ6Z^JKZGN+%.7E[C1]A#56R-@$?I4MU]57U/<6*<O+
MW&C["&JMD; (_2I;KZJOJ>XL4Y>7N-'V$-5;(V 1^E2W7U5?4]Q8IR\O<:/L
M(:JV1L C]*ENOJJ^I[BQ3EY>XT?80U5LC8!'Z5+=?55]3W%BG+R]QH^PAJK9
M&P"/TJ6Z^JKZGN+%.7E[C1]A#56R-@$?I4MU]57U/<6*<O+W&C["&JMD; (_
M2I;KZJOJ>XL4Y>7N-'V$-5;(V 1^E2W7U5?4]Q8IR\O<:/L(:JV1L C]*ENO
MJJ^I[BQ3EY>XT?80U5LC8!'Z5+=?55]3W%BG+R]QH^PAJK9&P"/TJ6Z^JKZG
MN+%.7E[C1]A#56R-@$?I4MU]57U/<6*<O+W&C["&JMD; (_2I;KZJOJ>XL4Y
M>7N-'V$-5;(V 1^E2W7U5?4]Q8IR\O<:/L(:JV1L C]*ENOJJ^I[BQ3EY>XT
M?80U5LC8!'Z5+=?55]3W%BG+R]QH^PAJK9&P"/TJ6Z^JKZGN+%.7E[C1]A#5
M6R-@$?I4MU]57U/<6*<O+W&C["&JMD; (_2I;KZJOJ>XL4Y>7N-'V$-5;(V
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M"""FHZ>#<_ZP+ T(* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * IO,&31#EF<$S,&
M0G">XED-(C$")2(\6K,: )A9IVN95=:AZB5?T6/\TD*CA4U(I8Z#J(>3+7$2
M;31*JP!JUMIEP(LX1AHG_O+EE+S+:(B:*C(J0D#JJHO#)26GIHRXMB%!5I9%
M(E 2HBJKBIY-.("*BC>%B<4!"2>0*7FQAKBQ,J#C8!8(92@% * 4 H!0"@%
M* 4 H!0"@./.GO-/PB/=AKG,]>JXHSJU6QQMU9^%L-/>:?A$>[#7.9Z7%&=6
MJV%NK/PMAI[S3\(CW8:YS/2XHSJU6PMU9^%L-/>:?A$>[#7.9Z7%&=6JV%NK
M/PMAI[S3\(CW8:YS/2XHSJU6PMU9^%L-/>:?A$>[#7.9Z7%&=6JV%NK/PMAI
M[S3\(CW8:YS/2XHSJU6PMU9^%L-/>:?A$>[#7.9Z7%&=6JV%NK/PMAI[S3\(
MCW8:YS/2XHSJU6PMU9^%L-/>:?A$>[#7.9Z7%&=6JV%NK/PMAI[S3\(CW8:Y
MS/2XHSJU6PMU9^%L-/>:?A$>[#7.9Z7%&=6JV%NK/PMAI[S3\(CW8:YS/2XH
MSJU6PMU9^%L-/>:?A$>[#7.9Z7%&=6JV%NK/PMAI[S3\(CW8:YS/2XHSJU6P
MMU9^%L-/>:?A$>[#7.9Z7%&=6JV%NK/PMAI[S3\(CW8:YS/2XHSJU6PMU9^%
ML-/>:?A$>[#7.9Z7%&=6JV%NK/PMAI[S3\(CW8:YS/2XHSJU6PMU9^%L-/>:
M?A$>[#7.9Z7%&=6JV%NK/PMAI[S3\(CW8:YS/2XHSJU6PMU9^%L-/>:?A$>[
M#7.9Z7%&=6JV%NK/PMAI[S3\(CW8:YS/2XHSJU6PMU9^%L-/>:?A$>[#7.9Z
M7%&=6JV%NK/PMAI[S3\(CW8:YS/2XHSJU6PMU9^%L-/>:?A$>[#7.9Z7%&=6
MJV%NK/PMAI[S3\(CW8:YS/2XHSJU6PMU9^%L-/>:?A$>[#7.9Z7%&=6JV%NK
M/PMAI[S3\(CW8:YS/2XHSJU6PMU9^%L-/>:?A$>[#7.9Z7%&=6JV%NK/PMAI
M[S3\(CW8:YS/2XHSJU6PMU9^%L-/>:?A$>[#7.9Z7%&=6JV%NK/PMAI[S3\(
MCW8:YS/2XHSJU6PMU9^%L-/>:?A$>[#7.9Z7%&=6JV%NK/PMAI[S3\(CW8:Y
MS/2XHSJU6PMU9^%L-/>:?A$>[#7.9Z7%&=6JV%NK/PMAI[S3\(CW8:YS/2XH
MSJU6PMU9^%L-/>:?A$>[#7.9Z7%&=6JV%NK/PMAI[S3\(CW8:YS/2XHSJU6P
MMU9^%L-/>:?A$>[#7.9Z7%&=6JV%NK/PMAI[S3\(CW8:YS/2XHSJU6PMU9^%
ML-/>:?A$>[#7.9Z7%&=6JV%NK/PMAI[S3\(CW8:YS/2XHSJU6PMU9^%L-/>:
M?A$>[#7.9Z7%&=6JV%NK/PMAI[S3\(CW8:YS/2XHSJU6PMU9^%L-/>:?A$>[
M#7.9Z7%&=6JV%NK/PMAI[S3\(CW8:YS/2XHSJU6PMU9^%L-/>:?A$>[#7.9Z
M7%&=6JV%NK/PMAI[S3\(CW8:YS/2XHSJU6PMU9^%L-/>:?A$>[#7.9Z7%&=6
MJV%NK/PMAI[S3\(CW8:YS/2XHSJU6PMU9^%L-/>:?A$>[#7.9Z7%&=6JV%NK
M/PMAI[S3\(CW8:YS/2XHSJU6PMU9^%L-/>:?A$>[#7.9Z7%&=6JV%NK/PMAI
M[S3\(CW8:YS/2XHSJU6PMU9^%L-/>:?A$>[#7.9Z7%&=6JV%NK/PMAI[S3\(
MCW8:YS/2XHSJU6PMU9^%L-/>:?A$>[#7.9Z7%&=6JV%NK/PMAI[S3\(CW8:Y
MS/2XHSJU6PMU9^%L-/>:?A$>[#7.9Z7%&=6JV%NK/PMAI[S3\(CW8:YS/2XH
MSJU6PMU9^%L-/>:?A$>[#7.9Z7%&=6JV%NK/PMAI[S3\(CW8:YS/2XHSJU6P
MMU9^%L-/>:?A$>[#7.9Z7%&=6JV%NK/PMAI[S3\(CW8:YS/2XHSJU6PMU9^%
ML-/>:?A$>[#7.9Z7%&=6JV%NK/PMAI[S3\(CW8:YS/2XHSJU6PMU9^%L-/>:
M?A$>[#7.9Z7%&=6JV%NK/PMAI[S3\(CW8:YS/2XHSJU6PMU9^%L-/>:?A$>[
M#7.9Z7%&=6JV%NK/PMAI[S3\(CW8:YS/2XHSJU6PMU9^%L-/>:?A$>[#7.9Z
M7%&=6JV%NK/PMAI[S3\(CW8:YS/2XHSJU6PMU9^%L-/>:?A$>[#7.9Z7%&=6
MJV%NK/PMAI[S3\(CW8:YS/2XHSJU6PMU9^%L-/>:?A$>[#7.9Z7%&=6JV%NK
M/PMBDEUUMMMUUV.%MMN&-UUV..&&%MN&'EQQQQQ_XPPPPP\N../_ !AA78R4
MJCJ6,R\HM5FS@TFQ%9Z*'THHZJ@1B($OD95'BM=6 "I!\B2(HNHHR G'BV#
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M]+)!!V'LU-J(4IM)ODI<<)EXLU32JIEQ%-32AR[-+JC+EC+^$E@ZT9% * 4
MH!0"@% * 4 H!0"@% ,<,,<,<,</+AC_ ,8X8_\ K'#_ /YC0%,6WEEDIKH3
M?B1*G$!/R]M5?2U%";"2PSR5+0#30G $X4:+AI8*O_V3U)*7EBK?'-$HX(NL
M^S0>KPZ]88%-+1GG8<6;7[4^$8M8.'4FO"X>-NI-MV?W-<6Y4\)LQQRQA/&#
MXD\IBW98W&DHR@2.Q)'KFD-Y1LTB[$$).Q+7WXBOQ")%W8][GD:(NEO,HG)#
MEZO)R<SFJI',0T&YP+:J,E&AU=8;P=6";:40TWP3<N4DWD^XM\XQ:2;G!I1P
M22AN%.+YX8F[(V6T)(#1 \'B(8]C982V6W#'%!M"]8"+VDK>N..'M@3T0E_J
M?E]@^42VWTG_ /,8^;_VMC")_P#AT<,XQ\< ZI;<<:[7'QP\^"#P\@B&4<)=
M0++4:*::J!1((\CCS@M >K]%4(K9K+8E][ =BZYAT=F);L0&&AV'DQ:9KXO0
MSXJNJH!XHI*(1DEF[QF:?_G%TRYIA82\$X[\6:?M6US46HBII?N;JQ2Q<-N,
M5R^?^%<BZL"[R;L,22R3*B05)=$%<XL-C#2>ZT*7$!YH9I.?LC&Y+,GUXZU0
M723M;0B:FH#< +) @!AJC7'$X1 +V;33E83RQ:J33EMMX2X7#4EYA$/%4X6L
M%9AX*,)C'C\<YMD?+,ER%"<9Q,;5T8P=B@>/51N*SI9X+K:JJM,%&Q0+>M;%
M%6DSVP@KJ295"A](+.5-.E,3X9I/6@3A$ QCIT6J4F\5#3B5*48I\NT_,BKB
MIU0_W3*3AXN<'#AI]F:&ULI;BCP=MNZ-WQ&;+DU*,R4"JFDB"227%JBW)1[/
ML5A$)QRVGXW%P XCC14PS:*Y5R17,NB")B@35C*@DJ)-/1HJ&H:=*:F8I40T
MN6'!K!SXP*ZYE--K!XU-U2IYM/C+E))<.:EQ?AT=:<43$@@5>4>N$\+&B%&;
MN<4G0,WI%5Q2S?67:IE'8P"ZDZB2 S70:*/)1(*99>17\T#XR<@'Q6MZ,@?3
MEC*]E'!I\FZJ4^;<J7">,/D^,26\<SBE+:5-3IX\FTI:P4<&L<<5%BD[+*32
MS:2.5=F(99'S(F\P98F&W@ 0\+3#"4F*$S+?0J@8(()<%0P/V+0)>VS'U>TE
M8B!67X#AZL<,4HK5:A<EP7'SX,V^.'&BSQ[S+S(5>>1 9V *B6-(C554%=NG
M?UQ(?T38/LHV3,W3(_I:&=,=)YM^IJ"VY 0 WWBUL'8M(KKM42[>0E0NE(_H
M326;C]G+XX-MM-3#=4RL<'#B7,Y95>TB'#E6<55$V:52D\'*<3&'%EXF&WCS
M28[.:JFIE%I0;+706^=5R"8,BDE0RCI95.%/E4@PJ+@Z8 ;O+XCAD15A4$*V
MWX W'S6-GIK^E*BE)\DEH8;EMYMLVRJ04 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
MBR7(RLE5":Z+>M7(>#:E.)I,P,VI^"EB<OBV0VZ_K$;$'$Z1]7M6[F_@E7*&
M @V*=:;Q.X$CN(&!46-2H[IZ-/\ \+2[+GM4OJI=+\,E.J04 H!0"@% * 4
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-?^YZOQ'Z3^3T?D?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g796801g60v33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g796801g60v33.jpg
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M$0'_Q  ?  $  00" P$             "08'" H$!0$" PO_Q !($  !! ,
M 00" 0, !08(#P $ @,%!@ !!P@)$1(3%!4A%B(Q"ADC0587&"1AE]0E,C4Y
M0U%WMS0V.$)%4E-D>'F!@Y&TM?_$ !T! 0  !P$!               " P0%
M!@<( 0G_Q !,$0 " 0,# P($ P4#!PH$!P ! @, !!$%$B$&$S$B00<4,E$C
M0F$(%5)Q@19BDS-R@I&AP=$D-%-S=)*QL]+P-39#5&-U@Y2BPM/_V@ , P$
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MC,L@B#RP1I+)'W8]Z.3&'*@XVA@/)*YR:J_EM-DBN%@V/VT,A5)9&1'V/M8
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M]M-;CEL,(4%MM&QMM;0GV@#NK%E=E8YRP8ACN^K)!R<^_P!_>HBJD!2JE1C
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MS^VAV7GW-(VAEIQS:4;IU5G94499V"J.!EF( '.!R2!R<5/9@JEF. H+$_8
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MYN6_6Y]T5H%Q<WL.K7$;1V=JQD@+C'S-P 50Q@\F.%OQ&D'I,B*B[COV]#_
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MX+\=$/!A/DAB@10BUH2;-2Q@4<RM21F729!T<)^S:SKMAHD*R7CL9),]FWB
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M5?:CH'>8N]G (KRQ1F.3\O%/LGA4DD]OYIXDR%B2-%"U>_Q6]*#QH\8++']
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M0LX7V%RN_!8!1XR_\-/$CG_@!Y)L(\C AY^VV$+\7CG9MZ<9Y["$%(6'*-B
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M>%#:0./+5RZ!UIBP% #,HDHB4'.9"V<))O/[-T?59>JM(U'0[UU_> M=\$Y
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M*3(X+1S2]RXN60X9(YXHY%25)%$B2_3\\$%_^-X7^*O^=[_M\?\ E2-[WO\
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M&L/E#/M3(+ZFX8KB>"3NR!F2?)<.#B53P2,\$C/ZC!P?2:NLL$%PACC*J\.
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M(4ZMMZU.MK6P$&PM:8?2RGWREGKEY=$,DAF*V5DN(AG)SCN8^IW;^'W)/U<
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M,,C _P#>*%O])&_7ZKK>-'D':K'.RO!^X1#]?[G2!%N$O?C[U&7>#$^IM-D
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MIW;P!LFKC1?WU]\9;"2$U>JN4\DV=H\FXED/=C$<2@<?6R%)1]1VFA0C_=N
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MI%EX!Z(G2OKD"28<]4D=*:QZEZ,_><[ZAITD<-W)S<0RY6&=@,=U74,8YF
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MT5$0!41%"HJ@8"JJ@!0!P   !XK/H88;:*.WMX8H((46.*&&-(HHHU&%2.-
MJ(B@ *JJ% X  KGY%4VF*5%/ZLGAE9/*WBD#/\V!U*=6XX=+S=?@DJ0@BUUJ
M<&";M=;CUKVA&YI:HB'EH9MUSXE/19$4RG1,JTXWA_6.ARZQ81R6J[[RQ9Y(
MH^ 9HI HFB7/F3T(\8)Y*%!RXK2WQLZ!N^M.G[:ZTF+O:UH,L]Q:VPP'O;2Y
M2,7MI$3@&X)@MY[<,<.T+PJ-\ZD:;TK$RD%)'PTW&GP\Q%EO@2<5*AD1\E''
M#.*:)#.!+;9*$*'=2IM\<AIMYIQ*D.(2K6]9I%T>-VCD1D="5='4JZL#@JRL
M 5(/!! (/FN#)H9K:62WN(I8)X7:*:&:-HI8I$)5XY(W"O&Z,"K(RAE(((!%
M9 >+_BWU7RPZ9$\ZYG"%OLN%B*M=N>$?76J-!..ZT7.6 ].D,-):82\J/C=/
MI/FBVT@1K3I#G]ERTG2+S6+M+6UC)!(,TQ![5O'GU22-X&!G:N=TC8502:R?
MH[HW6NMM7@TK2+=V4NAO;YHV-IIUL6]=S=2#"J%4,8HMPEN) (H59SQOA\UH
M,#ROGE'YI5VW&J[0:G7Z?"I>VE1"HVNQ8L4*\4M*4Z=+(:%2^6]\=;>)<==5
M_<O>\Z%M;>.TMK>UB!$5M#'!'GSLB0(I/ZD#)/N237TDTC3+;1=*T[2+,$6N
MF65K86^[!8Q6L*0HSD>78)N=OS.68\FJVR?5QIBE,4IBE8;-4CB/AX#TGM]K
MFY:8L%JEY LBR6<IJ8MYVI%]9<?1ZSMSZG2''EM:^Q>U)>+2.DV9,9C(MM0%
M;OGO3% JJJHH&U0508&#(_G^@\#.%&6P:+9!9B6=V9F<D[G(9SGD1KG'V_KC
M+' &+1\PY=<?)VW@>1?D<#J)H,3I9W(N0'+W^J#BO=)#-EL[)"6D$LD-M,F*
M4:RVY8'&VBBV1*T+&19DZ:9+5#;6QS(>)IA]1;QM4CW]N.$\#+EF$B&)[IQ<
MW(Q&.88C]('D,P/D>Y)QO."?0 I[&8]02IQW3]1\;5I*6X3$R+=0LO800SWX
MT*WG?)T!<?MAE094 ,.(7I].E[E)1C;DK#LNA@CLS9=.8Q>IPMP1O6$D [!Y
M#<Y#$D?W5.%8Y)VQ-J*B7 0F '8TP!P'/C'MMP#^K#)' Y=?Y!9N=V9'E9XI
M+$/,/$;EN@\]B7-%5OIE<*TDXB8AAP5*9(/)95LYYD'W>,=WJ8AE:E_R!IGR
M&995^4NP1@[8Y&X:-AP%;/(QX!/CZ6]/(30M&WS=H0<C=)&#E95/)9<<$D<D
M#GW7U<-0/DY7.9>?WAUT*W4"/=(ZA4J-83H*-'VTFWP]DC8QZ7?H4FTVVI<A
M'V)0C@D7[HT*80^.> X,^DQE-CZAMKM='U>QB!9KFQG5%4$B4JI90@_C;;LQ
M_>P<@@UBO7U@_4/0_4MK8HSWKZ/>FWB0$RR310M,+50/J-QV^R@\%G'CFM,G
M>MZWO6]>V]?QO6_\ZW_ZMYS37S;IBE3;>CYTN<\?)/HO5;34IA[A]YE*SS&>
MO(8I+XM?M42@V=&<4AG2TE("!FFER GUZ+6)(:?C5D%"KCC=M?#'3I)TUBY!
MV@"UAA4\"9T[SS 9]XU:+G. 9 &P#D=4?LV6US:_VGU>2)QIT[:=IJR@'8US
M"+FYE ]B8(YX"P\XN!MR<@S@]CXW8ZE8Q_*_Q.(#*G2PT2]VI$.M)=;ZG6RT
MH-)DHP4)?T&2!C/L62*&K3LH[IN8AG&;(UO4QMB&974V=X"%!VH[<-$PX )/
M@#P"?I^ELH?3U--"R,+NS()(W21KRLJGDL /)(Y(')^I<./5WTC&\C\_.2A6
M" -<JG1JHXA<=)M*TBV\UM:/8A,?(;'4,2= F$CZ>'?:4PT:VRDX!8$P"\T'
M"#-ITQ5AOB?R#]$J?<>0KJ#CG.,X.Y6YC(AU"$,IV2)X/YXG\X.,$J2.#QG&
M1A@0/+KO(O #D38PS;MKZ+:W=:::UK6[?T^W[U\=..:3^41'UZ/)*TE*4_DL
M1C!.FV]2<_)J5)OQM0FY]$2?]V)/]@+MC^N/95X\_!T^' &^5^ /SRO_ +2%
M4G^F<<LW,2?E/Y6V7Q9M0/0.@QT-T'S+O<.S/UJKV!MTJB^-])+60W!DF0C!
M2-F74Q.B55^NZ,;:@&=/3\\2;*'(1)X7UCUE'H:+I>EHDETZ;Y'?)2-&) >0
M*5,CR$'8F5! #MB/8DFD/BE\5#T,T5A80P7W5%Y +@+<9>ST:T<LL4T\2,K3
M74Q5S;6V]%C0?,W#,&CCGC4(]4CSU(GMV'?D19&2_O\ O2"/7Z0U H_O^26=
M5Y-8_2K83KV1];P+GS1K_:*6K:E;U,>K>HC)W?WG*&SG:([<1^?':[7;Q_-?
MYUS6WQD^)37)NO[4W:ONW"-;73A;#G(46OR?RY4>,&,Y'DD\UDYKU2:?9*;(
M=H[$Z3RORFY*+&FU6_<RK1Q</W$'\AB,55K1 #:> K]H9&>]T2\F4/3IF)V9
M"R*8T9,8!FV.@NKI=?N5T*_CA^:E21H9 1''.L:EY $).V95!E*1Y#A7DC6,
MQE7W_P##7XPCJR7]T]0)#9]1Q1M+97EI&8[;5XXE)EB>#+"WOHX@TIV-\O/$
MLNU(.V$;Y&>0WJ)>M64-R/E]9YMXN<,A18JQ6F[V I2;5*--MZ'*L$#)GLNW
M D8GYO+$CN;Q,9'QZ#405PZ"2#(L$D;7%MIFA@SRO+=SME4C4913G(5@/1GC
M!,I).-R1@C W9\Q>ZMB%%B@C4!W<_4<<%E)]6/TC QG:SX/.4WB!X+U+F<O?
M>&^*]YN5M'MS</'^4WE-87MC!6@6*)/(U3^>U\!]8$;!%%G2+FT.2<Y/6HE;
MVS;*NH"..R%)>Z@\HCGNT1"FXVMHG)0D %Y&(R7P!SA5C X3N' G6]H TD%J
M[,K;1<W3>' SZ(U' 4Y)QDLY\ML&3*ST?H].\3J?5^!<"J[=BZS8FT"5"H!H
M2>;HT]/UO72ZO-_4LA\A32R4I)6-HQ(V]:5'0$>XZ):(HGO)'N+A]D*\NYX4
M 'Z$SX SCC)R?S.W-SDD2T1;>W3=,W"(.3D\=R3[^/?&<>RCBFN1]QOM$M.O
M''S%&CW9BTC.IIU]-0(75;P#,:VV369<G8H\8^\ETER*'=<&8;=5M$1(CH><
MCR92.:".1/FK(G"?Y2,9#QE>=RC)(X]1 )XRRG 8)!%.\;_+7N"7^B0@%) W
MY&. /)V@X )])YP6I*R5RZ>!UT+OU #E+9XP6R4:<N](:=<+/YU(%N(83+1*
MGU[^ ^O=MD$]YQ#!S26*]87FRT04WN)&34$$<A"72 ['\"0#)(( _JRCD<N@
MQO40.KV$ADC!>U<^N/.3&3[C/^H$^1A6.=K5FG0JCQ*Z647R0H<;"RE@MM<;
MCFKA'*=1LL#:])(V2#\D,CSR/I1%2A!0C<TPT%J)+6VAAP?*&1YXU-M(6"HV
M=AP<'VP?.WW !VG.X><U6QI!(PN8PI9UQO&1D>^1XW<8)(W#&T^,5?+)%5%,
M4IBE,4IBE,4K2E]7F<GYCSZ[,+.+?_'KP?/8.NCN[7MH2 _Y/*Q,-(%^6]ZT
MP7)S$I*+TC^S\L\K^-*^6M:)ZTDD?J*^$F<1+;1Q ^!'\M$XQ^C.[OQ[L:^?
M7QRN+F?XF:^EP6VVJ:7;VJ-G;';?NJSG4)G\LDT\TQQQOE?^51HYBM:DJ[7
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MD7NQ;F$%[;%E,UG=(#B2WG4;6!&Y&VRQ%)HXW7?HYQ>8CI_/:+TBO_9J"O\
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MD@X]F&-RG[@G_:/!'!K$+D77K3R>T:\5O*K8LBW(BN1/-NDRK>B:YT&NDZV
MQ SSY^G&7BG67$Q[;D@I;JG5ZAIG:RE@G2U;-"DR?.6>1@[I8APT;#DLH'@#
M&2!QCU+QN5*.&5X7^4N_4""L4K<K(O@*Q/DX. 3D_E;G!:[_ !7QJG.$=3N!
MU'NOT\-M 2I%KFA[1)Y<1;'GDHVY&&O.:;$CQ!6_@T;]CQQXC@\7*#%+BPYC
M),]TMQ$@>/\ '0X[@P 4]\C[D_E\ Y92 Q6IT%JUO*Y23\!QGMD9(?/L?8 #
MSY((!!V@UEYE%593%*8I3%*8I3%*@Z]63TY;;Y&OQG?>&1S,MU&O0;4!<J3I
MX<,J\UV.6^_%2<$^2M@5VTP:"" W0"WFU3D/^&,"^B0B X^6P#K'IB;4RNHZ
M>@>[BC[<\&0K7$29*/&20IFC!*E209$VJIW(JOSK\;/A3?=5M#U-TY$L^LVM
MLMM?Z?N6-]1M8BS0S6S.51KVV#-&8G8&YM^VD;"6".*?5OG><="J]K;H=EHM
MPK]W><TRQ3IFM3,9:'W5+=;2@>!,"9E'U+<8>0C30J_FIES2/E\%>VJ'L;V.
M0Q26ERD@.#&T$JN#QP5* ^X]O<?>N/+C1=8M;HV-SI.I6]Z&V?*3V-U%<[LX
MV]AXED)SP %Y]JG4]+CTP^FKZ=4_(SR%J4C1*K0SQK)0*+9A' +5:+8$K3\%
M.2\&2E!\!!5XQ+<P*U*M!R<I*B1VVPMQ&GGR<]Z2Z3NS=PZIJ4+6\-LPEMK>
M52LTTR\QR/&1NBCB;$B[PKNZKA>WDGHKX.?!_5SK%EU7U392Z;9:;*EWIFG7
M:&*]O+Z,AK:YGMG EM;:UD G19Q'--/'%B,V^YGV@<VS78=,4IBE,4IBE,4I
MBE,4IBE,4IBE,4IBE,4IBE,4IBE:V?KX\=L;\AQ/O$>&0960XF6YA92F6UK:
MA)%4B[8ZPX5M.MZ;:FDFV$=M]7Q;01&,CK7ITL9"]7?$6QE+6&HJI:)4>TE(
M&1&VXRPEOL)-THR>,H!G+ 5R9^TOH5TTO3W4D4;R6<<$^CW;J"5MY>ZUW9E\
M#@7 DNE#'"AH54G<Z ZX>:PKE*NV@8&9M,Y#UJNQADU/V"4 A82(CV5DGRDM
M)E-!1\>&.WK:WBC"WFF&&DZ]UN.)3K_.1QQR32)%$C222.J1HH)9W8A550.2
M22 !]ZG6UM/>7$%I:PR7%S=316]O!$I>2:>9UCBBC4<L\CLJJHY+$"OT$_'S
MG17(>$\<Y:>^V3(\]YC1Z?)DM+^;)$I7ZY'1LF^PK_>P\>.0XQK7\::4C6OX
MUG2&FVILM/L;1B"UM:6\#D'(+QQ*CD?H6!(_2OI[TOI3Z'TWH&C2L'FTO1].
ML)G4Y5YK6TBAF93_  M*CE?[I%7?RMJ^TQ2F*4Q2L=?*GR3I?B?Q6T]DNK;I
M[$1IB-KU=%?;&/MELD_L;A*Z$^XAU+&REM/%GF?21^MAPI*3_&*_#_'=MFKZ
MI!H]A-?3@L(\+%$" TTSY$<2DYQD@LS8.R-7?:=N#BO6G5NG]$]/WFO:@#*L
M&V&UM48)+>WTV1;VL;$$+O*M)+)M;M6\<TVQ^WM.H#VGU._,[LUD.F-]GMG,
MX9PAQ<54>33$C0HF'#VO>VA/SX,D6PS"D)]OM+G9>1?=7M7PVPQ]8[6E;[JS
M7;Z5G^>FM4))2&S=K=$'LNZ,B5_U,CN3^@P!PMU!\7^O]?NY+C^T%]I$!<F"
MQT2XETR"W3/IC[ML\=U.1^9[F>5F.<;5VHMZ/%/U>/)7BELB!.N6V;[CRLDM
M@>Q15N(;E+K& NN)01+5BWE_&7(E!&_9Y$783Y"(D$-K#3J*()U+"UVC]::K
M83(M[-)J%F6 E28A[A%/!>&=O67'G9*S(V"OH+;QD'1?QRZNZ?OH$UR^N.HM
M%9U6[@OF6;4(8B0'GL[]\3M/&,,(;J66WE"F/\!Y/F$V_*=;J[?JG6KQ49-B
M:J]O@HJR5Z6&^7T2,--!,R$<6VE>DN(^X4AI:FG4(>95M33J$.(4C6ZH)HKF
M&*XA<20S1I+$Z^&1U#*P]^01P>1X/-=T6%]:ZG96FHV,RW%G?6T-W:SIG;+;
MW$:RQ2 $ C<C [6 93E6 ((%29-JKIBE,4IBE,4J-:_W6[^9-TF.*\@..K'#
MJT?N/Z[U-IIQEVRNLN>Q-1K/V)1]P[WQ4VM&_P"V03_TR0TB"T.-/72-([%!
M/, ]PPS#$3PF?#MCW]_;;X!WY*6R1WO7,$)*6ZG$TN/KQY1?T/\ M\MZ>'SV
MY]SZI<NJ412:3$,0U?AF--##-:^3K[JO91)YY*M?:;(FN_)\TQ]2GGWE;4K>
MDZ2E-OEE>9VDD;<S?Z@/8 >P X 'BKA'&D2!$ 55& /_ !)/N3Y)/)-5GDNH
MZI^U56O7:O2U4M<2'.5Z<#<!E(LYO[!R1W/;>OYUM+C+S+B4/BE,+:)$);:)
M&=:(:;<3$CM&RNC%64Y!'D'_ '@^"#P1D$$&H719%9'4,K#!!\$?[B/((Y!P
M001491-BZ9Z?LF? /14WU?QWLCAZ^=N(?U^ZI=J*0^2#5C2]M.-CBR1GLV^A
M+'XYS:G9V%&3*LS$(9=0L6HJ&RL-RF.YQPZ# + >3@>.<J<(QVE6%KW2:<Q4
MAI;=\F/GU(_D*?89/G P>64;MRU<CDG ;C;)"<\E/)1*9+IDE"2#](H[[:M0
M_,8?\(IV/;1'.J=0/-#MN[6((YMQV'=<=//>)LY+Y$?)GN411;6OIB4@/(#S
M*<C/(\@^[?F\#" !IL%NSL;JY]4K#*1GZ8EP<<<\XY _*22<N<K')_HT?_R*
M>Q__ (I+3_[IN.9=.J?^?0?]D3_SIZI- _YI+_VAO_+BK8HS&JOE=)9*W W"
M!E:Q9XH.;@)L-T"4BCVM/"F"O:_N0M._92%H5I+K#[2D/C/H;('<:?:;<3$K
M,C!T)5E.01Y!_P#?D>".#Q4+*KJ4<!E88(/@C_WX/D'D<U&V"?<? :WM0TV]
M,7'Q/MTNM,/,*0](S'*)8]U3JA"D-(4XY'N+4MQX=EO34NVER2C&FIU$C&R=
MS(34$RH5+M!R. )0./)_I@GZ3Z6.TAA; 7T]\-N>T<\'R8F/W Y_F!]0]2C<
M"I\##7'SZN")"0;F*=XG4^85L #:G8^8ZU,1[RD;??VC:5M1S2TJ0ZXA2FHA
MM2PPUNS[AAD0.S3TP-KW;CD^1$I''G].1X+>3Z0 ?1OU!\G<EHAX'AI6'^[[
M_P (X'JR5Q;]3STMI7LSL7V?QG@HAF[P%<C*U:>9#*!A&+9!5X1(,!)UE\A8
MT<S8X:*:8AWXTX@9B8APHY(1+,G':$FM5]8]+W&JRG5+ "2\V!;F!F56N0G"
M2QNQ"]Y5]#*Q =%4*0Z[7T)\9OA#=]33KU/TO%')JT=O';ZCIA9(3J,-NH2W
MN+61RL?SD,06!XI71;B".+M.LT(CN==8CQ5\G!9_=7?\>.VHL.G_ ,;41KEU
MV68MWY?#6VFVX1?W,JW[*00UM8[C>].H=4UO2]ZO.D:J).R=,OQ+G&SY2XW$
MYP,#M\@^Q'!\@XKE-NC.KTN?DVZ6ZB%UNV"#]S:B9"V<>E1;G<I\AERI'J!*
M\U/OZ77I:W'E]O#\A_)>"#B)Z-CSF.=\M-6'*&1Y$R"_'&6>Z-,J*C6"6XDP
MH2'KNW2BA7S79"61'2$>()FQ^D.D[BRN$U74T[4T8)M+7(9XV8$&>8J2%=5)
M$48)96)=]CJHKIKX-?!W4=$U"'JSJN!;:\MT?]T:0S)+-!)-&T;7U]L+Q1R+
M"[K;6VYY(WD,TXAFAC2LU[]R3MOBI;)>Y>*D6NT4'HI&XZ9Y8\._*"U"URNO
MPH>Q1(22&5)B1S76/<C[D,QXR=Q\RIR'0(7&[>CF@NT"79VR1#*RY"F1!RRD
MX/J(SQC+'U+ABP?HV2&>T9GM!O20X,1!(1SPK 9'I!]\C X;(P1D3XU>-?\
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M,?*;O;=VA>[,\XWX]ZU<LU+7'-,4K=X]*+4\GP#\?M6'[_RMQMVV!^3\OO\
MT*NE7'=?]_E_/T;A]A[!]O[?U^Q/C_;[9OKH_N?V<TWN9SMN-N?/;^;G[?\
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MV6E/P!UAB"@A(<;64220&S\G%)&0O33R6H8H'FW,"B(F-SR-M1=QX&3DDGV
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MMW2+#$6ERH!2T6]$=-D-'35:F*N7,I3(,C?6PD*18F 'VGD.$I92IQ"&9YO
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..4Q2F*4Q2F*4Q2F*5_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g796801g63c22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g796801g63c22.jpg
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M96-T<R!C:&%N9V5D('1O(&=R87ES8V%L92XF(WA!.R8C>$$[(" @(" @(.*
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MV2(TC!$!9F. !^DDDX   )9B0% )) !-19E12S'"CN?[@ !U))Z #))( !)
MK48YFR;HD!;%LJ.(A*.$6/(TS3I2VG$>L*\@F,M6U\#.OA3]H8=;9D(:G)>,
MJE)-2P>[FQVZ.B;!!:P5A&V([I""'F'O[I%XJG@7Z.XR/50LK9CNE.9!A <I
M'\.H:3KAF\0O54/7UF 89*S7AJ'E0:E7X>1NVPYD51D+1X!0^)!4>E[(SEAL
M,@4XU&5&GAD84V;9IY\85TA'RB#9G+,5&0$AQ(]P+LPCC!PTC9QG&=J@9+N1
MV503XMM7+ SX(507<C(1<9Q]IB>BJ#W9B!GH,L0#)H/IX=M7IRV_90&].KRE
MYG5T1@IC3L)WSAQ(TE$EH8/VL:.KQ0]+; :572"!!)B UW39##N%Q:X"=+=3
M'X<UL&9O>#VA!\!'ZX!*M+(*DL&[K,0_\6,B(>/4'K*?>_JG *QH:V?889&9
M9&&9:''':;8''8;0TRPRTC#;3++3>$MM--(2E#;:$I0A"<)3C&,8QS*2222<
MD]23W)\S6GMVKEXI3BE.*4XI3BE= V.8-QY96^*2E'BR<&YE@QGMG*D>+F,*
M0\TAS.'<B%MD O+3C!(KZ.Z,R#$>1'BIZ@_\0<=,@AAX$&KHIVB/LI)'G+0R
MKOB?P.1D,C%<KS8FCF0$\N1&ZU'19=X:0;JUJ0.LB2;(;A)3#*41=H8:8<>,
MCG&%^;05B$#;>(-AEJ6S*1C1$U"J>&%GHVN39 5YL><+C>N<M$20 V>YC8D!
M7[JQ"/@E&DVSV<4]L]_8!C#%M%]:.=\U@9&6..4M@&?3YY&6*.YVAK>X=+.\
M57ELI[^DIWIX36LNR^AI,+7Y2<K??UN>T0_IV>5WRXL<> $PHK6AY2\NX3.Z
M]0'%H.-)F[-2+R6VR-RU;C?TN 9!V$H^F7WECTE Z>K)DX 5)(QUKQ&@V]82
M$/<H>L3?!1UC)\TP,G<R.>E1*N79$I+FTVS0IU)V)%!Y-EJ3..,.OD1N'6QL
MV*JRH^<QMRIQ#[K+;%AAEKP&\2S$V8"N69!U?"DR8 =6#QDX5QY]]KCNC@=U
M;OW4LN&, ^248;' ZHWB/M*>SI^</@P5LJ(]%?>3I]*7+Z^C3['I]UYPFV:=
MC&7"Y&G(=<4Z9;=*A([K;;9RI95CU$+C$9.-)<EM>#Q%P1(5_8DB5N!MD(6;
MZDYZ!_))SV.>RS'JIZ2ED(:+@W0'* F+N\0ZE>N2\77IWRT0Z,!F,!\K)/\
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M$7&2[I@H!(N(L&!P3N<)U6(GOO7&8&[Y'*Z@Q\NHD1%B0#!)D3*>RENADZG
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MMMX^LCLVQ3@J!&K'/K.S(F0"(]X=\+UK-<7 B 1<M,_1%52Y&0278#'155F
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M+6,76.LV03-@20#,M*2LHP\76M950D@D-%TMS SXKQKII(9P5*IPYH,I>9D
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M@IA\$"4ZT!<D(ACF'5[9@5?J,[H0V"P/?E_2*""H= S+.ZTA[R9UL[.:QU=
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MFC6(V'A(XZ7EI$I?IC 1D:,Z8>:0Y[^# HK+K[R^V?%MM2OTY6 6(5026(
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M1#J\X0TP.PVXZZXO.$H;0I2LXQC/*@"2  220 !W)/0 >\FID@ DG  ))/8
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M4@;VSU(UKS[=V](7?X;O]<8>OFOOCO'O],9]"/\ +QSGR[(\NWBCO>/]&?\
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M1AMR+G;S.BJ9;=P[C/;HX=81^\+L;^=+%I?=E7)CR/:6-32W&5,OXX[U_FP
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MA\^RKPC"T*3*CBG2HY8ZE-N5G,.EIIEY9V"(,A#+"N2[%0X\3(Y'S?GZF0K
M]1('[C;CSM1VV2"SW$2QQB;4W.=QNW'-:V8G#!;%2D,L;J&6^6[+,Z"'9K;J
M8"5#H<0;8 W8VR6HJ>V#9XI_MZD-9=CV"5OD_ ^6,J\V:_*V(N$%4I65?"1[
M&,Y]NV+IBID8*<JNV-2/K+&HC5OZ2J&/O->%&"$!;HS%G8>3.Q<CI]DMM'N
MJ']  V;%'=0FZ7\?$+W%O ^6KTQC'9,QK:&JE;:UVOQSW6AZ,B),B%,94K/H
M'1Q3.,8\,XY;J!V&W@[<B *Z_9E9VYH^]AN'F"#4+(;A/-WYLQ*MYQJJ\O\
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MCRG\@&8DQOY;V*,2<M'@!MT,%CJFV& 1Z;J!Z1123M^#KQCT6*.>Y=I+"X.
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MD6K39:_3'&NL2PCX>GV$Q:6R!\-UN8(3'HBBX;=:W"@<B8X3/S4IR>2Q.2&
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MC9%]0SH4W3; 0PR0ZBK7F%>*K\P[@0]<.^_&6V/ ?L%8A%L0C9065\F.0;7
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M0^Y#5L%YXEX.,]=#3A911!$K-$#C$292F HD"+ID=3ZD2E(@<A6(+L>H#R,
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MB AGCB-7V"4)6XZ1?*1&C$.PY$@ZN2O-!!1/8*F[#6MA&A[&(F4S* '&.>@
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MID63Z:-7/XQ#RI?O8 HY)ZLTD<CG[8K@5T^BD*C[##F1_<"0Z@>"HZ*/LU.
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MZQ#R,J6K+KS8;JO45S@66=F/K.W=W9NPZ#<[N<*!T&YV '09H3'$JCU4'95
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MP_KEO_S*?LNX4_A/P]_;6F_]33^LMTY?V_Z3_O5HG^?<?A72_P I6']<M_\
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M&WXP.$SN  IRAD[0 TZS+.*MFH:T(R^J]EE1V8Q9>))(D3(22A<!.Q3LG5^
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M!)\!56+9VUN'\LI$SHO63_LZ.R8*C>%R"7[*:6=&$&Q>G88UK"L9<C#IS9Y
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M$$$$9!!Z$$'H01W%4(BF;$U#^9JIQ=_UXS[KT_9YE(]AK8J?QJ8U+?)A[+.
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MZXM6>_=2UKKZE*5GOGOG.<YSWS[\N%U=#M<W ^$T@_\ E51MK<]X(3\8D/\
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M4*LJR6E[I]R\^DZF(%>UO8D++%>VAF22&561@7C8,]O(3%,JRH0,"YU@[U/
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MQCFX         #  '0  =  .@ [5[R(D:JB*J(BA41%"JJJ,*JJ  J@
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M"#,HQA#3 [#;;++2,82VVA*$XQC&,<\HDDDDDDDDD]R3U)/O)KT    !@
M#L .@'W5W.<KM.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3B
ME.*4XI3BE.*4XI3BE.*5HIOOHO;W5U0=/N_6[IF K^MFV1=LT/Y:HMO;@-$M
M(>SM&"OF^NVS')UKMH<BW=WQC?CV32 F<"*6IY6^WO>1:W%OLW-+UBDSCDF1
M#%.<>/-A(3PP0#U[5DFM>;<0S;]HCZ2)CZ4(PDB!.1CER MXYSBL;!=#,:#U
M9;CW[,V]4MKK95-M($!J-("Q1Z9?]JUS6]-W3>P99!&5?&WFL:CIHJ$LM-N
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J<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g796801g65f35.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g796801g65f35.jpg
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M(=9=627&(RM_V=>-;+ [>3DI;00PRJL4T4/9FULH@RZR GW0&T6-M;F:H?\
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MREEQ.)J\=GW32#2:F^ACDA=.LL\4X68H6SCEZFX')AAE%I*;4WE#8BBQ=[A
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MM0B6&"2VT%V:!2U44TT4<M@<-')+&QSGMDBEV"C:]R2;V50"68VN;*H+&PY
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MI==H@"FHT^DLZ.J1D[1+.6"?()6(DV.IBB$\UL 92IZ7#(I')@QVN+C!&J4
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M;]XF1Y8Y.OJ]T#E^[F%U6.!L)%55:I)A#HU^)6<LDV*K]6-/?XAWAO[BY'N
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MP'\ZCG%H^WO@N1@ N)[/N)\/"2+:I(<RP.(=0>I6(ZK= 2>M;'ZQ_P!F[/\
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M4MS/9R]C9LL YGO@:7<;^EW&:&^R2"5)(JRM5DL4TNOG>$?&9=+&@(G5 \)
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M%8B!CL<587.(-*.N*P*!I1!M+9["HK:P^]N*A(+$LP,;6W-T)-@&-@03R"N
M%)-@"%)(4&JG!!#@7 !$B@7+)SN!U*&Y W)!< $D5UB4Y]1_#X[<L,7I4K['
M^'IZJ] 59X/1S(/8XWT_]H[B)\]U@K^14FJP^G.S6SRV.<.>K:*G(F('(AB
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M2T!R9LLB^%(<;2D?5>&_4_+[6^+T=G=5>SAB 2RJS6\M9!<>EFVZ50Z*B,R
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B[#W+R'P K>5%6^E0">9 W/O/,^\DU)^1J5.*4XI3BE?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g796801g70u41.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g796801g70u41.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X4R>:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX
M;7 Z0W)E871E1&%T93XR,#(P+3 W+3,P5#$W.C4Y.C R*S U.C,P/"]X;7 Z
M0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!)
M;&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @
M(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(P+3 W+3,P5#$W.C4Y.C S*S U
M.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A
M=&4^,C R,"TP-RTS,%0Q-SHU.3HP,RLP-3HS,#PO>&UP.DUE=&%D871A1&%T
M93X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F
M.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U
M-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M:&5I9VAT/C$U,CPO>&UP1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @(" @
M(#QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @(" @
M(" @(" @(" @(" @/'AM<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G
M14%304))04%$+S=107-51VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!
M04%"04%304%!04%%028C>$$[05%"24%!04%!44%"+RLT041K1FMB,DIL04=4
M04%!04%!9B]B04E104)G445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+
M0W=O2R8C>$$[1$)!341!=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C
M2'@X9DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[
M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF+SA!04519T%M045!07=%4B8C>$$[04%)4D%135)!
M9B]%06%)04%!04A!445"05%%04%!04%!04%!04%11D%W24=!44%(0T%K2T-W
M14%!9TE$05%%0D%114%!04%!04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!
M04-!44U$06=10T)G8T1"04E'06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%
M54UP1VA">%=X46E00B8C>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-0
M0TY546YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y
M-"]0128C>$$[,4]4,%I85T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N
M9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[
M<6)N2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#
M04U$8E%%04%H141"0T53355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T
M4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H
M9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&19
M5U9P8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H
M66%(:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ
M2VUQ<39Y=')Q*W8O84%!=T1!44%#15%-4D%$.$$Y531Q:UAN1'DQ3'(K;C(X
M1G9D<B8C>$$[6EA6<&-P9#(P-WA'9$$V2WE594U015=(1U$O=&IF1E=+95=V
M>69L,$LT,49O9%E%;'1Q14@Q8WA#,V1(;TE:66QA4C%U2U-K1U=O0B8C>$$[
M6&=+8DQY*TU',5-B4G9Y1#%N4G!"2G!V;F$K=#):3%-+67AX36YQ4C)8<4Q&
M1V5%-B]#235&440R2C-,8D)746%(*U=V;6I4<E-E2R8C>$$[-C@V-FAF5'I7
M5C-:<F-Y97162'573%)4<7(S17%I4T-V=W0Q.7=-5E%$9FQ"-6M2<FU7,#@V
M6'1N8UAK-C-&=SA8,6]Q>&IT-$E&0B8C>$$[1#-J<S%0<2\R;5ES5E!%:SA1
M8U91,34K5E@U:71Q55-7;FYE-UA41U8R;FYE83@K<U)Y1S$Y14-/3#%I:F\P
M,5IJ>6-C9&=L2U9+<28C>$$[94@X=&1B3W V9&8O04]+-S!3,E9H65=C.5!6
M53--=&IC4$TP.#-'6E$O<7)+>49(1&1A:W1I<4)M+TIL>C5J3W1183E,0C9.
M*V12<R8C>$$[3%991DM1=#8S<DQ#>$PQ84E.4&165F50.3DQ;W4V<5!J+TQB
M5S1:=%EK9S@P,VM1,4],5D5T-# Y65(R>C9L3DI02$Q(1THK2$\R828C>$$[
M6#17059J-')I<51A,RM46&UJ56],*WI8>C-Q165N6'!U:T9P34HW9TQB,TLX
M56A:;G5H-F=J56QA=#EO94)Q4W%N3W8O;'@U:C%05R8C>$$[5&97,VY85DQ'
M,F%"-&US:TY%.5)L8T-11T9R9%8T=#96049R4D<S<DE70W%6,V8U3V$W9%%4
M97(U=W9*3'55>4ES,'8Q<#%J9VQJ9R8C>$$[57=2<6)W3W$X;TA9:U-69FQ2
M>3-(-&Q55G)V-59A-7%5<65J-7%U3%,S9V=G:G1R6E5N-%)3,C92;TI5160Q
M1'A0-W-S3TY'<7I66B8C>$$[;&]!5E$O.$%Y<6)Z9V)O>5 K64=Q3F)T3F-3
M4&)G>DPX139H5FI$<F-";#E08V=J+UEH9316<E9F>6@X>3,P>' U-#%!5UIL
M;6LK<28C>$$[5$<T:U5Q>6QB94YI;#%&5EEA250S8V=K:T9S5E9R6#AP+TU6
M=#9A4BMC-S5)651%631O>F-O=C=Q3FMO548Q=S1L;35C5E5!+W1C:B8C>$$[
M=FA66F$O;$PU;&<P;E9,52MD8C$Y4S%'1WET,#%F:DM,;4I,2V4T;6](*W-&
M,D0O049O<E1M2T%D-C1&535F>6DX,&TR;7-O=D]D>"8C>$$[2%E3:65L=#9D
M,5-S."]Q;FUY,W%-=T-F1%%C86MK.41X=W%J3$PX=5!.82M75S!U6'I69#(Q
M,DPY-31B<4M3850P-U%24$1$8G!2-R8C>$$[8V=*>D5O0G%/4V=.>E5B:%=P
M4'EP,6%+,#!7>3!Z>E9E86):85A$3$9D45%E=78Q<5-C>4Y*2S=,8TMY<UAL
M-4$W:T5B2$97=$TO2R8C>$$[2S1T-'149W8O34YZ9G=A;F)T8E1H,$Q334AH
M4TIJ2DIC4UA,2#1O*V15-'17;GAE2G15;F<O24]E1C=I438U8C--,3))<&)M
M838P."8C>$$[>71,9$I)<S!Z>4%82V\P53AO6FYJ-#DV8W-B5D]D0R]*,C,P
M;E-,=3%45D,K;S-F,4Y7=C!G5TE+;&XY6&]Q>'$Y4GDK<F9Z,$9E;28C>$$[
M,C=A<C=Z.'-F37,R:6%F<#%V-3(Q3S!U3$M74C5B.4=L95=A3U)54'!U6DHS
M2C1Y4CAG>D4P57-O;T1G5C%J*U=0;4,Q=4Y1=4<X,B8C>$$[,U8Q4&57.3=A
M=U,S2U-Y=&)P9&U)>&U-3F-C87<K:V%F1'54,G!U<7AB568K8V%X8W!$1$0U
M;W5)<F%";V=K5#(V=GEH=%I793%J;"8C>$$[-'E2<3-O<$DV06A2,7)48D97
M56%F*U9E<&%F-69T9$IS4$U$-F59<C<V-V-.<#A-;'!%-FU.67I&2$9(8U93
M<%1M951S<%ES5U4Q,B8C>$$[5E<R2#5895IO3'DR;'5V4$=Q6&QT17-A6$9U
M>GI2*W0V9'=*5%8P;D)8;$=V<&MG5C<Q;V5/2W!P<2\U9&9P0TAZ0D)$<DXS
M<'-/=B8C>$$[>65P8TQA0TE'<&=J:%I895I:;DMN,'HY9W!S>%AW3TMP5G$O
M-6)E8G(V6EEB3'I:96%263(Q:F$R:T0R.&MH85-A14%3>E!#<&A34"8C>$$[
M:W%+045C:714,TE*5D1Y9FQ,-75E,G9)>C4K,4U4,T5R4U%4:')L9E)2>DA6
M06]U9T-0,V4S:%4P-S1&96Y9<3=&6%EQ-T9867$W1B8C>$$[6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867%L.3DU:#!/=R8C>$$[=5IB83AV;UE,:4<P;#%'84HR
M05I,4T%H6DHR2%I&3&14:7%),#=58DQ58D]/.7-:;&YT6F=42$MT84=H2VYR
M=E5%1459<6E-5F1I<B8C>$$[<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-6
M9&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<D=D
M9B],=B8C>$$[>3%R;7!0<58S2$Y(97DR,&QL4$YB>E!#6F)E56]74BM*,T@W
M;UEQ:DIB0TA14$M6,V(V8WIO3$\R=4I9<%AB;DE:0TAL85)M8G%Z4R8C>$$[
M17-C5E1R1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T97;55-<%4Q;W=O845G-R8C>$$[*T)'-'A61"]!
M2U!G+VYM+S5(>F8X,31Q,DQ+3D1Z:F%4,4%$>#5Y>75T860Q3%5/2W-)='9*
M4&YI6%)R1S(Q5'I(2S)O=V%P2F-8;"8C>$$[-5IZ5%%#97=M:TQ005904&EA
M54-"86-"<W)$97%R1C1F>34O3W%,4DEB4TQZ2$A$9'=7.7I(2DI*<65O6%)U
M6C=U,49V-GI44U%Q."8C>$$[26A:9E9I4D$S1G$P238T<7E$>3,U2#@O-E8U
M='1R,C<Q,7(W4DE48TQ,0DYE6&MR3DA),7<X445%9UI/86U736-N;&9:841T
M:7(P9B8C>$$[1E=#*V%F2VYN92\X=UAD.6\K<'@R;&YC-EI.64I'.7AC<55M
M;6]&;5=*03!994]L5F131'94,WA6330Y3S%$5&9Y*W4W3%5:=EAU-"8C>$$[
M<D\V-75*2DIG07=K6D5%<V]%:FE.0T4U34MM;&-66E!I<G-69&ER<U9D:7)S
M5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5B8C>$$[9&ER<U9D:7)S
M5F1I<E1K<7!92U=)0DE557%F659)1TMQ54TX<VI&6'1P25)3=DIZ1U(X=F=D
M:FA).#%8>'E-,&9.-#)I3SE586AB8B8C>$$[+U5,1$5H6&XK;B]M;G%7;V%.
M639L6F%(2&1F6$Y43VMS<TXX<E)X>45!>'DK<5EL1%(W:U!X2$I32U5B96ER
M2&LO-7E.<VIO8T=Q9B8C>$$[;VA:43%R8UA6,G1T94-E3S%:3%E45S!.>$MK
M3DDU3&EA<TE69T-P1F%(<&=63R],6#5V6&UR96-B5'DU96%-=6YY,TEU1F%T
M>5I:;"8C>$$[:W0R;D)":#E+3G=V1S-"3$]&1EA!<EAQ<3E*>%9G9FUJ>C=R
M,FHK66(O5#=B5&9R9'1"<&ML,6%/:T8R-U-8;% S54IE3D1'95(V<28C>$$[
M=31'.6$O1&A63EDY5'8X054O>2MU<C8O9RMR,V,Q;&1E<$AW94E%2TI&5G=K
M=GAQ2D953T$R.41G5FMR97)5.%-T4&AP54AX*TPX3R8C>$$[;4MR954T27%I
M:T5M<$1D0GE!6'%0-61Z:7):;&]2>5)H56MD2R]T0E(Y;797=&9L,7A6=$I9
M;D%+<T1Y05EE3D<V1VYV5$96,DMU>"8C>$$[5C)+=7A6,DMU>%8R2W5X5C)+
M=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A62G8X86559G%Y6%$Q
M;7IA,FM-<7AZ3$]J228C>$$[>E%%0U)6645G;&51,GA66D0U-CAM>C)I,VM7
M<S)J,G),33940U9E3$QB4D-A6F=A-VE/2F<W94$S>%96,"]Z:#56,4LV:71,
M1%8W4R8C>$$[-G5P,&%31T-+6D=D;%%S<D5+1%A9;S%F:V9$1E='+VQ"-7@Q
M+W=!>#-V;4YD8799<FTT<TIO23!T-V%0,#19031K4$-H6&PV:' X9B8C>$$[
M-S9296Q$,7%Q>DQ5+TYE:6%:8S-.=F543DA,6C)5;7!4+W4U0T)B4D5+-T%H
M4T=A<"MY=%<Y<U958C=68E!6=DIM;U@Y;7I.8GDR;"8C>$$[,$8U<3!B0F\Q
M9$A6;%E"9U9:4T181E5&-3!F47)/-S!V56143G!#-&PY1T,V=F)6<%EL8VM-
M;D\T1D)".%@R4S5P>3DX;$=-1#E1="8C>$$[>#@R2&E)231B2&5,+W-43#E$
M85=H94\Q:6YJ6%5V:6UU<F%A4E%#;GAQ95%F:W9+<'!X1D0P3U9J14M04FU9
M04=Q3S9J0W5L>E@Y="8C>$$[8C(R=50O5W)/:71A:61(855)>$Q#5EI&8W98
M;WA'.4\T>5HP.'="3#%5,6EC1$QH17953VQQ.'-0;4M#3V556$YN9$]'1#(V
M>E)08B8C>$$[:$5&95EE4EAL<CA*,E!!9#AR<6949'-01TQ.:C=M:S%'-&=E
M2S)L<S5B8T=,,41E4FQ:-TE&66E3<&-L6D%Q,#9L1G(Y3U!%46%)528C>$$[
M6D1Y22M05#AF0D<R5W$R9#=B<&,R<W%81G4U2W)0031L4W9)2V]*6'5E5E1T
M=#-Y46M$>5IX;4I#=V)#3'=S;EEQ-T9867$W1EA9<28C>$$[-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6$560D(V2&)B8CE72W%F;TIX-#%E;&$O8F5V
M,S%Y4$-I;7A#;TI)6F=32U8U13 K9R8C>$$[:VI#071-6G-V>34X=E<R;3)7
M;GDK<&52,D8K=7 R.'1Y26UK*W-*<W!:;&I3=$]N4W1.<3!!=W!32"]L479K
M:S)%5FLX,399-V5#4R8C>$$[,G175U=/2F]O<&]V46U!.4M+3EAA5TEC2&%1
M37A(9D95,3!J.'%F3$]K*UI99DU&:DID4C-%2'$K;F)E;VAH+V5M56M%;%!6
M64$S3"8C>$$[:TM:3TYD-E9!3TMP4BM41W$K6C<R,C%72%<Q94=',F5)869A
M;7II=$5J:6(Q4'-M3DEG-TYX0F(T048R07(Q=VQ786$Q-5<P2%=Z6"8C>$$[
M5DQ16$HY2F]$5FY51TM19W5H0TUT5EEQ2V<T1E5D5# R>#!Z>61F,DYJ14EB
M5T-Y=4)(1T-7<%=.;4I,35-X2DI*2DIQ5&EQ8WEX4B8C>$$[5%)01DMI>5)/
M0W)X=4%Y<T1S45%D:4U667@O>7)R4F)9<S)I6$XW;TA,8WAA8F-.2$%$,7%T
M<DM*8EIE=F%01E9Z95A03T-!:41Z8B8C>$$[32LQ1F$V<W)/4F=A.50V2U=W
M3S-T:7%G3D0X+S(X,#AK1W%A3F1*8VM'-&EM,'EA2C-O;D@T<%DW=&=F<&I/
M,E,T>G1V>5EI15)E,R8C>$$[4&UH64Y1.'IA1$9-=#4U67!"3EAN96%"34QT
M54Y$4U0V;D]T=DEV6#=-878Y3U-L:TUI3TQE;45C35EG.$\Q;W%Y,6913F-S
M;TQZ5"8C>$$[<'IQ;"]P.'9+-%-Z9')/-FI::41*-G1S>DDT2D%(2T]18C5(
M=S1Z;"].651I4D5'=4EJ=3(O5#EI66UB5EDT;G5R83=K;4XU249T3"8C>$$[
M5SAT5U995'I02EA-36%U<3 R1% X-FY);D9-13!19FMO;6%S13<X<DA,-40W
M,%=M<#,V6%5&<&-71$TW>&AP-3=E5THT;S(S<CA,="8C>$$[2$U6*TA9:5!)
M,TQQ1V9'8D%)+T@S+UER861Q*VXV:D5:3%=1:T)J1U5K4C181$M!>$)35E5F
M;U(R>&I-2&MY:$U31FA'6DIM-T98628C>$$[<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T9867$W1EA'=$YU=F)&5G1:9C56+S1)+S!Y3FQ807E6,U5!97A*+VAI
M3%9H8VUK9FU(3'!';28C>$$[>$A6;6HQ1U!5-VQ.4VY625 S=6U36&-P:EI6
M<'A34F)C4F-A5C0Q3E%4:VQ99$):+W=$3U)+84Q$2'I2-S9+1S9&,4I.3F%I
M4U=E-"8C>$$[=%)&05EU061/3G9/4%9Q>%-T85505$-R,')Y8F%E6DQ44TAT
M=DU.>6)Y*VIU6GA(9$AH.&1V-FA-2BM!3"MX44=O<F=69W8U1S8W<B8C>$$[
M1W%Y86XK:V16;C%0-G99-EE)6&UO0E)Z9$U:2%9:-VM,3RMW;%4X5TA&86IP
M:7%F95IV>31V=%@Q-U5.5G1T6%-Y+U-';E!P:G%B9"8C>$$[<%I%:FQ8:2]'
M4EIO=F@O859A8DYV=FEQ6E)A1S)H+VPY9&%5,'%Z1S)S<G(T;S Y2TU">$DT
M4T]-<R]"135C55AK84M":7)*.%9D:28C>$$[<G-69&ER<U938EA02B]L,U<U
M575,-C!!=C124S,Q1T)M=#=U3"]J2&-21DI6*UA+;4MP6B]H-WHS66)A5C5L
M4SEH52]$8C9Z84Q/,R8C>$$[2"M8-GAA=F%0.&U:5U!J6$952F979C5G5$]*
M3'91=$(Q3C!(=WI,95A6<$YS9F@T36)7-$LK4#(X<VAL;$AK5W%E1T4Y-4%7
M=#%#-R8C>$$[.'=3,W1V96%X-5!U3'1,53%I4WAU-T\V5TYG86E:56Y.<$IY
M+W="6&5N8DE':4M)0WEX0U5G5#!5=$LX>%A&>')&,6$V6G%W6%5,9R8C>$$[
M;59.03%Y2V4Q;FE!87)M24]/8VDP4%9+;TYS:TEW<G)F>D@T*TQ565I226U*
M0D(V2' X5U9T<G-&<CE7:#%3;')E5&A1>7AR3$Q#2"8C>$$[8VM"4E V87!U
M4C-P:V%01'A(-S)Z>&=#0DQA4CDY9D]Q5%!!,T]X5C)+=7A6,DMU>%8R2W5X
M5C)+=7A6,DMU>%8R2W5X5C)+=7A6,B8C>$$[2W5X5C5**U$P;'HY6C@P45A4
M6$@Q;4LT9TUI6&EZ451$:TIA571:<#=H;V]T<4EX;WHW.'$P,DMS-#%,52].
M34]S,EII<V8Y=WE3>B8C>$$[<&5#34-A95)&9TQW>4I2:'=":TA(:5)5*T]"
M57(P3RLX,UAV-69A<DXU<71H839N-D4T.4U)12M(-G-R3CA)3$-I>6PP53$S
M54$Y."8C>$$[2W,S=TLW1EA9<3=&6%EQ-T9867$W1EA9<6QN;41Y,6]N;4-Y
M*W V<F),4$=P-7=Y06Q*67!",&MH;%5H-#-(6FQ)3TMS9FDQ:E@O2R8C>$$[
M8D,Q.'AE='$R:$Q28F)Z1D1'6DHT:%=G4R]G:4A,8B]!2"]'=D4Y6$,Y4W%J
M=$]4>7IQ9#9U<6%&<EA)>G0V:VDR5C!K,$UX3S5,4B8C>$$[;C%&*WE0,F%:
M64UH06]G169J<GIC8S9C8UA%0U%F9G-F9V1L5G1C,5-X;750,&=,3S1T;VQD
M,64P:TMZ+T0Y;$1!-6%R9DIV-EI62"8C>$$[;'9Z.&LX5U%(8T%X.'5F>2]A
M;5=M87IA86I"0DQ%2%)P,%IX1S9-<%AG,T)L86]O1T1B54\K4T%S5TYW>FAL
M17$X,%A(3D1,6# S5B8C>$$[*TIO,T5G,%!V5$5G:FUZ16=E4R]!;#)+=7A6
M,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=DLO=T%J5FM4.4UH;VM54TQA
M5$TP9"8C>$$[=#E8.4]35#%J2F%Y5D,O=EE#2TUM-%-O,S,R2E9M96\K94Y'
M<W1E<TY%<$ID6$XY2DI%,'1U66YJ=#)I54]W=4MY2S8W169:53!Q3R8C>$$[
M5D%29U9"5V9N1%1F3F9K8E9D53 K2V5'1#9T36]3-59&8V@W5EHT,F]J>4-J
M>%1)=S-R=E%G2&)&5UA9<3=&6%EQ-T9867$W1EA9<28C>$$[-T9867$W1EA9
M<6MU;RM39DIM<'I'8E5T03 V.6U*2DUT>&%14W-397 U3VI(1E9+3#AV9DE-
M36)2>&57=$MJ:F8W84I9,GEG.71W128C>$$[,WA60TXK5U!K,DYV53!Y>F92
M2G=A<DQP13!T:%$O-FQU>5)S4%IL23ES5E%3*U9F3BMJ,U%V3DMU-TA7>DAY
M-$IQ<T,R,3-1.6AF5R8C>$$[:6-454=N>%<U.7IL:'EY27%Z5%=-34),:6]C
M6&5U;#@W>C988E1,<D]M,W5J>G9)6%<W=6\R=G)"95)"4"MK5UIK.4]0<4(V
M;U-N>28C>$$[>$)"279L-4M9:T$X2C,X,#<P8GI,839J<&(V:7)W6$YU:$%%
M*VYY:3EJ:T)P.%-E:T,O9F-&86I#64%M;VXU-TU2:VM):WI&5C-B+R8C>$$[
M04Q5>FLQ0WAJ84I:8FE/2C5H>6E34F=J34YU:711.3AI25-026-M6GE21E=2
M=7(U0FTW1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ."8C>$$[<R]),WI$<E=S
M>659,C%$541Q8U9T8U)25SEW:S@P='5P<$IY:6I7-'0W5UI3;S1L,V%O979W
M,'!41E=E879O+VQ'+S%#,$]S5TYH9"8C>$$[86IX9$Q%,V-536LS1VQ:1FDY
M449Q52LP1GA61%AD<F]6=#51,6%04DER5T=Y*W(S8D9,2EDQ:3E5;S-Q1VM6
M1C5C=G1D-C1Q>41&6"8C>$$[67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ
M-T9867$W1EA9<7@O579)6&Q7*W57=F9Q47,Y4V9R<59G>C)D,%-$56-P<F-X
M=3-Y628C>$$[:V4R2V]#9GDW-3!T059S.5=T=&-S="\Y0C%Y0F5D3WER9#)Y
M<E1W*T]&>C<U2TUI3U1'55))55)A;DHU=$]N:3)4>D)O=6]A2D9A:R8C>$$[
M8V)M,$)V3$1I0GA!6C=4:W=4="LY:5%$1'AN9G)A3T%B9$M48GDW-6]T=%I,
M9E9P<F4K=&I6;V11<TI&;6=:83=+.4-Z4GE!9%9B*R8C>$$[>DI3:D=R:69G
M=VA/6$9W>4AX2$PY:%1X2%(Q1$EW6E<S1$$Q0DAZ>6]H=4)T=D9867$W1EA9
M<3=&6%EQ-T9867$X8B]!3V-E-WDO=B8C>$$[8FIZ0DYQ1C@Q.64R.%9H651Z
M<T%Z3S%U8FLK;SEW:SDS1E!),W$P6FMK-T-U2W,U,6XX=C1.4S$V>#%L9%1U
M-V4T<UI:3&E*07EY<28C>$$[2DA1>&IH-F]B:7%G;C10<RLQ9#A654Y-.&TR
M9FQ(>4AQ=6Q7;'A,8WAF5G S.5=924=O;'%S2T0T06\R:FA7<#=M<#<T<7I,
M1EA9<28C>$$[-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&56DQ9GE0-5<Q5V,S5GI93$AF:T5$56)6;G1B<U8X3&E!>"8C>$$[
M>2\X0419<6QT=#58.#-A2D=)=$(Q=$QU>%-P5%1T6&=6<58S25,V='929&9I
M,W$V4TA*4VM38DQ'35)%54YG=B]W06)A;G!X-"M:4"8C>$$[3#$U66]+5G9R
M14A5-U1F8G)!;W5&2'4X0VI)<VLX,&9Z1&]7=%%T3G!.+T)F4F]E36AG:U9Y
M:D19<39G,55J=V)F1E5W>%8R2W5X5B8C>$$[,DMU>%8R2V],5&1%,&)3+U4O
M4G1H8E=0<F-F5BMR47AW."M.95!,9T9R5&MA5GA6:BMU3BM9>2M9=$QN,#9#
M,&LX=C(Y>$]D470T-28C>$$[>70Q3D5B9#%H<C9S65)E37!";W(Y94\Y2VM+
M;UA1-&9/55@U9C9S;FTV45-A<#9%-356:5!W+U9L-3!-24,X9E<Y47 S0V-1
M9#A+<R8C>$$[,W=+-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ-T9867$W1E5L,7)Y6#57,7%:8FI59$]I:W9%+R8C>$$[
M=3<V4&Q"9$HO<5A%2FIM6"]9=&EQ02]W-35S,#-F4E!-1#--23973W12+U=L
M*U,S35IH=48K8FU41E9V*TTY5# R:2M:9$-U8D9"<R8C>$$[,F]73F12<R]#
M<$U+:35194IE04M02$95+W="2C%R4TY9=$)D-E9E=U@Q<U14,7)E4EI&0C=Q
M4W!.0T\T3RM+;WI&6%EQ-T9867%X3"8C>$$[6%!Z1C W4V9.1VPV1DY#5E<O
M859:<GED;70P:3E*47=+3$EN-S57,RM.1'A7;35X5D0V3C4P9S@T95%.5C%A
M1S)A,%0V=E!(-E1/2B8C>$$[4'17<7I$-&=&2$E,2T9C9G-S0W9B1E=A-'$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<28C>$$[-T9867$W1EA9<6M'<F52+TPR;S-2=GA#,6AQ>#9A<EE/8E<V
M-C$K2U-/;G%$8R]$24=8,GA63#)M."]E6'A75D8X,397=E=325(R=28C>$$[
M<5)Q2V)M3W$R,7=F.5@P:C1+8U94;GDO-7(P4%AO-41P,7AY;F=01S9S<%9A
M1S5G8BM784-13$EH*UDS-UEQ;3)+=7A63#<O0494428C>$$[-$PK>G-,-C1G
M4RMV95ES<F55<GIK-&HT*T%/2W!F96%V;S)Q*U5D5G5D27598G4P1G1D25I,
M9&=Y8WA'>%EF1#,S<C<Q<FER24U69"8C>$$[:7)S5F1I<G-69&ER<U9D:7)S
M5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S
M5E,K.#AV84QE86YA828C>$$[<&-7:V(V;%EK+U9B=T%R2V=954LX,6]X43$S
M42]$-UEQ;4=+=7A6:2MR9FQX-6(Q3%=O3F):6G)B5DQD<$AJ=6]*3TQH-48T
M;&=71"8C>$$[.&%5+UIO4$=U2V]Z>34U33!4>2]O:VUI,DM34%E3,45I5$]8
M67 V4W=+;DQB-%9I:E9",V].-FYF1E58*V=,2"]F=#4O=T)*=#4O,28C>$$[
M5GA6,S9!<V8Y*S-N+U-B968Y5F-69"MG3$@O9G0U+S!M,VXO0496>%8S-D%S
M9CA!9G0U+S!M,VXO5EA&6&9O0W@O,S=E9CA!4V)E9B8C>$$[.59C5F0K9TQ(
M+V9T-2\P;3-N+U981EAF;T-X+S,W968Y2G0U+W="5F-69"MG3$@O04@W968Y
M2G0U+S%6>%8S-D%S9CDK,VXO045M,R8C>$$[;B]66$989F]#>"\S-V5F.4IT
M-2\Q5GA6,S9!<V8Y*S-N+U-B968X05981EAF;T-X+W="*S-N+U-B968Y5F-6
M9"MG3$@O9G0U+W="2B8C>$$[=#4O,59X5C,V07-F.2LS;B]38F5F.59C5F0K
M9TQ(+V9T-2\P;3-N+T%&5GA6,S9!<V8X069T-2\P;3-N+U981EAF;T-X+S,W
M968X028C>$$[4V)E9CE68U9D*V=,2"]F=#4O,&TS;B]66$989F]#>"\S-V5F
M.4IT-2]W0E9C5F0K9TQ(+T%(-V5F.4IT-2\Q5GA6,S9!<V8Y*S-N+R8C>$$[
M045M,VXO5EA&6&9O0W@O,S=E9CE*=#4O,59X5C,V07-F.2LS;B]38F5F.$%6
M6$989F]#>"]W0BLS;B]38F5F.59C5F0K9TQ(+V9T-28C>$$[+W="2G0U+S%6
M>%8S-D%S9CDK,VXO4V)E9CE68U9D*V=,2"]F=#4O,&TS;B]!1E9X5C,V07-F
M.$%F=#4O,&TS;B]66$97,#!/>5(Q8R8C>$$[4UA:2VM%0G)Y-UE61RLT37!"
M*VY&57=X5C)+=7A6,DMU>%9I.7(U9#AX4B]M1F0V-TIQ4F91-7)145$V8UI:
M4W%39G4Y>$114D1D2"8C>$$[8FY5:SAQ54<U2W)+359D:7%895DY3W4Y4S!'
M+W-,3S9K<W)U-6=E3S)U-&YA2C0U0W9W34A4-&QO,U=M.4U64S=Y<F]E=#9D
M<4]U,R8C>$$[3W S4')X-FID;65Y:D9X3D]S8U97;W9#5E(V8E5)0C1(:E%!
M04-M-G))<U9D:7)$9GI".' K6CEC5D@P2%8U9$]F,$1"3$-,:5=#3B8C>$$[
M-C-%171F,U-V4FI&2$I(>DMM;DQP,7A6:S)I,G0W86%065=T.5 X05=B,C-T
M-&]R<35(22MP2VE"6&5R170X5$%N8S%X5D=9<3=&6"8C>$$[;FIE4W90-V5B
M;3%A2'I!3%A3:G%59#%,<'9Q6$4V>C)S9DEE;652:D5,8UA.5EAK:F9"<U!4
M<39R,%!&6%EQ>'8X=V1",3-84$QK=28C>$$[;C9(94-W=C-D5U,V33 P2$-G
M4'A";U%Z17$Q1S1K56%L3G9T0E9R>40U9C$W43E,=6)B5W(O.$%31GA,8RMR
M1DPV:W,Q13E'2TYI5R8C>$$[;&]W37-S8GI&4CA+;"M+-T1&5U,T<3=&6&UN
M;6)Y0C4Y,4QZ6DQQ96XV.#%L<&(S3G!..553-W5K-4I!<$1H;W='4E)5,31+
M85 X028C>$$[-4(S2E8V6&=6,DMP1#4S,&9Z1G)(;#9A>#AV-G%.1S%&,E)L
M=D-J3V5+;FM50E(T,E1N4VA98C!X5E(X:F%&<C)J,F0Y2').,SEB=28C>$$[
M3'$W931J65A%,7=I27EQ;U906%5/;C)E4E=P2$EK:6=.07%Y5$9867%W:CAX
M9DM0;EA8-3=*.4$Q+SA!4F1R8G!-='I99WEW*W5:628C>$$[6%%-,#A42#=*
M6F5+;4TP4'AB,#1L5FLS;'EX=CE0,$14<DA53&HV,V97='9&1F,S4EIN36MI
M2T9:>7HO04)-5TER531Q;4]+=7A6,B8C>$$[2W5X5C)+=7A6,DMU>%8R2W5X
M5C)+=7A6,DMU>%8R2W9)5S!N.#DR,6TT831V4S)H0C=G2D)A>3)S5C X4G5K
M:V@T4T]P5DA%5$UG<B8C>$$[*WEU+WA-34MQ=6YA3"ME8GEX<'$R<4M94D-R
M=$IA=&)O,S%G>E=A4TIU;3AF;W!C3VAO1'E99R]S-'%U=DY*+U!(-C9H:78P
M:W,Q;B8C>$$[:6%.13E'2G935S5U*U-Z3WIV>5!O=$%79%9P4VDK;5=$3FER
M,69!<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69B\O6CPO>&UP
M1TEM9SII;6%G93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]X;7 Z5&AU;6)N86EL<SX*(" @
M(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@
M<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]P9&8O,2XS+R(^"B @(" @(" @(#QP9&8Z4')O9'5C97(^
M06-R;V)A="!$:7-T:6QL97(@,3 N,2XQ-B H5VEN9&]W<RD\+W!D9CI0<F]D
M=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H
M='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD
M8SIC<F5A=&]R/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @
M(" @/')D9CIL:3YR<C(Y,SDY.#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D
M9CI397$^"B @(" @(" @(#PO9&,Z8W)E871O<CX*(" @(" @(" @/&1C.G1I
M=&QE/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D
M9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CY-:6-R;W-O9G0@5V]R9" M($97
M7S$Q,3$Q.3DY7S$U7U!R;VIE8W0@1V%L;&5O;B M(%,M,3PO<F1F.FQI/@H@
M(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @
M(" @(" @(#QD8SID97-C<FEP=&EO;CX*(" @(" @(" @(" @/')D9CI!;'0^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M<F5P86ER(CY&
M:6QE($YA;64Z(" @(" @(" @(" @(" @4U0P,#(N86DF(WA!.U5S97)N86UE
M.B @(" @(" @(" @(" @<G(R.30V,3DF(WA!.TQO8V%L(%1I;64Z(" @(" @
M(" @(" @(#,P+4IU;"TR,#(P(#$W.C4W.C4X)B-X03M%4U0@5&EM93H@(" @
M(" @(" @(" @(#,P+4IU;"TR,#(P(# X.C(W.C4X)B-X03M38W)I<'0@5F5R
M<VEO;CH@(" @(" @(" R+C8F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @
M(#$V+C N,"8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!,:6YE($-H87)T
M)B-X03LF(WA!.R @(" @("#B@*(@,2!P871H(&]B:F5C=',@:&%V92!T;W1A
M;"!I;FL@8V]V97)A9V4@;W9E<B R.# N)B-X03LJ*BI&25@@04Y$(%)%4E5.
M(%!2149,24=(5"!30U))4%0J*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!C
M;VQO<G,@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @
M(" @($)L86-K)B-X03L@(" @(" @(" @0TU92R8C>$$[)B-X03LM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF(WA!
M.T9I;&4@3F%M93H@(" @(" @(" @(" @("!35# P,BYA:28C>$$[57-E<FYA
M;64Z(" @(" @(" @(" @("!R<C(Y-#8Q.28C>$$[3&]C86P@5&EM93H@(" @
M(" @(" @(" @,S M2G5L+3(P,C @,3<Z-3@Z-3<F(WA!.T535"!4:6UE.B @
M(" @(" @(" @(" @,S M2G5L+3(P,C @,#@Z,C@Z-3<F(WA!.U-C<FEP="!6
M97)S:6]N.B @(" @(" @(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@
M(" @,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($QI;F4@0VAA
M<G0F(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H="!C:&5C:R!I<R!C;VUP;&5T
M92X@4&QE87-E(&5N<W5R92!M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T960@
M<&5R('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@8V]L;W)S
M(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!"
M;&%C:R8C>$$[(" @(" @(" @($--64LF(WA!.R8C>$$[+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03L\+W)D
M9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.F1E
M<V-R:7!T:6]N/@H@(" @(" @(" \9&,Z9F]R;6%T/F%P<&QI8V%T:6]N+W!O
M<W1S8W)I<'0\+V1C.F9O<FUA=#X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^
M"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @
M(" @('AM;&YS.GAM<%109STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+W0O<&<O(@H@(" @(" @(" @("!X;6QN<SIS=$1I;3TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+W-4>7!E+T1I;65N<VEO;G,C(@H@(" @(" @(" @
M("!X;6QN<SIX;7!'/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R\B
M/@H@(" @(" @(" \>&UP5%!G.DUA>%!A9V53:7IE(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T1&EM.G<^-C$R+C P,# P,#PO
M<W1$:6TZ=SX*(" @(" @(" @(" @/'-T1&EM.F@^-SDR+C P,# P,#PO<W1$
M:6TZ:#X*(" @(" @(" @(" @/'-T1&EM.G5N:70^4&]I;G1S/"]S=$1I;3IU
M;FET/@H@(" @(" @(" \+WAM<%109SI-87A086=E4VEZ93X*(" @(" @(" @
M/'AM<%109SI.4&%G97,^,3PO>&UP5%!G.DY086=E<SX*(" @(" @(" @/'AM
M<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/D9A;'-E/"]X;7!44&<Z2&%S
M5FES:6)L951R86YS<&%R96YC>3X*(" @(" @(" @/'AM<%109SI(87-6:7-I
M8FQE3W9E<G!R:6YT/E1R=64\+WAM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT
M/@H@(" @(" @(" \>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(" @(#QR
M9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI/D-Y86X\+W)D9CIL:3X*
M(" @(" @(" @(" @(" @/')D9CIL:3Y-86=E;G1A/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D^665L;&]W/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D^0FQA8VL\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z
M4V5Q/@H@(" @(" @(" \+WAM<%109SI0;&%T94YA;65S/@H@(" @(" @(" \
M>&UP5%!G.E-W871C:$=R;W5P<SX*(" @(" @(" @(" @/')D9CI397$^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<$YA;64^1&5F875L="!3
M=V%T8V@@1W)O=7 \+WAM<$<Z9W)O=7!.86UE/@H@(" @(" @(" @(" @(" @
M(" \>&UP1SIG<F]U<%1Y<&4^,#PO>&UP1SIG<F]U<%1Y<&4^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @
M(" @(#PO>&UP5%!G.E-W871C:$=R;W5P<SX*(" @(" @/"]R9&8Z1&5S8W)I
M<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @
M(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(*(" @(" @
M(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]S5'EP92]297-O=7)C945V96YT(R(^"B @(" @(" @(#QX;7!-33I$97)I
M=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z13$R1D,W1#@U1$0R14$Q,3A&
M,C9#-$4W0C8Q,D0X,$0\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @
M(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z13$R1D,W1#@U1$0R14$Q,3A&
M,C9#-$4W0C8Q,D0X,$0\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @
M(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#I$1C)&0S=$.#5$
M1#)%03$Q.$8R-D,T13="-C$R1#@P1#PO<W12968Z;W)I9VEN86Q$;V-U;65N
M=$E$/@H@(" @(" @(" @(" \<W12968Z<F5N9&ET:6]N0VQA<W,^9&5F875L
M=#PO<W12968Z<F5N9&ET:6]N0VQA<W,^"B @(" @(" @(#PO>&UP34TZ1&5R
M:79E9$9R;VT^"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z
M13(R1D,W1#@U1$0R14$Q,3A&,C9#-$4W0C8Q,D0X,$0\+WAM<$U-.D1O8W5M
M96YT240^"B @(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z13(R
M1D,W1#@U1$0R14$Q,3A&,C9#-$4W0C8Q,D0X,$0\+WAM<$U-.DEN<W1A;F-E
M240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^>&UP+F1I
M9#I$1C)&0S=$.#5$1#)%03$Q.$8R-D,T13="-C$R1#@P1#PO>&UP34TZ3W)I
M9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @
M(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z1$8R1D,W1#@U1$0R14$Q
M,3A&,C9#-$4W0C8Q,D0X,$0\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C M,#<M,S!4,3<Z-34Z,#<K,#4Z
M,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T
M=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+W-T
M179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC
M:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS
M=&%N8V5)1#YX;7 N:6ED.D4R,D9#-T0X-41$,D5!,3$X1C(V0S1%-T(V,3)$
M.#!$/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z=VAE;CXR,#(P+3 W+3,P5#$W.C4Y.C S*S U.C,P/"]S=$5V=#IW:&5N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B
M92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G
M96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V
M=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @
M(" @(#QX;7!-33I296YD:71I;VY#;&%S<SYD969A=6QT/"]X;7!-33I296YD
M:71I;VY#;&%S<SX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F
M.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X
M<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( 5("00,!$0 "$0$#$0'_Q  ?  $
M 04! 0$! 0          "04&!P@*! ,! @O_Q !($   !@,  0(#!08$ 0@)
M!0 " P0%!@<  0@)$1(3%!46(5>7V!<B(SAWN HD,3(S)28T-D)88988&1I!
M0U%6<8*!E9C4U__$ !L! 0 " P$!               ! @,%!@0'_\0 21$
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M[!Y,E#PUP5$LM267 T/I-J.#0S)WI6399;<XIF-I5$-)[H%D5EG'+!DG*C]
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MA)"HDE/L$6ASXY/'&<DZ<#TW[:=#EYA:,(Y*+35O;9H3T);OZ?O:+U^6WLO
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M"*&I@FIE:_;JJJ\JKH.77:ESV86;MQ40D#'J-'+]FDE&;6&-@E&S"BQ[,]P
M[T)R\YR\]_$O1DKBO(TN9W2.0.&1]SCL4# X^XLD78VI<Q08"M,X AC.K0(2
M%#9% KT2-:&.HC"&<*M(F4Z1Z.(*& 0>%54E4K4,X:UE95ZK;;..$ILEN50N
M-GH;"4#*T0,^<)#6T:>6'"(UHD1K\6X#$5K1>Q;!K0<#+[].A;2+G+GIMB[W
M!VZAZ900J2IV1)(X@BJ^$)8N_I(SZ_9Q*]Q\AC+:75/'_7?T0E<D/+:O7?R
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MUQ E*RL ?#K14HA\>.4UX#Y,EO\ 9!CS&X1L2!\@F3H?:P";]?)D$IO3X)0
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , _D8P%@&88,)9981#,,&+0
M#6Q"&,0MZ"$(0ZWL0M[UK6M;WO>M:P"'_F;R33;ISR)33GV)P.,M_)1?+TJN
M6F+;5ENHYU=CO![OC-//\^CI@7O3$DI9T>'"4M4&$='#7B8D1=/83:__ &3D
MC0B,%W%*.<^MS)-=DUGSZ? P'U)Y.>IJHM;KV>UQ%:+5<E\ VYRY4EW1Z7M,
MX579;"J^3( .<2"NY4TRMMB4(!6Z>SXP4S-;[#I3N3'M[ZJ/6IRS$" (**>%
MOF2DUOLL9ZK#SEQ?1K!/]@H, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M)N:7LXQF\[J4W!8P]\J$\O.-L+KG.V'CC[3]&?@Y5'Y]R3__  /-A]VX?_\
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M@^DZ=6G*4)Q?A*,FGW*IES,, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MMMC?PQL7EUI_.[XI_P"N'3O]E5XX(727P_=$CV"!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & 1R=V>-RK>S?LQ9;%)'[GSKJI]_/T5UE5P0MUDP)S3_
M !C$K/(-)SD()_7BLT]00\PE^4_+FH'!V(:%S,:[.)RH6C)QRNJ?5/H_H_?X
M&K] ^3"RJ$L6/\@^6J-1^@[R<3_HM2]3LVQ).3.KBDNP$IW"/S%20C;*QLE6
M7LHU[@,JTRI=+CBC$!;"-[8(L(2XK'-%Y75K;,?COEKWI$W(!@,"$8!!& 80
MC , M"", M:V$01:WO0@BUO6PBUO>MZWK>M^F"A37MC99*TKV&1L[6_L;JF,
M1NC*]MZ1U:7)(;KT-2KVY<2>C6)C-?<80H),*'K[A!WE*E.G5A*G5A"I3FG&
M=.I&,X3B^L91DG&2?BFFC#<6UO=T*MM=T*-U;5X.G6M[BE"M0K0?6%6E4C*G
M4@_&,XM/Q1C9AH:HHA)AS6$0",0>6?9DV(D/,2:4C&!.R#TB^$FTS("R8^H$
MDVW-X4ARMJ/.((2%(P&:1^]./<U==UBMI%+0:NH7%32:%2G5MK.HXU*=M.C3
MG2I*W=2,IT:5.%2:C0IRC06<NFVDUSMGP5PKIFK3UW2M#T[2M7G83TUWNG6T
M+-NUFZ4N2=M04+.K.#H4>2K5MYU80IQI1FJ3E!Z4JF7R7T0!;] F%5]C0TL)
MYB0N51M-65QMP0BV:202!H>V&"R),45[R#SUCLG>%1FRCDB;]W:$SF- H75E
MJM&'$=[<ZIP^XUOO%72[:TI:[1GZ*?W=TJ=Q6H6%:E&OR?>'.IZ>5+F=&#J<
ML3@+^A]M'#-M7>CWO#WV@48^M0AJUL]%UFG'G4G!?=+BWT^ZC&ESQYZE>%>=
M3DE&&,TGL+7?2*\BB5UT=-1$CFXML<79(H:)@[?+*U25M"$I*H(;W).A<2G5
M]<"7%$P1LH#@Y/84R)4T#<"G=#H73ZA1T.5]94="U6K<VFH2MJ%*MK5M'0JE
MO?75S.VA9W'WRK&DL2]%+[USTZ$U5S!N$.>71:%QK?T^$+GB?[0='I\$RLZM
MVJMK<7;KSK6]M3BX5Z5&5*E<1KW=6->C::<HU[JX]%2G0=57-)&5JCNB%W:R
MN$@@X9%MK;EX4 SY!&'N-?-B-3%*R53<%X1I?GT1Q!P!A/3['[/703P%"&7H
M>77.'[_AZO1MM0E9NK7H^FBK.]MKU1CS.#C4E;U*BIS4D_5ECF6\7))XWG"O
M&&C\96=Q?:-'45;VUPK>4]0TR]TUU7*G&K"I;J\HTO3T90FFIT\N+VG&#<>;
M+&:0ZD8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & <-5SNW <)GZ=EX<L#R5<D6/'[:9^H6GGETY.N2]^=I!9%6RQ,H
M1V8&FYB87,&Y"&3JD;6Z2B*3 $>(3N:)MVQJ"OIS?L9DFUF7(UA1SS)-+ME;
M-X7BF_>=I-+2203*G*FE\L$2*4RJLX'))*),QNL83BD#Y%FIS>1)XT^[V^1X
MG;BJ4[*8WG>W5I![4#COYM.=@POJ_P"?H9,P"RIA6]>V&HARJ>P:(S557DP;
M;#@2B5QQHD!\*GK,E<$+1-8H:ZI%0X_*VM$ZNB1OD#4)*ZHTSBN(3JBRE1X1
MAEKH^NS]Z[&*9=R!RE/HQ.85-N;:,E42LV?&VM8D<?:KA3DT3>T#B"4IUD2A
M$I93"7N>&I2"4IDO< GR :8L*<3ALGU!L3E[/+RMD\O9=EV,VQ:*QB#1MCAT
M*CC%$(C&&M$QQN+1AH0,,=C[*VD 2M[0R,K4G2MK4V(4Q9:=&@0IB$J8D "B
M2@ #H.A'7J1_]:?SN^*?^N'3O]E5XX)727P_=$CV"!@# & , 8 P!@# & ,
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M8<E]1(CT70O.--V\,XG9 '::P&.NLF0@V#X?N:):-""4,AX2_P"&%2SO"%2
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M1I$Y99"9*G*+(()+ 44   A#H".[K3^=WQ3_ -<.G?[*KQP2NDOA^Z)'L$#
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M#R+L]6\M.P*YN&2.\VF9T+',U[^CAGBZM.-%$)4MT!G EK-/)\R5LYE"==?
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M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P"TIO
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M 8 P!@# +?E,3BTX87&*S6-1^81AX(VE=XY*69ND#"Z)A;UL2=Q9W9,K;UQ
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M!'CUI_.[XI_ZX=._V57C@E=)?#]T2/8(& , 8 P!@# & , 8 P!@# & , 8
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M:?SN^*?^N'3O]E5XX)727P_=$CV"!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M>."%TE\/W1(]@@8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M & , 8 P".'K3^=WQ3_UPZ=_LJO'!*Z2^'[HD>P0, 8 P!@# & , 8 P!@#
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , ^1YY*8DY2I.*3ITY1AZA0>8 HD@DH&S#3CC3-A
M+*** $0S#!B"   [$+>M:WO -$>;/(QS[U58 ('5[7<25.^Q60SNK[#F]22V
M&U;>$)B<D(BLBE%03=W2@;Y.W-SLK1B"0M S.CDTJR7YG;G%CT<X%"7%KKCW
M[]'V:\'W[=.IOG@@8 P!@# & 6M-YS"JSB;[/;&E\8@,'BZ ;I)9C,WYKC$6
MC[:6,!9B]Z?WI4B:FM&$PPLO:E:J()T886#W^\8=;!)O9++[(T"UY6^1W#G2
M&=-PUSL:RX/:5S/]!TW&JVKA^F%EW-9<>>Y*SJ&FMX.W!VX.Z)61$'^0HG=>
M8TMWV=1:7K5"(U2F2G"W*\M8PTLO.V%C._FO?G8VCYAZ<JGKNHVFYZ>7/IT9
M7O$DB[HSRV..D/FL.F<->5<=F$)FL3>B2'./2B,O:%2WNC<H ,O8@%JT2E8W
MJDBL\0TT\/\ GO3Z->]&P>"!@# & , _-[UK6][WK6M:WO>][]-:UK[][WO?
MW:UK7^N\ CQ;?*EPZ_1WK*;1>Z6B9U_Q:VPEQNRPH,2.;PH!E@(G53'6J#/T
M4&\)I\[&JV@]A4I8WI8!/(CB&;XPUGS $[/U\RW++;;\71/;Y^Y?'X]#+W,?
M8]8=3K;-CD4CEJUQ8U-.$316?4UW5Z[5K9,/(GS&;)(&\.3 X&*TYK+,&5*N
M6,BY Y+-"VW."1:6B6I#DP1#37;?HUNF;8X(& , 8 P!@&D76O?E(\<NT,BT
M]8K?L.>3J/S2:M%=435\@MB;HZ[KDAO/GED/S.Q: !BA,6"ZMQ2YV<59)JI0
MIVG:$CD<E7 2BRBY=,?-I+/9-^+['CF?D@Y$A+/QX]K+- \)N\)?7T0YG21]
MJ7+W><#LD3,6RR)4SG%HW&/15L.D<?22=V>DR04?<7IN:ER4+HI"CP%%OF_R
MIMY]W7Y[,WIP5& , 8 P!@$?'4WDRYLY$L ZN++26](WF/UXCM^TG"J:GE5D
MQ^C:C<9"HB[=95PNL>(-#%8PN=T#L CY8EW>=HV=R<S&@MN**5'"RBVLKOA;
MK=]EW?\ .Q0S?*OR6&_T%!)U]DN.E]KQ6@?VX-E;OR[G!)?TXC2661*DE5P$
MZVR:L5\9W!KVF:TY"AO)7NB%K6NB5Q,,3%!RMK.W3.,[M9QE+X_HR2/!48 P
M!@# & :'=8>12@N/98UP:PV:X9M+%%;R2ZI.QTM54CM%;6E(1!Q):)+<MD@8
M@:#&*\:7(PU&<ZB$K6G'(U_RC:H"C/$ 647+=8ZXW:66^B6?$M9\\I?*K7:#
M/6C*=:E@(51U,)97;%<51+I?3%6+NAVQM>Z60VA/V])I+%CYXR/;"\I!Z1KD
MK&U/K0X2M0P)5@#=!RO?IMG;*SMG.-]\8^A(U@J, 8 P!@# -4+/[5Y]J/I6
M@N1I=+3_ -O'2">5N%>0UI;S',Q,RQ!@>Y"OD$N5$F!)BS*XIHX_(H\K</03
M^YL[LE;2C]-3F:C?S^>9.&TWC9=7\\?N83YY\IG+'35OL5.UUNV4"V?M5A/U
M(S^<51*H=5'1+)5#L!FL5UHN>.R<#;.4D34F%GN6PEMQPV\>G%&2J1^INA+B
MTLO'AE965GIE=4_T\21O!48 P!@# & 6S-)E%*ZB$GGTZD#5$X5"F!VE,LD[
MXK*0,T?CK"A/<WAX=%IP@E)4+<@3'JE)P]^@"BA;^_?IK8)9>%U>R(WD_EYY
M2?*CH:W:_9;YME+TDVW#(ZK@-7TS))99[C"Z$E2N'6M.GJ)D#3_9N+Q9Z3D%
M"4/3@D<77ZDWIV9L<' T]$G%N1IM/"QC+SMOTW6>I(#4%LP"^*LKZZ*K?RI1
M7%HQ%CG$*D!298BTZ1V1("7%M4FH'$A*XMZK9!X0+&YP2I5[>K <C6IB%1!I
M0!#33:?5/#^*,C8(& , 8 P!@# & , 8 P!@# +*LF' L.NI]7YB\YJ+G,*E
M4.&YIP[&>V@DS$O91+R :&5L1R,*W:@L.C"]B&6'6A@WOW:!;-'.[XJ_'AUA
MR[?M'+Y;4AE PFC>;)W2E^S5'T9^UV-]M34V0L9-2S"+5Z2]+U<!C]>L3.N<
MFQ5,6*&R%C1.J2 ,S!M@0;/",DY)I^.7E;;QZY6?'.WNVSU.E?!C& , 8 P!
M@%+>F-EDC4M8I$SM;^R.1/R[BSO3>D=6I>1[PF? 6MZXD](J)]X #^&>28#W
M@"+V^H=;T!SDH.9O(SS?P9$J@YIYN@#K?Y_9/2\V!+54DH94_P#/M)V3:]AR
M)MGE,'3U_!"4-I2.$R-N9(YHT3@EBJ1<YDR2/GB+*0A&1N+DVV\<JPM]VDEA
MX\,K?Y8)7O')4*ZC.8F*NG2@I;SR[MTKF3L^1RP+CBE]V#.9%)W<<CDMM3NS
MX<::T2"5V#(71S='8.@IA(32PHTJ!M:B6U F%)/+RVG\/=LET7@C>S! P!@#
M & -ZUO6];UZZW]V];_TWK_Y;P#GAZ#\='1TA)\US'1->5Q$6+L2,<4M5!M9
MBR!,D:G;/4T+):[\BH&PI \I:\?) @'(HM&Y1(XVWA12A];Y<W+4VD&WY#&^
M7\$E^?Q[]C)S+U,Y>%+/7JV\/WXV\L&P_BTY=O"B+4Z_L&:5#*^>:@NE31IM
M<4];=[M73]W)Y77L%<(K/9G+;H1RNQ7)3%7LG4:;85#WBS9=MC(9W)4VMD)2
M.&V=7/\ /Y_.GD1)II)8;6<M+"W>=EA=-]\+.W;"F7P4& , 8 P!@$+?E-@'
M<EH3&M(+RSSV.4U-)X1*HYTK=%<V1156=(+X$^+@ ,H"KK!ME;M=7<:E8T)3
MU/I0T,#TM4IS&A)&E#([HER[8O%I)MO=-.*>>7/=X_)>>QH9<?B)Z[DCYS/<
MM"2J+TX;'+EX;+8>;I?7\$LMSXAICFL @)6V,7(==+>UVM%87)1NUFRZ#QUH
M:WJXY3(@F/$A<5K&V+4XE36Z?:6_=RRO-YPGX=MWGJ5#H6@AT,6ABT'6A"T'
MVZ$+6M>HM!]=^W6]^N_;Z[]/7T]=X,9_6 , 8 P!@$%/EJH?M+IQ@M#GFN^9
M8S<]-6A747/JRSX1>Z.A9A4%[-"B3M2I5TJSR6:)6R_*%2HGQJE397K1#Y0A
M7+6UQ;9!$'%U#&I&SB\'%--_-83RO=V?O_/J:M1_QV]V-+RX\MR.!P^5U1/?
M*!5OD:G7937/(7'V)*T,B>NYG8];-5+!,*L-LG:VPH"H988I:6(R#)XV^IC5
MCLUEMQB08GFCC.^>1QQ[WE9S\'E^_H=/>#&, 8 P!@# (7?*_4G7U]QN;T;6
M/,K7T#1-O4&_19,^U_?A/.=QUA?OS[ZD8W:R']]L&+L=E\X*V-\;EKK6K>Q2
M14X/3,\%R./R)L<&I&G%HX36^-]\K*QMTV>_7ZHBO+\1W<T$M$X#/!VJ7VU/
MK-XHMAE[P@M[I:OB'.#G5<%K"+]/LNN?D3A&W!])G@X+(&.*MD.@CE'Y%"W^
M,-TB'&"HJD9T8OS1:ZXQ&2PTVWG/+OTRFT\OQRT=>6#$, 8 P!@# .=:V_&!
MV2V>0&F.L('?,9MF-KNO+*OBR2WVF(>SS.MJV.IV80&!U.7*W^XP*+"BR"$N
M(*3AC>T1^/HH:YREWMY>S*G)9)"W49.9<K6/[4EOU>4\M)==LYZ[8W+@X#H[
MM0SJZ/W=VQQ;JOW6+Q^S(-1:N W=0(.:^/:JDH=+]PFI*+KER62AZF5B#9V5
MHL"TWM0L=5^S"42%OC<7;S$:E_/E_/YMDAM8PG[WL\M^]XZ+K\>N=L=!."@P
M!@# & , T;[VY+GO9%7P>M87>2&ED,;MN'6;+4S[52:XH?:+9!MKW1CKZ<PM
M3.("2ZQ(,SU&I@O;53PJ:WA7%&]K>FAR:E*I.(2GAYQG;OC'OV.>N.>+GOJ(
M59RNU7I5KKU7$JL2]Y-2BEJ"NN#\A6]64@Z+M)4^Q>4&W8W6BUE6!7\Q;@/,
MHD\01S] 0S!FS-&Y!7\YU!=E.@R.46Y8>,\N&TI+$5TQCOC&WAO@Z-/'U45N
MT'Q-S)2U[KHNX6Q6%1Q:%RX<,2H$D:1',:7:-J9&P#6WM3<HU'6$MK8%;BA0
M)TSJO;53F3\0"O1Q@QR:<FUG#;>_7?\ G^IN)@@8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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6 P!@# & , 8 P!@# & , 8 P!@'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g796801g82t16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g796801g82t16.jpg
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M 0$! 0$!_\  $0@ ] &% P$1  (1 0,1 ?_$ !X  0 " @,! 0$
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MRI(D:5+;3=?[]+2'>-MCBW2!GDB%.Y+@K&=#W,O+*[NB*9O.().0*"@1Q,Q
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M6>7BX ]\!;%',QTT,&/?#9]FO*!TPB81,(F$3")A$PB81,(F$3")A%YZ^?\
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M$I-XVUQTIG:@F*- V\L/\QJQO-=1NY98>G>RVXP70+0=AWNWAUA69WF>"IS
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M,(F$3")A$PB81,(F$4/^3?..@^*^F]DF[ZX2JTI%U1,*H^MFX<SMV9KE?2%
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MK6OCWO?Q:U\>\^!9E1#A//\ X262?:J: \J:+F!M(1:13FUM1ZQ8XZ A<(B
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M80XL:XL&]^.DUH,L\B_Z3X#@>+-_9Y7E+F<KY"/22.COR\#0D^(:6L=<DA>
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M;A%2KX8#P@[UQ(B2*E-56USLKD?4UL1T^1;F"N.F1$"ML)B8E937J-O07H8
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M$D \36PY0R0V*MAC@K)0-Y2Y^D*UO:TQR]>H3H4))JH)JQ8>0E3 -/-++$0
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9PB81,(F$3")A$PB81,(F$3")A$PB81?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g796801g87s26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g796801g87s26.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
M$0@ S )= P$1  (1 0,1 ?_$ !X  0 " @,! 0$            ("08' P0%
M 0H"_\0 1A   00# 0  ! ,$" (&" < !0,$!@<  0(("1$2$Q05%A<8(2(C
M,598EYC6V#)!&20E)C-"-SA$47>1MO *-5-48H'!_\0 '0$!  $% 0$!
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MY',EE;L-L0Z8TZ:]Q&N'S7\2.&3CR[)?0'H]..T^K [FD=#'NXPY-S6.3><
M^A>V"M3M10XE)I:WDG)720D6)9FG_:HPLORNX8,U7:=;^!EAR$=*@7VA-4CN
ML\P,BDBA?U;%DN<V.(Q].W.<YC=.;O1.E=SCP2R>*Y[1X=PEUWDC<OQFERVF
M+[*N+NXK%6O:!,WD,EB:"CCGTC6+K$]B2K$&SUF%C)I6QNXKW^*OYZK#S)-_
M0U>JOK/*1";AJTW5Y01.ZUDZ4^).$73F.S!$] 7YBOMM8NB;D30M)XXV"&E
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M1$T"XCB?XHGI9?:C?>UA"G.DUM]^-#&XG(V+4=#VZ8,Q5N>*&R(V3LN1/B;
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MQPI\U'#A9193KKOOKK<G'FLM%&R*/(VV1QL:QC&S/#6,8 UK6C?9K6@ #X
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M9:-R 8HLX;\$0AQ@X%E6':[19N[0X=L'2[?I9JX0<)Z4WV@LDKSSWR118)>
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M.GK?.]T<;(R\L#MN;W?L1@'?6=.Z=7MOB;4$KMJ\>1FU@\8'KL0MFS(H!BW
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MN>>>>=?/KKKK?RUKG6M;WO>]ZUK6OGO^&5 )( !))T .Y)/H /B2K20 22
M"22=  =R23V  [DGT4-?-G/5MSVS_5#_ )Z5%RYPI5M(_=YW\FM-P4LZ2=2%
MIKKZ.N.;+G'!:2];43UVJ$'1?KE3I+GC6N@<OU@L9AN$Q$">BT9OD>O5_(,G
M PLJ2:WO['QI@IZ!TVS+=[ DKB/A>#S+D/*_%NP"^GF9'<2X'U#M%PCC]R9D
MV2AV&N:.4Y]MS*'K;U/H5L20XL 4R\Y\NWIA$PB81,(F$3")A%$RVZ8EH.7N
M+_\ .^V VV>&K9"=05\Y_+H9?4=':W]H')>N=;;AYR.;[43A<_TEMPP5ZY#G
M=NX^X[TQWG!<AHV<>WBW*_-FP9>]^,R<3/.R'&+<I]ZS3'Z]C&2OT<CB^KHE
M:#8K".VP&3C_ #'A&9H9F3Q$\-C7J\P;%%'G^/V)15P?B'C:P(90RK@#'1S]
M6+J;@N1AADK/(I9#S\;(YL&V*;N:)77&%CT<T_%E0[]4%-(5(&VQLP@,J9ZU
MR1C$K#J;VLP(M%/JVDKKZV9%K]M\.<.6BO"NX/D''KW';C:MORIX+$3;..R-
M5_G4,I1D[PW*-@>[+%(-=3>TD+^J*9C)&EJV_A/.,-SK%/R&,]HJ6Z5A^/SF
M"R,?LV:X]EX.UK%9>DX]=>S"[?0_WH+4738K22PO:\[;R"6XIA$PB81:Q)7'
M7(BP!U6D#ZS>>%T=N1@'0&1K=/6O&QO*[Q B@(5$=,V?9D0B0>?C]-AS@FP;
MOU6Z[M!/O(;5G="ZPU@,+3IS^N,:/O:!:7A^R&N+1T[<&D@$ E3L'&LU8P\^
M?AJ-?B*SA'/;]KI-$4A\\LB?"^RVR)916L.AB\GS)V03/A:]D;W#9V8Z@DPB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBAI[4K>F#U<ZMBZ/0-K>7@
M-,,#916Z*PO,_2_,;$25<$T*LY.FFZ<P29L"Q(7'6XH/.HE*]IF^&2$9;-BA
M-;A\51O>@-[^&M_^/Y+7'@B(><3H$Q>M#^M;I]C)F.B5?/K%M.^CUE-8VL-=
MC"AF(MJ^8MXG7L D/"W 1^6Z1K@',73#L3T^?+B'+/A4AW\1KZ:U_P")_%6)
M85$PB81,(F$5:WKTD3@GIOR19XRN&A]V*-3D$UDSZQ20%F]5?U);G"\07C;<
M0?:L?PK9YU)$I<F&?/'2J7,<[VU;*;=)2^$Q]3)WFT[=RQ2$L<ABEKTH[Q,D
M;'2EDD<EZCT,,;'D2-?([K#&&/I<Z1FL<NS>2X]AI<MC<91RKJ\T#;-:[EK&
M(#8)Y6UQ+!-!A\QYTK9Y80Z&2&!AA=+()R^-L,O=OFT;6L0@EY2YBL3B$AMV
M2H5\>D$4L@W*"@>N=1T1,[2D; >1K"'M^6B,$)[BZ;UT4;+IR61C&S1D[Y4T
MY3Z)QC#8/$Q'FYO7K]7 TWY2K4O8BM2@L9?VN?'X2G++%F;[C([)P^VF-D#V
MNITYWOD9TEIX;XA<LY=R6Q'X1#$X?"Y+F>5BXYD,CA^47\M<H\9&-IYWEF4K
MU[/%,+&(8^/V3B63RVXI&Y7)U(H8)@X2ML*"AQD=#B8^$9(#0P(:Q#B!S7C[
M;8>,&-4F3!DWX_C]"#5H@D@CQ\]_2FGSK_EG*K%B:W8GM69'36+,TMB>5YV^
M6:9[I)9'GXN>]SG./Q)*^CZ-*IC:53'4((ZM&A5KTJ=:)O3%7JU8F05X(V_W
M8XHF,C8/@UH"]+/%9281,(M:3RZ*>JQ'IQ9MK5M7:/''W.E9S.(S$^-<?+ZM
M=?,\38?/6]?QY^7S^KYZ^GY[WK,B&K:LG5>M/.2=:AADE.__ (&N4YB.,<EY
M X,P/'LYFGD](;B<3?R)W\1JI!-Z?'Y?%1;=?$G\B.7*PZ!3R378:3[Z23#T
M+5=HW(NY6Y_AM) E X@9CVN][WK7.W!I#CKYZWSUO7SWJ0&!R8 =-#'49K9?
M=LUJH ^9;/*Q^NWP8=?'2WZ/P0\1F,9/E\10XM5< 3:Y=R# <98QI_O/@R^2
MK72 -D]%5Y '<>FXN^K?>_KL17+ YY5\)>GGAM23,V*Q6SJA;.FS@8N.*K*Z
M1KV(3(U9K3C2Z#17\W+QL.-0Z3V/=N&[M^QY6D<;AL8Z=S,EF,<&!A(;7M$$
M.#F_Z^6)E<]B1TMD>X_K-!#7+?O#WPB\.+&;FJ^('BSP-E1M"69E?!<DDBD9
M.V>NUO5F<EC*F"D=T/E;[-6NVIW@^?&Q\<,Q;NJOB'Q.K:@L0,F"/ECSSQ(8
MX'(OUGT'N"SK-'+O6**[C\QA<D=4X"BQA-53O3J/DOSOH:MSTT6<=]I]=;Q)
MF\?K32L:,C>Z)'M:&RU:]=P!(&IHQ:?*SXM>WHZAHK5LS#X$\=RV2K5H.?\
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MP+= *2/GCS7'_/+.4?@9M.['D$N_1[,M+[#7BW9W<>KR)CX3!(T@C#8M#P?
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MJ2O6OH4.,Y&OV4%926RXY;\=;<[^Q#)\-KJ.2[3IRC_'41EJ;1T3CCW[2?\
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M7!/2J^(EEQ5QD&:JS-$L7E0167LB?TMF<8GBRZLV%TSI>KI<PM)C+MN/IW'
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M8>GR@'0ABSX>L1;.32;19<>^S\;EL/C;;+$&/N;C#@V>6V)97=0Z7-,,3:L
M!:7=WF4!P:0PD=0W7P_\4/"?P\Y+5S>&X)RMTU"*=L&9R?*6Y#(S&PSV>6"3
M$8^#CN&CBEKR3.+[+\FR*=L+XZAD8R>+/J2^&8&@U2U_7T^]%^KC?Z4C0\([
MBT1])3Z%ULT_!\;XVPCPB#-8"\Y"\:^6FR1#7;KG6]_<4Z[_ )]^%O/NFLSS
M04<:SS)'/$DM"":=VSOJD?,9QUD]STG7R41RGQTLY;D.8S&(X5X>U?M"]-:C
MR&1X1B,IG)/,((FN6<M)F(S:=K](Z$B,_P!UH&@-K)?#,\1]J<+GJ5YGCGCK
M2G3FT+"M.TE55=;^>U%N;"F\D1[ZZW_'?/VM)_QWK7&N=_+,?^L&7'9EOR1Z
M:KP5JX ^7Z"&/^*U]WCIXIM:8ZG*#B(R"T1X'#<?P#6M_P +3AL51< /0'JZ
MOF2>ZW/%?(7E&#?:ZA_FBA(TJC\M\.@]1P)D^WUK^KM1^B!Y>K*:_P#U%5^U
M/_Y9B29/)3?VM^[(/D^U,X?]4OT/P"UC(>(_B%E>H9+G/+KS7;W'9Y'EY80#
MZAL+K9B:T_%K6 ?1;V:C68<?VS #!@]-%)3\&Q:H)#1^EM<;^UQWPR;[Y02Z
M[USRIVDW4[XX^?7*?>]:YWAEQ<[;W.<21MQ/4[7XGN=>FRM2DGDLS"6Y//,7
M.;YDLCW3S=&_>(,KP7N V6ASV@GL7 ':KR)>;+J&/K,O6.\0.)>AVATM-H,Y
M@1TY(!5BB78EIP4I6TF,ACL*;%8R37 C^8Z8TZ_,8^9**F&"XC8[KDKO^ Y+
MCF,K\;S8FN<3O211766&MCGP]@O+&Y[$2QFR^O;KME<ZQ"UCHKM>,UYV2]37
M1Z9XX<8Q^;^PN<^%5C+X_P 2>&<:EQ=>?(T*%2IR^A1EL7X>+YZM6RT\5_'9
M62>6"&6S/7L8*XVM?H6_>L1KN^(O19HG$P]*>@XZA2]W -]#XS"9$/-Q5S.H
M>@W;=C3T:1DW/V3+Q)11V/*,0A4HX35']O\ MJQ;N.4$9?Q'XE6@O6.1<5MN
MY%QNUJ6WDJDM:ZS&WWN>)JMQU,]5=C@UDL$EF"!CFRB(/D>PN=Q;P'\3+]O#
MTN"^)&,CX-SW';KXO Y*M?Q$F?PL<43JF0Q3,KMEZ9A=-6N04;=J5CZS[#H:
M\4@C98GG)U]*IA%%>63V"LO7M/1EY-(FTDG[$+]&?I]S(PZ!O\R.SKR\]"#_
M ,I5></_ ,:89CW[L4T_#_?(-F3M=HFLDV6[XD8X9CC+4@BE,?M=-W6(W%G2
MR'(![NH#ITTN <=Z:2 =$A= QV'RTOAOR6_%B\C)1_K5P^?VV.E9?4\BIB>>
MQ6IO:&Q&'RJTLT,=B3KZ(9)8V2%KGM!E1D<N?KHDQ8PTQ<## Y@6&N^-INAY
M-HW?L7*>_P"M-PT=)JH+<;_Y\J)]<[_]V5:YS"'-<6N'<.:2"#\P1HC\%ZP6
M)ZLK)ZTTM>>,]4<T$CXI6.^;)(W->T_5I!42)E\/OQ=.2&S!3SG6X4]OKI3]
M2UZ+<53*/O=?QVX_4U8NXB=VY^?RWIQLAM;6]<_S_P NOE)Q9O*PMZ&WIWQ^
MGESN%F/7R\NP)6:^G3KZ+HV,\8O$_$P^S5^:YNU4T&FCF9V<@H%@]&>PYZ/)
M5/+_ /9^3T'O[O<J =T?#1VEZ7\R6!7A7UE-8?6LTC<@F#>16Y#;*B;6,Q\\
MM(Q4-;KW-;H*Q=B$S8U!(Z%29R8-Q'942? ^G!Q%\&>S57/[H7X9V8R*6>*2
M.(LJRP2F1[!&Z4BI6?!U]#B6/+HW=<36N 86O'7N+^.(/!>=X;,P>'N+R><Q
M=ZGC'TN.Y/!Y"6_=ILHV,G(SC''+>%]I-2=[JEITM&R;N/@AMAE1T5J*\'-1
M7RLF$3")A$PB81,(F$3")A$PB81,(F$3")A%6+\6!\1?^72T 9Q4P05ETGJ8
MK&)<*DOG02I'K7A'HVB#E2@&H+TI-X; Y0:ELK4X<BF!C\RC*B$7)BSZ*KPU
M'@QTKF^OY]M'TT=^G?T_\PNQ\+6;VI+J;M8==1 DZL:#WJ4BQD<:9^36!8"V
M<U;5$N%#7K3QU)I56J72["4I&$-GR",Z[;DTNB3-./[C*R[\-?E^XE' #6O0
MC?H1\2/B3\E9EA6IA$PB81,(J!?BD5-^I_;7A:81^._]^GTMB4##RY>)6'T,
MX3Y.S8XVCI6::E2-6NV/3I=8RK#T(R,L9+MHD8ZFGZ:7Y$\=0\+OLR'(YW(7
MY)]T.*\AF$$+0W<$F/?6GE,SF2@/#+!BBC$>_,D;(2YK#$_YZ_I$_P!8;>!X
M=@\+#1Z,WXD<'J26KDCG%MJ'-19"G VJR2NY\9FHMGL2FP (87PM;&^5MB';
M%*O/B[6O:]QQ"QYC$O/571PT30KRQR-"P^5G)B XDA-F-= !*%F+# I=8(U'
M/U=21"2,$$B"G/V';AKSM?7+PXM7AKS5(9[DL@W)6-^0" EC7=$THJ1&4-)+
M2Z)D!>YNPV,.TW]&LY#_ $?>-\4XA?ITK/.^66L=1_K-C,=R7+X'%5,M]FUG
MWWNCLXV[=&.=D'V6UZU;(BU&R..)]Z3;IECEX_##E=DW_0M@V-8UZ^IX_$S#
M-W9[2RY/4HB#E0*FI'V[CP:"!!D+;BV'1/H'V5%,ACIJ^CA(XCR3>$>$6'5:
M?((Z]*Y!!!3QSY&D5S7CLOF8_P#1Z>^9[I2YW2'=+G.!$C6$M#=N4MQ3QWQ^
M#X?R[#83"\3X!<R%:6/ OP='D5C*P6Q[$([EK+6I\H^Q,*XMBO8EGCDBO05'
M&". OF%T$1AD0@ !A%()%8Y"XP+3^T-CD4"#8\"'I_+6OH9"1#9HP;<[^6OG
MI%#CY[UK>_GO-5EEEG>Z6:2261QVZ21[GO<?JYQ+C^)7S%D<GDLQ<FR&6R%W
M*7[!ZI[N1M3W;<SOG+8LR232'N>[GE9+GFL%,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(J.?B,/P\?\ 0<19RDE/ U?/*E3+L1M.65XAJ:1+3Y[.
M)+H^9DRWILN.DLF'DA"(E-EV"00$#"+(BJHY*$2SW@3-X\.=7>6-8Z02Z)EB
MO3-$88WI:WV5I:T@[_6]X@_  ;B+Q#9V@E[6&($"*6G$XO+W@EWM!#G C6M>
MZ"#ZD]KMA&^.A0S:>U=I['LM\;74;++;XVV2WSM95EOIFJKO7RVHHTWMMWW\
M^D-[2WQO(4^I^\^F]>OU[_GW^:EF^@^X>OKZ?3LO0RBJF$6M+ED,XB55SZ45
ML(BIV;QZ,DS  7-CA:.Q=PN/1VZ<]EBH,!)RJ:35@FZ>-V;01WT5>-VXI5^%
M0>JFA_K"UCY8V2%[6.<&DL:'.&^PT'.:.YT"2>PV=.(Z3YRN>V-[HPQSVM):
M'N+6G7KLM:X]AL@ =SH;&]BHZ3?$3OB.Q^&V"D,KDB-%U%X_DDJJ[B.F-3"T
M9-Z<KV;2@X<@YOB6:W&P$()1IM^7"]QJ4]OV(J:ID2J:K=@L/E68^![GQ]4@
M<9;;6R]0Z(FUI&-:V0=!ZG/#CLAS-$QZ!V08Q]Z9H:_49#8JKGQ])ZY'6&/<
MYS#U::UA:- M=L-D!(UL34\57Y95Q\6.#LPU I@2APZEI,.F=;@'T:CSMG<E
M4 [&7BRPQ[*9C]9&(/""R2)),SQV2C96-N7@YL^Z<.7V%<@CA,9C;(P/,S2R
M1P<X&&5T?5L,9V> #KI[.#@"1Z9=2:27K$A8XM$3P]C2UI$L8DZ-%SN[-ZWO
MNTM) /K$ );%%^@_BGF8]'HBLI-?.Z0&O+!6D\48,?N2EU%?3;M$D/<\KO.)
M"T<BXM&G(DN]XY>,V;$:FV39;Y41UL^%SV9CXURG"1Y.XW%#%U[0HMG>(&3O
MY#A(9'QMWN,2Q6)FS1L+8YA(XRL>=$<VY5PWBS^?^&_,7X#&'E Y+<H_;?LL
M8ONJP<)Y;<KLDE  EDJV:56:I8D:^Q4,$8K2Q-!:;0*A8LF!.Y4V+-JS3W;I
M#6TVC=%OQO7,*@WTZWRCQQSO7/U=?3_#^'U;^7]>\B<V28, 223]A1=R=G_U
MCDOFMIXQ8GL7>9F>>:<LYA:8PS2/D+&?8> /2WK<[I;LD](T-DG6RO)E7_K,
M4I_\(/0W_P!4>>,C(_\ :-G_ -YI_P#T[JZWC_\ <+RC_I+PS_N_FJV?+J_@
M<_9?EL\A,1FP[?/7&V$NC8:2,M\=?\7'X4RR>H?3U_YN?M_+?_/6\\8IIH3U
M0S2Q._Q12/C/YL(*@L=F,OAY?/Q&5R6+FV#YV.O6J,NQZ'S*TL3]CX':JL]<
M?#/\?2GJMG\<\A<K+:L0<]F"-""P\#YZB"#9S^<)&!HH[$1:^G*JS33#EJV4
M=_6FZ^E1'G?7W-BQF?RD8G;)E"!Y#A$;CG3?I21TEKG,E<- 'JV==QZ_#O\
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MD1LFFI&J@)@;&GK)CHN/-*3AC4 TBD97ZW73$4SF:#J1D2J0#LC0V!T#M\7
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MO"1%:%EM@<G>)PY<KNXO%*A,L8TR48BDAI<L82GSL[TJ#!QQN;*X =).QO\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g796801g92g85.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g796801g92g85.jpg
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M 0$! 0$! 0$! 0$! ?_  !$( -X"70,!$0 "$0$#$0'_Q  ?  $  @(!!0$
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MPI];; PHH[;CY!#SB&F66UN.+2A*E8@ 20 "22  !DDG@  <DD]A4R0 22
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M-W-(\2$["*-P>V<$\@PRE1)@C#)SMCG5L[-JXDDR1T%%>AM+93.EYX=NXWF
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M%&<&9AW4'N$'[8XY'NKACE=6XN-AZ<>#(1ECP1&I[$CS8_14\<%FXPK\>O\
M)QM+;$NFO=W_ !'.H:?GK]O'JJMY\!#W:W$O2$Z3KZHR'AF#!BW^^&8ZP7)E
MT!H$;RPPA:3'#!L#BH0US;O9"%B@ "C E90,!001"@'DJH6<8[]8DY/-:ML@
M+R2]\$QJ2<DG(,KENY+-M1LDX,1'':O89D*_9:+8CMEZA0,W8)!UHJ]Z^**Q
M'U/;# S+0WG$KRE0U:V0* PT' WYAG'KAQ@*]=F9B!"A'ZSIAE=1%-DJ 1'(
M!EX23GCS:,GEHSVR63:Q.[8(9&,D7O'ET)PLH QR>=K@<*X[\*^5 V_EJVI7
M>HQROT6GD$NTH5@>T;K D!E RH184H6! Z3M$8XKQ@2Q=DA962V+"K>?PW7J
ML+79<*0K.S!2WBQ-;;G<>V?9@((*D$9:=#Y@*P$;<>TY92'B(&6D6?:BYVC#
M2@Y!!!(6)AD$$L"77D;5"L"L@)R=_M$K A1$-4P19C85XEVZI0(4U3J8\B>(
M$*/)EYQP=2'QZK4H4&3M=J(86DQ4+#E 1""Y\^(CC<1H&+,Y*QHN^0COM! V
MKGC>Y(1 >-Q!.%!(.Q& HR[G:@.<;L$Y;'(50"S>>!@>T0#L/JS6L3JRJ-5Z
M/**F90TPB=M]LDT,XG+M;Y)#.)FTS:V$I9P4;EA@4&/%2U%UZ"!B*O "Q]>A
M(J.$UY9#*^X@* -J(ONH@SA5\\#)))R68LS$LQ)OCC$:[02Q)W.QQEV/=CCC
MG   X50%4!0!5C\KJRG%*<4IQ2G%*<4IQ2G%*_,]^V>V<8SVSVSG'?&,_LSG
M&,XSG'?[X[X[_P!N/OQ3[?\ Y_;6+1+,),:C3>P1[_F9$:=5C+,@EI&7',QY
M&<)02MIM*UO"YPV:PVVM]T9(N6B'9;3C<.0.Y'=<\>T.XYQ@\J20 <Y V&MG
M,33Q?C84VB5E&&A+$*!-'DM&K,5"2>U"[,$60R!XUQIU+JTA\PR1"!(5+MOM
M2[@25QKTPR2VIHD>7>CEBNR@[[:E(>'/60RYA6?&WGOR2S2KMPY]@@H#[00@
MY!0-D*01P5P?G6S#JVHP=#9=RD6K(]JLQ6X6U>,AHWM4G$BVTB$ J\(1UP,$
M8J$ 5B:U@R\[6#IRUTQKNXNCR+K<C+5L1'O_ -@9%2&C"(\1O"DII<P^<C R
M6&*I(PZ &:],7&1+DXD5(ICVF4;4D8_GUY4$_GD"\Y,JON,B=>?4;3Q%(BZA
M#9Z;JK<#6(%:"VOY2?\ _-P O$D\K8)U:U2$]0N^IP79G>^M(9,ZWA-K:\7"
MP$PU$&T^?^?Z9OT:,DEVH'O1+$O7"0@/,%\ZO!1EB)HDY5\DB#S](3(UTMP)
M$@OTLFD:*;<ZDF1=MS&Q]\ARCY//MLT?5#8)60AAG'/,\16\S72/=H\&HRP!
M[P.,RQZA;S3V-Q,[YS+)>/:F\N')(EDNI1N=2':O*78DWZN3$7;($2-LL*=)
M479U)+RB4#B;(**QB7B\Y*':^;5N=BI "PUB0,"%_$=)L$#,N@"HE,B-9D3I
ML"C$HP$D3C@LA)VMP>&4@JX!.V167)VYKSZG>I# !@2DB=P& Y'(Y4@AE) W
M(RM@9Q4 HM@-U?LFHPLR:21BJ/0FJGI8Y]QXFUZ,V9-*CM*RTD2ZM9L_:]0;
MB0'IXETE^0*%K&QG+]8BTR-XRE-CJ)8G( ]K=*%&!LGC&9@   J30YFP !OB
MZ:C""JT8QR(I)PF(R2?>AD.(B222S12@1'))VR;R<N:Y$^<ZM^G%*<4IQ2G%
M*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4KUEOCT_', Z"J\9TR]-4K%S/5U<(5+TW/
M8P-)1V@ZU+#>(.9D!%X=&*V#,"NX+K$&8A;$6$MFQ2XSC#\2+(="TM58":89
M3]JC.1U2#@LWF(E((.,%V!52 '(T[B<@F*,X;CJ/]0'G:OD9",'D$(I#,,LH
M,1_D[?358M?=(<WU4[8-E[)O+K.MINS+);;263*6@ZE1QAX%1Q)24BM\]Y^=
M-<G[>0\M_L>/.13CJ,J%:7RV]D+,D7DBAFQ@#>X!  & %2/8H4 !"'"C!JJV
M0 ,_DQ*KY^RA()).2S-(79G))<;223R>;4F&LVM+#(['U&*DE^4)S(;%U5ZD
M<"!V8G"4()FX593C$;5MM#C-I3&V5;@D/<VF1ZSL)S R*Y<*)KAED41S'@#$
M<N"6B_@L!DO"3W7EDY>,9W));AHV,D7GR\60%D^8S@+)WPW ?W9.-K)^RVRJ
M_P!1UB@A:B:[(:LU^_%66V8?%) ?E=LLK;D*[0)^*.;9-C3]390/;;C7I0(<
M^,OAE!9\T:2JEAC.!$ULK;QB63<JX(.(2,-(K#((FR41@2#&)."KJ:&19V7:
M<QIAFR,9DQ[*,".#&#N=2 0YCY!5A60O$Q8'"J_KZB.,-[#V"\:'!FD#).#J
M,#%H&7;=CRX*LXP7%4\,X% 8+N6Q9VXS50J91D:S8U28>(U7#229Z<>"P'!=
MCG9&#Y%R#D]U17<!MNTY<ME43\H^0I\E QN<\'A 1@=F<JI(#9&T-!HM>UM5
M(JG5@=]J+BT/K40:0HV5EY,\IZ0FK!/23N,/RUAL,L4;,STN3E1,G+'%FOJR
MZ\KFM)(TKEVQD^0X50!A54>2JH"JHX"@ =JV$18U"+V&>3R22<LS'S9B2S$\
MDDFIAR%3IQ2G%*<4IQ2G%*<4K57??6YTL],Q\7#;EW/3*K8Y2:KT,FJ)E1Y:
MW1R+,M[$?/SE6BEF3L)4FF!B"SK3* "P@H[6,*,4^^*P_P!.QT?4M15GM+2:
M6-4D?J[2D3&(#=&DK81Y22H$2L7).<  D?2O!7H@])'I#@N;OPGX2U?4K"VM
M+Z[.IFUDMM+G;3PG7L;/4KE8K*\U1GD2.'3;>>2\E=CB((DCIL!3[Q3=C5L*
MWZZN%6O55E,EHBK34)Z+M%;D' 2WX\U(4S!F&1QGHSQ20BTC%+R.6.^,[X'F
MEH3HS0S6\C0W$,L$JXWQ31M%(NX!AN1U#+E2",CD$$9!KP^JZ/JV@:A-I>O:
M5J6BZE;=(W.FZK97.FZA LT23PF:TO(HKB+JPR1S1&2(!XG21<HRD\6/Q;2]
MG6;5FK]6:=ZCZ;T\[2N.QQGP(:S;,5JJ3VC%1P;@;D-6;EF4CF7QHV<EH(LZ
M)6(Z^?(/U\=;L:\XP'+^E\+"WCNKFZNM/FO[:& AGCMO6EMF8[@\D.UCEHTD
M ;. HD.&P2OZ2_4P1^'=.\2>(_$GBOP#JOCKPWI6@2)/=Z=X>'B6W\-W,\HE
M6[U'2O5IW22XL[6]BANA(J00)?2!;A%>6UG,BC8^*%K+HY@9:#N?5=)ZKJS'
M4/NQ@$M^#U=5"(Y,7.;(OWCD''+K?;J0+(#Z]H\^8\+=K(U(W*=C(^EQ$@(Y
M0AM^O<:LZO#IB7,IL+,L ]S*&W);V^%'1@A!4SS(H,$96%':9U-<6 Z!^&_$
M/I6O;6\TGT9V_B747\"^$7FB2\\1ZG'.;FR\/Z(1 HTC1-'CDMWUW6+*)9-'
MT]K?2;.XGU>Z@D7:?5^F8?ICHC-*HC$M:M9L/2,C88R<0/.WI4C./+,M5Q>E
MV &)#8!DW)/&3EHCIUN1LIJS3_PW(%,!05&>YMS=OJ,_6G*17)"K&R$QP;4X
MCB"DE8 BX2-D*QKM7J*"7F'S?Q'XMN_2)K3ZOK3VVF^(G6W@L+BR+V6C"WLU
M6'3=*2U>9X-#BL[=(K/39[)H-/B6& 7\$;S7FLIUW#5Z]B4&#)JTM'@;'UN7
M)%ZFN;KJS L">+M$0=B,"\YV<H^P*<F" NHS.7U%-O"6>)P';Z]6Y6)IZG3F
M;>IZ<H7KQXVD-C\854XV212[^GG&,%#F-F5O%Z]$9+Z67IM!<2A+B1'1HC%?
M.BC4H6A*JT4:Z@MU"82H,:(H7E$:H! RL%MNAF,S4$XP-+CS=2O%+FO LV"F
M@GBH"X4^9R*YEIPJ*D63HU9H#[@,BRAF7AC"HTP Y[+!H9!M;E2'1UX#*<,C
MKGG### 'D9P0""*XP*RH<C@Y5T;N",JR-\P<CC@]P2"#6 U7;Y:K[;B(FTR#
MQTY(BA:9N\J6K&2;5B.C[+=NG;:YJNS(S#]DKD;M36UXEL,BKL&U(F-B8L-N
M&C85O,Y5#PL5&%!,R*!PFXHES$.YPK&*2,<[8F)8[BU1C=EE 8DD@1.?-L!G
M@D/ '*B1'/ ,@ ' %;Y\T*W:<4KQBS P&'"CBA@AFL>)TDM]H9AM/]KCSRT-
MHQ_BI6,<P6502Q"@=R2 !]I/%0>1(E+R.D:+RSNP10/B68@#[S5+V7J;Z;Z;
MYB;7O[3%=<:[X4/,;.I8!>58_J($(FD%.N?LPVVRMS.?;"<\T)=6TN#/6U*P
MB([A[N!6_HF0$GY 9K@7?B_PG89]>\3:!:$?1N-8T^)R?@$>X#L?X*J3\JT"
MZ\_B!Z\K?2ULPGI^V0J<V'-"Q=8@K%58:TDQD"/898..FIL:XCPJ:V!(BP;L
MBB$)^=L%-3#P!('FD,H;5YSQ%XEM8M(NSIMUU+J15ACEACF*1B5PDD@G$?25
MA&7$;=0'J%2N2,5\R])?I/TNS\&:N_AC5O6=5N(X;.VNK*"\>&U6[GCAN+E;
MY;?U2*5+9I1;L;A7%PT3Q[F4*>$<SX>U9;38+03N)HZN?DNUO:H,)AR/?O)V
MR+4/KJ2OU4FHQ>%+$CJ5$7N+L3\XXPADX"[:^''(+.,FDA^ ;PU$!),;X-%Z
MG:S1J"IN&NIA:M<PNG.U+=+E)3(1AEN+4 LS2;?SR_HLL\W5X^O"6T_ VDWU
MO&IB;4I-6O5TJ;4[*XB(RD6GP:E!=-<E=LL>HZ8JN\CW CQDWT-T:O6^DT=;
MV\K4N^;*<KS.QZA4X<[5])KS'4?(Z+?B+A-*:<6FX#@169J6-2]&@PDY/5J"
MS R@\A\RYB3P_;Q3V]N3J$QN;LQ"ZAAC:T@B&J/IQ2>3!_'A4ZCG*+'))#'T
MW#[ZHN/1QIMK?:=IS-XDO3J>KFU75K"RMY-&TZU7Q9+X<:"_N"K$7Z10^L3R
M Q1V]Q=6EOZM,DAEK.W;H)US2U2\]B6VU< 8:JQTZ[JG7.:!L39)C,SM2V:T
MBK0!;J<1,TPJG_\ 95V0EO11)TS S4A&5";&CCBUR L[CP[;6X>7?>3JD*R>
MIVOJUS<MU+R>T299X#) UOB$LY5&DCD=() C-N&SJ/HRTG3^O==?7+^.WLHK
MEM%TG\%ZKJTBW&M7VD0WD5]8//I[V'^1-+/TX);BVGEAL;A(I)#*D6N?P\2Z
MI1-WV(:Y%3-@H,]9"M>PGI8:.*N% URJ 5LV4EHA4N9*@V*OM6&4;4!%?,XT
M&1U/M.-//4\%$K(IG\--#;W\HG9Y+>68VT>U%:>VM.GZV[IO9TEBZKC:F]%>
MSO$=LJF=*_\ 16]EIOB*Z34)+BYTRYNGTNWV6\3WVEZ4;4ZQ-/ 9Y)XKNU6Z
MG!BAZL4<NB:S#+(6C@W6_-?#0UM W:= 9VQ,W"E!["W33XR0@%Q0,XR]IO5]
MGMT_6K2$J&FRX.V1]LK:X8EYJ%/"EJQ(1%I@P'FY9@5G>D\*6L=Q(HO7G@6Z
MOX%:/8L@-C9S3R13*4=HYEFAV$[&5X72:-2'"COS^B#2+;4+J-=<N+_3X]4\
M06$,MJ8([A3H.CWE]<VEY'ZO</;WT5[:&W=EMY(YK.6"\MXF$ZHNOCO1G '!
MYLL.3?V*<% ]64C8Y8L1@\*JR6@]:-W*D1TU.9KD$,%^.I8R)#RF4C(@PT"7
MC\1(K91+2E\S\!QLIEC-P(%CUEI7*AEA;3;7KP+))TXPOK+M&/;1&*R)L&2"
M?+-Z/[61/6[=]46PCMO&\MW.Z++'93>&=(6_TZ&XN/5+98OPC.\*8GA@DDBG
MB$"!V!-P7GX>6M(:Y5;7<3LB?@[5LBT7C6^M'['+T>UU^;NU4K=4M 4C8RZ!
MZ^0I,/*.S;U-/J]BCQ+G S,M6K"2,3 9D&\;UQX9M8YXK5+J2.:ZFN+6TZK6
M\T<D\,4,JO*UL7:"-RY@:&5%GBD>*5E,6\#NZEZ*]'M]0L]*@U:ZMKW5KW4=
M)T=KN?3KVUN=0LK2RO(Y;M]+ZDNGV\QG:PEL[J*._MKB>TNV1[;JK4?HG1#I
MG:,=1)O7MQVC-U:Q[/A*K9;3)QL;5UUNGS>V2=81-DCZY.UX5%N8L+;<=,B2
M-3L\VFORTRY4+!"-O5V5G7:K;0+&\6WDMI[N2&6[CAEF9%BZ4$EZ;-)%BDB7
MK=4;)%>&601/(8)8\PO(=;3/1SX?UJ+3;C2K_6;BRN]8M[*[O)HH;,VEC/K;
MZ1#=Q6MS:(+Y+I5AN(Y;*\N/59[@V-U;AK2:X;\@?A_T*+B:^??=O/3!LY8;
MLD,;6@3\W#%U$6KQ=AU5+2ECC8"VJI'Y3H^2%LZ)*;@Y$.LUJ9JS<^$#(S:_
M0(_#=NB1-<WI=I);C M%:2,P+"DMF[RI%-ZOZVKK+N>-UAADAZJJTGLXM?1=
MID4%M+J>NM/)<7>H"--(C:X@>Q2SBNM$GGNHK6^.G'6(I8[P37%M+':6=Q9B
MYCCEN#T^8#X0=QV! %]3W2K=53:XKIUO<6/2AK#*1LY+5V'LA]M#,JY,I"NO
M0[@XS]:&EA68MU8*#9>:P)Y8^&FD>V\%3W,9U;1[CJ;-,N$$"RNLCQ)*TRM"
M70E" 8@X"':&>3;QP/NOH+O]3M7\8>"M0]9,'A34H4T];J:&YGM;>\DO4>S>
M:W9H&1'M%GC$),0>>?9M7:HYJN>\K]!4XI3BE:8_$!ZT*!T!=*.T^IJ_^28W
M38GT5-K"W\#D7C8DUAP2G5 16%8=Q\SD^S\F\QAQZ/@ I>52TXD!:,WV\)GE
M"9VJ 7D;ZL:^\>>-QX5 >&=E7SJJ>7I1EL98^RBGZ3GL#YX&"S$=E#'RKY)6
MY=P[CZTNHVR;4V9-2%UVYN^]CK*?5YCN5R4_(,1L+ PP>,Y0%#Q++H4-!1(J
M6Q8^.&%#&;;::2G'<50[1QKA$RL:#NL:YP/N&2S'NQ+,W))KE,=BNY)8^T['
MZ3MC)/PR0  .P "C"@ ?5ZZ7-(PW3;TYZ3T- LL,@:JUK4Z<XH?"<-F2D7$C
MHGI3Z4I3EV8G%2,J^I*4X6^8XO"<85VQR9Y.K-)(!A68E0?HH.$7^:@51\A6
M]"ACB1"<LJC<?BYY=OYS$G[ZN*PST358"<L\^:U&P5<B)*>FI$C.<,1\3#A/
MR$D:]E.,YPT*&.\^YG&,YPAM7;&<^W(*K.RHH)9F"J!W+,< #YDG%39@JEF.
M%4%B3V  R2?L%5KHZ"DXZCHLEECUQEWV;)E;,O ;Z4X-CINT,"9CJT<XGZ27
M:#4@JSKH<K&$Y(CZB$ZM/F*7G-D[ OM4@I$!$A'8JI.7'P$CEY<>1<^55P@A
M-S##R'J/\<L!A3\=B!8P?,(,U8.@X?%TMUQW?()\T%I^:U5JE"_= M1KDVD:
M_P!G'3GW:(O^P8-8?G-K>"DZ=KV@S,>MO$J;Y]<[;$2 =SMFE^;LN8USYB.-
MLXX(>213G:,60#>SS$<9:.+Y(IP[?:[KCX%$0CN:VPYJULTXI3BE.*4XI3BE
M.*4XI3BE.*5XQ@0<@.L0\08X5S*,N#&,-$CN9;6EUO*V7D+;7EMU"'$94G.4
M+0E:>RDXSC()4Y4E2.Q!((\NXY[<59%-+!(LL$LD,JYVR1.T<B[@5;:Z$,-R
MDJ<'D$@\$U&WJX6+G*ZY89**?1C"_123KMDA7L^Z6TD@RA.9,89M&'$LL0,W
M!-^-*%.^>AGR<V"0'B2-7'UE_%N/L91M)/F9$<]\8)S6^M_%)Q?V-O<H<CJV
MZKI]VG8L8YK:/U>21CM+/>V=ZP!(4(7W5W8:Q+,.?@I@),-9!A\FY P1DL.3
MC4N-LKEH&04P+F2 8(>9%D$."B2,24^*W) C#R4.7)GCPH="7C)V[L896[[7
M7)VL0,K@E6 .UB5<+&[L!%"E[:RF[L)).B)]G3EM[@JSBUO8 \GJ\[HCR0$2
M2074:2M;S2/;W<=OB*_%L5ZXVN/%3@>.L# 5L"%QC#;*98DR2'MOH6D82TEI
MPQ41-R*L(R^],6,TLAUS):$MRD8R11,>6C+1$^>P!3%N/<G&]%\@D:@=JVKZ
MY>^TO39I3U)[%Y=,ED]Y_58XH)-+ZS$EBRQ"ZL[?D(EI80Q(JB(EJ&W;#8H6
MQZAN !/DP=S(@]1;2;1CLQ@B4D7A]0W)Y./'_I<?<95W7!.!V4OR8VQH4J4*
M^74H!MFR$]2-X3[R!IHCYX49F3["@ZN2>.D0!ES7FYAL=91V<K%)]Y(B;[0Y
MZ?S#C)PH%5%U'5MD^E/6KUKL1FL@3<;8YH9*<%1NM;@&W#7V50Y_2I51640^
MXXMH;'J7[9JRKI9SA2>_+;9R) N-VXJ57XR(=T:X_P!(<PGX+*U4SJ-N_.-@
M;)'<1L,.<]_8]F4 <EHE%;J:HN3^PM:4:ZFB-QLI8JQ$2$[$M+4O$'9%"-M6
M2 7E?UX?@9YN1AR4+^ML@%U"_J3GFG*@CD= <A6(5C])<Y5OYRX8?(UN1OOC
M1R,%E!(^#8]I3\U;(/S%6#RNITXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5QJ
M_%@^(+6?AN]'5\WN9Z"2V+)8Q1]*5,U:5)LFSIT4K,0X4-A6'7H*M##EV:PY
M3X$.@1GRS! Y<H&I6S:P=>3VLB*,;Y"/AG 0'R:1B%!YP"7P0IJBXEZ2>SCJ
M.=J _'S8_)!EB/,@+G+"OE7583:76EU45F-L\_*7/;74CN:#BYFQR[SQLE,6
MC8EJ%"+D2G,YRXK&'Y%;OEHRE#+#:6FL-M-IPGM AFRP 0#+!?9"1HN2%'DJ
M1K@#G  '-<PY52!RQX!/)9V/&?B68\_$FOK=:[HM?U?0*/K6IB( J^OJC7*5
M70T)0A(L)5X@.$BV?"C"48RV$$RE64XQC*L9S]\\X\CF1WD;WG9G/VL23CY<
M\5T$4(BH.RJ%'QP!CGY_&FP[I':YHMNODJP06#4J_*3KH >$J/E'(\1U\6'C
M6U?T\K,%)9C(L9.%+*D"QAVTK<=2G*-#)(D8P"[!<GL,G!8GR51RQ[  D]J.
MX1&<\A5+8'<X' 'S)X \R0*Q&I*A(4F@041//#%VTQ)MDO4B)W]+)7VUG$V.
MYG!^+'C1&.6*3D6X89>58CX5J.C6LX'#92G,KAY&*Y"#"Q@]Q&@"H#C@MM W
M'S;)[FHQ*40!L%CEG([%V)9R/EN)P/(8 P !4ZZ<(C%A'L.])!/F$;.4.+0\
MKQWQ':<@"#$4IT//TIRF^D%2FSGRO)'.=CK778&4P_\ A./RS"X.TK /VOF3
MYS,!OS_)@"+&2,HS#WS5D W;ICWDP$^42D[/Z9)D\CAE4^Z*V>YK5L4XI3BE
M.*4XI3BE.*4XI7J1?&'^'_U=;/ZMY/;VMZ-/[LJM\IXY4:BA5!31%#CZ%$ Q
MS]7L;S+BVY:9-_2R< 2HAR8LF"G8B+CE.13(2?J/A37=*MM+2TN)DLY8)2&,
MTN1.T[LPEC!Y51PL@P$CP&9O:+5_3_\ 4J^G#T7>'/1?;^%O$&LV7A#4M%U6
M2.X;6M4WQZW/K=U-.FI6",H:UM8?9MKZ(1K::?TUNKFX N7F/.9\+30.SNF?
MHOUKK?;<F&Y8%YDKN-76X/$&=KN+O?I[410[&^M>7YFQP4])3K\S*%(:4*0?
MFOCX=CX(,I_QOB2^MM1U>XN+16V>S"9-^\7#PYB$T8 PD;QK&$49R%ZA]IR!
M^-OU27CGPYZ0/2SXB\1>&H)(]/18-)FU%[WUNWUR?1!)IJZY8K@1V>GWEC;V
M:VMO&S+)'!Z_(4GO)HTTAZENHKITZZ[7!],9'34%L_9<G/&@:#LU_LJX&M5F
M32UE%WO-NF:19(BP1M)A0P(^1:K-<L4R1M0P6%KN HX]\ @7Z-<> =:\%Z9#
MKDFLH!) UQJFGV-K/+/':J8A#M]8MVB+[YQ#/-<PVPLGD)C,Z]0K\@_4L?JA
M=2;Q1XTUO1=;U?T?> /#QTS2]=U\W7ARXG\9ZQ=#5)M(\%:#HFI"_L[SQ-JZ
MZ?JD^CWL$>H)I.CP:OK5]+8111VFH7=T]=1'2?I"P;CT%6ME;09WCJZZ8&W7
M-W_7EKN\QN^^N!,@2%_; J(-IL!,&AL%N$@@H(JL"5R*#K\>+#FP#,7F1^7^
M([XV::;?:J(HK34H93ID%FEQ,UO! R%X%C@A<[U,R/(9$D,C2.VX2%]GU#TY
MZKJVD67@#QKX_L]'L_"GCW2+V7T>:3X474+IO#FB:9-;SS:'#;Z?I\RI>0MJ
MEM=W\M]::A-J%U>7<S727[W0M]N8GK-KLYX0H7274O/3J1LE.QD;HV]08[PG
MJGPVI2,D]FQ>N62X4YX=Q0$@6S&/+;RE)X4<9AT-KRKZO">;:RUBZC)PD@TJ
M[MU8X!VYO$MU# $9]LKG.&8#-?G"Y\6V?,VDZ)XTUFP>3IP7J>#]9TJ*23II
M*8';6X=.@2XB5U$R)<30ALF*XFBVRMC:SN7=3)MAA*;T>;.'#5(-V"-;V%L;
M2=,:!CIY"T8;=8@[]?Y0<=<W&3[@@N(]Q0$=Z01L889H45&9=2U*81R1:%>8
M(*%[J[TZW#,G.2L5U=2#V&3<3&&8DD@MN-7ZAXI\4:G%8WMOX UI<PFQDNM7
MU;PSIXN+BR8$N8;35M4ND*V=Q8B622V1YY>K*W4F:5C1-[)ZLJKM$>YL:MT9
MKJ(W?(P]3E I+;5ROHH^Q*]6ITJ(MTPS"ZKIP\9(6>H5\.DE*;E90:3)JM%B
MFBXXUQM,O:D_B&XBV+9:3;]!2RF;4+JXDZ;,H*;(K")"$=BX FR-\AR5&5X;
MW/C^20/'HGA;34F(4^LZ_J>I2"158AVAM=!LHAN5=C8NFR50!N1FJM[4GJN3
M'1^PW=DZACY>(+KT*+$T?55F\\B3<O=2M&N29&8M6SY$$UJ&VY6:,ETPFO"L
M0%7F;K(Y24*1(P\M;!#K\I,<FJ:;:HP8D0:7-,P'3=9<23ZB%!,+/VA]IUC&
M 0&%<MAX\F DE\0^'+'!50FG^&KVXDR75DS<7_B!HCB4(,FR "ER1@D'=JJZ
MCV3LFKUNX']9^\I&O6R A[+#MTBJ:)U^&5%3T</)@/9>;U1/V-M+P9;+B4(L
M>'&\YQV=SG&<JTFTN_W,EQKFH95BK+;PZ=;*&4X(R+*67&0?VW/S[YW%\-ZW
M=*KWGCSQ$Z, PCTZR\-Z;&0P!]\:)<78&.V+H$?'-9_\T"@R'_B_8W4C>TY]
MUCV#J2W)&1KJO]9Z%I%NJ,(YC[_HU1N6>V<I\OP9\/,?@2V;\O=:I<_$2ZI?
M(A^V.WF@C/V;,?*L_K&TR7_/]5\5ZD/-;KQ9KT,1/Q:WTZ^L;9OL,)7RQCBO
M(%Z)NDYA]LHW0NO+.6UGQ(+OD/G8A>%_Z^2KV]8WUN=_?*UN*7G/OE7?F5T#
M1E.6TZVF;ZURGK3?:6N3*Q/S)S4T]'W@I6#R^&M+O''(DU.#\*OGGG?J37;$
M\GDDFKIK6K-8TS#>*?KFAU3#/;RL5JH5^"PUX?MY>(N/%\';]GA[=OV<WH;.
MTM\="UMH<=NC!%'C[-BKBN_::-I&GX]0TK3;+';U2QM;;'V=&),?=43ZAM(5
M7J/TS?=+W);X\)>(? /S$5"'#(65"+&E8&>";<REMTF%FP8^3;'<6AHOTRA'
MU>0^[C-.IZ?#JEC<V$^1'<1[=X&6C=2'CD49&3'(JN 2 V-IX)K2\4>';+Q7
MH&I^']0++;:C!TNJ@!DMYHW2:VN8P< O;W$<4H4D*^PHQVL:]3O9/PINOJ@W
M&5$KU,,V7'+2D *]TJ[P:&)N(%].@!DL*=GX>R1_D#A1Z51TB!Z05P5E@$HU
MD1DC/QVZ\'>([>=UB@-VA&T7$%Q&!(@QM#++)'*N J^RR[00 K,%!K\2ZOZ%
M/2;I=_,EI82:Q$0(H]2T_4;91<0)L$2R1W-U!=Q;5CB'2EC,:%%6-Y%16J&-
M?#Q^)$R,^&SI[9C09,PW821&KW66QB)]IY!#4X^PBYX:=F&R&VWVY-Q"C4/(
M0ZE_"TI5B@>&/%(!46-T 7ZI N8<&0'(D(]8P7!YWGVL\YKGKZ+/2TJ-&NA:
MPJ/.+IT74[,(]T&#BY91J #3A@&$Q!D# ,&R :Z0OAW?$?C2A3H[3>R@#04G
M(!,"O-8%*#1*.N/R:!2&+FVZ.F1>==>.2RM&"W7''",.+6K.<+X8\4(59+&Z
M5E#!66YA4J')+A2+@$!B26QC<2<YS2/T5^EF%TDBT'5XI(A*(WCU*S1XQ.2T
MP1EU ,@F9F:4*0)"27R2:\1'PW_B(-O!D-Z.OZ'XX0L"/?1<*DEX$$]1JC@@
MW$W#"QA#524BHL9A2&25'FY>0O)3^7,?K6\394_@^XRJLJGUB#*JV[<JGK\*
MV]MP'!W-GN<UCT3^E4-&X\.ZF'B1XHF&H6(:*.4R&6.-A?Y1)#-,712%<RR%
M@=[9\T7X>/Q(@379,+3VS Y%XXF4>D!;W61S79,UEP<R1=+:N:'W#BQW76"2
MU.9(?9=<:=<6A:DYD/#'BE6+K8W2L6+EA<PAB[ AF+"XR68$@MG)!()JU/1;
MZ6HI#-'H6L1RM*\S2IJ=FDC32*4DE+KJ 8RNA*O(3N9258D$BA'P\?B1%CS
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MT\^C73I<VZW%K=0B*[M6<="_L9&#!X;A!(@8.BS6=Y$).A<Q)*H?IO&V%B[
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M)MUZM#%LUZ%=D#7#2XV+&,*:%>?6*Q9.ZR2NZ!E4D8#D%C@ ;F*@#<Q&YL#
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M*O,[?;.<,3/E>+[]GO!V[+[S?_-CSQUTP/LC?)_K&?NJ*?EQ_(OD_P ],?\
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MK_\ P=/^57X-_>[XF_HZ5_[C3^=JTM^[?:'_  ZI_P!1\?L$>(_W7T3^E?\
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M]BD!4&/(]-5+#R8M6P_->KZ<4IQ2G%*<4IQ2G%*<4IQ2L'/0(L\*PVZXZ(<
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M!B-CA4YSVSE(X8S+6,]O?"._.>S%V9V.69BS'XEB23]Y-;ZJ%554850% ^
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MC8R8F/<_$QL??4<@^V@W;E?4N("QZD8]L##+VZ@';Y!U'ND\$>PQ VLFCO\
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M37)U^^U;!SM)LGH:GO.6E24F2Y=F/DGW*IO&SFMM,-/R#T]+FU'8,BR$.*/
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MW6V6&6UNO/.K2VTTTVG*W'77%Y2AMMM"<K6M><)2G&5*SC&,YYYP D@ $DG
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M\84.]T-XMF/B]HP4?C*1,-&$*;"A-BU\=3K=1LQ:FHZ1%4JH6YYJ%>A[!3,
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M-A=IP,:PR#!S)SPD/;8<82DW0P,$.I6V@ 5D412':!GIRX),9/)5L<M$QY8
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M,-P4S P]CC!$SA4&MR06@;JJ!DJ!B5!_#CY) \WC+H!C<5)VU-9QD+*.DQP
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M\*$J6KPI4M79.,YSX4(PI:U=L>R4)4I6>V$XSG.,<?\ SX?VUD#) &,D@#)
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M !CJQ#/XIC@;E!))A=C[)[QL>FY]QY*D<HPBD))/Y.0]I ,G:3P!*H&6'&\
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MY*TV>5?.L5IE4M9\KYK8923D<M8PWDK*$I3BAY'D(+L3CA1P%4'R11A4'R4
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M)/85UY-'])\5W?6<GB>Y2;3(R^H[O&\8CLL7:V/3N9?PITX9C=,(5B=@[-G
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M86WR\$.,(\-\FJ,H:64/ZF*;.U3"PAZ[$*#*854YWLRJ&D(&,!4W(&).=S@
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MN3$9Q!,80"3*(W,>!W.[&-H((+9P#P3FK3<0"00F:(2D@",NN_)&0-N<Y(Y
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M3@8!.>W%3/7FW-6;<#F)#5>Q:3L>/KTHB$G3J/9X>T!0\TY'!2V(B2*A3#&
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MO;7$2+))!-'&^-CO&ZJV>0 Q !) R!GD<CBLI/#(S(DL;NF=RJZEEP<$D Y
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5G%*<4IQ2G%*<4IQ2G%*<4IQ2O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g796801g93b67.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g796801g93b67.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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M5'JJM774_P!ZP&W%U%6%?B"(>GH$;,VDOQ8F;./08XMQR84ALDBKSE:+NQ6
M#A=D@Q#E+'2):H4]$7E#IGZ+60ZJ[W^S6!'L[*L4%=VF6M'LBJ'"LDZ1<FT1
M)4MVWVQE&T-J:E/WQNU.P'Y<9%P8BIFP%RL1V0VK7N^"0I\\^ M3GA%:F'P<
M//3F6XRE/-,HD25JMTM32(*I2)"&73'<=++X:BI_;'6Q5@ NTV'</4:)KQK
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M8?O#[GC,#*CEX7?Q[S<A50M"CA*DDC.0% D;JBE6@.=% I/)0(.M6*%@9*5
M'&"4D Y&\-2,:I(4.8.1I6'D5X_#!"K1+!F(M:.D3 @)8I R:P",%JZR(D6
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M*&BSYPR#)*R!XN0T/8FDA\1Z6MEN1.B,J6^V?076'FTD!3C3B$DY !6@I!.
M3C)UP"<=AJ&5AMYIQ62EMQ"R!C)"5!1QD@9P-,D#/:*W+;]T#&EP=_#V?5-&
MBBXX(34]+U*M4,1.!5FN'=SIV!N/$PWL(W=K37[#L6JS#8!ZQA)Q2:/=GIC!
MD@HR/"T\?P0@H*7%DE14ZI2R%*(:*&]$!*%)0H)5ND '!WM[A7($H$*"D)
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MX=$OTZS@;Z4N;9?S*Z1K1<+DM*WU%,Q1!ZB6>ICO%I\+L>CXR":IT+ C-=F
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M.IPEKM]U.&\?E5_/--T_$&FGP$]GDK+6;J&UG4$NNGJYJ:-%:UQ;=LHGQ]8
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M,A<3,74\"3&C&9I=@UIE8!VKP@(YHO/FW9!NJCU46$L6^P0%R[C@''.PWV)
M-PBT^TI<[ROE7/G*]/+RU&Z>.ZG'/=3KKC337733MK)$NIBE-T6=?ZWJNF7,
M8*G3H)D>-U?1:J7KJA0Y\P8DVQG:,B@0J;#%!V,%93]LGA>^0)@M^$B6DN+\
M+;RL9ZQT_P#$=.W7./ZQ0#7&$]WO0<]PPDYSP\=1JC=9>H;\#LID70*H->JH
M6S6,B /Z-@BK#*"5%$-P]-"CW!+B#KPWQF(9)BQ,F68"3#80>?'BIY:!&D M
M1&>L<T_WCV?UV4*<'!2GYJ?5_797-"ZSM#3(,"9@1KB.Z3@AYD 4]HV0X:(/
MF7*]%0%#C(=4E2;#9!).V5L'9J]74ER]6/FQ82P1!Q*=%C.M\_*N?//F[SSQ
MG%3NGXJ?FI[]3IH-#C.,XJ/Q>N_I[>R>?E!M7P1 5P'X.=\U=<,0+!"/UBV7
M6&9!QJU#.&5@&*?2+/:)YPD*&#(($,3*2)*(8PD[#C?/RKGSCRSX].WE3</Q
M4]H^"G0@XP=,<35S5;?&M[J:L5>J]?U$6+5:0]&,QFM8!V&T+BEBM?F.#YDL
M-'A'(D"P C5?)3@<@C"''Q!().D1RD*3$;MO*^4<T_WS4$8XI3K_ +J?'RY$
M'Q:U//*N%\7VJOHYK'V'C*_E'/GFHT^*GYJ?54ZUK8XLJZA6$4K70]3GC'N2
MQ5&KXZ>SV1,]>>\3(L1M]GOF$Y:=["\=\96XTKNH6K&:J*MTY6L\-"HD<>52
MD D:)'B2G/#Q56MK_2FR_M\Q_$9/)3P'B'U5%1"$6%D9):' (PILL"0;$FXT
M62R^^(*/"AAQH<2::6I<*:Z%-""S<:0EMY8XG F)1F/+8<7-*H7=^B*GU$CJ
M\M^U66GG:42N,(/9ZP/J!*3B%9JZ8H%_J9FM[*I]UIEEJ]F!D98\L/,5B<VX
M[&'D1DN,_%9D*@@''=GTC7CH=/ZXU9*BG.-<XR->PY&H((P==#6L%3]R[T-3
M[K3+L/N6SI2Z6QK]N'!FIU1B<05KNGKI0K+^Q!^JX&W D P*=><M%?I.PJI6
M3KLB1"?#("27Q+M=P<^7G'?Q'B]-6+JB",#7//M.>&<'NR":O&Y=&NK[4TVB
M"<O=3?&575]:J\L2>B&YE5EZ=W'"WMK^SPI=Z%VZ87.C-@C1\F6BTR3P<J)C
M8%313C+SZW)W1WC3''D<U4+([ =2=>W>3NG@1V<M<UT-']&54T)?1]YK>T=J
MV*($U/6M.@J;=5:T,5RO52MPQN'7 !*)K<7=@<VT'Q[MSNC(JW0PMGM$U,HF
M(='@:F-KP)P<YTQC&/V^G3&M2I94,$ :DDC.22>W4C0:#30>>MQN[C'=[N<8
M[F.[G\N/R8_+^7/O8_)G\N?R?DS[V>6JE?O%*D%F_.,;]WZE_*H;D#AY5?6:
MD\?(GZA5%;'TOKO;1*ESMB5P3;H5'GFB0VNV,,#L%;FS#@22!>>*"3@LBT^Y
M$B2GG(#D=45UA]65+6ZTI32A )!/9GTT"BG.#C/:,@Z>*J&=Z;=35Z\3M_F]
MAWE,+7Y&YV?, X2"(I=/@QBT2QGXD:,]5VB,&MUYZO82.BPR+<*"+CY4QW^4
MMXC)@)&<Y.G8> ^P9&.56WCC=P-<'(XGTZY[?-61=Z=='!A>G=6/6"T0Y=).
MT:=6VYEDE2R-VS4:H3CLU4QDG%F!Y%9L@.AS2MOJ%9B 19!5;9EK@PFFXZ'6
MZG0<L=^>.GBT^OAFH"CJ<#4$<.&O$=XSC.IUK!U;I8U(DSLAVK7XPT>.W\SL
M8E($UW38VXTV[F]R$]K0"N+!%U;&N!:*.M\(P-!B]ADK:"+5A+X\A".1L,3$
MMT$G7MSP&0<\\9X@_;4E:L $: 8XG!&Z!PSCA@Z '.M3/7_2%J2C6UB]RH#=
MUM<-\A/'$;36M?)BUXT2)"2CYJH!ZY30 NG$$/!!V$/UR*.<DNMO%BBR5AG$
M#,L$@'/UX]7&H*R1C@.W!.N.>2<_UBMIN6JM2 Y_9*S^[^/XT:Y5/X7^(_LI
M59WRG#MA4JV48M)GP1UNKQ:O2B(ER,R7%H*PGH:2H=^9%G18Q@6XZ@@)E/PY
M344C&C2%1WL-=[58Z@CG4@X(/(@Z\-*U=)=#6I92):A9R]UZ:ZYK%T?/&$P<
MAT,O56K[#IX'X#'+UTE#>02I%G*1#S1*/.9FD/ R+#<1Z*C"JE UU/9Z!@5;
MK%=W;V<R%'TC^LUE2VD-+4"GTG7-MNYX32BV[ 12H5^8?@5=H[>) >7FI4&+
M/JXP 27"B60:B_UV% FP2[5K BFVRC@."@"ZW0!C)XYXXR?1X_'49)).,G'+
M.!G4]OB).F#6O0'HUI5Z)O@:IMDD0T=1KW-=@#PQ\*5LE;VCJ\?4==!ZUX1*
MHJI,5.J8VN0-:2J;;C<0@,K8T+8*D_8$G+D9C=SP.@/E!&@'#LY_^]6*R-2/
M?$=O A1))\N?M[!?-CZ2^G:!1!"=EQ,V6E:W=/WNRKODB 4K!A+=&V/7CIFR
M5QP<BJ"DQQ>P[0?E$*B#K)%9IB$5E39+K#Z9,[HQKKVG)\?FXU7?5G(T)TTY
M:8',\ ,'.FE8F)T*ZUC%V3+MZV;/EQY6N2*7)Y"FO2<'=9Q]4#J^;Q/Q2T3H
MY"4$T]41!?P-^*P19D&I;K."$R#*&MT<SV8X<=->'$X\M25D]@[>&>TDXX\/
M?''DK%1.@'7<8=B&]LS;Y.;@NZ?4:*F:G.+/F.]]/B(DN9+<IV'IN8BNFZD.
M8\*6Z^^LM:EO2,KD@5UYN\R?'V]GU8H5]PTTX:?A9TX:[Q\6!5K:FZ6Z?IVT
M"+'6K3<9L8'5C59'5PJW2D!6G;*.U6-L)[*PE-"EL$B:-05F3B$P48KL"3--
MMC@D4>X%@ Y"0.&?ZQZJ@J*LYQJ<]O9G';WGO[ZV:Y-5K3[W42TV>E]*.S+'
M3K&>J=A@#=,)@GJT7( C,),L[KV%+3$*"Y$6=&Q*AR'XDC#+Z,/1GWF'.TTX
MM"M[LPRT_>8K3[3;S:A*WFW4)<0K=8>4,H6"DX(!&1H0"-17NOW-EJM=[Z9-
ME+;>;; N]ND-;0%^!<X<>?"?+.S=V>:+T64VZPX6GFVW6RMM6XZA#B<+2DC^
M6'TG>I3]87>/TLWWV_SU3V*M?^S8'Z''_P!.OU)]J[HS_N[V%_5&P?R^GI.]
M2GZPN\?I9OOM_CV*M?\ LV!^AQ_].GM7=&?]W>POZHV#^7T])WJ4_6%WC]+-
M]]O\>Q5K_P!FP/T./_IT]J[HS_N[V%_5&P?R^MBM7,]<^X*(:V!2NH/8[XL1
M/M@QD45ZA+.%L1\A1Z.YL>TPZV))65A1>0*IK+YA;+3R'9*6%Q8:)$S+;"^#
M);L<5Y++UNB!2DMJ*DV]E;:$NO!ALN*2T=T*=(3DC SDD#6NF7ZU]"FS=VBV
M>Z='FRB7Y+5N?4_'V!M$J%#9NUU39+>Y.D,6U8CHD7-:(P6I)2@K2MPH;RL?
MML"^Z44^YEZ'/,=7Q&P!H10NZFNV'<I^#/KX:>V+)6<//&27XY:KQ2+S,)RP
M05/"DRGV6,RL.O-H5#0V<=:2\EFT)0I24#K&8:%!Q8*DMJ2I(*7"D%6X<*P"
M<8!I;X7W/ERMD:[LV3HH9AR78\9)F6?9"&ZU,E,E]B!)9D1T+CW!;*5."$Z$
MR"A"UALI22(HR8]T/DO0(\<OUG/R"M8>NPMADCNYUXC38^8.'[9!;;>4N76V
M5%!B73;"7!K:B,#"Y.,S(V'<I8V> 42S9@$N!E1+<(!+IWL-$E. X=U6$'WW
MO5:>].-@K9_H&0EY:['T1H1'G)M<A:K9L:E+%S7UVY;GE%@!N<OP=_=B+*7U
M=0]AL]4YN\U+/]<FP*1(V)6-S[LFU5C8U.U0U,7NNW,2I][O2G< @HT8Y9\$
M9WY$,Y(3&(JH0[,X<W*?0[.C-N'H]C8>##D" EPL.R<> L$!EGX:U*#6ZGMW
M03E6ZK T-5N>SG0K:+HBS3]AMAF9Z[+<MH5-_>79E-LVFU;@ERGY";86&0"I
M74MK<#K_ %3Y;0I++A3-RU;]T,BPZQ-JVV=V;8;MCYV(.9TKNJZ;:G19E<%T
MTX7A&!M'L!B>)E0PVPJ5.DM38S683EABB"&8A^,2$PL*!L^HN)<@P8Q:""HR
MX+$8$.*=0DH4\VE*P5L/)!22#N%2<H*5'5QXO0.MV>U/V+V&V>5;T1''E[4;
M%V/9UEQJ;(N<2,[&?NUNBLR&W9-ENC3:FEJZU,-R2SUD1QB0[ J/9^M_8E#V
MSLFJ[HW?-JNE((*??I+VYKG#EPF[#,GQH4<:/DV-N68G,11!LV2A#VGY VO@
MC1J6AJ".D.IS/1K&P]&CN0( <EJ6E@"$P0HMA)45*#1" 2M"$E1 4M:$#*E
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M#8C!.0ZOOTA.),<7&>8""@XP?( &>\Y-023C/8,#ZOJ JX^34586JOT] _\
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M)'YL@4C%B#"Y=+:8)=OQQ!3GMX8\ITSGR =HYU 61V<_(#G&..-2KGQK!(Z
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M:^-[S9LY2?"3V6)T*R4+=QRK1F,*6IAV1,ENHQEN*K(@ZD:' QXQG]AJP4
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ML<039(EZ/3;+?R3=5CB.W.IX''=VX/9VZYJ=].NF.!T QD;W9G.@(QKV:8&
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M:8M=*.\M3C([@J_; W@#K;=?",T;&P,5E6QJ[ 2%@"(EBCY347*8UKZ$+0Y
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MH@Q$0#L7+,!N2Y,1".UNR1B(ENM-,NRD1CM)U*9+K+++3CX0'5M---J44-I
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M-%#>0#NYJ(^AAU+?%HOYVT3[T<Y_MR]&WY2#Z(OO\KK3>Y3Z??R!5^LVQO\
MU#3T,.I;XM%_.VB?>CCVY>C;\I!]$7W^5T]RGT^_D"K]9MC?^H:>AAU+?%HO
MYVT3[T<>W+T;?E(/HB^_RNGN4^GW\@5?K-L;_P!0T]##J6^+1?SMHGWHX]N7
MHV_*0?1%]_E=/<I]/OY J_6;8W_J&GH8=2WQ:+^=M$^]''MR]&WY2#Z(OO\
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MEP L^!2V<O J2<JU=L,F5EUE&(#T4K<@+#,29WF3+1)>>C-.-1)*F@(/#O\
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M3X0SK3:'>H9BX,#X#C8T..)E._>+89B ^^V^WQ%$C&N!KDXSXJY2 #G0*.F
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MA 8\!FM,"I040.&1V9/?Y\C'#Q\B4H* 3C.%9R<9.N[Y@DYT[1G.0#-M:^Z
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M:1]GX]O;;_\ &+7]&-?OT]QMT*?B.T7ZP2/]*GH&=/W^'VKYS2/L_'M[;?\
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M!O6KZV*F5582_6DP)KC(VXE)1YNZA A1UQ\,\/2A,0M&0!)QW@^@@<_/4J2
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MHS]FP!%<58M4&JZ0D24V5K&#.L=QAI66YMV #<8C*SG&-#V8_:.SSC.N: (
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M"UMZ1*B,G2@QB9*@BGI4&"3FQFILAMN.X_%'3Y#*%J<:B2%I2TIG"01K@"F
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M_P"?CV(MOXDQ\S[:>TST5?D'LY^@(]=;4C!@X*.@!P\"&*$BH<8<,&#HS,*
M.'PF41H<&%#CH;CQ8D6.VVQ'CL-H:9:0AMM"4)QC&P2E*$A*0$I2 E*4@ )
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MC;_8VVOT;9/^HJ]%=9[,I6WZ4$V!0#4<[6CL?#T64SGL/QGT=Q,H:2BJSEZ
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M&5=IQR[ZZ5,G]>!J[AQM[A1*D"?M$I5O(5M&NY]:'@APJUSJY'I<\G")V2/
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MFI G*<F1HAC13(:1(Z[>F.)<:;$2/U33H\(6EQ3B>M+;6ZTO><3I6!YY;2F
MF.\^'GDM+4UU>&$E"U=<[OK0>J24A*MP+7E:<)-:+=:&[.H'5D_2U4Z<ZP&M
MEWVB7V,/0(*5&);WY3U/UX4M@B+&BE-QZ1$C(<TM"C1#AF;;W%C1+LB7#%SI
M+2&%\11(P ,YSZ/**Y2 DY*B0!C.#CB<?%5KY*UH3[H)?Z5=9,O;Y?38<=7-
MC;:HFT.GJMC3$S=&LZ=J/35PV5-W?)LTB[N-F:A8B53')#LR-:@PI"N[(HK
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M?47*R(E>ZC7 <-]D*0L<:S1"5IUOJ&&W:*_D>->$;(8?FP +IH,Y!;QUTX'
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M9#W*CX2O^'ZJ5K?N_8MBUN,KQ.M5RNVHL2+."Q5>*&)\"QV<V]'RL=4:/!'
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M/IY,[<9IE8UL:#[7TI5<I.WH)9ZCBM76[:?8N$L[8ZY')IKF:X"O5B!6')"
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M1KJOZC&VTV!C5I,\!@:IGU=2V:BZ*A'.H^7K\YL^E/N"Y!Q=Y%URWBHVO*K
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M#^'IYL=;?%[1_FF!]G\>#Q_D&?S2/W:?>SLY^3]D^BH'\/3S8ZV^+VC_ #3
M^S^/!X_R#/YI'[M/O9V<_)^R?14#^'IYL=;?%[1_FF!]G\>#Q_D&?S2/W:?>
MSLY^3]D^BH'\/3S8ZV^+VC_-,#[/X\'C_(,_FD?NT^]G9S\G[)]%0/X>GFQU
MM\7M'^:8'V?QX/'^09_-(_=I][.SGY/V3Z*@?P]3=*4I2E*4X2E.,)2E.,82
ME.,=S"4XQW,8QC&,8QC&.YC'Y,<S5N@         ,  :  #0 #@*_>*FG%*<
M4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2
MG%*D!C\UU3]BS/YD/<J/A*_X?JI54W#6FN-A.AG[]K^DWA^NO29-?>N%4!65
MT%(FXCIF2 SAJ!-6,>EIB14R7866''\1H^'5+PRWV;$ \0#XZD$C."1GC@D9
M\=1F?T_Z'*K4X4TIJ0FXHY/LRED-<4^:O-D*H2V4/]J4&=5XZ(H2E$\IC/AL
MM*<)D/N8QC'(P.0\U,D<"1ICB>'+Q59T06,@2"DN .@PI1N<V4-28D2/&D%R
M;0P<%:(E'F6T.3YS0<0)$MRY:G9"!@L= 2YB+"C--34?LX5WN*4XI3BE.*4X
MI3BE.*4XI3BE.*586JOT] _\4_@Q'E5_!/D^L59'PAY?J-1RU_I39?V^8_B,
MGDIX#Q#ZJK6 Y-*IW<VQCVMQU)EUX$.L<ZT[$ TQ8TD6C FE1S$ U)4^R6F/
MM0X3[+PYC.%OHF9<:R\Q%@39SL6.N"2,8&<G'+G4@ YR<8&>?:*U1%^Z"U7-
M9M-Y+T>Q.4ZM"JW<)LL8L*R=A5#8<8XO7K":[-.J>/625+JQV-:FADQ@=78^
M1Y/#TP;XUE"Z[_;C3.._N^HYY=]7ZO@,C7//&G'7&@P1CM/(9%9H_P!<$*EW
M^W4VX4(DPNMZN$7KO%;(B[4E9ERX;)J9&K,6$1/D"BU@(KK-:)AJI$A1;.+
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)59'PAY?J-?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>g796801g94a22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g796801g94a22.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2'*4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (:Z^AB(X0DE-! 0      %X< 5H  QLE1QP!6@ #&R5'' (   )\91P"
M4  (<G(R.3,Y.3@< @4 -4UI8W)O<V]F="!7;W)D("T@1E=?,3$Q,3$Y.3E?
M,35?4')O:F5C="!'86QL96]N("T@4RTQ.$))300E       0<,\L^CS5V#]/
MBM'KL'$,Z3A"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@
M    #@             _@   .$))30/R       *  #_______\  #A"24T$
M#0      !    '@X0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          (X0DE- _4      $@ +V9F  $
M;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M  $ -0    $ +0    8       $X0DE- _@      '   /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      S4    &              (]   '9
M   !                          $             !V0   (]
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   (]     %)G
M:'1L;VYG   '9     9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   "/0    !29VAT;&]N9P  !V0    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
M   "/_         X0DE-!!$       $! #A"24T$%       !     ,X0DE-
M! P     %QP    !    H    #    '@  !:    %P  &  !_]C_X@Q824-#
M7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q
M  !A8W-P35-&5     !)14,@<U)'0@               0  ]M8  0    #3
M+4A0("
M         !%C<')T   !4    #-D97-C   !A    &QW='!T   !\    !1B
M:W!T   "!    !1R6%E:   "&    !1G6%E:   "+    !1B6%E:   "0
M !1D;6YD   "5    '!D;61D   "Q    (AV=65D   #3    (9V:65W   #
MU    "1L=6UI   #^    !1M96%S   $#    "1T96-H   $,     QR5%)#
M   $/   " QG5%)#   $/   " QB5%)#   $/   " QT97AT     $-O<'ER
M:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P
M       2<U)'0B!)14,V,3DV-BTR+C$              !)S4D="($E%0S8Q
M.38V+3(N,0
M                6%E:(        /-1  $    !%LQ865H@
M         %A96B        !OH@  ./4   .06%E:(        &*9  "WA0
M&-I865H@        )*    ^$  "VSV1E<V,         %DE%0R!H='1P.B\O
M=W=W+FEE8RYC:               %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                                          !D
M97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S
M<&%C92 M('-21T(              "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@
M4D="(&-O;&]U<B!S<&%C92 M('-21T(
M9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%
M0S8Q.38V+3(N,0              +%)E9F5R96YC92!6:65W:6YG($-O;F1I
M=&EO;B!I;B!)14,V,3DV-BTR+C$
M '9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A96B
M $P)5@!0    5Q_G;65A<P         !                         H\
M   "<VEG(     !#4E0@8W5R=@        0     !0 *  \ %  9 !X (P H
M "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4
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MZ"<8)TDG>B>K)]PH#2@_*'$HHBC4*08I."EK*9TIT"H"*C4J:"J;*L\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MLL/$Q2=78F:7H^+_Q  = 0$! 0$  P$! 0           0(#! 8'!0@)_\0
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M!M'BO^%_9/R8X#L;C.S.+7;:SR>7W%]G,4VQP._8])AN%^5W!-IMM,6Q#:W
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MWS#)KC>;.[V.]93V=I/:7>2SF%I+\&?LB-0F[%A,?;I6EA+3FDEKLB=XH=]
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M ..Z^/#8#QVCE#"$,(0PA#"$;M4;V=:;NKR:2JDN9=;DM]TMK%5A56DV>3\
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MS%XLTL;Y=KQ=[S96=G()EU4Q_5<>C0PA#"$,(0PA'[4__1TO[B:HO_*1>/\
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M6H"S5F>O$Y\1J7.5U% 7R1I8*S3,0F#1!0F3RIJ=^N&()D0B./E.S_D'\F.
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M;#O>[,<Y;7_U^.V'JZ^^[S]LOYH>U#=TA]ZL\?PGIM^6V'K;#G_XNS_#:_\
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ME1[,*N[ 4J<N]3KDYG201%0^B*!@R@'F73Y,**4,Y!5%8G#*G'DA2+PRIAF
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MKMGI:G*;:B6CF%EN--4(4Z88$D:"52)!]W)&'?IFE::.<=,JF\H9PI*(4HB
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M]BJE/W2HEIQ$Y(B6B#G+(KG2";C3XPAF&4B.F68YC-C+O$'A,H0JFKY9'0F
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M%HC9&NKQ7$*2UG@AI+1/2"!&0G+)<ZN&U-NNN\I%*E4EF 8S$TF9V(+.@GG
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MLLO1U:?[M>9*0!]:!2>Y\JLEA299&44%NJ02BI264@%'#*4 F,QXFM5B[X=
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MI"_2:K)(PDS"TUX70REM+<K5,D(C387TER0EY4A374]41U*!0*&TK,TI( !
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M5BX#*JUXL4%(#YQOPW9::Z6O:]QS$-V [ FN;UI545$# YQ 6T":N'U4'--
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MUT=R8*V^#R:BZ=%NRL4KR4J.]:2N/[4H[[A<0\$S +>:P:XN^%" Y"LI["J
MYI7JC'1^\>]LV- 2BG-:)#R4J0VLM).6GZTI6X96*<-/GPWY743/QE!KFN:A
MZ=D59:$G1ZZ.S4X:U> 4I4=RTE<_UI2',<[_ %);?SZ[8;XH0=:RT#5[JUR@
MH'VCX":/WN(>2E2O]>DK[TI9V'3ZD^0.>66&_+H?Q2^!UJF3O%66JC-\^VO
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MRMU.@9#3?JE)*4A1&;XK9R:C/@L>;4J6XEFH!-<7S<TA/58FHS' GHAE%.J
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MQ[('><+%I;CF(#2GIK?66[/4)ZV3KC=0I[4RYI+0/D222WSC<@EW9B9=\@@
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MCL-'T+YU)1XDT\TU=2<ZFN><9;W9V#B/RY_%\>]4LOSC$!SY@/+4.NX!Z\L
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MI4=R5!9NZAXT-8S"_+MXWX!PN&\0"V=\5$^8TYFBH<@2"R+"(O?CRMUC\5@
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MW*N58=%^A*2*C>GIS7NAY5S_ +A)6?&<I#Y_HS?V<-</-I]NFDLHY(LGUU8
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M7,0N-PWCKU\,M.2 J@% 6HP*!#D*<M7T%)55= 5")0@!\@"%T7GRL-[\K=?
M?CW<<94(G%>6H^&<9)&>:G(HQ" !\@AH45H@;V'JOH/QWMZB-L\4(HYI4?!%
M\ *T4(S@J0<@5KQ-5;B "'BNN@0!QK5]ZF< ,^,^/.V[K#/&;,$R2IE*"6T
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M"J!@**=?YLD3/5A0+:T&8/.67Z?&'0*Z>+4?X&2OQ/JS\V\1=&I<-R3\1(X
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M$LEHZ,GDTI)32<J"033TU.+RB9$B4D0 $$DL4*R94B1*@ (9<J7#"&4..C\
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M%D<LOQ)+BH(149OUI(_SU2_U2;?=EJ'#KW8K*0&*2/R\XQ2G4OP,=9OX4O\
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M1>SAEF9()T)Z=*I!+4$Q"CO4%AEH5XJ(U93"0DG0HSJ6&1HJ]0C8T   "&$
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MJ.2":=#PLAF<3PZ0*!$80_65'(8O"+0C$%[ (@(@ B #T1ME.DC>R<G#REP
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MZ,3NQ2(\1W]_W>D RW8!E8TSETZ_"J5K#S,^A_M_-"\C[M3L_P"42.ZV[O\
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MZ%.8*,DMZ80C,N5:<T_PLNE--+55@L15)Y<LG'!*.14@ ,"IH0S#.BHJ*\9
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MJ,Y3G..O+:9%;7"7<Z(W%TS4:EU"7 UY4%0Z5-J0XXI*TY2E2$Q9-F6N]"B
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MCF$4*?Z3U$1 VZQ#/GGU!>W'+A?%"\@6X-S*+H^J140?U"H%$&95'[R:Q-@
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MOU9;%3J8.L#8MJH39<#,71(S82RC+3'&D&4DY/3S$<J= 642TDU&8(&(Y$Z
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M$!4<FNJ)HV=(=!*SHNDM0--[2(\D\D/^$D>ON+QS /KM:^>OGPWR?LY?>&2
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M_7AO3(#NM4/J1PJ5S^4#N,IFU'1DSX+Q^>4/)-)T]D<SX&M\2L'#UOB><S
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MQH*.SYL_5&(M1&)SCBHLJ)5&5WZN!-7W$K'UE;-F#!Z.%*(S"""DTJA5&F0
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M>&O5Z!#UZP'S64\."$7CX8U5#._G]1]/HROH\'MR[N-<EA >.60#KSW\@R'
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MZN_C;=QAY?-B;\VJ<@%SS3C&?1K+2;MA[%$G[4Q]_'XA 0_1UW;\S.&X =J
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MJ<E^IXQP]BB1]H8OQ[_%?T!ESM\>&_-1:\!]/'7$]&LM)NV'L52?M3'W\?\
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MDGXF.'L521_O3&__  \7 0X<\-^;7N&JZ>*4C/HUEI-VP]BJ3;]B8Z^_C?\
M_#B;\VO</D(>C66DW;#V*)/VIC[^-];_ &N+OS:]2 CO!B^C66A[3XX_HT/8
MJD_:F/OX[AZNP>6)OS:]P^D3T:RTF[?'/]&B?8JD_:3_ +^/S>H@&&_-KW#Z
M0]&LOYNW](CV*I/VIC[\/^[B[\W#LY:\N\P]&LM)NWQX'-:L03RR;)BD%0C"
K7%,&:/3B&,>E%##".=@L%H RMK?&23,YJB=D=9+.6S!$JH2J$J[#Y"/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>g796801g94n52.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g796801g94n52.jpg
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MUG^O[+ZM_07YW6ME_P#LQ_?'Z+?_ )AO?\_6QO\ _P!7_P"5KT]]W'>UI_\
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M3W5>]K/]?V3[A;G=^3'ZAO?XO3WW<=[7]O[I[JO>UG^O[)]PMSN_)C]0WO\
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M;7Q1A*XV)DZL1('![&&SJ5R:*)HE;CE$0^TX]KV3OQIH<1&@GC=,ID- @_\
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M:CVY?(#''Y<8;/8#%R"3[,&/>Q\XDL8P0R&Y8"2"Z3I1NU65PS-G7\- 3H-
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M\653Q<.',6&8@VJ^#5G(F/O- (>T DAK722229(R@DZZ$Z[>BA(+3H"7-(
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ML+ XQ)D":":^-H-5O\@W3L\8"VCM;+D7(&FS]8<J4-&1OC$NTU?B E,?8[9
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MWS0;J\A"0(V/*$)!]K!%GI3K69I2-#6LGX0-3(R6M:"2"2,@(F!F>'.K2?"
M&D>8$D]#:KC!L^4;9U1]H)KB"5ED<V-N?5,@+Q5F['1:4D]+;?G&I7,PCHU\
M1,NQ(R5YPSQZP)<R:RCSM\[ 6-FL1F)5X^/K]"1_K_M5EP ,"8(:1.HS-#HF
MDQ,3 G6 K"464HB41*(E$2B)1$HB41*(JM\KYGM#7\3UA)-;RD!&VKGDEQ>@
M\\:E8?>2E9'!]I\B]6:QD(2.%%Y /&1%ZZ%2Y]@]-OHY+G&0W-RU"(1XVHPD
MXIZ[1TG4@?[F5M@!)!!/@>16((8X@FE=-)%=9%# >H=Z;1DG(8.+,[!\;#SC
M9G,S7Y;2=PL-;(ZGC?&_8R$.U]/AI 8!9[ R4F 1M'34IO-9%( Q%QN2*+QA
MI'AS8:@2@(WDU$4@0?A.GKU"TYH#=((##FKXB\20>E*Q$?A(,FH@QWO[;@%I
ME.AO(TW*9J?YA\HM*)<?"8[3KD*AK* [4WO%1I>-CP\ &;,&D]50. A]@N3A
MB7&A9,;'S+>1L"&)UDY'V:#K4B*#J1T ,@ &I/761%RB8R@#(QV;Q:EK">L>
M(NC2DB-% ,7YO\GCT9XN1=;8F2,[@D/V>TY6&/LI#TW$\DDNXC<AMT<6S7L+
MQ_(2&<GHKJ1EN65BXDS"M&A4Q&@^:5XT[<"G\:9RZ:&:?^I(_P 3OH>JT6,'
M,(;0QDJ:0]K7]9,$Y03TDZP1?3AUL7:LC@XJ2S;8AV4EY +TXHLAMO:?',H*
MR3E>5KR=Y$&6@==@BXN0K8KIH@X]-5%43!%R,$MW(Y5$D[M021)W'0==:M '
M?7I%5S> # $"N@=TZ',>FXGYJ>9[,]H N5W'V'#Y4 0U)/H+N9:0P_&'Y9RA
M[+H6VBCX2:6G3F0.$4@3=F;4;H1L9$QCWW^SA^1DQ1HLU$#Y)F.A!Z;$=?GT
M^<J #(XP<P+8,T@S(B-::S\EJNE]B;<*Z\Y2N-CS !)I?J_;>VXK&S<6AF$*
M", <=A<:.1MFRCCT[,7GUAJI53)TY.220.R3V[AQFN@Q4:B6 36>A_T$<&RR
M 0"T$@F3,D&L#Z +SNU[O7FA]DH495D^[ES!;A8ERN2!;8'<7SSG<9[4TYXY
MRB=QC4:>D(UB[C *;0*8RO7QMCL=PSD.+O:6O"L'2"%XG*B."3/72@AH)((,
M -!UJV3N#TIT+65HT1:9)!?#00X NS&L$ B/*9,$ SD&WWL#=NP->K)[X*:M
MXY\C]@<A2NHYU%6L#&DRL3T0*U= =?:YB\KEL6.L;]?3>.\^1XPY=J\DQ77<
M0%BHP^%ATR>:RIZP.A $]*3'6KAJ8^:SE#09;+FAL@Z N))) \HRL(D0XUK"
MN/Q!V#)]B:N//))+>I*$4VWMO7<4VO[H#99;2AL$G!:/ I>X3B[ 5%W1)/!F
MO&#9B,"Q<<D)V.$Y $%"AI1L-:@9^M=ZZT_Z9BD+#Q!TB0"6U\)(TK7U$R0"
M 2356FJK*41*(E$2B+3I*-U_,Q>8.8,(=*PJJR+A0/)6H4Z+4<-\OKMU\QY1
M-TTS60SO?)%7)&^:65_K898W_O5RG8]BBQKR)ZG( DXN_C6O'T91#.HXC'7@
M:-.024>?+,'+T"F(6;9C\ SQP*%N'0O%O9BX6&L%5D,U&;?)-!V/8I)W.L_/
M?XK\T(?J)L1C1=M%M<-RT,$*1^'E$ D92(Q0"LA=JL$C3U-KBY!"%6U[MU!H
MM5JR40O=')&Z=[XTRG8[:'39636IJ9-=3N=RM?MJ+CQ80I'[:PTQ8 LH.65!
MVA4'L(55$/RQ42JH-\,]RS4%DSQTB.SR0ODR?FBSQM=)P1>*+,IB,IC:*=DS
M.US&=Y/H/\ #Y!;>U":V8R=_-F0B#LYD5&M@Q26M6 %O)R0AG=/)F*?GD4L"
MKP:TR12NV8N':C5"Z2=TDL+X8_0AVQVT.@T"DF(DQMT[+9O&0_=1OGFOS:0=
MCV*)XR'[J-\\U^;2#L>Q1/&0_=1OGFOS:0=CV*)XR'[J-\\U^;2#L>Q1/&0_
M=1OGFOS:0=CV*)XR'[J-\\U^;2#L>Q1/&0_=1OGFOS:0=CV*)XR'[J-\\U^;
M2#L>Q1/&0_=1OGFOS:0=CV*)XR'[J-\\U^;2#L>Q1/&0_=1OGFOS:0=CV*)X
MR'[J-\\U^;2#L>Q1/&0_=1OGFOS:0=CV*)XR'[J-\\U^;2#L>Q1/&0_=1OGF
MOS:0=CV*)XR'[J-\\U^;2#L>Q1/&0_=1OGFOS:0=CV*)XR'[J-\\U^;2#L>Q
M1/&0_=1OGFOS:0=CV*+JO'<:())H/W(-\BDZ9/DD7BS!RDF]&O$" YXFFMEG
MA@Z8/VS9\R<8VLLU>-T'*&::R2>>*#L>Q1:T<B^JI.9%2*21W7TAD +V7@AT
MX(CA8R']@XN[1\*)OV[AZ/\ 8N[W<I>Z+H^S<7NMA]"E_K4RGRGLDG<K(.1N
MOWJ[AR\80YVY=KNW+MPY:A%UW3D@&0CK]PX553S467>Q]JU!.U5,LE'(9L@+
M6RS9(IH8H.Q[%).Y6NJ:]TDK(DY>K!]5J2U)9LX2E"D:B6<B2<,FZ31FNF;R
M97)X+-&J"+9LKBYMF@W1212RP33PQLRF9RF=XKW5DZ28VE9,Y&-5R>,(PB2Q
M[7\AAC=(<@WB)P3'"T801#W1N(11 /V[@4DD+NW;W')X-,<&-T$;MK)>RP^J
MRG8]B@)!D$@[@P>ZV!1:*JJCEU58^JL'S45$+*9CLU1:BK18>JH.4RO?-CFH
MP<+LE,VUTLLVBZS;*]T5,\,D.V/8J+I8LX)A[I]1K$L/#S;^2L/JH!\?<9&4
MN2N3/M/HQM[L;(W,F+ORJ/U'SRY4E=PNI[\Z]JAVQ['_ +J>Z+%.8KJEY,6.
MPW<<UZZGXQBH+&SER'C:\Q'C%<5<%1S&3*M\C31BI@NOBHT0>IM\\5E<<D[V
M4SM=E.L&=)@Z;*R8B3!U$T[+</&0_=1OGFOS:0=CV*B>,A^ZC?/-?FT@['L4
M3QD/W4;YYK\VD'8]BB>,A^ZC?/-?FT@['L43QD1W4;YYK\VJ :T.FQW")XR'
M[J-\\U^;4@['L43QD/W4;YYK\VD'8]BB>,A^ZC?/-?FT@['L43QD/W4;YYK\
MVD'8]BB>,A^ZC?/-?FT@['L46LS$+KW84:*PZ;-HU)XP;111)A2ZS-TR<V;.
MD'S-;ZN2MLT'@\@U:$AC]MFB]&$FC0BP<-GK5NNFRGRGL@)!D4*T9UIG0#W5
M^&EW<-@SG5N!!F8O#%[ME12IQC+D9^WD#F^;F[MU(OMTW2F;B0.7*IEY*;9G
MWCY<JJJZS93Y3V5S&9DSI,UB(CX12-J:+&-^/_&1K$U(*WU?JE.(+M)NR=QZ
MP4%<:00V4&4CVP?%$<L<KE5YH"5S$R9V1R=.S+"]FSY99/''&P C1NO_ *_;
MKUWZJESB9+C-*R9I41M'3;HNA)>-G%J89-\Y%K#69!1H0S*-5K-6+-9N_4B,
M,@.;A%9@NU53RSA6NH'&,L,,[)7#1&/L;X>Q&-<4Q:3JW_\ K]E,SM).VIW)
M_P DGXDJ0!,!T^#!%XP-C\-2CL@CK"(G@B]F+X8;C L,I'6($NS?JN4"0M$$
MJJ)R9O,%D5V*JC=QBK@IG:Z#IEH/_7[5^:2=S2HKH=UAXEJ/1,%B4H@L6BL-
M%Q6;X/$ID)NND_QE:3\(WC+A&1O"3MX0-(VC3-E'&R)%VX28Q]BQ"LL&XQDU
M:I,I\I[?9"YQ,DF1H9TK--JUIUKJMA<PW5#UQ@Z=A(:Z73@Y#6ELG"8U7'+7
MY7-BH1AZB>>622T?>9C65UAJN&;?*R%L?J6QS4MFRGRGYB?]:;C0]4D[G6=>
MN_Q]5I<AT3QSE,)@VN34#@"T,UBR'#=;!&>#01AK\>*"VC;%G"WH=PP)1=LE
M';7 *(A'C+!R$S5%.K+,%56^;*?*>W^*43,X$F3)UKK6:[UK7K529%!D @D;
M"0V%,XG$XG&QS81'XU'4Q0<&%%L\+)M6 P8PL@S9-$,+?0FBW1PPM_>_T?3>
M][H.Q[*$DF222=2:D_-;!XR'[J-\\U^;2#L>Q1/&0_=1OGFOS:0=CV*)XR'[
MJ-\\U^;2#L>Q1/&0_=1OGFOS:0=CV*)XR'[J-\\U^;2#L>Q1/&0_=1OGFOS:
M0=CV*)XR'[J-\\U^;2#L>Q1/&0_=1OGFOS:0=CV*)XR'[J-\\U^;2#L>Q1/&
M0_=1OGFOS:0=CV*+J/749)(X-R+@$_02=L'Z2+U8>Z13?"WK<D,>X)KY*88.
MQQ%HU(,'..-EFCULW=-\TUT4U,4'8]BBPS(-KD;)3,S'"H2PF$C:L6,AE;)B
M":R4ZQ%X>S&,S)U!),H4:CD_^@Q;OG2Z+3#_ *+?!/'^U,IV/8I)B),;=.RZ
M(^):E$&S$F%1G70R22'%W@?D \+&F1LY@05LN_Q,%FS9)^3Q>KVLL[Q>N%[.
M5;646MGG;Z:936AKK0U^*2=RN]8+KC&UK8B81C;&Z%[6LP VM:[8&XC#:]K6
M2^BUV\:>.X\A>W]T@;IP)3^JP75;Y(=L>Q23N5@ &N](13-56+0754:577'N
MEU $9B(;-9R)=6?"G"N8YBVR47&/;6>#UL[W49.K6<-LDE;6SIE(T:1\E9.Y
M[K>%7497=M""[@$L_'X.4V#U54>H[98/<4L'F#1SGEDLVP=XHHXN<4<\++XI
M)8JVSLGA:R';'L5%\(JQ5O@_304CZ"91PN[)IHYC4\"+IRDF@Y<O\<+XXNW#
MA!))%=9Q9115)---3++##&UD'8]BB_!!.&-E1:[;",-UP@QP%"K(8BDE1 =W
MX==T)%J)VQS8#'-Q GWA@TNDU6\+'>T2R]R;>R0[8]BBP9F)ZGD<33@4AC6N
MST%1;LFB4+,AHT4B:30;[/PYLG''S9</@W8>R2]R1Q9V3:^S3]ABG]3'Z$'8
M]BJ"09!(.X->ZV4<XBXA@R%"5P(L6-:-V X:.5'LF#!BT2Q0:LV3-MDDW:M&
MR&&"+=N@FFBBEABFGACAC:UD'8]BHNYXR'[J-\\U^;2#L>Q1/&0_=1OGFOS:
M0=CV*)XR'[J-\\U^;2#L>Q1/&0_=1OGFOS:0=CV*)XR'[J-\\U^;2#L>Q1>6
M/+'D 5XWP*+3T=&F<H8N]E1D#+FSIVY:+"M?^YFY%/Y()Q;)+9OSD?B$<,$P
MXC/'%(L_00'YJI7<8J8_LM'E@! FH!^$$D_(!:8W,8F*&/CT!]"8!/05Z0H(
M)_U"8?$MH[EB<S"-4HG$I/K^':C+BI-$A)+9YPNTW.VV)[P1V-)X) HVRA$H
MT3L0 FZ,2X>@4< ?<V2SLX9!AWF3;-!,Q ( ((KK.I H6D:_"=5L61+6D&I#
MBZ03E RQ^$.)D/::"DUH"MU?_P!070#%8%G9:2/ \HUHYVG&S37&)8YG8^WT
MH;Y W2'1%Y+VFQU+J:TCI=YC(5(4E TI"S6ACJ7MY8FH'P&V8-S0F1&@:7[S
MH-HFDJ<MT'2A@CUS9=8RZ])F*Q%5M<LY3H,- \G=M@X+)PTIXY0&>2E_!-BM
MQ8UX0(1W43?;L8]LM%3LG:XA9."*!<_I2(8G1>;A\-,"11L>Z'I#:>![@""T
M:.IT!&A-""/_ -!"@9+F-D0\@2-*NRG6-#\O515K[F',S>S1.KI%& JKY[LS
M7T06-_93:6JB%PD]U?O:<XO,=9[>!A9PWN+)Z8P&M93;!_"I0F<)CPI+[00V
M3#F)KW$Y3EF1H'"F5Q-'0=6Q-1\P0*6#*7 F@)BAJ',&K21H_34$5H0IGY0[
MPE&ED=,MHF,9/R&U=KO->.';R%;&V+F&9,=1;5V=F19PO53$C,C;E9QKIL(R
MLQ:YMAS0FZ+O\L6@]7*UM'%N4"/$2"2"8 !,PVO3_@HQH=FDQ#9U _,UNKB
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MYCE+I#2\C,8H"&B*ZD3H9@@ZUZ-(R^*(+@T>$2!(+C,30$ 5ZR-%T.+VP,\
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MF>L[:;E+64$S:^I)#&ED@S,NH!$'2-59#BD;*']6D'C@Z9E<9;[-VP,UG+)
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MGDRU9)4VX?WV]B6O=E0=XT+PZ<#'3AJ^&NGF#H"=&HEX>=39CI(N6&X>"0(
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MZ-_A$Z?Q3MN?GG_J:<VT\WT;_")T_BG;<_//_4TYMIYOHW^$3I_%.VY^>?\
MJ:<VT\WT;_")T_BG;<_//_4TYMIYOHW^$3I_%.VY^>?^IIS;3S?1O\(G3^*=
MMS\\_P#4TYMIYOHW^$3I_%.VY^>?^IIS;3S?1O\ ")T_BG;<_//_ %-.;:>;
MZ-_A$Z?Q3MN?GG_J:<VT\WT;_")T_BG;<_//_4TYMIYOHW^$3I_%.VY^>?\
MJ:<VT\WT;_")T_BG;<_//_4TYMIYOHW^$3I_%.VY^>?^IIS;3S?1O\(G3^*=
MMS\\_P#4TYMIYOHW^$3I_%.VY^>?^IIS;3S?1O\ ")T_BG;<_//_ %-.;:>;
MZ-_A$Z?Q3MN?GG_J:<VT\WT;_")T_BG;<_//_4TYMIYOHW^$3I_%.VY^>?\
MJ:<VT\WT;_")T_BG;<_//_4TYMIYOHW^$3I_%.W9_P!__KGWJ:O->9\6@D4&
ML@;;$HG3^*=MS\\_]34YMIYOHW^$3I_%.VY^>?\ J:<VT\WT;_")T_BG;<_/
M/_4TYMIYOHW^$3I_%.VY^>?^IIS;3S?1O\(G3^*=MS\\_P#4TYMIYOHW^$3I
M_%.VY^>?^IIS;3S?1O\ ")T_BG;<_//_ %-.;:>;Z-_A$Z?Q3MN?GG_J:<VT
M\WT;_")T_BG;<_//_4TYMIYOHW^$3I_%.VY^>?\ J:<VT\WT;_")T_BG;<_/
M/_4TYMIYOHW^$3I_%.VY^>?^IIS;3S?1O\(G3^*=MS\\_P#4TYMIYOHW^$3I
M_%.VY^>?^IIS;3S?1O\ ")T_BG;<_//_ %-.;:>;Z-_A$Z?Q3MN?GG_J:<VT
M\WT;_")T_BG;<_//_4TYMIYOHW^$3I_%.VY^>?\ J:<VT\WT;_")T_BG;<_/
M/_4TYMIYOHW^$3I_%.VY^>?^IIS;3S?1O\(G3^*=MS\\_P#4TYMIYOHW^$3I
M_%.VY^>?^IIS;3S?1O\ ")T_BG;<_//_ %-.;:>;Z-_A$Z?Q3MN?GG_J:<VT
M\WT;_")T_BG;<_//_4TYMIYOHW^$3I_%.VY^>?\ J:<VT\WT;_")T_BG;<_/
M/_4TYMIYOHW^$3I_%.VY^>?^IIS;3S?1O\(G3^*=MS\\_P#4TYMIYOHW^$3I
M_%.VY^>?^IIS;3S?1O\ ")T_BG;<_//_ %-.;:>;Z-_A$Z?Q3MN?GG_J:<VT
M\WT;_")T_BG;<_//_4TYMIYOHW^$3I_%.VY^>?\ J:<VT\WT;_")T_BG;<_/
M/_4TYMIYOHW^$3I_%.VY^>?^IIS;3S?1O\(G3^*=MS\\_P#4TYMIYOHW^$3I
M_%.VY^>?^IIS;3S?1O\ ")T_BG;<_//_ %-.;:>;Z-_A%4/^H%JG8NX-8ZQC
MFK$26,U";WAD[CQ=A=UBUC$E@\=FDB@TFD"C3+"^,:$[#91%0TFOGBT=M<[L
M'-_9NKVOR()B#!F9F.ACZPNEF0TG-H6D=R 0(])7GI?_ (SA.Q=E\@ ,!W%K
MEGR=):%E.RVK4$<(S?7<' #.9("$0X8#":8Y$%!<D$  G&='; ^+ZIE#\/))
M:]R)J!@Q<Q*1D,ZB1.7U@>(=&F"/#-"9)/65T\! ;+3DS!ITDDV9))+FT)+\
MI+A0?);I+=O_ -1)H0&HL0&XT)2UU4\&2-L,U:D:B)"7N^!LEFPJ6 6(_1KV
M*"G6/+[*-1)1JINV5%VQYN1C96 B-?*MBKY)I\IH#TDG0Z$ 1-=H)4#;*:Y8
MGS5CF@0?%/\ _')_"*09FBLIM2'\A"O$C^HYJPV5V/MDZ0TWM #HXB<C<;:R
M^6.9KQ3$J.8_&V\"B\1'&\;;:)R8:%0;B523,@Z4CR;U5J.'-F>NCO@Z/FV@
M[T'7Z+(+<]DX -AP+@"8$/H:G6(FL=:*I,#ADJUCML/L4!JB7):/#;RT9+2%
MM-<,]P<?@[)ZQTAS#A$SR$<6K-Y=L4LY8OY7J926[::!$V$GM)HO'+(JH:V=
M/F\H"-(] 8DM<)BO6), ] # 6G$%I!,O+2/$]K_SV9'CT @.ALT@G5U;Y<HD
M1VTH_P ;9F>UM/MC<>&6TWDCW9JYSJ2<FI(1C;C66Q T')S70;R-9[ F<?B^
MS7T3*DH)G!S11H3^S\WSC;AK$E'K*G3<2":5(@C36)(D1.E*$C#*%P#@UT0T
MR )D3#IAI(FL@1(FJH[NS3\9.1N$O8MQKFD-@8R+;_8:EU;LCB[LODUK99*7
M3H:0;(M-4Z\)1S:G#Z:RE(2W.:O/X/H@%UK#SRX$@-CAP->)C88@4$5BA(UF
MHI$S30 ;&0MM<02"X$^$N<'AAH*C,9:\"8(J7$4D55MM6\9(6ERQ$;DD'&:!
M1(ZXXQZT/DI&O#XU(R0'?;F;2Y],U+[*4%JD9#LEDQ=LFQJ<YD59&?9X-G[T
MBNFXPRNBI, :=08-9$]:4E8+SDRYR1F-)(!; BF@$Z#HL;LG:<MU2OS V'=X
M89R@%RUX30L5<7&W$OD;GCI*B'%,$_!Q:+MQ)LL>&'SFP>1@T0B!#O3:LV,3
M)K%LOM$P:YMKH9@ZMZ:BD@;UD#MJ@ =E'_I:$UCQ /(DF *!I-=(W4:J2/G!
MM M(SX25;[UC$T]B0!E"!J.H(%'R1"!33G1,]?24Z8#[$U67D316(\3K@Y>S
M8F6PYZ&9*"I=,12QAN\2SE8D'J*0.KG T(FC0.\[J^ 4(:?"23)-19@@"#U?
M(IZ@44^R2:\F83PZF[Y@\DA+?@>3\A81!#<@U!*-A2<Z,C>R=LQK1\G(0[4L
M14;7(R*% ]?GOM6]B;>"/<B&!<P/Q9%TFZEZ&)_-$Q)@F-A7X* ,+VZ92&$^
M* )#2ZI/0R(F?5<\BFI?<_$X&I*@TN,>)3V&%I4UB>@9X;20%Q;85WR#B9<7
MMDL&FT-BZ\]N'%(377[<9E)9$$<.))%T5&*3!>A@[Q3T-".E9^52*A&>%](!
M@@$N B1T>* [$T!H51:$:SB"$GUTZWSP^)3#4P77_*B/0$-!^)6Y7,7=GY/M
MC3<CC4DB>C9>VV%*.)[R6M6LW2CL>D\ABHL#<81-BB\?#'&J+>#4$T S'0FI
M@T!D@ZQ.L4*V2[Q97P3D)E[10!P(+@0'Q22)F=#"NS<)M6$\<N!@><O2#[D7
M&Y_QDC1?-Z8M(##XLX"X@=^,S!M-=RG*W@[22FW"9LUFLZ1*$ 6<JP4R<MVK
MI*F?4D1IN!!/J(FM2?B96)!=:$#PD/T$ "9; Z>++3Y+T0HN:41*(E$2B)1$
MHB41*(E$2B*JW+L3'S6N03&4PF2S@#G,T\G;,1K:8;LBP9[:'S+&/2+:FD-?
MDA\TV_KIA)\PJ#N&Q_%XNE*7L4E+],:'C9*0!GU]#4?,=1,4^?21IFI@@&*5
M#3J) <:-,34ZB1J0#Y: M6;=<BN,C!M!-_1;?T7C,6C4VG[^!S@U,#.N?^&X
MU!VLBA6^B,H1UIJ 5'SI5[+Y=QQV$NC-)GMT8-0=KC[J"YJ4@_+0S%36?PQJ
M:"#6#0F)C5=26RZK2TDD"1 .>8+0)=(IF;0-TTA6IX. -GP&)<A9,ZAG3J#X
MQG7G3N'8:MW,"2<SZ'ZY)VV5.[ZLE8QIM4T2FI):)_:-,"%S(RZ4!33( 2G1
M;"\\EH>M .@I4:D#U$::D&)-3FT@EM9,F22W0F@D4$5B= 1H*"R?%><[:V;"
MITEN91\B;;S2>,1*Z6G=PZ.?)0PG-YI]BLV=]E HVX)YH0:T9]Q?QY-4H&QP
M13ECY>4*.'CB_6IZ>ICZ1]]5EX (C83X@ZL"=/\ VG_2\^)UK$V'T)!]0S#7
M.Z941([C_J!#@,VE4,W[OH3JV,'^3^PG6N=SR:-ZZC\RV'.]O_8,W'37'XX?
M/0YO8<2F$IPV.))H"T"TB:&DEU36*FNI)-:'XG,.O0&7$@M'ALYJUI)#!+07
M$- G\5#H*%;EQQU]MH+S6?2XL,V([&.R6\A<D+2[5D]C9Q;7KD5KAMJ*437D
M&9LU@6YV!>T/Q)0[2P"/ Y3IA[L*1,#F>;J&'LB83))K6LBND SUTT&DE9<6
MED=1EB' B:Y@&BK=:F2'0"!4%>QM5<DHB41*(E$2J-'?#_81*B)1$HB41*(E
M$4?;;14<:JV8W2#S"1*.-?S)# !KTOB GQS)6.D4["(.=S(B, LP)7R]SC);
M,L+Q'&EF3O(BQLC=TD[_ "U_R._14:C05%34"O4;;K^?C9^G-L&!.Q0D!@4Z
MCFEBLJWR>U(X'<2-[I @,L,:$T9$==1V(\85R3+9&I)VQE@Z=2>,\KCKAK!
MFSA\]D^46;9[*'+M,G2@@3L8F!%*$5FH%#.X7Z 6@B:D!H=XVR0'/+I?H01
MR:D%L$P5?C08%V<Y9OID6U]M?4LAC]M@CI"0E4"W)(36YRA@<";.6TJWJYA
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M>4;C<%FQ&*GR(:9QTJW6&RB.!'-T<%J+0%KG"8:"3,=!)T)^<Z(;-P<&TEQ
M&HU,#4"FQT/0E:.IR=V5%9!F$VEK4%!A6<7CJR,])FS0F"(RHC'X =,Y.90>
M"#XHK&Q")[:"KA!G*5I(P'Z2*.BXYBOL&'LL,&T<##F@ C6L33KH:$Z&D=9
M3*#^$DF30"3$D"@,SIT_-30J<Y_O6.PP9K0A'X])]N*[@-Y@]=L-5K0XK:1J
M)P:3[&N4;GI-+XG#D 2D3B)A^V+NI*BT?*^X,F.;ET19I*[+P,L NS:98/2>
MI'3_ *5 TDF2&Y1))FE0W0 G4CHJ_P (YTQ"5&CRBL*F^6O'<B##M=[&%"!R
MP<VV+\28?RN;A#@=W(&\U931>+$)A@DQ81%V#:V$!A90RQ/F&[%?(MA608D9
M3&LLSP03,T(TC2NJT;,B*B8JTS(_\ALZ&((D#K.M($K!-?ZB>J"9Z&-![)Y9
ME)I1,=98A\#,#DLH,[>',-&F81 X61@,[ENNY"[E@?=@QXX=)S:S&.V9/[RA
M['DP,CS&SG-D;5'0DF&D %I(J#UTBL"JILG">L .D!P ;X@200'""W:O29"E
M6+<I6,R.%(9&(;-I-(!4IED7D<DCT78O8?KA=#<>TM/0IW.&*TQ;2Q^R)F]8
M%U3+N%C#Z(40WO*Y9>#QDDR>(Z%I- "362!X6F2!-9Z28Z5HLEA !) D @$U
M/A:XQ2! <-8G02:*;=/[#2VOK&%;"3'W#KR<$U>DPF3BSS($>1OFQD0&[RR2
M.+VX,ZU(B;O4T4DGGN?O*6&*:N-K::[,T.B)%1L="/D5DB"1K!UW'0_-216E
M$HB41*(E$2B)1$HB41*(E$2B)1$HB\SHUSU/S5Z@.C4(CB;[8DI;QS3#.2Y[
M/BZA!CU0Z?D94;('];"XY+PHD)=.7F[ZL/25./&G@?7)I\U<GP\O=?G%LXQ#
M1XC#:GJZ)-*@5F)K1=391,D^$$N/AI20(#I$F@D"14"A"V\9S&GZEV+XQII%
MC'&BNPX=*)*D=.6B[39>MI_MK4YY%E,WD2;1%C$<MD:S" VN<F+AI;<%L9E.
M7<=91:%R=]?7-=KDIXI-8D$C6  ,P -9@SH"5"P#\WE($"8(:[29F#-)%(DD
MTN]$92 FD<%2:,22.2\*30SNVD42*,S4=)+-%U6)#(62'NWS5=%N1:NVBF.#
MM?-NNW5:KY^\(JXVZM(< 009ZBH7,@@P00=C0K9*J)1$HB41*(E$7-O\9?Z?
M[VJ'5OQ_T47%5$HB41*(E$2B)1$HBI'-N7R$2Y!/=4K# 8N%Q C  4^G,J3V
M ,&L#6Q1#\X.20EXZ"%=6QO </O'K,FL\G$>>S4H<=@PN(\@+&6E'(VA#RV
M (DF>H)Z"-HDUKM!V&2T.U)F&B"8$#20XR9T!@"=)C31/-2;S..[#E&O--Y2
M<?#]T)P84T2+&7)0E '^CH)MV(RZ0L04;-.8,]V"]E]@#%26-Q<8U\U4;O\
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M92M)\6BA5R_$$HJ?^U@_..EFSJ/R5:3PJ-2-N5%$$WPDF+;Y"G;1*ZN"K("
M'5@1MH09 Z&0.O13,02123,:CJ(KT@D+3YUQBATQ&:,C@\U*H;%]'RXC*!C6
M+2R:A9.5P>ZSV!KNS/+8 :5BIBT>*93Q<X7-NRAA](%FKIJ6LX5+N"*!UF'9
M1) ;.A,F01K,]?54/(+C0EP@R! \0=I$=( B!TT7[O.)/'M]#GNOU]=ML88_
M=9.W$>;'92R8V4RT#AQ?LFW]S-H+-&F&C4TX0DR:K(M$<<,9 DCA*+>-5#9L
MC+$"9@?_ %R?_P":?75,[I!FHT,#S9]J^*M?AI18RW#C02V$GN5C<FD;N98%
MLI"5E&S-ER$T[?FPVOP+TVS,%9:Y(A)"@.U5KK (= N1A2+N8<#>Q=T&>,\%
MZ<I@G6NM23TZFLB!!F:?%7.ZE132&M I)T @CQ&0:&3*RR?%O48P]:6QH.5!
M29,F_D-U$YGL!2-FI.XGDUVF-,3>(M9>/#SC$#L?84LE89F<Q4P%.BGNHE8:
MT'!4Q=Y;=1,@SJ8D$D$B@,$S53.XT)D4&@F  VAB10 ?*JE#6,!&:MU[#M>!
MW+E\QB( >&Q)OK)6(&'39&WB)PE[#'!"Y,X1R=%R62"::.3YZXR2333OCACI
MK0T!HZ*$R2=R2M[JJ)1$HB41*(E$2B)1$HB41*(E$2B)1%6-;A_HI94JOD!D
MV*[UTH]!K)[$V!AGKMRO.1VS'.>J;VDGT:R2>3T.'D;YK"[!VCY00(#NVZT<
M$C@S7GRFZUGIXC23)RUI431;SN%)'K05H1XJ>*A($S&HJ25O2>@]5X00;K-6
M-JO(2,'3$?B'('#[]5_GL >>&34P9,.R:QTU)9*UE<KR+R8F3='GKR3GB2Q#
M(D16=WILVEH;%!-)US @D^M29W,J9G3,UIT T@BD0 (%!2@HMT@\&CFNH\E&
M(N@02&ID#)=94P<-R8P_+2$N].FR94_)"!4X5?$2Q%VZ6<$"#C/"RF#9#V+1
M!NW2TUH:($ZDU,DDF223ZJ$DF3Z= -! H(&BVZJHE$2B)1$HB41<V_QE_I_O
M:H=6_'_11<542B)1$HB41*(E$2B*$I3QXU3-)REL"1@B) O=6.NB@B\GDR$)
MDQ&'9O%8@7ET!;EDH;*B\75?*JAB)T(^=-U6P991196-QO,1@L:3)&L2)H8T
MD:&/]!:#B! ._02)U@Q(GT(Z[E=T'H'3T6:;&81: @8PRVV6'F-B-(\U\':R
M9P-C@&((M'39CDB@V#K1N.L13P(/39B7>#DT[79YD)"<=D 8T9H$9HD#2E/]
M5^Z9G'+4^'\/I4GO)UUTV"RT*U% M>R"8R>*"7K S/'JC^1+.Y#(S+;)5:12
MF7.$1 XT6(#HVQ=2J;RZ1.AT=:"V+@L??.EF^=_=\4*U@:21U["230=*DE0N
M) !Z:4 Z =!6@ KLI*K2B41*(E$2B)1$HB41*(E$2B)1$HB41*(E$6J3B$1K
M8T5,0N7L%"4?.(H)O6[=^1$O4EF;MN1'$19@.[8& ID039LRH8T(?,BH<JR9
MDAKQJ]:H+IP@$$'0J@D$$:C_ +0T(W!H="H(9\/-)CSPZ6,D]G,I</;F&ZTK
M&[SW4(D)RTA.(2(ZM)R0>>CU9(L6)LAEGF1FSS'(6$CP!+!(!'08P?CE-D$9
M@0")#C)DR9/4GJ371:SN(@Q%*96T@0(I3Y14DZDE;_L'0FK]I>_7G ,@64(N
MT7#MPUD\H O%6:<:,1!:/9O8\9%/,XB_ 2.2LRD247SCI)62''SP:L0(+.KU
MUFUTS-=8)%(B/A!/<[K(<6Z?X!ZSU!K(%=5,=;42B)1$HB41*(E$2B)1%8"8
M2;6&OFX%W.2\-B+642R.0...)$N)$HFYI+R& J+148J]]C@\/2$FHF/#C$+Y
MNR#Q3!NV245RQQO^#,=S6@J==E0"9@$P"3 F -2?0=2@>2ZQD$KF,$!%X:7F
M>O,8[G.XL.7$NSL0QEX]P5BUY&,0^NZ$7D QJX("+/4T;OV2.;EO;-&UL[LQ
M\Q[_ '2# ,&#,&*&-8/6.J_66']<01DT(S,A%(PQ?.7;)DZ-7',$7;Q@#,29
MXU;9KXX67<-H]'SAE9%/ZRF X2_=7Q]DV5RQ2=SW_P"__*J $Z GX?&/\D#X
ME;,F)"*X8*IC!F::F&*B>>+%K?'/#.ULL<L;^R_O;+&]KVO_ .-KTD[GN47W
MX,'[4-\BU^523N>Y188&YA4F;/'<>RCIIJ.,FXZ_<#4V#M%H>C11T#D AQFC
MAGBD0#&&+P82:YWLJT>M5VZV.*B>6-DNW/?[I_W?19GP8/VH;Y%K\JDG<]RB
MUT06U]('KL<!>Q,T]8-K/'B I060R;-[F3L=NHMDT]KAA[,_&)$%7QOE]=N4
M"$V"^*;EFNG@D[G8UT^/U['8I!&H(_\ P'_!!^!"V+P8/VH;Y%K\JDG<]RBZ
M1-&+!1I P80 BQ(EB[)E"9!)@S8#AS!!1T]?OG;C%-!JS9MDE7#ERNI@B@BG
MFJKGCACEE9)W/=%A61O7A&&M=ALW,;5A#R-)3%O*,D&B(C.++#+&DSN3I=%/
M%(;D*RL0NX5MAC@U^E7/ZN-K_0D[GOO\T@S$5TCK.R[4>?0:6,<R<94CAT>F
MYS:9O1B3%VVQ<II(K9H^V23RPOGBDX04O:U[_P#05PRM?Z,K4D[GNBSO@P?M
M0WR+7Y5).Y[E$\&#]J&^1:_*I)W/<HG@P?M0WR+7Y5).Y[E$\&#]J&^1:_*I
M)W/<HG@P?M0WR+7Y5).Y[E$\&#]J&^1:_*I)W/<HG@P?M0WR+7Y5).Y[E$\&
M#]J&^1:_*I)W/<HG@P?M0WR+7Y5).Y[E$\&#]J&^1:_*I)W/<HG@P?M0WR+7
MY5).Y[E$\&#]J&^1:_*I)W/<HG@P?M0WR+7Y5).Y[E%U7S2-#&3PD2; QXX>
MU</G[]\BP:,F+)HEFX=/'CIQBF@V:MD$U%G#A93!)%+#-13/'#'+*S,=SW**
M,@NW^/,C@A;:,>V7IX[K4 Y59'-@!Y=#B4,#/$;,<E6923,WZP9@[QQ)C,_=
MG3Q):^!(?GCA?%ZUNJS'S'NJ6N!@M(.Q!GMJLH,V)I(W/C6J@TVU>6V=&V>1
M"0Z[&R&+/IP#8X8#%5'A:*MG:IP>V12-A%5UG;%+!!,T'45RPP*,<G#,?,9V
MFO:9"08F#!T,&#KUTZ'L=EM3IS"F1T1&'>4=;2(^P,E @19-@F3*C8ZH)1.O
MF#/+"RSEJ(5/!4R"R6&6#7,HQQ6OC=RE]9)W/=3_ +_NQ69\&#]J&^1:_*I)
MW/<HG@P?M0WR+7Y5).Y[E$\&#]J&^1:_*I)W/<HG@P?M0WR+7Y5).Y[E$\&#
M]J&^1:_*I)W/<HG@P?M0WR+7Y5).Y[E$\&#]J&^1:_*I)W/<HG@P?M0WR+7Y
M54$UJ=-SN$3P8/VH;Y%K\JI)W/<HG@P?M0WR+7Y5).Y[E$\&#]J&^1:_*I)W
M/<HG@P?M0WR+7Y5).Y[E$\&#]J&^1:_*I)W/<HG@P?M0WR+7Y5).Y[E$\&#]
MJ&^1:_*I)W/<HH><;MXUM"4[#.]LZ1:%M7#W1?98UW.(,V>Z]%,5F[9\3FS9
M<FFK%A[%R[:-WSPW@Q;LW#ILBY42572PS9CYOKMO6GS6LKJ'*Z'4!@U.PI7Y
M+J(;]XN.DH*X:;GT*[;[0>N1NM7#386OW+?8!!F;2C+ME"UT"RB,G=-I*NWC
MBZ 7-ZHD?<-PN>.))=%KFS&)S4Z5UZ4K7Y)E<)EKAEUH:2)$TI(K7HI3/.85
M%A^!61Y1T&-4* @B;\HFP9M<R\G.#HS'1N*R^&&%WIN0EQ848WM?VCPD0:-$
M,<UET\,DG<]UF"=!.I^0$D_(5/HLSX,'[4-\BU^523N>Y1/!@_:AOD6ORJ2=
MSW*)X,'[4-\BU^523N>Y1/!@_:AOD6ORJ2=SW*)X,'[4-\BU^523N>Y1/!@_
M:AOD6ORJ2=SW*)X,'[4-\BU^523N>Y1/!@_:AOD6ORJ2=SW*)X,'[4-\BU^5
M23N>Y1/!@_:AOD6ORJ2=SW*)X,'[4-\BU^523N>Y1/!@_:AOD6ORJ2=SW*)X
M,'[4-\BU^523N>Y1/!@_:AOD6ORJ2=SW*)X,'[4-\BU^523N>Y1/!@_:AOD6
MORJ2=SW*+29_,M1ZI _:K:$GUYKJ,W>MQMI#.2\<B@7(B[Q64:L,29QPQ99/
M7";=PHBUQ6NNJDW74P3O@BIEBS$:N(^:H!<8:"3L 2>P6L8[HXW92IG!<=L:
M0RFQ&/X2P?#L9W [RI_%5 2\IPDK./6*W+NH_G&&SF1X&4&>8[($W7+V<W'I
M*.,68^8]U<KHG*Z)B8,3,1,:S2-UL>O9OIW;01:3:KEFM]DQQL16$.#T#-QJ
M6AVY5NW:NUQJY("Y?LTGZ3-\Q>9M%%L5[-'K-U[/W=TW449CK)C>2H01J"/B
M(_RMA%N84;?2,:(RCI(A$#*$=E+)DFP<.8^><QX#+&X@NBGAEFQ(+1B41P\D
MU<6P6S%&QCW'&Z#Q#/-F.Y[E2#2FM1ZB2)'S!'Q!69\&#]J&^1:_*I)W/<HG
M@P?M0WR+7Y5).Y[E$\&#]J&^1:_*I)W/<HG@P?M0WR+7Y5).Y[E$\&#]J&^1
M:_*I)W/<HG@P?M0WR+7Y5).Y[E$\&#]J&^1:_*I)W/<HG@P?M0WR+7Y5).Y[
ME$\&#]J&^1:_*I)W/<HJH\TN.YKDUKF'Z]#OVH>S+90^3D#RJWL7T:190Z;B
M1DJ 6]BK9:21:3&P,@"8?2CDD^&INL%L%&^%LLD3'2#/T.GK.BVQV0D^D1O4
M2/@1(*\]#'"#E<:,F=GR7[+NI/M@IJB<\@H+#):RR;3,X"3YA-[0EJ]EPIF
MD\=U$QVUH(!&KRI,8S.BM:VDS=%K*(O'V)%$F3$&"1\) $D'0$1N .L+>=L9
M1-)RN(TGEUH9!.5Q.OXHT)7W.>#?*,X-#CE,D9?L40)9N1&^#^\SSHT %M>
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MDT.7/F#0T"F<&")((RR 1!!\/X25Z%<,=13O3T$FXB;($A",AV*O)(I$2$D
MR%.) <H7"P+IBP;1<..CT8:EI,"D$D5CX<C(VSA\9=RQZ5:G928 AK3H(K](
M'H.L]]5A[@X@ZD""8B3)/4DFA DQ01$ %7!HL)1$HB41*(E$2B)1$HB41:-L
M\*1DFMMA1X/'H9+BQZ$2L,,BFQT%7.O90_* G[%I'9VW09D5EH<;773&29-(
M<04S"NGN.#!YE>S95O\  _\ 'TW5!@@DD009&HKJ/7;U7DMLOA'R;W+ >1/L
M)1&X+CM2=RO8@?4NX&B6X'AR5.M+ZTUA$2DCF\"F&NQ$?:P)]#C;C6P)TVV8
M' XNXS,R#7&81N/,XM""9TK-(TH!T.X,:@ S$Z=0]K2VA.4 $@Q3,XT!!UD3
MH9D" 23:6-::W,MRB@6P3D4B,5B^ND]T)FS,1+CFNO=C([0S;D&4JCVK\F3^
M61;<A(PFR4V)*3\I>C?"Q188)>RB\MN\!VO_ &D=@9G7IJ9)-,$C*0"3.4P1
M4%M*G0M T'T$5JU/^'_(XAL.3RP'#8Z9,Y..1;60; *[<D-GVUH1NCD]J#8L
M.C3"+(OPB+4GK#C[$I)K44)EY85!KFA@"%NTCVIY%)4\)!_Z:U$:QH!&W31;
M#V0 20/#3**%K'-)F#0N,D"M2[\037.A^1$3F/'W4!DO(&C8R8V^?W2BWDQ4
ML,%:>UGR9,<A^+[05(XY&X_" M_:2O'0<P@@UB#5?00L3%QP23@\%;*9W3+M
M6:#0.S : =0#$""0! *%S#G(U :&TB2YF5Y())Z%P-2"*F75M=P2TGM_2$<F
MX#9K1-L/>JP[,&N3F?VVFQ@\-".1\V/RPZ%;@H9(K%G:8A49.FT$@FP9RHF3
M,[0!XF;#L\0T_P"F:3I2)T-"1J)6;1P<9&YF! @FD R1 Z20/RF%?2BYI1$H
MB41*(E4:.^'^PB5$2B)1$HB41*(E$7D[LWC'NC8&S#4A5U:%&Q*.1_;8'&,0
M_;[>! =ALI_R9U)NQO(-:* 8SC*-;[2E@O7;R3[@D$A*"F4DVDJV$,RCD.9<
M['CDZF*4C4]7!TB(J(K02=Q5=0YH;$U):9+9(AA;!!,%HD!L20),#\)Z2.@.
M3IDB CD^@F,BU46((/Y0MGM< =W8_A$?W5*)OJ;2&SML3 <7D$CA>L@KIK(#
M#B.$2,OEAN3.XO?9JPN,E#6R+\HT^-#(!-3$:U)J0#YF9HJ#6"-#$EH#G-$B
MI,BL"*Y03#9(Y3\;-J[6W0#E(&.#)> 3,<0R44-E-C$XLGII;1_)=QMG=#Q&
M,H(+I&U=J02T<"M?#$7*TA(1=J#F"@L&* OKB)(Z:#_^TD_,0/6*]%&. !!,
M4>--<S,K:^ADUTDQJ54-II#F+H^)RO8";/ =M=V[XLK:IBH26')G"CO(1E)M
MR0+=ZAD:+'FI.ZA6P-=;@0R;;'VQ(IA+7C>& YAML^#=Q(6Q'02-(FAKI-09
M%)!D07$GJ8-!O,QT#\HSR8 =EAKFUTD.;4- %2&@@R;::1XN;:T]R<9R%FX?
MG]6"X8+B#N93O8+B42(P CVH]?0D(D 2') )"S+DYA$G<GF,4V0GL6')E",A
MV'#Y0*E\P(AF-K)J2( $GH(C3K2LR*R#,K!<TLB@,S ; !+B3U(B# (RF@!!
M !7I?1<THB41*(E$2B)1$HB41*(E$2B)1$HBKUR+CTV/1R,YP:#M9H1&2,BL
MZ7'20-#=F0MH6@\OC'VRT[+)&R> 0DV;+G4@!)8BH.NO 9%,T6;Y=[D@$-)(
M!C7Y3U%)&M=Q2==%II )DP(V)!@@PX @Q2?B!TJ/.*(<1>2FMH<#B$?@<;.D
MF>K 4;V6/+;T./N..\8[&>%@W1#73I[2[L$P$A7I?948A;4C,V,.9J_8("ZD
MZ$L:Y'B&FTT:#49:U)!(;&AJ)(&@B()\JZ%[2222/%+?",S?_)FS9I), FA.
MIB*!RLQ&='[N)<>>2XDI<A$^1F\6A5X3FS^:B&30])<=?@X8"0 .-9C4<M40
M\:% CX<#\)P/S2.L$LY4_D$ME^3DT2:@U@F2>H!( F=8I\0!-2LYFAS#JUL4
MBL DUG\1DDF8!T@"@I3L+A1R?+Q[<;+5>N8[JUAL.9[@G6LH\PW#=V<U1+B7
M'KBKK/51Q4H_0,1$&BQE&I-FELR,0 22=Z_R(1<%K"4Q !(IF62F^E9@[&!!
M%*5'02* &)*V'L!;))RAH/AHX9WEPC4B' 5(!$R"8"D@UHC=NVRO)8:,<S4C
MKZ ;/0CVGP>4I^S!(TCL3843Y#\CQ)!OL2,FH!LF,Q:<IA-8PX02QM!W\)C\
MN@(69QJRSA8=3^828D5ZD4)UH:Z Q00353, &&DD>*D@$ L;^$Y@8J8K,&#1
M>F_'Z-36&Z2U?%-C)A49M'8:&#R!"/%)$:#MW;!MBW3;M"LK+'I ^]W:IMT7
M"Y R3ODZP7LV>+,[-\[NV@F)UZZKDX@N)$P22)U^E%,-%$HB41*(E$2B)1%$
M/5?#L67Q*WH*[\@^8=BB=5\.Q9?$K>@IR#YAV*)U7P[%E\2MZ"G(/F'8HG5?
M#L67Q*WH*<@^8=BB=5\.Q9?$K>@IR#YAV*)U7P[%E\2MZ"G(/F'8HG5?#L67
MQ*WH*<@^8=BB=5\.Q9?$K>@IR#YAV*)U7P[%E\2MZ"G(/F'8HG5?#L67Q*WH
M*<@^8=BB=5\.Q9?$K>@IR#YAV*)U7P[%E\2MZ"G(/F'8HG5?#L67Q*WH*<@^
M8=BB=5\.Q9?$K>@IR#YAV*)U7P[%E\2MZ"G(/F'U1.J^'8LOB5O04Y!\P[%$
MZKX=BR^)6]!3D'S#L43JOAV++XE;T%.0?,.Q1.J^'8LOB5O04Y!\P[%$ZKX=
MBR^)6]!3D'S#L43JOAV++XE;T%.0?,.Q1.J^'8LOB5O04Y!\P[%$ZKX=BR^)
M6]!3D'S#L43JOAV++XE;T%.0?,.Q1.J^'8LOB5O04Y!\P[%$ZKX=BR^)6]!3
MD'S#L43JOAV++XE;T%.0?,.Q1.J^'8LOB5O04Y!\P[%$ZKX=BR^)6]!3D'S#
ML43JOAV++XE;T%.0?,.Q1.J^'8LOB5O04Y!\P[%$ZKX=BR^)6]!3D'S#L43J
MOAV++XE;T%.0?,.Q1.J^'8LOB5O04Y!\P[%$ZKX=BR^)6]!3D'S#L43JOAV+
M+XE;T%.0?,.Q1.JV']_^PLO[?_<K?\[6_P#(?^M.21^85IH?C_I$ZKX=BR^)
M6]!3D'S#L43JOAV++XE;T%.0?,.Q1.J^'8LOB5O04Y!\P[%$ZKX=BR^)6]!3
MD'S#L43JOAV++XE;T%.0?,.Q1.J^'8LOB5O04Y!\P[%$ZKX=BR^)6]!3D'S#
ML43JOAV++XE;T%.0?,.Q1.J^'8LOB5O04Y!\P[%$ZKX=BR^)6]!3D'S#L43J
MOAV++XE;T%.0?,.Q1.J^'8LOB5O04Y!\P[%$ZKX=BR^)6]!3D'S#L43JOAV+
M+XE;T%.0?,.Q1.J^'8LOB5O04Y!\P[%$ZKX=BR^)6]!3D'S#L43JOAV++XE;
MT%.0?,.Q1.J^'8LOB5O04Y!\P[%$ZKX=BR^)6]!3D'S#L43JOAV++XE;T%.0
M?,.Q1.J^'8LOB5O04Y!\P[%$ZKX=BR^)6]!3D'S#L43JOAV++XE;T%.0?,.Q
M1.J^'8LOB5O04Y!\P[%$ZKX=BR^)6]!3D'S#L43JOAV++XE;T%.0?,.Q1.J^
M'8LOB5O04Y!\P[%$ZKX=BR^)6]!3D'S#L43JOAV++XE;T%.0?,.Q1.J^'8LO
MB5O04Y!\P[%$ZKX=BR^)6]!3D'S#L43JOAV++XE;T%.0?,.Q1.J^'8LOB5O0
M4Y!\P[%$ZKX=BR^)6]!3D'S#L43JOAV++XE;T%.0?,.Q1.J^'8LOB5O04Y!\
MP[%$ZKX=BR^)6]!3D'S#L43JOAV++XE;T%.0?,.Q1.J^'8LOB5O04Y!\P[%%
MYR<RM;2+:\!UY#X\#CI^[G>>L'IMG,X&MLR$(1T>2=KE7TS@Z)R-6/QMKA9/
M-\V6/"V^"EVZZKJUDK89];0$@ :YFZC,!6I(VC6H"VPY23)'A.ARGY&#!^15
M>Y]&.3.H!TQ :7Q8 HG =9<>E 42T9IB-:XUF3D&Q.06TFW(V61&,8PG>DO3
MET*T^/C9]G& 2\\L@8)6D>4"FA<Z/CKO#A:-_"= W\+0T',YP<8K4-C2=UL%
MCB"ZI+GR7N)= 8W("9:(+I!)BE,S8E1PZV[RPC3&"EI]*MOQIL]E>B0<*S&:
M@8%0<Y9S;F+)(#/V6[3)W1L<>P0BST0\U?\ 9UX8"Z%(E'1U^:&1]W+57T6
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M2#0BA6"V)M"&ZL'"2,Q>&$[2 S:/1\7&XE+YY)SYJPDL?5' 8A! 4EE1EPU
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M-1XTN73UX;A0V2.5QS$T8]@(-MMDQY:)9.\1Q-S]FI>]<LL@[F-$"!K\Q%"
MX$B14D$;$B*]=E',RS4$M(!C2LQT]*_$=9"M!7182B)1$HB41*(E$2B)1$HB
M41*(E$2B+HDVKAZ-(,FCU0:Z=L7;5L1211<*L'#A!1)%ZDW<XYMUU&JF>*^"
M+C#-%7).V"N.6&65KB)!&XA%YV:/X62[64&V+KYX5A0>/[.U3!=)29O&"TZ/
MK9!H=!=H14IM$*]E^5WD?EDN7F4311URW6>PJ%!XBOX6:,%#3EUCP;9%H<)
MS-#3$U #@7#2"29 %!H.D=76F8@UD.+A,#4M.6FH$'Q4))T$*5-!<>)KJ:&;
M*#$G479JRJ)1R-!8?!9;L05%<#<9BQ0&4V.M*G.:4TBTSVB]?LG<L?QK%<H
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M+FW^,O\ 3_>U0ZM^/^BBXJHE$2B)1$HB41*(H35UY*DMF;'VL@3 DCKO6X>
MZC%%T2%A,1Q9J&9!(G!95M?)WCA.I:ZC/VIR#VP5= 8%$D[8Y/1N&59RG,74
MF(:#H/CUJ=8Z?34B V.I+CU.@ ^0F/5Q49P_B\0AG(]WO=KMJ;'&!T)M9.10
M^1L]?.$5#>QI#K<B.;#C8K7H>5*1:) ]?C8X"9&I,5+CQ(&)C$BJ@YF6;E,M
M80[-F-09%-21Z3 BE9TGK-+Y;ER@01!&;H#-"2)),F *D^D?4$T=,(UR,G6X
M"&6-PDN%M0B3?KQO"49H- IF>E1;K+7\EM]A&V+ZTVR3QCZ"RH&#W9Y_8I!K
M[X\S<@PAY=T,?G>= ?RFE9$ _AK&J%P+ WJ"2?"T:P-17I\^JQ\%U!NH#M"<
M;*E:^L),;>7FPK7!?,S,D6\'A$FG(L\C#A$&:@A\;!^*"!0U[/Y4U>E);.)F
M'&OS!9<"T#!8]&M<"7'*36#)\(G0"( W.I.IB !+<H S#0D0*D UFI-28I0$
M]9GZTKQVDFMMO2*?KH:ZB@1^)V,-)#-9Y2U'JX=GFR!T\';(V6*D;ARV$R^%
MLF9@ )28EI=D[O.9<Y3." UPL7&F,+730"' @3XB7 R9%(^>ITJ"<Z6@5.D%
MU<H B!Z&AZ: 1U-Q*ZK"41*(E$2B)1$HB41*(E$2B)1$HB415\Y*ZA+;H@ F
M,B%0ZRH2?PF<N(_(21T %EZ,-,)F48Z_E4537E,2^L118F&,B -7SQF4#L47
M0XD(=$A[G#VEP $4<#4D2!TD5'R6F.RDG<$2 "1(B0#0['T)ZJ& '&[:<,US
MHJ-QXUKY^7XZS'#84#%DUI2S /GIX'O."237A8]9H:.)16*:XV\."028KBS<
MJ*&(MB=F(YVN17QMG(X!H&49#F $Q^8$:3$. &I,&=5HO!+S!\8@FDT+3FB@
MDELD @"8&B[4OXORDCQ=BFA!IIL5-LFJMI+(&VP]F:@'."I=4H7D+\:GKQ4@
M1?B%#Y5UX3$I(J1$M1MVJCE9R1&ME\ALSD#-=9.9S=3/Y=14T(C39&O ?FZ=
M! <?29@?$C_!6Y[/U;N62:OUW#8&?"1@F)*I9SY1_L+8A V4C-@9MB[C\7W(
M_&&-G"'Q,B^&^)3-#PZ:9 D"0P0=!O'Z91K7-<6@ @$&LDGPUD!Q!=)I)U-5
M 6YB721TAHUD5+9RQ$TTF)!$A:IL3CO)9=K[7$(0UOQT)@M9LAHJ*P*0*[!:
M1:+M,=:7AN#V-&1".;EFZAA)R\PC**\857(QNS;!N8A4D32.MLN8X@"&0* 2
MX"HCH.G2E?1 Z"XYG^*9-)/BFH]1K77<45J->1LI#8!!H>;DY*;&HI#XS&R\
MS,VO8O+B@(*R%OY.5MDLYRL2/.VJI5]:[AQ>SIVK:ZRM_P#K,NH$  U@ 3\
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5B41*(E$2B)1$HB41*(E$2B)1%__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
